PT AU BA BE GP AF BF CA TI SO SE BS LA DT

CT CY CL SP HO DE ID AB C1 RP EM RI OI
FU FX CR NR TC Z9 U1 U2 PU PI PA SN EI
BN J9 JI PD PY VL IS PN SU SI MA BP EP
AR DI D2 EA PG WC SC GA UT PM OA HC HP
DA
J Roncero, C; Ortega, L; Perez-Pazos, J; Lligona, A; Abad, AC; Gual, A;
Sorribes, M; Grau-Lopez, L; Casas, M; Daigre, C Roncero, Carlos;
Ortega, Lluisa; Perez-Pazos, Jesus; Lligona, Anna; Abad, Alfonso C.; Gual, Antoni;
Sorribes, Marta; Grau-Lopez, Lara; Casas, Miquel; Daigre, Constanza
Psychiatric Comorbidity in Treatment-Seeking Alcohol Dependence Patients With
and Without ADHD JOURNAL OF ATTENTION DISORDERS English
Article adult ADHD; alcohol dependence;
comorbidity DEFICIT HYPERACTIVITY DISORDER; ATTENTION-DEFICIT/HYPERACTIVITY
DISORDER; SUBSTANCE USE DISORDER; SELF-MEDICATION HYPOTHESIS; REPORT SCALE ASRS;
ADULT ADHD; DSM-IV; ANXIETY DISORDERS; PREVALENCE; ABUSE Objective: To estimate
the prevalence of ADHD in adult patients treated for alcohol dependence and to
analyze the characteristics of consumption and psychiatric comorbidity, in function
of a possible ADHD in adulthood. Method: We administered the Adult ADHD Self-Report
Scale (ASRS) to 726 alcohol-dependent patients. Clinical diagnosis, following
Diagnostic and Statistical Manual of Mental Disorders (4th ed., text rev.; DSM-IV-
TR) criteria was made in the first four weeks of treatment. A subsample of 297
patients was evaluated using Conners' Adult ADHD Diagnostic Interview for DSM-IV
(CAADID-II) to test the psychometric properties of ASRS. Results: After analyzing
the properties of the ASRS (sensitivity: 83.3%; specificity: 66.1%), the prevalence
of ADHD, in the whole sample, was estimated to be 16.2%. Being younger, lifetime
history of cocaine dependence and the presence of an affective, anxiety or
personality disorder were associated with a possible ADHD. Conclusion: The
estimated prevalence of ADHD in patients being treated for alcohol dependence is
high, and the presence of a possible ADHD in adulthood is associated with an
increase in psychiatric comorbidity. [Roncero, Carlos; Perez-Pazos, Jesus;
Abad, Alfonso C.; Sorribes, Marta; Grau-Lopez, Lara; Casas, Miquel; Daigre,
Constanza] Hosp Univ Vall dHebron, Dept Psychiat, Outpatient Clin Drug Dependent
Patients, Barcelona, Spain; [Perez-Pazos, Jesus; Abad, Alfonso C.; Sorribes, Marta;
Grau-Lopez, Lara; Daigre, Constanza] Hosp Univ Vall dHebron, Dept Psychiat,
Barcelona, Spain; [Casas, Miquel] Hosp Univ Vall dHebron, Dept Psychiat & Legal
Med, Barcelona, Spain; [Roncero, Carlos; Perez-Pazos, Jesus; Abad, Alfonso C.;
Sorribes, Marta; Grau-Lopez, Lara; Daigre, Constanza] Barcelona Publ Hlth Agcy
ASPB, Barcelona, Spain; [Roncero, Carlos; Casas, Miquel] Biomed Network Res Ctr
Mental Hlth CIBERSAM, Barcelona, Spain; [Roncero, Carlos; Casas, Miquel] Univ
Autonoma Barcelona, Dept Psychiat & Legal Med, Barcelona, Spain; [Grau-Lopez, Lara;
Daigre, Constanza] Univ Autonoma Barcelona, Barcelona, Spain; [Ortega, Lluisa;
Lligona, Anna; Gual, Antoni] Inst Clin Neurociencies, Barcelona, Spain; [Ortega,
Lluisa; Lligona, Anna; Gual, Antoni] Unitat Conductes Adict, Barcelona, Spain
Roncero, C (reprint author), Hosp Univ Vall dHebron, Dept Psychiat, CAS Vall
dHebron, Passeig Vall dHebron 119-129, Barcelona 08035, Spain.
croncero@vhebron.net Roncero, Carlos/F-6785-2015 Roncero, Carlos/0000-
0003-1421-7385; Abad Gonzalez, Alfonso Carlos/0000-0001-5706-7693; GRAU-LOPEZ,
LARA/0000-0003-1297-1819; Daigre, Constanza/0000-0003-0064-3404 Able
SL, 2007, PSYCHOL MED, V37, P97, DOI 10.1017/S0033291706008713; American
Psychiatric Association, 1994, DIAGN STAT MAN MENT; American Psychiatric
Association, 2000, DIAGN STAT MAN MENT; Ramos-Quiroga JA, 2012, REV PSIQUIATR
SALUD, V5, P229, DOI 10.1016/j.rpsm.2012.05.004; Arias AJ, 2008, ADDICT BEHAV, V33,
P1199, DOI 10.1016/j.addbeh.2008.05.003; Biederman J, 2000, AM J PSYCHIAT, V157,
P816, DOI 10.1176/appi.ajp.157.5.816; BIEDERMAN J, 1993, AM J PSYCHIAT, V150,
P1792; Biederman J, 1998, BIOL PSYCHIAT, V44, P269, DOI 10.1016/S0006-
3223(97)00406-X; Brinkman WB, 2015, DRUG ALCOHOL DEPEN, V147, P183, DOI
10.1016/j.drugalcdep.2014.11.018; Capusan AJ, 2015, AM J MED GENET B, V168, P414,
DOI 10.1002/ajmg.b.32300; Charach A, 2011, J AM ACAD CHILD PSY, V50, P9, DOI
10.1016/j.jaac.2010.09.019; Clark DB, 2014, EXP CLIN PSYCHOPHARM, V22, P141, DOI
10.1037/a0036140; Daigre C, 2009, ACTAS ESP PSIQUIATRI, V37, P299; Daigre C, 2015,
J ATTEN DISORD, V19, P328, DOI 10.1177/1087054714529819; Daigre C, 2013, AM J
ADDICTION, V22, P466, DOI 10.1111/j.1521-0391.2013.12047.x; Daigre C, 2013,
ADICCIONES, V25, P171, DOI 10.20882/adicciones.65; Dakwar E, 2012, J CLIN PSYCHIAT,
V73, P960, DOI [10.4088/JCP.11m07484, 10.4088/JCP.12m07895]; Edwards AC, 2012, J
STUD ALCOHOL DRUGS, V73, P185, DOI 10.15288/jsad.2012.73.185; Epstein J., 1999,
CONNERS ADULT ADHS D; Ercan ES, 2003, ALCOHOL ALCOHOLISM, V38, P352, DOI
10.1093/alcalc/agg084; Fayyad J, 2007, BRIT J PSYCHIAT, V190, P402, DOI
10.1192/bjp.bp.106.034389; Government Office for National Drugs Plan, 2015, SURV
ALC OTH DRUGS U; Grella CE, 2001, J NERV MENT DIS, V189, P384, DOI
10.1097/00005053-200106000-00006; Johann M, 2003, ALCOHOL CLIN EXP RES, V27, P1527,
DOI 10.1097/01.ALC.0000090143.00703.07; Kessler RC, 2005, PSYCHOL MED, V35, P245,
DOI 10.1017/S0033291704002892; Kessler RC, 2006, AM J PSYCHIAT, V163, P716, DOI
10.1176/appi.ajp.163.4.716; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI
10.1001/archpsyc.62.6.593; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI
10.3109/10673229709030550; Kooij SJJ, 2010, BMC PSYCHIATRY, V10, DOI 10.1186/1471-
244X-10-67; Kushner MG, 1999, AM J PSYCHIAT, V156, P723; Lee SS, 2011, CLIN PSYCHOL
REV, V31, P328, DOI 10.1016/j.cpr.2011.01.006; Mariani JJ, 2014, AM J ADDICTION,
V23, P189, DOI 10.1111/j.1521-0391.2013.12086.x; McAweeney M, 2010, J ATTEN DISORD,
V13, P601, DOI 10.1177/1087054708329973; McGough JJ, 2005, AM J PSYCHIAT, V162,
P1621, DOI 10.1176/appi.ajp.162.9.1621; Nogueira M, 2014, COMPR PSYCHIAT, V55,
P639, DOI 10.1016/j.comppsych.2013.12.002; Ohlmeier MD, 2008, ALCOHOL ALCOHOLISM,
V43, P300, DOI 10.1093/alcalc/agn014; Rehm J, 2005, EUR NEUROPSYCHOPHARM, V15,
P377, DOI 10.1016/j.euroneuro.2005.04.005; Roncero C, 2014, EXPERT REV NEUROTHER,
V14, P849, DOI 10.1586/14737175.2014.932691; Sartor CE, 2007, ADDICTION, V102,
P216, DOI 10.1111/j.1360-0443.2006.01661.x; Schuckit MA, 1997, ADDICTION, V92,
P1289; van de Glind G, 2014, DRUG ALCOHOL DEPEN, V134, P158, DOI
10.1016/j.drugalcdep.2013.09.026; van de Glind G, 2013, DRUG ALCOHOL DEPEN, V132,
P587, DOI 10.1016/j.drugalcdep.2013.04.010; van Emmerik-van Oortmerssen K, 2015,
ADDICT BEHAV, V45, P214, DOI 10.1016/j.addbeh.2015.01.040; van Emmerik-van
Oortmerssen K, 2012, DRUG ALCOHOL DEPEN, V122, P11, DOI
10.1016/j.drugalcdep.2011.12.007; van Emmerik-van Oortmerssen K, 2014, ADDICTION,
V109, P262, DOI 10.1111/add.12370; Wilens TE, 2011, J AM ACAD CHILD PSY, V50, P543,
DOI 10.1016/j.jaac.2011.01.021; Young JT, 2015, DRUG ALCOHOL REV, V34, P683, DOI
10.1111/dar.12249 47 8 8 2 2 SAGE PUBLICATIONS INC THOUSAND
OAKS 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA 1087-0547 1557-1246
J ATTEN DISORD J. Atten. Disord. OCT 2019 23 12 SI
1497 1504 10.1177/1087054715598841 8 Psychology,
Developmental; Psychiatry Psychology; Psychiatry IV8IJ WOS:000484508800012
26269096 2019-09-25
J Dassieu, L; Kabore, JL; Choiniere, M; Arruda, N; Roy, E
Dassieu, Lise; Kabore, Jean-Luc; Choiniere, Manon; Arruda, Nelson; Roy, Elise
Understanding the link between substance use and chronic pain: A
qualitative study among people who use illicit drugs in Montreal, Canada DRUG
AND ALCOHOL DEPENDENCE English Article
Substance use; Chronic noncancer pain; Qualitative research; Opioids; Canada
PRESCRIPTION OPIOID USE; USE DISORDER; INJECT DRUGS; CARE; MANAGEMENT;
DEPENDENCE; HEALTH; INDIVIDUALS; EXPERIENCES; BARRIERS Background Chronic
noncancer pain (CNCP) is highly prevalent among people who use illicit drugs
(PWUD). PWUD suffering from CNCP are at the crossroads of two opioid crises: the
prescription opioid crisis and the street-opioid overdose crisis. This qualitative
study aims to improve knowledge of the substance use habits of PWUD suffering from
CNCP and to assess the role of CNCP in the evolution of their substance use
patterns. Methods In-depth semi-structured interviews were conducted with PWUD
suffering from CNCP recruited in Montreal (Canada). To be eligible, participants
had to self-report using cocaine and/or street opioids and having pain for at least
three months. Twenty-five participants were recruited (10 women, 15 men; aged 27 to
61). Interviews were analyzed within a thematic framework. Results CNCP could
contribute to either increasing or distancing from substance use. Participants
described patterns of substance use with several interlaced purposes: recreational,
CNCP relief, "emotional" pain relief, and withdrawal symptom control. In several
cases, participants' awareness of their CNCP was delayed by the relieving effects
of the substances they used for recreational purposes. Self-medication for CNCP was
seldom the primary purpose of the participants' substance use. Many participants
were reluctant to self-manage CNCP with street drugs, but some did so when
experiencing recurrent problems accessing healthcare services for CNCP. Conclusions
Suffering from CNCP complexifies PWUD's substance use patterns. In the opioid
crisis context, new health policies and interventions should be implemented to
improve PWUD's pain management and foster their addiction recovery. [Dassieu,
Lise; Arruda, Nelson; Roy, Elise] Univ Sherbrooke, Fac Med & Hlth Sci, Addict Res &
Study Program, 150 Pl Charles Le Moyne, Longueuil, PQ J4K 0A8, Canada; [Dassieu,
Lise; Kabore, Jean-Luc; Choiniere, Manon] CRCHUM, St Antoine Bldg,850 St Denis
St,OfficeS01-135-03, Montreal, PQ H2X 0A9, Canada; [Kabore, Jean-Luc] Univ
Montreal, Fac Med, Dept Pharmacol & Physiol, Pavillon Roger Gaudry,CP 6128,
Montreal, PQ H3C 3J7, Canada; [Choiniere, Manon] Univ Montreal, Fac Med, Dept
Anesthesiol & Pain Med, Pavillon Roger Gaudry,CP 6128, Montreal, PQ H3C 3J7,
Canada; [Roy, Elise] Inst Natl Sante Publ Quebec, 190 Cremazie Blvd East, Montreal,
PQ H2P 1E2, Canada Dassieu, L (reprint author), Univ Sherbrooke, Fac Med &
Hlth Sci, Addict Res & Study Program, 150 Pl Charles Le Moyne, Longueuil, PQ J4K
0A8, Canada.; Dassieu, L (reprint author), CRCHUM, St Antoine Bldg,850 St Denis
St,OfficeS01-135-03, Montreal, PQ H2X 0A9, Canada. lise.dassieu@umontreal.ca
Dassieu, Lise/0000-0002-6311-3681 Elise Roy holds the Addiction Research
Chair of the Universite de Sherbrooke Elise Roy holds the Addiction Research
Chair of the Universite de Sherbrooke. Lise Dassieu obtained a postdoctoral
fellowship from this chair for this study. Angst MS, 2006, ANESTHESIOLOGY,
V104, P570, DOI 10.1097/00000542-200603000-00025; Baldacchino A, 2010, ADDICT
BEHAV, V35, P270, DOI 10.1016/j.addbeh.2009.10.008; Bell K, 2009, INT J DRUG
POLICY, V20, P170, DOI 10.1016/j.drugpo.2008.06.002; Berends L, 2005, ADDICT RES
THEORY, V13, P373, DOI 10.1080/16066350500102237; Busse JW, 2017, CAN MED ASSOC J,
V189, pE659, DOI 10.1503/cmaj.170363; Centers for Disease Control and Prevention,
2016, RECOMMENDATIONS AND; Clark MR, 2008, CAN J PSYCHIAT, V53, P496, DOI
10.1177/070674370805300804; Corbin J. M., 2015, BASICS QUALITATIVE R; Dassieu Lise,
2019, Int J Drug Policy, DOI 10.1016/j.drugpo.2019.03.023; Davis WR, 2008, DRUG
ALCOHOL DEPEN, V92, P267, DOI 10.1016/j.drugalcdep.2007.08.008; Dennis BB, 2015,
SUBST ABUS-RES TREAT, V9, P59, DOI 10.4137/SART.S30120; Fibbi M, 2012, PAIN MED,
V13, P1040, DOI 10.1111/j.1526-4637.2012.01439.x; Fischer B, 2012, PUBLIC HEALTH,
V126, P749, DOI 10.1016/j.puhe.2012.04.010; Garcia A, 2010, PASTORAL CLIN ADDICT;
Heimer R, 2015, DRUG ALCOHOL DEPEN, V151, P92, DOI
10.1016/j.drugalcdep.2015.03.007; Kabore J.-L., 2018, CAN J PAIN, V2, pA79; Karasz
A, 2004, J PAIN SYMPTOM MANAG, V28, P517, DOI 10.1016/j.jpainsymman.2004.02.025;
Kerr T, 2013, ADDICTION, V108, P1270, DOI 10.1111/add.12151; Knight KR, 2017, SOC
SCI MED, V186, P87, DOI 10.1016/j.socscimed.2017.05.043; Lopez-Quintero C, 2011,
ADDICTION, V106, P657, DOI 10.1111/j.1360-0443.2010.03194.x; McCaffery Margo, 2005,
Pain Manag Nurs, V6, P122, DOI 10.1016/j.pmn.2005.08.002; McCreaddie M, 2010, J
CLIN NURS, V19, P2730, DOI 10.1111/j.1365-2702.2010.03284.x; McNeil R, 2014, SOC
SCI MED, V105, P59, DOI 10.1016/j.socscimed.2014.01.010; Merrill J, 2002, J GEN
INTERN MED, V17, P327, DOI 10.1007/s11606-002-0034-5; Miles M., 2014, QUALITATIVE
DATA ANA; Moore D, 2004, SOC SCI MED, V59, P1547, DOI
10.1016/j.socscimed.2004.01.029; Morley G, 2015, PAIN MANAG NURS, V16, P701, DOI
10.1016/j.pmn.2015.03.005; Murphy Y, 2015, PAIN PHYSICIAN, V18, pE605; Neale J,
2008, HEALTH SOC CARE COMM, V16, P147, DOI 10.1111/j.1365-2524.2007.00739.x; Roy E,
2013, INT J DRUG POLICY, V24, P142, DOI 10.1016/j.drugpo.2012.10.004; St Marie B,
2014, PAIN MED, V15, P2075, DOI 10.1111/pme.12493; Stumbo SP, 2017, J SUBST ABUSE
TREAT, V73, P47, DOI 10.1016/j.jsat.2016.11.003; Ti LP, 2015, PAIN RES MANAG, V20,
P84, DOI 10.1155/2015/868746; Vasilenko SA, 2017, DRUG ALCOHOL DEPEN, V180, P260,
DOI 10.1016/j.drugalcdep.2017.08.027; Voon P, 2018, HARM REDUCT J, V15, DOI
10.1186/s12954-018-0241-y; Voon P, 2015, DRUG ALCOHOL REV, V34, P221, DOI
10.1111/dar.12226; Voon P, 2014, PAIN MANAG, V4, P27, DOI [10.2217/PMT.13.62,
10.2217/pmt.13.62]; Whittemore R, 2001, QUAL HEALTH RES, V11, P522, DOI
10.1177/104973201129119299; Wisniewski AM, 2008, J ADDICT DIS, V27, P1, DOI
[10.1300/J069v27n0l_01, 10.1300/J069v27n01_01] 39 0 0 2 2
ELSEVIER IRELAND LTD CLARE ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK
SHANNON, CO, CLARE, 00000, IRELAND 0376-8716 1879-0046 DRUG ALCOHOL DEPEN
Drug Alcohol Depend. SEP 1 2019 202 50
55 10.1016/j.drugalcdep.2019.07.004 6 Substance
Abuse; Psychiatry Substance Abuse; Psychiatry IT0AM WOS:000482509100008
31301552 2019-09-25
J Volpe, U; Ventriglio, A; Bellomo, A; Kadhum, M; Lewis, T; Molodynski, A;
Sampogna, G; Fiorillo, A Volpe, Umberto; Ventriglio,
Antonio; Bellomo, Antonello; Kadhum, Murtaza; Lewis, Thomas; Molodynski, Andrew;
Sampogna, Gaia; Fiorillo, Andrea Mental health and wellbeing among
Italian medical students: a descriptive study INTERNATIONAL REVIEW OF PSYCHIATRY
English Article; Early Access
Italian medical students; mental healthcare; burnout; wellbeing; substance
abuse UNIVERSITY-STUDENTS; BURNOUT; DEPRESSION Medical students (MSs) are an
important part of the workforce for delivery of tomorrow's healthcare. Their ever
changing knowledge base and long periods of training may significantly affect their
mental health and wellbeing over the years. Following a global call for
participation, it was decided to include Italian medical schools based in the
Universities of Ancona and Foggia between January and April 2019. Students were
invited to participate in an online survey. A total of 360 completed responses were
received and analysed. Of these, 8.6% of samples reported mental health issues
whilst at medical school, ranking as follows: Anxiety Disorders > Major Depression
> Eating Disorders > ADHD > Burnout Syndrome; 7.2% of them had been treated with
psychotropic medications whereas 7.8% were self-medicating; 8.9% reported problems
related to alcohol-drinking, and 22.8% admitted using illicit drugs (mostly
cannabis and cocaine). The levels of burnout syndrome were quite low. It is
important to ensure that the future workforce are looked after and, as the students
are in the vulnerable age group, they should have access to early and prompt help-
seeking and early interventions if needed. [Volpe, Umberto] Univ Politecn
Marche, Dept Neurosci DIMSC, Sect Psychiat, Ancona, Italy; [Ventriglio, Antonio;
Bellomo, Antonello] Univ Foggia, Dept Clin & Expt Med, Foggia, Italy; [Kadhum,
Murtaza] Univ Oxford, Clin Acad Grad Sch, Oxford, England; [Lewis, Thomas] Tees Esk
& Wear Valleys NHS Fdn Trust, Gen Adult Psychiat, Newcastle Upon Tyne, Northd,
England; [Molodynski, Andrew] Oxford Hlth NHS Fdn Trust, Dept Psychiat, Oxford,
England; [Sampogna, Gaia; Fiorillo, Andrea] Univ Campania L Vanvitelli, Dept
Psychiat, Naples, Italy Ventriglio, A (reprint author), Univ Foggia, Dept Clin &
Expt Med, Osped Riuniti Foggia, Viale Pinto, I-71100 Foggia, Italy.
a.ventriglio@libero.it Bhugra D., 2019, INT REV
PSYCHIAT; Bhui KS, 2016, WORLD PSYCHIATRY, V15, P300, DOI 10.1002/wps.20360;
Christensen H, 2017, WORLD PSYCHIATRY, V16, P327, DOI 10.1002/wps.20437; Cuijpers
P, 2019, INT J METH PSYCH RES, V28, DOI 10.1002/mpr.1762; Deb T, 2019, BMC MED
EDUC, V19, DOI 10.1186/s12909-019-1472-7; Evans-Lacko S, 2014, EUR PSYCHIAT, V29,
P381, DOI 10.1016/j.eurpsy.2014.02.007; EWING JA, 1984, JAMA-J AM MED ASSOC, V252,
P1905, DOI 10.1001/jama.252.14.1905; Frajerman A, 2019, EUR PSYCHIAT, V55, P36, DOI
10.1016/j.eurpsy.2018.08.006; Halbesleben JRB, 2005, WORK STRESS, V19, P208, DOI
10.1080/02678370500340728; Jovanovic N, 2019, J AFFECT DISORDERS, V249, P192, DOI
10.1016/j.jad.2019.02.023; Kenne DR, 2017, SUBST ABUS-RES TREAT, V11, DOI
10.1177/1178221817733736; Kiekens G, 2019, EUR PSYCHIAT, V59, P44, DOI
10.1016/j.eurpsy.2019.04.002; Lietz F, 2018, HEALTH PROMOT INT, V33, P288, DOI
10.1093/heapro/daw082; Maslach C, 2016, WORLD PSYCHIATRY, V15, P103, DOI
10.1002/wps.20311; Messina G, 2016, ANN IG MED PREV COMU, V28, P245, DOI
10.7416/ai.2016.2103; O'Connor K, 2018, EUR PSYCHIAT, V53, P74, DOI
10.1016/j.eurpsy.2018.06.003; Peterson U, 2008, J ADV NURS, V62, P84, DOI
10.1111/j.1365-2648.2007.04580.x; Pighi M, 2018, BRAIN SCI, V8, DOI
10.3390/brainsci8110197; Pingani L, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-
016-0734-8; Pingani L, 2015, AM J ORTHOPSYCHIAT, V85, P139, DOI 10.1037/ort0000053;
Pingani L, 2012, SOC PSYCH PSYCH EPID, V47, P993, DOI 10.1007/s00127-011-0407-3;
Piumatti G, 2018, PSYCHIAT RES, V260, P412, DOI [10.1016/j.psychres.2017.12.009,
10.10164/j.psychres.2017.12.009]; Reynolds CF, 2017, WORLD PSYCHIATRY, V16, P316,
DOI 10.1002/wps.20459; Roncero C, 2015, ACTAS ESP PSIQUIATRI, V43, P109; Volpe U,
2014, J PSYCHIATR MENT HLT, V21, P774, DOI 10.1111/jpm.12137; Zulkefly NS, 2010,
GLOB J HLTH SCI, V2, P73, DOI DOI 10.5539/GJHS.V2N1P73 26 0 0 0
0 TAYLOR & FRANCIS LTD ABINGDON 2-4 PARK SQUARE, MILTON PARK,
ABINGDON OR14 4RN, OXON, ENGLAND 0954-0261 1369-1627 INT REV PSYCHIATR
Int. Rev. Psych.
10.1080/09540261.2019.1654718 AUG 2019 5 Psychiatry Psychiatry
IV3UU WOS:000484200500001 31469033 2019-09-25
J Koller, G; Schwarzer, A; Halfter, K; Soyka, M Koller,
Gabi; Schwarzer, Andreas; Halfter, Kathrin; Soyka, Michael Pain
management in opioid maintenance treatment EXPERT OPINION ON PHARMACOTHERAPY
English Review; Early Access
Methadone; buprenorphine; pain; opioids; opioid dependence; therapy CANCER
PAIN; DEPENDENT PATIENTS; SUBSTANCE USE; USE DISORDER; PRECIPITATED WITHDRAWAL;
SUBSTITUTION TREATMENT; CROSS-TOLERANT; DRUG-USE; METHADONE; BUPRENORPHINE
Introduction: Opioid addiction is a worldwide disease with a significant
impact. A multitude of physical and mental comorbidities are associated with opioid
addiction, pain being one of the most relevant. Insufficient pain management may
lead to a disruption in medical treatment, self-medication, and subsequent harm to
patients. Areas covered: In this review, the authors provide a general overview of
opioid addiction. A literature search for pain management and opioid maintenance
treatment was conducted. Different settings of acute or chronic pain and situations
specific to patients addicted to opioids are described. Pain management therapy in
addiction is also addressed with an emphasis on treatment strategies such as the
optimization of methadone and buprenorphine medication, additional opioid
analgesia, and multimodal pain management. Expert opinion: Opioid addiction is a
growing global health concern, and maintenance therapy remains an effective and
lifesaving treatment option. However, there remains uncertainty on the appropriate
pain management for this patient group. The backbone of pain management in opiate-
addicted patients remains maintenance therapy while adjunctive treatment such as
regional analgesia, non-opioid analgesia, antidepressants, steps to improve sleep,
acceptance and commitment therapy, biofeedback, and hypnosis should be considered.
Additional opioid medication is possible as well. [Koller, Gabi; Soyka,
Michael] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Psychiat & Psychotherapy,
Munich, Germany; [Schwarzer, Andreas] Ruhr Univ Bochum, BG Univ Hosp Bergmannsheil,
Dept Pain Med, Bochum, Germany; [Halfter, Kathrin] Ludwig Maximilians Univ Munchen,
Inst Med Informat Biometry & Epidemiol, Munich, Germany; [Soyka, Michael] Med Pk
Chiemseeblick, Bernau, Germany Koller, G (reprint author), Ludwig Maximilians
Univ Munchen, Univ Hosp, Dept Psychiat & Psychotherapy, Munich, Germany.
gabi.koller@med.uni-muenchen.de Al-Husseini A,
2018, INT J MENT HEALTH AD, V16, P642, DOI 10.1007/s11469-017-9813-4; Alford DP,
2006, ANN INTERN MED, V144, P127, DOI 10.7326/0003-4819-144-2-200601170-00010;
Anaya AMC, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011709; Andrade S, 2016, J
CLIN PHARM THER, V41, P459, DOI 10.1111/jcpt.12422; Arango-Dávila Cesar A., 2018,
rev.colomb.psiquiatr., V47, P46, DOI 10.1016/j.rcp.2016.10.007; Athanasos P, 2006,
PAIN, V120, P267, DOI 10.1016/j.pain.2005.11.005; Bakker A, 2017, J
PSYCHOPHARMACOL, V31, P62, DOI 10.1177/0269881116675508; Bao Jiayi, 2017, Shanghai
Arch Psychiatry, V29, P343, DOI 10.11919/j.issn.1002-0829.217030; Blaudszun G,
2012, ANESTHESIOLOGY, V116, P1312, DOI 10.1097/ALN.0b013e31825681cb; Blinderman
Craig D, 2009, J Opioid Manag, V5, P107; Bonnet U, 2018, PSYCHIAT DANUB, V30, P142,
DOI 10.24869/psyd.2018.142; Bonnet U, 2018, FORTSCHR NEUROL PSYC, V86, P82, DOI
10.1055/s-0043-122392; Brewer DD, 1998, ADDICTION, V93, P73, DOI 10.1046/j.1360-
0443.1998.931738.x; Cairns R, 2019, ADDICTION, V114, P1026, DOI 10.1111/add.14412;
Chiang CN, 2003, DRUG ALCOHOL DEPEN, V70, pS39, DOI 10.1016/S0376-8716(03)00058-9;
Coe MA, 2019, J ADDICT MED, V13, P93, DOI 10.1097/ADM.0000000000000457; Compton P,
2000, J PAIN SYMPTOM MANAG, V20, P237, DOI 10.1016/S0885-3924(00)00191-3; Connock
M, 2007, HEALTH TECHNOL ASSES, V11, P1; Connolly I, 2013, AM J HOSP PALLIAT ME,
V30, P83, DOI 10.1177/1049909112443586; Cotton BP, 2018, J SUBST ABUSE TREAT, V92,
P40, DOI 10.1016/j.jsat.2018.06.002; Daitch J, 2012, PAIN PHYSICIAN, V15, pES59;
Dharmshaktu P, 2012, J CLIN PHARMACOL, V52, P6, DOI 10.1177/0091270010394852;
Dhingra L, 2015, DRUG ALCOHOL DEPEN, V149, P285, DOI
10.1016/j.drugalcdep.2015.02.007; Dhingra L, 2013, DRUG ALCOHOL DEPEN, V128, P161,
DOI 10.1016/j.drugalcdep.2012.08.003; Donroe JH, 2016, CAN MED ASSOC J, V188,
P1232, DOI 10.1503/cmaj.160290; Doverty M, 2001, PAIN, V93, P155, DOI
10.1016/S0304-3959(01)00306-2; Doverty M, 2001, PAIN, V90, P91, DOI 10.1016/S0304-
3959(00)00391-2; Dunn KE, 2014, PAIN MED, V15, P1540, DOI 10.1111/pme.12430;
EMCDDA, 2016, EUR DRUG REP 2016 TR; European Monitoring Centre for Drugs and Drug
Addiction, 2018, EUR DRUG REP 2018 TR; Eyler ECH, 2013, AM J ADDICTION, V22, P75,
DOI 10.1111/j.1521-0391.2013.00308.x; Fareed A, 2012, J ADDICT DIS, V31, P8, DOI
10.1080/10550887.2011.642758; Fisher E, 2015, COCHRANE DB SYST REV, DOI
10.1002/14651858.CD011118.pub2; Fishman MA, 2018, CURR PAIN HEADACHE R, V22, DOI
10.1007/s11916-018-0732-2; Garcia-Henares JF, 2018, FRONT PHARMACOL, V9, DOI
10.3389/fphar.2018.00921; Goel A, 2019, CAN J ANESTH, V66, P201, DOI
10.1007/s12630-018-1255-3; Grosser T, 2017, TRENDS PHARMACOL SCI, V38, P733, DOI
10.1016/j.tips.2017.05.008; Haber PS, 2017, DRUG ALCOHOL DEPEN, V181, P132, DOI
10.1016/j.drugalcdep.2017.09.024; Hauser W, 2018, EUR J PAIN, V22, P1547, DOI
10.1002/ejp.1297; Hale M, 2017, J PAIN RES, V10, P233, DOI 10.2147/JPR.S120170;
Hammig R, 2016, SUBST ABUSE REHABIL, V7, P99, DOI 10.2147/SAR.S109919; Harirforoosh
S, 2013, J PHARM PHARM SCI, V16, P821, DOI 10.18433/J3VW2F; Hay JL, 2009, J PAIN,
V10, P316, DOI 10.1016/j.jpain.2008.10.003; Hines S, 2008, DRUG ALCOHOL REV, V27,
P519, DOI 10.1080/09595230802245519; Ho KKN, 2019, OSTEOARTHR CARTILAGE, V27, P196,
DOI 10.1016/j.joca.2018.09.014; HOFFMAN M, 1991, CANCER, V68, P1121, DOI
10.1002/1097-0142(19910901)68:5<1121::AID-CNCR2820680539>3.0.CO;2-1; Hser YI, 2016,
ADDICTION, V111, P695, DOI 10.1111/add.13238; Huhn AS, 2019, ANESTHESIOLOGY, V130,
P131, DOI 10.1097/ALN.0000000000002492; Huxtable CA, 2011, ANAESTH INTENS CARE,
V39, P804, DOI 10.1177/0310057X1103900505; Jackson JL, 2017, J GEN INTERN MED, V32,
P1351, DOI 10.1007/s11606-017-4121-z; Jones CM, 2015, MMWR-MORBID MORTAL W, V64,
P719; Kampman K, 2015, J ADDICT MED, V9, P358, DOI 10.1097/ADM.0000000000000166;
Kelly E, 2013, BRIT J PHARMACOL, V169, P1430, DOI 10.1111/bph.12222; Launonen E,
2015, INT J DRUG POLICY, V26, P875, DOI 10.1016/j.drugpo.2015.03.007; Lee M, 2011,
PAIN PHYSICIAN, V14, P145; Lieb M, 2010, HEROIN ADDICT REL CL, V12, P5; Lotsch J,
2002, CLIN PHARMACOKINET, V41, P31, DOI 10.2165/00003088-200241010-00004; Macintyre
PE, 2013, ANAESTH INTENS CARE, V41, P222, DOI 10.1177/0310057X1304100212; Maizels
M, 2005, AM FAM PHYSICIAN, V71, P483; Mammen K, 2009, EXPERT OPIN PHARMACO, V10,
P2537, DOI 10.1517/14656560903213405; Mancino M, 2010, AM J DRUG ALCOHOL AB, V36,
P155, DOI 10.3109/00952991003736389; Manfredi PL, 2001, J PAIN SYMPTOM MANAG, V21,
P169, DOI 10.1016/S0885-3924(00)00252-9; Marschall U, 2016, EUR J PAIN, V20, P767,
DOI 10.1002/ejp.802; Mathias JL, 2018, SLEEP MED, V52, P198, DOI
10.1016/j.sleep.2018.05.023; Mattia C, 2002, Minerva Anestesiol, V68, P105; Mattick
RP, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002209.pub2; McNicol ED,
2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012499.pub2; Miller Adam, 2005,
Psychiatr Pol, V39, P21; Mitchell AM, 2008, POSTGRAD MED, V120, P75, DOI
10.3810/pgm.2008.04.1763; Mucke M, 2018, COCHRANE DB SYST REV, DOI
10.1002/14651858.CD012182.pub2; Munoz MCS, 2017, J CLIN ANESTH, V38, P140, DOI
10.1016/j.jclinane.2017.02.003; Nielsen RV, 2019, EUR J PAIN, V23, P455, DOI
10.1002/ejp.1317; Nissen SE, 2016, NEW ENGL J MED, V375, P2519, DOI
10.1056/NEJMoa1611593; Okoli CTC, 2018, ADDICT BEHAV, V85, P131, DOI
10.1016/j.addbeh.2018.06.005; Ostgathe C, 2008, J PAIN SYMPTOM MANAG, V35, P229,
DOI 10.1016/j.jpainsymman.2007.08.008; Peles E, 2005, PAIN, V113, P340, DOI
10.1016/j.pain.2004.11.011; Peles E, 2011, J PAIN, V12, P41, DOI
10.1016/j.jpain.2010.04.009; Peng XM, 2017, SCI REP-UK, V7, P01, DOI
10.1038/srep43826; PRESTON KL, 1988, J PHARMACOL EXP THER, V246, P441; PRESTON KL,
1989, J PHARMACOL EXP THER, V248, P929; Rigo FK, 2017, PAIN PHYSICIAN, V20, P207;
Rock EM, 2018, PSYCHOPHARMACOLOGY, V235, P3259, DOI 10.1007/s00213-018-5034-1;
Rowley D, 2011, AM J HOSP PALLIAT ME, V28, P183, DOI 10.1177/1049909110380897;
Saxon AJ, 2013, DRUG ALCOHOL DEPEN, V128, P71, DOI
10.1016/j.drugalcdep.2012.08.002; Schuckit MA, 2016, NEW ENGL J MED, V375, P1596,
DOI 10.1056/NEJMc1610830; Schuning J, 2018, DEUT MED WOCHENSCHR, V143, P1363, DOI
10.1055/a-0584-9667; Scimeca MM, 2000, MT SINAI J MED, V67, P412; Sen S, 2016, CURR
PAIN HEADACHE R, V20, DOI 10.1007/s11916-016-0549-9; Shaheed CA, 2016, JAMA INTERN
MED, V176, P958, DOI 10.1001/jamainternmed.2016.1251; Sharon H, 2018, J PAIN RES,
V11, P1411, DOI 10.2147/JPR.S159852; Siuda ER, 2017, CURR OPIN PHARMACOL, V32, P77,
DOI 10.1016/j.coph.2016.11.007; Smith SR, 2016, OSTEOARTHR CARTILAGE, V24, P962,
DOI 10.1016/j.joca.2016.01.135; Soyka M, 2017, EUR ADDICT RES, V23, P97, DOI
10.1159/000468518; Soyka M, 2014, AM J ADDICTION, V23, P563, DOI 10.1111/j.1521-
0391.2014.12131.x; Soyka M, 2011, WORLD J BIOL PSYCHIA, V12, P160, DOI
10.3109/15622975.2011.561872; Soyka M, 2008, INT J NEUROPSYCHOPH, V11, P641, DOI
10.1017/S146114570700836X; STRAIN EC, 1993, J PHARMACOL EXP THER, V267, P624;
STRAIN EC, 1992, J PHARMACOL EXP THER, V261, P985; Sulistio M, 2013, J PAIN SYMPTOM
MANAG, V46, P598, DOI 10.1016/j.jpainsymman.2012.10.231; Tang WX, 2018, MEDICINE,
V97, DOI 10.1097/MD.0000000000012061; Taveros MC, 2017, BMJ SUPPORT PALLIAT, V7,
P383, DOI 10.1136/bmjspcare-2016-001126; Trelle S, 2011, BMJ-BRIT MED J, V342, DOI
10.1136/bmj.c7086; Umeda S, 2005, BIOL PHARM BULL, V28, P212, DOI
10.1248/bpb.28.212; Umehara K, 2002, BIOL PHARM BULL, V25, P682, DOI
10.1248/bpb.25.682; United Nations Office on
Drugs and Crime, 2016, WORLD DRUG REP 2016; Volpe DA, 2018, J PHARM SCI-US, V107,
P2983, DOI 10.1016/j.xphs.2018.08.025; Voon P, 2015, J PAIN, V16, P887, DOI
10.1016/j.jpain.2015.06.003; Voon P, 2014, PAIN MANAG, V4, P27, DOI
[10.2217/PMT.13.62, 10.2217/pmt.13.62]; Wahawisan Joy, 2011, Ann Pharmacother, V45,
pe34, DOI 10.1345/aph.1P759; Walley AY, 2012, J ADDICT MED, V6, P50, DOI
10.1097/ADM.0b013e318231de51; Walsh SL, 2017, JAMA PSYCHIAT, V74, P894, DOI
10.1001/jamapsychiatry.2017.1874; Wang JS, 2003, DRUG METAB DISPOS, V31, P742, DOI
10.1124/dmd.31.6.742; Wang L, 2016, CAN J ANESTH, V63, P311, DOI 10.1007/s12630-
015-0551-4; Webster L, 2016, PAIN MED; Webster Lynn R, 2006, Am J Ther, V13, P300,
DOI 10.1097/00045391-200607000-00004; Wilens T, 2015, AM J ADDICTION, V24, P173,
DOI 10.1111/ajad.12159; Zahari Z, 2018, IRAN J PHARM RES, V17, P8; Zellner N, 2017,
DEUT MED WOCHENSCHR, V142, pE140, DOI 10.1055/s-0043-104228; Zis P, 2017, CLIN
INTERV AGING, V12, P709, DOI 10.2147/CIA.S113576 119 0 0 2 2
TAYLOR & FRANCIS LTD ABINGDON 2-4 PARK SQUARE, MILTON PARK, ABINGDON
OR14 4RN, OXON, ENGLAND 1465-6566 1744-7666 EXPERT OPIN PHARMACO Expert
Opin. Pharmacother.
10.1080/14656566.2019.1652270 AUG 2019 13 Pharmacology & Pharmacy
Pharmacology & Pharmacy IR6HQ WOS:000481540700001 31418602
2019-09-25
J Testa, M; Wang, WJ; Derrick, JL; Brown, WC; Collins, RL
Testa, Maria; Wang, Weijun; Derrick, Jaye L.; Brown, Whitney C.; Collins, R.
Lorraine Does morning affect contribute to daily Cannabis use?
ADDICTIVE BEHAVIORS English Article
Cannabis; Affect; Daily diary; Reinforcement MARIJUANA USE; ALCOHOL-
USE; SELF-MEDICATION; STRESS; SYMPTOMS; ASSOCIATION; ANTECEDENTS; IMPULSIVITY;
DISORDERS; SMOKING Several theories posit that cannabis and other substances
are used to reduce negative affect. This daily report study considered whether
variations in positive and negative affect, reported each morning, contributed to
the likelihood of cannabis use later that day. We also explored whether levels of
positive and negative affect reported immediately after cannabis use improved,
relative to that day's morning levels. The sample included 183 men and 183 women
representing heterosexual, cannabis-using couples from the community. Participants
made independent, daily reports of affect and cannabis use episodes for 30
consecutive days. Using multilevel modeling, we modeled men's and women's use of
cannabis on a given day as a function of morning levels of positive, hostile, and
anxious affect, accounting for partner cannabis use that day, and mean levels of
positive and negative affect. Men and women were more likely to use cannabis on a
given day when morning positive affect was lower than typical for the person and
when partner used cannabis that day. Neither hostile nor anxious affect contributed
to later use of cannabis. Immediately after cannabis use, positive affect
increased, and hostile and anxious affect decreased relative to that day's morning
levels. The improved affect immediately after use suggests a mechanism of positive
reinforcement. [Testa, Maria; Wang, Weijun; Brown, Whitney C.] SUNY Buffalo,
Dept Psychol, 1021 Main St, Buffalo, NY 14203 USA; [Testa, Maria; Wang, Weijun;
Brown, Whitney C.] SUNY Buffalo, Clin & Res Inst Addict, 1021 Main St, Buffalo, NY
14203 USA; [Derrick, Jaye L.] Univ Houston, Dept Psychol, 3695 Cullen Blvd,
Houston, TX 77204 USA; [Collins, R. Lorraine] SUNY Buffalo, Sch Publ Hlth & Hlth
Profess, Dept Community Hlth & Hlth Behav, 3435 Main St, Buffalo, NY 14214 USA
Testa, M (reprint author), SUNY Buffalo, Dept Psychol, 1021 Main St, Buffalo,
NY 14203 USA.; Testa, M (reprint author), SUNY Buffalo, Clin & Res Inst Addict,
1021 Main St, Buffalo, NY 14203 USA. testa@ria.buffalo.edu Brown,
Whitney/0000-0001-8311-6401; Testa, Maria/0000-0003-4549-4457 National Institute
on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes
of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01DA033994];
National Institute on Alcohol Abuse and AlcoholismUnited States Department of
Health & Human ServicesNational Institutes of Health (NIH) - USANIH National
Institute on Alcohol Abuse & Alcoholism (NIAAA) [T32AA007583] This work was
supported by a National Institute on Drug Abuse grant R01DA033994 to Maria Testa
and by National Institute on Alcohol Abuse and Alcoholism grant T32AA007583. Ansell
EB, 2015, DRUG ALCOHOL DEPEN, V148, P136, DOI 10.1016/j.drugalcdep.2014.12.029;
Armeli S, 2000, J STUD ALCOHOL, V61, P862, DOI 10.15288/jsa.2000.61.862; Bresin K,
2018, PSYCHOL ADDICT BEHAV, V32, P617, DOI 10.1037/adb0000383; Buckner JD, 2019,
EXP CLIN PSYCHOPHARM, V27, P38, DOI 10.1037/pha0000231; Buckner JD, 2016, J
PSYCHOPHARMACOL, V30, P363, DOI 10.1177/0269881116629115; Buckner JD, 2015, DRUG
ALCOHOL DEPEN, V147, P20, DOI 10.1016/j.drugalcdep.2014.12.022; Buckner JD, 2013,
PSYCHOL ADDICT BEHAV, V27, P236, DOI 10.1037/a0029763; Buckner JD, 2012, J BEHAV
THER EXP PSY, V43, P647, DOI 10.1016/j.jbtep.2011.09.010; Chakroun N, 2010, PSYCHOL
ADDICT BEHAV, V24, P129, DOI 10.1037/a0018184; Cooper ZD, 2014, DRUG ALCOHOL DEPEN,
V136, P85, DOI 10.1016/j.drugalcdep.2013.12.013; Cuttler C, 2018, J AFFECT
DISORDERS, V235, P198, DOI 10.1016/j.jad.2018.04.054; Derrick JL, 2017, ADDICT
BEHAV, V75, P12, DOI 10.1016/j.addbeh.2017.06.012; Dvorak RD, 2018, EXP CLIN
PSYCHOPHARM, V26, P377, DOI 10.1037/pha0000210; Greeley J, 1999, PSYCHOL THEOR
DRINKI, V2, P14; Green B, 2003, DRUG ALCOHOL REV, V22, P453, DOI
10.1080/09595230310001613976; Gruber S. A., 2012, MENT HLTH SUBST USE, V5, P228;
Hogarth L, 2018, EXP CLIN PSYCHOPHARM, V26, P138, DOI 10.1037/pha0000177; Howard
AL, 2015, PSYCHOL ADDICT BEHAV, V29, P430, DOI 10.1037/adb0000023; Hu LT, 1999,
STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Hussong AM, 2017,
PSYCHOL ADDICT BEHAV, V31, P137, DOI 10.1037/adb0000247; Kaysen D, 2014, PSYCHOL
ADDICT BEHAV, V28, P62, DOI 10.1037/a0033588; Khantzian EJ, 1997, HARVARD REV
PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550; Lee CM, 2017, DRUG ALCOHOL
DEPEN, V180, P391, DOI 10.1016/j.drugalcdep.2017.08.029; Leeies M, 2010, DEPRESS
ANXIETY, V27, P731, DOI 10.1002/da.20677; LEVENSON RW, 1980, J ABNORM PSYCHOL, V89,
P528, DOI 10.1037/0021-843X.89.4.528; Metrik J, 2011, J COGN PSYCHOTHER, V25, P31,
DOI 10.1891/0889-8391.25.1.31; Mohr C, 2010, SUBSTANCE ABUSE EMOT, P189, DOI DOI
10.1037/12067-008; Muthen L. K., 2017, MPLUS USERS GUIDE; Park CL, 2004, J STUD
ALCOHOL, V65, P126, DOI 10.15288/jsa.2004.65.126; Peeters F, 2006, EMOTION, V6,
P383, DOI 10.1037/1528-3542.6.3.383; Phillips KT, 2018, ADDICT BEHAV, V83, P154,
DOI 10.1016/j.addbeh.2018.01.004; Ross CS, 2018, ADDICT BEHAV, V76, P61, DOI
10.1016/j.addbeh.2017.07.020; Sarvet AL, 2018, DRUG ALCOHOL DEPEN, V186, P10, DOI
10.1016/j.drugalcdep.2018.01.009; Schermelleh-Engel K., 2003, METHODS PSYCHOL RES,
V8, P23, DOI DOI 10.1002/0470010940; Shrier LA, 2014, J STUD ALCOHOL DRUGS, V75,
P781, DOI 10.15288/jsad.2014.75.781; Shrier LA, 2012, PSYCHOL ADDICT BEHAV, V26,
P821, DOI 10.1037/a0029197; Testa M, 2018, J STUD ALCOHOL DRUGS, V79, P432, DOI
10.15288/jsad.2018.79.432; Trull TJ, 2016, ADDICTION, V111, P2052, DOI
10.1111/add.13471; Watson D, 1994, PANAS X MANUAL POSIT; Weinstein A, 2008, J
PSYCHOPHARMACOL, V22, P441, DOI 10.1177/0269881108088194 40 0 0 1
1 PERGAMON-ELSEVIER SCIENCE LTD OXFORD THE BOULEVARD, LANGFORD LANE,
KIDLINGTON, OXFORD OX5 1GB, ENGLAND 0306-4603 1873-6327 ADDICT BEHAV
Addict. Behav. AUG 2019 95 64 69
10.1016/j.addbeh.2019.03.001 6 Psychology, Clinical;
Substance Abuse Psychology; Substance Abuse IE9OH WOS:000472703300011
30856545 2019-09-25
J Somohano, VC; Rehder, KL; Dingle, T; Shank, T; Bowen, S
Somohano, Vanessa C.; Rehder, Kristoffer L.; Dingle, Tyree; Shank, Taylor;
Bowen, Sarah PTSD Symptom Clusters and Craving Differs by Primary
Drug of Choice JOURNAL OF DUAL DIAGNOSIS English Article;
Early Access Substance use disorder;
posttraumatic stress disorder; PTSD symptom clusters; craving; dual diagnosis;
self-medication hypothesis POSTTRAUMATIC-STRESS-DISORDER; SUBSTANCE USE
DISORDERS; NATIONAL EPIDEMIOLOGIC SURVEY; PSYCHOMETRIC PROPERTIES; NEGATIVE AFFECT;
SELF-MEDICATION; MENTAL-HEALTH; RELAPSE PREVENTION; CANNABIS USE; ALCOHOL-USE
Objective: Research has demonstrated a cyclical relationship between
posttraumatic stress disorder (PTSD) and substance use disorder. Identifying
factors that link PTSD symptom clusters and substance use disorder may illuminate
mechanisms underlying the PTSD-substance use disorder relationship, better
informing interventions that target this comorbidity. The current study of
individuals enrolled in an outpatient aftercare chemical dependency program in King
County, Washington, assessed whether overall PTSD symptoms and specific PTSD
symptom clusters predicted craving depending on individuals identified primary drug
of choice (DOC). Methods: Participants eligible for the parent study were at least
18 years of age, fluent in English, medically cleared from substance withdrawal,
and able to participate in treatment sessions and agreed to random assignment.
Random assignment to either a mindfulness-based relapse prevention group, a
standard relapse prevention group, or a treatment as usual group was conducted on a
computer randomization program. A secondary analysis of baseline data was employed
in the current study to determine which of the PTSD symptom clusters (avoidance,
hyperarousal, and intrusion) predicted substance craving. Results: Covarying for
severity of dependence, results suggest that overall PTSD scores predicted craving
in participants who identified alcohol, stimulants, and opiates as their primary
DOC. Further, avoidance-related PTSD symptoms alone predicted a significant
proportion of the variability in craving in stimulant users, and hyperarousal
symptoms alone predicted a significant proportion of the variability in craving in
alcohol users. No specific PTSD cluster significantly predicted a proportion of the
variability in craving in marijuana or opiates users. Conclusions: Findings suggest
that craving may play a role in maintaining the relationship between specific PTSD
symptom clusters and substance use disorder, and the nature of this relationship
may differ by primary DOC. The clinical trial on which this secondary analysis of
data was conducted is registered as NCT01159535 at . The original trial from which
data for this study was drawn was supported by the National Institutes of Health
[NIH/NIDA 5 R01 DA025764-02]. [Somohano, Vanessa C.; Rehder, Kristoffer L.; Dingle,
Tyree; Shank, Taylor; Bowen, Sarah] Pacific Univ, Grad Psychol, 430 SE 32nd Ave,
Hillsboro, OR 97123 USA Somohano, VC (reprint author), Pacific Univ, Grad Psychol,
430 SE 32nd Ave, Hillsboro, OR 97123 USA. vsomohano@pacificu.edu
NIDAUnited States Department of Health & Human ServicesNational Institutes of
Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [5 R01 DA025764-02]
Funding for the original study was provided by NIDA 5 R01 DA025764-02. NIDA
had no role in the study design, collection, analysis, or interpretation of the
data, writing the manuscript, or the decision to submit the article for
publication. Afful SE, 2010, DRUG ALCOHOL DEPEN, V112, P46, DOI
10.1016/j.drugalcdep.2010.05.012; American Psychiatric Association, 2013, DIAGN
STAT MAN MENT; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Avant
E. M., 2011, J AGGRESS MALTREAT T, V20, P539, DOI DOI 10.1080/10926771.2011.588153;
Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2;
Bonn-Miller MO, 2011, PSYCHOL ADDICT BEHAV, V25, P485, DOI 10.1037/a0021945;
Borsari B, 2008, J COLL STUD PSYCHOTH, V22, P61, DOI 10.1080/87568220801960720;
Boscarino JA, 2009, SOC PSYCH PSYCH EPID, V44, P887, DOI 10.1007/s00127-009-0011-y;
Bowen S, 2014, JAMA PSYCHIAT, V71, P547, DOI 10.1001/jamapsychiatry.2013.4546;
Bowen S, 2009, SUBST ABUS, V30, P295, DOI 10.1080/08897070903250084; Bradizza CM,
2006, CLIN PSYCHOL REV, V26, P162, DOI 10.1016/j.cpr.2005.11.005; Buckner JD, 2018,
AM J DRUG ALCOHOL AB, V44, P532, DOI 10.1080/00952990.2018.1430149; Cavazos-Rehg P,
2015, DRUG ALCOHOL DEPEN, V146, pe242, DOI DOI 10.1016/J.DRUGALCDEP.2014.09.126;
Center for Substance Abuse Treatment. Treatment for Stimulant Use Disorders
Rockville (MD ): Substance Abuse and Mental Health Services Administration (US),
1999, CTR SUBST AB TREATM, V33; Chen KW, 2011, DRUG ALCOHOL DEPEN, V118, P92, DOI
10.1016/j.drugalcdep.2011.03.003; Coffey SF, 2007, DRUG ALCOHOL DEPEN, V87, P241,
DOI 10.1016/j.drugalcdep.2006.08.025; Coffey SF, 2010, EXP CLIN PSYCHOPHARM, V18,
P340, DOI 10.1037/a0019790; Conrod PJ, 2003, TRAUMA AND SUBSTANCE ABUSE: CAUSES,
CONSEQUENCES, AND TREATMENT OF COMORBID DISORDERS, P57, DOI 10.1037/10460-003;
Cougle JR, 2011, PSYCHOL ADDICT BEHAV, V25, P554, DOI 10.1037/a0023076; Debell F,
2014, SOC PSYCH PSYCH EPID, V49, P1401, DOI 10.1007/s00127-014-0855-7; Dworkin ER,
2018, ADDICT BEHAV, V76, P188, DOI 10.1016/j.addbeh.2017.08.019; Dworkin ER, 2017,
PSYCHOL TRAUMA-US, V9, P500, DOI 10.1037/tra0000212; Ertl V, 2016, BMC PSYCHIATRY,
V16, DOI 10.1186/s12888-016-0905-7; Fatseas M, 2015, ADDICTION, V110, P1035, DOI
10.1111/add.12882; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI
10.3758/BF03193146; Flanagan JC, 2016, CURR PSYCHIAT REP, V18, DOI 10.1007/s11920-
016-0709-y; Flannery BA, 1999, ALCOHOL CLIN EXP RES, V23, P1289, DOI
10.1111/j.1530-0277.1999.tb04349.x; Garland EL, 2013, J BEHAV MED, V36, P175, DOI
10.1007/s10865-012-9413-5; Gielen N, 2012, EUR J PSYCHOTRAUMATO, V3, DOI
10.3402/ejpt.v3i0.17734; Goldstein RB, 2016, SOC PSYCH PSYCH EPID, V51, P1137, DOI
10.1007/s00127-016-1208-5; GOSSOP M, 1995, ADDICTION, V90, P607, DOI
10.1046/j.1360-0443.1995.9056072.x; Grant BF, 2016, JAMA PSYCHIAT, V73, P39, DOI
10.1001/jamapsychiatry.2015.2132; Grubaugh AL, 2005, J NERV MENT DIS, V193, P658,
DOI 10.1097/01.nmd.0000180740.02644.ab; Hien DA, 2010, AM J PSYCHIAT, V167, P95,
DOI 10.1176/appi.ajp.2009.09091261; Hill MN, 2013, PSYCHONEUROENDOCRINO, V38,
P2952, DOI 10.1016/j.psyneuen.2013.08.004; Kaysen D, 2014, PSYCHOL ADDICT BEHAV,
V28, P62, DOI 10.1037/a0033588; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259;
Khoury L, 2010, DEPRESS ANXIETY, V27, P1077, DOI 10.1002/da.20751; Kilpatrick DG,
2013, J TRAUMA STRESS, V26, P537, DOI 10.1002/jts.21848; Leeies M, 2010, DEPRESS
ANXIETY, V27, P731, DOI 10.1002/da.20677; Loree AM, 2015, DRUG ALCOHOL REV, V34,
P119, DOI 10.1111/dar.12132; Mills KL, 2006, AM J PSYCHIAT, V163, P652, DOI
10.1176/appi.ajp.163.4.652; Mo C, 2016, INT J MENT HEALTH AD, V14, P761, DOI
10.1007/s11469-015-9626-2; Mota NP, 2016, WORLD PSYCHIATRY, V15, P185, DOI
10.1002/wps.20313; Mylle J, 2004, J AFFECT DISORDERS, V78, P37, DOI 10.1016/S0165-
0327(02)00218-5; Najt P, 2011, PSYCHIAT RES, V186, P159, DOI
10.1016/j.psychres.2010.07.042; National Institute on Drug Abuse (NIDA), 2013,
METH; Neumeister A, 2013, DEPRESS ANXIETY, V30, P93, DOI 10.1002/da.22031; Ouimette
P, 2010, ADDICT BEHAV, V35, P64, DOI 10.1016/j.addbeh.2009.08.009; Pietrzak RH,
2011, J ANXIETY DISORD, V25, P456, DOI 10.1016/j.janxdis.2010.11.010; Porter M,
2014, SPRINGERBRIEF CASE, P53, DOI 10.1007/978-3-319-01463-0_8; Possemato K, 2015,
PSYCHOL ADDICT BEHAV, V29, P894, DOI 10.1037/adb0000129; Read JP, 2012, J CONSULT
CLIN PSYCH, V80, P426, DOI 10.1037/a0028210; Ruggiero KJ, 2003, J TRAUMA STRESS,
V16, P495, DOI 10.1023/A:1025714729117; Saladin ME, 2003, ADDICT BEHAV, V28, P1611,
DOI 10.1016/j.addbeh.2003.08.037; Schlauch RC, 2013, ADDICT BEHAV, V38, P1970, DOI
[10.1016/j.addbeh.2012.12.003, 10.1016/j.addbeh.2013.02.010]; Seal KH, 2011, DRUG
ALCOHOL DEPEN, V116, P93, DOI 10.1016/j.drugalcdep.2010.11.027; Serre F, 2015, DRUG
ALCOHOL DEPEN, V148, P1, DOI 10.1016/j.drugalcdep.2014.12.024; Shadur JM, 2015,
DRUG ALCOHOL REV, V34, P571, DOI 10.1111/dar.12260; Simpson TL, 2012, PSYCHOL
ADDICT BEHAV, V26, P724, DOI 10.1037/a0027169; Slofstra C, 2018, PSYCHOTHER
PSYCHOSOM, V87, P243, DOI 10.1159/000489044; Smith KZ, 2016, ADDICT BEHAV, V58,
P167, DOI 10.1016/j.addbeh.2016.02.019; Smith RC, 2010, ADDICT BEHAV, V35, P625,
DOI 10.1016/j.addbeh.2010.01.010; Tull MT, 2018, BEHAV THER, V49, P57, DOI
10.1016/j.beth.2017.05.005; Weathers F., 1993, M INT SOC TRAUM STRE; Weiss F, 2005,
CURR OPIN PHARMACOL, V5, P9, DOI 10.1016/j.coph.2004.11.001; Weiss NH, 2013, DRUG
ALCOHOL DEPEN, V128, P45, DOI 10.1016/j.drugalcdep.2012.07.017; Wieferink CEM,
2017, ADDICT BEHAV, V74, P122, DOI 10.1016/j.addbeh.2017.06.005; Wilkins KC, 2011,
DEPRESS ANXIETY, V28, P596, DOI 10.1002/da.20837; Witkiewitz K, 2010, J CONSULT
CLIN PSYCH, V78, P362, DOI 10.1037/a0019172; Wolff N, 2011, PSYCHIAT SERV, V62,
P954, DOI 10.1176/ps.62.8.pss6208_0954 71 0 0 1 1 ROUTLEDGE
JOURNALS, TAYLOR & FRANCIS LTD ABINGDON 2-4 PARK SQUARE, MILTON PARK,
ABINGDON OX14 4RN, OXON, ENGLAND 1550-4263 1550-4271 J DUAL DIAGN
J. Dual Diagn.
10.1080/15504263.2019.1637039 JUL 2019 10 Psychology, Clinical;
Substance Abuse; Psychiatry Psychology; Substance Abuse; Psychiatry IK1PS
WOS:000476362700001 31304887 2019-09-25
J Wiss, DA Wiss, David A. A Biopsychosocial
Overview of the Opioid Crisis: Considering Nutrition and Gastrointestinal Health
FRONTIERS IN PUBLIC HEALTH English Article
biopsychosocial (BPS) model multidisciplinary; opioid; nutrition;
gastrointestinal; trauma; addiction; substance use disorder; microbiome
POSTTRAUMATIC-STRESS-DISORDER; BODY-MASS INDEX; NEIGHBORHOOD SOCIOECONOMIC-
STATUS; ADVERSE CHILDHOOD EXPERIENCES; SUBSTANCE-ABUSE TREATMENT; DRUG-MONITORING
PROGRAMS; BRAIN DISEASE-MODEL; UNITED-STATES; METHADONE-MAINTENANCE; BEHAVIORAL
ECONOMICS The opioid crisis has reached epidemic proportions in the United States
with rising overdose death rates. Identifying the underlying factors that
contribute to addiction vulnerability may lead to more effective prevention
strategies. Supply side environmental factors are a major contributing component.
Psychosocial factors such as stress, trauma, and adverse childhood experiences have
been linked to emotional pain leading to self-medication. Genetic and epigenetic
factors associated with brain reward pathways and impulsivity are known predictors
of addiction vulnerability. This review attempts to present a biopsychosocial
approach that connects various social and biological theories related to the
addiction crisis. The emerging role of nutrition therapy with an emphasis on
gastrointestinal health in the treatment of opioid use disorder is presented. The
biopsychosocial model integrates concepts from several disciplines, emphasizing
multicausality rather than a reductionist approach. Potential solutions at multiple
levels are presented, considering individual as well as population health. This
single cohesive framework is based on the interdependency of the entire system,
identifying risk and protective factors that may influence substance-seeking
behavior. Nutrition should be included as one facet of a multidisciplinary approach
toward improved recovery outcomes. Cross-disciplinary collaborative efforts, new
ideas, and fiscal resources will be critical to address the epidemic. [Wiss, David
A.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Los Angeles, CA 90095 USA
Wiss, DA (reprint author), Univ Calif Los Angeles, Fielding Sch Publ Hlth,
Los Angeles, CA 90095 USA. davidawiss@nutritioninrecovery.com Wiss, David/V-
9543-2019 Wiss, David/0000-0003-1788-7368 Acharya C, 2017, ALIMENT
PHARM THER, V45, P319, DOI [10.1111/apt.13858, 10.1111/apt.14585]; Ali MM, 2017,
ADDICT BEHAV, V69, P65, DOI [10.1016/jaddbeh.2017.01.011,
10.1016/j.addbeh.2017.01.011]; Alves D, 2011, HEROIN ADDICT REL CL, V13, P11;
Amundsen EJ, 2015, SCAND J PUBLIC HEALT, V43, P571, DOI 10.1177/1403494815585909;
Anda RF, 2002, PSYCHIAT SERV, V53, P1001, DOI 10.1176/appi.ps.53.8.1001; Arora NS,
2018, SUBST ABUS, V39, P6, DOI 10.1080/08897077.2017.1356788; Austin AE, 2018,
CHILD YOUTH SERV REV, V86, P84, DOI 10.1016/j.childyouth.2018.01.023; Austin AE,
2018, ADDICT BEHAV, V76, P265, DOI 10.1016/j.addbeh.2017.08.033; Babrowski T, 2012,
ANN SURG, V255, P386, DOI 10.1097/SLA.0b013e3182331870; Banerjee S, 2016, MUCOSAL
IMMUNOL, V9, P1418, DOI 10.1038/mi.2016.9; Barbadoro P, 2011, ALCOHOL ALCOHOLISM,
V46, P77, DOI 10.1093/alcalc/agq075; Barengolts E, 2018, PLOS ONE, V13, DOI
10.1371/journal.pone.0194171; Bart G, 2012, J ADDICT DIS, V31, P207, DOI
10.1080/10550887.2012.694598; Ben-Shlomo Y, 2002, INT J EPIDEMIOL, V31, P285, DOI
10.1093/ije/31.2.285; Bickel WK, 2014, PREV MED, V68, P37, DOI
10.1016/j.ypmed.2014.06.032; Bickel WK, 2016, PREV MED, V92, P16, DOI
10.1016/j.ypmed.2016.06.002; Bickel WK, 2015, CLIN PSYCHOL SCI, V3, P140, DOI
10.1177/2167702614541260; Bickel WK, 2014, ANNU REV CLIN PSYCHO, V10, P641, DOI
10.1146/annurev-clinpsy-032813-153724; BICKEL WK, 1993, DRUG ALCOHOL DEPEN, V33,
P173, DOI 10.1016/0376-8716(93)90059-Y; Bickel WK, 2001, ADDICTION, V96, P73, DOI
10.1046/j.1360-0443.2001.961736.x; Bishehsari F, 2017, ALCOHOL RES-CURR REV, V38,
P163; Black AC, 2018, AM J DRUG ALCOHOL AB, V44, P524, DOI
10.1080/00952990.2018.1454935; Blendon RJ, 2018, NEW ENGL J MED, V378, P407, DOI
10.1056/NEJMp1714529; Blum K, 1996, J ROY SOC MED, V89, P396; Blum K, 2014, MOL
NEUROBIOL, V50, P765, DOI 10.1007/s12035-014-8726-5; Blum K, 2011, INT J ENV RES
PUB HE, V8, P4425, DOI 10.3390/ijerph8124425; Borrell-Carrio F, 2004, ANN FAM MED,
V2, P576, DOI 10.1370/afm.245; Bossaerts P, 2015, CURR OPIN BEHAV SCI, V5, P37, DOI
10.1016/j.cobeha.2015.07.001; Braveman P, 2006, ANNU REV PUBL HEALTH, V27, P167,
DOI 10.1146/annurev.publhealth.27.021405.102103; Camacho A, 2017, BEHAV BRAIN RES,
V330, P46, DOI 10.1016/j.bbr.2017.05.014; Camerer CF, 2008, NEURON, V60, P416, DOI
10.1016/j.neuron.2008.10.027; Camilleri M, 2017, CLIN GASTROENTEROL H, V15, P1338,
DOI 10.1016/j.cgh.2017.05.014; Campbell CI, 2018, PREV MED, V110, P31, DOI
10.1016/j.ypmed.2018.01.019; Canan F, 2017, EAT WEIGHT DISORD-ST, V22, P249, DOI
10.1007/s40519-017-0378-9; Cao-Lei L, 2017, NEUROSCI BIOBEHAV R, P1, DOI
[10.1016/j.neubiorev.2017.05.016, DOI 10.1016/J.NEUBIOREV.2017.05.016]; Chan JC,
2018, BIOL PSYCHIAT, V83, P886, DOI 10.1016/j.biopsych.2017.10.005; Chen DY, 2012,
J HUAZHONG U SCI-MED, V32, P422, DOI 10.1007/s11596-012-0073-z; Cicero TJ, 2017,
ADDICT BEHAV, V74, P63, DOI 10.1016/j.addbeh.2017.05.030; Cicero TJ, 2015, JAMA
PSYCHIAT, V72, P424, DOI 10.1001/jamapsychiatry.2014.3043; Cochran Gerald, 2015, J
Pharm Pract, V28, P404, DOI 10.1177/0897190014522064; Colvonen PJ, 2019, BEHAV
SLEEP MED, V17, P524, DOI 10.1080/15402002.2018.1425869; Comings DE, 1996, BIOL
PSYCHIAT, V40, P368, DOI 10.1016/0006-3223(95)00519-6; Cook A, 2005, PSYCHIAT ANN,
V35, P390, DOI 10.3928/00485713-20050501-05; Cowan J, 2008, APPETITE, V50, P33, DOI
10.1016/j.appet.2007.05.006; Cowan JA, 2013, J NUTR EDUC BEHAV, V45, P154, DOI
10.1016/j.jneb.2011.10.011; Cowan JA, 2012, PUBLIC HEALTH NUTR, V15, P1159, DOI
10.1017/S1368980012000572; Cryan JF, 2016, CAN J PSYCHIAT, V61, P201, DOI
10.1177/0706743716635538; Cunningham P. M, 2016, J ADDICT RES THER, V7, P282; Curd
P, 2013, J CORRECT HEALTH CAR, V19, P144, DOI 10.1177/1078345812474645; Cussotto S,
2019, PSYCHOPHARMACOLOGY, V236, P1411, DOI 10.1007/s00213-019-5185-8; Cussotto S,
2018, FRONT NEUROENDOCRIN, V51, P80, DOI 10.1016/j.yfrne.2018.04.002; Danovitch I,
2016, J ADDICT DIS, V35, P169, DOI 10.1080/10550887.2016.1168212; Dasgupta N, 2018,
AM J PUBLIC HEALTH, V108, P182, DOI 10.2105/AJPH.2017.304187; de Timary P, 2017,
NEUROPHARMACOLOGY, V122, P148, DOI 10.1016/j.neuropharm.2017.04.013; Denhardt DT,
2018, J CELL PHYSIOL, V233, P1975, DOI 10.1002/jcp.25837; Dowell D, 2016, JAMA-J AM
MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464; Dube SR, 2003, PEDIATRICS,
V111, P564, DOI 10.1542/peds.111.3.564; Dursteler-Macfarland KM, 2011, DRUG ALCOHOL
REV, V30, P577, DOI 10.1111/j.1465-3362.2010.00242.x; Egervari G, 2018, NEUROSCI
BIOBEHAV R, V85, P117, DOI 10.1016/j.neubiorev.2017.05.019; Eitan S, 2017, NEUROSCI
BIOBEHAV R, V83, P697, DOI 10.1016/j.neubiorev.2017.05.017; ENGEL GL, 1980, AM J
PSYCHIAT, V137, P535; Epstein LH, 2010, PHYSIOL BEHAV, V100, P438, DOI
10.1016/j.physbeh.2010.04.029; Evans C. J., 2016, F1000RES, V5, P1748, DOI DOI
10.12688/F1000RESEARCH.8369.1; Fava GA, 2000, PSYCHOTHER PSYCHOSOM, V69, P184, DOI
10.1159/000012393; Felger JC, 2017, NEUROPSYCHOPHARMACOL, V42, P216, DOI
10.1038/npp.2016.143; Felitti VJ, 1998, AM J PREV MED, V14, P245, DOI
10.1016/S0749-3797(98)00017-8; Fenn JM, 2015, J SUBST ABUSE TREAT, V51, P59, DOI
10.1016/j.jsat.2014.10.007; Finan PH, 2018, PROG NEURO-PSYCHOPH, V87, P255, DOI
10.1016/j.pnpbp.2017.07.029; Ford JA, 2017, INT J DRUG POLICY, V46, P47, DOI
10.1016/j.drugpo.2017.05.001; Frances A, 2014, LANCET PSYCHIAT, V1, P496, DOI
10.1016/S2215-0366(14)00058-3; Garcia MC, 2016, MMWR-MORBID MORTAL W, V65, P1125,
DOI 10.15585/mmwr.mm6541a1; Gebauer S, 2017, J AM BOARD FAM MED, V30, P775, DOI
10.3122/jabfm.2017.06.170061; Glanz K, 2010, ANNU REV PUBL HEALTH, V31, P399, DOI
10.1146/annurev.publhealth.012809.103604; Glass TA, 2006, SOC SCI MED, V62, P1650,
DOI 10.1016/j.socscimed.2005.08.044; Gordon EL, 2018, NUTRIENTS, V10, DOI
10.3390/nu10040477; Gorwood P, 2012, HUM GENET, V131, P803, DOI 10.1007/s00439-012-
1145-7; Grant LP, 2004, J AM DIET ASSOC, V104, P604, DOI
10.1016/j.jada.2004.01.008; Gray JC, 2018, PSYCHIAT RES, V259, P398, DOI
10.1016/j.psychres.2017.10.047; Griffiths M. D., 2005, J SUBST USE, V10, P191, DOI
DOI 10.1080/14659890500114359; Grigoras CA, 2018, DRUGS, V78, P111, DOI
10.1007/s40265-017-0846-6; Guy GP, 2017, MMWR-MORBID MORTAL W, V66, P697, DOI
10.15585/mmwr.mm6626a4; Haegerich TM, 2014, DRUG ALCOHOL DEPEN, V145, P34, DOI
10.1016/j.drugalcdep.2014.10.001; Hand DJ, 2017, J SUBST ABUSE TREAT, V76, P58, DOI
10.1016/j.jsat.2017.01.011; Hardy R, 2018, APPETITE, V120, P367, DOI
10.1016/j.appet.2017.09.026; Hassan AN, 2017, DRUG ALCOHOL DEPEN, V179, P260, DOI
10.1016/j.drugalcdep.2017.07.012; Hays GP, 2018, ACAD EMERG MED, V25, P594, DOI
10.1111/acem.13397; Hemmingsson E, 2014, OBES REV, V15, P882, DOI
10.1111/obr.12216; Hemmingsson E, 2018, CURR OBES REP, V7, P204, DOI
10.1007/s13679-018-0310-2; Herd P, 2018, NAT HUM BEHAV, V2, P808, DOI
10.1038/s41562-018-0452-y; Housova J, 2005, PHYSIOL RES, V54, P73; Hser YI, 2017, J
SUBST ABUSE TREAT, V77, P26, DOI 10.1016/j.jsat.2017.03.006; Hsu DJ, 2017,
ADDICTION, V112, P1558, DOI 10.1111/add.13795; Huang RX, 2016, NUTRIENTS, V8, DOI
10.3390/nu8080483; Jacka FN, 2017, EBIOMEDICINE, V17, P24, DOI
10.1016/j.ebiom.2017.02.020; Jadhav KS, 2018, NEUROPHARMACOLOGY, V141, P249, DOI
10.1016/j.neuropharm.2018.08.026; Jasinska AJ, 2014, NEUROSCI BIOBEHAV R, V38, P1,
DOI 10.1016/j.neubiorev.2013.10.013; Jentsch JD, 2014, ANN NY ACAD SCI, V1327, P1,
DOI 10.1111/nyas.12388; Jeynes KD, 2017, DRUG ALCOHOL DEPEN, V179, P229, DOI
10.1016/j.drugalcdep.2017.07.006; Johnson KVA, 2018, NAT REV MICROBIOL, V16, P647,
DOI 10.1038/s41579-018-0014-3; Jones CM, 2018, ADDICT
BEHAV, V78, P145, DOI [10.1016/j.adclbeh.2017.10.018,
10.1016/j.addbeh.2017.10.018]; Jones CM, 2015, MMWR-MORBID MORTAL W, V64, P719;
Jones CM, 2013, DRUG ALCOHOL DEPEN, V132, P95, DOI
10.1016/j.drugalcdep.2013.01.007; Joynt M, 2013, J GEN INTERN MED, V28, P1604, DOI
10.1007/s11606-013-2516-z; Kadam M, 2017, INDIAN J PSYCHOL MED, V39, P627, DOI
[10.4103/IJPSYM.IJPSYM_356_17, DOI 10.4103/IJPSYM.IJPSYM_356_17]; Kaiser SK, 2008,
J ADDICT NURS, V19, P125, DOI 10.1080/10884600802305935; Kang M, 2017, SCI REP-UK,
V7, DOI 10.1038/srep42658; Kertesz SG, 2017, SUBST ABUS, V38, P3, DOI
10.1080/08897077.2016.1261070; Khantzian EJ, 1987, SELF MED HYPOTHESIS; Koob George
F, 2018, Neurosci Biobehav Rev, DOI 10.1016/j.neubiorev.2018.09.008; KRIEGER N,
1994, SOC SCI MED, V39, P887, DOI 10.1016/0277-9536(94)90202-X; Lam YY, 2017,
NUTRIENTS, V9, DOI 10.3390/nu9060602; Langford DJ, 2018, J PAIN, V19, P506, DOI
10.1016/j.jpain.2017.12.262; Leclercq S, 2016, CAN J PSYCHIAT, V61, P204, DOI
10.1177/0706743716635535; Leclercq S, 2014, P NATL ACAD SCI USA, V111, pE4485, DOI
10.1073/pnas.1415174111; Leclercq S, 2012, BRAIN BEHAV IMMUN, V26, P911, DOI
10.1016/j.bbi.2012.04.001; Lee JD, 2016, NEW ENGL J MED, V374, P1232, DOI
10.1056/NEJMoa1505409; Lee K, 2018, NEUROPSYCHOPHARMACOL, V43, P2606, DOI
10.1038/s41386-018-0211-9; Lehrner A, 2018, PSYCHOL TRAUMA-US, V10, P22, DOI
10.1037/tra0000302; Lei MK, 2018, DEV PSYCHOPATHOL, V30, P1797, DOI
10.1017/S0954579418000937; Leppert W, 2015, DRUG DES DEV THER, V9, P2215, DOI
10.2147/DDDT.S32684; Lerner A, 2017, MICROORGANISMS, V5, DOI
10.3390/microorganisms5040066; Lindau ST, 2003, PERSPECT BIOL MED, V46, pS74, DOI
10.1353/pbm.2003.0055; Lindsay AR, 2012, J SUBST ABUSE TREAT, V43, P61, DOI
10.1016/j.jsat.2011.10.027; Loveland D, 2014, SUBST ABUSE TREAT PR, V9, DOI
10.1186/1747-597X-9-41; Lu Michael C, 2003, Matern Child Health J, V7, P13, DOI
10.1023/A:1022537516969; Lubman DI, 2018, J PSYCHOPHARMACOL, V32, P957, DOI
10.1177/0269881118791741; Lyapustina T, 2017, PAIN PRACT, V17, P1097, DOI
10.1111/papr.12568; MacKillop J, 2016, ALCOHOL CLIN EXP RES, V40, P672, DOI
10.1111/acer.13004; Mansouri MT, 2018, EXP NEUROL, V303, P134, DOI
10.1016/j.expneurol.2018.02.009; Marinova Z, 2015, EUR J PSYCHOTRAUMATO, V6, DOI
10.3402/ejpt.v6.25913; Marshall JR, 2019, SUBST ABUS, V40, P80, DOI
10.1080/08897077.2018.1442899; Martin BC, 2011, J GEN INTERN MED, V26, P1450, DOI
10.1007/s11606-011-1771-0; Martins SS, 2017, ADDICT BEHAV, V65, P236, DOI
10.1016/j.addbeh.2016.08.033; Maxwell JC, 2015, J ADDICT DIS, V34, P127, DOI
10.1080/10550887.2015.1059667; McCrory EJ, 2015, DEV PSYCHOPATHOL, V27, P493, DOI
10.1017/S0954579415000115; McDonald E., 2017, HEDONIC MECH WEIGHT; MCLEROY KR,
1988, HEALTH EDUC QUART, V15, P351, DOI 10.1177/109019818801500401; Meng JJ, 2013,
PLOS ONE, V8, DOI 10.1371/journal.pone.0054040; Mersky JP, 2013, CHILD ABUSE
NEGLECT, V37, P917, DOI 10.1016/j.chiabu.2013.07.011; Mirhashem R, 2017, ADDICT
BEHAV, V69, P98, DOI 10.1016/j.addbeh.2017.02.012; Moeller SJ, 2018, PROG NEURO-
PSYCHOPH, V80, P143, DOI 10.1016/j.pnpbp.2017.03.003; Moeller SJ, 2016, NEUROSCI
BIOBEHAV R, V61, P35, DOI 10.1016/j.neubiorev.2015.11.010; Montalvo-Martinez L,
2018, BIOMED RES INT, DOI 10.1155/2018/8061389; Monterosso J, 2012, BIOL PSYCHIAT,
V72, P107, DOI 10.1016/j.biopsych.2012.03.012; Moore K., 2016, Journal of the
Academy of Nutrition and Dietetics, V116, pA20, DOI 10.1016/j.jand.2016.06.058;
Mora AL, 2012, AM J MED SCI, V343, P277, DOI 10.1097/MAJ.0b013e31822f42eb; MORABIA
A, 1989, BRIT J ADDICT, V84, P173; Nabipour S, 2014, IRAN J PUBLIC HEALTH, V43,
P1022; Nawijn L, 2015, NEUROSCI BIOBEHAV R, V51, P189, DOI
10.1016/j.neubiorev.2015.01.019; Neale J, 2012, ADDICTION, V107, P635, DOI
10.1111/j.1360-0443.2011.03660.x; NIMMO WS, 1975, BRIT J CLIN PHARMACO, V2, P509,
DOI 10.1111/j.1365-2125.1975.tb00568.x; Nolan LJ, 2007, SUBST USE MISUSE, V42,
P1555, DOI 10.1080/10826080701517727; Nunes EV, 2018, J SUBST ABUSE TREAT, V85,
P49, DOI 10.1016/j.jsat.2017.04.016; O'Doherty JP, 2015, CURR OPIN BEHAV SCI, V5,
pV, DOI 10.1016/j.cobeha.2015.10.004; Patel RS, 2017, CUREUS, V9, DOI
10.7759/cureus.1647; Pauly NJ, 2018, DRUG ALCOHOL DEPEN, V184, P26, DOI
10.1016/j.drugalcdep.2017.12.002; Peles E, 2016, SUBST ABUS, V37, P613, DOI
10.1080/08897077.2016.1179705; Penm J, 2017, J AM PHARM ASSOC, V57, pS148, DOI
10.1016/j.japh.2017.01.001; Pergolizzi JV, 2017, PAIN THER, V6, P1, DOI
10.1007/s40122-017-0068-3; Piper BJ, 2017, PHARMACOTHERAPY, V37, P791, DOI
10.1002/phar.1952; Poulsen JL, 2016, J NEUROGASTROENTEROL, V22, P282, DOI
10.5056/jnm15175; Prescott SL, 2018, BIOPSYCHOSOC MED, V12, DOI 10.1186/s13030-018-
0126-z; Puetz V. B., 2017, CURR ADDICT REP, DOI [10.1007/s40429-015-0073-8, DOI
10.1007/S40429-015-0073-8]; Ressler KJ, 2018, BIOL PSYCHIAT, V83, P792, DOI
10.1016/j.biopsych.2018.03.007; Richardson RA, 2015, J BEHAV HEALTH SER R, V42,
P401, DOI 10.1007/s11414-013-9371-x; Rickles NM, 2019, RES SOC ADMIN PHARM, V15,
P959, DOI 10.1016/j.sapharm.2018.02.004; Rousseau D, 2015, SYST RES BEHAV SCI, V32,
P522, DOI 10.1002/sres.2354; Roux AVD, 2007, ANN EPIDEMIOL, V17, P569, DOI
10.1016/j.annepidem.2007.03.001; Rubin LP, 2016, PEDIATR RES, V79, P127, DOI
10.1038/pr.2015.203; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI
10.15585/mmwr.mm655051e1; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI
10.15585/mmwr.mm6450a3; Rustichini A, 2009, CURR OPIN NEUROBIOL, V19, P672, DOI
10.1016/j.conb.2009.09.012; Sandwell H, 2009, PRISON SERVICE J, P15; Sarris J,
2015, LANCET PSYCHIAT, V2, P271, DOI 10.1016/S2215-0366(14)00051-0; Sason A, 2018,
J SUBST ABUSE TREAT, V86, P52, DOI 10.1016/j.jsat.2017.12.008; Schroeder RD, 2017,
SUBST USE MISUSE, V52, P10, DOI 10.1080/10826084.2016.1212603; Schulte EM, 2019,
PSYCHOL ADDICT BEHAV, V33, P144, DOI 10.1037/adb0000441; Schulte EM, 2018, EUR EAT
DISORD REV, V26, P112, DOI 10.1002/erv.2575; Schwartz RP, 2013, AM J PUBLIC HEALTH,
V103, P917, DOI 10.2105/AJPH.2012.301049; Seal KH, 2016, J CLIN PSYCHIAT, V77,
P1182, DOI 10.4088/JCP.15m09893; Seymour RB, 2017, J BONE JOINT SURG AM, V99, DOI
10.2106/JBJS.17.00066; Shechter A, 2018, APPETITE, V122, P32, DOI
10.1016/j.appet.2016.12.009; Smith KZ, 2016, ADDICT BEHAV, V58, P167, DOI
10.1016/j.addbeh.2016.02.019; Smith RC, 2002, J GEN INTERN MED, V17, P309, DOI
10.1046/j.1525-1497.2002.20210.x; Smith RJ, 2015, PAIN MED, V16, P1122, DOI
10.1111/pme.12700; Sokol R, 2018, J SUBST ABUSE TREAT, V84, P78, DOI
10.1016/j.jsat.2017.11.003; Soto M, 2018, MOL PSYCHIATR, V23, P2287, DOI
10.1038/s41380-018-0086-5; Stark EA, 2015, NEUROSCI BIOBEHAV R, V56, P207, DOI
10.1016/j.neubiorev.2015.07.007; Steiger H, 2016, PHYSIOL BEHAV, V162, P181, DOI
10.1016/j.physbeh.2016.01.041; Stein MD, 2017, DRUG ALCOHOL DEPEN, V179, P325, DOI
10.1016/j.drugalcdep.2017.07.007; Stojek MMK, 2017, CLIN PSYCHOL REV, V55, P1, DOI
10.1016/j.cpr.2017.04.007; Sweis BM, 2018, LEARN MEMORY, V25, P501, DOI
10.1101/lm.047795.118; Taylor Andrew M, 2018, Nutr Neurosci, P1, DOI
10.1080/1028415X.2018.1493808; Taylor SE, 1997, ANNU REV PSYCHOL, V48, P411, DOI
10.1146/annurev.psych.48.1.411; Tripathi A, 2018, NAT REV GASTRO HEPAT, V15, P397,
DOI 10.1038/s41575-018-0011-z; Tsuruya A, 2016, SCI REP-UK, V6, DOI
10.1038/srep27923; Umberson D, 2010, ANNU REV SOCIOL, V36, P139, DOI
10.1146/annurev-soc-070308-120011; van de Guchte M, 2018, MICROBIOME, V6, DOI
10.1186/s40168-018-0466-8; van de Wouw M, 2017, J NUTR, V147, P727, DOI
10.3945/jn.116.240481; Van den Bergh B. R. H, 2017, NEUROSCI BIOBEHAV R, DOI
[10.1016/j.neubiorev.2017.07.003, DOI 10.1016/J.NEUBIOREV.2017.07.003]; Vanamala
JKP, 2015, CELL METAB, V22, P960, DOI 10.1016/j.cmet.2015.11.009; Vassoler FM,
2014, NEUROSCIENCE, V264, P198, DOI 10.1016/j.neuroscience.2013.07.064; Vassoler
FM, 2016, NEUROPHARMACOLOGY, V103, P112, DOI 10.1016/j.neuropharm.2015.11.026;
Verdino J, 2017, HEALTH PSYCHOL OPEN, V4, DOI 10.1177/2055102917724335; Vigo D,
2016, LANCET PSYCHIAT, V3, P171, DOI 10.1016/S2215-0366(15)00505-2; Volkow ND,
2019, JAMA PSYCHIAT, V76, P208, DOI 10.1001/jamapsychiatry.2018.3126; Volkow ND,
2018, AM J PSYCHIAT, V175, P729, DOI 10.1176/appi.ajp.2018.17101174; Volkow ND,
2016, NEW ENGL J MED, V374, P363, DOI 10.1056/NEJMra1511480; Volkow ND, 2015,
LANCET PSYCHIAT, V2, P677, DOI 10.1016/S2215-0366(15)00236-9; Waddington F, 2015,
NUTR DIET, V72, P276, DOI 10.1111/1747-0080.12192; Wall-Bassett ED, 2016, GLOB
QUALIT NURS RES, V3, DOI 10.1177/2333393616680902; Wallace CJK, 2017, ANN GEN
PSYCHIATR, V16, DOI 10.1186/s12991-017-0138-2; Wang F., 2015, TEMPORAL MODULATION;
Wang FY, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21915-8; Wassum KM, 2016,
ADDICT BIOL, V21, P221, DOI 10.1111/adb.12172; Wegman MP, 2017, LANCET GLOB HEALTH,
V5, pE198, DOI 10.1016/S2214-109X(16)30303-5; Wei LN, 2008, EPIGENETICS-US, V3,
P119, DOI 10.4161/epi.3.3.6296; Weiner SG, 2016, ACAD EMERG MED, V23, P1086, DOI
10.1111/acem.12992; Weiss NH, 2013, CHILD ABUSE NEGLECT, V37, P944, DOI
10.1016/j.chiabu.2013.03.014; Willson AE, 2007, AM J SOCIOL, V112, P1886, DOI
10.1086/512712; Wiss DA, 2019, ASSESSMENT TREATMENT, P21, DOI [10.1016/B978-0-323-
54856-4.00002-X, DOI 10.1016/B978-0-323-54856-4.00002-X]; Wiss DA, 2018, J ACAD
NUTR DIET, V118, P2217, DOI 10.1016/j.jand.2017.08.113; Wiss DA, 2019, J COMMUN
HEALTH, V44, P88, DOI 10.1007/s10900-018-0557-2; Wiss DA, 2017, APPETITE, V115,
P19, DOI 10.1016/j.appet.2016.12.019; Yang C, 2019, TRANSL PSYCHIAT, V9, DOI
10.1038/s41398-019-0379-8; Zador D, 1996, ADDICTION, V91, P1053, DOI
10.1046/j.1360-0443.1996.917105311.x; Zalar B, 2018, PSYCHIAT DANUB, V30, P136, DOI
10.24869/psyd.2018.136; Zoorob MJ, 2018, PHARMACOEPIDEM DR S, V27, P541, DOI
10.1002/pds.4417 228 0 0 3 3 FRONTIERS MEDIA SA LAUSANNE
AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND 2296-2565
FRONT PUBLIC HEALTH Front. Public Health JUL 9 2019 7
193 10.3389/fpubh.2019.00193
16 Public,
Environmental & Occupational Health Public, Environmental & Occupational
Health IH9QL WOS:000474841400001 31338359 DOAJ Gold 2019-
09-25
J Rehder, K; Bowen, S Rehder, Kristoffer; Bowen, Sarah
PTSD Symptom Severity, Cannabis, and Gender: A Zero-Inflated Negative
Binomial Regression Model SUBSTANCE USE & MISUSE English
Article PTSD; cannabis; gender; zero-
inflated negative binomial model; college students POSTTRAUMATIC-STRESS-
DISORDER; SUBSTANCE USE DISORDER; MARIJUANA-RELATED PROBLEMS; SELF-REPORT MEASURES;
USE COPING MOTIVES; MILITARY VETERANS; MENTAL-HEALTH; SOCIAL NORMS; ALCOHOL-USE;
DRUG-USE Introduction: In the general population, significant relations have
been shown between experienced trauma and cannabis use. Approximately three out of
four college students report experiencing at least one-lifetime traumatic event,
putting them at greater risk for developing substance use disorder (SUD), and
college students report using cannabis to cope with negative effect and stress.
However, PTSD symptom severity predicting cannabis use in the college population
has not been investigated. Methods: This cross-sectional survey study investigated
the relation between PTSD symptom severity and cannabis use, and explored the
moderating effect of gender on this relation, using a non-directional, exploratory
analysis, in a sample of college students (N=536; 68% female). Due to excessive
zero values in the primary outcome, a zero-inflated negative binomial regression
model was used. Results: Gender predicted number of cannabis using days [incidence
rate ratio (IRR) = 2.17; 95%CI = 1.41, 3.35; p < .001]. The probability of being a
cannabis user was moderated by gender [odds ratio (OR) = 0.96; 95%CI= 0.93, 0.99;
p=.026], such that for males, as PTSD symptom severity increased, likelihood of
being a cannabis user increased. This relation was not supported in females,
however. Conclusion/Implication: Discussion includes the potential role of the
endocannabinoid system, social norms, and motives in gender differences in PTSD-
related cannabis use, and explores the self-medication hypothesis in this context.
 [Rehder, Kristoffer; Bowen, Sarah] Pacific Univ, Grad Sch Psychol, Hillsboro,
OR 97116 USA Rehder, K (reprint author), Pacific Univ, Grad Sch Psychol,
Hillsboro, OR 97116 USA. rehd6829@pacificu.edu Adkins
JW, 2008, J ANXIETY DISORD, V22, P1393, DOI 10.1016/j.janxdis.2008.02.002; Agosti
V, 2002, AM J DRUG ALCOHOL AB, V28, P645, DOI 10.1081/ADA-120015873; Aiken LS,
1991, MULTIPLE REGRESSION; Atkins DC, 2007, J FAM PSYCHOL, V21, P726, DOI
10.1037/0893-3200.21.4.726; Avant E. M., 2011, J AGGRESS MALTREAT T, V20, P539, DOI
DOI 10.1080/10926771.2011.588153; Bernat JA, 1998, J TRAUMA STRESS, V11, P645, DOI
10.1023/A:1024485130934; Betthauser K, 2015, AM J HEALTH-SYST PH, V72, P1279, DOI
10.2146/ajhp140523; Boden MT, 2013, AM J ADDICTION, V22, P277, DOI 10.1111/j.1521-
0391.2012.12018.x; Bonn-Miller MO, 2007, J TRAUMA STRESS, V20, P577, DOI
10.1002/jts.20243; Bonn-Miller MO, 2014, DRUG ALCOHOL DEPEN, V136, P162, DOI
10.1016/j.drugalcdep.2013.12.008; Bonn-Miller MO, 2011, PSYCHOL ADDICT BEHAV, V25,
P485, DOI 10.1037/a0021945; Bonn-Miller Marcel O., 2011, Cognitive Behaviour
Therapy, V40, P34, DOI 10.1080/16506073.2010.525253; Bonn-Miller MO, 2010, J DUAL
DIAGN, V6, P111, DOI 10.1080/15504261003751887; Bremner JD, 1996, AM J PSYCHIAT,
V153, P369; Breslau N, 2003, ARCH GEN PSYCHIAT, V60, P289, DOI
10.1001/archpsyc.60.3.289; BROWN PJ, 1994, DRUG ALCOHOL DEPEN, V35, P51, DOI
10.1016/0376-8716(94)90110-4; Buckman JF, 2011, J STUD ALCOHOL DRUGS, V72, P586,
DOI 10.15288/jsad.2011.72.586; Buckner JD, 2013, J STUD ALCOHOL DRUGS, V74, P720,
DOI 10.15288/jsad.2013.74.720; Buckner JD, 2012, ADDICT BEHAV, V37, P1294, DOI
10.1016/j.addbeh.2012.06.013; Buckner JD, 2011, ADDICT BEHAV, V36, P129, DOI
10.1016/j.addbeh.2010.08.015; Bujarski SJ, 2012, ADDICT BEHAV, V37, P1181, DOI
10.1016/j.addbeh.2012.05.014; Chilcoat H. D., 2003, EPIDEMIOLOGICAL INVE; Chilcoat
HD, 1998, ADDICT BEHAV, V23, P827, DOI 10.1016/S0306-4603(98)00069-0; Cooper ZD,
2009, DRUG ALCOHOL DEPEN, V103, P107, DOI 10.1016/j.drugalcdep.2009.01.023; Cougle
JR, 2011, PSYCHOL ADDICT BEHAV, V25, P554, DOI 10.1037/a0023076; Courtenay WH,
2000, SOC SCI MED, V50, P1385, DOI 10.1016/S0277-9536(99)00390-1; COX WM, 1988, J
ABNORM PSYCHOL, V97, P168, DOI 10.1037/0021-843X.97.2.168; Cuttler Carrie, 2016,
Cannabis Cannabinoid Res, V1, P166, DOI 10.1089/can.2016.0010; Earleywine M, 2014,
J PSYCHOACTIVE DRUGS, V46, P171, DOI 10.1080/02791072.2014.920118; Edwards C, 2006,
ADDICT BEHAV, V31, P2094, DOI 10.1016/j.addbeh.2006.02.009; Eisenlohr-Moul TA,
2012, ASSESSMENT, V19, P276, DOI 10.1177/1073191112446658; Fogel JS, 2017,
PHARMACOL BIOCHEM BE, V152, P44, DOI 10.1016/j.pbb.2016.01.007; Gaher RM, 2015,
ADDICT BEHAV, V42, P180, DOI 10.1016/j.addbeh.2014.11.014; Hardin J., 2001, GEN
LINEAR MODELS EX, P141; Harrington T, 2007, ADDICT BEHAV, V32, P2788, DOI
10.1016/j.addbeh.2007.04.016; HEILBRON DC, 1994, BIOMETRICAL J, V36, P531, DOI
10.1002/bimj.4710360505; Jacobsen LK, 2001, AM J PSYCHIAT, V158, P1184, DOI
10.1176/appi.ajp.158.8.1184; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI
10.1001/archpsyc.1995.03950240066012; Keyser-Marcus L, 2015, J INTERPERS VIOLENCE,
V30, P3, DOI 10.1177/0886260514532523; Khantzian EJ, 1997, HARVARD REV PSYCHIAT,
V4, P231, DOI 10.3109/10673229709030550; Kilpatrick DG, 2000, J CONSULT CLIN PSYCH,
V68, P19, DOI 10.1037/0022-006X.68.1.19; Kimerling R, 2006, ADDICT BEHAV, V31,
P2074, DOI 10.1016/j.addbeh.2006.02.008; Kohn Laurence, 2004, Int J Adolesc Med
Health, V16, P359; Krebs-Kraft DL, 2010, P NATL ACAD SCI USA, V107, P20535, DOI
10.1073/pnas.1005003107; Lewis TF, 2008, J COLL COUNS, V11, P19, DOI
10.1002/j.2161-1882.2008.tb00021.x; Loflin M, 2017, ADDICT BEHAV, V68, P18, DOI
10.1016/j.addbeh.2017.01.008; Long J. S., 2006, REGRESSION MODELS CA; Mahalik J.
R., 2006, PSYCHOL MEN MASCULIN, V7, P191, DOI DOI 10.1037/1524-9220.7.4.191;
Mahalik JR, 2007, SOC SCI MED, V64, P2201, DOI 10.1016/j.socscimed.2007.02.035;
Mahalik JR, 2015, SOC SCI MED, V143, P71, DOI 10.1016/j.socscimed.2015.08.013;
Manhapra A, 2015, DRUG ALCOHOL DEPEN, V156, P70, DOI
10.1016/j.drugalcdep.2015.08.036; Marx BP, 2003, ADDICT BEHAV, V28, P1631, DOI
10.1016/j.addbeh.2003.08.039; Marx BP, 2002, BEHAV THER, V33, P563, DOI
10.1016/S0005-7894(02)80017-X; MCFALL ME, 1992, J STUD ALCOHOL, V53, P357, DOI
10.15288/jsa.1992.53.357; Metrik J, 2016, PSYCHOL ADDICT BEHAV, V30, P743, DOI
10.1037/adb0000210; Najavits LM, 2013, J CLIN PSYCHOL, V69, P433, DOI
10.1002/jclp.21980; Neighbors C, 2008, PSYCHOL ADDICT BEHAV, V22, P433, DOI
10.1037/0893-164X.22.3.433; Neumeister A, 2013, MOL PSYCHIATR, V18, P1034, DOI
10.1038/mp.2013.61; Neumeister A, 2015, PSYCHONEUROENDOCRINO, V51, P577, DOI
10.1016/j.psyneuen.2014.10.012; Neumeister A, 2013, DEPRESS ANXIETY, V30, P93, DOI
10.1002/da.22031; Onaivi ES, 1999, PROG NEURO-PSYCHOPH, V23, P1063, DOI
10.1016/S0278-5846(99)00052-4; Ouimette P, 2005, J TRAUMA STRESS, V18, P43, DOI
10.1002/jts.20009; Passie T, 2012, DRUG TEST ANAL, V4, P649, DOI 10.1002/dta.1377;
Patton GC, 2002, BRIT MED J, V325, P1195, DOI 10.1136/bmj.325.7374.1195; PEREZREYES
M, 1981, J CLIN PHARMACOL, V21, pS201, DOI 10.1002/j.1552-4604.1981.tb02596.x; Read
JP, 2012, J CONSULT CLIN PSYCH, V80, P426, DOI 10.1037/a0028210; Reich CG, 2009,
BEHAV BRAIN RES, V203, P264, DOI 10.1016/j.bbr.2009.05.013; Resnicow K, 1999,
ADDICT BEHAV, V24, P251, DOI 10.1016/S0306-4603(98)00059-8; Reynolds M, 2005, DRUG
ALCOHOL DEPEN, V77, P251, DOI 10.1016/j.drugalcdep.2004.08.017; Rose CE, 2006, J
BIOPHARM STAT, V16, P463, DOI 10.1080/10543400600719384; Ruggiero KJ, 2003, J
TRAUMA STRESS, V16, P495, DOI 10.1023/A:1025714729117; Schafer I, 2007, CURR OPIN
PSYCHIATR, V20, P614, DOI 10.1097/YCO.0b013e3282f0ffd9; SCHAFER J, 1991, J CONSULT
CLIN PSYCH, V59, P558, DOI 10.1037/0022-006X.59.4.558; Simons J, 1998, J COUNS
PSYCHOL, V45, P265, DOI 10.1037/0022-0167.45.3.265; Simons JS, 2006, ADDICT BEHAV,
V31, P1578, DOI 10.1016/j.addbeh.2005.12.004; Simons JS, 2006, AM J DRUG ALCOHOL
AB, V32, P41, DOI 10.1080/00952990500328539; Simons JS, 2005, ADDICT BEHAV, V30,
P1619, DOI 10.1016/j.addbeh.2005.02.003; Smyth JM, 2008, J AM COLL HEALTH, V57,
P69, DOI 10.3200/JACH.57.1.69-76; Stewart SH, 1998, ADDICT BEHAV, V23, P797, DOI
10.1016/S0306-4603(98)00070-7; VUONG QH, 1989, ECONOMETRICA, V57, P307, DOI
10.2307/1912557; Wade JC, 2008, PSYCHOL MEN MASCULIN, V9, P5, DOI 10.1037/1524-
9220.9.1.5; Walsh K, 2014, ADDICT BEHAV, V39, P684, DOI
10.1016/j.addbeh.2013.12.006; Weathers FW, 1994, PTSD CHECKLIST CIVIL; WINDLE M,
1995, AM J PSYCHIAT, V152, P1322; Wolff N, 2011, PSYCHIAT SERV, V62, P954, DOI
10.1176/ps.62.8.pss6208_0954 85 0 0 6 8 TAYLOR & FRANCIS INC
PHILADELPHIA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
1082-6084 1532-2491 SUBST USE MISUSE Subst. Use Misuse JUL 3 2019
54 8 1309 1318
10.1080/10826084.2019.1575421 10 Substance Abuse; Psychiatry;
Psychology Substance Abuse; Psychiatry; Psychology HY5TT WOS:000468191700007
30767607 2019-09-25
J Alexander, D; Schnell, M Alexander, Diane; Schnell,
Molly Just what the nurse practitioner ordered: Independent
prescriptive authority and population mental health JOURNAL OF HEALTH ECONOMICS
English Article SELF-
MEDICATION HYPOTHESIS; PRIMARY-CARE OUTCOMES; ANTIDEPRESSANT MEDICATION; SOCIAL
CONSTRUCTION; SUBSTANCE USE; SUICIDE; DISORDERS; IMPACT; COMORBIDITY; INSURANCE
We examine whether relaxing occupational licensing to allow nurse
practitioners (NPs)-registered nurses with advanced degrees-to prescribe medication
without physician oversight improves population mental health. Exploiting time-
series variation in independent prescriptive authority for NPs from 1990 to 2014,
we find that broadening prescriptive authority leads to improvements in self-
reported mental health and decreases in mental health-related mortality. These
improvements are concentrated in areas that are underserved by physicians and among
populations that have difficulty accessing physician-provided care. Our results
demonstrate that extending independent prescriptive authority to NPs can help
mitigate physician shortages and extend care to disadvantaged populations. (C) 2019
Elsevier B.V. All rights reserved. [Alexander, Diane] Fed Reserve Bank Chicago,
Chicago, IL 60604 USA; [Schnell, Molly] Northwestern Univ, Evanston, IL 60208 USA;
[Schnell, Molly] NBER, Cambridge, MA 02138 USA Alexander, D (reprint author), Fed
Reserve Bank Chicago, Chicago, IL 60604 USA. dalexander@frbchi.org;
schnell@northwestern.edu Center for Health and Wellbeing at
Princeton UniversityPrinceton University Matthew Basilico, Alice Chen, Janet
Currie, Henry Farber, David Krol, Ilyana Kuziemko, Ellen Meara, Karin Marton-
Rollins, and Beth Rom-Rymer provided helpful comments. We thank participants in
seminars at Princeton University, the 2016 Society of Labor Economists Meeting, the
2016 and 2018 American Society of Health Economists Meetings, and the 2016
Population Health Sciences Research Workshop at Boston University School of Public
Health. Generous financial support from the Center for Health and Wellbeing at
Princeton University is gratefully acknowledged. The statements, findings,
conclusions, views, and opinions contained and expressed herein are not necessarily
those of IQVIA or any of its affiliated or subsidiary entities. American
Association of Nurse Practitioners, 2012, TECHNICAL REPORT; American Association of
Nurse Practitioners, 2014, TECHNICAL REPORT; American Association of Nurse
Practitioners, 2017, TECHNICAL REPORT; Baicker K, 2013, NEW ENGL J MED, V368,
P1713, DOI 10.1056/NEJMsa1212321; Barkus E, 2010, ANNU REV CLIN PSYCHO, V6, P365,
DOI 10.1146/annurev.clinpsy.121208.131220; Bishop TF, 2014, JAMA PSYCHIAT, V71,
P176, DOI 10.1001/jamapsychiatry.2013.2862; Bjorkenstam C, 2014, POPUL HEALTH METR,
V12, DOI 10.1186/1478-7954-12-11; Buerhaus PI, 2015, NURS OUTLOOK, V63, P144, DOI
10.1016/j.outlook.2014.08.008; Bureau of Health Workforce, 2016, TECHNICAL REPORT;
Carlsten A, 2001, PHARMACOEPIDEM DR S, V10, P525, DOI 10.1002/pds.618; Case A,
2017, BROOKINGS PAP ECO AC, P397; Case A, 2015, P NATL ACAD SCI USA, V112, P15078,
DOI 10.1073/pnas.1518393112; Cooper PN, 1995, MED SCI LAW, V35, P319, DOI
10.1177/002580249503500409; Cunningham PJ, 2009, HEALTH AFFAIR, V28, pW490, DOI
10.1377/hlthaff.28.3.w490; Currie J, 2006, J HEALTH ECON, V25, P1094, DOI
10.1016/j.jhealeco.2006.03.001; Dueker MJ, 2005, J REGUL ECON, V27, P309, DOI
10.1007/s11149-005-6626-3; Ettner SL, 1997, IND LABOR RELAT REV, V51, P64, DOI
10.2307/2525035; Everett CM, 2009, J RURAL HEALTH, V25, P407, DOI 10.1111/j.1748-
0361.2009.00252.x; Finkelstein A, 2012, Q J ECON, V127, P1057, DOI
10.1093/qje/qjs020; Frances A, 2011, PSYCHIAT TIMES; Greenberg GA, 2008, PSYCHIAT
SERV, V59, P170, DOI 10.1176/ps.2008.59.2.170; Grumbach Kevin, 2003, Ann Fam Med,
V1, P97, DOI 10.1370/afm.49; HOLDING TA, 1977, BRIT J PSYCHIAT, V130, P244, DOI
10.1192/bjp.130.3.244; Horrocks S, 2002, BRIT MED J, V324, P819, DOI
10.1136/bmj.324.7341.819; Institute of Medicine, 2011, FUT NURS LEAD CHANG; Jougla
E, 2002, REV EPIDEMIOL SANTE, V50, P49; Kelleher MJ, 1996, IRISH MED J, V89, P14;
Kessler R, 2008, PRIMARY CARE IS DE F, P9; Kessler RC, 2008, AM J PSYCHIAT, V165,
P703, DOI 10.1176/appi.ajp.2008.08010126; Khantzian EJ, 1997, HARVARD REV PSYCHIAT,
V4, P231, DOI 10.3109/10673229709030550; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142,
P1259; Kleiner M, 2010, 16560 NBER; Kleiner MM, 2016, J LAW ECON, V59, P261, DOI
10.1086/688093; Larson E., 2003, HLTH SERV RES, V38; Laurant MGH, 2008, J CLIN
NURS, V17, P2690, DOI 10.1111/j.1365-2702.2008.02288.x; Lenz ER, 2004, MED CARE RES
REV, V61, P332, DOI 10.1177/1077558704266821; Lindqvist P, 2002, FORENSIC SCI INT,
V128, P136, DOI 10.1016/S0379-0738(02)00188-3; Maniam T, 1995, Asia Pac J Public
Health, V8, P181; Marier A, 2011, WORKING PAPER; McHugh PJ, 2004, CANC DRUG DISC
DEV, P31; Meara E., 2016, N ENGL J MED; Meinhofer A, 2018, AM J HEALTH ECON, V4,
P504, DOI 10.1162/ajhe_a_00101; Merikangas KR, 2010, J AM ACAD CHILD PSY, V49,
P980, DOI 10.1016/j.jaac.2010.05.017; Mundinger MO, 2000, JAMA-J AM MED ASSOC,
V283, P59, DOI 10.1001/jama.283.1.59; Naylor MD, 2010, HEALTH AFFAIR, V29, P893,
DOI 10.1377/hlthaff.2010.0440; Nock MK, 2010, MOL PSYCHIATR, V15, P868, DOI
10.1038/mp.2009.29; Ohberg A, 1998, ACTA PSYCHIAT SCAND, V98, P214, DOI
10.1111/j.1600-0447.1998.tb10069.x; Olfson M, 2003, ARCH GEN PSYCHIAT, V60, P978,
DOI 10.1001/archpsyc.60.9.978; Pei Z., 2018, J BUS EC STAT; PHILLIPS DP, 1993,
SUICIDE LIFE-THREAT, V23, P307; PLATT S, 1988, SOC PSYCH PSYCH EPID, V23, P217, DOI
10.1007/BF01787820; Rabinowitz HK, 2008, ACAD MED, V83, P235, DOI
10.1097/ACM.0b013e318163789b; REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511;
Rockett IRH, 2006, SOC SCI MED, V63, P2165, DOI 10.1016/j.socscimed.2006.05.017;
Rockett IRH, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-705; Rockett
IRH, 2010, BMC PSYCHIATRY, V10, DOI 10.1186/1471-244X-10-35; ROCKETT IRH, 1993, SOC
SCI MED, V36, P1467, DOI 10.1016/0277-9536(93)90388-K; Sadeghi C., 2017, NURSE
PRACTITIONERS; Scheffler R M, 1996, J Allied Health, V25, P207; Schnell M, 2018, AM
J HEALTH ECON, V4, P383, DOI 10.1162/ajhe_a_00113; Simon K, 2017, J POLICY ANAL
MANAG, V36, P390, DOI 10.1002/pam.21972; Skillman S., 2012, TECHNICAL REPORT;
Stange K, 2014, J HEALTH ECON, V33, P1, DOI 10.1016/j.jhealeco.2013.10.009;
Substance Abuse and Mental Health Services Administration, 2014, NSDUH SER H, V48;
Substance Abuse and Mental Health Services Administration, 2015, TECHNICAL REPORT;
Substance Abuse and Mental Health Services Administration, 2017, NSDUH SER H, VH-
52; Thomas K., 2009, PSYCHIAT SERV, V60; Tollefsen IM, 2012, BMC PSYCHIATRY, V12,
DOI 10.1186/1471-244X-12-9; Traczynski J, 2018, J HEALTH ECON, V58, P90, DOI
10.1016/j.jhealeco.2018.01.001; Whitt HP, 2006, SOCIOL INQ, V76, P166, DOI
10.1111/j.1475-682X.2006.00150.x; Wong J., 2017, BR MED J; Xue Y, 2016, NURS
OUTLOOK, V64, P71, DOI 10.1016/j.outlook.2015.08.005; Zalsman G, 2016, LANCET
PSYCHIAT, V3, P646, DOI 10.1016/S2215-0366(16)30030-X 73 0 0 3 3
ELSEVIER AMSTERDAM RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS 0167-
6296 1879-1646 J HEALTH ECON J. Health Econ. JUL 2019 66
145 162 10.1016/j.jhealeco.2019.04.004
18 Economics; Health Care Sciences & Services; Health Policy & Services
Business & Economics; Health Care Sciences & ServicesIS9ZD
WOS:000482505600011 31220792 2019-09-25
J Ranjit, A; Korhonen, T; Buchwald, J; Heikkila, K; Tuulio-Henriksson, A; Rose,
RJ; Kaprio, J; Latvala, A Ranjit, Anu; Korhonen, Tellervo;
Buchwald, Jadwiga; Heikkila, Kauko; Tuulio-Henriksson, Annamari; Rose, Richard J.;
Kaprio, Jaakko; Latvala, Antti Testing the reciprocal association
between smoking and depressive symptoms from adolescence to adulthood: A
longitudinal twin study DRUG AND ALCOHOL DEPENDENCE English
Article Cigarette smoking; Depressive
symptoms; Twins; Adolescence; Adulthood GENERAL BEHAVIOR INVENTORY; CIGARETTE-
SMOKING; MAJOR DEPRESSION; GENDER-DIFFERENCES; SUBSTANCE USE; PSYCHIATRIC-
DISORDERS; NICOTINE DEPENDENCE; SELF-MEDICATION; YOUNG-ADULTS; PATHWAYS
Background: Longitudinal studies enhance understanding of the complex
reciprocal relationship between smoking and depression from adolescence to young
adulthood. Examining bi-directional associations between cigarette smoking and
depressive symptoms in a genetically informative twin design can help to understand
whether the associations are independent of shared genetic and environmental
factors. Methods: We analyzed longitudinal data on smoking and depressive symptoms
in twins participating in the adolescent (mean age 17.5) and young adult (mean age
21.9) surveys of the FinnTwin12 study (maximum N = 2,954 individuals; 1,154 twin
pairs). At both waves, self-reported depressive symptoms, assessed with the 10-item
version of the General Behavior Inventory (GBI), and smoking status were analyzed.
The bi-directional associations were first studied among individuals and then
within monozygotic and dizygotic twin pairs. Results: When adjusted for multiple
covariates and baseline depressive symptoms, daily smokers at age 17 had higher
depressive symptom scores at age 22 than never smokers (Incidence Rate Ratio =
1.17, 95% CI: 1.03-1.33). Similarly, when adjusted for covariates and baseline
smoking, higher score in GBI at age 17 was associated with an increased likelihood
of being a non-daily (Relative Risk Ratio (RRR) = 1.06, 95% CI: 1.01-1.11) or daily
(RRR = 1.05, 95% CI: 1.00-1.10) smoker at age 22. No associations were found in
within-pair analyses, suggesting that the individual-level association is explained
by shared familial liabilities. Conclusion: During the developmental period from
adolescence to adulthood, cigarette smoking and depressive symptoms are
reciprocally associated. However, these associations are confounded by shared
genetic and other familial liabilities. [Ranjit, Anu; Kaprio, Jaakko] Univ
Helsinki, Dept Publ Hlth, POB 20, FIN-00014 Helsinki, Finland; [Korhonen, Tellervo;
Buchwald, Jadwiga; Heikkila, Kauko; Kaprio, Jaakko; Latvala, Antti] Univ Helsinki,
Inst Mol Med Finland, Helsinki, Finland; [Tuulio-Henriksson, Annamari] Univ
Helsinki, Dept Psychol & Logoped, Helsinki, Finland; [Rose, Richard J.] Indiana
Univ, Dept Psychol & Brain Sci, Bloomington, IN USA Ranjit, A (reprint author),
Univ Helsinki, Dept Publ Hlth, POB 20, FIN-00014 Helsinki, Finland.
anu.ranjit@helsinki.fi ; Ranjit, Anu/O-8993-2016; Buchwald, Jadwiga/F-5463-
2019 Kaprio, Jaakko/0000-0002-3716-2455; Ranjit, Anu/0000-0001-5967-3312;
Buchwald, Jadwiga/0000-0001-6688-8346 National Institute of Alcohol Abuse and
AlcoholismUnited States Department of Health & Human ServicesNational Institutes of
Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [AA-
12502, AA-00145, AA-09203]; Academy of FinlandAcademy of Finland [100499, 205585,
118555, 141054, 265240, 263278, 264146, 308248, 312073, 277209, 308698, 309119];
Juho Vainio Foundation; University of Helsinki; Foundation of the Finnish Anti-
Tuberculosis Association This work was supported by the National Institute of
Alcohol Abuse and Alcoholism (AA-12502, AA-00145 and AA-09203 to RJR); Academy of
Finland (100499, 205585, 118555, 141054, 265240, 263278, 264146, 308248, 312073 to
JK, 277209, 308698 to AL and 309119 to TK); Juho Vainio Foundation; University of
Helsinki; and the Foundation of the Finnish Anti-Tuberculosis Association to AR.
The funding agencies played no role in analysis and interpretation of the data,
preparation of the manuscript, and decision to submit the report for publication.
Allison P. D., 2009, FIXED EFFECTS REGRES; [Anonymous], 2013, SMOK MENT HLTH;
Anttila V, 2018, SCIENCE, V360, P1313, DOI 10.1126/science.aap8757; Audrain-
McGovern J, 2009, ADDICTION, V104, P1743, DOI 10.1111/j.1360-0443.2009.02617.x;
Avenevoli S, 2015, J AM ACAD CHILD PSY, V54, P37, DOI 10.1016/j.jaac.2014.10.010;
Balfour DJK, 2000, PHARMACOL BIOCHEM BE, V66, P79, DOI 10.1016/S0091-3057(00)00205-
7; Beal SJ, 2014, PREV SCI, V15, P506, DOI 10.1007/s11121-013-0402-x; Brown RA,
1996, J AM ACAD CHILD PSY, V35, P1602, DOI 10.1097/00004583-199612000-00011;
Chaiton M, 2015, ADDICT BEHAV, V42, P154, DOI 10.1016/j.addbeh.2014.11.026; Chaiton
MO, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-356; Danielson CK, 2003, J
ABNORM CHILD PSYCH, V31, P29, DOI 10.1023/A:1021717231272; Depue R. A., 1987, GEN
BEHAV INVENTORY; DEPUE RA, 1981, J ABNORM PSYCHOL, V90, P381, DOI 10.1037/0021-
843X.90.5.381; Epping-Jordan MP, 1998, NATURE, V393, P76; Findling RL, 2002,
BIPOLAR DISORD, V4, P34, DOI 10.1034/j.1399-5618.2002.40102.x; Fluharty M, 2017,
NICOTINE TOB RES, V19, P3, DOI 10.1093/ntr/ntw140; GJERDE PF, 1995, CHILD DEV, V66,
P1277, DOI 10.1111/j.1467-8624.1995.tb00935.x; Hankin BL, 1998, J ABNORM PSYCHOL,
V107, P128, DOI 10.1037/0021-843X.107.1.128; Kaprio J, 2002, TWIN RES, V5, P366,
DOI 10.1375/twin.5.5.366; Kaprio J, 2006, TWIN RES HUM GENET, V9, P772, DOI
10.1375/twin.9.6.772; Kaprio J, 2013, TWIN RES HUM GENET, V16, P157, DOI
10.1017/thg.2012.142; KENDLER KS, 1993, ARCH GEN PSYCHIAT, V50, P36; Khantzian EJ,
1997, HARVARD REV PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550; Kokko K, 1998,
J ADULT DEV, V5, P205, DOI 10.1023/A:1021450208639; Leventhal AM, 2012, NICOTINE
TOB RES, V14, P559, DOI 10.1093/ntr/ntr253; Lyons M, 2008, NICOTINE TOB RES, V10,
P97, DOI 10.1080/14622200701705332; Martin J, 2018, PSYCHOL MED, V48, P1759, DOI
10.1017/S0033291717003440; Mathew AR, 2017, ADDICTION, V112, P401, DOI
10.1111/add.13604; McCaffery JM, 2008, HEALTH PSYCHOL, V27, pS207, DOI
10.1037/0278-6133.27.3(Suppl.).S207; McGue M, 2010, PERSPECT PSYCHOL SCI, V5, P546,
DOI 10.1177/1745691610383511; Minica CC, 2018, BEHAV GENET, V48, P337, DOI
10.1007/s10519-018-9904-4; Needham BL, 2007, SOC SCI MED, V65, P1166, DOI
10.1016/j.socscimed.2007.04.037; Pedersen W, 2009, ADDICTION, V104, P129, DOI
10.1111/j.1360-0443.2008.02395.x; Rao U, 2006, AM J PREV MED, V31, pS161, DOI
10.1016/j.amepre.2006.07.002; Rimpela A, 2007, USE TOBACCO PRODUCTS; Rose RJ, 2010,
HANDBOOK OF BEHAVIOR GENETICS, P411, DOI 10.1007/978-0-387-76727-7_28; Salmela-Aro
K, 2014, TWIN RES HUM GENET, V17, P236, DOI [10.1017/thg.2014.33,
10.1017/thg..2014.33]; Shiffman S, 2014, CANCER EPIDEM BIOMAR, V23, P1264, DOI
10.1158/1055-9965.EPI-13-1014; Silberg J, 2003, J CHILD PSYCHOL PSYC, V44, P664,
DOI 10.1111/1469-7610.00153; StataCorp, 2013, STATA STAT SOFTW REL; Unger JB, 2011,
ASIA-PAC J PUBLIC HE, V23, P568, DOI 10.1177/1010539509351052; Wilkinson AL, 2016,
ADDICT BEHAV, V60, P64, DOI 10.1016/j.addbeh.2016.03.036; Williams RL, 2000,
BIOMETRICS, V56, P645, DOI 10.1111/j.0006-341X.2000.00645.x; Windle M, 2001, J
CONSULT CLIN PSYCH, V69, P215, DOI 10.1037//0022-006X.69.2.215; Wu LT, 1999, AM J
PUBLIC HEALTH, V89, P1837, DOI 10.2105/AJPH.89.12.1837 45 0 0 0
0 ELSEVIER IRELAND LTD CLARE ELSEVIER HOUSE, BROOKVALE PLAZA, EAST
PARK SHANNON, CO, CLARE, 00000, IRELAND 0376-8716 1879-0046 DRUG ALCOHOL
DEPEN Drug Alcohol Depend. JUL 1 2019 200 64
70 10.1016/j.drugalcdep.2019.03.012 7 Substance
Abuse; Psychiatry Substance Abuse; Psychiatry IH2JB WOS:000474319900010
31100637 2019-09-25
J Love, HA; Torgerson, CN Love, Heather A.; Torgerson,
Chelsey N. Traumatic Experiences in Childhood and Adult Substance Use
in a Nonclinical Sample: The Mediating Role of Arousal/Reactivity JOURNAL OF
MARITAL AND FAMILY THERAPY English Article
POSTTRAUMATIC-STRESS-DISORDER; PTSD SYMPTOM CLUSTERS; DRUG-USE;
SELF-MEDICATION; SEXUAL ASSAULT; MENTAL-HEALTH; ALCOHOL-USE; EXPOSURE; FAMILY;
ABUSE The vast majority of adults in the United States experience at least one
traumatic event during childhood. According to the self-medication hypothesis of
substance use disorders, adult survivors of childhood trauma may cope with trauma-
related symptoms via alcohol or drug use. The purpose of this study is to identify
through which specific PTSD symptom clusters childhood trauma exposure are
associated with adult substance use. Participants of this study (N = 627) were not
recruited based on substance use or traumatic exposure. Results of this study
demonstrate that arousal/reactivity partially mediates the association between
childhood trauma and current substance use. Implications for treatment include
recommendations for trauma-informed approaches that aim to decrease
arousal/reactivity and subsequently substance use. [Love, Heather A.; Torgerson,
Chelsey N.] Kansas State Univ, Couple & Family Therapy Program, Dept Family Studies
& Human Serv, 303 Justin Hall,1324 Lovers Lane, Manhattan, KS 66506 USA Love,
HA (reprint author), Kansas State Univ, Couple & Family Therapy Program, Dept
Family Studies & Human Serv, 303 Justin Hall,1324 Lovers Lane, Manhattan, KS 66506
USA. halove@ksu.edu Abel NJ, 2010, J EMDR PRACT RES,
V4, P50, DOI 10.1891/1933-3196.4.2.50; AMERICAN PSYCHIATRIC ASSOCIATION (A.P.A),
2013, DIAGN STAT MAN MENT; Anda RF, 2006, EUR ARCH PSY CLIN N, V256, P174, DOI
10.1007/s00406-005-0624-4; Babor T, 2001, AUDIT ALCOHOL USE DI; Bardin A., 2012,
HDB EMDR FAMILY THER, P325; Billette V, 2008, BEHAV MODIF, V32, P876, DOI
10.1177/0145445508319280; Bowen S, 2009, SUBST ABUS, V30, P295, DOI
10.1080/08897070903250084; Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI
10.1037/0022-006X.68.5.748; Buhrmester M, 2011, PERSPECT PSYCHOL SCI, V6, P3, DOI
10.1177/1745691610393980; Cartwright WS, 2008, J SUBST ABUSE TREAT, V34, P224, DOI
10.1016/j.jsat.2007.04.003; CHEN K, 1995, AM J PUBLIC HEALTH, V85, P41, DOI
10.2105/AJPH.85.1.41; Chilcoat HD, 1998, ADDICT BEHAV, V23, P827, DOI
10.1016/S0306-4603(98)00069-0; Copeland WE, 2007, ARCH GEN PSYCHIAT, V64, P577, DOI
10.1001/archpsyc.64.5.577; Coulter S., 2011, J FAM THER, V35, P381; Cross D, 2015,
CHILD ABUSE NEGLECT, V44, P26, DOI 10.1016/j.chiabu.2015.01.007; Degenhardt L,
2014, DRUG ALCOHOL REV, V33, P4, DOI 10.1111/dar.12088; Dunn EC, 2017, J PSYCHIATR
RES, V84, P119, DOI 10.1016/j.jpsychires.2016.09.004; Dworkin ER, 2018, ADDICT
BEHAV, V76, P188, DOI 10.1016/j.addbeh.2017.08.019; Dworkin ER, 2017, PSYCHOL
TRAUMA-US, V9, P500, DOI 10.1037/tra0000212; Elliott M, 2015, SOC PSYCH PSYCH EPID,
V50, P19, DOI 10.1007/s00127-014-0867-3; Enoch MA, 2011, PSYCHOPHARMACOLOGY, V214,
P17, DOI 10.1007/s00213-010-1916-6; Epstein JN, 1998, CHILD ABUSE NEGLECT, V22,
P223, DOI 10.1016/S0145-2134(97)00133-6; Evans EA, 2018, SOC PSYCH PSYCH EPID, V53,
P421, DOI 10.1007/s00127-017-1463-0; Feldman G, 2010, BEHAV RES THER, V48, P1002,
DOI 10.1016/j.brat.2010.06.006; Ford J. D., 1997, TRAUMATIC EVEN UNPUB; Franke HA,
2014, CHILDREN-BASEL, V1, P390, DOI 10.3390/children1030390; Garland EL, 2013, J
BEHAV MED, V36, P175, DOI 10.1007/s10865-012-9413-5; Greenberg L., 1998,
EMOTIONALLY FOCUSED; Hanney L, 2002, FAM PROCESS, V41, P37, DOI 10.1111/j.1545-
5300.2002.40102000037.x; Hayes AF, 2009, COMMUN MONOGR, V76, P408, DOI
10.1080/03637750903310360; Homish D. L., 2017, DRUG ALCOHOL DEPEN, V171, pe91, DOI
[10.1016/j.drugalcdep.2016.08.255, DOI 10.1016/J.DRUGALCDEP.2016.08.255]; Johnson
S. M., 1996, PRACTICE EMOTIONALLY; Kelly A, 2015, SMITH COLL STUD SOC, V85, P194,
DOI 10.1080/00377317.2015.1021191; Keyser-Marcus L, 2015, J INTERPERS VIOLENCE,
V30, P3, DOI 10.1177/0886260514532523; Khantzian EJ, 1997, HARVARD REV PSYCHIAT,
V4, P231, DOI 10.3109/10673229709030550; Kilpatrick DG, 2013, J TRAUMA STRESS, V26,
P537, DOI 10.1002/jts.21848; Kline R. B., 2011, PRINCIPLES PRACTICE; Koenen KC,
2007, PSYCHOL MED, V37, P181, DOI 10.1017/S0033291706009019; Little TD, 2002,
STRUCT EQU MODELING, V9, P151, DOI 10.1207/S15328007SEM0902_1; MacIntosh HB, 2008,
J MARITAL FAM THER, V34, P298, DOI 10.1111/j.1752-0606.2008.00074.x; McCutcheon VV,
2010, J TRAUMA STRESS, V23, P811, DOI 10.1002/jts.20577; Monson C. M., 2012,
COGNITIVE BEHAV CONJ; Monson CM, 2012, JAMA-J AM MED ASSOC, V308, P700, DOI
10.1001/jama.2012.9307; Monson CM, 2004, J TRAUMA STRESS, V17, P341, DOI
10.1023/B:JOTS.0000038483.69570.5b; Nosen E, 2014, BEHAV RES THER, V61, P35, DOI
10.1016/j.brat.2014.07.003; Orford J, 2010, DRUG-EDUC PREV POLIC, V17, P36, DOI
10.3109/09687637.2010.514801; Possemato K, 2015, PSYCHOL ADDICT BEHAV, V29, P894,
DOI 10.1037/adb0000129; Powers MB, 2010, CLIN PSYCHOL REV, V30, P635, DOI
10.1016/j.cpr.2010.04.007; Pukay- Martin ND, 2016, CURR TREAT OPTIONS P, V3, P37;
Shapiro F, 2012, EUR REV APPL PSYCHOL, V62, P193, DOI 10.1016/j.erap.2012.09.005;
Shapiro F., 2001, EMDR BASIC PRINCIPLE; Sheinberg M, 2008, FAM PROCESS, V47, P173,
DOI 10.1111/j.1545-5300.2008.00247.x; Simpson TL, 2014, J ABNORM PSYCHOL, V123,
P237, DOI 10.1037/a0035193; SKINNER HA, 1982, ADDICT BEHAV, V7, P363, DOI
10.1016/0306-4603(82)90005-3; Sullivan TP, 2008, J TRAUMA STRESS, V21, P173, DOI
10.1002/jts.20318; Toner J, 2013, PSYCHOSIS, V5, P175, DOI
10.1080/17522439.2012.697484; Torgerson CN, 2018, J SUBST ABUSE TREAT, V88, P44,
DOI 10.1016/j.jsat.2018.02.005; Walsh F, 2007, FAM PROCESS, V46, P207, DOI
10.1111/j.1545-5300.2007.00205.x; Weathers F, 2013, PTSD CHECKLIST DSM 5; Williams
J, 2008, STRUCT EQU MODELING, V15, P23, DOI 10.1080/10705510701758166 60 0
0 0 0 WILEY HOBOKEN 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
0194-472X 1752-0606 J MARITAL FAM THER J. Marital Fam. Ther.
JUL 2019 45 3 508 520
10.1111/jmft.12348 13 Psychology, Clinical; Family
Studies Psychology; Family Studies IH9BN WOS:000474801300010 30009525
2019-09-25
J Rodriguez, T; Ward, JT; Tillyer, MS; Ray, JV Rodriguez,
Thalia; Ward, Jeffrey T.; Tillyer, Marie Skubak; Ray, James V. The
Influence of Delinquent Peer Affiliation on Substance Use: The Moderating Effects
of Anxiety and Depression JOURNAL OF DRUG ISSUES English
Article peer delinquency; anxiety;
depression; substance use SELF-MEDICATION HYPOTHESIS; USE DISORDERS; GROUP
CONTEXT; BEHAVIOR; SUSCEPTIBILITY; ADOLESCENTS; ALCOHOL; FRIENDS; ASSOCIATION;
COMORBIDITY Although the effects of peer substance use on adolescent substance use
are well documented, little is known about whether internalizing behaviors-anxiety
and depression-exacerbate or attenuate the link between peer substance use and
substance use. The present study uses data from the 12- and 15-year-old cohorts
from the Project on Human Development in Chicago Neighborhoods (PHDCN) and
multivariate generalized regression models to examine whether anxiety and/or
depression moderate peer effects on adolescent substance use. Results indicate that
adolescents who exhibited high anxiety and depressive symptoms are uninfluenced by
their peers' substance use, but those who exhibit lower levels of anxiety and
depressive symptoms use substances more when they have more substance using peers.
Our findings support social learning and peer contagion explanations of substance
use, but suggest these processes are contingent on current emotional states.
Interventions should consider the differential effects of peers given one's level
of anxiety and depression. [Rodriguez, Thalia] Univ Indianapolis, Clin Psychol,
Indianapolis, IN 46227 USA; [Ward, Jeffrey T.] Temple Univ, Dept Criminal Justice,
527 Gladfelter Hall,1115 Polett Walk, Philadelphia, PA 19122 USA; [Tillyer, Marie
Skubak] Univ Texas San Antonio, Dept Criminal Justice, San Antonio, TX USA; [Ray,
James V.] Univ Cent Florida, Dept Criminal Justice, Orlando, FL 32816 USA Ward,
JT (reprint author), Temple Univ, Dept Criminal Justice, 527 Gladfelter Hall,1115
Polett Walk, Philadelphia, PA 19122 USA. jeffrey.ward@temple.edu
Achen Christopher H., 2000, ANN M POL METH SECT; AGNEW R, 1991, CRIMINOLOGY,
V29, P47, DOI 10.1111/j.1745-9125.1991.tb01058.x; Agnew R, 2016, CRIMINOLOGY, V54,
P181, DOI 10.1111/1745-9125.12104; Akers R. L., 2003, SOCIAL LEARNING THEO; Akers
R. L, 1973, DEVIANT BEHAV SOCIAL; AKERS RL, 1979, AM SOCIOL REV, V44, P636, DOI
10.2307/2094592; Allen JP, 2006, DEV PSYCHOPATHOL, V18, P155, DOI
10.1017/S0954579406060093; Babowitch JD, 2016, J AFFECT DISORDERS, V201, P25, DOI
10.1016/j.jad.2016.04.018; Boman JH, 2014, CRIM JUSTICE BEHAV, V41, P91, DOI
10.1177/0093854813496998; Boman JH, 2014, DEVIANT BEHAV, V35, P555, DOI
10.1080/01639625.2013.863098; Boman JH, 2012, J CRIM JUST, V40, P463, DOI
10.1016/j.jcrimjus.2012.07.003; BRADY EU, 1992, PSYCHOL BULL, V111, P244, DOI
10.1037/0033-2909.111.2.244; Britt CL, 2018, J QUANT CRIMINOL, V34, P591, DOI
10.1007/s10940-017-9346-9; Brown BB, 2004, HDB ADOLESCENT PSYCH, P363, DOI DOI
10.1002/9780471726746.CH12; Buss A.H., 1984, TEMPERAMENT EARLY DE; Cohen GL, 2006,
CHILD DEV, V77, P967, DOI 10.1111/j.1467-8624.2006.00913.x; Cruwys T, 2014, PERS
SOC PSYCHOL REV, V18, P215, DOI 10.1177/1088868314523839; Cruwys T, 2014, J AFFECT
DISORDERS, V159, P139, DOI 10.1016/j.jad.2014.02.019; Cummings CM, 2014, PSYCHOL
BULL, V140, P816, DOI 10.1037/a0034733; Degenhardt L, 2001, ADDICTION, V96, P1603,
DOI 10.1046/j.1360-0443.2001.961116037.x; EMPEY LT, 1982, AM DELINQUENCY ITS M;
ERICKSON ML, 1971, SOC PROBL, V19, P114, DOI 10.1525/sp.1971.19.1.03a00090;
ERICKSON ML, 1977, J CRIM LAW CRIM, V68, P262, DOI 10.2307/1142849; Gardner TW,
2008, J ABNORM CHILD PSYCH, V36, P273, DOI 10.1007/s10802-007-9176-6; Gold M.,
1970, DELINQUENT BEHAV AM; Grant BF, 2004, ARCH GEN PSYCHIAT, V61, P807, DOI
10.1001/archpsyc.61.8.807; Hoeben EM, 2016, J CRIM JUST, V47, P108, DOI
10.1016/j.jcrimjus.2016.08.001; Kaplow JB, 2001, J CLIN CHILD PSYCHOL, V30, P316,
DOI 10.1207/S15374424JCCP3003_4; Kerr M, 2012, J CHILD PSYCHOL PSYC, V53, P826, DOI
10.1111/j.1469-7610.2011.02492.x; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4,
P231, DOI 10.3109/10673229709030550; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142,
P1259; KLEIN MW, 1969, SOCIOL SOC RES, V54, P63; Lai HMX, 2015, DRUG ALCOHOL DEPEN,
V154, P1, DOI 10.1016/j.drugalcdep.2015.05.031; Liu J, 2011, J PSYCHIATR MENT HLT,
V18, P884, DOI 10.1111/j.1365-2850.2011.01743.x; Loeber R, 1999, J CLIN CHILD
PSYCHOL, V28, P322, DOI 10.1207/S15374424jccp280304; Mackie C. J., 2012, DRUG ABUSE
ADDICTION, P275; Matthews T, 2016, SOC PSYCH PSYCH EPID, V51, P339, DOI
10.1007/s00127-016-1178-7; Meldrum RC, 2009, J RES CRIME DELINQ, V46, P353, DOI
10.1177/0022427809335171; Miller HV, 2010, JUSTICE Q, V27, P473, DOI
10.1080/07418820903218974; Mrug S, 2012, J ABNORM CHILD PSYCH, V40, P201, DOI
10.1007/s10802-011-9550-2; Myers MG, 2003, PSYCHOL ADDICT BEHAV, V17, P277, DOI
10.1037/0893-164X.17.4.277; Osgood DW, 1996, AM SOCIOL REV, V61, P635, DOI
10.2307/2096397; Paulhus D. L., 2007, HDB RES METHODS PERS, P224; Pratt TC, 2010,
JUSTICE Q, V27, P765, DOI 10.1080/07418820903379610; Prinstein MJ, 2007, J CLIN
CHILD ADOLESC, V36, P159, DOI 10.1080/15374410701274934; REISS AJ, 1991, J CRIM LAW
CRIM, V82, P360, DOI 10.2307/1143811; Rubin KH, 2009, ANNU REV PSYCHOL, V60, P141,
DOI 10.1146/annurev.psych.60.110707.163642; Sampson R, 2012, GREAT AMERICAN CITY;
Steinberg L, 2007, DEV PSYCHOL, V43, P1531, DOI 10.1037/0012-1649.43.6.1531;
Sweeten G, 2012, J QUANT CRIMINOL, V28, P533, DOI 10.1007/s10940-011-9160-8; Thomas
KJ, 2013, CRIMINOLOGY, V51, P435, DOI 10.1111/1745-9125.12010; Vitaro F, 2000, J
ABNORM CHILD PSYCH, V28, P313, DOI 10.1023/A:1005188108461; Vitulano ML, 2010, J
PSYCHOPATHOL BEHAV, V32, P315, DOI 10.1007/s10862-009-9160-2; Walters KS, 2018, J
CHILD ADOLES SUBST, V27, P103, DOI 10.1080/1067828X.2017.1420507; Ward JT, 2018,
CRIME DELINQUENCY, V64, P510, DOI 10.1177/0011128717707716; Warr M, 1996,
CRIMINOLOGY, V34, P11, DOI 10.1111/j.1745-9125.1996.tb01193.x; Warr M., 2002,
COMPANIONS CRIME SOC; Watts SJ, 2015, YOUTH VIOLENCE JUV J, V13, P190, DOI
10.1177/1541204014523797; Wechsler D., 1974, WECHSLER INTELLIGENC; Wills TA, 2004,
J CLIN CHILD ADOLESC, V33, P69, DOI 10.1207/S15374424JCCP3301_7; Wills TA, 2001,
PSYCHOL ADDICT BEHAV, V15, P118, DOI 10.1037/0893-164X.15.2.118; Yu RQ, 2013, J
PERS, V81, P499, DOI 10.1111/jopy.12027; Zimmerman MA, 1997, J YOUTH ADOLESCENCE,
V26, P117, DOI 10.1023/A:1024596313925 63 0 0 1 1 SAGE
PUBLICATIONS INC THOUSAND OAKS 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
0022-0426 1945-1369 J DRUG ISSUES J. Drug Issues JUL 2019
49 3 450 464 10.1177/0022042619832019
15 Substance Abuse Substance Abuse IC6ZW
WOS:000471122700003 2019-09-25
J Single, A; Bilevicius, E; Johnson, EA; Keough, MT
Single, Alanna; Bilevicius, Elena; Johnson, Edward A.; Keough, Matthew T.
Specific Facets of Trait Mindfulness Reduce Risk for Alcohol and Drug
Use Among First-Year Undergraduate Students MINDFULNESS English
Article Mindfulness; Alcohol use; Drug use;
Young adults; Emotional psychopathology; Longitudinal GENERALIZED ANXIETY DISORDER;
SUBSTANCE USE DISORDERS; COLLEGE-STUDENTS; HEAVY DRINKING; PSYCHOMETRIC PROPERTIES;
IDENTIFICATION TEST; RELAPSE PREVENTION; PSYCHOLOGICAL SYMPTOMS; SELF-MEDICATION;
MARIJUANA USE ObjectivesThe first year of university is associated with the
heaviest alcohol and drug use for young adults. Trait mindfulness decreases risk
for harmful substance use broadly, but less is known about its protective role
against alcohol and drug use during the first year of university. We hypothesized
that specific facets of trait mindfulness (acting with awareness, nonjudging of
inner experience, and nonreactivity to inner experience) would predict reduced
alcohol and drug use among first-year university students. Given that the same
facets of trait mindfulness protect against anxiety and depression (i.e., emotional
psychopathology), we expected low levels of emotional psychopathology to mediate
these effects.MethodsFirst-year undergraduates (N=308) completed online self-
reports in a longitudinal study. Facets of trait mindfulness were assessed at the
beginning of the semester (Time 1). Emotional psychopathology, alcohol use, and
drug use were assessed 4months later (Time 2).ResultsResults revealed that the
acting with awareness, nonjudging of inner experience, and nonreactivity to inner
experience facets predicted decreased alcohol and drug use at Time 2 (controlling
for Time 1 outcomes). These effects were mediated by low levels of emotional
psychopathology.ConclusionsOur study demonstrates that first-year students who are
high in specific facets of trait mindfulness are less likely to experience elevated
emotional psychopathology, and in turn, are less likely to engage in harmful
alcohol and drug use. [Single, Alanna; Bilevicius, Elena; Johnson, Edward A.;
Keough, Matthew T.] Univ Manitoba, Dept Psychol, 190 Dysart Rd, Winnipeg, MB R3T
2N2, Canada Keough, MT (reprint author), Univ Manitoba, Dept Psychol, 190 Dysart
Rd, Winnipeg, MB R3T 2N2, Canada. matthew.keough@umanitoba.ca
Arria AM, 2016, DRUG ALCOHOL DEPEN, V159, P158, DOI
10.1016/j.drugalcdep.2015.12.009; Baer RA, 2006, ASSESSMENT, V13, P27, DOI
10.1177/1073191105283504; Baer RA, 2004, ASSESSMENT, V11, P191, DOI
10.1177/1073191104268029; Baer RA, 2003, CLIN PSYCHOL-SCI PR, V10, P125, DOI
10.1093/clipsy/bpg015; Baer RA, 2008, ASSESSMENT, V15, P329, DOI
10.1177/1073191107313003; Bajaj B, 2016, PERS INDIV DIFFER, V94, P96, DOI
10.1016/j.paid.2016.01.020; Baker TB, 2004, PSYCHOL REV, V111, P33, DOI
10.1037/0033-295X.111.1.33; Bodenlos JS, 2013, J AM COLL HEALTH, V61, P371, DOI
10.1080/07448481.2013.805714; Bohlmeijer E, 2011, ASSESSMENT, V18, P308, DOI
10.1177/1073191111408231; Borsari B, 2007, ADDICT BEHAV, V32, P2062, DOI
10.1016/j.addbeh.2007.01.017; Bowen S, 2014, ADDICT BEHAV, V39, P532, DOI
10.1016/j.addbeh.2013.10.026; Briere FN, 2014, COMPR PSYCHIAT, V55, P526, DOI
10.1016/j.comppsych.2013.10.007; Brown KW, 2003, J PERS SOC PSYCHOL, V84, P822, DOI
10.1037/0022-3514.84.4.822; Brown SA, 2008, PEDIATRICS, V121, pS290, DOI
10.1542/peds.2007-2243D; Calvete E, 2017, PERS INDIV DIFFER, V105, P158, DOI
10.1016/j.paid.2016.09.055; Carmody J, 2008, J BEHAV MED, V31, P23, DOI
10.1007/s10865-007-9130-7; Cooper M. L., 1994, PSYCHOL ASSESSMENT, V6, P117, DOI
[DOI 10.1037/1040-3590.6.2.117, 10.1037/1040-3590.6.2.117]; Costello EJ, 2011, J
CHILD PSYCHOL PSYC, V52, P1015, DOI 10.1111/j.1469-7610.2011.02446.x; Delgadillo J,
2012, DRUG ALCOHOL DEPEN, V125, P37, DOI 10.1016/j.drugalcdep.2012.03.011;
Dvorakova K, 2017, J AM COLL HEALTH, V65, P259, DOI 10.1080/07448481.2017.1278605;
Enders C. K., 2010, APPL MISSING DATA AN; Feldman G, 2007, J PSYCHOPATHOL BEHAV,
V29, P177, DOI 10.1007/s10862-006-9035-8; Fritz MS, 2007, PSYCHOL SCI, V18, P233,
DOI 10.1111/j.1467-9280.2007.01882.x; Giluk TL, 2009, PERS INDIV DIFFER, V47, P805,
DOI 10.1016/j.paid.2009.06.026; Girz L, 2013, APPETITE, V69, P145, DOI
10.1016/j.appet.2013.06.002; Grant BF, 2015, JAMA PSYCHIAT, V72, P757, DOI
10.1001/jamapsychiatry.2015.0584; Grant VV, 2007, ADDICT BEHAV, V32, P2611, DOI
10.1016/j.addbeh.2007.07.004; Hann D, 1999, J PSYCHOSOM RES, V46, P437, DOI
10.1016/S0022-3999(99)00004-5; Hayes AF, 2009, COMMUN MONOGR, V76, P408, DOI
10.1080/03637750903310360; Hofmann SG, 2010, J CONSULT CLIN PSYCH, V78, P169, DOI
10.1037/a0018555; Homel J, 2014, J STUD ALCOHOL DRUGS, V75, P674, DOI
10.15288/jsad.2014.75.674; Hsu SH, 2013, ADDICT BEHAV, V38, P1852, DOI
10.1016/j.addbeh.2012.11.002; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI
10.1080/10705519909540118; Kabat-Zinn J., 1990, FULL CATASTROPHE LIV; Kaloyanides
KB, 2007, PHARMACOTHERAPY, V27, P666, DOI 10.1592/phco.27.5.666; Karyadi KA, 2015,
MINDFULNESS, V6, P1242, DOI 10.1007/s12671-015-0386-7; Karyadi KA, 2014, DRUG
ALCOHOL DEPEN, V143, P1, DOI 10.1016/j.drugalcdep.2014.07.014; Khantzian EJ, 1997,
HARVARD REV PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550; Khoury B, 2013, CLIN
PSYCHOL REV, V33, P763, DOI 10.1016/j.cpr.2013.05.005; Kline R. B., 2013,
SIGNIFICANCE TESTING; Kline R. B., 2010, PRINCIPLES PRACTICE; Knol MJ, 2010, J CLIN
EPIDEMIOL, V63, P728, DOI 10.1016/j.jclinepi.2009.08.028; Koh L, 2005, FLUIDS
BARRIERS CNS, V2, DOI 10.1186/1743-8454-2-6; Kokotailo PK, 2004, ALCOHOL CLIN EXP
RES, V28, P914, DOI 10.1097/01.ALC.0000128239.87611.F5; Kuntsche E, 2005, CLIN
PSYCHOL REV, V25, P841, DOI 10.1016/j.cpr.2005.06.002; Lambdin C, 2012, THEOR
PSYCHOL, V22, P67, DOI 10.1177/0959354311429854; LePera N., 2011, NEW SCH PSYCHOL
B, V8, P15; Levin ME, 2014, PSYCHOL ADDICT BEHAV, V28, P498, DOI 10.1037/a0034706;
Lilja Josefine L., 2011, Cognitive Behaviour Therapy, V40, P291, DOI
10.1080/16506073.2011.580367; Lowe B, 2008, MED CARE, V46, P266, DOI
10.1097/MLR.0b013e318160d093; Martin RJ, 2014, J GAMBL STUD, V30, P321, DOI
10.1007/s10899-013-9367-8; McCabe SE, 2006, J SUBST ABUSE TREAT, V31, P297, DOI
10.1016/j.jsat.2006.04.010; Medvedev ON, 2018, MINDFULNESS, V9, P1757, DOI
10.1007/s12671-018-0917-0; Mermelstein LC, 2015, PSYCHOL ADDICT BEHAV, V29, P259,
DOI 10.1037/adb0000040; Moffitt TE, 2007, ARCH GEN PSYCHIAT, V64, P651, DOI
10.1001/archpsyc.64.6.651; Moreno MA, 2012, ARCH PEDIAT ADOL MED, V166, P157, DOI
10.1001/archpediatrics.2011.180; Morrison R, 2005, J CLIN PSYCHOL, V61, P447, DOI
10.1002/jclp.20021; Murphy C, 2012, PSYCHOPHARMACOLOGY, V219, P527, DOI
10.1007/s00213-011-2573-0; Muthen L. K., 2012, MPLUS USERS GUIDE VE; National
Institute on Drug Abuse, 2009, NIDA MOD ASSIST PRES; Nyklicek I, 2008, ANN BEHAV
MED, V35, P331, DOI 10.1007/s12160-008-9030-2; O'Neill SE, 2001, PSYCHOL ADDICT
BEHAV, V15, P350, DOI 10.1037/0893-164X.15.4.350; Palmer RS, 2012, J COLL STUDENT
DEV, V53, P124, DOI 10.1353/csd.2012.0014; Parkerson HA, 2015, J ANXIETY DISORD,
V31, P38, DOI 10.1016/j.janxdis.2015.01.005; Phelps CL, 2018, DRUG ALCOHOL DEPEN,
V183, P78, DOI 10.1016/j.drugalcdep.2017.10.026; RADLOFF L S, 1977, Applied
Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Ramler TR,
2016, MINDFULNESS, V7, P179, DOI 10.1007/s12671-015-0398-3; Raphiphatthana B, 2016,
PERS INDIV DIFFER, V93, P104, DOI 10.1016/j.paid.2015.08.005; Reese ED, 2015, PERS
INDIV DIFFER, V72, P41, DOI 10.1016/j.paid.2014.08.008; Reynolds A, 2015, ADDICT
BEHAV, V42, P222, DOI 10.1016/j.addbeh.2014.11.027; Roos CR, 2015, PSYCHOL ADDICT
BEHAV, V29, P176, DOI 10.1037/a0038529; Rudkin E, 2018, MINDFULNESS, V9, P230, DOI
10.1007/s12671-017-0766-2; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI
10.1111/j.1360-0443.1993.tb02093.x; Selin KH, 2003, ALCOHOL CLIN EXP RES, V27,
P1428, DOI 10.1097/01.ALC.0000085633.23230.4A; Shadur JM, 2015, DRUG ALCOHOL REV,
V34, P571, DOI 10.1111/dar.12260; Sher KJ, 2007, ADDICT BEHAV, V32, P819, DOI
10.1016/j.addbeh.2006.06.024; SKINNER HA, 1982, ADDICT BEHAV, V7, P363, DOI
10.1016/0306-4603(82)90005-3; Snipes DJ, 2015, ADDICT BEHAV, V41, P136, DOI
10.1016/j.addbeh.2014.10.010; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI
10.1001/archinte.166.10.1092; Stappenbeck CA, 2010, ADDICT BEHAV, V35, P479, DOI
10.1016/j.addbeh.2009.12.027; Thygesen LC, 2008, ADDICTION, V103, P1149, DOI
10.1111/j.1360-0443.2008.02241.x; Walach H, 2006, PERS INDIV DIFFER, V40, P1543,
DOI 10.1016/j.paid.2005.11.025; Waszczuk MA, 2016, PSYCHOL MED, V46, P161, DOI
10.1017/S0033291715001634; Weiss NH, 2018, ADDICT BEHAV, V79, P131, DOI
10.1016/j.addbeh.2017.12.015; White AM, 2006, ALCOHOL CLIN EXP RES, V30, P1006, DOI
10.1111/j.1530-0277.2006.00122.x; White HR, 2005, J DRUG ISSUES, V35, P281, DOI
10.1177/002204260503500204; White IR, 2010, STAT MED, V29, P2920, DOI
10.1002/sim.3944; Witkiewitz K, 2005, J COGN PSYCHOTHER, V19, P211, DOI
10.1891/088983905780907522; Witkiewitz K, 2013, ADDICT BEHAV, V38, P1563, DOI
10.1016/j.addbeh.2012.04.001; Yang L., 2015, LIB INFORM, V1, P15; Yudko E, 2007, J
SUBST ABUSE TREAT, V32, P189, DOI 10.1016/j.jsat.2006.08.002; Zgierska A, 2009,
SUBST ABUS, V30, P266, DOI 10.1080/08897070903250019; Zhao XS, 2010, J CONSUM RES,
V37, P197, DOI 10.1086/651257 93 0 0 4 4 SPRINGER DORDRECHT
VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS 1868-8527 1868-
8535 MINDFULNESS Mindfulness JUL 2019 10 7
1269 1279 10.1007/s12671-019-1092-7 11 Psychology,
Clinical; Psychiatry Psychology; Psychiatry IC3CM WOS:000470836600007
2019-09-25
J Cannella, LA; McGary, H; Ramirez, SH Cannella, Lee
Anne; McGary, Hannah; Ramirez, Servio H. Brain interrupted: Early life
traumatic brain injury and addiction vulnerability EXPERIMENTAL NEUROLOGY
English Review Early-life traumatic
brain injury; Neuroinflammation; Substance use disorders; Addiction; Animal models
of addiction MEDIAL PREFRONTAL CORTEX; SUBSTANCE USE; NUCLEUS-ACCUMBENS;
PSYCHIATRIC-DISORDERS; RESPONSE-INHIBITION; ALCOHOL-CONSUMPTION; SELF-MEDICATION;
MILD; OUTCOMES; CHILDHOOD Recent reports provide evidence for increased risk of
substance use disorders (SUD) among patients with a history of early-life traumatic
brain injury (TBI). Preclinical research utilizing animal models of TBI have
identified injury-induced inflammation, blood-brain barrier permeability, and
changes to synapses and neuronal networks within regions of the brain associated
with the perception of reward. Importantly, these reward pathway networks are
underdeveloped during childhood and adolescence, and early-life TBI pathology may
interrupt ongoing maturation. As such, maladaptive changes induced by juvenile
brain injury may underlie increased susceptibility to SUD. In this review, we
describe the available clinical and preclinical evidence that identifies SUD as a
persistent psychiatric consequence of pediatric neurotrauma by discussing (1) the
incidence of early-life TBI, (2) how preclinical studies model TBI and SUD, (3)
TBI-induced neuropathology and neuroinflammation in the corticostriatal regions of
the brain, and (4) the link between childhood or adolescent TBI and addiction in
adulthood. In summary, preclinical research utilizes an innovative combination of
models of early-life TBI and SUD to recapitulate clinical features and to determine
how TBI promotes a risk for the development of SUD. However, causal processes that
link TBI and SUD remain unclear. Additional research to identify and
therapeutically target underlying mechanisms of aberrant reward pathway development
will provide a launching point for TBI and SUD treatment strategies. [Cannella,
Lee Anne; McGary, Hannah; Ramirez, Servio H.] Temple Univ, Lewis Katz Sch Med, Dept
Pathol & Lab Med, 3500 N Broad St MERB 844, Philadelphia, PA 19140 USA; [Cannella,
Lee Anne; Ramirez, Servio H.] Temple Univ, Lewis Katz Sch Med, Ctr Subst Abuse Res,
Philadelphia, PA 19140 USA; [Ramirez, Servio H.] Temple Univ, Lewis Katz Sch Med,
Shriners Hosp Pediat Res Ctr, Philadelphia, PA 19140 USA Ramirez, SH (reprint
author), Temple Univ, Lewis Katz Sch Med, Dept Pathol & Lab Med, 3500 N Broad St
MERB 844, Philadelphia, PA 19140 USA. servio@temple.edu ramirez,
servio/0000-0002-4609-5653 National Institutes of Health/National Institute on
Drug Abuse (NIH/NIDA)United States Department of Health & Human ServicesNational
Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [P30
DA013429-16, R01DA046833 01, T32 DA007237]; NIH/National Institute of Neurological
Disorders and Stroke (NINDS)United States Department of Health & Human
ServicesNational Institutes of Health (NIH) - USANIH National Institute of
Neurological Disorders & Stroke (NINDS) [R01 NS086570-01]; PA-CURE program
(Pennsylvania Department of Health) The authors acknowledge funding support from
the National Institutes of Health/National Institute on Drug Abuse (NIH/NIDA) P30
DA013429-16 (SHR), R01DA046833 01 (SHR), T32 DA007237 (LAC), NIH/National Institute
of Neurological Disorders and Stroke (NINDS), R01 NS086570-01 (SHR), and the PA-
CURE program (Pennsylvania Department of Health). Anderson VA, 2006,
NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Badanich KA, 2006, EUR J
PHARMACOL, V550, P95, DOI 10.1016/j.ejphar.2006.08.034; Badaut J, 2015,
NEUROSCIENCE, V285, P215, DOI 10.1016/j.neuroscience.2014.10.035; Baumann CR, 2007,
BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2009, ANN NEUROL, V66,
P555, DOI 10.1002/ana.21836; Baumann CR, 2005, NEUROLOGY, V65, P147, DOI
10.1212/01.wnl.0000167605.02541.f2; Beauchamp MH, 2011, INT J DEV NEUROSCI, V29,
P137, DOI 10.1016/j.ijdevneu.2010.12.003; Beschorner R, 2002, ACTA NEUROPATHOL,
V103, P541, DOI 10.1007/s00401-001-0503-7; Cannella L. A., 2019, J NEUROTRAU IN
PRESS; Chen Yuan-Hao, 2018, Oncotarget, V9, P10016, DOI 10.18632/oncotarget.24245;
Chen YH, 2017, NEUROSCIENCE, V348, P180, DOI 10.1016/j.neuroscience.2017.02.001;
Columbia C., 2012, AB VIRT INSTR, P1; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76,
P302, DOI 10.1016/S0003-9993(95)80654-7; Corrigan JD, 2013, ARCH PHYS MED REHAB,
V94, P1940, DOI 10.1016/j.apmr.2013.05.018; Corrigan JD, 2012, BRAIN INJURY, V26,
P139, DOI 10.3109/02699052.2011.648705; Corso P, 2006, INJURY PREV, V12, P212, DOI
10.1136/ip.2005.010983; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI
10.1007/s002590000308; Elliott JE, 2018, SLEEP, V41, DOI 10.1093/sleep/zsx212;
Fadel J, 2002, NEUROSCIENCE, V111, P379, DOI 10.1016/S0306-4522(02)00017-9; Faul M,
2010, TRAUMATIC BRAIN INJU; Felde AB, 2005, BRAIN INJURY, V20, P41, DOI
10.1080/02699050500309718; Fishbein D, 2016, INT J OFFENDER THER, V60, P575, DOI
10.1177/0306624X14554778; Forsyth JK, 2017, TRENDS COGN SCI, V21, P760, DOI
10.1016/j.tics.2017.06.006; Frieden T. R., 2015, REPORT C TRAUMATIC B; Fukuda AM,
2012, NEUROSCIENCE, V222, P366, DOI 10.1016/j.neuroscience.2012.06.033;
GARCIAESTRADA J, 1993, BRAIN RES, V628, P271, DOI 10.1016/0006-8993(93)90964-O;
Gentile TA, 2018, ADDICT BIOL, V23, P247, DOI 10.1111/adb.12507; Gill J, 2018,
NEUROLOGY, V91, pE1385, DOI 10.1212/WNL.0000000000006321; Gogtay N, 2004, P NATL
ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Goldstein FC, 2017, J
NEUROTRAUM, V34, P115, DOI 10.1089/neu.2015.4313; GOLDSTEIN LB, 1993, J NEURAL
TRANSP PLAS, V4, P175, DOI 10.1155/NP.1993.175; Groman SM, 2009, NEUROSCI BIOBEHAV
R, V33, P690, DOI 10.1016/j.neubiorev.2008.08.008; Haarbauer-Krupa J, 2017, J HEAD
TRAUMA REHAB, V32, P367, DOI 10.1097/HTR.0000000000000287; Hall DH, 2007, J
PSYCHOACTIVE DRUGS, V39, P151, DOI 10.1080/02791072.2007.10399873; Harris GC, 2005,
NATURE, V437, P556, DOI 10.1038/nature04071; Hartley CA, 2015, CURR OPIN BEHAV SCI,
V5, P108, DOI 10.1016/j.cobeha.2015.09.004; Hehar H, 2015, PLOS ONE, V10, DOI
10.1371/journal.pone.0139842; Howell DR, 2018, AM J SPORT MED, V46, P3254, DOI
10.1177/0363546518796830; Ichkova A, 2017, NEUROCHEM INT, V111, P93, DOI
10.1016/j.neuint.2017.03.022; Ilie G, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-
011824; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Karelina K,
2018, BRAIN BEHAV IMMUN, V69, P532, DOI 10.1016/j.bbi.2018.01.012; Karelina K,
2017, EXP NEUROL, V297, P110, DOI 10.1016/j.expneurol.2017.08.003; Kennedy E, 2017,
EUR CHILD ADOLES PSY, V26, P1197, DOI 10.1007/s00787-017-0975-1; Kim HJ, 2017, MOL
PSYCHIATR, V22, P1576, DOI 10.1038/mp.2016.103; Kogachi S, 2017, BRAIN STRUCT
FUNCT, V222, P215, DOI 10.1007/s00429-016-1212-2; Kopec AM, 2018, NAT COMMUN, V9,
DOI 10.1038/s41467-018-06118-z; Kozak K, 2019, ANN NY ACAD SCI, V1451, P71, DOI
10.1111/nyas.13977; Kraus MF, 2005, BRAIN INJURY, V19, P471, DOI
10.1080/02699050400025059; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI
10.1097/00001199-200609000-00001; Lawrence AJ, 2009, PSYCHOPHARMACOLOGY, V207,
P163, DOI 10.1007/s00213-009-1645-x; Ley EJ, 2013, J TRAUMA ACUTE CARE, V75, P682,
DOI 10.1097/TA.0b013e31829d024f; Lim MM, 2013, SCI TRANSL MED, V5, DOI
10.1126/scitranslmed.3007092; Lim YW, 2015, PLOS ONE, V10, DOI
10.1371/journal.pone.0125130; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI
10.1016/j.nurt.2010.07.002; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI
10.2147/NDT.S65815; Lu XY, 2016, WORLD NEUROSURG, V90, P199, DOI
10.1016/j.wneu.2016.02.110; Lutton EM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-
017-03309-4; Martin-Fardon R, 2018, ADDICT BIOL, V23, P6, DOI 10.1111/adb.12441;
Max JE, 2015, J NEUROPSYCH CLIN N, V27, P112, DOI 10.1176/appi.neuropsych.13080190;
Mayeux JP, 2015, BEHAV BRAIN RES, V279, P22, DOI 10.1016/j.bbr.2014.10.053;
McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; McHugo GJ,
2017, J HEAD TRAUMA REHAB, V32, pE65, DOI 10.1097/HTR.0000000000000249; McKinlay A,
2014, J HEAD TRAUMA REHAB, V29, P498, DOI 10.1097/HTR.0000000000000001; McKinlay A,
2009, J HEAD TRAUMA REHAB, V24, P221, DOI 10.1097/HTR.0b013e3181a40590; Meadows EA,
2017, J INT NEUROPSYCH SOC, V23, P451, DOI 10.1017/S1355617717000352; Merkel SF,
2017, CELL TRANSPLANT, V26, P1178, DOI 10.1177/0963689717714341; Merkel SF, 2017,
NEUROSCI BIOBEHAV R, V77, P209, DOI 10.1016/j.neubiorev.2017.03.015; Merkel SF,
2017, J NEUROTRAUM, V34, P165, DOI 10.1089/neu.2015.4275; Miller SC, 2013, AM J
PSYCHIAT, V170, P383, DOI 10.1176/appi.ajp.2012.12010126; Muelbl MJ, 2018, SCI REP-
UK, V8, DOI 10.1038/s41598-018-28062-0; Mychasiuk R, 2015, NEUROSCIENCE, V288,
P145, DOI 10.1016/j.neuroscience.2014.12.034; Mychasiuk R, 2014, BEHAV BRAIN RES,
V259, P284, DOI 10.1016/j.bbr.2013.10.048; Naneix F, 2012, J NEUROSCI, V32, P16223,
DOI 10.1523/JNEUROSCI.3080-12.2012; Narad ME, 2018, JAMA PEDIATR, V172, P437, DOI
10.1001/jamapediatrics.2017.5746; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI
10.1016/j.brainres.2005.09.011; Paolicelli RC, 2011, SCIENCE, V333, P1456, DOI
10.1126/science.1202529; Parry-Jones BL, 2006, NEUROPSYCHOL REHABIL, V16, P537, DOI
10.1080/09602010500231875; Perez EJ, 2016, NEUROBIOL DIS, V94, P73, DOI
10.1016/j.nbd.2016.06.007; Perron Brian E, 2008, Crim Behav Ment Health, V18, P243,
DOI 10.1002/cbm.702; Prince C, 2017, BRAIN SCI, V7, DOI 10.3390/brainsci7080105;
Rhine T, 2018, J HEAD TRAUMA REHAB, V33, P210, DOI 10.1097/HTR.0000000000000319;
Rodriguez-Grande B, 2018, GLIA, V66, P1663, DOI 10.1002/glia.23336; ROOF RL, 1993,
BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Ryan NP, 2018, PSYCHOL
MED, V48, P679, DOI 10.1017/S0033291717002057; SAMHSA Center for Behavioral Health
Statistics
and Quality, 2015, SDUH SER; Schachar R, 2004, DEV NEUROPSYCHOL, V25, P179, DOI
10.1207/s15326942dn2501&2_10; SCHENK S, 1991, BRAIN RES, V543, P227, DOI
10.1016/0006-8993(91)90032-Q; Schmithorst VJ, 2010, BRAIN COGNITION, V72, P16, DOI
10.1016/j.bandc.2009.06.005; Scott C, 2015, NEUROPSYCHOLOGY, V29, P501, DOI
10.1037/neu0000074; Semple BD, 2017, BEHAV BRAIN RES, V319, P48, DOI
10.1016/j.bbr.2016.10.045; Semple BD, 2015, NEUROBIOL DIS, V74, P263, DOI
10.1016/j.nbd.2014.12.003; Shah S, 2012, BRAIN INJURY, V26, P201, DOI
10.3109/02699052.2012.654591; Skopin MD, 2015, J NEUROTRAUM, V32, P289, DOI
10.1089/neu.2014.3664; Tau GZ, 2010, NEUROPSYCHOPHARMACOL, V35, P147, DOI
10.1038/npp.2009.115; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI
10.15585/mmwr.ss6609a1; Thomasy Hannah E, 2017, Neurobiol Sleep Circadian Rhythms,
V2, P71, DOI 10.1016/j.nbscr.2016.03.001; Vaughn M. G., 2018, PSYCHIAT Q; Vaughn
MG, 2014, CRIM BEHAV MENT HEAL, V24, P188, DOI 10.1002/cbm.1900; Vonder Haar C.,
2018, EUR J NEUROSCI, P1; Wade SL, 2017, ARCH PHYS MED REHAB, V98, P1614, DOI
10.1016/j.apmr.2017.03.006; Wade SL, 2016, JAMA PEDIATR, V170, P343, DOI
10.1001/jamapediatrics.2015.4485; Wake H, 2013, TRENDS NEUROSCI, V36, P209, DOI
10.1016/j.tins.2012.11.007; Walker DM, 2017, J NEUROSCI, V37, P10855, DOI
10.1523/JNEUROSCI.1834-17.2017; Walker KR, 2013, FRONT AGING NEUROSCI, V5, DOI
10.3389/fnagi.2013.00029; Washington PM, 2012, J NEUROTRAUM, V29, P2283, DOI
10.1089/neu.2012.2456; Weil ZM, 2016, J NEUROTRAUM, V33, P895, DOI
10.1089/neu.2015.3953; Weil ZM, 2016, NEUROSCI BIOBEHAV R, V62, P89, DOI
10.1016/j.neubiorev.2016.01.005; WEISS RD, 1992, AM J DRUG ALCOHOL AB, V18, P121,
DOI 10.3109/00952999208992825; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24,
P324, DOI 10.1097/HTR.0b013e3181a712aa; Williams WH, 2018, LANCET PSYCHIAT, V5,
P836, DOI 10.1016/S2215-0366(18)30062-2; Wills T.A., 1996, ADV CLIN CHILD PSYCH,
V18; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yeates KO,
2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; Yu FS, 2017, J NEUROTRAUM,
V34, P1364, DOI 10.1089/neu.2016.4569; Zakharova E, 2009, PHARMACOL BIOCHEM BE,
V92, P131, DOI 10.1016/j.pbb.2008.11.002; Zhao J, 2018, J NEUROTRAUM, V35, P149,
DOI 10.1089/neu.2016.4898 117 0 0 0 0 ACADEMIC PRESS INC
ELSEVIER SCIENCE SAN DIEGO 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
0014-4886 1090-2430 EXP NEUROL Exp. Neurol. JUL 2019 317
191 201 10.1016/j.expneurol.2019.03.003
11 Neurosciences Neurosciences & Neurology IC2PY
WOS:000470803400018 30862466 2019-09-25
J Ramirez-Castillo, D; Garcia-Roda, C; Guell, F; Fernandez-Montalvo, J;
Bernacer, J; Moron, I Ramirez-Castillo, David; Garcia-Roda,
Carlos; Guell, Francisco; Fernandez-Montalvo, Javier; Bernacer, Javier; Moron,
Ignacio Frustration Tolerance and Personality Traits in Patients
With Substance Use Disorders FRONTIERS IN PSYCHIATRY English
Article substance addiction; frustration
tolerance; ambulatory treatment; MCMI-III; therapeutic community DISTRESS
TOLERANCE; ADULT ATTACHMENT; DISORGANIZED ATTACHMENT; EMOTIONAL REACTIVITY; CHILD
ATTACHMENT; ALCOHOL-USE; ADDICTION; ABUSE; ANXIETY; RELAPSEPrevious research has
suggested the prevalence of certain personality traits, some of which are related
to a disorganized attachment, in substance abuse disorders. Further, frustration
tolerance (FT) has been proposed as an important factor in addiction, both at the
inception-following the "self-medication" hypothesis-and regarding treatment
compliance. In turn, an inadequate response to frustrating events has been also
associated with a disrupted attachment. Our goal is to explore the mediational role
of FT in the relationship between personality traits and two different treatments
for substance addiction: therapeutic community (TC) and ambulatory treatment (AT).
Eighty-four subjects with substance abuse disorder were recruited in total (22
female), including 46 volunteers (13 female) in TC and 38 (9 female) in AT. They
were assessed with Rosenzweig's test for FT and the Millon Clinical Multiaxial
Inventory-III (MCMI-III) test to evaluate personality factors. By comparing with a
control sample (335 volunteers, 268 female), we found that FT was lower in
patients. Between therapeutic groups, FT was significantly lower in TC. Depressive,
antisocial, sadistic, negativistic, schizotypal, borderline, paranoid, anxiety,
dysthymia, alcohol use, drug use, posttraumatic stress disorder (PTSD), thought
disorder, and delusional disorder traits were suggestive of pathology in the
clinical samples and were significantly different between control, AT, and TC
groups. Further, anxiety and PTSD traits were higher in TC than in AT. A
mediational analysis revealed that the effect of anxiety and PTSD scales on
therapeutic group was partially mediated by FT. In conclusion, FT and its interplay
with personality traits commonly related to disorganized attachment (anxiety and
PTSD) might be important factors to consider within therapeutic programs for
persons with substance addiction. [Ramirez-Castillo, David; Garcia-Roda, Carlos;
Guell, Francisco; Bernacer, Javier] Univ Navarra, Inst Culture & Soc, Mind Brain
Grp, Pamplona, Spain; [Ramirez-Castillo, David; Garcia-Roda, Carlos] Univ Navarra,
Fac Educ & Psychol, Pamplona, Spain; [Ramirez-Castillo, David; Fernandez-Montalvo,
Javier] Univ Publ Navarra, Dept Hlth Sci, Pamplona, Spain; [Moron, Ignacio] Univ
Granada, Dept Psychobiol, Granada, Spain; [Moron, Ignacio] Univ Granada, Res Ctr
Mind Brain & Behav CIMCYC, Granada, Spain Bernacer, J (reprint author), Univ
Navarra, Inst Culture & Soc, Mind Brain Grp, Pamplona, Spain. jbernacer@unav.es
Fernandez-Montalvo, Javier/C-1782-2008; Bernacer, Javier/P-5810-2014
Fernandez-Montalvo, Javier/0000-0001-5946-1934; Bernacer, Javier/0000-0002-
4341-9763 Fundacion Caja de Ahorros de Navarra [70721]; Spanish Ministerio de
Sanidad, Servicios Sociales e Igualdad [2016/057] The authors are grateful to
Drs. Gonzalo Arrondo, Maite Aznarez, and Jose Ignacio Murillo for their technical
and theoretical advice on this research. We also acknowledge the collaboration of
the users and personnel of Fundacion Proyecto Hombre Navarra and Asociacion
Proyecto Hombre Granada for making possible this research. This project was funded
by Fundacion Caja de Ahorros de Navarra (grant number 70721) and the Spanish
Ministerio de Sanidad, Servicios Sociales e Igualdad (2016/057). Aaronson CJ, 2006,
PSYCHIAT QUART, V77, P69, DOI 10.1007/s11126-006-7962-x; Abuelgasim AI, 2015, INT J
ADV APPL SCI, V2, P1; Ainsworth M. D., 2015, PATTERNS ATTACHMENT, DOI
[10.4324/9780203758045, DOI 10.4324/9780203758045]; AMSEL A, 1992, PSYCHOL BULL,
V112, P396, DOI 10.1037/0033-2909.112.3.396; Baars MY, 2013, NEUROPSYCHOBIOLOGY,
V67, P241, DOI 10.1159/000350483; Bakermans-Kranenburg MJ, 2009, ATTACH HUM DEV,
V11, P223, DOI 10.1080/14616730902814762; Baumeister RF, 1996, PSYCHOL INQ, V7, P1,
DOI 10.1207/s15327965pli0701_1; Baumeister RF, 2018, PERSPECT PSYCHOL SCI, V13,
P141, DOI 10.1177/1745691617716946; Benoit Diane, 2004, Paediatr Child Health, V9,
P541; Bifulco Antonia, 2019, Br J Clin Psychol, DOI 10.1111/bjc.12221; Bjork JM,
2008, NEUROIMAGE, V42, P1609, DOI 10.1016/j.neuroimage.2008.06.035; BOWLBY J, 1958,
INT J PSYCHOANAL, V39, P350; Brown RA, 2002, J ABNORM PSYCHOL, V111, P180, DOI
10.1037//0021-843X.111.1.180; Chen GL, 2006, INT J OFFENDER THER, V50, P306, DOI
10.1177/0306624X05279038; CICCHETTI D, 1995, ADV CLIN CHILD PSYCH, V17, P1;
Cirasola A, 2017, PERSONAL MENT HEALTH, V11, P77, DOI 10.1002/pmh.1365; Cosci F,
2015, EXP CLIN PSYCHOPHARM, V23, P464, DOI 10.1037/pha0000048; Craig R, 2005, NEW
DIRECTIONS INTER, P71; Craig RJ, 1997, SUBST USE MISUSE, V32, P1385, DOI
10.3109/10826089709039384; Dakwar E, 2016, CURR PSYCHIAT REP, V18, DOI
10.1007/s11920-016-0703-4; Daughters SB, 2005, J ABNORM PSYCHOL, V114, P729, DOI
10.1037/0021-843X.114.4.729; Daughters SB, 2005, PSYCHOL ADDICT BEHAV, V19, P208,
DOI 10.1037/0893-164X.19.2.208; De Wilde J, 2006, INT J SOC WELF, V15, P150, DOI
10.1111/j.1468-2397.2006.00374.x; Delmonico RL, 1998, J HEAD TRAUMA REHAB, V13,
P10, DOI 10.1097/00001199-199812000-00004; Dollard J., 1939, FRUSTRATION AGGRESS,
DOI [10.1037/10022-000, DOI 10.1037/10022-000]; DORSHAV NK, 1990, J GEN PSYCHOL,
V117, P47, DOI 10.1080/00221309.1990.9917772; Dozier M., 2008, HDB ATTACHMENT
THEOR, V2, P718; Eiden RD, 2011, J STUD ALCOHOL DRUGS, V72, P926, DOI
10.15288/jsad.2011.72.926; Ellis, 2012, ESSENTIAL GUIDE EFFE, DOI
[10.1017/CBO9780511761676, DOI 10.1017/CBO9780511761676]; Ellis A, 2010, CURRENT
PSYCHOTHERAP, P196; Enlow MB, 2014, DEV PSYCHOPATHOL, V26, P41, DOI
10.1017/S0954579413000515; Fernandez-Montalvo J, 2008, SUBST USE MISUSE, V43,
P1362, DOI 10.1080/10826080801922231; Fernandez-Serrano MJ, 2011, NEUROSCI BIOBEHAV
R, V35, P377, DOI 10.1016/j.neubiorev.2010.04.008; Fonagy P, 2010, PSYCHODYNAMIC
PSYCHO, P37; Franz CE, 2014, AM J GERIAT PSYCHIAT, V22, P1603, DOI
10.1016/j.jagp.2014.02.003; Fuller JR, 2010, BEHAV COGN PSYCHOTH, V38, P485, DOI
10.1017/S1352465810000019; Gidhagen Y, 2018, PSYCHOL PSYCHOTHER-T, V91, P490, DOI
10.1111/papt.12172; Glassman LH, 2016, J RATION-EMOT COGN-B, V34, P87, DOI
10.1007/s10942-015-0224-9; Gomez A, 2005, J STUD ALCOHOL, V66, P305, DOI
10.15288/jsa.2005.66.305; Grant BF, 2004, ARCH GEN PSYCHIAT, V61, P807, DOI
10.1001/archpsyc.61.8.807; Herr N.R., 2016, MEDIATION DICHOTOMOU; Hiebler-Ragger M,
2016, PSYCHOPATHOLOGY, V49, P341, DOI 10.1159/000448177; HODDING GC, 1980, WESTERN
J MED, V133, P383; Humeniuk R, 2008, ADDICTION, V103, P1039, DOI 10.1111/j.1360-
0443.2007.02114.x; Jacobsen LK, 2001, AM J PSYCHIAT, V158, P1184, DOI
10.1176/appi.ajp.158.8.1184; Jacobsen T, 1997, J GENET PSYCHOL, V158, P411, DOI
10.1080/00221329709596679; Kahn-Greene ET, 2006, PERS INDIV DIFFER, V41, P1433, DOI
10.1016/j.paid.2006.06.002; Kant CK, 2012, INT J PSYCHOSOC REHA, V16, P50; Kaplan
C, 2003, INT J SOC WELF, V12, P204; Karoly HC, 2015, ALCOHOL CLIN EXP RES, V39,
P2073, DOI 10.1111/acer.12884; Kenny B, 2018, RETHINK INT DEV, P1, DOI 10.1007/978-
3-319-69551-8_1; Kerns KA, 2007, ATTACH HUM DEV, V9, P33, DOI
10.1080/14616730601151441; Kerns KA, 2014, CHILD DEV PERSPECT, V8, P12, DOI
10.1111/cdep.12054; Knott V, 2008, ADDICT BEHAV, V33, P616, DOI
10.1016/j.addbeh.2007.11.006; Koob GF, 2015, EUR J PHARMACOL, V753, P73, DOI
10.1016/j.ejphar.2014.11.044; Koob GF, 2014, NEUROPHARMACOLOGY, V76, P370, DOI
10.1016/j.neuropharm.2013.05.024; Lilienfeld SO, 2000, PSYCHOL SCI, P27, DOI
10.1111/1529-1006.002; Lopez-Goni JJ, 2017, J SUBST ABUSE TREAT, V76, P28, DOI
10.1016/j.jsat.2017.02.014; MACKINNON DP, 1993, EVALUATION REV, V17, P144, DOI
10.1177/0193841X9301700202; Magor-Blatch LE, 2014, MENTAL HLTH SUBSTANC, V7, P110,
DOI [10.1080/17523281.2013.806345, DOI 10.1080/17523281.2013.806345]; Manzo L,
2015, BEHAV BRAIN RES, V278, P90, DOI 10.1016/j.bbr.2014.09.017; McLellan AT, 2000,
JAMA-J AM MED ASSOC, V284, P1689, DOI 10.1001/jama.284.13.1689; MILLER L, 1991, J
SUBST ABUSE TREAT, V8, P277, DOI 10.1016/0740-5472(91)90051-B; MILLER L, 1990, J
SUBST ABUSE TREAT, V7, P31, DOI 10.1016/0740-5472(90)90034-N; Millon T, 2004,
COMPREHENSIVE HDB PS, V2; Oltean HR, 2019, INT J PSYCHOL, V54, P495, DOI
10.1002/ijop.12492; Paetzold RL, 2015, REV GEN PSYCHOL, V19, P146, DOI
10.1037/gpr0000042; Papini MR, 2003, BRAIN BEHAV EVOLUT, V62, P83, DOI
10.1159/000072439; Patock-Peckham JA, 2010, J STUD ALCOHOL DRUGS, V71, P95, DOI
10.15288/jsad.2010.71.95; Perlman SB, 2014, NEUROIMAGE, V85, P326, DOI
10.1016/j.neuroimage.2013.04.057; Psaros C, 2012, ARCH WOMEN MENT HLTH, V15, P15,
DOI 10.1007/s00737-011-0250-2; Riggs SA, 2007, DEV PSYCHOPATHOL, V19, P263, DOI
10.1017/S0954579407070149; ROSENZWEIG S, 1945, J PERS, V14, P3, DOI 10.1111/j.1467-
6494.1945.tb01036.x; ROSENZWEIG S, 1977, J PERS ASSESS, V41, P578, DOI
10.1207/s15327752jpa4106_1; ROSENZWEIG S, 1975, J PERS ASSESS, V39, P3, DOI
10.1207/s15327752jpa3901_1; Ross S, 2003, AM J DRUG ALCOHOL AB, V29, P263, DOI
10.1081/ADA-120020511; Sarkar J., 2012, ADV PSYCHIAT TREAT, V18, P162; Schindler A,
2015, SUBST ABUS, V36, P304, DOI 10.1080/08897077.2014.983586; Shaver PR, 2007, HDB
EMOTION REGULATI; Skinstad AH, 2001, AM J DRUG ALCOHOL AB, V27, P45, DOI
10.1081/ADA-100103118; Solar A, 2012, AUSTRALAS PSYCHIATRY, V20, P356, DOI
10.1177/1039856212449674; Sroufe L. A., 1995, DEV PSYCHOPATHOL, V1, P581; SROUFE
LA, 1986, J CHILD PSYCHOL PSYC, V27, P841, DOI 10.1111/j.1469-7610.1986.tb00203.x;
Stovall-McClough KC, 2006, J CONSULT CLIN PSYCH, V74, P219, DOI 10.1037/0022-
006X.74.2.219; Timko C, 2016, J SUBST ABUSE TREAT, V70, P64, DOI
10.1016/j.jsat.2016.07.010; Torres LB, 2005, SALUD MENT, V28, P61; Torres S, 2016,
QUAL QUANT METHODS L, P71; Unterrainer HF, 2016, BRAIN IMAGING BEHAV, V10, P1096,
DOI 10.1007/s11682-015-9475-4; Unterrainer HF, 2017, FRONT HUM NEUROSCI, V11, DOI
10.3389/fnhum.2017.00208; van Ijzendoorn MH, 1999, DEV PSYCHOPATHOL, V11, P225, DOI
10.1017/S0954579499002035; Volkow ND, 2001, AM J PSYCHIAT, V158, P1181, DOI
10.1176/appi.ajp.158.8.1181; Waltman D, 1995, J SUBST ABUSE TREAT, V12, P429, DOI
10.1016/0740-5472(95)02018-7; WASHTON AM, 1988, J CLIN PSYCHIAT, V49, P34; Wedekind
D, 2013, SUBST ABUSE TREAT PR, V8, DOI 10.1186/1747-597X-8-1; Wei MF, 2005, J COUNS
PSYCHOL, V52, P14, DOI 10.1037/0022-0167.52.1.14; Westen D, 2006, J CONSULT CLIN
PSYCH, V74, P1065, DOI 10.1037/0022-006X.74.6.1065; Williams CL, 2015, ADDICT
BEHAV, V50, P89, DOI 10.1016/j.addbeh.2015.06.025; Winward JL, 2014, ALCOHOL CLIN
EXP RES, V38, P1761, DOI 10.1111/acer.12415; Ziegler DJ, 2004, PSYCHOL REP, V94,
P1009 99 0 0 3 3 FRONTIERS MEDIA SA LAUSANNE AVENUE DU
TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND 1664-0640 FRONT
PSYCHIATRY Front. Psychiatry JUN 14 2019 10
421 10.3389/fpsyt.2019.00421 12 Psychiatry
Psychiatry ID7VS WOS:000471891500001 31258496 DOAJ Gold
2019-09-25
J Kun, B; Urban, R; Paksi, B; Griffiths, MD; Richman, MJ; Demetrovics, Z
Kun, Bernadette; Urban, Robert; Paksi, Borbala; Griffiths, Mark D.;
Richman, Mara J.; Demetrovics, Zsolt The Effects of Trait
Emotional Intelligence on Adolescent Substance Use: Findings From a Hungarian
Representative Survey FRONTIERS IN PSYCHIATRY English Article
emotional intelligence; adolescent substance use;
adolescent drug use; adolescent alcohol use; adolescent tobacco use SELF-
MEDICATION HYPOTHESIS; SMOKING RISK-FACTORS; USE DISORDERS; ALCOHOL-USE; DRUG-USE;
SENSATION SEEKING; QUOTIENT INVENTORY; UNITED-STATES; CANNABIS USE; SHORT-FORM
Previous research has emphasized the importance of emotions in the
development of adult and adolescent substance use. There is substantial evidence
for deficits in emotional processing among teenagers with substance use, but few
studies have investigated the association between emotional intelligence and
adolescent substance use. The aim of the present study was to examine the
relationship between the use of tobacco, alcohol, and illicit drugs and level of
emotional intelligence among adolescents. A representative sample of high school
students participated in the study (N = 2,380). Substance use patterns were
assessed using data from the European School Survey Project on Alcohol and Other
Drugs (ESPAD) Survey, and emotional intelligence was assessed with the Bar-On
Emotional Quotient Inventory Youth Version. Self-esteem and depressive
symptomatology were also assessed to compare their effects on the frequency of
substance use with the effect of emotional intelligence. Results demonstrated that
greater difficulty in stress management and empathy predicted a higher frequency of
tobacco, alcohol, and cannabis use. However, the level of emotional intelligence
showed only a weak relationship to substance use habits. Latent profile analyses
supported the hypothesis that different emotional patterns and problems underlie
different types of psychoactive substances. Using a multiple linear regression
model, the present study found that although emotional intelligence is not a key
factor underlying substance use habits, it has an individual effect on substance
use beyond depressive tendencies and self-esteem. These results can be applied to
both drug prevention programs and interventions in substance abuse treatment.
[Kun, Bernadette; Urban, Robert; Demetrovics, Zsolt] Eotvos Lorand Univ, Inst
Psychol, Budapest, Hungary; [Paksi, Borbala] Eotvos Lorand Univ, Inst Educ,
Budapest, Hungary; [Griffiths, Mark D.] Nottingham Trent Univ, Dept Psychol,
Nottingham, England; [Richman, Mara J.] Eotvos Lorand Univ, Doctoral Sch Psychol,
Budapest, Hungary Kun, B (reprint author), Eotvos Lorand Univ, Inst Psychol,
Budapest, Hungary. kun.bernadette@ppk.elte.hu Demetrovics, Zsolt/0000-
0001-5604-7551 Janos Bolyai Research Fellowship - Hungarian Academy of Sciences;
Hungarian National Research, Development and Innovation Office [K111938,
KKP126835]; Hungarian Ministry of Human Capacities (ELTE Institutional Excellence
Program) [783-3/2018/FEKUTSRAT] BK acknowledges the financial support of the
Janos Bolyai Research Fellowship awarded by the Hungarian Academy of Sciences. The
study was also supported by the Hungarian National Research, Development and
Innovation Office (grant numbers: K111938, KKP126835). The study was completed with
the support of the Hungarian Ministry of Human Capacities (ELTE Institutional
Excellence Program, 783-3/2018/FEKUTSRAT). Adan A, 2013, J SUBST USE, V18,
P171, DOI 10.3109/14659891.2011.632060; Bachman J. G., 2008, ED DRUG USE CONNECTI;
Bar-On R, 2000, BAR ON EQ I YV TTECH; Bar-On R., 1997, BAR ON EMOTIONAL QUO; Bar-On
R, 2006, PSICOTHEMA, V18, P13; Best D, 2005, DRUG ALCOHOL REV, V24, P483, DOI
10.1080/09595230500292920; Block JH, 1980, DEV COGNITION AFFECT, P41; Bolland JM,
2003, J ADOLESCENCE, V26, P145, DOI 10.1016/S0140-1971(02)00136-7; BROOK JS, 1990,
GENET SOC GEN PSYCH, V116, P111; BURGE V, 1995, J SCHOOL HEALTH, V65, P222, DOI
10.1111/j.1746-1561.1995.tb03366.x; BUTLER JT, 1982, J STUD ALCOHOL, V43, P603, DOI
10.15288/jsa.1982.43.603; Castellanos N, 2006, J MENTAL HLTH, V15, P645, DOI DOI
10.1080/09638230600998912; Chabrol H, 2002, ENCEPHALE, V28, P429; Chen CY, 2009,
ADDICT BEHAV, V34, P319, DOI 10.1016/j.addbeh.2008.10.021; Chen CY, 2005, DRUG
ALCOHOL DEPEN, V79, P11, DOI 10.1016/j.drugalcdep.2004.11.014; Ciarrochi JV, 2000,
PERS INDIV DIFFER, V28, P539, DOI 10.1016/S0191-8869(99)00119-1; Coelho Ken
Russell, 2012, Depress Res Treat, V2012, P281019, DOI 10.1155/2012/281019; Di Fabio
A, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.01182; Dir AL, 2016, ADDICT
BEHAV, V58, P47, DOI 10.1016/j.addbeh.2016.02.014; Edward K, 2005, J AM PSYCHIAT
NURSES, V11, P101, DOI DOI 10.1177/1078390305277526; ESPAD Group, 2016, ESPAD REP
2015 RES E; Extremera N, 2016, PERS INDIV DIFFER, V102, P98, DOI
10.1016/j.paid.2016.06.051; Fergus S, 2005, ANNU REV PUBL HEALTH, V26, P399, DOI
10.1146/annurev.publhealth.26.021304.144357; Franck E, 2008, PSYCHOL BELG, V48,
P25, DOI 10.5334/pb-48-1-25; GALIZIO M, 1983, ADDICT BEHAV, V8, P243, DOI
10.1016/0306-4603(83)90019-9; Gasper J, 2011, J DRUG ISSUES, V41, P587, DOI
10.1177/002204261104100407; Gatta M, 2014, NEUROSCIENCE MED, V5, P60; Goodwin RD,
2004, J PSYCHIATR RES, V38, P295, DOI 10.1016/j.jpsychires.2003.09.002; Griffin KW,
2010, CHILD ADOL PSYCH CL, V19, P505, DOI 10.1016/j.chc.2010.03.005; Grubb WL,
2007, HUM PERFORM, V20, P43, DOI 10.1207/s15327043hup2001_3; Gunnarsson M, 2008,
PERS INDIV DIFFER, V45, P356, DOI 10.1016/j.paid.2008.05.004; Hallfors DD, 2005, AM
J PREV MED, V29, P163, DOI 10.1016/j.amepre.2005.06.002; Hibell B., 2004, ESPAD
REPORT 2003 AL; Hittner JB, 2006, ADDICT BEHAV, V31, P1383, DOI
10.1016/j.addbeh.2005.11.004; IBM Corp, 2016, IBM SPSS STAT WIND V; Inchley J,
2016, GROWING UNEQUAL GEND; Jaffee WB, 2009, BEHAV THER, V40, P93, DOI
10.1016/j.beth.2008.03.001; Kaminer Yifrah, 2007, Psychiatry (Edgmont), V4, P32;
KAUHANEN J, 1992, BEHAV MED, V18, P121, DOI 10.1080/08964289.1992.9936962; Kelly
TM, 2004, DRUG ALCOHOL DEPEN, V73, P87, DOI 10.1016/j.drugalcdep.2003.10.004;
Khantzian E J, 1991, NIDA Res Monogr, V110, P211; Khantzian EJ, 1997, HARVARD REV
PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550; KHANTZIAN EJ, 1985, AM J
PSYCHIAT, V142, P1259; Kirisci L, 2004, DRUG ALCOHOL DEPEN, V76, P125, DOI
10.1016/j.drugalcdep.2004.04.015; Kokkevi A, 2006, J ADOLESCENT HEALTH, V39, P712,
DOI 10.1016/j.jadohealth.2006.05.009; Kraus L, 2016, ESPAD REPORT 2015 RE; Krystal
H, 1970, DRUG DEPENDENCE ASPE; Kun B, 2012, PSYCHOL ASSESSMENT, V24, P518, DOI
10.1037/a0026013; Kun B, 2010, SUBST USE MISUSE, V45, P1131, DOI
10.3109/10826080903567855; Kuntsche E, 2008, PERS INDIV DIFFER, V45, P796, DOI
10.1016/j.paid.2008.08.009; Laghi F, 2019, J HEALTH PSYCHOL, DOI
10.1177/1359105318820715; Lembke A, 2012, AM J DRUG ALCOHOL AB, V38, P524, DOI
10.3109/00952990.2012.694532; Antunez JM, 2013, CHRONOBIOL INT, V30, P981, DOI
10.3109/07420528.2013.790397; Maremmani I, 2007, PSYCHOPATHOLOGY, V40, P269, DOI
10.1159/000104742; Martinez Pons M., 2000, IMAGINATION COGNITIO, V19, P331; Mayer
JD, 1997, MULTIFACTOR EMOTIONA; Mayer JD, 1997, EMOTIONAL DEV EMOTIO, P3; McKernan
Lindsey Colman, 2015, Psychodyn Psychiatry, V43, P243, DOI
10.1521/pdps.2015.43.2.243; Miller-Johnson S, 1998, J ABNORM CHILD PSYCH, V26,
P221, DOI 10.1023/A:1022676302865; MOFFITT TE, 1993, PSYCHOL REV, V100, P674, DOI
10.1037/0033-295X.100.4.674; Muthen L. K., 1998, MPLUS USERS GUIDE; National
Institute on Drug Abuse, 1997, NIH PUBLICATION, V97; National Institute on Drug
Abuse, 2003, PREV DRUG US CHILDR; Paksi B, 2007, ADDIKTOLOGIA, V3, P212; Paksi B,
2003, ADDIKTOLOGIA, V2, P275; Petrides KV, 2010, IND ORGAN PSYCHOL-US, V3, P136,
DOI 10.1111/j.1754-9434.2010.01213.x; Pirkle EC, 2006, J ADOLESCENT HEALTH, V38,
P44, DOI 10.1016/j.jadohealth.2004.09.012; Pokhrel P, 2010, AM J HEALTH BEHAV, V34,
P374, DOI 10.5993/AJHB.34.3.12; RADLOFF L S, 1977, Applied Psychological
Measurement, V1, P385, DOI 10.1177/014662167700100306; Resurreccion DM, 2014, J
ADOLESCENCE, V37, P461, DOI 10.1016/j.adolescence.2014.03.012; Rizwan M., 2012, INT
J ED PSYCHOL ASS, V10, P125; Robins RW, 2001, J PERS, V69, P617, DOI 10.1111/1467-
6494.694157; Rohde P, 1996, J AM ACAD CHILD PSY, V35, P101, DOI 10.1097/00004583-
199601000-00018; Rosenberg M., 1965, SOC ADOLESCENT SELF, DOI
[10.1515/9781400876136, DOI 10.1515/9781400876136]; Salovey P, 2002, PSYCHOL
HEALTH, V17, P611, DOI 10.1080/08870440290025812; Salovey P., 1990, IMAGINATION
COGNITIO, V9, P185, DOI [DOI 10.2190/DUGG-P24E-52WK-6CDG, 10.2190/DUGG-P24E-52WK-
6CDG]; SHEDLER J, 1990, AM PSYCHOL, V45, P612, DOI 10.1037/0003-066X.45.5.612;
Siegel JP, 2015, J CHILD ADOLES SUBST, V24, P67, DOI 10.1080/1067828X.2012.761169;
Stolarski M, 2015, BIOL RHYTHM RES, V46, P417, DOI 10.1080/09291016.2015.1020199;
Tamir M, 2011, EMOT REV, V3, P3, DOI 10.1177/1754073910388685; Thompson LL, 2006,
ASSESSMENT, V13, P3, DOI 10.1177/1073191105282247; Trinidad DR, 2005, SUBST USE
MISUSE, V40, P1697, DOI 10.1080/10826080500222925; Trinidad DR, 2002, PERS INDIV
DIFFER, V32, P95, DOI 10.1016/S0191-8869(01)00008-3; Trinidad DR, 2004, PERS INDIV
DIFFER, V36, P945, DOI 10.1016/S0191-8869(03)00163-6; Trinidad DR, 2004, J
ADOLESCENT HEALTH, V34, P46, DOI 10.1016/j.jadohealth.2003.02.001; Vaidya JG, 2008,
J PERS, V76, P267, DOI 10.1111/j.1467-6494.2007.00486.x; Veselska Z, 2009, ADDICT
BEHAV, V34, P287, DOI 10.1016/j.addbeh.2008.11.005; Vilagut G, 2016, PLOS ONE, V11,
DOI 10.1371/journal.pone.0155431; Vucina T., 2007, REV PSYCHOL, V14, P59; Watts AL,
2017, J BIOL RHYTHM, V32, P369, DOI 10.1177/0748730417709111; Wild LG, 2004, J DRUG
EDUC, V34, P1, DOI 10.2190/07C2-P41F-4U2P-JH0Q; Wilens TE, 2013, DRUG ALCOHOL
DEPEN, V132, P114, DOI 10.1016/j.drugalcdep.2013.01.015; Wills TA, 2002, J ABNORM
PSYCHOL, V111, P3,
DOI 10.1037//0021-843X.111.1.3; Wills TA, 2006, PSYCHOL ADDICT BEHAV, V20, P265,
DOI 10.1037/0893-164X.20.3.265; Woods-Jaeger BA, 2016, J CHILD ADOLES SUBST, V25,
P245, DOI 10.1080/1067828X.2015.1012611; WURMSER L, 1974, J AM PSYCHOANAL ASS, V22,
P820, DOI 10.1177/000306517402200407; YOUNG M, 1989, J SCHOOL HEALTH, V59, P251,
DOI 10.1111/j.1746-1561.1989.tb04716.x; Zeidner M, 2012, APPL PSYCHOL-HLTH WE, V4,
P1, DOI 10.1111/j.1758-0854.2011.01062.x 98 0 0 5 5 FRONTIERS
MEDIA SA LAUSANNE AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015,
SWITZERLAND 1664-0640 FRONT PSYCHIATRY Front. Psychiatry JUN 7 2019
10 367 10.3389/fpsyt.2019.00367
12 Psychiatry Psychiatry IC7RW WOS:000471175600001
31231253 DOAJ Gold, Green Accepted 2019-09-25
J Seker, BC; Dinc, M; Isik, S; Ogel, K Seker, Burcu
Catin; Dinc, Mehmet; Isik, Sultan; Ogel, Kultegin Incidence and
Characteristics of Psychological Trauma in Alcohol and Substance Abuse Disorder
ADDICTA-THE TURKISH JOURNAL ON ADDICTIONS English Article
PTSD; Addiction; Psychological trauma; Mental health;
Substance abuse POSTTRAUMATIC-STRESS-DISORDER; SELF-MEDICATION HYPOTHESIS;
ADDICTION; VALIDITY; REACTIVITY; SEVERITY There are many researches show the
relationship between addiction and trauma. Increasing the number of these
researches indicates the importance of this issue. In company with existing
researches, our purpose in this research was to analyze traumatic events and its
effects on addiction among individuals who applied an outpatient addiction service.
This research carried out on 322 individuals who applied Green Crescent Counseling
Center (YEDAM) for addiction treatment. Various scales are used in this study for
measuring the severity and characteristics of addiction, family characteristics,
and the characteristics of traumatic events. These scales are the BAPI (Bagamlilik
Profil Indeksi [Addiction Profile Index[), BAPI-K (BAPI Clinical Form, BAPI-A (BAPI
Family Assessment Form) and the Kocaeli Short Screening Scale for Psychological
Trauma (Kocaeli-SHORT). 97.5% of the applicants have been exposed at least one
traumatic event and 21.7% of those applicants met the Post Traumatic Stress
Disorder (PTSD) risk criteria. Demographic features show that, PTSD risk group has
higher average point of economic difficulties which an individual cannot afford
even their basic needs than others. Characteristics of addiction of PTSD risk group
indicates that, PTSD risk group has higher average points on the severity of
addiction, substance-use features, effects of substances on their lives and
severity of craving than others. Besides, PTSD risk group also has higher average
points on depression, anxiety, impulsivity and lack of assertiveness. There is no
significance on family relationship between PSTD risk group and others. Result: It
has been analyzing the relationship between addiction and trauma with acquired data
in this research. According to the results of this research, we emphasize that
traumatic events and PTSD risk have effects on addiction and its severity. Besides,
it is necessary to focus on trauma symptoms while treating addiction. [Seker,
Burcu Catin] Turkish Green Crescent Soc, Counseling Ctr, Istanbul, Turkey; [Dinc,
Mehmet] Hasan Kalyoncu Univ, Dept Psychol, Gaziantep, Turkey; [Isik, Sultan]
Turkish Green Crescent Soc, Istanbul, Turkey; [Ogel, Kultegin] Istanbul Bilgi Univ,
Fac Hlth Sci, Istanbul, Turkey; [Ogel, Kultegin] Moodist Psychiat Hosp, Istanbul,
Turkey Seker, BC (reprint author), Turkish Green Crescent Soc, Counseling Ctr,
Istanbul, Turkey. burcu.cetin@yesilay.org.tr; mehmetdinc@gmail.com;
sultan.isik@yesilay.org.tr; ogelk@ogelk.net Aker AT,
2007, DUNSEN ADAM, V20, P172; Aldemir S., 2011, YENI TIP DERGISI, V28, P198;
Bernstein D. P., 2000, ALCOHOLISM TREATMENT, V18, P19; Bilgic S., 2011, THESIS;
BRESLAU N, 1992, AM J PSYCHIAT, V149, P671; Brown PJ, 1999, PSYCHOL ADDICT BEHAV,
V13, P115, DOI 10.1037/0893-164X.13.2.115; Carruth Bruce, 2006, J CHEM DEPENDENCY
TR, V8, P1, DOI [10.1300/J034v08n02_01, DOI 10.1300/J034V08N02_01]; Coffey SF,
2010, EXP CLIN PSYCHOPHARM, V18, P340, DOI 10.1037/a0019790; Coffey SF, 2002, DRUG
ALCOHOL DEPEN, V65, P115, DOI 10.1016/S0376-8716(01)00157-0; Dalbudak E., 2015,
TRAVMA SONRASI STRES; Evren C, 2009, NOROPSIKIYATRI ARS, V46, P3; Hammersley R,
2016, ADDICT RES THEORY, V24, P135, DOI 10.3109/16066359.2015.1093120; Hildebrand
A, 2015, PSYCHOTHER RES, V25, P565, DOI 10.1080/10503307.2014.923125; Jacobsen LK,
2001, AM J PSYCHIAT, V158, P1184, DOI 10.1176/appi.ajp.158.8.1184; Khantzian EJ,
1997, HARVARD REV PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550; Kural S.,
2004, B CLIN PSYCHOPHARMAC, V14, P1; Lotzin A, 2016, ALCOHOL CLIN EXP RES, V40,
P543, DOI 10.1111/acer.12990; McCauley JL, 2012, CLIN PSYCHOL-SCI PR, V19, P283,
DOI 10.1111/cpsp.12006; Mueser KT, 2003, INTEGRATED TREATMENT; Ogel K., 2017,
BAGIMLILIK VE TEDAVA; Ogel K., 2014, 113S050 TUBITAK; Ogel K, 2015, BAMLLK DERGISI,
V16, P57; Ogel K, 2017, KLIN PSIKIYATR DERG, V20, P255, DOI 10.5505/kpd.2017.46220;
Ogel K, 2012, TURK PSIKIYATR DERG, V23, P264; Saladin ME, 2003, ADDICT BEHAV, V28,
P1611, DOI 10.1016/j.addbeh.2003.08.037; Suh JJ, 2008, PSYCHOANAL PSYCHOL, V25,
P518, DOI 10.1037/0736-9735.25.3.518 26 0 0 0 0 TURKISH
GREEN CRESCENT SOC ISTANBUL SEPETCILER KASRIKENNEDY CAD NO 3 SARAYBURNU,
FATIH, ISTANBUL, 34110, TURKEY 2148-7286 2149-1305 ADDICTA
Addicta JUN 2019 6 2 331 336
10.15805/addicta.2019.6.2.0046 6 Substance Abuse
Substance Abuse IF7YT WOS:000473303900006 Bronze
2019-09-25
J Bingham, B; Moniruzzaman, A; Patterson, M; Distasio, J; Sareen, J; O'Neil, J;
Somers, JM Bingham, Brittany; Moniruzzaman, Akm; Patterson,
Michelle; Distasio, Jino; Sareen, Jitender; O'Neil, John; Somers, Julian M.
Indigenous and non-Indigenous people experiencing homelessness and mental
illness in two Canadian cities: A retrospective analysis and implications for
culturally informed action BMJ OPEN English Article
CARE; HEALTH Objectives Indigenous people in
Canada are not only over-represented among the homeless population but their
pathways to homelessness may differ from those of non-Indigenous people. This study
investigated the history and current status of Indigenous and non-Indigenous people
experiencing homelessness and mental illness. We hypothesised that compared with
non-Indigenous people, those who are Indigenous would demonstrate histories of
displacement earlier in life, higher rates of trauma and self-medication with
alcohol and other substances. Design and setting Retrospective data were collected
from a sample recruited through referral from diverse social and health agencies in
Winnipeg and Vancouver. Participants Eligibility included being 19 years or older,
current mental disorder and homelessness. Measures Data were collected via
interviews, using questionnaires, on sociodemographics (eg, age, ethnicity,
education), mental illness, substance use, physical health, service use and quality
of life. Univariate and multivariable models were used to model the association
between Indigenous ethnicity and dependent variables. Results A total of 1010
people met the inclusion criteria, of whom 439 self-identified as Indigenous. In
adjusted models, Indigenous ethnicity was independently associated with being
homeless at a younger age, having a lifetime duration of homelessness longer than 3
years, post-traumatic stress disorder, less severe mental disorder, alcohol
dependence, more severe substance use in the past month and infectious disease.
Indigenous participants were also nearly twice as likely as others (47% vs 25%) to
have children younger than 18 years. Conclusions Among Canadians who are homeless
and mentally ill, those who are Indigenous have distinct histories and current
needs that are consistent with the legacy of colonisation. Responses to Indigenous
homelessness must be developed within the context of reconciliation between
Indigenous and non-Indigenous Canadians, addressing trauma, substance use and
family separations. Trial registration number ISRCTN42520374, ISRCTN57595077,
ISRCTN66721740. [Bingham, Brittany; Moniruzzaman, Akm; Patterson, Michelle;
O'Neil, John; Somers, Julian M.] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC,
Canada; [Distasio, Jino] Univ Winnipeg, Geog, Winnipeg, MB, Canada; [Sareen,
Jitender] Univ Manitoba, Psychol & Community Hlth Sci, Winnipeg, MB, Canada
Bingham, B (reprint author), Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC,
Canada. bld@sfu.ca Distasio, Jino/0000-0003-2630-4865 Simon Fraser
University from Health Canada; Mental Health Commission of Canada [2009s0231]
This work was supported by a grant to Simon Fraser University from Health
Canada and the Mental Health Commission of Canada Grant Number: 2009s0231. Aguiar
W, 2015, ABORIGINAL PEOPLES H, P1; Allan B, 2015, 2 CLASS TREATMENT RO; Anderson
JT, 2014, HOUSING STUD, V29, P959, DOI 10.1080/02673037.2014.923091; BARKER S,
1994, COMMUNITY MENT HLT J, V30, P459, DOI 10.1007/BF02189063; Bird C, 2010,
ABORIGINAL HOMELESSN; Bombay A, 2009, J ABORIG HLTH, V1-42; Browne AJ, 2016, BMC
HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1707-9; Browne AJ, 2011, QUAL HEALTH
RES, V21, P333, DOI 10.1177/1049732310385824; Canadian Centre on Substance Abuse,
2007, SUBST AB CAN YOUTH F, P1; Canadian Collaborative Mental Health Initiative,
2006, EST COLL IN MENT HLT; City of Vancouver, 2018, HOM COUNT; Evans GW, 2003, J
SOC ISSUES, V59, P475, DOI 10.1111/1540-4560.00074; Forchuk Cheryl, 2007, Health
Res Policy Syst, V5, P14, DOI 10.1186/1478-4505-5-14; Fowler PJ, 2009, AM J PUBLIC
HEALTH, V99, P1453, DOI 10.2105/AJPH.2008.142547; Goering PN, 2011, BMJ OPEN, V1,
DOI 10.1136/bmjopen-2011-000323; Kelly M, 2007, PREVENTION HARMFUL E; Margetts H,
2016, POLITICAL TURBULENCE: HOW SOCIAL MEDIA SHAPE COLLECTIVE ACTION, P1; Marshall
BDL, 2008, HARM REDUCT J, V5, DOI 10.1186/1477-7517-5-35; McCormick R. M., 2000,
CANADIAN J COUNSELIN, V34, P25; Miller CL, 2006, J ADOLESCENT HEALTH, V38, P462,
DOI 10.1016/j.jadohealth.2005.03.004; Monette LE, 2011, CAN J PUBLIC HEALTH, V102,
P215, DOI 10.1007/BF03404900; Nelson G., 2010, J SOCIOLOGY SOCIAL W, V37, P123;
Patrick C., 2014, ABORIGINAL HOMELESSN; Patterson M. L., 2015, BIOMED CENTRAL
PSYCH, V15, P1, DOI DOI 10.1186/S12888-015-0411-3; Perissini T., 2009, FINDING HOME
POLICY, P1; Rawana JS, 2012, J YOUTH ADOLESCENCE, V41, P229, DOI 10.1007/s10964-
011-9716-9; Rog DJ, 2014, PSYCHIAT SERV, V65, P287, DOI 10.1176/appi.ps.201300261;
Roos LE, 2014, CHILD ABUSE NEGLECT, V38, P1618, DOI 10.1016/j.chiabu.2013.08.018;
Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Somers
JM, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-0758-0; Somers JM, 2016, BMJ
OPEN, V6, DOI 10.1136/bmjopen-2015-009043; Somers JM, 2013, TRIALS, V14, DOI
10.1186/1745-6215-14-365; Strehlau V, 2017, CONT CLIN TRIAL COMM, V7, P48, DOI
10.1016/j.conctc.2017.05.001; Tang SY, 2008, ETHNIC HEALTH, V13, P109, DOI
10.1080/13557850701830307; The Truth and Reconciliation Commission of Canada, 2015,
WHAT WE HAV LEARN PR; Thistle J, 2017, INDIGENOUS DEFINITIO; Thomson M, 2016,
VANCOUVER HOMELESS C, P1; Turner D, 2010, ABORIGINAL HOMELESSN; Wesley-Esquimaux
Cynthia C., 2004, HIST TRAUMA ABORIGIN 39 0 0 4 4 BMJ
PUBLISHING GROUP LONDON BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON
WC1H 9JR, ENGLAND 2044-6055 BMJ OPEN BMJ Open JUN 2019 9
4 e024748 10.1136/bmjopen-2018-
024748 10 Medicine, General & Internal General & Internal
Medicine IC7MA WOS:000471157200073 30962229 DOAJ Gold 2019-
09-25
J Vayr, F; Herin, F; Jullian, B; Soulat, JM; Franchitto, N
Vayr, Flora; Herin, Fabrice; Jullian, Benedicte; Soulat, Jean Marc;
Franchitto, Nicolas Barriers to seeking help for physicians with
substance use disorder: A review DRUG AND ALCOHOL DEPENDENCE
English Review Substance use disorder;
Impaired physician; Mandatory reporting; Occupational health; Psychiatric
comorbidity IMPAIRED MEDICAL PRACTITIONERS; HEALTH; ANESTHESIOLOGIST; ADDICTION;
DOCTORS; ABUSE Background: Substance use disorders (SUD) might concern as many
as 8-15% of physicians. Previous studies suggest that self-diagnosis and self-
medication are common practices among physicians. The aim of this review was to
identify if barriers to seeking help and medical care for impaired physicians
exist. We also aimed at characterizing the nature of these barriers. Methods: The
review included scientific papers published on the MEDLINE and PsychINFO databases
between January 2000 and September 2018. The inclusion criteria were: (i) articles
that focused on SUD in physicians. The exclusion criteria were: (i) no mention of
SUD; (ii) no mention of barriers to seeking help; (iii) articles focused on burn-
out and work-related stress; (iv) articles focused on risk factors or treatments
for SUD; (v) articles focused on psychiatric comorbidities and (vi) those focused
on other professionals. Results: Potential barriers to seeking help that were
identified for impaired physicians with SUD included denial of the disease and of
loss of performance, fear of stigma, psychiatric comorbidities, fear of
familial/social/ professional and economic consequences and a lack of knowledge.
Conclusions: Different barriers to seeking help could be identified. Priority
should be given to educating medical students to ameliorate this. Increased
awareness should reduce the stigma, which, even nowadays, still prevents some
physicians from seeking help. [Vayr, Flora; Herin, Fabrice; Soulat, Jean Marc]
Toulouse Purpan Univ Hos, Occupat Dis Dept, F-31000 Toulouse, France; [Herin,
Fabrice; Soulat, Jean Marc] Univ Toulouse III, INSERM, UMR 1027, F-31000 Toulouse,
France; [Jullian, Benedicte; Franchitto, Nicolas] Toulouse Purpan Univ Hosp, Dept
Addict Med, F-31000 Toulouse, France Herin, F (reprint author), Univ Hosp,
Occupat Dis Dept, Batiment Turiaf,Pl Dr Baylac, F-31059 Toulouse 9, France.
herin.f@chu-toulouse.fr Baldisseri MR, 2007, CRIT
CARE MED, V35, pS106, DOI 10.1097/01.CCM.0000252918.87746.96; Bismark MM, 2014,
INTERN MED J, V44, P1165, DOI 10.1111/imj.12613; Bismark MM, 2016, BMJ OPEN, V6,
DOI 10.1136/bmjopen-2016-011988; Boisaubin EV, 2001, AM J MED SCI, V322, P31, DOI
10.1097/00000441-200107000-00006; Breen KJ, 2011, MED J AUSTRALIA, V194, P191;
Brewster JM, 2010, JAMA-J AM MED ASSOC, V304, P1896, DOI 10.1001/jama.2010.1559;
Brown Stephen D, 2009, J Am Coll Radiol, V6, P479, DOI 10.1016/j.jacr.2008.11.029;
Bryson EO, 2008, ANESTHESIOLOGY, V109, P905, DOI 10.1097/ALN.0b013e3181895bc1;
Bryson EO, 2010, J CLIN ANESTH, V22, P311, DOI 10.1016/j.jclinane.2010.02.004;
Cottler LB, 2013, J ADDICT MED, V7, P108, DOI 10.1097/ADM.0b013e31827fadc9;
Cummings SM, 2011, J ADDICT DIS, V30, P195, DOI 10.1080/10550887.2011.581962;
DesRoches CM, 2010, JAMA-J AM MED ASSOC, V304, P187, DOI 10.1001/jama.2010.921;
Dhai A, 2006, SAMJ S AFR MED J, V96, P1069; FOX J de W, 1954, Med Arts Sci, V8,
P96; Gentile Julie P, 2008, Psychiatry (Edgmont), V5, P42; Harty-Golder Barbara,
2009, MLO Med Lab Obs, V41, P36; Henderson DRF, 2015, INTERN MED J, V45, P684, DOI
10.1111/imj.12777; Holtman MC, 2007, SOC SCI MED, V64, P543, DOI
10.1016/j.socscimed.2006.09.016; Johnson BA, 2009, AM FAM PHYSICIAN, V80, P1007;
Killewich LA, 2009, J VASC SURG, V50, P440, DOI 10.1016/j.jvs.2009.05.001; Kunz K,
2016, J MED TOXICOL, V12, P76, DOI 10.1007/s13181-015-0524-6; Lawson ND, 2018,
SUBST ABUSE TREAT PR, V13, DOI 10.1186/s13011-018-0168-z; Magnavita N, 2010, RADIOL
MED, V115, P826, DOI 10.1007/s11547-010-0539-7; Marshall EJ, 2008, OCCUP MED-
OXFORD, V58, P334, DOI 10.1093/occmed/kqn081; McLellan A. T., 2008, BMJ-BRIT MED J,
V4, P337; Merlo LJ, 2008, HARVARD REV PSYCHIAT, V16, P181, DOI
10.1080/10673220802160316; Merlo LJ, 2010, AM J ADDICTION, V19, P529, DOI
10.1111/j.1521-0391.2010.00088.x; Montgomery AJ, 2011, OCCUP MED-OXFORD, V61, P490,
DOI 10.1093/occmed/kqr098; Samuelson ST, 2017, CAN J ANESTH, V64, P219, DOI
10.1007/s12630-016-0780-1; Seppala Marvin D, 2010, Minn Med, V93, P46; Sudan R,
2016, SURG CLIN N AM, V96, P89, DOI 10.1016/j.suc.2015.09.006; Taub S, 2006, OCCUP
MED-OXFORD, V56, P77, DOI 10.1093/occmed/kqj025; Truex RC, 2010, JAMA-J AM MED
ASSOC, V304, P1895, DOI 10.1001/jama.2010.1558; Tyssen R, 2007, IND HEALTH, V45,
P599, DOI 10.2486/indhealth.45.599; WALL J H, 1958, Fed Bull, V45, P144; Watkins
Derek, 2010, J Healthc Risk Manag, V30, P26, DOI 10.1002/jhrm.20040; Wijesinghe CP,
2001, PSYCHIAT QUART, V72, P181, DOI 10.1023/A:1010323710929; Wilson A, 2009,
AUSTRALAS PSYCHIATRY, V17, P6, DOI 10.1080/10398560802579351; Wunsch MJ, 2007, J
ADDICT DIS, V26, P35, DOI 10.1300/J069v26m02_05 39 0 0 0 0
ELSEVIER IRELAND LTD CLARE ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK
SHANNON, CO, CLARE, 00000, IRELAND 0376-8716 1879-0046 DRUG ALCOHOL DEPEN
Drug Alcohol Depend. JUN 1 2019 199 116
121 10.1016/j.drugalcdep.2019.04.004 6 Substance
Abuse; Psychiatry Substance Abuse; Psychiatry IC4OV WOS:000470946100017
31035230 2019-09-25
J Bosk, EA; Paris, R; Hanson, KE; Ruisard, D; Suchman, NE
Bosk, Emily A.; Paris, Ruth; Hanson, Karen E.; Ruisard, Debra; Suchman, Nancy
E. Innovations in child welfare interventions for caregivers with
substance use disorders and their children CHILDREN AND YOUTH SERVICES REVIEW
English Article DRUG-
DEPENDENT MOTHERS; PARENTING INTERVENTION; MATERNAL SENSITIVITY; TODDLERS PROGRAM;
SELF-MEDICATION; RISK MODEL; ATTACHMENT; ABUSE; BEHAVIOR; REPRESENTATIONS
Families who enter the Child Welfare System (CWS) as a result of a
caregiver's substance use fare worse at every stage from investigation to removal
to reunification (Marsh, Smith, & Bruni, 2011). Intervening with caregivers with
Substance Use Disorders (SUDs) and their children poses unique challenges related
to the structure and focus of the current CWS. Research demonstrates that
caregivers with SUDs are at a greater risk for maladaptive parenting practices,
including patterns of insecure attachment and difficulties with attunement and
responsiveness (Suchman, Paulo, DeCoste, & Mayes, 2006). Caregivers with SUDs have
also often experienced early adversity and trauma. However, traditional addiction
services generally offer limited opportunities to focus on parenting or trauma, and
traditional parenting programs rarely address the special needs of parents with
SUDs. This article details four innovative interventions that integrate trauma-
informed addiction treatments with parenting for families involved in the child
welfare system. Common mechanisms for change across programs are identified as
critical components for intervention. This work suggests the need for a paradigm
shift in how cases involving caregivers with substance use disorders are approached
in the child welfare system. [Bosk, Emily A.] State Univ New Jersey, Rutgers Univ,
Sch Social Work, New Brunswick, NJ 08901 USA; [Paris, Ruth] Boston Univ, Sch Social
Work, Clin Practice Dept, Boston, MA 02215 USA; [Hanson, Karen E.; Suchman, Nancy
E.] Yale Univ, Sch Med, Yale Child Study Ctr, New Haven, CT 06520 USA; [Ruisard,
Debra] Ctr Great Expectat, Somerset, NJ USA; [Suchman, Nancy E.] Yale Univ, Sch
Med, Dept Psychiat, New Haven, CT 06520 USA Bosk, EA (reprint author), State
Univ New Jersey, Rutgers Univ, Sch Social Work, New Brunswick, NJ 08901 USA.
emily.bosk@ssw.rutgers.edu Bosk, Emily/0000-0003-2135-3713 SAMHSA
[1U79SM063114, 1U79SM059460, SM636062]; HRSAUnited States Department of Health &
Human ServicesUnited States Health Resources & Service Administration (HRSA)
[R40MC31764]; State of Connecticut; Social Finance LLC; NIH/NIDAUnited States
Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
National Institute on Drug Abuse (NIDA) [R01DA17294, K02 DA023504, K23 DA14606]
Funding for Project BRIGHT has been provided by the following grants: SAMHSA
1U79SM063114 (PI: Finkelstein), HRSA R40MC31764 (PI: Paris), and SAMSHA
1U79SM059460 (PI: Finkelstein). Funding for the C.A.R.E. Model has been provided by
SAMHSA SM636062 (PI: Ruisard). Funding for Family-Based Recovery has been provided
by the following grants: State of Connecticut and Social Finance LLC. Funding for
Mothering from the Inside Out has been provided by the following grants: NIH/NIDA
R01DA17294 (PI: Suchman), K02 DA023504 (PI: Suchman), K23 DA14606. Alvarez-
Monjaras M, 2019, PSYCHOANAL PSYCHOL, V36, P82, DOI 10.1037/pap0000166; Barnard M,
2004, ADDICTION, V99, P552, DOI 10.1111/j.1360-0443.2003.00664.x; Beeghly M, 2011,
PSYCHOL RES PROGR MA; Behnke M, 2013, PEDIATRICS, V131, pE1009, DOI
10.1542/peds.2012-3931; Bernier A, 2010, CHILD DEV, V81, P326, DOI 10.1111/j.1467-
8624.2009.01397.x; Borelli JL, 2010, EMOTION, V10, P475, DOI 10.1037/a0018490; Bosk
EA, 2017, BRIT J SOC WORK, V47, P1669, DOI 10.1093/bjsw/bcx095; Brems C, 2004, AM J
DRUG ALCOHOL AB, V30, P799, DOI 10.1081/ADA-200037546; Center for Substance Abuse
Treatment, 2009, TREATMENT IMPROVEMEN, V51; Chaplin T. M, 2013, PARENTING
SUBSTANCE; Child Welfare and Well-Being Research Unit Rutgers University, 2018, DCF
NEEDS ASS 2018 S; Choi S, 2007, CHILD YOUTH SERV REV, V29, P1395, DOI
10.1016/j.childyouth.2007.05.013; Doyle C, 2017, CLIN PSYCHOL-SCI PR, V24, P203,
DOI 10.1111/cpsp.12192; Edwards EP, 2009, ADDICT BEHAV, V34, P100, DOI
10.1016/j.addbeh.2008.08.006; Eiden RD, 2006, PSYCHOL ADDICT BEHAV, V20, P1, DOI
10.1037/0893-164X.20.1.1; Eiden RD, 2009, PSYCHOL ADDICT BEHAV, V23, P36, DOI
10.1037/a0014839; Feldman R, 2010, INFANT BEHAV DEV, V2011, P310; Flanagan JC,
2016, CURR PSYCHIAT REP, V18, DOI 10.1007/s11920-016-0709-y; Flykt M, 2012, INFANT
MENT HEALTH J, V33, P123, DOI 10.1002/imhj.21313; Grella CE, 2006, PSYCHIAT SERV,
V57, P1007, DOI 10.1176/appi.ps.57.7.1007; Hanson K, 2015, CHILD WELFARE, V94;
Hanson KE, 2019, CHILD ABUSE REV, V28, P69, DOI 10.1002/car.2545; Harkin B, 2011,
FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2011.00078; Hesse E, 2006, DEV PSYCHOPATHOL,
V18, P309, DOI 10.1017/S0954579406060172; Huth-Bocks AC, 2014, ATTACH HUM DEV, V16,
P535, DOI 10.1080/14616734.2014.967787; Kelley ML, 2015, CHILD ABUSE NEGLECT, V43,
P42, DOI 10.1016/j.chiabu.2015.01.017; Khantzian EJ, 1997, HARVARD REV PSYCHIAT,
V4, P231, DOI 10.3109/10673229709030550; Kim J, 2010, J CHILD PSYCHOL PSYC, V51,
P706, DOI 10.1111/j.1469-7610.2009.02202.x; Kim S, 2017, HUM BRAIN MAPP, V38,
P5421, DOI 10.1002/hbm.23731; Kirst M, 2017, INT J MENTAL HLTH AD, V15; Levy M,
2019, INT J ADV COUNS, V41, P15, DOI 10.1007/s10447-018-9341-3; Lieberman AF, 2005,
J AM ACAD CHILD PSY, V44, P1241, DOI 10.1097/01.chi.0000181047.59702.58; Lieberman
AF, 2004, INFANT MENT HEALTH J, V25, P336, DOI 10.1002/imhj.20009; Lieberman AF,
2005, DONT HIT MY MOMMY MA; MacKenzie MJ, 2011, CHILD YOUTH SERV REV, V33, P2392,
DOI 10.1016/j.childyouth.2011.08.030; MacKenzie MJ, 2011, CHILD YOUTH SERV REV,
V33, P1638, DOI 10.1016/j.childyouth.2011.04.018; MacKenzie MJ, 2011, CHILD YOUTH
SERV REV, V33, P1364, DOI 10.1016/j.childyouth.2011.04.007; Marsh JC, 2011, CHILD
YOUTH SERV REV, V33, P466, DOI 10.1016/j.childyouth.2010.06.017; Minnes S, 2005, J
DEV BEHAV PEDIATR, V26, P194, DOI 10.1097/00004703-200506000-00005; Moss HB, 2002,
AM J PSYCHIAT, V159, P607, DOI 10.1176/appi.ajp.159.4.607; Onken LS, 2014, CLIN
PSYCHOL SCI, V2, P22, DOI 10.1177/2167702613497932; Pajulo M, 2013, PARENTING
SUBSTANCE, P282, DOI DOI 10.1093/MED:PSYCH/9780199743100.003.0014; Pajulo Marjukka,
2008, J Prenat Perinat Psychol Health, V23, P13; Paris R, 2018, MOTHERHOOD FACE
TRAU, P181; Paris R, 2015, CHILD ABUSE NEGLECT, V50, P206, DOI
10.1016/j.chiabu.2015.09.007; Raby KL, 2015, CHILD DEV, V86, P695, DOI
10.1111/cdev.12325; Rounsaville BJ, 2001, CLIN PSYCHOL-SCI PR, V8, P133, DOI
10.1093/clipsy/8.2.133; Rutherford H, 2013, PARENTING SUBSTANCE; Salo S, 2013,
PARENTING SUBSTANCE, P195, DOI DOI 10.1093/MED:PSYCH/9780199743100.001.0001;
Sameroff AJ, 2003, DEV PSYCHOPATHOL, V15, P613, DOI 10.1017/S0954579403000312;
Slade A, 2005, ATTACH HUM DEV, V7, P269, DOI 10.1080/14616730500245906; Slade A,
2005, PSYCHOANAL STUD CHIL, V60, P74; Slesnick N, 2014, ADDICT BEHAV, V39, P897,
DOI 10.1016/j.addbeh.2014.02.003; Sokolowski MS, 2007, INFANT MENT HEALTH J, V28,
P344, DOI 10.1002/imhj.20140; Sroufe LA, 2005, ATTACH HUM DEV, V7, P349, DOI
10.1080/14616730500365928; Strathearn L, 2011, J NEUROENDOCRINOL, V23, P1054, DOI
10.1111/j.1365-2826.2011.02228.x; Strathearn L, 2009, NEUROPSYCHOPHARMACOL, V34,
P2655, DOI 10.1038/npp.2009.103; Suchman N, 2006, FAM RELAT, V55, P211, DOI
10.1111/j.1741-3729.2006.00371.x; Suchman N, 2004, J SUBST ABUSE TREAT, V27, P179,
DOI 10.1016/j.jsat.2004.06.008; Suchman Nancy E, 2018, Attach Hum Dev, P1, DOI
10.1080/14616734.2018.1559210; Suchman NE, 2018, J SUBST ABUSE TREAT, V85, P21, DOI
10.1016/j.jsat.2017.11.006; Suchman NE, 2012, INFANT MENT HEALTH J, V33, P360, DOI
10.1002/imhj.21311; Suchman NE, 2011, INFANT MENT HEALTH J, V32, P427, DOI
10.1002/imhj.20303; Suchman NE, 2010, ATTACH HUM DEV, V12, P483, DOI
10.1080/14616734.2010.501983; Suchman NE, 2017, DEV PSYCHOPATHOL, V29, P617, DOI
10.1017/S0954579417000220; Tronick EZ, 2005, DEV PSYCHOL, V41, P711, DOI
10.1037/0012-1649.41.5.711; Tuten L. M, 2012, REINFORCEMENT BASED; van der Kolk BA,
2005, PSYCHIAT ANN, V35, P401, DOI 10.3928/00485713-20050501-06; Van Niel C, 2014,
J DEV BEHAV PEDIATR, V35, P549, DOI 10.1097/DBP.0000000000000102; Volkow ND, 2003,
J CLIN INVEST, V111, P1444, DOI 10.1172/JCI200318533 70 2 2 2 2
PERGAMON-ELSEVIER SCIENCE LTD OXFORD THE BOULEVARD, LANGFORD LANE,
KIDLINGTON, OXFORD OX5 1GB, ENGLAND 0190-7409 1873-7765 CHILD YOUTH SERV
REV Child. Youth Serv. Rev. JUN 2019 101 99
112 10.1016/j.childyouth.2019.03.040 14 Family
Studies; Social Work Family Studies; Social Work HZ9CS WOS:000469154000011
2019-09-25
J Berg, NJ; Kiviruusu, OH; Lintonen, TP; Huurre, TM Berg,
Noora J.; Kiviruusu, Olli H.; Lintonen, Tomi P.; Huurre, Taina M.
Longitudinal prospective associations between psychological symptoms and
heavy episodic drinking from adolescence to midlife SCANDINAVIAN JOURNAL OF
PUBLIC HEALTH English Article
alcohol; heavy episodic drinking; life course; mental health; psychological
symptoms SUBSTANCE USE; DEPRESSIVE SYMPTOMS; MENTAL-DISORDERS; MAJOR DEPRESSION;
ALCOHOL; AGE; BURDEN; ONSET Aim: This study examined whether development of
psychological symptoms (PS) differed between persons with different longitudinal
profiles of heavy episodic drinking (HED) from adolescence to midlife. In addition,
the reciprocal associations between PS and HED were studied. Methods: Participants
of a Finnish cohort study in 1983 at age 16 (N = 2194) were followed up at ages 22
(N = 1656), 32 (N = 1471), and 42 (N = 1334). HED was assessed with frequency of
intoxication (16-22 years) and having six or more drinks in a session (32-42
years). Using latent class analysis, the participants were allocated to steady
high, increased, moderate, and steady low groups according to their longitudinal
profiles of HED. The PS scale (16-42 years) covered five mental complaints. The
latent growth curve of PS was estimated in the HED groups for comparisons. In
addition, the prospective associations between symptoms and HED were examined using
cross-lagged autoregressive models. Results: PS grew from 16 to 32 years, but
declined after that, with women having higher level of PS than men. PS trajectory
followed a path at highest and lowest level in the steady high and steady low HED
groups, respectively. Symptoms predicted later HED, but the association in the
opposite direction was not found. Conclusions: The more the HED trajectory
indicated frequent HED, the higher was the level of PS throughout the follow-up.
Results support the self-medication hypothesis, suggesting that alcohol is used to
ease the burden of PS. More attention should be paid to alcohol use of people with
mental symptoms in health services. [Berg, Noora J.] Uppsala Univ, Uppsala, Sweden;
[Berg, Noora J.; Kiviruusu, Olli H.; Huurre, Taina M.] Natl Inst Hlth & Welf, POB
30, Helsinki 00271, Finland; [Lintonen, Tomi P.] Finnish Fdn Alcohol Studies,
Helsinki, Finland; [Lintonen, Tomi P.] Univ Tampere, Tampere, Finland Berg, NJ
(reprint author), Natl Inst Hlth & Welf, POB 30, Helsinki 00271, Finland.
noora.berg@thl.fi Lintonen, Tomi/0000-0003-3455-2439 Finnish Foundation
for Alcohol Studies; Signe and Ane Gyllenberg Foundation The author(s) disclosed
receipt of the following financial support for the research, authorship, and/or
publication of this article: This study was supported by the Finnish Foundation for
Alcohol Studies and Signe and Ane Gyllenberg Foundation. Andersen A, 2004,
ADDICTION, V99, P1489, DOI 10.1111/j.1360-0443.2004.00940.x; Aro S, 1981, Scand J
Soc Med Suppl, V25, P1; Babor T, 2001, AUDIT ALCOHOL USE DI; Bell S, 2015, DRUG
ALCOHOL DEPEN, V155, P111, DOI 10.1016/j.drugalcdep.2015.08.008; Bell S, 2014, BMC
MED, V12, DOI 10.1186/1741-7015-12-91; Boden JM, 2011, ADDICTION, V106, P906, DOI
10.1111/j.1360-0443.2010.03351.x; Cyranowski JM, 2000, ARCH GEN PSYCHIAT, V57, P21,
DOI 10.1001/archpsyc.57.1.21; Deecher D, 2008, PSYCHONEUROENDOCRINO, V33, P3, DOI
10.1016/j.psyneuen.2007.10.006; Fergusson DM, 2009, ARCH GEN PSYCHIAT, V66, P260,
DOI 10.1001/archgenpsychiatry.2008.543; Fleming CB, 2008, PSYCHOL ADDICT BEHAV,
V22, P186, DOI 10.1037/0893-164X.22.2.186; Holdcraft LC, 2002, ADDICTION, V97,
P1025, DOI 10.1046/j.1360-0443.2002.00142.x; Hu LT, 1999, STRUCT EQU MODELING, V6,
P1, DOI 10.1080/10705519909540118; Huurre T, 2006, EDUC RES-UK, V48, P41, DOI
10.1080/00131880500498438; Kessler RC, 2004, BIOL PSYCHIAT, V56, P730, DOI
10.1016/j.biopsych.2004.06.034; Kessler RC, 2007, CURR OPIN PSYCHIATR, V20, P359,
DOI 10.1097/YCO.0b013e32816ebc8c; Kuntsche E, 2004, SOC SCI MED, V59, P113, DOI
10.1016/j.socscimed.2003.10.009; Lai HMX, 2015, DRUG ALCOHOL DEPEN, V154, P1, DOI
10.1016/j.drugalcdep.2015.05.031; Lintonen TP, 2001, J SUBST USE, V6, P145; Lund R,
2004, INT J EPIDEMIOL, V33, P389, DOI 10.1093/ije/dyh065; Maggs JL, 2004, ALCOHOL
RES HEALTH, V28, P195; Marmorstein NR, 2009, ALCOHOL CLIN EXP RES, V33, P49, DOI
10.1111/j.1530-0277.2008.00810.x; MIROWSKY J, 1992, J HEALTH SOC BEHAV, V33, P187,
DOI 10.2307/2137349; Pape H, 2016, DRUG ALCOHOL REV, V35, P170, DOI
10.1111/dar.12290; Rimpela M, 1982, SOSIAALILAAKETIETEEL, V19, P219; Schuler MS,
2015, DRUG ALCOHOL DEPEN, V157, P75, DOI 10.1016/j.drugalcdep.2015.10.005; Swendsen
JD, 2000, CLIN PSYCHOL REV, V20, P173, DOI 10.1016/S0272-7358(99)00026-4; Wang JL,
2001, CAN J PSYCHIAT, V46, P422, DOI 10.1177/070674370104600507; Whiteford HA,
2013, LANCET, V382, P1575, DOI 10.1016/S0140-6736(13)61611-6; Wittchen HU, 2011,
EUR NEUROPSYCHOPHARM, V21, P655, DOI 10.1016/j.euroneuro.2011.07.018 29 0
0 0 0 SAGE PUBLICATIONS LTD LONDON 1 OLIVERS YARD, 55 CITY
ROAD, LONDON EC1Y 1SP, ENGLAND 1403-4948 1651-1905 SCAND J PUBLIC
HEALT Scand. J. Public Health JUN 2019 47 4 420
427 10.1177/1403494818769174 8 Public,
Environmental & Occupational Health Public, Environmental & Occupational Health
HZ7AK WOS:000469003700005 29644935 2019-09-25
J Rougemont-Bucking, A; Jungaberle, H; Scheidegger, M; Merlo, MCG; Grazioli,
VS; Daeppen, JB; Gmel, G; Studer, J Rougemont-Bucking, Ansgar;
Jungaberle, Henrik; Scheidegger, Milan; Merlo, Marco C. G.; Grazioli, Veronique S.;
Daeppen, Jean-Bernard; Gmel, Gerhard; Studer, Joseph Comparing Mental
Health across Distinct Groups of Users of Psychedelics, MDMA, Psychostimulants, and
Cannabis JOURNAL OF PSYCHOACTIVE DRUGS English Article
Cannabis; MDMA; mental health; psychedelics;
psychostimulants; stress events ILLICIT DRUG-USE; MAJOR DEPRESSION INVENTORY;
SUBSTANCE USE DISORDERS; RISK-FACTORS; PSYCHOMETRIC PROPERTIES; PSYCHOLOGICAL
DISTRESS; ECSTASY USERS; UNITED-STATES; CHILDHOOD; STRESS Differences in mental
health (MH) of users of distinct psychoactive substances have been shown. Both
substance use (SU) and MH in users are influenced by stressful life events. This
study compared MH parameters in distinct groups of substance users and evaluated
the impact of stress factors on these outcomes. Data stem from the longitudinal
Swiss Cohort Study on Substance Use Risk Factors (C-SURF) involving 4,475 young
adult men. Distinct groups were created for the past 12 months' use of
psychedelics, MDMA, psychostimulants, and cannabis. MH measurements (depressive
symptoms, overall MH, perceived stress, life satisfaction) were used as outcome
variables, while indicators of past family functioning and stressful life events
served as covariates. The MH of psychedelics users was not significantly different
from the no-drug-use group, whereas poorer MH was found in the other SU groups.
Observed effects were influenced by the tested stress factors. The absence of
association between use of psychedelics and worsening of MH deserves further
investigation in male and female samples. Stressful life experiences must be
considered when assessing the MH of users of illicit substances. These findings
suggest that some men practice SU as self-medication to cope with life adversity.
[Rougemont-Bucking, Ansgar; Merlo, Marco C. G.] Univ Fribourg, Dept Neurosci
& Movement Sci NMS, Fac Sci & Med, Med Sect,Psychiat & Psychotherapy, Ch Musee 5,
CH-1700 Fribourg, Switzerland; [Jungaberle, Henrik] FINDER Inst Prevent Res,
Berlin, Germany; [Jungaberle, Henrik] MIND European Fdn Psychedel Sci, Berlin,
Germany; [Scheidegger, Milan] Univ Hosp Psychiat Zurich, Dept Psychiat
Psychotherapy & Psychosomat, Neuropsychopharmacol & Brain Imaging, Zurich,
Switzerland; [Grazioli, Veronique S.; Daeppen, Jean-Bernard; Gmel, Gerhard; Studer,
Joseph] Lausanne Univ Hosp, Dept Psychiat, Addict Med Ctr, Lausanne, Switzerland;
[Gmel, Gerhard] Addict Switzerland, Res Dept, Lausanne, Switzerland; [Gmel,
Gerhard] Ctr Addict & Mental Hlth, Inst Mental Hlth Policy Res, Toronto, ON,
Canada; [Gmel, Gerhard] Univ West England, Fac Hlth & Social Sci, Frenchay Campus,
Bristol, Avon, England Rougemont-Bucking, A (reprint author), Univ Fribourg, Dept
Neurosci & Movement Sci NMS, Fac Sci & Med, Med Sect,Psychiat & Psychotherapy, Ch
Musee 5, CH-1700 Fribourg, Switzerland. ansgar.rougemont-buecking@unifr.ch ;
Jungaberle, Henrik/G-4038-2013; Scheidegger, Milan/S-2358-2017 Studer,
Joseph/0000-0002-1390-7707; Jungaberle, Henrik/0000-0001-7634-4211; Scheidegger,
Milan/0000-0003-1313-2208; Grazioli, Veronique S./0000-0003-1956-7712 Swiss
National Science FoundationSwiss National Science Foundation (SNSF) [FN 33CSC0-
122679, FN 33CS30_139467, FN 33CS30_148493] This work was supported by the
Swiss National Science Foundation [FN 33CSC0-122679, FN 33CS30_139467 and FN
33CS30_148493]. Alemany S, 2014, ACTA PSYCHIAT SCAND, V129, P54, DOI
10.1111/acps.12108; Anthony James C., 1994, Experimental and Clinical
Psychopharmacology, V2, P244, DOI 10.1037/1064-1297.2.3.244; Baggio Stephanie,
2014, Int J Adolesc Med Health, V26, P525, DOI 10.1515/ijamh-2013-0330; Bahr
Stephen J, 2005, J Prim Prev, V26, P529, DOI 10.1007/s10935-005-0014-8; Baker A,
2005, AUST PSYCHOL, V40, P88, DOI 10.1080/00050060500094654; Bao YP, 2013, PLOS
ONE, V8, DOI 10.1371/journal.pone.0060544; Barnwell SS, 2006, SUBST ABUSE TREAT PR,
V1, DOI 10.1186/1747-597X-1-2; Bech P, 2001, J AFFECT DISORDERS, V66, P159, DOI
10.1016/S0165-0327(00)00309-8; Brady KT, 2005, AM J PSYCHIAT, V162, P1483, DOI
10.1176/appi.ajp.162.8.1483; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI
10.2307/2136404; Copeland J, 2013, CURR OPIN PSYCHIATR, V26, P325, DOI
10.1097/YCO.0b013e328361eae5; Cuttler C, 2018, J AFFECT DISORDERS, V235, P198, DOI
10.1016/j.jad.2018.04.054; Danielson CK, 2009, ADDICT BEHAV, V34, P395, DOI
10.1016/j.addbeh.2008.11.009; Degenhardt L, 2012, LANCET, V379, P55, DOI
10.1016/S0140-6736(11)61138-0; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI
10.1207/s15327752jpa4901_13; Dube SR, 2003, PEDIATRICS, V111, P564, DOI
10.1542/peds.111.3.564; Fergusson DM, 2008, ADDICTION, V103, P969, DOI
10.1111/j.1360-0443.2008.02221.x; Foa EB, 1997, PSYCHOL ASSESSMENT, V9, P445, DOI
10.1037/1040-3590.9.4.445; Fothergill K, 2016, J HEALTH SOC BEHAV, V57, P223, DOI
10.1177/0022146516646808; Gray MJ, 2004, ASSESSMENT, V11, P330, DOI
10.1177/1073191104269954; Haasen Christian, 2005, World Psychiatry, V4, P173; Hall
W, 2015, ADDICTION, V110, P19, DOI 10.1111/add.12703; Hendricks PS, 2015, J
PSYCHOPHARMACOL, V29, P280, DOI 10.1177/0269881114565653; Heyne A, 2000, J NEURAL
TRANSM, V107, P613, DOI 10.1007/s007020070065; Hibell B., 2012, 2011 ESPAD REPORT
SU; Hooper LM, 2011, J LOSS TRAUMA, V16, P258, DOI 10.1080/15325024.2011.572035;
Huizink AC, 2006, BRIT MED J, V332, P825, DOI 10.1136/bmj.38743.539398.3A; Hyman
SE, 2005, AM J PSYCHIAT, V162, P1414, DOI 10.1176/appi.ajp.162.8.1414; Johansen PO,
2015, J PSYCHOPHARMACOL, V29, P270, DOI 10.1177/0269881114568039; Jungaberle H.,
2008, THERAPIE PSYCHOAKTIV; Karila L, 2014, CURR PHARM DESIGN, V20, P4112, DOI
10.2174/13816128113199990620; Kedzior KK, 2014, BMC PSYCHIATRY, V14, DOI
10.1186/1471-244X-14-136; Kendler KS, 2003, ARCH GEN PSYCHIAT, V60, P929, DOI
10.1001/archpsyc.60.9.929; Keyes KM, 2008, DRUG ALCOHOL DEPEN, V97, P139, DOI
10.1016/j.drugalcdep.2008.04.001; Kogan SM, 2017, AM J ADDICTION, V26, P400, DOI
10.1111/ajad.12555; Krebs TS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063972;
Levant RF, 2014, AM J MENS HEALTH, V8, P110, DOI 10.1177/1557988313494408; Lieb R,
2002, DRUG ALCOHOL DEPEN, V68, P195, DOI 10.1016/S0376-8716(02)00190-4; Marconi A,
2016, SCHIZOPHRENIA BULL, V42, P1262, DOI 10.1093/schbul/sbw003; MCLELLAN AT, 1980,
J NERV MENT DIS, V168, P26, DOI 10.1097/00005053-198001000-00006; Miller P.PlantM,
2003, J SUBST USE, V8, P19, DOI DOI 10.1080/1465989021000067209; Mithoefer MC,
2016, LANCET PSYCHIAT, V3, P481, DOI 10.1016/S2215-0366(15)00576-3; Montgomery C,
2008, DRUG ALCOHOL REV, V27, P640, DOI 10.1080/09595230802392790; Moonzwe LS, 2011,
J PSYCHOACTIVE DRUGS, V43, P199, DOI 10.1080/02791072.2011.605671; Nakagawa S,
2007, BIOL REV, V82, P591, DOI 10.1111/j.1469-185X.2007.00027.x; Olsen LR, 2003,
PSYCHOL MED, V33, P351, DOI 10.1017/S0033291702006724; Parks KA, 2004, J
PSYCHOACTIVE DRUGS, V36, P295, DOI 10.1080/02791072.2004.10400030; Parrott AC,
2014, J PSYCHOACTIVE DRUGS, V46, P37, DOI 10.1080/02791072.2014.873690; Patel R,
2015, THER ADV PSYCHOPHARM, V5, P179, DOI 10.1177/2045125315583786; Peralta RL,
2016, ADDICT RES THEORY, V24, P389, DOI 10.3109/16066359.2016.1140745; Pries LK,
2018, SCHIZOPHRENIA BULL, V44, P710, DOI 10.1093/schbul/sby051; Prinzleve M, 2004,
EUR ADDICT RES, V10, P147, DOI 10.1159/000079835; Rao U, 2009, AM J PSYCHIAT, V166,
P361, DOI 10.1176/appi.ajp.2008.08030412; Rougemont-Bucking A, 2017, EUR ADDICT
RES, V23, P284, DOI 10.1159/000485031; Schellekens AFA, 2013, ADDICT BIOL, V18,
P344, DOI 10.1111/j.1369-1600.2012.00438.x; Scott RM, 2013, ADDICT BEHAV, V38,
P2465, DOI 10.1016/j.addbeh.2013.05.005; Sinha R, 2008, ANN NY ACAD SCI, V1141,
P105, DOI 10.1196/annals.1441.030; Solomon SR, 2009, J MOD APPL STAT METH, V8,
P448; Studerus E, 2011, J PSYCHOPHARMACOL, V25, P1434, DOI
10.1177/0269881110382466; Tornay L, 2013, EUR J PEDIATR, V172, P1229, DOI
10.1007/s00431-013-2029-0; Van Ryzin MJ, 2012, ADDICT BEHAV, V37, P1314, DOI
10.1016/j.addbeh.2012.06.020; Wardle MC, 2014, PSYCHOPHARMACOLOGY, V231, P4219, DOI
10.1007/s00213-014-3570-x; Ware JE, 1996, MED CARE, V34, P220, DOI
10.1097/00005650-199603000-00003 63 0 0 0 1 ROUTLEDGE
JOURNALS, TAYLOR & FRANCIS LTD ABINGDON 2-4 PARK SQUARE, MILTON PARK,
ABINGDON OX14 4RN, OXON, ENGLAND 0279-1072 2159-9777 J PSYCHOACTIVE
DRUGS J. Psychoact. Drugs MAY 27 2019 51 3
236 246 10.1080/02791072.2019.1571258 11 Psychology,
Clinical; Substance Abuse Psychology; Substance Abuse IM3GW
WOS:000477882600004 30836844 2019-09-25
J Lemyre, A; Gauthier-Legare, A; Belanger, RE Lemyre,
Alexandre; Gauthier-Legare, Audrey; Belanger, Richard E. Shyness,
social anxiety, social anxiety disorder, and substance use among normative
adolescent populations: A systematic review AMERICAN JOURNAL OF DRUG AND
ALCOHOL ABUSE English Review
Systematic review; shyness; social anxiety; social anxiety disorder;
substance use; adolescence HIGH-SCHOOL-STUDENTS; ALCOHOL-USE DISORDER; CANNABIS
USE; NATIONAL COMORBIDITY; ROMANTIC RELATIONSHIPS; LIFETIME PREVALENCE; CIGARETTE-
SMOKING; MENTAL-DISORDERS; SELF-MEDICATION; COGNITIVE MODELResearchers have
increasingly studied shyness, social anxiety, and social anxiety disorder (SAD) as
potential precursors of substance use. Objectives. The objective of this study was
to review the relationships between these variables and tobacco use, alcohol use,
and cannabis/drug use in normative adolescent populations and the extent to which
these associations differ by gender. Methods. A systematic search in PsycINFO and
PubMed was conducted, reference screening was performed, and five experts were
consulted. Results. Fifty articles published between 1980 and 2016 were included
for review. Shyness was frequently associated with lower use of tobacco, alcohol,
and cannabis/drug. Similar findings emerged for social anxiety. In contrast, SAD
tended to be associated with higher use of tobacco and cannabis/drug, although the
association between SAD and the use of alcohol appeared inconclusive. Furthermore,
limited evidence suggests that shy females use less tobacco than shy males and that
males with social anxiety use less drugs than socially anxious females.
Conclusions. In conclusion, these results highlight that shyness, social anxiety,
and SAD may exert different effects on substance use. Higher use of substances
among adolescents suffering from a SAD may be explained, among other possibilities,
by a self-medication mechanism. While all adolescents should benefit from
prevention efforts targeted at substance use, a systematic screening for substance
use disorders during the clinical evaluation that precedes SAD treatments is
advised. [Lemyre, Alexandre; Gauthier-Legare, Audrey] Univ Laval, Sch Psychol,
Quebec City, PQ, Canada; [Lemyre, Alexandre; Belanger, Richard E.] CHU Quebec Res
Ctr, Populat Hlth & Optimal Hlth Practices Branch, Quebec City, PQ, Canada;
[Gauthier-Legare, Audrey] Univ Ctr Res Youth & Families, Quebec City, PQ, Canada;
[Belanger, Richard E.] CHU Quebec Univ, CHU Quebec, Ctr Mere Enfant Soleil, Dept
Paediat, Quebec City, PQ, Canada Belanger, RE (reprint author), Hop St
Sacrement, 1050 Chemin Ste Foy,Bur JS1-22, Quebec City, PQ G1S 4L8, Canada.
Richard.Belanger@chudequebec.ca Lemyre, Alexandre/0000-0003-3803-
9341 Aikins JW, 2010, J ADOLESCENCE, V33, P813, DOI
10.1016/j.adolescence.2010.07.007; Allen O., 1994, HEALTH VALUES, V18, P34;
American Psychiatric Association, 2013, DIAGN STAT MAN MENT; Anderson KG, 2011, J
STUD ALCOHOL DRUGS, V72, P61, DOI 10.15288/jsad.2011.72.61; Battista Susan R, 2010,
Curr Drug Abuse Rev, V3, P3; Bekman NM, 2010, J STUD ALCOHOL DRUGS, V71, P570, DOI
10.15288/jsad.2010.71.570; Biggs BK, 2011, SOCIAL ANXIETY ADOLE, P143, DOI DOI
10.1037/12315-008; Bittner A, 2007, J CHILD PSYCHOL PSYC, V48, P1174, DOI
10.1111/j.1469-7610.2007.01812.x; BLOCK J, 1988, CHILD DEV, V59, P336, DOI
10.1111/j.1467-8624.1988.tb01470.x; Blumenthal H, 2016, ANXIETY STRESS COPIN, V29,
P432, DOI 10.1080/10615806.2015.1058366; Blumenthal H, 2010, PSYCHOL ADDICT BEHAV,
V24, P529, DOI 10.1037/a0019794; BOTVIN GJ, 1989, J DEV BEHAV PEDIATR, V10, P181;
Brook CA, 2019, J PERS ASSESS, V101, P54, DOI 10.1080/00223891.2017.1388808;
Buckner JD, 2012, DRUG ALCOHOL DEPEN, V124, P128, DOI
10.1016/j.drugalcdep.2011.12.023; Burstein M, 2011, PEDIATRICS, V128, P917, DOI
10.1542/peds.2011-1434; Burstein M, 2011, J AM ACAD CHILD PSY, V50, P870, DOI
10.1016/j.jaac.2011.06.005; BUSH PJ, 1992, DRUG ALCOHOL DEPEN, V30, P275, DOI
10.1016/0376-8716(92)90062-H; Carrigan MH, 2003, ADDICT BEHAV, V28, P269, DOI
10.1016/S0306-4603(01)00235-0; Chabrol H, 2012, ADDICT BEHAV, V37, P1109, DOI
10.1016/j.addbeh.2012.05.005; Chavira DA, 2002, J ANXIETY DISORD, V16, P585, DOI
10.1016/S0887-6185(02)00124-X; Cloutier RM, 2016, SUBST USE MISUSE, V51, P408, DOI
10.3109/10826084.2015.1110174; Conway KP, 2016, J AM ACAD CHILD PSY, V55, P280, DOI
10.1016/j.jaac.2016.01.006; Cox BJ, 2005, BEHAV RES THER, V43, P1019, DOI
10.1016/j.brat.2004.07.006; Creemers HE, 2010, ADDICTION, V105, P699, DOI
10.1111/j.1360-0443.2009.02819.x; Creemers HE, 2009, DRUG ALCOHOL DEPEN, V104,
P113, DOI 10.1016/j.drugalcdep.2009.04.010; Crisp AH, 1998, POSTGRAD MED J, V74,
P473, DOI 10.1136/pgmj.74.874.473; Dahne J, 2014, J STUD ALCOHOL DRUGS, V75, P929,
DOI 10.15288/jsad.2014.75.929; de Jong PJ, 2012, PSYCHOL MED, V42, P475, DOI
10.1017/S0033291711001358; DeLay D, 2016, DEV PSYCHOL, V52, P117, DOI
10.1037/a0039882; Di Blasi M, 2015, J CHILD ADOLES SUBST, V24, P397, DOI
10.1080/1067828X.2013.872066; Doey L, 2014, SEX ROLES, V70, P255, DOI
10.1007/s11199-013-0317-9; Findlay LC, 2009, INT J BEHAV DEV, V33, P47, DOI
10.1177/0165025408098017; FLEMING JP, 1982, DRUG ALCOHOL DEPEN, V9, P285, DOI
10.1016/0376-8716(82)90068-0; Fothergill KE, 2009, J HEALTH SOC BEHAV, V50, P65,
DOI 10.1177/002214650905000105; Fothergill KE, 2006, DRUG ALCOHOL DEPEN, V82, P61,
DOI 10.1016/j.drugalcdep.2005.08.009; Frojd S, 2011, ALCOHOL ALCOHOLISM, V46, P192,
DOI 10.1093/alcalc/agq096; Griesler PC, 2011, ADDICTION, V106, P1010, DOI
10.1111/j.1360-0443.2011.03403.x; Halldorsson B, 2017, BEHAV RES THER, V99, P19,
DOI 10.1016/j.brat.2017.08.013; Heiser NA, 2003, BEHAV RES THER, V41, P209, DOI
10.1016/S0005-7967(02)00003-7; Heiser NA, 2009, J ANXIETY DISORD, V23, P469, DOI
10.1016/j.janxdis.2008.10.002; Henry SL, 2012, ANN BEHAV MED, V43, P383, DOI
10.1007/s12160-011-9340-7; Hodson KJ, 2008, BEHAV COGN PSYCHOTH, V36, P449, DOI
10.1017/S1352465808004487; Hoffman BR, 2006, SUBST USE MISUSE, V41, P103, DOI
10.1080/10826080500368892; JONES WH, 1986, J PERS SOC PSYCHOL, V51, P629, DOI
10.1037/0022-3514.51.3.629; Kennedy DP, 2011, ADDICT BEHAV, V36, P320, DOI
10.1016/j.addbeh.2010.11.014; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI
10.1001/archpsyc.62.6.593; Kessler RC, 2012, INT J METH PSYCH RES, V21, P169, DOI
10.1002/mpr.1359; Kingery JN, 2010, CLIN CHILD FAM PSYCH, V13, P91, DOI
10.1007/s10567-009-0063-2; Kley H, 2012, J BEHAV THER EXP PSY, V43, P548, DOI
10.1016/j.jbtep.2011.07.008; Korhonen T, 2008, DRUG ALCOHOL DEPEN, V97, P33, DOI
10.1016/j.drugalcdep.2008.03.015; Krahn D, 1996, J SUBST ABUSE, V8, P293, DOI
10.1016/S0899-3289(96)90161-3; Kreager DA, 2011, AM SOCIOL REV, V76, P737, DOI
10.1177/0003122411416934; Lemyre A, 2018, PSYCHOL ADDICT BEHAV, V32, P132, DOI
10.1037/adb0000328; Leventhal AM, 2016, J PSYCHIATR RES, V73, P71, DOI
10.1016/j.jpsychires.2015.11.008; Lewinsohn PM, 1997, J ANXIETY DISORD, V11, P377,
DOI 10.1016/S0887-6185(97)00017-0; Marmorstein NR, 2010, J CLIN CHILD ADOLESC, V39,
P545, DOI 10.1080/15374416.2010.486325; Marmorstein NR, 2010, J ABNORM CHILD PSYCH,
V38, P211, DOI 10.1007/s10802-009-9360-y; Marschall-Levesque S, 2014, ADDICT BEHAV,
V39, P48, DOI 10.1016/j.addbeh.2013.09.025; Mermelstein RJ, 2009, NICOTINE TOB RES,
V11, P1226, DOI 10.1093/ntr/ntp127; Morris EP, 2005, CLIN PSYCHOL REV, V25, P734,
DOI 10.1016/j.cpr.2005.05.004; Moylan S, 2013, PLOS ONE, V8, DOI
10.1371/journal.pone.0063252; Myers MG, 2003, PSYCHOL ADDICT BEHAV, V17, P277, DOI
10.1037/0893-164X.17.4.277; Nelemans SA, 2016, EUR CHILD ADOLES PSY, V25, P483, DOI
10.1007/s00787-015-0747-8; Nelemans SA, 2014, DEV PSYCHOPATHOL, V26, P181, DOI
10.1017/S0954579413000503; O'Callaghan F, 2001, J SUBST ABUSE, V13, P459, DOI
10.1016/S0899-3289(01)00089-X; Ohannessian CM, 2014, SUBST ABUS, V35, P418, DOI
10.1080/08897077.2014.953663; Pacek LR, 2013, J DUAL DIAGN, V9, P271, DOI
10.1080/15504263.2013.835164; PAGE RM, 1990, ADOLESCENCE, V25, P803; PAGE RM, 1989,
J SCHOOL HEALTH, V59, P432, DOI 10.1111/j.1746-1561.1989.tb04658.x; Pardee CS,
2014, PSYCHOL ADDICT BEHAV, V28, P1246, DOI 10.1037/a0038372; Piko BF, 2016, EUR J
PEDIATR, V175, P785, DOI 10.1007/s00431-016-2709-7; Ponti L, 2015, J PSYCHOPATHOL-G
PSI, V21, P30; Poole KL, 2017, PERS INDIV DIFFER, V110, P55, DOI
10.1016/j.paid.2017.01.020; Sartor CE, 2016, ALCOHOL CLIN EXP RES, V40, P1515, DOI
10.1111/acer.13113; SCHLENKER BR, 1982, PSYCHOL BULL, V92, P641, DOI 10.1037/0033-
2909.92.3.641; Schmits E, 2016, J CHILD ADOLES SUBST, V25, P348, DOI
10.1080/1067828X.2015.1039683; Schmits E, 2015, J ADOLESCENCE, V41, P43, DOI
10.1016/j.adolescence.2015.02.009; Schneier FR, 2010, PSYCHOL MED, V40, P977, DOI
10.1017/S0033291709991231; Schreiber F, 2012, INT J COGN THER, V5, P341, DOI
10.1521/ijct.2012.5.3.341; Simons-Morton BG, 2010, J PRIM PREV, V31, P191, DOI
10.1007/s10935-010-0220-x; Spence SH, 2016, BEHAV RES THER, V86, P50, DOI
10.1016/j.brat.2016.06.007; Substance Abuse and Mental Health Services
Administration, 2013, RES 2013 NAT SURV DR; Tercyak KP, 2003, SUBST USE MISUSE,
V38, P1953, DOI 10.1081/JA-120025121; Tomlinson KL, 2013, J CHILD ADOLES SUBST,
V22, P163, DOI 10.1080/1067828X.2012.747994; Tomlinson KL, 2012, ADDICT BEHAV, V37,
P179, DOI 10.1016/j.addbeh.2011.09.016; Tucker JS, 2006, PSYCHOL ADDICT BEHAV, V20,
P363, DOI 10.1037/0893-164X.20.4.363; Vaananen JM, 2014, BMC PSYCHIATRY, V14, DOI
10.1186/1471-244X-14-79; van der Zwaluw CS, 2009, EUR CHILD ADOLES PSY, V18, P407,
DOI 10.1007/s00787-009-0748-6; Van Zalk N, 2011, SCAND J PSYCHOL, V52, P341, DOI
10.1111/j.1467-9450.2011.00877.x; Van Zalk N, 2011, J PERS, V79, P499, DOI
10.1111/j.1467-6494.2011.00682.x; Varga S, 2015, BMC PUBLIC HEALTH, V15, DOI
10.1186/s12889-015-2474-y; Vassilopoulos SP, 2017, HELLENIC J PSYCHOL, V14, P1;
Voelkel EA, 2013, HDB TREATING VARIANT, P177; Walburg V., 2014, NEUROPSYCHIAT
ENFAN,
V62, P163, DOI [10.1016/j.neurenf.2014.02.001, DOI 10.1016/J.NEURENF.2014.02.001];
Walther B, 2012, EUR ADDICT RES, V18, P167, DOI 10.1159/000335662; Weeks M, 2016, J
EARLY ADOLESCENCE, V36, P1095, DOI 10.1177/0272431615593175; Wolitzky-Taylor K,
2012, ADDICT BEHAV, V37, P982, DOI 10.1016/j.addbeh.2012.03.026; WORKMAN M, 1992,
PSYCHOL REP, V71, P279, DOI 10.2466/PR0.71.5.279-286; Wu P, 2010, J YOUTH
ADOLESCENCE, V39, P177, DOI 10.1007/s10964-008-9385-5; Zehe JM, 2013, ADDICT BEHAV,
V38, P1931, DOI 10.1016/j.addbeh.2012.11.013 100 0 0 21 26 TAYLOR
& FRANCIS INC PHILADELPHIA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA
19106 USA 0095-2990 1097-9891 AM J DRUG ALCOHOL AB Am. J. Drug
Alcohol Abuse MAY 4 2019 45 3 230 247
10.1080/00952990.2018.1536882 18 Psychology, Clinical;
Substance Abuse Psychology; Substance Abuse HS4JG WOS:000463827500002
30422012 2019-09-25
J Bountress, KE; Cusack, SE; Sheerin, CM; Hawn, S; Dick, DM; Kendler, KS;
Amstadter, AB Bountress, Kaitlin E.; Cusack, Shannon E.;
Sheerin, Christina M.; Hawn, Sage; Dick, Danielle M.; Kendler, Kenneth S.;
Amstadter, Ananda B. Alcohol Consumption, Interpersonal Trauma, and
Drinking to Cope With Trauma-Related Distress: An Auto-Regressive, Cross-Lagged
Model PSYCHOLOGY OF ADDICTIVE BEHAVIORS English Article
college students; alcohol use; interpersonal trauma;
drinking to cope; longitudinal modeling POSTTRAUMATIC-STRESS-DISORDER; HEAVY
EPISODIC DRINKING; SUBSTANCE USE; COLLEGE-STUDENTS; SEXUAL ASSAULT; PTSD SYMPTOMS;
ENVIRONMENTAL-INFLUENCES; PSYCHOLOGICAL DISTRESS; PROBLEMATIC ALCOHOL; ANXIETY
DISORDERS Alcohol consumption and interpersonal trauma (IPT) co-occur at high
rates, particularly in college populations. Two non-mutually-exclusive theories of
this comorbidity are the risky behavior model, suggesting that substance use
increases likelihood of IPT, and the self-medication model, suggesting that
individuals use substances to cope with trauma-related symptoms. Few have
simultaneously tested these theories in a sample of college students. Thus, the
overarching aim of this longitudinal study (n = 1320) was to identify whether
alcohol consumption and IPT arc associated with one another, and if IPT and/or
posttraumatic stress disorder (PTSD) impacts use of alcohol to cope with trauma-
related distress. Data were collected from a longitudinal study of college students
attending a large public university. Participants in the current study were on
average 18.46 years old at study entry, primarily female (70%), and of diverse
racial/ethnic backgrounds (e.g., 49.4% White, 19.7% Black, 17.2% Asian). Results
from auto-regressive, cross-lagged models indicated that alcohol consumption
preceded IPT exposure. In contrast, IPT was not prospectively associated with
alcohol consumption. Those reporting probable PTSD, but not IPT, reported more use
of alcohol to cope with trauma-related distress. These findings provide support for
the risky behavior model, indicating that those with higher levels of alcohol
consumption may be a vulnerable group in terms of likelihood of IPT. Findings also
suggest that those reporting probable PTSD may be at risk for use of alcohol to
cope with trauma-related distress. Implications of these findings, in light of
study limitations, are discussed. [Bountress, Kaitlin E.; Sheerin, Christina M.;
Kendler, Kenneth S.; Amstadter, Ananda B.] Virginia Commonwealth Univ, Virginia
Inst Psychiat & Behav Genet, Richmond, VA 23284 USA; [Cusack, Shannon E.; Hawn,
Sage; Dick, Danielle M.] Virginia Commonwealth Univ, Dept Psychol, Richmond, VA
23284 USA Bountress, KE (reprint author), 800 Leigh St,Biotech One,POB 980126,
Richmond, VA 23298 USA. kaitlin.bountress@vcuhealth.org National
Institute on Alcohol Abuse and AlcoholismUnited States Department of Health & Human
ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol
Abuse & Alcoholism (NIAAA) [P20 AA017828, R37AA011408, K02AA018755, P50 AA022537];
National Center for Research ResourcesUnited States Department of Health & Human
ServicesNational Institutes of Health (NIH) - USANIH National Center for Research
Resources (NCRR) [UL1RR031990]; National Institutes of Health Roadmap for Medical
ResearchUnited States Department of Health & Human ServicesNational Institutes of
Health (NIH) - USA; Virginia Commonwealth University; [F31AA025820]; [T32
MH020030]; [AA025692] Spit for Science has been supported by Virginia
Commonwealth University, P20 AA017828, R37AA011408, K02AA018755, and P50 AA022537
from the National Institute on Alcohol Abuse and Alcoholism, and UL1RR031990 from
the National Center for Research Resources and National Institutes of Health
Roadmap for Medical Research. We thank the Spit for Science participants for making
this study a success, as well as the many university faculty, students, and staff
who contributed to the design and implementation of the project. Additional funding
for this project has come from F31AA025820 (PI: Sage Hawn), and T32 MH020030 and
AA025692 (Christina M. Sheerin). These data have not been presented at a conference
or meeting, posted on a listserv, shared on a website, etc.Abbey A, 2002, J STUD
ALCOHOL, P118, DOI 10.15288/jsas.2002.s14.118; Bachrach RL, 2017, PSYCHOL ADDICT
BEHAV, V31, P576, DOI 10.1037/adb0000285; Banks DE, 2017, SUBST USE MISUSE, V52,
P992, DOI 10.1080/10826084.2016.1268629; Beseler CL, 2011, ALCOHOL CLIN EXP RES,
V35, P1004, DOI 10.1111/j.1530-0277.2010.01431.x; Brady KT, 2000, J CLIN PSYCHIAT,
V61, P22; Breslau N, 2002, CAN J PSYCHIAT, V47, P923; Bush K, 1998, ARCH INTERN
MED, V158, P1789, DOI 10.1001/archinte.158.16.1789; Chang EC, 1998, J CLIN PSYCHOL,
V54, P137, DOI 10.1002/(SICI)1097-4679(199802)54:2<137::AID-JCLP2>3.0.CO;2-P;
Chilcoat HD, 1998, ARCH GEN PSYCHIAT, V55, P913, DOI 10.1001/archpsyc.55.10.913;
Cohen J., 2003, APPL MULTIPLE REGRES; Cooper M. L., 1994, PSYCHOL ASSESSMENT, V6,
P117, DOI [DOI 10.1037/1040-3590.6.2.117, 10.1037/1040-3590.6.2.117]; Cooper M. L.,
1992, PSYCHOL ASSESSMENT, V4, P123, DOI [DOI 10.1037/1040-3590.4.2.123,
10.1037/1040-3590.4.2.123]; Cross D, 2015, CHILD ABUSE NEGLECT, V44, P26, DOI
10.1016/j.chiabu.2015.01.007; Davis KC, 2009, VIOLENCE AGAINST WOM, V15, P1106, DOI
10.1177/1077801209340759; Dawson DA, 2004, J STUD ALCOHOL, V65, P477, DOI
10.15288/jsa.2004.65.477; Dawson DA, 2000, ALCOHOL CLIN EXP RES, V24, P1820, DOI
10.1111/j.1530-0277.2000.tb01986.x; Delker E, 2016, ALCOHOL RES-CURR REV, V38, P7;
Dick DM, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00047; Dixon LJ, 2009,
ADDICT BEHAV, V34, P1065, DOI 10.1016/j.addbeh.2009.06.008; Goldstein AL, 2010,
ADDICT BEHAV, V35, P636, DOI 10.1016/j.addbeh.2010.02.002; Grant BF, 2004, ARCH GEN
PSYCHIAT, V61, P807, DOI 10.1001/archpsyc.61.8.807; Haller M, 2014, PSYCHOL ADDICT
BEHAV, V28, P841, DOI 10.1037/a0035878; Ham LS, 2007, J ANXIETY DISORD, V21, P991,
DOI 10.1016/j.janxdis.2006.10.014; Hankin BL, 2005, J ABNORM PSYCHOL, V114, P96,
DOI 10.1037/0021-843X.114.1.96; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI
10.1016/j.jbi.2008.08.010; Holahan CJ, 2001, J STUD ALCOHOL, V62, P190, DOI
10.15288/jsa.2001.62.190; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI
10.1080/10705519909540118; Jakupcak M, 2010, ADDICT BEHAV, V35, P840, DOI
10.1016/j.addbeh.2010.03.023; Johnson L. D, 2007, MONITORING FUTURE NA, V1; Kaplow
JB, 2001, J CLIN CHILD PSYCHOL, V30, P316, DOI 10.1207/S15374424JCCP3003_4; KESSLER
RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012;
KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259; Kilpatrick DG, 1997, J CONSULT CLIN
PSYCH, V65, P834, DOI 10.1037/0022-006X.65.5.834; Kilpatrick DG, 2003, J CONSULT
CLIN PSYCH, V71, P692, DOI 10.1037/0022-006X.71.4.692; Krug EG, 2002, LANCET, V360,
P1083, DOI 10.1016/S0140-6736(02)11133-0; Kushner MG, 2000, CLIN PSYCHOL REV, V20,
P149, DOI 10.1016/S0272-7358(99)00027-6; McDevitt-Murphy ME, 2010, J TRAUMA STRESS,
V23, P108, DOI 10.1002/jts.20482; McLeod DS, 2001, J TRAUMA STRESS, V14, P259, DOI
10.1023/A:1011157800050; Messman-Moore TL, 2008, J INTERPERS VIOLENCE, V23, P1730,
DOI 10.1177/0886260508314336; Messman-Moore TL, 2013, PSYCHOL ADDICT BEHAV, V27,
P125, DOI 10.1037/a0031073; Muthen B, 2009, MISSING X VARIABLES; Muthen L.K., 2017,
MPLUS VERSION 8 USER; National Institute on Alcohol Abuse and Alcoholism, 2017, ALC
FACTS STAT; Prins A, 2016, J GEN INTERN MED, V31, P1206, DOI 10.1007/s11606-016-
3703-5; Read JP, 2016, PSYCHOL TRAUMA-US, V8, P393, DOI 10.1037/tra0000087; Read
JP, 2014, PSYCHOL ADDICT BEHAV, V28, P1052, DOI 10.1037/a0038348; Read JP, 2013, J
ABNORM PSYCHOL, V122, P984, DOI 10.1037/a0034918; Read JP, 2012, J CONSULT CLIN
PSYCH, V80, P426, DOI 10.1037/a0028210; Roberts AL, 2011, PSYCHOL MED, V41, P71,
DOI 10.1017/S0033291710000401; Sabina C, 2017, J FAM VIOLENCE, V32, P305, DOI
10.1007/s10896-017-9907-6; Salvatore JE, 2016, PSYCHOL ADDICT BEHAV, V30, P335, DOI
10.1037/adb0000145; Schafer JL, 2002, PSYCHOL METHODS, V7, P147, DOI 10.1037//1082-
989X.7.2.147; Schmitz N, 2000, QUAL LIFE RES, V9, P185, DOI
10.1023/A:1008931926181; Sher KJ, 1996, J ABNORM PSYCHOL, V105, P561, DOI
10.1037/0021-843X.105.4.561; Shin SH, 2013, DRUG ALCOHOL DEPEN, V127, P31, DOI
10.1016/j.drugalcdep.2012.06.005; Slutske WS, 2005, ARCH GEN PSYCHIAT, V62, P321,
DOI 10.1001/archpsyc.62.3.321; Slutske WS, 2004, J ABNORM PSYCHOL, V113, P530, DOI
10.1037/0021-843X.113.4.530; Squeglia LM, 2016, CURR PSYCHIAT REP, V18, DOI
10.1007/s11920-016-0689-y; Stewart SH, 1996, PSYCHOL BULL, V120, P83, DOI
10.1037/0033-2909.120.1.83; Sundstrom C, 2017, INT J BEHAV MED, V24, P646, DOI
10.1007/s12529-016-9601-8; Todd DM, 1997, J COUNS PSYCHOL, V44, P294, DOI
10.1037/0022-0167.44.3.294; Ullman SE, 2013, ADDICT BEHAV, V38, P2219, DOI
10.1016/j.addbeh.2013.01.027; Ullman SE, 2005, J STUD ALCOHOL, V66, P610, DOI
10.15288/jsa.2005.66.610; Veilleux JC, 2014, PERS INDIV DIFFER, V59, P96, DOI
10.1016/j.paid.2013.11.012; Waldrop AE, 2007, ADDICT BEHAV, V32, P634, DOI
10.1016/j.addbeh.2006.06.001; Walsh K, 2012, J ADOLESCENT HEALTH, V50, P54, DOI
10.1016/j.jadohealth.2011.05.017; Weathers F. W., 2013, INSTRUMENT AVAILABLE, DOI
DOI 10.1177/1073191104269954; Wechsler H, 2000, J AM COLL HEALTH, V48, P199, DOI
10.1080/07448480009599305; White A, 2013, ALCOHOL RES-CURR REV, V35, P201; Widom
CS, 2008, CHILD ABUSE NEGLECT, V32, P785, DOI 10.1016/j.chiabu.2007.12.006; WINDLE
M, 1994, ADDICTION, V89, P175, DOI 10.1111/j.1360-0443.1994.tb00876.x; Wolff JM,
2017, J SEX RES, V54, P362, DOI 10.1080/00224499.2016.1143439 72 0 0
5 5 EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
WASHINGTON 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA 0893-164X 1939-
1501 PSYCHOL ADDICT BEHAV Psychol. Addict. Behav. MAY 2019 33 3
221 231 10.1037/adb0000457 11
Substance
Abuse; Psychology, Multidisciplinary Substance Abuse; Psychology HU9PH
WOS:000465625800005 30869917 2019-09-25
J Cloutier, RM; Blumenthal, H; Trim, RS; Douglas, ME; Anderson, KG
Cloutier, Renee M.; Blumenthal, Heidemarie; Trim, Ryan S.; Douglas, Megan E.;
Anderson, Kristen G. Real-Time Social Stress Response and Subsequent
Alcohol Use Initiation Among Female Adolescents PSYCHOLOGY OF ADDICTIVE BEHAVIORS
English Article adolescent;
alcohol incidence; social stress responding; anticipatory anxiety; discrete-time
survival analysis (DTSA) SUBSTANCE USE; USE DISORDERS; RISK-TAKING;
PROSPECTIVE ASSOCIATION; INTERNALIZING SYMPTOMS; GENDER-DIFFERENCES; SELF-
MEDICATION; CIGARETTE USE; ANXIETY; DRINKING Adolescents who are particularly
sensitive to social stress may be vulnerable to earlier alcohol consumption and
related problems. Although a small literature supports this contention, previous
studies mostly relied on retrospective self-report. The current study used
discrete-time survival analysis (DTSA) to test whether real-time social stress
responding (via laboratory induction) and social anxiety symptoms predicted 12-
month alcohol onset in an alcohol-naive sample of young female adolescents. Anxiety
elicited by the task was expected to predict greater and earlier rates of alcohol
incidence, particularly among girls with higher levels of self-reported social
anxiety symptoms. Participants were 104 community-recruited girls (ages 12-15
years) who completed a modified Trier Social Stress Test and questionnaires;
follow-up calls were conducted at 3,6,9, and 12 months after the laboratory visit.
Self-reported anxiety was assessed in response to the stressor following
acclimation (baseline), instruction (anticipation), and speech (posttask). By 12
months. 30.8% of the sample had consumed a full alcoholic beverage. The DTSA
revealed that girls with higher levels of social anxiety and greater elevations in
anticipatory (but not posttask) anxiety compared to baseline had earlier alcohol
initiation. This is the first study to examine the role of both laboratory-induced
anxious responding and retrospective reports of social anxiety as prospective
predictors of alcohol incidence. These preliminary findings suggest that adolescent
girls who are more sensitive to social stress may be at risk for experimenting with
alcohol earlier than their peers. [Cloutier, Renee M.; Blumenthal, Heidemarie]
Univ North Texas, Dept Psychol, Teen Stress & Alcohol Res Lab, 1155 Union Circle
311280, Denton, TX 76203 USA; [Trim, Ryan S.] Univ Calif San Diego, Dept Psychiat,
La Jolla, CA 92093 USA; [Douglas, Megan E.] Univ North Texas, Dept Psychol, Denton,
TX 76203 USA; [Anderson, Kristen G.] Reed Coll, Dept Psychol, Portland, OR 97202
USA Cloutier, RM; Blumenthal, H (reprint author), Univ North Texas, Dept Psychol,
Teen Stress & Alcohol Res Lab, 1155 Union Circle 311280, Denton, TX 76203 USA.
reneecloutier@my.unt.edu; heidemarie.blumenthal@unt.edu Cloutier, Renee
M/D-2249-2019 Cloutier, Renee M/0000-0003-1795-9149 National Institute on
Drug Abuse National Research Service Award [1F31DA041105]; National Institute on
Alcohol Abuse and AlcoholismUnited States Department of Health & Human
ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol
Abuse & Alcoholism (NIAAA) [R15 AA026079-01] Renee M. Cloutier was partially
supported by National Institute on Drug Abuse National Research Service Award
1F31DA041105 during the writing of this article. This project also was partially
supported by a National Institute on Alcohol Abuse and Alcoholism grant awarded to
Heidemarie Blumenthal (R15 AA026079-01). This article has not been, nor will it be,
published by any other journal and is not under consideration for publication
elsewhere. Earlier versions of the ideas and data appearing in this article were
presented at poster sessions at the Collaborative Perspectives on Addiction
Conference (2016) and a Research Society on Alcoholism meeting (2018). Abrams K,
2002, PSYCHOL ADDICT BEHAV, V16, P121, DOI 10.1037//0893-164X.16.2.121; Anderson
KG, 2014, J STUD ALCOHOL DRUGS, V75, P953, DOI 10.15288/jsad.2014.75.953; Anderson
KG, 2011, J CHILD ADOLES SUBST, V20, P48, DOI 10.1080/1067828X.2011.534362;
Asparouhov T., 2006, P JOINT STAT M SEATT, P180; Battista Susan R, 2010, Curr Drug
Abuse Rev, V3, P3; Blumenthal H, 2019, DESIRE DRINK FUNCTIO; Blumenthal H, 2016,
ANXIETY STRESS COPIN, V29, P432, DOI 10.1080/10615806.2015.1058366; Blumenthal
Heidemarie, 2011, J Exp Psychopathol, V2, P318; Blumenthal H, 2010, PSYCHOL ADDICT
BEHAV, V24, P529, DOI 10.1037/a0019794; Boden JM, 2011, YOUNG PEOPLE AND ALCOHOL:
IMPACT, POLICY, PREVENTION, TREATMENT, P32; Brady KT, 1999, PSYCHIAT CLIN N AM,
V22, P241, DOI 10.1016/S0193-953X(05)70074-5; Buckner JD, 2008, J PSYCHIATR RES,
V42, P230, DOI 10.1016/j.jpsychires.2007.01.002; Buckner JD, 2013, DEPRESS ANXIETY,
V30, P276, DOI 10.1002/da.22032; Buckner JD, 2009, J PSYCHIATR RES, V43, P477, DOI
10.1016/j.jpsychires.2008.04.012; Caldwell LC, 2005, ALCOHOL ALCOHOLISM, V40, P194,
DOI 10.1093/alcalc/agh134; Chorpita BF, 2000, BEHAV RES THER, V38, P835, DOI
10.1016/S0005-7967(99)00130-8; Cloutier RM, 2016, SUBST USE MISUSE, V51, P408, DOI
10.3109/10826084.2015.1110174; Colder CR, 2017, ALCOHOL CLIN EXP RES, V41, P2185,
DOI 10.1111/acer.13512; Colder CR, 2018, ADDICT BEHAV, V76, P82, DOI
10.1016/j.addbeh.2017.07.030; Colder CR, 2013, J ABNORM CHILD PSYCH, V41, P667, DOI
10.1007/s10802-012-9701-0; Conners C. K., 1999, CONNERS ADULT ADHD R; Conrod PJ,
2006, J CLIN CHILD ADOLESC, V35, P550, DOI 10.1207/s15374424jccp3504_6; Conrod PJ,
2013, JAMA PSYCHIAT, V70, P334, DOI 10.1001/jamapsychiatry.2013.651; Cuijpers P,
2002, ADDICT BEHAV, V27, P1009, DOI 10.1016/S0306-4603(02)00295-2; de Wit H, 2003,
ALCOHOL CLIN EXP RES, V27, P1270, DOI 10.1097/01.ALC.0000081617.37539.D6; Diehl A,
2007, EUR ARCH PSY CLIN N, V257, P344, DOI 10.1007/s00406-007-0737-z; Dunn ME,
2000, ALCOHOL CLIN EXP RES, V24, P1639, DOI 10.1111/j.1530-0277.2000.tb01965.x;
Ennett ST, 2016, PSYCHOL ADDICT BEHAV, V30, P18, DOI 10.1037/adb0000119; Evans BE,
2012, ADDICTION, V107, P312, DOI 10.1111/j.1360-0443.2011.03568.x; Field M, 2007,
ALCOHOL ALCOHOLISM, V42, P560, DOI 10.1093/alcalc/agm064; Forman-Hoffman VL, 2017,
J STUD ALCOHOL DRUGS, V78, P853, DOI 10.15288/jsad.2017.78.853; Foster KT, 2014,
PSYCHOL ADDICT BEHAV, V28, P322, DOI 10.1037/a0035488; Frojd S, 2011, ALCOHOL
ALCOHOLISM, V46, P192, DOI 10.1093/alcalc/agq096; Fromme K, 2000, PSYCHOL ADDICT
BEHAV, V14, P206, DOI 10.1037/0893-164X.14.2.206; Gibbons FX, 2016, PSYCHOL ADDICT
BEHAV, V30, P325, DOI 10.1037/adb0000178; Goeders NE, 2003, EUR NEUROPSYCHOPHARM,
V13, P435, DOI 10.1016/j.euroneuro.2003.08.004; Gotlib IH, 2005, J CHILD PSYCHOL
PSYC, V46, P84, DOI 10.1111/j.1469-7610.2004.00333.x; Hussong AM, 2017, PSYCHOL
ADDICT BEHAV, V31, P137, DOI 10.1037/adb0000247; Hussong AM, 2011, PSYCHOL ADDICT
BEHAV, V25, P390, DOI 10.1037/a0024519; Jenkins MB, 2011, AM J ADDICTION, V20,
P429, DOI 10.1111/j.1521-0391.2011.00151.x; JESSOR R, 1991, J ADOLESCENT HEALTH,
V12, P597, DOI 10.1016/1054-139X(91)90007-K; Johnson PB, 2005, SUBST USE MISUSE,
V40, P1139, DOI 10.1081/JA-200042281; Johnston L. D., 2017, MONITORING FUTURE NA;
Kann L, 2016, MMWR-MORBID MORTAL W, V65, P106, DOI 10.15585/mmwr.mm6505a2; Keough
MT, 2016, PERS INDIV DIFFER, V88, P45, DOI 10.1016/j.paid.2015.08.036; Kessler RC,
2006, AM J PSYCHIAT, V163, P716, DOI 10.1176/appi.ajp.163.4.716; KHANTZIAN EJ,
1985, AM J PSYCHIAT, V142, P1259; Kudielka BM, 2007, SOCIAL NEUROSCIENCE, P56, DOI
DOI 10.1007/978-1-4614-6852-3; Kuntsche E, 2007, J STUD ALCOHOL DRUGS, V68, P76,
DOI 10.15288/jsad.2007.68.76; Lejuez C, 2003, J ADOLESCENCE, V26, P475, DOI
10.1016/S0140-1971(03)00036-8; Lejuez CW, 2002, J EXP PSYCHOL-APPL, V8, P75, DOI
10.1037//1076-898X.8.2.75; Magrys SA, 2015, ALCOHOL ALCOHOLISM, V50, P213, DOI
10.1093/alcalc/agu101; Marder E, 2013, MMWR-MORBID MORTAL W, V62, P1; Marmorstein
NR, 2010, J CLIN CHILD ADOLESC, V39, P545, DOI 10.1080/15374416.2010.486325; Medina
KL, 2008, ALCOHOL CLIN EXP RES, V32, P386, DOI 10.1111/j.1530-0277.2007.00602.x;
Merikangas KR, 2010, J AM ACAD CHILD PSY, V49, P980, DOI
10.1016/j.jaac.2010.05.017; Miech R. A., 2017, MONITORING FUTURE NA, V1; Miller TR,
2006, J STUD ALCOHOL, V67, P519, DOI 10.15288/jsa.2006.67.519; Moberg D., 1991, J
ADOLESCENT CHEM DE, V2, P75, DOI DOI 10.1080/10678289109512338; Moberg D. P., 2000,
ADOLESCENT ALCOHOL D; Moss HB, 2014, DRUG ALCOHOL DEPEN, V136, P51, DOI
10.1016/j.drugalcdep.2013.12.011; Muthen B, 2005, J EDUC BEHAV STAT, V30, P27, DOI
10.3102/10769986030001027; Nesic J, 2006, PHARMACOL BIOCHEM BE, V83, P239, DOI
10.1016/j.pbb.2006.02.006; Nolen-Hoeksema S, 2006, J GEN PSYCHOL, V133, P357, DOI
10.3200/GENP.133.4.357-374; Ollendick TH, 2002, BIOL PSYCHIAT, V51, P44, DOI
10.1016/S0006-3223(01)01305-1; Sandler I, 2014, ANNU REV CLIN PSYCHO, V10, P243,
DOI 10.1146/annurev-clinpsy-050212-185524; Savage JE, 2016, PSYCHOL ADDICT BEHAV,
V30, P462, DOI 10.1037/adb0000183; Schulte MT, 2009, CLIN PSYCHOL REV, V29, P535,
DOI 10.1016/j.cpr.2009.06.003; Singer JD, 2003, APPL LONGITUDINAL DA, P644, DOI DOI
10.1093/ACPROF:OSO/9780195152968.001.0001; Smit K, 2018, CLIN PSYCHOL REV, V60,
P136, DOI 10.1016/j.cpr.2018.02.002; Starcke K, 2013, ALCOHOL CLIN EXP RES, V37,
P1343, DOI 10.1111/acer.12103; Steinberg L, 2007, CURR DIR PSYCHOL SCI, V16, P55,
DOI 10.1111/j.1467-8721.2007.00475.x; Stockwell T, 2002, J STUD ALCOHOL, V63, P372,
DOI 10.15288/jsa.2002.63.372; Stroud LR, 2000, ANN BEHAV MED, V22, P204, DOI
10.1007/BF02895115; Tomlinson KL, 2012, ADDICT BEHAV, V37, P179, DOI
10.1016/j.addbeh.2011.09.016; U. S. Census Bureau, 2016, QUICKFACTS DENT COUN; van
den Bos E, 2014, CHILD DEV, V85, P220, DOI 10.1111/cdev.12118; Westenberg PM, 2004,
J CHILD PSYCHOL PSYC, V45, P481; Williams KD, 2006, BEHAV RES METHODS, V38, P174,
DOI 10.3758/BF03192765; Wittchen HU, 2008, INT J METH PSYCH RES, V17, pS16, DOI
10.1002/mpr.254; Wolpe J., 1958,
PSYCHOTHERAPY RECIPR; Yim IS, 2010, PSYCHONEUROENDOCRINO, V35, P241, DOI
10.1016/j.psyneuen.2009.06.014; Zvolensky M. J., 2001, REV GEN PSYCHOL, V5, P371,
DOI DOI 10.1037/1089-2680.5.4.371 83 0 0 2 2 EDUCATIONAL
PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC WASHINGTON 750 FIRST ST, NE,
WASHINGTON, DC 20002-4242 USA 0893-164X 1939-1501 PSYCHOL ADDICT BEHAV
Psychol. Addict. Behav. MAY 2019 33 3 254
265 10.1037/adb0000454 12 Substance Abuse;
Psychology, Multidisciplinary Substance Abuse; Psychology HU9PH
WOS:000465625800008 30869921 2019-09-25
J Ehlke, SJ; Kelley, ML Ehlke, Sarah J.; Kelley, Michelle
L. Drinking to Cope Motivations as a Mediator of the Relationship
Between Sexual Coercion Victimization and Alcohol Use Among College Women: The Role
of Depressive Symptoms VIOLENCE AGAINST WOMEN English Article
sexual coercion victimization; alcohol use;
depression POSTTRAUMATIC-STRESS-DISORDER; PROTECTIVE BEHAVIORAL STRATEGIES;
SUBSTANCE USE; MAJOR DEPRESSION; SELF-MEDICATION; NATIONAL SAMPLE; MENTAL-HEALTH;
ASSAULT; RISK; RAPE This cross-sectional study examined whether depressive
symptoms strengthened the relationship between different forms of sexual coercion
victimization and drinking to cope motivations, which was hypothesized to influence
alcohol use. Participants were 214 female undergraduates who completed an online
survey. Participants who experienced any lifetime sexual coercion and reported
higher depressive symptoms were the most likely to report drinking to cope
motivations, which in turn were associated with alcohol use. Depressive symptoms
did not strengthen the relationship between specific forms of sexual coercion,
drinking to cope, and alcohol use. Increasing emotion regulation strategies among
sexual coercion victims may reduce drinking. [Ehlke, Sarah J.; Kelley, Michelle
L.] Old Dominion Univ, Dept Psychol, 5115 Hampton Blvd, Norfolk, VA 23529 USA;
[Kelley, Michelle L.] Virginia Consortium Program Clin Psychol, Norfolk, VA USA
Ehlke, SJ (reprint author), Old Dominion Univ, Dept Psychol, 5115 Hampton
Blvd, Norfolk, VA 23529 USA. sehlk001@odu.edu Abbey A,
2002, J STUD ALCOHOL, P118, DOI 10.15288/jsas.2002.s14.118; American Psychiatric
Association, 2013, DIAGN STAT MAN MENT; Armell S, 2014, J STUD ALCOHOL DRUGS, V75,
P766, DOI 10.15288/jsad.2014.75.766; Bird ER, 2016, ADDICT BEHAV, V52, P28, DOI
10.1016/j.addbeh.2015.08.001; Boden JM, 2011, ADDICTION, V106, P906, DOI
10.1111/j.1360-0443.2010.03351.x; Bolton JM, 2009, J AFFECT DISORDERS, V115, P367,
DOI 10.1016/j.jad.2008.10.003; Briere FN, 2014, COMPR PSYCHIAT, V55, P526, DOI
10.1016/j.comppsych.2013.10.007; Brown AL, 2009, VIOLENCE AGAINST WOM, V15, P898,
DOI 10.1177/1077801209335491; Chang EC, 2017, J INTERPERS VIOLENCE, V32, P1249, DOI
10.1177/0886260515588534; Chang EC, 2015, SOC WORK, V60, P211, DOI
10.1093/sw/swv017; COLLINS RL, 1985, J CONSULT CLIN PSYCH, V53, P189, DOI
10.1037/0022-006X.53.2.189; Conner KR, 2009, J SUBST ABUSE TREAT, V37, P127, DOI
10.1016/j.jsat.2008.11.007; COOPER ML, 1995, J PERS SOC PSYCHOL, V69, P990, DOI
10.1037/0022-3514.69.5.990; DeGue S, 2005, AGGRESS VIOLENT BEH, V10, P513, DOI
10.1016/j.avb.2004.09.001; Dvorak RD, 2013, J AFFECT DISORDERS, V149, P326, DOI
10.1016/j.jad.2013.01.046; Dyson R, 2006, J CLIN PSYCHOL, V62, P1231, DOI
10.1002/jclp.20295; Eaton W. W., 2004, USE PSYCHOL TESTING, P363, DOI DOI
10.4324/9781410610614; Fair CD, 2011, J AM COLL HEALTH, V59, P273, DOI
10.1080/07448481.2010.508085; Filipas HH, 2006, J INTERPERS VIOLENCE, V21, P652,
DOI 10.1177/0886260506286879; Fisher B. S., 2000, RES REPORT; Fossos N, 2011,
ADDICT BEHAV, V36, P1001, DOI 10.1016/j.addbeh.2011.06.001; Frazier PA, 2005, J
COUNS PSYCHOL, V52, P267, DOI 10.1037/0022-0167.52.3.267; French B. H., 2008, BLACK
WOMEN GENDER F, V2, P77; Gonzalez VM, 2011, EXP CLIN PSYCHOPHARM, V19, P303, DOI
10.1037/a0022720; Grant VV, 2007, ADDICT BEHAV, V32, P2611, DOI
10.1016/j.addbeh.2007.07.004; Greeley J, 1999, PSYCHOL THEOR DRINKI, V2, P14; Hayes
A.F., 2013, INTRO MEDIATION MODE; Humphrey JA, 2000, J ADOLESCENT HEALTH, V27,
P419, DOI 10.1016/S1054-139X(00)00168-3; Jeffrey NK, 2017, VIOLENCE AGAINST WOM,
V23, P911, DOI 10.1177/1077801216652507; Kaukinen C, 2005, J INTERPERS VIOLENCE,
V20, P1244, DOI 10.1177/0886260505277732; Kaysen D, 2007, ADDICT BEHAV, V32, P1272,
DOI 10.1016/j.addbeh.2006.09.007; Kaysen D, 2006, ADDICT BEHAV, V31, P1820, DOI
10.1016/j.addbeh.2005.12.025; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259; Koss
MP, 2004, J CONSULT CLIN PSYCH, V72, P1063, DOI 10.1037/0022-006X.72.6.1063; Krahe
B, 2017, PSYCHOL TRAUMA-US, V9, P147, DOI 10.1037/tra0000198; Krebs CP, 2009, J AM
COLL HEALTH, V57, P639, DOI 10.3200/JACH.57.6.639-649; Kubany ES, 2000, PSYCHOL
ASSESSMENT, V12, P210, DOI 10.1037//1040-3590.12.2.210; Lewis MA, 2004, PSYCHOL
ADDICT BEHAV, V18, P334, DOI 10.1037/0893-164X.18.4.334; Livingston JA, 2004,
PSYCHOL WOMEN QUART, V28, P287, DOI 10.1111/j.1471-6402.2004.00146.x; Marlatt GA,
1998, J CONSULT CLIN PSYCH, V66, P604, DOI 10.1037/0022-006X.66.4.604; McCauley JL,
2010, J INTERPERS VIOLENCE, V25, P1655, DOI 10.1177/0886260509354580; Messman-Moore
TL, 2008, J INTERPERS VIOLENCE, V23, P1730, DOI 10.1177/0886260508314336; Miranda
Robert Jr, 2002, Violence Vict, V17, P205, DOI 10.1891/vivi.17.2.205.33650; Mouilso
ER, 2012, VIOLENCE VICTIMS, V27, P78, DOI 10.1891/0886-6708.27.1.78; Najdowski CJ,
2011, J TRAUMA STRESS, V24, P218, DOI 10.1002/jts.20610; Neighbors C, 2004, J
CONSULT CLIN PSYCH, V72, P434, DOI 10.1037/0022-006X.72.3.434; Neilson EC, 2018, J
INTERPERS VIOLENCE, V33, P137, DOI 10.1177/0886260515603977; Orchowski LM, 2013,
VIOLENCE VICTIMS, V28, P940, DOI 10.1891/0886-6708.VV-D-12-00049; Palmer RS, 2010,
J INTERPERS VIOLENCE, V25, P1563, DOI 10.1177/0886260509354581; Park CL, 2004, J
STUD ALCOHOL, V65, P126, DOI 10.15288/jsa.2004.65.126; Pritchard ME, 2007, J AM
COLL HEALTH, V56, P15, DOI 10.3200/JACH.56.1.15-22; Rice KG, 2010, J COUNS PSYCHOL,
V57, P439, DOI 10.1037/a0020221; Sabina C, 2008, VIOLENCE VICTIMS, V23, P667, DOI
10.1891/0886-6708.23.6.667; Salwen JK, 2015, PARTN ABUSE, V6, P367, DOI
10.1891/1946-6560.6.4.367; Sarkar N. N., 2005, SEX RELATSH THER, V20, P407, DOI DOI
10.1080/14681990500249502; Struckman-Johnson C, 2003, J SEX RES, V40, P76, DOI
10.1080/00224490309552168; Suliman S, 2009, COMPR PSYCHIAT, V50, P121, DOI
10.1016/j.comppsych.2008.06.006; Testa M, 1999, J INTERPERS VIOLENCE, V14, P548,
DOI 10.1177/088626099014005006; Ullman SE, 2003, AGGRESS VIOLENT BEH, V8, P471, DOI
10.1016/S1359-1789(03)00032-6; Weitzman ER, 2004, J NERV MENT DIS, V192, P269, DOI
10.1097/01.nmd.0000120885.17362.94; Wingo AP, 2010, J AFFECT DISORDERS, V126, P411,
DOI 10.1016/j.jad.2010.04.009; Zinzow HM, 2010, DEPRESS ANXIETY, V27, P708, DOI
10.1002/da.20719; Zweig JM, 1997, J INTERPERS VIOLENCE, V12, P291, DOI
10.1177/088626097012002009 63 0 0 7 7 SAGE PUBLICATIONS INC
THOUSAND OAKS 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA 1077-8012
1552-8448 VIOLENCE AGAINST WOM Violence Against Women MAY 2019
25 6 721 742 10.1177/1077801218796334
22 Women's Studies Women's Studies HS5LC
WOS:000463911800005 30236032 2019-09-25
J Narvaez, JCD; Remy, L; Bermudez, MB; Scherer, JN; Ornell, F; Surratt, H;
Kurtz, SP; Pechansky, F de Magalhaes Narvaez, Joana Correa; Remy,
Lysa; Bermudez, Mariane Bagatin; Scherer, Juliana Nichterwitz; Ornell, Felipe;
Surratt, Hilary; Kurtz, Steven P.; Pechansky, Flavio Re-traumatization
Cycle: Sexual Abuse, Post-Traumatic Stress Disorder and Sexual Risk Behaviors among
Club Drug Users SUBSTANCE USE & MISUSE English Article
Trauma; club drug users; post-traumatic stress disorder;
sexual abuse SELF-MEDICATION HYPOTHESIS; EARLY-LIFE STRESS; MAJOR DEPRESSION;
CHILDHOOD TRAUMA; ANXIETY DISORDERS; HEALTH OUTCOMES; SUBSTANCE USE; HIV; ALCOHOL;
EXPERIENCES Background: Club drug users are high risk and vulnerable population for
adverse drug-related consequences and sexual risk behaviors. Few investigations
have addressed the possible interrelationship between early trauma and PTSD among
young club drug using populations. Objective: Exposure to traumatic experiences -
especially in childhood, has been linked to risk behaviors exposure and substance
use disorder. This study aimed to assess and compare drug use patterns and the
presence of childhood sexual abuse (CSA) experiences among ecstasy and LSD users
with and without Posttraumatic Stress Disorder (PTSD). Method: This cross-sectional
study employed targeted sampling and ethnographic mapping approaches via face-to-
face interviews conducted at bars and electronic music festivals. The Global
Appraisal of Individual Needs questionnaire was used as the primary assessment
instrument. Participants were from 18 to 39 years of age, had used ecstasy and/or
LSD in the 90 days prior to the interview, and were not in treatment for alcohol
and other drug problems. Results: Out of the 240 participants, 123 (51.2%)
presented PTSD symptoms. Those presenting PTSD were younger, less educated, with
lower income, and presented higher drug use severity than those without PTSD
symptoms. Moreover, a higher prevalence of sexual risk behavior was verified among
those with PTSD. There was an association between PTSD symptoms and CSA history,
where 64.2% of individuals with PTSD also presented CSA, compared to 47% among
those without PTSD (p = .028). Individuals with co-occurring history of CSA and
PTSD symptoms reported earlier use of ecstasy, LSD, and cocaine compared to
individuals with a history of CSA but without PTSD. Conclusions: In the present
study, participants with a history of PTSD demonstrate a history of CSA, as well as
pronounced severity in several areas - precocity of use, severity of addiction, and
greater exposure to situations of sexual risk. Thus, a cycle of traumatization may
be established through early potential trauma, which can remain unprocessed and
contribute to earlier and more severe substance use and sexual risk behaviors.
Identification of PTSD symptoms and risk for HIV and other STIs among young club
drug users is critical to address focused treatment approaches for this vulnerable
population. [de Magalhaes Narvaez, Joana Correa; Remy, Lysa; Bermudez, Mariane
Bagatin; Scherer, Juliana Nichterwitz; Ornell, Felipe; Pechansky, Flavio] Univ Fed
Rio Grande do Sul, HCPA, Ctr Drug & Alcohol Res, Rua Prof Alvaro Alvim 400, BR-
90420020 Porto Alegre, RS, Brazil; [Surratt, Hilary] Univ Kentucky, Ctr Hlth Serv
Res, Lexington, KY USA; [Kurtz, Steven P.] Nova Southeastern Univ, Ctr Appl Res
Subst Use & Hlth Dispar ARSH, Miami, FL USA Narvaez, JCD (reprint author), Univ
Fed Rio Grande do Sul, HCPA, Ctr Drug & Alcohol Res, Rua Prof Alvaro Alvim 400, BR-
90420020 Porto Alegre, RS, Brazil. jonarvaez@gmail.com Scherer, Juliana/M-6344-
2016 Scherer, Juliana/0000-0002-9235-0416 Fogarty International CenterUnited
States Department of Health & Human ServicesNational Institutes of Health (NIH) -
USANIH Fogarty International Center (FIC) [1R03TW007612-01A1]; Fundo de Incentivo a
Pesquisa (FIPE) from Hospital de Clinicas de Porto Alegre [GPPG 07-391] This
research was funded by the Fogarty International Center (Grant number 1R03TW007612-
01A1) and Fundo de Incentivo a Pesquisa (FIPE) from Hospital de Clinicas de Porto
Alegre (GPPG 07-391). Adewuya AO, 2007, J PSYCHOSOM RES, V63, P203, DOI
10.1016/j.jpsychores.2007.03.006; Amaya-Jackson L, 1999, J TRAUMA STRESS, V12,
P709, DOI 10.1023/A:1024781504756; Brady K. T., 2012, ALCOHOL RES CURRENT; Bremner
JD, 1996, AM J PSYCHIAT, V153, P369; Breslau N, 2003, ARCH GEN PSYCHIAT, V60, P289,
DOI 10.1001/archpsyc.60.3.289; Breslau N, 2001, J CLIN PSYCHIAT, V62, P55; Capell
H., 1987, ALCOHOL TENSION REDU; Chan YF, 2011, AIDS BEHAV, V15, P114, DOI
10.1007/s10461-010-9702-3; Chilcoat HD, 1998, ARCH GEN PSYCHIAT, V55, P913, DOI
10.1001/archpsyc.55.10.913; Chilcoat HD, 1998, ADDICT BEHAV, V23, P827, DOI
10.1016/S0306-4603(98)00069-0; Corsi Karen F, 2008, Curr Drug Abuse Rev, V1, P292;
Craparo G, 2014, PSYCHIAT INVEST, V11, P330, DOI 10.4306/pi.2014.11.3.330; De
Bellis MD, 1999, BIOL PSYCHIAT, V45, P1259, DOI 10.1016/S0006-3223(99)00044-X;
Degenhardt L, 2010, INT J DRUG POLICY, V21, P347, DOI 10.1016/j.drugpo.2009.11.007;
Dennis ML, 2002, GLOBAL APPRAISAL IND; Dentato MP, 2013, J GAY LESBIAN SOC SE, V25,
P509, DOI 10.1080/10538720.2013.829395; Diekhoff T, 2013, PLOS ONE, V8, DOI
10.1371/journal.pone.0076816; Drumright LN, 2006, SUBST USE MISUSE, V41, P1551, DOI
10.1080/10826080600847894; Enoch MA, 2011, PSYCHOPHARMACOLOGY, V214, P17, DOI
10.1007/s00213-010-1916-6; Evren C, 2018, J DUAL DIAGN, V14, P40, DOI
10.1080/15504263.2017.1404665; Fattore L, 2018, PSYCHOPHARMACOLOGY, V235, P433, DOI
10.1007/s00213-017-4793-4; Fergusson DM, 1996, J AM ACAD CHILD PSY, V35, P1365, DOI
10.1097/00004583-199610000-00024; Fiorentine R, 1999, J PSYCHOACTIVE DRUGS, V31,
P363, DOI 10.1080/02791072.1999.10471766; Fryers Tom, 2013, Clin Pract Epidemiol
Ment Health, V9, P1, DOI 10.2174/1745017901309010001; Furukawa TA, 1999, J AFFECT
DISORDERS, V52, P85, DOI 10.1016/S0165-0327(98)00054-8; Gisquet-Verrier P, 2017,
THERAPIE, V72, P357, DOI 10.1016/j.therap.2016.07.005; Grassi-Oliveira R, 2008,
BIOL PSYCHIAT, V64, P281, DOI 10.1016/j.biopsych.2008.02.023; Heim C, 2001, BIOL
PSYCHIAT, V49, P1023, DOI 10.1016/S0006-3223(01)01157-X; Heim C, 1999, BIOL
PSYCHIAT, V46, P1509, DOI 10.1016/S0006-3223(99)00224-3; Heim C, 1997,
PSYCHOPHARMACOL BULL, V33, P185; Helmreich DL, 2005, NEUROENDOCRINOLOGY, V81, P183,
DOI 10.1159/000087001; Ibanez GE, 2010, ARCH SEX BEHAV, V39, P959, DOI
10.1007/s10508-010-9606-3; Inciardi JA, 2007, PAIN MED, V8, P171, DOI
10.1111/j.1526-4637.2006.00255.x; Julnes PS, 2016, PSYCHOSOMATICS, V57, P423, DOI
10.1016/j.psym.2016.02.015; Kapoor P, 2013, J ADV PHARM TECHNOL, V4, P173, DOI
10.4103/2231-4040.121410; Kessler RC, 2000, J CLIN PSYCHIAT, V61, P4; Khantzian EJ,
1997, HARVARD REV PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550; KHANTZIAN EJ,
1985, AM J PSYCHIAT, V142, P1259; Kilpatrick DG, 2003, J CONSULT CLIN PSYCH, V71,
P692, DOI 10.1037/0022-006X.71.4.692; King JA, 2001, PSYCHIAT CLIN NEUROS, V55,
P71, DOI 10.1046/j.1440-1819.2001.00787.x; Klitzman RL, 2000, AM J PSYCHIAT, V157,
P1162, DOI 10.1176/appi.ajp.157.7.1162; Kurtz SP, 2013, J SUBST ABUSE TREAT, V44,
P301, DOI 10.1016/j.jsat.2012.08.004; Liu F, 2010, NEUROBIOL AGING, V31, P1831, DOI
10.1016/j.neurobiolaging.2008.09.015; Luz MP, 2016, J PSYCHIATR RES, V72, P51, DOI
10.1016/j.jpsychires.2015.10.011; Maniglio R, 2009, CLIN PSYCHOL REV, V29, P647,
DOI 10.1016/j.cpr.2009.08.003; Maria MMMS, 2010, PSYCHONEUROENDOCRINO, V35, P1492,
DOI 10.1016/j.psyneuen.2010.05.001; Mayer KH, 2006, CLIN INFECT DIS, V42, P1011,
DOI 10.1086/500463; Mullen PE, 1996, CHILD ABUSE NEGLECT, V20, P7, DOI
10.1016/0145-2134(95)00112-3; Mustanski BS, 2011, J SEX RES, V48, P218, DOI
10.1080/00224499.2011.558645; Narvaez JCM, 2012, COMPR PSYCHIAT, V53, P238, DOI
10.1016/j.comppsych.2011.04.058; Olatunji BO, 2007, CLIN PSYCHOL REV, V27, P572,
DOI 10.1016/j.cpr.2007.01.015; Palamar JJ, 2016, AM J DRUG ALCOHOL AB, V42, P530,
DOI 10.1080/00952990.2016.1178269; Patel RS, 2017, CUREUS, V9, DOI
10.7759/cureus.1647; Pechansky F, 2011, J DRUG ISSUES, V41, P217, DOI
10.1177/002204261104100204; Perkonigg A, 2000, ACTA PSYCHIAT SCAND, V101, P46, DOI
10.1034/j.1600-0447.2000.101001046.x; Reed PL, 2007, ARCH GEN PSYCHIAT, V64, P1435,
DOI 10.1001/archpsyc.64.12.1435; Remy LL, 2014, ENVIRON HEALTH-GLOB, V13, DOI
10.1186/1476-069X-13-88; Remy L, 2015, REV BRAS PSIQUIATR, V37, P351, DOI
10.1590/1516-4446-2015-1774; Rich SL, 2016, J CHILD ADOLES SUBST, V25, P194, DOI
10.1080/1067828X.2015.1007197; Schwandt ML, 2013, ALCOHOL CLIN EXP RES, V37, P984,
DOI 10.1111/acer.12053; Seedat S, 2012, CURR HIV-AIDS REP, V9, P344, DOI
10.1007/s11904-012-0139-3; Sherr L, 2011, PSYCHOL HEALTH MED, V16, P612, DOI
10.1080/13548506.2011.579991; Shin KM, 2017, J KOREAN MED SCI, V32, P1680, DOI
10.3346/jkms.2017.32.10.1680; Shoptaw S, 2007, ADDICTION, V102, P130, DOI
10.1111/j.1360-0443.2006.01775.x; Singer LT, 2004, DRUG ALCOHOL DEPEN, V74, P245,
DOI 10.1016/j.drugalcdep.2003.12.015; Sinha R, 2008, ANN NY ACAD SCI, V1141, P105,
DOI 10.1196/annals.1441.030; Stewart SH, 1998, ADDICT BEHAV, V23, P797, DOI
10.1016/S0306-4603(98)00070-7; Tractenberg Saulo Gantes, 2012, J. bras. psiquiatr.,
V61, P206, DOI 10.1590/S0047-20852012000400003; Tull MT, 2010, J ANXIETY DISORD,
V24, P55, DOI 10.1016/j.janxdis.2009.08.006; Ulibarri MD, 2015, J CHILD SEX ABUS,
V24, P35, DOI 10.1080/10538712.2015.976303; Volkow ND, 2007, AM J PSYCHIAT, V164,
P157, DOI 10.1176/appi.ajp.164.1.157; Weiser M, 2003, BIOL PSYCHIAT, V54, P655, DOI
10.1016/S0006-3223(03)00110-0; Wu P, 2010, DRUG ALCOHOL DEPEN, V106, P193, DOI
10.1016/j.drugalcdep.2009.08.020; Zuckerman MD, 2012, CURR OPIN PEDIATR, V24, P219,
DOI 10.1097/MOP.0b013e32834faa9b 74 0 0 3 3 TAYLOR & FRANCIS
INC PHILADELPHIA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
1082-6084 1532-2491 SUBST USE MISUSE Subst. Use Misuse JUL 29
2019 54 9 1499 1508
10.1080/10826084.2019.1589521 APR
2019 10 Substance Abuse; Psychiatry; Psychology Substance Abuse; Psychiatry;
Psychology IK9RR WOS:000470592900001 31020892 2019-09-25
J Mak, HW; Iacovou, M Mak, Hei Wan; Iacovou, Maria
Dimensions of the Parent-Child Relationship: Effects on Substance Use in
Adolescence and Adulthood SUBSTANCE USE & MISUSE English
Article Adolescent health; substance use
problems; depression; parenting styles; longitudinal analysis ALCOHOL-USE; DRUG-
USE; SELF-MEDICATION; DSM-IV; USE DISORDERS; SENSITIVE PERIODS; MENTAL-DISORDERS;
RISK BEHAVIORS; STYLE; AGE Background: Several studies have uncovered a
relationship between parenting styles and the likelihood that adolescents use
tobacco, alcohol or illegal drugs. Objectives: This paper extends existing research
in two ways. First, we consider a longer time-frame, investigating the relationship
between parenting in adolescence and substance use in adulthood. Second, we explore
the pathways by which this relationship is expressed, in particular the extent to
which the relationships in question are mediated by age at first use and
depression. Methods: Our analysis is based on data from the National Longitudinal
Study of Adolescent Health (Add Health), N = 2954, and is conducted using
structural equation modeling (SEM). We consider warmth and control as distinct
dimensions of parenting, as well as a typology of parenting which combines the two
dimensions. Results: Warmth is associated with reduced risks of problem substance
use in adulthood, via reduced risks of early initiation and a lower risk of
depression. Parental control also has a protective effect via reduced risks of
early initiation, but this is offset by a detrimental effect on depression,
particularly in the case of older adolescents. We also find that indulgent
parenting is not associated with extra risk of any kind compared with the
authoritative style, whereas authoritarian and neglectful styles are.
Conclusions/Importance: The nexus of relationships which we uncover has
implications for policy aimed at reducing substance use in the longer term,
suggesting that initiatives to promote warm and responsive parenting may be most
effective in reducing the risks of later substance use problems. [Mak, Hei Wan;
Iacovou, Maria] Univ Cambridge, Dept Sociol, Free Sch Lane, Cambridge CB2 3RQ,
England Mak, HW (reprint author), Univ Cambridge, Dept Sociol, Free Sch Lane,
Cambridge CB2 3RQ, England. hwm24@cam.ac.uk Abraham HD,
1999, COMPR PSYCHIAT, V40, P44, DOI 10.1016/S0010-440X(99)90076-7;
Adalbjarnardottir S, 2001, J RES ADOLESCENCE, V11, P401, DOI 10.1111/1532-
7795.00018; Allen ML, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-4425; ANTHONY
JC, 1995, DRUG ALCOHOL DEPEN, V40, P9, DOI 10.1016/0376-8716(95)01194-3; Aquilino
WS, 2001, J FAM ISSUES, V22, P289, DOI 10.1177/019251301022003002; Bailey JA, 2016,
J ADOLESCENT HEALTH, V59, P262, DOI 10.1016/j.jadohealth.2016.04.010; Barnes GM,
2000, J MARRIAGE FAM, V62, P175, DOI 10.1111/j.1741-3737.2000.00175.x; Bartholomew
DJ, 2008, CH CRC STAT SOC BEHA, P1; BAUMRIND D, 1966, CHILD DEV, V37, P887, DOI
10.2307/1126611; BAUMRIND D, 1968, ADOLESCENCE, V3, P255; BAUMRIND D, 1971,
MONOGRAPH, V4, P1; Baumrind D., 1991, J EARLY ADOLESC, V11, P56, DOI DOI
10.1177/0272431691111004; BELSKY J, 1984, CHILD DEV, V55, P83, DOI 10.2307/1129836;
Bolton JM, 2009, J AFFECT DISORDERS, V115, P367, DOI 10.1016/j.jad.2008.10.003;
Bronte-Tinkew J, 2006, J FAM ISSUES, V27, P850, DOI 10.1177/0192513X05285296;
Brownstein N., 2010, NONRESPONSE WAVE 4 N; BURI JR, 1988, PERS SOC PSYCHOL B, V14,
P271, DOI 10.1177/0146167288142006; Calafat A, 2014, DRUG ALCOHOL DEPEN, V138,
P185, DOI 10.1016/j.drugalcdep.2014.02.705; Chan TW, 2011, EUR SOCIOL REV, V27,
P385, DOI 10.1093/esr/jcq013; Choquet M, 2008, ALCOHOL ALCOHOLISM, V43, P73, DOI
10.1093/alcalc/agm060; Clark TT, 2015, HEALTH PSYCHOL, V34, P697, DOI
10.1037/hea0000150; Dawson DA, 2008, ALCOHOL CLIN EXP RES, V32, P2149, DOI
10.1111/j.1530-0277.2008.00806.x; DeWit DJ, 2000, AM J PSYCHIAT, V157, P745, DOI
10.1176/appi.ajp.157.5.745; DEYKIN EY, 1987, AM J PUBLIC HEALTH, V77, P178, DOI
10.2105/AJPH.77.2.178; DORNBUSCH SM, 1987, CHILD DEV, V58, P1244, DOI
10.1111/j.1467-8624.1987.tb01455.x; Dubow EF, 2008, ADDICTION, V103, P36, DOI
10.1111/j.1360-0443.2008.02175.x; Englund MM, 2013, DEV PSYCHOL, V49, P1554, DOI
10.1037/a0030229; Eun JD, 2018, SOC PSYCH PSYCH EPID, V53, P11, DOI 10.1007/s00127-
017-1435-4; Garcia F, 2009, ADOLESCENCE, V44, P101; Grant BF, 1998, J SUBST ABUSE,
V10, P163, DOI 10.1016/S0899-3289(99)80131-X; Grant BF, 2001, J SUBST ABUSE, V13,
P493, DOI 10.1016/S0899-3289(01)00096-7; Guttmannova K, 2011, J STUD ALCOHOL DRUGS,
V72, P221, DOI 10.15288/jsad.2011.72.221; Haggerty KP, 2013, J CHILD SERV, V8,
P229, DOI 10.1108/JCS-04-2013-0016; Harris KM, 1994, WAVES 1 2, V1996, P2001, DOI
DOI 10.3886/ICPSR27021.V9; Hasin D, 2006, ADDICTION, V101, P59, DOI 10.1111/j.1360-
0443.2006.01584.x; Hellevik O, 2009, QUAL QUANT, V43, P59, DOI 10.1007/s11135-007-
9077-3; Hill KG, 2005, J ADOLESCENT HEALTH, V37, P202, DOI
10.1016/j.jadohealth.2004.08.014; Hingson RW, 2006, ARCH PEDIAT ADOL MED, V160,
P739, DOI 10.1001/archpedi.160.7.739; Jackson C, 1997, AM J PUBLIC HEALTH, V87,
P359, DOI 10.2105/AJPH.87.3.359; Jordan CJ, 2017, DEV COGN NEUROS-NETH, V25, P29,
DOI 10.1016/j.dcn.2016.10.004; KANDEL DB, 1978, J YOUTH ADOLESCENCE, V7, P13, DOI
10.1007/BF01538684; KHANTZIAN EJ, 1974, AM J PSYCHIAT, V131, P160, DOI
10.1176/ajp.131.2.160; King KM, 2007, J STUD ALCOHOL DRUGS, V68, P256, DOI
10.15288/jsad.2007.68.256; Kosterman R, 2000, AM J PUBLIC HEALTH, V90, P360, DOI
10.2105/AJPH.90.3.360; LAMBORN SD, 1991, CHILD DEV, V62, P1049, DOI 10.1111/j.1467-
8624.1991.tb01588.x; Lembke A, 2012, AM J DRUG ALCOHOL AB, V38, P524, DOI
10.3109/00952990.2012.694532; Lerman C, 1996, ADDICT BEHAV, V21, P9, DOI
10.1016/0306-4603(95)00032-1; Lerman C, 1998, HEALTH PSYCHOL, V17, P56, DOI
10.1037/0278-6133.17.1.56; Maccoby EE, 1983, HDB CHILD PSYCHOL, P1; MacKinnon DP,
2002, PSYCHOL METHODS, V7, P83, DOI 10.1037//1082-989X.7.1.83; Maggs JL, 2008,
ADDICTION, V103, P7, DOI 10.1111/j.1360-0443.2008.02173.x; Maimaris W, 2014, J
EPIDEMIOL COMMUN H, V68, P268, DOI 10.1136/jech-2013-203402; Martinez I, 2019,
COMPUT HUM BEHAV, V90, P84, DOI 10.1016/j.chb.2018.08.036; Martinez I, 2017, FRONT
PSYCHOL, V8, DOI 10.3389/fpsyg.2017.00865; Martinez I, 2013, ADICCIONES, V25, P235,
DOI 10.20882/adicciones.51; McCambridge J, 2011, PLOS MED, V8, DOI
10.1371/journal.pmed.1000413; McGue M, 2001, ALCOHOL CLIN EXP RES, V25, P1156, DOI
10.1097/00000374-200108000-00010; Mogro-Wilson C, 2008, HISPANIC J BEHAV SCI, V30,
P89, DOI 10.1177/0739986307310881; Ozer EJ, 2013, YOUTH SOC, V45, P365, DOI
10.1177/0044118X11418539; Parent J, 2014, J ABNORM CHILD PSYCH, V42, P173, DOI
10.1007/s10802-013-9777-1; Piko BF, 2012, ADDICT BEHAV, V37, P353, DOI
10.1016/j.addbeh.2011.11.022; Rabe-Hesketh S, 2004, PSYCHOMETRIKA, V69, P167, DOI
10.1007/BF02295939; RADLOFF LS, 1991, J YOUTH ADOLESCENCE, V20, P149, DOI
10.1007/BF01537606; Richmond-Rakerd LS, 2017, PSYCHOL ADDICT BEHAV, V31, P664, DOI
10.1037/adb0000304; Roberts R. E., 1990, PSYCHOL ASSESSMENT, V2, P122, DOI DOI
10.1037/1040-3590.2.2.122; ROBINSON CC, 1995, PSYCHOL REP, V77, P819, DOI
10.2466/pr0.1995.77.3.819; Robinson J, 2009, J ANXIETY DISORD, V23, P38, DOI
10.1016/j.janxdis.2008.03.013; Roche KM, 2008, SOC SCI MED, V66, P2023, DOI
10.1016/j.socscimed.2008.01.009; Sacks Jeffrey J, 2015, Am J Prev Med, V49, pe73,
DOI 10.1016/j.amepre.2015.05.031; Schinke SP, 2011, SUBST USE MISUSE, V46, P35, DOI
10.3109/10826084.2011.521074; Schofield TJ, 2012, MERRILL PALMER QUART, V58, P255,
DOI 10.1353/mpq.2012.0008; SHAFFER JP, 1995, ANNU REV PSYCHOL, V46, P561, DOI
10.1146/annurev.ps.46.020195.003021; SHEDLER J, 1990, AM PSYCHOL, V45, P612, DOI
10.1037/0003-066X.45.5.612; Sobel M. E., 1982, SOCIOL METHODOL, P290, DOI DOI
10.2307/270723; Solon G, 2015, J HUM RESOUR, V50, P301, DOI 10.3368/jhr.50.2.301;
Stafford M, 2016, J POSIT PSYCHOL, V11, P326, DOI 10.1080/17439760.2015.1081971;
STEINBERG L, 1994, CHILD DEV, V65, P754, DOI 10.2307/1131416; STEINBERG L, 1989,
CHILD DEV, V60, P1424, DOI 10.1111/j.1467-8624.1989.tb04014.x; Stone AL, 2012,
ADDICT BEHAV, V37, P747, DOI 10.1016/j.addbeh.2012.02.014; Udry J. R, 2001,
REFERENCES INSTRUMEN; US Department of Health and Human Services (HHS), 2016, FAC
ADD AM SURG GEN; Valente JY, 2017, DRUG ALCOHOL DEPEN, V180, P272, DOI
10.1016/j.drugalcdep.2017.08.015; van Dulmen MHM, 2002, J ADOLESCENT HEALTH, V31,
P475, DOI 10.1016/S1054-139X(02)00453-6; Van Ryzin MJ, 2012, ADDICT BEHAV, V37,
P1314, DOI 10.1016/j.addbeh.2012.06.020; Velleman RDB, 2005, DRUG ALCOHOL REV, V24,
P93, DOI 10.1080/09595230500167478; von Sydow K, 2002, DRUG ALCOHOL DEPEN, V68,
P49, DOI 10.1016/S0376-8716(02)00102-3; WEISS RD, 1992, AM J DRUG ALCOHOL AB, V18,
P121, DOI 10.3109/00952999208992825; White HR, 2000, J SUBST ABUSE, V12, P287, DOI
10.1016/S0899-3289(00)00056-0; Whiteford HA, 2013, LANCET, V382, P1575, DOI
10.1016/S0140-6736(13)61611-6; WINSHIP C, 1994, SOCIOL METHOD RES, V23, P230, DOI
10.1177/0049124194023002004; Xu X., 2015, AM J PREV MED, V48, P95; Young SE, 2002,
DRUG ALCOHOL DEPEN, V68, P309, DOI 10.1016/S0376-8716(02)00225-9 92 0 0
7 8 TAYLOR & FRANCIS INC PHILADELPHIA 530 WALNUT STREET, STE
850, PHILADELPHIA, PA 19106 USA 1082-6084 1532-2491 SUBST USE MISUSE
Subst. Use Misuse APR 16 2019 54 5 724
736 10.1080/10826084.2018.1536718 13 Substance Abuse;
Psychiatry; Psychology Substance Abuse; Psychiatry; Psychology HU2OH
WOS:000465110200003 30457893 2019-09-25
J Wolitzky-Taylor, K; Schiffman, J Wolitzky-Taylor, Kate;
Schiffman, Jason Predictive Associations Among the Repeated
Measurements of Anxiety, Depression, and Craving in a Dual Diagnosis Program
JOURNAL OF DUAL DIAGNOSIS English Article
Dual diagnosis; comorbidity; community treatment; treatment
mechanisms NATIONAL EPIDEMIOLOGIC SURVEY; SUBSTANCE USE DISORDERS; SELF-
MEDICATION; ALCOHOL; COMORBIDITY; MOOD; PREVALENCE; ONSET; RISK Objective: Anxiety
and depression commonly co-occur with substance use disorders. Conceptual models
would presume that changes in anxiety and depression should lead to changes in drug
and alcohol craving during treatment for co-occurring disorders, but no
longitudinal investigation has explored this assumption. This study examined the
associations among craving, anxiety, and depression in a dual diagnosis program.
Methods: In all, 93 adult patients at a community-based dual diagnosis program for
substance use disorders and comorbid anxiety and mood disorders provided daily
ratings of anxiety and depression. We examined whether these ratings predicted
changes in craving and vice versa. Results: Using hierarchical linear modeling to
examine day-to-day change over time, we observed that anxiety and depression
ratings uniquely and independently predicted subsequent craving ratings, and
craving ratings also predicted subsequent anxiety and depression ratings.
Conclusions: These preliminary findings support mutual maintenance models of
substance use and psychiatric comorbidity, thus providing preliminary support for
integrated programs that simultaneously address both problems. Implications and
future directions are discussed. [Wolitzky-Taylor, Kate] Univ Calif Los Angeles,
Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA; [Schiffman, Jason] Univ
Calif Los Angeles, Dept Psychiat & Biobehav Sci, Camden Ctr, Los Angeles, CA 90024
USA Wolitzky-Taylor, K (reprint author), Univ Calif Los Angeles, Dept Psychiat &
Biobehav Sci, Integrated Subst Abuse Programs, 11075 Santa Monica Blvd,Suite 200,
Los Angeles, CA 90024 USA. kbtaylor@mednet.ucla.edu Wolitzky-Taylor,
Kate/0000-0001-6199-4350 Brown SA, 2006, J PSYCHOACTIVE DRUGS,
V38, P449, DOI 10.1080/02791072.2006.10400584; Brunette MF, 2001, PSYCHIATR SERV,
V52, P526, DOI 10.1176/appi.ps.52.4.526; Buckner JD, 2008, J PSYCHIATR RES, V42,
P230, DOI 10.1016/j.jpsychires.2007.01.002; CONGER JJ, 1956, Q J STUD ALCOHOL, V17,
P296; Conway KP, 2006, J CLIN PSYCHIAT, V67, P247, DOI 10.4088/JCP.v67n0211; Grant
BF, 2004, ARCH GEN PSYCHIAT, V61, P807, DOI 10.1001/archpsyc.61.8.807; Greeley J,
1999, PSYCHOL THEOR DRINKI, V2, P14; Hien DA, 2010, DRUG ALCOHOL DEPEN, V111, P114,
DOI 10.1016/j.drugalcdep.2010.04.011; Kay-Lambkin FJ, 2009, ADDICTION, V104, P378,
DOI 10.1111/j.1360-0443.2008.02444.x; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62,
P593, DOI 10.1001/archpsyc.62.6.593; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142,
P1259; Kushner MG, 2008, SER ANXIETY RELAT DI, P3, DOI 10.1007/978-0-387-74290-8_1;
KUSHNER MG, 1990, AM J PSYCHIAT, V147, P685; Kushner MG, 2006, J MENTAL HLTH, V15,
P697, DOI DOI 10.1080/09638230600998946; McHugo GJ, 1999, PSYCHIATR SERV, V50,
P818, DOI 10.1176/ps.50.6.818; Petry NM, 2005, J CLIN PSYCHIAT, V66, P564, DOI
10.4088/JCP.v66n0504; Raudenbush SW, 2002, HIERARCHICAL LINEAR, V1; Robinson J,
2011, ARCH GEN PSYCHIAT, V68, P800, DOI 10.1001/archgenpsychiatry.2011.75; Schade
A, 2005, ALCOHOL CLIN EXP RES, V29, P794, DOI 10.1097/01.ALC.0000163511.24583.33;
Schatz David Beck, 2006, J Atten Disord, V10, P141, DOI 10.1177/1087054706286698;
SHER KJ, 1982, J ABNORM PSYCHOL, V91, P350, DOI 10.1037/0021-843X.91.5.350; Stewart
SH, 2008, SER ANXIETY RELAT DI, P239, DOI 10.1007/978-0-387-74290-8_13; Wolitzky-
Taylor K, 2012, ADDICT BEHAV, V37, P982, DOI 10.1016/j.addbeh.2012.03.026;
Zvolensky MJ, 2003, CLIN PSYCHOL-SCI PR, V10, P29, DOI 10.1093/clipsy/10.1.29
24 0 0 0 0 ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
ABINGDON 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
1550-4263 1550-4271 J DUAL DIAGN J. Dual Diagn. JUL 3 2019
15 3 140 146
10.1080/15504263.2019.1589660 APR 2019 7 Psychology, Clinical;
Substance Abuse; Psychiatry Psychology; Substance Abuse; Psychiatry IT6AJ
WOS:000466283100001 30982462 2019-09-25
J Contractor, AA; Weiss, NH; Dixon-Gordon, KL; Blumenthal, H
Contractor, Ateka A.; Weiss, Nicole H.; Dixon-Gordon, Katherine L.;
Blumenthal, Heidemarie Heterogeneity in the Co-occurrence of Substance
Use and Posttraumatic Stress Disorder: A Latent Class Analysis Approach
JOURNAL OF DUAL DIAGNOSIS English Article
PTSD; alcohol use; drug use; latent class analyses; depression;
reckless behaviors; aggression SELF-MEDICATION HYPOTHESIS; ALCOHOL-USE;
PRECISION MEDICINE; PTSD SYMPTOMS; DEPRESSIVE DISORDER; POLYSUBSTANCE USE;
COMORBIDITY; PATTERNS; ABUSE; ASSOCIATIONS Objective: Posttraumatic stress
disorder (PTSD) often co-occurs with substance use (SU). Although there has been
independent research on subgroups of participants based on their PTSD or SU
responses, rarely are PTSD-SU typologies examined consistent with a precision
medicine approach (and corresponding person-centered statistical approaches). The
current study examined the nature and construct validity (covariates of depression,
physical aggression, verbal aggression, anger, hostility, reckless and self-
destructive behaviors [RSDB]) of the best-fitting latent class solution in
categorizing participants based on PTSD (PTSD Checklist for DSM-5) and alcohol/drug
use responses (Alcohol Use and Disorders Identification Test Alcohol Consumption
Questions, Drug Abuse Screening Test). Methods: The sample included 375 trauma-
exposed participants recruited from Amazon's Mechanical Turk online labor market.
Results: Latent class analyses indicated an optimal three-class solution (low
PTSD/SU, moderate PTSD/drug and high alcohol, and high PTSD/SU). Multinomial
logistic regressions indicated that depression (OR=1.22) and frequency of RSDBs
(OR=1.20) were significant predictors of the moderate PTSD/drug and high alcohol
class versus the low PTSD/SU class. Depression (OR=1.55) and frequency of RSDBs
(OR=1.19) were significant predictors of the high PTSD/SU class versus the low
PTSD/SU class. Only depression (OR=1.27) was a significant predictor of the high
PTSD/SU class versus the moderate PTSD/drug and high alcohol class. Conclusions:
Results provide construct validity support for three meaningful latent classes with
unique relations with depression and RSDBs. These findings improve our
understanding of heterogeneous PTSD-SU comorbidity patterns and highlight
acknowledgment of such subtyping (subgrouping) in considering differential
treatment options, treatment effectiveness, and resource allocation. [Contractor,
Ateka A.; Blumenthal, Heidemarie] Univ North Texas, Dept Psychol, 369 Terrill Hall,
Denton, TX 76203 USA; [Weiss, Nicole H.] Univ Rhode Isl, Dept Psychol, Kingston, RI
02881 USA; [Dixon-Gordon, Katherine L.] Univ Massachusetts, Dept Psychol & Brain
Sci, Amherst, MA 01003 USA Contractor, AA (reprint author), Univ North Texas,
Dept Psychol, 369 Terrill Hall, Denton, TX 76203 USA. ateka.c@gmail.com
National Institute on Drug AbuseUnited States Department of Health & Human
ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug
Abuse (NIDA) [K23DA039327, L30DA038349]; National Institute on Alcohol Abuse and
AlcoholismUnited States Department of Health & Human ServicesNational Institutes of
Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R15
AA026079-01] The research described here was supported, in part, by grants
from the National Institute on Drug Abuse [K23DA039327; L30DA038349] awarded to the
second author.; The research described here was supported, in part, by grants from
the National Institute on Alcohol Abuse and Alcoholism [R15 AA026079-01] awarded to
the last author. Anderson RE, 2018, J SUBST ABUSE TREAT, V86, P45, DOI
10.1016/j.jsat.2017.12.009; Asparouhov T, 2014, STRUCT EQU MODELING, V21, P329, DOI
10.1080/10705511.2014.915181; Babor TF, 2006, ADDICTION, V101, P104, DOI
10.1111/j.1360-0443.2006.01595.x; Baker TB, 2004, PSYCHOL REV, V111, P33, DOI
10.1037/0033-295X.111.1.33; Bonde JP, 2016, BRIT J PSYCHIAT, V208, P330, DOI
10.1192/bjp.bp.114.157859; Bradley KA, 2003, ARCH INTERN MED, V163, P821, DOI
10.1001/archinte.163.7.821; BRADY KT, 1994, AM J ADDICTION, V3, P160; Brady KT,
2004, CURR DIR PSYCHOL SCI, V13, P206, DOI 10.1111/j.0963-7214.2004.00309.x; Brady
KT, 2000, J CLIN PSYCHIAT, V61, P22; Brown PJ, 1999, PSYCHOL ADDICT BEHAV, V13,
P115, DOI 10.1037/0893-164X.13.2.115; Bush K, 1998, ARCH INTERN MED, V158, P1789,
DOI 10.1001/archinte.158.16.1789; BUSS AH, 1992, J PERS SOC PSYCHOL, V63, P452, DOI
10.1037/0022-3514.63.3.452; Carlson RG, 2005, DRUG ALCOHOL DEPEN, V79, P167, DOI
10.1016/j.drugalcdep.2005.01.011; Cavanaugh C, 2014, WORKPLACE HEALTH SAF, V62,
P224, DOI 10.3928/21650799-20140514-01; Chermack ST, 2008, DRUG ALCOHOL DEPEN, V98,
P35, DOI 10.1016/j.drugalcdep.2008.04.010; Connor JP, 2014, CURR OPIN PSYCHIATR,
V27, P269, DOI 10.1097/YCO.0000000000000069; Contractor A. A., ASSESSMENT PTS
UNPUB; Contractor AA, 2018, J CLIN PSYCHOL, V74, P1137, DOI 10.1002/jclp.22586;
Contractor AA, 2018, PERS INDIV DIFFER, V125, P1, DOI 10.1016/j.paid.2017.12.022;
Contractor AA, 2017, PSYCHIAT RES, V252, P215, DOI 10.1016/j.psychres.2017.03.008;
Contractor AA, 2017, J AFFECT DISORDERS, V212, P17, DOI 10.1016/j.jad.2017.01.029;
Contractor AA, 2016, J ANXIETY DISORD, V37, P10, DOI 10.1016/j.janxdis.2015.10.005;
Contractor AA, 2015, J PSYCHIATR RES, V68, P19, DOI
10.1016/j.jpsychires.2015.05.014; Contractor AA, 2015, PSYCHOL TRAUMA-US, V7, P138,
DOI 10.1037/a0037112; Cooper ML, 2002, J STUD ALCOHOL, P101, DOI
10.15288/jsas.2002.s14.101; Cranford JA, 2014, ADDICT BEHAV, V39, P1006, DOI
10.1016/j.addbeh.2014.02.009; Curran PJ, 1996, PSYCHOL METHODS, V1, P16, DOI
10.1037/1082-989X.1.1.16; Currie SR, 2005, CAN J PSYCHIAT, V50, P660, DOI
10.1177/070674370505001013; Darke S, 2013, ADDICTION, V108, P1411, DOI
10.1111/add.12191; DiStefano C, 2006, EDUC PSYCHOL MEAS, V66, P778, DOI
10.1177/0013164405284033; Erol A, 2015, DRUG ALCOHOL DEPEN, V156, P1, DOI
10.1016/j.drugalcdep.2015.08.023; Fricker R. D., 2008, SAGE HDB ONLINE RES, P195,
DOI DOI 10.4135/9780857020055; Galatzer-Levy IR, 2013, DEPRESS ANXIETY, V30, P489,
DOI 10.1002/da.22048; Grant S, 2016, J STUD ALCOHOL DRUGS, V77, P509, DOI
10.15288/jsad.2016.77.509; Hall DH, 2007, J PSYCHOACTIVE DRUGS, V39, P151, DOI
10.1080/02791072.2007.10399873; Hamburg MA, 2010, NEW ENGL J MED, V363, P301, DOI
10.1056/NEJMp1006304; Hien DA, 2010, AM J PSYCHIAT, V167, P95, DOI
10.1176/appi.ajp.2009.09091261; Hruska B, 2014, J ANXIETY DISORD, V28, P644, DOI
10.1016/j.janxdis.2014.06.009; Insel TR, 2014, AM J PSYCHIAT, V171, P395, DOI
10.1176/appi.ajp.2014.14020138; Jackson N, 2014, DRUG ALCOHOL DEPEN, V135, P133,
DOI 10.1016/j.drugalcdep.2013.11.021; Jacob T, 2010, J STUD ALCOHOL DRUGS, V71,
P629, DOI 10.15288/jsad.2010.71.629; Jacobsen LK, 2001, AM J PSYCHIAT, V158, P1184,
DOI 10.1176/appi.ajp.158.8.1184; Jakupcak M, 2007, J TRAUMA STRESS, V20, P945, DOI
10.1002/jts.20258; Jameson JL, 2015, NEW ENGL J MED, V372, P2229, DOI
10.1056/NEJMsb1503104; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P617, DOI
10.1001/archpsyc.62.6.617; Khantzian E. J., 1999, TREATING ADDICTION H; Khantzian
EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550; Kilpatrick
DG, 2013, J TRAUMA STRESS, V26, P537, DOI 10.1002/jts.21848; Kline R. B., 2011,
PRINCIPLES PRACTICE; Konig IR, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.00391-
2017; Kolehmainen Christine, 2015, J Grad Med Educ, V7, P475, DOI 10.4300/JGME-D-
14-00424.1; Kotov R, 2010, PSYCHOL BULL, V136, P768, DOI 10.1037/a0020327; Kroenke
K, 2002, PSYCHIAT ANN, V32, P509, DOI 10.3928/0048-5713-20020901-06; Kroenke K,
2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lembke
A, 2012, AM J DRUG ALCOHOL AB, V38, P524, DOI 10.3109/00952990.2012.694532; Lynskey
MT, 2006, TWIN RES HUM GENET, V9, P523, DOI 10.1375/twin.9.4.523; Marshall-Berenz
EC, 2011, PERS INDIV DIFFER, V50, P588, DOI 10.1016/j.paid.2010.11.033; McCauley
JL, 2012, CLIN PSYCHOL-SCI PR, V19, P283, DOI 10.1111/cpsp.12006; McCutcheon A. L.,
1987, LATENT CLASS ANAL; McGrath S, 2016, BMC MED GENOMICS, V9, DOI 10.1186/s12920-
016-0183-8; McLeod DS, 2001, J TRAUMA STRESS, V14, P259, DOI
10.1023/A:1011157800050; Meade AW, 2012, PSYCHOL METHODS, V17, P437, DOI
10.1037/a0028085; Mills KL, 2006, AM J PSYCHIAT, V163, P652, DOI
10.1176/appi.ajp.163.4.652; Moss HB, 2015, ADDICT BEHAV, V50, P192, DOI
10.1016/j.addbeh.2015.06.041; Mowbray O, 2015, J SUBST ABUSE TREAT, V54, P21, DOI
10.1016/j.jsat.2015.01.012; Najavits LM, 2013, J CLIN PSYCHOL, V69, P433, DOI
10.1002/jclp.21980; Nylund K, 2007, CHILD DEV, V78, P1706, DOI 10.1111/j.1467-
8624.2007.01097.x; Nylund KL, 2007, STRUCT EQU MODELING, V14, P535, DOI
10.1080/10705510701575396; Olatunji BO, 2010, BEHAV THER, V41, P93, DOI
10.1016/j.beth.2009.01.004; Prins A, 2004, PRIMARY CARE PSYCHIA, V9, P151; Prins
A., 2015, PRIMARY CARE PTSD SC; Prins A, 2016, J GEN INTERN MED, V31, P1206, DOI
10.1007/s11606-016-3703-5; Raftery AE, 1995, SOCIOL METHODOL, V25, P111, DOI
10.2307/271063; Read JP, 2004, ADDICT BEHAV, V29, P1665, DOI
10.1016/j.addbeh.2004.02.061; Roberts NP, 2015, CLIN PSYCHOL REV, V38, P25, DOI
10.1016/j.cpr.2015.02.007; Schuler MS, 2015, PSYCHIAT SERV, V66, P1221, DOI
10.1176/appi.ps.201400160; Simons JS, 2005, AM J DRUG ALCOHOL AB, V31, P285, DOI
10.1081/ADA-200047937; SKINNER HA, 1982, ADDICT BEHAV, V7, P363, DOI 10.1016/0306-
4603(82)90005-3; Stander VA, 2014, CLIN PSYCHOL REV, V34, P87, DOI
10.1016/j.cpr.2013.12.002; Stewart SH, 1998, ADDICT BEHAV, V23, P797, DOI
10.1016/S0306-4603(98)00070-7; Swendsen JD, 2000, CLIN PSYCHOL REV, V20, P173, DOI
10.1016/S0272-7358(99)00026-4; Thomas KA, 2017, COMPUT HUM BEHAV, V77, P184, DOI
10.1016/j.chb.2017.08.038; Tomczyk S, 2016, DRUG ALCOHOL DEPEN, V160, P12, DOI
10.1016/j.drugalcdep.2015.11.035; Tull M. T., 2015, COMPREHENSIVE GUIDE, P803;
Vaidyanathan U, 2011,
COMPR PSYCHIAT, V52, P527, DOI 10.1016/j.comppsych.2010.10.006; Vaughn MG, 2011, J
CRIM JUST, V39, P75, DOI 10.1016/j.jcrimjus.2010.12.001; Vermeulen-Smit E, 2015, J
AFFECT DISORDERS, V171, P111, DOI 10.1016/j.jad.2014.09.031; Vermunt JK, 2010,
POLIT ANAL, V18, P450, DOI 10.1093/pan/mpq025; Wallen GR, 2019, BEHAV SLEEP MED,
V17, P514, DOI 10.1080/15402002.2018.1425867; Walther B, 2012, EUR ADDICT RES, V18,
P167, DOI 10.1159/000335662; Weathers F, 2013, PTSD CHECKLIST DSM 5; Weathers F.
W., 2013, LIFE EVENTS CHECKLIS; Weich S, 2011, PSYCHOL MED, V41, P2201, DOI
10.1017/S0033291711000249; Weiss NH, 2015, DRUG ALCOHOL DEPEN, V155, P147, DOI
10.1016/j.drugalcdep.2015.07.679; Wortmann JH, 2016, PSYCHOL ASSESSMENT, V28,
P1392, DOI 10.1037/pas0000260; Yudko E, 2007, J SUBST ABUSE TREAT, V32, P189, DOI
10.1016/j.jsat.2006.08.002 96 0 0 0 1 ROUTLEDGE JOURNALS,
TAYLOR & FRANCIS LTD ABINGDON 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14
4RN, OXON, ENGLAND 1550-4263 1550-4271 J DUAL DIAGN J. Dual
Diagn. APR 3 2019 15 2 105 117
10.1080/15504263.2019.1572258 13 Psychology, Clinical;
Substance Abuse; Psychiatry Psychology; Substance Abuse; Psychiatry ID8YL
WOS:000471974400005 30838935 2019-09-25
J Stapinski, LA; Prior, K; Newton, NC; Deady, M; Kelly, E; Lees, B; Teesson, M;
Baillie, AJ Stapinski, Lexine A.; Prior, Katrina; Newton, Nicola
C.; Deady, Mark; Kelly, Erin; Lees, Briana; Teesson, Maree; Baillie, Andrew J.
Protocol for the Inroads Study: A Randomized Controlled Trial of an
Internet-Delivered, Cognitive Behavioral Therapy-Based Early Intervention to Reduce
Anxiety and Hazardous Alcohol Use Among Young People JMIR RESEARCH PROTOCOLS
English Article alcohol abuse; alcohol-
related disorders; anxiety; comorbidity; early medical intervention; cognitive
behavioral therapy; young adult SUBSTANCE USE DISORDERS; AGE-OF-ONSET; SELF-
MEDICATION HYPOTHESIS; 2007 NATIONAL-SURVEY; DSM-IV DISORDERS; MENTAL-HEALTH;
COOCCURRING ANXIETY; DRINKING MOTIVES; COMORBID ANXIETY; SOCIAL ANXIETY
Background: The transition to adulthood is a unique developmental period
characterized by numerous personal and social role changes and increased
opportunities for alcohol consumption. Using alcohol to cope with anxiety symptoms
is commonly reported, and young people with anxiety are at a greater risk of
hazardous alcohol use and progression to alcohol use disorder. Anxiety and alcohol
use tend to fuel each other in an exacerbating feed-forward cycle, leading to
difficult-to-treat chronic problems. The peak in onset of anxiety and alcohol
disorders suggests this developmental window represents a promising opportunity for
early intervention before these problems become entrenched. Objective: This study
aims to evaluate the efficacy of the Inroads program, a therapist-supported,
internet-delivered early intervention for young adults that targets alcohol use,
anxiety symptoms, and the interconnections between these problems. Methods: A
randomized controlled trial will be conducted nationally among young Australians
(aged 17-24 years) who experience anxiety symptoms and drink alcohol at hazardous
or harmful levels. Participants will be individually randomized on a 1:1 basis to
receive the Inroads intervention or assessment plus alcohol guidelines.
Participants randomized to the Inroads intervention will receive access to 5 Web-
based cognitive behavioral therapy (CBT) modules and weekly therapist support via
email and/or phone. The primary outcome assessment will be 8 weeks post baseline,
with follow-up assessment 6 months post baseline to determine the sustainability of
the intervention effects. Primary outcomes will be the total number of standard
drinks consumed in the past month (assessed by the Timeline Follow-Back procedure),
severity of alcohol-related harms (assessed by the Brief Young Adult Alcohol
Consequences Questionnaire), and anxiety symptoms across multiple disorders
(assessed by the Generalized Anxiety Disorder-7). Secondary outcomes will include
alcohol outcome expectancies; functional impairment and quality of life; and
symptoms of social anxiety, anxious arousal, and depression. Results will be
analyzed by intention-to-treat using multilevel mixed effects analysis for repeated
measures. Results: The study is funded from 2017 to 2020 by Australian Rotary
Health. Recruitment is expected to be complete by late-2018, with the 6-month
follow-ups to be completed by mid-2019. Results are expected to be published in
2020. Conclusions: The study will be the first to evaluate the benefits of a youth-
focused early intervention that simultaneously targets anxiety and hazardous
alcohol use. By explicitly addressing the interconnections between anxiety and
alcohol use and enhancing CBT coping skills, the Inroads program has the potential
to interrupt the trajectory toward co-occurring anxiety and alcohol use disorders.
The Web-based format of the program combined with minimal therapist support means
that if effective, the program could be widely disseminated to reach young people
who are not currently able or willing to access face-to-face treatment.
[Stapinski, Lexine A.; Prior, Katrina; Newton, Nicola C.; Kelly, Erin; Lees,
Briana; Teesson, Maree] Univ New South Wales, Natl Drug & Alcohol Res Ctr, Ctr Res
Excellence Mental Hlth & Subst Use, Sydney, NSW, Australia; [Stapinski, Lexine A.;
Prior, Katrina; Newton, Nicola C.; Kelly, Erin; Lees, Briana; Teesson, Maree;
Baillie, Andrew J.] Univ Sydney, Matilda Ctr, Level 6,Jane Foss Russell Bldg G02,
Sydney, NSW 2006, Australia; [Deady, Mark] Univ New South Wales, Black Dog Inst,
Sydney, NSW, Australia; [Baillie, Andrew J.] Univ Sydney, Fac Hlth Sci, Sydney,
NSW, Australia Stapinski, LA (reprint author), Univ Sydney, Matilda Ctr, Level
6,Jane Foss Russell Bldg G02, Sydney, NSW 2006, Australia.
lexine.stapinski@sydney.edu.au Prior, Katrina/Y-5735-2019; Deady,
Mark/E-8146-2014; Lees, Briana/S-6039-2017 Prior, Katrina/0000-0002-7784-2885;
Kelly, Erin/0000-0003-2549-2796; Stapinski, Lexine/0000-0002-3656-4655; Deady,
Mark/0000-0002-5230-2401; Lees, Briana/0000-0002-9888-8794; Baillie, Andrew/0000-
0003-3424-5703 Australian Rotary Health; NHMRC Translating Research into
Practice FellowshipNational Health and Medical Research Council of Australia; NHMRC
research fellowshipNational Health and Medical Research Council of Australia
[APP1870487] This research is funded by Australian Rotary Health. Australian
Rotary Health did not influence the design of the study or the writing of the
manuscript. LAS is supported by a NHMRC Translating Research into Practice
Fellowship. MT is supported by an NHMRC research fellowship (APP1870487).
[Anonymous], 2017, STAT STAT SOFTW REL; Arnett JJ, 2007, CHILD DEV PERSPECT,
V1, P68, DOI 10.1111/j.1750-8606.2007.00016.x; Australian Institute of Health and
Welfare, 2017, NAT DRUG STRAT HOUS; Babor T. F., 2001, ALCOHOL USE DISORDER;
Baillie AJ, 2010, DRUG ALCOHOL REV, V29, P518, DOI 10.1111/j.1465-
3362.2010.00206.x; Baumeister H, 2014, INTERNET INTERVENTIO, V1, P205, DOI DOI
10.1016/J.INVENT.2014.08.003; Bebbington P, 1995, INT J METHODS PSYCHI; Beseler CL,
2008, ALCOHOL CLIN EXP RES, V32, P607, DOI 10.1111/j.1530-0277.2008.00619.x;
Birrell L, 2015, J ANXIETY DISORD, V31, P108, DOI 10.1016/j.janxdis.2015.02.008;
Blume AW, 2000, COGN BEHAV PRACT, V7, P379, DOI 10.1016/S1077-7229(00)80048-6;
Boddapati S, 2014, J SUBST USE, V19, P152, DOI 10.3109/14659891.2013.765512;
Boydell KM, 2014, J CAN ACAD CHILD ADO, V23, P87; Brueton VC, 2014, BMJ OPEN, V4,
DOI 10.1136/bmjopen-2013-003821; Conway KP, 2016, J AM ACAD CHILD PSY, V55, P280,
DOI 10.1016/j.jaac.2016.01.006; Crum RM, 2013, DEPRESS ANXIETY, V30, P174, DOI
10.1002/da.22024; Day V, 2013, BEHAV RES THER, V51, P344, DOI
10.1016/j.brat.2013.03.003; de Lijster JM, 2017, CAN J PSYCHIAT, V62, P237, DOI
10.1177/0706743716640757; Deady M., 2009, REV SCREENING ASSESS; Deady M, 2016, J
MED INTERNET RES, V18, DOI 10.2196/jmir.5178; Degenhardt L, 2016, LANCET PSYCHIAT,
V3, P251, DOI 10.1016/S2215-0366(15)00508-8; DiClemente CC, 1999, PSYCHOL SCI, V10,
P209, DOI 10.1111/1467-9280.00137; Donkin L, 2012, J MED INTERNET RES, V14, P262,
DOI 10.2196/jmir.2100; Edwards PJ, 2009, COCHRANE DB SYST REV, DOI
10.1002/14651858.MR000008.pub4; Elkins IJ, 2006, J ABNORM PSYCHOL, V115, P26, DOI
10.1037/0021-843X.115.1.26; Falk DE, 2008, DRUG ALCOHOL DEPEN, V94, P234, DOI
10.1016/j.drugalcdep.2007.11.022; Farris SG, 2012, ALCOHOL ALCOHOLISM, V47, P143,
DOI 10.1093/alcalc/agr155; Fernandez E, 2015, J CONSULT CLIN PSYCH, V83, P1108, DOI
10.1037/ccp0000044; Grant VV, 2007, ADDICT BEHAV, V32, P2611, DOI
10.1016/j.addbeh.2007.07.004; Gueorguieva R, 2004, ARCH GEN PSYCHIAT, V61, P310,
DOI 10.1001/archpsyc.61.3.310; Gullone E, 2012, PSYCHOL ASSESSMENT, V24, P409, DOI
10.1037/a0025777; Gustavson K, 2018, BMC PSYCHIATRY, V18, DOI 10.1186/s12888-018-
1647-5; Hall WD, 2016, LANCET PSYCHIAT, V3, P265, DOI 10.1016/S2215-0366(16)00013-
4; Hatcher RL, 2006, PSYCHOTHER RES, V16, P12, DOI 10.1080/10503300500352500; Haver
B, 2003, EUR ADDICT RES, V9, P39, DOI 10.1159/000067735; HUNSLEY J, 1992, J
PSYCHOPATHOL BEHAV, V14, P55, DOI 10.1007/BF00960091; Hussong AM, 2011, PSYCHOL
ADDICT BEHAV, V25, P390, DOI 10.1037/a0024519; Hustad JTP, 2010, ADDICT BEHAV, V35,
P183, DOI 10.1016/j.addbeh.2009.10.012; Johnston L, 2014, AUST NZ J PSYCHIAT, V48,
P819, DOI 10.1177/0004867414527524; Kahler CW, 2008, J STUD ALCOHOL DRUGS, V69,
P611, DOI 10.15288/jsad.2008.69.611; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62,
P593, DOI 10.1001/archpsyc.62.6.593; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4,
P231, DOI 10.3109/10673229709030550; Kroenke K, 2007, ANN INTERN MED, V146, P317,
DOI 10.7326/0003-4819-146-5-200703060-00004; Kuntsche E, 2005, CLIN PSYCHOL REV,
V25, P841, DOI 10.1016/j.cpr.2005.06.002; Kushner MG, 2013, J CONSULT CLIN PSYCH,
V81, P429, DOI 10.1037/a0031301; KUSHNER MG, 1994, ALCOHOL CLIN EXP RES, V18, P852,
DOI 10.1111/j.1530-0277.1994.tb00050.x; Kushner MG, 2000, CLIN PSYCHOL REV, V20,
P149, DOI 10.1016/S0272-7358(99)00027-6; Kypri K, 2004, ADDICTION, V99, P1410, DOI
10.1111/j.1360-0443.2004.00847.x; Kypri K, 2007, ADDICTION, V102, P62, DOI
10.1111/j.1360-0443.2006.01632.x; LOVIBOND PF, 1995, BEHAV RES THER, V33, P335, DOI
10.1016/0005-7967(94)00075-U; McCambridge J, 2011, PLOS ONE, V6, DOI
10.1371/journal.pone.0023748; McCambridge J, 2011, PLOS MED, V8, DOI
10.1371/journal.pmed.1000413; McEvoy PM, 2008, J ANXIETY DISORD, V22, P1087, DOI
10.1016/j.janxdis.2007.11.007; McEvoy PM, 2011, AUST NZ J PSYCHIAT, V45, P957, DOI
10.3109/00048674.2011.624083; McHugh RK, 2015, HARVARD REV PSYCHIAT, V23, P99, DOI
10.1097/HRP.0000000000000058; Merrill JE, 2014, J STUD ALCOHOL DRUGS, V75, P93, DOI
10.15288/jsad.2014.75.93; Morley KC, 2014, ALCOHOL ALCOHOLISM, V49, P654, DOI
10.1093/alcalc/agu062; National Institute for Health and Care Excellence, 2018, INT
HARMF DRINK ALC; National Institute of Mental Health, 2017, MENT HLTH INF STAT;
Newton NC, 2016, J CHILD PSYCHOL PSYC, V57, P1056, DOI 10.1111/jcpp.12558; O'Dea
Bridianne, 2015, Internet Interventions, V2, P183, DOI
10.1016/j.invent.2015.03.005;
Peters L, 2012, PSYCHOL ASSESSMENT, V24, P66, DOI 10.1037/a0024544; Raes F, 2011,
CLIN PSYCHOL PSYCHOT, V18, P250, DOI 10.1002/cpp.702; Robinson J, 2011, ARCH GEN
PSYCHIAT, V68, P800, DOI 10.1001/archgenpsychiatry.2011.75; Rueger SY, 2012, J STUD
ALCOHOL DRUGS, V73, P829, DOI 10.15288/jsad.2012.73.829; Saunders SM, 2006, J SUBST
ABUSE TREAT, V30, P261, DOI 10.1016/j.jsat.2006.01.003; Seeley-Wait Elizabeth,
2009, Prim Care Companion J Clin Psychiatry, V11, P231, DOI 10.4088/PCC.07m00576;
Sheehan D. V, 1983, ANXIETY DIS; Simon GE, 2010, PSYCHIAT SERV, V61, P684, DOI
10.1176/ps.2010.61.7.684; Slade T, 2009, AUST NZ J PSYCHIAT, V43, P594, DOI
10.1080/00048670902970882; Smith JP, 2012, ALCOHOL RES-CURR REV, V34, P414; SOBELL
LC, 1992, MEASURING ALCOHOL CONSUMPTION, P41; Spitzer RL, 2006, ARCH INTERN MED,
V166, P1092, DOI 10.1001/archinte.166.10.1092; Spybrook J, 2011, OPTIMAL DESIGN
PROGR; Stapinski L, 2019, DEV INROADS PROGRAM; Stapinski L, 2019, BJ PSYCH;
Stapinski LA, 2016, PREV SCI, V17, P584, DOI 10.1007/s11121-016-0652-5; Stapinski
LA, 2015, COGN BEHAV PRACT, V22, P504, DOI 10.1016/j.cbpra.2014.05.004; Stewart SH,
2008, SER ANXIETY RELAT DI, P239, DOI 10.1007/978-0-387-74290-8_13; Teesson M,
2010, ADDICTION, V105, P2085, DOI 10.1111/j.1360-0443.2010.03096.x; Vourakis C,
2005, J CHILD ADOL PS NURS, V18, P161, DOI 10.1111/j.1744-6171.2005.00031.x;
Weathers F, 2013, PTSD CHECKLIST DSM 5; Weathers F. W., 2013, LIFE EVENTS CHECKLIS;
Wells JE, 2006, AUST NZ J PSYCHIAT, V40, P845, DOI 10.1080/j.1440-
1614.2006.01903.x; West BT, 2014, LINEAR MIXED MODELS; White IR, 2011, BMJ-BRIT MED
J, V342, DOI 10.1136/bmj.d40; Woicik PA, 2009, ADDICT BEHAV, V34, P1042, DOI
10.1016/j.addbeh.2009.07.001; Zgierska A, 2014, J FAM PRACTICE, V63, P524 87
0 0 2 2 JMIR PUBLICATIONS, INC TORONTO 59 WINNERS CIRCLE,
TORONTO, ON M4L 3Y7, CANADA 1929-0748 JMIR RES PROTOC JMIR RES.
Protoc. APR 2019 8 4 e12370
10.2196/12370 14 Health Care Sciences & Services Health
Care Sciences & Services HW2EW WOS:000466496800004 30977742 DOAJ Gold
2019-09-25
J Knowles, EEM; Mathias, SR; Pearlson, GD; Barrett, J; Mollon, J; Denbow, D;
Aberzik, K; Zatony, M; Glahn, DC Knowles, Emma E. M.; Mathias,
Samuel R.; Pearlson, Godfrey D.; Barrett, Jennifer; Mollon, Josephine; Denbow,
Dominique; Aberzik, Katrina; Zatony, Molly; Glahn, David C. Clinical
correlates of subsyndromal depression in African American individuals with
psychosis: The relationship with positive symptoms and comorbid substance
dependence SCHIZOPHRENIA RESEARCH English Article
Psychosis; Depression; Structural equation modeling; Crowd
sourcing; Substance Dependence SELF-MEDICATION HYPOTHESIS; MAJOR DEPRESSION;
PSYCHIATRIC-DISORDERS; NEGATIVE SYMPTOMS; MENTAL-DISORDERS; MECHANICAL TURK;
BIFACTOR MODELS; DUAL-DIAGNOSIS; INVENTORY-II; SAMPLE-SIZE Patients with psychosis
exhibit subsyndromal depressive symptoms during the course of illness and yet the
clinical correlates of these symptoms remain under-investigated. We aimed to
investigate the clinical correlates of subsyndromal depression in psychosis
including the extent to which they mediate commonly observed comorbid substance
dependence. We developed a model of depression in a non-clinical sample recruited
via Amazon's Mechanical Turk (N = 266), and confirmed that model in a locally
recruited African-American clinical sample comprising psychotic and non-psychotic
individuals (N = 256). Using scores from this model we tested: the strength of
relationships between depressive symptomatology and positive, negative and
disorganized symptoms in a range of psychotic disorders; whether depressive
symptoms were higher in individuals with affective psychoses versus schizophrenia;
and if depressive symptomatology mediated the relationship between psychosis and
substance dependence. Subsyndromal depressive symptomatology was significantly
higher in individuals with psychosis than without psychosis, but did not
significantly differ between affective and non-affective psychotic groups.
Depressive symptomatology was significantly related to positive (but not negative
or disorganized) psychotic symptoms, and mediated the relationship between
psychosis and substance dependence. The present study underlines the importance of
assessing subsyndromal depression in patients with psychosis, and generates a
number of testable predictions for future work. In particular, the examination of
the relationships between comorbid psychopathology, namely depression and substance
abuse, may improve insight into the neurobiology of psychosis. (C) 2018 Elsevier
B.V. All rights reserved. [Knowles, Emma E. M.; Mathias, Samuel R.; Pearlson,
Godfrey D.; Mollon, Josephine; Glahn, David C.] Yale Univ, Sch Med, Dept Psychiat,
New Haven, CT 06510 USA; [Pearlson, Godfrey D.; Barrett, Jennifer; Denbow,
Dominique; Aberzik, Katrina; Zatony, Molly; Glahn, David C.] Inst Living, Olin
Neuropsychiat Res Ctr, Hartford, CT USA Knowles, EEM (reprint author), Yale Univ,
Suite 6E 40 Temple St, New Haven, CT 06510 USA. emma.knowles@yale.edu Knowles,
Emma/V-2567-2019 National Institute of Mental Health (NIMH)United States
Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
National Institute of Mental Health (NIMH) [R01MH106324-01]This work is supported
by a grant from the National Institute of Mental Health (NIMH), grant number
R01MH106324-01. Al-Turkait FA, 2010, BMC PSYCHIATRY, V10, DOI 10.1186/1471-244X-
10-60; Allan R, 2009, J EVAL CLIN PRACT, V15, P134, DOI 10.1111/j.1365-
2753.2008.00968.x; Amazon, 2015, AM MECH TURK BET REQ, P2018; ANDREASEN NC, 1995,
LANCET, V346, P477, DOI 10.1016/S0140-6736(95)91325-4; Bearden CE, 2006, TRENDS
GENET, V22, P306, DOI 10.1016/j.tig.2006.04.004; Beck AT, 1996, MANUAL BECK
DEPRESSI; Benjamini Y, 2001, ANN STAT, V29, P1165; Birchwood M, 2005, EUR ARCH PSY
CLIN N, V255, P202, DOI 10.1007/s00406-005-0588-4; BRADY KT, 1993, AM J PSYCHIAT,
V150, P1255; Brouwer D, 2013, PSYCHOL ASSESSMENT, V25, P136, DOI 10.1037/a0029228;
Brown T., 2006, CONFIRMATORY FACTOR; Buckley PF, 2006, J CLIN PSYCHIAT, V67, P5;
Buckley PF, 2009, SCHIZOPHRENIA BULL, V35, P383, DOI 10.1093/schbul/sbn135;
Buhrmester M, 2011, PERSPECT PSYCHOL SCI, V6, P3, DOI 10.1177/1745691610393980;
Canty A, 2017, R PACKAGE, V1, P3, DOI DOI 10.1093/gerona/glq232; Cho H, 2017,
SCHIZOPHR RES, V183, P49, DOI 10.1016/j.schres.2016.11.016; Craddock N, 2007, WORLD
PSYCHIATRY, V6, P20; Crawford JR, 2003, BRIT J CLIN PSYCHOL, V42, P111, DOI
10.1348/014466503321903544; Davis L, 2008, CURR OPIN PSYCHIATR, V21, P14, DOI
10.1097/YCO.0b013e3282f32408; Davison A. C., 2017, BOOTSTRAP METHODS TH; First M.,
2002, STRUCTURED CLIN INTE; Fitzgerald PB, 2002, AUST NZ J PSYCHIAT, V36, P340, DOI
10.1046/j.1440-1614.2001.01004.x; FOULDS GA, 1975, PSYCHOL MED, V5, P181, DOI
10.1017/S0033291700056452; Freeman D, 2003, BEHAV RES THER, V41, P923, DOI
10.1016/S0005-7967(02)00104-3; Freeman D, 2001, PSYCHOL MED, V31, P1293, DOI
10.1017/S003329170100455X; Garety PA, 2001, PSYCHOL MED, V31, P189, DOI
10.1017/S0033291701003312; Gibbons RD, 2012, ARCH GEN PSYCHIAT, V69, P1104, DOI
10.1001/archgenpsychiatry.2012.14; Gordon J., 2017, RDOC OUTCOMES CAUSES; Hafner H,
1999, ACTA PSYCHIAT SCAND, V100, P105, DOI 10.1111/j.1600-0447.1999.tb10831.x;
Hartley S, 2013, ACTA PSYCHIAT SCAND, V128, P327, DOI 10.1111/acps.12080; Hasin D,
2002, ARCH GEN PSYCHIAT, V59, P375, DOI 10.1001/archpsyc.59.4.375; Helfer B, 2016,
AM J PSYCHIAT, V173, P876, DOI 10.1176/appi.ajp.2016.15081035; Holzinger K. J.,
1937, PSYCHOMETRIKA, V47, P51; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI
10.1080/10705519909540118; Jung S, 2011, BEHAV RES METHODS, V43, P701, DOI
10.3758/s13428-011-0077-9; Kenny D. A., 2016, MEDIATION; KESSLER RC, 1994, ARCH GEN
PSYCHIAT, V51, P8; Ketter TA, 2004, J PSYCHIATR RES, V38, P47, DOI 10.1016/S0022-
3956(03)00099-2; Keyes KM, 2013, PSYCHOL MED, V43, P1673, DOI
10.1017/S0033291712002292; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI
10.3109/10673229709030550; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259; Kline R.
B., 2005, MULTISAMPLE SEM, P289; Knowles EEM, 2016, J AFFECT DISORDERS, V191, P123,
DOI 10.1016/j.jad.2015.11.012; Knowles EEM, 2015, BIOL PSYCHIAT, V78, P786, DOI
10.1016/j.biopsych.2015.01.018; Knowles EEM, 2015, AM J PSYCHIAT, V172, P190, DOI
10.1176/appi.ajp.2014.14030311; Knowles EEM, 2014, AM J MED GENET B, V165, P84, DOI
10.1002/ajmg.b.32211; Kotov R, 2017, AM J PSYCHIAT, V174, P1064, DOI
10.1176/appi.ajp.2017.16101191; Kotov R, 2017, J ABNORM PSYCHOL, V126, P454, DOI
10.1037/abn0000258; Krausz M, 1996, PSYCHOPATHOLOGY, V29, P95, DOI
10.1159/000284977; Lako IM, 2012, J AFFECT DISORDERS, V140, P38, DOI
10.1016/j.jad.2011.10.014; Le S, 2008, J STAT SOFTW, V25, P1; Levinson DF, 2002,
SCHIZOPHRENIA BULL, V28, P683, DOI 10.1093/oxfordjournals.schbul.a006972; Li CH,
2016, BEHAV RES METHODS, V48, P936, DOI 10.3758/s13428-015-0619-7; Li Y, 2014,
PSYCHOL MED, V44, P1391, DOI 10.1017/S003329171300192X; LIDDLE PF, 1987, BRIT J
PSYCHIAT, V151, P145, DOI 10.1192/bjp.151.2.145; MacCallum RC, 1999, PSYCHOL
METHODS, V4, P84, DOI 10.1037/1082-989X.4.1.84; Majadas S, 2012, COMPR PSYCHIAT,
V53, P145, DOI 10.1016/j.comppsych.2011.03.009; Mansolf M, 2017, INTELLIGENCE, V61,
P120, DOI 10.1016/j.intell.2017.01.012; Mao YM, 2015, NEUROPSYCH DIS TREAT, V11,
P701, DOI 10.2147/NDT.S62266; Mathias SR, 2018, SCHIZOPHR RES, V193, P100, DOI
10.1016/j.schres.2017.08.015; Maxwell SE, 2008, ANNU REV PSYCHOL, V59, P537, DOI
10.1146/annurev.psych.59.103006.093735; Mullin K, 2012, AUST NZ J PSYCHIAT, V46,
P826, DOI 10.1177/0004867412440192; Muthen B. O., 2016, REGRESSION MEDIATION;
Muthen L. K, 2011, MPLUS USERS GUIDE; Negrete JC, 2003, CAN J PSYCHIAT, V48, P14;
Oorschot M, 2009, PSYCHOL ASSESSMENT, V21, P498, DOI 10.1037/a0017077; Paolacci G,
2014, CURR DIR PSYCHOL SCI, V23, P184, DOI 10.1177/0963721414531598; Potvin S,
2007, AUST NZ J PSYCHIAT, V41, P792, DOI 10.1080/00048670701579041; Preacher K. J.,
2006, COMPUTING POWER MINI; R Core Team, 2017, R LANG ENV STAT COMP; Raiche G.,
2010, NFACTORS R PACKAGE P; REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511;
Reininghaus U, 2016, BRIT J PSYCHIAT, V209, P107, DOI 10.1192/bjp.bp.115.167882;
Reise SP, 2010, J PERS ASSESS, V92, P544, DOI 10.1080/00223891.2010.496477; Revelle
W., 2017, PSYCH PROCEDURES PER; Sands JR, 1999, SCHIZOPHRENIA BULL, V25, P157, DOI
10.1093/oxfordjournals.schbul.a033362; Scheller-Gilkey G, 2002, SCHIZOPHRENIA BULL,
V28, P223, DOI 10.1093/oxfordjournals.schbul.a006933; Seddon JL, 2016,
SCHIZOPHRENIA BULL, V42, P619, DOI 10.1093/schbul/sbv154; Shafer AB, 2006, J CLIN
PSYCHOL, V62, P123, DOI 10.1002/jclp.20213; Sim K, 2004, PSYCHIAT RES, V129, P141,
DOI 10.1016/j.psychres.2004.07.007; Siris S., 2003, SCHIZOPHRENIA, P142; SIRIS SG,
1988, AM J PSYCHIAT, V145, P1532; Swendsen JD, 2000, CLIN PSYCHOL REV, V20, P173,
DOI 10.1016/S0272-7358(99)00026-4; Tamminga CA, 2013, AM J PSYCHIAT, V170, P1263,
DOI 10.1176/appi.ajp.2013.12101339; Tandon R, 2009, SCHIZOPHR RES, V110, P1, DOI
10.1016/j.schres.2009.03.005; TAYLOR MA, 1992, AM J PSYCHIAT, V149, P22; Thoma P,
2013, PSYCHIAT CLIN NEUROS, V67, P367, DOI 10.1111/pcn.12072; Upthegrove R, 2010,
ACTA PSYCHIAT SCAND, V122, P211, DOI 10.1111/j.1600-0447.2009.01506.x; Upthegrove
R, 2017, SCHIZOPHRENIA BULL, V43, P240, DOI 10.1093/schbul/sbw097; van Loo HM,
2012, BMC MED, V10, DOI 10.1186/1741-7015-10-156; Vanheule S, 2008, ASSESSMENT,
V15, P177, DOI 10.1177/1073191107311261; Venables W. N., 2002, MODERN APPL STAT S;
Vrieze E, 2014, J AFFECT DISORDERS, V155, P35, DOI 10.1016/j.jad.2013.10.020;
Walker J, 2002, INT CLIN PSYCHOPHARM, V17, pS11; Ward LC, 2006, PSYCHOL ASSESSMENT,
V18, P81, DOI 10.1037/1040-3590.18.1.81; Wigman JTW, 2015, PSYCHOL MED, V45, P2375,
DOI 10.1017/S0033291715000331; 2006, NEUROTOX RES, V10, P235; 2012, SCHIZOPHR RES,
V142, P129, DOI DOI 10.1016/J.SCHRES.2012.08.020; 2011, SCHIZOPHR RES, V132, P177,
DOI DOI 10.1016/J.SCHRES.2011.07.032 99 0 0 0 0 ELSEVIER
SCIENCE BV AMSTERDAM PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS 0920-9964
1573-2509 SCHIZOPHR RES Schizophr. Res. APR 2019 206
333 346 10.1016/j.schres.2018.10.022
14 Psychiatry Psychiatry HY0NX WOS:000467810100047 30482645
2019-09-25
J Miloyan, B; Van Doorn, G Miloyan, Beyon; Van Doorn,
George Longitudinal association between social anxiety disorder
and incident alcohol use disorder: results from two national samples of US adults
SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY English
Article Social phobia; Alcoholism;
Incidence; Prospective cohort study; Epidemiology PSYCHIATRIC-DISORDERS;
EPIDEMIOLOGIC SURVEY; ADOLESCENT SYMPTOMS; SELF-MEDICATION; SUBSTANCE USE; RISK-
FACTOR; PHOBIA; PREVALENCE; DRINKING; COMORBIDITY This study assessed the
association between subclinical social fears and a 12-month diagnosis of Social
Anxiety Disorder (SAD) at baseline and the risk of incident Alcohol Use Disorder
(AUD) at follow-up, compared to those without subclinical social fears and a 12-
month diagnosis of SAD. We performed an individual participant meta-analysis based
on data from two national longitudinal surveys. Wave 1 of the National
Epidemiologic Survey on Alcohol and Related Conditions (NESARC) was conducted in
2001-2002 in a sample of 43,093 adults and Wave 2 was conducted in 2004-2005 in
34,653 of the original respondents. Wave 1 of the National Comorbidity Survey was
conducted in 1990-1992 in a sample of 8098 respondents and Wave 2 was conducted in
2001-2002 in 5001 of the original respondents. Binary logistic regression analyses
were performed independently in each study and then the effect estimates were
combined using random-effects meta-analysis. Neither subclinical social fears nor
12-month SAD at baseline were associated with incident AUD at follow-up. These
findings conflict with reports of previous studies that a diagnosis of SAD is a
risk factor for AUD in adults, and suggest that subclinical social fears are not
associated with differential risk of incident AUD. [Miloyan, Beyon; Van Doorn,
George] Federat Univ Australia, Fac Hlth, Dept Psychol, Northways Rd, Churchill,
Vic 3842, Australia; [Miloyan, Beyon] Johns Hopkins Univ, Dept Mental Hlth,
Bloomberg Sch Publ Hlth, Baltimore, MD 21218 USA Miloyan, B (reprint author),
Federat Univ Australia, Fac Hlth, Dept Psychol, Northways Rd, Churchill, Vic 3842,
Australia.; Miloyan, B (reprint author), Johns Hopkins Univ, Dept Mental Hlth,
Bloomberg Sch Publ Hlth, Baltimore, MD 21218 USA. b.miloyan@federation.edu.au
Van Doorn, George/0000-0001-7311-7099 Johns Hopkins Epidemiology and
Biostatistics of Aging Training Program of the National Institute on Aging (NIA)
[T32AG000247] BM received funding from the Johns Hopkins Epidemiology and
Biostatistics of Aging Training Program of the National Institute on Aging (NIA)
under award number T32AG000247. Bacon AK, 2010, ADDICT BEHAV, V35, P925, DOI
10.1016/j.addbeh.2010.06.002; Beesdo K, 2007, ARCH GEN PSYCHIAT, V64, P903, DOI
10.1001/archpsyc.64.8.903; Behrendt S, 2011, PSYCHOL MED, V41, P1073, DOI
10.1017/S0033291710001418; Bekman NM, 2010, J STUD ALCOHOL DRUGS, V71, P570, DOI
10.15288/jsad.2010.71.570; Brook CA, 2016, DEV PSYCHOL, V52, P835, DOI
10.1037/dev0000110; Buckner JD, 2008, J PSYCHIATR RES, V42, P230, DOI
10.1016/j.jpsychires.2007.01.002; Buckner JD, 2013, DEPRESS ANXIETY, V30, P276, DOI
10.1002/da.22032; Buckner JD, 2010, PSYCHOL ADDICT BEHAV, V24, P640, DOI
10.1037/a0020968; Buckner JD, 2008, DEPRESS ANXIETY, V25, P1028, DOI
10.1002/da.20442; Buckner JD, 2009, DRUG ALCOHOL DEPEN, V100, P128, DOI
10.1016/j.drugalcdep.2008.09.018; Bulley A, 2016, J AFFECT DISORDERS, V196, P62,
DOI 10.1016/j.jad.2016.02.028; Burstein M, 2011, J AM ACAD CHILD PSY, V50, P870,
DOI 10.1016/j.jaac.2011.06.005; Carrigan MH, 2003, ADDICT BEHAV, V28, P269, DOI
10.1016/S0306-4603(01)00235-0; Crum RM, 2001, AM J PSYCHIAT, V158, P1693, DOI
10.1176/appi.ajp.158.10.1693; Dahne J, 2014, J STUD ALCOHOL DRUGS, V75, P929, DOI
10.15288/jsad.2014.75.929; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI
10.1016/0197-2456(86)90046-2; Grant B, 2005, SOURCE ACCURACY STAT; Grant B.F.,
2003, SOURCE ACCURACY STAT; Grant BF, 2003, DRUG ALCOHOL DEPEN, V71, P7, DOI
10.1016/S0376-8716(03)00070-X; Grant BF, 2004, ARCH GEN PSYCHIAT, V61, P807, DOI
10.1001/archpsyc.61.8.807; Kessler R. C., 2011, Textbook in psychiatric
epidemiology, P221; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Kessler Ronald
C., 1994, International Review of Psychiatry, V6, P365, DOI
10.3109/09540269409023274; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259;
Mackinnon SP, 2014, PSYCHOL ADDICT BEHAV, V28, P1000, DOI 10.1037/a0037244; Martins
SS, 2012, PUBLIC MENTAL HLTH; McKenzie M, 2011, MED J AUSTRALIA, V195, pS27;
Norberg MM, 2010, BEHAV THER, V41, P555, DOI 10.1016/j.beth.2010.03.002; Pardee CS,
2014, PSYCHOL ADDICT BEHAV, V28, P1246, DOI 10.1037/a0038372; Power C, 1999,
ADDICTION, V94, P1477, DOI 10.1046/j.1360-0443.1999.941014774.x; ROSS HE, 1988,
ARCH GEN PSYCHIAT, V45, P1023; Santesso DL, 2004, PERS INDIV DIFFER, V37, P5, DOI
10.1016/j.paid.2003.08.023; Schneier FR, 2010, PSYCHOL MED, V40, P977, DOI
10.1017/S0033291709991231; SCHNEIER FR, 1992, ARCH GEN PSYCHIAT, V49, P282; Schry
AR, 2013, ADDICT BEHAV, V38, P2690, DOI 10.1016/j.addbeh.2013.06.014; Thomas SE,
2003, ALCOHOL CLIN EXP RES, V27, P1937, DOI 10.1097/01.ALC.0000100942.30743.8C;
WITTCHEN HU, 1994, J PSYCHIAT RES, V28, P57, DOI 10.1016/0022-3956(94)90036-1;
Zimmermann P, 2003, PSYCHOL MED, V33, P1211, DOI 10.1017/S0033291703008158 38
1 1 5 5 SPRINGER HEIDELBERG HEIDELBERG TIERGARTENSTRASSE
17, D-69121 HEIDELBERG, GERMANY 0933-7954 1433-9285 SOC PSYCH PSYCH
EPID Soc. Psychiatry Psychiatr. Epidemiol. APR 2019 54 4
469 475 10.1007/s00127-018-1569-z 7
Psychiatry Psychiatry HR3HC WOS:000463026400007 30054643
2019-09-25
J Cetty, L; Shahwan, S; Satghare, P; Devi, F; Chua, BY; Verma, S; Lee, H;
Chong, SA; Subramaniam, M Cetty, Laxman; Shahwan, Shazana;
Satghare, Pratika; Devi, Fiona; Chua, Boon Yiang; Verma, Swapna; Lee, Helen; Chong,
Siow Ann; Subramaniam, Mythily Hazardous alcohol use in a sample
of first episode psychosis patients in Singapore BMC PSYCHIATRY
English Article Hazardous alcohol use;
Psychosis; Singapore; Hazardous drinking; AUDIT DISORDERS IDENTIFICATION TEST;
SUBSTANCE-USE; 1ST-EPISODE PSYCHOSIS; SELF-MEDICATION; DRUG-ABUSE; SCHIZOPHRENIA;
PREVALENCE; SMOKING; COMORBIDITY; OUTPATIENTS BackgroundHazardous alcohol use has
often been found to be more prevalent amongst psychiatric outpatients than the
general population. Additionally, it has also been associated with poorer outcomes.
The study aimed to investigate (1) the prevalence and (2) socio-demographic and
clinical correlates of hazardous alcohol use, as well as (3) the relationship
between hazardous alcohol use and quality of life in an outpatient sample with
First Episode Psychosis (FEP) in Singapore.MethodsBaseline data (N=280) was
extracted from a longitudinal study investigating smoking and alcohol use amongst
outpatients with FEP in a psychiatric hospital. Information on socio-demographics,
hazardous alcohol use, and quality of life was collected through a self-report
survey. Hazardous alcohol use was ascertained by total scores of 8 or higher on the
Alcohol Use Disorders Identification Test (AUDIT). Data was analysed using logistic
regression and linear regression analyses.ResultsThe prevalence of hazardous
alcohol use over the past 12-month period was 12.9%. Those who had never smoked in
their lifetime (vs current smokers) and those with a diagnosis of brief psychotic
disorder (vs schizophrenia spectrum disorders) were found to have significantly
lower odds of hazardous alcohol use. Hazardous alcohol use was also associated with
lower negative symptom scores. Lastly, hazardous alcohol use was found to
significantly predict lower scores on the physical health, social relationship and
environment domains of quality of life.ConclusionsThe association between hazardous
alcohol use and lower negative symptom scores is a surprising finding that needs to
be further explored. The significant impact of hazardous alcohol use in reductions
in quality of life suggests that early screening and interventions could benefit
patients with hazardous alcohol use and comorbid psychosis.[Cetty, Laxman; Shahwan,
Shazana; Satghare, Pratika; Devi, Fiona; Chua, Boon Yiang; Chong, Siow Ann;
Subramaniam, Mythily] Buangkok Green Med Pk, Inst Mental Hlth, Res Div, 10 Buangkok
View, Singapore 539747, Singapore; [Verma, Swapna; Lee, Helen] Buangkok Green Med
Pk, Inst Mental Hlth, Dept Early Psychosis Intervent, 10 Buangkok View, Singapore
539747, Singapore; [Subramaniam, Mythily] Lee Kong Chian Sch Med, Novena Campus,11
Mandalay Rd, Singapore 308232, Singapore Cetty, L (reprint author), Buangkok Green
Med Pk, Inst Mental Hlth, Res Div, 10 Buangkok View, Singapore 539747, Singapore.
Laxman_Cetty@imh.com.sg Ministry of Health, National Medical
Research Council, Singapore (NMRC) under its Centre Grant program
[NMRC/CG/004/2013] This study was funded by the Ministry of Health, National
Medical Research Council, Singapore (NMRC) under its Centre Grant program
NMRC/CG/004/2013). The funding body had no role in the design of the study and
collection, and interpretation of data and in writing the manuscript. Aas RW,
2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186503; Alvarez-Jimenez M, 2011,
SCHIZOPHRENIA BULL, V37, P619, DOI 10.1093/schbul/sbp129; American Psychiatric
Association, 2013, DIAGN STAT MAN MENT; American Psychiatric Association, 2000,
DIAGN STAT MAN MENT; Archie S, 2007, SCHIZOPHRENIA BULL, V33, P1354, DOI
10.1093/schbul/sbm011; Babor T, 2001, AUDIT ALCOHOL USE DI; Bahorik AL, 2016, J
AFFECT DISORDERS, V206, P169, DOI 10.1016/j.jad.2016.07.039; Batki SL, 2008,
SCHIZOPHR RES, V105, P201, DOI 10.1016/j.schres.2008.06.020; Cassidy CM, 2008, CAN
J PSYCHIAT, V53, P26, DOI 10.1177/070674370805300105; Cheung YB, 2017, ANN ACAD MED
SINGAP, V46, P461; Compton MT, 2007, J CLIN PSYCHIAT, V68, P1939, DOI
10.4088/JCP.v68n1215; Cooper J, 2012, AUST NZ J PSYCHIAT, V46, P851, DOI
10.1177/0004867412449876; Drake RE, 2002, ALCOHOL RES HEALTH, V26, P99; Eberhard S,
2015, J MENT HEALTH, V24, P162, DOI 10.3109/09638237.2015.1036967; Etter M, 2004,
SCHIZOPHRENIA BULL, V30, P947, DOI 10.1093/oxfordjournals.schbul.a007144; Harper A,
1998, PSYCHOL MED, V28, P551, DOI 10.1017/S0033291798006667; Harris KM, 2005,
HEALTH SERV RES, V40, P117, DOI 10.1111/j.1475-6773.2005.00345.x; Hart CL, 2010,
BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-789; Hartz SM, 2014, JAMA
PSYCHIAT, V71, P248, DOI 10.1001/jamapsychiatry.2013.3726; Huang MC, 2009, PSYCHIAT
CLIN NEUROS, V63, P94, DOI 10.1111/j.1440-1819.2008.01909.x; Jones RM, 2011, J CLIN
PSYCHIAT, V72, P775, DOI 10.4088/JCP.10m06320; KAY SR, 1987, SCHIZOPHRENIA BULL,
V13, P261, DOI 10.1093/schbul/13.2.261; Khantzian EJ, 1997, HARVARD REV PSYCHIAT,
V4, P231, DOI 10.3109/10673229709030550; Kumar CN, 2015, ADDICT BEHAV, V45, P22,
DOI 10.1016/j.addbeh.2015.01.009; Lange EH, 2014, COMPR PSYCHIAT, V55, P274, DOI
10.1016/j.comppsych.2013.08.018; Leonard KE, 2007, ANNU REV CLIN PSYCHO, V3, P285,
DOI 10.1146/annurev.clinpsy.3.022806.091424; McCreadie RG, 2002, BRIT J PSYCHIAT,
V181, P321, DOI 10.1192/bjp.181.4.321; Messias E, 2003, J NERV MENT DIS, V191,
P387, DOI 10.1097/00005053-200306000-00006; Moyer A, 2002, ADDICTION, V97, P279,
DOI 10.1046/j.1360-0443.2002.00018.x; OSHER FC, 1994, J CLIN PSYCHIAT, V55, P109;
Picco L, 2012, ANN ACAD MED SINGAP, V41, P325; Pristach CA, 1996, PSYCHIATR SERV,
V47, P421; REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511; Reinert DF, 2002,
ALCOHOL CLIN EXP RES, V26, P272, DOI 10.1111/j.1530-0277.2002.tb02534.x; Reinert
DF, 2007, ALCOHOL CLIN EXP RES, V31, P185, DOI 10.1111/j.1530-0277.2006.00295.x;
Roehrs T, 2001, SLEEP MED REV, V5, P287, DOI 10.1053/smrv.2001.0162; Room R, 2004,
BIOMED PHARMACOTHER, V58, P111, DOI 10.1016/j.biopha.2003.12.003; SAUNDERS JB,
1990, CAN MED ASSOC J, V143, P1060; Saunders JB, 2000, COMPR PSYCHIAT, V41, P95,
DOI 10.1016/S0010-440X(00)80015-2; Strawbridge RJ, 2018, TRANSL PSYCHIAT, V8, DOI
10.1038/s41398-017-0079-1; Subramaniam M, 2017, ALCOHOL, V65, P63, DOI
10.1016/j.alcohol.2017.07.008; Subramaniam M, 2012, ADDICTION, V107, P1443, DOI
10.1111/j.1360-0443.2012.03830.x; Talamo A, 2006, SCHIZOPHR RES, V86, P251, DOI
10.1016/j.schres.2006.04.004; Tay ATS, 2016, ANN ACAD MED SINGAP, V45, P138; Verma
S, 2012, ASIAN J PSYCHIATR, V5, P63, DOI 10.1016/j.ajp.2012.02.001; White AM, 2003,
ALCOHOL RES HEALTH, V27, P186; 2014, GLOB STAT REP VIOL, P147 0 0 0
0 BMC LONDON CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND 1471-
244X BMC PSYCHIATRY BMC Psychiatry MAR 15 2019 19
91 10.1186/s12888-019-2073-z
9 Psychiatry Psychiatry HO9OG WOS:000461294300001 30876474 DOAJ
Gold, Green Published 2019-09-25
J Tatch, A; Yigit, IH; Brown, D; Robertson, A Tatch,
Andrew; Yigit, Ismail Hakki; Brown, Dustin; Robertson, Angela
Examining the Role of Race and Gender as Moderators of the Relationship
Between Depressive Symptoms and Hazardous Alcohol Consumption among DUI Offenders
SOCIOLOGICAL SPECTRUM English Article
IDENTIFICATION TEST AUDIT; SUBSTANCE USE DISORDERS; UNITED-
STATES; ANXIETY DISORDERS; SELF-MEDICATION; DRINKING CONSEQUENCES; PSYCHIATRIC-
DISORDERS; MAJOR DEPRESSION; COLLEGE-STUDENTS; BINGE DRINKING Research
consistently documents a positive association between depressive symptoms and
hazardous drinking. Fewer studies have examined this relationship among high-risk
populations such as Driving Under the Influence (DUI) offenders and rarely evaluate
whether the association between depression and hazardous drinking varies by race
and gender. We examined the relationship between depressive symptoms and hazardous
drinking in a diverse sample of DUI offenders, extending previous research by
examining the moderating effects of race and gender. We analyzed survey data
collected from DUI offenders (N=10,082) enrolled in the 2012 Mississippi Alcohol
and Safety Education Program. We estimated a series of nested regression models to
assess the relationship between depressive symptoms and hazardous drinking. The
analyses also assessed the extent to which the hypothesized association between
depression symptomology and hazardous drinking varied by race and gender. We
documented a positive association between depressive symptoms and hazardous
drinking among DUI offenders. The association between depressive symptoms and
hazardous drinking was stronger for black offenders relative to white. We found no
significant differences by gender. The incorporation of culturally specific needs
of DUI offenders may help intervention efforts more efficiently reduce negative
consequences associated with impaired driving. [Tatch, Andrew; Yigit, Ismail
Hakki; Brown, Dustin; Robertson, Angela] Mississippi State Univ, Social Sci Res
Ctr, 1 Res Blvd,Suite 103, Starkville, MS 39759 USA Tatch, A (reprint author),
Mississippi State Univ, Social Sci Res Ctr, 1 Res Blvd,Suite 103, Starkville, MS
39759 USA. andrew.tatch@ssrc.msstate.edu Bagnardi V, 2001,
ALCOHOL RES HEALTH, V25, P263; BARRY KL, 1993, ALCOHOL ALCOHOLISM, V28, P33; Becker
U, 1996, HEPATOLOGY, V23, P1025, DOI 10.1002/hep.510230513; Blincoe Lawrence, 2015,
EC SOC IMPACT MOTOR; Blume Sheila B, 1997, GENDER ALCOHOL INDIV, P462; Bolton J,
2006, J NERV MENT DIS, V194, P818, DOI 10.1097/01.nmd.0000244481.63148.98; Bolton
JM, 2009, J AFFECT DISORDERS, V115, P367, DOI 10.1016/j.jad.2008.10.003; Bray RM,
2010, MIL MED, V175, P390, DOI 10.7205/MILMED-D-09-00132; Bush K, 1998, ARCH INTERN
MED, V158, P1789, DOI 10.1001/archinte.158.16.1789; Cavaiola AA, 2003, ADDICT
BEHAV, V28, P971, DOI 10.1016/S0306-4603(01)00291-X; Center for Behavioral Health
Statistics and Quality, 2015, BEH HLTH TRENDS US R; COOPER ML, 1992, J ABNORM
PSYCHOL, V101, P139, DOI 10.1037/0021-843X.101.1.139; FLEMING MF, 1991, INT J
ADDICT, V26, P1173, DOI 10.3109/10826089109062153; Flowers NT, 2008, ALCOHOL CLIN
EXP RES, V32, P639, DOI 10.1111/j.1530-0277.2008.00622.x; GEORGE WH, 1988, J APPL
SOC PSYCHOL, V18, P1295, DOI 10.1111/j.1559-1816.1988.tb01208.x; GRANT BF, 1995,
DRUG ALCOHOL DEPEN, V39, P197, DOI 10.1016/0376-8716(95)01160-4; Harrell Z. A.,
2002, J COGN PSYCHOTHER, V16, P391, DOI DOI 10.1891/JC0P.16.4.391.52526; HAYS RD,
1995, BEHAV RES METH INSTR, V27, P277, DOI 10.3758/BF03204745; Holt LJ, 2009, AM J
DRUG ALCOHOL AB, V35, P117, DOI 10.1080/00952990802585398; Husaini B. A., 1980, J
COMMUNITY PSYCHOL, V8, P20, DOI [10.1002/1520-6629(198001)8:1<20::AID-
JC0P2290080105>3.0.00:2-Y, DOI 10.1002/1520-6629(198001]; HUSAINI BA, 1994, J
GERONTOL SOC WORK, V21, P177, DOI 10.1300/J083V21N03_12; Jane-Llopis E, 2006, DRUG
ALCOHOL REV, V25, P515, DOI 10.1080/09595230600944461; Kanny D, 2013, MMWR-MORBID
MORTAL W, V62, P77; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI
10.1001/archpsyc.62.6.593; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Keyes KM,
2008, DRUG ALCOHOL DEPEN, V93, P21, DOI 10.1016/j.drugalcdep.2007.08.017; Khantzian
EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550; Lapham SC,
2001, ARCH GEN PSYCHIAT, V58, P943, DOI 10.1001/archpsyc.58.10.943; LEMLE R, 1989,
J SUBST ABUSE TREAT, V6, P213, DOI 10.1016/0740-5472(89)90045-7; LOWINGER R, 2012,
COLL STUDENT J, V46, P829; Martens MP, 2008, J COUNS PSYCHOL, V55, P289, DOI
10.1037/0022-0167.55.2.289; MCMILLEN DL, 1992, ADDICT BEHAV, V17, P407, DOI
10.1016/0306-4603(92)90001-C; Merikangas KR, 1998, ADDICT BEHAV, V23, P893, DOI
10.1016/S0306-4603(98)00076-8; Miller JW, 2004, AM J PREV MED, V27, P197, DOI
10.1016/j.amepre.2004.05.004; Miller W. R., 1995, PROJECT MATCH MONOGR, V4; Moore
AA, 2005, AM J PUBLIC HEALTH, V95, P458, DOI 10.2105/AJPH.2003.019471; Mulia N,
2008, J STUD ALCOHOL DRUGS, V69, P824, DOI 10.15288/jsad.2008.69.824; National
Institute of Mental Health, 2015, DEPRESSION; Neighbors H W, 1983, Prev Hum Serv,
V2, P5; Nochajski TH, 2006, CLIN PSYCHOL REV, V26, P179, DOI
10.1016/j.cpr.2005.11.006; PEARLIN LI, 1989, J HEALTH SOC BEHAV, V30, P241, DOI
10.2307/2136956; Piccinelli M, 2000, BRIT J PSYCHIAT, V177, P486, DOI
10.1192/bjp.177.6.486; RADLOFF L S, 1977, Applied Psychological Measurement, V1,
P385, DOI 10.1177/014662167700100306; Riolo SA, 2005, AM J PUBLIC HEALTH, V95,
P998, DOI 10.2105/AJPH.2004.047225; Robertson A, 2016, AM J DRUG ALCOHOL AB, V42,
P597, DOI 10.3109/00952990.2016.1167898; Robinson J, 2009, J ANXIETY DISORD, V23,
P38, DOI 10.1016/j.janxdis.2008.03.013; Roehrs T, 2001, SLEEP MED REV, V5, P287,
DOI 10.1053/smrv.2001.0162; SCHMIDT A, 1995, SOUTHERN MED J, V88, P52, DOI
10.1097/00007611-199501000-00007; SCHUCKIT MA, 1990, J STUD ALCOHOL, V51, P34, DOI
10.15288/jsa.1990.51.34; SELZER ML, 1971, AM J PSYCHIAT, V127, P1653, DOI
10.1176/ajp.127.12.1653; Smith GS, 1999, ANN EMERG MED, V33, P659, DOI
10.1016/S0196-0644(99)70195-2; SOMERVELL PD, 1989, AM J EPIDEMIOL, V130, P725, DOI
10.1093/oxfordjournals.aje.a115394; Substance Abuse and Mental Health Services
Administration, 2015, MENT DIS; Swendsen JD, 2000, CLIN PSYCHOL REV, V20, P173, DOI
10.1016/S0272-7358(99)00026-4; Vaillant G, 1983, NATURAL HIST ALCOHOL; VAILLANT GE,
1982, AM PSYCHOL, V37, P494, DOI 10.1037/0003-066X.37.5.494; WARHEIT GJ, 1975, J
HEALTH SOC BEHAV, V16, P243, DOI 10.2307/2136874; Weitzman ER, 2003, HEALTH PLACE,
V9, P1, DOI 10.1016/S1353-8292(02)00014-X; Wells-Parker E, 2002, J STUD ALCOHOL,
V63, P655, DOI 10.15288/jsa.2002.63.655; Williams D R, 1991, WHO Reg Publ Eur Ser,
V37, P147; Williams D R, 1997, J Health Psychol, V2, P335, DOI
10.1177/135910539700200305; Wilsnack R. W., 2005, ALCOHOL GENDER DRINK, P1;
Wilsnack RW, 2000, ADDICTION, V95, P251, DOI 10.1046/j.1360-0443.2000.95225112.x;
WINDLE M, 1989, J STUD ALCOHOL, V50, P406, DOI 10.15288/jsa.1989.50.406; World
Health Organization, 2001, AUDIT ALCOHOL USE DI 65 0 0 1 1 TAYLOR
& FRANCIS INC PHILADELPHIA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA
19106 USA 0273-2173 1521-0707 SOCIOL SPECTRUM Sociol. Spectr. MAR 4
2019 39 2 131 145
10.1080/02732173.2019.1608342 15 Sociology Sociology IK8JD
WOS:000476840500004 2019-09-25
J Levy, M Levy, Michael The Many Faces
(and Potential Dangers) of Self-Medication as an Explanatory Concept for Substance
Use INTERNATIONAL JOURNAL FOR THE ADVANCEMENT OF COUNSELLING
English Article Self-medication; Dual
diagnosis; Substance use; Addiction; Counseling USE DISORDERS; FOLLOW-UP;
HYPOTHESIS; DEPRESSION; COMORBIDITY; ALCOHOL; COCAINE; REWARD; RISK The self-
medication hypothesis of addictive disorders maintains that individuals use
substances to cope with dysphoric affect, and that painful emotional states are
etiologically relevant to the development of a substance use disorder. While this
hypothesis may be relevant for some, this paper proposes that self-medication
understood in this fashion is an over-used concept. Furthermore, viewing substance
use as being caused by some underlying emotional issue will affect how counselling
is conducted and it is suggested that intervention may often be misguided. In this
paper, other ways that substance use and mental suffering can become related that
have nothing to do with emotional anguish being the causal agent for substance use
will be elucidated. The implications that this has on counselling intervention will
then be highlighted. Broadening of our understanding of self-medication and the
many ways that substance use and psychological distress can become linked will help
counselors to offer optimal care to this vulnerable population. [Levy, Michael]
Florida House Experience, 500 A South Fed Highway, Deerfield, FL 33441 USA Levy,
M (reprint author), Florida House Experience, 500 A South Fed Highway, Deerfield,
FL 33441 USA. mlevy@fherehab.com Adinoff B, 2004,
HARVARD REV PSYCHIAT, V12, P305, DOI 10.1080/10673220490910844; Dick DM, 2010,
HANDBOOK OF BEHAVIOR GENETICS, P433, DOI 10.1007/978-0-387-76727-7_29; Frances RJ,
1997, HARVARD REV PSYCHIAT, V4, P287, DOI 10.3109/10673229709030556; Gau SSF, 2007,
LONGITUDINAL STUDY B, V190, P42, DOI [10.1192/bjp.bp.106.022871, DOI
10.1192/BJP.BP.106.022871]; Goswami S, 2004, AM J ADDICTION, V13, P139, DOI
10.1080/10550490490435795; Hall DH, 2007, J PSYCHOACTIVE DRUGS, V39, P151, DOI
10.1080/02791072.2007.10399873; HARRINGTON R, 1990, ARCH GEN PSYCHIAT, V47, P465;
Heath AC, 1995, ALCOHOL HEALTH RES W, V19, P166; Henwood B, 2007, AM J ADDICTION,
V16, P160, DOI 10.1080/10550490701375368; Kendler KS, 2003, AM J PSYCHIAT, V160,
P687, DOI 10.1176/appi.ajp.160.4.687; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62,
P593, DOI 10.1001/archpsyc.62.6.593; Kessler RC, 2008, ANNU REV PUBL HEALTH, V29,
P115, DOI 10.1146/annurev.publhealth.29.020907.090847; Khantzian E. J., 1999,
TREATING ADDICTION H; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI
10.3109/10673229709030550; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259; Koob GF,
2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0; Levy MS,
2008, J PSYCHOACTIVE DRUGS, V40, P167, DOI 10.1080/02791072.2008.10400627; Levy MS,
2002, J PSYCHOACTIVE DRUGS, V34, P409, DOI 10.1080/02791072.2002.10399982; Lo CC,
2015, SUBST USE MISUSE, V50, P1274, DOI 10.3109/10826084.2014.998236; Merikangas
KR, 1998, ARCH GEN PSYCHIAT, V55, P973, DOI 10.1001/archpsyc.55.11.973; Meyer R.
E., 1986, PSYCHOPATHOLOGY ADDI, P3; National Institute on Drug Abuse, 2016, SCI
SUBST AB ADD BAS; Publications Office of the European Union, 2013, COM SUBST MENT
DIS E; RAO U, 1995, J AM ACAD CHILD PSY, V34, P566, DOI 10.1097/00004583-199505000-
00009; Rhee SH, 2003, ARCH GEN PSYCHIAT, V60, P1256, DOI
10.1001/archpsyc.60.12.1256; Schuckit MA, 1996, ARCH GEN PSYCHIAT, V53, P202;
SCHUCKIT MA, 1994, AM J PSYCHIAT, V151, P184; Schuckit MA, 1996, J STUD ALCOHOL,
V57, P368, DOI 10.15288/jsa.1996.57.368; Teesson M, 2009, AUST NZ J PSYCHIAT, V43,
P606, DOI 10.1080/00048670902970908; Vaillant G, 1983, NATURAL HIST ALCOHOL; WEISS
RD, 1992, AM J DRUG ALCOHOL AB, V18, P121, DOI 10.3109/00952999208992825; Wilens
TE, 2011, J AM ACAD CHILD PSY, V50, P543, DOI 10.1016/j.jaac.2011.01.021; Wilkinson
AL, 2016, ADDICT BEHAV, V60, P64, DOI 10.1016/j.addbeh.2016.03.036 33 1
1 3 3 SPRINGER NEW YORK 233 SPRING ST, NEW YORK, NY 10013
USA 0165-0653 1573-3246 INT J ADV COUNS Int. J. Adv. Couns. MAR
2019 41 1 15 24 10.1007/s10447-
018-9341-3 10 Psychology, Applied Psychology HK7UB
WOS:000458194100002 2019-09-25
J Marsh, B; Carlyle, M; Carter, E; Hughes, P; McGahey, S; Lawn, W; Stevens, T;
McAndrew, A; Morgan, CJA Marsh, Beth; Carlyle, Molly;
Carter, Emily; Hughes, Paige; McGahey, Sarah; Lawn, Will; Stevens, Tobias;
McAndrew, Amy; Morgan, Celia J. A. Shyness, alcohol use disorders and
'hangxiety': A naturalistic study of social drinkers PERSONALITY AND INDIVIDUAL
DIFFERENCES English Article
Alcohol; Social anxiety; Hangover; Shyness; Alcohol use disorders
NATIONAL EPIDEMIOLOGIC SURVEY; PSYCHOMETRIC PROPERTIES; PHOBIA INVENTORY;
SELF-MEDICATION; SUBSTANCE USE; ANXIETY; DRINKING; HANGOVER; GLUTAMATE Social
anxiety disorder (SAD) has been related to alcohol use disorder (AUD). Shyness can
be considered a subclinical analogue of SAD, yet there is little research into the
effect of alcohol on anxiety levels in highly-shy individuals. This naturalistic
study investigated acute and sub-acute effects of alcohol in high and low shy
social drinkers. 97 individuals were tested at home and assigned to either consume
alcohol to normal levels (n = 50) or to remain sober (n = 47). Baseline measures of
AUD symptoms, shyness and social phobia were taken. Measures of state anxiety were
taken at baseline, following a period of alcohol consumption or sobriety, and the
following morning. Marginally decreased acute anxiety resulting from alcohol
consumption in high shyness was observed. A significant increase in anxiety the day
following drinking was observed in highly-shy participants. There was a significant
correlation between anxiety elevation on the second day and AUDIT scores in highly-
shy participants. This study suggests anxiety during hangover is linked to AUD
symptoms in highly-shy individuals, providing a potential marker for increased AUD
risk, which could inform prevention and treatment. [Marsh, Beth; Carlyle, Molly;
Carter, Emily; Hughes, Paige; McGahey, Sarah; Stevens, Tobias; McAndrew, Amy;
Morgan, Celia J. A.] Univ Exeter, Psychopharmacol & Addict Res Ctr, Exeter, Devon,
England; [Marsh, Beth; Lawn, Will; Morgan, Celia J. A.] UCL, Clin Psychopharmacol
Unit, 1-19 Torrington Pl, London WC1E 7HB, England Marsh, B (reprint author),
UCL, Clin Psychopharmacol Unit, 1-19 Torrington Pl, London WC1E 7HB, England.
b.marsh@ucl.ac.uk Lawn, Will/0000-0002-0143-2724 Medical Research
Council GB (MRC) grant [MR L/0230321] This work was supported by an Medical
Research Council GB (MRC) grant (MR L/0230321) to CJAM. Antony MM, 2006, BEHAV
RES THER, V44, P1177, DOI 10.1016/j.brat.2005.08.013; Babor T.F., 1992, AUDIT
ALCOHOL USE DI; Ballard J, 2016, BRIT J GEN PRACT, V66, P32, DOI
10.3399/bjgp16X683173; Bermudo-Soriano CR, 2012, PHARMACOL BIOCHEM BE, V100, P752,
DOI 10.1016/j.pbb.2011.04.010; Buckner JD, 2013, DEPRESS ANXIETY, V30, P276, DOI
10.1002/da.22032; Carrigan MH, 2003, ADDICT BEHAV, V28, P269, DOI 10.1016/S0306-
4603(01)00235-0; Cheek J., 2007, ENCY SOCIAL PSYCHOL, V1, P875, DOI
[10.4135/9781412956253.n516, DOI 10.4135/9781412956253.N516]; CHEEK JM, 1985,
EMOTION PERSONALITY; Clark DM, 1995, SOCIAL PHOBIA DIAGNO, P69, DOI DOI
10.1192/BJP.BP.114.146761; Connor KM, 2000, BRIT J PSYCHIAT, V176, P379, DOI
10.1192/bjp.176.4.379; Cooper M. L., 1994, PSYCHOL ASSESSMENT, V6, P117, DOI [DOI
10.1037/1040-3590.6.2.117, 10.1037/1040-3590.6.2.117]; Department for Transport,
2010, ENF PROC DRINK DRIV; Leite LE, 2012, NEUROSCIENCE, V213, P93, DOI
10.1016/j.neuroscience.2012.04.009; Gilman JM, 2008, J NEUROSCI, V28, P4583, DOI
10.1523/JNEUROSCI.0086-08.2008; Grant BF, 2015, JAMA PSYCHIAT, V72, P757, DOI
10.1001/jamapsychiatry.2015.0584; Heiser NA, 2003, BEHAV RES THER, V41, P209, DOI
10.1016/S0005-7967(02)00003-7; Henniger MSH, 2002, NEUROPSYCHOPHARMACOL, V26, P729,
DOI 10.1016/S0893-133X(01)00408-0; JOHNSTON AL, 1991, BRIT J ADDICT, V86, P719;
Karadayian AG, 2013, BEHAV BRAIN RES, V253, P128, DOI 10.1016/j.bbr.2013.07.011;
Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550;
Kirkpatrick MG, 2013, PSYCHOPHARMACOLOGY, V230, P215, DOI 10.1007/s00213-013-3147-
0; Koob G F, 1992, Recent Dev Alcohol, V10, P201; Lewis BA, 2000, ADDICT BEHAV,
V25, P295, DOI 10.1016/S0306-4603(99)00063-5; LINDMAN R, 1982, PHYSIOL BEHAV, V28,
P1093, DOI 10.1016/0031-9384(82)90181-0; Mayer FB, 2016, BMC MED EDUC, V16, DOI
10.1186/s12909-016-0791-1; McKinney A, 2006, ALCOHOL ALCOHOLISM, V41, P54, DOI
10.1093/alcalc/agh226; MELCHIOR LA, 1990, J SOC BEHAV PERS, V5, P117; Meneses-Gaya
Carolina de, 2009, Psychol. Neurosci., V2, P83, DOI 10.3922/j.psns.2009.1.12;
National Health Service (NHS), 2013, ALC MIS; NEWLIN DB, 1990, ALCOHOL CLIN EXP
RES, V14, P713, DOI 10.1111/j.1530-0277.1990.tb01231.x; Robinson SL, 2016,
NEUROPHARMACOLOGY, V108, P474, DOI 10.1016/j.neuropharm.2015.12.005; Santesso DL,
2004, PERS INDIV DIFFER, V37, P5, DOI 10.1016/j.paid.2003.08.023; Schneier FR,
2010, PSYCHOL MED, V40, P977, DOI 10.1017/S0033291709991231; Schry AR, 2013, ADDICT
BEHAV, V38, P2690, DOI 10.1016/j.addbeh.2013.06.014; Smith JP, 2012, ALCOHOL RES-
CURR REV, V34, P414; Span SA, 1999, ADDICT BEHAV, V24, P121, DOI 10.1016/S0306-
4603(98)00002-1; Spielberger C. D., 1983, MANUAL STATE TRAIT A; Struzynska L, 2004,
J INORG BIOCHEM, V98, P951, DOI 10.1016/j.jinorgbio.2004.02.010; Thomas SE, 2003,
ALCOHOL CLIN EXP RES, V27, P1937, DOI 10.1097/01.ALC.0000100942.30743.8C; Weiner
JL, 2006, PHARMACOL THERAPEUT, V111, P533, DOI 10.1016/j.pharmthera.2005.11.002;
Young CM, 2015, ALCOHOL CLIN EXP RES, V39, P1749, DOI 10.1111/acer.12799 41
0 0 4 9 PERGAMON-ELSEVIER SCIENCE LTD OXFORD THE
BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND 0191-8869
PERS INDIV DIFFER Pers. Individ. Differ. MAR 1 2019 139
13 18 10.1016/j.paid.2018.10.034 6
Psychology, Social Psychology HI9GV WOS:000456764200003 Green
Accepted 2019-09-25
J Jankowski, RL; Black, AC; Lazar, CM; Brummett, BR; Rosen, MI
Jankowski, Rebecca L.; Black, Anne C.; Lazar, Christina M.; Brummett, Bradley
R.; Rosen, Marc I. Consideration of substance use in compensation
and pension examinations of veterans filing PTSD claims PLOS ONE
English Article POSTTRAUMATIC-
STRESS-DISORDER; SELF-MEDICATION HYPOTHESIS; DISABILITY COMPENSATION; SERVICE
CONNECTION; INVENTORY-II; AFGHANISTAN; IRAQ; ASSOCIATIONS; SPECIFICITY; COMORBIDITY
Veterans filing claims that service-induced PTSD impairs them worry that
claims examiners may attribute their difficulties to conditions other than PTSD,
such as substance use. Substance use commonly co-occurs with PTSD and complicates
establishing a PTSD diagnosis because symptoms may be explained by PTSD alone,
PTSD-induced substance use, or by a substance use condition independent of PTSD.
These alternative explanations of symptoms lead to different conclusions about
whether a PTSD diagnosis can be made. How substance use impacts an examiner's
diagnosis of PTSD in a Veteran's service-connection claim has not been previously
studied. In this study, we tested the hypothesis that mention of risky substance
use in the Compensation & Pension (C&P) examination would result in a lower
likelihood of service-connection award, presumably because substance use reflected
an alternative explanation for symptoms. Data were analyzed from 208 Veterans' C&P
examinations, medical records, and confidentially-collected research assessments.
In this sample, 165/208 (79%) Veterans' claims were approved for a mental health
condition; 70/83 (84%) with risky substance use mentioned and 95/125 (76%) without
risky use mentioned (p = .02). Contrary to the a priori hypothesis, Veterans with
risky substance use were more likely to get a service-connection award, even after
controlling for baseline PTSD severity and other potential confounds. They had
almost twice the odds of receiving any mental health award and 2.4 times greater
odds of receiving an award for PTSD specifically. These data contradict assertions
of bias against Veterans with risky substance use when their claims are reviewed.
The data are more consistent with substance use often being judged as a symptom of
PTSD. The more liberal granting of awards is consistent with literature concerning
comorbid PTSD and substance use, and with claims procedures that make it more
likely that substance use will be attributed to trauma exposure than to other
causes. [Jankowski, Rebecca L.; Brummett, Bradley R.] VA Cent Western
Massachusetts Healthcare Syst, Leeds, MA 01053 USA; [Black, Anne C.; Lazar,
Christina M.; Rosen, Marc I.] VA Connecticut Healthcare Syst, West Haven, CT USA;
[Black, Anne C.; Lazar, Christina M.; Rosen, Marc I.] Yale Univ, New Haven, CT USA
Jankowski, RL (reprint author), VA Cent Western Massachusetts Healthcare
Syst, Leeds, MA 01053 USA. Rebecca.Jankowski@va.gov Jankowski,
Rebecca/0000-0003-2548-8025 US Department of Veterans Affairs, Veterans Health
Administration, Health Services Research and Development ServiceUS Department of
Veteran Affairs [IIR 11-091]; VISN1 Mental Illness Research Education and Clinical
Center (MIRECC) The research reported here was supported by the US Department of
Veterans Affairs, Veterans Health Administration, Health Services Research and
Development Service (MIR received grant funding for Project # IIR 11-091), and by
the VISN1 Mental Illness Research Education and Clinical Center (MIRECC). The
funders had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript. American Psychiatric Association,
2013, DIAGNOSTIC STAT MANU; Back SE, 2005, J SUBST ABUSE TREAT, V29, P29, DOI
10.1016/j.jsat.2005.03.002; Back SE, 2006, J NERV MENT DIS, V194, P690, DOI
10.1097/01.nmd.0000235794.12794.8a; Beamer K, 2017, CRESCENZ VAMC, P4; Beck AT,
1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13; BLAKE DD, 1995, J
TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Bountress KE, 2017, BRAIN SCI, V7,
DOI 10.3390/brainsci7010006; Brady KT, 1998, AM J ADDICTION, V7, P128; Bremner JD,
1996, AM J PSYCHIAT, V153, P369; Brust JCM, 1993, NEUROLOGICAL ASPECTS; Chilcoat
HD, 1998, ARCH GEN PSYCHIAT, V55, P913, DOI 10.1001/archpsyc.55.10.913; Comings DE,
1996, BIOL PSYCHIAT, V40, P368, DOI 10.1016/0006-3223(95)00519-6; COTTLER LB, 1992,
AM J PSYCHIAT, V149, P664; Department of Veterans Affairs Office of Inspector
General, 2005, REV STAT VAR VA DIS; Drew D, 2001, PSYCHIATR SERV, V52, P1479, DOI
10.1176/appi.ps.52.11.1479; Frueh BC, 1997, J PERS ASSESS, V68, P369, DOI
10.1207/s15327752jpa6802_8; GAWIN FH, 1991, SCIENCE, V251, P1580, DOI
10.1126/science.2011738; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI
10.1056/NEJMoa040603; Homaifar BY, 2009, ARCH PHYS MED REHAB, V90, P652, DOI
10.1016/j.apmr.2008.10.028; Jackson JC, 2011, J TRAUMA STRESS, V24, P609, DOI
10.1002/jts.20688; Jacobsen LK, 2001, AM J PSYCHIAT, V158, P1184, DOI
10.1176/appi.ajp.158.8.1184; Jacobson IG, 2008, JAMA-J AM MED ASSOC, V300, P663,
DOI 10.1001/jama.300.6.663; Jakupcak M, 2010, ADDICT BEHAV, V35, P840, DOI
10.1016/j.addbeh.2010.03.023; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI
10.1001/archpsyc.1995.03950240066012; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4,
P231, DOI 10.3109/10673229709030550; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142,
P1259; Kosten T R, 1988, Recent Dev Alcohol, V6, P49; Marx BP, 2017, CLIN ADM PTSD
SCALE; Marx BP, 2017, PSYCHOL ASSESSMENT, V29, P710, DOI 10.1037/pas0000378; Marx
BP, 2016, J CLIN PSYCHIAT, V77, P517, DOI 10.4088/JCP.14m09666; McDevitt-Murphy ME,
2015, ADDICT RES THEORY, V23, P148, DOI 10.3109/16066359.2014.949696; MCFALL ME,
1992, J STUD ALCOHOL, V53, P357, DOI 10.15288/jsa.1992.53.357; McLeod DS, 2001, J
TRAUMA STRESS, V14, P259, DOI 10.1023/A:1011157800050; Meshberg-Cohen S, 2017,
PSYCHIAT SERV, V68, P396, DOI 10.1176/appi.ps.201500533; Meshberg-Cohen S, 2014,
ADDICT BEHAV, V39, P445, DOI 10.1016/j.addbeh.2013.09.005; Murdoch M, 2005, MED
CARE, V43, P112, DOI 10.1097/00005650-200502000-00004; Murdoch M, 2003, MED CARE,
V41, P536, DOI 10.1097/00005650-200304000-00009; Murdoch M, 2011, ARCH GEN
PSYCHIAT, V68, P1072, DOI 10.1001/archgenpsychiatry.2011.105; Muthen L. K., 2007,
MPLUS USERS GUIDE; National Center for PTSD, PTSD SUBST AB VET; National Institute
on Alcohol Abuse and Alcoholism, DRINK LEV DEF; Ouimette P, 2007, ADDICT BEHAV,
V32, P1719, DOI 10.1016/j.addbeh.2006.11.020; Ouimette P, 2010, ADDICT BEHAV, V35,
P64, DOI 10.1016/j.addbeh.2009.08.009; SALADIN ME, 1995, ADDICT BEHAV, V20, P643,
DOI 10.1016/0306-4603(95)00024-7; Sayer NA, 2005, MIL MED, V170, P867, DOI
10.7205/MILMED.170.10.867; Schnurr PP, 2005, CONTEMP CLIN TRIALS, V26, P626, DOI
10.1016/j.cct.2005.09.001; Seal KH, 2011, DRUG ALCOHOL DEPEN, V116, P93, DOI
10.1016/j.drugalcdep.2010.11.027; Sobell L, 1992, MEASURING ALCOHOL CO, V17;
Speroff T, 2012, J TRAUMA STRESS, V25, P607, DOI 10.1002/jts.21759; Stewart SH,
1998, ADDICT BEHAV, V23, P797, DOI 10.1016/S0306-4603(98)00070-7; Terrio HP, 2011,
REHABIL PSYCHOL, V56, P26, DOI 10.1037/a0022685; U.S. Department of Veterans
Affairs Veterans Benefits Administration, 2017, VBA ANN BEN REP FISC; Weathers FW,
1999, PSYCHOL ASSESSMENT, V11, P124, DOI 10.1037/1040-3590.11.2.124; Worthen MD,
2011, PSYCHOL INJ LAW, V4, P187, DOI 10.1007/s12207-011-9115-2 54 0 0
2 2 PUBLIC LIBRARY SCIENCE SAN FRANCISCO 1160 BATTERY STREET, STE
100, SAN FRANCISCO, CA 94111 USA 1932-6203 PLOS ONE PLoS One
FEB 6 2019 14 2 e0210938
10.1371/journal.pone.0210938 14 Multidisciplinary Sciences
Science & Technology - Other Topics HK4EL WOS:000457874000038 30726261
DOAJ Gold, Green Published 2019-09-25
J Blakey, SM; Yi, JY; Calhoun, PS; Beckham, JC; Elbogen, EB
Blakey, Shannon M.; Yi, Jennifer Y.; Calhoun, Patrick S.; Beckham, Jean C.;
Elbogen, Eric B. Why do trauma survivors become depressed? Testing the
behavioral model of depression in a nationally representative sample PSYCHIATRY
RESEARCH English Article
Posttraumatic stress disorder; Major depressive disorder; Avoidance; Self-
medication; Behavior therapy POSTTRAUMATIC-STRESS-DISORDER; SUBSTANCE USE
DISORDERS; SELF-MEDICATION HYPOTHESIS; EPIDEMIOLOGIC SURVEY; ACTIVATION TREATMENT;
CUMULATIVE TRAUMA; ALCOHOL; PTSD; SYMPTOMS; COMORBIDITY Despite accumulated
evidence linking trauma exposure to major depressive disorder (MDD), there is
limited understanding as to why some trauma survivors subsequently develop MDD. The
behavioral model of depression points to a negative reinforcement cycle of trauma-
related avoidance and depressed mood, but no study has evaluated this framework in
trauma survivors. This study tested the hypothesis that traumatic stress symptom
related interference with daily activities and with relationships and self-
medicating traumatic stress symptoms with alcohol and with drugs would predict MDD
onset in a nationally representative sample after controlling for established risk
factors. Data were drawn from Waves 1 and 2 of the National Epidemiologic Survey on
Alcohol and Related Conditions (NESARC) using two samples: adults reporting
lifetime trauma exposure but no history of MDD at Wave 1 (n = 8301) and a subset of
those participants who met criteria for lifetime PTSD prior to Wave 1 (n = 1055).
Younger age, female gender, a greater number of different trauma types, traumatic
stress-related interference with daily activities, and self-medicating traumatic
stress symptoms with alcohol significantly predicted MDD onset in both groups.
Findings underscore the role of traumatic stress-related interference and self-
medication in the development of MDD. [Blakey, Shannon M.; Yi, Jennifer Y.]
Univ N Carolina, Dept Psychol & Neurosci, Davie Hall CB 3270, Chapel Hill, NC 27599
USA; [Calhoun, Patrick S.; Beckham, Jean C.; Elbogen, Eric B.] Vet Affairs
Midatlantic Mental Illness Res Educ &, Durham, NC 27705 USA; [Calhoun, Patrick S.;
Beckham, Jean C.; Elbogen, Eric B.] Durham Vet Affairs Med Ctr, Durham, NC 27705
USA; [Calhoun, Patrick S.; Beckham, Jean C.; Elbogen, Eric B.] Duke Univ, Dept
Psychiat & Behav Sci, Med Ctr, Durham, NC 27705 USA Blakey, SM (reprint author),
Univ N Carolina, Dept Psychol & Neurosci, Davie Hall CB 3270, Chapel Hill, NC 27599
USA. sblakey@unc.edu Blakey, Shannon/0000-0002-9291-3688
American Psychiatric Association, 2013, DIAGN STAT MAN MENT; American
Psychiatric Association, 2000, DIAGN STAT MAN MENT; Blume AW, 2000, COGN BEHAV
PRACT, V7, P379, DOI 10.1016/S1077-7229(00)80048-6; Bremner JD, 1996, AM J
PSYCHIAT, V153, P369; Briere J, 2016, PSYCHOL TRAUMA-US, V8, P439, DOI
10.1037/tra0000107; Bryan CJ, 2016, GEN HOSP PSYCHIAT, V41, P13, DOI
10.1016/j.genhosppsych.2016.05.001; Burcusa SL, 2007, CLIN PSYCHOL REV, V27, P959,
DOI 10.1016/j.cpr.2007.02.005; Chilcoat HD, 1998, ARCH GEN PSYCHIAT, V55, P913, DOI
10.1001/archpsyc.55.10.913; Chinn S, 2000, STAT MED, V19, P3127, DOI 10.1002/1097-
0258(20001130)19:22<3127::AID-SIM784>3.0.CO;2-M; Cohen J., 1988, STAT POWER ANAL
BEHA; COOPER ML, 1995, J PERS SOC PSYCHOL, V69, P990, DOI 10.1037/0022-
3514.69.5.990; Daughters SB, 2008, J CLIN PSYCHIAT, V69, P122, DOI
10.4088/JCP.v69n0116; DeBeer BB, 2014, PSYCHIAT RES, V216, P357, DOI
10.1016/j.psychres.2014.02.010; Foa E. B., 2007, PROLONGED EXPOSURE T; Follette VM,
1996, J TRAUMA STRESS, V9, P25, DOI 10.1002/jts.2490090104; Gaher RM, 2006, ADDICT
BEHAV, V31, P1319, DOI 10.1016/j.addbeh.2005.10.006; Grant B, 2005, SOURCE ACCURACY
STAT; Grant B.F., 2003, SOURCE ACCURACY STAT; Grant BF, 2004, ARCH GEN PSYCHIAT,
V61, P361, DOI 10.1001/archpsyc.61.4.361; Grant BF, 2006, ALCOHOL RES HEALTH, V29,
P74; Hutchison KE, 1997, ALCOHOL CLIN EXP RES, V21, P1312, DOI 10.1111/j.1530-
0277.1997.tb04454.x; Jacobsen LK, 2001, AM J PSYCHIAT, V158, P1184, DOI
10.1176/appi.ajp.158.8.1184; Jakupcak M, 2006, J TRAUMA STRESS, V19, P387, DOI
10.1002/jts.20125; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI
10.1001/archpsyc.1995.03950240066012; Kessler RC, 1997, ANNU REV PSYCHOL, V48,
P191, DOI 10.1146/annurev.psych.48.1.191; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62,
P617, DOI 10.1001/archpsyc.62.6.617; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4,
P231, DOI 10.3109/10673229709030550; Leeies M, 2010, DEPRESS ANXIETY, V27, P731,
DOI 10.1002/da.20677; Lejuez CW, 2011, BEHAV MODIF, V35, P111, DOI
10.1177/0145445510390929; Lejuez CW, 2001, BEHAV MODIF, V25, P255, DOI
10.1177/0145445501252005; Lewinsohn P. M., 1974, ESSENTIAL PAPERS DEP, P150; Love
J, 2014, PSYCHIAT SERV, V65, P918, DOI 10.1176/appi.ps.201300399; Magidson JF,
2011, ADDICT BEHAV, V36, P615, DOI 10.1016/j.addbeh.2011.01.016; Mash HBH, 2016,
MIL MED, V181, P811, DOI 10.7205/MILMED-D-15-00122; MIRIN SM, 1975, MIL MED, V140,
P482; National Institute on Alcohol Abuse and Alcoholism (NIAAA), 2010, ALC US ALC
US DIS US; Nixon RDV, 2011, J TRAUMA STRESS, V24, P451, DOI 10.1002/jts.20654;
North CS, 1999, JAMA-J AM MED ASSOC, V282, P755, DOI 10.1001/jama.282.8.755;
Ouimette P, 2010, ADDICT BEHAV, V35, P64, DOI 10.1016/j.addbeh.2009.08.009;
Pietrzak RH, 2011, J ANXIETY DISORD, V25, P456, DOI 10.1016/j.janxdis.2010.11.010;
Possemato K, 2010, PSYCHOL TRAUMA-US, V2, P218, DOI 10.1037/a0019236; Ramsawh HJ,
2014, J AFFECT DISORDERS, V161, P116, DOI 10.1016/j.jad.2014.03.016; Research
Triangle Institute (RTI), 2008, SOFTW SURV DAT AN SU; Resick P. A., 2017, COGNITIVE
PROCESSING; Stander VA, 2014, CLIN PSYCHOL REV, V34, P87, DOI
10.1016/j.cpr.2013.12.002; Strachan M, 2012, BEHAV THER, V43, P560, DOI
10.1016/j.beth.2011.03.003; Tabachnick B. G., 2007, USING MULTIVARIATE S; Tull MT,
2010, J ANXIETY DISORD, V24, P55, DOI 10.1016/j.janxdis.2009.08.006 48 1
1 2 2 ELSEVIER IRELAND LTD CLARE ELSEVIER HOUSE, BROOKVALE
PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND 0165-1781
PSYCHIAT RES Psychiatry Res. FEB 2019 272
587 594 10.1016/j.psychres.2018.12.150 8
Psychiatry Psychiatry HO5UW WOS:000460994400085 30616128
2019-09-25
J Wall, MM; Liu, J; Hasin, DS; Blanco, C; Olfson, M Wall,
Melanie M.; Liu, Jun; Hasin, Deborah S.; Blanco, Carlos; Olfson, Mark
Use of marijuana exclusively for medical purposes DRUG AND ALCOHOL
DEPENDENCE English Article
Medical marijuana; Self-medication ALCOHOL-USE DISORDER; ADULTS; RELIABILITY
Objectives: To characterize the socio-demographic characteristics, medical
conditions, and psychiatric comorbidities of users of marijuana for medical and
non-medical purposes. Methods: Data were from the National Epidemiological Survey
on Alcohol and Related Conditions III, a US nationally representative in-person
interview of 36,309 adults age 18 years in 2012-2013. Results: In relation to non-
medical only users (n = 3339), combined (n = 362) and medical only (n = 82) users
had higher prevalence of every medical condition examined. As compared to the
combined use group, those using marijuana only for medical purposes were much less
likely to have anxiety, alcohol, or non-medical prescription opioid use disorders.
Conclusions: Medical-only users appear to use it for evidence-based medical reasons
and have lower prevalence of substance use disorder than other marijuana users.
Nonetheless, because most medical marijuana users also use non-medically, screening
for psychiatric disorders and prevention efforts for cannabis use disorder should
be implemented when authorizing medical marijuana. [Wall, Melanie M.; Hasin,
Deborah S.; Olfson, Mark] Columbia Univ, Dept Psychiat, 1051 Riverside Dr, New
York, NY 10032 USA; [Wall, Melanie M.; Liu, Jun; Hasin, Deborah S.; Olfson, Mark]
New York State Psychiat Inst & Hosp, New York, NY 10032 USA; [Blanco, Carlos] Natl
Inst Drug Abuse, 6001 Execut Blvd, Rockville, MD 20852 USA Wall, MM (reprint
author), Columbia Univ, Dept Psychiat, 1051 Riverside Dr, New York, NY 10032 USA.
mmw2177@cumc.columbia.edu National Institute of Drug
AbuseUnited States Department of Health & Human ServicesNational Institutes of
Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA019606]; New York
State Psychiatric Institute [R01DA034244] Work on this manuscript was supported by
DA019606 from the National Institute of Drug Abuse (Drs. Olfson and Wall),
R01DA034244 (Drs. Hasin and Wall), and the New York State Psychiatric Institute
(Drs. Olfson, Wall, Hasin and Liu). The sponsors had no role in the design and
conduct of the study; collection, management, analysis and no interpretation of the
data; and preparation or approval of the manuscript. AMERICAN PSYCHIATRIC
ASSOCIATION (A.P.A), 2013, DIAGN STAT MAN MENT; Choi NG, 2017, AM J ADDICTION, V26,
P697, DOI 10.1111/ajad.12598; Compton WM, 2017, JAMA-J AM MED ASSOC, V317, P209,
DOI 10.1001/jama.2016.18900; Grant BF, 2015, JAMA PSYCHIAT, V72, P757, DOI
10.1001/jamapsychiatry.2015.0584; Grant BF, 2015, DRUG ALCOHOL DEPEN, V148, P27,
DOI 10.1016/j.drugalcdep.2014.11.026; Han B, 2018, DRUG ALCOHOL DEPEN, V186, P120,
DOI 10.1016/j.drugalcdep.2018.01.022; Spiegel J, 2013, PSYCHOL TODAY; Stockings E,
2018, PAIN, V159, P1932, DOI 10.1097/j.pain.0000000000001293; Ware JE, 1996, MED
CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Ware JE, 2002, SF 12 SCORE
SF 12 PH; Whiting PF, 2015, JAMA-J AM MED ASSOC, V313, P2456, DOI
10.1001/jama.2015.6358 11 0 0 6 11 ELSEVIER IRELAND LTD CLARE
ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND
0376-8716 1879-0046 DRUG ALCOHOL DEPEN Drug Alcohol Depend.
FEB 1 2019 195 13 15
10.1016/j.drugalcdep.2018.11.009 3 Substance Abuse;
Psychiatry Substance Abuse; Psychiatry HL4QV WOS:000458709100003 30557813
2019-09-25
J Dowd, DA; Keough, MT; Jakobson, LS; Bolton, JM; Edgerton, JD
Dowd, Damien A.; Keough, Matthew T.; Jakobson, Lorna S.; Bolton, James M.;
Edgerton, Jason D. A latent class analysis of young adult gamblers
from the Manitoba Longitudinal Survey of Young Adults INTERNATIONAL GAMBLING
STUDIES English Article
Gambling; gambler subtypes; pathways; young adult; emerging adulthood; latent
class analysis NATIONAL EPIDEMIOLOGIC SURVEY; GAMBLING BEHAVIOR; SUBSTANCE USE;
SENSATION-SEEKING; SELF-MEDICATION; IMPULSIVITY; COMORBIDITY; DEPRESSION;
PREVALENCE; DISORDERS Informed by the Pathways Model, the current study utilized
latent class analysis (LCA) to empirically derive subtypes of gamblers based on
measures of impulsivity, anxiety, depression, drug use and alcohol dependence. The
sample in this study (N = 566) was comprised of young adult gamblers (18-22 years
of age) who participated in the Manitoba Longitudinal Survey of Young Adults
(MLSYA). Multinomial regression was utilized to examine how demographic variables
and participant scores on the Problem Gambling Severity Index (PGSI) predicted
membership in gambler classes from the LCA. Results of the LCA revealed three
classes of gamblers: emotionally vulnerable, non-problem and impulsive. Multinomial
regression showed that older age (i.e. 20-22 years of age), lower income (< $20,000
per year), living independently and PGSI scores were associated with increased odds
of being classified as an impulsive gambler. Identifying as European, living
independently and PGSI scores were associated with increased odds of being grouped
in the emotionally vulnerable class of gambler. These results suggest that young
adult gamblers are not a homogeneous group but instead are best understood as
falling into different subtypes based on shared characteristics outlined in the
Pathways Model. [Dowd, Damien A.; Keough, Matthew T.; Jakobson, Lorna S.; Bolton,
James M.] Univ Manitoba, Dept Psychol, Winnipeg, MB R3T 2N2, Canada; [Bolton, James
M.] Univ Manitoba, Dept Psychiat, Winnipeg, MB, Canada; [Bolton, James M.] Univ
Manitoba, Dept Community Hlth Sci, Winnipeg, MB, Canada; [Edgerton, Jason D.] Univ
Manitoba, Dept Sociol, Winnipeg, MB, Canada Jakobson, LS (reprint author), Univ
Manitoba, Dept Psychol, Winnipeg, MB R3T 2N2, Canada. lorna.jakobson@umanitoba.ca
Manitoba Gambling Research Program [314592] This work was supported
by the Manitoba Gambling Research Program[314592]. AKAIKE H, 1987,
PSYCHOMETRIKA, V52, P317, DOI 10.1007/BF02294359; American Psychiatric Association,
2013, DIAGN STAT MAN MENT; American Psychiatric Association, 2000, DIAGN STAT MAN
MENT; ANDERSON G, 1984, BRIT J PSYCHOL, V75, P401, DOI 10.1111/j.2044-
8295.1984.tb01910.x; Bagby RM, 2007, PERS INDIV DIFFER, V43, P873, DOI
10.1016/j.paid.2007.02.011; Barnes GA, 2005, PSYCHOL ADDICT BEHAV, V19, P165, DOI
10.1037/0893-164X.19.2.165; Bernardon S, 2011, CAN J BEHAV SCI, V43, P40, DOI
10.1037/a0021199; Blaszczynski A, 1997, ADDICTION, V92, P75; Blaszczynski A, 2002,
ADDICTION, V97, P487, DOI 10.1046/j.1360-0443.2002.00015.x; Blum K, 2000, J
PSYCHOACTIVE DRUGS, V32, P1, DOI DOI 10.1080/02791072.2000.10736099; Bonnaire C,
2007, ENCEPHALE, V33, P798, DOI 10.1016/j.encep.2006.08.010; Bulloch A, 2014,
DEPRESS ANXIETY, V31, P72, DOI 10.1002/da.22173; Calado F, 2017, J GAMBL STUD, V33,
P397, DOI 10.1007/s10899-016-9627-5; CARLTON PL, 1992, NEUROPSYCHOBIOLOGY, V25,
P44, DOI 10.1159/000118808; Clarke D, 2006, PERS INDIV DIFFER, V40, P5, DOI
10.1016/j.paid.2005.05.008; Cox BJ, 2005, CAN J PSYCHIAT, V50, P213, DOI
10.1177/070674370505000404; Edgerton J. D., 2014, J GAMBLING STUDIES; Edgerton JD,
2015, J YOUTH STUD, V18, P743, DOI 10.1080/13676261.2014.992326; El-Guebaly N,
2006, J GAMBL STUD, V22, P275, DOI 10.1007/s10899-006-9016-6; Ferris J., 2001,
CANADIAN PROBLEM GAM; Grant G. F., 2001, ALCOHOL USE DISORDER; Gupta R., 2013, J
GAMBL STUD, V29, P588; Huang JH, 2007, CAN J PSYCHIAT, V52, P657, DOI
10.1177/070674370705201006; Kessler RC, 2008, PSYCHOL MED, V38, P1351, DOI
10.1017/S0033291708002900; Kessler R. C., 1998, INT J METH PSYCH RES, V7, P171, DOI
DOI 10.1002/MPR.47; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259; Korn David A.,
1999, J Gambl Stud, V15, P289, DOI 10.1023/A:1023005115932; Ladouceur R, 1996,
TRENDS COGNITIVE BEH, P89; Ledgerwood DM, 2010, PSYCHOL ADDICT BEHAV, V24, P680,
DOI 10.1037/a0019906; Ledgerwood DM, 2009, DRUG ALCOHOL DEPEN, V105, P89, DOI
10.1016/j.drugalcdep.2009.06.011; Lesieur H. R., 1991, FEMINIST PERSPECTIVE, P181,
DOI DOI 10.5860/CHOICE.29-3595; Li XP, 2013, J BUS RES, V66, P1598, DOI
10.1016/j.jbusres.2012.12.003; Lloyd J, 2010, BIOL PSYCHIAT, V68, P733, DOI
10.1016/j.biopsych.2010.03.038; Lo YT, 2001, BIOMETRIKA, V88, P767, DOI
10.1093/biomet/88.3.767; Miller MA, 1996, AM J PSYCHIAT, V153, P845; Milosevic A,
2010, CLIN PSYCHOL REV, V30, P988, DOI 10.1016/j.cpr.2010.06.013; Moon M, 2017, J
GAMBL STUD, V33, P841, DOI 10.1007/s10899-016-9658-y; Muthen L. K., 1998, MPLUS
USERS GUIDE; Myrseth H, 2009, PERS INDIV DIFFER, V47, P933, DOI
10.1016/j.paid.2009.07.018; Nower L, 2004, GAMBLING PROBLEMS IN YOUTH: THEORETICAL
AND APPLIED PERSPECTIVES, P189; Nower L., 2006, INT GAMBL STUD, V6, P61, DOI DOI
10.1080/14459790600644192; Nower L, 2017, PSYCHOL ADDICT BEHAV, V31, P95, DOI
10.1037/adb0000234; Nower L, 2013, ADDICTION, V108, P789, DOI 10.1111/add.12012;
Patton JH, 1995, J CLIN PSYCHOL, V51, P768, DOI 10.1002/1097-
4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1; Petry NM, 2005, J CLIN
PSYCHIAT, V66, P564, DOI 10.4088/JCP.v66n0504; Pietrzak R. H., 2005, J NERV MENT
DIS, V181, P107; RUGLE L, 1993, J NERV MENT DIS, V181, P107, DOI 10.1097/00005053-
199302000-00006; Schull S., 2002, ESCAPE MECH WOMEN CA; SCHWARZ G, 1978, ANN STAT,
V6, P461, DOI 10.1214/aos/1176344136; Shaffer HJ, 2001, CAN J PUBLIC HEALTH, V92,
P168, DOI 10.1007/BF03404298; Specker S M, 1995, Ann Clin Psychiatry, V7, P175, DOI
10.3109/10401239509149623; Spunt B, 1998, SUBST USE MISUSE, V33, P2535, DOI
10.3109/10826089809059340; Stanford MS, 2009, PERS INDIV DIFFER, V47, P385, DOI
10.1016/j.paid.2009.04.008; Statistics Canada, 2003, CAN COMM HLTH SURV C;
Steinberg L, 2008, DEV REV, V28, P78, DOI 10.1016/j.dr.2007.08.002; Vachon J, 2004,
PSYCHOL ADDICT BEHAV, V18, P398, DOI 10.1037/0893-164X.18.4.398; Vitaro F, 1998,
PSYCHOL ADDICT BEHAV, V12, P185, DOI 10.1037/0893-164X.12.3.185; Vitaro F, 1999,
ADDICTION, V94, P565, DOI 10.1046/j.1360-0443.1999.94456511.x; Welte JW, 2008, J
GAMBL STUD, V24, P119, DOI 10.1007/s10899-007-9086-0; Welte JW, 2004, J GAMBL STUD,
V20, P405, DOI 10.1007/s10899-004-4582-y; Wenzel H. G., 2009, INT J MENT HEALTH AD,
V7, P190, DOI DOI 10.1007/S11469-008-9174-0; Xian H, 2008, J ADDICT MED, V2, P85,
DOI 10.1097/ADM.0b013e31816d699f 62 1 1 1 1 ROUTLEDGE
JOURNALS, TAYLOR & FRANCIS LTD ABINGDON 2-4 PARK SQUARE, MILTON PARK,
ABINGDON OX14 4RN, OXON, ENGLAND 1445-9795 1479-4276 INT GAMBL STUD
Int. Gambl. Stud. JAN 2 2019 19 1 148 166
10.1080/14459795.2018.1520909 19 Substance Abuse Substance
Abuse HJ0XP WOS:000456886800009 2019-09-25
J Smith, P Smith, Paula A Qualitative
Examination of the Self-Medicating Hypothesis Among Female Juvenile Offenders
WOMEN & CRIMINAL JUSTICE English Article
female juvenile offenders; self-medication hypothesis; trauma;
substance misuse SUBSTANCE USE; DRUG-USE; PREDICTING ADOLESCENT; DISORDERS;
TRAUMA; ONSET; GIRLS; PATHWAYS; BEHAVIOR; 1ST Substance misuse among criminally
delinquent youth has typically been described as a concurrent part of their
participation in risky and delinquent behavior. Using Khantzian's self-medication
hypothesis, this article presents an alternative view by presenting qualitative
data which suggests that substance misuse for female juvenile offenders may serve
as self-medication for mental health problems stemming from early trauma, often at
the hands of their families. Based on the narratives of 30 female juvenile
offenders, this article examines the lived experiences of girls with childhood
trauma and substance misuse, followed by arrest and incarceration. The paper
concludes with recommendations for juvenile justice and child welfare
practitioners. [Smith, Paula] Univ Utah, Educ Leadership & Policy, 1721 S Campus
Ctr Dr,SAEC 2222, Salt Lake City, UT 84112 USA Smith, P (reprint author), Univ
Utah, Educ Leadership & Policy, 1721 S Campus Ctr Dr,SAEC 2222, Salt Lake City, UT
84112 USA. paula.smith@utah.edu Utah Commission on Juvenile Justice
This work was sponsored by Utah Commission on Juvenile Justice (Nos. N/A).
Abrantes AM, 2005, INT J OFFENDER THER, V49, P179, DOI
10.1177/0306624X04269673; Aharonovich E, 2001, AM J ADDICTION, V10, P327; Behrendt
S, 2009, DRUG ALCOHOL DEPEN, V99, P68, DOI 10.1016/j.drugalcdep.2008.06.014; Best
D, 2001, ADDICT RES THEORY, V9, P151, DOI 10.3109/16066350109141746; Brawn KM,
2008, CHILD YOUTH SERV REV, V30, P1395, DOI 10.1016/j.childyouth.2008.04.011;
Carliner H, 2016, J AM ACAD CHILD PSY, V55, P701, DOI 10.1016/j.jaac.2016.05.010;
Cernkovich SA, 2008, CRIME DELINQUENCY, V54, P3, DOI 10.1177/0011128706294395;
Chassin L., 2008, JUVENILE JUSTICE, V18, P165; Dembo R, 2003, CRIME DELINQUENCY,
V49, P201, DOI 10.1177/0011128702251054; Dembo Richard, 2007, J Child Sex Abus,
V16, P75, DOI 10.1300/J070v16n03_05; Foy DW, 2012, EUR J PSYCHOTRAUMATO, V3, DOI
10.3402/ejpt.v3i0.17247; Garland EL, 2013, J BEHAV MED, V36, P175, DOI
10.1007/s10865-012-9413-5; Goldstein NE, 2003, INT J LAW PSYCHIAT, V26, P565, DOI
10.1016/S0160-2527(03)00087-6; Granot T., 2005, YOU CHILDREN YOUNG P; Hallfors DD,
2005, AM J PREV MED, V29, P163, DOI 10.1016/j.amepre.2005.06.002; Hamburger ME,
2008, J STUD ALCOHOL DRUGS, V69, P291, DOI 10.15288/jsad.2008.69.291; HENRY B,
1993, J ABNORM CHILD PSYCH, V21, P469, DOI 10.1007/BF00916314; Herrera Veronica M,
2003, Violence Vict, V18, P319, DOI 10.1891/vivi.2003.18.3.319; Jaaskelainen M,
2016, DRUG ALCOHOL REV, V35, P728, DOI 10.1111/dar.12417; Johnston L. D., 2017,
MONITORING FUTURE NA; Jones MD, 2014, POLICY STUD J, V42, P644, DOI
10.1111/psj.12072; Khantzian E. J., 2003, PRIMARY PSYCHIAT, V10, p[47, 53]; Kumpfer
K. L., 2007, PREVENTING YOUTH SUB, P159, DOI 10.1037/11488-007; Lederman CS, 2004,
INT J LAW PSYCHIAT, V27, P321, DOI 10.1016/j.ijlp.2004.03.009; Leve L., 2004, J
CHILD FAM STUD, V13, P439, DOI DOI 10.1023/B:JCFS.0000044726.07272.B5; Mallett CA,
2015, CRIM BEHAV MENT HEAL, V25, P1, DOI 10.1002/cbm.1946; Marsiglio Mary C, 2014,
J Child Adolesc Trauma, V7, P217; Menard S., 2002, 191210 NCJ OFF JUV J; Moffitt
TE, 2001, DEV PSYCHOPATHOL, V13, P355, DOI 10.1017/S0954579401002097; Mullis R. L.,
2004, J CHILD FAM STUD, V13, P205, DOI DOI 10.1023/B:JCFS.0000015708.71295.2A;
National Institute of Justice, 2003, 2000 ARR DRUG AB MON; Oetting ER, 1998, SUBST
USE MISUSE, V33, P995, DOI 10.3109/10826089809056252; Office of Juvenile Justice
Delinquency Prevention (OJJDP), 2015, STAT BRIEF BOOK; Phillips S. D., 2006,
CRIMINOL PUBLIC POL, V5, P677, DOI DOI 10.1111/J.1745-9133.2006.00404.X; Putnins
AL, 2006, SUBST USE MISUSE, V41, P415, DOI 10.1080/10826080500409068; Rothman EF,
2008, PEDIATRICS, V122, pE298, DOI 10.1542/peds.2007-3412; Saldana J., 2013, CODING
MANUAL QUALIT; Schoen C., 1997, COMMONWEALTH FUND SU; Sickmund M., 2015, EASY
ACCESS JUVENILE; Smith DK, 2006, CHILD MALTREATMENT, V11, P346, DOI
10.1177/1077559506291950; Smith DK, 2013, J CHILD ADOLES SUBST, V22, P450, DOI
10.1080/1067828X.2013.788895; Smith P., 2005, J CONTEMP CRIM JUST, V21, P364; Smith
P, 2017, WOMEN CRIM JUSTICE, V27, P302, DOI 10.1080/08974454.2016.1250699; Teplin
L. A., 2006, PSYCHIAT DISORDERS Y; Thornberry TP, 2006, J DRUG ISSUES, V36, P1, DOI
10.1177/002204260603600101; Veysey B. M., 2003, ADOLESCENT GIRLS MEN 46 2
2 0 0 ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD ABINGDON 2-4
PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND 0897-4454 1541-0323
WOMEN CRIM JUSTICE Women Crim. Justice 2019 29 1
14 31 10.1080/08974454.2017.1377673 18
Criminology & Penology; Women's Studies Criminology & Penology; Women's
Studies ID3KX WOS:000471576800002 2019-09-25
J Sorensen, JK Sorensen, Johanne Korsdal
How physicians professional socialisation and social technologies may affect
colleagues in substance use disorders ADDICTION RESEARCH & THEORY
English Article Medical socialisation;
physicians' self-prescription; substance use disorder; functional use; disciplinary
paradox and social technologies DANISH PHYSICIANS; ALCOHOL-USE; DOCTORS; DRUG;
ADDICTION Often, discussions of physicians' substance use (both licit and
illicit) are framed in quantitative terms. The present article provides a
complimentary qualitative and posthumanist perspective on substance use challenges
illuminated through in-depth interviews with substance use disorder (SUD) recovered
physicians' about their experiences with substance use and SUD within their work
culture. SUD recovered physicians' experiences include descriptions of fears about
being revealed as a substance user, self-medicating to enhance performances during
operation or morning conferences and the like. The article draws attention to the
role of physician work culture in the development and management of physicians own
substance use and SUD. It reports results from my Danish study analysing how
professional socialisation and social technologies affect physicians disclosure of
their own SUD and their help seeking at work. The work-related aspects that in some
cases affect the development of substance use and SUD include hierarchical
pressure, emotional strain from critical patient cases and work-related
competition. In the analysis a disciplinary paradox concerning the social
technologies intended to normalise and standardise physicians' conduct and ensure
the quality of treatment. Ironically, the social technologies seemed to have an
unintended consequence: to conserve and maintain SUD rather than facilitating
treatment and recovery. For instance, I show how the fear of social sanctions in
the form of a loss of certification and prescription rights keeps physicians in SUD
from seeking external treatment. Rather than producing normalisation as intended,
the social technologies in some cases seem to have an adverse effect of
strengthening deviance. [Sorensen, Johanne Korsdal] Aarhus Univ, Fac Hlth, Dept
Publ Hlth, Sect Gen Med Practice, Aarhus, Denmark Sorensen, JK (reprint
author), Aarhus Univ, Fac Hlth, Dept Publ Hlth, Sect Gen Med Practice, Aarhus,
Denmark. jks@ph.au.dk Armstrong D, 2006, SOCIOL
HEALTH ILL, V28, P866, DOI 10.1111/j.1467-9566.2006.00469.x; Bottorff JL, 2014, MED
RATIONALITY EXPE, V13, P114; Boys A, 2001, UNDERSTANDING REASON; BROOKE D, 1991,
BRIT J ADDICT, V86, P1011; Cicala RS., 2003, HOSP PHYS, V3, P39; Cummings SM, 2011,
J ADDICT DIS, V30, P195, DOI 10.1080/10550887.2011.581962; DOMENIGHETTI G, 1991,
SOC SCI MED, V33, P269, DOI 10.1016/0277-9536(91)90360-O; Douglas M., 1996, PURITY
DANGER ANAL C; Farber NJ, 2005, SOC SCI MED, V61, P1772, DOI
10.1016/j.socscimed.2005.03.029; Foucault Michel, 1989, BIRTH CLIN ARCHAEOLO; Fox
F, 2009, BRIT J GEN PRACT, V59, P811, DOI 10.3399/bjgp09X472872; Hahn R., 1985, MED
ANTHROPOL Q, V16, P87, DOI [10.1111/j.1937-6219.1985.tb00993.x, DOI 10.1111/J.1937-
6219.1985.TB00993.X]; Hansen Elisabet Tornberg, 2002, Ugeskr Laeger, V164, P5505;
Holtman MC, 2007, SOC SCI MED, V64, P543, DOI 10.1016/j.socscimed.2006.09.016;
Johncke S., 2004, VIDEN VERDEN GRUNDBO, P385; Jones P., 2005, DOCTORS AS PATIENTS;
Lende DH, 2007, ADDICT RES THEORY, V15, P465, DOI 10.1080/16066350701284552; Marsh
H., 2014, DO NO HARM STORIES L; Merlo LJ, 2013, J ADDICT MED, V7, P349, DOI
10.1097/ADM.0b013e31829da074; MOL Annemarie, 2002, BODY MULTIPLE ONTOLO; Nielsen
B., 2001, LAEGEN SOM PATIENT; Nimb M., 1975, MISBRUG EUFORISEREND; Noreik K, 1999,
Tidsskr Nor Laegeforen, V119, P1138; Oreskovich MR, 2012, ARCH SURG-CHICAGO, V147,
P168, DOI 10.1001/archsurg.2011.1481; Palm J., 2003, NORDISK ALKOHOL NARK, V20,
P129; Pedersen AF, 2016, DRUG ALCOHOL DEPEN, V160, P119, DOI
10.1016/j.drugalcdep.2015.12.038; Raikhel E., 2013, ADDICTION TRAJECTORI; Ringgaard
A, 2013, DANMARKS FORSTE NARK; RisOr T., 1998, STUD MED REJSE LAEGE; Ro KEI, 2007,
BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-36; Rosenthal M M, 1994,
Lakartidningen, V91, P4651; Rosenthal MM., 1994, INCOMPENTENT DOCTOR; Rosvold EO,
1998, SOC SCI MED, V46, P581, DOI 10.1016/S0277-9536(97)00203-7; SOrensen AS, 1989,
UGESKRIFT LAEGER, V41, P2660; SOrensen JK, PASSING STIGMA UNPUB; Sorensen JK, 2016,
J ADDICT MED, V10, P248, DOI 10.1097/ADM.0000000000000228; Sorensen JK, 2015, DAN
MED J, V62; Spradley JP., 2006, PARTICIPANT OBSERVAT; Sundhedsstyrelsen, 2013, SYV
LAEG VERS; Tavory I., 2014, ABDUCTIVE ANAL THEOR; Wallace JE, 2009, LANCET, V374,
P1714, DOI 10.1016/S0140-6736(09)61424-0; Weinberg D, 2013, INT J DRUG POLICY, V24,
P173, DOI 10.1016/j.drugpo.2013.01.009; Wile C, 2013, AUSTRALAS PSYCHIATRY, V19,
P202; WINICK C, 1961, SOC PROBL, V9, P174, DOI 10.1525/sp.1961.9.2.03a00070 44
0 0 0 0 TAYLOR & FRANCIS LTD ABINGDON 2-4 PARK SQUARE,
MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND 1606-6359 1476-7392 ADDICT
RES THEORY Addict. Res. Theory 2019 27 2
104 113 10.1080/16066359.2018.1457654 10 Substance
Abuse; Social Issues Substance Abuse; Social Issues HP4WL
WOS:000461676900006 Bronze 2019-09-25
J Prince, DM; Epstein, M; Nurius, PS; Gorman-Smith, D; Henry, DB
Prince, Dana M.; Epstein, Marina; Nurius, Paula S.; Gorman-Smith, Deborah;
Henry, David B. Reciprocal Effects of Positive Future Expectations,
Threats to Safety, and Risk Behavior Across Adolescence JOURNAL OF CLINICAL
CHILD AND ADOLESCENT PSYCHOLOGY English Article
AFRICAN-AMERICAN ADOLESCENTS; SELF-MEDICATION HYPOTHESIS;
SUBSTANCE USE; TIME PERSPECTIVE; POSSIBLE SELVES; GENDER-DIFFERENCES; YOUTH;
ORIENTATION; DISORDERS; DRINKING We examined the reciprocal relationships among
positive future expectations, expected threats to future safety, depression, and
individual substance use and delinquency using 4 waves of data (N = 248-338) from
African American and Latino adolescent male participants in the Chicago Youth
Development Study. Individual positive future expectations and expected threats to
safety were assessed at each wave and modeled as latent constructs. Individual
substance use and delinquency were assessed at each wave and represented as ordinal
variables ranging from low to high. Categorical autoregressive cross-lagged
structural models were used to examine the hypothesized reciprocal relationships
between both aspects of future expectations construct and risk behavior across
adolescence. Analyses show that future expectations has important effects on youth
substance use and involvement in delinquency, both of which in turn decrease
positive expectations and increase expectation of threats to future safety across
adolescence. Similarly, low positive expectations for the future continued to
predict increased substance use and involvement in delinquency. The expected
threats to safety construct was significantly correlated with delinquency within
time. These effects are observed across adolescence after controlling for youth
depression and race. Findings support the reciprocal effects hypothesis of a
negative reinforcing cycle in the relationships between future expectations and
both substance use and involvement in delinquent behavior across adolescence. The
enduring nature of these relationships underscores the importance of future
expectation as a potential change mechanism for intervention and prevention efforts
to promote healthy development; vulnerable racial and ethnic minority male
adolescents may especially benefit from such intervention. [Prince, Dana M.] Case
Western Reserve Univ, Jack Joseph & Morton Mandel Sch Appl Social Sci, Cleveland,
OH 44106 USA; [Epstein, Marina] Univ Washington, Social Dev Res Grp, Seattle, WA
98195 USA; [Nurius, Paula S.] Univ Washington, Sch Social Work, Seattle, WA 98195
USA; [Gorman-Smith, Deborah] Univ Chicago, Sch Social Serv Adm, Chicago, IL 60637
USA; [Henry, David B.] Univ Illinois, Inst Hlth Res & Policy, Chicago, IL 60680 USA
Prince, DM (reprint author), 11235 Bellflower Rd, Cleveland, OH 44106 USA.
dana.prince@case.edu National Center for Research Resources, a
component of the National Institutes of HealthUnited States Department of Health &
Human ServicesNational Institutes of Health (NIH) - USANIH National Center for
Research Resources (NCRR) [TL1 RR 025016]; National Institute on Drug AbuseUnited
States Department of Health & Human ServicesNational Institutes of Health (NIH) -
USANIH National Institute on Drug Abuse (NIDA) [T32 DA019426] This publication
was made possible with grant support from the National Center for Research
Resources, a component of the National Institutes of Health (TL1 RR 025016), and
the National Institute on Drug Abuse funded Postdoctoral Training Program (T32
DA019426). Alexander J. F., 2011, FUNCTIONAL FAMILY TH, P245; Alexander J. F.,
1982, FUNCTIONAL FAMILY TH; Allwood M. A., 2012, J CHILD ADOLESCENT T, V5, P114,
DOI DOI 10.1080/19361521.2012.671795; Aloise-Young PA, 2001, J EARLY ADOLESCENCE,
V21, P158, DOI 10.1177/0272431601021002002; Anderson E., 2000, CODE STREET DECENCY;
Anthis KS, 2004, J ADOLESCENCE, V27, P147, DOI 10.1016/j.adolescence.2003.11.010;
Apostolidis T, 2006, ADDICT BEHAV, V31, P2339, DOI 10.1016/j.addbeh.2006.03.008;
Aronowitz T, 2004, RES NURS HEALTH, V27, P29, DOI 10.1002/nur.20004; BECK AT, 1988,
CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; Beyers JM, 2003, J
ABNORM CHILD PSYCH, V31, P247, DOI 10.1023/A:1023225428957; Bolland JM, 2003, J
ADOLESCENCE, V26, P145, DOI 10.1016/S0140-1971(02)00136-7; Borowsky IW, 2009,
PEDIATRICS, V124, pE81, DOI 10.1542/peds.2008-3425; Brezina T., 2008, MIGHT NOT BE
TOMORRO; Caldwell RM, 2006, J YOUTH ADOLESCENCE, V35, P591, DOI 10.1007/s10964-006-
9031-z; Chemers MM, 2001, J EDUC PSYCHOL, V93, P55, DOI 10.1037//0022-0663.93.1.55;
Chen E, 2012, PERSPECT PSYCHOL SCI, V7, P135, DOI 10.1177/1745691612436694; Chen P,
2013, J YOUTH ADOLESCENCE, V42, P67, DOI 10.1007/s10964-012-9785-4; Cohen J., 2013,
APPL MULTIPLE REGRES; Corte C, 2010, J CHILD ADOLES SUBST, V19, P406, DOI
10.1080/1067828X.2010.515882; Deblinger E, 2006, J AM ACAD CHILD PSY, V45, P1474,
DOI 10.1097/01.chi.0000240839.56114.bb; Dubow EF, 2001, J EARLY ADOLESCENCE, V21,
P5, DOI 10.1177/0272431601021001001; Duke NN, 2009, ACAD PEDIATR, V9, P256, DOI
10.1016/j.acap.2009.02.004; Ekendahl M, 2007, EUR ADDICT RES, V13, P148, DOI
10.1159/000101551; Fazel S, 2008, J AM ACAD CHILD PSY, V47, P1010, DOI
[10.1097/CHI.0b013e31817eeef3, 10.1097/CHI.ObO13e31817eecf3]; Gaylord-Harden NK,
2010, J CONSULT CLIN PSYCH, V78, P843, DOI 10.1037/a0020063; Ginwright S., 2002,
SOCIAL JUSTICE, V29, P82; Gomez R, 2010, SUBST ABUS, V31, P24, DOI
10.1080/08897070903442566; Gorman-Smith D, 1998, DEV PSYCHOPATHOL, V10, P101, DOI
10.1017/S0954579498001539; Guerra NG, 2008, NEW DIR CHILD ADOLES, V122, P1, DOI
10.1002/cd.225; Hayes SC, 1996, J CONSULT CLIN PSYCH, V64, P1152, DOI 10.1037/0022-
006X.64.6.1152; Henry DB, 2001, J CLIN CHILD PSYCHOL, V30, P172, DOI
10.1207/S15374424JCCP3002_5; Hill EM, 1997, HUM NATURE-INT BIOS, V8, P287, DOI
10.1007/BF02913037; Hoffman J. S., 2004, YOUTH VIOLENCE RESIL; Hoyle RH, 2006, J
PERS, V74, P1673, DOI 10.1111/j.1467-6494.2006.00424.x; Huizinga D., 1995, RECENT
FINDINGS PROG; Keough KA, 1999, BASIC APPL SOC PSYCH, V21, P149, DOI
10.1207/S15324834BA210207; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI
10.3109/10673229709030550; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259; Knox M,
2000, YOUTH SOC, V31, P287, DOI 10.1177/0044118X00031003002; Koestner R, 2002, J
PERS SOC PSYCHOL, V83, P231, DOI 10.1037//0022-3514.83.1.231; KOVACS M, 1985,
PSYCHOPHARMACOL BULL, V21, P995; KOVACS M, 1981, ACTA PAEDOPSYCHIATR, V46, P305;
Lloyd DA, 2008, DRUG ALCOHOL DEPEN, V93, P217, DOI
10.1016/j.drugalcdep.2007.09.012; MARKUS H, 1986, AM PSYCHOL, V41, P954, DOI
10.1037/0003-066X.41.9.954; Mason MJ, 2009, ADDICT RES THEORY, V17, P453, DOI
10.1080/16066350802068847; McInerney D. M., 2003, INT ADV SELF RES, V1, P315; Mello
ZR, 2007, J BLACK PSYCHOL, V33, P150, DOI 10.1177/0095798407299514; Monahan KC,
2009, DEV PSYCHOL, V45, P1654, DOI 10.1037/a0015862; Nurius PS, 2006, POSSIBLE
SELVES: THEORY, RESEARCH AND APPLICATIONS, P97; NURIUS PS, 1993, SOC SERV REV, V67,
P261, DOI 10.1086/603981; NURMI JE, 1991, DEV REV, V11, P1, DOI 10.1016/0273-
2297(91)90002-6; Nuttin J. R., 1984, MOTIVATION PLANNING; Oesterle S, 2012, J DRUG
ISSUES, V42, P337, DOI 10.1177/0022042612461769; Oman RF, 2004, AM J PUBLIC HEALTH,
V94, P1425, DOI 10.2105/AJPH.94.8.1425; Oyserman D, 2006, J PERS SOC PSYCHOL, V91,
P188, DOI 10.1037/0022-3514.91.1.188; Peters RJ, 2005, AM J ADDICTION, V14, P478,
DOI 10.1080/10550490500247206; Petry NM, 1998, ADDICTION, V93, P729, DOI
10.1046/j.1360-0443.1998.9357298.x; Prince D, 2014, CHILD YOUTH SERV REV, V43,
P145, DOI 10.1016/j.childyouth.2014.05.003; Prince D, 2014, J YOUTH STUD, V17,
P697, DOI 10.1080/13676261.2013.836591; Prince DM, 2016, J CHILD FAM STUD, V25,
P2089, DOI 10.1007/s10826-016-0384-y; Rhew IC, 2011, HEALTH PLACE, V17, P775, DOI
10.1016/j.healthplace.2011.02.003; Rich JA, 2005, AM J PUBLIC HEALTH, V95, P816,
DOI 10.2105/AJPH.2004.044560; Robbins RN, 2004, J ADOLESCENT RES, V19, P428, DOI
10.1177/0743558403258860; Roeser R. W., 2002, UNDERSTANDING EARLY, P91; Rothman EF,
2008, PEDIATRICS, V122, pE298, DOI 10.1542/peds.2007-3412; Rothman EF, 2010, SUBST
USE MISUSE, V45, P2281, DOI 10.3109/10826084.2010.482369; Schechter DE, 2010, HUM
NATURE-INT BIOS, V21, P140, DOI 10.1007/s12110-010-9084-2; Schmid KL, 2011, J POSIT
PSYCHOL, V6, P45, DOI 10.1080/17439760.2010.536777; Sheidow AJ, 2001, J COMMUNITY
PSYCHOL, V29, P345, DOI 10.1002/jcop.1021; Sipsma HL, 2012, AM J COMMUN PSYCHOL,
V50, P169, DOI 10.1007/s10464-011-9487-1; Stoddard SA, 2011, AM J COMMUN PSYCHOL,
V48, P238, DOI 10.1007/s10464-010-9383-0; TAYLOR SE, 1995, PERS SOC PSYCHOL B, V21,
P1278, DOI 10.1177/01461672952112005; Tolan P. H., 1990, RO148248 NAT I MENT; Tolan
PH, 2003, DEV PSYCHOL, V39, P274, DOI 10.1037/0012-1649.39.2.274; WERNER EE, 1989,
SCI AM, V260, P106, DOI 10.1038/scientificamerican0489-106; Wills TA, 2001, PSYCHOL
ADDICT BEHAV, V15, P118, DOI 10.1037/0893-164X.15.2.118; Wilson M, 1997, BRIT MED
J, V314, P1271, DOI 10.1136/bmj.314.7089.1271; WYMAN PA, 1993, DEV PSYCHOPATHOL,
V5, P649, DOI 10.1017/S0954579400006210; Zimbardo PG, 1999, J PERS SOC PSYCHOL,
V77, P1271, DOI 10.1037/0022-3514.77.6.1271 79 4 4 4 5
ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD ABINGDON 2-4 PARK SQUARE, MILTON
PARK, ABINGDON OX14 4RN, OXON, ENGLAND 1537-4416 1537-4424 J CLIN CHILD
ADOLESC J. Clin. Child Adolesc. Psychol. 2019 48 1
54 67 10.1080/15374416.2016.1197835 14
Psychology, Clinical; Psychology, Developmental Psychology HM2RC
WOS:000459315600005 27617781 2019-09-25
J Blumenthal, H; Taylor, DJ; Cloutier, RM; Baxley, C; Lasslett, H
Blumenthal, Heidemarie; Taylor, Daniel J.; Cloutier, Renee M.; Baxley,
Catherine; Lasslett, Heather The Links Between Social Anxiety
Disorder, Insomnia Symptoms, and Alcohol Use Disorders: Findings From a Large
Sample of Adolescents in the United States BEHAVIOR THERAPY
English Article insomnia; social
anxiety; alcohol; adolescents; youth NATIONAL EPIDEMIOLOGIC SURVEY; COGNITIVE-
BEHAVIORAL THERAPY; LIFETIME MENTAL-DISORDERS; SUBSTANCE USE; HPA AXIS; SUBSEQUENT
ALCOHOL; SELF-MEDICATION; CO-MORBIDITY; RISK-FACTOR; DRUG-USE Social anxiety
disorder (SAD) is associated with increased risk of developing an alcohol use
disorder (AUD). Most of the current literature has focused on the role of acute
stress responding in this relation; however, both SAD and AUDs also are linked to
insomnia symptoms (i.e., difficulty falling or staying asleep). As adolescence is a
sensitive period for the onset of these disorders, the present study examined if
insomnia symptoms might partially account for the SAD-AUD link in a large sample of
adolescents. Data from the National Comorbidity Survey Adolescent Supplement were
examined. Participants (N = 10,140) completed interviews to assess past 12-month
SAD and AUD diagnostic status as well as insomnia symptoms. Analyses tested whether
insomnia symptoms accounted for a significant proportion of the SAD-AUD relation.
Results indicated that insomnia symptoms were positively related to both SAD and
AUD status, and the relation between SAD and AUD status was significantly reduced
when insomnia symptoms were included in the model. Findings remained significant
after controlling for the effects of age, gender, posttraumatic stress disorder,
major depressive disorder, and other drug dependence status. Experimental
examination and intensive longitudinal assessment of these relationships are needed
before strong conclusions can be inferred about causality and temporal
relationships. The current findings do indicate insomnia may be an important
indirect and stigma-free treatment target to address in prevention and treatment
efforts for SAD, AUDs, and their co-occurrence. [Blumenthal, Heidemarie; Taylor,
Daniel J.; Cloutier, Renee M.; Baxley, Catherine; Lasslett, Heather] Univ North
Texas, Denton, TX 76203 USA Blumenthal, H (reprint author), Univ North Texas,
Dept Psychol, 1155 Union Circle 311280, Denton, TX 76203 USA.
Heidemarie.Blumenthal@unt.edu Cloutier, Renee M/D-2249-2019 Cloutier, Renee
M/0000-0003-1795-9149 Alegria M, 2004, INT J METH PSYCH RES, V13,
P208, DOI 10.1002/mpr.178; American Psychiatric Association, 2013, DIAGN STAT MAN
MENT; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Anker JJ, 2016,
DRUG ALCOHOL DEPEN, V159, P93, DOI 10.1016/j.drugalcdep.2015.11.031; Babson KA,
2008, DEPRESS ANXIETY, V25, P670, DOI 10.1002/da.20374; Bakken K, 2005, DRUG
ALCOHOL DEPEN, V80, P321, DOI 10.1016/j.drugalcdep.2005.04.011; Battista Susan R,
2010, Curr Drug Abuse Rev, V3, P3; Beidel D. C., 1994, INT HDB PHOBIC ANXIE, P111,
DOI 10.1007/978-1-4899-1498-9_6; Blank M, 2015, SLEEP, V38, P197, DOI
10.5665/sleep.4396; Blumenthal H, 2016, ANXIETY STRESS COPIN, V29, P432, DOI
10.1080/10615806.2015.1058366; Blumenthal Heidemarie, 2011, J Exp Psychopathol, V2,
P318; Blumenthal H, 2010, PSYCHOL ADDICT BEHAV, V24, P529, DOI 10.1037/a0019794;
Bootzin RR, 2005, CLIN PSYCHOL REV, V25, P629, DOI 10.1016/j.cpr.2005.04.007;
Brower KJ, 2001, AM J PSYCHIAT, V158, P399, DOI 10.1176/appi.ajp.158.3.399; Buckley
TM, 2005, J CLIN ENDOCR METAB, V90, P3106, DOI 10.1210/jc.2004-1056; Buckner JD,
2008, J PSYCHIATR RES, V42, P230, DOI 10.1016/j.jpsychires.2007.01.002; Buckner JD,
2008, DEPRESS ANXIETY, V25, P124, DOI 10.1002/da.20282; Carpenter KM, 1999, J STUD
ALCOHOL, V60, P694, DOI 10.15288/jsa.1999.60.694; Casey BJ, 2010, J AM ACAD CHILD
PSY, V49, P1189, DOI 10.1016/j.jaac.2010.08.017; Castellanos-Ryan N, 2013, J ABNORM
PSYCHOL, V122, P782, DOI 10.1037/a0033133; Clark DM, 1995, SOCIAL PHOBIA DIAGNO,
P69, DOI DOI 10.1192/BJP.BP.114.146761; Cludius B, 2013, PSYCHOL ADDICT BEHAV, V27,
P806, DOI 10.1037/a0032295; Colrain IM, 2011, NEUROPSYCHOL REV, V21, P5, DOI
10.1007/s11065-010-9155-5; Compas BE, 2001, PSYCHOL BULL, V127, P87, DOI
10.1037//0033-2909.127.1.87; Compton WM, 2007, ARCH GEN PSYCHIAT, V64, P566, DOI
10.1001/archpsyc.64.5.566; Condren RM, 2002, PSYCHONEUROENDOCRINO, V27, P693, DOI
10.1016/S0306-4530(01)00070-1; Conrod PJ, 2013, JAMA PSYCHIAT, V70, P334, DOI
10.1001/jamapsychiatry.2013.651; Conrod PJ, 2011, J CONSULT CLIN PSYCH, V79, P296,
DOI 10.1037/a0022997; Conway KP, 2016, J AM ACAD CHILD PSY, V55, P280, DOI
10.1016/j.jaac.2016.01.006; Cooper M. L., 1994, PSYCHOL ASSESSMENT, V6, P117, DOI
[DOI 10.1037/1040-3590.6.2.117, 10.1037/1040-3590.6.2.117]; Crowley SJ, 2007, SLEEP
MED, V8, P602, DOI 10.1016/j.sleep.2006.12.002; Crum RM, 2004, AM J PSYCHIAT, V161,
P1197, DOI 10.1176/appi.ajp.161.7.1197; de Bruin EJ, 2015, SLEEP, V38, P1913, DOI
10.5665/sleep.5240; Ebrahim IO, 2013, ALCOHOL CLIN EXP RES, V37, DOI
10.1111/acer.12006; Edinger JD, 2005, CLIN PSYCHOL REV, V25, P539, DOI
10.1016/J.CPR.2005.04.003; Eiland L, 2013, NEUROSCIENCE, V249, P162, DOI
10.1016/j.neuroscience.2012.10.048; Essau CA, 1999, BEHAV RES THER, V37, P831, DOI
10.1016/S0005-7967(98)00179-X; Grant BF, 2005, J CLIN PSYCHIAT, V66, P1351, DOI
10.4088/JCP.v66n1102; Hagenauer MH, 2009, DEV NEUROSCI-BASEL, V31, P276, DOI
10.1159/000216538; Ham Lindsay S., 2009, Cognitive Behaviour Therapy, V38, P133,
DOI 10.1080/16506070802610889; Hayes A.F., 2013, INTRO MEDIATION MODE; Hayes A. F.,
2012, CISC VIS NETW IND GL; Hudson JL, 2009, BEHAV RES THER, V47, P339, DOI
10.1016/j.brat.2009.01.006; Jester JM, 2015, ADDICTION, V110, P71, DOI
10.1111/add.12704; Johnson EO, 2006, PEDIATRICS, V117, pE247, DOI
10.1542/peds.2004-2629; Johnson EO, 2006, J PSYCHIATR RES, V40, P700, DOI
10.1016/j.jpsychires.2006.07.008; Kendall PC, 2004, J CONSULT CLIN PSYCH, V72,
P276, DOI 10.1037/0022-006X.72.2.276; Kessler RC, 2003, JAMA-J AM MED ASSOC, V289,
P3095, DOI 10.1001/jama.289.23.3095; Kessler RC, 2009, INT J METH PSYCH RES, V18,
P69, DOI 10.1002/mpr.279; Kessler RC, 2009, J AM ACAD CHILD PSY, V48, P380, DOI
10.1097/CHI.0b013e3181999705; Kilpatrick DG, 2003, J CONSULT CLIN PSYCH, V71, P692,
DOI 10.1037/0022-006X.71.4.692; Kraemer HC, 2000, AM J PSYCHIAT, V157, P163, DOI
10.1176/appi.ajp.157.2.163; Kuntsche E, 2005, CLIN PSYCHOL REV, V25, P841, DOI
10.1016/j.cpr.2005.06.002; Labouvie E., 2002, STAGES PATHWAYS DRUG, P19, DOI
[10.1017/CBO9780511499777.004, DOI 10.1017/CBO9780511499777.004]; Lammers J, 2015,
ADDICTION, V110, P1101, DOI 10.1111/add.12952; MACKINNON DP, 1993, EVALUATION REV,
V17, P144, DOI 10.1177/0193841X9301700202; Mcmanus F, 2008, J BEHAV THER EXP PSY,
V39, P147, DOI 10.1016/j.jbtep.2006.12.002; Merikangas KR, 2009, J AM ACAD CHILD
PSY, V48, P367, DOI 10.1097/CHI.0b013e31819996f1; Merikangas KR, 2011, J AM ACAD
CHILD PSY, V50, P32, DOI 10.1016/j.jaac.2010.10.006; Merikangas KR, 2010, J AM ACAD
CHILD PSY, V49, P980, DOI 10.1016/j.jaac.2010.05.017; Nelson EC, 2000, PSYCHOL MED,
V30, P797, DOI 10.1017/S0033291799002275; Noland H, 2009, J SCHOOL HEALTH, V79,
P224, DOI 10.1111/j.1746-1561.2009.00402.x; Peterman JS, 2016, J ANXIETY DISORD,
V37, P78, DOI 10.1016/j.janxdis.2015.11.006; Preacher KJ, 2008, BEHAV RES METHODS,
V40, P879, DOI 10.3758/BRM.40.3.879; Rapee RM, 1997, BEHAV RES THER, V35, P741, DOI
10.1016/S0005-7967(97)00022-3; Roane BM, 2008, SLEEP, V31, P1351; Schell TL, 2005,
PSYCHOL ADDICT BEHAV, V19, P217, DOI 10.1037/0893-164X.19.2.217; Schneier FR, 2010,
PSYCHOL MED, V40, P977, DOI 10.1017/S0033291709991231; Stapinski LA, 2015, COGN
BEHAV PRACT, V22, P504, DOI 10.1016/j.cbpra.2014.05.004; STEIN MB, 1993, PSYCHIAT
RES, V49, P251, DOI 10.1016/0165-1781(93)90065-O; Suveg C, 2004, J CLIN CHILD
ADOLESC, V33, P750, DOI 10.1207/s15374424jccp3304_10; Swendsen J, 2012, ARCH GEN
PSYCHIAT, V69, P390, DOI 10.1001/archgenpsychiatry.2011.1503; Tarullo AR, 2006,
HORM BEHAV, V50, P632, DOI 10.1016/j.yhbeh.2006.06.010; Taylor Daniel J, 2003,
Behav Sleep Med, V1, P227, DOI 10.1207/S15402010BSM0104_5; Taylor DJ, 2005, SLEEP,
V28, P1457, DOI 10.1093/sleep/28.11.1457; Terlecki MA, 2015, ADDICT BEHAV, V40,
P77, DOI 10.1016/j.addbeh.2014.09.008; Thayer JF, 2006, INT J PSYCHOPHYSIOL, V59,
P244, DOI 10.1016/j.ijpsycho.2005.10.013; Thomas SE, 2003, ALCOHOL CLIN EXP RES,
V27, P1937, DOI 10.1097/01.ALC.0000100942.30743.8C; Tomlinson KL, 2012, ADDICT
BEHAV, V37, P179, DOI 10.1016/j.addbeh.2011.09.016; Turk C. L., 2001, SOCIAL
ANXIETY SOCIA, P281; Velting ON, 2001, J CHILD PSYCHOL PSYC, V42, P127, DOI
10.1111/1469-7610.00705; Windle M, 2012, ADDICT BEHAV, V37, P1003, DOI
10.1016/j.addbeh.2012.04.009; Wittchen HU, 2008, INT J METH PSYCH RES, V17, pS16,
DOI 10.1002/mpr.254; Wong MM, 2004, ALCOHOL CLIN EXP RES, V28, P578, DOI
10.1097/01.ALC.0000121651.75952.39; Zhang JH, 2017, J PEDIATR-US, V182, P137, DOI
10.1016/j.jpeds.2016.11.007; Zimmermann P, 2003, PSYCHOL MED, V33, P1211, DOI
10.1017/S0033291703008158 86 3 3 4 5 ELSEVIER INC SAN
DIEGO 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA 0005-7894 1878-1888
BEHAV THER Behav. Therapy JAN 2019 50 1
50 59 10.1016/j.beth.2018.03.010 10 Psychology,
Clinical; Psychiatry Psychology; Psychiatry HK6MR WOS:000458095300005
30661566 2019-09-25
J Homish, GG; Hoopsick, RA; Heavey, SC; Homish, DL; Cornelius, JR
Homish, Gregory G.; Hoopsick, Rachel A.; Heavey, Sarah Cercone; Homish, D.
Lynn; Cornelius, Jack R. Drug use and hazardous drinking are
associated with PTSD symptoms and symptom clusters in US Army Reserve/National
Guard Soldiers AMERICAN JOURNAL ON ADDICTIONS English
Article POSTTRAUMATIC-STRESS-
DISORDER; NATIONAL EPIDEMIOLOGIC SURVEY; RISK-FACTORS; ALCOHOL; HEALTH;
COMORBIDITY; DEPLOYMENT; VETERANS; MILITARY; SMOKING Background and Objectives
There is strong evidence of the association between Posttraumatic Stress Disorder
(PTSD) symptoms and substance use. Previous work has found sex differences in these
associations. With revisions to the DSM, it is important to understand how overall
PTSD symptoms and the new symptom clusters relate to substance use among
Reserve/Guard soldiers-a high risk group. Methods Data are from the baseline
assessment of Operation: SAFETY (Soldiers and Families Excelling Through the
Years), a longitudinal study of US Army Reserve/National Guard (USAR/NG) soldiers
(N = 389 males, N = 84 females). We examined associations between current substance
use (drug use, hazardous drinking, and smoking) and overall PTSD symptoms, and
symptom clusters. Additionally, we examined PTSD by sex interactions. Results
Greater overall PTSD symptoms were associated with higher odds of drug use (OR =
1.08; 95%CI: 1.05, 1.12) and hazardous drinking (OR = 1.04; 95%CI: 1.02, 1.07).
Greater individual symptom cluster scores were associated with higher odds of drug
use (ps < .001) and hazardous drinking (ps < .01). Interaction models revealed no
differences in these associations on the basis sex (ps > .05). There were no
associations between PTSD symptoms or symptom clusters on smoking (ps > .05).
Discussion and Conclusion Soldiers experiencing PTSD symptoms are reporting current
drug and hazardous alcohol use, suggestive of self-medication. Scientific
Significance It is imperative to consider the impact of PTSD on substance use
broadly, as this work shows that overall symptoms and symptom clusters have an
impact on male and female USAR/NG soldiers. [Homish, Gregory G.; Hoopsick,
Rachel A.; Heavey, Sarah Cercone; Homish, D. Lynn] SUNY Buffalo, Dept Community
Hlth & Hlth Behav, 325 Kimball Tower,3435 Main St, Buffalo, NY 14214 USA; [Homish,
Gregory G.] SUNY Buffalo, Dept Pediat, 3435 Main St, Buffalo, NY 14214 USA;
[Homish, Gregory G.] SUNY Buffalo, Dept Family Med, 3435 Main St, Buffalo, NY 14214
USA; [Cornelius, Jack R.] Univ Pittsburgh, Dept Psychiat, 3811 OHara St,
Pittsburgh, PA 15213 USA Homish, GG (reprint author), SUNY Buffalo, Dept
Community Hlth & Hlth Behav, 325 Kimball Tower,3435 Main St, Buffalo, NY 14214 USA.
ghomish@buffalo.edu Homish, Gregory G/A-9576-2009 Hoopsick, Rachel/0000-
0001-5992-9007 National Institute on Drug Abuse of the National Institutes of
HealthUnited States Department of Health & Human ServicesNational Institutes of
Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01DA034072];
National Center for Advancing Translational Sciences of the National Institutes of
HealthUnited States Department of Health & Human ServicesNational Institutes of
Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)
[UL1TR001412] This work was supported by the National Institute on Drug Abuse
of the National Institutes of Health R01DA034072 to GGH and the National Center for
Advancing Translational Sciences of the National Institutes of Health under award
number UL1TR001412 to the University at Buffalo. The content is solely the
responsibility of the authors and does not necessarily represent the official views
of the National Institutes of Health. Ali R, 2002, ADDICTION, V97, P1183; Babor
T, 2001, AUDIT ALCOHOL USE DI; BABOR TF, 1992, MEASURING ALCOHOL CONSUMPTION, P3;
Brady KT, 2004, CURR DIR PSYCHOL SCI, V13, P206, DOI 10.1111/j.0963-
7214.2004.00309.x; Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI
10.1037/0022-006X.68.5.748; Bruffaerts R, 2012, BRIT J PSYCHIAT, V200, P454, DOI
10.1192/bjp.bp.111.097519; Chilcoat HD, 1998, ADDICT BEHAV, V23, P827, DOI
10.1016/S0306-4603(98)00069-0; Craske M, 2013, SEVERITY MEASURE GEN; Dabbs C, 2014,
MIL MED, V179, P885, DOI 10.7205/MILMED-D-14-00012; Department of Defense, 2015,
2015 DEM PROF MIL CO; Dursa EK, 2014, J TRAUMA STRESS, V27, P542, DOI
10.1002/jts.21956; El-Gabalawy R, 2018, J AFFECT DISORDERS, V227, P849, DOI
10.1016/j.jad.2017.11.058; Fink DS, 2018, DEPRESS ANXIETY, V35, P1048, DOI
10.1002/da.22819; Fu SS, 2007, NICOTINE TOB RES, V9, P1071, DOI
10.1080/14622200701488418; Gadermann AM, 2012, DEPRESS ANXIETY, V29, P797, DOI
10.1002/da.21924; Goldstein RB, 2016, SOC PSYCH PSYCH EPID, V51, P1137, DOI
10.1007/s00127-016-1208-5; Greenberg JB, 2012, PSYCHOL ADDICT BEHAV, V26, P89, DOI
10.1037/a0024328; Griffith J, 2011, INT REV PSYCHIATR, V23, P181, DOI
10.3109/09540261.2010.541904; Griffith J, 2010, MIL PSYCHOL, V22, P176, DOI
10.1080/08995601003638967; Griffith J, 2009, ARMED FORCES SOC, V36, P38, DOI
10.1177/0095327X08327819; Jacobsen LK, 2001, AM J PSYCHIAT, V158, P1184, DOI
10.1176/appi.ajp.158.8.1184; Jakupcak M, 2010, ADDICT BEHAV, V35, P840, DOI
10.1016/j.addbeh.2010.03.023; Kachadourian LK, 2014, J PSYCHIATR RES, V55, P35, DOI
10.1016/j.jpsychires.2014.04.018; KOZLOWSKI LT, 1994, DRUG ALCOHOL DEPEN, V34,
P211, DOI 10.1016/0376-8716(94)90158-9; Kroenke K, 2009, J AFFECT DISORDERS, V114,
P163, DOI 10.1016/j.jad.2008.06.026; Lapp CA, 2010, J FAM NURS, V16, P45, DOI
10.1177/1074840709357347; Marmar CR, 2015, JAMA PSYCHIAT, V72, P875, DOI
10.1001/jamapsychiatry.2015.0803; Marshall RD, 2001, AM J PSYCHIAT, V158, P1467,
DOI 10.1176/appi.ajp.158.9.1467; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298,
P2141, DOI 10.1001/jama.298.18.2141; Norman SB, 2014, J STUD ALCOHOL DRUGS, V75,
P557, DOI 10.15288/jsad.2014.75.557; Pietrzak RH, 2011, PSYCHOSOM MED, V73, P697,
DOI 10.1097/PSY.0b013e3182303775; Pietrzak RH, 2011, J ANXIETY DISORD, V25, P456,
DOI 10.1016/j.janxdis.2010.11.010; Renshaw KD, 2010, J TRAUMA STRESS, V23, P815,
DOI 10.1002/jts.20575; Riviere LA, 2011, BRIT J PSYCHIAT, V198, P136, DOI
10.1192/bjp.bp.110.084863; Ryan MAK, 2007, J CLIN EPIDEMIOL, V60, P181, DOI
10.1016/j.jclinepi.2006.05.009; Sareen J, 2007, PSYCHOSOM MED, V69, P242, DOI
10.1097/PSY.0b013e31803146d8; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI
10.1111/j.1360-0443.1993.tb02093.x; Scott JC, 2013, DRUG ALCOHOL DEPEN, V127, P15,
DOI 10.1016/j.drugalcdep.2012.06.003; Shea MT, 2010, J TRAUMA STRESS, V23, P100,
DOI 10.1002/jts.20497; Smith KZ, 2016, ADDICT BEHAV, V58, P167, DOI
10.1016/j.addbeh.2016.02.019; Smith KZ, 2015, J TRAUMA STRESS, V28, P469, DOI
10.1002/jts.22048; Smith TC, 2008, EPIDEMIOLOGY, V19, P505, DOI
10.1097/EDE.0b013e31816a9dff; Steenkamp MM, 2012, BEHAV MODIF, V36, P857, DOI
10.1177/0145445512450908; Tolin DF, 2006, PSYCHOL BULL, V132, P959, DOI
10.1037/0033-2909.132.6.959; Vest BM, 2013, ARMED FORCES SOC, V39, P602, DOI
10.1177/0095327X12457725; Vujanovic AA, 2016, PSYCHOL ADDICT BEHAV, V30, P713, DOI
10.1037/adb0000222; Weathers F, 2013, PTSD CHECKLIST DSM 5 47 0 0 0
5 WILEY HOBOKEN 111 RIVER ST, HOBOKEN 07030-5774, NJ USA 1055-0496
1521-0391 AM J ADDICTION Am. J. Addict. JAN 2019 28 1
22 28 10.1111/ajad.12829 7
Substance Abuse Substance Abuse HF3IY WOS:000454129900003 30548523
2019-09-25
J Maremmani, AGI; Bacciardi, S; Somers, JM; Nikoo, M; Schutz, C; Jang, KL;
Krausz, M Maremmani, Angelo G. I.; Bacciardi, Silvia; Somers,
Julian M.; Nikoo, Mohammadali; Schutz, Christian; Jang, Kerry L.; Krausz, Michael
Substance Dependence Among Bipolar, Unipolar Depression and Psychotic
Homeless: A Canadian National Study FRONTIERS IN PSYCHIATRY English
Article substance dependence; alcohol
dependence; homeless; bipolar disorder; unipolar depression; psychotic disorder
USE DISORDERS; DRUG-ABUSE; EPIDEMIOLOGIC SURVEY; DSM-IV; SELF-MEDICATION;
MENTAL-ILLNESS; DUAL DIAGNOSIS; CANNABIS USE; ALCOHOL; COMORBIDITY
Introduction: Homeless individuals are often mischaracterized as members of a
homogeneous population that suffers from a wide mental health and addiction issues,
with little consideration of potentially important differences within or between
samples. The aim of the present study was to investigate the comorbidy of alcohol
and/or substance dependence (ASD) andmajor psychiatric diagnoses (bipolar disorder,
unipolar depression, and psychotic disorder) in a large Canadian sample of homeless
individuals, and to examine potential sources of variability including location and
ethnicity. Materials and Methods: A sample of 1,585 homeless individuals were
assessed for alcohol and/or substance dependence and bipolar disorder, unipolar
depression and psychotic disorder with the Mini-International Neuropsychiatric
Interview (version 6.0). Regional and ethnic differences in major psychiatric
diagnoses between homeless with and without ASD were examined using univariate
(i.e., chi-square) and multivariate (i.e., logistic regression) statistics.
Results: Members of the sample with ASD were found to be younger, Aboriginal, less
well-educated, and born in the Americas. They were more significantly more
prevalent in Western Canada and less prevalent in Central and Eastern Canada. The
odds of having ASD were higher among people affected by bipolar disorder and (to a
less extent) unipolar depression. Limitations: Data collected were self-reported
and no urinalyses were performed. We considered diagnosis of ASD according to the
previous 12 months only. Conclusions: Homeless people with major mental illness are
at high risk for concurrent ASD, however the prevalence of ASD varies significantly
between cities, and based on ethnicity and specific psychiatric diagnosis (with
greater prevalence in individuals affected by bipolar disorder and, to a less
extent, unipolar depression). Clinicians, administrators and policy makers should
develop and deliver services based on careful assessment of the local population.\
[Maremmani, Angelo G. I.] Assoc Applicat Neurosci Knowledge Social Aims AU,
Pietrasanta, Lucca, Italy; [Maremmani, Angelo G. I.] North Western Tuscany Reg,
Local Hlth Unit Versilia Zone, Dept Psychiat, Viareggio, Italy; [Bacciardi, Silvia]
Univ Pisa, Vincent P Dole Dual Diag Unit, Dept Clin & Expt Med, Pisa, Italy;
[Somers, Julian M.] Simon Fraser Univ, Somers Res Grp, Fac Hlth Sci, Barnaby, BC,
Canada; [Nikoo, Mohammadali; Schutz, Christian; Jang, Kerry L.; Krausz, Michael]
Univ British Columbia, Inst Mental Hlth, Dept Psychiat, Vancouver, BC, Canada;
[Krausz, Michael] St Pauls Hosp, Ctr Hlth Evaluat & Outcome Sci, Vancouver, BC,
Canada; [Krausz, Michael] Univ British Columbia, Sch Populat & Publ Hlth,
Vancouver, BC, Canada Maremmani, AGI (reprint author), Assoc Applicat Neurosci
Knowledge Social Aims AU, Pietrasanta, Lucca, Italy.; Maremmani, AGI (reprint
author), North Western Tuscany Reg, Local Hlth Unit Versilia Zone, Dept Psychiat,
Viareggio, Italy. angelogimaremmani@gmail.com MentalHealth Commission
of Canada (MHCC) - a Health Canada mandate The database-source At Home/Chez
Soi Vancouver was funded by the MentalHealth Commission of Canada (MHCC) - a Health
Canada mandate. The Mental Health Commission of Canada (MHCC) played NO role in
study design; nor in the collection, analysis and interpretation of data; nor in
the writing of the report; nor in the decision to submit the paper for publication.
Albanese Mark J, 2006, J Psychiatr Pract, V12, P124, DOI 10.1097/00131746-
200603000-00010; Angst J, 2005, BIPOLAR DISORD, V7, P4, DOI 10.1111/j.1399-
5618.2005.00210.x; Angst Jules, 2008, Dialogues Clin Neurosci, V10, P129; Angst J,
2015, PSYCHIATR POL, V49, P663, DOI 10.12740/PP/58259; APA, 1994, DIAGN STAT MAN
MENT; Bacciardi S, 2013, HEROIN ADDICT REL CL, V15, P29; Bagot KS, 2015, SUBST
ABUS, V36, P524, DOI 10.1080/08897077.2014.995332; Buckley PF, 2006, J CLIN
PSYCHIAT, V67, P5; Buckley PF, 2009, SCHIZOPHRENIA BULL, V35, P383, DOI
10.1093/schbul/sbn135; Camacho A, 2005, J AFFECT DISORDERS, V85, P217, DOI
10.1016/j.jad.2003.10.014; Chartier KG, 2009, J STUD ALCOHOL DRUGS, V70, P337, DOI
10.15288/jsad.2009.70.337; Compton WM, 2007, ARCH GEN PSYCHIAT, V64, P566, DOI
10.1001/archpsyc.64.5.566; Compton WM, 2000, AM J ADDICTION, V9, P126; Currie CL,
2013, SOC SCI MED, V88, P1, DOI 10.1016/j.socscimed.2013.03.032; Do EK, 2013, J
AFFECT DISORDERS, V150, P974, DOI 10.1016/j.jad.2013.05.023; Edens EL, 2011, WOMEN
HEALTH ISS, V21, P383, DOI 10.1016/j.whi.2011.03.004; Elton-Marshall T, 2011, CAN
MED ASSOC J, V183, pE480, DOI 10.1503/cmaj.101913; Farren CK, 2012, CURR PSYCHIAT
REP, V14, P659, DOI 10.1007/s11920-012-0320-9; Fazel S, 2008, PLOS MED, V5, P1670,
DOI 10.1371/journal.pmed.0050225; Fendrich M, 2005, J URBAN HEALTH, V82, pIII67,
DOI 10.1093/jurban/jti065; Foster A, 2012, PSYCHIAT CLIN N AM, V35, P717, DOI
10.1016/j.psc.2012.06.010; Gill K., 2001, J ETHN SUBST ABUSE, V1, P7, DOI
[10.1300/J233v01n01_02, DOI 10.1300/J233V01N01_02]; Goering PN, 2011, BMJ OPEN, V1,
DOI 10.1136/bmjopen-2011-000323; Goldberg J F, 2001, J Psychiatr Pract, V7, P109,
DOI 10.1097/00131746-200103000-00004; Goodwin RD, 2002, COMPR PSYCHIAT, V43, P245,
DOI 10.1053/comp.2002.33500; Grant BF, 2009, MOL PSYCHIATR, V14, P1051, DOI
10.1038/mp.2008.41; Hasin DS, 2015, SOC PSYCH PSYCH EPID, V50, P1609, DOI
10.1007/s00127-015-1088-0; Hasin DS, 2005, ARCH GEN PSYCHIAT, V62, P1097, DOI
10.1001/archpsyc.62.10.1097; Hooley JM, 2010, CURR DIR PSYCHOL SCI, V19, P238, DOI
10.1177/0963721410377597; Jacobs K. W. J., 2002, J ETHN SUBST ABUSE, V1, P19, DOI
DOI 10.1300/J233V01N02_03; Jainchill N, 2000, AM J DRUG ALCOHOL AB, V26, P553, DOI
10.1081/ADA-100101895; Kavanagh DJ, 2002, DRUGS, V62, P743, DOI 10.2165/00003495-
200262050-00003; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI
10.1001/archpsyc.62.6.593; Khan S, 2017, HEALTH REP, V28, P3; Khantzian EJ, 2009, J
CLIN PSYCHIAT, V70, P935, DOI 10.4088/JCP.08lr04878; KHANTZIAN EJ, 1985, AM J
PSYCHIAT, V142, P1259; Krausz RM, 2013, SOC PSYCH PSYCH EPID, V48, P1235, DOI
10.1007/s00127-012-0649-8; Krystal JH, 2006, NEUROTOX RES, V10, P235, DOI
10.1007/BF03033360; Lappin JM, 2017, ADDICTION, V112, P927, DOI 10.1111/add.13663;
Maremmani AGI, 2012, NATURAL HIST ADDICTI, P31, DOI [10.1097/ADT.0b013e31824c5d1b,
DOI 10.1097/ADT.0B013E31824C5D1B]; Maremmani AGI, 2014, EUROPEAN REV MED PHA;
Maremmani AGI, 2016, HEROIN ADDICT REL CL, V18, P23; Maremmani AGI, 2013, HEROIN
ADDICT REL CL, V15, P25; Maremmani AGI, 2011, ANN GEN PSYCHIATR, V10, DOI
10.1186/1744-859X-10-17; Maremmani AGI, 2011, J ADDICT DIS, V30, P123, DOI
10.1080/10550887.2011.554779; Maremmani I, 2006, J AFFECT DISORDERS, V93, P1, DOI
10.1016/j.jad.2006.02.022; Maremmani I, 2012, ANN GEN PSYCHIATR, V11, DOI
10.1186/1744-859X-11-23; Maremmani I, 2010, J PSYCHOACTIVE DRUGS, V42, P89, DOI
10.1080/02791072.2010.10399789; Merikangas KR, 1998, ADDICT BEHAV, V23, P893, DOI
10.1016/S0306-4603(98)00076-8; Nation M, 2006, AM J DRUG ALCOHOL AB, V32, P415, DOI
10.1080/00952990600753867; Nishimura Stephanie T, 2005, Cultur Divers Ethnic Minor
Psychol, V11, P239; O'Toole TP, 2004, J URBAN HEALTH, V81, P606, DOI
10.1093/jurban/jth144; Palepu A, 2013, J URBAN HEALTH, V90, P740, DOI
10.1007/s11524-012-9775-6; Patterson M, 2013, SOC PSYCH PSYCH EPID, V48, P1245, DOI
10.1007/s00127-013-0719-6; Perugi G, 2012, PSYCHOPATHOLOGY, V45, P390, DOI
10.1159/000338047; Pettinati HM, 2013, AM J PSYCHIAT, V170, P23, DOI
10.1176/appi.ajp.2012.12010112; REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511;
Santa Maria DM, 2018, J ADDICT NURS, V29, P23, DOI 10.1097/JAN.0000000000000206;
Schimmelmann BG, 2011, SCHIZOPHR RES, V129, P52, DOI 10.1016/j.schres.2011.03.023;
Schutz C, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-288; Sheehan DV,
1998, J CLIN PSYCHIAT, V59, P34; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI
10.4088/JCP.09m05305whi; SOYKA M, 1993, EUR ARCH PSY CLIN N, V242, P362, DOI
10.1007/BF02190250; Stergiopoulos V, 2015, JAMA-J AM MED ASSOC, V313, P905, DOI
10.1001/jama.2015.1163; Strakowski SM, 2000, CLIN PSYCHOL REV, V20, P191, DOI
10.1016/S0272-7358(99)00025-2; Swann AC, 2004, BIPOLAR DISORD, V6, P204, DOI
10.1111/j.1399-5618.2004.00110.x; Taplin C, 2014, SUBST USE MISUSE, V49, P1311, DOI
10.3109/10826084.2014.901383; Torchalla I, 2011, DRUG ALCOHOL DEPEN, V118, P173,
DOI 10.1016/j.drugalcdep.2011.03.016; Uzelac S, 2006, J NERV MENT DIS, V194, P654,
DOI 10.1097/01.nmd.0000235767.00901.e2; Vila-Rodriguez F, 2013, AM J PSYCHIAT,
V170, P1413, DOI 10.1176/appi.ajp.2013.12111439; Westermeyer J, 1984, Adv Alcohol
Subst Abuse, V4, P9; World Health Organization, 1992, ICD 10 CLASS MENT BE 72
0 0 0 6 FRONTIERS MEDIA SA LAUSANNE AVENUE DU TRIBUNAL
FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND 1664-0640 FRONT
PSYCHIATRY Front. Psychiatry DEC 18 2018 9
701 10.3389/fpsyt.2018.00701 7 Psychiatry
Psychiatry HE8AD WOS:000453663600001 30618874 DOAJ Gold, Green
Published 2019-09-25
J Shaffer, HJ; Tom, MA; Wiley, RC; Wong, MFY; Chan, EML; Cheng, GLF; Lo, CKM;
Ma, EKY; Wong, RHY; Lee, M Shaffer, Howard J.; Tom, Matthew
A.; Wiley, Rhiannon C.; Wong, Margaret F. Y.; Chan, Elda M. L.; Cheng, Gordon L.
F.; Lo, Camilla K. M.; Ma, Eric K. Y.; Wong, Ryan H. Y.; Lee, Mary
Using the Syndrome Model of Addiction: a Preliminary Consideration of
Psychological States and Traits INTERNATIONAL JOURNAL OF MENTAL HEALTH AND
ADDICTION English Article; Proceedings Paper 1st Asia Pacific
Conference of Addiction Professionals (APCAP) MAY 18-19, 2017 Hong Kong, HONG
KONG Tung Wah Grp Hosp, Integrated Ctr Addict Prevent, Hong Kong Polytechn Univ,
Dept Appl Social Sci Syndrome model; Addiction; Treatment seekers; Hong
Kong NATIONAL EPIDEMIOLOGIC SURVEY; SUBSTANCE USE DISORDERS; ADVERSE CHILDHOOD
EXPERIENCES; SELF-MEDICATION HYPOTHESIS; SENSATION SEEKING; INTERNET ADDICTION;
MENTAL-DISORDERS; HEROIN-ADDICTS; ALCOHOL; PERSONALITY This article describes a
collaborative research project between the Division on Addiction, Cambridge Health
Alliance, a Harvard Medical School Teaching Hospital, and the Integrated Centre on
Addiction Prevention and Treatment (ICAPT) of the Tung Wah Group of Hospitals
(TWGHs) in Hong Kong. The goal of this research is to better understand the
syndrome model of addiction by establishing an epidemiology of addiction treatment
seekers across various expressions of addiction (e.g., alcohol and other
psychoactive drugs, gambling, sexual behaviors, online gaming). This paper presents
initial findings about the demographic and psychological characteristics of three
groups of treatment seekers in TWGHs in Hong Kong: (1) a group seeking treatment
for chemical expressions of addiction (n=35); (2) a group seeking treatment for
behavioral expressions of addiction (n=125); and (3) a comparison group seeking
services (n=18) unrelated to addiction. The initial findings identified various
common psychological vulnerabilities (i.e., trait anxiety, state anxiety,
depression, using emotional support and venting as psychological coping, higher
levels of attentional impulsiveness) shared among both the behavioral expression
and chemical expression groups, and possible unique psychological characteristics
associated with each expression of addiction (e.g., coping mechanisms). These
findings provide support for conceptualizing addiction as a syndrome. [Shaffer,
Howard J.; Tom, Matthew A.; Wiley, Rhiannon C.] Harvard Med Sch, Teaching Hosp,
Cambridge Hlth Alliance, Div Addict, 101 Stn Landing,Suite 2100, Medford, MA 02155
USA; [Wong, Margaret F. Y.] Tung Wah Grp Hosp, Community Serv Div, Youth & Family
Serv, Sai Wan, Peoples R China; [Chan, Elda M. L.; Lo, Camilla K. M.; Ma, Eric K.
Y.; Wong, Ryan H. Y.; Lee, Mary] Tung Wah Grp Hosp, Integrated Ctr Addict Prevent &
Treatment, Sai Wan, Peoples R China; [Cheng, Gordon L. F.] Castle Peak Hosp, Dept
Clin Psychol, Tuen Mun, Peoples R China Shaffer, HJ (reprint author), Harvard Med
Sch, Teaching Hosp, Cambridge Hlth Alliance, Div Addict, 101 Stn Landing,Suite
2100, Medford, MA 02155 USA. howard_shaffer@hms.harvard.edu; mtom@challiance.org;
rcwiley@challiance.org; margaret.wong@tungwah.org.hk; elda.chan@tungwah.org.hk;
gordon.chg@gmail.com; camilla.lo@tungwah.org.hk; eric.ky.ma@tungwah.org.hk;
ryan.wong@tungwah.org.hk; mary.lee@tungwah.org.hk Lo, Camilla Kin
Ming/0000-0002-4381-9361; Wiley, Rhiannon/0000-0003-1077-6470 Hong Kong Jockey
Club Charities Trust; Foundation for Advancing Alcohol Responsibility (FAAR);
National Institutes of Health (NIDA)United States Department of Health & Human
ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug
Abuse (NIDA); Substance Abuse and Mental Health Services Administration
(SAMHSA)United States Department of Health & Human Services; National Center for
Responsible Gambling (NCRG); Massachusetts Council on Compulsive Gambling;
Massachusetts Gaming Commission; DUNES of Easthampton; University of Nevada, Las
Vegas; DraftKings; Las Vegas Sands Corp.; DaviesWard Phillips Vineberg, LLP;
bwin.party Interactive Entertainment, AG; National Institutes of Health
(NIAAA)United States Department of Health & Human ServicesNational Institutes of
Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA);
National Institutes of Health (NIMH)United States Department of Health & Human
ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental
Health (NIMH) This study was funded by the Hong Kong Jockey Club Charities
Trust. During the preparation of this article, the Division on Addiction at the
Cambridge Health Alliance received funding support from a variety of sources,
including the following: bwin.party Interactive Entertainment, AG; The Foundation
for Advancing Alcohol Responsibility (FAAR); National Institutes of Health (i.e.,
NIDA, NIAAA, NIMH); Substance Abuse and Mental Health Services Administration
(SAMHSA); The National Center for Responsible Gambling (NCRG); Massachusetts
Council on Compulsive Gambling; The Massachusetts Gaming Commission; The University
of Nevada, Las Vegas; and DraftKings. Dr. Shaffer has received funding for
consultation from Las Vegas Sands Corp., DaviesWard Phillips & Vineberg, LLP, and
the DUNES of Easthampton. Albanese M. J., 2012, APA ADDICTION SYNDRO, VI, P3;
Albanese M. J, 2003, PSYCHIAT TIMES, V2003, P57; American Psychiatric Association,
2013, DIAGNOSTIC STAT MANU; [Anonymous], 2013, IBM SPSS STAT WIND V; Ashe ML, 2015,
J EXP ANAL BEHAV, V103, P234, DOI 10.1002/jeab.122; BAGBY RM, 1994, J PSYCHOSOM
RES, V38, P23, DOI 10.1016/0022-3999(94)90005-1; Beck A. T., 1996, MANUAL BECK
DEPRESSI, V1, p[82, 82]; Berg L, 2016, ADDICTION, V111, P1795, DOI
10.1111/add.13454; BLASZCZYNSKI AP, 1985, BRIT J ADDICT, V80, P315; Boudreau A,
2009, ADDICT RES THEORY, V17, P406, DOI 10.1080/16066350902802301; Byrne B., 2004,
INT J TESTING, V4, P199, DOI DOI 10.1207/S15327574IJT0403_1; Carver CS, 2010, ANNU
REV PSYCHOL, V61, P679, DOI 10.1146/annurev.psych.093008.100352; Carver CS, 1997,
INT J BEHAV MED, V4, P92, DOI 10.1207/s15327558ijbm0401_6; CARVER CS, 1989, J PERS
SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; Chau JPC, 1998, J
ADOLESCENT HEALTH, V22, P247, DOI 10.1016/S1054-139X(97)00206-1; Cheng GLF, 2015,
EUR NEUROPSYCHOPHARM, V25, P1968, DOI 10.1016/j.euroneuro.2015.07.023; Connor-Smith
JK, 2007, J PERS SOC PSYCHOL, V93, P1080, DOI 10.1037/0022-3514.93.6.1080; Corrigan
JD, 2013, AM J PSYCHIAT, V170, P351, DOI 10.1176/appi.ajp.2012.12121602; CRAIG RJ,
1979, INT J ADDICT, V14, P513, DOI 10.3109/10826087909054599; Dannon PN, 2004, EUR
PSYCHIAT, V19, P299, DOI 10.1016/j.eurpsy.2004.04.012; Deditius-Island HK, 2002,
EDUC PSYCHOL MEAS, V62, P728, DOI 10.1177/0013164402062004012; Druss B. G., 2011,
MENTAL DISORDERS MED; Ersche KD, 2010, BIOL PSYCHIAT, V68, P770, DOI
10.1016/j.biopsych.2010.06.015; Eysenck HJ, 1997, HUM PSYCHOPHARM CLIN, V12, pS79;
Felitti VJ, 1998, AM J PREV MED, V14, P245, DOI 10.1016/S0749-3797(98)00017-8;
Fergus TA, 2014, J PSYCHOPATHOL BEHAV, V36, P318, DOI 10.1007/s10862-013-9398-6;
GENDREAU P, 1971, CAN PSYCHIAT ASSOC J, V16, P265, DOI 10.1177/070674377101600313;
Goudriaan AE, 2006, ADDICTION, V101, P534, DOI 10.1111/j.1360-0443.2006.01380.x;
Grant BF, 2004, ARCH GEN PSYCHIAT, V61, P807, DOI 10.1001/archpsyc.61.8.807; Grant
JE, 2005, COMPR PSYCHIAT, V46, P34, DOI 10.1016/j.comppsych.2004.07.022; Gray JM,
2007, PERS INDIV DIFFER, V42, P641, DOI 10.1016/j.paid.2006.08.019; Hasin DS, 2007,
ARCH GEN PSYCHIAT, V64, P830, DOI 10.1001/archpsyc.64.7.830; Hughes K, 2017, LANCET
PUBLIC HEALTH, V2, pE356, DOI 10.1016/S2468-2667(17)30118-4; Ilie G, 2015, J
NEUROTRAUM, V32, P1130, DOI 10.1089/neu.2014.3619; Kessler RC, 2008, PSYCHOL MED,
V38, P1351, DOI 10.1017/S0033291708002900; Kessler RC, 1996, AM J ORTHOPSYCHIAT,
V66, P17, DOI 10.1037/h0080151; Khantzian E.J., 2008, UNDERSTANDING ADDICT;
Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550;
KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259; Korn David A., 1999, J Gambl Stud,
V15, P289, DOI 10.1023/A:1023005115932; Langenbucher J, 2001, PSYCHOL ADDICT BEHAV,
V15, P77, DOI 10.1037/0893-164X.15.1.77; LaPlante DA, 2002, RESPONSIBLE GAMING Q,
V1, P12; LaPlante DA, 2002, RESPONSIBLE GAMING Q, V1, P6; Lawrence AJ, 2009,
ADDICTION, V104, P1006, DOI 10.1111/j.1360-0443.2009.02533.x; Lazarus R. S., 1984,
STRESS APPRAISAL COP; LAZARUS RS, 1993, PSYCHOSOM MED, V55, P234, DOI
10.1097/00006842-199305000-00002; Lee HW, 2012, CYBERPSYCH BEH SOC N, V15, P373,
DOI 10.1089/cyber.2012.0063; Leedes R, 2001, SEX ADDICT COMPULSIV, V8, P215, DOI
DOI 10.1080/107201601753459928; Leeman RF, 2012, PSYCHOPHARMACOLOGY, V219, P469,
DOI 10.1007/s00213-011-2550-7; Linden D. J, 2012, COMPASS PLEASURE OUR; MacLaren
VV, 2011, CLIN PSYCHOL REV, V31, P1057, DOI 10.1016/j.cpr.2011.02.002; Mai YJ,
2012, COMPUT HUM BEHAV, V28, P2376, DOI 10.1016/j.chb.2012.07.009; Miller SC, 2013,
AM J PSYCHIAT, V170, P383, DOI 10.1176/appi.ajp.2012.12010126; Morie Kristen P,
2016, Curr Addict Rep, V3, P239; Morosini PL, 2000, ACTA PSYCHIAT SCAND, V101,
P323, DOI 10.1111/j.1600-0447.2000.tb10933.x; Moulding R, 2011, ASSESSMENT, V18,
P357, DOI 10.1177/1073191110376490; Nelson Sarah E, 2015, Arch Sci Psychol, V3, P8;
O'Driscoll MP, 2013, STRESS HEALTH, V29, P89, DOI 10.1002/smi.2489; Patton JH,
1995, J CLIN PSYCHOL, V51, P768, DOI 10.1002/1097-4679(199511)51:6<768::AID-
JCLP2270510607>3.0.CO;2-1; Petry NM, 2005, J CLIN PSYCHIAT, V66, P564, DOI
10.4088/JCP.v66n0504; Potenza MN, 2008, PHILOS T R SOC B, V363, P3181, DOI
10.1098/rstb.2008.0100; Raviv M., 1993, J GAMBL STUD, V9, P17, DOI DOI
10.1007/BF01019922; REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511; Reuter J,
2005, NAT NEUROSCI, V8, P147, DOI 10.1038/nn1378; Ridgeway D, 1980, J CONSULT CLIN
PSYCH, V48, P1; Robbins TW, 2015, CURR OPIN NEUROBIOL, V30, P66, DOI
10.1016/j.conb.2014.09.005;
Shaffer H. J., 2012, APA ADDICTION SYNDRO, V1; Shaffer H. J., 2003, GAMBLING WHO
WINS WH, P175; Shaffer H. J., 2016, ENCY MENTAL HLTH, V1, P135; Shaffer H. J.,
2012, APA ADDICTION SYNDRO, V2; Shaffer HJ, 2004, HARVARD REV PSYCHIAT, V12, P367,
DOI 10.1080/10673220490905705; Shaffer HJ, 1999, ADDICTION, V94, P1445, DOI
10.1046/j.1360-0443.1999.941014451.x; Shaffer HJ, 2000, ENCY PSYCHOL, P35; Shek
DTL, 2012, SCI WORLD J, DOI 10.1100/2012/458953; SHEK DTL, 1988, J PSYCHOPATHOL
BEHAV, V10, P303, DOI 10.1007/BF00960624; Sher KJ, 1997, J STUD ALCOHOL, V58, P414,
DOI 10.15288/jsa.1997.58.414; Spielberger C. D., 1983, MANUAL STATE TRAIT A; Taylor
S, 2006, J ANXIETY DISORD, V20, P85, DOI 10.1016/j.janxdis.2004.11.005; Thege BK,
2015, ADDICT BEHAV, V42, P24, DOI 10.1016/j.addbeh.2014.10.025; Thorberg FA, 2009,
ADDICT BEHAV, V34, P237, DOI 10.1016/j.addbeh.2008.10.016; Wang W, 2000, PERS INDIV
DIFFER, V28, P169, DOI 10.1016/S0191-8869(99)00092-6; Weiss NH, 2017, ADDICTION,
V112, P695, DOI 10.1111/add.13698; Yen JY, 2008, PSYCHIAT CLIN NEUROS, V62, P9, DOI
10.1111/j.1440-1819.2007.01770.x; Zhou ZH, 2014, FRONT BEHAV NEUROSCI, V8, DOI
10.3389/fnbeh.2014.00288; Zhu XZ, 2007, COMPR PSYCHIAT, V48, P489, DOI
10.1016/j.comppsych.2007.04.007; Zuckerman M, 2000, J PERS, V68, P999, DOI
10.1111/1467-6494.00124; ZUCKERMAN M, 1978, J CONSULT CLIN PSYCH, V46, P139, DOI
10.1037/0022-006X.46.1.139 87 0 0 3 6 SPRINGER NEW YORK
233 SPRING ST, NEW YORK, NY 10013 USA 1557-1874 1557-1882 INT J
MENT HEALTH AD Int. J. Mental Health Addict. DEC 2018 16 6
SI 1373 1393 10.1007/s11469-018-9952-2 21
Psychology, Clinical; Substance Abuse; Psychiatry Psychology; Substance
Abuse; Psychiatry HE3SL WOS:000453279900007 2019-09-25
J Mellentin, AI; Mejldal, A; Nielsen, B; Nielsen, AS
Mellentin, Angelina Isabella; Mejldal, Anna; Nielsen, Bent; Nielsen, Anette
Sogaard Comorbid social phobia does not predict the outcome in
alcohol use disorder outpatient treatment DRUG AND ALCOHOL DEPENDENCE
English Article Alcohol use disorders;
Social phobia; Treatment; Outpatient NATIONAL EPIDEMIOLOGIC SURVEY; ANXIETY
DISORDER; DEPENDENT PATIENTS; BEHAVIORAL-THERAPY; SELF-MEDICATION; SUBSTANCE-ABUSE;
UNITED-STATES; DEPRESSION; DETOXIFICATION; COOCCURRENCE Background: Social
phobia (SP) is one of the most prevalent anxiety disorders among patients entering
treatment for alcohol use disorders (AUD). However, few studies have examined the
association between SP and alcohol related treatment outcomes in naturalistic
settings. Aims: The aims of this study were to estimate the prevalence of co-morbid
SP and to investigate the impact of the co-morbidity on the treatment course,
dropout rates and treatment outcomes in a large sample of AUD patients treated in
an outpatient alcohol treatment clinic. Methods: The study was conducted as an
observational cohort study. A consecutive sample of 3.197 treatment seeking
outpatients, with an AUD diagnosis according to the ICD-10 Diagnostic Criteria for
Research, was assessed by means of the Addiction Severity Index at treatment start
and at treatment conclusion. Results: Approximately 15% of the patients suffered
from SP when entering treatment and patients with and without SP did not differ on
the treatment course, compliance or dropout rates. SP did not predict any alcohol
related treatment outcomes either, where no association was found on change scores
for abstinence, drinking days and days with excessive drinking relative to AUD
patients without co-morbidity. Conclusion: AUD patients with and without co-morbid
SP were equally likely to achieve benefits when treated similarly with evidence-
based pharmacological and psychosocial approaches in a naturalistic setting.
[Mellentin, Angelina Isabella; Mejldal, Anna; Nielsen, Bent; Nielsen, Anette
Sogaard] Univ Southern Denmark, Dept Clin Res, Unit Psychiat Res, Unit Clin Alcohol
Res, Aabenraa, Denmark; [Mellentin, Angelina Isabella] Univ Southern Denmark, Inst
Reg Hlth Serv Res, Unit Psychiat Res, Aabenraa, Denmark Mellentin, AI (reprint
author), JB Winslowsvej Univ Hosp, Dept Psychiat, Psychiat Res Unit, 18,220 B, DK-
5000 Odense C, Denmark. amellentin@health.sdu.dk Mejldal, Anna/0000-0002-
4612-4338; Mellentin, Angelina Isabella/0000-0002-6515-2852 Baillie AJ,
2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-199; Bakken K, 2005, DRUG
ALCOHOL DEPEN, V80, P321, DOI 10.1016/j.drugalcdep.2005.04.011; Barkowski S, 2016,
J ANXIETY DISORD, V39, P44, DOI 10.1016/j.janxdis.2016.02.005; Brady Kathleen T.,
1993, Psychiatric Quarterly (New York), V64, P135, DOI 10.1007/BF01065866; Burns L,
2005, ADDICTION, V100, P787, DOI 10.1111/j.1360-0443.2005.001069.x; Butler AC,
2006, CLIN PSYCHOL REV, V26, P17, DOI 10.1016/j.cpr.2005.07.003; Carrigan MH, 2003,
ADDICT BEHAV, V28, P269, DOI 10.1016/S0306-4603(01)00235-0; CHUTUAPE MAD, 1995,
PSYCHOPHARMACOLOGY, V121, P91, DOI 10.1007/BF02245595; Clark DM, 2006, J CONSULT
CLIN PSYCH, V74, P568, DOI 10.1037/0022-006X.74.3.568; Danish Health Authority,
2015, NAT KLIN RETN BEH AL; Driessen M, 2001, ALCOHOL ALCOHOLISM, V36, P249, DOI
10.1093/alcalc/36.3.249; Fuller RK, 1999, ALCOHOL RES HEALTH, V23, P69; Grant BF,
2005, J CLIN PSYCHIAT, V66, P1351, DOI 10.4088/JCP.v66n1102; Grant BF, 2004, ARCH
GEN PSYCHIAT, V61, P807, DOI 10.1001/archpsyc.61.8.807; Kessler RC, 1997, ARCH GEN
PSYCHIAT, V54, P313; Kushner MG, 2005, ALCOHOL CLIN EXP RES, V29, P1432, DOI
10.1097/01.alc.0000175072.17623.f8; KUSHNER MG, 1990, AM J PSYCHIAT, V147, P685;
Kushner MG, 2000, CLIN PSYCHOL REV, V20, P149, DOI 10.1016/S0272-7358(99)00027-6;
LABOUNTY LP, 1992, ADDICT BEHAV, V17, P9, DOI 10.1016/0306-4603(92)90048-Z; Mann K,
2004, EUR ARCH PSY CLIN N, V254, P172, DOI 10.1007/s00406-004-0465-6; Marquenie LA,
2006, ALCOHOL ALCOHOLISM, V41, P168, DOI 10.1093/alcalc/agh252; McGahan P. L.,
1986, ADDICITON SEVERITY I; MCLELLAN AT, 1980, J NERV MENT DIS, V168, P26, DOI
10.1097/00005053-198001000-00006; MCLELLAN AT, 1992, J SUBST ABUSE TREAT, V9, P199,
DOI 10.1016/0740-5472(92)90062-S; Mellentin AI, 2015, NORD J PSYCHIAT, V69, P331,
DOI 10.3109/08039488.2014.981857; Miller WR, 1999, ALCOHOL RES HEALTH, V23, P116;
Modesto-Lowe V, 1999, ALCOHOL RES HEALTH, V23, P144; Moreno-Peral P, 2014, J AFFECT
DISORDERS, V168, P337, DOI 10.1016/j.jad.2014.06.021; Morris EP, 2005, CLIN PSYCHOL
REV, V25, P734, DOI 10.1016/j.cpr.2005.05.004; National Institute for Health and
Care Excellence, 2011, ALC US DIS ASS MAN H; Randall CL, 2001, ALCOHOL CLIN EXP
RES, V25, P210, DOI 10.1097/00000374-200102000-00009; Rapee RM, 2009, J CONSULT
CLIN PSYCH, V77, P317, DOI 10.1037/a0014800; Rubin DB, 1987, MULTIPLE IMPUTATION;
Schade A, 2005, ALCOHOL CLIN EXP RES, V29, P794, DOI
10.1097/01.ALC.0000163511.24583.33; Schellekens AFA, 2015, EUR PSYCHIAT, V30, DOI
10.1016/j.eurpsy.2013.08.006; SCHUCKIT MA, 1988, BRIT J ADDICT, V83, P1373; Stein
MB, 2008, LANCET, V371, P1115, DOI 10.1016/S0140-6736(08)60488-2; Swendsen JD,
1998, COMPR PSYCHIAT, V39, P176, DOI 10.1016/S0010-440X(98)90058-X; Terra MB, 2006,
COMPR PSYCHIAT, V47, P463, DOI 10.1016/j.comppsych.2006.02.004; Terra MB, 2006, J
SUBST ABUSE TREAT, V31, P403, DOI 10.1016/j.jsat.2006.05.013; Tomasson K, 1997, EUR
ARCH PSY CLIN N, V247, P320, DOI 10.1007/BF02922262; Witkiewitz K, 2011, ALCOHOL
RES HEALTH, V33, P313; World Health Organization, 1993, ICD 10 CLASS MENT BE; World
Health Organization, 1992, ICD 10 CLASS MENT BE 44 0 0 2 3
ELSEVIER IRELAND LTD CLARE ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK
SHANNON, CO, CLARE, 00000, IRELAND 0376-8716 1879-0046 DRUG ALCOHOL DEPEN
Drug Alcohol Depend. DEC 1 2018 193 148
153 10.1016/j.drugalcdep.2018.09.004 6 Substance
Abuse; Psychiatry Substance Abuse; Psychiatry HD5NW WOS:000452578200022
30384322 2019-09-25
J Gomez-Coronado, N; Sethi, R; Bortolasci, CC; Arancini, L; Berk, M; Dodd, S
Gomez-Coronado, Nieves; Sethi, Rickinder; Bortolasci, Chiara
Cristina; Arancini, Lauren; Berk, Michael; Dodd, Seetal A review of
the neurobiological underpinning of comorbid substance use and mood disorders
JOURNAL OF AFFECTIVE DISORDERS English Review
Neurobiology; Dual diagnosis; Glutamate; Dopamine;
Oxidative stress; Inflammation MAJOR DEPRESSIVE DISORDER; ALCOHOL-USE
DISORDERS; GRAM-NEGATIVE ENTEROBACTERIA; PARAOXONASE (PON)1 ACTIVITY; SELF-
MEDICATION HYPOTHESIS; INCREASED OXIDATIVE STRESS; GAMMA-AMINOBUTYRIC-ACID; C-
REACTIVE PROTEIN; BIPOLAR DISORDER; INFLAMMATORY MARKERS Background: There is
evidence that substance use disorders and other mental disorders may have shared
biological mechanisms. However, the neurobiological basis of this comorbidity
remains only partially explained. This review describes the historical evolution of
the dual disorders concept and approach, and reviews the existing literature on
neurobiological findings specifically regarding comorbid substance use and mood
disorders. Methods: Searches were conducted using PubMed and Scopus in December
2017. A Boolean search was performed using combinations of "dual diagnosis" or
"dual disorder" or "depression" or "bipolar" or "affective disorder" or "mood
disorder" and "substance use" or "substance abuse" and "neurobiology" or
"functional neuroimaging" or "genetics" or "neurotransmitters" or
"neuroendocrinology" in the title or abstract, or as keywords, using no language
restriction, Results: 32 studies met the inclusion criteria. We found robust
evidence for involvement of the neurotransmitters dopamine, GABA and glutamate and
their receptors, as well as by the central corticotrophin-releasing hormone,
hypothalamic pituitary adrenal axis activation, oxidative stress and inflammation.
Recent studies focusing on neuroimaging and genetics have not shown consistent
results. Limitations: Only two search tools were used; most identified studies
excluded the population of interest (comorbid mood and substance abuse disorders).
Conclusions: The neurobiological relevance for the occurrence of comorbid mood and
substance abuse disorders has not been fully elucidated. Considering the high
levels of individuals who experience comorbidity in these areas as well as the
negative associated outcomes, this is clearly an area that requires further in-
depth investigation. Furthermore, findings from this area can help to inform drug
abuse prevention and intervention efforts, and especially how they relate to
populations with psychiatric symptoms. [Gomez-Coronado, Nieves] Hosp Univ Virgen
del Rocio, Unidad Gest Clin Salud Mental, Seville, Spain; [Sethi, Rickinder]
Western Univ, London Hlth Sci Ctr, London, ON, Canada; [Bortolasci, Chiara
Cristina] Deakin Univ, Sch Med, Ctr Mol & Med Res, Geelong, Vic, Australia;
[Arancini, Lauren; Berk, Michael; Dodd, Seetal] Deakin Univ, IMPACT Strateg Res
Ctr, Geelong, Vic, Australia; [Berk, Michael; Dodd, Seetal] Univ Hosp Geelong,
Barwon Hlth, Geelong, Vic, Australia; [Berk, Michael; Dodd, Seetal] Univ Melbourne,
Dept Psychiat, Parkville, Vic, Australia; [Berk, Michael; Dodd, Seetal] Natl Ctr
Excellence Youth Mental Hlth, Orygen, Parkville, Vic, Australia; [Berk, Michael]
Florey Inst Neurosci & Mental Hlth, Parkville, Vic, Australia; [Gomez-Coronado,
Nieves] Hosp San Agustin ORL, Dept Psychiat, Seville, SpainDodd, S (reprint
author), Deakin Univ, Sch Med, IMPACT Strateg Res Ctr, POB 281, Geelong, Vic 3220,
Australia. seetald@banvonhealth.org.au Berk, Michael/M-7891-2013; Berk,
Michael/M-3585-2019 Berk, Michael/0000-0002-5554-6946; Berk, Michael/0000-0002-
5554-6946; Gomez-Coronado, Nieves/0000-0001-5277-9595; Dodd, Seetal/0000-0002-7918-
4636 National Health and Medical Research Council (NHMRC) Senior Principal
Research FellowshipNational Health and Medical Research Council of Australia
[1059660] MB is supported by a National Health and Medical Research Council
(NHMRC) Senior Principal Research Fellowship (grant number 1059660). Achur RN,
2010, J NEUROIMMUNE PHARM, V5, P83, DOI 10.1007/s11481-009-9185-z; Belujon P, 2017,
INT J NEUROPSYCHOPH, V20, P1036, DOI 10.1093/ijnp/pyx056; Berk M, 2017, WORLD
PSYCHIATRY, V16, P236, DOI 10.1002/wps.20441; Berman RM, 2000, BIOL PSYCHIAT, V47,
P351, DOI 10.1016/S0006-3223(99)00230-9; Berton F, 1998, ALCOHOL CLIN EXP RES, V22,
P183, DOI 10.1111/j.1530-0277.1998.tb03636.x; Bhagwagar Z, 2004, AM J PSYCHIAT,
V161, P368, DOI 10.1176/appi.ajp.161.2.368; Bhagwagar Z, 2008, INT J NEUROPSYCHOPH,
V11, P255, DOI 10.1017/S1461145707007924; Block W, 2009, INT J NEUROPSYCHOPH, V12,
P415, DOI 10.1017/S1461145708009516; Blokhina EA, 2005, EUR NEUROPSYCHOPHARM, V15,
P219, DOI 10.1016/j.euroneuro.2004.07.005; Bobadilla L, 2013, ADDICT BEHAV, V38,
P2555, DOI 10.1016/j.addbeh.2013.05.014; Bortolasci CC, 2014, J AFFECT DISORDERS,
V159, P23, DOI 10.1016/j.jad.2014.02.018; Brody AL, 2009, BIOL PSYCHIAT, V66, P898,
DOI 10.1016/j.biopsych.2009.06.011; Busto UE, 2009, SYNAPSE, V63, P681, DOI
10.1002/syn.20646; Camardese G, 2014, J PSYCHIATR RES, V51, P7, DOI
10.1016/j.jpsychires.2013.12.006; Chang CC, 2015, PLOS ONE, V10, DOI
10.1371/journal.pone.0125855; Chung CP, 2013, PSYCHIAT RES, V206, P213, DOI
10.1016/j.psychres.2012.10.018; Comings DE, 1996, PHARMACOGENETICS, V6, P223, DOI
10.1097/00008571-199606000-00004; Contoreggi C, 2003, BIOL PSYCHIAT, V54, P873, DOI
10.1016/S0006-3223(03)00167-7; Cosgrove KP, 2010, CURR TOP BEHAV NEURO, V3, P199,
DOI 10.1007/7854_2009_24; Costello EJ, 2013, DRUG ALCOHOL DEPEN, V133, P712, DOI
10.1016/j.drugalcdep.2013.08.027; Covault J, 2004, AM J MED GENET B, V129B, P104,
DOI 10.1002/ajmg.b.30091; Cunha AB, 2008, EUR ARCH PSY CLIN N, V258, P300, DOI
10.1007/s00406-007-0797-0; De Biasi M, 2011, ANNU REV NEUROSCI, V34, P105, DOI
10.1146/annurev-neuro-061010-113734; DICHIARA G, 1985, EUR J PHARMACOL, V115, P131,
DOI 10.1016/0014-2999(85)90598-9; Dunlop BW, 2007, ARCH GEN PSYCHIAT, V64, P327,
DOI 10.1001/archpsyc.64.3.327; Edenberg HJ, 2004, AM J HUM GENET, V74, P705, DOI
10.1086/383283; Edwards S, 2010, FUTUR NEUROL, V5, P393, DOI 10.2217/FNL.10.14;
Esterlis I, 2009, SYNAPSE, V63, P1089, DOI 10.1002/syn.20688; Frey BN, 2007, PROG
NEURO-PSYCHOPH, V31, P283, DOI 10.1016/j.pnpbp.2006.06.011; Friedman SD, 2004, BIOL
PSYCHIAT, V56, P340, DOI 10.1016/j.biopsych.2004.06.012; Gardner EL, 2000, AM J
ADDICTION, V9, P285, DOI 10.1080/105504900750047355; GERNER RH, 1984, AM J
PSYCHIAT, V141, P1533; GERNER RH, 1981, AM J PSYCHIAT, V138, P1098; Glaus J, 2014,
J PSYCHIATR RES, V58, P36, DOI 10.1016/j.jpsychires.2014.07.012; GOLD BI, 1980, AM
J PSYCHIAT, V137, P362; Goldstein BI, 2015, J CLIN PSYCHIAT, V76, P1556, DOI
10.4088/JCP.14m09395; Gorwood P, 2000, EUR PSYCHIAT, V15, P103, DOI 10.1016/S0924-
9338(00)00205-4; Grotenhermen Franjo, 2005, Current Drug Targets - CNS and
Neurological Disorders, V4, P507, DOI 10.2174/156800705774322111; Hagele C, 2015,
PSYCHOPHARMACOLOGY, V232, P331, DOI 10.1007/s00213-014-3662-7; Han C, 2016, CLIN
PSYCHOPHARM NEU, V14, P43, DOI 10.9758/cpn.2016.14.1.43; Hashimoto K, 2013, EUR
ARCH PSY CLIN N, V263, P367, DOI 10.1007/s00406-013-0399-y; Hassel R., 2006, BASIC
NEUROCHEMISTRY; Hermens DF, 2015, J AFFECT DISORDERS, V186, P95, DOI
10.1016/j.jad.2015.07.009; Huang SY, 2004, ALCOHOL CLIN EXP RES, V28, P374, DOI
10.1097/01.ALC.0000117832.62901.61; Joffe ME, 2014, WIRES COGN SCI, V5, P151, DOI
10.1002/wcs.1273; Kapczinski F, 2008, NEUROSCI BIOBEHAV R, V32, P675, DOI
10.1016/j.neubiorev.2007.10.005; KASA K, 1982, BIOL PSYCHIAT, V17, P877; Kendler
KS, 2003, ARCH GEN PSYCHIAT, V60, P929, DOI 10.1001/archpsyc.60.9.929; Kertes DA,
2011, ALCOHOL CLIN EXP RES, V35, P496, DOI 10.1111/j.1530-0277.2010.01366.x;
KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259; Koob G F, 1992, Recent Dev Alcohol,
V10, P201; Koob GF, 2004, NEUROSCI BIOBEHAV R, V27, P739, DOI
10.1016/j.neubiorev.2003.11.007; Koob GF, 1997, SCIENCE, V278, P52, DOI
10.1126/science.278.5335.52; Korhonen T, 2014, PLOS ONE, V9, DOI
10.1371/journal.pone.0098199; Kotyuk Eszter, 2009, Neuropsychopharmacol Hung, V11,
P59; Kucukibrahimoglu E, 2009, EUR J CLIN PHARMACOL, V65, P571, DOI 10.1007/s00228-
009-0650-7; Kuloglu M, 2002, CELL BIOCHEM FUNCT, V20, P171, DOI 10.1002/cbf.940;
Kushnir V, 2013, INT J NEUROPSYCHOPH, V16, P997, DOI 10.1017/S1461145710000696;
Levinson AJ, 2010, BIOL PSYCHIAT, V67, P458, DOI 10.1016/j.biopsych.2009.09.025; Li
C, 2016, EUR NEUROPSYCHOPHARM, V26, P45, DOI 10.1016/j.euroneuro.2015.11.009; Lin
SC, 2007, PROG NEURO-PSYCHOPH, V31, P1526, DOI 10.1016/j.pnpbp.2007.07.012; Lodge
D, 2015, BRIT J PHARMACOL, V172, P4254, DOI 10.1111/bph.13222; Lopez LS, 2005, BIOL
PSYCHIAT, V57, P999, DOI 10.1016/j.biopsych.2005.01.030; Maes M, 2008,
NEUROENDOCRINOL LETT, V29, P117; Maes M, 2007, J AFFECT DISORDERS, V99, P237, DOI
10.1016/j.jad.2006.08.021; Maes M, 2011, PROG NEURO-PSYCHOPH, V35, P676, DOI
10.1016/j.pnpbp.2010.05.004; Maes M, 2009, METAB BRAIN DIS, V24, P27, DOI
10.1007/s11011-008-9118-1; Magalhaes P. V., 2012, INT J; Markou A, 1998,
NEUROPSYCHOPHARMACOL, V18, P135, DOI 10.1016/S0893-133X(97)00113-9; Marques-Vidal
P, 2012, ATHEROSCLEROSIS, V222, P245, DOI 10.1016/j.atherosclerosis.2012.02.011;
McEwen BS, 2000, BRAIN RES, V886, P172, DOI 10.1016/S0006-8993(00)02950-4; Mitchell
ND, 2010, ACTA PSYCHIAT SCAND, V122, P192, DOI 10.1111/j.1600-0447.2009.01529.x;
Modabbernia A, 2013, BIOL PSYCHIAT, V74, P15, DOI 10.1016/j.biopsych.2013.01.007;
Moeller SJ, 2018, PROG NEURO-PSYCHOPH, V80, P143, DOI 10.1016/j.pnpbp.2017.03.003;
Morgan D, 2002, NAT NEUROSCI, V5, P169, DOI 10.1038/nn798; Muhonen LH, 2008, J CLIN
PSYCHIAT, V69, P392, DOI 10.4088/JCP.v69n0308; Nabati S, 2013, IMMUNOL LETT, V152,
P42, DOI 10.1016/j.imlet.2013.04.003; Nakagawa T, 2001, EUR J PHARMACOL, V419, P39,
DOI 10.1016/S0014-2999(01)00965-7; Nathan PE, 2016, ANNU REV CLIN PSYCHO,
V12, P29, DOI 10.1146/annurev-clinpsy-021815-093546; Nedic G, 2013, PROG NEURO-
PSYCHOPH, V40, P193, DOI 10.1016/j.pnpbp.2012.09.005; Nemeroff CB, 1996, MOL
PSYCHIATR, V1, P336; Nery FG, 2010, J PSYCHIATR RES, V44, P278, DOI
10.1016/j.jpsychires.2009.09.006; Nestler EJ, 2005, NAT NEUROSCI, V8, P1445, DOI
10.1038/nn1578; Neupane SP, 2014, CNS NEUROSCI THER, V20, P898, DOI
10.1111/cns.12303; Neupane SP, 2015, ALCOHOL, V49, P471, DOI
10.1016/j.alcohol.2015.01.012; Neupane SP, 2015, ALCOHOL CLIN EXP RES, V39, P514,
DOI 10.1111/acer.12651; Noble E P, 2000, Pharmacogenomics, V1, P309, DOI
10.1517/14622416.1.3.309; Novak G, 2010, GENES BRAIN BEHAV, V9, P910, DOI
10.1111/j.1601-183X.2010.00631.x; O'Brien CP, 2005, PHARMACOL THERAPEUT, V108, P18,
DOI 10.1016/j.pharmthera.2005.06.018; O'Brien CP, 1998, J PSYCHOPHARMACOL, V12,
P15, DOI 10.1177/026988119801200103; OLDS J, 1954, J COMP PHYSIOL PSYCH, V47, P419,
DOI 10.1037/h0058775; Parsey RV, 2001, BIOL PSYCHIAT, V50, P313, DOI 10.1016/S0006-
3223(01)01089-7; Pasquali MA, 2018, EUR ARCH PSY CLIN N, V268, P771, DOI
10.1007/s00406-017-0812-z; PETTY F, 1981, J AFFECT DISORDERS, V3, P339, DOI
10.1016/0165-0327(81)90003-3; PETTY F, 1982, RES COMMUN PSYCH PSY, V7, P431; PETTY
F, 1984, J AFFECT DISORDERS, V6, P131, DOI 10.1016/0165-0327(84)90018-1; de Castro
MRP, 2015, J AFFECT DISORDERS, V172, P347, DOI 10.1016/j.jad.2014.10.023; Porjesz
B, 2002, P NATL ACAD SCI USA, V99, P3729, DOI 10.1073/pnas.052716399; Post RM,
2013, BRIT J PSYCHIAT, V202, P172, DOI 10.1192/bjp.bp.112.116855; Prisciandaro JJ,
2017, TRANSL PSYCHIAT, V7, DOI 10.1038/tp.2017.141; Reichenberg A, 2001, ARCH GEN
PSYCHIAT, V58, P445, DOI 10.1001/archpsyc.58.5.445; Robinson TE, 2000, ADDICTION,
V95, pS91; Robinson TE, 2003, ANNU REV PSYCHOL, V54, P25, DOI
10.1146/annurev.psych.54.101601.145237; ROBINSON TE, 1993, BRAIN RES REV, V18,
P247, DOI 10.1016/0165-0173(93)90013-P; ROSSETTI ZL, 1992, ANN NY ACAD SCI, V654,
P513, DOI 10.1111/j.1749-6632.1992.tb26016.x; ROY A, 1991, ARCH GEN PSYCHIAT, V48,
P428; ROY A, 1991, PSYCHOL MED, V21, P613, DOI 10.1017/S0033291700022248; Rybka J,
2013, FREE RADICAL BIO MED, V63, P187, DOI 10.1016/j.freeradbiomed.2013.05.019;
Salim S, 2014, CURR NEUROPHARMACOL, V12, P140, DOI
10.2174/1570159X11666131120230309; Sanacora G, 2004, ARCH GEN PSYCHIAT, V61, P705,
DOI 10.1001/archpsyc.61.7.705; Sanacora G, 2003, AM J PSYCHIAT, V160, P577, DOI
10.1176/appi.ajp.160.3.577; Sarandol A, 2007, HUM PSYCHOPHARM CLIN, V22, P67, DOI
10.1002/hup.829; Schafer M, 2004, BRAIN RES, V1005, P84, DOI
10.1016/j.brainres.2004.01.037; Sinha R, 2001, PSYCHOPHARMACOLOGY, V158, P343, DOI
10.1007/s002130100917; Slusher BS, 2001, SYNAPSE, V41, P22, DOI 10.1002/syn.1056;
Song JZ, 2003, AM J MED GENET B, V117B, P39, DOI 10.1002/ajmg.b.10022; Stapleton
JA, 2011, PHARMACOGENET GENOM, V21, P447, DOI 10.1097/FPC.0b013e328347473a;
Stefanescu C, 2012, J AFFECT DISORDERS, V143, P34, DOI 10.1016/j.jad.2012.05.022;
STOLERMAN I, 1992, TRENDS PHARMACOL SCI, V13, P170, DOI 10.1016/0165-6147(92)90059-
F; Stoy M, 2012, J PSYCHOPHARMACOL, V26, P677, DOI 10.1177/0269881111416686; Su N,
2011, BRAIN RES, V1415, P119, DOI 10.1016/j.brainres.2011.08.005; Sulzer D, 2011,
NEURON, V69, P628, DOI 10.1016/j.neuron.2011.02.010; Szczepankiewicz A, 2007,
ALCOHOL ALCOHOLISM, V42, P70, DOI 10.1093/alcalc/agl106; Szuster-Ciesielska A,
2008, PROG NEURO-PSYCHOPH, V32, P686, DOI 10.1016/j.pnpbp.2007.11.012; Tidey JW,
1997, PSYCHOPHARMACOLOGY, V130, P203, DOI 10.1007/s002130050230; Tidey JW, 1996,
BRAIN RES, V721, P140, DOI 10.1016/0006-8993(96)00159-X; Tsai MC, 2016, PSYCHIAT
RES, V235, P38, DOI 10.1016/j.psychres.2015.12.005; Umene-Nakano W, 2009, HUM
PSYCHOPHARM CLIN, V24, P409, DOI 10.1002/hup.1035; Uys JD, 2014, BIOMED
PHARMACOTHER, V68, P799, DOI 10.1016/j.biopha.2014.06.001; Vargas HO, 2013,
NEUROSCI LETT, V544, P136, DOI 10.1016/j.neulet.2013.03.059; Nunes SOV, 2015,
NEUROSCI LETT, V585, P132, DOI 10.1016/j.neulet.2014.11.002; Nunes SOV, 2014,
PSYCHIAT GENET, V24, P87, DOI 10.1097/YPG.0000000000000023; Nunes SOV, 2012,
NICOTINE TOB RES, V14, P540, DOI 10.1093/ntr/ntr247; VOLKOW ND, 1993, SYNAPSE, V14,
P169, DOI 10.1002/syn.890140210; Volkow ND, 2015, CELL, V162, P712, DOI
10.1016/j.cell.2015.07.046; Volkow ND, 2015, ACS CHEM NEUROSCI, V6, P522, DOI
10.1021/acschemneuro.5b00067; Wegerer M, 2013, PSYCHOL MED, V43, P1207, DOI
10.1017/S0033291711002923; Xu W, 2014, BMC MED GENET, V15, DOI 10.1186/1471-2350-
15-2; Yap JJ, 2015, PSYCHOPHARMACOLOGY, V232, P1555, DOI 10.1007/s00213-014-3796-7;
Yasseen B, 2010, PSYCHIAT RES, V176, P30, DOI 10.1016/j.psychres.2008.12.009;
Yildiz-Yesiloglu A, 2006, PSYCHIAT RES-NEUROIM, V147, P1, DOI
10.1016/j.pscychresns.2005.12.004; Zarate CA, 2004, AM J PSYCHIAT, V161, P171, DOI
10.1176/appi.ajp.161.1.171 142 5 5 9 50 ELSEVIER SCIENCE BV
AMSTERDAM PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS 0165-0327 1573-
2517 J AFFECT DISORDERS J. Affect. Disord. DEC 1 2018 241
388 401 10.1016/j.jad.2018.08.041
14 Clinical Neurology; Psychiatry Neurosciences & Neurology;
Psychiatry GS6OK WOS:000443816800052 30145509 2019-09-25
J Hudson, A; Thompson, K; MacNevin, PD; Ivany, M; Teehan, M; Stuart, H;
Stewart, SH Hudson, Amanda; Thompson, Kara; MacNevin, Parnell D.;
Ivany, Meredith; Teehan, Michael; Stuart, Heather; Stewart, Sherry H.
University Students' Perceptions of Links Between Substance Use and Mental
Health A Qualitative Focus Group Study EMERGING ADULTHOOD
English Article lay perceptions;
substance use; mental health; campus initiatives; comorbidity ALCOHOL-USE
DISORDERS; NATIONAL EPIDEMIOLOGIC SURVEY; SELF-MEDICATION HYPOTHESIS; HIGH-RISK
DRINKING; COLLEGE-STUDENTS; PUBLIC CONCEPTIONS; CANNABIS USE; ANXIETY DISORDERS;
EARLY ADOLESCENCE; YOUNG ADULTHOOD There is a consensus among addictions
researchers and clinicians that mental health concerns and substance use problems
are often interrelated. It is less clear to what extent the general public, and
university students in particular, understand connections between substance use and
mental health. The current study aimed to understand university students' perceived
links between substance use and mental health by conducting three semistructured
focus groups (N = 24 participants, 67% female). Thematic analysis of the data
yielded five themes: (1) Students use substances to cope with mental health issues,
(2) substance use can lead to mental health problems, (3) links between mental
health and substance use are cyclical, (4) substance use is an aspect/indicator of
mental health, and (5) substance use and mental health are not always linked.
Findings provide insight into the understudied area of perceived links between
substance use and mental health and have implications for campus programming.
[Hudson, Amanda; MacNevin, Parnell D.; Ivany, Meredith; Stewart, Sherry H.]
Dalhousie Univ, Dept Psychol & Neurosci, Halifax, NS B3H 4R2, Canada; [Thompson,
Kara] St Francis Xavier Univ, Dept Psychol, Antigonish, NS, Canada; [Teehan,
Michael; Stewart, Sherry H.] Dalhousie Univ, Dept Psychiat, Halifax, NS, Canada;
[Stuart, Heather] Queens Univ, Dept Publ Hlth Sci, Kingston, ON, Canada
Hudson, A (reprint author), Dalhousie Univ, Dept Psychol & Neurosci, Halifax,
NS B3H 4R2, Canada. a.hudson@dal.ca Movember Canada [35361] The
authors disclosed receipt of the following financial support for the research,
authorship, and/or publication of this article: The Caring Campus Project was
funded by Movember Canada (Grant # 35361), H. Stuart, S.-P. Chen, T. Krupa, K.
Dobson, S. Stewart, and M. Teehan. Alberts A, 2007, J YOUTH ADOLESCENCE, V36, P71,
DOI 10.1007/s10964-006-9144-4; American Psychiatric Association, 2013, DIAGN STAT
MAN MENT; [Anonymous], 2010, MHGAP INT GUID MENT; BOWERS MB, 1983, PSYCHIAT RES,
V9, P91, DOI 10.1016/0165-1781(83)90030-6; Braun V., 2006, QUALITATIVE RES PSYC,
V3, P77, DOI DOI 10.1191/1478088706QP0630A; Burns L, 2002, DRUG ALCOHOL DEPEN, V68,
P299, DOI 10.1016/S0376-8716(02)00220-X; Carpenter KM, 1999, J STUD ALCOHOL, V60,
P694, DOI 10.15288/jsa.1999.60.694; Chen P, 2012, J ADOLESCENT HEALTH, V50, P154,
DOI 10.1016/j.jadohealth.2011.05.013; Cuffel B J, 1996, New Dir Ment Health Serv,
P93; Curran C, 2004, BRIT J PSYCHIAT, V185, P196, DOI 10.1192/bjp.185.3.196; Davies
J, 2000, J AM COLL HEALTH, V48, P259, DOI 10.1080/07448480009596267; Dawson DA,
2005, DRUG ALCOHOL DEPEN, V77, P139, DOI 10.1016/j.drugalcdep.2004.07.012; de Beurs
E, 2011, CLIN PSYCHOL PSYCHOT, V18, P1, DOI 10.1002/cpp.696; Degenhardt L, 2003,
ADDICTION, V98, P1493, DOI 10.1046/j.1360-0443.2003.00437.x; DeJong W, 2002, J STUD
ALCOHOL, P182, DOI 10.15288/jsas.2002.s14.182; Eisenberg D, 2007, MED CARE, V45,
P594, DOI 10.1097/MLR.0b013e31803bb4c1; Geyer MA, 2008, TRENDS PHARMACOL SCI, V29,
P445, DOI 10.1016/j.tips.2008.06.006; Glassman TJ, 2010, SOC MARK Q, V16, P94, DOI
10.1080/15245001003746741; Gonzalez-Maeso J, 2008, NATURE, V452, P93, DOI
10.1038/nature06612; Grant BF, 2004, ARCH GEN PSYCHIAT, V61, P807, DOI
10.1001/archpsyc.61.8.807; Grant VV, 2007, ADDICT BEHAV, V32, P2611, DOI
10.1016/j.addbeh.2007.07.004; Hall W, 1998, DRUG ALCOHOL REV, V17, P433, DOI
10.1080/09595239800187271; Hasin DS, 2002, ARCH GEN PSYCHIAT, V59, P794, DOI
10.1001/archpsyc.59.9.794; Hasin DS, 2005, ARCH GEN PSYCHIAT, V62, P1097, DOI
10.1001/archpsyc.62.10.1097; Howard DE, 2007, J AM COLL HEALTH, V56, P247, DOI
10.3200/JACH.56.3.247-254; Hunt J, 2010, J ADOLESCENT HEALTH, V46, P3, DOI
10.1016/j.jadohealth.2009.08.008; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593,
DOI 10.1001/archpsyc.62.6.593; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231,
DOI 10.3109/10673229709030550; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259;
Krueger R. A., 2009, FOCUS GROUPS PRACTIC; Kuppin S, 2008, AM J PUBLIC HEALTH, V98,
pS120, DOI 10.2105/AJPH.2004.060855; KUSHNER MG, 1990, AM J PSYCHIAT, V147, P685;
Kwan MYW, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-548; Larimer ME,
2002, J STUD ALCOHOL, P148, DOI 10.15288/jsas.2002.s14.148; Lasser K, 2000, JAMA-J
AM MED ASSOC, V284, P2606, DOI 10.1001/jama.284.20.2606; Levy KB, 2005, SUBST USE
MISUSE, V40, P1427, DOI 10.1081/JA-200066810; Link BG, 1999, AM J PUBLIC HEALTH,
V89, P1328, DOI 10.2105/AJPH.89.9.1328; LINSZEN DH, 1994, ARCH GEN PSYCHIAT, V51,
P273; Mann M, 2004, HEALTH EDUC RES, V19, P357, DOI 10.1093/her/cyg041; Martin JK,
2000, J HEALTH SOC BEHAV, V41, P208, DOI 10.2307/2676306; Menezes PR, 1996, BRIT J
PSYCHIAT, V168, P612, DOI 10.1192/bjp.168.5.612; Moreira MT, 2009, COCHRANE DB SYST
REV, DOI 10.1002/14651858.CD006748.pub2; Morgan D., 1988, QUALITATIVE RES METH,
V16; Nutbeam D, 2000, HEALTH PROMOT INT, V15, P259, DOI 10.1093/heapro/15.3.259;
O'Malley PM, 2002, J STUD ALCOHOL, P23, DOI 10.15288/jsas.2002.s14.23; Patel V,
2007, LANCET, V369, P1302, DOI 10.1016/S0140-6736(07)60368-7; Patton GC, 2002, BRIT
MED J, V325, P1195, DOI 10.1136/bmj.325.7374.1195; Phelan JC, 2000, J HEALTH SOC
BEHAV, V41, P188, DOI 10.2307/2676305; Pratt Laura A, 2008, NCHS Data Brief, P1;
Rhodes T., 2000, UNDERSTANDING RESPON, P21; ROSS HE, 1995, DRUG ALCOHOL DEPEN, V39,
P111, DOI 10.1016/0376-8716(95)01150-W; Schulenberg JE, 2002, J STUD ALCOHOL, P54,
DOI 10.15288/jsas.2002.s14.54; Simons J, 1998, J COUNS PSYCHOL, V45, P265, DOI
10.1037/0022-0167.45.3.265; Stewart S. H., 2016, OXFORD HDB SUBSTANCE, V2, DOI DOI
10.1093/OXFORDHB/9780199381708.001.0001; Stewart S. H., 2006, J MENTAL HLTH, V15,
P671, DOI [DOI 10.1080/09638230600998904, 10.1080/09638230600998904]; Stewart SH,
2008, SER ANXIETY RELAT DI, P1, DOI 10.1007/978-0-387-74290-8; Stewart SH, 2001,
PERS INDIV DIFFER, V31, P157, DOI 10.1016/S0191-8869(00)00213-0; von Sydow K, 2002,
DRUG ALCOHOL DEPEN, V68, P49, DOI 10.1016/S0376-8716(02)00102-3; Whiteford HA,
2013, LANCET, V382, P1575, DOI 10.1016/S0140-6736(13)61611-6; Woicik PA, 2009,
ADDICT BEHAV, V34, P1042, DOI 10.1016/j.addbeh.2009.07.001; Young AM, 2005, SUBST
USE MISUSE, V40, P241, DOI 10.1081/JA-200048464 61 1 1 0 4 SAGE
PUBLICATIONS INC THOUSAND OAKS 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
2167-6968 2167-6984 EMERG ADULTHOOD Emerg. Adulthood DEC 2018
6 6 399 410 10.1177/2167696817748106
12 Family Studies; Psychology, Developmental; Psychology,
Social Family Studies; Psychology HA1YI WOS:000450024100004
 2019-09-25
J Vermeulen, JM; Schirmbeck, F; Blankers, M; van Tricht, M; Bruggeman, R; van
den Brink, W; de Haan, L Vermeulen, Jentien M.; Schirmbeck,
Frederike; Blankers, Matthijs; van Tricht, Mirjam; Bruggeman, Richard; van den
Brink, Wim; de Haan, Lieuwe Genetic Risk Outcome Psychosis Grp Association
Between Smoking Behavior and Cognitive Functioning in Patients With Psychosis,
Siblings, and Healthy Control Subjects: Results From a Prospective 6-Year Follow-Up
Study AMERICAN JOURNAL OF PSYCHIATRY English Article
SELF-MEDICATION HYPOTHESIS; MIXED-EFFECTS MODELS;
TOBACCO SMOKING; CIGARETTE-SMOKING; SCHIZOPHRENIA; METAANALYSIS; ABSTINENCE;
DISORDERS; RISK; NEUROCOGNITION Objective: The high prevalence of smoking and
cognitive deficits in schizophrenia patients is well known, but findings regarding
the association between the two are contradictory, and longitudinal studies are
lacking. The authors sought to examine the multi-cross-sectional association
between smoking behavior and performance in specific cognitive domains and the
longitudinal association between change in smoking behavior and change in cognitive
functioning in a large prospective study. Method: The authors conducted a cohort
study of patients with nonaffective psychosis (N=1,094), their siblings (N=1,047),
and healthy control subjects (N=579). At baseline and at 3- and 6-year follow-ups,
smoking behavior was assessed with the Composite International Diagnostic Interview
and cognitive functioning with a test battery. Multivariate linear mixed-effects
regression analyses were conducted to assess associations between smoking and
cognitive domains while adjusting for variation in demographic factors,
psychopathology, medication, and substance use. Bonferroni correction for multiple
testing was applied. Results: At baseline, 66.6% of the patients smoked, compared
with 38.3% of the siblings and 25.2% of the control subjects. Significant multi-
cross-sectional associations were found between smoking and lower processing speed
in the patient and control groups compared with the nonsmoking patient group
(estimate=-22.38, SE=0.84) and the nonsmoking control group (estimate=-23.13,
SE=1.06). In siblings, smoking was significantly associated with lower performance
in working memory and reasoning and problem solving compared with nonsmoking. Also,
the number of cigarettes smoked per day was negatively associated with these
domains. Patients, but not siblings and control subjects, who quit smoking showed a
significant improvement in processing speed (estimate=4.90, SE=1.73). Conclusions:
The study findings indicate that smoking is associated with poorer cognitive
performance in patients, their siblings, and healthy control subjects compared with
nonsmoking. Smoking cessation may improve processing speed in patients.
[Vermeulen, Jentien M.] Univ Amsterdam, Acad Med Ctr, Dept Psychiat,
Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Amsterdam Inst Addict Res,
Amsterdam, Netherlands; Arkin Mental Hlth Care, Amsterdam, Netherlands; Univ
Groningen, Univ Med Ctr Groningen, Rob Giel Res Ctr, Dept Psychiat, Groningen,
Netherlands; Netherlands Inst Mental Hlth & Addict, Trimbos Inst, Utrecht,
Netherlands Vermeulen, JM (reprint author), Univ Amsterdam, Acad Med Ctr, Dept
Psychiat, Amsterdam, Netherlands. j.m.vermeulen@amc.uva.nl Schirmbeck,
Frederike/0000-0003-1700-0958 Geestkracht program of the Dutch Health Research
Council (ZonMw) [10-000-1001]; LundbeckLundbeck Corporation;
AstraZenecaAstraZeneca; Eli LillyEli Lilly; Janssen-CilagJohnson & Johnson
USAJanssen Biotech Inc; Academic Psychiatric Center of the Academic Medical Center;
GGZ Ingeest; Arkin; Dijk en Duin; GGZ Rivierduinen; Erasmus Medical Center; GGZ
Noord Holland Noord; Groningen: University Medical Center Groningen; Lentis; GGZ
Friesland; GGZ Drenthe; Dimence; Mediant; GGNet Warnsveld; Yulius Dordrecht;
Parnassia Psycho-Medical Center The Hague; Maastricht: Maastricht University
Medical Center; GGzE; GGZ Breburg; GGZOost-Brabant; Vincent vanGogh voor
Geestelijke Gezondheid; Mondriaan; Virenze riagg; Zuyderland GGZ; MET ggz;
Universitair Centrum Sint-Jozef Kortenberg; CAPRI University of Antwerp; PC
Ziekeren Sint-Truiden; PZ Sancta Maria Sint-Truiden; GGZ Overpelt; OPZ Rekem;
Utrecht: University Medical Center Utrecht; Altrecht; GGZ Centraal; Delta The
infrastructure for the GROUP study is funded through the Geestkracht program of the
Dutch Health Research Council (ZonMw, grant number 10-000-1001), and matching funds
from participating pharmaceutical companies (Lundbeck, AstraZeneca, Eli Lilly,
Janssen-Cilag), universities, and mental health care organizations (Amsterdam:
Academic Psychiatric Center of the Academic Medical Center and the mental health
institutions GGZ Ingeest, Arkin, Dijk en Duin, GGZ Rivierduinen, Erasmus Medical
Center, GGZ Noord Holland Noord. Groningen: University Medical Center Groningen and
the mental health institutions Lentis, GGZ Friesland, GGZ Drenthe, Dimence,
Mediant, GGNet Warnsveld, Yulius Dordrecht and Parnassia Psycho-Medical Center The
Hague. Maastricht: Maastricht University Medical Center and the mental health
institutions GGzE, GGZ Breburg, GGZOost-Brabant, Vincent vanGogh voor Geestelijke
Gezondheid, Mondriaan, Virenze riagg, Zuyderland GGZ, MET ggz, Universitair Centrum
Sint-Jozef Kortenberg, CAPRI University of Antwerp, PC Ziekeren Sint-Truiden, PZ
Sancta Maria Sint-Truiden, GGZ Overpelt, OPZ Rekem. Utrecht: University Medical
Center Utrecht and the mental health institutions Altrecht, GGZ Centraal, and
Delta.) American Psychiatric Association, 2000, DIAGN STAT MAN MENT;
[Anonymous], 1990, COMP INT DIAGN INT C; Anstey KJ, 2007, AM J EPIDEMIOL, V166,
P367, DOI 10.1093/aje/kwm116; Bates D, 2015, J STAT SOFTW, V67, P1; Boggs DL, 2018,
SCHIZOPHR RES, V194, P62, DOI 10.1016/j.schres.2017.03.047; Boggs DL, 2014, CURR
PHARM DESIGN, V20, P5077; BRAND N, 1985, J GEN PSYCHOL, V112, P201, DOI
10.1080/00221309.1985.9711004; Chambers RA, 2001, BIOL PSYCHIAT, V50, P71, DOI
10.1016/S0006-3223(01)01134-9; Clark V, 2017, J DUAL DIAGN, V13, P6, DOI
10.1080/15504263.2016.1271489; COTTLER LB, 1989, BRIT J ADDICT, V84, P801; D'Souza
DC, 2012, AM J PSYCHIAT, V169, P326, DOI 10.1176/appi.ajp.2011.11020189; de Leon J,
2005, SCHIZOPHR RES, V76, P135, DOI 10.1016/j.schres.2005.02.010; Depp CA, 2015,
ACTA PSYCHIAT SCAND, V131, P333, DOI 10.1111/acps.12380; Durazzo TC, 2012, DRUG
ALCOHOL DEPEN, V122, P105, DOI 10.1016/j.drugalcdep.2011.09.019; Durazzo TC, 2010,
INT J ENV RES PUB HE, V7, P3760, DOI 10.3390/ijerph7103760; Fioravanti M, 2005,
NEUROPSYCHOL REV, V15, P73, DOI 10.1007/s11065-005-6254-9; Halekoh U, 2014, J STAT
SOFTW, V59, P1; Harvey PD, 2016, NEUROPSYCHOLOGY, V30, P28, DOI 10.1037/neu0000245;
Heishman SJ, 2010, PSYCHOPHARMACOLOGY, V210, P453, DOI 10.1007/s00213-010-1848-1;
Hickling LM, 2018, SCHIZOPHR RES, V192, P269, DOI 10.1016/j.schres.2017.04.018; KAY
SR, 1987, SCHIZOPHRENIA BULL, V13, P261, DOI 10.1093/schbul/13.2.261; Keefe RSE,
2006, NEUROPSYCHOPHARMACOL, V31, P2033, DOI 10.1038/sj.npp.1301072; Korver N, 2012,
INT J METH PSYCH RES, V21, P205, DOI 10.1002/mpr.1352; Luke SG, 2017, BEHAV RES
METHODS, V49, P1494, DOI 10.3758/s13428-016-0809-y; Mackowick KM, 2014, PROG NEURO-
PSYCHOPH, V52, P79, DOI 10.1016/j.pnpbp.2013.07.010; Manzella F, 2015, WORLD J
PSYCHIATR, V5, P35, DOI 10.5498/wjp.v5.i1.35; Mons U, 2013, EUR J EPIDEMIOL, V28,
P823, DOI 10.1007/s10654-013-9840-9; Morisano D, 2013, AM J ADDICTION, V22, P46,
DOI 10.1111/j.1521-0391.2013.00313.x; Mossaheb N, 2012, SCHIZOPHR RES, V141, P210,
DOI 10.1016/j.schres.2012.08.008; Nuechterlein KH, 2008, AM J PSYCHIAT, V165, P203,
DOI 10.1176/appi.ajp.2007.07010042; NUECHTERLEIN KH, 1984, SCHIZOPHRENIA BULL, V10,
P160, DOI 10.1093/schbul/10.2.160; Olfson M, 2015, JAMA PSYCHIAT, V72, P1172, DOI
10.1001/jamapsychiatry.2015.1737; Parikh V, 2016, SCHIZOPHR RES, V171, P1, DOI
10.1016/j.schres.2016.01.020; PATRICK DL, 1994, AM J PUBLIC HEALTH, V84, P1086, DOI
10.2105/AJPH.84.7.1086; R Core Team, 2016, R LANG ENV STAT COMP; Sabia S, 2008,
ARCH INTERN MED, V168, P1165, DOI 10.1001/archinte.168.11.1165; Schulte MHJ, 2014,
CLIN PSYCHOL REV, V34, P531, DOI 10.1016/j.cpr.2014.08.002; Stevens L, 2014, J
SUBST ABUSE TREAT, V47, P58, DOI 10.1016/j.jsat.2014.01.008; Szoke A, 2008, BRIT J
PSYCHIAT, V192, P248, DOI 10.1192/bjp.bp.106.029009; Wechsler D, 1997, WAIS 3
WECHSLER ADUL; Zhang XY, 2013, PSYCHOL MED, V43, P1651, DOI
10.1017/S0033291712002590 41 6 6 1 8 AMER PSYCHIATRIC
PUBLISHING, INC WASHINGTON 800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA
0002-953X 1535-7228 AM J PSYCHIAT Am. J. Psychiat. NOV 2018
175 11 1121 1128
10.1176/appi.ajp.2018.18010069 8 Psychiatry Psychiatry
GY9FM WOS:000448945300013 30138044 2019-09-25
J Scalzo, F; Hulbert, CA; Betts, JK; Cotton, SM; Chanen, AM
Scalzo, Franco; Hulbert, Carol A.; Betts, Jennifer K.; Cotton, Sue M.;
Chanen, Andrew M. SUBSTANCE USE IN YOUTH WITH BORDERLINE PERSONALITY
DISORDER JOURNAL OF PERSONALITY DISORDERS English Article
 NATIONAL EPIDEMIOLOGIC SURVEY; ALCOHOL-USE
DISORDERS; DRUG-USE; LIFETIME PREVALENCE; SELF-MEDICATION; ADOLESCENCE;
COMORBIDITY; DEPENDENCE; HEALTH; ABUSE Co-occurring substance misuse and
borderline personality disorder (BPD) in adults is associated with more severe
dysfunction and poorer prognosis than BPD alone. However, it is unknown to what
extent substance use in youth with BPD is normative for this age group or
pathological. This study compared substance use in 117 help-seeking youth (aged 15-
25 years) with their first presentation for treatment of BPD, with an
epidemiological general population sample and with healthy, age-and gender-matched
controls. Established instruments were used to diagnose BPD and assess substance
use. Alcohol dependence, daily tobacco use, and use of illicit substances in the
past month were between four and nine times more prevalent in the BPD group than in
the general population. Similarly, the prevalence of substance use was
disproportionately higher in youth with BPD than in matched controls. The findings
indicate a non-normative, alarmingly high rate of substance use among youth with
BPD. [Scalzo, Franco; Hulbert, Carol A.] Univ Melbourne, Melbourne Sch Psychol
Sci, Melbourne, Vic, Australia; [Betts, Jennifer K.; Cotton, Sue M.; Chanen, Andrew
M.] Natl Ctr Excellence Youth Mental Hlth, Melbourne, Vic, Australia; [Betts,
Jennifer K.; Cotton, Sue M.; Chanen, Andrew M.] Univ Melbourne, Ctr Youth Mental
Hlth, Melbourne, Vic, Australia Chanen, AM (reprint author), Orygen, Locked Bag
10, Parkville, Vic 3052, Australia. andrew.chanen@orygen.org.au Chanen,
Andrew/0000-0003-4468-622X; Cotton, Sue/0000-0002-9386-8348National Health and
Medical Research Council (NHMRC)National Health and Medical Research Council of
Australia [GNT0628739]; NHMRC Career Development FellowshipNational Health and
Medical Research Council of Australia [APP1061998] This project was conducted
within a clinical trial (ACTRN12610000100099) that is supported by a National
Health and Medical Research Council (NHMRC) Project Grant (GNT0628739). The content
is solely the responsibility of the authors and does not necessarily represent
official views of the NHMRC. S.C. was supported by an NHMRC Career Development
Fellowship (APP1061998). Allen JP, 1997, ALCOHOL CLIN EXP RES, V21, P613, DOI
10.1097/00000374-199706000-00008; American Psychiatric Association, 2000, DIAGN
STAT MAN MENT; Australian Bureau of Statistics, 2013, CENS POP HOUS SOC IN;
Australian Institute for Health and Welfare, 2013, NAT DRUG STRAT HOUS; Babor T.
F., 2001, ALCOHOL USE DISORDER; Baggio S, 2014, ADDICTION, V109, P937, DOI
10.1111/add.12490; Barrachina J, 2011, COMPR PSYCHIAT, V52, P725, DOI
10.1016/j.comppsych.2010.11.009; Behrendt S, 2009, DRUG ALCOHOL DEPEN, V99, P68,
DOI 10.1016/j.drugalcdep.2008.06.014; Benowitz NL, 2010, NEW ENGL J MED, V362,
P2295, DOI 10.1056/NEJMra0809890; BERKSON J, 1946, BIOMETRICS BULL, V2, P47, DOI
10.2307/3002000; Bolton JM, 2009, J AFFECT DISORDERS, V115, P367, DOI
10.1016/j.jad.2008.10.003; Bornovalova MA, 2005, CLIN PSYCHOL REV, V25, P790, DOI
10.1016/j.cpr.2005.05.005; Bornovalova MA, 2013, PERSONAL DISORD, V4, P23, DOI
10.1037/a0027178; Chanen A, 2015, TRIALS, V16, DOI 10.1186/s13063-015-1001-x;
Chanen AM, 2007, J CLIN PSYCHIAT, V68, P297, DOI 10.4088/JCP.v68n0217; Chanen AM,
2015, J CLIN PSYCHOL, V71, P778, DOI 10.1002/jclp.22205; Chanen Andrew M, 2013, Br
J Psychiatry Suppl, V54, ps24, DOI 10.1192/bjp.bp.112.119180; Cohen J., 1988, STAT
POWER ANAL BEHA; Cohen P, 2007, DRUG ALCOHOL DEPEN, V88, pS71, DOI
10.1016/j.drugalcdep.2006.12.012; Darke S., 1991, OPIATE TREATMENT IND; de Wit H,
2009, ADDICT BIOL, V14, P22, DOI 10.1111/j.1369-1600.2008.00129.x; Degenhardt L,
2012, LANCET, V379, P55, DOI 10.1016/S0140-6736(11)61138-0; Feng C, 2013, J
ADOLESCENT HEALTH, V52, P499, DOI 10.1016/j.jadohealth.2012.07.011; Ferguson CJ,
2009, PROF PSYCHOL-RES PR, V40, P532, DOI 10.1037/a0015808; First M, 2001,
STRUCTURED CLIN INTE; First M. B., 1997, USERS GUIDE STRUCTUR; Fok MLY, 2014, PLOS
ONE, V9, DOI 10.1371/journal.pone.0100979; Fok MLY, 2012, J PSYCHOSOM RES, V73,
P104, DOI 10.1016/j.jpsychores.2012.05.001; Fuller E., 2014, SMOKING DRINKING DRU;
Grant BF, 2008, J CLIN PSYCHIAT, V69, P533, DOI 10.4088/JCP.v69n0404; Harned MS,
2011, J NERV MENT DIS, V199, P832, DOI 10.1097/NMD.0b013e318234c02c; Heilbronn C,
2013, MED J AUSTRALIA, V199, P395, DOI 10.5694/mja13.10149; Keuroghlian AS, 2013, J
PSYCHIATR RES, V47, P1499, DOI 10.1016/j.jpsychires.2013.06.012; Lev-Ran S, 2013,
AM J ADDICTION, V22, P93, DOI 10.1111/j.1521-0391.2013.00304.x; McGorry PD, 2012,
MED TODAY, V13, P46; Meneses-Gaya Carolina de, 2009, Psychol. Neurosci., V2, P83,
DOI 10.3922/j.psns.2009.1.12; Merikangas KR, 2010, J AM ACAD CHILD PSY, V49, P980,
DOI 10.1016/j.jaac.2010.05.017; Ministerial Council on Drug Strategy, 2011, NAT
DRUG STRAT 2010; National Cannabis Prevention and Information Centre, 2014, POL US
CANN US; Pennay A, 2011, J SUBST ABUSE TREAT, V41, P363, DOI
10.1016/j.jsat.2011.05.004; PERITZ E, 1984, J CHRON DIS, V37, P909, DOI
10.1016/0021-9681(84)90067-5; Rehm J, 2013, EUR NEUROPSYCHOPHARM, V23, P89, DOI
10.1016/j.euroneuro.2012.08.001; Robinson J, 2011, ARCH GEN PSYCHIAT, V68, P800,
DOI 10.1001/archgenpsychiatry.2011.75; Rohde P, 2001, J AM ACAD CHILD PSY, V40,
P83, DOI 10.1097/00004583-200101000-00020; Samokhvalov AV, 2010, ALCOHOL CLIN EXP
RES, V34, P1871, DOI 10.1111/j.1530-0277.2010.01275.x; SAUNDERS JB, 1993,
ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Scott N, 2015,
ADDICTION, V110, P120, DOI 10.1111/add.12740; Stepp SD, 2005, J PERS DISORD, V19,
P711, DOI 10.1521/pedi.2005.19.6.711; Stone AL, 2012, ADDICT BEHAV, V37, P747, DOI
10.1016/j.addbeh.2012.02.014; Tompsett CJ, 2013, AM J COMMUN PSYCHOL, V51, P520,
DOI 10.1007/s10464-013-9569-3; Tragesser SL, 2013, J PERS DISORD, V27, P427, DOI
10.1521/pedi_2013_27_094; Trull TJ, 2010, J PERS DISORD, V24, P412, DOI
10.1521/pedi.2010.24.4.412; Trull TJ, 2000, CLIN PSYCHOL REV, V20, P235, DOI
10.1016/S0272-7358(99)00028-8; Tull MT, 2012, DRUG ALCOHOL DEPEN, V121, P97, DOI
10.1016/j.drugalcdep.2011.08.014; Viner RM, 2012, LANCET, V379, P1641, DOI
10.1016/S0140-6736(12)60149-4; Walter M, 2009, ADDICTION, V104, P97, DOI
10.1111/j.1360-0443.2008.02413.x; Zanarini MC, 2011, ADDICTION, V106, P342, DOI
10.1111/j.1360-0443.2010.03176.x 57 0 1 0 5 GUILFORD
PUBLICATIONS INC NEW YORK 370 SEVENTH AVE, SUITE 1200, NEW YORK, NY 10001-1020
USA 0885-579X 1943-2763 J PERS DISORD J. Pers. Disord. OCT 2018
32 5 603 617 10.1521/pedi_2017_31_315
15 Psychiatry Psychiatry GY7TS WOS:000448818500002
28926304 2019-09-25
J Fond, G; Bourbon, A; Micoulaud-Franchi, JA; Auquier, P; Boyer, L; Lancon, C
Fond, G.; Bourbon, A.; Micoulaud-Franchi, J-A.; Auquier, P.;
Boyer, L.; Lancon, C. Psychiatry: A discipline at specific risk of
mental health issues and addictive behavior? Results from the national BOURBON
study JOURNAL OF AFFECTIVE DISORDERS English Article
Interns; Mental health; Tobacco; Alcohol; Cannabis
MEDICAL-STUDENTS; DEPRESSIVE SYMPTOMS; METAANALYSIS; PREVALENCE; RESIDENT;
PHYSICIANS; DRINKING Background: Physicians are at risk for burnout, anxiety and
depression. Objective: To explore the self-reported mental health status, substance
use behavior and motives of a national sample of interns in psychiatry compared to
other specialties. Methods: Interns of the 35 French Medicine faculties were
recruited through mailing lists and social networks between December 2016 and May
2018 and fulfilled internet anonymized questionnaires. Results: Overall, 2165
interns (302 interns in psychiatry and 1863 in other specialties) mean aged 25.9
years (+/- 2.8), 35% males were included in the present study. In multivariate
analyses, interns in psychiatry were found to have higher rates of current tobacco
smoking (aOR = 1.9 [1.4-2.5], p < 0.001), alcohol use disorder (aOR = 1.5 [1.2-
2.0], p= 0.001), cannabis use disorder (aOR = 2.7 [1.8-4.2], p < 0.001)). They were
more frequently followed by a psychiatrist and/or a psychologist (aOR = 2.5 1.9-
3.3], p < 0.001), they consumed more often antidepressants (aOR = 3.8 [2.2-6.6], p
< 0.001) and anxiolytic (aOR = 1.8[1.2-2.8]; p = 0.006). They reported to have been
more frequently exposed to sexual assault (aOR = 2.2 [1.1-4.8], p = 0.04) and
physical assault (aOR = 1.9[1.3-2.9], p = 0.002), and to have lower vitality (beta=
3.5 [0.6-6.4], p = 0.02). Interns in psychiatry reported to have more often
experienced ecstasy (aOR = 1.6 [1.2-2.3], p= 0.004), mushrooms (aOR = 1.5 [1.1-
2.2], p = 0.04), amphetamines (aOR = 1.9 [1.2-3.1], p = 0.009) and LSD (aOR= 1.8
[1.1-3.1], p = 0.04). Beyond classical motives for this consumption (party, group
effect), interns in psychiatry reported to seek more frequently disinhibition (aOR
= 1.7 [1.3-2.2], p < 0.001), dealing with anxiety (aOR = 1.7 [1.3-2.3], p = 0.001),
and to seek both stimulant (aOR = 1.4 [1.1-1.9], p = 0.04) and sedative effects
(aOR = 1.9[1.3-2.7], p = 0.001). Conclusions: Interns in psychiatry are more
exposed to violence during medical studies, they report lower vitality and
increased substance use behavior. Their motives for consumption suggest mental
health problems associated with increased engagement in psychotherapy and self-
medication of antidepressant/anxiolytic. This population should be targeted as a
specific vulnerable population among interns in medicine to prevent ulterior bad
health outcomes. [Fond, G.; Bourbon, A.; Auquier, P.; Boyer, L.; Lancon, C.] Aix
Marseille Univ, Fac Med, CEReSS Ctr Etudeetde Rech Serv Santeetla Qual Vie, Sect
Timone,EA 3279, 27 Blvd Jean Moulin, F-13005 Marseille, France; [Micoulaud-Franchi,
J-A.] Univ Bordeaux, Ctr Natl Rech Sci Sommeil Addict & Neuropsychiat, USR 3413,
Bordeaux, France Fond, G (reprint author), Aix Marseille Univ, Fac Med, CEReSS Ctr
Etudeetde Rech Serv Santeetla Qual Vie, Sect Timone,EA 3279, 27 Blvd Jean Moulin,
F-13005 Marseille, France. guillaume.fond@ap-hm.fr Fond, Guillaume/D-7646-2011
Fond, Guillaume/0000-0003-3249-2030 Antonius D, 2010, AM J
PSYCHIAT, V167, P253, DOI 10.1176/appi.ajp.2009.09010063; Armstrong Grayson W,
2017, J Prev Med Public Health, V50, P177, DOI 10.3961/jpmph.15.061; Cairns KE,
2014, J AFFECT DISORDERS, V169, P61, DOI 10.1016/j.jad.2014.08.006; Chidiac A,
2016, ANN THORAC MED, V11, P183, DOI 10.4103/1817-1737.185757; Duroy D, 2017,
ENCEPHALE, V43, P334, DOI 10.1016/j.encep.2016.02.019; Dyrbye LN, 2006, ACAD MED,
V81, P354, DOI 10.1097/00001888-200604000-00009; FOND G, 2016, MEDICINE, V95; Gache
P, 2005, ALCOHOL CLIN EXP RES, V29, P2001, DOI 10.1097/01.alc.0000187034.58955.64;
Gandek B, 1998, J CLIN EPIDEMIOL, V51, P1171, DOI 10.1016/S0895-4356(98)00109-7;
Kwok Stephanie, 2012, J Grad Med Educ, V4, P296, DOI 10.4300/JGME-D-11-00184.1;
Lapeyre N., 2005, REV FRANCAISE AFFAIR, V1, P59; Legleye S, 2011, DRUG ALCOHOL
DEPEN, V113, P229, DOI 10.1016/j.drugalcdep.2010.08.011; Lindsay DL, 2017, SUBST
ABUS, V38, P464, DOI 10.1080/08897077.2017.1342735; Mata DA, 2015, JAMA-J AM MED
ASSOC, V314, P2373, DOI 10.1001/jama.2015.15845; Micoulaud-Franchi JA, 2014, EUR
REV MED PHARMACO, V18, P1875; Sanchez AR, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-
2017-018728; Rotenstein LS, 2016, JAMA-J AM MED ASSOC, V316, P2214, DOI
10.1001/jama.2016.17324; Sadrabad A. Z., 2016, J INTERPERS VIOLENCE, DOI [10.1177/,
DOI 10.1177/]; Shanafelt TD, 2003, AM J MED, V114, P513, DOI 10.1016/S0002-
9343(03)00117-7; Terebessy A, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-
0884-8; Wong LL, 2012, CAN J PSYCHIAT, V57, P375 21 3 3 1 15
ELSEVIER SCIENCE BV AMSTERDAM PO BOX 211, 1000 AE AMSTERDAM,
NETHERLANDS 0165-0327 1573-2517 J AFFECT DISORDERS J. Affect. Disord.
OCT 1 2018 238 534 538
10.1016/j.jad.2018.05.074 5 Clinical Neurology;
Psychiatry Neurosciences & Neurology; Psychiatry GN9VF WOS:000439557000073
29936392 2019-09-25
J Bartoli, F; Lev-Ran, S; Crocamo, C; Carra, G Bartoli, F.;
Lev-Ran, S.; Crocamo, C.; Carra, G. The interplay between cannabis use
and suicidal behaviours: epidemiological overview, psychopathological and clinical
models JOURNAL OF PSYCHOPATHOLOGY English Article
Cannabis; Suicide; Epidemiology; Psychopathology SELF-
MEDICATION HYPOTHESIS; MARIJUANA USE; DUAL DIAGNOSIS; USE DISORDERS; SUBSTANCE USE;
DEPRESSION; RISK; IMPULSIVITY; IDEATION; ASSOCIATION Objectives The clinical and
psychopathological relationships between substance use and suicidal behaviours are
deserving growing attention. Understanding and identifying factors that may be
associated with suicidal behaviours can help clinicians to early detect high-risk
individuals. Methods We conducted a narrative review, summarising main
epidemiological data from longitudinal studies, on the potential association
between cannabis use and suicidal behaviours. In addition, we discuss possible
psychopathological models that may explain and disentangle this clinical
relationship. Results Individuals who use cannabis, the most common psychoactive
drug apart from alcohol and nicotine, may have higher risk of suicidal behaviours.
Despite the mixed findings, evidence seems to suggest that an early and heavy
cannabis use may be associated with suicidal ideation, attempt, and completion.
Conclusions Findings from our review show that it is likely that cannabis is
associated with increased rates of suicidal behaviours. This relationship could be
explained by the reciprocal influence of cannabis on severity of depression,
psychotic features, and impulsivity. Cannabis may play a key role in the complex
clinical pathways that link mental disorders and suicide-related behaviours.
Nevertheless, various potential mechanisms and contributing factors to this
association remain to be investigated. [Bartoli, F.; Crocamo, C.; Carra, G.]
Univ Milano Bicocca, Dept Med & Surg, Via Cadore 48, I-20900 Monza, Italy; [Lev-
Ran, S.] Lev Hasharon Med Ctr, Dual Diag Clin, Pardesiya, Israel; [Lev-Ran, S.] Tel
Aviv Univ, Sackler Fac Med, Tel Aviv, Israel; [Carra, G.] UCL, Div Psychiat,
London, England Carra, G (reprint author), Univ Milano Bicocca, Dept Med & Surg,
Via Cadore 48, I-20900 Monza, Italy. giuseppe.carra@unimib.it Bartoli,
Francesco/K-5755-2016; Crocamo, Cristina/B-5404-2014 Bartoli, Francesco/0000-0003-
2612-4119; Crocamo, Cristina/0000-0002-2979-2107 Agrawal A, 2017,
LANCET PSYCHIAT, V4, P706, DOI 10.1016/S2215-0366(17)30280-8; Agrawal A, 2017, J
AFFECT DISORDERS, V213, P96, DOI 10.1016/j.jad.2016.12.060; Agrawal A, 2014,
ADDICTION, V109, P360, DOI 10.1111/add.12436; Anderson DM, 2014, AM J PUBLIC
HEALTH, V104, P2369, DOI 10.2105/AJPH.2013.301612; [Anonymous], 2017, EUR DRUG REP
2017 TR; Ansell EB, 2015, DRUG ALCOHOL DEPEN, V148, P136, DOI
10.1016/j.drugalcdep.2014.12.029; Arendt M, 2007, PSYCHOL MED, V37, P935, DOI
10.1017/S0033291706009688; Atakan Z, 2012, THER ADV PSYCHOPHARM, V2, P241, DOI
10.1177/2045125312457586; Baggio S, 2014, J ADOLESCENT HEALTH, V54, P235, DOI
10.1016/j.jadohealth.2013.08.013; Bersani G, 2016, EUR REV MED PHARMACO, V20, P547;
Black DW, 2015, CAN J PSYCHIAT, V60, P309, DOI 10.1177/070674371506000703;
Bloomfield MAP, 2016, NATURE, V539, P369, DOI 10.1038/nature20153; Borges G, 2017,
J PSYCHIATR RES, V91, P74, DOI 10.1016/j.jpsychires.2017.02.025; Borges G, 2016, J
AFFECT DISORDERS, V195, P63, DOI 10.1016/j.jad.2016.02.007; Buckner JD, 2017,
PSYCHIAT RES, V253, P256, DOI 10.1016/j.psychres.2017.04.001; Buckner JD, 2012,
ADDICT BEHAV, V37, P387, DOI 10.1016/j.addbeh.2011.11.019; Calabria B, 2010, DRUG
ALCOHOL REV, V29, P318, DOI 10.1111/j.1465-3362.2009.00149.x; Carra G, 2006, AM J
ADDICTION, V15, P125, DOI 10.1080/10550490500528340; Carra G, 2015, J PSYCHOPATHOL-
G PSI, V21, P390; Carra G, 2015, SUBST ABUS, V36, P75, DOI
10.1080/08897077.2014.960551; Carra G, 2015, BIPOLAR DISORD, V17, P113, DOI
10.1111/bdi.12282; Center for Behavioral Health Statistics and Quality, 2017, 2016
NAT SURV DRUG U; Clarke MC, 2014, WORLD PSYCHIATRY, V13, P322, DOI
10.1002/wps.20170; Conner KR, 2019, SUICIDE LIFE-THREAT, V49, P278, DOI
10.1111/sltb.12422; Curtin Sally C, 2016, NCHS Data Brief, P1; D'Souza DC, 2008,
NEUROPSYCHOPHARMACOL, V33, P2505, DOI 10.1038/sj.npp.1301643; Danielsson AK, 2016,
J AFFECT DISORDERS, V193, P103, DOI 10.1016/j.jad.2015.12.045; Delforterie MJ,
2015, DRUG ALCOHOL DEPEN, V150, P98, DOI 10.1016/j.drugalcdep.2015.02.019;
Eurostat, ALM 60 000 SUIC EU; Foglia E, 2017, PSYCHOL MED, V47, P1691, DOI
10.1017/S0033291717000046; Freeman TP, 2014, LANCET PSYCHIAT, V1, P416, DOI
10.1016/S2215-0366(14)00005-4; Fu QA, 2002, ARCH GEN PSYCHIAT, V59, P1125, DOI
10.1001/archpsyc.59.12.1125; Gillespie NA, 2018, ADDICTION, V113, P1488, DOI
10.1111/add.14209; Huckins LM, 2017, LANCET PSYCHIAT, V4, P654, DOI 10.1016/S2215-
0366(17)30311-5; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI
10.3109/10673229709030550; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259; Kjelby
E, 2015, EUR PSYCHIAT, V30, P830, DOI 10.1016/j.eurpsy.2015.07.003; Klonsky ED,
2010, SUICIDE LIFE-THREAT, V40, P612, DOI 10.1521/suli.2010.40.6.612; Lev-Ran S,
2013, COMPR PSYCHIAT, V54, P589, DOI 10.1016/j.comppsych.2012.12.021; Leventhal AM,
2017, ADDICTION, V112, P2182, DOI 10.1111/add.13912; Marconi A, 2016, SCHIZOPHRENIA
BULL, V42, P1262, DOI 10.1093/schbul/sbw003; Murray RM, 2016, WORLD PSYCHIATRY,
V15, P195, DOI 10.1002/wps.20341; Pedersen W, 2008, ACTA PSYCHIAT SCAND, V118,
P395, DOI 10.1111/j.1600-0447.2008.01259.x; Potvin S, 2003, ENCEPHALE, V29, P193;
Price C, 2009, BRIT J PSYCHIAT, V195, P492, DOI 10.1192/bjp.bp.109.065227; Reiman
A, 2014, LANCET PSYCHIAT, V1, P416, DOI 10.1016/S2215-0366(14)00007-8; Rylander M,
2014, AM J DRUG ALCOHOL AB, V40, P269, DOI 10.3109/00952990.2014.910520; Schauer
GL, 2016, AM J PREV MED, V50, P1, DOI 10.1016/j.amepre.2015.05.027; Schoeler T,
2016, LANCET PSYCHIAT, V3, P215, DOI 10.1016/S2215-0366(15)00363-6; Serafini
Gianluca, 2013, Front Psychiatry, V4, P125, DOI 10.3389/fpsyt.2013.00125; Serafini
G, 2012, CURR PHARM DESIGN, V18, P5165, DOI 10.2174/138161212802884663; Shalit N,
2016, J AFFECT DISORDERS, V205, P216, DOI 10.1016/j.jad.2016.07.010; Silins E,
2014, LANCET PSYCHIAT, V1, P286, DOI 10.1016/S2215-0366(14)70307-4; Soderberg S,
2001, NORD J PSYCHIAT, V55, P163, DOI 10.1080/08039480152036038; Trull TJ, 2016,
ADDICTION, V111, P2052, DOI 10.1111/add.13471; Turecki G, 2016, LANCET, V387,
P1227, DOI 10.1016/S0140-6736(15)00234-2; van Ours JC, 2013, J HEALTH ECON, V32,
P524, DOI 10.1016/j.jhealeco.2013.02.002; Volkow ND, 2014, NEW ENGL J MED, V371,
P879, DOI 10.1056/NEJMc1407928; Winer ES, 2016, ARCH SUICIDE RES, V20, P265, DOI
10.1080/13811118.2015.1025119; Wong Z, 2013, COMPR PSYCHIAT, V54, P611, DOI
10.1016/j.comppsych.2012.12.022; World Health Organization, SUIC DAT; Wrege J,
2014, CURR PHARM DESIGN, V20, P2126, DOI 10.2174/13816128113199990428 62 1
1 0 1 PACINI EDITORE PISA VIA DELLA GHERARDESCA-ZONA
INDUSTRIALE OSPEDALETTO, 56121 PISA, ITALY 1592-1107 2499-6904 J
PSYCHOPATHOL J. Psychopathol. SEP 2018 24 3 SI
180 186 7 Psychiatry Psychiatry HH1JF
WOS:000455474900010 2019-09-25
J Turner, S; Mota, N; Bolton, J; Sareen, J Turner, Sarah;
Mota, Natalie; Bolton, James; Sareen, Jitender Self-medication with
alcohol or drugs for mood and anxiety disorders: A narrative review of the
epidemiological literature DEPRESSION AND ANXIETY English Review
addiction; alcoholism/alcohol use disorders;
anxiety/anxiety disorders; coping; depression; epidemiology; substance use
disorders SUBSTANCE USE DISORDERS; NATIONALLY REPRESENTATIVE SAMPLE; ECOLOGICAL
MOMENTARY ASSESSMENT; PSYCHIATRIC-DISORDERS; MAJOR DEPRESSION; COMORBIDITY-SURVEY;
CANNABIS USE; DEPENDENCE; SYMPTOMS; PREVALENCE Background: The comorbidity of mood
and anxiety disorders (MD and AD) with substance use disorders (SUD) is common. One
explanation for this comorbidity is the self-medication hypothesis, which posits
that individuals with MD or AD use substances to cope with the difficult symptoms
associated with the disorder. Over time, self-medication (SM) can develop into an
independent SUD. This narrative review will present the prevalence and correlates
of SM with alcohol and/or drugs for MD and AD and the relationship between SM and
subsequent SUD using both cross-sectional and longitudinal epidemiological data.
Methods: Scopus and PsycINFO were searched from January 1997 to April 2018 to
identify original research articles that examined the prevalence and correlates of
SM and the temporal relationship between MD/AD and SUD in the general population
(n=22). Results: The prevalence of SM with alcohol and/or drugs among those with MD
or AD ranged from 21.9% to 24.1%. Male sex, younger age, being separated, divorced
or widowed, and being Caucasian were characteristics associated with higher
proportions of respondents endorsing SM with alcohol/drugs for MD and AD.
Longitudinal data supports the temporal onset of primary MD/AD and secondary SUD
among those who self-report SM. Conclusion: Providing and promoting alternate
coping strategies for those with MD/AD may reduce SM, the development of SUD, and
the comorbidity of MD/AD with SUD. The concurrent treatment of MD/AD and substance
use is the current gold standard model of care, and the results of this review
support its use. [Turner, Sarah] Univ Manitoba, Dept Psychiat & Community Hlth
Sci, Winnipeg, MB, Canada; [Mota, Natalie] Univ Manitoba, Dept Clin Hlth Psychol,
Winnipeg, MB, Canada; [Bolton, James; Sareen, Jitender] Dept Psychiat Psychol &
Community Hlth Sci, PZ 430 771 Bannatyne Ave, Winnipeg, MB R3E 3N4, Canada
Sareen, J (reprint author), Dept Psychiat Psychol & Community Hlth Sci, PZ
430 771 Bannatyne Ave, Winnipeg, MB R3E 3N4, Canada. sareen@umanitoba.ca
CIHR Foundations grant This research was supported by funding from a CIHR
Foundations grant (Sareen). Alegria AA, 2010, J CLIN PSYCHIAT, V71, P1187, DOI
10.4088/JCP.09m05328gry; [Anonymous], 2006, AM J PSYCHIAT, V163, P1; Baker AL,
2012, J AFFECT DISORDERS, V139, P217, DOI 10.1016/j.jad.2011.08.004; Bolton J,
2006, J NERV MENT DIS, V194, P818, DOI 10.1097/01.nmd.0000244481.63148.98; Bolton
JM, 2009, J AFFECT DISORDERS, V115, P367, DOI 10.1016/j.jad.2008.10.003; Conway KP,
2006, J CLIN PSYCHIAT, V67, P247, DOI 10.4088/JCP.v67n0211; Crum RM, 2013, JAMA
PSYCHIAT, V70, P718, DOI 10.1001/jamapsychiatry.2013.1098; Crum RM, 2013, DEPRESS
ANXIETY, V30, P174, DOI 10.1002/da.22024; Demetrovics Z, 2009, ADDICT RES THEORY,
V17, P420, DOI 10.1080/16066350802601324; Dimeff Linda A, 2008, Addict Sci Clin
Pract, V4, P39; Donovan D, 2005, J STUD ALCOHOL, P119, DOI
10.15288/jsas.2005.s15.119; Driessen M, 2001, ALCOHOL ALCOHOLISM, V36, P249, DOI
10.1093/alcalc/36.3.249; Farmer RF, 2017, J STUD ALCOHOL DRUGS, V78, P222, DOI
10.15288/jsad.2017.78.222; Feingold D, 2016, EUR NEUROPSYCHOPHARM, V26, P493, DOI
10.1016/j.euroneuro.2015.12.037; Feingold D, 2015, J AFFECT DISORDERS, V172, P211,
DOI 10.1016/j.jad.2014.10.006; Fergusson DM, 2009, ARCH GEN PSYCHIAT, V66, P260,
DOI 10.1001/archgenpsychiatry.2008.543; Gorka SM, 2017, DRUG ALCOHOL DEPEN, V173,
P31, DOI 10.1016/j.drugalcdep.2016.12.012; Grant B, 2005, SOURCE ACCURACY STAT;
Grant B.F., 2003, SOURCE ACCURACY STAT; Grant BF, 2004, ARCH GEN PSYCHIAT, V61,
P807, DOI 10.1001/archpsyc.61.8.807; Grant BF, 2015, JAMA PSYCHIAT, V72, P757, DOI
10.1001/jamapsychiatry.2015.0584; Kessler RC, 1997, ARCH GEN PSYCHIAT, V54, P313;
KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Kessler RC, 2012, PSYCHIAT CLIN N AM,
V35, P1, DOI 10.1016/j.psc.2011.11.005; Khantzian EJ, 1997, HARVARD REV PSYCHIAT,
V4, P231, DOI 10.3109/10673229709030550; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142,
P1259; Kraemer HC, 2001, AM J PSYCHIAT, V158, P848, DOI 10.1176/appi.ajp.158.6.848;
Kuo PH, 2006, PSYCHOL MED, V36, P1153, DOI 10.1017/S0033291706007860; Kushner MG,
1999, AM J PSYCHIAT, V156, P723; Lai HMX, 2015, DRUG ALCOHOL DEPEN, V154, P1, DOI
10.1016/j.drugalcdep.2015.05.031; Lazareck S, 2012, J CLIN PSYCHIAT, V73, pE588,
DOI 10.4088/JCP.11m07345; Leeies M, 2010, DEPRESS ANXIETY, V27, P731, DOI
10.1002/da.20677; Lembke A, 2012, AM J DRUG ALCOHOL AB, V38, P524, DOI
10.3109/00952990.2012.694532; Liang WB, 2011, ADDICTION, V106, P1126, DOI
10.1111/j.1360-0443.2011.03362.x; Martins SS, 2012, PSYCHOL MED, V42, P1261, DOI
10.1017/S0033291711002145; Martins SS, 2009, DRUG ALCOHOL DEPEN, V103, P16, DOI
10.1016/j.drugalcdep.2009.01.019; McIntyre RS, 2012, ANN CLIN PSYCHIATRY, V24,
P163; Menary KR, 2011, J ANXIETY DISORD, V25, P335, DOI
10.1016/j.janxdis.2010.10.006; Merikangas KR, 2012, HUM GENET, V131, P779, DOI
10.1007/s00439-012-1168-0; Mojtabai R, 2002, ARCH GEN PSYCHIAT, V59, P77, DOI
10.1001/archpsyc.59.1.77; Possemato K, 2015, PSYCHOL ADDICT BEHAV, V29, P894, DOI
10.1037/adb0000129; Prior K, 2017, DRUG ALCOHOL REV, V36, P317, DOI
10.1111/dar.12419; REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511; Robinson J,
2011, ARCH GEN PSYCHIAT, V68, P800, DOI 10.1001/archgenpsychiatry.2011.75; Robinson
J, 2009, J ANXIETY DISORD, V23, P38, DOI 10.1016/j.janxdis.2008.03.013; Robinson
JA, 2009, J NERV MENT DIS, V197, P873, DOI 10.1097/NMD.0b013e3181c299c2; Sareen J,
2006, PSYCHIAT RES, V142, P11, DOI 10.1016/j.psychres.2006.01.009; Sareen J, 2001,
CAN J PSYCHIAT, V46, P733; Swendsen JD, 1998, COMPR PSYCHIAT, V39, P176, DOI
10.1016/S0010-440X(98)90058-X; Walley AY, 2012, J ADDICT MED, V6, P50, DOI
10.1097/ADM.0b013e318231de51; Wittchen HU, 2002, DEPRESS ANXIETY, V16, P162, DOI
10.1002/da.10065; Wolitzky-Taylor K, 2012, ADDICT BEHAV, V37, P982, DOI
10.1016/j.addbeh.2012.03.026; Yaworski D, 2011, CAN J PSYCHIAT, V56, P161, DOI
10.1177/070674371105600306; Zhou H, 2017, JAMA PSYCHIAT, V74, P1234, DOI
10.1001/jamapsychiatry.2017.3275 54 12 11 1 18 WILEY HOBOKEN
111 RIVER ST, HOBOKEN 07030-5774, NJ USA 1091-4269 1520-6394
DEPRESS ANXIETY Depress. Anxiety SEP 2018 35 9
851 860 10.1002/da.22771 10 Psychology, Clinical;
Psychiatry; Psychology Psychology; Psychiatry GS3VS WOS:000443554000005
29999576 Other Gold, Green Published 2019-09-25
J Banerjee, N; Ironson, G; Fitch, C; Boroughs, MS; Safren, SA; Powell, A;
O'Cleirigh, C Banerjee, Nikhil; Ironson, Gail; Fitch, Calvin;
Boroughs, Michael S.; Safren, Steven A.; Powell, Alexis; O'Cleirigh, Conall
The Indirect Effect of Posttraumatic Stress Disorder Symptoms on Current
Alcohol Use Through Negative Cognitions in Sexual Minority Men JOURNAL OF
TRAUMATIC STRESS English Article
ADDICTION SEVERITY INDEX; SUBSTANCE USE; GENDER-DIFFERENCES; RISK BEHAVIOR;
DRUG-USE; PTSD; ABUSE; CHILDHOOD; DEPENDENCE; HIV Self-medication theory posits
that some trauma survivors use alcohol to cope with posttraumatic stress disorder
(PTSD) symptoms, but the role of negative posttraumatic cognitions in this
relationship is not well defined. We examined associations among PTSD symptoms,
posttraumatic cognitions, and alcohol intoxication frequency in 290 men who have
sex with men (MSM), who reported a history of childhood sexual abuse (CSA). Using a
bootstrap approach, we examined the indirect effects of PTSD symptoms on alcohol
intoxication frequency through posttraumatic cognitions regarding the self, world,
and self-blame. In separate regression models, higher levels of PTSD symptoms and
posttraumatic cognitions were each associated with more frequent intoxication,
accounting for 2.6% and 5.2% of the variance above demographics, respectively. When
examined simultaneously, posttraumatic cognitions remained significantly correlated
with intoxication frequency whereas PTSD symptoms did not. Men reporting elevated
posttraumatic cognitions faced increased odds for current alcohol dependence, odds
ratio (OR)=2.19, 95% CI [1.13, 4.22], compared with men reporting low posttraumatic
cognitions, independent of current PTSD diagnosis. A higher level of PTSD symptom
severity was indirectly associated with more frequent alcohol intoxication through
cognitions about the self and world; the indirect to total effect ratios were 0.74
and 0.35, respectively. Negative posttraumatic cognitions pertaining to
individuals' self-perceptions and appraisals of the world as dangerous may play a
role in self-medication with alcohol among MSM with a history of CSA. Interventions
targeting these cognitions may offer potential for reducing alcohol misuse in this
population, with possible broader implications for HIV-infection risk. [Banerjee,
Nikhil; Ironson, Gail; Fitch, Calvin; Safren, Steven A.] Univ Miami, Dept Psychol,
5665 Ponce de Leon Blvd, Coral Gables, FL 33124 USA; [O'Cleirigh, Conall] Harvard
Med Sch, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA USA; [Boroughs, Michael
S.] Univ Windsor, Dept Psychol, Windsor, ON, Canada; [Powell, Alexis] Univ Miami,
Miller Sch Med, Miami, FL 33136 USA Banerjee, N (reprint author), Univ Miami, Dept
Psychol, 5665 Ponce de Leon Blvd, Coral Gables, FL 33124 USA.
n.banerjee@umiami.edu National Institute of Mental HealthUnited
States Department of Health & Human ServicesNational Institutes of Health (NIH) -
USANIH National Institute of Mental Health (NIMH) [R01 MH095624]; NIHUnited States
Department of Health & Human ServicesNational Institutes of Health (NIH) - USA
[9K24DA040489] This study was supported by the National Institute of Mental
Health (R01 MH095624, PI: Dr. O'Cleirigh). Subcontract for Miami site (PI: Dr. G.
Ironson). Some of the author time (Safren) was supported by the NIH (9K24DA040489).
The content is solely the responsibility of the authors and does not necessarily
represent the official views of the National Institutes of Health. Allwood MA,
2014, J TRAUMA STRESS, V27, P208, DOI 10.1002/jts.21907; Alterman AI, 1998, PSYCHOL
ADDICT BEHAV, V12, P233; American Psychiatric Association, 2013, DIAGN STAT MAN
MENT; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; BARON RM, 1986,
J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Boroughs MS, 2015,
ARCH SEX BEHAV, V44, P1891, DOI 10.1007/s10508-015-0546-9; Bremner JD, 1996, AM J
PSYCHIAT, V153, P369; Cacciola JS, 2007, DRUG ALCOHOL DEPEN, V87, P297, DOI
10.1016/j.drugalcdep.2006.09.002; Chaplin TM, 2008, ALCOHOL CLIN EXP RES, V32,
P1242, DOI 10.1111/j.1530-0277.2008.00679.x; Chilcoat HD, 1998, ADDICT BEHAV, V23,
P827, DOI 10.1016/S0306-4603(98)00069-0; Coffey SF, 2006, PSYCHOL ADDICT BEHAV,
V20, P425, DOI 10.1037/0893-164X.20.4.425; Dalgleish T, 2004, PSYCHOL BULL, V130,
P228, DOI 10.1037/0033-2909.130.2.228; Davidson JRT, 1997, PSYCHOL MED, V27, P153,
DOI 10.1017/S0033291796004229; Debell F, 2014, SOC PSYCH PSYCH EPID, V49, P1401,
DOI 10.1007/s00127-014-0855-7; Dolezal C, 2000, J SUBST ABUSE, V11, P323, DOI
10.1016/S0899-3289(00)00030-4; DOLL LS, 1992, CHILD ABUSE NEGLECT, V16, P855, DOI
10.1016/0145-2134(92)90087-8; Dunmore E, 2001, BEHAV RES THER, V39, P1063, DOI
10.1016/S0005-7967(00)00088-7; Ehlers A, 2000, BEHAV RES THER, V38, P319, DOI
10.1016/S0005-7967(99)00123-0; First M.B., 1997, STRUCTURAL CLIN INTE; Foa E. B.,
2001, TREATING TRAUMA RAPE; Foa EB, 1999, PSYCHOL ASSESSMENT, V11, P303, DOI
10.1037/1040-3590.11.3.303; Green KE, 2012, PSYCHOL ADDICT BEHAV, V26, P265, DOI
10.1037/a0025424; Hartzler B, 2011, AM J DRUG ALCOHOL AB, V37, P460, DOI
10.3109/00952990.2011.602995; Hayes A. F., 2012, PROCESS VERSATILE CO; Hruska B,
2012, PSYCHOL ADDICT BEHAV, V26, P734, DOI 10.1037/a0027584; Irwin TW, 2006, AIDS
BEHAV, V10, P299, DOI 10.1007/s10461-005-9045-7; Jakupcak M, 2010, ADDICT BEHAV,
V35, P840, DOI 10.1016/j.addbeh.2010.03.023; Jayawickreme N, 2012, PSYCHOL ADDICT
BEHAV, V26, P13, DOI 10.1037/a0023363; Kalichman SC, 2007, PREV SCI, V8, P141, DOI
10.1007/s11121-006-0061-2; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI
10.1001/archpsyc.1995.03950240066012; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4,
P231, DOI 10.3109/10673229709030550; Kilpatrick DG, 2003, J CONSULT CLIN PSYCH,
V71, P692, DOI 10.1037/0022-006X.71.4.692; Koblin BA, 2006, AIDS, V20, P731, DOI
10.1097/01.aids.0000216374.61442.55; Lehavot K, 2014, PSYCHOL ADDICT BEHAV, V28,
P42, DOI 10.1037/a0032266; Lenderking WR, 1997, J GEN INTERN MED, V12, P250, DOI
10.1046/j.1525-1497.1997.012004250.x; Marshall BDL, 2015, ALCOHOL CLIN EXP RES,
V39, P380, DOI 10.1111/acer.12631; McFarlane AC, 1998, ADDICT BEHAV, V23, P813, DOI
10.1016/S0306-4603(98)00098-7; Mimiaga MJ, 2009, JAIDS-J ACQ IMM DEF, V51, P340,
DOI 10.1097/QAI.0b013e3181a24b38; Najavits LM, 2004, COGNITIVE THER RES, V28, P159,
DOI 10.1023/B:COTR.0000021537.18501.66; O'Cleirigh C, 2008, HEALTH PSYCHOL, V27,
P297, DOI 10.1037/a0012607; O'Cleirigh C, 2012, JAIDS-J ACQ IMM DEF, V59, P331, DOI
10.1097/QAI.0b013e31824aed80; O'Hare T, 2011, ADDICT BEHAV, V36, P465, DOI
10.1016/j.addbeh.2011.01.006; Paul JP, 2001, CHILD ABUSE NEGLECT, V25, P557, DOI
10.1016/S0145-2134(01)00226-5; Preacher KJ, 2008, BEHAV RES METHODS, V40, P879, DOI
10.3758/BRM.40.3.879; Preacher KJ, 2011, PSYCHOL METHODS, V16, P93, DOI
10.1037/a0022658; Reisner SL, 2010, AIDS CARE, V22, P577, DOI
10.1080/09540120903311482; RESICK PA, 1992, J CONSULT CLIN PSYCH, V60, P748, DOI
10.1037/0022-006X.60.5.748; Riggs DS, 2003, ADDICT BEHAV, V28, P1717, DOI
10.1016/j.addbeh.2003.08.044; Room R, 2005, LANCET, V365, P519, DOI 10.1016/S0140-
6736(05)17870-2; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI
10.4088/JCP.09m05305whi; Sonne SC, 2003, AM J ADDICTION, V12, P412, DOI
10.1080/10550490390240783; Stall R, 2001, ADDICTION, V96, P1589, DOI
10.1046/j.1360-0443.2001.961115896.x; Stewart SH, 1999, PSYCHOL ADDICT BEHAV, V13,
P78, DOI 10.1037/0893-164X.13.2.78; Substance Abuse and Mental Health Services
Administration, 2014, SDUH SER H, VH- 48; Substance Abuse and Mental Health
Services Administration, 2014, HHS PUBL, V(SMA). 14-4884; Sweet T, 2012, JAIDS-J
ACQ IMM DEF, V59, P400, DOI 10.1097/QAI.0b013e3182400e75; Waldrop AE, 2007, ADDICT
BEHAV, V32, P634, DOI 10.1016/j.addbeh.2006.06.001 57 0 0 1 4
WILEY HOBOKEN 111 RIVER ST, HOBOKEN 07030-5774, NJ USA 0894-9867 1573-
6598 J TRAUMA STRESS J. Trauma Stress AUG 2018 31 4
602 612 10.1002/jts.22304 11 Psychology,
Clinical; Psychiatry Psychology; Psychiatry GR3MQ WOS:000442495900014
30028033 2019-09-25
J Roehler, DR; Heinze, JE; Stoddard, SA; Bauermeister, JA; Zimmerman, MA
Roehler, Douglas R.; Heinze, Justin E.; Stoddard, Sarah A.;
Bauermeister, Jose A.; Zimmerman, Marc A. The Association Between Early
Exposure to Violence in Emerging Adulthood and Substance Use in Early-Adulthood
Among Inner-City Individuals EMERGING ADULTHOOD English
Article violence; substance use; abuse;
alcohol use; abuse; health behavior; injury MENTAL-HEALTH; ADOLESCENT SMOKING;
POLYSUBSTANCE USE; DRUG-USE; ALCOHOL; CONSEQUENCES; CIGARETTES; DISORDERS;
MARIJUANA; PATTERNS This study investigated whether being exposed to violence
early in life is a risk factor for substance use later in life. Tenets of the
stress-coping model and the self-medication hypothesis guided the analyses.
Participants included 850 individuals from an economically challenged, urban
community in Flint, MI (83% Black/African American; 50% male). Exposure to violence
was measured 4 times in sequential years during emerging adulthood (ages 20-23) and
substance use 4 times during early adulthood (ages 29-32). Multilevel growth models
investigated the relationship between early exposure to violence and later rates of
substance use. Youth who had above-average exposure to violence during emerging
adulthood had increasing substance use during early adulthood compared to those
with a below-average score, after controlling for prior use. These findings may
inform practitioners to screen for substance use among individuals exposed to
violence and intervene earlier before substance use becomes problematic.
[Roehler, Douglas R.] Rush Univ, Med Ctr, Dept Pediat, 1645W Jackson
Blvd,Suite 450, Chicago, IL 60612 USA; [Roehler, Douglas R.; Heinze, Justin E.;
Stoddard, Sarah A.; Bauermeister, Jose A.; Zimmerman, Marc A.] Michigan Youth
Violence Prevent Ctr, Ann Arbor, MI USA; [Heinze, Justin E.; Zimmerman, Marc A.]
Univ Michigan, Sch Publ Hlth, Dept Hlth Behav & Hlth Educ, Ann Arbor, MI USA;
[Stoddard, Sarah A.] Univ Michigan, Sch Nursing, Ann Arbor, MI 48109 USA;
[Bauermeister, Jose A.] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA
 Roehler, DR (reprint author), Rush Univ, Med Ctr, Dept Pediat, 1645W Jackson
Blvd,Suite 450, Chicago, IL 60612 USA. douglas_roehler@rush.edu
Bauermeister, Jose/X-8960-2018 Bauermeister, Jose/0000-0002-9276-2306;
Roehler, Douglas/0000-0003-3646-7174 American Psychiatric
Association, 2013, DIAGN STAT MAN MENT; Anda RF, 1999, JAMA-J AM MED ASSOC, V282,
P1652, DOI 10.1001/jama.282.17.1652; Arnett JJ, 2007, CHILD DEV PERSPECT, V1, P68,
DOI 10.1111/j.1750-8606.2007.00016.x; Berton MW, 1996, ADOLESCENCE, V31, P489;
Brenner AB, 2015, SUBST USE MISUSE, V50, P1606, DOI 10.3109/10826084.2015.1027927;
Bryant A L, 2000, Prev Sci, V1, P71, DOI 10.1023/A:1010038130788; CDC (Centers for
Disease Control and Prevention), 2014, WEB BAS INJ STAT QUE; de Souza DPO, 2005,
REV SAUDE PUBL, V39, P585, DOI 10.1590/S0034-89102005000400011; Dermody S. S.,
2015, DRUG ALCOHOL DEPEN, V146, pe263; Derogatis LR, 1993, BRIEF SYMPTOM INVENT;
DiezRoux AV, 1997, AM J EPIDEMIOL, V146, P48; Fergus S, 2005, ANNU REV PUBL HEALTH,
V26, P399, DOI 10.1146/annurev.publhealth.26.021304.144357; Finkelstein DM, 2006, J
ADOLESCENT HEALTH, V39, P678, DOI 10.1016/j.jadohealth.2006.04.011; Galea S, 2007,
AM J PREV MED, V32, pS195, DOI 10.1016/j.amepre.2007.04.003; Goldmann E, 2014, ANNU
REV PUBL HEALTH, V35, P169, DOI 10.1146/annurev-publhealth-032013-182435; Huang GC,
2014, J ADOLESCENT HEALTH, V54, P508, DOI 10.1016/j.jadohealth.2013.07.001; Jamal
A, 2014, MMWR-MORBID MORTAL W, V63, P1108; Johnston LD, 2010, MONITORING FUTURE NA,
VII; Kassel JD, 2007, J ABNORM PSYCHOL, V116, P543, DOI 10.1037/0021-
843X.116.3.543; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI
10.3109/10673229709030550; Khantzian EJ, 2007, TREATING ADDICTION H; Leung RK,
2014, HEALTH PSYCHOL REV, V8, P426, DOI 10.1080/17437199.2011.587961; Macinko J,
2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134153; Menard S, 2015, CHILD ABUSE
NEGLECT, V42, P30, DOI 10.1016/j.chiabu.2015.01.006; Mistry R, 2015, J YOUTH
ADOLESCENCE, V44, P1871, DOI 10.1007/s10964-015-0309-x; Moss HB, 2014, DRUG ALCOHOL
DEPEN, V136, P51, DOI 10.1016/j.drugalcdep.2013.12.011; Nakao K., 1992, 1989
SOCIOECONOMIC I; Nemeroff CB, 2004, J CLIN PSYCHIAT, V65, P18; Roberts ME, 2008, J
ADOLESCENT HEALTH, V42, P266, DOI 10.1016/j.jadohealth.2007.08.029; Sabbagh L.,
2006, SCI AM MIND, V17, P20; Salom CL, 2016, ADDICTION, V111, P156, DOI
10.1111/add.13058; SCHUBINER H, 1993, J ADOLESCENT HEALTH, V14, P214, DOI
10.1016/1054-139X(93)90008-D; Schulenberg JE, 2004, DEV PSYCHOPATHOL, V16, P799,
DOI 10.1017/S0954579404040015; SHIFFMAN S, 1993, J CONSULT CLIN PSYCH, V61, P732,
DOI 10.1037/0022-006X.61.5.732; StataCorp, 2015, STAT STAT SOFTW REL; Stoddard SA,
2015, J ADOLESCENCE, V44, P191, DOI 10.1016/j.adolescence.2015.07.017; Stoddard SA,
2012, J RES ADOLESCENCE, V22, P542, DOI 10.1111/j.1532-7795.2012.00786.x; Substance
Abuse and Mental Health Services Administration, 2014, USITC PUBL, V( SMA) 13-
4795; Substance Abuse and Mental Health Services Administration, 2014, NSDUH SER H,
V46; Sullivan TN, 2004, J CLIN CHILD ADOLESC, V33, P488, DOI
10.1207/s15374424jccp3303_6; Vermeiren R, 2003, PEDIATRICS, V111, P535, DOI
10.1542/peds.111.3.535; Wills T. A., 1985, COPING SUBSTANCE USE, P3; Wills TA,
1996, J PERS SOC PSYCHOL, V71, P937, DOI 10.1037/0022-3514.71.5.937; Zimmerman MA,
2002, J APPL SOC PSYCHOL, V32, P86, DOI 10.1111/j.1559-1816.2002.tb01421.x;
Zimmerman MA, 2000, RESILIENCE ACROSS CONTEXTS: FAMILY, WORK, CULTURE, AND
COMMUNITY, P233 45 0 0 2 5 SAGE PUBLICATIONS INC THOUSAND
OAKS 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA 2167-6968 2167-6984
EMERG ADULTHOOD Emerg. Adulthood AUG 2018 6 4
235 242 10.1177/2167696817725455 8 Family
Studies; Psychology, Developmental; Psychology, Social Family Studies;
Psychology GK3IS WOS:000436037600002 2019-09-25
J Rasmussen, IS; Arefjord, K; Winje, D; Dovran, A Rasmussen,
Ingvild S.; Arefjord, Kjersti; Winje, Dagfinn; Dovran, Anders
Childhood maltreatment trauma: a comparison between patients in treatment for
substance use disorders and patients in mental health treatment EUROPEAN JOURNAL
OF PSYCHOTRAUMATOLOGY English Article
Child abuse; neglect; post-raumatic stress symptoms; Childhood Trauma
Questionnaire; avoidance symptoms; self-medication model; dual diagnosis
POSTTRAUMATIC-STRESS-DISORDER; PSYCHOMETRIC PROPERTIES; PHYSICAL ABUSE;
HOUSEHOLD DYSFUNCTION; SEXUAL-ABUSE; QUESTIONNAIRE; EXPERIENCES; NEGLECT; IMPACT;
RISK Background: While previous research has found strong associations between
childhood maltreatment trauma and substance use disorders (SUDs), the role of
possible moderating effects of gender and mediating effects of psychopathology and
SUD is unclear. Objective: The objective of this study was to investigate
differences in self-reported childhood maltreatment trauma, general psychological
distress, and post-traumatic stress symptoms between 112 patients in treatment for
substance use disorders (SUD group) and 112 matched controls with mild to moderate
mental health disorders (comparison group). Methods: Childhood maltreatment trauma
was measured by the Childhood Trauma Questionnaire - Short Form (CTQ-SF). General
psychological distress was measured by the Symptom Checklist-90 - Revised (SCL-90-
R), and post-traumatic stress symptoms were measured by the Impact of Event Scale
-Revised (IES-R). Results: The SUD group reported more severe childhood
maltreatment trauma than the comparison group. Females in the SUD group reported
more severe and various forms of trauma compared to males. The SUD group reported
higher mean scores on the SCL-90-R, but the proportions of people with caseness
scores on the IES-R and the SCL-90-R were similar in the two samples. The SUD group
reported more avoidance symptoms than the comparison group. Conclusion: This study
adds further evidence to the repeatedly found strong associations between childhood
maltreatment trauma and SUD, implying that the prevention of childhood maltreatment
trauma may reduce the occurrence of SUD. Furthermore, patients with SUD should be
screened for childhood maltreatment trauma, and the results should be applied in
trauma-informed as well as trauma-focused interventions aimed to help this
population. The association appears to be particularly strong for female substance
users. [Rasmussen, Ingvild S.] Karmoy Dist Psychiat Ctr, Outpatient Dept,
Kopervik, Norway; [Arefjord, Kjersti; Winje, Dagfinn; Dovran, Anders] Univ Bergen,
Dept Clin Psychol, Fac Psychol, Bergen, Norway; [Dovran, Anders] Stine Sofies Fdn,
Grimstad, Norway; [Dovran, Anders] Stine Sofie Ctr, Grimstad, Norway Rasmussen,
IS (reprint author), Haugesund Kommune, Helsestasjon & Skolehelsetjeneste, Post Box
2160, N-5504 Haugesund, Norway. Ingvild.Rasmussen@haugesund.kommune.no
Alisic E, 2014, BRIT J PSYCHIAT, V204, P335, DOI
10.1192/bjp.bp.113.131227; [Anonymous], 2015, STATISTICA; Back Sudie E., 2007,
PSYCHIAT TIMES, V24, P48; Baker AJL, 2010, CHILD YOUTH SERV REV, V32, P740, DOI
10.1016/j.childyouth.2010.01.011; Banyard VL, 2001, J TRAUMA STRESS, V14, P697, DOI
10.1023/A:1013085904337; Bernstein DP, 2003, CHILD ABUSE NEGLECT, V27, P169, DOI
10.1016/S0145-2134(02)00541-0; Bernstein DP, 1998, CHILDHOOD TRAUMA QUE; Brady K.
T., 2015, TXB ADDICITON TREATM; Breslau N, 2009, TRAUMA VIOLENCE ABUS, V10, P198,
DOI 10.1177/1524838009334448; Butchart A, 2006, PREVENTING CHILD MAL; Cloitre M,
2013, EUR J PSYCHOTRAUMATO, V4, DOI 10.3402/ejpt.v4i0.20706; Cloitre M, 2009, J
TRAUMA STRESS, V22, P399, DOI 10.1002/jts.20444; Creamer M, 2003, BEHAV RES THER,
V41, P1489, DOI 10.1016/j.brat.2003.07.010; Daigre C, 2015, PSYCHIAT RES, V229,
P743, DOI 10.1016/j.psychres.2015.08.008; De Bellis MD, 2002, PSYCHONEUROENDOCRINO,
V27, P155, DOI 10.1016/S0306-4530(01)00042-7; Derogatis L. R., 2009, SYMPTOM
CHECKLIST 90; Dong MX, 2004, CHILD ABUSE NEGLECT, V28, P771, DOI
10.1016/j.chiabu.2004.01.008; Douglas KR, 2010, ADDICT BEHAV, V35, P7, DOI
10.1016/j.addbeh.2009.07.004; Dovran A, 2013, SCAND J PSYCHOL, V54, P286, DOI
10.1111/sjop.12052; Dube SR, 2003, PEDIATRICS, V111, P564, DOI
10.1542/peds.111.3.564; Fergusson DM, 2008, CHILD ABUSE NEGLECT, V32, P607, DOI
10.1016/j.chiabu.2006.12.018; Fergusson DM, 2013, CHILD ABUSE NEGLECT, V37, P664,
DOI 10.1016/j.chiabu.2013.03.013; Finkelhor D, 2007, CHILD ABUSE NEGLECT, V31, P7,
DOI 10.1016/j.chiabu.2006.06.008; Gielen N, 2012, EUR J PSYCHOTRAUMATO, V3, DOI
10.3402/ejpt.v3i0.17734; Gilbert R, 2009, LANCET, V373, P68, DOI 10.1016/S0140-
6736(08)61706-7; Green JG, 2010, ARCH GEN PSYCHIAT, V67, P113, DOI
10.1001/archgenpsychiatry.2009.186; Hardt J, 2004, J CHILD PSYCHOL PSYC, V45, P260,
DOI 10.1111/j.1469-7610.2004.00218.x; Hayes SC, 1996, J CONSULT CLIN PSYCH, V64,
P1152, DOI 10.1037/0022-006X.64.6.1152; Heir T, 2009, BRIT J PSYCHIAT, V194, P510,
DOI 10.1192/bjp.bp.108.056580; HERMAN JL, 1992, J TRAUMA STRESS, V5, P377, DOI
10.1002/jts.2490050305; Kessler RC, 2010, BRIT J PSYCHIAT, V197, P378, DOI
10.1192/bjp.bp.110.080499; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259;
MacDonald K, 2015, J INTERPERS VIOLENCE, V30, P988, DOI 10.1177/0886260514539761;
Min M, 2007, J TRAUMA STRESS, V20, P833, DOI 10.1002/jts.20250; Rash CJ, 2008,
ADDICT BEHAV, V33, P1039, DOI 10.1016/j.addbeh.2008.04.006; Read JP, 2004, ADDICT
BEHAV, V29, P1665, DOI 10.1016/j.addbeh.2004.02.061; Reed PL, 2007, ARCH GEN
PSYCHIAT, V64, P1435, DOI 10.1001/archpsyc.64.12.1435; Simpson TL, 2002, CLIN
PSYCHOL REV, V22, P27, DOI 10.1016/S0272-7358(00)00088-X; Taplin C, 2014, SUBST USE
MISUSE, V49, P1311, DOI 10.3109/10826084.2014.901383; Teodorescu DS, 2012, SCAND J
PSYCHOL, V53, P316, DOI 10.1111/j.1467-9450.2012.00954.x; Tolin DF, 2006, PSYCHOL
BULL, V132, P959, DOI 10.1037/0033-2909.132.6.959; Tonmyr L, 2010, CURR PSYCHIATRY
REV, V6, P223, DOI 10.2174/157340010791792581; Vachon DD, 2015, JAMA PSYCHIAT, V72,
P1135, DOI 10.1001/jamapsychiatry.2015.1792; van der Kolk BA, 2005, J TRAUMA
STRESS, V18, P389, DOI 10.1002/jts.20047; Weiss D, 1997, ASSESSING PSYCHOL TR,
P168; Weiss D. S., 2008, PSYCHOL TRAUMA-US, V5, P3, DOI [10.1037/1942-9681.S.1.3,
DOI 10.1037/1942-9681.S.1.3]; Winje D., 2001, NORWEGIAN UNPUB; Winje D., 2003,
SPORRESKJEMA TRAUMER; World Health Organization, 1992, ICD 10 CLASS MENT BE; World
Health Organization, 2016, HLTH TOP CHILD MALTR 50 1 1 2 9 TAYLOR
& FRANCIS LTD ABINGDON 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN,
OXON, ENGLAND 2000-8066 EUR J PSYCHOTRAUMATO Eur. J.
Psychotraumatol. JUL 17 2018 9 1
1492835 10.1080/20008198.2018.1492835 10 Psychology,
Clinical; Psychiatry Psychology; Psychiatry GU8SL WOS:000445612100001
30034641 DOAJ Gold, Green Published 2019-09-25
J Balayssac, D; Pereira, B; Darfeuille, M; Cuq, P; Vernhet, L; Collin, A;
Vennat, B; Authier, N Balayssac, David; Pereira, Bruno;
Darfeuille, Maxime; Cuq, Pierre; Vernhet, Laurent; Collin, Aurore; Vennat,
Brigitte; Authier, Nicolas Use of Psychotropic Medications and
Illegal Drugs, and Related Consequences Among French Pharmacy Students - SCEP
Study: A Nationwide Cross-Sectional Study FRONTIERS IN PHARMACOLOGY
English Article psychotropic drugs;
street drugs; pharmacy student; self-medication; comorbidity SELF-MEDICATION;
COLLEGE-STUDENTS; SUBSTANCE USE; CANNABIS USE; MENTAL-DISORDERS; USE BEHAVIORS;
ALCOHOL; PREVALENCE; RISK; MISUSE Background: The use of psychotropic medications
and illegal drugs is a worldwide public health issue, leading to addiction,
psychiatric and somatic disorders, and death. Pharmacy students are more exposed to
psychotropic medications than other students (non-medical), which could lead to an
overuse. The main objective of this study was to assess the prevalence of
psychotropic drug use (medications and illegal drugs) by French pharmacy students,
by carrying out a nationwide cross-sectional study. The relation of these
medications and illegal drug use with several comorbidities and academic
achievement was also assessed. Methods: This online survey was performed by emails
sent to all French pharmacy faculties over a period of 66 days (March 16, 2016 to
May 20, 2016). The survey assessed the prevalence of uses of psychotropic
medications and illegal drugs during the last 3 months. These uses were compared to
student characteristics (personal and university) and comorbidities (anxiety,
depression, stress, and fatigue). Results: Of the 2,609 questionnaires received,
2,575 were completed and useable for the analysis. Among French pharmacy students
and during the 3 last months, 9.4% have used psychotropic medications, 21.5%
illegal drugs and 3.3% both psychotropic medications and illegal drugs.
Psychotropic medications were used in the cases of a medical prescription (49.0%),
a self-medication (42.4%) or a non-medical intent (26.3%). Stress scores of the
last 7 days were higher for psychotropic medication users compared to non-users and
illegal drug users. Proportions of anxiety and depression at the time of answer
were higher for psychotropic medication users than for non-users and illegal drug
users. Fatigue scores of the last 7 days were lower for illegal drug users compared
to non-users and self-medicated students. Annual average marks of the last year,
attendance and perception of study difficulty were lower for illegal drug users
than for non-users. Conclusion: French pharmacy students were less exposed to
psychotropic medications and illegal drugs than the general French population.
However, in comparison to other students in other countries, the use of
psychotropic medications seemed to be lower, but with a proportionally higher use
of anxiety/sedative medications and a lower use of opioid medications. [Balayssac,
David] Univ Clermont Auvergne, Fac Pharm, CHU Clermont Ferrand, Inserm U1107,NEURO
DOL,Lab Toxicol,Delegat Rech C, Clermont Ferrand, France; [Pereira, Bruno] CHU
Clermont Ferrand, Delegat Rech Clin & Innovat, Clermont Ferrand, France;
[Darfeuille, Maxime] Univ Clermont Auvergne, Fac Pharm, Lab Toxicol, Clermont
Ferrand, France; [Cuq, Pierre] Univ Montpellier, Fac Pharm, IBMM, ENSCM,UMR
5247,CNRS, Montpellier, France; [Vernhet, Laurent] Univ Rennes 1, IRSET, UMR Inserm
1085, Rennes, France; [Collin, Aurore] Univ Clermont Auvergne, NEURO DOL, Inserm
U1107, Fac Pharm,Lab Toxicol, Clermont Ferrand, France; [Vennat, Brigitte] Univ
Clermont Auvergne, ACCePPT, Fac Pharm, Clermont Ferrand, France; [Authier, Nicolas]
Univ Clermont Auvergne, Inserm U1107, CHU Clermont Ferrand, Fac Med,NEURO
DOL,Pharmacol Med, Clermont Ferrand, France Balayssac, D (reprint author), Univ
Clermont Auvergne, Fac Pharm, CHU Clermont Ferrand, Inserm U1107,NEURO DOL,Lab
Toxicol,Delegat Rech C, Clermont Ferrand, France. dbalayssac@chu-
clermontferrand.fr Balayssac, David/K-2265-2015; Collin, Aurore/K-2251-2015
Collin, Aurore/0000-0002-1568-2775; Balayssac, David/0000-0002-6126-6588;
CUQ, Pierre/0000-0002-5440-9165 Agence nationale de securite du
medicament et des produits de sante (ANSM), 2017, ET LIEUX CONS BENZ P; Alkhatatbeh
MJ, 2016, INT J CLIN PHARM TH, V54, P390, DOI 10.5414/CP202451; Auerbach RP, 2016,
PSYCHOL MED, V46, P2955, DOI 10.1017/S0033291716001665; Bachhuber MA, 2016, AM J
PUBLIC HEALTH, V106, P686, DOI 10.2105/AJPH.2016.303061; Balayssac D, 2017, PEERJ,
V5, DOI 10.7717/peerj.3973; Balayssac D, 2017, PLOS ONE, V12, DOI
10.1371/journal.pone.0182956; Baldwin JN, 2011, SUBST ABUS, V32, P27, DOI
10.1080/08897077.2011.540470; Beck F, 2005, PSYCHOTROPES, V11, P31, DOI [DOI
10.3917/PSYT.113.0031, 10.3917/psyt.113.0031]; Beck F, 2014, SUBST USE MISUSE, V49,
P878, DOI 10.3109/10826084.2014.889910; Benard-Laribiere A, 2016, EUR J CLIN
PHARMACOL, V72, P869, DOI 10.1007/s00228-016-2044-y; Blanco C, 2016, JAMA PSYCHIAT,
V73, P388, DOI 10.1001/jamapsychiatry.2015.3229; Boudreau D, 2009, PHARMACOEPIDEM
DR S, V18, P1166, DOI 10.1002/pds.1833; Carrasco-Garrido P, 2010, PHARMACOEPIDEM DR
S, V19, P1293, DOI 10.1002/pds.2034; Casati A, 2012, EUR ADDICT RES, V18, P228, DOI
10.1159/000337028; Braquehais MD, 2014, J DUAL DIAGN, V10, P148, DOI
10.1080/15504263.2014.929331; Durrieu G, 2007, BRIT J CLIN PHARMACO, V64, P233, DOI
10.1111/j.1365-2125.2007.02882.x; Domingues PHF, 2015, REV SAUDE PUBL, V49, DOI
10.1590/S0034-8910.2015049005709; Feise Ronald J, 2002, BMC Med Res Methodol, V2,
P8, DOI 10.1186/1471-2288-2-8; Fortney JC, 2016, GEN HOSP PSYCHIAT, V38, P99, DOI
10.1016/j.genhosppsych.2015.09.007; Garasic MD, 2016, BMC MED ETHICS, V17, DOI
10.1186/s12910-016-0102-8; Ghandour LA, 2013, EUR ADDICT RES, V19, P202, DOI
10.1159/000345445; Gignon M, 2015, WORKPLACE HEALTH SAF, V63, P54, DOI
10.1177/2165079915570917; Gualano MR, 2015, EUR J PUBLIC HEALTH, V25, P444, DOI
10.1093/eurpub/cku207; Guo L, 2016, JAMA PEDIATR, V170, P971, DOI
10.1001/jamapediatrics.2016.1802; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI
10.1016/j.jbi.2008.08.010; Hider-Mlynarz K, 2018, BRIT J CLIN PHARMACO, V84, P1324,
DOI 10.1111/bcp.13564; Hill KP, 2017, JAMA-J AM MED ASSOC, V317, P1070, DOI
10.1001/jama.2016.19706; Holbrook AM, 2004, BRIT MED J, V329, P1198, DOI
10.1136/bmj.329.7476.1198; James H, 2008, INT J CLIN PHARM TH, V46, P23; Jerez-Roig
J, 2014, DRUG AGING, V31, P883, DOI 10.1007/s40266-014-0217-x; Kasulkar AA, 2015,
INDIAN J PHARM SCI, V77, P178, DOI 10.4103/0250-474X.156569; Kovess-Masfety
Viviane, 2016, BMC Psychol, V4, P20, DOI 10.1186/s40359-016-0124-5; Lukovic JA,
2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114644; McCabe SE, 2014, ADDICT
BEHAV, V39, P1176, DOI 10.1016/j.addbeh.2014.03.008; Morley KI, 2017, PAIN, V158,
P1138, DOI 10.1097/j.pain.0000000000000892; OFDT, 2017, CANN SYNTH CONN OFDT; OFDT,
2017, TAB CIG EL SYNTH CON; OFDT, 2017, ALC SYNTH CONN OFDT; Oliver W, 2014, AM J
PHARM EDUC, V78, DOI 10.5688/ajpe78230; Oquendo MA, 2018, NEW ENGL J MED, V378,
P1567, DOI 10.1056/NEJMp1801417; Patil SB, 2014, J CLIN DIAGN RES, V8, pHC20, DOI
10.7860/JCDR/2014/10579.5313; Peck Kelly R, 2016, J Opioid Manag, V12, P205, DOI
10.5055/jom.2016.0333; Pergolizzi JV, 2017, PAIN THER, V6, P1, DOI 10.1007/s40122-
017-0068-3; Pickard M, 2000, MED EDUC, V34, P148, DOI 10.1046/j.1365-
2923.2000.00491.x; Pottier P, 2011, MED EDUC, V45, P678, DOI 10.1111/j.1365-
2923.2011.03935.x; Punja S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108416;
Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010;
Sachs J, 2015, NEUROTHERAPEUTICS, V12, P735, DOI 10.1007/s13311-015-0380-8; Sommet
A, 2012, THERAPIE, V67, P429, DOI 10.2515/therapie/2012056; Soyka M, 2017, NEW ENGL
J MED, V376, P1147, DOI 10.1056/NEJMra1611832; Stockwell T, 2016, ADDICTION, V111,
P1203, DOI 10.1111/add.13373; Tavolacci MP, 2013, BMC PUBLIC HEALTH, V13, DOI
10.1186/1471-2458-13-724; United Nations Office on Drugs and Crime (UNODC), 2016,
WORLD DRUG REP 2016; von Elm E, 2007, EPIDEMIOLOGY, V18, P800, DOI
10.1097/EDE.0b013e3181577654; WHO, 2018, WHO CANN; Younes F, 2016, PLOS ONE, V11,
DOI 10.1371/journal.pone.0161126; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361,
DOI 10.1111/j.1600-0447.1983.tb09716.x 57 0 0 2 8 FRONTIERS
MEDIA SA LAUSANNE AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015,
SWITZERLAND 1663-9812 FRONT PHARMACOL Front. Pharmacol. JUL 17
2018 9 725
10.3389/fphar.2018.00725 12 Pharmacology & Pharmacy
Pharmacology & Pharmacy GN3TA WOS:000438930200001 30065649 DOAJ Gold,
Green Published 2019-09-25
J Fuchshuber, J; Hiebler-Ragger, M; Kresse, A; Kapfhammer, HP; Unterrainer, HF
Fuchshuber, Juergen; Hiebler-Ragger, Michaels; Kresse, Adetheid;
Kapfhammer, Hans-Peter; Unterrainer, Human F. Depressive Symptoms and
Addictive Behaviors in Young Adults After Childhood Trauma: The Mediating Role of
Personality Organization and Despair FRONTIERS IN PSYCHIATRY
English Article substance use disorder;
depression; structural equation modeling; childhood trauma; primary emotions;
personality organization; mediation PSYCHOMETRIC PROPERTIES; GENDER-DIFFERENCES;
SELF-MEDICATION; RIGHT BRAIN; DISORDERS; NEUROSCIENCE; EPIDEMIOLOGY; ATTACHMENT;
INVENTORY; ALCOHOL Background:There is substantial evidence that traumatic
experiences in childhood increase the likelihood of mood pathology and addictive
behaviors in adolescence and young adulthood. Furthermore, both forms of
psychopathology have been linked to deficiencies in personality organization and a
common primary emotion core. In this study, we intended to further investigate
these interactions by assuming a mediating role of personality organization and
despair regarding the relationship between childhood trauma and psychiatric symptom
burden later in life. Methods: A total sample of 500 young adults (Age: M = 26, SD
= 5.51;63.2% female) were investigated. Structural Equation Modeling was applied in
order to investigate the pathways between the latent variables Childhood Trauma,
Structural Deficit, Despair (comprised of the primary emotions SEEKING and
SADNESS), as well as symptoms of addiction and depression. Results: The results
indicate that the influence of Childhood Trauma on Addictive Behaviors was mediated
by Structural Deficit (p < 0.01), whereas its influence on Depressive Symptoms was
mediated by Despair (decreased SEEKING and increased SADNESS) (p < 0.01).
Furthermore, Addictive Behaviors seemed to be stronger represented in males (p <
0.001). The final model was able to explain 39% of the variance of Addictive
Behaviors and 85% of the variance of Depressive Symptoms. Discussion: The findings
underline the importance of early experiences in the development of adult affective
and personality functioning, which is linked to the development of psychiatric
disorders. Regarding clinical practice, addiction treatment might focus on the
improvement of personality organization, while treatment of depressed patients
should primarily emphasize the restructuring of dysfunctional primary emotion
dispositions. [Fuchshuber, Juergen; Hiebler-Ragger, Michaels; Unterrainer,
Human F.] Gruner Kreis Soc, Ctr Integrat Addict Res, Vienna, Austria; [Fuchshuber,
Juergen; Hiebler-Ragger, Michaels; Kapfhammer, Hans-Peter; Unterrainer, Human F.]
Med Univ Graz, Univ Clin Psychiat & Psychotherapeut Med, Graz, Austria; [Kresse,
Adetheid] Med Univ Graz, Inst Pathophysiol & Immunol, Graz, Austria; [Unterrainer,
Human F.] Univ Vienna, Dept Religious Studies, Vienna, Austria Unterrainer, HF
(reprint author), Gruner Kreis Soc, Ctr Integrat Addict Res, Vienna, Austria.;
Unterrainer, HF (reprint author), Med Univ Graz, Univ Clin Psychiat &
Psychotherapeut Med, Graz, Austria.; Unterrainer, HF (reprint author), Univ Vienna,
Dept Religious Studies, Vienna, Austria. human.unterrainer@univie.ac.at
Albert PR, 2015, J PSYCHIATR NEUROSCI, V40, P219, DOI
10.1503/jpn.150205; Alcaro A, 2011, NEUROSCI BIOBEHAV R, V35, P1805, DOI
10.1016/j.neubiorev.2011.03.002; Benedetti F, 2011, BIOL PSYCHIAT, V69, P309, DOI
10.1016/j.biopsych.2010.07.028; Bernstein DP, 1997, J AM ACAD CHILD PSY, V36, P340,
DOI 10.1097/00004583-199703000-00012; Berridge KC, 2009, INQUIRY, V52, P378, DOI
10.1080/00201740903087359; Bora E, 2012, ADDICT BIOL, V17, P141, DOI
10.1111/j.1369-1600.2010.00266.x; Brady KT, 1999, PSYCHIAT CLIN N AM, V22, P241,
DOI 10.1016/S0193-953X(05)70074-5; Carr CP, 2013, J NERV MENT DIS, V201, P1007, DOI
10.1097/NMD.0000000000000049; Cheung GW, 2008, ORGAN RES METHODS, V11, P296, DOI
10.1177/1094428107300343; CLARK LA, 1994, J ABNORM PSYCHOL, V103, P103, DOI
10.1037/0021-843X.103.1.103; Daigre C, 2015, PSYCHIAT RES, V229, P743, DOI
10.1016/j.psychres.2015.08.008; Daniels JK, 2013, DEPRESS ANXIETY, V30, P207, DOI
10.1002/da.22044; Davis K.L., 2003, NEUROPSYCHOANALYSIS, V5, P57, DOI DOI
10.1080/15294145.2003.10773410; Davis KL, 2011, NEUROSCI BIOBEHAV R, V35, P1946,
DOI 10.1016/j.neubiorev.2011.04.004; Derogatis LR, 2000, BSI 18 ADM SCORING P, DOI
[10.1037/t07502-000, DOI 10.1037/T07502-000]; Erikson E. H., 1993, CHILDHOOD SOC;
Fernand SC, 2012, PSYCHONEUROENDOCRINO, V37, P1659, DOI
10.1016/j.psyneuen.2012.02.012; Fonagy P., 2018, ATTACHMENT THEORY PS; Fonagy P.,
2010, EARLY DEV ITS DISTUR, P53, DOI 10.4324/9780429474057-2; Freud S., 1906, EUR
NEUROL, V18, P285, DOI [10.1159/000213436, DOI 10.1159/000213436]; Garland EL,
2013, J BEHAV MED, V36, P175, DOI 10.1007/s10865-012-9413-5; Gergely G., 2002,
AFFECT REGULATION ME; Gosling SD, 2004, AM PSYCHOL, V59, P93, DOI 10.1037/0003-
066X.59.2.93; Granieri A, 2018, FRONT PSYCHIATRY, V9, DOI 10.3389/fpsyt.2018.00206;
Grant BF, 2016, JAMA PSYCHIAT, V73, P39, DOI 10.1001/jamapsychiatry.2015.2132;
Grant BF, 2015, JAMA PSYCHIAT, V72, P757, DOI 10.1001/jamapsychiatry.2015.0584;
Heim C, 2001, BIOL PSYCHIAT, V49, P1023, DOI 10.1016/S0006-3223(01)01157-X;
Hiebler-Ragger M, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.00370; Hiebler-
Ragger M, 2016, PSYCHOPATHOLOGY, V49, P341, DOI 10.1159/000448177; Hiebler-Ragger
M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158069; Humeniuk R, 2008,
ADDICTION, V103, P1039, DOI 10.1111/j.1360-0443.2007.02114.x; Janet P., 1889,
AUTOMATISME PSYCHOL; KERNBERG O, 1967, J AM PSYCHOANAL ASS, V15, P641, DOI
10.1177/000306516701500309; Kernberg O. F., 1985, BORDERLINE CONDITION; Kernberg
OF, 1993, SEVERE PERSONALITY D; Kernberg OF, 2015, INT FORUM PSYCHOANAL, V24, P38,
DOI 10.1080/0803706X.2014.912352; Kessler RC, 2003, J AFFECT DISORDERS, V74, P5,
DOI 10.1016/S0165-0327(02)00426-3; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593,
DOI 10.1001/archpsyc.62.6.593; Kessler RC, 2010, BRIT J PSYCHIAT, V197, P378, DOI
10.1192/bjp.bp.110.080499; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI
10.3109/10673229709030550; Kienast T, 2014, DTSCH ARZTEBL INT, V111, P280, DOI
10.3238/arztebl.2014.0280; Kilpatrick DG, 2000, J CONSULT CLIN PSYCH, V68, P19, DOI
10.1037/0022-006X.68.1.19; Kim J, 2010, J CHILD PSYCHOL PSYC, V51, P706, DOI
10.1111/j.1469-7610.2009.02202.x; Kline RB, 2015, PRINCIPLES PRACTICE; Lai CH,
2014, PSYCHOL MED, V44, P2825, DOI 10.1017/S0033291714000440; Laplanche Jean, 1988,
LANGUAGE PSYCHOANALY; Lenzenweger MF, 2001, PSYCHOL ASSESSMENT, V13, P577, DOI
10.1037//1040-3590.13.4.577; Mentzos S., 2017, LEHRBUCH PSYCHODYNAM; Montag C,
2017, COMPR PSYCHIAT, V73, P136, DOI 10.1016/j.comppsych.2016.11.007; Montag C,
2016, FRONT PSYCHOL, V7, DOI [10.3389/fpsyg.2016.01906, 10.3389/fpsyq.2016.01906];
Murphy ML, 2011, BIOL MOOD ANXIETY DI, V1, DOI 10.1186/2045-5380-1-3; Nestler EJ,
2006, BIOL PSYCHIAT, V59, P1151, DOI 10.1016/j.biopsych.2005.09.018; Newcombe DAL,
2005, DRUG ALCOHOL REV, V24, P217, DOI 10.1080/09595230500170266; NOLENHOEKSEMA S,
1994, PSYCHOL BULL, V115, P424, DOI 10.1037/0033-2909.115.3.424; Panksepp J, 2012,
ARCHAEOLOGY MIND NEU; Panksepp J., 2004, AFFECTIVE NEUROSCIEN; Panksepp J, 2012,
TRENDS COGN SCI, V16, P6, DOI 10.1016/j.tics.2011.11.005; Panksepp J, 2011, PLOS
ONE, V6, DOI 10.1371/journal.pone.0021236; Panksepp Jaak, 2010, Dialogues Clin
Neurosci, V12, P533; Riva-Posse P, 2018, MOL PSYCHIATR, V23, P843, DOI
10.1038/mp.2017.59; Rudolf G., 2002, STRUKTUR PERSONLICHK, P2; Schimmenti A, 2018,
J TRAUMA DISSOCIATIO, V19, P552, DOI 10.1080/15299732.2017.1402400; Schore AN,
2001, INFANT MENT HEALTH J, V22, P7, DOI 10.1002/1097-0355(200101/04)22:1<7::AID-
IMHJ2>3.0.CO;2-N; Schore AN, 2002, AUST NZ J PSYCHIAT, V36, P9, DOI 10.1046/j.1440-
1614.2002.00996.x; Solms M, 2015, FEELING BRAIN SELECT, P109, DOI
[10.4324/9780429481758-8, DOI 10.4324/9780429481758-8]; Solms M, 2012, BRAIN SCI,
V2, P147, DOI 10.3390/brainsci2020147; Soloff PH, 2002, J PERS DISORD, V16, P201,
DOI 10.1521/pedi.16.3.201.22542; Spitzer C, 2011, FORTSCHR NEUROL PSYC, V79, P517,
DOI 10.1055/s-0031-1281602; Treadway MT, 2011, NEUROSCI BIOBEHAV R, V35, P537, DOI
10.1016/j.neubiorev.2010.06.006; Unterrainer HF, 2018, NERVENARZT, V89, P1043, DOI
10.1007/s00115-017-0462-4; Unterrainer HF, 2016, BRAIN IMAGING BEHAV, V10, P1096,
DOI 10.1007/s11682-015-9475-4; Unterrainer HF, 2017, FRONT HUM NEUROSCI, V11, DOI
10.3389/fnhum.2017.00208; Volkow ND, 2016, NEW ENGL J MED, V374, P363, DOI
10.1056/NEJMra1511480; Watt DF, 2009, NEUROPSYCHOANALYSIS, V11, P7, DOI DOI
10.1080/15294145.2009.10773593; Wingenfeld K, 2010, PSYCHOTHER PSYCH MED, V60,
P442, DOI 10.1055/s-0030-1247564; Wittchen HU, 2005, EUR NEUROPSYCHOPHARM, V15,
P357, DOI 10.1016/j.euroneuro.2005.04.012; Wurmser L., 1978, HIDDEN DIMENSION PSY;
Zellner MR, 2011, NEUROSCI BIOBEHAV R, V35, P2000, DOI
10.1016/j.neubiorev.2011.01.003; Zimmermann J, 2013, DIAGNOSTICA, V59, P3, DOI
10.1026/0012-1924/a000076 79 5 5 0 4 FRONTIERS MEDIA SA
LAUSANNE AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
1664-0640 FRONT PSYCHIATRY Front. Psychiatry JUL 16 2018
9 318 10.3389/fpsyt.2018.00318
12 Psychiatry Psychiatry GN1AV WOS:000438715800001
30061848 DOAJ Gold, Green Published 2019-09-25
J Levin, FR; Choi, CJ; Pavlicova, M; Mariani, JJ; Mahony, A; Brooks, DJ; Nunes,
EV; Grabowski, J Levin, Frances R.; Choi, C. Jean; Pavlicova,
Martina; Mariani, John J.; Mahony, Amy; Brooks, Daniel J.; Nunes, Edward V.;
Grabowski, John How treatment improvement in ADHD and cocaine
dependence are related to one another: A secondary analysisDRUG AND ALCOHOL
DEPENDENCE English Article
Cocaine dependence; ADHD; Treatment; Adderall ATTENTION-
DEFICIT/HYPERACTIVITY DISORDER; DEFICIT HYPERACTIVITY DISORDER; SELF-MEDICATION
HYPOTHESIS; PLACEBO-CONTROLLED TRIAL; SUBSTANCE USE DISORDERS; DOUBLE-BLIND; ADULT
ADHD; AGONIST-LIKE; METHYLPHENIDATE; PREVALENCE Background: Attention-deficit
hyperactivity disorder (ADHD) is overrepresented among individuals seeking
treatment for substance use disorders. We previously reported that treatment with
extended release mixed amphetamine salts (MAS-XR) increased abstinence, compared to
placebo, among patients with co-occurring ADHD and cocaine dependence. This
secondary analysis investigates the temporal relationship between ADHD improvement
and cocaine abstinence in the first six weeks of the trial. Methods: The study was
a three-arm, randomized, double-blinded, placebo-controlled, 14-week trial
comparing MAS-XR (60 mg or 80 mg daily) versus placebo among 126 participants with
ADHD and cocaine dependence. An autoregressive cross-lagged structural equation
model was fit and evaluated weekly ADHD improvement (defined as >= 30% reduction in
the Adult ADHD Investigator Symptom Rating Scale) and urine-confirmed abstinence
over the first six weeks. Results: The proportion of patients with each of the
possible overall patterns of response was: ADHD improves before cocaine abstinence:
24%; Cocaine abstinence occurs before ADHD improvement: 12%; ADHD improvement and
abstinence occur during the same week: 6%; ADHD improves but abstinence never
achieved: 34%; Abstinence achieved but ADHD never improves: 6%; Neither ADHD
improvement nor abstinence: 18%. A significant cross-lagged association was found;
subjects with ADHD improvement at week 2 had significantly higher odds of cocaine
abstinence at week 3 (p = .014). Conclusion: When treating co-occurring ADHD and
cocaine dependence with stimulant medication, abstinence is most likely preceded by
improvement in ADHD, which tends to occur early with medication treatment. Other
observed temporal patterns suggest the potential complexity of the relationship
between ADHD and cocaine dependence. [Levin, Frances R.; Mariani, John J.;
Mahony, Amy; Brooks, Daniel J.; Nunes, Edward V.] New York State Psychiat Inst &
Hosp, Div Subst Abuse, 1051 Riverside Dr, New York, NY 10032 USA; [Levin, Frances
R.; Mariani, John J.; Nunes, Edward V.] Columbia Univ Coll Phys & Surg, Dept
Psychiat, 630 West 168th St, New York, NY 10032 USA; [Pavlicova, Martina] Columbia
Univ, Mailman Sch Publ Hlth, Dept Biostat, 722 West 168th St, New York, NY 10032
USA; [Grabowski, John] Univ Minnesota, Med Sch, Dept Psychiat West F282 2A, 2450
Riverside Ave, Minneapolis, MN 55454 USA; [Choi, C. Jean] New York State Psychiat
Inst & Hosp, Div Biostat, 1051 Riverside Dr, New York, NY 10032 USA Levin, FR
(reprint author), New York State Psychiat Inst & Hosp, 1051 Riverside Dr,Unit 120,
New York, NY 10032 USA. frances.levin@nyspi.columbia.edu National
Institute on Drug Abuse (NIDA) grants [R01DA 023652, K24 DA029647, K24 DA022412]
Funding for this research was provided by the National Institute on Drug
Abuse (NIDA) grants R01DA 023652, K24 DA029647, and K24 DA022412. NIDA had no
further role in study design, in the collection, analysis and interpretation of
data, in the writing of the report, or in the decision to submit the paper for
publication. Arnsten AFT, 2009, CNS DRUGS, V23, P33, DOI 10.2165/00023210-
200923000-00005; Ayanga D, 2016, EXPERT OPIN PHARMACO, V17, P2307, DOI
10.1080/14656566.2016.1244529; Biederman J, 2010, PSYCHIAT RES, V177, P299, DOI
10.1016/j.psychres.2009.12.010; Carpentier PJ, 2005, ADDICTION, V100, P1868, DOI
10.1111/j.1360-0443.2005.01272.x; Centers for Disease Control and Prevention (CDC),
2005, MMWR Morb Mortal Wkly Rep, V54, P842; Elrashidi MY, 2014, EXPERT OPIN EMERG
DR, V19, P243, DOI 10.1517/14728214.2014.899580; Epstein J. N., 2001, CONNERS ADULT
ADHD D; First M. B., 1995, STRUCTURED CLIN INTE; Grabowski J, 2004, ADDICT BEHAV,
V29, P1439, DOI 10.1016/j.addbeh.2004.06.018; Grabowski J, 2004,
NEUROPSYCHOPHARMACOL, V29, P969, DOI 10.1038/sj.npp.1300392; Grabowski J, 2001, J
CLIN PSYCHOPHARM, V21, P522, DOI 10.1097/00004714-200110000-00010; Khantzian EJ,
1997, HARVARD REV PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550; Laursen B,
2012, HDB DEV RES METHODS; Levin FR, 2006, DRUG ALCOHOL DEPEN, V81, P137, DOI
10.1016/j.drugalcdep.2005.06.012; Levin FR, 1998, DRUG ALCOHOL DEPEN, V52, P15, DOI
10.1016/S0376-8716(98)00049-0; Levin FR, 1998, J CLIN PSYCHIAT, V59, P300, DOI
10.4088/JCP.v59n0605; Levin FR, 2007, DRUG ALCOHOL DEPEN, V87, P20, DOI
10.1016/j.drugalcdep.2006.07.004; Levin FR, 2015, JAMA PSYCHIAT, V72, P593, DOI
10.1001/jamapsychiatry.2015.41; Mariani JJ, 2014, AM J ADDICTION, V23, P189, DOI
10.1111/j.1521-0391.2013.12086.x; Mattingly GW, 2013, BMC PSYCHIATRY, V13, DOI
10.1186/1471-244X-13-39; Mooney ME, 2009, DRUG ALCOHOL DEPEN, V101, P34, DOI
10.1016/j.drugalcdep.2008.10.016; Muthen L. K., 2007, MPLUS USERS GUIDE; Nuijten M,
2016, LANCET, V387, P2226, DOI 10.1016/S0140-6736(16)00205-1; Nunes EV, 2013, J
CLIN PSYCHIAT, V74, P983, DOI 10.4088/JCP.12m08155; de los Cobos JP, 2011, PSYCHIAT
RES, V185, P205, DOI 10.1016/j.psychres.2009.03.019; Robinson SM, 2014, PSYCHOL
ADDICT BEHAV, V28, P154, DOI 10.1037/a0030992; Roster M., 2009, EUR ARCH PSY CLIN
N, V259, P120; Rubio Morell B., 2017, APPL NEUROPSYCH-CHIL, V15, P1; Schubiner H,
2002, EXP CLIN PSYCHOPHARM, V10, P286, DOI 10.1037//1064-1297.10.3.286; Shiels K,
2009, EXP CLIN PSYCHOPHARM, V17, P291, DOI 10.1037/a0017259; Sibley MH, 2016,
LANCET PSYCHIAT, V3, P1157, DOI 10.1016/S2215-0366(16)30190-0; Somoza EC, 2004, J
ADDICT DIS, V23, P77, DOI 10.1300/J069v23n01_07; Spencer TJ, 2010, J ATTEN DISORD,
V14, P57, DOI 10.1177/1087054709347435; van de Glind G, 2014, DRUG ALCOHOL DEPEN,
V134, P158, DOI 10.1016/j.drugalcdep.2013.09.026; van Emmerik-van Oortmerssen K,
2012, DRUG ALCOHOL DEPEN, V122, P11, DOI 10.1016/j.drugalcdep.2011.12.007; van
Emmerik-van Oortmerssen K, 2014, ADDICTION, V109, P262, DOI 10.1111/add.12370
36 2 2 1 5 ELSEVIER IRELAND LTD CLARE ELSEVIER HOUSE,
BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND 0376-8716 1879-
0046 DRUG ALCOHOL DEPEN Drug Alcohol Depend. JUL 1 2018 188
135 140 10.1016/j.drugalcdep.2018.03.043
6 Substance Abuse; Psychiatry Substance Abuse; Psychiatry GL1ZL
WOS:000436912700020 29775957 Green Accepted 2019-09-25
J Bilevicius, E; Single, A; Bristow, LA; Foot, M; Ellery, M; Keough, MT;
Johnson, EA Bilevicius, Elena; Single, Alanna; Bristow, Lindsay
A.; Foot, Melody; Ellery, Michael; Keough, Matthew T.; Johnson, Edward A.
Shame mediates the relationship between depression and addictive behaviours
ADDICTIVE BEHAVIORS English Article
Shame; Mediation; Depression; Alcohol; Gambling; Longitudinal
ANXIETY STRESS SCALES; ALCOHOL-USE; PROBLEMATIC ALCOHOL; MAJOR DEPRESSION;
COLLEGE-STUDENTS; SELF-MEDICATION; USE DISORDERS; SUBSTANCE USE; GUILT; SYMPTOMS
Background: Alcohol and gambling problems are common in young adults. Self-
medication theory states that young adults with depression drink and/or gamble to
escape negative emotions. Research shows that depression is a risk factor for
drinking/gambling problems, but more work is needed to examine mediators underlying
these associations. One potential mediator is shame. Shame is a self-directed
emotion that follows a negative life event and is characterized by intense feelings
of inferiority, worthlessness, and embarrassment. Depressed individuals are
especially susceptible to shame (and associated emotions). Shame has also been
implicated in risk for addiction. Accordingly, we predicted that elevated shame
would explain why depression is associated with both alcohol and gambling problems.
Methods: A longitudinal design was used to examine this hypothesis. Undergraduates
(N = 210) completed self reports of depression at baseline (Time 1) and then
completed self-reports of shame, alcohol misuse, gambling problems one month later
(Time 2). Results: Results showed that individuals with elevated depression at Time
1 endorsed high levels of shame at Time 2, which in turn predicted more gambling
(beta = .038, 95% CI [.010, .087]) and alcohol problems (beta = .249, 95% CI [.123,
.435]) at Time 2. We found that increased levels of shame explained the effects of
depression on problem drinking and gambling. Conclusions: Study findings improve
our understanding of the depressive pathway to addiction by providing evidence for
shame as a potential mechanism of this pathway. Impact: Reducing shame can be a
target of clinical interventions for young adults with depression and
alcohol/gambling problems. [Bilevicius, Elena; Single, Alanna; Bristow, Lindsay
A.; Foot, Melody; Keough, Matthew T.; Johnson, Edward A.] Univ Manitoba, Dept
Psychol, 190 Dysart Rd, Winnipeg, MB R3T 2N2, Canada; [Ellery, Michael] Univ
Winnipeg, Dept Psychol, 515 Portage Ave, Winnipeg, MB R3B 2E9, Canada Johnson, EA
(reprint author), Univ Manitoba, Dept Psychol, 190 Dysart Rd, Winnipeg, MB R3T 2N2,
Canada. Ed.Johnson@umanitoba.ca Keough, Matthew/L-1252-2019 Johnson,
Edward/0000-0001-9804-3575 Adlaf E. M., 2005, CANADIAN CAMPUS SURV;
Adlaf E. M., 2005, CANADIAN ADDICTION S; American Psychiatric Association, 2013,
DIAGN STAT MAN MENT; Antony MM, 1998, PSYCHOL ASSESSMENT, V10, P176, DOI
10.1037/1040-3590.10.2.176; Ashby JS, 2006, J COUNS DEV, V84, P148, DOI
10.1002/j.1556-6678.2006.tb00390.x; BAUMEISTER RF, 1994, PSYCHOL BULL, V115, P243,
DOI 10.1037/0033-2909.115.2.243; Black SW, 2016, J DRUG EDUC, V46, P82, DOI
10.1177/0047237917728357; BLASZCZYNSKI A, 1989, INT J ADDICT, V24, P337, DOI
10.3109/10826088909047292; Bravo AJ, 2017, SUBST USE MISUSE, V52, P52, DOI
10.1080/10826084.2016.1214151; Briere FN, 2014, COMPR PSYCHIAT, V55, P526, DOI
10.1016/j.comppsych.2013.10.007; Carpenter KM, 1999, J STUD ALCOHOL, V60, P694, DOI
10.15288/jsa.1999.60.694; Dearing RL, 2005, ADDICT BEHAV, V30, P1392, DOI
10.1016/j.addbeh.2005.02.002; Ehret AM, 2015, COGNITION EMOTION, V29, P1496, DOI
10.1080/02699931.2014.992394; Enders C. K., 2010, APPL MISSING DATA AN; Engwall D,
2004, J AM COLL HEALTH, V52, P245, DOI 10.3200/JACH.52.6.245-256; Ferris J., 2001,
CANADIAN PROBLEM GAM; Fritz MS, 2007, PSYCHOL SCI, V18, P233, DOI 10.1111/j.1467-
9280.2007.01882.x; Gilbert P, 2005, COMPASSION CONCEPTUA; Harrell Z. A., 2002, J
COGN PSYCHOTHER, V16, P391, DOI DOI 10.1891/JC0P.16.4.391.52526; Henry JD, 2005,
BRIT J CLIN PSYCHOL, V44, P227, DOI 10.1348/014466505X29657; Hingson R, 2005, ANNU
REV PUBL HEALTH, V26, P259, DOI 10.1146/annurev.publhealth.26.021304.144652;
Hogarth L, 2018, PSYCHOPHARMACOLOGY, V235, P269, DOI 10.1007/s00213-017-4765-8; Hu
LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Johnson EA,
2013, J SOC CLIN PSYCHOL, V32, P939; Kaloyanides KB, 2007, PHARMACOTHERAPY, V27,
P666, DOI 10.1592/phco.27.5.666; Keough MT, 2015, SUBST ABUS-RES TREAT, V9, P33,
DOI 10.4137/SART.S31434; Keough MT, 2016, ADDICT BEHAV, V55, P19, DOI
10.1016/j.addbeh.2015.12.013; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231,
DOI 10.3109/10673229709030550; Kim S, 2011, PSYCHOL BULL, V137, P68, DOI
10.1037/a0021466; Kline R. B., 2010, PRINCIPLES PRACTICE; Knol MJ, 2010, J CLIN
EPIDEMIOL, V63, P728, DOI 10.1016/j.jclinepi.2009.08.028; Leary MR, 2007, J PERS
SOC PSYCHOL, V92, P887, DOI 10.1037/0022-3514.92.5.887; LEWIS HB, 1971, PSYCHOANAL
REV, V58, P419; Lorains FK, 2011, ADDICTION, V106, P490, DOI 10.1111/j.1360-
0443.2010.03300.x; Lovibund S, 1995, MANUAL DEPRESSION AN; Luoma J, 2017, SUBST USE
MISUSE, V52, P1692, DOI 10.1080/10826084.2017.1305416; Martens MP, 2007, J STUD
ALCOHOL DRUGS, V68, P597, DOI 10.15288/jsad.2007.68.597; McGaffin BJ, 2013, SUBST
ABUS, V34, P396, DOI 10.1080/08897077.2013.781564; Meehan W, 1996, J PSYCHOACTIVE
DRUGS, V28, P125, DOI 10.1080/02791072.1996.10524385; Miller BE, 2002, J DRUG EDUC,
V32, P41, DOI 10.2190/JDFM-AVAK-G9FV-0MYY; Muthen L. K., 2012, MPLUS USERS GUIDE
ST; Neff KD, 2003, SELF IDENTITY, V2, P223, DOI 10.1080/15298860390209035; Nolen-
Hoeksema S, 2000, J ABNORM PSYCHOL, V109, P504, DOI 10.1037/0021-843X.109.3.504;
OCONNOR LE, 1994, J SUBST ABUSE TREAT, V11, P503, DOI 10.1016/0740-5472(94)90001-9;
Orth U, 2006, PERS SOC PSYCHOL B, V32, P1608, DOI 10.1177/0146167206292958; Petry
NM, 2005, J CLIN PSYCHIAT, V66, P564, DOI 10.4088/JCP.v66n0504; Quigley L, 2015, J
GAMBL STUD, V31, P1135, DOI 10.1007/s10899-014-9488-8; Rahim M, 2015, PEERJ, V3,
DOI 10.7717/peerj.737; Rizvi SL, 2010, J PSYCHOPATHOL BEHAV, V32, P438, DOI
10.1007/s10862-009-9172-y; Rotenstein LS, 2016, JAMA-J AM MED ASSOC, V316, P2214,
DOI 10.1001/jama.2016.17324; Sterne JA, 2009, BMJ, V338; Tabachnick B. G., 2013,
USING MULTIVARIATE S; Takamatsu SK, 2016, J GAMBL STUD, V32, P535, DOI
10.1007/s10899-015-9562-x; TANGNEY JP, 1992, J ABNORM PSYCHOL, V101, P469, DOI
10.1037/0021-843X.101.3.469; Tangney JP, 2007, ANNU REV PSYCHOL, V58, P345, DOI
10.1146/annurev.psych.56.091103.070145; Teesson M, 2009, AUST NZ J PSYCHIAT, V43,
P606, DOI 10.1080/00048670902970908; Thombs DL, 2009, J STUD ALCOHOL DRUGS, V70,
P776, DOI 10.15288/jsad.2009.70.776; Thomsen KR, 2009, BEHAV PHARMACOL, V20, P527,
DOI 10.1097/FBP.0b013e3283305e7a; Thygesen LC, 2008, ADDICTION, V103, P1149, DOI
10.1111/j.1360-0443.2008.02241.x; Treeby M, 2012, PERS INDIV DIFFER, V53, P613, DOI
10.1016/j.paid.2012.05.011; Tsai W, 2015, CULT DIVERS ETHN MIN, V21, P584, DOI
10.1037/cdp0000012; Whelton WJ, 2005, PERS INDIV DIFFER, V38, P1583, DOI
10.1016/j.paid.2004.09.024; WHITE HR, 1989, J STUD ALCOHOL, V50, P30, DOI
10.15288/jsa.1989.50.30; White IR, 2010, STAT MED, V29, P2920, DOI
10.1002/sim.3944; Wiechelt SA, 2007, SUBST USE MISUSE, V42, P399, DOI
10.1080/10826080601142196; Wiers RW, 2005, ADDICTION, V100, P806, DOI
10.1111/j.1360-0443.2005.01064.x; Wohl MJA, 2011, J GAMBL STUD, V27, P155, DOI
10.1007/s10899-010-9186-0; Wynne H., 2002, INTRO CANADIAN PROBL; Yi S., 2012, J
GAMBLING ISSUES, DOI [10.4309/jgi.2012.27.7, DOI 10.4309/JGI.2012.27.7]; Yi SW,
2011, J GAMBL STUD, V27, P371, DOI 10.1007/s10899-010-9216-y 70 5 6
0 22 PERGAMON-ELSEVIER SCIENCE LTD OXFORD THE BOULEVARD, LANGFORD
LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND 0306-4603 1873-6327 ADDICT BEHAV
Addict. Behav. JUL 2018 82 94 100
10.1016/j.addbeh.2018.02.023 7 Psychology, Clinical;
Substance Abuse Psychology; Substance Abuse GD5CO WOS:000430522800015
29505986 2019-09-25
J Moggi, F Moggi, Franz Epidemiology,
etiology and treatment of patients with psychosis and co-morbid substance use
disorder THERAPEUTISCHE UMSCHAU German Review
RANDOMIZED CONTROLLED-TRIAL; SEVERE MENTAL ILLNESSES; DRUG-
ABUSE; PEOPLE; SCHIZOPHRENIA; INTERVENTION; COMORBIDITY; HYPOTHESIS; OUTCOMES;
ALCOHOL More than 25 years ago, when the research on the efficacy of treatments
for patients with a comorbidity of psychosis and substance use disorder has been
systematically started, some authors described the treatment of these patients as a
"mission impossible". Approximately half of all individuals with schizophrenia
develop substance use disorders in the course of their life; about one third of
them a comorbid alcohol use disorder and about one quarter a comorbid substance use
disorder with other addictive substances. There is no universally valid aetiology
model to explain the relationship between psychosis and addiction. Contrary to
expectations, the self-medication model was not empirically confirmed, while the
psychological affect regulation model, the vulnerability-stress model of a specific
sensitivity to addictive substances given a predisposition of psychosis, or the
neurobiological common factor model of a dysfunction of dopamine regulation in the
mesocorticolimbic reward system that predispose to primary substance use disorder
found some empirical support. Research on the psycho-social-psychotherapeutic and
pharmacological treatment of patients with psychosis and addiction are so
heterogeneous in terms of characteristics of patients, disorders, treatments,
settings and outcomes that hardly two comparable studies can be found. Thus, it is
hardly possible to make scientifically based statements on the efficacy and
effectiveness of therapies. -Integrative treatment programs are promising, which
combine psycho- and pharmacotherapeutic interventions for the treatment of
psychotic and substance use disorders in a coherent manner and which can be
flexibly adapted to the individual patient's needs. Such treatments are carried out
at the same time, in the same setting and by the same treatment providers and
practioners. Successful integrative treatment programs usually include motivational
interventions, cognitive-behavioral interventions specific to schizophrenia and
addiction, interventions that may reduce the substance use such as relapse
prevention, contingency management and/or family interventions. These interventions
are best combined with second-generation antipsychotics, if necessary with
medication to reduce substance use. Although no "mission impossible" treating
patients with psychosis and addiction remains a complex challenge for research and
practice. [Moggi, Franz] Univ Bern, Univ Klin Psychiat & Psychotherapie, Bern,
Switzerland Moggi, F (reprint author), Univ Bern, Univ Klin Psychiat &
Psychotherapie, Klin Psychol Dienst, Bolligenstr 111, CH-3000 Bern 60,
Switzerland.; Moggi, F (reprint author), Univ Bern, Univ Klin Psychiat &
Psychotherapie, Kompetenzzentrum Psychotherapie, Bolligenstr 111, CH-3000 Bern 60,
Switzerland.; Moggi, F (reprint author), Univ Bern, Univ Klin Psychiat &
Psychotherapie, Grp Suchtforsch, Bolligenstr 111, CH-3000 Bern 60, Switzerland.;
Moggi, F (reprint author), Univ Bern, Univ Klin Psychiat & Psychotherapie, Netzwerk
Suchtpsychiat, Bolligenstr 111, CH-3000 Bern 60, Switzerland.
franz.moggi@upd.unibe.ch Moggi, Franz/G-5769-2014 Moggi, Franz/0000-
0003-3302-7229 Akerman Sarah C, 2014, Curr Addict Rep, V1, P251;
Azorin JM, 2016, EXPERT OPIN PHARMACO, V17, P231, DOI
10.1517/14656566.2016.1114101; Barrowclough C, 2010, BMJ-BRIT MED J, V341, DOI
10.1136/bmj.c6325; Bellack AS, 2006, ARCH GEN PSYCHIAT, V63, P426, DOI
10.1001/archpsyc.63.4.426; Blanchard JJ, 2000, CLIN PSYCHOL REV, V20, P207, DOI
10.1016/S0272-7358(99)00033-1; Chambers RA, 2001, BIOL PSYCHIAT, V50, P71, DOI
10.1016/S0006-3223(01)01134-9; Chow CM, 2012, MENTAL HLTH SUBSTANC, P1; Cleary M,
2010, COCHRANE LIB, V3, DOI [10.1002/14651858.CD001088.pub2, DOI
10.1002/14651858.CD001088.PUB2]; Cleary M, 2009, J ADV NURS, V65, P238, DOI
10.1111/j.1365-2648.2008.04879.x; Dauber H, 2018, INT J MENT HEALTH AD, V16, P66,
DOI 10.1007/s11469-017-9784-5; De Hert M., 2015, COOCCURRING ADDICTIV, P349, DOI
10.1007/978-3-642-45375-5_23; De Witte NAJ, 2014, EUR ADDICT RES, V20, P105, DOI
10.1159/000355267; Drake RE, 2004, PSYCHIATR REHABIL J, V27, P360, DOI
10.2975/27.2004.360.374; Drake RE, 2008, J SUBST ABUSE TREAT, V34, P123, DOI
10.1016/j.jsat.2007.01.011; Gouzoulis-Mayfrank E, 2010, PSYCHIAT PSYCHOTHER, V4,
P81; Haddock G, 2003, BRIT J PSYCHIAT, V183, P418, DOI 10.1192/bjp.183.5.418;
Horsfall J, 2009, HARVARD REV PSYCHIAT, V17, P24, DOI 10.1080/10673220902724599;
Hunt GE, 2013, COCHRANE LIB, V10, DOI [10.1002/14651858.CD001088.pub3, DOI
10.1002/14651858.CD001088.PUB3]; Kavanagh DJ, 2004, SCHIZOPHR RES, V66, P115, DOI
10.1016/S0920-9964(03)00130-0; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231,
DOI 10.3109/10673229709030550; Khokhar JY, 2018, SCHIZOPHR RES, V194, P78, DOI
10.1016/j.schres.2017.04.016; Miller WR, 2009, MOTIVIERENDE GESPRAC; Moggi F, 2015,
COOCCURRING ADDICTIV, P261; Moggi F., 2014, PSYCHISCHE STORUNGEN, P13; Moore E,
2012, AUST NZ J PSYCHIAT, V46, P864, DOI 10.1177/0004867412443900; Moore THM, 2007,
LANCET, V370, P319, DOI 10.1016/S0140-6736(07)61162-3; Mueser KT, 2013,
SCHIZOPHRENIA BULL, V39, P658, DOI 10.1093/schbul/sbr203; Mueser KT, 2007,
DOPPELDIAGNOSEN KOMO, P109; OSHER FC, 1989, HOSP COMMUNITY PSYCH, V40, P1025;
PROCHASKA JO, 1992, AM PSYCHOL, V47, P1102, DOI 10.1037/0003-066X.47.9.1102; REGIER
DA, 1990, JAMA-J AM MED ASSOC, V264, P2511; ROBERTS LJ, 1992, NEW DIR MENT HLTH SE,
V53, P55 32 1 1 1 9 VERLAG HANS HUBER BERN 9 LANGGASS-
STRASSE 76, CH-3000 BERN 9, SWITZERLAND 0040-5930 1664-2864 THER UMSCH
Ther. Umsch. JUN 2018 75 1 37 43
10.1024/0040-5930/a000964 7 Medicine, General & Internal
General & Internal Medicine GJ8NZ WOS:000435648000006 29909760
2019-09-25
J Masillo, A; Brandizzi, M; Nelson, B; Lo Cascio, N; Saba, R; Lindau, JF;
Telesforo, L; Montanaro, D; D'Alema, M; Girardi, P; McGorry, P; Nastro, PF
Masillo, Alice; Brandizzi, Martina; Nelson, Barnaby; Lo Cascio, Nella;
Saba, Riccardo; Lindau, Juliana Fortes; Telesforo, Ludovica; Montanaro, Dori;
D'Alema, Marco; Girardi, Paolo; McGorry, Patrick; Nastro, Paolo Fiori
Youth mental health services in Italy: An achievable dream?EARLY INTERVENTION
IN PSYCHIATRY English Article
early psychosis; mental health services; youth mental health ULTRA-HIGH
RISK; AGE-OF-ONSET; SELF-MEDICATION HYPOTHESIS; SUBSTANCE USE DISORDERS; HIGH
CLINICAL RISK; YOUNG-ADULTS; INTERPERSONAL SENSITIVITY; PSYCHIATRIC-DISORDERS;
LIFETIME PREVALENCE; FOLLOW-UP AimLiberiamo il futuro (LIF) project was
designed to assess psychological problems of adolescents and young adults and to
identify individuals at high-risk for developing a psychosis through a
collaboration between a University team, Child and Adolescent Mental Health
Services and Adult Mental Health Services. This paper presents the baseline
demographic and clinical characteristics of the cohort, particularly the nature and
severity of psychopathology. MethodAll help-seeking young people aged 12-35 years
residing in the health district involved in LIF were invited to participate in the
study and completed a battery of self- report and interviewer-administered measures
of psychopathology and functioning at baseline. ResultsA total of 338 adolescents
and young people (mean age 17.42) participated in the study. The majority of the
sample (n=107, 35%) had an anxiety disorder, followed by mood disorders (n=62,
21%). Only 35 (12%) participants had no psychiatric diagnosis. After a screening
phase, 166 (52%) individuals were assessed to detect the presence of an Ultra High
Risk (UHR) state. Of these, 38.60% (n=64) met UHR criteria. Overall, the majority
of the sample resulted moderately functionally impaired at baseline. ConclusionsLIF
project showed that psychological problems, associated with impaired psychosocial
functioning, are very common among help-seeking young people. The help-seeking
behaviour of young people is in contrast with the barriers presented by the Italian
community mental health system that is modelled around adults' requirements. A need
of a strong, stigma-free, young oriented system of care for young people up to the
mid-20s emerged. [Masillo, Alice; Brandizzi, Martina; Lo Cascio, Nella; Saba,
Riccardo; Nastro, Paolo Fiori] Sapienza Univ Rome, Fac Med & Odontol, Dept Neurol &
Psychiat, I-00156 Rome, Italy; [Lo Cascio, Nella] Bambino Gesu Pediat Hosp, Dept
Neurosci & Neurorehabil, Rome, Italy; [Lindau, Juliana Fortes; Telesforo, Ludovica;
Girardi, Paolo] Sapienza Univ Rome, St Andrea Hosp, Fac Med & Psychol, Neurosci
Mental Hlth & Sensory Funct NESMOS Dept, Rome, Italy; [Montanaro, Dori; D'Alema,
Marco] ASL Rome H, Community Mental Hlth Serv, Rome, Italy; [Nelson, Barnaby;
McGorry, Patrick] Univ Melbourne, Orygen, Parkville, Vic, Australia Masillo, A
(reprint author), Sapienza Univ Rome, Fac Med & Odontol, Dept Neurol & Psychiat, I-
00156 Rome, Italy. alice.masillo@gmail.com McGorry, Patrick/O-4115-2019 SABA,
Riccardo/0000-0002-1594-1183; Nelson, Barnaby/0000-0002-6263-2332
Addington J, 2011, AM J PSYCHIAT, V168, P800, DOI
10.1176/appi.ajp.2011.10081191; Amaddeo F, 2001, SOC PSYCH PSYCH EPID, V36, P500,
DOI 10.1007/s001270170015; AMERICAN PSYCHIATRIC ASSOCIATION (A.P.A), 2013, DIAGN
STAT MAN MENT; BOYCE P, 1989, AUST NZ J PSYCHIAT, V23, P341; Brandizzi M, 2015, J
PSYCHIATR RES, V65, P115, DOI 10.1016/j.jpsychires.2015.03.005; Brandizzi M, 2014,
SCHIZOPHR RES, V160, P110, DOI 10.1016/j.schres.2014.10.005; Burgess PM, 2009, AUST
NZ J PSYCHIAT, V43, P615, DOI 10.1080/00048670902970858; Cornblatt BA, 2007,
SCHIZOPHRENIA BULL, V33, P688, DOI 10.1093/schbul/sbm029; Costello EJ, 2005, J AM
ACAD CHILD PSY, V44, P972, DOI 10.1097/01.chi.0000172552.41596.6f; Costello EJ,
2003, ARCH GEN PSYCHIAT, V60, P837, DOI 10.1001/archpsyc.60.8.837; Davis M, 2006,
PSYCHIAT SERV, V57, P1594, DOI 10.1176/appi.ps.57.11.1594; de Girolamo G, 2012,
EPIDEMIOL PSYCH SCI, V21, P47, DOI 10.1017/S2045796011000746; Del Vecchio V, 2015,
INT J SOC PSYCHIATR, V61, P631, DOI 10.1177/0020764014568129; Fagioli Massimo,
1975, TEORIA NASCITA CASTR; First MB, 2012, STRUCTURED CLIN INTE; Fulford D, 2013,
SCHIZOPHR RES, V147, P125, DOI 10.1016/j.schres.2013.03.024; Fusar-Poli P., 2012,
ARCH GEN PSYCHIAT, V69, P1, DOI [DOI 10.1001/ARCHGENPSYCHIATRY.2011.1472,
10.1001/archgenpsychiatry.2011.1592]; Fusar-Poli P, 2013, JAMA PSYCHIAT, V70, P107,
DOI 10.1001/jamapsychiatry.2013.269; Fux L, 2013, SCHIZOPHR RES, V146, P69, DOI
10.1016/j.schres.2013.02.014; Green CEL, 2011, BEHAV COGN PSYCHOTH, V39, P21, DOI
10.1017/S1352465810000457; Griffin KW, 2015, J CHILD ADOLES SUBST, V24, P228, DOI
10.1080/1067828X.2013.812530; GROSS G, 1989, British Journal of Psychiatry, V155,
P21; Gross G., 1989, BR J PSYCHIAT S, P37; Hansen AH, 2015, BMC HEALTH SERV RES,
V15, DOI 10.1186/s12913-015-1146-z; Hermens DF, 2013, BMJ OPEN, V3, DOI
10.1136/bmjopen-2012-002229; Herres J, 2015, J AFFECT DISORDERS, V186, P312, DOI
10.1016/j.jad.2015.07.031; Huber G, 1989, Recenti Prog Med, V80, P646; Illback RJ,
2011, EARLY INTERV PSYCHIA, V5, P22, DOI 10.1111/j.1751-7893.2010.00236.x; Ising
HK, 2012, SCHIZOPHRENIA BULL, V38, P1288, DOI 10.1093/schbul/sbs068; Joo Hong Jin,
2012, Clin Psychopharmacol Neurosci, V10, P54, DOI 10.9758/cpn.2012.10.1.54;
Kataoka SH, 2002, AM J PSYCHIAT, V159, P1548, DOI 10.1176/appi.ajp.159.9.1548;
Kaufman J, 1996, SCHEDULE AFFECTIVE D; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62,
P593, DOI 10.1001/archpsyc.62.6.593; Kessler RC, 2007, WORLD PSYCHIATRY, V6, P168;
Kessler RC, 2007, CURR OPIN PSYCHIATR, V20, P359, DOI 10.1097/YCO.0b013e32816ebc8c;
Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550;
Loewy RL, 2005, SCHIZOPHR RES, V77, P141, DOI 10.1016/j.schres.2005.03.007; Luciano
M, 2012, INT REV PSYCHIATR, V24, P149, DOI 10.3109/09540261.2012.656306; Magliano
L, 2006, PSYCHIAT SERV, V57, P1784, DOI 10.1176/appi.ps.57.12.1784; Mariani JJ,
2014, AM J ADDICTION, V23, P189, DOI 10.1111/j.1521-0391.2013.12086.x; Masillo A,
2016, EUR CHILD ADOLES PSY, V25, P7, DOI 10.1007/s00787-015-0692-6; Masillo A,
2014, J AFFECT DISORDERS, V156, P164, DOI 10.1016/j.jad.2013.12.012; Masillo A,
2012, PSYCHOL MED, V42, P1835, DOI 10.1017/S0033291711002996; McGlashan T, 2010,
PSYCHOSIS RISK SYNDR; McGorry PD, 2007, MED J AUSTRALIA, V187, pS53; McGorry PD,
2011, AUST FAM PHYSICIAN, V40, P94; Miller TJ, 2002, AM J PSYCHIAT, V159, P863, DOI
10.1176/appi.ajp.159.5.863; Montgomery MJ, 2005, J ADOLESCENT RES, V20, P346, DOI
10.1177/0743558404273118; Nelson B, 2013, JAMA PSYCHIAT, V70, P793, DOI
10.1001/jamapsychiatry.2013.1270; Patrick D, 2007, MED J AUSTRALIA, V187, P5;
Pottick KJ, 2008, J BEHAV HEALTH SER R, V35, P373, DOI 10.1007/s11414-007-9080-4;
Purcell R, 2015, EARLY INTERV PSYCHIA, V9, P487, DOI 10.1111/eip.12133; Rietdijk J,
2012, ACTA PSYCHIAT SCAND, V126, P21, DOI 10.1111/j.1600-0447.2012.01839.x;
Rockhill C, 2010, CURR PROB PEDIATR AD, V40, P66, DOI 10.1016/j.cppeds.2010.02.002;
Schlosser DA, 2012, SCHIZOPHRENIA BULL, V38, P1225, DOI 10.1093/schbul/sbr098;
Schultze-Lutter F., 2007, SCHIZOPHRENIA PRONEN; Schultze-Lutter F, 2014, SCHIZOPHR
RES, V154, P100, DOI 10.1016/j.schres.2014.02.010; Schultze-Lutter F, 2009,
SCHIZOPHRENIA BULL, V35, P5, DOI 10.1093/schbul/sbn139; Scott EM, 2012, MED J
AUSTRALIA, V196, P136, DOI 10.5694/mja11.10481; Simon AE, 2013, PSYCHIAT RES, V209,
P266, DOI 10.1016/j.psychres.2013.03.004; Singh SP, 2010, BRIT J PSYCHIAT, V197,
P305, DOI 10.1192/bjp.bp.109.075135; Singh SP, 2009, CURR OPIN PSYCHIATR, V22,
P386, DOI 10.1097/YCO.0b013e32832c9221; Stagi P, 2015, EUR CHILD ADOLES PSY, V24,
P1535, DOI 10.1007/s00787-015-0735-z; Tandon SD, 2013, J ADOLESCENT HEALTH, V52,
P627, DOI 10.1016/j.jadohealth.2012.10.001; Valmaggia LR, 2007, BRIT J PSYCHIAT,
V191, pS63, DOI 10.1192/bjp.191.51.s63; van Os J, 2009, PSYCHOL MED, V39, P179, DOI
10.1017/S0033291708003814; Volpe U, 2014, INT J SOC PSYCHIATR, V60, P508, DOI
10.1177/0020764013501648; Wang PS, 2007, WORLD PSYCHIATRY, V6, P177; Wang PS, 2007,
LANCET, V370, P841, DOI 10.1016/S0140-6736(07)61414-7; Whiteford HA, 2013, LANCET,
V382, P1575, DOI 10.1016/S0140-6736(13)61611-6; Yung AR, 2007, SCHIZOPHRENIA BULL,
V33, P673, DOI 10.1093/schbul/sbm015 71 1 1 1 6 WILEY
HOBOKEN 111 RIVER ST, HOBOKEN 07030-5774, NJ USA 1751-7885 1751-7893
EARLY INTERV PSYCHIA Early Interv. Psychiatry JUN 2018 12 3
433 443 10.1111/eip.12328 11
Psychiatry Psychiatry GI0WG WOS:000434090500019 27061589
2019-09-25
J Mortele, O; Vervliet, P; Gys, C; Degreef, M; Cuykx, M; Maudens, K; Covaci, A;
van Nuijs, ALN; Lai, FY Mortele, Olivier; Vervliet, Philippe;
Gys, Celine; Degreef, Maarten; Cuykx, Matthias; Maudens, Kristof; Covaci, Adrian;
van Nuijs, Alexander L. N.; Lai, Foon Yin In vitro Phase I and Phase II
metabolism of the new designer benzodiazepine cloniprazepam using liquid
chromatography coupled to quadrupole time-of-flight mass spectrometry JOURNAL OF
PHARMACEUTICAL AND BIOMEDICAL ANALYSIS English Article
Cloniprazepam; Designer benzodiazepines; In vitro
biotransformation; Human liver microsomes; Cytosolic fractions; Liquid
chromatography-mass spectrometry; High resolution-mass spectrometry HUMAN LIVER-
MICROSOMES; PSYCHOACTIVE SUBSTANCES; HEPATOCYTE CULTURES; CLONAZEPAM;
IDENTIFICATION; URINE; MECLONAZEPAM; HUMANS; 7-AMINOCLONAZEPAM; CLONAZOLAM
Designer benzodiazepines have recently emerged as a class of new psychoactive
substances. These substances are used in recreational settings and as alternatives
to prescription benzodiazepines as self medication for patients suffering from
anxiety or other mental disorders. Due to the limited information available on the
metabolic fate of these new substances, it is challenging to reliably detect their
usage in bioanalytical (e.g. clinical and forensic) settings. The objective of this
study was to investigate the in vitro Phase I and Phase II metabolism of the new
designer benzodiazepine cloniprazepam and identify potential biomarkers for its
detection in human biological fluids. Cloniprazepam was incubated with human liver
microsomes and cytosolic fractions to generate both Phase I and II metabolites. The
extracts were analysed using liquid chromatography coupled to quadrupole time-of-
flight mass spectrometry. Identification of the metabolites was performed using two
complementary workflows, including a suspect screening based on in silico
predictions and a non-targeted screening. A total of nine metabolites were
identified, eight Phase I metabolites and one Phase II metabolite, of which five
were specific for cloniprazepam. Clonazepam was the major metabolite of
cloniprazepam. Hydroxy-cloniprazepam, dihydroxy-cloniprazepam, 3-keto-
cloniprazepam, 7-amino-cloniprazepam, hydroxy-clonazepam, 7-amino-clonazepam and 3-
hydroxy-7-amino-clonazepam were formed through oxidation, hydroxylation, and/or
reduction of the nitro-group. Glucuronidated hydroxy-cloniprazepam was the only
Phase II metabolite detected. Five metabolites were specific for cloniprazepam.
This study provided a set of human in vitro biotransformation products which can
assist specific detection of cloniprazepam consumption in future studies. (C) 2018
Elsevier B.V. All rights reserved. [Mortele, Olivier; Vervliet, Philippe; Gys,
Celine; Degreef, Maarten; Cuykx, Matthias; Maudens, Kristof; Covaci, Adrian; van
Nuijs, Alexander L. N.; Lai, Foon Yin] Univ Antwerp, Toxicol Ctr, Univ Pl 1, B-2610
Antwerp, Belgium Mortele, O; van Nuijs, ALN (reprint author), Univ Antwerp,
Toxicol Ctr, Univ Pl 1, B-2610 Antwerp, Belgium.
olivier.mortele@uantwerpen.be; alexander.vannuijs@uantwerpen.be Vervliet,
Philippe/K-4385-2019; Degreef, Maarten/T-5928-2019; van Nuijs, Alexander/P-9160-
2016; Covaci, Adrian/A-9058-2008; Mortele, Olivier/J-2613-2017; Maudens, Kristof/E-
9579-2010 Vervliet, Philippe/0000-0003-2644-6820; Degreef, Maarten/0000-0001-
6173-7178; van Nuijs, Alexander/0000-0002-9377-6160; Covaci, Adrian/0000-0003-0527-
1136; Mortele, Olivier/0000-0002-6366-2154; Maudens, Kristof/0000-0003-0924-7168
University of Antwerp (UA, Belgium); Research Foundation Flanders (FWO)FWO;
FWOFWO; University of Antwerp's BOF post-doctoral funding; Marie Sklodowska-Curie
Individual Fellowship of the European Commission (Horizon) [749845 APOLLO]
Olivier Mortele acknowledges funding of the University of Antwerp (UA,
Belgium). Matthias Cuykx and Alexander van Nuijs acknowledge the Research
Foundation Flanders (FWO) for their scholarships. Celine Gys and Philippe Vervliet
acknowledge the provision of their scholarship from two FWO projects. Foon Yin Lai
acknowledges the University of Antwerp's BOF post-doctoral funding and Marie
Sklodowska-Curie Individual Fellowship (project no. 749845 APOLLO) of the European
Commission (Horizon 2020). ALLEN MD, 1979, J CLIN PHARMACOL, V19, P445, DOI
10.1002/j.1552-4604.1979.tb02506.x; Ballesteros-Gomez A, 2015, TOXICOL LETT, V232,
P203, DOI 10.1016/j.toxlet.2014.11.007; BARTOSEK I, 1970, EUR J PHARMACOL, V11,
P249, DOI 10.1016/0014-2999(70)90054-3; Baselt RC, 2014, DISPOSITION TOXIC DR;
BERRUETA LA, 1992, J PHARMACEUT BIOMED, V10, P109, DOI 10.1016/0731-7085(92)80019-
J; Bolton J, 2006, J NERV MENT DIS, V194, P818, DOI
10.1097/01.nmd.0000244481.63148.98; Brandt SD, 2014, DRUG TEST ANAL, V6, P587, DOI
10.1002/dta.1686; BRODIE RR, 1981, BIOPHARM DRUG DISPOS, V2, P59, DOI
10.1002/bdd.2510020107; Cheze M, 2004, FORENSIC SCI INT, V145, P123, DOI
10.1016/j.forsciint.2004.04.066; Ekins S, 2000, J PHARMACOL TOX MET, V44, P313, DOI
10.1016/S1056-8719(00)00110-6; EMCDDA, 2008, SEX ASS FAC DRUGS AL; EMCDDA, 2015,
NEW PSYCH SUBST EUR; Erratico C, 2016, ENVIRON SCI TECHNOL, V50, P8263, DOI
10.1021/acs.est.6b01059; Fisher MB, 2000, DRUG METAB DISPOS, V28, P560; Hewitt NJ,
2001, DRUG METAB DISPOS, V29, P1042; Holcapek M, 2010, J CHROMATOGR A, V1217,
P3908, DOI 10.1016/j.chroma.2010.02.049; HOOPER WD, 1992, EUR J DRUG METAB PH, V17,
P51, DOI 10.1007/BF03189988; Huppertz LM, 2015, FORENSIC TOXICOL, V33, P388, DOI
10.1007/s11419-015-0277-6; KAPLAN SA, 1974, J PHARM SCI-US, V63, P527, DOI
10.1002/jps.2600630407; Knights K. M, 2016, CURR PROTOC PHARM, V74; Lai FY, 2015, J
PHARMACEUT BIOMED, V114, P355, DOI 10.1016/j.jpba.2015.06.016; Manchester KR, 2017,
DRUG TEST ANAL; Mandrioli R, 2008, CURR DRUG METAB, V9, P827, DOI
10.2174/138920008786049258; Meyer MR, 2016, ANAL BIOANAL CHEM, V408, P3571, DOI
10.1007/s00216-016-9439-6; Moosmann B, 2016, J MASS SPECTROM, V51, P1080, DOI
10.1002/jms.3840; Moosmann B, 2015, WORLD PSYCHIATRY, V14, P248, DOI
10.1002/wps.20236; Nakamura M, 2011, BIOMED CHROMATOGR, V25, P1283, DOI
10.1002/bmc.1598; Nardi AE, 2006, INT CLIN PSYCHOPHARM, V21, P131, DOI
10.1097/01.yic.0000194379.65460.a6; Negreira N, 2016, ANAL BIOANAL CHEM, V408,
P5221, DOI 10.1007/s00216-016-9616-7; Negreira N, 2016, J PHARMACEUT BIOMED, V117,
P474, DOI 10.1016/j.jpba.2015.09.029; Negreira N, 2015, ANAL BIOANAL CHEM, V407,
P5803, DOI 10.1007/s00216-015-8763-6; Negrusz A, 2003, ANAL BIOANAL CHEM, V376,
P1198, DOI 10.1007/s00216-003-2050-7; NICE, 2017, NICE PATHW EP OV; PENG DR, 1984,
BIOCHEM SOC T, V12, P39, DOI 10.1042/bst0120039; Penner N, 2012, ADME ENABLING
TECHNO, P545; PETTERS I, 1984, J CHROMATOGR, V306, P241, DOI 10.1016/S0378-
4347(00)80886-5; Pluskal T, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-
11-395; Ramanathan R, 2000, ANAL CHEM, V72, P1352, DOI 10.1021/ac9911692; Richter
LHJ, 2017, J PHARMACEUT BIOMED, V143, P32, DOI 10.1016/j.jpba.2017.05.028; Schifano
F, 2015, WORLD PSYCHIATRY, V14, P15, DOI 10.1002/wps.20174; Schymanski EL, 2014,
ENVIRON SCI TECHNOL, V48, P2097, DOI 10.1021/es5002105; Storhaug LW, 2012, FORENSIC
SCI INT, V222, pE33, DOI 10.1016/j.forsciint.2012.06.018; Van den Eede N, 2013,
TOXICOL LETT, V223, P9, DOI 10.1016/j.toxlet.2013.08.012; Vikingsson S, 2017, AAPS
J, V19, P736, DOI 10.1208/s12248-016-0040-x 44 10 10 2 22
ELSEVIER SCIENCE BV AMSTERDAM PO BOX 211, 1000 AE AMSTERDAM,
NETHERLANDS 0731-7085 1873-264X J PHARMACEUT BIOMED J. Pharm. Biomed.
Anal. MAY 10 2018 153 158 167
10.1016/j.jpba.2018.02.032 10 Chemistry, Analytical;
Pharmacology & Pharmacy Chemistry; Pharmacology & Pharmacy GB6NC
WOS:000429184900021 29494888 2019-09-25
J Goodman, FR; Stiksma, MC; Kashdan, TB Goodman, Fallon
R.; Stiksma, Melissa C.; Kashdan, Todd B. Social Anxiety and the
Quality of Everyday Social Interactions: The Moderating Influence of Alcohol
Consumption BEHAVIOR THERAPY English Article
social anxiety; alcohol consumption; experience sampling NATIONAL
EPIDEMIOLOGIC SURVEY; EMOTIONAL FACIAL EXPRESSIONS; DRINKING MOTIVES; COLLEGE-
STUDENTS; SELF-MEDICATION; USE DISORDERS; EXPERIENTIAL AVOIDANCE; SUBSTANCE USE;
PROBLEMATIC DRINKING; ANXIOUS INDIVIDUALS Most research on the link between social
anxiety and alcohol consumption has examined problematic outcomes without
consideration of potential adaptive functions. Alcohol is an anxiolytic that has
the short-term benefit of reducing anxiety; consumption may act as a social
lubricant that facilitates higher quality social interactions. Using experience-
sampling methodology, we examined how consuming alcohol attenuates the adverse
effects of social anxiety in naturally occurring social interactions. Participants
(N= 160) completed demographic and trait measures, then completed daily assessments
for 14 consecutive days. Results from multilevel model analyses revealed that
during face-to-face social interactions, state social anxiety was inversely related
to 10 indicators of healthy social interactions (e.g., enjoyment, laughter,
feelings of acceptance). Alcohol consumption moderated seven of these associations,
such that when participants consumed alcohol in social situations, state social
anxiety was no longer associated with social interaction quality. The quantity of
alcoholic drinks consumed moderated two of these associations. Furthermore, we
found evidence for directionality, such that social anxiety in a given social
interaction predicted alcohol consumption in a subsequent social interaction, but
not the reverse (i.e., alcohol consumption did not prospectively predict state
social anxiety). In social situations that involved alcohol, experiences of social
anxiety no longer thwarted one's ability to derive social benefits. These results
should be interpreted in the context of a participant sample with relatively low
levels of trait social anxiety and frequency of alcohol use. Nonetheless, obtaining
social rewards may be a reinforcement mechanism that maintains the link between
social anxiety and alcohol consumption. [Goodman, Fallon R.; Stiksma, Melissa C.;
Kashdan, Todd B.] George Mason Univ, Fairfax, VA 22030 USA Kashdan, TB (reprint
author), George Mason Univ, Dept Psychol, MS 3F5, Fairfax, VA 22030 USA.
tkashdan@gmu.edu National Institute on Alcohol Abuse and
Alcoholism NIAAA grant [F31-AA024372]; Center for the Advancement of Well-Being,
George Mason University This research was supported in part by a National Institute
on Alcohol Abuse and Alcoholism NIAAA) grant F31-AA024372 awarded to Fallon
Goodman. Dr. Todd Kashdan received funding from the Center for the Advancement of
Well-Being, George Mason University. Abrams K, 2002, PSYCHOL ADDICT BEHAV,
V16, P121, DOI 10.1037//0893-164X.16.2.121; Abrams K, 2001, DRUG ALCOHOL DEPEN,
V64, P219, DOI 10.1016/S0376-8716(01)00125-9; Alden LE, 2004, CLIN PSYCHOL REV,
V24, P857, DOI 10.1016/j.cpr.2004.07.006; Bacon AK, 2010, ADDICT BEHAV, V35, P925,
DOI 10.1016/j.addbeh.2010.06.002; Battista SR, 2015, J SOC CLIN PSYCHOL, V34, P508,
DOI 10.1521/jscp.2015.34.6.508; Battista SR, 2012, J SOC CLIN PSYCHOL, V31, P1074,
DOI 10.1521/jscp.2012.31.10.1074; Battista Susan R, 2010, Curr Drug Abuse Rev, V3,
P3; Boden Matthew Tyler, 2016, Curr Drug Abuse Rev, V9, P113, DOI
10.2174/1874473710666170308163310; Brown EJ, 1997, PSYCHOL ASSESSMENT, V9, P21, DOI
10.1037/1040-3590.9.1.21; Buckner JD, 2006, BEHAV THER, V37, P381, DOI
10.1016/j.beth.2006.02.007; Buckner JD, 2016, ADDICT BEHAV, V58, P7, DOI
10.1016/j.addbeh.2016.02.006; Buckner JD, 2012, ADDICT BEHAV, V37, P533, DOI
10.1016/j.addbeh.2011.11.026; Buckner JD, 2008, DEPRESS ANXIETY, V25, P1028, DOI
10.1002/da.20442; Caballo VE, 2015, PSYCHOL ASSESSMENT, V27, P997, DOI
10.1037/a0038828; Carrigan MH, 2008, ADDICT BEHAV, V33, P1162, DOI
10.1016/j.addbeh.2008.04.020; Carrigan MH, 2003, ADDICT BEHAV, V28, P269, DOI
10.1016/S0306-4603(01)00235-0; CHUTUAPE MAD, 1995, PSYCHOPHARMACOLOGY, V121, P91,
DOI 10.1007/BF02245595; Cooper M. L., 1994, PSYCHOL ASSESSMENT, V6, P117, DOI [DOI
10.1037/1040-3590.6.2.117, 10.1037/1040-3590.6.2.117]; Cooper R, 2014, ANXIETY
STRESS COPIN, V27, P113, DOI 10.1080/10615806.2013.823482; Cox BJ, 1998, BEHAV
MODIF, V22, P285, DOI 10.1177/01454455980223004; Curtin JJ, 2001, PSYCHOL SCI, V12,
P527, DOI 10.1111/1467-9280.00397; Davila J, 2002, BEHAV THER, V33, P427, DOI
10.1016/S0005-7894(02)80037-5; DEBOER MC, 1993, ADDICT BEHAV, V18, P117, DOI
10.1016/0306-4603(93)90041-7; Dufour MC, 1999, ALCOHOL RES HEALTH, V23, P5; FARBER
PD, 1980, J CONSULT CLIN PSYCH, V48, P780, DOI 10.1037/0022-006X.48.6.780; Farmer
Antonina Savostyanova, 2012, Cognitive Behaviour Therapy, V41, P152, DOI
10.1080/16506073.2012.666561; Fleeson W, 2004, CURR DIR PSYCHOL SCI, V13, P83, DOI
10.1111/j.0963-7214.2004.00280.x; Fleeson W, 2001, J PERS SOC PSYCHOL, V80, P1011,
DOI 10.1037/0022-3514.80.6.1011; Foster DW, 2016, SUBST USE MISUSE, V51, P165, DOI
10.3109/10826084.2015.1082596; Franken IHA, 2007, ALCOHOL CLIN EXP RES, V31, P919,
DOI 10.1111/j.1530-0277.2007.00424.x; Gilles DM, 2006, ADDICT BEHAV, V31, P388, DOI
10.1016/j.addbeh.2005.05.020; Grant BF, 2005, J CLIN PSYCHIAT, V66, P1351, DOI
10.4088/JCP.v66n1102; Ham LS, 2007, J ANXIETY DISORD, V21, P991, DOI
10.1016/j.janxdis.2006.10.014; Ham LS, 2016, ADDICT RES THEORY, V24, P9, DOI
10.3109/16066359.2015.1036242; Ham Lindsay S., 2009, Cognitive Behaviour Therapy,
V38, P133, DOI 10.1080/16506070802610889; Ham LS, 2009, COGNITIVE THER RES, V33,
P615, DOI 10.1007/s10608-009-9248-8; Ham LS, 2003, CLIN PSYCHOL REV, V23, P719, DOI
10.1016/S0272-7358(03)00071-0; Hart TA, 1999, DEPRESS ANXIETY, V10, P28, DOI
10.1002/(SICI)1520-6394(1999)10:1<28::AID-DA5>3.0.CO;2-I; Hayes SC, 2006, BEHAV RES
THER, V44, P1, DOI 10.1016/j.brat.2005.06.006; Hayes SC, 1996, J CONSULT CLIN
PSYCH, V64, P1152, DOI 10.1037/0022-006X.64.6.1152; HEIMBERG RG, 1992, BEHAV THER,
V23, P53, DOI 10.1016/S0005-7894(05)80308-9; Heinrichs N, 2001, CLIN PSYCHOL REV,
V21, P751, DOI 10.1016/S0272-7358(00)00067-2; Hingson RW, 2010, ALCOHOL RES HEALTH,
V33, P45; Hofmann Stefan G., 2007, Cognitive Behaviour Therapy, V36, P193, DOI
10.1080/16506070701421313; HOLROYD KA, 1978, J STUD ALCOHOL, V39, P737, DOI
10.15288/jsa.1978.39.737; Horley K, 2004, PSYCHIAT RES, V127, P43, DOI
10.1016/j.psychres.2004.02.016; Kashdan TB, 2006, PSYCHOL SCI, V17, P120, DOI
10.1111/j.1467-9280.2006.01674.x; Kashdan TB, 2014, EMOTION, V14, P769, DOI
10.1037/a0035935; Kashdan TB, 2013, J ABNORM PSYCHOL, V122, P645, DOI
10.1037/a0032733; Kashdan TB, 2011, CLIN PSYCHOL REV, V31, P786, DOI
10.1016/j.cpr.2011.03.012; Kashdan TB, 2011, BEHAV RES THER, V49, P352, DOI
10.1016/j.brat.2011.03.004; Kashdan TB, 2010, CURR DIR PSYCHOL SCI, V19, P47, DOI
10.1177/0963721409359280; Kashdan TB, 2009, BEHAV RES THER, V47, P559, DOI
10.1016/j.brat.2009.03.010; Keough MT, 2016, ADDICT BEHAV, V55, P19, DOI
10.1016/j.addbeh.2015.12.013; Kessler RC, 1997, ARCH GEN PSYCHIAT, V54, P313;
Kidorf M, 1999, PSYCHOL ADDICT BEHAV, V13, P134, DOI 10.1037/0893-164X.13.2.134;
Kiko S, 2012, BEHAV RES THER, V50, P617, DOI 10.1016/j.brat.2012.06.001; Kuntsche
E, 2005, CLIN PSYCHOL REV, V25, P841, DOI 10.1016/j.cpr.2005.06.002; Kuntsche E,
2010, DRUG ALCOHOL DEPEN, V110, P259, DOI 10.1016/j.drugalcdep.2010.02.021; KUSHNER
MG, 1990, AM J PSYCHIAT, V147, P685; Lazareck S, 2012, J CLIN PSYCHIAT, V73, pE588,
DOI 10.4088/JCP.11m07345; Ledley DR, 2006, J SOC CLIN PSYCHOL, V25, P755, DOI
10.1521/jscp.2006.25.7.755; Lewis BA, 2002, ADDICT BEHAV, V27, P529, DOI
10.1016/S0306-4603(01)00190-3; Lewis MA, 2008, PSYCHOL ADDICT BEHAV, V22, P58, DOI
10.1037/0893-164X.22.1.58; Maggs JL, 2011, ADDICT BEHAV, V36, P197, DOI
10.1016/j.addbeh.2010.10.005; Mattick RP, 1998, BEHAV RES THER, V36, P455, DOI
10.1016/S0005-7967(97)10031-6; Mckay D, 1999, ADDICT BEHAV, V24, P633, DOI
10.1016/S0306-4603(99)00021-0; McKnight P. E., 2007, MISSING DATA A GENTL; Mcmanus
F, 2008, J BEHAV THER EXP PSY, V39, P147, DOI 10.1016/j.jbtep.2006.12.002; Moberg
CA, 2009, J ABNORM PSYCHOL, V118, P335, DOI 10.1037/a0015636; Morris EP, 2005, CLIN
PSYCHOL REV, V25, P734, DOI 10.1016/j.cpr.2005.05.004; Nezlek J. B., 2012, HDB RES
METHODS STUD, P357; Nezlek JB, 2001, PERS SOC PSYCHOL B, V27, P771, DOI
10.1177/0146167201277001; Nezlek JB, 2011, MULTILEVEL MODELING; Nezlek JB, 2007,
EUR J PERSONALITY, V21, P789, DOI 10.1002/per.640; Nicholls J, 2014, PSYCHIAT RES,
V220, P909, DOI 10.1016/j.psychres.2014.08.040; Nolen-Hoeksema S, 2004, CLIN
PSYCHOL REV, V24, P981, DOI 10.1016/j.cpr.2004.08.003; Norberg MM, 2009, PSYCHOL
ADDICT BEHAV, V23, P586, DOI 10.1037/a0016994; O'Grady MA, 2011, J SOC CLIN
PSYCHOL, V30, P599, DOI 10.1521/jscp.2011.30.6.599; O'Hara RE, 2014, J STUD ALCOHOL
DRUGS, V75, P606, DOI 10.15288/jsad.2014.75.606; Piasecki TM, 2014, PSYCHOL
ASSESSMENT, V26, P363, DOI 10.1037/a0035153; Preacher KJ, 2006, J EDUC BEHAV STAT,
V31, P437, DOI 10.3102/10769986031004437; Raudenbush S.W., 2011, HLM 7; Richards
JM, 1999, PERS SOC PSYCHOL B, V25, P1033, DOI 10.1177/01461672992511010; Robinson
J, 2011, ARCH GEN PSYCHIAT, V68, P800, DOI 10.1001/archgenpsychiatry.2011.75;
Rodebaugh TL, 2006, PSYCHOL ASSESSMENT, V18, P231, DOI 10.1037/1040-3590.18.2.231;
Schry AR, 2013, ADDICT BEHAV, V38, P2690, DOI 10.1016/j.addbeh.2013.06.014;
Shiffman S, 2009, PSYCHOL ASSESSMENT, V21, P486, DOI 10.1037/a0017074; Sparrevohn
RM, 2009, BEHAV RES THER, V47, P1074, DOI 10.1016/j.brat.2009.07.016; Stevens S,
2008, J ANXIETY DISORD, V22, P940, DOI 10.1016/j.janxdis.2007.09.007; Stevens S,
2009, BRIT J CLIN PSYCHOL, V48, P125, DOI 10.1348/014466508X368856; Stewart
S. H., 2006, J MENTAL HLTH, V15, P671, DOI [DOI 10.1080/09638230600998904,
10.1080/09638230600998904]; TROWER P, 1989, CLIN PSYCHOL REV, V9, P19, DOI
10.1016/0272-7358(89)90044-5; Walters KS, 1998, BEHAV THER, V29, P387, DOI
10.1016/S0005-7894(98)80039-7; WECHSLER H, 1994, JAMA-J AM MED ASSOC, V272, P1672,
DOI 10.1001/jama.272.21.1672; White A, 2013, ALCOHOL RES-CURR REV, V35, P201; Xu Y,
2012, J ANXIETY DISORD, V26, P12, DOI 10.1016/j.janxdis.2011.08.006 97 4
4 5 12 ASSOC ADV BEHAVIOR THERAPY NEW YORK 305 7TH AVE #16A,
NEW YORK, NY 10001-6008 USA 0005-7894 1878-1888 BEHAV THER Behav.
Therapy MAY 2018 49 3 373 387
15 Psychology, Clinical; Psychiatry Psychology; Psychiatry GE8GW
WOS:000431471200006 29704967 2019-09-25
J Foster, KT; Hicks, BM; Zucker, RA Foster, Katherine T.;
Hicks, Brian M.; Zucker, Robert A. Positive and Negative Effects of
Internalizing on Alcohol Use Problems From Childhood to Young Adulthood: The
Mediating and Suppressing Role of Externalizing JOURNAL OF ABNORMAL PSYCHOLOGY
English Article alcohol use
problems; internalizing; externalizing; mediation; suppression MAJOR DEPRESSIVE
DISORDER; SUBSTANCE-USE DISORDERS; NATIONAL EPIDEMIOLOGIC SURVEY; AGE-OF-ONSET;
DRUG-USE; PSYCHIATRIC-DISORDERS; GENERAL-POPULATION; COMORBIDITY SURVEY; GENDER-
DIFFERENCES; ANXIETY DISORDERS A longstanding hypothesis is that some alcohol
use problems (AUP) develop and are maintained through the "self-medication" of
internalizing (INT; depression and anxiety) problems. However, their high rate of
co-occurrence with one another and with externalizing (EXT; antisocial behavior and
impulse control) problems obscures any causal association because EXT may account
for the INT-AUP link. Using a large community sample, we estimated prospective
effects of INT and EXT on AUP via latent cross-lagged mediation panel spanning 14
years from childhood (ages 9-11) to young adulthood (ages 21-23). After adjusting
for the cross-lagged, concurrent, and stability effects across factors, INT
decreased AUP risk through its direct and indirect effects and increased AUP risk
through shared variance with EXT. Between childhood and young adulthood, unique
aspects of INT reduced risk for AUP while aspects of INT shared with EXT increased
risk for AUP. [Foster, Katherine T.] Univ Michigan, Dept Psychol, 530 Church
St, Ann Arbor, MI 48109 USA; [Hicks, Brian M.; Zucker, Robert A.] Univ Michigan,
Dept Psychiat, Ann Arbor, MI 48109 USA Foster, KT (reprint author), Univ
Michigan, Dept Psychol, 530 Church St, Ann Arbor, MI 48109 USA. ktfoster@umich.edu
United States Public Health Service Grants from the National
Institute on Alcohol Abuse and Alcoholism [F31 AA023121, R01 AA007065]; United
States Public Health Service Grants from the National Institute on Drug Abuse [R01
DA034606, DA039112] This research was supported by United States Public Health
Service Grants F31 AA023121 (Katherine T. Foster) and R01 AA007065 (Robert A.
Zucker) from the National Institute on Alcohol Abuse and Alcoholism and R01
DA034606 (Brian M. Hicks) and DA039112 (Durbin) from the National Institute on Drug
Abuse. The content is solely the responsibility of the authors and does not
necessarily represent the official views of the National Institutes of Health.
Katherine T. Foster developed the analytic model, performed all data analysis and
interpretation, and composed the article under the supervision of Brian M. Hicks
and Robert A. Zucker. The Michigan Longitudinal Study was designed by Robert A.
Zucker and data were collected at the University of Michigan Addiction Research
Center under his supervision. All authors approved the final version of the article
for submission. Achenbach T. M., 1991, MANUAL CHILD BEHAV C; Achenbach TM, 1987,
MANUAL YOUTH SELF RE; Achenbach TM, 1997, MANUAL YOUNG ADULT S; BABOR TF, 1992,
ARCH GEN PSYCHIAT, V49, P599; Bobo JK, 1998, PSYCHIATR SERV, V49, P693, DOI
10.1176/ps.49.5.693; Boden JM, 2011, ADDICTION, V106, P906, DOI 10.1111/j.1360-
0443.2010.03351.x; BROWN SA, 1995, AM J PSYCHIAT, V152, P45; Chassin L, 2004, J
ABNORM PSYCHOL, V113, P483, DOI 10.1037/0021-843X.113.4.483; CHEN K, 1995, AM J
PUBLIC HEALTH, V85, P41, DOI 10.2105/AJPH.85.1.41; Clark DB, 1998, DRUG ALCOHOL
DEPEN, V49, P115, DOI 10.1016/S0376-8716(97)00154-3; CLONINGER CR, 1987, SCIENCE,
V236, P410, DOI 10.1126/science.2882604; CORNELIUS JR, 1995, AM J PSYCHIAT, V152,
P358; Crum RM, 2013, JAMA PSYCHIAT, V70, P718, DOI
10.1001/jamapsychiatry.2013.1098; Curran GM, 2000, J SUBST ABUSE TREAT, V19, P259,
DOI 10.1016/S0740-5472(00)00107-0; Donohue B, 1996, ADDICT BEHAV, V21, P211, DOI
10.1016/0306-4603(95)00051-8; Driessen M, 2001, ALCOHOL ALCOHOLISM, V36, P249, DOI
10.1093/alcalc/36.3.249; Edwards AC, 2014, ALCOHOL CLIN EXP RES, V38, P1680, DOI
10.1111/acer.12402; Farmer RF, 2016, DRUG ALCOHOL DEPEN, V164, P38, DOI
10.1016/j.drugalcdep.2016.04.021; Fergusson DM, 2009, ARCH GEN PSYCHIAT, V66, P260,
DOI 10.1001/archgenpsychiatry.2008.543; Foster KT, 2015, PSYCHOL MED, V45, P3047,
DOI 10.1017/S0033291715001014; Grant BF, 2004, ARCH GEN PSYCHIAT, V61, P807, DOI
10.1001/archpsyc.61.8.807; Greenfield SF, 1998, ARCH GEN PSYCHIAT, V55, P259, DOI
10.1001/archpsyc.55.3.259; Hasin DS, 2002, ARCH GEN PSYCHIAT, V59, P794, DOI
10.1001/archpsyc.59.9.794; Hasin DS, 2005, ARCH GEN PSYCHIAT, V62, P1097, DOI
10.1001/archpsyc.62.10.1097; Hussong AM, 2017, PSYCHOL ADDICT BEHAV, V31, P137, DOI
10.1037/adb0000247; Hussong AM, 2011, PSYCHOL ADDICT BEHAV, V25, P390, DOI
10.1037/a0024519; Johnstone BM, 1996, J STUD ALCOHOL, V57, P494, DOI
10.15288/jsa.1996.57.494; Kessler RC, 1997, ARCH GEN PSYCHIAT, V54, P313; Kessler
RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; King SM,
2004, ADDICTION, V99, P1548, DOI 10.1111/j.1360-0443.2004.00893.x; Kovacs M, 2016,
J AFFECT DISORDERS, V203, P374, DOI 10.1016/j.jad.2016.05.042; Krueger RF, 1999, J
PERS, V67, P39, DOI 10.1111/1467-6494.00047; Krueger RE, 2006, ANNU REV CLIN
PSYCHO, V2, P111, DOI 10.1146/annurev.clinpsy.2.022305.095213; Kuo PH, 2006,
PSYCHOL MED, V36, P1153, DOI 10.1017/S0033291706007860; Kushner MG, 2000, CLIN
PSYCHOL REV, V20, P149, DOI 10.1016/S0272-7358(99)00027-6; Lahey BB, 2012, J ABNORM
PSYCHOL, V121, P971, DOI 10.1037/a0028355; Lejoyeux M, 2011, ALCOHOL ALCOHOLISM,
V46, P61, DOI 10.1093/alcalc/agq077; MACCALLUM RC, 1993, PSYCHOL BULL, V114, P185,
DOI 10.1037/0033-2909.114.1.185; MacKinnon D P, 2000, Prev Sci, V1, P173, DOI
10.1023/A:1026595011371; Maggs JL, 2008, ADDICTION, V103, P7, DOI 10.1111/j.1360-
0443.2008.02173.x; McGue M, 2001, ALCOHOL CLIN EXP RES, V25, P1156, DOI
10.1097/00000374-200108000-00010; Meyer C, 2004, SOC PSYCH PSYCH EPID, V39, P435,
DOI 10.1007/s00127-004-0755-3; Muthen L., 2015, MPLUS; NOLENHOEKSEMA S, 1992, J
ABNORM PSYCHOL, V101, P405, DOI 10.1037/0021-843X.101.3.405; Paulhus DL, 2004,
MULTIVAR BEHAV RES, V39, P303, DOI 10.1207/s15327906mbr3902_7; Pettinati HM, 1997,
ALCOHOL CLIN EXP RES, V21, P1742; REGIER DA, 1990, JAMA-J AM MED ASSOC, V264,
P2511; ROGGLA H, 1995, INT J ADDICT, V30, P337, DOI 10.3109/10826089509048730; ROSS
HE, 1995, DRUG ALCOHOL DEPEN, V39, P111, DOI 10.1016/0376-8716(95)01150-W; SALLOUM
IM, 1995, COMPR PSYCHIAT, V36, P260, DOI 10.1016/S0010-440X(95)90070-5; Selig JP,
2009, RES HUM DEV, V6, P144, DOI 10.1080/15427600902911247; SOBEL ME, 1990,
PSYCHOMETRIKA, V55, P495, DOI 10.1007/BF02294763; STEELE RG, 1995, AM J
ORTHOPSYCHIAT, V65, P380, DOI 10.1037/h0079694; Tackett JL, 2013, J ABNORM PSYCHOL,
V122, P1142, DOI 10.1037/a0034151; Wilson S, 2015, PSYCHOL MED, V45, P505, DOI
10.1017/S0033291714001640; World Health Organization (WHO), 2015, WORLD HLTH STAT
2015; Zucker R, 1990, DRINKING DRUG HIST; Zucker R. A., 1994, DEV ALCOHOL PROBLEMS,
V94-3495, P255 58 1 1 0 6 AMER PSYCHOLOGICAL ASSOC
WASHINGTON 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA 0021-843X 1939-
1846 J ABNORM PSYCHOL J. Abnorm. Psychol. MAY 2018 127 4
394 403 10.1037/abn0000337 10
Psychology, Clinical; Psychiatry Psychology; Psychiatry GF3JG
WOS:000431850600006 29745704 2019-09-25
J Sarvet, AL; Wall, MM; Keyes, KM; Olfson, M; Cerda, M; Hasin, DS
Sarvet, Aaron L.; Wall, Melanie M.; Keyes, Katherine M.; Olfson, Mark; Cerda,
Magdalena; Hasin, Deborah S. Self-medication of mood and anxiety
disorders with marijuana: Higher in states with medical marijuana laws DRUG AND
ALCOHOL DEPENDENCE English Article
General population; Mood and anxiety disorders; Self-medication; Laws;
Medical marijuana; NESARC NATIONAL EPIDEMIOLOGIC SURVEY; PSYCHIATRIC DIAGNOSTIC
MODULES; GENERAL-POPULATION SAMPLE; CROSS-SECTIONAL SURVEYS; ALCOHOL-USE DISORDERS;
DRUG-USE DISORDERS; IV AUDADIS-IV; UNITED-STATES; SUBSTANCE USE; CANNABIS USE
Background: Self-medication with drugs or alcohol is commonly reported among
adults with mood or anxiety disorders, and increases the risk of developing
substance use disorders. Medical marijuana laws (MML) may be associated with
greater acceptance of the therapeutic value of marijuana, leading individuals to
self-medicate. Methods: The study utilized data from Wave 2 of the National
Epidemiologic Survey on Alcohol and Related Conditions (2004-2005). Participants
were sampled from households in the general population and included adults with a
mood or anxiety disorder in the past 12 months (n = 7418), and the subset of those
who used marijuana and no other drug (n = 314). Weighted logistic regression models
predicted the prevalence of self medication with drugs in U.S. states with and
without MML, adjusting for individual and state-level covariates. As a negative
control, analyses were repeated for self-medication with alcohol. Results: Overall,
self-medication with drugs was 3.73 percentage points higher (95% confidence
interval [CI]: 0.93-6.53) among those living in MML states (p = 0.01). For the
subpopulation that only used marijuana, self medication with drugs was 21.22
percentage points higher (95% CI: 3.91-38.53) among those living in MML states (p =
0.02). In contrast, self-medication with alcohol had nearly identical prevalence in
MML and non-MML states, overall and for drinkers. Conclusions: Among adults with
mood or anxiety disorders, living in a medical marijuana law state is associated
with self-medication with marijuana. While additional research is needed to
determine the reasons for this association, clinical screening for self-medication
with marijuana may be particularly important in states with medical marijuana laws.
 [Sarvet, Aaron L.; Wall, Melanie M.; Keyes, Katherine M.; Olfson, Mark;
Hasin, Deborah S.] Columbia Univ, Coll Phys & Surg, Dept Psychiat, 722 W 168th St,
New York, NY 10032 USA; [Sarvet, Aaron L.; Wall, Melanie M.; Olfson, Mark; Hasin,
Deborah S.] New York State Psychiat Inst & Hosp, 722 W 168th St, New York, NY 10032
USA; [Wall, Melanie M.] Columbia Univ, Mailman Sch Publ Hlth, Dept Biostat, 722 W
168th St, New York, NY 10032 USA; [Keyes, Katherine M.; Hasin, Deborah S.] Columbia
Univ, Mailman Sch Publ Hlth, Dept Epidemiol, 722 W 168th St, New York, NY 10032
USA; [Cerda, Magdalena] Univ Calif Davis, Dept Emergency Med, 2315 Stockton Blvd,
Sacramento, CA 95817 USA Hasin, DS (reprint author), Columbia Univ, Coll Phys
& Surg, Dept Epidemiol & Psychiat, 1051 Riverside Dr 123, New York, NY 10032 USA.
dsh2@cumc.columbia.edu National Institute on Alcohol Abuse and
Alcoholism (NIAAA)United States Department of Health & Human ServicesNational
Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse &
Alcoholism (NIAAA); New York State Psychiatric Institute; National Institute on
Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of
Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01DA034244,
R01DA019606, R01DA040924, K01DA030449]; National Institute on Alcohol Abuse and
AlcoholismUnited States Department of Health & Human ServicesNational Institutes of
Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)
[K01AA021511] The National Institute on Alcohol Abuse and Alcoholism (NIAAA)
funded the NESARC. The secondary data analysis of these data for this study was
funded by the New York State Psychiatric Institute (Sarvet, Hasin), the National
Institute on Drug Abuse [grant numbers R01DA034244 (Hasin, Wall, Sarvet),
R01DA019606 (Olfson), R01DA040924 (Cerda), and K01DA030449 (Cerda)], and the
National Institute on Alcohol Abuse and Alcoholism [grant number K01AA021511
(Keyes)]. Sponsors and funders of the NESARC had no role in the design and conduct
of the study; collection, management analysis, and interrelation of the data;
preparation, review and approval of the manuscript; and decision to submit the
manuscript for publication. AKERS RL, 1979, AM SOCIOL REV, V44, P636, DOI
10.2307/2094592; American Psychiatric Association, 2013, DIAGN STAT MAN MENT;
Armitage CJ, 2001, BRIT J SOC PSYCHOL, V40, P471, DOI 10.1348/014466601164939;
Bahorik AL, 2017, J AFFECT DISORDERS, V213, P168, DOI 10.1016/j.jad.2017.02.016;
Banes KE, 2014, DRUG ALCOHOL DEPEN, V139, P41, DOI
10.1016/j.drugalcdep.2014.02.706; Bieler GS, 2010, AM J EPIDEMIOL, V171, P618, DOI
10.1093/aje/kwp440; Blevins CE, 2016, ADDICT BEHAV, V57, P42, DOI
10.1016/j.addbeh.2016.02.005; Bolton JM, 2009, J AFFECT DISORDERS, V115, P367, DOI
10.1016/j.jad.2008.10.003; Bonn-Miller MO, 2007, ADDICT BEHAV, V32, P49, DOI
10.1016/j.addbeh.2006.03.018; Bonn-Miller MO, 2012, PSYCHOL SERV, V9, P404, DOI
10.1037/a0027622; Bradford AC, 2016, HEALTH AFFAIR, V35, P1230, DOI
10.1377/hlthaff.2015.1661; Brady JE, 2014, AM J EPIDEMIOL, V179, P692, DOI
10.1093/aje/kwt327; Brooks C, 2006, ANNU REV SOCIOL, V32, P191, DOI
10.1146/annurev.soc.32.061604.123142; Buckner JD, 2013, J STUD ALCOHOL DRUGS, V74,
P720, DOI 10.15288/jsad.2013.74.720; Burstein P, 2003, POLIT RES QUART, V56, P29,
DOI 10.1177/106591290305600103; Carpenter KM, 1998, ADDICT BEHAV, V23, P41, DOI
10.1016/S0306-4603(97)00015-4; Cerda M, 2012, DRUG ALCOHOL DEPEN, V120, P22, DOI
10.1016/j.drugalcdep.2011.06.011; Compton WM, 2016, LANCET PSYCHIAT, V3, P954, DOI
10.1016/S2215-0366(16)30208-5; Crum RM, 2013, JAMA PSYCHIAT, V70, P718, DOI
10.1001/jamapsychiatry.2013.1098; Crum RM, 2013, DEPRESS ANXIETY, V30, P174, DOI
10.1002/da.22024; Fox CL, 2011, PSYCHOL ADDICT BEHAV, V25, P492, DOI
10.1037/a0024331; Grant BF, 2009, MOL PSYCHIATR, V14, P1051, DOI
10.1038/mp.2008.41; Grant B.F., 2003, SOURCE ACCURACY STAT; Grant BF, 2003, DRUG
ALCOHOL DEPEN, V71, P7, DOI 10.1016/S0376-8716(03)00070-X; Grant BF, 2004, ARCH GEN
PSYCHIAT, V61, P361, DOI 10.1001/archpsyc.61.4.361; Graubard BI, 1999, BIOMETRICS,
V55, P652, DOI 10.1111/j.0006-341X.1999.00652.x; Harris KM, 2005, HEALTH SERV RES,
V40, P117, DOI 10.1111/j.1475-6773.2005.00345.x; Hasin DS, 2017, JAMA PSYCHIAT,
V74, P579, DOI 10.1001/jamapsychiatry.2017.0724; Hasin DS, 2015, JAMA PSYCHIAT,
V72, P1235, DOI 10.1001/jamapsychiatry.2015.1858; Hasin DS, 2015, LANCET PSYCHIAT,
V2, P601, DOI 10.1016/S2215-0366(15)00217-5; Holahan CJ, 2003, J ABNORM PSYCHOL,
V112, P159, DOI 10.1037/0021-843X.112.1.159; Johnston LD, 2014, USE ALCOHOL
CIGARETT; Kessler RC, 1996, AM J ORTHOPSYCHIAT, V66, P17, DOI 10.1037/h0080151;
Kessler RC, 2004, BIOL PSYCHIAT, V56, P730, DOI 10.1016/j.biopsych.2004.06.034;
Keyes KM, 2011, ADDICTION, V106, P1790, DOI 10.1111/j.1360-0443.2011.03485.x; Koob
GF, 2006, ADDICTION, V101, P23, DOI 10.1111/j.1360-0443.2006.01586.x; Kuntsche E,
2005, CLIN PSYCHOL REV, V25, P841, DOI 10.1016/j.cpr.2005.06.002; Kushner MG, 2000,
CLIN PSYCHOL REV, V20, P149, DOI 10.1016/S0272-7358(99)00027-6; Lai HMX, 2015, DRUG
ALCOHOL DEPEN, V154, P1, DOI 10.1016/j.drugalcdep.2015.05.031; Lazareck S, 2012, J
CLIN PSYCHIAT, V73, pE588, DOI 10.4088/JCP.11m07345; Lee CM, 2007, ADDICT BEHAV,
V32, P1384, DOI 10.1016/j.addbeh.2006.09.010; Lembke A, 2012, AM J DRUG ALCOHOL AB,
V38, P524, DOI 10.3109/00952990.2012.694532; Lipperman-Kreda S, 2010, J COMMUN
HEALTH, V35, P249, DOI 10.1007/s10900-010-9229-6; Lipperman-Kreda S, 2009, NICOTINE
TOB RES, V11, P531, DOI 10.1093/ntr/ntp033; Lipsitch M, 2010, EPIDEMIOLOGY, V21,
P383, DOI 10.1097/EDE.0b013e3181d61eeb; Moitra E, 2015, PSYCHOL ADDICT BEHAV, V29,
P627, DOI 10.1037/adb0000083; Pacek LR, 2015, DRUG ALCOHOL DEPEN, V149, P232, DOI
10.1016/j.drugalcdep.2015.02.009; Pacula Rosalie Liccardo, 2014, J Drug Policy
Anal, V7, P1; REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511; Research Triangle
Institute, 2012, SUDAAN LANG MAN REL; Robinson J, 2011, ARCH GEN PSYCHIAT, V68,
P800, DOI 10.1001/archgenpsychiatry.2011.75; Robinson J, 2009, J ANXIETY DISORD,
V23, P38, DOI 10.1016/j.janxdis.2008.03.013; Robinson JA, 2009, J NERV MENT DIS,
V197, P873, DOI 10.1097/NMD.0b013e3181c299c2; Ruan WJ, 2008, DRUG ALCOHOL DEPEN,
V92, P27, DOI 10.1016/j.drugalcdep.2007.06.001; Simons JS, 2005, PSYCHOL ADDICT
BEHAV, V19, P326, DOI 10.1037/0893-164X.19.3.326; Substance Abuse and Mental Health
Services Administration (SAMHSA), 2013, DRUG AB WARN NETW DA; The Associated Press,
2017, VET ARE KEY SURGE ST; Weiss RD, 2004, J AFFECT DISORDERS, V79, P279, DOI
10.1016/S0165-0327(02)00454-8; Wen HF, 2015, J HEALTH ECON, V42, P64, DOI
10.1016/j.jhealeco.2015.03.007; Whiting PF, 2015, JAMA-J AM MED ASSOC, V313, P2456,
DOI 10.1001/jama.2015.6358; Wilkinson ST, 2015, J CLIN PSYCHIAT, V76, P1174, DOI
10.4088/JCP.14m09475 61 7 7 2 5 ELSEVIER IRELAND LTD CLARE
ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND
0376-8716 1879-0046 DRUG ALCOHOL DEPEN Drug Alcohol Depend.
MAY 1 2018 186 10 15
10.1016/j.drugalcdep.2018.01.009 6 Substance Abuse;
Psychiatry Substance Abuse; Psychiatry GG3TR WOS:000432616400003 29525698
Green Accepted 2019-09-25
J Haracz, K; Hazelton, M; James, C Haracz, Kirsti;
Hazelton, Michael; James, Carole The "Double Whammy": Women's
Experiences of Weight Gain After Diagnosis and Treatment for Schizophrenia Spectrum
Disorders JOURNAL OF NERVOUS AND MENTAL DISEASE English
Article Schizophrenia; obesity; lifestyle;
women; grounded theory AUSTRALIAN NATIONAL-SURVEY; HEALTH-RELATED QUALITY; SELF-
MEDICATION HYPOTHESIS; SEVERE MENTAL-ILLNESS; PHYSICAL-ACTIVITY; OF-LIFE;
ANTIPSYCHOTIC MEDICATIONS; DUAL DIAGNOSIS; OBESITY; PEOPLE High levels of lifestyle
risk factors compound medication side effects, resulting in high rates of obesity
among people with schizophrenia spectrum disorders (SSDs). Obesity and related
comorbidities increase the levels of disability and disadvantage in this
population. Little research has explored the lived experiences in relation to this
issue, and less has considered the experiences of women. Our aim in this study was
to understand the experiences of women who gained weight after their diagnosis and
treatment for SSDs. We carried out up to three in-depth qualitative interviews with
11 women over 2 years. Data were analyzed using constructivist grounded theory
procedures. The women described a double whammy-like experience whereby weight gain
and obesity came with their diagnosis and treatment of an SSD and brought with it
additional challenges. The double whammy parallels the co-occurrence of mental
illness and substance misuse. Implications of these parallels for service provision
are discussed. [Haracz, Kirsti; James, Carole] Univ Newcastle, Sch Hlth Sci,
Hunter Bldg,Univ Dr, Callaghan, NSW 2308, Australia; [Hazelton, Michael] Univ
Newcastle, Sch Nursing & Midwifery, Callaghan, NSW, Australia Haracz, K (reprint
author), Univ Newcastle, Sch Hlth Sci, Hunter Bldg,Univ Dr, Callaghan, NSW 2308,
Australia. Kirsti.haracz@newcastle.edu.au HAZELTON, MICHAEL JOHN/G-7440-2013;
James, Carole L/G-7414-2013 James, Carole L/0000-0002-6321-9347
Addington J, 2003, CAN J PSYCHIAT, V48, P272; Allison DB, 2003, PSYCHIAT
SERV, V54, P565, DOI 10.1176/appi.ps.54.4.565; American Psychiatric Association,
2013, DIAGN STAT MAN MENT, DOI [10.1176/appi.books.9780890425596, DOI
10.1176/APPI.BOOKS.9780890425596]; [Anonymous], 2015, OXFORD DICT ENGLISH, DOI DOI
10.1093/ACREF/9780199571123.001.0001/M_EN_GB0241150?RSKEY=KQHMFK&RESULT=4; Bazeley
Patricia, 2013, QUALITATIVE DATA ANA; Birks M, 2011, GROUNDED THEORY PRAC; Bonfioli
E, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-78; Caemmerer J, 2012,
SCHIZOPHR RES, V140, P159, DOI 10.1016/j.schres.2012.03.017; Canaway R, 2010, AUST
HEALTH REV, V34, P262, DOI 10.1071/AH08723; Carbon M, 2014, CNS SPECTRUMS, V19,
P38, DOI 10.1017/S1092852914000601; Chafetz L, 2006, PSYCHIAT SERV, V57, P225, DOI
10.1176/appi.ps.57.2.225; Charmaz K., 2000, HDB QUALITATIVE RES, P509, DOI DOI
10.1177/0891241609342193; Charmaz K, 2006, CONSTRUCTING GROUNDE; Chen HL, 2008, J
AM GERIATR SOC, V56, P689, DOI 10.1111/j.1532-5415.2007.01624.x; Chernomas WM,
2000, PSYCHIATR SERV, V51, P1517, DOI 10.1176/appi.ps.51.12.1517; Dallman MF, 2005,
BRAIN BEHAV IMMUN, V19, P275, DOI 10.1016/j.bbi.2004.11.004; Dey I., 1999,
GROUNDING GROUNDED T; Dipasquale S, 2013, J PSYCHIATR RES, V47, P197, DOI
10.1016/j.jpsychires.2012.10.005; Drake RE, 2001, PSYCHIATR SERV, V52, P469, DOI
10.1176/appi.ps.52.4.469; Forhan M, 2011, OTJR-OCCUP PART HEAL, V31, P135, DOI
10.3928/15394492-20101025-02; Galletly CA, 2012, AUST NZ J PSYCHIAT, V46, P753, DOI
10.1177/0004867412453089; Green J, 2007, AUST NZ J PUBL HEAL, V31, P545, DOI
10.1111/j.1753-6405.2007.00141.x; Jaaskelainen E, 2013, SCHIZOPHR B, V39, P126;
Kasen S, 2008, INT J OBESITY, V32, P558, DOI 10.1038/sj.ijo.0803736; Kelly DL,
2006, J WOMENS HEALTH, V15, P1132, DOI 10.1089/jwh.2006.15.1132; Khantzian EJ,
1997, HARVARD REV PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550; KHANTZIAN EJ,
1985, AM J PSYCHIAT, V142, P1259; Koenders PG, 2011, J OCCUP ENVIRON MED, V53,
P1287, DOI 10.1097/JOM.0b013e31823078a2; Kolotkin RL, 2008, OBESITY, V16, P749, DOI
10.1038/oby.2007.133; Lahti M, 2012, PSYCHOL MED, V42, P2275, DOI
10.1017/S0033291712000396; Lillis J, 2011, J HEALTH PSYCHOL, V16, P722, DOI
10.1177/1359105310388321; Lindamer LA, 2008, SCHIZOPHR RES, V104, P294, DOI
10.1016/j.schres.2008.04.040; Longenecker J, 2010, SCHIZOPHR RES, V119, P240, DOI
10.1016/j.schres.2010.03.023; Manley David, 2005, Br J Nurs, V14, P100; McCann
Terence V, 2003, Nurse Res, V11, P29; McCloughen A, 2011, INT J MENT HEALTH NU,
V20, P202, DOI 10.1111/j.1447-0349.2010.00721.x; McDevitt J, 2006, J NURS
SCHOLARSHIP, V38, P50, DOI 10.1111/j.1547-5069.2006.00077.x; Mestdagh A, 2014, SOC
PSYCH PSYCH EPID, V49, P79, DOI 10.1007/s00127-013-0729-4; Milder IEJ, 2014, J
EPIDEMIOL COMMUN H, V68, P471, DOI 10.1136/jech-2013-203127; Minichiello V, 2008,
IN DEPTH INTERVIEWIN; Morgan VA, 2008, AUST NZ J PSYCHIAT, V42, P74, DOI
10.1080/00048670701732699; Morgan VA, 2012, AUST NZ J PSYCHIAT, V46, P735, DOI
10.1177/0004867412449877; Morse J. M., 2007, SAGE HDB GROUNDED TH, P229, DOI [DOI
10.4135/9781848607941, DOI 10.4135/9781848607941.N11]; Noiseux S, 2008, INT J NURS
STUD, V45, P1148, DOI 10.1016/j.ijnurstu.2007.07.008; O'Connor DB, 2008, HEALTH
PSYCHOL, V27, pS20, DOI 10.1037/0278-6133.27.1(Suppl.).S20; Parsons B, 2009,
SCHIZOPHR RES, V110, P103, DOI 10.1016/j.schres.2008.09.025; Pogge DL, 2005, J
CHILD ADOL PSYCHOP, V15, P901, DOI 10.1089/cap.2005.15.901; Rashid NAA, 2013,
SCHIZOPHR RES, V151, P107, DOI 10.1016/j.schres.2013.09.020; Reavley NJ, 2011, AUST
NZ J PSYCHIAT, V45, P1086, DOI 10.3109/00048674.2011.621061; Ronis RJ, 2008, J DUAL
DIAGN, V4, P420, DOI 10.1080/15504260802086743; Rutters F, 2009, OBESITY, V17, P72,
DOI 10.1038/oby.2008.493; Seacat JD, 2014, J HEALTH PSYCHOL, DOI
[10.1177/1359105314525067, DOI 10.1177/1359105314525067]; Seeman MV, 2009,
SCHIZOPHRENIA BULL, V35, P937, DOI 10.1093/schbul/sbn023; Soundy A, 2013, INT J
THER REHABIL, V20, P588, DOI 10.12968/ijtr.2013.20.12.588; Sterling S, 2011,
ALCOHOL RES HEALTH, V33, P338; Strassnig Martin, 2013, Innov Clin Neurosci, V10,
P15; Strassnig M, 2011, SCHIZOPHR RES, V126, P103, DOI
10.1016/j.schres.2010.10.025; Theisen FM, 2003, J NEURAL TRANSM, V110, P111, DOI
10.1007/s00702-002-0792-6; Thomas SL, 2008, NUTR J, V7, DOI 10.1186/1475-2891-7-34;
Torrey WC, 2002, COMMUNITY MENT HLT J, V38, P507, DOI 10.1023/A:1020888403586;
Usher K, 2013, J PSYCHIATR MENT HLT, V20, P801, DOI 10.1111/jpm.12019; Vandyk AD,
2012, INT J MENT HEALTH NU, V21, P349, DOI 10.1111/j.1447-0349.2011.00790.x; Volman
L, 2007, J PSYCHIATR MENT HLT, V14, P411, DOI 10.1111/j.1365-2850.2007.01099.x; Wee
CC, 2011, ANN INTERN MED, V154, P645, DOI 10.7326/0003-4819-154-10-201105170-00003;
Weiden PJ, 2004, SCHIZOPHR RES, V66, P51, DOI 10.1016/S0920-9964(02)00498-X; Wuest
J, 2007, NURSING RES QUALITAT, P239; Xiao S, 2012, J PSYCHIATR MENT HLT, V19, P241,
DOI 10.1111/j.1365-2850.2011.01773.x 67 2 2 0 1 LIPPINCOTT
WILLIAMS & WILKINS PHILADELPHIA TWO COMMERCE SQ, 2001 MARKET ST,
PHILADELPHIA, PA 19103 USA 0022-3018 1539-736X J NERV MENT DIS J.
Nerv. Ment. Dis. MAY 2018 206 5 303 309
10.1097/NMD.0000000000000803 7 Clinical Neurology;
Psychiatry Neurosciences & Neurology; Psychiatry GE1UQ WOS:000431002700001
29528882 2019-09-25
J Torgerson, CN; Love, HA; Vennum, A Torgerson, Chelsey N.;
Love, Heather A.; Vennum, Amber The buffering effect of belonging
on the negative association of childhood trauma with adult mental health and risky
alcohol use JOURNAL OF SUBSTANCE ABUSE TREATMENT English
Article Belonging; Childhood trauma; Mental
health; Resiliency; Risky alcohol use POSTTRAUMATIC-STRESS-DISORDER; SUBSTANCE
USE DISORDERS; GENDER-DIFFERENCES; SELF-MEDICATION; ABUSE; SENSE; PREVENTION;
EVENTS; DEPRESSION; MEDIATION More than half of the American population has
experienced at least one childhood traumatic event in their lifetime, which can
lead to alcohol misuse and mental and physiological health issues. A sense of
belonging in close relationships is hypothesized to promote resiliency against the
negative outcomes of childhood trauma experiences. Using a sample of 654 adults
aged 26-40 years old, this study examined the relationship between childhood
traumatic experiences and adult risky alcohol use mediated by mental health status
and perceptions of belonging. Results indicated that having a greater sense of
belonging was associated with greater mental health and reduced reports of risky
alcohol use. The negative total association of childhood trauma on adult mental
health was partially mediated by a sense of belonging, indicating that a sense of
belonging may buffer the impact of childhood trauma on later mental health outcomes
and therefor potentially decrease later risky alcohol use in adulthood.
Recommendations for systemic treatment and increasing close relationships across
the lifespan as resiliency factors are explored. Implementations for public policy
changes for Marriage and Family Therapists are discussed. (C) 2018 Elsevier Inc.
All rights reserved. [Torgerson, Chelsey N.; Love, Heather A.; Vennum, Amber]
Kansas State Univ, Sch Family Studies & Human Serv, 139 Campus Creek Complex,
Manhattan, KS 66506 USA Torgerson, CN (reprint author), Kansas State Univ, Sch
Family Studies & Human Serv, 139 Campus Creek Complex, Manhattan, KS 66506 USA.
chelseyt@ksu.edu AAMFT, 2008, FAM THER SCH; Ackard
DM, 2006, AM J PREV MED, V30, P59, DOI 10.1016/j.amepre.2005.09.013; Ainsworth
M.D.S., 1979, PATTERNS ATTACHMENT; Anda RF, 2006, EUR ARCH PSY CLIN N, V256, P174,
DOI 10.1007/s00406-005-0624-4; Aspelmeier JE, 2007, CHILD ABUSE NEGLECT, V31, P549,
DOI 10.1016/j.chiabu.2006.12.002; AUKETT R, 1988, SEX ROLES, V19, P57, DOI
10.1007/BF00292464; Babor T, 2001, AUDIT ALCOHOL USE DI; Blum R., 2005, SCH
CONNECTEDNESS IM; Bowlby J., 1969, ATTACHMENT ATTACHMEN, V1; Brown SM, 2017, CHILD
ABUSE NEGLECT, V63, P211, DOI 10.1016/j.chiabu.2016.11.006; Buhrmester M, 2011,
PERSPECT PSYCHOL SCI, V6, P3, DOI 10.1177/1745691610393980; Campbell SB, 2013, J
ANXIETY DISORD, V27, P494, DOI 10.1016/j.janxdis.2013.06.007; CBHSQ] Center for
Behavioral Health Statistics and Quality, 2016, HHS PUBL, VSMA 16- 4984; Centers
for Disease Control and Prevention, 2009, FOST SCH CONN INF SC; Chapman C., 2015,
DRUG ALCOHOL DEPEN, V146, pe217; Clark DB, 1997, J AM ACAD CHILD PSY, V36, P1744,
DOI 10.1097/00004583-199712000-00023; Cole S. F., 2013, HELPING TRAUMATIZED, V2;
Cooper M. L., 1994, PSYCHOL ASSESSMENT, V6, P117, DOI [DOI 10.1037/1040-
3590.6.2.117, 10.1037/1040-3590.6.2.117]; Copeland WE, 2007, ARCH GEN PSYCHIAT,
V64, P577, DOI 10.1001/archpsyc.64.5.577; Drolet M, 2013, CHILD ADOLESC SOC WO,
V30, P535, DOI 10.1007/s10560-013-0305-5; Duke NN, 2010, PEDIATRICS, V125, pE778,
DOI 10.1542/peds.2009-0597; Enoch MA, 2011, PSYCHOPHARMACOLOGY, V214, P17, DOI
10.1007/s00213-010-1916-6; Esper LH, 2013, J ALCOHOL DRUG DEPEN, V1, P116, DOI
[10.4172/2329-6488.1000116, DOI 10.4172/2329-6488.1000116]; Fisher LB, 2015,
PSYCHIATRY, V78, P29, DOI 10.1080/00332747.2015.1015867; Foneska R. W., 2015, PLOS
ONE, V10, P1, DOI [10.1371/journal.pone.0136321, DOI 10.1371/JOURNAL.PONE.0136321];
Ford J. D., 1997, TRAUMATIC EVENTS SCR; Franke HA, 2014, CHILDREN-BASEL, V1, P390,
DOI 10.3390/children1030390; Garland EL, 2013, J BEHAV MED, V36, P175, DOI
10.1007/s10865-012-9413-5; Hagerty BM, 1996, ARCH PSYCHIAT NURS, V10, P235, DOI
10.1016/S0883-9417(96)80029-X; Hayes AF, 2009, COMMUN MONOGR, V76, P408, DOI
10.1080/03637750903310360; HERTH K, 1992, J ADV NURS, V17, P1251, DOI
10.1111/j.1365-2648.1992.tb01843.x; Huh HJ, 2014, ANN GEN PSYCHIATR, V13, DOI
10.1186/s12991-014-0026-y; Hurd N, 2010, AM J COMMUN PSYCHOL, V46, P36, DOI
10.1007/s10464-010-9325-x; IBM Corp, 2013, IBM SPSS STATISTICS; Jacobsen LK, 2001,
AM J PSYCHIAT, V158, P1184, DOI 10.1176/appi.ajp.158.8.1184; Johnson S. M., 2004,
BASIC PRINCIPLES PRA; Johnson SM, 2002, GUIL FAM TH, P3; Kawachi I, 2001, J URBAN
HEALTH, V78, P458, DOI 10.1093/jurban/78.3.458; Kaysen D, 2008, J BEHAV MED, V31,
P115, DOI 10.1007/s10865-007-9140-5; Kessler RC, 1996, AM J ORTHOPSYCHIAT, V66,
P17, DOI 10.1037/h0080151; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI
10.3109/10673229709030550; Kilpatrick DG, 2013, J TRAUMA STRESS, V26, P537, DOI
10.1002/jts.21848; Kittur A, 2008, CHI 2008: 26TH ANNUAL CHI CONFERENCE ON HUMAN
FACTORS IN COMPUTING SYSTEMS VOLS 1 AND 2, CONFERENCE PROCEEDINGS, P453; Kline R.
B., 2011, PRINCIPLES PRACTICE; Koenen KC, 2007, PSYCHOL MED, V37, P181, DOI
10.1017/S0033291706009019; Kuo WH, 2004, SOC PSYCH PSYCH EPID, V39, P497, DOI
10.1007/s00127-004-0775-z; Lambert NM, 2013, PERS SOC PSYCHOL B, V39, P1418, DOI
10.1177/0146167213499186; Lander L, 2013, SOC WORK PUBLIC HLTH, V28, P194, DOI
10.1080/19371918.2013.759005; Leung A, 2011, J HAPPINESS STUD, V12, P443, DOI
10.1007/s10902-010-9208-8; Marlatt GA, 1996, ADDICTION, V91, pS37, DOI
10.1111/j.1360-0443.1996.tb02326.x; Maschi T., 2013, TRAUMATOLOGY, V19, P49, DOI
[10.1177/1534765612437377, DOI 10.1177/1534765612437377]; Muthen L. K., 1998, MPLUS
USERS GUIDE; Neumann T, 2004, ALCOHOL CLIN EXP RES, V28, P1693, DOI
10.1097/01.ALC.0000145696.58084.08; PULAKOS J, 1989, J PSYCHOL, V123, P237, DOI
10.1080/00223980.1989.10542978; Reczek C, 2017, ADDICT BEHAV, V65, P198, DOI
10.1016/j.addbeh.2016.10.014; Reinert DF, 2007, ALCOHOL CLIN EXP RES, V31, P185,
DOI 10.1111/j.1530-0277.2006.00295.x; Richardson J, 2014, PATIENT, V7, P85, DOI
10.1007/s40271-013-0036-x; Sani F, 2015, BRIT J HEALTH PSYCH, V20, P466, DOI
10.1111/bjhp.12119; Sheinberg M., 2001, RELATIONAL TRAUMA IN; Shields Margot, 2008,
Health Rep, V19, P51; Sigmon ST, 1995, SEX ROLES, V33, P565, DOI
10.1007/BF01547718; [Substance Abuse and Mental Health Services Administration
(SAMHSA) National Survey on Drug Use and Health (NSDUH)], 2015, TABL 2 46B ALC US
BI; Sullivan TP, 2006, J TRAUMA STRESS, V19, P229, DOI 10.1002/jts.20092; Swendsen
J, 2010, ADDICTION, V105, P1117, DOI 10.1111/j.1360-0443.2010.02902.x; Tolin DF,
2006, PSYCHOL BULL, V132, P959, DOI 10.1037/0033-2909.132.6.959; Uchino BN, 1996,
PSYCHOL BULL, V119, P488, DOI 10.1037/0033-2909.119.3.488; Williams J, 2008, STRUCT
EQU MODELING, V15, P23, DOI 10.1080/10705510701758166; Woicik PA, 2009, ADDICT
BEHAV, V34, P1042, DOI 10.1016/j.addbeh.2009.07.001 68 2 2 0 5
PERGAMON-ELSEVIER SCIENCE LTD OXFORD THE BOULEVARD, LANGFORD LANE,
KIDLINGTON, OXFORD OX5 1GB, ENGLAND 0740-5472 J SUBST ABUSE TREAT
J. Subst. Abus. Treat. MAY 2018 88 44
50 10.1016/j.jsat.2018.02.005 7 Psychology,
Clinical; Substance Abuse Psychology; Substance Abuse GD2ZJ
WOS:000430372000005 29606225 2019-09-25
J DuPont, RL DuPont, Robert L. The opioid
epidemic is an historic opportunity to improve both prevention and treatment BRAIN
RESEARCH BULLETIN English Article; Proceedings Paper 3rd Annual
Addiction Dinner and Symposium APR 03-04, 2017 Penn State Univ, Coll Med,
State College, PA Penn State Univ, Coll Med Opioid use disorder; Overdose
death; Addiction treatment; Prevention PHYSICIAN HEALTH-PROGRAMS; RECOVERY;
STANDARD The current narrative describing the national opioid epidemic as the
result of overprescribing opioid pain medicines fails to capture the full
dimensions of the problem and leads to inadequate and even confounding solutions.
Overlooked is the fact that polysubstance use is nearly ubiquitous among overdose
deaths, demonstrating that the opioid overdose death problem is bigger than
opioids. The foundation of the nation's opioid overdose crisis - and the totality
of the nation's drug epidemic - is widespread recreational pharmacology, the use of
drugs for fun or "self-medication." The national focus on opioid overdose deaths
provides important new opportunities in both prevention and treatment to make
fundamental changes to the way that substance use disorders and related problems
are understood and managed. The first-ever US Surgeon General's report on addiction
provides a starting point for systemic changes in the nation's approach to
preventing, treating and managing substance use disorders as serious, chronic
diseases. New prevention efforts need to encourage youth to grow to adulthood not
using alcohol, nicotine, marijuana or other drugs for reasons of health. New
addiction treatment efforts need to focus on achieving long-term recovery including
no use of alcohol, marijuana and other drugs. [DuPont, Robert L.] Inst Behav &
Hlth Inc, 6191 Execut Blvd, Rockville, MD 20852 USA DuPont, RL (reprint author),
Inst Behav & Hlth Inc, 6191 Execut Blvd, Rockville, MD 20852 USA.
ContactUs@ibhinc.org AAP Committee on Substance
Use and Prevention, 2016, PEDIATRICS, V138; DuPont R.L., 2016, ASAM ONLINE MAG;
DuPont R.L., 2015, ITS TIME RETHINK PRE; DuPont RL, 2015, J SUBST ABUSE TREAT, V58,
P1, DOI 10.1016/j.jsat.2015.06.024; DuPont RL, 2009, J SUBST ABUSE TREAT, V37, P1,
DOI 10.1016/j.jsat.2009.03.010; DuPont RL, 2009, J SUBST ABUSE TREAT, V36, P159,
DOI 10.1016/j.jsat.2008.01.004; Kilmer B., 2017, ASAM PRINCI IN PRESS; Levy S. J.,
2016, PEDIATRICS, V138; McLellan AT, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a2038;
Merlo LJ, 2016, J SUBST ABUSE TREAT, V64, P47, DOI 10.1016/j.jsat.2016.02.004;
Monitoring the Future, 2014, MON FUT SURV 2014; Rudd RA, 2016, MMWR-MORBID MORTAL
W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; State of New York Office of Alcoholism
and Substance Abuse Services, 2012, SURV 10 PERC AM AD R; Substance Abuse and
Mental Health Administration, 2014, RES 2013 NAT SURV DR; [Substance Abuse and
Mental Health Services Administration (SAMHSA) Center for Behavioral Health
Stateistices and Quality (CBHSQ)], 2016, 2015 NAT SURV DRUG U; University of
Florida College of Medicine, 2017, FLOR DRUG REL OUTC S; US Department of Health
and Human Services, 2016, FAC ADD AM SURG GEN 17 5 5 1 13
PERGAMON-ELSEVIER SCIENCE LTD OXFORD THE BOULEVARD, LANGFORD LANE,
KIDLINGTON, OXFORD OX5 1GB, ENGLAND 0361-9230 1873-2747 BRAIN RES BULL
Brain Res. Bull. APR 2018 138 SI 116 118
10.1016/j.brainresbull.2017.06.008 3 Neurosciences
Neurosciences & Neurology GD6MR WOS:000430623600015 28627395
2019-09-25
J Moses, TEH; Lundahl, LH; Greenwald, MK Moses, Tabitha E.
H.; Lundahl, Leslie H.; Greenwald, Mark K. Factors associated with
sedative use and misuse among heroin users DRUG AND ALCOHOL DEPENDENCE
English Article Heroin; Sedatives;
Benzodiazepines; Health outcomes; Consequences EMERGENCY-DEPARTMENT VISITS;
SUBSTANCE USE DISORDERS; BENZODIAZEPINE USE; UNITED-STATES; NONMEDICAL USE; OPIOID
USERS; PRESCRIPTION; ADDICTION; METHADONE; SYMPTOMS Background: Rates of both
opioid and sedative use and misuse are rising. Comorbid opioid and sedative use is
associated with especially severe consequences (e.g., overdose and poor health
outcomes). Heroin users report multiple motivations for sedative use, including
self-medication. We aimed to understand differences in lifetime substance use
characteristics between heroin users with different sedative use histories.
Methods: Substance use data were collected from 385 non-treatment seeking heroin
users. Subjects were divided into four lifetime sedative-use groups: no use,
medical use only, non-medical use only, and mixed medical and non-medical use. We
examined patterns of use of various substances of abuse (tobacco, alcohol,
marijuana, cocaine, heroin, and sedatives) and individual characteristics
associated with each. Results: Non-medical sedative use (alone or in addition to
medical use) was associated with more negative consequences from using all
substances. Medical sedative use alone was not related to increased overdose or
emergency room visits associated with heroin use. Non-medical sedative use was
associated with increases in 15 of the 21 measured heroin consequences and only one
of those health problems was also associated with medical sedative use.
Conclusions: Concomitant non-medical sedative use and heroin use is associated with
significantly greater negative outcomes than those experienced by heroin users who
report use of sedatives only as prescribed. Understanding these differences offers
insight into risks related to using both substances and may help treatment
providers create targeted harm reduction interventions for this population.
[Moses, Tabitha E. H.; Lundahl, Leslie H.; Greenwald, Mark K.] Wayne State
Univ, Sch Med, Dept Psychiat & Behav Neurosci, Detroit, MI 48201 USA; [Greenwald,
Mark K.] Wayne State Univ, Dept Pharm Practice, Eugene Applebaum Coll Pharm & Hlth
Sci, Detroit, MI 48201 USA Greenwald, MK (reprint author), Wayne State Univ,
Dept Psychiat & Behav Neurosci, 3901 Chrysler Serv Dr,Suite 2A, Detroit, MI 48201
USA. mgreen@med.wayne.edu Moses, Tabitha/0000-0002-6978-5032 NIH grants
from the National Institute on Drug Abuse [P50 DA00254, R01 DA015462, R01
DA022243]; State of Michigan; Detroit Wayne Mental Health Authority NIH grants
P50 DA00254, R01 DA015462 and R01 DA022243 (to MKG) from the National Institute on
Drug Abuse, a research grant (Joe Young, Sr./Helene Lycaki Funds) from the State of
Michigan, and the Detroit Wayne Mental Health Authority, supported this research.
Bachhuber MA, 2016, AM J PUBLIC HEALTH, V106, P686, DOI
10.2105/AJPH.2016.303061; Bachhuber MA, 2016, INT J DRUG POLICY, V28, P120, DOI
10.1016/j.drugpo.2015.08.005; Brett J, 2015, AUST PRESCR, V38, P152, DOI
10.18773/austprescr.2015.055; Darke S, 2010, DRUG ALCOHOL REV, V29, P250, DOI
10.1111/j.1465-3362.2009.00101.x; Fatseas M, 2009, J SUBST ABUSE TREAT, V37, P407,
DOI 10.1016/j.jsat.2009.03.006; First M. B., 1996, STRUCTURED CLIN INTE; Ghitza UE,
2008, DRUG ALCOHOL DEPEN, V97, P150, DOI 10.1016/j.drugalcdep.2008.04.003; Goldner
EM, 2014, ADDICT BEHAV, V39, P520, DOI 10.1016/j.addbeh.2013.11.022; Grant BF,
2004, ARCH GEN PSYCHIAT, V61, P807, DOI 10.1001/archpsyc.61.8.807; Jamadarkhana
Sunil, 2010, J Anaesthesiol Clin Pharmacol, V26, P439; Jann Michael, 2014, J Pharm
Pract, V27, P5, DOI 10.1177/0897190013515001; Jitendra M, 2015, J EVOL MED DENT
SCI-, V4, P9033, DOI 10.14260/jemds/2015/1311; Jones CM, 2015, AM J PREV MED, V49,
P493, DOI 10.1016/j.amepre.2015.03.040; Jones JD, 2012, DRUG ALCOHOL DEPEN, V125,
P8, DOI 10.1016/j.drugalcdep.2012.07.004; Kaye S, 2014, DRUG ALCOHOL DEPEN, V144,
P70, DOI 10.1016/j.drugalcdep.2014.08.008; Lader M, 2014, BRIT J CLIN PHARMACO,
V77, P295, DOI 10.1111/j.1365-2125.2012.04418.x; Lintzeris N, 2010, AM J ADDICTION,
V19, P59, DOI 10.1111/j.1521-0391.2009.00007.x; Lipari R. N., 2015, CBHSQ REPORT
TRENDS; Lister JJ, 2015, ADDICT BEHAV, V41, P1, DOI 10.1016/j.addbeh.2014.09.017;
Longo LP, 2000, AM FAM PHYSICIAN, V61, P2121; Maremmani AGI, 2015, J AFFECT
DISORDERS, V179, P156, DOI 10.1016/j.jad.2015.03.046; Mateu-Gelabert P, 2017, INT J
DRUG POLICY, V46, P17, DOI 10.1016/j.drugpo.2017.05.016; McCabe SE, 2017, ADDICT
BEHAV, V65, P296, DOI 10.1016/j.addbeh.2016.08.021; McCabe SE, 2014, ADDICT BEHAV,
V39, P959, DOI 10.1016/j.addbeh.2014.01.009; McCance-Katz EF, 2010, AM J ADDICTION,
V19, P4, DOI 10.1111/j.1521-0391.2009.00005.x; Megarbane B, 2003, ANN MED INTERNE,
V154, pS64; Moses T. E., 2018, EXAMINING R IN PRESS; Moses TEH, 2018, ADDICT BEHAV,
V77, P260, DOI 10.1016/j.addbeh.2017.07.027; Murphy Y, 2016, CLIN DRUG INVEST, V36,
P519, DOI 10.1007/s40261-016-0397-8; National Institute on Drug Abuse, 2011,
DRUGFACTS TREATM SAT; Norman SB, 2007, DRUG ALCOHOL DEPEN, V90, P89, DOI
10.1016/j.drugalcdep.2007.03.002; O'Brien PL, 2017, DRUG ALCOHOL DEPEN, V178, P223,
DOI 10.1016/j.drugalcdep.2017.05.014; Olfson M, 2015, JAMA PSYCHIAT, V72, P136, DOI
10.1001/jamapsychiatry.2014.1763; Paulozzi LJ, 2014, J AM BOARD FAM MED, V27, P329,
DOI 10.3122/jabfm.2014.03.130290; Peles E, 2014, ISR J PSYCHIATR REL, V51, P285;
Peters SM, 2015, GEN HOSP PSYCHIAT, V37, P595, DOI
10.1016/j.genhosppsych.2015.06.004; Schellekens AFA, 2015, EUR PSYCHIAT, V30, DOI
10.1016/j.eurpsy.2013.08.006; Scott N, 2016, DRUG ALCOHOL DEPEN, V168, P140, DOI
10.1016/j.drugalcdep.2016.08.638; Stein MD, 2016, J SUBST ABUSE TREAT, V68, P57,
DOI 10.1016/j.jsat.2016.06.008; Substance Abuse and Mental Health Services
Administration, 2014, NSDUH SER H, V48; Substance Abuse and Mental Health Services
Administration, 2012, TEDS REP ADM REP BEN; Substance Abuse and Mental Health
Services Administration, 2016, PRESCR DRUG US MIS U; Substance Abuse and Mental
Health Services Administration (SAMHSA), 2011, TEDS REP SUBST AB TR; Ullman SE,
2013, ADDICT BEHAV, V38, P2219, DOI 10.1016/j.addbeh.2013.01.027; Wang JG, 2017,
CRIT CARE, V21, DOI 10.1186/s13054-017-1610-8; Woodcock EA, 2015, ADDICT BEHAV,
V45, P287, DOI 10.1016/j.addbeh.2015.02.014; Young AM, 2012, J ADOLESCENT HEALTH,
V51, P6, DOI 10.1016/j.jadohealth.2012.01.011; Zachary R. A., 1991, MANUAL SHIPLEY
I LIV 48 6 6 0 4 ELSEVIER IRELAND LTD CLARE ELSEVIER HOUSE,
BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND 0376-8716 1879-
0046 DRUG ALCOHOL DEPEN Drug Alcohol Depend. APR 1 2018 185
10 16 10.1016/j.drugalcdep.2017.11.035
7 Substance Abuse; Psychiatry Substance Abuse; Psychiatry GD8TD
WOS:000430784100002 29413433 Green Accepted 2019-09-25
J Acuff, SF; Luciano, MT; Soltis, KE; Joyner, KJ; McDevitt-Murphy, M; Murphy,
JG Acuff, Samuel F.; Luciano, Matthew T.; Soltis, Kathryn E.;
Joyner, Keanan J.; McDevitt-Murphy, Meghan; Murphy, James G. Access
to Environmental Reward Mediates the Relation Between Posttraumatic Stress Symptoms
and Alcohol Problems and Craving EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY
English Article PTSD; behavioral
economics; reward deprivation; college student drinking BEHAVIORAL ECONOMIC-
ANALYSIS; SUBSTANCE USE DISORDERS; SELF-MEDICATION HYPOTHESIS; COLLEGE-STUDENTS;
PTSD SYMPTOMS; THERAPEUTIC EXPOSURE; TRAUMA HISTORY; 1ST YEAR; DRINKING; DEPRESSION
Symptoms of posttraumatic stress (PTS) show significant comorbidity with
alcohol use, but little is known about the mechanisms that might account for this
comorbidity. Deficits in reward functioning have long been implicated in alcohol
misuse and more recently in PTS reactions, but no study has examined whether reward
deprivation may serve as a transdiagnostic risk factor for comorbid PTS-alcohol
misuse. The current cross-sectional study sought to test the behavioral economic
hypothesis that reward deprivation would be related to both PTS symptoms and
alcohol problems, and would mediate the relation between PTS symptoms and alcohol
problems in college students. We recruited a diverse sample of urban college
students (N = 203, M-age = 21.5 years, SD = 5.5; 79.5% female; 56.8% White, 28.1%
Black, .9% Asian, 9.8% Multiracial) who endorsed both alcohol use and PTS symptoms.
Reward deprivation (lack of access to, and ability to, experience reward) was
related to alcohol problems, and a lack of access to reward was related to PTS
symptoms. Furthermore, reward access mediated the relation between PTS symptoms and
alcohol problems and craving, after controlling for alcohol use, age, gender, and
race. These data provide preliminary support for behavioral economic models of
alcohol comorbidity and suggest that treatments for combined PTS and alcohol misuse
should attempt to reduce barriers to accessing natural rewards. [Acuff, Samuel F.;
Luciano, Matthew T.; Soltis, Kathryn E.; McDevitt-Murphy, Meghan; Murphy, James G.]
Univ Memphis, Dept Psychol, 400 Innovat Dr, Memphis, TN 38152 USA; [Joyner, Keanan
J.] Florida State Univ, Dept Psychol, Tallahassee, FL 32306 USA Murphy, JG
(reprint author), Univ Memphis, Dept Psychol, 400 Innovat Dr, Memphis, TN 38152
USA. jgmurphy@memphis.edu Acuff, Samuel/K-8687-2019; Luciano, Matthew/K-1216-
2019 National Institute of HealthUnited States Department of Health & Human
ServicesNational Institutes of Health (NIH) - USA [R01 AA020829] This work was
supported by National Institute of Health Grant R01 AA020829 ( PI: James G.
Murphy). The funding source had no role other than financial support. The content
is solely the responsibility of the authors and does not necessarily represent the
official views of the National Institute on Alcohol Abuse and Alcoholism or the
National Institutes of Health. Some of the data presented in this article were
presented in posters at the Research Society on Alcoholism's annual meeting and the
meeting of the International Society for Traumatic Stress Studies in 2017. These
data have not been disseminated in any other form. Samuel F. Acuff and James G.
Murphy formulated the study question and collected the data. Samuel F. Acuff,
Matthew T. Luciano, and Kathryn E. Soltis wrote the first draft. Meghan McDevitt-
Murphy and Matthew T. Luciano provided expertise in PTSD. Keanan J. Joyner and
James G. Murphy provided expertise in reward. All authors contributed to subsequent
versions of the manuscript and have approved of the final draft of the manuscript.
Acierno R, 2016, DEPRESS ANXIETY, V33, P415, DOI 10.1002/da.22476; American
Psychiatric Association, 2013, DIAGN STAT MAN MENT; Amlung M, 2014, ALCOHOL CLIN
EXP RES, V38, P1780, DOI 10.1111/acer.12423; Arria AM, 2013, ACAD OPPORTUNITY COS;
Bickel WK, 2017, NEBR SYM MOTIV, V64, P227, DOI 10.1007/978-3-319-51721-6_8; Bickel
WK, 2014, ANNU REV CLIN PSYCHO, V10, P641, DOI 10.1146/annurev-clinpsy-032813-
153724; Black M. C., 2011, NATL INTIMATE PARTNE; Blanco C, 2013, DRUG ALCOHOL
DEPEN, V132, P630, DOI 10.1016/j.drugalcdep.2013.04.016; Blevins CA, 2015, J TRAUMA
STRESS, V28, P489, DOI 10.1002/jts.22059; Borsari B, 2017, AM J ORTHOPSYCHIAT, V87,
P166, DOI 10.1037/ort0000199; Brown PJ, 1999, PSYCHOL ADDICT BEHAV, V13, P115, DOI
10.1037/0893-164X.13.2.115; Carvalho JP, 2011, BEHAV THER, V42, P249, DOI
10.1016/j.beth.2010.05.004; Coffey SF, 2010, EXP CLIN PSYCHOPHARM, V18, P340, DOI
10.1037/a0019790; Coffey SF, 2003, EXP CLIN PSYCHOPHARM, V11, P18, DOI
10.1037/1064-1297.11.1.18; COLLINS RL, 1985, J CONSULT CLIN PSYCH, V53, P189, DOI
10.1037/0022-006X.53.2.189; Correia CJ, 2005, ADDICT BEHAV, V30, P19, DOI
10.1016/j.addbeh.2004.04.006; Craner JR, 2015, J CHILD SEX ABUS, V24, P484, DOI
10.1080/10538712.2015.1026014; Cuthbert BN, 2013, BMC MED, V11, DOI 10.1186/1741-
7015-11-126; Dennhardt AA, 2016, PSYCHOL ADDICT BEHAV, V30, P819, DOI
10.1037/adb0000197; Dennhardt AA, 2011, PSYCHOL ADDICT BEHAV, V25, P595, DOI
10.1037/a0025807; Elman I, 2005, PSYCHIAT RES, V135, P179, DOI
10.1016/j.psychres.2005.04.002; Flannery BA, 1999, ALCOHOL CLIN EXP RES, V23,
P1289, DOI 10.1111/j.1530-0277.1999.tb04349.x; Fortney JC, 2016, GEN HOSP PSYCHIAT,
V38, P99, DOI 10.1016/j.genhosppsych.2015.09.007; Geisner IM, 2015, ADDICT BEHAV,
V42, P36, DOI 10.1016/j.addbeh.2014.10.030; Gros DF, 2012, BEHAV MODIF, V36, P580,
DOI 10.1177/0145445512448097; Heinz A, 2004, AM J PSYCHIAT, V161, P1783, DOI
10.1176/appi.ajp.161.10.1783; Heinz Adrienne J, 2012, Curr Drug Abuse Rev, V5,
P257; Hingson R, 2017, J STUD ALCOHOL DRUGS, V78, P540, DOI
10.15288/jsad.2017.78.540; Hooper JW, 2008, J PSYCHIATR RES, V42, P802, DOI
10.1016/j.jpsychires.2007.10.008; Joyner KJ, 2016, ALCOHOL CLIN EXP RES, V40,
P2685, DOI 10.1111/acer.13255; Kahler CW, 2005, ALCOHOL CLIN EXP RES, V29, P1180,
DOI 10.1097/01.ALC.0000171940.95813.A5; Kalebasi N, 2015, BRAIN BEHAV, V5, DOI
10.1002/brb3.357; Kaysen D, 2014, PSYCHOL ADDICT BEHAV, V28, P62, DOI
10.1037/a0033588; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI
10.3109/10673229709030550; Lembke A, 2012, AM J DRUG ALCOHOL AB, V38, P524, DOI
10.3109/00952990.2012.694532; Lubman DI, 2009, ARCH GEN PSYCHIAT, V66, P205, DOI
10.1001/archgenpsychiatry.2008.522; MacKillop J, 2010, ADDICTION, V105, P1599, DOI
10.1111/j.1360-0443.2010.03004.x; Meshesha LZ, 2017, PSYCHOL REC, V67, P241, DOI
10.1007/s40732-017-0235-2; Murphy JG, 2006, EXP CLIN PSYCHOPHARM, V14, P219, DOI
10.1037/1064-1297.14.2.219; Murphy JG, 2013, DRUG ALCOHOL DEPEN, V127, P129, DOI
10.1016/j.drugalcdep.2012.06.022; Murphy JG, 2012, J CONSULT CLIN PSYCH, V80, P876,
DOI 10.1037/a0028763; Nawijn L, 2015, NEUROSCI BIOBEHAV R, V51, P189, DOI
10.1016/j.neubiorev.2015.01.019; Ouimette P, 2006, ADDICT BEHAV, V31, P1415, DOI
10.1016/j.addbeh.2005.11.010; Owens MM, 2015, J EXP ANAL BEHAV, V103, P77, DOI
10.1002/jeab.114; Pedrelli P, 2016, Curr Addict Rep, V3, P91; Pedrelli P, 2016, J
AM COLL HEALTH, V64, P535, DOI 10.1080/07448481.2016.1191016; Radomski S, 2016,
SUBST USE MISUSE, V51, P1034, DOI 10.3109/10826084.2016.1152497; Read JP, 2013, J
ABNORM PSYCHOL, V122, P984, DOI 10.1037/a0034918; Read JP, 2012, J CONSULT CLIN
PSYCH, V80, P426, DOI 10.1037/a0028210; Read JP, 2011, PSYCHOL TRAUMA-US, V3, P148,
DOI 10.1037/a0021260; Sailer U, 2008, NEUROPSYCHOLOGIA, V46, P2836, DOI
10.1016/j.neuropsychologia.2008.05.022; Sayette MA, 2012, PSYCHOL SCI, V23, P869,
DOI 10.1177/0956797611435134; Schulenberg J.E., 2017, MONITORING FUTURE NA, VII;
Soltis KE, 2017, ALCOHOL CLIN EXP RES, V41, P1191, DOI 10.1111/acer.13395;
Tabachnick B. G., 2013, USING MULTIVARIATE S; Treadway MT, 2011, NEUROSCI BIOBEHAV
R, V35, P537, DOI 10.1016/j.neubiorev.2010.06.006; Tripp JC, 2015, EXP CLIN
PSYCHOPHARM, V23, P324, DOI 10.1037/pha0000040; Tripp JC, 2015, J DUAL DIAGN, V11,
P107, DOI 10.1080/15504263.2015.1025013; Tucker JA, 2002, J STUD ALCOHOL, V63,
P334, DOI 10.15288/jsa.2002.63.334; VRANA S, 1994, J TRAUMA STRESS, V7, P289, DOI
10.1002/jts.2490070209; VUCHINICH R, 2003, CHOICE BEHAV EC ADDI; VUCHINICH RE,
1988, J ABNORM PSYCHOL, V97, P181, DOI 10.1037/0021-843X.97.2.181; Vujanovic AA,
2017, CURR OPIN PSYCHOL, V14, P49, DOI 10.1016/j.copsyc.2016.11.004; Weathers F,
2013, PTSD CHECKLIST DSM 5; Wrase J, 2007, NEUROIMAGE, V35, P787, DOI
10.1016/j.neuroimage.2006.11.043 65 2 2 2 3 AMER PSYCHOLOGICAL
ASSOC WASHINGTON 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA 1064-1297 1936-
2293 EXP CLIN PSYCHOPHARM Exp. Clin. Psychopharmacol. APR 2018 26
 2 177 185 10.1037/pha0000181
9 Psychology, Biological; Psychology, Clinical; Pharmacology & Pharmacy;
Psychiatry Psychology; Pharmacology & Pharmacy; Psychiatry GC3NY
WOS:000429692000010 29355348 Green Accepted 2019-09-25
J Dennison, CR Dennison, Christopher R.
Intergenerational Mobility and Changes in Drug Use Across the Life Course
JOURNAL OF DRUG ISSUES English Article
socioeconomic status; drug use; social mobility; add healthSUBJECTIVE
SOCIAL-STATUS; NEIGHBORHOOD SOCIOECONOMIC-STATUS; SELF-MEDICATION HYPOTHESIS;
SUBSTANCE USE DISORDERS; GENERAL STRAIN THEORY; YOUNG-ADULTS; STATUS-INCONSISTENCY;
ETHNIC-DIFFERENCES; EDUCATIONAL-LEVEL; MENTAL-HEALTH The consequences of "falling
from grace"-or experiencing downward intergenerational mobility-are indeed becoming
an abrupt reality for many entering the labor force. Scholars of social mobility
speculate that such life course trajectories can result in antisocial behavior, but
few have examined whether these trajectories lead to drug use. Thus, with the
United States in the midst of a drug epidemic, as well as recovering from an
economic recession, the study of social mobility may contribute to a better
understanding of what causes individuals to turn to drugs. Using data from The
National Longitudinal Study of Adolescent to Adult Health (Add Health) and a series
of logistic diagonal reference models, this study examines the association between
intergenerational social mobility and drug use. Overall, I find evidence that
downward mobility is associated with increases in drug use, with the relationship
strongest among those experiencing the greatest loss in status. [Dennison,
Christopher R.] Univ Buffalo, Buffalo, NY USA Dennison, CR (reprint author), Univ
Buffalo State Univ New York, Dept Sociol, Buffalo, NY 14260 USA.
crdennis@buffalo.edu Eunice Kennedy Shriver National Institute
of Child Health and Human DevelopmentUnited States Department of Health & Human
ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver
National Institute of Child Health & Human Development (NICHD) [P01-HD31921] The
author(s) disclosed receipt of the following financial support for the research,
authorship, and/or publication of this article: This research uses data from Add
Health, a program project directed by Kathleen Mullan Harris and designed by J.
Richard Udry, Peter S. Bearman, and Kathleen Mullan Harris at the University of
North Carolina at Chapel Hill, and funded by grant P01-HD31921 from the Eunice
Kennedy Shriver National Institute of Child Health and Human Development, with
cooperative funding from 23 other federal agencies and foundations. Special
acknowledgment is due Ronald R. Rindfuss and Barbara Entwisle for assistance in the
original design. Information on how to obtain the Add Health data files is
available on the Add Health website. No direct support was received from grant P01-
HD31921 for this analysis. Agnew R, 2001, J RES CRIME DELINQ, V38, P319, DOI
10.1177/0022427801038004001; AGNEW R, 1992, CRIMINOLOGY, V30, P47, DOI
10.1111/j.1745-9125.1992.tb01093.x; Agnew R, 2006, J RES CRIME DELINQ, V43, P119,
DOI 10.1177/0022427805280052; Alexander Michelle., 2011, NEW JIM CROW MASS IN; Amey
CH, 1998, J DRUG ISSUES, V28, P283, DOI 10.1177/002204269802800202; Anderson E,
1999, CODE STREET DECENCY; Andrews JA, 2002, HEALTH PSYCHOL, V21, P349, DOI
10.1037//0278-6133.21.4.349; [Anonymous], 2009, J DRUG ISSUES, V39, P231, DOI
10.1177/002204260903900119; ARNETT J, 1992, DEV REV, V12, P339, DOI 10.1016/0273-
2297(92)90013-R; Bachman J. G., 2008, ED DRUG USE CONNECTI; Bahr Stephen J, 2005, J
Prim Prev, V26, P529, DOI 10.1007/s10935-005-0014-8; Balemain K., 2013, 1
GENERATION STUDENT; Beaver KM, 2009, CRIM JUSTICE BEHAV, V36, P1158, DOI
10.1177/0093854809342859; Bernburg JG, 2003, CRIMINOLOGY, V41, P1287, DOI
10.1111/j.1745-9125.2003.tb01020.x; Bjelland I, 2008, SOC SCI MED, V66, P1334, DOI
10.1016/j.socscimed.2007.12.019; BLALOCK HM, 1967, AM SOCIOL REV, V32, P790, DOI
10.2307/2092026; Boardman JD, 2001, J HEALTH SOC BEHAV, V42, P151, DOI
10.2307/3090175; Brewer DD, 1998, ADDICTION, V93, P73, DOI 10.1046/j.1360-
0443.1998.931738.x; Brody GH, 2001, CHILD DEV, V72, P1231, DOI 10.1111/1467-
8624.00344; Bureau of Labor Statistics (US), 2015, EMPL PROJ; CAETANO R, 1995,
ADDICTION, V90, P351, DOI 10.1111/j.1360-0443.1995.tb03783.x; Center on Budget and
Policy Priorities, 2017, CHART BOOK LEG GREAT; Center on Education and the
Workforce, 2013, REC JOB GROWTH ED RE; Cherlin Andrew, 2016, NY TIMES; Chetty R,
2017, SCIENCE, V356, P398, DOI 10.1126/science.aal4617; Cho SJ, 2008, J DIVERS HIGH
EDUC, V1, P95, DOI 10.1037/1938-8926.1.2.95; COHEN S, 1983, J HEALTH SOC BEHAV,
V24, P385, DOI 10.2307/2136404; Compton WM, 2014, DRUG ALCOHOL DEPEN, V142, P350,
DOI 10.1016/j.drugalcdep.2014.06.012; Conner BT, 2010, J SUBST ABUSE TREAT, V38,
P178, DOI 10.1016/j.jsat.2009.07.004; Crum RM, 1996, DRUG ALCOHOL DEPEN, V43, P155,
DOI 10.1016/S0376-8716(96)01298-7; DeSimone J, 2002, J LABOR ECON, V20, P952, DOI
10.1086/342893; DiPrete TA, 2006, ANNU REV SOCIOL, V32, P271, DOI
10.1146/annurev.soc.32.061604.123127; Dishion TJ, 2002, DEV PSYCHOL, V38, P480, DOI
10.1037//0012-1649.38.4.480; Duan L, 2009, J YOUTH ADOLESCENCE, V38, P454, DOI
10.1007/s10964-008-9310-y; Dube SR, 2003, PEDIATRICS, V111, P564, DOI
10.1542/peds.111.3.564; Economic Policy Institute, 2017, MISS WORK MISS PART; ELDER
GH, 1994, SOC PSYCHOL QUART, V57, P4; Elder GH, 1998, CHILD DEV, V69, P1, DOI
10.2307/1132065; Erickson J, 2016, DEPRESS ANXIETY, V33, P1013, DOI
10.1002/da.22515; Fagan AA, 2013, J DRUG ISSUES, V43, P69, DOI
10.1177/0022042612462218; FAUPEL CE, 1988, J DRUG ISSUES, V18, P467, DOI
10.1177/002204268801800311; Finch KA, 2013, PSYCHOL ADDICT BEHAV, V27, P901, DOI
10.1037/a0032900; Fitzgerald B, 2002, CONDITION ACCESS HIG, P3; Fleury MJ, 2014,
CAN J PSYCHIAT, V59, P203; Ford CA, 1999, JAMA-J AM MED ASSOC, V282, P2227, DOI
10.1001/jama.282.23.2227; Froggio G, 2007, J CRIM JUST, V35, P81, DOI
10.1016/j.jcrimjus.2006.11.017; Giatti L, 2012, BMC PUBLIC HEALTH, V12, DOI
10.1186/1471-2458-12-1096; Haider SI, 2009, J AM GERIATR SOC, V57, P62, DOI
10.1111/j.1532-5415.2008.02040.x; Halpern CT, 2000, J ADOLESCENT HEALTH, V26, P213,
DOI 10.1016/S1054-139X(99)00061-0; HAMMER T, 1992, BRIT J ADDICT, V87, P1571;
Hanson MD, 2007, J HEALTH PSYCHOL, V12, P32, DOI 10.1177/1359105306069073;
HENDRICKX J, 1993, QUAL QUANT, V27, P335, DOI 10.1007/BF01102497; Henkel Dieter,
2011, Curr Drug Abuse Rev, V4, P4; Hirschfield PJ, 2008, SOCIOL FORUM, V23, P575,
DOI 10.1111/j.1573-7861.2008.00077.x; Hoffmann JP, 2016, J DRUG ISSUES, V46, P267,
DOI 10.1177/0022042616638492; Houle JN, 2017, SOCIOL EDUC, V90, P89, DOI
10.1177/0038040716685873; Houle JN, 2014, SOCIOL EDUC, V87, P53, DOI
10.1177/0038040713512213; Houle JN, 2011, RES SOC STRAT MOBIL, V29, P193, DOI
10.1016/j.rssm.2010.11.001; Houle JN, 2011, SOC SCI RES, V40, P757, DOI
10.1016/j.ssresearch.2010.11.008; Hout M, 2011, WHITHER OPPORTUNITY?: RISING
INEQUALITY, SCHOOLS, AND CHILDREN'S LIFE CHANCES, P165; Humensky JL, 2010, SUBST
ABUSE TREAT PR, V5, DOI 10.1186/1747-597X-5-19; Ireland TO, 2002, CRIMINOLOGY, V40,
P359, DOI 10.1111/j.1745-9125.2002.tb00960.x; Jarjoura GR, 1996, J RES CRIME
DELINQ, V33, P232, DOI 10.1177/0022427896033002004; Johnston L.D., 2011, MONITORING
FUTURE NA; Karriker-Jaffe KJ, 2013, DRUG ALCOHOL DEPEN, V133, P212, DOI
10.1016/j.drugalcdep.2013.04.033; Kelly J., 2002, RELIG MORALITY PUBLI, P64;
Kendler KS, 2000, ARCH GEN PSYCHIAT, V57, P953, DOI 10.1001/archpsyc.57.10.953;
Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550;
KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259; Kirkcaldy BD, 2004, PERS INDIV
DIFFER, V36, P247, DOI 10.1016/S0191-8869(03)00082-5; Kuhl DC, 2016, SOCIOL
PERSPECT, V59, P345, DOI 10.1177/0731121415586635; Lee JO, 2015, SOC SCI MED, V143,
P36, DOI 10.1016/j.socscimed.2015.08.016; Lizardo O, 2007, DIAGREF PROGRAM FIT;
Luthar SS, 2005, CURR DIR PSYCHOL SCI, V14, P49, DOI 10.1111/j.0963-
7214.2005.00333.x; Luthar SS, 2003, CHILD DEV, V74, P1581, DOI 10.1046/j.1467-
8624.2003.00625.x; Luthar SS, 1999, DEV PSYCHOPATHOL, V11, P845, DOI
10.1017/S0954579499002357; Luthar SS, 2008, DEV PSYCHOPATHOL, V20, P591, DOI
10.1017/S0954579408000291; Martins SS, 2015, SOC PSYCH PSYCH EPID, V50, P713, DOI
10.1007/s00127-014-0980-3; Moffitt TE, 2011, P NATL ACAD SCI USA, V108, P2693, DOI
10.1073/pnas.1010076108; Nagelhout GE, 2017, INT J DRUG POLICY, V44, P69, DOI
10.1016/j.drugpo.2017.03.013; National Center for Education Statistics (NCES),
2016, DIG ED STAT 2014; National Survey on Drug Use and Health, 2012, 2010 2011 NAT
SURV D; Newman Katherine S., 1988, FALLING GRACE EXPERI; Nicklett EJ, 2009, AM J
EPIDEMIOL, V170, P793, DOI 10.1093/aje/kwp192; Organization for Economic Co-
operation and Development, 2016, ED GLANC 2016; Patrick ME, 2012, J STUD ALCOHOL
DRUGS, V73, P772, DOI 10.15288/jsad.2012.73.772; RADLOFF L S, 1977, Applied
Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Redonnet B,
2012, DRUG ALCOHOL DEPEN, V121, P231, DOI 10.1016/j.drugalcdep.2011.09.002; Reiman
J., 2010, RICH GET RICHER POOR; Rocheleau GC, 2015, DEVIANT BEHAV, V36, P167, DOI
10.1080/01639625.2014.923275; ROSS CE, 1989, J HEALTH SOC BEHAV, V30, P206, DOI
10.2307/2137014; Rubin DB, 1987, MULTIPLE IMPUTATION; Rudd RA, 2016, MMWR-MORBID
MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; Sampson R., 1997, DEV THEORIES
CRIME D, V7, P133; Sampson R. J., 1993, CRIME MAKING PATHWAY; Savolainen J, 2015,
BRIT J CRIMINOL, V55, P164, DOI 10.1093/bjc/azu057; Shavers VL, 2007, J NATL MED
ASSOC, V99, P1013; Singh-Manoux A, 2005, PSYCHOSOM MED, V67, P855, DOI
10.1097/01.psy.0000188434.52941.a0; Singh-Manoux A, 2003, SOC SCI MED, V56, P1321,
DOI 10.1016/S0277-9536(02)00131-4; Sinha R, 2008, ANN NY ACAD SCI, V1141, P105, DOI
10.1196/annals.1441.030; Smeeding TM, 2011, PERSISTENCE, PRIVILEGE, AND PARENTING:
THE COMPARATIVE STUDY OF INTERGENERATIONAL MOBILITY, P1; Snedker KA, 2016, YOUTH
SOC, V48, P695, DOI 10.1177/0044118X13512335; SOBEL ME, 1981, AM SOCIOL REV, V46,
P893, DOI 10.2307/2095086; SOBEL ME, 1985, AM SOCIOL REV, V50, P699, DOI
10.2307/2095383; SOROKIN P, 1959, SOCIAL CULTURAL MOBI; Sorokin P. A., 1927, SOCIAL
MOBILITY; Swisher RR, 2016, J RES CRIME DELINQ, V53, P840, DOI
10.1177/0022427816645380; Swisher RR, 2013, SOC FORCES, V91, P1399, DOI
10.1093/sf/sot008; Swisher RR, 2012, J RES ADOLESCENCE, V22, P597, DOI
10.1111/j.1532-7795.2012.00810.x; Tate KA, 2015, J CAREER ASSESSMENT, V23, P427,
DOI 10.1177/1069072714547498; Teruya Cheryl, 2010, Curr Drug Abuse Rev, V3, P189;
Thornberry T. P., 1997, HDB ANTISOCIAL BEHAV, P218; Tiffin PA, 2005, J EPIDEMIOL
COMMUN H, V59, P870, DOI 10.1136/jech.2005.035246; Torche F., 2017,
INTERGENERATIONAL MO; Torche F, 2015, ANN AM ACAD POLIT SS, V657, P37, DOI
10.1177/0002716214547476; U. S. Department of Health and Human Services, 2014, RES
2013 NAT SURV DR; Uggen C, 2000, AM SOCIOL REV, V65, P529, DOI 10.2307/2657381;
WEISS RD, 1992, AM J DRUG ALCOHOL AB, V18, P121, DOI 10.3109/00952999208992825;
WELLISCH DK, 1984, J DRUG ISSUES, V14, P233, DOI 10.1177/002204268401400204; White
HR, 2005, J DRUG ISSUES, V35, P281, DOI 10.1177/002204260503500204; Williams CT,
2007, AM J PREV MED, V32, pS203, DOI 10.1016/j.amepre.2007.02.006; Wilson HW, 2009,
J YOUTH ADOLESCENCE, V38, P340, DOI 10.1007/s10964-008-9331-6; Wright J, 2008,
JUSTICE Q, V25, P544, DOI 10.1080/07418820701864599; Wu SY, 2016, AM J DRUG ALCOHOL
AB, V42, P657, DOI 10.1080/00952990.2016.1176176; Zang E, 2016, SOCIOL SCI, V3,
P779, DOI 10.15195/v3.a33 125 2 2 1 3 SAGE PUBLICATIONS INC
THOUSAND OAKS 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA 0022-0426
1945-1369 J DRUG ISSUES J. Drug Issues APR 2018 48 2
205 225 10.1177/0022042617746974
21 Substance Abuse Substance Abuse GB4YI WOS:000429068600004
2019-09-25
J Khokhar, JY; Dwiel, LL; Henricks, AM; Doucette, WT; Green, AI
Khokhar, Jibran Y.; Dwiel, Lucas L.; Henricks, Angela M.; Doucette, Wilder
T.; Green, Alan I. The link between schizophrenia and substance
use disorder: A unifying hypothesis SCHIZOPHRENIA RESEARCH English
Article Psychosis; Addiction; Adolescent;
Primary addiction; Self-medication CANNABIS USE DISORDER; NATIONAL EPIDEMIOLOGIC
SURVEY; VENTRAL HIPPOCAMPAL-LESIONS; ADULT MALE RATS; NUCLEUS-ACCUMBENS; GENERAL-
POPULATION; CIGARETTE-SMOKING; ETHANOL EXPOSURE; ILLICIT DRUGS; BEHAVIORAL
SENSITIZATION Substance use disorders occur commonly in patients with
schizophrenia and dramatically worsen their overall clinical course. While the
exact mechanisms contributing to substance use in schizophrenia are not known, a
number of theories have been put forward to explain the basis of the co-occurrence
of these disorders. We propose here a unifying hypothesis that combines recent
evidence from epidemiological and genetic association studies with brain imaging
and pre-clinical studies to provide an updated formulation regarding the basis of
substance use in patientswith schizophrenia. We suggest that the genetic
determinants of risk for schizophrenia (especially within neural systems that
contribute to the risk for both psychosis and addiction) make patients vulnerable
to substance use. Since this vulnerability may arise prior to the appearance of
psychotic symptoms, an increased use of substances in adolescencemay both enhance
the risk for developing a later substance use disorder, and also serve as an
additional risk factor for the appearance of psychotic symptoms. Future studies
that assess brain circuitry in a prospective longitudinal manner during adolescence
prior to the appearance of psychotic symptoms could shed further light on the
mechanistic underpinnings of these co-occurring disorders while identifying
potential points of intervention for these difficult-to-treat co-occurring
disorders. (C) 2017 Elsevier B.V. All rights reserved. [Khokhar, Jibran Y.;
Dwiel, Lucas L.; Henricks, Angela M.; Doucette, Wilder T.; Green, Alan I.] Geisel
Sch Med Dartmouth, Dept Psychiat, One Med Ctr Dr, Lebanon, NH 03756 USA; [Green,
Alan I.] Geisel Sch Med Dartmouth, Dept Mol & Syst Biol, Lebanon, NH 03756 USA;
[Green, Alan I.] Dartmouth Coll, Dartmouth Clin & Translat Sci Inst, Hanover, NH
03755 USA Green, AI (reprint author), Geisel Sch Med Dartmouth, Dept Psychiat,
One Med Ctr Dr, Lebanon, NH 03756 USA. Alan.I.Green@dartmouth.edu
National Institute of Drug AbuseUnited States Department of Health & Human
ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug
Abuse (NIDA) [DA032533, DA034699]; National Center for Advancing Translational
Science [NCATS UL1TR001086]; Canadian Institute of Health ResearchCanadian
Institutes of Health Research (CIHR) [MFE-140852] This work was supported in
part by grants from the National Institute of Drug Abuse (AIG; DA032533 and
DA034699), from the National Center for Advancing Translational Science (AIG; NCATS
UL1TR001086) and by a Canadian Institute of Health Research Fellowship (JYK; MFE-
140852). Abdel-Baki A, 2017, PSYCHIAT RES, V247, P113, DOI
10.1016/j.psychres.2016.11.007; Agrawal A, 2004, BEHAV GENET, V34, P217, DOI
10.1023/B:BEGE.0000017868.07829.45; Agrawal A, 2004, PSYCHOL MED, V34, P1227, DOI
10.1017/S0033291704002545; Alajaji M, 2016, NEUROPHARMACOLOGY, V105, P308, DOI
10.1016/j.neuropharm.2016.01.032; Apud JA, 2007, CNS DRUGS, V21, P535, DOI
10.2165/00023210-200721070-00002; Arranz B, 2015, J DUAL DIAGN, V11, P153, DOI
10.1080/15504263.2015.1113761; Arseneault L, 2002, BRIT MED J, V325, P1212, DOI
10.1136/bmj.325.7374.1212; Berg SA, 2011, BEHAV BRAIN RES, V218, P346, DOI
10.1016/j.bbr.2010.12.017; Berg SA, 2008, NEUROPHARMACOLOGY, V54, P1201, DOI
10.1016/j.neuropharm.2008.03.011; Berg SA, 2014, ADDICT BIOL, V19, P1020, DOI
10.1111/adb.12082; Boehme R, 2015, J NEUROSCI, V35, P10103, DOI
10.1523/JNEUROSCI.0805-15.2015; Boggs D.L., 2017, SCHIZOPHR RES; Boutros N, 2015,
INT J NEUROPSYCHOPH, V18, DOI 10.1093/ijnp/pyu003; Brady AM, 2008,
PSYCHOPHARMACOLOGY, V200, P205, DOI 10.1007/s00213-008-1195-7; Brunette MF, 2006,
SCHIZOPHRENIA BULL, V32, P637, DOI 10.1093/schbul/sbl003; Brunette MF, 2011, J DUAL
DIAGN, V7, P50, DOI 10.1080/15504263.2011.570118; Brunette MF, 2008, J DUAL DIAGN,
V4, P344, DOI 10.1080/15504260802313816; Buckley P, 1999, SCHIZOPHR RES, V36, P272;
Carey CE, 2016, FRONT GENET, V7, DOI 10.3389/fgene.2016.00149; Cariaga-Martinez A,
2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00202; Caspi A, 2005, BIOL
PSYCHIAT, V57, P1117, DOI 10.1016/j.biopsych.2005.01.026; Chadwick Benjamin, 2013,
Front Psychiatry, V4, P129, DOI 10.3389/fpsyt.2013.00129; Chambers RA, 2013, GENES
BRAIN BEHAV, V12, P564, DOI 10.1111/gbb.12051; Chambers RA, 2010, AM J PSYCHIAT,
V167, P600, DOI 10.1176/appi.ajp.2010.10010099; Chambers RA, 2001, BIOL PSYCHIAT,
V50, P71, DOI 10.1016/S0006-3223(01)01134-9; Chambers RA, 2004, BIOL PSYCHIAT, V56,
P308, DOI 10.1016/j.biopsych.2004.05.019; Chambers RA, 2010, PSYCHOPHARMACOLOGY,
V212, P73, DOI 10.1007/s00213-010-1929-1; Cheah SY, 2014, ALCOHOL ALCOHOLISM, V49,
P491, DOI 10.1093/alcalc/agu040; Clark JJ, 2012, PLOS ONE, V7, DOI
10.1371/journal.pone.0037357; Conroy SK, 2007, PHARMACOL BIOCHEM BE, V86, P386, DOI
10.1016/j.pbb.2006.07.017; Degenhardt L, 2001, Nicotine Tob Res, V3, P225; DEQUARDO
JR, 1994, J PSYCHIAT RES, V28, P267, DOI 10.1016/0022-3956(94)90010-8; Deserno L,
2015, TRANSL PSYCHIAT, V5, DOI 10.1038/tp.2015.139; Di Forti M, 2012, BIOL
PSYCHIAT, V72, P811, DOI 10.1016/j.biopsych.2012.06.020; Di Forti M, 2009, BRIT J
PSYCHIAT, V195, P488, DOI 10.1192/bjp.bp.109.064220; Dickey B, 1996, AM J PUBLIC
HEALTH, V86, P973, DOI 10.2105/AJPH.86.7.973; DIXON L, 1991, AM J PSYCHIAT, V148,
P224; Donoghue K, 2014, PSYCHIAT RES, V215, P528, DOI
10.1016/j.psychres.2013.12.038; Dow-Edwards D, 2012, PHARMACOL BIOCHEM BE, V100,
P587, DOI 10.1016/j.pbb.2011.09.003; Drake RE, 2000, SCHIZOPHRENIA BULL, V26, P441,
DOI 10.1093/oxfordjournals.schbul.a033464; Drake RE, 1998, SCHIZOPHRENIA BULL, V24,
P589, DOI 10.1093/oxfordjournals.schbul.a033351; Ellgren M, 2007,
NEUROPSYCHOPHARMACOL, V32, P607, DOI 10.1038/sj.npp.1301127; Emamian ES, 2004, NAT
GENET, V36, P131, DOI 10.1038/ng1296; Eranti SV, 2013, PSYCHOL MED, V43, P155, DOI
10.1017/S003329171200089X; Esslinger C, 2012, SCHIZOPHR RES, V140, P114, DOI
10.1016/j.schres.2012.06.025; Fergusson DM, 2003, PSYCHOL MED, V33, P15, DOI
10.1017/S0033291702006402; Finch DM, 1996, HIPPOCAMPUS, V6, P495; Fischer AS, 2014,
SCHIZOPHR RES, V158, P176, DOI 10.1016/j.schres.2014.04.033; FOWLES DC, 1992, ANNU
REV PSYCHOL, V43, P303, DOI 10.1146/annurev.ps.43.020192.001511; Furberg H, 2010,
NAT GENET, V42, P441, DOI 10.1038/ng.571; Gage S. H., 2016, PSYCHOL MED, V47, P1;
Gage SH, 2016, BIOL PSYCHIAT, V79, P549, DOI 10.1016/j.biopsych.2015.08.001; Gage
SH, 2015, LANCET PSYCHIAT, V2, P778, DOI 10.1016/S2215-0366(15)00333-8; Gage SH,
2015, LANCET PSYCHIAT, V2, P118, DOI 10.1016/S2215-0366(14)00057-1; GEORGE TP,
1995, J CLIN PSYCHIAT, V56, P344; Gradin VB, 2013, PSYCHIAT RES-NEUROIM, V211,
P104, DOI 10.1016/j.pscychresns.2012.06.003; Grant BF, 2004, ARCH GEN PSYCHIAT,
V61, P1107, DOI 10.1001/archpsyc.61.11.1107; GRAY NS, 1992, PSYCHOPHARMACOLOGY,
V107, P425, DOI 10.1007/BF02245170; Green AI, 1999, HARVARD REV PSYCHIAT, V6, P287,
DOI 10.3109/10673229909017206; Green AI, 2007, AM J PSYCHIAT, V164, P402, DOI
10.1176/appi.ajp.164.3.402; Green IW, 2016, SCHIZOPHRENIA BULL, V42, P542, DOI
10.1093/schbul/sbv136; Guillin O, 2001, NATURE, V411, P86, DOI 10.1038/35075076;
Hambrecht M, 1996, BIOL PSYCHIAT, V40, P1155, DOI 10.1016/S0006-3223(95)00609-5;
Hambrecht M, 2000, AUST NZ J PSYCHIAT, V34, P468, DOI 10.1046/j.1440-
1614.2000.00736.x; Hartmann M, 2001, EMBO J, V20, P5887, DOI
10.1093/emboj/20.21.5887; Hartz SM, 2017, SCHIZOPHR RES; Henquet C, 2010, BRIT J
PSYCHIAT, V196, P447, DOI 10.1192/bjp.bp.109.072249; Ira E, 2013, J PSYCHIATR
NEUROSCI, V38, P366, DOI 10.1503/jpn.120178; Jeanblanc J, 2015, ADDICT BIOL, V20,
P490, DOI 10.1111/adb.12146; Jones HJ, 2016, JAMA PSYCHIAT, V73, P221, DOI
10.1001/jamapsychiatry.2015.3058; Juckel G, 2006, NEUROIMAGE, V29, P409, DOI
10.1016/j.neuroimage.2005.07.051; Kalkman HO, 2006, PHARMACOL THERAPEUT, V110,
P117, DOI 10.1016/j.pharmthera.2005.10.014; Kandel DB, 2014, NEW ENGL J MED, V371,
P2038, DOI 10.1056/NEJMc1411785; Kantrowitz JT, 2009, PSYCHIAT QUART, V80, P213,
DOI 10.1007/s11126-009-9108-4; Karam EG, 2002, COMPR PSYCHIAT, V43, P463, DOI
10.1053/comp.2002.35910; Kendler KS, 2015, AM J PSYCHIAT, V172, P1092, DOI
10.1176/appi.ajp.2015.15010126; Kendler KS, 1996, ARCH GEN PSYCHIAT, V53, P1022;
Khan SS, 2013, DRUG ALCOHOL DEPEN, V130, P101, DOI
10.1016/j.drugalcdep.2012.10.015; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4,
P231, DOI 10.3109/10673229709030550; KIVLAHAN DR, 1991, HOSP COMMUNITY PSYCH, V42,
P609; KNUDSEN P, 1984, ACTA PSYCHIAT SCAND, V69, P162, DOI 10.1111/j.1600-
0447.1984.tb02482.x; Koukouli F, 2017, NAT MED, V23, P347, DOI 10.1038/nm.4274;
Kristensen K, 2007, PSYCHIAT RES, V151, P151, DOI 10.1016/j.psychres.2006.10.001;
Large M, 2011, ARCH GEN PSYCHIAT, V68, P555, DOI 10.1001/archgenpsychiatry.2011.5;
LAVIN A, 1994, SYNAPSE, V18, P104, DOI 10.1002/syn.890180205; Lee ML, 1998, CAN J
PSYCHIAT, V43, P855; Levine A, 2011, SCI TRANSL MED, V3, DOI
10.1126/scitranslmed.3003062; LINSZEN DH, 1994, ARCH GEN PSYCHIAT, V51, P273;
Lipska BK, 2000, NEUROPSYCHOPHARMACOL, V23, P223, DOI 10.1016/S0893-133X(00)00137-
8; Liu W, 2015, NEUROSCIENCE, V293, P92, DOI 10.1016/j.neuroscience.2015.02.014;
Lynskey MT, 2003, JAMA-J AM MED ASSOC, V289, P427, DOI 10.1001/jama.289.4.427;
Machielsen MWJ, 2014, J PSYCHOPHARMACOL, V28, P633, DOI 10.1177/0269881114527357;
Marconi A, 2016, SCHIZOPHRENIA BULL, V42, P1262, DOI 10.1093/schbul/sbw003; McClory
AJ, 2014, ALCOHOL, V48, P755, DOI 10.1016/j.alcohol.2014.05.006; Mesholam-Gately
RI, 2014, SCHIZOPHR RES, V155, P45, DOI 10.1016/j.schres.2014.03.002; Moran LV,
2013, SCHIZOPHRENIA BULL, V39, P1373, DOI 10.1093/schbul/sbs149; Moran LV, 2012,
SCHIZOPHR RES, V142, P223, DOI 10.1016/j.schres.2012.08.033; MUESER KT, 1990,
SCHIZOPHRENIA BULL, V16, P31, DOI 10.1093/schbul/16.1.31; MUESER KT, 1995,
SCHIZOPHRENIA BULL, V21, P367, DOI 10.1093/schbul/21.3.367; Mulder AB, 1998, J
NEUROSCI, V18, P5095; Negrete J C, 1986, NIDA Res Monogr, V67, P321; Nguyen-Louie
TT, 2015, J STUD ALCOHOL DRUGS, V76, P738; Nielsen MO, 2012, BIOL PSYCHIAT, V71,
P898, DOI 10.1016/j.biopsych.2012.02.007; ODONNELL P, 1995, J NEUROSCI, V15, P3622;
Peraala J, 2007, ARCH GEN PSYCHIAT, V64, P19, DOI 10.1001/archpsyc.64.1.19; PERALTA
V, 1992, ACTA PSYCHIAT SCAND, V85, P127, DOI 10.1111/j.1600-0447.1992.tb01456.x;
Pomfrey RL, 2015, PHARMACOL BIOCHEM BE, V137, P30, DOI 10.1016/j.pbb.2015.08.004;
Potvin S, 2016, SCHIZOPHR RES, V173, P30, DOI 10.1016/j.schres.2016.03.011; Rabin
RA, 2017, SCHIZOPHR RES; Rais M, 2008, AM J PSYCHIAT, V165, P490, DOI
10.1176/appi.ajp.2007.07071110; REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511;
Ringen PA, 2008, PSYCHOL MED, V38, P1241, DOI 10.1017/S003329170700236X; Ripke S,
2014, NATURE, V511, P421, DOI 10.1038/nature13595; Rodriguez-Arias M, 2016, NEURAL
PLAST, V2016; Romaniuk L, 2010, ARCH GEN PSYCHIAT, V67, P1246, DOI
10.1001/archgenpsychiatry.2010.169; Salom CL, 2016, ADDICTION, V111, P156, DOI
10.1111/add.13058; Sayers SL, 2005, J NERV MENT DIS, V193, P379, DOI
10.1097/01.nmd.0000165089.14736.bf; Scheid MP, 2001, NAT REV MOL CELL BIO, V2,
P760, DOI 10.1038/35096067; Schlagenhauf F, 2013, HUM BRAIN MAPP, V34, P1490, DOI
10.1002/hbm.22000; Schlagenhauf F, 2009, BIOL PSYCHIAT, V65, P1032, DOI
10.1016/j.biopsych.2008.12.016; Schubart CD, 2011, PSYCHOL MED, V41, P1301, DOI
10.1017/S003329171000187X; Schwab SG, 2013, EUR ARCH PSY CLIN N, V263, pS147, DOI
10.1007/s00406-013-0450-z; Simon JJ, 2015, SCHIZOPHRENIA BULL, V41, P1370, DOI
10.1093/schbul/sbv067; Simon JJ, 2010, SCHIZOPHR RES, V118, P154, DOI
10.1016/j.schres.2009.11.007; Smith CM, 1997, J CLIN PHARMACOL, V37, P147, DOI
10.1002/j.1552-4604.1997.tb04773.x; Smith MJ, 2008, SCHIZOPHR RES, V106, P294, DOI
10.1016/j.schres.2008.07.015; Spear LP, 2016, NEUROSCI BIOBEHAV R, V70, P228, DOI
10.1016/j.neubiorev.2016.07.026; Spoelder M, 2015, NEUROPSYCHOPHARMACOL, V40,
P2873, DOI 10.1038/npp.2015.139; Stefanis NC, 2013, SCHIZOPHRENIA BULL, V39, P251,
DOI 10.1093/schbul/sbs188; Stinson FS, 2006, PSYCHOL MED, V36, P1447, DOI
10.1017/S0033291706008361; Stone WS, 2001, BIOL PSYCHIAT, V50, P434, DOI
10.1016/S0006-3223(01)01116-7; Strong C, 2016, SUBST USE MISUSE, V51, P141, DOI
10.3109/10826084.2015.1073323; Swendsen J, 2012, ARCH GEN PSYCHIAT, V69, P390, DOI
10.1001/archgenpsychiatry.2011.1503; Swendsen J, 2011, AM J PSYCHIAT, V168, P202,
DOI 10.1176/appi.ajp.2010.10030463; Swiech L, 2008, BBA-PROTEINS PROTEOM, V1784,
P116, DOI 10.1016/j.bbapap.2007.08.015; Thompson JL, 2013, MOL PSYCHIATR, V18,
P909, DOI 10.1038/mp.2012.109; TREFFERT DA, 1978, AM J PSYCHIAT, V135, P1213; Tseng
KY, 2009, BEHAV BRAIN RES, V204, P295, DOI 10.1016/j.bbr.2008.11.039; van Dijk D,
2012, SCHIZOPHR RES, V137, P50, DOI 10.1016/j.schres.2012.01.016; van Winkel R,
2011, NEUROPSYCHOPHARMACOL, V36, P2529, DOI 10.1038/npp.2011.141; Vaucher J., 2017,
MOL PSYCHIAT; Vetreno RP, 2015, FRONT NEUROSCI-SWITZ, V9, DOI
10.3389/fnins.2015.00035; Volkow ND, 2014, NEW ENGL J MED, V371, P879, DOI
10.1056/NEJMc1407928; Volkow ND, 2009, SCHIZOPHRENIA BULL, V35, P469, DOI
10.1093/schbul/sbp016; Waltz JA, 2009, NEUROPSYCHOPHARMACOL, V34, P1567, DOI
10.1038/npp.2008.214; WEINBERGER DR, 1995, SCHIZOPHR RES, V16, P87, DOI
10.1016/0920-9964(95)00013-C; Weiser M, 2004, AM J PSYCHIAT, V161, P1219, DOI
10.1176/appi.ajp.161.7.1219; Wu BJ, 2013, J CLIN PSYCHOPHARM, V33, P319, DOI
10.1097/JCP.0b013e31828b2575; Zimmet SV, 2000, J CLIN PSYCHOPHARM, V20, P94, DOI
10.1097/00004714-200002000-00016 149 9 9 2 16 ELSEVIER SCIENCE
BV AMSTERDAM PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS 0920-9964 1573-
2509 SCHIZOPHR RES Schizophr. Res. APR 2018 194
78 85 10.1016/j.schres.2017.04.016 8
Psychiatry Psychiatry GA0PD WOS:000428015700012 28416205 Green
Accepted 2019-09-25
J Ertl, V; Preusse, M; Neuner, F Ertl, Verena; Preusse,
Melissa; Neuner, Frank Are Drinking Motives Universal? Characteristics
of Motive Types in Alcohol-Dependent Men from Two Diverse Populations FRONTIERS IN
PSYCHIATRY English Article
addiction; alcohol use disorder; drinking motives; reward- and relief-
drinking; self-medication; trauma; childhood maltreatment; mental health
CHILDHOOD TRAUMA QUESTIONNAIRE; ECOLOGICAL MOMENTARY ASSESSMENT;
POSTTRAUMATIC-STRESS-DISORDER; NATIONAL EPIDEMIOLOGIC SURVEY; SUBSTANCE USE
DISORDERS; EMOTION REGULATION; GERMAN VERSION; MOTIVATIONAL PATHWAYS; MOOD
DISORDERS; SEXUAL ASSAULT Background and Aims: Since alcohol use disorders are
among the most prevalent and destructive mental disorders, it is critical to
address factors contributing to their development and maintenance. Drinking motives
are relevant driving factors for consumption. Identifying groups of drinkers with
similar motivations may help to specialize intervention components and make
treatment more effective and efficient. We aimed to identify and describe distinct
motive types of drinkers in dependent males from two diverse cultures (Uganda and
Germany) and to explore potential differences and similarities in addiction-related
measures. Moreover, we investigated specific links between motive types and
childhood maltreatment, traumatic experiences, and symptoms of comorbid
psychopathologies. Methods: To determine distinct drinking motive types, we
conducted latent class analyses concerning drinking motives (Drinking Motive Scale)
in samples of treatment-seeking alcohol-dependent men (N = 75). Subsequently we
compared the identified motive types concerning their alcohol consumption and
alcohol-related symptoms (Alcohol Use Disorders Identification Test), history of
childhood maltreatment (Childhood Trauma Questionnaire), trauma exposure (Violence,
War and Abduction Exposure Scale), psychopathology (Posttraumatic Stress Diagnostic
Scale, Depression-section of the Hopkins Symptom Checklist, and Brief Symptom
Inventory) and deficits in emotion regulation (Difficulties in Emotion Regulation
Scale). Results: We found two congruent drinking motive types in both contexts.
Reward-oriented drinking motives like the generation of positive feelings and
enhancing performance were endorsed almost equally by both motive types, whereas
high relief motive endorsement characterized one group, but not the other. The
relief motive type drank to overcome aversive feelings, withdrawal, and daily
hassles and was characterized by higher adversity in general. Emotional
maltreatment in childhood and psychopathological symptoms were reported to a
significantly greater extent by relief drinkers (effect sizes of comparisons
ranging from r = 0.25 to r = 0.48). However, the motive types did not differ
significantly on alcohol consumption or alcohol-related symptoms and traumatic
experiences apart from childhood maltreatment. Conclusion: The chronology of
addiction development and patterns of drinking motivation seem to be similar across
cultures, i.e., that motive targeting interventions might be applicable cross-
culturally. Addressing comorbid symptomatology should be a key treatment component
for relief drinkers, whereas finding alternatives for the creation of positive
feelings and ways to counteract boredom and inactivity should be a general
treatment element. [Ertl, Verena; Preusse, Melissa; Neuner, Frank] Bielefeld
Univ, Dept Psychol, Clin Psychol & Psychotherapy, Bielefeld, Germany; [Ertl,
Verena; Preusse, Melissa; Neuner, Frank] Vivo Int, Constance, Germany Ertl, V
(reprint author), Bielefeld Univ, Dept Psychol, Clin Psychol & Psychotherapy,
Bielefeld, Germany.; Ertl, V (reprint author), Vivo Int, Constance, Germany.
verena.ertl@uni-bielefeld.de Bielefeld Young Researchers Fund
This research was supported by a grant of the "Bielefeld Young Researchers
Fund" awarded to VE. Ahmed SP, 2015, DEV COGN NEUROS-NETH, V15, P11, DOI
[10.1016/j.den.2015.07.006, 10.1016/j.dcn.2015.07.006]; Allen JP, 1997, ALCOHOL
CLIN EXP RES, V21, P613, DOI 10.1097/00000374-199706000-00008; American Psychiatric
Association, 1994, DIAGN STAT MAN MENT; Armeli S, 2010, PSYCHOL ADDICT BEHAV, V24,
P38, DOI 10.1037/a0017530; Babor T, 2001, AUDIT ALCOHOL USE DI; Bader K, 2009, Z KL
PSYCH PSYCHOTH, V38, P223, DOI 10.1026/1616-3443.38.4.223; Baker TB, 2004, PSYCHOL
REV, V111, P33, DOI 10.1037/0033-295X.111.1.33; Bernstein DP, 2003, CHILD ABUSE
NEGLECT, V27, P169, DOI 10.1016/S0145-2134(02)00541-0; BERNSTEIN DP, 1994, AM J
PSYCHIAT, V151, P1132; Beseler CL, 2008, ALCOHOL CLIN EXP RES, V32, P607, DOI
10.1111/j.1530-0277.2008.00619.x; Blake D.D., 1990, BEHAV THER, V13, P187, DOI DOI
10.1007/BF02105408; Blanco C, 2013, DRUG ALCOHOL DEPEN, V132, P630, DOI
10.1016/j.drugalcdep.2013.04.016; Bolton P, 2002, J NERV MENT DIS, V190, P631, DOI
10.1097/01.NMD.0000030568.45847.AE; Brady KT, 2004, CURR DIR PSYCHOL SCI, V13,
P206, DOI 10.1111/j.0963-7214.2004.00309.x; Bremner JD, 1996, AM J PSYCHIAT, V153,
P369; Burstein M, 2011, J AM ACAD CHILD PSY, V50, P870, DOI
10.1016/j.jaac.2011.06.005; Cloninger CR, 1996, ALCOHOL HEALTH RES W, V20, P18;
Colder CR, 2001, PSYCHOL ADDICT BEHAV, V15, P237, DOI 10.1037/0893-164X.15.3.237;
CONGER JJ, 1956, Q J STUD ALCOHOL, V17, P296; Cooper M. L., 1994, PSYCHOL
ASSESSMENT, V6, P117, DOI [DOI 10.1037/1040-3590.6.2.117, 10.1037/1040-
3590.6.2.117]; Cooper ML, 2008, J ABNORM PSYCHOL, V117, P485, DOI 10.1037/a0012592;
COOPER ML, 1995, J PERS SOC PSYCHOL, V69, P990, DOI 10.1037/0022-3514.69.5.990;
COOPER ML, 1992, J ABNORM PSYCHOL, V101, P139, DOI 10.1037/0021-843X.101.1.139;
Cooper R, 2014, ANXIETY STRESS COPIN, V27, P113, DOI 10.1080/10615806.2013.823482;
Cox WM, 2006, ADDICT BEHAV, V31, P2147, DOI 10.1016/j.addbeh.2006.02.023; COX WM,
1988, J ABNORM PSYCHOL, V97, P168, DOI 10.1037/0021-843X.97.2.168; Crum RM, 2013,
DEPRESS ANXIETY, V30, P174, DOI 10.1002/da.22024; Crutzen R, 2013, EUR ADDICT RES,
V19, P222, DOI 10.1159/000345457; Crutzen R, 2013, PSYCHOL ADDICT BEHAV, V27, P197,
DOI 10.1037/a0029824; Debell F, 2014, SOC PSYCH PSYCH EPID, V49, P1401, DOI
10.1007/s00127-014-0855-7; Demmel R, 2004, ADDICT RES THEORY, V12, P125, DOI
10.1080/1606635310001634519; Demmel R, 2009, BEER IN HEALTH AND DISEASE PREVENTION,
P177, DOI 10.1016/B978-0-12-373891-2.00016-X; DEROGATIS LR, 1974, BEHAV SCI, V19,
P1, DOI 10.1002/bs.3830190102; Di Nicola M, 2015, DRUG ALCOHOL DEPEN, V148, P118,
DOI 10.1016/j.drugalcdep.2014.12.028; Douglas KR, 2010, ADDICT BEHAV, V35, P7, DOI
10.1016/j.addbeh.2009.07.004; Driessen M, 2008, ALCOHOL CLIN EXP RES, V32, P481,
DOI 10.1111/j.1530-0277.2007.00591.x; Dvorak RD, 2014, EXP CLIN PSYCHOPHARM, V22,
P285, DOI 10.1037/a0037157; Ehring T, 2008, PERS INDIV DIFFER, V44, P1574, DOI
10.1016/j.paid.2008.01.013; Ertl V, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-
016-0905-7; Ertl V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102786; Ertl V,
2010, PSYCHOL ASSESSMENT, V22, P318, DOI 10.1037/a0018810; Foa EB., 1995,
POSTTRAUMATIC DIAGNO; Franke G. H., 2000, BRIEF SYMPTOM INVENT; FUNKE W, 1987,
TRIERER ALKOHOLISMUS; Geisheim C, 2002, DIAGNOSTICA, V48, P28, DOI 10.1026//0012-
1924.48.1.28; Goldstein AL, 2010, ADDICT BEHAV, V35, P636, DOI
10.1016/j.addbeh.2010.02.002; Graham K, 2011, ADDICTION, V106, P1391, DOI
10.1111/j.1360-0443.2011.03425.x; Grant BF, 2004, ARCH GEN PSYCHIAT, V61, P807, DOI
10.1001/archpsyc.61.8.807; Gratz KL, 2004, J PSYCHOPATHOL BEHAV, V26, P41, DOI
10.1023/B:JOBA.0000007455.08539.94; Grayson CE, 2005, J TRAUMA STRESS, V18, P137,
DOI 10.1002/jts.20021; Haller M, 2014, PSYCHOL ADDICT BEHAV, V28, P841, DOI
10.1037/a0035878; Holahan CJ, 2001, J STUD ALCOHOL, V62, P190, DOI
10.15288/jsa.2001.62.190; Hull C. L., 1952, BEHAV SYSTEM INTRO B; Jahng S, 2011, J
ABNORM PSYCHOL, V120, P572, DOI 10.1037/a0024686; Kafuko A, 2008, QUALITATIVE RES
UGAN; Kaplow JB, 2001, J CLIN CHILD PSYCHOL, V30, P316, DOI
10.1207/S15374424JCCP3003_4; Kaysen D, 2007, ADDICT BEHAV, V32, P1272, DOI
10.1016/j.addbeh.2006.09.007; Kessler RC, 1997, ARCH GEN PSYCHIAT, V54, P313;
Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550;
Klinitzke G, 2012, PSYCHOTHER PSYCH MED, V62, P47, DOI 10.1055/s-0031-1295495;
Kuntsche E, 2005, CLIN PSYCHOL REV, V25, P841, DOI 10.1016/j.cpr.2005.06.002;
Kuntsche E, 2008, J STUD ALCOHOL DRUGS, V69, P388, DOI 10.15288/jsad.2008.69.388;
Kuntsche E, 2007, J STUD ALCOHOL DRUGS, V68, P76, DOI 10.15288/jsad.2007.68.76;
Kuntsche E, 2006, EUR ADDICT RES, V12, P161, DOI 10.1159/000092118; Kuntsche E,
2006, ADDICT BEHAV, V31, P1844, DOI 10.1016/j.addbeh.2005.12.028; Kuntsche E, 2006,
ALCOHOL ALCOHOLISM, V41, P566, DOI 10.1093/alcalc/agl046; Kuntsche E, 2014, J STUD
ALCOHOL DRUGS, V75, P428, DOI 10.15288/jsad.2014.75.428; Kuntsche E, 2012, EXP CLIN
PSYCHOPHARM, V20, P318, DOI 10.1037/a0027480; Kuntsche E, 2010, EXP CLIN
PSYCHOPHARM, V18, P436, DOI 10.1037/a0019724; Kuntsche E, 2010, DRUG ALCOHOL DEPEN,
V110, P259, DOI 10.1016/j.drugalcdep.2010.02.021; Kuntsche E, 2009, J CLIN CHILD
ADOLESC, V38, P899, DOI 10.1080/15374410903258967; Lai HMX, 2015, DRUG ALCOHOL
DEPEN, V154, P1, DOI 10.1016/j.drugalcdep.2015.05.031; Lehavot K, 2014, PSYCHOL
ADDICT BEHAV, V28, P42, DOI 10.1037/a0032266; Leigh BC, 1990, PSYCHOL ADDICT BEHAV,
V4, P91, DOI DOI 10.1037/H0080578; Lindgren KP, 2012, ADDICT BEHAV, V37, P323, DOI
10.1016/j.addbeh.2011.10.009; Littlefield AK, 2013, ADDICTION, V108, P497, DOI
10.1111/j.1360-0443.2012.04090.x; Littlefield AK, 2010, J ABNORM PSYCHOL, V119,
P93, DOI 10.1037/a0017512; Mackinnon SP, 2017, DRUG ALCOHOL REV, V36, P721, DOI
10.1111/dar.12464; Martinotti G, 2013, COMPR PSYCHIAT, V54, P925, DOI
10.1016/j.comppsych.2013.03.023; Merrill JE, 2014, J STUD ALCOHOL DRUGS, V75, P93,
DOI 10.15288/jsad.2014.75.93; Merrill JE, 2010, PSYCHOL ADDICT BEHAV, V24, P705,
DOI 10.1037/a0020135; Metcalfe J, 1999, PSYCHOL
REV, V106, P3, DOI 10.1037/0033-295X.106.1.3; Miranda Robert Jr, 2002, Violence
Vict, V17, P205, DOI 10.1891/vivi.17.2.205.33650; Mokdad AH, 2016, LANCET, V387,
P2383, DOI 10.1016/S0140-6736(16)00648-6; MOLLICA RF, 1987, AM J PSYCHIAT, V144,
P497; Mollica RF, 1996, TORTURE, V6, P35; Nylund KL, 2007, STRUCT EQU MODELING,
V14, P535, DOI 10.1080/10705510701575396; Obot IS, 2005, ALCOHOL GENDER DRINK;
OETTING ER, 1990, J CONSULT CLIN PSYCH, V58, P385, DOI 10.1037/0022-006X.58.4.385;
Olema DK, 2014, J TRAUMA STRESS, V27, P35, DOI 10.1002/jts.21892; Onyut Lamaro P,
2009, Confl Health, V3, P6, DOI 10.1186/1752-1505-3-6; Ooteman W, 2006, ALCOHOL
ALCOHOLISM, V41, P284, DOI 10.1093/alcalc/agl012; Ouimette P, 2007, ADDICT BEHAV,
V32, P1719, DOI 10.1016/j.addbeh.2006.11.020; Ouimette P, 2010, ADDICT BEHAV, V35,
P64, DOI 10.1016/j.addbeh.2009.08.009; Pettorruso M, 2014, FRONT PSYCHIATRY, V5,
DOI 10.3389/fpsyt.2014.00173; Potthast N, 2014, ADDICT BEHAV, V39, P949, DOI
10.1016/j.addbeh.2014.01.015; Rehm J, 2009, LANCET, V373, P2223, DOI 10.1016/S0140-
6736(09)60746-7; Roberts B, 2011, ADDICT BEHAV, V36, P870, DOI
10.1016/j.addbeh.2011.03.006; Roberts B, 2008, BMC PSYCHIATRY, V8, DOI
10.1186/1471-244X-8-38; Saile R, 2014, CHILD ABUSE NEGLECT, V38, P135, DOI
10.1016/j.chiabu.2013.10.007; Saile R, 2013, SOC SCI MED, V86, P17, DOI
10.1016/j.socscimed.2013.02.046; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI
10.1111/j.1360-0443.1993.tb02093.x; Shrestha NM, 1998, JAMA-J AM MED ASSOC, V280,
P443, DOI 10.1001/jama.280.5.443; Simons JS, 2006, ADDICT BEHAV, V31, P1578, DOI
10.1016/j.addbeh.2005.12.004; Simons JS, 2014, J ABNORM PSYCHOL, V123, P676, DOI
10.1037/a0036926; Simons JS, 2010, ADDICT BEHAV, V35, P1045, DOI
10.1016/j.addbeh.2010.07.001; Simons JS, 2009, PSYCHOL ADDICT BEHAV, V23, P415, DOI
10.1037/a0016003; Simons JS, 2005, ADDICT BEHAV, V30, P1370, DOI
10.1016/j.addbeh.2005.01.018; Simons JS, 2002, PSYCHOL ADDICT BEHAV, V16, P72, DOI
10.1037//0893-164X.16.1.72; Simpson TL, 2014, J ABNORM PSYCHOL, V123, P237, DOI
10.1037/a0035193; Solomon RL, 1977, PSYCHOPATHOLOGY EXPT, P66; Stappenbeck CA,
2013, ADDICT BEHAV, V38, P1831, DOI 10.1016/j.addbeh.2012.10.012; Steinberg L,
2005, TRENDS COGN SCI, V9, P69, DOI 10.1016/j.tics.2004.12.005; Tragesser SL, 2007,
EXP CLIN PSYCHOPHARM, V15, P282, DOI 10.1037/1064-1297.15.3.282; Verheul R, 1999,
ALCOHOL ALCOHOLISM, V34, P197, DOI 10.1093/alcalc/34.2.197; Waldrop AE, 2007,
ADDICT BEHAV, V32, P634, DOI 10.1016/j.addbeh.2006.06.001; WHO, 2014, GLOBAL STATUS
REPORT ON VIOLENCE PREVENTION 2014, P1; Wicki M, 2017, DRUG ALCOHOL REV, V36, P731,
DOI 10.1111/dar.12572; Wicki M, 2010, ADDICT BEHAV, V35, P913, DOI
10.1016/j.addbeh.2010.06.015; WIKLER A, 1948, AM J PSYCHIAT, V105, P329, DOI
10.1176/ajp.105.5.329; Wills T. A., 1985, COPING SUBSTANCE USE, P3; Wills TA, 2006,
PSYCHOL ADDICT BEHAV, V20, P265, DOI 10.1037/0893-164X.20.3.265; Wingenfeld K,
2010, PSYCHOTHER PSYCH MED, V60, P442, DOI 10.1055/s-0030-1247564; Wolitzky-Taylor
K, 2012, ADDICT BEHAV, V37, P982, DOI 10.1016/j.addbeh.2012.03.026; General
Assembly of the World Medical Association, 2014, J Am Coll Dent, V81, P14, DOI
10.1001/jama.2013.281053; Wurdak Mara, 2016, Prev Med Rep, V3, P83, DOI
10.1016/j.pmedr.2015.12.009 126 0 0 1 9 FRONTIERS MEDIA SA
LAUSANNE AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
1664-0640 FRONT PSYCHIATRY Front. Psychiatry FEB 13 2018
9 38 10.3389/fpsyt.2018.00038
16 Psychiatry Psychiatry FV9XI WOS:000424943300001
29487544 DOAJ Gold, Green Published 2019-09-25
J Roncero, C; de Miguel, A; Fumero, A; Abad, AC; Martin, R; Bethencourt, JM;
Grau-Lopez, L; Rodriguez-Cintas, L; Daigre, C Roncero, Carlos;
de Miguel, Adelia; Fumero, Ascension; Abad, Alfonso C.; Martin, Rita; Manuel
Bethencourt, Juan; Grau-Lopez, Lara; Rodriguez-Cintas, Laia; Daigre, Constanza
Anxiety and Depression in Drug-Dependent Patients with Cluster C
Personality Disorders FRONTIERS IN PSYCHIATRY English Article
addiction; substance-use disorder; personality;
cluster C; anxiety; depression SUBSTANCE USE DISORDERS; NATIONAL EPIDEMIOLOGIC
SURVEY; SELF-MEDICATION HYPOTHESIS; PSYCHOMETRIC PROPERTIES; ALCOHOL DEPENDENCE;
COMORBIDITY; PREVALENCE; INVENTORY; ABUSERS; FEATURES Objective: Comorbidity
between personality disorders (PD) and substance-use disorders (SUD) is one of the
most common findings in the psychiatric field. The patients with Cluster C
disorders present maladjustment traits often characterized by high levels of
anxiety. The main aim of this study was to find evidences about higher anxiety and
depression prevalence on Cluster C than others Clusters, analyzing similarities and
differences within, with other Cluster A and B PD patients and patients without PD.
Method: A total of 822 substance dependent patients (ages18-78; Mean = 38.35, SD =
10.14) completed the structured clinical interview for DSM-IV Axis I and Axis II
disorders, Beck Depression Inventory, and State-Trait Anxiety Inventory. Results:
Results supported poly-consumption in Cluster C patients, being greater alcohol
consumption as well as abuse of both stimulants and depressants. Anxiety and
depression did not show just one pattern for all patients with SUD-Cluster C PD.
There was a relation between anxiety and depression for all the groups except for
the Dependent-PD. Conclusion: Interventions should focus on aspects like depression
and anxiety more than on the substance consumed. [Roncero, Carlos] Univ
Salamanca, Psychiat Serv, Inst Biomed Salamanca, Hlth Care Complex, Salamanca,
Spain; [Roncero, Carlos; Abad, Alfonso C.; Grau-Lopez, Lara; Rodriguez-Cintas,
Laia; Daigre, Constanza] Hosp Univ Vall dHebron ASPB, Addict & Dual Diag Unit,
Barcelona, Spain; [Roncero, Carlos; Grau-Lopez, Lara; Rodriguez-Cintas, Laia;
Daigre, Constanza] Univ Autonoma Barcelona, Dept Psychiat, Barcelona, Spain; [de
Miguel, Adelia; Fumero, Ascension; Martin, Rita; Manuel Bethencourt, Juan] Univ La
Laguna, Sch Hlth Sci, Tenerife, Spain; [Abad, Alfonso C.; Grau-Lopez, Lara; Daigre,
Constanza] Hosp Univ Vall dHebron, Psychiat Serv, CIBERSAM, Barcelona, Spain
Roncero, C (reprint author), Univ Salamanca, Psychiat Serv, Inst Biomed
Salamanca, Hlth Care Complex, Salamanca, Spain.; Roncero, C (reprint author), Hosp
Univ Vall dHebron ASPB, Addict & Dual Diag Unit, Barcelona, Spain.; Roncero, C
(reprint author), Univ Autonoma Barcelona, Dept Psychiat, Barcelona, Spain.
croncero@saludcastillayleon.es Hernandez, Ascension Fumero/G-8597-2011;
Roncero, Carlos/W-6357-2019; Perez, Juan Manuel Bethencourt/G-5878-2011; de Miguel
Negredo, Adelia/G-6133-2011 Roncero, Carlos/0000-0003-1421-7385; Perez, Juan
Manuel Bethencourt/0000-0002-9191-1234; GRAU-LOPEZ, LARA/0000-0003-1297-1819;
Daigre, Constanza/0000-0003-0064-3404 Subdireccio General de Drogodependencies
(Department of Health. Generalitat de Catalunya); Instituto Carlos IIIInstituto de
Salud Carlos III [FIS PI13/1911]; Delegacion del Gobierno para el Plan Nacional
sobre Drogas [2013/044] The authors would like to thank the support of Grant of the
Subdireccio General de Drogodependencies (Department of Health. Generalitat de
Catalunya) for the study of cocaine - dependence and a grant from the Instituto
Carlos III: FIS PI13/1911 "Alucinaciones cenestesicas: factor pronostico en
dependientes de cocaina" and a grant from the Delegacion del Gobierno para el Plan
Nacional sobre Drogas 2013/044: "Complicaciones clinicas y accidentabilidad
asociadas a la presencia de sintomas psicoticos en consumidores de cocaina." These
funding sources had not played any role in this research. The authors are also
grateful to our research team for their support, particularly Dr. Joan Alvaros, Dr.
Angel Egido, Dr. Abderraman Esojo, Dr. Maria Robles, Dr. Felipe Palma, Dr. Elena
Ros-Cucurull (Psychiatrists), Nina Vela, Alejandra Herrero, Marta Sorribes, and
Marta Perea (Psychologists). Agrawal A, 2013, PERSONAL DISORD, V4, P55, DOI
10.1037/a0030224; American Psychiatric Association, 2000, DIAGN STAT MAN MENT;
Arendt M, 2007, PSYCHOL MED, V37, P935, DOI 10.1017/S0033291706009688; Barnes LLB,
2002, EDUC PSYCHOL MEAS, V62, P603, DOI 10.1177/001316402128775049; Barral C, 2016,
J SUBST USE, V21, P128, DOI 10.3109/14659891.2014.980859; BECK AT, 1961, ARCH GEN
PSYCHIAT, V4, P561; Becker DF, 2009, COMPR PSYCHIAT, V50, P463, DOI
10.1016/j.comppsych.2008.10.002; Benito A, 2012, ADICCIONES, V24, P131, DOI
10.20882/adicciones.106; Blecha L, 2010, ARCH PEDIATRIE, V17, P191, DOI
10.1016/j.arcped.2009.09.018; Comin M, 2016, PSYCHIAT RES, V246, P587, DOI
10.1016/j.psychres.2016.10.083; Crews FT, 2016, PHARMACOL REV, V68, P1074, DOI
10.1124/pr.115.012138; DEJONG CAJ, 1993, COMPR PSYCHIAT, V34, P87, DOI
10.1016/0010-440X(93)90052-6; Dimaggio G, 2015, J CLIN PSYCHOL, V71, P157, DOI
10.1002/jclp.22151; Echeburua E, 2005, ALCOHOL ALCOHOLISM, V40, P323, DOI
10.1093/alcalc/agh158; First M. B., 1997, USERS GUIDE STRUCTUR; First MB, 2012,
STRUCTURED CLIN INTE; Fonseca-Pedrero E, 2013, ACTAS ESP PSIQUIATRI, V41, P97; Funk
D, 2006, ALCOHOL RES HEALTH, V29, P186; Grant BF, 2009, MOL PSYCHIATR, V14, P1051,
DOI 10.1038/mp.2008.41; Grant BF, 2004, J CLIN PSYCHIAT, V65, P948; Grant BF, 2005,
J PSYCHIAT RES, V39, P1, DOI 10.1016/j.jpsychires.2004.05.004; Grau-Lopez L, 2016,
ACTAS ESP PSIQUIATRI, V44, P64; HARDY GE, 1995, J CONSULT CLIN PSYCH, V63, P997,
DOI 10.1037/0022-006X.63.6.997; HARRISON ER, 1993, AM J DRUG ALCOHOL AB, V19, P423,
DOI 10.3109/00952999309001632; Hatzigiakoumis Daniele Stavros, 2011, Front
Psychiatry, V2, P10, DOI 10.3389/fpsyt.2011.00010; Hishinuma ES, 2000, ASSESSMENT,
V7, P17, DOI 10.1177/107319110000700102; Jahng S, 2011, J ABNORM PSYCHOL, V120,
P656, DOI 10.1037/a0023539; Kabacoff RI, 1997, J ANXIETY DISORD, V11, P33, DOI
10.1016/S0887-6185(96)00033-3; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231,
DOI 10.3109/10673229709030550; Kokkevi A, 1998, ADDICT BEHAV, V23, P841, DOI
10.1016/S0306-4603(98)00071-9; KRANZLER HR, 1994, COMPR PSYCHIAT, V35, P335, DOI
10.1016/0010-440X(94)90272-0; Langas AM, 2012, BMC PSYCHIATRY, V12, DOI
10.1186/1471-244X-12-180; Lev-Ran S, 2013, AM J ADDICTION, V22, P93, DOI
10.1111/j.1521-0391.2013.00304.x; Duran AL, 2006, PSICOTHEMA, V18, P578; Lorea I,
2009, ADICCIONES, V21, P57, DOI 10.20882/adicciones.252; Lysaker PH, 2014, ADDICT
BEHAV, V39, P558, DOI 10.1016/j.addbeh.2013.11.007; MCCANCE EF, 1995, J PHARMACOL
EXP THER, V274, P215; Moreno-Lopez L, 2014, FRONT PSYCHIATRY, V5, DOI
10.3389/fpsyt.2014.00052; Morse JQ, 2005, AM J GERIAT PSYCHIAT, V13, P808, DOI
10.1176/appi.ajgp.13.9.808; NACE EP, 1991, AM J PSYCHIAT, V148, P118; Pedrero E.,
2003, TRASTORNOS ADICTIVOS, V5, P241, DOI DOI 10.1016/S1575-0973(03)70117-2; Preuss
UW, 2009, EUR ADDICT RES, V15, P188, DOI 10.1159/000228929; Roncero C, 2014, PLOS
ONE, V9, DOI 10.1371/journal.pone.0106111; Sher KJ, 2007, HDB EMOTION REGULATI,
P560; Skinstad AH, 2001, AM J DRUG ALCOHOL AB, V27, P45, DOI 10.1081/ADA-100103118;
SPIELBERGER CD, 1970, STAT TRAIT ANXIETY I; Thomas VH, 1999, J STUD ALCOHOL, V60,
P271, DOI 10.15288/jsa.1999.60.271; Van Horn DHA, 1998, AM J DRUG ALCOHOL AB, V24,
P395, DOI 10.3109/00952999809016905; Vautier S, 2004, J PERS ASSESS, V83, P167, DOI
10.1207/s15327752jpa8302_11; Vergara-Moragues E, 2013, J ADDICT DIS, V32, P343, DOI
10.1080/10550887.2013.854154; Verheul R, 2001, EUR PSYCHIAT, V16, P274, DOI
10.1016/S0924-9338(01)00578-8 51 0 0 0 9 FRONTIERS MEDIA SA
LAUSANNE PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
SWITZERLAND 1664-0640 FRONT PSYCHIATRY Front. Psychiatry FEB 8 2018
9 19 10.3389/fpsyt.2018.00019
8 Psychiatry Psychiatry FV3JF WOS:000424463500001
29472875 DOAJ Gold, Green Published 2019-09-25
J Austin, AE; Shanahan, ME Austin, Anna E.; Shanahan,
Meghan E. Association of childhood abuse and neglect with
prescription opioid misuse: Examination of mediation by adolescent depressive
symptoms and pain CHILDREN AND YOUTH SERVICES REVIEW English
Article Child abuse and neglect;
Depression; Pain; Prescription opioid misuse POSTTRAUMATIC-STRESS-DISORDER;
ILLICIT DRUG-USE; DIRECTED ACYCLIC GRAPHS; SUBSTANCE USE DISORDERS; UNITED-STATES;
NONMEDICAL USE; NATIONAL-SURVEY; RISK-FACTORS; HOUSEHOLD DYSFUNCTION; PSYCHIATRIC-
DISORDERS Previous research has demonstrated an association between childhood
abuse and neglect and prescription opioid misuse in adulthood. However, potential
mechanisms underlying this association remain unclear. Based on the self-medication
hypothesis and the existing research literature, we hypothesized that pain and
depressive symptoms would mediate this association. Data were from Waves I (1994-
1995) and III (2002) of the National Longitudinal Study of Adolescent to Adult
Health (Add Health; N = 14,322). We conducted structural equation modeling to
examine the association of childhood abuse and neglect with prescription opioid
misuse in early adulthood and to assess for mediation by depressive symptoms and
pain in adolescence. One in five respondents (20.1%) reported prescription opioid
misuse in early adulthood. Childhood abuse and neglect was directly associated with
an increase in the predicted probability of prescription opioid misuse (beta =
0.232, p < 0.001). Pain, but not depressive symptoms, in adolescence was a
significant mediator of this association (beta = 0.019, p < 0.001). Pain may
represent a complex stress-related response to early trauma among adolescents and
may contribute to subsequent prescription opioid misuse as a coping mechanism.
Results highlight the need to promote positive coping skills among adolescents who
have experienced childhood abuse and neglect and underscore the importance of
trauma-informed treatment services for individuals misusing prescription opioids.
Univ North Carolina Chapel Hill, Gillings Sch Global Publ Hlth, Dept Maternal
& Child Hlth, 135 Dauer Dr,401 Roseanu Hall, Chapel Hill, NC 27599 USA; Univ North
Carolina Chapel Hill, Injury Prevent Res Ctr, 137 East Franklin St,Suite 500,
Chapel Hill, NC 27599 USA Austin, AE (reprint author), 137 East Franklin
St,Suite 500, Chapel Hill, NC 27599 USA. anna.austin@unc.edu Eunice
Kennedy Shriver National Institute of Child Health and Human DevelopmentUnited
States Department of Health & Human ServicesNational Institutes of Health (NIH) -
USANIH Eunice Kennedy Shriver National Institute of Child Health & Human
Development (NICHD) [P01-HD31921]; National Center for Injury Prevention and
Control, Centers for Disease Control and PreventionUnited States Department of
Health & Human ServicesCenters for Disease Control & Prevention - USA
[R49/CE002479] This research uses data from Add Health, a program project
directed by Kathleen Mullan Harris and designed by J. Richard Udry, Peter S.
Bearman, and Kathleen Mullan Harris at the University of North Carolina at Chapel
Hill, and funded by grant P01-HD31921 from the Eunice Kennedy Shriver National
Institute of Child Health and Human Development, with cooperative funding from 23
other federal agencies and foundations. Special acknowledgment is due Ronald R.
Rindfuss and Barbara Entwisle for assistance in the original design. Information on
how to obtain the Add Health data files is available on the Add Health Web site
(http://www.cpc.unc.edu/addhealth). No direct support was received from grant P01-
HD31921 for this analysis.; This study was supported in part by an award to the
University of North Carolina Injury Prevention Research Center from the National
Center for Injury Prevention and Control, Centers for Disease Control and
Prevention (R49/CE002479). Anda RF, 2006, EUR ARCH PSY CLIN N, V256, P174, DOI
10.1007/s00406-005-0624-4; Atluri S, 2014, PAIN PHYSICIAN, V17, pE119; Avenevoli S,
2015, J AM ACAD CHILD PSY, V54, P37, DOI 10.1016/j.jaac.2014.10.010; Back SE, 2010,
ADDICT BEHAV, V35, P1001, DOI 10.1016/j.addbeh.2010.06.018; Bair MJ, 2003, ARCH
INTERN MED, V163, P2433, DOI 10.1001/archinte.163.20.2433; Becker WC, 2008, DRUG
ALCOHOL DEPEN, V94, P38, DOI 10.1016/j.drugalcdep.2007.09.018; Bohman H, 2012, BMC
PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-90; Bohman H, 2010, ACTA PAEDIATR, V99,
P1724, DOI 10.1111/j.1651-2227.2010.01906.x; Byrne B. M., 2013, STRUCTURAL
EQUATION; Chantala K., 2004, NONRESPONSE WAVE III; CHARNEY DS, 1993, ARCH GEN
PSYCHIAT, V50, P294; Conroy E, 2009, CHILD ABUSE NEGLECT, V33, P343, DOI
10.1016/j.chiabu.2008.09.009; Danovitch I, 2016, J ADDICT DIS, V35, P169, DOI
10.1080/10550887.2016.1168212; Dart RC, 2015, NEW ENGL J MED, V372, P241, DOI
[10.1056/NEJMsa1406143, 10.1056/NEJMc1501822]; Davis DA, 2005, CLIN J PAIN, V21,
P398, DOI 10.1097/01.ajp.0000149795.08746.31; De Bellis MD, 2001, DEV PSYCHOPATHOL,
V13, P539, DOI 10.1017/S0954579401003078; Dong M, 2003, CHILD ABUSE NEGLECT, V27,
P625, DOI 10.1016/S0145-2134(03)00105-4; Douglas KR, 2010, ADDICT BEHAV, V35, P7,
DOI 10.1016/j.addbeh.2009.07.004; Drouineau MH, 2017, CHILD ABUSE NEGLECT, V65,
P248, DOI 10.1016/j.chiabu.2017.02.002; Dube SR, 2003, PEDIATRICS, V111, P564, DOI
10.1542/peds.111.3.564; Eccleston C., 2014, PSYCHOL THERAPIES MA; Edlund MJ, 2015,
DRUG ALCOHOL DEPEN, V152, P131, DOI 10.1016/j.drugalcdep.2015.04.010; Fergusson DM,
2008, CHILD ABUSE NEGLECT, V32, P607, DOI 10.1016/j.chiabu.2006.12.018; FINKELHOR
D, 1994, PEDIATRICS, V94, P413; Garland EL, 2015, J ADDICT MED, V9, P61, DOI
10.1097/ADM.0000000000000090; GARRISON CZ, 1991, J AM ACAD CHILD PSY, V30, P636,
DOI 10.1097/00004583-199107000-00017; Gilbert R, 2009, LANCET, V373, P68, DOI
10.1016/S0140-6736(08)61706-7; Glaser D, 2000, J CHILD PSYCHOL PSYC, V41, P97, DOI
10.1111/1469-7610.00551; GOODMAN JE, 1991, PAIN, V46, P247, DOI 10.1016/0304-
3959(91)90108-A; Grattan A, 2012, ANN FAM MED, V10, P304, DOI 10.1370/afm.1371;
Green TC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027244; Greenland S, 1999,
EPIDEMIOLOGY, V10, P37, DOI 10.1097/00001648-199901000-00008; Han B, 2017, ANN
INTERN MED, V167, P293, DOI 10.7326/M17-0865; Hardt J, 2004, J CHILD PSYCHOL PSYC,
V45, P260, DOI 10.1111/j.1469-7610.2004.00218.x; Heffernan K, 2000, ADDICT BEHAV,
V25, P797, DOI 10.1016/S0306-4603(00)00066-6; Hussey JM, 2006, PEDIATRICS, V118,
P933, DOI 10.1542/peds.2005-2452; Infurna MR, 2016, J AFFECT DISORDERS, V190, P47,
DOI 10.1016/j.jad.2015.09.006; Jonson-Reid M, 2003, CHILD ABUSE NEGLECT, V27, P899,
DOI 10.1016/S0145-2134(03)00138-8; Kaufman J, 2000, BIOL PSYCHIAT, V48, P778, DOI
10.1016/S0006-3223(00)00998-7; Kecojevic A, 2015, DRUG ALCOHOL DEPEN, V150, P156,
DOI 10.1016/j.drugalcdep.2015.02.031; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4,
P231, DOI 10.3109/10673229709030550; KHANTZIAN EJ, 1985, ARCH GEN PSYCHIAT, V42,
P1067; Killeen TK, 2015, DRUG ALCOHOL REV, V34, P234, DOI 10.1111/dar.12229; Kim K,
2017, CHILD FAM SOC WORK, V22, P492, DOI 10.1111/cfs.12268; King S, 2011, PAIN,
V152, P2729, DOI 10.1016/j.pain.2011.07.016; Landry BW, 2015, PM&R, V7, pS295, DOI
10.1016/j.pmrj.2015.09.006; Lindert J, 2014, INT J PUBLIC HEALTH, V59, P359, DOI
10.1007/s00038-013-0519-5; Lo CC, 2007, AM J DRUG ALCOHOL AB, V33, P139, DOI
10.1080/00952990601091119; Lumley MA, 2011, J CLIN PSYCHOL, V67, P942, DOI
10.1002/jclp.20816; Lutz P. E., 2017, BIOL PSYCHIAT; Martins SS, 2012, PSYCHOL MED,
V42, P1261, DOI 10.1017/S0033291711002145; McCabe SE, 2005, DRUG ALCOHOL DEPEN,
V77, P37, DOI 10.1016/j.drugalcdep.2004.07.005; McCabe SE, 2007, ADDICT BEHAV, V32,
P562, DOI 10.1016/j.addbeh.2006.05.022; Meagher M. W., 2004, LINKS TRAUMATIC FAMI;
Moore D., 1995, DISCIPLINING CHILDRE; Moran PB, 2004, CHILD ABUSE NEGLECT, V28,
P565, DOI 10.1016/j.chiabu.2003.12.002; Motl RW, 2005, EDUC PSYCHOL MEAS, V65, P90,
DOI 10.1177/0013164404266256; Nelson EC, 2006, PSYCHOL MED, V36, P1473, DOI
10.1017/S0033291706008397; Nemeroff CB, 2014, J AM ACAD CHILD PSY, V53, P395, DOI
10.1016/j.jaac.2014.02.004; Phillips GA, 2006, MULTIVAR BEHAV RES, V41, P147, DOI
10.1207/s15327906mbr4102_3; Quinn K, 2016, DRUG ALCOHOL DEPEN, V169, P190, DOI
10.1016/j.drugalcdep.2016.09.021; RADLOFF L S, 1977, Applied Psychological
Measurement, V1, P385, DOI 10.1177/014662167700100306; RADLOFF LS, 1991, J YOUTH
ADOLESCENCE, V20, P149, DOI 10.1007/BF01537606; ROBERTS RE, 1991, J AM ACAD CHILD
PSY, V30, P58, DOI 10.1097/00004583-199101000-00009; Rodgers CS, 2004, CHILD ABUSE
NEGLECT, V28, P575, DOI 10.1016/j.chiabu.2004.01.002; Rudd RA, 2016, AM J
TRANSPLANT, V16, P1323, DOI 10.1111/ajt.13776; RYAN ND, 1987, ARCH GEN PSYCHIAT,
V44, P854; Saha TD, 2016, J CLIN PSYCHIAT, V77, P772, DOI 10.4088/JCP.15m10386;
Schuck AM, 2001, CHILD ABUSE NEGLECT, V25, P1069, DOI 10.1016/S0145-2134(01)00257-
5; Sedlak A. J., 2010, 4 NATL INCIDENCE STU; Straus M. A., 1995, MULTIDIMENSIONAL
NEG; Substance Abuse and Mental Health Services Administration, 2010, HHS PUBL, V8;
Sung HE, 2005, J ADOLESCENT HEALTH, V37, P44, DOI 10.1016/j.jadohealth.2005.02.013;
Tesarz J, 2016, PAIN, V157, P1799, DOI 10.1097/j.pain.0000000000000586; Thapar A,
2012, LANCET, V379, P1056, DOI 10.1016/S0140-6736(11)60871-4; Vachon DD, 2015, JAMA
PSYCHIAT, V72, P1135, DOI 10.1001/jamapsychiatry.2015.1792; VANDERKOLK BA, 1994, B
MENNINGER CLIN, V58, P145; VanderWeele TJ, 2008, EPIDEMIOLOGY, V19, P720, DOI
10.1097/EDE.0b013e3181810e29; VanderWeele TJ, 2007, AM J EPIDEMIOL, V166, P1096,
DOI 10.1093/aje/kwm179; Volkow ND, 2016, NEW ENGL J MED, V374, P1253, DOI
10.1056/NEJMra1507771; Warner M., 2014, TRENDS DRUG POISONIN; White HR, 2008, J
STUD ALCOHOL DRUGS, V69, P337, DOI 10.15288/jsad.2008.69.337; Widom CS, 2006,
PSYCHOL ADDICT BEHAV, V20, P394, DOI 10.1037/0893-164X.20.4.394; Wu LT, 2008, DRUG
ALCOHOL DEPEN, V94, P1, DOI 10.1016/j.drugalcdep.2007.09.023; Young
A, 2012, J ADDICT DIS, V31, P332, DOI 10.1080/10550887.2012.735564; Young A, 2011,
J ADDICT NURS, V22, P25, DOI 10.3109/10884601003628138 86 1 1 2
11 PERGAMON-ELSEVIER SCIENCE LTD OXFORD THE BOULEVARD, LANGFORD LANE,
KIDLINGTON, OXFORD OX5 1GB, ENGLAND 0190-7409 1873-7765 CHILD YOUTH SERV
REV Child. Youth Serv. Rev. FEB 2018 86 84
93 10.1016/j.childyouth.2018.01.023 10 Family
Studies; Social Work Family Studies; Social Work GB1ST WOS:000428831200010
2019-09-25
J Phelps, CL; Paniagua, SM; Willcockson, IU; Potter, JS
Phelps, Cynthia L.; Paniagua, Samantha M.; Willcockson, Irmgard U.; Potter,
Jennifer S. The relationship between self-compassion and the risk for
substance use disorder DRUG AND ALCOHOL DEPENDENCE English
Article Self-compassion; Substance use
disorder; Drug addiction treatment; Self-medication; Shame RANDOMIZED CONTROLLED-
TRIAL; PROBLEMATIC ALCOHOL-USE; CLINICAL-PRACTICE; CHILDHOOD; DEPRESSION
Objective: This study explored the relationship between substance use
disorder risk and self-compassion and posits a model for how the two are related
through the mitigation of suffering. Method: Study participants were recruited
using social media to complete an online survey that included a basic socio-
demographic survey and two validated instruments, the Self-Compassion Survey and
the National Institute on Drug Abuse (NIDA) Alcohol Smoking and Substance
Involvement Screening Test (ASSIST), which screens for substance use disorder (SUD)
risk. Established cut scores for ASSIST were used to divide participants into low,
moderate and high-risk groups. Results: Participants (n = 477) were 31 years old on
average, almost evenly split by gender, mostly non Hispanic white, slightly more
likely to be single and to hold an Associate's degree or higher. Overall, 89% of
participants reported using drugs and/or alcohol in their lifetime. SUD risk was
distributed between low risk (52%), moderate risk (37%) and a smaller percentage of
high risk (11%). Self-compassion was inversely related to SUD risk. The low risk
group had a higher mean self-compassion score (M = 2.86, SD = 0.75) than the people
who were high risk (M = 2.25, SD = 0.61) (t(298) = 5.58 p < 0.0001). Bivariate
Pearson correlations showed strong associations between high risk and all self-
compassion subscales, as well as low risk and five of the subscales. Conclusions:
This study suggests SUD risk has an inverse relationship to self-compassion.
Raising self-compassion may be a useful addition to substance use disorder
prevention and treatment interventions. [Phelps, Cynthia L.] InnerAlly, 110 East
Houston,7th Floor, San Antonio, TX 78205 USA; [Paniagua, Samantha M.; Potter,
Jennifer S.] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, Dept Psychiat, 7703
Floyd Curl Dr, San Antonio, TX 78229 USA; [Willcockson, Irmgard U.] Univ Texas Hlth
Sci Ctr Houston, Sch Biomed Informat, 7000 Fannin St Suite 600, Houston, TX 77030
USA Phelps, CL (reprint author), InnerAlly, 110 East Houston,7th Floor, San
Antonio, TX 78205 USA. cynthia@innerally.com; willcocksonconsulting@gmail.com;
potterjs@uthscsa.edu Ali R, 2002, ADDICTION, V97, P1183;
Allen AB, 2010, SOC PERSONAL PSYCHOL, V4, P107, DOI 10.1111/j.1751-
9004.2009.00246.x; [Anonymous], 2013, DIAGN STAT MAN MENT; [Anonymous], 2012, NIH
DRUG PUBL, V3; Bowen S., 2011, MINDFULNESS BASED RE; Brooks M, 2012, MINDFULNESS,
V3, P308, DOI 10.1007/s12671-012-0106-5; Center for Behavioral Health Statistics
and Quality, 2016, NSDUH SER H; Centers for Disease Control and Prevention, 2014,
EXC DRINK COSTS US 2; Germer CK, 2013, J CLIN PSYCHOL, V69, P856, DOI
10.1002/jclp.22021; Green KM, 2012, ADDICT BEHAV, V37, P1240, DOI
10.1016/j.addbeh.2012.06.008; Kelly AC, 2015, PSYCHOL PSYCHOTHER-T, V88, P285, DOI
10.1111/papt.12044; Kelly AC, 2010, J SOC CLIN PSYCHOL, V29, P727, DOI
10.1521/jscp.2010.29.7.727; KHANTZIAN EJ, 1974, AM J PSYCHIAT, V131, P160, DOI
10.1176/ajp.131.2.160; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI
10.3109/10673229709030550; Miron LR, 2014, SELF IDENTITY, V13, P364, DOI
10.1080/15298868.2013.836131; National Institute on Drug Abuse (NIDA), 2011, TREATM
STAT; Neff K. D., 2014, MINDFULNESS SELF REG, P121, DOI 10.1007/978-1-4939-2263-
5_10; Neff KD, 2016, MINDFULNESS, V7, P264, DOI 10.1007/s12671-015-0479-3; Neff KD,
2003, SELF IDENTITY, V2, P223, DOI 10.1080/15298860390209035; Neff KD, 2013, J CLIN
PSYCHOL, V69, P28, DOI 10.1002/jclp.21923; Newcombe DAL, 2005, DRUG ALCOHOL REV,
V24, P217, DOI 10.1080/09595230500170266; Rudd RA, 2016, AM J TRANSPLANT, V16,
P1323, DOI 10.1111/ajt.13776; Schuling R, 2016, CONTEMP CLIN TRIALS, V50, P77, DOI
10.1016/j.cct.2016.07.014; Smith Joshua P, 2008, Psychiatr Times, V25, P19; Vettese
LC, 2011, INT J MENT HEALTH AD, V9, P480, DOI 10.1007/s11469-011-9340-7; Weiss NH,
2015, CURR OPIN PSYCHOL, V3, P22, DOI 10.1016/j.copsyc.2015.01.013; Yarnell LM,
2013, SELF IDENTITY, V12, P146, DOI 10.1080/15298868.2011.649545 27 3 3
0 12 ELSEVIER IRELAND LTD CLARE ELSEVIER HOUSE, BROOKVALE PLAZA,
EAST PARK SHANNON, CO, CLARE, 00000, IRELAND 0376-8716 1879-0046 DRUG
ALCOHOL DEPEN Drug Alcohol Depend. FEB 1 2018 183
78 81 10.1016/j.drugalcdep.2017.10.026 4
Substance Abuse; Psychiatry Substance Abuse; Psychiatry FV6XI
WOS:000424725000013 29241104 2019-09-25
J Blakey, SM; Love, H; Lindquist, L; Beckham, JC; Elbogen, EB
Blakey, Shannon M.; Love, Holly; Lindquist, Lisa; Beckham, Jean C.; Elbogen,
Eric B. Disentangling the Link Between Posttraumatic Stress
Disorder and Violent Behavior: Findings From a Nationally Representative Sample
JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY English
Article posttraumatic stress disorder;
violence; anger; alcohol PTSD SYMPTOM CLUSTERS; COMBAT VETERANS; PHYSICAL
AGGRESSION; COMORBIDITY SURVEY; MILITARY VETERANS; ALCOHOL-PROBLEMS; SUBSTANCE USE;
TRAIT ANGER; IRAQ; INDIVIDUALS Objective: Although research using combat
veteran samples has demonstrated an association between posttraumatic stress
disorder (PTSD) and violence toward others, there has been relatively little
research examining this relationship among individuals with no combat history.
Method: Data representative of the United States population collected from the two
wave National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) were
analyzed to determine the risk factors for violent behavior of individuals
reporting no history of active military combat (N = 33,215). Results: In chi(2)
analyses, participants meeting criteria for lifetime PTSD at Wave 1 reported higher
rates of violence between Waves 1 and 2 compared with participants without a
history of PTSD (7 vs. 3%). An increase in anger after trauma and use of alcohol to
cope with PTSD symptoms were stronger predictors of physically aggressive or
violent acts than a lifetime diagnosis of PTSD without anger. When controlling for
these and other covariates, PTSD alone no longer significantly predicted any
subtype of physical aggression or violence toward others. Conclusions: Results
suggest that although PTSD is related to violent behavior, specific sequelae of
trauma (specifically, increased anger and self-medicating with alcohol) are more
critical than diagnosis per se in predicting violent behavior in the general
population. Clinical implications and future research directions are discussed.
[Blakey, Shannon M.] Univ North Carolina Chapel Hill, Dept Psychol &
Neurosci, Campus Box 3270,Davie Hall, Chapel Hill, NC 27599 USA; [Love, Holly;
Lindquist, Lisa] Univ North Carolina Chapel Hill, Sch Med, Dept Psychiat, Chapel
Hill, NC USA; [Beckham, Jean C.; Elbogen, Eric B.] Duke Univ, Med Ctr, Dept
Psychiat, Durham, NC 27710 USA; [Beckham, Jean C.; Elbogen, Eric B.] Durham VA Med
Ctr, Durham, NC USA Blakey, SM (reprint author), Univ North Carolina Chapel
Hill, Dept Psychol & Neurosci, Campus Box 3270,Davie Hall, Chapel Hill, NC 27599
USA. sblakey@unc.edu Blakey, Shannon/0000-0002-9291-3688
American Psychiatric Association, 2013, DIAGN STAT MAN MENT; American
Psychiatric Association, 2000, DIAGN STAT MAN MENT; BANDURA A, 1978, J COMMUN, V28,
P12, DOI 10.1111/j.1460-2466.1978.tb01621.x; Beck R, 1998, COGNITIVE THER RES, V22,
P63, DOI 10.1023/A:1018763902991; Birkley EL, 2015, CLIN PSYCHOL REV, V37, P40, DOI
10.1016/j.cpr.2015.01.002; Bisby JA, 2010, BIOL PSYCHIAT, V68, P280, DOI
10.1016/j.biopsych.2010.01.010; Blakey SM, 2016, CLIN PSYCHOL REV, V49, P1, DOI
10.1016/j.cpr.2016.07.002; Blanco C, 2013, DRUG ALCOHOL DEPEN, V132, P630, DOI
10.1016/j.drugalcdep.2013.04.016; Carver CS, 2009, PSYCHOL BULL, V135, P183, DOI
10.1037/a0013965; Chemtob CM, 1997, J TRAUMA STRESS, V10, P17, DOI
10.1002/jts.2490100104; Chemtob CM, 1997, J CONSULT CLIN PSYCH, V65, P184, DOI
10.1037/0022-006X.65.1.184; Chinn S, 2000, STAT MED, V19, P3127, DOI 10.1002/1097-
0258(20001130)19:22<3127::AID-SIM784>3.0.CO;2-M; Corrigan PW, 2005, PSYCHIAT RES,
V136, P153, DOI 10.1016/j.psychres.2005.06.005; Deffenbacher J. L., 2006, ANGER
RELATED DISORD, P43; Dewey D, 2014, PSYCHOL REP, V115, P1, DOI
10.2466/16.02.PR0.115c11z7; DiGiuseppe R, 2003, CLIN PSYCHOL-SCI PR, V10, P70, DOI
10.1093/clipsy/10.1.70; Elbogen EB, 2016, CLIN PSYCHOL SCI, V4, P747, DOI
10.1177/2167702615619363; Elbogen EB, 2014, BRIT J PSYCHIAT, V204, P368, DOI
10.1192/bjp.bp.113.134627; Finkel EJ, 2014, ADV EXP SOC PSYCHOL, V49, P1, DOI
10.1016/B978-0-12-800052-6.00001-9; Flanagan JC, 2016, CURR PSYCHIAT REP, V18, DOI
10.1007/s11920-016-0709-y; Forbes D, 2003, J NERV MENT DIS, V191, P93, DOI
10.1097/01.NMD.0000051903.60517.98; Gable PA, 2015, J PERS SOC PSYCHOL, V109, P163,
DOI 10.1037/a0039226; Gallaway MS, 2012, AGGRESSIVE BEHAV, V38, P357, DOI
10.1002/ab.21436; Garfinkel SN, 2016, SOC COGN AFFECT NEUR, V11, P150, DOI
10.1093/scan/nsv099; Genovese T, 2017, COMPR PSYCHIAT, V73, P23, DOI
10.1016/j.comppsych.2016.10.008; Grant B, 2005, SOURCE ACCURACY STAT; Grant B. F.,
2001, ALCOHOL USE DISORDER; Grant B.F., 2003, SOURCE ACCURACY STAT; Grant BF, INTRO
NATL EPIDEMIOL; Hellmuth JC, 2012, J TRAUMA STRESS, V25, P527, DOI
10.1002/jts.21732; Jakupcak M, 2007, J TRAUMA STRESS, V20, P945, DOI
10.1002/jts.20258; Jakupcak Matthew, 2005, Violence Vict, V20, P589, DOI
10.1891/vivi.2005.20.5.589; Kaczkurkin AN, 2016, J TRAUMA STRESS, V29, P325, DOI
10.1002/jts.22116; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P617, DOI
10.1001/archpsyc.62.6.617; Khantzian E. J., 2003, PRIMARY PSYCHIAT, V10, p[47, 53];
Killeen TK, 2011, J DUAL DIAGN, V7, P194, DOI 10.1080/15504263.2011.620421; Kolla
NJ, 2017, J FORENSIC SCI, V62, P137, DOI 10.1111/1556-4029.13234; Kulka RA, 1990,
TRAUMA VIETNAM WAR G; Leeies M, 2010, DEPRESS ANXIETY, V27, P731, DOI
10.1002/da.20677; Levinson CA, 2011, EXP CLIN PSYCHOPHARM, V19, P64, DOI
10.1037/a0022113; Longabaugh R, 2005, ALCOHOL CLIN EXP RES, V29, P235, DOI
10.1097/01.ALC.0000153541.78005.1F; Lowenstein J, 2016, BORDER PERS DIS EMOT, V3,
DOI 10.1186/s40479-016-0046-0; MacManus D, 2013, LANCET, V381, P907, DOI
10.1016/S0140-6736(13)60354-2; Marshall AD, 2005, CLIN PSYCHOL REV, V25, P862, DOI
10.1016/j.cpr.2005.05.009; McHugh T, 2012, CLIN PSYCHOL REV, V32, P93, DOI
10.1016/j.cpr.2011.07.013; Miller MW, 2007, BEHAV THER, V38, P58, DOI
10.1016/j.beth.2006.04.003; Miller MW, 2004, J ABNORM PSYCHOL, V113, P636, DOI
10.1037/0021-843X.113.4.636; Mills KL, 2012, JAMA-J AM MED ASSOC, V308, P690, DOI
10.1001/jama.2012.9071; Monahan J, 1994, VIOLENCE MENTAL DISO; Monahan J, 2001,
RETHINKING RISK ASSE; Morland LA, 2010, J CLIN PSYCHIAT, V71, P855, DOI
10.4088/JCP.09m05604blu; National Institute on Alcohol Abuse and Alcoholism
(NIAAA), 2010, NIH PUBLICATION, V10-7677; Novaco RW, 2015, PSYCHOL TRAUMA-US, V7,
P485, DOI 10.1037/tra0000067; Owens G. P., 2008, J AGGRESS MALTREAT T, V17, P439,
DOI DOI 10.1080/10926770802473908; Pietrzak RH, 2011, J ANXIETY DISORD, V25, P456,
DOI 10.1016/j.janxdis.2010.11.010; Possemato K, 2015, PSYCHOL ADDICT BEHAV, V29,
P894, DOI 10.1037/adb0000129; Read JP, 2014, AM J ADDICTION, V23, P108, DOI
10.1111/j.1521-0391.2013.12075.x; Renshaw KD, 2012, MIL PSYCHOL, V24, P221, DOI
10.1080/08995605.2012.678197; Research Triangle Institute (RTI), 2008, SOFTW SURV
DAT AN SU; ROTHENBERG A, 1971, AM J PSYCHIAT, V128, P454, DOI
10.1176/ajp.128.4.454; Steadman HJ, 1998, ARCH GEN PSYCHIAT, V55, P393, DOI
10.1001/archpsyc.55.5.393; Stewart SH, 1996, PSYCHOL BULL, V120, P83, DOI
10.1037/0033-2909.120.1.83; Strom T, 2013, J TRAUMA STRESS, V26, P405, DOI
10.1002/jts.21808; Swanson JW, 2006, ARCH GEN PSYCHIAT, V63, P490, DOI
10.1001/archpsyc.63.5.490; Tabachnick B. G., 2007, USING MULTIVARIATE S; Taft CT,
2007, J ABNORM PSYCHOL, V116, P498, DOI 10.1037/0021-843X.116.3.498; Taft CT, 2016,
J CLIN PSYCHIAT, V77, P1168, DOI 10.4088/JCP.15m10020; Thomas JL, 2010, ARCH GEN
PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; Whiting D., 2007, CLIN
PSYCHOL, V11, P33, DOI DOI 10.1080/13284200601178136; WIDOM CS, 1989, SCIENCE,
V244, P160, DOI 10.1126/science.2704995; Wilk JE, 2015, AGGRESSIVE BEHAV, V41,
P556, DOI 10.1002/ab.21595 71 3 3 0 7 AMER PSYCHOLOGICAL ASSOC
WASHINGTON 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA 0022-006X 1939-
2117 J CONSULT CLIN PSYCH J. Consult. Clin. Psychol. FEB 2018 86
2 169 178 10.1037/ccp0000253
10 Psychology, Clinical Psychology FT9IR WOS:000423466200006
29172589 2019-09-25
J Smith, NDL; Cottler, LB Smith, Nathan D. L.; Cottler, Linda
B. The Epidemiology of Post-Traumatic Stress Disorder and Alcohol
Use Disorder ALCOHOL RESEARCH-CURRENT REVIEWS English
Article alcohol use disorder; epidemiology;
NESARC; post-traumatic stress disorder; veterans SUBSTANCE USE DISORDERS;
MENTAL-HEALTH; UNITED-STATES; PSYCHIATRIC-DISORDERS; GENERAL-POPULATION; TRAUMA
EXPOSURE; DRUG DISORDERS; WAR VETERANS; PTSD; ABUSE For more than 40 years,
research has shown that individuals with post-traumatic stress disorder (PTSD) use
alcohol and experience alcohol use disorder (AUD) to a greater degree than those
with no PTSD. AUD and PTSD have shown a durable comorbidity that has extended
through decades and through changes in disorder definitions. Some research shows
that veterans who have experienced PTSD have a high likelihood of developing AUD,
perhaps reflecting the self-medication hypothesis. Other research shows that people
with substance use disorder are likely to be exposed to traumatic situations and
develop PTSD. These two areas of research could represent two separate
relationships between PTSD and AUD. Finally, there is still no clear determination
of which cluster of PTSD symptoms is most closely associated with AUD. [Smith,
Nathan D. L.; Cottler, Linda B.] Univ Florida, Dept Epidemiol, Gainesville, FL
32611 USA Smith, NDL (reprint author), Univ Florida, Dept Epidemiol, Gainesville,
FL 32611 USA. National Institute on Drug AbuseUnited States
Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
National Institute on Drug Abuse (NIDA) [DA035167]; University of Florida Substance
Abuse Training Center in Public Health and National Center for Research Resources
[5KL2RR029888]; University of Florida Clinical and Translational Science Award
This article was supported by the National Institute on Drug Abuse grant
DA035167, University of Florida Substance Abuse Training Center in Public Health
and National Center for Research Resources grant 5KL2RR029888, and the University
of Florida Clinical and Translational Science Award. Alonso J, 2004, ACTA PSYCHIAT
SCAND, V109, P28; American Psychiatric Association, 2013, DIAGN STAT MAN MENT;
American Psychiatric Association, 1987, DIAGN STAT MAN MENT; American Psychiatric
Association, 1980, DIAGN STAT MAN MENT; American Psychiatric Association, 1952,
DIAGN STAT MAN MENT; American Psychiatric Association, 1968, DIAGN STAT MAN MENT;
American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Anthony James C.,
1994, Experimental and Clinical Psychopharmacology, V2, P244, DOI 10.1037/1064-
1297.2.3.244; Back SE, 2006, J NERV MENT DIS, V194, P690, DOI
10.1097/01.nmd.0000235794.12794.8a; Breslau N, 2003, ARCH GEN PSYCHIAT, V60, P289,
DOI 10.1001/archpsyc.60.3.289; Burri Andrea, 2014, BMC Res Notes, V7, P407, DOI
10.1186/1756-0500-7-407; Chen CM, 2016, ALCOHOL USE ALCOHOL; Chilcoat HD, 1998,
ARCH GEN PSYCHIAT, V55, P913, DOI 10.1001/archpsyc.55.10.913; Coffey SF, 2002, DRUG
ALCOHOL DEPEN, V65, P115, DOI 10.1016/S0376-8716(01)00157-0; Cottler LB, 2001,
COMPR PSYCHIAT, V42, P111, DOI 10.1053/comp.2001.21219; COTTLER LB, 1992, AM J
PSYCHIAT, V149, P664; Goldstein RB, 2016, SOC PSYCH PSYCH EPID, V51, P1137, DOI
10.1007/s00127-016-1208-5; Goldstein RB, 2012, J STUD ALCOHOL DRUGS, V73, P938, DOI
10.15288/jsad.2012.73.938; Grant B., 2014, SOURCE ACCURACY STAT; Grant BF, 2015,
JAMA PSYCHIAT, V72, P757, DOI 10.1001/jamapsychiatry.2015.0584; Grob GN, 1987,
MENTAL ILLNESS AM SO; HELZER JE, 1988, J STUD ALCOHOL, V49, P219, DOI
10.15288/jsa.1988.49.219; HELZER JE, 1987, NEW ENGL J MED, V317, P1630, DOI
10.1056/NEJM198712243172604; Hooper R, 2008, ADDICT BEHAV, V33, P1067, DOI
10.1016/j.addbeh.2008.03.010; Jakupcak M, 2010, ADDICT BEHAV, V35, P840, DOI
10.1016/j.addbeh.2010.03.023; Johnson SD, 2003, DRUG ALCOHOL DEPEN, V70, P169, DOI
10.1016/S0376871602003459; Johnson SD, 2006, ADDICT BEHAV, V31, P2063, DOI
10.1016/j.addbeh.2006.02.007; Jones E, 2011, INT REV PSYCHIATR, V23, P166, DOI
10.3109/09540261.2010.550868; Kendler KS, 2000, ARCH GEN PSYCHIAT, V57, P953, DOI
10.1001/archpsyc.57.10.953; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI
10.1001/archpsyc.1995.03950240066012; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142,
P1259; King DW, 1998, PSYCHOL ASSESSMENT, V10, P90, DOI 10.1037/1040-3590.10.2.90;
Maguen S, 2009, MIL MED, V174, P779, DOI 10.7205/MILMED-D-03-2808; MCFALL ME, 1992,
J STUD ALCOHOL, V53, P357, DOI 10.15288/jsa.1992.53.357; MCFARLANE AC, 1992, J NERV
MENT DIS, V180, P498, DOI 10.1097/00005053-199208000-00004; McFarlane AC, 1998,
ADDICT BEHAV, V23, P813, DOI 10.1016/S0306-4603(98)00098-7; Mills KL, 2006, AM J
PSYCHIAT, V163, P652, DOI 10.1176/appi.ajp.163.4.652; Najavits LM, 1997, AM J
ADDICTION, V6, P273; North CS, 1999, JAMA-J AM MED ASSOC, V282, P755, DOI
10.1001/jama.282.8.755; NORTH CS, 1994, AM J PSYCHIAT, V151, P82; Pietrzak RH,
2011, J ANXIETY DISORD, V25, P456, DOI 10.1016/j.janxdis.2010.11.010; REGIER DA,
1988, ARCH GEN PSYCHIAT, V45, P977; REGIER DA, 1978, ARCH GEN PSYCHIAT, V35, P685;
REGIER DA, 1984, ARCH GEN PSYCHIAT, V41, P934; ROBINS LN, 1981, ARCH GEN PSYCHIAT,
V38, P381; Shipherd JC, 2005, ADDICT BEHAV, V30, P595, DOI
10.1016/j.addbeh.2004.07.004; Stappenbeck CA, 2014, PSYCHOL TRAUMA-US, V6, P65, DOI
10.1037/a0031468; Triffleman E, 1995, NIDA RES MONOGR, V153, P345; WIDOM CS, 1995,
J STUD ALCOHOL, V56, P207, DOI 10.15288/jsa.1995.56.207 49 0 0 0
0 NATL INST ALCOHOL ABUSE ALCOHOLISM ROCKVILLE 6000 EXECUTIVE BLVD,
ROCKVILLE, MD 20892-7003 USA 1535-7414 1930-0573 ALCOHOL RES-CURR REV
Alcohol Res.-Curr. Rev. 2018 39 2 113
120 8 Substance Abuse Substance Abuse IA2RX
WOS:000469410300002 31198651 2019-09-25
J Zapata, ALF Fajardo Zapata, Alvaro Luis
Consumption of psychopharmaceuticals in the city of Bogota (Colombia): a new
reality ARCHIVOS DE MEDICINA Spanish Article
mental health; depression; anxiety; psychotropic drugs; sleep;
self medication ALCOHOL Objective: to estimate the consumption and self-
medication of psychotropic drugs in the city of Bogota and to characterize the
consumer population. A psychotropic drug is any substance that is used in: the
diagnosis, treatment, mitigation, modification or prevention of a disease, an
abnormal physical or mental state or their symptoms in humans. Materials and
methods: a descriptive cross-sectional study realized in the city of Bogota, D.C
(Colombia), through a survey applied to the study participants. Results: this study
showed that 26% of the participants reported consuming or having consumed
psychotropic drugs and the majority reported their consumption for sleep-related
disorders followed by anxiety and depression;. ere was an association between the
age groups and the consumption of psychotropic drugs (Chi2 = 14.3955 p = 0.0061).
The participants did not report self-medication. Conclusions: the consumption of
psychotropic drugs has been increasing due to the increase of diseases of the
mental sphere, as well as those related to sleep disorders.[Fajardo Zapata, Alvaro
Luis] Fdn Univ Area Andina, Bogota, Colombia Zapata, ALF (reprint author), Fdn
Univ Area Andina, Bogota, Colombia. afajardo@areandina.edu.co
Castillo BAA, 2008, REV LAT-AM ENFERM, V16, P509, DOI 10.1590/S0104-
11692008000700002; Antich S, 2006, PHERM CARE ESP, V8, P57; Bruntun L., 2012, BASES
FARMACOLOGICAS; Calderon-Vallejo GA, 2015, REV VIRTUAL U CATOLI, V44, P153; Cardeno
C, 2010, CUADERNOS PSIQUIATRI, V46, P4; Carrera-Lasfuentes P, 2013, ATEN PRIM, V45,
P528, DOI 10.1016/j.aprim.2013.05.006; Comision Europea, 2008, DOC CONS SAL MENT
PE; de Lima MS, 2003, SUBST USE MISUSE, V38, P51, DOI 10.1081/JA-120016565;
Dusetzina SB, 2013, PSYCHIAT SERV, V64, P83, DOI 10.1176/appi.ps.201200002;
European Comission, 2010, EUR 73 2 MENTALHEALT; Fajardo-Zapata Alvaro L., 2013,
Salud, Barranquilla, V29, P226; Fletscher P., 2012, THESIS; Gobierno de Espana.
Ministerio de Sanidad Consumo y Bienestar Social, 2018, ENC NAC SAL ESP 2017;
Instituto Nacional de la Salud Mental, 2009, TRAST ANS; Khan A, 2003, AM J
PSYCHIAT, V160, P790, DOI 10.1176/appi.ajp.160.4.790; Leiderman ES, 2006, VERTEX
REV ARG PSIQU, V17, P85; Hidalgo JLT, 2007, QUAL LIFE RES, V16, P279, DOI
10.1007/s11136-006-9125-9; Ministerio de salud y proteccion social de la Republica
de Colombia, 2017, B SAL MENT DEPR SUBD; Ministerio de salud y Proteccion social de
la Republica de Colombia y Colciencias, 2017, COL ENC NAC SAL MENT, VI; Ministerio
de Salud y Proteccion Social de la Republica de Colombia y Colciencias, 2016, ENC
NAC SAL BIEN ENV; Montero F., 2014, THESIS; Nazer LH, 2012, AM J HEALTH-SYST PH,
V69, P863, DOI 10.2146/ajhp110195; Organizacion Mundial de la salud OMS, 2016, SAL
MENT AD MAYOR 20; Organizacion Mundial de la salud OMS, 2016, INV TRAT DEPR ANS TI;
Paulose-Ram R, 2007, PHARMACOEPIDEM DR S, V16, P560, DOI 10.1002/pds.1367; Perez M,
2014, CUAD MED SOC, V54, P8; Rojas G, 2005, J MENTAL HLTH, V14, P407, DOI DOI
10.1080/09638230500195221 27 0 0 0 0 UNIV MANIZALEZ, FAC
MEDICINA MANIZALEZ CARRERA NO 9 NO 19-03 OFIC 146, MANIZALEZ, 00000, COLOMBIA
1657-320X 2339-3874 ARCH MED Arch. Med. 2018 18 2
10.30554/archmed.18.2.2743.2018
10 Medicine, General & Internal General & Internal Medicine HS8JV
WOS:000464116900013 DOAJ Gold 2019-09-25
B de Lint, W; Marmo, M DeLint, W; Marmo, M de Lint, Willem;
Marmo, Marinella DeLint, W; Marmo, M Victims of Crimes, Self-Medication
and Narratives of (In)Justice NARRATING INJUSTICE SURVIVAL: SELF-MEDICATION BY
VICTIMS OF CRIME Palgrave Studies in Victims and Victimology English
Article; Book Chapter POSTTRAUMATIC-
STRESS-DISORDER; SUBSTANCE USE DISORDERS; SEXUAL ASSAULT; SOCIAL SUPPORT; VIOLENCE
PREVENTION; POLY-VICTIMIZATION; PARTNER VIOLENCE; HUMAN-DIGNITY; ALCOHOL; IMPACT
Allen AB, 2010, SOC PERSONAL
PSYCHOL, V4, P107, DOI 10.1111/j.1751-9004.2009.00246.x; Andersen SL, 2008, J
NEUROPSYCH CLIN N, V20, P292, DOI 10.1176/appi.neuropsych.20.3.292; Ashcroft RE,
2005, J MED ETHICS, V31, P679, DOI 10.1136/jme.2004.011130; Australian Human Rights
Commission, 2018, VICT; Australian Institute of Criminology (AIC), 2006, DRUG US
CRIM; Bal M., 1999, ACTS MEMORY CULTURAL; Barnes R, 2013, PARTN ABUSE, V4, P380,
DOI 10.1891/1946-6560.4.3.380; Bennett T, 2009, BRIT J CRIMINOL, V49, P513, DOI
10.1093/bjc/azp014; Beyleveld D, 2001, HUMAN DIGNITY BIOETH; Budde S, 2004, J
INTERPERS VIOLENCE, V19, P341, DOI 10.1177/0886260503261157; Campbell R, 2001, J
INTERPERS VIOLENCE, V16, P1239, DOI 10.1177/088626001016012002; Choy O, 2017,
CRIMINOLOGY, V55, P465, DOI 10.1111/1745-9125.12138; Clark H, 2010, FAMILY MATTERS,
P28; Conroy SA, 2014, ACAD MANAGE REV, V39, P67, DOI 10.5465/amr.2011.0396;
CRUIKSHANK B, 1993, ECON SOC, V22, P327, DOI 10.1080/03085149300000022; Daly K,
2006, BRIT J CRIMINOL, V46, P334, DOI 10.1093/bjc/azi071; Daly K, 2006, THEOR
CRIMINOL, V10, P9, DOI 10.1177/1362480606059980; Daly K, 2010, CRIME JUSTICE, V39,
P565, DOI 10.1086/653101; de Lint W, 2017, INT REV VICT, V23, P159, DOI
10.1177/0269758016686280; de Lint W, 2013, CRIT CRIMINOL-NETH, V21, P157, DOI
10.1007/s10612-013-9179-2; Dingwall G., 2005, ALCOHOL AND CRIME; Dore G, 2012, DRUG
ALCOHOL REV, V31, P294, DOI 10.1111/j.1465-3362.2011.00314.x; Durkheim Emile, 1982,
RULES SOCIOLOGICAL M, p[85, 85]; Eck J. E, 2001, PROCESS STRUCTURE CR, P249;
Ellison L, 2009, BRIT J CRIMINOL, V49, P202, DOI 10.1093/bjc/azn077; Farrell G.,
1995, CRIME JUSTICE, P469, DOI DOI 10.1086/449236; Farrell G., 2001, CRIME
PREVENTION STU, V12, P241; Farrell G., 1993, 46 POL RES GROUP CRI; Finkelhor D.,
2011, POLYVICTIMIZATION CH, P1; Finkelhor D, 2007, CHILD ABUSE NEGLECT, V31, P7,
DOI 10.1016/j.chiabu.2006.06.008; Flynn A, 2010, AGGRESS VIOLENT BEH, V15, P239,
DOI 10.1016/j.avb.2010.01.002; Ford JD, 2010, J ADOLESCENT HEALTH, V46, P545, DOI
10.1016/j.jadohealth.2009.11.212; FRIEZE IH, 1987, PROF PSYCHOL-RES PR, V18, P299,
DOI 10.1037/0735-7028.18.4.299; Gatowski SI, 1996, FEM LEGAL STUD, V4, P159, DOI
DOI 10.1007/BF02167608; GIDDENS A, 1986, SOC RES, V53, P529; Giddens A, 1991,
MODERNITY SELF IDENT; Glaser D, 2000, J CHILD PSYCHOL PSYC, V41, P97, DOI
10.1111/1469-7610.00551; GOLDSTEIN PJ, 1985, J DRUG ISSUES, V15, P493, DOI
10.1177/002204268501500406; Gray E., 2008, FEAR CRIME PUNITIVIT, V3; Grayson CE,
2005, J TRAUMA STRESS, V18, P137, DOI 10.1002/jts.20021; Guggisberg M., 2012, INT J
ARTS SCI, V5, P723; Guggisberg M., 2010, THESIS U W AUSTR; Guma M., 2004, SEXUAL
ABUSE YOUNG C, P95; Hindelang M. J., 1978, VICTIMS PERSONAL CRI; Holling C.S.,
1973, Annual Rev Ecol Syst, V4, P1, DOI 10.1146/annurev.es.04.110173.000245;
HORVATH P, 1993, PERS INDIV DIFFER, V14, P41, DOI 10.1016/0191-8869(93)90173-Z;
Isin Engin F., 2004, CITIZENSHIP STUD, V8, P217, DOI DOI
10.1080/1362102042000256970; Jacobsen LK, 2001, AM J PSYCHIAT, V158, P1184, DOI
10.1176/appi.ajp.158.8.1184; Jirek SL, 2017, QUAL SOC WORK, V16, P166, DOI
10.1177/1473325016656046; Jordan J., 2013, SEXUAL ABUSE AUSTR N, V5, P48; Kass
Leon., 2002, LIFE LIBERTY DEFENSE; Kaysen D, 2007, ADDICT BEHAV, V32, P1272, DOI
10.1016/j.addbeh.2006.09.007; KELMAN HC, 1977, INT STUD QUART, V21, P529, DOI
10.2307/2600236; Khantzian E, 2009, HARVARD REV PSYCHIAT, V4, P231; Konradi A.,
2007, TAKING STAND RAPE SU; Kunst M, 2015, TRAUMA VIOLENCE ABUS, V16, P336, DOI
10.1177/1524838014555034; Laslett A. M., 2015, HIDDEN HARM ALCOHOLS; Latta RE,
2011, COUNS PSYCHOL, V39, P973, DOI 10.1177/0011000011398504; Lens KME, 2015, EUR J
CRIMINOL, V12, P17, DOI 10.1177/1477370814538778; Liang B, 2005, AM J COMMUN
PSYCHOL, V36, P71, DOI 10.1007/s10464-005-6233-6; Lievore D, 2005, NO LONGER SILENT
STU; Logan TK, 2002, REV GEN PSYCHOL, V6, P325, DOI 10.1037//1089-2680.6.4.325;
Lugton J, 1997, J ADV NURS, V25, P1184, DOI 10.1046/j.1365-2648.1997.19970251184.x;
LURIGIO AJ, 1987, CRIME DELINQUENCY, V33, P452, DOI 10.1177/0011128787033004003;
Luthar SS, 2000, CHILD DEV, V71, P543, DOI 10.1111/1467-8624.00164; Maercker A,
2004, J TRAUMA STRESS, V17, P345, DOI 10.1023/B:JOTS.0000038484.15488.3d; McGarry
R, 2015, VICTIMS TRAUMA TESTI; Menard S, 2000, JUSTICE Q, V17, P543, DOI
10.1080/07418820000094661; MITCHELL RE, 1980, COMMUNITY MENT HLT J, V16, P27, DOI
10.1007/BF00780665; Morrison B, 2011, VICTIMS CRIME RES DI, V4, P15; Murphy LM,
2011, VIOLENCE VICTIMS, V26, P593, DOI 10.1891/0886-6708.26.5.593; Murray CE, 2007,
J INTERPERS VIOLENCE, V22, P1250, DOI 10.1177/0886260507304293; Neff KD, 2003, SELF
IDENTITY, V2, P223, DOI 10.1080/15298860390209035; O'Malley P, 2010, ECON SOC, V39,
P488, DOI 10.1080/03085147.2010.510681; Ousey GC, 2008, J QUANT CRIMINOL, V24,
P307, DOI 10.1007/s10940-008-9046-6; Pemberton A., 2011, THERAPEUTIC JURISPRU,
P229; Reivich K., 2002, RESILIENCE FACTOR 7; Reivich KJ, 2011, AM PSYCHOL, V66,
P25, DOI 10.1037/a0021897; Resnick HS, 2007, ADDICT BEHAV, V32, P2032, DOI
10.1016/j.addbeh.2007.01.001; Sanders A, 2001, CRIM LAW REV, P447; SCHACHTER O,
1983, AM J INT LAW, V77, P848, DOI 10.2307/2202536; Schreck CJ, 2008, CRIMINOLOGY,
V46, P871, DOI 10.1111/j.1745-9125.2008.00127.x; Schuck AM, 2001, CHILD ABUSE
NEGLECT, V25, P1069, DOI 10.1016/S0145-2134(01)00257-5; SKOGAN WG, 1987, CRIME
DELINQUENCY, V33, P135, DOI 10.1177/0011128787033001008; Smith P, 2019, WOMEN CRIM
JUSTICE, V29, P14, DOI 10.1080/08974454.2017.1377673; South Australian Police
(SAPOL), 2010, ALC CRIM; Teicher MH, 2003, NEUROSCI BIOBEHAV R, V27, P33, DOI
10.1016/S0149-7634(03)00007-1; Temkin J, 2000, J LAW SOC, V27, P219, DOI
10.1111/1467-6478.00152; Tillyer MS, 2014, CRIM JUSTICE BEHAV, V41, P593, DOI
10.1177/0093854813509370; UEHARA E, 1990, AM J SOCIOL, V96, P521, DOI
10.1086/229571; Ullman SE, 2007, PSYCHOL WOMEN QUART, V31, P23, DOI 10.1111/j.1471-
6402.2007.00328.x; Ullman SE, 2003, AGGRESS VIOLENT BEH, V8, P471, DOI
10.1016/S1359-1789(03)00032-6; Walklate S., 2005, CRIMINOLOGY BASICS; Zehr H.,
2003, RESTORATIVE JUSTICE, P40 94 0 0 0 0 PALGRAVE
BASINGSTOKE HOUNDMILLS, BASINGSTOKE RG21 6XS, ENGLAND 978-3-319-
93494-5; 978-3-319-93493-8 PALGR STUD VICTIM 2018
1 26 10.1007/978-3-319-93494-5_1 10.1007/978-3-319-
93494-5 26 Criminology & Penology; Rehabilitation; Psychology, Social
Criminology & Penology; Rehabilitation; Psychology BL8DU
WOS:000456148200002 2019-09-25
J Fallah, G; Moudi, S; Hamidia, A; Bijani, A Fallah,
Golnaz; Moudi, Sussan; Hamidia, Angela; Bijani, Ali Stimulant use in
medical students and residents requires more careful attention CASPIAN JOURNAL OF
INTERNAL MEDICINE English Article
Stimulants; Medical students; Residents METHYLPHENIDATE USE; NONMEDICAL
USE; DRUGS; ADHD Background: Stimulant pharmaceuticals are abused among academic
students to elevate mood, improve studying, intellectual capacity, memory and
concentration, and increase wakefulness. This study was designed to evaluate the
current situation of stimulant use among medical students and residents of Babol
University of Medical Sciences. Methods: This cross-sectional study was conducted
among 560 medical students and clinical residents of Babol University of Medical
Sciences during the academic year 2014-2015. A self-administered questionnaire was
used for data collection. Results: Four hundred and forty-four (79.3%) students
filled out the questionnaires. 49 (11%) individuals reported amphetamine and
methylphenidate (ritalin) use. The mean age of the stimulant drug users was 24.6
+/- 4.8 years. The main initiator factor was to improve concentration (29 persons;
59.2%). There were significant statistical correlations between stimulant drugs
abuse and male gender, living in dormitor in residence and internship and past
medical history of psychiatric disorders (depression, attention deficit
hyperactivity disorder and substance abuse) (p<0.05). 16 (32%) students started the
drug use on their friends' advice; 15 (30%) due to self-medication and 12 (24%)
persons with physician's prescription. Conclusions: Because of significant
prevalence of stimulant use, regulatory governmental policies and also planning to
improve essential life skills, awareness about the side effects and complications
of these drugs, screening of at-risk college students and early identification of
the abusers are suggested. [Fallah, Golnaz] Babol Univ Med Sci, Student Res
Comm, Babol Sar, Iran; [Moudi, Sussan] Babol Univ Med Sci, Hlth Res Inst, Canc Res
Ctr, Babol Sar, Iran; [Moudi, Sussan; Hamidia, Angela] Babol Univ Med Sci, Dept
Psychiary, Babol Sar, Iran; [Hamidia, Angela] Babol Univ Med Sci, Hlth Res Inst,
Social Determinants Hlth Res Ctr, Babol Sar, Iran; [Bijani, Ali] Babol Univ Med
Sci, Hlth Res Inst, Noncommunicable Pediat Dis Res Ctr, Babol Sar, Iran Moudi,
S (reprint author), Babol Univ Med Sci, Dept Psychiury, Babol Sar, Iran.
sussan.moudi@gmail.com Bijani, Ali/B-1718-2017 Bijani, Ali/0000-0003-2233-
8726 Vice-Chancellory for Research and Technology of Babol University of Medical
Sciences The financial support of the Vice-Chancellory for Research and
Technology of Babol University of Medical Sciences, and the kind cooperation of
medical students and clinical residents in their participation in the study are
greatly appreciated. Beyer C, 2014, BMC MED ETHICS, V15, DOI 10.1186/1472-6939-
15-20; Czerniak SM, 2013, HARVARD REV PSYCHIAT, V21, P151, DOI
10.1097/HRP.0b013e318293749e; Fazel G, 2011, IRANIAN J TOXICOLOGY, V4, P377; Finger
G, 2013, REV ASSOC MED BRAS, V59, P285, DOI 10.1016/j.ramb.2012.10.007; Fond G,
2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003366; Franke AG, 2011,
PHARMACOPSYCHIATRY, V44, P60, DOI 10.1055/s-0030-1268417; Habibzadeh A, 2011, DRUG
DES DEV THER, V5, P71, DOI 10.2147/DDDT.S13818; Katsurra Y., 2013, ROYAL COLL SURG
IREL, V6, P74; Khademi L, 2013, IRANIAN J PSYCHIAT C, V19, P20; LAPORTE JR, 1977,
EUR J CLIN PHARMACOL, V11, P449, DOI 10.1007/BF00562937; McCabe SE, 2007, J
ADOLESCENT HEALTH, V40, P76, DOI 10.1016/j.jadohealth.2006.07.016; Outram SM, 2010,
J MED ETHICS, V36, P198, DOI 10.1136/jme.2009.034421; Parrott AC, 2015, HUM
PSYCHOPHARM CLIN, V30, P213, DOI 10.1002/hup.2468; Repantis D, 2010, PHARMACOL RES,
V62, P187, DOI 10.1016/j.phrs.2010.04.002; Rubia K, 2014, BIOL PSYCHIAT, V76, P616,
DOI 10.1016/j.biopsych.2013.10.016; Simons-Morton BG, 2010, J PRIM PREV, V31, P191,
DOI 10.1007/s10935-010-0220-x; Spencer TJ, 2013, J CLIN PSYCHIAT, V74, P902, DOI
10.4088/JCP.12r08287; Taremian F, 2014, RES ADDICTION, V7, P9; Valipour M, 2009, J
LORESTAN U MED SCI, V15, P63; Wasserman JA, 2014, J AM OSTEOPATH ASSOC, V114, P643,
DOI 10.7556/jaoa.2014.129; Ziaee V., 2007, Journal of Pharmacology and Toxicology,
V2, P98 21 4 4 1 8 BABOL UNIV MEDICAL SCIENCES BABOL
ENGLISH JOURNAL OFFICE, GANJ AFROOZ AVE, BABOL, 00000, IRAN2008-6164 2008-
6172 CASP J INTERN MED Casp. J. Intern. Med. 2018 9 1
87 91 10.22088/cjim.9.1.87 5
Medicine, General & Internal General & Internal Medicine GE1YX
WOS:000431013800014 29387325 DOAJ Gold 2019-09-25
J Hogarth, L; Hardy, L Hogarth, Lee; Hardy, Lorna
Depressive statements prime goal-directed alcohol-seeking in individuals who
report drinking to cope with negative affect PSYCHOPHARMACOLOGY
English Article Incentive learning;
Goal-directed learning; Habit; Drug-seeking; Negative mood; Depression; Allostasis;
Negative reinforcement; Alcohol SUBSTANCE USE DISORDERS; POSTTRAUMATIC-STRESS-
DISORDER; NATIONAL EPIDEMIOLOGIC SURVEY; INCREASES ATTENTIONAL BIAS; COLLEGE-
STUDENTS; MOTIVES MEDIATE; SELF-MEDICATION; DRUG-SEEKING; COPING MOTIVES; MOOD
INDUCTION Most variants of negative reinforcement theory predict that acute
depressed mood can promote alcohol-seeking behaviour, but the precise mechanisms
underpinning this effect remain contested. One possibility is that mood-induced
alcohol-seeking is due to the formation of a stimulus-response (S-R) association,
enabling depressed mood to elicit alcohol-seeking automatically. A second
possibility is that depressed mood undergoes incentive learning, enabling it to
enhance the expected value of alcohol and thus promote goal-directed alcohol-
seeking. These two explanations were distinguished using a human outcome-
revaluation procedure. One hundred and twenty-eight alcohol drinkers completed
questionnaires of alcohol use disorder, drinking to cope with negative affect and
depression symptoms. Participants then learned that two responses earned alcohol
and food points respectively (baseline) in two alternative forced choice trials. At
test, participants rated the valence of randomly sampled negative and positive mood
statements and, after each statement, chose between the alcohol- and food-seeking
responses in extinction. The percentage of alcohol- versus food-seeking responses
was increased significantly in trials containing negative statements compared to
baseline and positive statement trials, in individuals who reported drinking to
cope with negative affect (p = .004), but there was no such interaction with
indices of alcohol use disorder (p = .87) or depression symptoms (p = .58).
Individuals who drink to cope with negative affect are more sensitive to the
motivational impact of acute depressed mood statements priming goal-directed
alcohol-seeking. Negative copers' vulnerability to alcohol dependence may be better
explained by excessive affective incentive learning than by S-R habit formation.
[Hogarth, Lee; Hardy, Lorna] Univ Exeter, Sch Psychol, Washington Singer
Bldg,Perry Rd, Exeter EX4 4QG, Devon, England Hogarth, L (reprint author), Univ
Exeter, Sch Psychol, Washington Singer Bldg,Perry Rd, Exeter EX4 4QG, Devon,
England. l.hogarth@exeter.ac.uk Hogarth, Lee/J-7823-2019 Hogarth, Lee/0000-
0002-0299-5748 ESRCEconomic & Social Research Council (ESRC); Alcohol Research
UK The work was supported by the ESRC and Alcohol Research UK.Anker JJ, 2016,
DRUG ALCOHOL DEPEN, V159, P93, DOI 10.1016/j.drugalcdep.2015.11.031; Armeli S,
2010, PSYCHOL ADDICT BEHAV, V24, P38, DOI 10.1037/a0017530; Asberg K, 2012, SUBST
USE MISUSE, V47, P799, DOI 10.3109/10826084.2012.669446; Austin JL, 2008, ADDICT
BEHAV, V33, P1572, DOI 10.1016/j.addbeh.2008.07.016; Babor TF, 2001, AUDIT ALCOHOL
USE DI, V41, P624; Back SE, 2010, DRUG ALCOHOL DEPEN, V106, P21, DOI
10.1016/j.drugalcdep.2009.07.016; Baker TB, 2004, PSYCHOL REV, V111, P33, DOI
10.1037/0033-295X.111.1.33; Banes KE, 2014, DRUG ALCOHOL DEPEN, V139, P41, DOI
10.1016/j.drugalcdep.2014.02.706; Beck AT, 1996, J PERS ASSESS, V67, P588, DOI
10.1207/s15327752jpa6703_13; Beseler CL, 2008, ALCOHOL CLIN EXP RES, V32, P607, DOI
10.1111/j.1530-0277.2008.00619.x; Birch CD, 2004, PSYCHOL ADDICT BEHAV, V18, P231,
DOI 10.1037/0893-164X.18.3.231; Blevins CE, 2016, ADDICT BEHAV, V58, P68, DOI
10.1016/j.addbeh.2016.02.024; Bolton JM, 2009, J AFFECT DISORDERS, V115, P367, DOI
10.1016/j.jad.2008.10.003; Bradizza CM, 2017, NICOTINE TOB RES, V19, P578, DOI
10.1093/ntr/ntw398; Bravo AJ, 2016, J STUD ALCOHOL DRUGS, V77, P661, DOI
10.15288/jsad.2016.77.661; BROWN SA, 1990, J ABNORM PSYCHOL, V99, P344, DOI
10.1037/0021-843X.99.4.344; CHANEY EF, 1978, J CONSULT CLIN PSYCH, V46, P1092, DOI
10.1037/0022-006X.46.5.1092; Conrod PJ, 2013, JAMA PSYCHIAT, V70, P334, DOI
10.1001/jamapsychiatry.2013.651; Cooney NL, 1997, J ABNORM PSYCHOL, V106, P243, DOI
10.1037/0021-843X.106.2.243; COOPER ML, 1995, J PERS SOC PSYCHOL, V69, P990, DOI
10.1037/0022-3514.69.5.990; Corbit LH, 2012, BIOL PSYCHIAT, V72, P389, DOI
10.1016/j.biopsych.2012.02.024; COX WM, 1988, J ABNORM PSYCHOL, V97, P168, DOI
10.1037/0021-843X.97.2.168; Crum RM, 2013, JAMA PSYCHIAT, V70, P718, DOI
10.1001/jamapsychiatry.2013.1098; Crum RM, 2013, DEPRESS ANXIETY, V30, P174, DOI
10.1002/da.22024; Dickinson A, 2002, Q J EXP PSYCHOL-B, V55, P331, DOI
10.1080/0272499024400016; Dickinson A, 2010, PLEASURES BRAIN, P74; Dvorak RD, 2014,
EXP CLIN PSYCHOPHARM, V22, P285, DOI 10.1037/a0037157; Eissenberg T, 2004,
ADDICTION, V99, P5, DOI 10.1111/j.1360-0443.2004.00735.x; Everitt BJ, 2016, ANNU
REV PSYCHOL, V67, P23, DOI 10.1146/annurev-psych-122414-033457; Fernandez AC, 2010,
PSYCHOL ADDICT BEHAV, V24, P608, DOI 10.1037/a0021742; Field M, 2007, ALCOHOL
ALCOHOLISM, V42, P560, DOI 10.1093/alcalc/agm064; Field M, 2009, EXP CLIN
PSYCHOPHARM, V17, P312, DOI 10.1037/a0017090; Fossos N, 2011, ADDICT BEHAV, V36,
P1001, DOI 10.1016/j.addbeh.2011.06.001; Fucito LM, 2009, PSYCHOL ADDICT BEHAV,
V23, P546, DOI 10.1037/a0016529; Gladwin TE, 2015, ALCOHOL CLIN EXP RES, V39, P101,
DOI 10.1111/acer.12602; Gonzalez VM, 2011, EXP CLIN PSYCHOPHARM, V19, P303, DOI
10.1037/a0022720; Gonzalez VM, 2009, PSYCHOL ADDICT BEHAV, V23, P443, DOI
10.1037/a0015543; Grant VV, 2007, ADDICT BEHAV, V32, P2226, DOI
10.1016/j.addbeh.2007.02.012; Grant VV, 2009, PSYCHOL ADDICT BEHAV, V23, P226, DOI
10.1037/a0015006; Grayson CE, 2005, J TRAUMA STRESS, V18, P137, DOI
10.1002/jts.20021; Hall FS, 2015, NEUROSCI BIOBEHAV R, V58, P168, DOI
10.1016/j.neubiorev.2015.06.004; Hardy L, 2017, PSYCHOPHARMACOLOGY, V234, P1977,
DOI 10.1007/s00213-017-4605-x; Heilig M, 2010, ADDICT BIOL, V15, P169, DOI
10.1111/j.1369-1600.2009.00194.x; Higley AE, 2011, PSYCHOPHARMACOLOGY, V218, P121,
DOI 10.1007/s00213-011-2355-8; HODGINS DC, 1995, J CONSULT CLIN PSYCH, V63, P400,
DOI 10.1037/0022-006X.63.3.400; Hogarth L, 2017, DRUG ALCOHOL DEPEN, V176, P1, DOI
10.1016/j.drugalcdep.2017.02.009; Hogarth L, 2015, PSYCHOPHARMACOLOGY, V232, P3235,
DOI 10.1007/s00213-015-3977-z; Hogarth L, 2013, ADDICT BIOL, V18, P88, DOI
10.1111/adb.12009; Hogarth L, 2012, J EXP PSYCHOL ANIM B, V38, P266, DOI
10.1037/a0028914; Hogarth L, 2011, J EXP PSYCHOL ANIM B, V37, P261, DOI
10.1037/a0022913; Holahan CJ, 2001, J STUD ALCOHOL, V62, P190, DOI
10.15288/jsa.2001.62.190; Holahan CJ, 2004, J CONSULT CLIN PSYCH, V72, P269, DOI
10.1037/0022-006X.72.2.269; HORE BD, 1971, BRIT J ADDICT, V66, P83; Hutcheson DM,
2001, NAT NEUROSCI, V4, P943, DOI 10.1038/nn0901-943; JONES SL, 1982, ADDICT BEHAV,
V7, P285, DOI 10.1016/0306-4603(82)90057-0; Kassel JD, 2003, PSYCHOL BULL, V129,
P270, DOI 10.1037/0033-2909.129.2.270; Kaysen D, 2007, ADDICT BEHAV, V32, P1272,
DOI 10.1016/j.addbeh.2006.09.007; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4,
P231, DOI 10.3109/10673229709030550; Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35,
P1051, DOI 10.1038/npp.2010.4; Kushner MG, 2013, J CONSULT CLIN PSYCH, V81, P429,
DOI 10.1037/a0031301; Lazareck S, 2012, J CLIN PSYCHIAT, V73, pE588, DOI
10.4088/JCP.11m07345; Littlefield AK, 2010, J ABNORM PSYCHOL, V119, P93, DOI
10.1037/a0017512; Marlatt GA, 1996, ADDICTION, V91, pS37, DOI 10.1111/j.1360-
0443.1996.tb02326.x; Marlatt GA, 1985, RELAPSE PREVENTION, P128; Mathew AR, 2017,
ADDICTION, V112, P401, DOI 10.1111/add.13604; McDevitt-Murphy ME, 2015, ADDICT RES
THEORY, V23, P148, DOI 10.3109/16066359.2014.949696; McGrath E, 2016, PSYCHOPHARM
IN PRESS; Menary KR, 2011, J ANXIETY DISORD, V25, P335, DOI
10.1016/j.janxdis.2010.10.006; Merrill JE, 2014, J STUD ALCOHOL DRUGS, V75, P93,
DOI 10.15288/jsad.2014.75.93; Merrill JE, 2013, ADDICT BEHAV, V38, P1672, DOI
10.1016/j.addbeh.2012.10.003; Miles FJ, 2003, BEHAV NEUROSCI, V117, P927, DOI
10.1037/0735-7044.117.5.927; MONTI PM, 1990, J STUD ALCOHOL, V51, P263, DOI
10.15288/jsa.1990.51.263; Monti PM, 1999, ALCOHOL RES HEALTH, V23, P107; Mooney JL,
2008, INT J OFFENDER THER, V52, P686, DOI 10.1177/0306624X07309754; Murphy C, 2012,
PSYCHOPHARMACOLOGY, V219, P527, DOI 10.1007/s00213-011-2573-0; O'Hare T, 2011,
ADDICT BEHAV, V36, P465, DOI 10.1016/j.addbeh.2011.01.006; Overup CS, 2015, ADDICT
BEHAV, V41, P152, DOI 10.1016/j.addbeh.2014.10.006; Owens MM, 2015, J EXP ANAL
BEHAV, V103, P77, DOI 10.1002/jeab.114; Pearson MR, 2015, MINDFULNESS, V6, P645,
DOI 10.1007/s12671-014-0300-8; PEIRCE RS, 1994, J HEALTH SOC BEHAV, V35, P291, DOI
10.2307/2137211; Pettinati HM, 2013, AM J PSYCHIAT, V170, P23, DOI
10.1176/appi.ajp.2012.12010112; Potthast N, 2015, ADDICT BEHAV, V48, P62, DOI
10.1016/j.addbeh.2015.05.004; Rafnsson FD, 2006, ANXIETY STRESS COPIN, V19, P241,
DOI 10.1080/10615800600679111; Reardon ML, 2002, ALCOHOL CLIN EXP RES, V26, P1188,
DOI 10.1097/01.ALC.0000023988.43694.FE; Robinson J, 2011, ARCH GEN PSYCHIAT, V68,
P800, DOI 10.1001/archgenpsychiatry.2011.75; Roos CR, 2015, PSYCHOL ADDICT BEHAV,
V29, P176, DOI 10.1037/a0038529; Rousseau GS, 2011, DRUG ALCOHOL DEPEN, V118, P1,
DOI 10.1016/j.drugalcdep.2011.02.010; Schuck AM, 2001, CHILD ABUSE NEGLECT, V25,
P1069, DOI 10.1016/S0145-2134(01)00257-5; Schuckit MA, 2006, DRUG ALCOHOL DEPEN,
V82, P194, DOI 10.1016/j.drugalcdep.2005.09.006; Schwabe L, 2011, EXP CLIN
PSYCHOPHARM, V19, P53, DOI 10.1037/a0022212; Shiffman S, 2005, J PERS, V73, P1715,
DOI 10.1111/j.1467-6494.2005.00364.x; Simpson TL, 2014, J ABNORM PSYCHOL, V123,
P237, DOI 10.1037/a0035193; Sinha R, 2001, PSYCHOPHARMACOLOGY, V158, P343, DOI
10.1007/s002130100917; Sinha R, 2009, NEUROPSYCHOPHARMACOL, V34, P1198, DOI
10.1038/npp.2008.78; Sinha R, 2011, ARCH GEN PSYCHIAT,
V68, P942, DOI 10.1001/archgenpsychiatry.2011.49; SOLOMON RL, 1973, J ABNORM
PSYCHOL, V81, P158, DOI 10.1037/h0034534; Stasiewicz PR, 2013, J SUBST ABUSE TREAT,
V45, P433, DOI 10.1016/j.jsat.2013.05.012; Stewart SH, 2001, PERS INDIV DIFFER,
V31, P157, DOI 10.1016/S0191-8869(00)00213-0; Thomas SE, 2014, J STUD ALCOHOL
DRUGS, V75, P115, DOI 10.15288/jsad.2014.75.115; Topper LR, 2011, ADDICT BEHAV,
V36, P6, DOI 10.1016/j.addbeh.2010.08.016; Tull MT, 2015, J ANXIETY DISORD, V29,
P52, DOI 10.1016/j.janxdis.2014.11.003; Turner NE, 1997, BEHAV RES THER, V35, P465,
DOI 10.1016/S0005-7967(96)00119-2; Ullman SE, 2005, J STUD ALCOHOL, V66, P610, DOI
10.15288/jsa.2005.66.610; VELTEN E, 1968, BEHAV RES THER, V6, P473, DOI
10.1016/0005-7967(68)90028-4; WATT M, 2006, J MENTAL HLTH, V15, P683, DOI DOI
10.1080/09638230600998938; Westermann R, 1996, EUR J SOC PSYCHOL, V26, P557, DOI
10.1002/(SICI)1099-0992(199607)26:4<557::AID-EJSP769>3.0.CO;2-4; Wikler A., 1984, J
SUBST ABUSE TREAT, V1, P279; Windle M, 2015, J STUD ALCOHOL DRUGS, V76, P465, DOI
10.15288/jsad.2015.76.465; Witkiewitz K, 2007, J ABNORM PSYCHOL, V116, P378, DOI
10.1037/0021-843X.116.2.378; Woud ML, 2015, J BEHAV THER EXP PSY, V47, P102, DOI
10.1016/j.jbtep.2014.11.012; Yeater EA, 2010, PSYCHOL TRAUMA-US, V2, P307, DOI
10.1037/a0021779; Young-Wolff KC, 2009, ALCOHOL CLIN EXP RES, V33, P1476, DOI
10.1111/j.1530-0277.2009.00978.x; Zack M, 2006, ADDICT BEHAV, V31, P169, DOI
10.1016/j.addbeh.2005.04.016; Zack M, 2003, EXP CLIN PSYCHOPHARM, V11, P176, DOI
10.1037/1064-1297.11.2.176; Zack M, 1999, J ABNORM PSYCHOL, V108, P518, DOI
10.1037/0021-843X.108.3.518; Zywiak WH, 1996, ADDICTION, V91, pS121, DOI
10.1111/j.1360-0443.1996.tb02332.x 116 6 6 2 11 SPRINGER NEW
YORK 233 SPRING ST, NEW YORK, NY 10013 USA 0033-3158 1432-2072
PSYCHOPHARMACOLOGY Psychopharmacology JAN 2018 235 1
269 279 10.1007/s00213-017-4765-8 11
Neurosciences; Pharmacology & Pharmacy; Psychiatry Neurosciences &
Neurology; Pharmacology & Pharmacy; Psychiatry FR5TS WOS:000419129700024
29082424 Green Published, Other Gold 2019-09-25
J Mbaba, M; Brown, SE; Wooditch, A; Kiss, M; Murphy, A; Kumari, S; Taxman, F;
Altice, F; Lawson, WB; Springer, SA Mbaba, Mary; Brown, Shan-
Estelle; Wooditch, Alese; Kiss, Marissa; Murphy, Amy; Kumari, Suneeta; Taxman,
Faye; Altice, Frederick; Lawson, William B.; Springer, Sandra A.
Prevalence, Diagnosis, and Treatment Rates of Mood Disorders among Opioid
Users under Criminal Justice Supervision SUBSTANCE USE & MISUSE
English Article Mood disorder; heroin;
opioid; buprenorphine; depression; bipolar; criminal justice; mental health
treatment NATIONAL EPIDEMIOLOGIC SURVEY; GENDER-DIFFERENCES; AFRICAN-AMERICANS;
SELF-MEDICATION; SUBSTANCE-ABUSE; PRISON-INMATES; PUBLIC-HEALTH; UNITED-STATES;
DRUG-ABUSE; DSM-IV Background: Individuals involved in the criminal justice
system have disproportionately high rates of psychiatric disorders when compared to
the general U.S. population. If left untreated, the likelihood of subsequent arrest
increases and risk for adverse health consequences is great, particularly among
opioid users. Objectives: To explore the prevalence, characteristics, and treatment
of mood disorders among justice involved opioid-dependent populations. Methods: The
current study enrolled 258 treatment-seeking opioid-dependent individuals under
community-based criminal justice supervision (e.g., probation, parole) screened
from the larger parent study, Project STRIDE, a seek/test/treat randomized control
trial (RCT) examining HIV and opioid use treatment. During baseline, individuals
were screened for depression using the Patient Health Questionnaire-9 (PHQ-9) and
screened for bipolar disorder using the Mood Disorder Questionnaire (MDQ) tool.
Results: Overall, 78 (30%) participants screened positive for moderate to severe
depression and 54 (21%) screened positive for bipolar disorder. Participants self-
reported mood disorders at higher rates than they screened positive for these
conditions. Participants screening positive for these conditions experienced
significantly greater family, legal, and medical problems on the Addiction Severity
Index-Lite (ASI-Lite) than those who did not screen positive. Incidence of a
lifetime suicide attempt was found to be associated with a positive screen for both
mood disorders. Prescribed psychotropic treatment utilization was similar among
those who screened positive for depression or bipolar disorder with approximately
38% reporting taking medication. Importance: Findings suggest universal mood
disorder screening to improve comprehensive psychiatric care and treatment of
opioid-dependent justice-involved individuals. [Mbaba, Mary] George Washington
Univ, Dept Psychol, 2125 G St NW, Washington, DC 20052 USA; [Brown, Shan-Estelle;
Altice, Frederick; Springer, Sandra A.] Yale Univ, Sch Med, Infect Dis Sect, AIDS
Program, New Haven, CT USA; [Wooditch, Alese] Temple Univ, Dept Criminal Justice,
Philadelphia, PA 19122 USA; [Kiss, Marissa; Murphy, Amy; Taxman, Faye] George Mason
Univ, Dept Criminol Law & Soc, Fairfax, VA 22030 USA; [Kumari, Suneeta] Howard
Univ, Coll Med & Hosp, Washington, DC 20059 USA; [Altice, Frederick] Yale Univ, Sch
Publ Hlth, Div Epidemiol Microbial Dis, New Haven, CT USA; [Lawson, William B.]
Univ Texas Austin, Dell Med Sch, Austin, TX 78712 USA Mbaba, M (reprint author),
George Washington Univ, Dept Psychol, 2125 G St NW, Washington, DC 20052 USA.
mmbaba@email.gwu.edu Altice, Frederick/0000-0002-7860-693X
National Institutes of HealthUnited States Department of Health & Human
ServicesNational Institutes of Health (NIH) - USA [NIDA R01 DA030768, NIDA K02
DA032322, NIDA K24 DA017072] Research reported in this publication was supported
by the National Institutes of Health under Award Numbers: NIDA R01 DA030768
(Altice, Lawson, Taxman, and Springer); NIDA K02 DA032322 (Springer); and NIDA K24
DA017072 (Altice). Acosta J., 2010, WR777DCDMH; Afifi TO, 2008, AM J PUBLIC
HEALTH, V98, P946, DOI 10.2105/AJPH.2007.120253; Altice FL, 2010, LANCET, V376,
P367, DOI 10.1016/S0140-6736(10)60829-X; American Psychiatric Association, 2015,
DIAGN STAT MAN MENT; Baillargeon J, 2000, PSYCHIATR SERV, V51, P1444, DOI
10.1176/appi.ps.51.11.1444; Baillargeon J, 2009, PSYCHIAT SERV, V60, P1516, DOI
10.1176/appi.ps.60.11.1516; Bennett T, 2008, AGGRESS VIOLENT BEH, V13, P107, DOI
10.1016/j.avb.2008.02.001; Binswanger IA, 2012, ADDICT SCI CLIN PRAC, V7, DOI
10.1186/1940-0640-7-3; Binswanger IA, 2010, AM J PUBLIC HEALTH, V100, P476, DOI
10.2105/AJPH.2008.149591; Bizzarri J, 2005, SUBST USE MISUSE, V40, P1765, DOI
10.1080/10826080500260800; Bolton JM, 2009, J AFFECT DISORDERS, V115, P367, DOI
10.1016/j.jad.2008.10.003; Chandler RK, 2009, JAMA-J AM MED ASSOC, V301, P183, DOI
10.1001/jama.2008.976; Conway KP, 2006, J CLIN PSYCHIAT, V67, P247, DOI
10.4088/JCP.v67n0211; Corruble E, 1999, J PSYCHIAT RES, V33, P457, DOI
10.1016/S0022-3956(99)00011-4; Di Paola Angela, 2014, Health Justice, V2, DOI
10.1186/s40352-014-0011-1; Eno Louden J., 2011, B CTR EVIDENCE BASED, V7, P1;
Gilbody S, 2007, J GEN INTERN MED, V22, P1596, DOI 10.1007/s11606-007-0333-y; Glaze
L. E., 2011, 236019 NCJ BUR JUST; Grella CE, 2009, ADDICT BEHAV, V34, P498, DOI
10.1016/j.addbeh.2009.01.002; Hansen H, 2014, SOC SCI MED, V103, P76, DOI
10.1016/j.socscimed.2013.06.033; Hartwell S., 2004, CRIMINAL JUSTICE POL, V15, P84,
DOI DOI 10.1177/0887403403255064; Hendrick V, 2000, J CLIN PSYCHIAT, V61, P393, DOI
10.4088/JCP.v61n0514; Hirschfeld RMA, 2000, AM J PSYCHIAT, V157, P1873, DOI
10.1176/appi.ajp.157.11.1873; Holden KB, 2012, J MENS HEALTH, V9, P63, DOI
10.1016/j.jomh.2012.03.002; HOSMER DW, 1980, COMMUN STAT A-THEOR, V9, P1043, DOI
10.1080/03610928008827941; James D. J., 2006, 213600 NCJ US DEP JU; Kessing LV,
2004, BIPOLAR DISORD, V6, P421, DOI 10.1111/j.1399-5618.2004.00135.x; KROENKE K,
2003, PSYCHIAT ANN, V32, P1; Kumari S, 2016, AM J ADDICTION, V25, P110, DOI
10.1111/ajad.12325; Lawson W. B., 2013, CRIME HIV HLTH INTER, P81; Lurigio A. J.,
2000, CRIMINAL JUSTICE 200, V3, P45; Mark TL, 2001, DRUG ALCOHOL DEPEN, V61, P195,
DOI 10.1016/S0376-8716(00)00162-9; Martins SS, 2011, DRUG ALCOHOL DEPEN, V119, P28,
DOI 10.1016/j.drugalcdep.2011.05.010; MCGLOTHLIN WH, 1977, AM J DRUG ALCOHOL AB,
V4, P179, DOI 10.3109/00952997709002759; MCLELLAN AT, 1980, J NERV MENT DIS, V168,
P26, DOI 10.1097/00005053-198001000-00006; Messina N, 2004, BEHAV SCI LAW, V22,
P503, DOI 10.1002/bsl.600; Miklowitz DJ, 2008, AM J PSYCHIAT, V165, P1408, DOI
10.1176/appi.ajp.2008.08040488; Nock MK, 2010, MOL PSYCHIATR, V15, P868, DOI
10.1038/mp.2009.29; Osher F, 2003, CRIME DELINQUENCY, V49, P79, DOI
10.1177/0011128702239237; Peters R. H., 2008, SCREENING ASSESSMENT; Peters R. H.,
1993, PROVIDING SERVICES O, P159; PRUSOFF BA, 1972, ARCH GEN PSYCHIAT, V26, P546;
Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi;
Sirdifield C, 2012, J MENT HEALTH, V21, P485, DOI 10.3109/09638237.2012.664305;
Springer SA, 2011, CLIN INFECT DIS, V53, P469, DOI 10.1093/cid/cir446; STEADMAN HJ,
1984, J CRIM LAW CRIM, V75, P474, DOI 10.2307/1143164; Substance Abuse and Mental
Health Services Administration, 2015, HHS PUBL, VSMA- 15- 4895; Taxman FS, 2007,
CRIM JUSTICE BEHAV, V34, P1216, DOI 10.1177/0093854807304431; Travis J., 2014, COMM
LAW JUST DIV BE; Vittinghoff E, 2005, STAT BIOL HEALTH, pVII; Wang PS, 2005, ARCH
GEN PSYCHIAT, V62, P629, DOI 10.1001/archpsyc.62.6.629; WEISS RD, 1992, AM J DRUG
ALCOHOL AB, V18, P121, DOI 10.3109/00952999208992825; Williams DR, 2007, ARCH GEN
PSYCHIAT, V64, P305, DOI 10.1001/archpsyc.64.3.305; Wooditch A, 2013, J DRUG
ISSUES, V43, P231, DOI 10.1177/0022042612470643 54 0 0 1 3 TAYLOR
& FRANCIS INC PHILADELPHIA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA
19106 USA 1082-6084 1532-2491 SUBST USE MISUSE Subst. Use Misuse
2018 53 9 1519 1528
10.1080/10826084.2017.1416400 10 Substance Abuse; Psychiatry;
Psychology Substance Abuse; Psychiatry; Psychology GM0FI WOS:000437723300014
29333954 2019-09-25
J Dangel, T; Webb, JR Dangel, Trever; Webb, Jon R.
Forgiveness and substance use problems among college students: Psychache,
depressive symptoms, and hopelessness as mediators JOURNAL OF SUBSTANCE USE
English Article Forgiveness;
substance use; psychache; college students SELF-MEDICATION HYPOTHESIS; SOCIAL
DESIRABILITY SCALE; ABUSE SCREENING-TEST; SUICIDAL-BEHAVIOR; ALCOHOL-PROBLEMS; USE
DISORDERS; MOOD; PREVALENCE; ADDICTION; PROMOTION Studies on forgiveness and
its relationship to substance abuse have consistently found salutary associations
between the two, yet empirical investigation of variables that may serve as
mediating factors in this relationship is in need of more attention. With recent
models positing psychological distress as a key component of the forgiveness-
substance abuse association, constructs such as psychache, depression, and
hopelessness may be likely candidates as mediators of this relationship. As such,
cross-sectional, self-report data from 577 undergraduate students was used to
perform multiple mediation analyses on the relationship of three dimensions of
forgiveness (i.e., of self, of others, of uncontrollable situations) with two
substance use outcomes (i.e., problematic alcohol use and problematic drug use), as
mediated by psychache, depressive symptoms, and hopelessness. Results indicated
that forgiveness of self and forgiveness of uncontrollable situations were
associated with lower levels of psychological distress and fewer substance use
problems, whereas forgiveness of others was associated with greater levels of
psychological distress and more substance use problems. Psychache and depressive
symptoms, but not hopelessness, played a role in the forgiveness-substance use
problems association. Implications of these findings are discussed, particularly in
the context of the self-medication hypothesis. [Dangel, Trever] East Tennessee
State Univ, Dept Psychol, Box 70649, Johnson City, TN 37614 USA; [Webb, Jon R.]
Texas Tech Univ, Dept Community Family & Addict Sci, Lubbock, TX 79409 USA
Dangel, T (reprint author), East Tennessee State Univ, Dept Psychol, Box
70649, Johnson City, TN 37614 USA. aurandtdange@etsu.edu
Alcoholics Anonymous, 1981, 12 STEPS 12 TRADITIO; [Anonymous], 1998, LIVING
SOBER; Babor T, 2001, AUDIT ALCOHOL USE DI; Barber L, 2005, PERS INDIV DIFFER, V39,
P253, DOI 10.1016/j.paid.2005.01.006; BECK AT, 1974, J CONSULT CLIN PSYCH, V42,
P861, DOI 10.1037/h0037562; Berlim MT, 2003, SUICIDE LIFE-THREAT, V33, P242, DOI
10.1521/suli.33.3.242.23220; Boduszek D, 2016, PSYCHOL ASSESSMENT, V28, P1325, DOI
10.1037/pas0000245; Connors GJ, 1996, PSYCHOL ADDICT BEHAV, V10, P90, DOI
10.1037/0893-164X.10.2.90; Davis T. A, 2014, MENTAL HLTH SUBSTANC, V7, P286, DOI
DOI 10.1080/17523281.2013.865663; Deasy C, 2015, HEALTH PROMOT INT, V30, P77, DOI
10.1093/heapro/dau086; DeLisle MM, 2009, MEAS EVAL COUNS DEV, V42, P46, DOI
10.1177/0748175609333562; Enright R. D., 1995, J PSYCHOL CHRISTIANI, V14, P38;
Enright Robert D., 2015, FORGIVENESS THERAPY; Flamenbaum R, 2007, J COUNS PSYCHOL,
V54, P51, DOI 10.1037/0022-0167.54.1.51; Grant BF, 2006, ALCOHOL RES HEALTH, V29,
P107; Hayes A.F., 2013, INTRO MEDIATION MODE; Hirsch JK, 2011, J CLIN PSYCHOL, V67,
P896, DOI 10.1002/jclp.20812; Holden RR, 2001, CAN J BEHAV SCI, V33, P224, DOI
10.1037/h0087144; Johnston L. D., 2017, MONITORING FUTURE NA; Khantzian EJ, 1997,
HARVARD REV PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550; Lavelock C., 2015,
FORGIVENESS HLTH SCI, P29; Lembke A, 2012, AM J DRUG ALCOHOL AB, V38, P524, DOI
10.3109/00952990.2012.694532; Lopez SJ, 2009, OXFORD HDB POSITIVE; Lovibond S. H.,
1995, MANUAL DEPRESSION AN; Maddock JE, 2001, ADDICT BEHAV, V26, P385, DOI
10.1016/S0306-4603(00)00116-7; Maremmani AGI, 2015, J AFFECT DISORDERS, V176, P164,
DOI 10.1016/j.jad.2015.01.059; McCabe SE, 2006, J SUBST ABUSE TREAT, V31, P297, DOI
10.1016/j.jsat.2006.04.010; Nsamenang SA, 2013, J AFFECT DISORDERS, V149, P282, DOI
10.1016/j.jad.2013.01.042; Patterson AA, 2012, SUICIDE LIFE-THREAT, V42, P147, DOI
10.1111/j.1943-278X.2011.00078.x; Pereira EJ, 2010, PERS INDIV DIFFER, V49, P912,
DOI 10.1016/j.paid.2010.07.029; REYNOLDS WM, 1982, J CLIN PSYCHOL, V38, P119, DOI
10.1002/1097-4679(198201)38:1<119::AID-JCLP2270380118>3.0.CO;2-I; Sacks J.J., 2015,
AM J PREV MED, V49, P73, DOI DOI 10.1016/J.AMEPRE.2015.05.031; Sansone RA, 2013,
MENT HEALTH RELIG CU, V16, P31, DOI 10.1080/13674676.2011.643860; Scherer M, 2011,
J ADDICT DIS, V30, P382, DOI 10.1080/10550887.2011.609804; Shneidman E. S., 1993,
SUICIDE PSYCHACHE CL; SKINNER HA, 1982, ADDICT BEHAV, V7, P363, DOI 10.1016/0306-
4603(82)90005-3; Thompson LY, 2005, J PERS, V73, P313, DOI 10.1111/j.1467-
6494.2005.00311.x; Toussaint L., 2015, FORGIVENESS HLTH SCI; Toussaint LL, 2008,
PERSONAL MENT HEALTH, V2, P89, DOI 10.1002/pmh.35; Toussaint LL, 2008, MENT HEALTH
RELIG CU, V11, P485, DOI 10.1080/13674670701564989; Troister T, 2015, PSYCHOL
ASSESSMENT, V27, P1500, DOI 10.1037/pas0000126; Troister T, 2013, SUICIDE LIFE-
THREAT, V43, P611, DOI 10.1111/sltb.12043; Troister T, 2012, J CLIN PSYCHOL, V68,
P1019, DOI 10.1002/jclp.21869; Troister T, 2010, PERS INDIV DIFFER, V49, P689, DOI
10.1016/j.paid.2010.06.006; Ventimiglia M, 2012, PERS INDIV DIFFER, V52, P487, DOI
10.1016/j.paid.2011.11.016; Webb J. R., 2017, HDB PSYCHOL SELF FOR, P265; Webb J.
R., POSITIVE PSYCHOL APP; Webb JR, 2018, ALCOHOL TREAT Q, V36, P15, DOI
10.1080/07347324.2017.1391057; Webb JR, 2015, SPIRITUAL CLIN PRACT, V2, P48, DOI
10.1037/scp0000054; Webb JR, 2011, ALCOHOL TREAT Q, V29, P245, DOI
10.1080/07347324.2011.585922; Webb JR, 2012, J HEALTH CARE CHAPL, V18, P57, DOI
10.1080/08854726.2012.667317; Woodyatt L., 2017, HDB PSYCHOL SELF FOR; Worthington
E. L., 2001, FAITH HLTH PSYCHOL P, P107; Yuodelis-Flores C, 2015, AM J ADDICTION,
V24, P98, DOI 10.1111/ajad.12185 54 0 0 1 3 TAYLOR & FRANCIS
INC PHILADELPHIA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
1465-9891 1475-9942 J SUBST USE J. Subst. Use 2018 23
6 618 625 10.1080/14659891.2018.1489003
8 Substance Abuse Substance Abuse GQ4RD WOS:000441660000012
 2019-09-25
J Bertholet, N; Cheng, DM; Palfai, TP; Lloyd-Travaglini, C; Samet, JH; Saitz, R
Bertholet, Nicolas; Cheng, Debbie M.; Palfai, Tibor P.;
Lloyd-Travaglini, Christine; Samet, Jeffrey H.; Saitz, Richard
Anxiety, Depression, and Pain Symptoms: Associations With the Course of
Marijuana Use and Drug Use Consequences Among Urban Primary Care Patients
JOURNAL OF ADDICTION MEDICINE English Article
anxiety; depression; drug; marijuana; pain; primary care
IMPAIRMENT SCALE OASIS; NATIONAL EPIDEMIOLOGIC SURVEY; CANNABIS USE; SELF-
MEDICATION; MENTAL-HEALTH; USE DISORDERS; REPRESENTATIVE SAMPLE; MOOD DISORDERS;
SUBSTANCE USE; ALCOHOL Objectives: This exploratory study aims to investigate
whether anxiety, depression, and pain are associated with changes in marijuana use
and drug use consequences among primary care patients. Methods: In all, 331 adult
primary care patients with marijuana as the only drug used were followed
prospectively to investigate associations between anxiety/depression symptoms
(no/minimal symptoms; anxiety or depression symptoms; symptoms of both) and pain
(1-10 scale: none [0]; low [1-3]; medium [4-6]; high [7-10]) (independent
variables) and substance use outcomes in regression models. These outcomes were
changes (over 6 months) in primary outcomes: marijuana use days (past 30); and drug
use consequences (Short Inventory of Problems-Drugs [SIP-D]); secondary outcomes-
drug use risk (Alcohol, Smoking, and Substance Involvement Screening Test [ASSIST]
score for drugs). Results: At baseline, 67% reported no/minimal anxiety/depression
symptoms, 16% anxiety or depression symptoms, 17% both; 14% reported no pain, 16%
low, 23% medium, 47% high pain level. Mean (SD) number of marijuana use days was
16.4 (11.6), mean SIP-D 5.9 (9.0), mean ASSIST 12.5 (7.8); no significant
association was found between anxiety/depression and marijuana use changes. Given
the same baseline status for SIP-D and ASSIST, respectively, those with anxiety or
depression had greater increases in SIP-D (adjusted mean difference [95% confidence
interval] thorn3.26 [1.20; 5.32], P = 0.004) and borderline significant increases
in ASSIST (+3.27 [-0.12; 6.65], P = 0.06) compared with those without anxiety or
depression; those with both anxiety and depression had greater increases in ASSIST
(+5.42 [2.05; 8.79], P = 0.003), but not SIP-D (+1.80 [-0.46; 4.06], P = 0.12).
There was no significant association between pain and marijuana use and SIP-D
changes. Given the same baseline ASSIST level, those with high pain level had
greater increases in ASSIST (+4.89 [1.05; 8.72], P = 0.04) compared with those with
no pain. Conclusion: In these exploratory analyses, anxiety, depression, and high
pain level appear to be associated with increases in drug-related harm among
primary care patients using marijuana. [Bertholet, Nicolas] Lausanne Univ Hosp,
Dept Community Med & Hlth, Alcohol Treatment Ctr, Lausanne, Switzerland; [Cheng,
Debbie M.; Samet, Jeffrey H.; Saitz, Richard] Boston Med Ctr, Dept Med, Gen
Internal Med Sect, Clin Addict Res & Educ CARE Unit, Boston, MA USA; [Cheng, Debbie
M.; Samet, Jeffrey H.; Saitz, Richard] Boston Univ, Sch Med, Boston, MA 02118 USA;
[Cheng, Debbie M.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA;
[Palfai, Tibor P.] Boston Univ, Dept Psychol & Brain Sci, Boston, MA 02215 USA;
[Lloyd-Travaglini, Christine] Boston Univ, Sch Publ Hlth, Data Coordinating Ctr,
Boston, MA USA; [Samet, Jeffrey H.; Saitz, Richard] Boston Univ, Sch Publ Hlth,
Dept Community Hlth Sci, Boston, MA USA Bertholet, N (reprint author), CHU
Vaudois, Alcohol Treatment Ctr, Beaumont 21b,P2,02, CH-1011 Lausanne, Switzerland.
Nicolas.Bertholet@chuv.ch /0000-0002-2535-1427; Bertholet,
Nicolas/0000-0001-5064-6377; Samet, Jeffrey/0000-0002-0897-3400 National Institute
on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes
of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01 DA025068];
Center for Substance Abuse Treatment, SAMHSA; National Center for Research
ResourcesUnited States Department of Health & Human ServicesNational Institutes of
Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025771]
The ASPIRE study was funded by an award from the National Institute on Drug
Abuse (R01 DA025068), a portion of which was funded by the Center for Substance
Abuse Treatment, SAMHSA. The study was also supported in part by the National
Center for Research Resources (UL1RR025771). Alford DP, 2016, J GEN INTERN MED,
V31, P486, DOI 10.1007/s11606-016-3586-5; Bannink R, 2015, BMC PUBLIC HEALTH, V15,
DOI 10.1186/s12889-015-1692-7; Bolton JM, 2009, J AFFECT DISORDERS, V115, P367, DOI
10.1016/j.jad.2008.10.003; Campbell-Sills L, 2009, J AFFECT DISORDERS, V112, P92,
DOI 10.1016/j.jad.2008.03.014; Copeland J, 2013, CURR OPIN PSYCHIATR, V26, P325,
DOI 10.1097/YCO.0b013e328361eae5; Danielsson AK, 2016, J AFFECT DISORDERS, V193,
P103, DOI 10.1016/j.jad.2015.12.045; Feingold D, 2016, EUR NEUROPSYCHOPHARM, V26,
P493, DOI 10.1016/j.euroneuro.2015.12.037; Feingold D, 2015, J AFFECT DISORDERS,
V172, P211, DOI 10.1016/j.jad.2014.10.006; Fuster D, 2014, J GEN INTERN MED, V29,
P133, DOI 10.1007/s11606-013-2605-z; Haberstick BC, 2014, DRUG ALCOHOL DEPEN, V136,
P158, DOI 10.1016/j.drugalcdep.2013.11.022; Harris KM, 2005, HEALTH SERV RES, V40,
P117, DOI 10.1111/j.1475-6773.2005.00345.x; Henry-Edwards S, 2003, ALCOHOL SMOKING
SUBS; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.1093/biomet/75.4.800;
Humeniuk R, 2008, ADDICTION, V103, P1039, DOI 10.1111/j.1360-0443.2007.02114.x;
Kedzior KK, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/1471-244X-14-136; Kroenke K,
2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x;
Lazareck S, 2012, J CLIN PSYCHIAT, V73, pE588, DOI 10.4088/JCP.11m07345; Lev-Ran S,
2014, PSYCHOL MED, V44, P797, DOI 10.1017/S0033291713001438; Madras BK, 2009, DRUG
ALCOHOL DEPEN, V99, P280, DOI 10.1016/j.drugalcdep.2008.08.003; Moitra E, 2016,
DEPRESS ANXIETY, V33, P332, DOI 10.1002/da.22460; Norman SB, 2006, DEPRESS ANXIETY,
V23, P245, DOI 10.1002/da.20182; Norman SB, 2011, J PSYCHIATR RES, V45, P262, DOI
10.1016/j.jpsychires.2010.06.011; Paddock S. M., 2012, EPIDEMIOL RES INT, V2012;
Robinson J, 2011, ARCH GEN PSYCHIAT, V68, P800, DOI
10.1001/archgenpsychiatry.2011.75; Robinson J, 2009, J ANXIETY DISORD, V23, P38,
DOI 10.1016/j.janxdis.2008.03.013; Saitz R, 2014, JAMA-J AM MED ASSOC, V312, P502,
DOI 10.1001/jama.2014.7862; Shrier LA, 2013, ADDICT BEHAV, V38, P1448, DOI
10.1016/j.addbeh.2012.05.026; Swift W, 2001, DRUG ALCOHOL DEPEN, V63, P147, DOI
10.1016/S0376-8716(00)00197-6; Thornton LK, 2012, ADDICT BEHAV, V37, P427, DOI
10.1016/j.addbeh.2011.11.039; Volkow ND, 2014, NEW ENGL J MED, V370, P2219, DOI
10.1056/NEJMra1402309; Vorspan F, 2015, CURR PSYCHIAT REP, V17, DOI 10.1007/s11920-
014-0544-y; WESTERBERG VS, 1998, SUBST ABUS, V19, P179, DOI DOI
10.1080/08897079809511386; Whiting PF, 2015, JAMA-J AM MED ASSOC, V313, P2456, DOI
10.1001/jama.2015.6358; Winstock AR, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c1571
34 2 2 1 3 LIPPINCOTT WILLIAMS & WILKINS PHILADELPHIA
TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA1932-0620 1935-
3227 J ADDICT MED J. Addict. Med. JAN-FEB 2018 12 1
45 52 10.1097/ADM.0000000000000362 8
Substance Abuse Substance Abuse GQ1KP WOS:000441390200008 28984682
2019-09-25
J Villarosa-Hurlocker, MC; Carroll, MG; Capron, DW; Madson, MB
Villarosa-Hurlocker, Margo C.; Carroll, Mallorie G.; Capron, Daniel W.;
Madson, Michael B. Are there social benefits? Exploring the role
of positive consequences in the relationship between social anxiety symptoms and
negative drinking consequences ADDICTION RESEARCH & THEORY
English Article College students;
alcohol use; social anxiety; positive consequences; negative consequences
COLLEGE-STUDENTS; ALCOHOL-USE; EVALUATION SCALE; HEAVY-DRINKING; SELF-
MEDICATION; USE DISORDERS; SUBSTANCE USE; BRIEF FEAR; CONSUMPTION; PHOBIA
Research has shown that college students with social anxiety experience more
alcohol-related negative consequences, regardless of the amount of alcohol they
consume. To better understand this relationship, it is important to examine social
anxiety as a multidimensional construct, as well as explore the positive outcomes
these students experience from drinking. The current study sought to examine the
impact of positive drinking consequences on the relationship between behavioral
(i.e. interaction and performance-type) and cognitive (i.e. fear of negative
evaluation) social anxiety symptoms and alcohol-related negative consequences.
Participants were 544 traditional age college students who reported consuming
alcohol in the past month and completed measures of social anxiety symptoms,
positive drinking consequences, and alcohol-related negative consequences. Positive
drinking consequences moderated the relationship between social anxiety and
alcohol-related negative consequences, such that students with more fear of
negative evaluation and that experienced more positive drinking consequences
reported more negative drinking consequences. Future directions and implications
are discussed. [Villarosa-Hurlocker, Margo C.; Carroll, Mallorie G.; Capron,
Daniel W.; Madson, Michael B.] Univ Southern Mississippi, Psychol, Hattiesburg, MS
39406 USA Madson, MB (reprint author), Univ Southern Mississippi, Psychol,
Hattiesburg, MS 39406 USA. michael.madson@usm.edu Blanco
C, 2008, ARCH GEN PSYCHIAT, V65, P1429, DOI 10.1001/archpsyc.65.12.1429; Buckner
JD, 2013, DEPRESS ANXIETY, V30, P276, DOI 10.1002/da.22032; Buckner JD, 2011, J
ANXIETY DISORD, V25, P631, DOI 10.1016/j.janxdis.2011.02.003; Buckner JD, 2008,
DEPRESS ANXIETY, V25, P1028, DOI 10.1002/da.20442; CAPPELL H, 1972, Q J STUD
ALCOHOL, V33, P33; Capron DW, 2012, ADDICT BEHAV, V37, P663, DOI
10.1016/j.addbeh.2012.02.002; Carleton RN, 2006, DEPRESS ANXIETY, V23, P297, DOI
10.1002/da.20142; Carrigan MH, 2003, ADDICT BEHAV, V28, P269, DOI 10.1016/S0306-
4603(01)00235-0; COLLINS RL, 1985, J CONSULT CLIN PSYCH, V53, P189, DOI
10.1037/0022-006X.53.2.189; Cooper M. L., 1994, PSYCHOL ASSESSMENT, V6, P117, DOI
[DOI 10.1037/1040-3590.6.2.117, 10.1037/1040-3590.6.2.117]; Corbin WR, 2008, ADDICT
BEHAV, V33, P54, DOI 10.1016/j.addbeh.2007.06.003; Crum RM, 2001, AM J PSYCHIAT,
V158, P1693, DOI 10.1176/appi.ajp.158.10.1693; Dimeff L. A., 1999, BRIEF ALCOHOL
SCREEN; Earleywine M, 2008, ADDICT BEHAV, V33, P1249, DOI
10.1016/j.addbeh.2008.05.006; Field A, 2013, DISCOVERING STAT USI; Frazier PA,
2004, J COUNS PSYCHOL, V51, P115, DOI 10.1037/0022-0167.51.1.115; Goldman MS, 1999,
PSYCHOL THEORIES DRI, V2, P203; Grant BF, 2004, ARCH GEN PSYCHIAT, V61, P807, DOI
10.1001/archpsyc.61.8.807; Ham LS, 2016, ADDICT RES THEORY, V24, P9, DOI
10.3109/16066359.2015.1036242; Ham LS, 2009, COGNITIVE THER RES, V33, P615, DOI
10.1007/s10608-009-9248-8; Johnston L. D., 2013, MONITORING FUTURE NA, V2; Kashdan
TB, 2006, PSYCHOL SCI, V17, P120, DOI 10.1111/j.1467-9280.2006.01674.x; KHANTZIAN
EJ, 1985, AM J PSYCHIAT, V142, P1259; LEARY MR, 1983, PERS SOC PSYCHOL B, V9, P371,
DOI 10.1177/0146167283093007; Lee CM, 2011, J ADOLESCENCE, V34, P87, DOI
10.1016/j.adolescence.2010.01.009; Lee CM, 2010, ADDICT BEHAV, V35, P764, DOI
10.1016/j.addbeh.2010.03.003; Lewis MA, 2008, PSYCHOL ADDICT BEHAV, V22, P58, DOI
10.1037/0893-164X.22.1.58; Mallett KA, 2013, ALCOHOL CLIN EXP RES, V37, P709, DOI
10.1111/acer.12031; Mattick RP, 1998, BEHAV RES THER, V36, P455, DOI 10.1016/S0005-
7967(97)10031-6; Meyers L. S., 2013, APPL MULTIVARIATE RE; Park A, 2013, PSYCHOL
ADDICT BEHAV, V27, P799, DOI 10.1037/a0032906; Park CL, 2005, ADDICT BEHAV, V30,
P755, DOI 10.1016/j.addbeh.2004.08.021; Park CL, 2004, ADDICT BEHAV, V29, P311, DOI
10.1016/j.addbeh.2003.08.006; Patrick ME, 2008, J ADOLESCENCE, V31, P307, DOI
10.1016/j.adolescence.2007.06.002; REISS S, 1986, BEHAV RES THER, V24, P1, DOI
10.1016/0005-7967(86)90143-9; Rodebaugh TL, 2004, PSYCHOL ASSESSMENT, V16, P169,
DOI 10.1037/1040-3590.16.2.169; Schry AR, 2013, ADDICT BEHAV, V38, P2690, DOI
10.1016/j.addbeh.2013.06.014; Schumacher J, 2015, FUNDAMENTALS MOTIVAT; Terlecki
MA, 2011, J COGN PSYCHOTHER, V25, P7, DOI 10.1891/0889-8391.25.1.7; Thomas SE,
2003, ALCOHOL CLIN EXP RES, V27, P1937, DOI 10.1097/01.ALC.0000100942.30743.8C;
Usala JM, 2015, ADDICT BEHAV, V41, P162, DOI 10.1016/j.addbeh.2014.10.016;
Villarosa M, 2016, ADDICT RES THEORY, V24, P124, DOI 10.3109/16066359.2015.1086758;
Villarosa MC, 2014, PSYCHOL ADDICT BEHAV, V28, P710, DOI 10.1037/a0036501; WATSON
D, 1969, J CONSULT CLIN PSYCH, V33, P448, DOI 10.1037/h0027806 44 0 0
0 0 TAYLOR & FRANCIS LTD ABINGDON 2-4 PARK SQUARE, MILTON PARK,
ABINGDON OR14 4RN, OXON, ENGLAND 1606-6359 1476-7392 ADDICT RES THEORY
Addict. Res. Theory 2018 26 4 275
281 10.1080/16066359.2017.1362692 7 Substance Abuse;
Social Issues Substance Abuse; Social Issues GM6VD WOS:000438314100004
2019-09-25
J Murphy, KD; Lambert, S; McCarthy, S; Sahm, LJ; Byrne, S
Murphy, Kevin D.; Lambert, Sharon; McCarthy, Suzanne; Sahm, Laura J.; Byrne,
Stephen "You Don't Feel": The Experience of Youth Benzodiazepine
Misuse in Ireland JOURNAL OF PSYCHOACTIVE DRUGS English Article
Adolescence; benzodiazepines; drug abuse; emotional
regulation; self-medication ADOLESCENT SUBSTANCE USE; PARADOXICAL REACTIONS;
MENTAL-DISORDERS; DRUG-USE; ADULTS; EDUCATION; HEALTH; RISK; SIZE; ADDICTION There
are negative effects to inappropriate use of benzodiazepines, yet the percentage of
young people in Ireland experimenting with benzodiazepines has increased. There is
a paucity of research about why Irish young people misuse benzodiazepines. In this
study, people between 18 and 25years attending substance misuse services in the
south of Ireland (N=13) were interviewed in a semi-structured style between June
2012 and April 2013. Content analysis was performed. The main motivations for
benzodiazepine misuse were to self-regulate negative emotions and to induce
dissociation from their environment. Interviewees also described the consequences
of benzodiazepine misuse, such as disengagement from family relationships and other
protective environments such as school and sports clubs. The consequences of
chronic misuse were discussed, such as the compulsion to take more benzodiazepines
despite experiencing severe side-effects. The incidence of paradoxical aggression
on benzodiazepines is also explored. Education about benzodiazepines and their
risks to young people, families, and the public may reduce benzodiazepine misuse.
Future research on the role of trauma and mental health in young people's substance
misuse is needed. [Murphy, Kevin D.] Univ Coll Cork, Sch Pharm, Room 1-52, Cork,
Ireland; [Lambert, Sharon] Univ Coll Cork, Sch Appl Psychol, Cork, Ireland;
[McCarthy, Suzanne; Sahm, Laura J.; Byrne, Stephen] Univ Coll Cork, Sch Pharm, Clin
Pharm, Cork, Ireland; [Sahm, Laura J.] Mercy Univ Hosp, Cork, Ireland Murphy, KD
(reprint author), Univ Coll Cork, Sch Pharm, Room 1-52, Cork, Ireland.
Kevin.Murphy@ucc.ie Murphy, Kevin/0000-0001-5630-4060
Apantaku-Olajide T, 2014, J CHILD ADOLES SUBST, V23, P169, DOI
10.1080/1067828X.2013.786921; Baker DP, 2011, POPUL DEV REV, V37, P307, DOI
10.1111/j.1728-4457.2011.00412.x; Ballymun Youth Action Project, 2004, BENZ WHOS
LITTL HELP; Bellerose D., 2010, PROBLEM BENZODIAZEPI; Bellerose D., 2011, TRENDS
TREATED PROBL; Boeuf-Cazou O, 2011, EUR J CLIN PHARMACOL, V67, P1045, DOI
10.1007/s00228-011-1047-y; Bramness JG, 2006, FORENSIC SCI INT, V159, P83, DOI
10.1016/j.forsciint.2005.06.009; Carruth Bruce, 2006, J CHEM DEPENDENCY TR, V8, P1,
DOI [10.1300/J034v08n02_01, DOI 10.1300/J034V08N02_01]; Dalgard OS, 2007, BMC
PSYCHIATRY, V7, DOI 10.1186/1471-244X-7-20; Darke S, 2013, ADDICTION, V108, P659,
DOI 10.1111/j.1360-0443.2012.04001.x; de Gage SB, 2012, BMJ-BRIT MED J, V345, DOI
10.1136/bmj.e6231; Department of Health and Children, 2002, BENZ GOOD PRACT GUID;
EMCDDA, 2013, BENZ; Felitti VJ, 1998, AM J PREV MED, V14, P245, DOI 10.1016/S0749-
3797(98)00017-8; Fletcher A, 2008, J ADOLESCENT HEALTH, V42, P209, DOI
10.1016/j.jadohealth.2007.09.020; Flores PJ, 2001, INT J GROUP PSYCHOTH, V51, P63,
DOI 10.1521/ijgp.51.1.63.49730; Francis JJ, 2010, PSYCHOL HEALTH, V25, P1229, DOI
10.1080/08870440903194015; Griffin CE, 2013, OCHSNER J, V13, P214; Hari J., 2015,
CHASING SCREAM 1 LAS; Health Research Board, 2016, NAT DRUG REL DEATHS; Heffernan
K, 2000, ADDICT BEHAV, V25, P797, DOI 10.1016/S0306-4603(00)00066-6; Hibell B.,
2012, 2011 ESPAD REPORT SU; Hibell B., 2004, ESPAD REPORT 2003 AL; International
Narcotics Control Board, 2011, REP INT NARC CONTR B; Jones KA, 2011, AUST FAM
PHYSICIAN, V40, P862; Keyes CLM, 2010, AM J PUBLIC HEALTH, V100, P2366, DOI
10.2105/AJPH.2010.192245; Kwan M, 2014, ADDICT BEHAV, V39, P497, DOI
10.1016/j.addbeh.2013.11.006; Longo LP, 2000, AM FAM PHYSICIAN, V61, P2121; Mancuso
CE, 2004, PHARMACOTHERAPY, V24, P1177, DOI 10.1592/phco.24.13.1177.38089; OECD,
2011, ED GLANC 2011; Olfson M, 2014, JAMA PSYCHIAT, V71, P81, DOI
10.1001/jamapsychiatry.2013.3074; Organisation for Economic Cooperation and
Development (OECD), 2015, ED GLANC 2015; Pechtel P, 2011, PSYCHOPHARMACOLOGY, V214,
P55, DOI 10.1007/s00213-010-2009-2; Peters RJ, 2007, J DRUG EDUC, V37, P417, DOI
10.2190/DE.37.4.e; Reynolds S., 2008, TRENDS TREATED PROBL; Ross CE, 1997, J HEALTH
SOC BEHAV, V38, P275, DOI 10.2307/2955371; Royal College of Psychiatrists Public
Education Editorial Board, 2013, BENZODIAZEPINES; SALZMAN C, 1990, PSYCHOPHARMACOL
BULL, V26, P61; Stewart SA, 2005, J CLIN PSYCHIAT, V66, P9; Tannenbaum C, 2014,
JAMA INTERN MED, V174, P890, DOI 10.1001/jamainternmed.2014.949; Umbricht A., 2015,
BENZODIAZEPINE ABUSE; Vaismoradi M, 2013, NURS HEALTH SCI, V15, P398, DOI
10.1111/nhs.12048; Vakalahi HF, 2001, J DRUG EDUC, V31, P29, DOI 10.2190/QP75-P9AR-
NUVJ-FJCB; Wittchen HU, 2011, EUR NEUROPSYCHOPHARM, V21, P655, DOI
10.1016/j.euroneuro.2011.07.018; Wittchen HU, 2005, EUR NEUROPSYCHOPHARM, V15,
P357, DOI 10.1016/j.euroneuro.2005.04.012 45 0 0 0 4 ROUTLEDGE
JOURNALS, TAYLOR & FRANCIS LTD ABINGDON 2-4 PARK SQUARE, MILTON PARK,
ABINGDON OX14 4RN, OXON, ENGLAND 0279-1072 2159-9777 J PSYCHOACTIVE
DRUGS J. Psychoact. Drugs 2018 50 2 121
128 10.1080/02791072.2017.1371365 8 Psychology,
Clinical; Substance Abuse Psychology; Substance Abuse GG4BD
WOS:000432636500004 28952880 2019-09-25
J Alexander, AC; Ward, KD Alexander, Adam C.; Ward, Kenneth
D. Understanding Postdisaster Substance Use and Psychological
Distress Using Concepts from the Self-Medication Hypothesis and Social Cognitive
Theory JOURNAL OF PSYCHOACTIVE DRUGS English Article
Disasters; psychological distress; self-efficacy; self-
medication; social cognitive theory; substance use POSTTRAUMATIC-STRESS-
DISORDER; ALCOHOL-USE; NEW-YORK; TERRORIST ATTACKS; NATURAL DISASTER; HUMAN AGENCY;
COLLECTIVE EFFICACY; MEDIATION ANALYSIS; MOOD DISORDERS; TOBACCO USE This article
applies constructs from the Self-Medication Hypothesis and Social Cognitive Theory
to explain the development of substance use and psychological distress after a
disaster. A conceptual model is proposed, which employs a sequential mediation
model, identifying perceived coping self-efficacy, psychological distress, and
self-medication as pathways to substance use after a disaster. Disaster exposure
decreases perceived coping self-efficacy, which, in turn, increases psychological
distress and subsequently increases perceptions of self-medication in vulnerable
individuals. These mechanisms lead to an increase in postdisaster substance use.
Last, recommendations are offered to encourage disaster researchers to test more
complex models in studies on postdisaster psychological distress and substance use.
[Alexander, Adam C.; Ward, Kenneth D.] Univ Memphis, Sch Publ Hlth, Div
Social & Behav Sci, 207 Robison Hall,3825 Desoto Ave, Memphis, TN 38111 USA
Alexander, AC (reprint author), Univ Memphis, Sch Publ Hlth, Div Social &
Behav Sci, 207 Robison Hall,3825 Desoto Ave, Memphis, TN 38111 USA.
clxnder1@memphis.edu NIDA NIH HHSUnited States Department of
Health & Human ServicesNational Institutes of Health (NIH) - USANIH National
Institute on Drug Abuse (NIDA) [R21 DA021782] Abrams K, 2002, PSYCHOL
ADDICT BEHAV, V16, P121, DOI 10.1037//0893-164X.16.2.121; Bandura A, 2000, CURR DIR
PSYCHOL SCI, V9, P75, DOI 10.1111/1467-8721.00064; BANDURA A, 1978, AM PSYCHOL,
V33, P344, DOI 10.1037/0003-066X.33.4.344; Bandura A, 2004, HEALTH EDUC BEHAV, V31,
P143, DOI 10.1177/1090198104263660; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI
10.1037/0033-295X.84.2.191; BANDURA A, 1982, AM PSYCHOL, V37, P122, DOI
10.1037/0003-066X.37.2.122; BANDURA A, 1989, AM PSYCHOL, V44, P1175, DOI
10.1037/0003-066X.44.9.1175; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI
10.1037/0022-3514.51.6.1173; Benight CC, 1999, J APPL SOC PSYCHOL, V29, P2443, DOI
10.1111/j.1559-1816.1999.tb00120.x; Benight CC, 2004, ANXIETY STRESS COPIN, V17,
P401, DOI 10.1080/10615800512331328768; Benight CC, 2004, BEHAV RES THER, V42,
P1129, DOI 10.1016/j.brat.2003.08.008; Bolton JM, 2009, J AFFECT DISORDERS, V115,
P367, DOI 10.1016/j.jad.2008.10.003; Boscarino JA, 2006, ADDICT BEHAV, V31, P606,
DOI 10.1016/j.addbeh.2005.05.035; Boscarino JA, 2011, J TRAUMA STRESS, V24, P515,
DOI 10.1002/jts.20673; Breslau N, 2003, ARCH GEN PSYCHIAT, V60, P289, DOI
10.1001/archpsyc.60.3.289; Cerda M, 2008, ADDICTION, V103, P1296, DOI
10.1111/j.1360-0443.2008.02247.x; Cerda M, 2011, DRUG ALCOHOL DEPEN, V115, P1, DOI
10.1016/j.drugalcdep.2010.09.011; Chilcoat HD, 1998, ADDICT BEHAV, V23, P827, DOI
10.1016/S0306-4603(98)00069-0; Childs E, 2010, NICOTINE TOB RES, V12, P449, DOI
[10.1093/ntr/ntq061, 10.1093/ntr/ntp214]; Cinciripini PM, 2003, J CONSULT CLIN
PSYCH, V71, P292, DOI 10.1037/0022-006X.71.2.292; Crum RM, 2013, JAMA PSYCHIAT,
V70, P718, DOI 10.1001/jamapsychiatry.2013.1098; de Wit H, 2003, ALCOHOL CLIN EXP
RES, V27, P1270, DOI 10.1097/01.ALC.0000081617.37539.D6; Engels RCME, 2005, SUBST
USE MISUSE, V40, P1883, DOI 10.1080/10826080500259612; Flory K, 2009, SUBST USE
MISUSE, V44, P1711, DOI 10.3109/10826080902962128; Forman-Hoffman V, 2005, PSYCHOL
ADDICT BEHAV, V19, P277, DOI 10.1037/0893-164X.19.3.277; Fullerton C., 2003,
TERRORISM DISASTER I, P1; Fullerton CS, 2015, PLOS ONE, V10, DOI
10.1371/journal.pone.0130863; Fullerton CS, 2013, DISASTER MED PUBLIC, V7, P89, DOI
10.1017/dmp.2013.6; Garnefski N, 2001, PERS INDIV DIFFER, V30, P1311, DOI
10.1016/S0191-8869(00)00113-6; Gordh AHVS, 2011, PHARMACOL BIOCHEM BE, V99, P696,
DOI 10.1016/j.pbb.2011.05.028; Hayes A.F., 2013, INTRO MEDIATION MODE; Hayes AF,
2009, COMMUN MONOGR, V76, P408, DOI 10.1080/03637750903310360; HOBFOLL SE, 1989, AM
PSYCHOL, V44, P513, DOI 10.1037/0003-066X.44.3.513; Jacobson IG, 2008, JAMA-J AM
MED ASSOC, V300, P663, DOI 10.1001/jama.300.6.663; Khantzian E., 2003,
NEUROPSYCHOANALYSIS, V5, P5, DOI DOI 10.1080/15294145.2003.10773403; KHANTZIAN EJ,
1974, AM J PSYCHIAT, V131, P160, DOI 10.1176/ajp.131.2.160; Khantzian EJ, 1997,
HARVARD REV PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550; KHANTZIAN EJ, 1985,
AM J PSYCHIAT, V142, P1259; KIRSCHBAUM C, 1993, NEUROPSYCHOBIOLOGY, V28, P76, DOI
10.1159/000119004; Kishore Vimal, 2008, Am J Disaster Med, V3, P345; Koenen KC,
2005, ARCH GEN PSYCHIAT, V62, P1258, DOI 10.1001/archpsyc.62.11.1258; Leeies M,
2010, DEPRESS ANXIETY, V27, P731, DOI 10.1002/da.20677; Lowe SR, 2015, PLOS ONE,
V10, DOI 10.1371/journal.pone.0125761; Luszczynska A, 2009, EUR PSYCHOL, V14, P51,
DOI 10.1027/1016-9040.14.1.51; Maxwell SE, 2007, PSYCHOL METHODS, V12, P23, DOI
10.1037/1082-989X.12.1.23; McKernan Lindsey Colman, 2015, Psychodyn Psychiatry,
V43, P243, DOI 10.1521/pdps.2015.43.2.243; McRae-Clark AL, 2011,
PSYCHOPHARMACOLOGY, V218, P49, DOI 10.1007/s00213-011-2376-3; Muthen L. K., 2010,
MPLUS USERS GUIDE; Nandi A, 2005, PSYCHIATRY, V68, P299, DOI
10.1521/psyc.2005.68.4.299; Nordlokken A, 2016, PUBLIC HEALTH, V132, P33, DOI
10.1016/j.puhe.2015.11.007; Norris FH, 2002, PSYCHIATRY, V65, P207, DOI
10.1521/psyc.65.3.207.20173; Norris FH, 2008, AM J COMMUN PSYCHOL, V41, P127, DOI
10.1007/s10464-007-9156-6; North CS, 2011, ARCH GEN PSYCHIAT, V68, P173, DOI
10.1001/archgenpsychiatry.2010.131; Parslow RA, 2006, ADDICTION, V101, P1044, DOI
10.1111/j.1360-0443.2006.01481.x; Prati G, 2010, ANXIETY STRESS COPIN, V23, P463,
DOI 10.1080/10615800903431699; Robinson J, 2009, J ANXIETY DISORD, V23, P38, DOI
10.1016/j.janxdis.2008.03.013; Rohrbach LA, 2009, PSYCHIATRY, V72, P222, DOI
10.1521/psyc.2009.72.3.222; Sandler IN, 2000, CHILD DEV, V71, P1099, DOI
10.1111/1467-8624.00212; Skutle A, 1999, ADDICT BEHAV, V24, P87, DOI 10.1016/S0306-
4603(98)00007-0; STRECHER VJ, 1986, HEALTH EDUC QUART, V13, P73, DOI
10.1177/109019818601300108; Suh JJ, 2008, PSYCHOANAL PSYCHOL, V25, P518, DOI
10.1037/0736-9735.25.3.518; Thomas SE, 2011, PSYCHOPHARMACOLOGY, V218, P19, DOI
10.1007/s00213-010-2163-6; Thompson RA, 1991, EDUC PSYCHOL REV, V3, P269, DOI
10.1007/BF01319934; Tomarken AJ, 2005, ANNU REV CLIN PSYCHO, V1, P31, DOI
10.1146/annurev.clinpsy.1.102803.144239; Ursano RJ, 2014, PLOS ONE, V9, DOI
10.1371/journal.pone.0088467; van der Velden PG, 2008, DRUG ALCOHOL DEPEN, V94,
P267, DOI 10.1016/j.drugalcdep.2007.11.001; Van der Velden PG, 2007, J CLIN
PSYCHIAT, V68, P87, DOI 10.4088/JCP.v68n0112; Vetter S, 2008, BMC PUBLIC HEALTH,
V8, DOI 10.1186/1471-2458-8-92; Vlahov D, 2004, AM J DRUG ALCOHOL AB, V30, P385,
DOI 10.1081/ADA-120037384; Vlahov D, 2004, AM J PUBLIC HEALTH, V94, P253, DOI
10.2105/AJPH.94.2.253; Vlahov D, 2002, AM J EPIDEMIOL, V155, P988, DOI
10.1093/aje/155.11.988; Walsh K, 2014, COMPR PSYCHIAT, V55, P621, DOI
10.1016/j.comppsych.2013.11.016; Wolitzky-Taylor K, 2012, ADDICT BEHAV, V37, P982,
DOI 10.1016/j.addbeh.2012.03.026; Zhao XS, 2010, J CONSUM RES, V37, P197, DOI
10.1086/651257 74 0 0 0 5 ROUTLEDGE JOURNALS, TAYLOR &
FRANCIS LTD ABINGDON 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON,
ENGLAND 0279-1072 2159-9777 J PSYCHOACTIVE DRUGS J. Psychoact.
Drugs 2018 50 2 177 186
10.1080/02791072.2017.1397304 10 Psychology, Clinical;
Substance Abuse Psychology; Substance Abuse GG4BD WOS:000432636500011
29125424 Green Accepted 2019-09-25
J Shoaib, M; Buhidma, Y Shoaib, Mohammed; Buhidma, Yazead
Why are Antidepressant Drugs Effective Smoking Cessation Aids?
CURRENT NEUROPHARMACOLOGY English Review
Antidepressant; smoking cessation; nicotine; withdrawal;
dependence; bupropion RANDOMIZED CLINICAL-TRIAL; MONOAMINE-OXIDASE INHIBITION;
SUSTAINED-RELEASE BUPROPION; PLACEBO-CONTROLLED TRIAL; RAT NUCLEUS-ACCUMBENS;
NICOTINE WITHDRAWAL; CIGARETTE-SMOKING; DOUBLE-BLIND; SUBSTANCE-USE; DELTA-FOSB
Background: Before the advent of varenicline, antidepressant drugs were
reported to exhibit better clinical efficacy than nicotine replacement therapy as
smoking cessation aids. The most studied is bupropion, a clinically-effective
antidepressant, the first to be marketed throughout Europe for smoking cessation.
Since depression and tobacco smoking have a high incidence of co-occurrence, this
would implicate an underlying link between these two conditions. If this
correlation can be confirmed, then by treating one condition the related state
would also be treated. Objectives: This review article will evaluate the various
theories relating to the use of antidepressant drugs as smoking cessation aids and
the underlying mechanisms link tobacco smoking and depression to explain the action
of antidepressants in smoking cessation. One plausible theory of self-medication
which proposes that people take nicotine to treat their own depressive symptoms and
the affective withdrawal symptoms seen with abstinence from the drug. If the
depression can instead be treated with antidepressants, then they may stop smoking
altogether. Another theory is that the neurobiological pathways underlying smoking
and depression may be similar. By targeting the pathways of depression in the
brain, antidepressants would also treat the pathways affected by smoking and ease
nicotine cravings and withdrawal. The role of genetic variation predisposing an
individual to depression and initiation of tobacco smoking has also been discussed
as a potential link between the two conditions. Such variation could either occur
within the neurobiological pathways involved in both disorders or it could lead to
an individual being depressed and self-medicating with nicotine. [Shoaib, Mohammed;
Buhidma, Yazead] Newcastle Univ, Med Sch, Inst Neurosci, Newcastle, NSW, Australia
Shoaib, M (reprint author), Newcastle Univ, Med Sch, Inst Neurosci,
Newcastle, NSW, Australia. mohammed.shoaib@newcastle.ac.uk
Albuquerque EX, 2009, PHYSIOL REV, V89, P73, DOI 10.1152/physrev.00015.2008;
Allison C, 2013, NEUROPHARMACOLOGY, V64, P314, DOI
10.1016/j.neuropharm.2012.06.055; Andreasen JT, 2012, PHARMACOL BIOCHEM BE, V100,
P624, DOI 10.1016/j.pbb.2011.11.004; ASCHER JA, 1995, J CLIN PSYCHIAT, V56, P395;
Benmansour S, 2004, BIOL PSYCHIAT, V55, P313, DOI 10.1016/S0006-3223(03)00676-0;
Benmansour S, 1999, J NEUROSCI, V19, P10494; Benowitz NL, 2010, NEW ENGL J MED,
V362, P2295, DOI 10.1056/NEJMra0809890; BENOWITZ NL, 1988, CLIN PHARMACOL THER,
V44, P23, DOI 10.1038/clpt.1988.107; BERLIN I, 1995, CLIN PHARMACOL THER, V58,
P444, DOI 10.1016/0009-9236(95)90058-6; Berlin I, 2010, ADDICTION, V105, P2209, DOI
10.1111/j.1360-0443.2010.03109.x; Biberman R, 2003, ADDICTION, V98, P1403, DOI
10.1046/j.1360-0443.2003.00524.x; BOWEN DJ, 1991, J BEHAV MED, V14, P97, DOI
10.1007/BF00846173; BRESLAU N, 1992, AM J PSYCHIAT, V149, P464; Brown RA, 2014,
NICOTINE TOB RES, V16, P197, DOI 10.1093/ntr/ntt134; Bruijnzeel AW, 2003, SYNAPSE,
V50, P20, DOI 10.1002/syn.10242; Carrao JL, 2007, EUR ARCH PSY CLIN N, V257, P383,
DOI 10.1007/s00406-007-0726-2; Carroll FI, 2014, ADV PHARMACOL, V69, P177, DOI
10.1016/B978-0-12-420118-7.00005-6; Chapman S, 2009, AUST NZ J PSYCHIAT, V43, P277,
DOI 10.1080/00048670802653372; Cheng W, 2016, BRAIN, V139, P3296, DOI
10.1093/brain/aww255; Chengappa KNR, 2001, J CLIN PSYCHIAT, V62, P503, DOI
10.4088/JCP.v62n07a01; Cinciripini PM, 2005, EXP CLIN PSYCHOPHARM, V13, P282, DOI
10.1037/1064-1297.13.4.282; Cinciripini PM, 2004, NICOTINE TOB RES, V6, P229; Cook
JW, 2004, PSYCHOPHARMACOLOGY, V173, P153, DOI 10.1007/s00213-003-1711-8; COOPER BR,
1980, J PHARMACOL EXP THER, V215, P127; Courbasson C, 2009, INT J ENV RES PUB HE,
V6, P2076, DOI 10.3390/ijerph6072076; Covey LS, 1997, AM J PSYCHIAT, V154, P263;
Covey LS, 2002, AM J PSYCHIAT, V159, P1731, DOI 10.1176/appi.ajp.159.10.1731; Cryan
JF, 2003, PSYCHOPHARMACOLOGY, V168, P347, DOI 10.1007/s00213-003-1445-7; da Costa
CL, 2002, CHEST, V122, P403, DOI 10.1378/chest.122.2.403; Damaj MI, 2004, MOL
PHARMACOL, V66, P675, DOI 10.1124/mol.104.001313; de Leon J, 2005, SCHIZOPHR RES,
V76, P135, DOI 10.1016/j.schres.2005.02.010; DELEON J, 1995, AM J PSYCHIAT, V152,
P453; Di Chiara G, 2007, CURR OPIN PHARMACOL, V7, P69, DOI
10.1016/j.coph.2006.11.003; Dion AM, 2012, PHARMACOL BIOCHEM BE, V100, P419, DOI
10.1016/j.pbb.2011.10.003; Dong J, 2001, PSYCHOPHARMACOLOGY, V155, P52, DOI
10.1007/s002130000665; Doty TJ, 2008, PSYCHIAT RES-NEUROIM, V163, P84, DOI
10.1016/j.pscychresns.2007.08.003; Dunn EC, 2009, J STUD ALCOHOL DRUGS, V70, P106,
DOI 10.15288/jsad.2009.70.106; EDWARDS NB, 1989, AM J PSYCHIAT, V146, P373; Egerton
A, 2010, NEUROIMAGE, V50, P260, DOI 10.1016/j.neuroimage.2009.11.077; Esteban S,
2004, MOL CELL BIOCHEM, V267, P39, DOI 10.1023/B:MCBI.0000049363.97713.74; Etkin A,
2011, TRENDS COGN SCI, V15, P85, DOI 10.1016/j.tics.2010.11.004; Fenster CP, 1999,
J NEUROSCI, V19, P4804; Ferris R. M., 1993, J CLIN PSYCHIATRY MO, V11, P2; FERRIS
RM, 1982, ADV BIOCHEM PSYCHOPH, V31, P277; Foulds J, 2006, AM J HEALTH BEHAV, V30,
P400, DOI 10.5993/AJHB.30.4.6; FREDERICK SL, 1997, NIDA RES MONOGR, V174, P208;
George TP, 2008, CLIN PHARMACOL THER, V83, P619, DOI 10.1038/sj.clpt.6100474;
George TP, 2003, BIOL PSYCHIAT, V53, P136, DOI 10.1016/S0006-3223(02)01454-3;
Goriounova NA, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a012120; Govind
AP, 2009, BIOCHEM PHARMACOL, V78, P756, DOI 10.1016/j.bcp.2009.06.011; Guillem K,
2005, J NEUROSCI, V25, P8593, DOI 10.1523/JNEUROSCI.2139-05.2005; Hahn B, 2002,
BEHAV PHARMACOL, V13, P621, DOI 10.1097/01/fbp.0000046506.84018.28; Hall SM, 2005,
J BEHAV HEALTH SER R, V32, P381, DOI 10.1007/BF02384199; Hall SM, 2004, AM J
PSYCHIAT, V161, P2100, DOI 10.1176/appi.ajp.161.11.2100; Hall SM, 1998, ARCH GEN
PSYCHIAT, V55, P683, DOI 10.1001/archpsyc.55.8.683; Henningfield JE, 2005, CA-
CANCER J CLIN, V55, P281, DOI 10.3322/canjclin.55.5.281; Hitsman B, 2007,
PSYCHOPHARMACOLOGY, V192, P317, DOI 10.1007/s00213-007-0722-2; Hong LE, 2009, ARCH
GEN PSYCHIAT, V66, P431, DOI 10.1001/archgenpsychiatry.2009.2; Houtsmuller EJ,
2002, PSYCHOPHARMACOLOGY, V163, P213, DOI 10.1007/s00213-002-1152-9; HUGHES J,
2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000031.PUB2; Huibers MJH,
2000, EUR RESPIR J, V16, P379, DOI 10.1034/j.1399-3003.2000.016003379.x; Hurt RD,
1997, NEW ENGL J MED, V337, P1195, DOI 10.1056/NEJM199710233371703; Jackson A,
2017, ADDICT BIOL, V22, P1316, DOI 10.1111/adb.12423; JACOBS MA, 1971, PSYCHOSOM
MED, V33, P545, DOI 10.1097/00006842-197111000-00007; Janes AC, 2014, PLOS ONE, V9,
DOI 10.1371/journal.pone.0088228; Jorenby DE, 1999, NEW ENGL J MED, V340, P685, DOI
10.1056/NEJM199903043400903; Juliano LM, 1998, EXP CLIN PSYCHOPHARM, V6, P45, DOI
10.1037/1064-1297.6.1.45; Killen JD, 2000, J CONSULT CLIN PSYCH, V68, P883, DOI
10.1037//0022-006X.68.5.883; Killen JD, 2004, J CONSULT CLIN PSYCH, V72, P729, DOI
10.1037/0022-006X.72.4.729; Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI
10.1038/npp.2009.110; Kotlyar M, 2013, PSYCHOSOM MED, V75, P236, DOI
10.1097/PSY.0b013e3182898f6d; Kripke C, 2005, AM FAM PHYSICIAN, V71, P67; Kroemer
NB, 2013, NEUROPSYCHOPHARMACOL, V38, P2307, DOI 10.1038/npp.2013.133; Kufe Donald
W., 2003, CANC MED; Lazev AB, 1999, EXP CLIN PSYCHOPHARM, V7, P56, DOI
10.1037/1064-1297.7.1.56; Learned-Coughlin SM, 2003, BIOL PSYCHIAT, V54, P800, DOI
10.1016/S0006-3223(02)01834-6; Lecca D, 2006, PSYCHOPHARMACOLOGY, V184, P435, DOI
10.1007/s00213-005-0280-4; Lerman C, 2004, PSYCHOL ADDICT BEHAV, V18, P362, DOI
10.1037/0893-164X.18.4.362; Lerman C, 2007, NAT REV DRUG DISCOV, V6, P746, DOI
10.1038/nrd2361; Malcolm E, 2015, PSYCHOPHARMACOLOGY, V232, P2763, DOI
10.1007/s00213-015-3908-z; Martinez-Raga J, 2003, ADDICT BIOL, V8, P13, DOI
10.1080/1355621031000069837; McGaugh JL, 2004, ANNU REV NEUROSCI, V27, P1, DOI
10.1146/annurev.neuro.27.070203.144157; Meyer JH, 2002, PSYCHOPHARMACOLOGY, V163,
P102, DOI 10.1007/s00213-002-1166-3; Mihov Y, 2012, NEUROPSYCHOLOGIA, V50, P1719,
DOI 10.1016/j.neuropsychologia.2012.04.028; Milham MP, 2005, BIOL PSYCHIAT, V57,
P961, DOI 10.1016/j.biopsych.2005.01.038; Miller DK, 2002, J PHARMACOL EXP THER,
V302, P1113, DOI 10.1124/jpet.102.033852; MOORE D, 2009, BRIT MED J, V338; MURPHY
JK, 1990, AM J PSYCHIAT, V147, P1353; Murphy JM, 2003, AM J PSYCHIAT, V160, P1663,
DOI 10.1176/appi.ajp.160.9.1663; Nestler EJ, 2001, P NATL ACAD SCI USA, V98,
P11042, DOI 10.1073/pnas.191352698; Nestler EJ, 2008, PHILOS T R SOC B, V363,
P3245, DOI 10.1098/rstb.2008.0067; Niaura R, 2002, J CONSULT CLIN PSYCH, V70, P887,
DOI 10.1037//0022-006X.70.4.887; NOMIKOS GG, 1992, NEUROPSYCHOPHARMACOL, V7, P7;
Noori Negin, 2014, Adv Biomed Res, V3, P251, DOI 10.4103/2277-9175.146377; NORDIN
C, 1995, CLIN PHARMACOKINET, V28, P26, DOI 10.2165/00003088-199528010-00004;
Nowakowska E, 2006, HUM EXP TOXICOL, V25, P199, DOI 10.1191/0960327106ht611oa;
Paterson NE, 2007, NEUROTOX RES, V11, P1, DOI 10.1007/BF03033479; Patterson F,
2009, BIOL PSYCHIAT, V65, P144, DOI 10.1016/j.biopsych.2008.08.028; Perlman SB,
2010, SOC NEUROSCI-UK, V5, P533, DOI 10.1080/17470911003683219; Perrotti LI, 2008,
SYNAPSE, V62, P358, DOI 10.1002/syn.20500; Perugini M, 2003, PHARMACOL BIOCHEM BE,
V74, P513, DOI 10.1016/S0091-3057(02)01038-9; Pinkofsky HB, 1997, J CLIN
PSYCHOPHARM, V17, P492, DOI 10.1097/00004714-199712000-00012; Piran N, 2006, ADDICT
BEHAV, V31, P1761, DOI 10.1016/j.addbeh.2005.12.021;
 Pontieri FE, 1996, NATURE, V382, P255, DOI 10.1038/382255a0; Poulos AM, 2010, P
NATL ACAD SCI USA, V107, P14881, DOI 10.1073/pnas.1005754107; Prochazka AV, 2004,
ARCH INTERN MED, V164, P2229, DOI 10.1001/archinte.164.20.2229; Prochazka AV, 1998,
ARCH INTERN MED, V158, P2035, DOI 10.1001/archinte.158.18.2035; RICHELSON E, 1984,
EUR J PHARMACOL, V104, P277, DOI 10.1016/0014-2999(84)90403-5; Rollema H, 2009, EUR
J PHARMACOL, V605, P114, DOI 10.1016/j.ejphar.2009.01.002; Salin-Pascual RJ, 2003,
REV INVEST CLIN, V55, P677; Saules KK, 2004, AM J ADDICTION, V13, P438, DOI
10.1080/10550490490512762; Schiltz CA, 2005, EUR J NEUROSCI, V21, P1703, DOI
10.1111/j.1460-9568.2005.04001.x; Seth P, 2002, PHARMACOL BIOCHEM BE, V71, P795,
DOI 10.1016/S0091-3057(01)00715-8; Shahan TA, 1999, PSYCHOPHARMACOLOGY, V147, P210,
DOI 10.1007/s002130051162; Shiffman S, 2000, HEALTH PSYCHOL, V19, P315, DOI
10.1037//0278-6133.19.4.315; Shoaib M, 2005, PSYCHOPHARMACOLOGY, V178, P211, DOI
10.1007/s00213-004-2004-6; Silton RL, 2011, J ABNORM PSYCHOL, V120, P272, DOI
10.1037/a0023204; Simon JA, 2004, ARCH INTERN MED, V164, P1797, DOI
10.1001/archinte.164.16.1797; Slemmer JE, 2000, J PHARMACOL EXP THER, V295, P321;
SUCKOW RF, 1986, DRUG METAB DISPOS, V14, P692; Wagena EJ, 2005, ADDICTION, V100,
P317, DOI 10.1111/j.1360-0443.2005.00998.x; Walker HK, 1990, CLIN METHODS; Warner
C, 2005, ADDICT BIOL, V10, P219, DOI 10.1080/13556210500222670; Washington Stuart
D, 2015, Int J Med Biol Front, V21, P207; Wei ZD, 2016, SCI REP-UK, V6, DOI
10.1038/srep21778; Weinberger AH, 2010, DRUG ALCOHOL DEPEN, V107, P188, DOI
10.1016/j.drugalcdep.2009.10.009; WELCH RM, 1987, XENOBIOTICA, V17, P287, DOI
10.3109/00498258709043939; Wilkinson JL, 2010, J PSYCHOPHARMACOL, V24, P817, DOI
10.1177/0269881109102518; Wing VC, 2007, PSYCHOPHARMACOLOGY, V195, P303, DOI
10.1007/s00213-007-0902-0; Wing VC, 2012, PSYCHOPHARMACOLOGY, V219, P847, DOI
10.1007/s00213-011-2413-2; Zhang D, 2012, J NEUROSCI, V32, P12366, DOI
10.1523/JNEUROSCI.5411-11.2012 131 2 2 0 6 BENTHAM SCIENCE
PUBL LTD SHARJAH EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH,
U ARAB EMIRATES 1570-159X 1875-6190 CURR NEUROPHARMACOL Curr.
Neuropharmacol. 2018 16 4 426 437
10.2174/1570159X15666170915142122 12 Neurosciences;
Pharmacology & Pharmacy Neurosciences & Neurology; Pharmacology & Pharmacy GF4EL
WOS:000431914200008 28925882 2019-09-25
J Lo, CC; Yang, F; Ash-Houchen, W; Cheng, TC Lo, Celia
C.; Yang, Fan; Ash-Houchen, William; Cheng, Tyrone C. Racial/Ethnic
Differences in Cigarette Use: The Roles of Mental Illness and Health-Care
Access/Utilization SUBSTANCE USE & MISUSE English Article
Racial; ethnic differences; cigarette use; mental
illness; health-care access; utilization TRADITIONAL CHINESE MEDICINE; SUBSTANCE
USE DISORDERS; COLLEGE-STUDENTS; SELF-MEDICATION; UNITED-STATES; RACIAL
DISPARITIES; NATIONAL-SURVEY; LUNG-CANCER; SMOKING; PREVALENCE Background:
Empirical evidence supports a hypothesis that cigarettes may be used to cope with
mental illness. Little research, however, addresses how race/ethnicity is linked to
mental health and cigarette use. Objectives: This study applied the self-medication
hypothesis. It asked whether mental status was associated, via health-care
access/utilization, with the cigarette use outcomes of four racial/ethnic groups.
It also tested whether race/ethnicity moderated any such associations. Methods: We
used nationally representative data from the 2009-2010 and 2011-2012 National
Health and Nutrition Examination Surveys to link cigarette use to mental status and
health-care access/utilization. The final sample included 3827 White respondents,
1635 African-American respondents, 1144 Mexican-American respondents, and 781
Hispanic American (other than Mexican-American) respondents. Results: Consistent
with earlier research and the self-medication hypothesis, we observed a positive
relationship between cigarette use and mental status. Associations of cigarette use
and health-care access/utilization sometimes failed to take expected directions.
Conclusions: We concluded from the findings that race/ethnicity's moderating role
in associations between cigarette use and health-care access was generally more
advantageous to Whites than other groups examined. Where treatment is delayed by
lack of access to, or lack of trust in, care providers, mental health may worsenand
it is often minority Americans who lack access and trust. If minority Americans'
health is to improve, shrinking racial health disparities, then access to adequate
health care must be available to them, facilitating prompt treatment of mental and
other illness. [Lo, Celia C.] Texas Womans Univ, Dept Sociol & Social Work, CFO
306, Denton, TX 76204 USA; [Yang, Fan] Univ Alabama, Sch Social Work, Tuscaloosa,
AL USA; [Ash-Houchen, William] Texas Womans Univ, Dept Sociol & Social Work,
Denton, TX 76204 USA; [Cheng, Tyrone C.] Montclair State Univ, Dept Social Work &
Child Advocacy, Montclair, NJ USA Lo, CC (reprint author), Texas Womans Univ,
Dept Sociol & Social Work, CFO 306, Denton, TX 76204 USA. clo@twu.edu
Agaku IT, 2014, MMWR-MORBID MORTAL W, V63, P29; Audrain-McGovern J,
2009, ADDICTION, V104, P1743, DOI 10.1111/j.1360-0443.2009.02617.x; Breslau N,
1998, ARCH GEN PSYCHIAT, V55, P161, DOI 10.1001/archpsyc.55.2.161; Cameron IM,
2008, BRIT J GEN PRACT, V58, P32, DOI 10.3399/bjgp08X263794; Carliner H, 2014,
COMPR PSYCHIAT, V55, P233, DOI 10.1016/j.comppsych.2013.09.009; Degenhardt L, 2001,
Nicotine Tob Res, V3, P225; Douglas KA, 1997, J AM COLL HEALTH, V46, P55, DOI
10.1080/07448489709595589; Dovidio JF, 2008, SOC SCI MED, V67, P478, DOI
10.1016/j.socscimed.2008.03.019; Eack SM, 2012, SOC WORK RES, V36, P41, DOI
10.1093/swr/svs014; Encrenaz G, 2006, SOC PSYCH PSYCH EPID, V41, P378, DOI
10.1007/s00127-006-0039-1; Eriksen M, 2012, TOBACCO ATLAS AM CAN; ESCOBAR JI, 1988,
ACTA PSYCHIAT SCAND, V78, P45, DOI 10.1111/j.1600-0447.1988.tb09001.x; Everett SA,
1999, J AM COLL HEALTH, V48, P55, DOI 10.1080/07448489909595674; Gee GC, 2006, AM J
PUBLIC HEALTH, V96, P1821, DOI 10.2105/AJPH.2005.080085; Haiman CA, 2006, NEW ENGL
J MED, V354, P333, DOI 10.1056/NEJMoa033250; Harris KM, 2005, MED CARE, V43, P775,
DOI 10.1097/01.mlr.0000170405.66264.23; Harris KM, 2005, HEALTH SERV RES, V40,
P117, DOI 10.1111/j.1475-6773.2005.00345.x; Hartz SM, 2014, JAMA PSYCHIAT, V71,
P248, DOI 10.1001/jamapsychiatry.2013.3726; Hilbe J, 2011, NEGATIVE BINOMIAL RE;
Holma IAK, 2013, DEPRESS ANXIETY, V30, P580, DOI 10.1002/da.22108; Jamal A, 2015,
MMWR-MORBID MORTAL W, V64, P1233, DOI 10.15585/mmwr.mm6444a2; Khantzian EJ, 1997,
HARVARD REV PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550; Land KC, 1996,
SOCIOL METHOD RES, V24, P387, DOI 10.1177/0049124196024004001; Lasser K, 2000,
JAMA-J AM MED ASSOC, V284, P2606, DOI 10.1001/jama.284.20.2606; Liao T., 1994,
INTERPRETING PROBABI; Lo CC, 2015, SUBST USE MISUSE, V50, P1274, DOI
10.3109/10826084.2014.998236; Lo CC, 2014, J PSYCHOACTIVE DRUGS, V46, P233, DOI
10.1080/02791072.2014.887161; Lo CC, 2013, J COMMUN HEALTH, V38, P727, DOI
10.1007/s10900-013-9671-3; Lo Celia C, 2012, Am J Addict, V21 Suppl 1, pS77, DOI
10.1111/j.1521-0391.2012.00292.x; Lo CC, 2012, J MENT HEALTH, V21, P430, DOI
10.3109/09638237.2012.664303; Lo CC, 2012, AM J ADDICTION, V21, P150, DOI
10.1111/j.1521-0391.2011.00205.x; Long J. S., 2006, REGRESSION MODELS CA; Ng M,
2014, JAMA-J AM MED ASSOC, V311, P183, DOI 10.1001/jama.2013.284692; Martins DC,
2008, PUBLIC HEALTH NURS, V25, P420, DOI 10.1111/j.1525-1446.2008.00726.x; Mason M.
J., 2013, PSYCHIAT SERVICES; McNeill A, 2001, S SMOK MENT HLTH SMO; Moriarty David
G, 2003, Health Qual Life Outcomes, V1, P37, DOI 10.1186/1477-7525-1-37; National
Center for Health Statistics Centers for Disease Control and Prevention (CDC),
2016, NAT HLTH NUTR EX SUR; Nawaz S, 2012, J DUAL DIAGN, V8, P180, DOI
10.1080/15504263.2012.697449; Ortega AN, 2007, ARCH INTERN MED, V167, P2354, DOI
10.1001/archinte.167.21.2354; Pfortner TK, 2016, ADDICT BEHAV, V53, P58, DOI
10.1016/j.addbeh.2015.09.016; Primack BA, 2013, SUBST USE MISUSE, V48, P211, DOI
10.3109/10826084.2012.750363; Purnell JQ, 2012, AM J PUBLIC HEALTH, V102, P844, DOI
10.2105/AJPH.2012.300694; Rigotti NA, 2000, JAMA-J AM MED ASSOC, V284, P699, DOI
10.1001/jama.284.6.699; Shen BJ, 2001, AM J COMMUN PSYCHOL, V29, P387, DOI
10.1023/A:1010338413293; Trinh NHT, 2011, BMC PSYCHIATRY, V11, DOI 10.1186/1471-
244X-11-166; Wanchek TN, 2011, PSYCHIAT SERV, V62, P194, DOI
10.1176/ps.62.2.pss6202_0194; Wilkinson AL, 2016, ADDICT BEHAV, V60, P64, DOI
10.1016/j.addbeh.2016.03.036; Williams DR, 2012, HEALTH SERV RES, V47, P1255, DOI
10.1111/j.1475-6773.2012.01404.x; Yang LH, 2008, CULT DIVERS ETHN MIN, V14, P10,
DOI 10.1037/1099-9809.14.1.10; Yang LH, 2009, J NERV MENT DIS, V197, P207, DOI
10.1097/NMD.0b013e3181999513; Young-Wolff KC, 2015, NICOTINE TOB RES, V17, P285,
DOI 10.1093/ntr/ntu141 52 0 0 0 0 TAYLOR & FRANCIS INC
PHILADELPHIA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
1082-6084 1532-2491 SUBST USE MISUSE Subst. Use Misuse 2018
 53 7 1184 1193
10.1080/10826084.2017.1400062 10 Substance Abuse; Psychiatry;
Psychology Substance Abuse; Psychiatry; Psychology GF0EG WOS:000431602100015
29172859 2019-09-25
J Canham, SL; Mahmood, A; Stalman, MN; King, D; O'Rourke, N
Canham, Sarah L.; Mahmood, Atiya; Stalman, Marissa N.; King, David; O'Rourke,
Norm Personal theories of substance use among middle-aged and older
adults with bipolar disorder AGING & MENTAL HEALTH English
Article Bipolar disorder; comorbidity;
self-medication; drug and alcohol misuse SELF-MEDICATION HYPOTHESIS; ALCOHOL-USE;
MENTAL-DISORDERS; DUAL DIAGNOSIS; UNITED-STATES; ABUSE; EXPECTANCIES; COMORBIDITY;
CANNABIS; SPECTRUM Objectives: Most persons with bipolar disorder (BD) misuse
alcohol and/or illicit drugs at some point, yet research specific to older adults
with BD is nascent. The current study sought an in-depth understanding of the
experiences and meanings of substance use in a sample of adults who self-reported
substance misuse.Methods: Semi-structured interviews were conducted and
thematically analyzed to understand the personal theories of substance use by 12
adults (9 women and 3 men; M = 49years old) who self-reported diagnoses of BD and
regular alcohol or illicit drug use.Results: Findings provide an in-depth picture
of the theories middle-aged and older adults with BD have developed to explain
their substance use. Participants' theories suggest multiple reasons for substance
use, including self-medication; increased confidence with substance use; rejection
of prescribed medications; easy access to alcohol; early social exposure/use as
facilitator; and living in a culture of substance use.Conclusion: Findings suggest
multiple theories for the comorbid link between BD and substance use, primarily
that persons with BD use drugs and/or alcohol to relieve stress or manage symptoms.
It is clinically relevant to incorporate personal reasons for actively and
regularly using substances as part of personalized substance treatment and BD
symptom management. [Canham, Sarah L.] Simon Fraser Univ, Gerontol Res Ctr,
Vancouver, BC, Canada; [Mahmood, Atiya] Simon Fraser Univ, Dept Gerontol,
Vancouver, BC, Canada; [Stalman, Marissa N.; King, David] Simon Fraser Univ, IRMACS
Ctr, Burnaby, BC, Canada; [O'Rourke, Norm] Ben Gurion Univ Negev, Dept Publ Hlth,
Beer Sheva, Israel; [O'Rourke, Norm] Ben Gurion Univ Negev, Ctr Multidisciplinary
Res Aging, Beer Sheva, Israel Canham, SL (reprint author), Simon Fraser Univ,
Gerontol Res Ctr, Vancouver, BC, Canada. scanham@sfu.ca Canham, Sarah/J-2927-
2019 Canham, Sarah/0000-0002-0421-2612; O'Rourke, Norm/0000-0001-5100-427X
Almeida OP, 2002, INT PSYCHOGERIATR, V14, P311, DOI
10.1017/S1041610202008517; Arndt S, 2011, AM J GERIAT PSYCHIAT, V19, P704, DOI
10.1097/JGP.0b013e31820d942b; Bearden CE, 2001, BIPOLAR DISORD, V3, P106, DOI
10.1034/j.1399-5618.2001.030302.x; Bizzarri JV, 2007, BIPOLAR DISORD, V9, P213, DOI
10.1111/j.1399-5618.2007.00383.x; Bizzarri JV, 2009, PSYCHIAT RES, V165, P88, DOI
10.1016/j.psychres.2007.10.009; Boeije H, 2002, QUAL QUANT, V36, P391, DOI
10.1023/A:1020909529486; Boyatzis R. E., 1998, TRANSFORMING QUALITA; Boyd MR, 2007,
ARCH PSYCHIAT NURS, V21, P70, DOI 10.1016/j.apnu.2006.11.001; Braun V., 2006,
QUALITATIVE RES PSYC, V3, P77, DOI DOI 10.1191/1478088706QP0630A; BROWN SA, 1980, J
CONSULT CLIN PSYCH, V48, P419, DOI 10.1037/0022-006X.48.4.419; Cassidy F, 2001,
BIPOLAR DISORD, V3, P181, DOI 10.1034/j.1399-5618.2001.30403.x; Clausen JA, 1998,
METHODS LIFE COURSE, P189; Depp CA, 2004, BIPOLAR DISORD, V6, P343, DOI
10.1111/j.1399-5618.2004.00139.x; Dupree L.W., 1998, J MENTAL HLTH AGING, V4, P215;
Eden J, 2012, MENTAL HLTH SUBSTANC; Gildengers AG, 2004, AM J PSYCHIAT, V161, P736,
DOI 10.1176/appi.ajp.161.4.736; Goldberg JF, 1999, J CLIN PSYCHIAT, V60, P733, DOI
10.4088/JCP.v60n1103; Han BH, 2017, ADDICTION, V112, P516, DOI 10.1111/add.13670;
Han B, 2009, ADDICTION, V104, P88, DOI 10.1111/j.1360-0443.2008.02411.x; Healey C,
2009, J AFFECT DISORDERS, V113, P118, DOI 10.1016/j.jad.2008.05.010; Henwood B,
2007, AM J ADDICTION, V16, P160, DOI 10.1080/10550490701375368; Khantzian EJ, 1997,
HARVARD REV PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550; King D.B., 2017,
ENCY GEROPSYCHOLOGY, P402, DOI [10.1007/978-981-287-080-3_203-1, DOI 10.1007/978-
981-287-080-3_203-1]; Kuerbis A, 2014, CLIN GERIATR MED, V30, P629, DOI
10.1016/j.cger.2014.04.008; Kvale S., 2008, DOING INTERVIEWS; Lachenmeier DW, 2015,
SCI REP-UK, V5, DOI 10.1038/srep08126; Lagerberg TV, 2010, BMC PSYCHIATRY, V10, DOI
10.1186/1471-244X-10-9; MARLATT GA, 1988, ANNU REV PSYCHOL, V39, P223, DOI
10.1146/annurev.psych.39.1.223; Merikangas KR, 2007, ARCH GEN PSYCHIAT, V64, P543,
DOI 10.1001/archpsyc.64.5.543; Mueser KT, 1998, ADDICT BEHAV, V23, P717, DOI
10.1016/S0306-4603(98)00073-2; Pastor AD, 2003, DRUG ALCOHOL DEPEN, V70, P201, DOI
10.1016/S0376-8716(03)00007-3; Patton MQ, 2002, QUALITATIVE RES EVAL; Ponce
Hernando, 1999, Journal of Geriatric Drug Therapy, V12, P55, DOI
10.1300/J089v12n03_06; REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511; REICH LH,
1974, AM J PSYCHIAT, V131, P83, DOI 10.1176/ajp.131.1.83; Rodgers B, 2005,
ADDICTION, V100, P1280, DOI 10.1111/j.1360-0443.2005.01158.x; Sajatovic M, 2004,
PSYCHIAT SERV, V55, P1014, DOI 10.1176/appi.ps.55.9.1014; Sajatovic M, 2002, J
GERIATR PSYCH NEUR, V15, P128, DOI 10.1177/089198870201500303; Sajatovic M, 2006,
INT J GERIATR PSYCH, V21, P582, DOI 10.1002/gps.1527; Sajatovic M, 2015, BIPOLAR
DISORD, V17, P689, DOI 10.1111/bdi.12331; Satre DD, 2001, AGING MENT HEALTH, V5,
P73, DOI 10.1080/13607860020020672; Sonne SC, 1999, PSYCHIAT CLIN N AM, V22, P609,
DOI 10.1016/S0193-953X(05)70098-8; Strakowski SM, 2000, CLIN PSYCHOL REV, V20,
P191, DOI 10.1016/S0272-7358(99)00025-2; STRAUSS Anselm, 1967, DISCOVERY GROUNDED
T; Thornton LK, 2012, ACTA PSYCHIAT SCAND, V126, P87, DOI 10.1111/j.1600-
0447.2012.01861.x; Weiss R D, 1985, Psychiatr Med, V3, P357; Westman J, 2013, BMJ
OPEN, V3, DOI 10.1136/bmjopen-2012-002373 47 2 2 1 3 ROUTLEDGE
JOURNALS, TAYLOR & FRANCIS LTD ABINGDON 2-4 PARK SQUARE, MILTON PARK,
ABINGDON OX14 4RN, OXON, ENGLAND 1360-7863 1364-6915 AGING MENT HEALTH
Aging Ment. Health 2018 22 6 813
818 10.1080/13607863.2017.1299689 6 Geriatrics &
Gerontology; Gerontology; Psychiatry Geriatrics & Gerontology; Psychiatry
GB8MS WOS:000429330600014 28271715 2019-09-25
J Balcioglu, YH; Kirlioglu, SS; Aydin, PC Balcioglu, Yasin
Hasan; Kirlioglu, Simge Seren; Aydin, Pinar Cetinay Polysubstance use
disorder as a probable self-medication in Isaacs' syndrome PSYCHIATRY AND CLINICAL
PSYCHOPHARMACOLOGY English Editorial Material
Cannabinoids; Isaacs' syndrome; neuromyotonia; opioids; substance
use disorder PAIN Isaacs' syndrome (IS) is an autoimmunological
hyperexcitability syndrome of the peripheral motor nerves, manifesting with
progressive muscle stiffness, involuntary continuous muscle twitching, muscle pain
and cramping, sweating, and decreased reflexes. We report a 31-year-old man who was
suffering from muscle twitches and stiffness in lower extremities and previously
diagnosed with IS in his age of 16 through electrophysiological studies and the
shown presence of autoantibodies against voltage-gated potassium channels. Without
any adherence to the prescribed treatment, he had been using synthetic cannabinoids
and opioids for 10 years. He admitted lessened complaints by using them. Current
literature offered cannabinoid receptor agonists not only for symptomatic relief in
IS, but also potential modulator effects on both potassium channels and
autoimmunity. Opioids were also recognized with their analgesic and antispastic
effects in the management of IS. This report aimed to discuss possible medicinal
effects and therapeutic mechanisms of aforementioned psychoactive molecules on the
symptomatology of IS. [Balcioglu, Yasin Hasan; Kirlioglu, Simge Seren; Aydin,
Pinar Cetinay] Bakirkoy Prof Mazhar Osman Training & Res Hosp Ps, Dept Psychiat,
Istanbul, Turkey Balcioglu, YH (reprint author), Bakirkoy Prof Mazhar Osman
Training & Res Hosp Ps, Dept Psychiat, Istanbul, Turkey.
yasinhasanbalcioglu@bakirkoyruhsinir.gov.tr Ahmed
A, 2015, MUSCLE NERVE, V52, P5, DOI 10.1002/mus.24632; Baker D, 2003, LANCET
NEUROL, V2, P291, DOI 10.1016/S1474-4422(03)00381-8; Chang JPC, 2009, PROG NEURO-
PSYCHOPH, V33, P739, DOI 10.1016/j.pnpbp.2009.03.015; Fijal K, 2016, CLIN
NEUROPHARMACOL, V39, P94, DOI 10.1097/WNF.0000000000000132; Klauke AL, 2014, EUR
NEUROPSYCHOPHARM, V24, P608, DOI 10.1016/j.euroneuro.2013.10.008; Maddison P, 2006,
CLIN NEUROPHYSIOL, V117, P2118, DOI 10.1016/j.clinph.2006.03.008; Meyniel C, 2011,
CLIN NEUROL NEUROSUR, V113, P323, DOI 10.1016/j.clineuro.2010.11.006; Wissel J,
2006, J NEUROL, V253, P1337, DOI 10.1007/s00415-006-0218-8 8 0 0 0
0 TAYLOR & FRANCIS LTD ABINGDON 2-4 PARK SQUARE, MILTON PARK,
ABINGDON OR14 4RN, OXON, ENGLAND 2475-0573 2475-0581 PSYCHIAT CLIN
PSYCH Psychiatry Clin. Psychopharmacol. 2018 28 1
116 118 10.1080/24750573.2017.1389627 3 Pharmacology
& Pharmacy; Psychiatry Pharmacology & Pharmacy; Psychiatry GA3BC
WOS:000428201300021 DOAJ Gold 2019-09-25
J Holzer, KJ; Oh, S; Salas-Wright, CP; Vaughn, MG; Landess, J
Holzer, Katherine J.; Oh, Sehun; Salas-Wright, Christopher P.; Vaughn,
Michael G.; Landess, Jacqueline Gender differences in the trends
and correlates of major depressive episodes among juvenile offenders in the United
States COMPREHENSIVE PSYCHIATRY English Article
MENTAL-HEALTH PROBLEMS; PSYCHIATRIC-DISORDERS;
SUBSTANCE USE; SELF-MEDICATION; YOUNG ADULTHOOD; DRUG-USE; ADOLESCENTS;
DELINQUENCY; PREVALENCE; COMORBIDITY Purpose: Although it is well-established
that juvenile offenders are at an elevated risk for depression and that, within
this group, females have the highest risk, little is known regarding the trends in
the prevalence of depression among juvenile offenders in the United States. In the
present study, we systematically examine secular trends in major depressive
episodes (MDE) and their correlates among male and female juvenile offenders and
non-offenders in the United States. Methods: Data were collected between 2005 and
2014 as part of the National Survey on Drug Use and Health (NSDUH). The NSDUH uses
multistage area probability sampling methods to select a representative sample of
the civilian, non-institutionalized population in the United States. Participants
included 171,118 youth aged 12-17 (159,449 non-offenders and 11,669 offenders). The
primary variable of interest was self-reported past year MDE. Logistic regression
assessed whether sociodemographic factors and psychosocial and behavioral
correlates affected the risk of MDE. Results: Between 2005 and 2014, the prevalence
of MDE among female youth increased for both offender and non-offender groups: from
24.4% to 33.0% for the offenders and from 12.4% to 16.7% for the non-offenders. No
significant trend changes were observed among male youth. In both male and female
juvenile offenders, MDEs were associated with increased risk of illicit drug use
(males OR = 1.61, 95% CI = 1.18-2.18; females OR = 1.83, 95% CI = 1.45-2.31).
Additional correlates include alcohol use among male offenders (OR = 1.36, 95% CI =
1.01-1.83), and binge drinking in female offenders (OR = 1.24, 95% CI = 1.02-1.49).
Conclusions: The prevalence of past year major depressive episodes is increasing
for female juvenile offenders, highlighting a need for improved efforts to target
these populations for prevention and treatment. (C) 2017 Elsevier Inc. All rights
reserved. [Holzer, Katherine J.; Vaughn, Michael G.] St Louis Univ, Coll Publ
Hlth & Social Justice, Sch Social Work, St Louis, MO 63103 USA; [Oh, Sehun] Univ
Texas Austin, Sch Social Work, Austin, TX 78712 USA; [Salas-Wright, Christopher P.]
Boston Univ, Sch Social Work, Boston, MA 02215 USA; [Landess, Jacqueline] St Louis
Univ, Sch Med, Dept Psychiat & Behav Neurosci, St Louis, MO USA Holzer, KJ
(reprint author), 3550 Lindell Blvd, St Louis, MO 63103 USA. holzerkj@slu.edu
Vaughn, Michael/W-2694-2019 National Institute on Drug Abuse at the
National Institutes of HealthUnited States Department of Health & Human
ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug
Abuse (NIDA) [R25 DA030310]; National Center for Advancing Translational Science
[KL2 TR001411] This research was supported in part by the National Institute on
Drug Abuse at the National Institutes of Health (R25 DA030310; PI: James C.
Anthony) and the National Center for Advancing Translational Science (KL2 TR001411;
PI: David Felson). The authors declare that there are no conflicts of interest
associated with this manuscript. Abram KM, 2014, JUVENILE JUSTICE B; Akse J,
2007, EUR J PERSONALITY, V21, P235, DOI 10.1002/per.604; Allwood M. A., 2012, J
CHILD ADOLESCENT T, V5, P114, DOI DOI 10.1080/19361521.2012.671795; American
Psychiatric Association, 2013, DIAGNOSTIC STAT MANU; American Psychiatric
Association, 1994, DIAGN STAT MAN MENT; Angold A, 1999, J CHILD PSYCHOL PSYC, V40,
P57, DOI 10.1111/1469-7610.00424; Audrain-McGovern J, 2009, ADDICTION, V104, P1743,
DOI 10.1111/j.1360-0443.2009.02617.x; Avenevoli S, 2015, J AM ACAD CHILD PSY, V54,
P37, DOI 10.1016/j.jaac.2014.10.010; AVISON WR, 1992, J HEALTH SOC BEHAV, V33, P77,
DOI 10.2307/2137248; Becker SJ, 2013, BROWN U CHILD ADOLES, V29; Breda CS, 2003,
CRIM JUSTICE BEHAV, V30, P644, DOI 10.1177/0093854803256451; Brent DA, 2002, NEW
ENGL J MED, V347, P667, DOI 10.1056/NEJMcp012249; Burke JD, 2015, J CHILD FAM STUD,
V24, P3774, DOI 10.1007/s10826-015-0185-8; Cauffman E, 2005, OUR CHILDREN THEIR C,
P390; Centers for Disease Control and Prevention, 2016, COND TREND AN YRBS D;
Chaiton MO, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-356; Deykin EY,
1986, PUBLIC HLTH, V76, P178; Diamantopoulou S, 2011, J ABNORM PSYCHOL, V120, P644,
DOI 10.1037/a0023669; Diego MA, 2003, ADOLESCENCE, V38, P35; Dunn V, 2006, BRIT J
PSYCHIAT, V188, P216, DOI 10.1192/bjp.188.3.216; Fazel S, 2008, J AM ACAD CHILD
PSY, V47, P1010, DOI [10.1097/CHI.0b013e31817eeef3, 10.1097/CHI.ObO13e31817eecf3];
Gallagher CA, 2006, J ADOLESCENT HEALTH, V38, P662, DOI
10.1016/j.jadohealth.2005.01.002; Greene RW, 2002, AM J PSYCHIAT, V159, P1214, DOI
10.1176/appi.ajp.159.7.1214; Hallfors DD, 2005, AM J PREV MED, V29, P163, DOI
10.1016/j.amepre.2005.06.002; Hankin BL, 1998, J ABNORM PSYCHOL, V107, P128, DOI
10.1037/0021-843X.107.1.128; Harvard School of Medicine, 2005, NAT COM SURV;
Hauenstein EJ, 2003, JOGNN, V32, P239, DOI 10.1177/0884217503252133; Johnson JE,
2011, INT J OFFENDER THER, V55, P1096, DOI 10.1177/0306624X10382637; Kang T, 2015,
LAW HUMAN BEHAV, V39, P593, DOI 10.1037/lhb0000145; KASHANI JH, 1980, PSYCHIAT RES,
V3, P185, DOI 10.1016/0165-1781(80)90035-9; Kessler RC, 2001, BIOL PSYCHIAT, V49,
P1002, DOI 10.1016/S0006-3223(01)01129-5; Kessler RC, 2003, JAMA-J AM MED ASSOC,
V289, P3095, DOI 10.1001/jama.289.23.3095; Kim JYS, 2002, PSYCHIATR SERV, V53, P70,
DOI 10.1176/appi.ps.53.1.70; Kovacs M, 2016, J AFFECT DISORDERS, V203, P374, DOI
10.1016/j.jad.2016.05.042; Lanctot N, 2007, CRIMINOLOGY, V45, P131, DOI
10.1111/j.1745-9125.2007.00074.x; Lenssen SAM, 2000, J ADOLESCENCE, V23, P287, DOI
10.1006/jado.2000.0315; Lewinsohn PM, 1998, CLIN PSYCHOL REV, V18, P765, DOI
10.1016/S0272-7358(98)00010-5; LEWINSOHN PM, 1994, J AM ACAD CHILD PSY, V33, P809,
DOI 10.1097/00004583-199407000-00006; Mace DE, 1997, J JUVENILE JUSTICE D, V12,
P18; Markou A, 1998, NEUROPSYCHOPHARMACOL, V18, P135, DOI 10.1016/S0893-
133X(97)00113-9; Merikangas KR, 2010, J AM ACAD CHILD PSY, V49, P980, DOI
10.1016/j.jaac.2010.05.017; Mojtabai R, 2016, PEDIATRICS, V138, DOI
10.1542/peds.2016-1878; Morris RE, 1998, J ADOLESCENT HEALTH, V23, P39, DOI
10.1016/S1054-139X(97)00268-1; NEIGHBORS B, 1992, ADDICT BEHAV, V17, P379, DOI
10.1016/0306-4603(92)90043-U; Overbeek G, 2006, INT J BEHAV DEV, V30, P433, DOI
10.1177/0165025406071491; Parker G, 2010, INT REV PSYCHIATR, V22, P429, DOI
10.3109/09540261.2010.492391; Paus T, 2008, NAT REV NEUROSCI, V9, P947, DOI
10.1038/nrn2513; PUIGANTICH J, 1982, J AM ACAD CHILD PSY, V21, P118, DOI
10.1016/S0002-7138(09)60910-9; PUTNINS AL, 1995, DRUG ALCOHOL REV, V14, P151, DOI
10.1080/09595239500185211; Richmond AD, 2015, J STUD ALCOHOL DRUGS, V76, P585, DOI
10.15288/jsad.2015.76.585; RIGGS PD, 1995, J AM ACAD CHILD PSY, V34, P764, DOI
10.1097/00004583-199506000-00017; Rogers K. M., 2001, J CHILD FAM STUD, V10, P485,
DOI DOI 10.1023/A:1016765525503; Salas-Wright CP, 2017, AM J PUBLIC HEALTH, V107,
P977, DOI 10.2105/AJPH.2017.303743; Salas-Wright CP, 2015, ADDICT BEHAV, V45, P218,
DOI 10.1016/j.addbeh.2015.01.039; Salas-Wright CP, 2017, DRUG ABUSE ANTISOCIA; SAS
L, 1985, JUVENILE FAM COURT J, V37, P49; Sherman F. T., 2015, GENDER INJUSTICE SYS;
Smith DK, 2013, J CHILD ADOLES SUBST, V22, P450, DOI 10.1080/1067828X.2013.788895;
Stahl AL, 2007, JUVENILE COURT STAT; Substance Abuse and Mental Health
Administration, 2014, RES 2013 NAT SURV DR; Teplin L. A., 2006, PSYCHIAT DISORDERS
Y; Teplin LA, 2002, ARCH GEN PSYCHIAT, V59, P1133, DOI 10.1001/archpsyc.59.12.1133;
Underwood LA, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13020228; United
States Department of Health and Human Services, 2014, NAT SURV DRUG US HLT; Vahl P,
2016, CHILD ABUSE NEGLECT, V62, P142, DOI 10.1016/j.chiabu.2016.10.008; Van Damme
L, 2014, PSYCHIAT RES, V220, P991, DOI 10.1016/j.psychres.2014.10.012; Vaughn MG,
2015, DRUG ALCOHOL DEPEN, V155, P97, DOI 10.1016/j.drugalcdep.2015.08.010; Vaughn
MG, 2015, COMPR PSYCHIAT, V59, P107, DOI 10.1016/j.comppsych.2015.02.012; Vaughn
MG, 2014, YOUTH VIOLENCE JUV J, V12, P3, DOI 10.1177/1541204013478973; Veen V,
2010, EUR CHILD ADOLES PSY, V19, P431, DOI 10.1007/s00787-009-0073-0; Wan YYT,
2012, DISCOVERY SS STUDENT, V1, P42; Wiesner M, 2006, J RES ADOLESCENCE, V16, P239,
DOI 10.1111/j.1532-7795.2006.00131.x; Wiesner M, 2006, DEV PSYCHOL, V42, P1220, DOI
10.1037/0012-1649.42.6.1220; Williams DR, 2007, ARCH GEN PSYCHIAT, V64, P305, DOI
10.1001/archpsyc.64.3.305 74 1 1 0 9 W B SAUNDERS CO-ELSEVIER
INC PHILADELPHIA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA
19103-2899 USA 0010-440X 1532-8384 COMPR PSYCHIAT Compr. Psychiat.
JAN 2018 80 72 80
10.1016/j.comppsych.2017.09.005 9 Psychiatry Psychiatry
FP5QC WOS:000417673000009 29065310 Green Accepted 2019-
09-25
J Grant, JE; Chamberlain, SR Grant, Jon E.; Chamberlain,
Samuel R. Caffeine's influence on gambling behavior and other types
of impulsivity ADDICTIVE BEHAVIORS English Article
Gambling; Caffeine; Impulsivity; Decision-making
SENSATION SEEKING; SUBSTANCE USE; RISK-TAKING; ADOLESCENTS; RELIABILITY;
CONSUMPTION; DEPENDENCE; INTERVIEW; DISORDER; CHILDREN Background: Young
adulthood is a developmental period frequently associated with occurrence of
impulsive behaviors including gambling. It is estimated that 73% of children and
87% of adults in the United States regularly use caffeine. Questions remain,
however, concerning the role of caffeine in the development and maintenance of
impulsive behaviors such as gambling. Methods: Sixty-one young adults with at least
some degree of disordered gambling were recruited from two Mid Western university
communities in the United States using media advertisements. Caffeine intake over
the preceding month was quantified using the Caffeine Use Questionnaire. Clinician
rating scales, questionnaires, and cognitive tests germane to impulsivity were
completed. Relationships between caffeine intake and demographic, gambling symptom,
and neurocognitive measures were evaluated using the statistical technique of
partial least squares (PLS). Results: Average weekly caffeine intake in the
gamblers was 1218.5 mg (a figure higher than previously reported in the general
population). PLS yielded an optimal model with one latent factor, which explained
14.8% of variation in demographic/clinical/cognitive measures and 32.3% of
variation in caffeine intake. In this model, higher caffeine intake was
significantly associated with earlier age at first gambling, higher personality-
related impulsiveness, more nicotine consumption, older age, and more impulsive
decision-making. Conclusions: These data suggest a particularly strong relationship
between caffeine intake, earlier age of first gambling, and certain types of
impulsivity in gamblers. Providing education about healthy caffeine use may be
especially valuable in gamblers. Future work should explore whether the
relationship between caffeine use and gambling is due to a common predisposing
factor (impulsive tendencies) or, rather, constitutes a form of self medication in
gamblers (or a means of sustaining gambling habits for longer). [Grant, Jon E.;
Chamberlain, Samuel R.] Univ Chicago, Pritzker Sch Med, Dept Psychiat & Behav
Neurosci, 5841 S Maryland Ave,MC 3077, Chicago, IL 60637 USA; [Grant, Jon E.;
Chamberlain, Samuel R.] Univ Cambridge, Dept Psychiat, Cambridge, England; [Grant,
Jon E.; Chamberlain, Samuel R.] Cambridge & Peterborough NHS Fdn Trust, Cambridge,
England Grant, JE (reprint author), Univ Chicago, Pritzker Sch Med, Dept
Psychiat & Behav Neurosci, 5841 S Maryland Ave,MC 3077, Chicago, IL 60637 USA.
jongrant@uchicago.edu Chamberlain, Samuel/V-1907-2019; Chamberlain, Samuel
R/O-7453-2018 Chamberlain, Samuel/0000-0001-7014-8121; Chamberlain, Samuel
R/0000-0001-7014-8121 NIMH, National Center for Responsible Gaming; American
Foundation for Suicide Prevention; TLC Foundation for Body Focused Repetitive
Behaviors; Brainsway; Forest; TakedaTakeda Pharmaceutical Company Ltd; Psyadon
Pharmaceuticals; Academy of Medical SciencesAcademy of Medical Sciences (AMS);
Wellcome TrustWellcome Trust [110049/Z/15/Z] Dr. Grant has received research
grants from NIMH, National Center for Responsible Gaming, the American Foundation
for Suicide Prevention, the TLC Foundation for Body Focused Repetitive Behaviors,
Brainsway, Forest, Takeda, and Psyadon Pharmaceuticals. He receives yearly
compensation from Springer Publishing for acting as Editor-in Chief of the Journal
of Gambling Studies and has received royalties from Oxford University Press,
American Psychiatric Publishing, Inc., Norton Press, and McGraw Hill. Dr.
Chamberlain consults for Cambridge Cognition and Shire; his involvement in this
research was funded by a grant from the Academy of Medical Sciences, and by a
Wellcome Trust Clinical Fellowship (110049/Z/15/Z). [Anonymous], J
PSYCHOPHARMACOLOGY, V28, P830; Aron AR, 2007, NEUROSCIENTIST, V13, P214, DOI
10.1177/1073858407299288; Arria AM, 2011, ALCOHOL CLIN EXP RES, V35, P365, DOI
10.1111/j.1530-0277.2010.01352.x; Black DW, 2013, COMPR PSYCHIAT, V54, P97, DOI
10.1016/j.comppsych.2012.07.001; Blanco C, 2012, PSYCHOL MED, V42, P497, DOI
10.1017/S0033291711001401; Branum AM, 2014, PEDIATRICS, V133, P386, DOI
10.1542/peds.2013-2877; Casey BJ, 2015, ANNU REV PSYCHOL, V66, P295, DOI
10.1146/annurev-psych-010814-015156; Castaneda AE, 2008, J AFFECT DISORDERS, V106,
P1, DOI 10.1016/j.jad.2007.06.006; Chambers R Andrew, 2003, J Gambl Stud, V19, P53,
DOI 10.1023/A:1021275130071; Frary CD, 2005, J AM DIET ASSOC, V105, P110, DOI
10.1016/j.jada.2004.10.027; GARTHWAITE PH, 1994, J AM STAT ASSOC, V89, P122, DOI
10.2307/2291207; Goudriaan AE, 2014, FRONT BEHAV NEUROSCI, V8, DOI
10.3389/fnbeh.2014.00141; Grant JE, 2004, PSYCHIAT RES, V128, P79, DOI
10.1016/j.psychres.2004.05.006; Grant JE, 2008, IMPULSE CONTROL DISO; Grant JE,
2016, PROG NEURO-PSYCHOPH, V65, DOI 10.1016/j.pnpbp.2015.10.007; Grant JE, 2014,
ADDICT BEHAV, V39, P1632, DOI 10.1016/j.addbeh.2014.04.022; Hoskuldsson A., 1988, J
CHEMOMETR, V2, P211, DOI DOI 10.1002/CEM.1180020306; Jones HA, 2005, EXP CLIN
PSYCHOPHARM, V13, P259, DOI 10.1037/1064-1297.13.3.259; Killgore WDS, 2012,
CHRONOBIOL INT, V29, P43, DOI 10.3109/07420528.2011.635230; Kponee KZ, 2014, ADDICT
BEHAV, V39, P253, DOI 10.1016/j.addbeh.2013.10.006; Krabbendam L, 2005, SCHIZOPHR
RES, V80, P137, DOI 10.1016/j.schres.2005.08.004; LOGAN GD, 1984, J EXP PSYCHOL
HUMAN, V10, P276, DOI 10.1037/0096-1523.10.2.276; Malinauskas BM, 2007, NUTR J, V6,
DOI 10.1186/1475-2891-6-35; Modi AA, 2010, HEPATOLOGY, V51, P201, DOI
10.1002/hep.23279; OWEN AM, 1991, NEUROPSYCHOLOGIA, V29, P993, DOI 10.1016/0028-
3932(91)90063-E; Pallanti S, 2005, J GAMBL STUD, V21, P431, DOI 10.1007/s10899-005-
5557-3; Quinn PD, 2011, J ABNORM PSYCHOL, V120, P543, DOI 10.1037/a0023159; Rogers
RD, 1999, J NEUROSCI, V19, P9029, DOI 10.1523/JNEUROSCI.19-20-09029.1999; Sheehan
DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Smith A, 2002,
FOOD CHEM TOXICOL, V40, P1243, DOI 10.1016/S0278-6915(02)00096-0; Somogyi L. P.,
2010, REPORT PREPARED FOOD; Stewart SH, 1997, J SUBST ABUSE, V9, P223, DOI
10.1016/S0899-3289(97)90018-3; Stone AL, 2012, ADDICT BEHAV, V37, P747, DOI
10.1016/j.addbeh.2012.02.014; Temple JL, 2017, J PSYCHOPHARMACOL, V31, P561, DOI
10.1177/0269881117691568; Tieges Z, 2009, BRAIN COGNITION, V69, P316, DOI
10.1016/j.bandc.2008.08.001; U. S. Department of Agriculture Agriculture Research
Service, 2008, NUTR INT FOOD MEAN A; Wold H., 1966, MULTIVARIATE ANAL, P391; Wold
S, 2001, CHEMOMETR INTELL LAB, V58, P109, DOI 10.1016/S0169-7439(01)00155-1 38
1 1 0 35 PERGAMON-ELSEVIER SCIENCE LTD OXFORD THE
BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND 0306-4603 1873-
6327 ADDICT BEHAV Addict. Behav. JAN 2018 76
156 160 10.1016/j.addbeh.2017.08.007 5
Psychology, Clinical; Substance Abuse Psychology; Substance Abuse FJ7ST
WOS:000412959900023 28822322 2019-09-25
J Subramaniam, M; Mahesh, MV; Peh, CX; Tan, J; Fauziana, R; Satghare, P; Gupta,
B; Gomathinayagam, K; Chong, SA Subramaniam, Mythily; Mahesh,
Mithila Valli; Peh, Chao Xu; Tan, Junda; Fauziana, Restria; Satghare, Pratika;
Gupta, Bhanu; Gomathinayagam, Kandasami; Chong, Siow Ann Hazardous
alcohol use among patients with schizophrenia and depression ALCOHOL
English Article Hazardous alcohol use;
Alcohol use disorders identification test; Asian; Depression; Schizophrenia
NATIONAL EPIDEMIOLOGIC SURVEY; SUBSTANCE USE DISORDERS; IDENTIFICATION TEST
AUDIT; DRUG-USE DISORDERS; PSYCHIATRIC OUTPATIENTS; SCREENING QUESTIONNAIRE;
ANXIETY DISORDERS; MAJOR DEPRESSION; ADULT INPATIENTS; SELF-MEDICATION Aims: The
current study aimed to 1) report the prevalence of hazardous alcohol use in an
outpatient population among those with schizophrenia and depressive disorders, 2)
assess the sociodemographic and clinical correlates of hazardous alcohol use, 3)
examine the association of hazardous alcohol use with severity of depression,
anxiety and smoking, and 4) assess the association of hazardous alcohol use with
quality of life. Methods: Three hundred ten outpatients seeking treatment at a
tertiary psychiatric institute with a diagnosis of either schizophrenia spectrum
disorder or depressive disorder were included in the study. Patients were assessed
for hazardous alcohol use using the Alcohol Use Disorders Identification Test.
Information on sociodemographic correlates, clinical history, severity of symptoms
of depression and anxiety, as well as quality of life (QOL) was collected. Results:
The overall prevalence of hazardous alcohol use among the sample was 12.6%. The
prevalence of hazardous alcohol use among patients with depression and
schizophrenia was 18.8% and 6.4%, respectively. Compared to those who were
students, patients who were gainfully employed or unemployed were more likely to
engage in hazardous alcohol use (Odds Ratio (OR) = 5.5 and 7.7, respectively).
Patients with depression compared to those with schizophrenia (OR = 11.1) and those
who were current smokers compared to those who had never smoked (OR = 14.5) were
more likely to engage in hazardous alcohol use. Hazardous alcohol use was
associated with lower QOL in the physical health domain (p = 0.002). Conclusion:
Given the significant prevalence of hazardous alcohol use in this population,
routine screening for hazardous alcohol use and brief interventions could be an
effective way of managing this comorbidity. There is a need to develop and evaluate
culturally appropriate brief interventions based on patient preference in this
setting. (C) 2017 The Authors. Published by Elsevier Inc. [Subramaniam, Mythily;
Mahesh, Mithila Valli; Peh, Chao Xu; Tan, Junda; Fauziana, Restria; Satghare,
Pratika; Chong, Siow Ann] Inst Mental Hlth, Div Res, Buangkok Green Med Pk,10
Buangkok View, Singapore 539747, Singapore; [Gupta, Bhanu] Inst Mental Hlth, Dept
Community Psychiat, Buangkok Green Med Pk,10 Buangkok View, Singapore 539747,
Singapore; [Gomathinayagam, Kandasami] Inst Mental Hlth, Natl Addict Management
Serv, Buangkok Green Med Pk,10 Buangkok View, Singapore 539747, Singapore
Subramaniam, M (reprint author), Inst Mental Hlth, Div Res, Buangkok Green
Med Pk,10 Buangkok View, Singapore 539747, Singapore. Mythily@imh.com.sg
Peh, Chao Xu/0000-0003-1247-883X Ministry of Health, National Medical
Research Council, Singapore (NMRC) under its Centre Grant program
[NMRC/CG/004/2013] Funding for this study was provided by Ministry of Health,
National Medical Research Council, Singapore (NMRC) under its Centre Grant program
(Grant no.: NMRC/CG/004/2013). Babor T, 2001, AUDIT ALCOHOL USE DI; Barnaby B,
2003, BRIT MED J, V327, P783, DOI 10.1136/bmj.327.7418.783; Beck A. T., 1996, BECK
DEPRESSION INVE; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-
006X.56.6.893; Beich A, 2002, BRIT MED J, V325, P870, DOI 10.1136/bmj.325.7369.870;
Bloomfield K, 2006, ALCOHOL ALCOHOLISM, V41, pI26, DOI 10.1093/alcalc/agl073; Boden
JM, 2011, ADDICTION, V106, P906, DOI 10.1111/j.1360-0443.2010.03351.x; Book SW,
2002, ALCOHOL RES HEALTH, V26, P130; Catalano R, 2011, ANNU REV PUBL HEALTH, V32,
P431, DOI 10.1146/annurev-publhealth-031210-101146; Centers for Disease Control and
Prevention, 2014, PLANN IMPL SCREEN BR; Chiolero A, 2006, PREV MED, V42, P348, DOI
10.1016/j.ypmed.2006.01.011; CONGER JJ, 1956, Q J STUD ALCOHOL, V17, P296; Conway
KP, 2006, J CLIN PSYCHIAT, V67, P247, DOI 10.4088/JCP.v67n0211; Daeppen JB, 2000,
ALCOHOL CLIN EXP RES, V24, P659, DOI 10.1111/j.1530-0277.2000.tb02037.x; Department
of Statistics Singapore, 2010, STAT REL 1 DEM CHAR; Drobes DJ, 2002, ALCOHOL RES
HEALTH, V26, P136; Eberhard S, 2015, J MENT HEALTH, V24, P162, DOI
10.3109/09638237.2015.1036967; Eng MY, 2007, ALCOHOL RES HEALTH, V30, P22; Falk DE,
2006, ALCOHOL RES HEALTH, V29, P162; Fergusson DM, 2009, ARCH GEN PSYCHIAT, V66,
P260, DOI 10.1001/archgenpsychiatry.2008.543; Fischer EH, 1998, AM J DRUG ALCOHOL
AB, V24, P453, DOI 10.3109/00952999809016909; Grant BF, 2004, ARCH GEN PSYCHIAT,
V61, P807, DOI 10.1001/archpsyc.61.8.807; Grothues JA, 2008, DRUG ALCOHOL DEPEN,
V94, P214, DOI 10.1016/j.drugalcdep.2007.11.015; HARADA S, 1981, LANCET, V2, P982;
Harper A, 1998, PSYCHOL MED, V28, P551, DOI 10.1017/S0033291798006667; Harris KM,
2005, HEALTH SERV RES, V40, P117, DOI 10.1111/j.1475-6773.2005.00345.x; Hart CL,
2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-789; Hearne R, 2002, J ROY
SOC MED, V95, P84, DOI 10.1258/jrsm.95.2.84; Huang MC, 2009, PSYCHIAT CLIN NEUROS,
V63, P94, DOI 10.1111/j.1440-1819.2008.01909.x; Hulse GK, 2003, ADDICTION, V98,
P1061, DOI 10.1046/j.1360-0443.2003.00404.x; Hulse GK, 2002, DRUG ALCOHOL REV, V21,
P105, DOI 10.1080/09595230220138993; Johansson E, 2007, HEALTH ECON, V16, P739, DOI
10.1002/hec.1201; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI
10.3109/10673229709030550; Kouri EM, 2004, DRUG ALCOHOL DEPEN, V75, P55, DOI
10.1016/j.drugalcdep.2004.01.011; Kuntsche S, 2006, ALCOHOL ALCOHOLISM, V41, pI37,
DOI 10.1093/alcalc/agl074; Kuo PH, 2006, PSYCHOL MED, V36, P1153, DOI
10.1017/S0033291706007860; Lim WY, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-
2458-13-992; Maisto SA, 2000, PSYCHOL ASSESSMENT, V12, P186, DOI 10.1037/1040-
3590.12.2.186; McCloud A, 2004, BRIT J PSYCHIAT, V184, P439, DOI
10.1192/bjp.184.5.439; McEachin RC, 2008, BIODATA MIN, V1, DOI 10.1186/1756-0381-1-
2; National Institute on Drug Abuse, 2010, COM ADD OTH MENT ILL; Nehlin C, 2013,
SUBST ABUS, V34, P162, DOI 10.1080/08897077.2012.728991; Nehlin C, 2012, ADDICT SCI
CLIN PRAC, V7, DOI 10.1186/1940-0640-7-23; Nehlin C, 2012, DRUG ALCOHOL REV, V31,
P538, DOI 10.1111/j.1465-3362.2011.00333.x; PEIRCE RS, 1994, J HEALTH SOC BEHAV,
V35, P291, DOI 10.2307/2137211; Picco L, 2012, ANN ACAD MED SINGAP, V41, P325; Rehm
J, 2010, ADDICTION, V105, P817, DOI 10.1111/j.1360-0443.2010.02899.x; Reinert DF,
2002, ALCOHOL CLIN EXP RES, V26, P272, DOI 10.1111/j.1530-0277.2002.tb02534.x;
Rodgers B, 2000, PSYCHOL MED, V30, P421, DOI 10.1017/S0033291799001865; Room R,
2004, BIOMED PHARMACOTHER, V58, P111, DOI 10.1016/j.biopha.2003.12.003; Rose JE,
2004, NICOTINE TOB RES, V6, P133, DOI 10.1080/14622200310001656957; Saha TD, 2007,
DRUG ALCOHOL DEPEN, V89, P82, DOI 10.1016/j.drugalcdep.2006.12.003; Schlaepfer
Isabel R, 2008, Curr Drug Abuse Rev, V1, P124; Schuckit MA, 2006, ADDICTION, V101,
P76, DOI 10.1111/j.1360-0443.2006.01592.x; Statistics Singapore, 2016, POPULATION
TRENDS; Subramaniam M, 2012, ADDICTION, V107, P1443, DOI 10.1111/j.1360-
0443.2012.03830.x; Tay ATS, 2016, ANN ACAD MED SINGAP, V45, P138; Virtanen M, 2015,
BMJ-BRIT MED J, V350, DOI 10.1136/bmj.g7772; Vuorilehto MS, 2009, PSYCHOL MED, V39,
P1697, DOI 10.1017/S0033291709005182; WHO, 2014, GLOBAL STATUS REPORT ON VIOLENCE
PREVENTION 2014, P1; World Health Organisation, 2016, GLOB DAT BOD MASS IN; World
Health Organization, 2000, INT GUID MON ALC CON; YOUNG RM, 1990, BRIT J ADDICT,
V85, P31 63 3 3 0 3 ELSEVIER SCIENCE INC NEW YORK 360
PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA 0741-8329 1873-6823
ALCOHOL Alcohol DEC 2017 65 63
69 10.1016/j.alcohol.2017.07.008 7 Substance Abuse;
Pharmacology & Pharmacy; Toxicology Substance Abuse; Pharmacology & Pharmacy;
Toxicology FN3OZ WOS:000415910000009 29084631 Other Gold 2019-
09-25
J Henderson, NL; Dressler, WW Henderson, Nicole L.;
Dressler, William W. Medical Disease or Moral Defect? Stigma
Attribution and Cultural Models of Addiction Causality in a University Population
CULTURE MEDICINE AND PSYCHIATRY English Article
Addiction; Stigma; Cultural models; Cultural consensus
analysis; Residual agreement analysis SOCIAL REJECTION; MENTAL-ILLNESS; LABELS;
DRUG; DISORDERS; CONSENSUS; ALCOHOL This study examines the knowledge individuals
use to make judgments about persons with substance use disorder. First, we show
that there is a cultural model of addiction causality that is both shared and
contested. Second, we examine how individuals' understanding of that model is
associated with stigma attribution. Research was conducted among undergraduate
students at the University of Alabama. College students in the 18-25 age range are
especially at risk for developing substance use disorder, and they are, perhaps
more than any other population group, intensely targeted by drug education. The
elicited cultural model includes different types of causes distributed across five
distinct themes: Biological, Self-Medication, Familial, Social, and Hedonistic.
Though there was cultural consensus among respondents overall, residual agreement
analysis showed that the cultural model of addiction causality is a multicentric
domain. Two centers of the model, the moral and the medical, were discovered.
Differing adherence to these centers is associated with the level of stigma
attributed towards individuals with substance use disorder. The results suggest
that current approaches to substance use education could contribute to stigma
attribution, which may or may not be inadvertent. The significance of these results
for both theory and the treatment of addiction are discussed. [Henderson, Nicole
L.; Dressler, William W.] Univ Alabama, Dept Anthropol, Tuscaloosa, AL 35487 USA
Henderson, NL (reprint author), Univ Alabama, Dept Anthropol, Tuscaloosa, AL
35487 USA. nlhenderson1@crimson.ua.edu; wdressle@ua.edu Graduate
School at the University of Alabama This study was funded by The Graduate School at
the University of Alabama. Ahern Jennifer, DRUG ALCOHOL DEPENDE, V88, P188;
BANDURA A, 1989, DEV PSYCHOL, V25, P729, DOI 10.1037/0012-1649.25.5.729; Barry CL,
2014, PSYCHIAT SERV, V65, P1269, DOI 10.1176/appi.ps.201400140; Borgatti S. P.,
1996, ANTHROPAC 4 0 REFERE; BORGATTI SP, 1999, ENHANCED ETHNOGRAPHI, P115; Caulkins
D. D., 1999, FIELD METHOD, V11, P5, DOI DOI 10.1177/1525822X9901100102; CONRAD P,
1992, ANNU REV SOCIOL, V18, P209, DOI 10.1146/annurev.so.18.080192.001233; Corrigan
PW, 2002, SCHIZOPHRENIA BULL, V28, P293, DOI 10.1093/oxfordjournals.schbul.a006939;
Corrigan PW, 1998, COGN BEHAV PRACT, V5, P201, DOI 10.1016/S1077-7229(98)80006-0;
Corrigan PW, 2000, CLIN PSYCHOL-SCI PR, V7, P48, DOI 10.1093/clipsy/7.1.48; Coulter
A, 1999, BRIT MED J, V319, P719, DOI 10.1136/bmj.319.7212.719; Dressler WW, 2015,
FIELD METHOD, V27, P22, DOI 10.1177/1525822X14542755; Drug Abuse Resistance
Education, 2014, EMP CHILDR LEAD SAF; Gaines A. D., 2006, ENCY ANTHR, V2, P862;
Gaines Atwood D., 1992, ETHNOPSYCHIATRY CULT; Gaucher J, 2005, STIGMA NOTES
MANAGEM; Good B., 1985, CULTURE DEPRESSION S; Hartzler B, 2003, J DRUG EDUC, V33,
P259, DOI 10.2190/2L2X-F8E1-32T9-UDMU; Haslam N, 2005, REV GEN PSYCHOL, V9, P35,
DOI 10.1037/1089-2680.9.1.35; JOHNSTON LD, 1975, MONITORING FUTURE NA, V2; KEELER
MH, 1968, AM J PSYCHIAT, V125, P386, DOI 10.1176/ajp.125.3.386; Lende DH, 2005,
ETHOS, V33, P100, DOI 10.1525/eth.2005.33.1.100; Link BG, 1999, AM J PUBLIC HEALTH,
V89, P1328, DOI 10.2105/AJPH.89.9.1328; LINK BG, 1987, AM J SOCIOL, V92, P1461, DOI
10.1086/228672; MacInnes Colin, 1966, Ment Health (Lond), V25, P24; Martin JK,
2000, J HEALTH SOC BEHAV, V41, P208, DOI 10.2307/2676306; Polak Frederick, 2000,
FORDHAM URBAN LAW J, V28, P351; REGIER DA, 1993, ARCH GEN PSYCHIAT, V50, P85;
ROMNEY AK, 1986, AM ANTHROPOL, V88, P313, DOI 10.1525/aa.1986.88.2.02a00020; Singer
M, 2001, SOC SCI MED, V53, P199, DOI 10.1016/S0277-9536(00)00331-2; Singer M.,
2014, SOCIAL VALUE DRUG AD; Strauss Claudia, 1994, ASSESSING CULTURAL A, P284;
Sturrock K., 2000, FIELD METHOD, V12, P49, DOI DOI 10.1177/1525822X0001200104;
Valverde Mariana, 1998, DIS WILL ALCOHOL DIL; WECHSLER H, 1995, AM J PUBLIC HEALTH,
V85, P921, DOI 10.2105/AJPH.85.7.921; Wright ER, 2000, J HEALTH SOC BEHAV, V41,
P68, DOI 10.2307/2676361; Wu LT, 2007, PSYCHIAT SERV, V58, P192, DOI
10.1176/appi.ps.58.2.192 37 0 0 3 22 SPRINGER DORDRECHT
VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS 0165-005X 1573-
076X CULT MED PSYCHIAT Cult. Med. Psychiatr. DEC 2017 41 4
480 498 10.1007/s11013-017-9531-1 19
Anthropology; Psychiatry; Social Sciences, BiomedicalAnthropology;
Psychiatry; Biomedical Social Sciences FM1TU WOS:000414765100003 28378037
2019-09-25
J Peyriere, H; Diot, C; Nogue, E; Verschave, M; Laure, M; Picot, MC; Petit, P;
Donnadieu-Rigole, H; Leglise, Y Peyriere, Helene; Diot,
Caroline; Nogue, Erika; Verschave, Marie; Laure, Morgan; Picot, Marie-Christine;
Petit, Pierre; Donnadieu-Rigole, Helene; Leglise, Yves Prevalence
of Antipsychotic-Treated Patients in a Cohort of Adult Addicted Patients
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY English Article
antipsychotic agents; addiction; antipsychotics;
addicted patients; prevalence; recreational substances; opiate maintenance therapy
SUBSTANCE USE DISORDERS; NATIONAL COMORBIDITY SURVEY; PSYCHIATRIC-DISORDERS;
MOOD DISORDERS; ABUSE; SCHIZOPHRENIA; METHADONE; OUTCOMES; ALCOHOL; FRANCE
Purpose The objective of this cross-sectional study was to describe and
estimate the prevalence of antipsychotics (AP) in a cohort of addicted patients,
and to compare the profiles of addictive patients receiving AP or not. Methods We
included all adult patients seen at the addiction care center of Montpellier
University Hospital, between January 1, 2015, and March 31, 2015. Demographic,
clinical, and therapeutic data were collected from the patients' medical records.
Results During the study period, 415 patients were included, with a mean age of 38
10 years. They were mostly men (73.3%), French (54.9%), and unemployed (61.8%).
Among the study population, 93 patients (patients treated with AP [trAP], 22.4%)
were treated by 111 different AP, mainly cyamemazine (29.0% of treated patients),
aripiprazole (20.4%), olanzapine (17.2%), and quetiapine (16.1%), mostly in
monotherapy (80.6%) and by oral route (93.2% of AP). Psychiatric history was more
frequent in trAP than in those without AP (untrAP) (55.9% vs 35.4% respectively; P
< 0.001). Professional activity tended to be less frequent in patients with AP
(25.3% vs 38.9%, P = 0.08). When compared with untrAP, trAP consumed more
amphetamine (10.8% vs 4.4%; P = 0.02) and tended to consume less opiates (7.5% vs
14.9%; P = 0.06); the consumptions of cannabis (43.0% vs 35.7%; P = 0.20) and
cocaine (22.6% vs 16.8%; P = 0.20) were not statistically different. Opiate
maintenance therapy was reported in 63.7% of trAP and 68.4% of untrAP (P = 0.41):
it consisted of methadone (trAP, 60.3% vs untrAP, 56.5%) and buprenorphine (trAP,
39.7% vs untrAP, 43.5%). Conclusions The concomitant management of psychiatric and
substance use disorders in the same center may explain the high prevalence of trAP
in this study. Cannabis and psychostimulants may have been used in these patients
as self-medication for mental disease-related symptoms or adverse effects of APs.
[Peyriere, Helene; Diot, Caroline; Laure, Morgan; Petit, Pierre] CHU
Montpellier, Dept Pharmacol Med & Toxicol, Ctr Addictovigilance, Montpellier,
France; [Nogue, Erika; Picot, Marie-Christine] CHU Montpellier, Dept Informat Med,
Unite Rech Clin & Epidemiol, Montpellier, France; [Verschave, Marie; Donnadieu-
Rigole, Helene; Leglise, Yves] CHU Montpellier, Dept Addictol, Med Interne,
Montpellier, France Peyriere, H (reprint author), Hop Lapeyronie, Serv
Pharmacol Med & Toxicol, 191 Ave Doyen Gaston Giraud, F-34295 Montpellier 5,
France. h-peyriere@chu-montpellier.fr Bizzarri JV, 2007,
BIPOLAR DISORD, V9, P213, DOI 10.1111/j.1399-5618.2007.00383.x; Bolton JM, 2009, J
AFFECT DISORDERS, V115, P367, DOI 10.1016/j.jad.2008.10.003; Breuer A, 2016, PLOS
ONE, V11, DOI 10.1371/journal.pone.0158779; Bruins J, 2016, J PSYCHOPHARMACOL, V30,
P354, DOI 10.1177/0269881116631652; Chambers RA, 2001, BIOL PSYCHIAT, V50, P71, DOI
10.1016/S0006-3223(01)01134-9; Dujourdy L, 2017, FORENSIC SCI INT, V272, P72, DOI
10.1016/j.forsciint.2017.01.007; Eiden C, 2012, THERAPIE, V67, P223, DOI
10.2515/therapie/2012025; Flynn PM, 2008, J SUBST ABUSE TREAT, V34, P36, DOI
10.1016/j.jsat.2006.11.013; Frauger E, 2013, FUND CLIN PHARMACOL, V27, P672, DOI
10.1111/fcp.12024; Green AI, 2007, AM J PSYCHIAT, V164, P402, DOI
10.1176/appi.ajp.164.3.402; Hallinan R, 2009, EUR J CLIN PHARMACOL, V65, P1113, DOI
10.1007/s00228-009-0706-8; Hashibe M, 2005, ALCOHOL, V35, P265, DOI
10.1016/j.alcohol.2005.04.008; Hasin D., 2004, DUAL DIAGNOSIS PSYCH, P1; Helseth V,
2009, NORD J PSYCHIAT, V63, P72, DOI 10.1080/08039480802450439; Jouanjus E, 2014, J
AM HEART ASSOC, V3, DOI 10.1161/JAHA.113.000638; Kessler RC, 1997, ARCH GEN
PSYCHIAT, V54, P313; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P617, DOI
10.1001/archpsyc.62.6.617; Kivimies K, 2016, NORD J PSYCHIAT, V70, P128, DOI
10.3109/08039488.2015.1059884; Lai HMX, 2015, DRUG ALCOHOL DEPEN, V154, P1, DOI
10.1016/j.drugalcdep.2015.05.031; Maremmani I, 2008, EUR ADDICT RES, V14, P134, DOI
10.1159/000130417; McCance-Katz EF, 2010, AM J ADDICTION, V19, P4, DOI
10.1111/j.1521-0391.2009.00005.x; Moracchini C, 2012, THERAPIE, V67, P437, DOI
10.2515/therapie/2012064; Najt P, 2011, PSYCHIAT RES, V186, P159, DOI
10.1016/j.psychres.2010.07.042; Peyriere H, 2016, RESEAU CTR ADDICTOVI; Rohleder
Cathrin, 2016, Front Pharmacol, V7, P422; Tenore PL, 2008, J ADDICT DIS, V27, P49,
DOI 10.1080/10550880802122646; Torrens M, 2012, SUBST USE MISUSE, V47, P1005, DOI
10.3109/10826084.2012.663296; Trull TJ, 2000, CLIN PSYCHOL REV, V20, P235, DOI
10.1016/S0272-7358(99)00028-8; Uehlinger C, 2007, J CLIN PSYCHOPHARM, V27, P273,
DOI 10.1097/JCP.0b013e3180592ad2 29 1 1 0 2 LIPPINCOTT
WILLIAMS & WILKINS PHILADELPHIA TWO COMMERCE SQ, 2001 MARKET ST,
PHILADELPHIA, PA 19103 USA 0271-0749 1533-712X J CLIN PSYCHOPHARM
J. Clin. Psychopharmacol. DEC 2017 37 6
669 674 10.1097/JCP.0000000000000806 6 Pharmacology
& Pharmacy; Psychiatry Pharmacology & Pharmacy; Psychiatry FM6AO
WOS:000415126900007 29045307 2019-09-25
J Smith, KE; Lawson, T Smith, Kirsten Elin; Lawson, Thomas
Prevalence and motivations for kratom use in a sample of substance
users enrolled in a residential treatment program DRUG AND ALCOHOL DEPENDENCE
English Article Kratom; Mitragyna
speciosa; Emerging drugs; Opioid; Harm-reduction MITRAGYNA-SPECIOSA KORTH.;
ALKALOID EXTRACT; INDOLE ALKALOIDS; OPIOID RECEPTORS; LEGAL HIGHS; DRUG-USE;
PHARMACOLOGY; ADDICTION; ABUSE; KRATHOM Background: Kratom use in the West has
increased recently, yet the prevalence and motives for use among individuals with a
history of substance use disorder (SUD) have not been fully examined. Kratom has
been documented as a means of treating chronic pain, mitigating drug dependence,
and easing withdrawal symptoms, yet it is unclear if substance users are utilizing
kratom as a self-medication. Abuse liability, side effects, and overall appeal of
kratom remain uncertain. Methods: In April 2017, an anonymous survey regarding
kratom use and motivations was completed by clients enrolled in a 12-Step-oriented
residential program. 500 respondents with a self-reported history of SUD completed
the survey. Results: 20.8% of respondents endorsed lifetime kratom use and 10.2%
reported past-12-month use. Kratomusers were younger (= 32.1 vs. 35.9, p < 0.001)
and were more versatile substance users. A majority (68.9%) of kratom-users
reported having used the drug as a means of reducing or abstaining from non-
prescription opioids (NPO) and/or heroin, and 64.1% reported using kratom as a
substitute for NPO/heroin. 18.4% of kratom-users reported using the drug due to a
disability or chronic pain. One-third of kratom-users stated that kratom was a
helpful substance and that they would try it again. However, kratom was not
preferred and was indicated as having less appeal than NPO, heroin, amphetamines,
and Suboxone. Conclusions: Among substance users, kratom use may be initiated for a
variety of reasons, including as a novel form of harm-reduction or drug
substitution, particularly in the context of dependence and withdrawal from other
substances. [Smith, Kirsten Elin; Lawson, Thomas] Univ Louisville, Kent Sch Social
Work, Louisville, KY 40292 USA Smith, KE (reprint author), Univ Louisville,
Kent Sch Social Work, Louisville, KY 40292 USA. kirstenelin.smith@louisville.edu
Ahmad K, 2012, J ETHNOPHARMACOL, V141, P446, DOI
10.1016/j.jep.2012.03.009; Anwar M, 2016, MMWR-MORBID MORTAL W, V65, P748, DOI
10.15585/mmwr.mm6529a4; Apryani E, 2010, J ETHNOPHARMACOL, V129, P357, DOI
10.1016/j.jep.2010.03.036; Arndt T, 2011, FORENSIC SCI INT, V208, P47, DOI
10.1016/j.forsciint.2010.10.025; Assanangkornchai S, 2007, SUBST USE MISUSE, V42,
P2145, DOI 10.1080/10826080701205869; Azizi J, 2010, MOLECULES, V15, P432, DOI
10.3390/molecules15010432; Babu KM, 2008, CLIN TOXICOL, V46, P146, DOI
10.1080/15563650701241795; Baker S., 2015, EXAMINATION REASONS; Bandura A, 2001,
ANNU REV PSYCHOL, V52, P1, DOI 10.1146/annurev.psych.52.1.1; Bandura A, 1999,
PSYCHOL SCI, V10, P214, DOI 10.1111/1467-9280.00138; Bandura A., 1997, SELF
EFFICACY EXERCI; Banerjee P, 2014, J FORENSIC SCI, V59, P865, DOI 10.1111/1556-
4029.12387; Baumeister R. F., 2010, FREE WILL CONSCIOUSN; Bonar EE, 2014, DRUG
ALCOHOL DEPEN, V143, P268, DOI 10.1016/j.drugalcdep.2014.07.009; Boyer EW, 2008,
ADDICTION, V103, P1048, DOI 10.1111/j.1360-0443.2008.02209.x; Boyer EW, 2007, AM J
ADDICTION, V16, DOI 10.1080/10550490701525368; Bronson J., 2015, DISABILITIES
PRISON; Brown PN, 2017, J ETHNOPHARMACOL, V202, P302, DOI
10.1016/j.jep.2017.03.020; Burkill I.H., 1935, DICT EC PRODUCTS MAL, VII, P1483;
Carpenter JM, 2016, FITOTERAPIA, V109, P87, DOI 10.1016/j.fitote.2015.12.001;
Castillo O., 2017, U MIAMI LAW REV, V72, P1; Cerda M, 2012, DRUG ALCOHOL DEPEN,
V120, P22, DOI 10.1016/j.drugalcdep.2011.06.011; Cicero TJ, 2014, JAMA PSYCHIAT,
V71, P821, DOI 10.1001/jamapsychiatry.2014.366; Cinosi E, 2015, BIOMED RES INT, DOI
10.1155/2015/968786; Compton WM, 2017, JAMA-J AM MED ASSOC, V317, P209, DOI
10.1001/jama.2016.18900; Connock M, 2007, NIHR HLTH TECHNOLOGY; Darke S, 1998, DRUG
ALCOHOL DEPEN, V51, P253, DOI 10.1016/S0376-8716(98)00028-3; Degenhardt L, 2008,
PLOS MED, V5, P1053, DOI 10.1371/journal.pmed.0050141; Denis C, 2012, SUBST USE
MISUSE, V47, P356, DOI 10.3109/10826084.2011.640732; Everitt BJ, 2016, ANNU REV
PSYCHOL, V67, P23, DOI 10.1146/annurev-psych-122414-033457; FARRELL M, 1994, BMJ-
BRIT MED J, V309, P997, DOI 10.1136/bmj.309.6960.997; Fluyau D, 2017, FRONT
PSYCHIATRY, V8, DOI 10.3389/fpsyt.2017.00062; Fuenffinger N, 2017, J PHARMACEUT
BIOMED, V134, P282, DOI 10.1016/j.jpba.2016.11.055; Grewal KS, 1932, J PHARMACOL
EXP THER, V46, P251; Griffin OH, 2016, J PSYCHOACTIVE DRUGS, V48, P330, DOI
10.1080/02791072.2016.1229876; Grundmann O, 2017, DRUG ALCOHOL DEPEN, V176, P63,
DOI 10.1016/j.drugalcdep.2017.03.007; Gunderson EW, 2014, SUBST ABUS, V35, P184,
DOI 10.1080/08897077.2013.846288; Hall MT, 2016, ADDICT BEHAV, V53, P113, DOI
10.1016/j.addbeh.2015.10.008; Harun N, 2015, PSYCHOPHARMACOLOGY, V232, P2227, DOI
10.1007/s00213-015-3866-5; Hassan Z, 2013, NEUROSCI BIOBEHAV R, V37, P138, DOI
10.1016/j.neubiorev.2012.11.012; Havemann-Reinecke U., 2011, J EUROPEAN PSYCHI S1,
V26, P50, DOI [10.1016/S0924-9338(11)71761-8, DOI 10.1016/S0924-9338(11)71761-8];
Hazim AI, 2014, J PHYSIOL SCI, V64, P161, DOI 10.1007/s12576-014-0304-0; Hazim AI,
2011, J MED PLANTS RES, V5, P5810; Heilig M, 2016, NAT REV NEUROSCI, V17, P592, DOI
10.1038/nrn.2016.67; Heyman G, 2009, ADDICTION DISORDER C; Holler JM, 2011, J ANAL
TOXICOL, V35, P54, DOI 10.1093/anatox/35.1.54; Ismail N.I.W., 2016, ADDICT BIO,
V22; Janchawee B, 2007, BIOMED CHROMATOGR, V21, P176, DOI 10.1002/bmc.731; Kandel
DB, 2017, DRUG ALCOHOL DEPEN, V178, P501, DOI 10.1016/j.drugalcdep.2017.05.047;
Kanouse Andrew B, 2015, J Pain Palliat Care Pharmacother, V29, P102, DOI
10.3109/15360288.2015.1037521; Kapp FG, 2011, J MED TOXICOL, V7, P227, DOI
10.1007/s13181-011-0155-5; Karinen R, 2014, FORENSIC SCI INT, V245, pE29, DOI
10.1016/j.forsciint.2014.10.025; Kertesz SG, 2017, SUBST ABUS, V38, P3, DOI
10.1080/08897077.2016.1261070; Kolodny A, 2015, ANNU REV PUBL HEALTH, V36, P559,
DOI 10.1146/annurev-publhealth-031914-122957; Kronstrand R, 2011, J ANAL TOXICOL,
V35, P242, DOI 10.1093/anatox/35.4.242; Kumarnsit E, 2007, NEUROSCI LETT, V416,
P128, DOI 10.1016/j.neulet.2007.01.061; Leon F, 2009, NAT PROD COMMUN, V4, P907;
Lesiak AD, 2014, FORENSIC SCI INT, V242, P210, DOI 10.1016/j.forsciint.2014.07.005;
LEWIS HD, 1983, NEW ENGL J MED, V309, P396, DOI 10.1056/NEJM198308183090703;
Likhitsathian S, 2015, EUR NEUROPSYCHOPHARM, V25, pS617, DOI 10.1016/S0924-
977X(15)30873-7; Low J.W., 2016, RES HIGHLIGHTS, P84; Lydecker AG, 2016, J MED
TOXICOL, V12, P341, DOI 10.1007/s13181-016-0588-y; MACKO E, 1972, ARCH INT
PHARMACOD T, V198, P145; Matsumoto K, 2005, LIFE SCI, V78, P2, DOI
10.1016/j.lfs.2004.10.086; Matsumoto K, 2004, LIFE SCI, V74, P2143, DOI
10.1016/j.lfs.2003.09.054; Matsumoto K, 2008, NEUROPHARMACOLOGY, V55, P154, DOI
10.1016/j.neuropharm.2008.05.003; Mattick R.P., 2008, COCHRANE DATABASE SY, V2;
McIntyre IM, 2015, J ANAL TOXICOL, V39, P152, DOI 10.1093/jat/bku137; McWhirter L,
2010, EUR ADDICT RES, V16, P229, DOI 10.1159/000320288; Mendelson J, 2008, EXP CLIN
PSYCHOPHARM, V16, P435, DOI 10.1037/a0013637; Miller BL, 2015, AM J CRIM JUSTICE,
V40, P523, DOI 10.1007/s12103-014-9270-6; Mohd Saleh Ahmad K, 2012, J PLANT STUD,
V1, P120, DOI DOI 10.5539/JPS.V1N2P120; Mossadeq WMS, 2009, MED PRIN PRACT, V18,
P378, DOI 10.1159/000226292; Muller CP, 2011, BEHAV BRAIN SCI, V34, P293, DOI
10.1017/S0140525X11000057; Neerman MF, 2013, J FORENSIC SCI, V58, pS278, DOI
10.1111/1556-4029.12009; Nelsen JL, 2010, J MED TOXICOL, V6, P424, DOI
10.1007/s13181-010-0079-5; Nelson ME, 2014, EMERG MED CLIN N AM, V32, P1, DOI
10.1016/j.emc.2013.09.001; Oliveira A.S., 2016, FORENSIC TOXICOL, P1; Orsolini L,
2015, CYBERPSYCH BEH SOC N, V18, P296, DOI 10.1089/cyber.2014.0486; Perrone D,
2013, DRUG-EDUC PREV POLIC, V20, P216, DOI 10.3109/09687637.2012.749392; Prozialeck
WC, 2012, J AM OSTEOPATH ASSOC, V112, P792; Prutipanlai S, 2017, TROP J PHARM RES,
V16, P1675, DOI 10.4314/tjpr.v16i7.28; Ralphs R, 2017, INT J DRUG POLICY, V40, P57,
DOI 10.1016/j.drugpo.2016.10.003; Rech MA, 2015, PHARMACOTHERAPY, V35, P189, DOI
10.1002/phar.1522; Ronka S, 2017, INT J DRUG POLICY, V39, P62, DOI
10.1016/j.drugpo.2016.08.013; Rudd RA, 2016, AM J TRANSPLANT, V16, P1323, DOI
10.1111/ajt.13776; Sabetghadam A, 2013, DRUG DEVELOP RES, V74, P23, DOI
10.1002/ddr.21052; Saingam D, 2016, J PSYCHOACTIVE DRUGS, V48, P76, DOI
10.1080/02791072.2016.1156791; Saingam D, 2014, SUBST ABUS, V35, P276, DOI
10.1080/08897077.2014.924464; Saingam D, 2013, INT J DRUG POLICY, V24, P351, DOI
10.1016/j.drugpo.2012.09.004; Schutt R.K., 2015, SOCIAL NEUROSCIENCE; Senik M. H.,
2012, Journal of Medicinal Plants Research, V6, P1234; Senik M.H., 2012, J MED
PLANTS RES, V6, P1007, DOI DOI 10.5897/JMPR11.601; Sheleg SV, 2011, J ADDICT MED,
V5, P300, DOI 10.1097/ADM.0b013e318221fbfa; Singh D, 2016, BRAIN RES BULL, V126,
P41, DOI 10.1016/j.brainresbull.2016.05.004; Singh D, 2015, J PSYCHOACTIVE DRUGS,
V47, P125, DOI 10.1080/02791072.2015.1012610; Srichana K, 2015, PHARMACEUTICS, V7,
P10, DOI 10.3390/pharmaceutics7020010; Suhaimi FW, 2016, BRAIN RES BULL, V126, P29,
DOI 10.1016/j.brainresbull.2016.03.015; Suwanlert S, 1975, B NARCO; Swogger MT,
2015, J PSYCHOACTIVE DRUGS, V47, P360, DOI 10.1080/02791072.2015.1096434; Takayama
H, 2004, CHEM PHARM BULL, V52, P916, DOI 10.1248/cpb.52.916; Takayama H, 1998,
TETRAHEDRON, V54, P8433, DOI 10.1016/S0040-4020(98)00464-5; Trakulsrichai S, 2015,
DRUG DES DEV THER, V9, P2421, DOI [10.2147/DDDT.579658, 10.2147/DDDT.S79658];
Tungtananuwat W, 2010, J HEALTH RES, V24, P43; Van Hout MC, 2017, BEHAV COGN
PSYCHOTH, V45, P238, DOI 10.1017/S1352465817000030; Vandrey R, 2012, DRUG ALCOHOL
DEPEN,
V120, P238, DOI 10.1016/j.drugalcdep.2011.07.011; Vicknasingam B, 2010, INT J DRUG
POLICY, V21, P283, DOI 10.1016/j.drugpo.2009.12.003; Volkow ND, 2016, NEW ENGL J
MED, V374, P363, DOI 10.1056/NEJMra1511480; Waljee JF, 2017, ANN SURG, V265, P728,
DOI 10.1097/SLA.0000000000001904; Ward J, 2011, CNS DRUGS, V25, P999, DOI
10.2165/11596830-000000000-00000; Warner ML, 2016, INT J LEGAL MED, V130, P127, DOI
10.1007/s00414-015-1279-y; Yusoff NHM, 2017, BEHAV BRAIN RES, V332, P1, DOI
10.1016/j.bbr.2017.05.059; Yusoff NHM, 2016, ADDICT BIOL, V21, P98, DOI
10.1111/adb.12185; ZANIS DA, 1994, DRUG ALCOHOL DEPEN, V35, P127, DOI 10.1016/0376-
8716(94)90119-8 114 27 27 0 9 ELSEVIER IRELAND LTD CLARE
ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND
0376-8716 1879-0046 DRUG ALCOHOL DEPEN Drug Alcohol Depend.
NOV 1 2017 180 340 348
10.1016/j.drugalcdep.2017.08.034 9 Substance Abuse;
Psychiatry Substance Abuse; Psychiatry FM2LP WOS:000414816600046 28950240
2019-09-25
J Elmore, K; Delva, J; Andrade, F Elmore, Kristen; Delva,
Jorge; Andrade, Fernando Gender differences in psychological
factors shaping smoking decisions of Chilean adolescents JOURNAL OF HEALTH
PSYCHOLOGY English Article
adolescence; gender; risk factors; smoking; symptoms SUBSTANCE USE;
DEPRESSIVE SYMPTOMS; INTERNALIZING PSYCHOPATHOLOGY; PSYCHIATRIC-DISORDERS;
CIGARETTE-SMOKING; SELF-MEDICATION; YOUNG ADULTHOOD; REGULAR SMOKING; TOBACCO USE;
CHILDHOOD This study examined gender differences in how internalizing and
externalizing symptoms affect adolescents' decisions about smoking in Chile, where
girls smoke at some of the highest rates in the world. In multivariate logistic
regression analyses with 607 adolescents, internalizing symptoms, such as depressed
mood and anxiety, predicted smoking among girls more than boys, with girls who were
low in internalizing symptoms being more likely to smoke than those who were high
in internalizing symptoms. In Chile's high-risk context, internalizing symptoms may
be indirectly protective for girls by decreasing their exposure to peer pressure
and related influences that encourage cigarette use. [Elmore, Kristen; Delva,
Jorge; Andrade, Fernando] Univ Michigan, Ann Arbor, MI 48109 USA Elmore, K (reprint
author), Univ Michigan, Sch Social Work, Ann Arbor, MI 48109 USA.
kelmore@umich.edu U.S. National Institute on Drug AbuseUnited
States Department of Health & Human ServicesNational Institutes of Health (NIH) -
USANIH National Institute on Drug Abuse (NIDA) [R01-DA-022720] The author(s)
disclosed receipt of the following financial support for the research, authorship,
and/or publication of this article: This study was funded by the U.S. National
Institute on Drug Abuse (Grant R01-DA-022720). Achenbach T. M., 1991, MANUAL CHILD
BEHAV C; ACHENBACH TM, 1978, PSYCHOL BULL, V85, P1275, DOI 10.1037/0033-
2909.85.6.1275; American Lung Association, 2009, DEADL PINK BIG TOB S; Amos A,
2012, TOB CONTROL, V21, P236, DOI 10.1136/tobaccocontrol-2011-050280; Borzekowski
DLG, 2013, PEDIATRICS, V132, pE825, DOI 10.1542/peds.2013-1150; Brook JS, 1998, J
AM ACAD CHILD PSY, V37, P322, DOI 10.1097/00004583-199803000-00018; Brook JS, 2006,
AM J ADDICTION, V15, P426, DOI 10.1080/10550490600996363; CICAD, 2015, REP DRUG US
AM; Costello EJ, 2003, ARCH GEN PSYCHIAT, V60, P837, DOI 10.1001/archpsyc.60.8.837;
Costello EJ, 1999, J CLIN CHILD PSYCHOL, V28, P298, DOI
10.1207/S15374424jccp280302; Crone MR, 2007, ADDICT BEHAV, V32, P1692, DOI
10.1016/j.addbeh.2006.11.006; Dierker LC, 2007, DRUG ALCOHOL DEPEN, V87, P83, DOI
10.1016/j.drugalcdep.2006.08.001; Eriksen M., 2015, TOBACCO ATLAS; Everett SA,
1999, PREV MED, V29, P327, DOI 10.1006/pmed.1999.0560; Fergusson DM, 1999, J CHILD
PSYCHOL PSYC, V40, P581, DOI 10.1111/1469-7610.00475; Fleming CB, 2008, PSYCHOL
ADDICT BEHAV, V22, P186, DOI 10.1037/0893-164X.22.2.186; Goodman E, 2000,
PEDIATRICS, V106, P748, DOI 10.1542/peds.106.4.748; Hitchman SC, 2011, B WORLD
HEALTH ORGAN, V89, P195, DOI 10.2471/BLT.10.079905; Hussong AM, 2011, PSYCHOL
ADDICT BEHAV, V25, P390, DOI 10.1037/a0024519; Iacono WG, 2008, ANNU REV CLIN
PSYCHO, V4, P325, DOI 10.1146/annurev.clinpsy.4.022007.141157; Jaccard J., 2001,
INTERACTION EFFECTS, V135; Jamal M, 2011, NICOTINE TOB RES, V13, P809, DOI
10.1093/ntr/ntr077; Johnston L. D., 2014, MONITORING FUTURE NA; Kendler KS, 2014,
AM J PSYCHIAT, V171, P426, DOI 10.1176/appi.ajp.2013.13101375; Khantzian EJ, 1997,
HARVARD REV PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550; King SM, 2004,
ADDICTION, V99, P1548, DOI 10.1111/j.1360-0443.2004.00893.x; Leadbeater BJ, 1999,
DEV PSYCHOL, V35, P1268, DOI 10.1037/0012-1649.35.5.1268; Lozoff B, 2003,
PEDIATRICS, V112, P846; Lozoff B, 2012, ARCH PEDIAT ADOL MED, V166, P208, DOI
10.1001/archpediatrics.2011.197; Miettunen J, 2014, PSYCHOL MED, V44, P1727, DOI
10.1017/S0033291713002328; Patton GC, 1998, AM J PUBLIC HEALTH, V88, P1518, DOI
10.2105/AJPH.88.10.1518; Poulin C, 2005, ADDICTION, V100, P525, DOI 10.1111/j.1360-
0443.2005.01033.x; Schwinn TM, 2010, ADDICT BEHAV, V35, P30, DOI
10.1016/j.addbeh.2009.08.005; Stice E, 1998, PSYCHOL ADDICT BEHAV, V12, P14, DOI
10.1037/0893-164X.12.1.14; Tomlinson KL, 2012, ADDICT BEHAV, V37, P179, DOI
10.1016/j.addbeh.2011.09.016; Tucker JS, 2003, J ADOLESCENT HEALTH, V32, P314, DOI
10.1016/S1054-139X(02)00709-7; US Department of Health and Human Services, 2014,
HLTH CONS SMOK 50 YE; West P, 1999, ADDICTION, V94, P1397, DOI 10.1046/j.1360-
0443.1999.949139711.x; Wu LT, 1999, AM J PUBLIC HEALTH, V89, P1837, DOI
10.2105/AJPH.89.12.1837; Wu P, 2010, J YOUTH ADOLESCENCE, V39, P177, DOI
10.1007/s10964-008-9385-5; Zahn-Waxler C, 2008, ANNU REV CLIN PSYCHO, V4, P275, DOI
10.1146/annurev.clinpsy.3.022806.091358 41 1 1 0 2 SAGE
PUBLICATIONS LTD LONDON 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP,
ENGLAND 1359-1053 1461-7277 J HEALTH PSYCHOL J. Health Psychol.
NOV 2017 22 13 1721 1730
10.1177/1359105316634451 10 Psychology, Clinical
Psychology FM7GO WOS:000415242500010 26956704 Green Accepted
2019-09-25
J Abelman, DD Abelman, Dor David Mitigating
risks of students use of study drugs through understanding motivations for use and
applying harm reduction theory: a literature review HARM REDUCTION JOURNAL
English Review Substance-related
disorders; Study drugs; Postsecondary education; Harm reduction; Self-medication
hypothesis; Qualitative research; Primary prevention; Methylphenidate; Adderall
PRESCRIPTION STIMULANT USE; COLLEGE-STUDENTS; MENTAL-DISORDERS; PUBLIC-
HEALTH; ADDICTION; METHYLPHENIDATE; ASSOCIATIONS; ENHANCEMENT; PREVALENCE As
postsecondary students' use of "study drugs" becomes more popular with increasingly
reported negative effects on health and academic performance, failing
prohibitionist policies to reduce consumption, and ambiguity in literature towards
best practices to address this population, we present a literature review that
seeks effective solutions educational institutions can apply to improve outcomes
for students who use drugs. Motivations for use, effects of the substances, an
analysis of efforts to control use from educational institutions, and suggestions
on promoting most effective outcomes based on harm reduction, are described.
Theory, quantitative, and qualitative works from systematic reviews, cohort
studies, and epidemiological assessments are examined on the "study drugs"
methylphenidate, dextroamphetamine, and amphetamine, also known as Adderall,
Ritalin, Focalin, and Concerta. There is a focus on postsecondary students ages 18-
25 in North America. Results show important risk factors for drug use including low
perceived self-efficacy or enjoyment in courses, poor accommodation of special
needs, reliance on external validation, having a low GPA, and experiencing a mental
health issue. There is much misconception on the health and academic effects of
these drugs in literature, among students, and on online knowledge sources. We
suggest these drugs do not improve GPA and learning, while they might temporarily
increase memory, but with detrimental negative health effects. Campaigns that
address underlying factors of use can be most successful in mitigating harms.
[Abelman, Dor David] Western Univ, Sch Hlth Studies, Fac Hlth Sci, London, ON
N6A 5B9, Canada Abelman, DD (reprint author), Western Univ, Sch Hlth Studies, Fac
Hlth Sci, London, ON N6A 5B9, Canada. dabelman@uwo.ca
American Addiction Centers, 2017, LONG TERM EFF HEAV A; [Anonymous], 2015,
TEV SEL BRANDS ADD M; Arria AM, 2017, ADDICT BEHAV, V65, P245, DOI
10.1016/j.addbeh.2016.07.016; Arria AM, 2010, J ADDICT DIS, V29, P417, DOI
10.1080/10550887.2010.509273; Beron KJ, 2016, SOC SCI QUART, V97, P142, DOI
10.1111/ssqu.12235; Bostrom N, 2009, SCI ENG ETHICS, V15, P311, DOI 10.1007/s11948-
009-9142-5; Chandler RK, 2009, JAMA-J AM MED ASSOC, V301, P183, DOI
10.1001/jama.2008.976; Chemers MM, 2001, J EDUC PSYCHOL, V93, P55, DOI
10.1037//0022-0663.93.1.55; Csete J, 2016, LANCET, V387, P1427, DOI 10.1016/S0140-
6736(16)00619-X; Currie J, 2013, NATL BUREAU EC RES W, P19105, DOI [10.3386/w19105,
DOI 10.3386/W19105]; Dackis C, 2005, NAT NEUROSCI, V8, P1431, DOI 10.1038/nn1105-
1431; DeSantis A, 2009, J STUD ALCOHOL DRUGS, V70, P952, DOI
10.15288/jsad.2009.70.952; Duke University Student Affairs, 2017, STUD COND AC
DISH; Giordano AL, 2015, SUBST USE MISUSE, V50, P358, DOI
10.3109/10826084.2014.980956; Habel LA, 2011, JAMA-J AM MED ASSOC, V306, P2673, DOI
10.1001/jama.2011.1830; Harm Reduction International, 2017, WHAT IS HARM RED POS;
Hightower TR, 2015, THESIS; Holloway KR, 2013, INT REV LAW COMPUT T, V27, P324, DOI
DOI 10.1080/13600869.2013.796707; Howell LL, 2008, BIOCHEM PHARMACOL, V75, P196,
DOI 10.1016/j.bcp.2007.08.003; Kam JA, 2013, HEALTH COMMUN, V28, P473, DOI
10.1080/10410236.2012.699873; Khatta M., 2008, TOP ADV PRACT NURS, V8; Kosse RC,
2017, J ADOLESC HLTH; Kudlow PA, 2013, J PSYCHOACTIVE DRUGS, V45, P360, DOI
10.1080/02791072.2013.825033; Lund C, 2011, LANCET, V378, P1502, DOI 10.1016/S0140-
6736(11)60754-X; Maahs JR, 2016, INT J OFFENDER THER, V60, P146, DOI
10.1177/0306624X14548530; McCabe SE, 2005, ADDICTION, V100, P96, DOI
10.1111/j.1360-0443.2005.00944.x; Mehta MA, 2000, J NEUROSCI, V20; Micali N, 2017,
EUR CHILD ADOLES PSY, V26, P231, DOI 10.1007/s00787-016-0877-7; National Institute
on Drug Abuse, 2014, DRUG FACTS STIM ADHD; National Institute on Drug Abuse, 2014,
INSTR DRUG AB SCREEN; Peng XL, 2013, PLOS ONE, V8, DOI
10.1371/journal.pone.0079476; Poulin C, 2007, ADDICTION, V102, P740, DOI
10.1111/j.1360-0443.2007.01758.x; Punja S, 2016, COCHRANE DB SYST REV, DOI
10.1002/14651858.CD009996.pub2; Reisinger KB, 2016, J COLL STUDENT DEV, V57, P65,
DOI 10.1353/csd.2016.0011; Repantis D, 2010, PHARMACOL RES, V62, P187, DOI
10.1016/j.phrs.2010.04.002; Saele RG, 2016, EDUC PSYCHOL-UK, V36, P1886, DOI
10.1080/01443410.2014.998630; Santiago CD, 2014, J COMMUNITY PSYCHOL, V42, P735,
DOI 10.1002/jcop.21649; Seixas M, 2012, J PSYCHOPHARMACOL, V26, P753, DOI
10.1177/0269881111412095; Shillington AM, 2006, J DRUG ISSUES, V36, P999, DOI
10.1177/002204260603600411; Skidmore CR, 2016, CHILD ADOL PSYCH CL, V25, P735, DOI
10.1016/j.chc.2016.06.004; Smith ME, 2011, PSYCHOL BULL, V137, P717, DOI
10.1037/a0023825; SWANN WB, 1989, J PERS SOC PSYCHOL, V57, P782, DOI 10.1037/0022-
3514.57.5.782; Tronnier CD, 2015, J SOC WORK PRACT ADD, V15, P233, DOI
10.1080/1533256X.2015.1056529; United States Food and Drug Administration, 2017,
FDA DRUG SAF COMM SA; Volkow ND, 2008, PLOS ONE, V3, DOI
10.1371/journal.pone.0002017; Vrecko Scott, 2013, AJOB Neurosci, V4, P4; Ward RM,
2016, J ALCOHOL DRUG EDUC, V60, P59; Watson GL, 2015, ETHICAL HUM PSYCHOL, V71, P5;
Western University, 2017, MENT WELLB 49 3 3 3 54 BMC LONDON
CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND 1477-7517 HARM
REDUCT J Harm Reduct. J. OCT 6 2017 14
UNSP 68 10.1186/s12954-017-0194-6 7 Substance Abuse
Substance Abuse FJ5ZN WOS:000412833300001 28985738 DOAJ Gold, Green
Published 2019-09-25
J Patwardhan, I; Mason, WA; Savolainen, J; Chmelka, MB; Miettunen, J; Jarvelin,
MR Patwardhan, Irina; Mason, W. Alex; Savolainen, Jukka;
Chmelka, Mary B.; Miettunen, Jouko; Jarvelin, Marjo-Riitta Childhood
cumulative contextual risk and depression diagnosis among young adults: The
mediating roles of adolescent alcohol use and perceived social support JOURNAL OF
ADOLESCENCE English Article
Cumulative contextual' risk; Adolescence; Adulthood; Alcohol use; Social
support; Depression; Gender SELF-MEDICATION HYPOTHESIS; SUBSTANCE USE DISORDERS;
EARLY-LIFE COURSE; MAJOR DEPRESSION; SOCIOECONOMIC-STATUS; FAMILY MEALS; GENDER-
DIFFERENCES; ANXIETY DISORDERS; SYMPTOMS; ABUSE This study examined associations
between cumulative contextual risk in childhood and depression diagnosis in early
adulthood, testing two adolescent mediating mechanisms, alcohol use and perceived
social support from family and friends, while accounting for the stability of
internalizing problems over time and examining possible gender moderation. Multiple
group mediation analyses were conducted using parent- and adolescent-report as well
as hospital records data from the Northern Finland Birth Cohort 1986 (N = 6963).
Our analyses demonstrated that the association between cumulative contextual risk
in childhood and depression diagnosis in adulthood is mediated by adolescent
alcohol use and perceived social support both for boys and girls. The findings
highlight potentially malleable mediating mechanisms associated with depression in
vulnerable youth that could be targets in selective depression preventive
interventions. (C) 2017 The Foundation for Professionals in Services for
Adolescents. Published by Elsevier Ltd. All rights reserved. [Patwardhan,
Irina; Mason, W. Alex; Chmelka, Mary B.] Boys Town Natl Res Inst Child & Family
Studies, 14100 Crawford St, Boys Town, NE 68010 USA; [Savolainen, Jukka] Univ
Michigan, Inst Social Res, ICPSR, Ann Arbor, MI USA; [Miettunen, Jouko] Univ Oulu,
Ctr Life Course Epidemiol & Syst Med, Oulu, Finland; [Miettunen, Jouko] Univ Oulu,
Oulu Univ Hosp, Med Res Ctr Oulu, Oulu, Finland; [Miettunen, Jouko] Univ Oulu, Dept
Psychiat, Unit Clin Neurosci, Oulu, Finland; [Jarvelin, Marjo-Riitta] Imperial Coll
London, Sch Publ Hlth, MRC PHE Ctr Environm & Hlth, Dept Epidemiol & Biostat,
London, England; [Jarvelin, Marjo-Riitta] Univ Oulu, Fac Med, Ctr Life Course
Epidemiol, POB 5000, FI-90014 Oulu, Finland; [Jarvelin, Marjo-Riitta] Oulu Univ
Hosp, Unit Primary Care, Oulu, Finland Patwardhan, I (reprint author), Boys Town
Natl Res Inst Child & Family Studies, 14100 Crawford St, Boys Town, NE 68010 USA.
irina.patwardhan@boystown.org National Institute on Drug Abuse
(NIDA), National Institutes of HealthUnited States Department of Health & Human
ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug
Abuse (NIDA) [R01 DA038450]; European CommissionEuropean Commission Joint Research
Centre [DynaHEALTH-H2020-633595]; EUEuropean Union (EU) [QLG1-CT-2000-01643,
E51560]; NorFA Grant [731, 20056, 30167]; USA/NIHH [2000 G DF682, 50945] The
analyses were supported by National Institute on Drug Abuse (NIDA), National
Institutes of Health, Grant # R01 DA038450. Support for the Northern Finland Birth
Cohort was provided by the European Commission (Grant DynaHEALTH-H2020-633595), EU
QLG1-CT-2000-01643 (EUROBLCS) Grant no. E51560, NorFA Grant no. 731, 20056, 30167,
and USA/NIHH 2000 G DF682 Grant no. 50945. The content is solely the responsibility
of the authors and does not necessarily represent the official views of the funding
agencies. Achenbach T. M., 2001, ASEBA SCH AGE FORMS; [Anonymous], 2016, NORDIC
CTR WELFARE S; Ary DV, 1999, BEHAV RES THER, V37, P217, DOI 10.1016/S0005-
7967(98)00133-8; Brendgen M, 2013, DEV PSYCHOPATHOL, V25, P277, DOI
10.1017/S0954579412001058; Choukas-Bradley S., 2014, HDB DEV PSYCHOPATHOL, P185,
DOI DOI 10.1007/978-1-4614-9608-3_10; Costello EJ, 1999, J CLIN CHILD PSYCHOL, V28,
P298, DOI 10.1207/S15374424jccp280302; Culpin I, 2015, J AFFECT DISORDERS, V183,
P269, DOI 10.1016/j.jad.2015.05.030; Cyranowski JM, 2000, ARCH GEN PSYCHIAT, V57,
P21, DOI 10.1001/archpsyc.57.1.21; DUNCAN GJ, 1994, CHILD DEV, V65, P296, DOI
10.1111/j.1467-8624.1994.tb00752.x; Eisenberg ME, 2004, ARCH PEDIAT ADOL MED, V158,
P792, DOI 10.1001/archpedi.158.8.792; Elander J, 1996, CHILD PSYCHOL PSYCHI, V1,
P31; Elovainio M, 2012, SOC SCI MED, V74, P923, DOI
10.1016/j.socscimed.2011.12.017; Evans GW, 2013, PSYCHOL BULL, V139, P1342, DOI
10.1037/a0031808; Gerard JM, 2004, CHILD DEV, V75, P1832, DOI 10.1111/j.1467-
8624.2004.00820.x; Gilman SE, 2002, INT J EPIDEMIOL, V31, P359, DOI
10.1093/ije/31.2.359; Goldfarb SS, 2015, J ADOLESCENCE, V44, P134, DOI
10.1016/j.adolescence.2015.07.008; Goosby BJ, 2013, J HEALTH SOC BEHAV, V54, P75,
DOI 10.1177/0022146512475089; HAWKINS JD, 1992, PSYCHOL BULL, V112, P64, DOI
10.1037/0033-2909.112.1.64; Horan JM, 2015, DEV PSYCHOPATHOL, V27, P927, DOI
10.1017/S095457941400090X; Hoyle R. H., 1999, STAT STRATEGIES SMAL, P195; Hurtig T,
2007, J AM ACAD CHILD PSY, V46, P1605, DOI 10.1097/chi.0b013e318157517a; Jackson
Benita, 2011, Race Soc Probl, V3, P119; January S.-A. A., 2016, J YOUTH
ADOLESCENCE; JARVELIN MR, 1993, BRIT J OBSTET GYNAEC, V100, P310, DOI
10.1111/j.1471-0528.1993.tb12971.x; Jerez-Roig J, 2014, DRUG AGING, V31, P883, DOI
10.1007/s40266-014-0217-x; Kendler KS, 2005, AM J PSYCHIAT, V162, P250, DOI
10.1176/appi.ajp.162.2.250; Keyes KM, 2008, DRUG ALCOHOL DEPEN, V93, P21, DOI
10.1016/j.drugalcdep.2007.08.017; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4,
P231, DOI 10.3109/10673229709030550; Lewinsohn PM, 1998, J ABNORM PSYCHOL, V107,
P109, DOI 10.1037/0021-843X.107.1.109; MacKinnon DP, 2004, MULTIVAR BEHAV RES, V39,
P99, DOI 10.1207/s15327906mbr3901_4; Malecki C. K., 1999, CHILD ADOLESCENT SOC;
Mason WA, 2008, J STUD ALCOHOL DRUGS, V69, P275, DOI 10.15288/jsad.2008.69.275;
Mason WA, 2016, ADDICT BEHAV, V58, P161, DOI 10.1016/j.addbeh.2016.02.031; Mason
WA, 2013, J ADOLESCENT HEALTH, V53, P350, DOI 10.1016/j.jadohealth.2013.04.002;
Mason WA, 2009, ADDICT BEHAV, V34, P599, DOI 10.1016/j.addbeh.2009.03.032; Matlin
SL, 2011, AM J ORTHOPSYCHIAT, V81, P108, DOI 10.1111/j.1939-0025.2010.01078.x;
MCFARLANE AH, 1995, AM J ORTHOPSYCHIAT, V65, P402, DOI 10.1037/h0079655; McLaughlin
KA, 2011, SOC SCI MED, V73, P1088, DOI 10.1016/j.socscimed.2011.06.011; Miech R.A.,
2016, MONITORING FUTURE NA, VI; Miettunen J, 2014, PSYCHOL MED, V44, P1727, DOI
10.1017/S0033291713002328; Mossakowski T., 2013, CITESEER; Muthen L. K., 1998,
MPLUS USERS GUIDE; Najman JM, 2010, AM J PUBLIC HEALTH, V100, P1719, DOI
10.2105/AJPH.2009.180943; Neumark-Sztainer D, 2010, PUBLIC HEALTH NUTR, V13, P1113,
DOI 10.1017/S1368980010000169; PEARLIN LI, 1989, J HEALTH SOC BEHAV, V30, P241, DOI
10.2307/2136956; PEARLIN LI, 1981, J HEALTH SOC BEHAV, V22, P337, DOI
10.2307/2136676; Platt J, 2014, SOC PSYCH PSYCH EPID, V49, P1279, DOI
10.1007/s00127-013-0798-4; Raykov T., 2012, 1 COURSE STRUCTURAL; Robinson J, 2009,
J ANXIETY DISORD, V23, P38, DOI 10.1016/j.janxdis.2008.03.013; Rubin K. H., 2010,
DEV SHYNESS SOCIAL W; Rueger SY, 2010, J YOUTH ADOLESCENCE, V39, P47, DOI
10.1007/s10964-008-9368-6; RUTTER M, 1967, J CHILD PSYCHOL PSYC, V8, P1, DOI
10.1111/j.1469-7610.1967.tb02175.x; Southwick SM, 2012, SCIENCE, V338, P79, DOI
10.1126/science.1222942; Sullivan H, 1953, COLLECTED WORKS; Swendsen JD, 2000, J
ABNORM PSYCHOL, V109, P198, DOI 10.1037//0021-843X.109.2.198; Trim RS, 2007,
PSYCHOL ADDICT BEHAV, V21, P97, DOI 10.1037/0893-164X.21.1.97; Van de Velde S,
2010, SOC SCI MED, V71, P305, DOI 10.1016/j.socscimed.2010.03.035; Wymbs BT, 2014,
J STUD ALCOHOL DRUGS, V75, P279; Zahn-Waxler C, 2000, DEV PSYCHOPATHOL, V12, P443,
DOI 10.1017/S0954579400003102; Zhou XY, 2015, ADDICTION, V110, P38, DOI
10.1111/add.12698 60 6 6 1 11 ACADEMIC PRESS LTD- ELSEVIER
SCIENCE LTD LONDON 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND 0140-1971 1095-
9254 J ADOLESCENCE J. Adolesc. OCT 2017 60
16 26 10.1016/j.adolescence.2017.07.008 11
Psychology, Developmental Psychology FJ3EO WOS:000412613500003
28750265 Green Accepted 2019-09-25
J Erwin, MC; Charak, R; Durham, TA; Armour, C; Lv, X; Southwick, SM; Elhai, JD;
Pietrzak, RH Erwin, Meredith Claycomb; Charak, Ruby; Durham,
Tory A.; Armour, Cherie; Lv, Xin; Southwick, Steven M.; Elhai, Jon D.; Pietrzak,
Robert H. The 7-factor hybrid model of DSM-5 PTSD symptoms and
alcohol consumption and consequences in a national sample of trauma-exposed
veterans JOURNAL OF ANXIETY DISORDERS English Article
Alcohol use; Posttraumatic stress disorder; Comorbidity;
Confirmatory factor analysis POSTTRAUMATIC-STRESS-DISORDER; SUBSTANCE USE
DISORDERS; IDENTIFICATION TEST AUDIT; SELF-MEDICATION HYPOTHESIS; DIMENSIONAL
STRUCTURE; DEPRESSIVE SYMPTOMS; MENTAL-DISORDERS; LATENT STRUCTURE; HEALTH;
RESILIENCE The purpose of the present study was to investigate associations
between the 7-factor hybrid model of DSM-5 posttraumatic stress disorder (PTSD)
symptoms, which includes intrusions, avoidance, negative affect, anhedonia,
externalizing behaviors, anxious arousal, and dysphoric arousal symptoms, and
alcohol consumption and consequences. A nationally representative sample of 916
trauma-exposed U.S. military veterans were administered the Trauma History Screen,
PTSD Checklist-5, and Alcohol Use Disorders Identification Test Confirmatory factor
analyses were conducted to determine associations between the 7-factor hybrid model
of PTSD symptoms, and alcohol consumption and consequences. Results revealed that
lifetime dysphoric arousal (r = 0.31), negative affect (r = 0.30), and anhedonia (r
= 0.29) symptom clusters were most strongly associated with past-year alcohol
consequences. No significant associations were observed for alcohol consumption.
While the cross-sectional study design does not allow one to ascertain causative
associations between PTSD factors and alcohol consumption and consequences, results
generally align with the self-medication hypothesis, as PTSD factors reflecting
internalizing were most strongly related to alcohol-related consequences. These
results underscore the importance of assessing for alcohol use problems in veterans
who score highly on PTSD symptoms reflecting internalizing symptomatology.
[Erwin, Meredith Claycomb; Durham, Tory A.; Lv, Xin; Elhai, Jon D.] Univ
Toledo, Dept Psychol, Mail Stop 948,2801 W Bancroft St, Toledo, OH 43606 USA;
[Charak, Ruby] Univ Texas Rio Grande Valley, Dept Psychol Sci, Edinburg, TX USA;
[Armour, Cherie] Ulster Univ, Psychol Res Inst, Belfast, Antrim, North Ireland;
[Southwick, Steven M.; Pietrzak, Robert H.] US Dept Vet Affairs, Natl Ctr
Posttraumat Stress Disorder, Clin Neurosci Div, VA Connecticut Healthcare Syst,
West Haven, CT USA; [Southwick, Steven M.; Pietrzak, Robert H.] Yale Univ, Sch Med,
Dept Psychiat, New Haven, CT USA; [Elhai, Jon D.] Univ Toledo, Dept Psychiat, 2801
W Bancroft St, Toledo, OH 43606 USA Elhai, JD (reprint author), Univ Toledo, Dept
Psychol, Mail Stop 948,2801 W Bancroft St, Toledo, OH 43606 USA. contact@jon-
elhai.com Elhai, Jon D/U-1901-2017 Elhai, Jon D/0000-0001-5205-9010
Angkaw AC, 2015, MIL MED, V180, P670, DOI 10.7205/MILMED-D-14-00473; Armour
C, 2016, CLIN PSYCHOL REV, V44, P60, DOI 10.1016/j.cpr.2015.12.003; Armour C, 2016,
J NERV MENT DIS, V204, P108, DOI 10.1097/NMD.0000000000000430; Armour C, 2015, EUR
J PSYCHOTRAUMATO, V6, DOI 10.3402/ejpt.v6.28074; Armour C, 2015, J PSYCHIATR RES,
V61, P106, DOI 10.1016/j.jpsychires.2014.10.012; Babor T, 2001, AUDIT ALCOHOL USE
DI; Benjamini Y, 2000, J EDUC BEHAV STAT, V25, P60, DOI 10.2307/1165312; Bovin MJ,
2016, PSYCHOL ASSESSMENT, V28, P1379, DOI 10.1037/pas0000254; Cao X, 2017, J ABNORM
CHILD PSYCH, V45, P803, DOI 10.1007/s10802-016-0193-1; Carlson EB, 2011, PSYCHOL
ASSESSMENT, V23, P463, DOI 10.1037/a0022294; Chilcoat HD, 1998, ARCH GEN PSYCHIAT,
V55, P913, DOI 10.1001/archpsyc.55.10.913; Cisler JM, 2011, J ANXIETY DISORD, V25,
P978, DOI 10.1016/j.janxdis.2011.06.006; CONIGRAVE KM, 1995, ADDICTION, V90, P1349,
DOI 10.1111/j.1360-0443.1995.tb03552.x; Debell F, 2014, SOC PSYCH PSYCH EPID, V49,
P1401, DOI 10.1007/s00127-014-0855-7; Doyle SR, 2007, J STUD ALCOHOL DRUGS, V68,
P474, DOI 10.15288/jsad.2007.68.474; Elhai JD, 2011, J ANXIETY DISORD, V25, P340,
DOI 10.1016/j.janxdis.2010.10.007; Flora DB, 2004, PSYCHOL METHODS, V9, P466, DOI
10.1037/1082-989X.9.4.466; Fuehrlein BS, 2016, ADDICTION, V111, P1786, DOI
10.1111/add.13423; Goldsmith AA, 2012, PSYCHOL ADDICT BEHAV, V26, P59, DOI
10.1037/a0024766; Grant BF, 2015, JAMA PSYCHIAT, V72, P757, DOI
10.1001/jamapsychiatry.2015.0584; Haller M, 2013, PSYCHOL TRAUMA-US, V5, P484, DOI
10.1037/a0029335; Hallinan P, 2011, J FORENSIC PSYCHI PS, V22, P586, DOI
10.1080/14789949.2011.607174; Hien DA, 2010, AM J PSYCHIAT, V167, P95, DOI
10.1176/appi.ajp.2009.09091261; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI
10.1080/10705519909540118; Jacobsen LK, 2001, AM J PSYCHIAT, V158, P1184, DOI
10.1176/appi.ajp.158.8.1184; Kenney S, 2015, J YOUTH ADOLESCENCE, V44, P1884, DOI
10.1007/s10964-015-0311-3; Kerper L., 2014, CLIN HLTH PROMOTION, V4, P5, DOI DOI
10.1177/0739986315608126; Kessler RC, 2011, CURR OPIN PSYCHIATR, V24, P307, DOI
10.1097/YCO.0b013e3283477b22; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231,
DOI 10.3109/10673229709030550; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259;
Kline R. B., 2011, PRINCIPLES PRACTICE; Kroenke K, 2009, PSYCHOSOMATICS, V50, P613,
DOI 10.1176/appi.psy.50.6.613; Langdon KJ, 2016, J AFFECT DISORDERS, V196, P234,
DOI 10.1016/j.jad.2016.02.048; Lijffijt M, 2014, FRONT PSYCHIATRY, V5, DOI
10.3389/fpsyt.2014.00083; Liu LY, 2016, J CHILD PSYCHOL PSYC, V57, P204, DOI
10.1111/jcpp.12462; Liu P, 2014, J ANXIETY DISORD, V28, P345, DOI
10.1016/j.janxdis.2014.03.008; Mallett KA, 2011, PSYCHOL ADDICT BEHAV, V25, P41,
DOI 10.1037/a0021494; MCFALL ME, 1992, J STUD ALCOHOL, V53, P357, DOI
10.15288/jsa.1992.53.357; McLeod DS, 2001, J TRAUMA STRESS, V14, P259, DOI
10.1023/A:1011157800050; Miller MW, 2007, BEHAV THER, V38, P58, DOI
10.1016/j.beth.2006.04.003; Miller MW, 2004, J ABNORM PSYCHOL, V113, P636, DOI
10.1037/0021-843X.113.4.636; Mushquash AR, 2013, ADDICT BEHAV, V38, P2180, DOI
10.1016/j.addbeh.2012.11.008; Muthen L., 2013, MPLUS VERSION 7 11; Nitka D, 2017,
ADDICT BEHAV, V65, P131, DOI 10.1016/j.addbeh.2016.10.005; Pietrzak RH, 2015, J
AFFECT DISORDERS, V174, P522, DOI 10.1016/j.jad.2014.12.007; Ray AE, 2009, ADDICT
BEHAV, V34, P911, DOI 10.1016/j.addbeh.2009.05.016; Read JP, 2004, ADDICT BEHAV,
V29, P1665, DOI 10.1016/j.addbeh.2004.02.061; Reinert DF, 2002, ALCOHOL CLIN EXP
RES, V26, P272, DOI 10.1111/j.1530-0277.2002.tb02534.x; Sartor CE, 2011, PSYCHOL
MED, V41, P1497, DOI 10.1017/S0033291710002072; SAUNDERS JB, 1993, ADDICTION, V88,
P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Seal KH, 2011, DRUG ALCOHOL DEPEN,
V116, P93, DOI 10.1016/j.drugalcdep.2010.11.027; Seligowski AV, 2016, PSYCHOL
TRAUMA-US, V8, P218, DOI 10.1037/tra0000104; Shevlin M, 2007, ALCOHOL ALCOHOLISM,
V42, P582, DOI 10.1093/alcalc/agm045; Stewart SH, 1999, PSYCHOL ADDICT BEHAV, V13,
P78, DOI 10.1037/0893-164X.13.2.78; Trautmann S, 2015, J ANXIETY DISORD, V29, P93,
DOI 10.1016/j.janxdis.2014.11.009; Tripp JC, 2015, J DUAL DIAGN, V11, P107, DOI
10.1080/15504263.2015.1025013; Tsai J, 2015, J CLIN PSYCHIAT, V76, P546, DOI
10.4088/JCP.14m09091; U.S. Census Bureau, 2010, US CURR POP SURV; Wade D, 2012, J
SUBST ABUSE TREAT, V43, P123, DOI 10.1016/j.jsat.2011.10.023; Wang L, 2015, J
ANXIETY DISORD, V31, P90, DOI 10.1016/j.janxdis.2015.02.006; Weathers FW, 2013,
CLIN ADM PTSD SCALE; Wirth RJ, 2007, PSYCHOL METHODS, V12, P58, DOI 10.1037/1082-
989X.12.1.58; Wortmann JH, 2016, PSYCHOL ASSESSMENT, V28, P1392, DOI
10.1037/pas0000260; Wright KM, 2012, J CLIN PSYCHOL, V68, P782, DOI
10.1002/jclp.21864; Yang HB, 2017, EUR J PSYCHOTRAUMATO, V8, DOI
10.1080/20008198.2016.1272789; Zhou X, 2017, PSYCHIAT RES, V254, P33, DOI
10.1016/j.psychres.2017.04.029 66 3 3 0 1 PERGAMON-ELSEVIER
SCIENCE LTD OXFORD THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB,
ENGLAND 0887-6185 1873-7897 J ANXIETY DISORD J. Anxiety Disord.
OCT 2017 51 14 21
10.1016/j.janxdis.2017.08.001 8 Psychology, Clinical;
Psychiatry Psychology; Psychiatry FJ5LW WOS:000412794000003 28843574
2019-09-25
J Menary, KR; Corbin, WR; Chassin, L Menary, Kyle R.; Corbin,
William R.; Chassin, Laurie Associations between early internalizing
symptoms and speed of transition through stages of alcohol involvement DEVELOPMENT
AND PSYCHOPATHOLOGY English Article
EXTERNALIZING BEHAVIOR PROBLEMS; NATIONAL EPIDEMIOLOGIC SURVEY; SELF-
MEDICATION HYPOTHESIS; SOCIAL ANXIETY DISORDER; SUBSTANCE USE; ADOLESCENT
PREDICTORS; RISK-FACTORS; PSYCHIATRIC COMORBIDITY; EARLY ADULTHOOD; UNITED-STATES
Alcohol use disorders and internalizing disorders are highly comorbid, but
how this comorbidity unfolds over development is not well understood. The present
study investigated effects of internalizing symptoms in late childhood on speed of
transition between three alcohol involvement milestones: first drink, first binge,
and onset of first alcohol dependence symptom. Greater early internalizing symptoms
were expected to predict a later age of first drink, a slower transition from first
drink to first binge, and a faster transition from first binge to first dependence
symptom. The effects of age and moderating effects of gender were also examined.
Data were from a longitudinal study of children of alcoholics and matched controls
(N = 454) followed from late childhood to midlife. Generally, stage-specific
hypotheses were not supported; rather, greater internalizing symptoms predicted an
earlier age of first drink and a faster transition through the full interval from
first drink to first dependence symptom. Regarding gender moderation, internalizing
significantly predicted a faster transition between each milestone as well as
through the full interval among women but not men. These results suggest that early
internalizing problems confer risk for a rapid transition through all stages of
alcohol involvement, and this risk may be limited to women.[Menary, Kyle R.;
Corbin, William R.; Chassin, Laurie] Arizona State Univ, Tempe, AZ 85287 USA
Menary, KR (reprint author), Arizona State Univ, Dept Psychol, Tempe, AZ
85287 USA. kmenary@asu.edu National Institute on Alcohol Abuse and
AlcoholismUnited States Department of Health & Human ServicesNational Institutes of
Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)
[R01-AA016213] The data used in this study were collected with support from the
National Institute on Alcohol Abuse and Alcoholism (R01-AA016213). ACHENBACH
TM, 1979, J CONSULT CLIN PSYCH, V47, P223, DOI 10.1037/0022-006X.47.2.223; Austin
AM, 2005, RES SOCIAL WORK PRAC, V15, P67, DOI 10.1177/1049731504271606; Buckner JD,
2008, J PSYCHIATR RES, V42, P230, DOI 10.1016/j.jpsychires.2007.01.002; Carrigan
MH, 2003, ADDICT BEHAV, V28, P269, DOI 10.1016/S0306-4603(01)00235-0; Chassin L,
2002, J CONSULT CLIN PSYCH, V70, P67, DOI 10.1037//0022-006X.70.1.67; CHASSIN L,
1991, J ABNORM PSYCHOL, V100, P449, DOI 10.1037/0021-843X.100.4.449; CHASSIN L,
1992, J STUD ALCOHOL, V53, P316, DOI 10.15288/jsa.1992.53.316; CLONINGER CR, 1987,
SCIENCE, V236, P410, DOI 10.1126/science.2882604; Colder CR, 2001, PSYCHOL ADDICT
BEHAV, V15, P237, DOI 10.1037/0893-164X.15.3.237; Conrod PJ, 2006, J CLIN CHILD
ADOLESC, V35, P550, DOI 10.1207/s15374424jccp3504_6; Conrod PJ, 2000, PSYCHOL
ADDICT BEHAV, V14, P243, DOI 10.1037/0893-164X.14.3.243; Cooney NL, 1997, J ABNORM
PSYCHOL, V106, P243, DOI 10.1037/0021-843X.106.2.243; Costa NM, 2006, J
PSYCHOPATHOL BEHAV, V28, P113, DOI 10.1007/s10862-006-7489-3; Costello EJ, 1999, J
CLIN CHILD PSYCHOL, V28, P298, DOI 10.1207/S15374424jccp280302; Dawson DA, 2000, J
STUD ALCOHOL, V61, P637, DOI 10.15288/jsa.2000.61.637; De Los Reyes A, 2005,
PSYCHOL BULL, V131, P483, DOI 10.1037/0033-2909.131.4.483; Dishion Thomas J, 2002,
Prev Sci, V3, P191, DOI 10.1023/A:1019994500301; Dishion TJ, 2003, BEHAV THER, V34,
P553, DOI 10.1016/S0005-7894(03)80035-7; Englund MM, 2008, ADDICTION, V103, P23,
DOI 10.1111/j.1360-0443.2008.02174.x; Guo J, 2001, J STUD ALCOHOL, V62, P754, DOI
10.15288/jsa.2001.62.754; Hasin DS, 2007, ARCH GEN PSYCHIAT, V64, P830, DOI
10.1001/archpsyc.64.7.830; HENRY B, 1993, J ABNORM CHILD PSYCH, V21, P469, DOI
10.1007/BF00916314; Hingson R, 2003, PEDIATRICS, V111, P34, DOI
10.1542/peds.111.1.34; Hussong A, 2008, J ABNORM PSYCHOL, V117, P63, DOI
10.1037/0021-843X.117.1.63; Hussong AM, 2011, PSYCHOL ADDICT BEHAV, V25, P390, DOI
10.1037/a0024519; Johnson TP, 2001, ADDICTION, V96, P1187, DOI 10.1046/j.1360-
0443.2001.968118711.x; Kaplow JB, 2001, J CLIN CHILD PSYCHOL, V30, P316, DOI
10.1207/S15374424JCCP3003_4; Kessler RC, 1997, ARCH GEN PSYCHIAT, V54, P313; Keyes
KM, 2010, AM J PSYCHIAT, V167, P969, DOI 10.1176/appi.ajp.2009.09081161; Khantzian
EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550; King SM,
2004, ADDICTION, V99, P1548, DOI 10.1111/j.1360-0443.2004.00893.x; Koob GF, 2003,
ALCOHOL CLIN EXP RES, V27, P232, DOI 10.1097/01.ALC.0000057122.36127.C2; Kushner
MG, 2013, J CONSULT CLIN PSYCH, V81, P429, DOI 10.1037/a0031301; Kushner MG, 2011,
J STUD ALCOHOL DRUGS, V72, P1019, DOI 10.15288/jsad.2011.72.1019; Kushner MG, 2005,
ALCOHOL CLIN EXP RES, V29, P1432, DOI 10.1097/01.alc.0000175072.17623.f8; Kushner
MG, 2000, CLIN PSYCHOL REV, V20, P149, DOI 10.1016/S0272-7358(99)00027-6; LEVENSON
RW, 1980, J ABNORM PSYCHOL, V89, P528, DOI 10.1037/0021-843X.89.4.528; LITT MD,
1990, ADDICT BEHAV, V15, P137, DOI 10.1016/0306-4603(90)90017-R; Maggs JL, 2008,
ADDICTION, V103, P7, DOI 10.1111/j.1360-0443.2008.02173.x; Marmorstein NR, 2010, J
ABNORM CHILD PSYCH, V38, P211, DOI 10.1007/s10802-009-9360-y; Meier MH, 2013, DEV
PSYCHOPATHOL, V25, P785, DOI 10.1017/S0954579413000175; Muthen L.K., 2010, MPLUS
STAT ANAL LATE; Najavits LM, 2005, J PSYCHOACTIVE DRUGS, V37, P425, DOI
10.1080/02791072.2005.10399816; National Institute on Alcohol Abuse and Alcoholism,
2015, ALC FACTS STAT; PIAZZA NJ, 1989, INT J ADDICT, V24, P19, DOI
10.3109/10826088909047272; Pitkanen T, 2008, ADDICTION, V103, P48, DOI
10.1111/j.1360-0443.2008.02176.x; Randall CL, 1999, J STUD ALCOHOL, V60, P252, DOI
10.15288/jsa.1999.60.252; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; ROBINSON
TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; ROELOFS SMGJ,
1985, ALCOHOL, V2, P501, DOI 10.1016/0741-8329(85)90123-5; Sartor CE, 2007,
ADDICTION, V102, P216, DOI 10.1111/j.1360-0443.2006.01661.x; Schneider U, 2001,
ALCOHOL ALCOHOLISM, V36, P219, DOI 10.1093/alcalc/36.3.219; Schneier FR, 2010,
PSYCHOL MED, V40, P977, DOI 10.1017/S0033291709991231; Schuckit MA, 1998, J STUD
ALCOHOL, V59, P581, DOI 10.15288/jsa.1998.59.581; SHER KJ, 1987, PSYCHOL THEORIES
DRI, P227; Sihvola E, 2008, ADDICTION, V103, P2045, DOI 10.1111/j.1360-
0443.2008.02363.x; STANGER C, 1993, J CLIN CHILD PSYCHOL, V22, P107, DOI
10.1207/s15374424jccp2201_11; STEELE RG, 1995, AM J ORTHOPSYCHIAT, V65, P380, DOI
10.1037/h0079694; Strine TW, 2008, PSYCHIAT SERV, V59, P1383, DOI
10.1176/appi.ps.59.12.1383; Swendsen JD, 2000, J ABNORM PSYCHOL, V109, P198, DOI
10.1037//0021-843X.109.2.198; TOMASSON K, 1995, ACTA PSYCHIAT SCAND, V92, P378, DOI
10.1111/j.1600-0447.1995.tb09600.x; Young SE, 2002, DRUG ALCOHOL DEPEN, V68, P309,
DOI 10.1016/S0376-8716(02)00225-9; Youngstrom E, 2000, J CONSULT CLIN PSYCH, V68,
P1038, DOI 10.1037/0022-006X.68.6.1038; Zimmermann P, 2003, PSYCHOL MED, V33,
P1211, DOI 10.1017/S0033291703008158 64 3 3 0 11 CAMBRIDGE
UNIV PRESS NEW YORK 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
 0954-5794 1469-2198 DEV PSYCHOPATHOL Dev. Psychopathol. OCT
2017 29 4 1455 1467
10.1017/S0954579417000384 13 Psychology, Developmental
Psychology FF5NT WOS:000409039500024 28397620 2019-
09-25
J Fein, G; Cardenas, VA Fein, George; Cardenas, Valerie A.
P3b amplitude is not reduced in abstinent alcoholics with a current MDD
ALCOHOL English Article
Alcohol dependence; Self-medication; P3b; Major depressive disorder
NATIONAL EPIDEMIOLOGIC SURVEY; EVENT-RELATED POTENTIALS; RESTING-STATE
SYNCHRONY; SUBSTANCE USE DISORDERS; MAJOR DEPRESSIVE DISORDER; FAMILY-HISTORY;
UNITED-STATES; PSYCHIATRIC-DISORDERS; ANXIETY DISORDERS; DECISION-MAKING
Background and aims: In two studies of long-term abstinent alcoholics
(LTAAs), we found that about 17% had a current major depressive disorder (MDD). We
tested the hypothesis that LTAAs with a current MDD diagnosis do not exhibit the
reduced P3b event-related potential amplitude endophenotype for alcoholism. This is
consistent with the majority of LTAAs with a current MDD having developed alcohol
dependence via self-medication of their MDD rather than their alcohol dependence
arising from the alcoholism endophenotype. We revisited the P3b data from the two
LTAAs studies, comparing LTAAs with a current MDD vs. LTAAs without a current MDD
to each other and to non-substance abusing controls (NSACs). In northern
California, 48 LTAAs and 48 non-substance abusing controls were studied, while in
Honolulu, 105 LTAAs and 77 NSACs were studied. A total of 26 LTAAs had a current
MDD (10 in California and 16 in Honolulu). The difference in P3b amplitude and
latency (measured in targets-standards) in a 3-condition visual oddball paradigm
was compared to MDD diagnoses gathered using the computerized Diagnostic Interview
Schedule. Across both study sites, LTAAs without a current MDD (either with no
lifetime MDD or a lifetime, but not current MDD) had lower P3b amplitudes than
NSACs. In contrast, P3b amplitudes in LTAAs with a current MDD did not differ from
controls. We conclude that alcohol dependence in LTAAs with a current MDD did not
derive from the alcoholism endophenotype. This group may not exhibit the
externalizing diathesis characterized by impulsive, disinhibited behavior and may
have developed alcohol dependence via excessive drinking in an attempt to self-
medicate their MDD. These results have major implications for targeted treatments
of alcoholism and comorbid MDD. (C) 2017 Elsevier Inc. All rights reserved. [Fein,
George; Cardenas, Valerie A.] Neurobehav Res Inc, 77 Hookele St,3rd Floor, Kahului,
HI 96732 USA; [Fein, George] Univ Hawaii, Dept Med & Psychol, Honolulu, HI 96822
USA Fein, G (reprint author), Neurobehav Res Inc, 77 Hookele St,3rd Floor,
Kahului, HI 96732 USA. george@nbresearch.com National Institute on
Alcohol Abuse and Alcoholism, National Institutes of HealthUnited States Department
of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National
Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01 AA011311, RO1 AA016303] This
work was supported by grants R01 AA011311 and RO1 AA016303 from the National
Institute on Alcohol Abuse and Alcoholism, National Institutes of Health.
Anderer P, 2002, METHOD FIND EXP CLIN, V24, P85; Andrew C, 2010, ALCOHOL CLIN
EXP RES, V34, P669, DOI 10.1111/j.1530-0277.2009.01136.x; Bange F, 1998, EVOKED
POTENTIAL, V108, P472, DOI 10.1016/S0168-5597(98)00024-0; Bauer LO, 1999,
NEUROPSYCHOPHARMACOL, V21, P51, DOI 10.1016/S0893-133X(98)00139-0; BEGLEITER H,
1984, SCIENCE, V225, P1493, DOI 10.1126/science.6474187; Begleiter H, 1999, ALCOHOL
CLIN EXP RES, V23, P1125, DOI 10.1111/j.1530-0277.1999.tb04269.x; BLACKWOOD DHR,
1987, BRIT J PSYCHIAT, V150, P154, DOI 10.1192/bjp.150.2.154; BROWN SA, 1995, AM J
PSYCHIAT, V152, P45; Bruder G, 1998, J ABNORM PSYCHOL, V107, P399, DOI
10.1037/0021-843X.107.3.399; BUCHOLZ KK, 1991, J PSYCHIAT RES, V25, P117, DOI
10.1016/0022-3956(91)90005-U; Burns L, 2005, ADDICTION, V100, P787, DOI
10.1111/j.1360-0443.2005.001069.x; Camchong J, 2013, ALCOHOL CLIN EXP RES, V37,
P794, DOI 10.1111/acer.12037; Camchong J, 2013, ALCOHOL CLIN EXP RES, V37, P75, DOI
10.1111/j.1530-0277.2012.01859.x; Cohen HL, 1997, BIOL PSYCHIAT, V42, P57, DOI
10.1016/S0006-3223(96)00221-1; Compumedics, 2003, COMP NEUR SCAN 4 3 E; Di Sclafani
V, 2007, ALCOHOL CLIN EXP RES, V31, P795, DOI 10.1111/j.1530-0277.2007.00361.x;
DINER BC, 1985, PSYCHIAT RES, V15, P175, DOI 10.1016/0165-1781(85)90074-5; ERDMAN
HP, 1992, J PSYCHIAT RES, V26, P85, DOI 10.1016/0022-3956(92)90019-K; Euser AS,
2012, NEUROSCI BIOBEHAV R, V36, P572, DOI 10.1016/j.neubiorev.2011.09.002; Fein G,
2006, ALCOHOL CLIN EXP RES, V30, P2000, DOI 10.1111/j.1530-0277.2006.00246.x; Fein
G, 2017, ALCOHOL, V59, P17, DOI 10.1016/j.alcohol.2016.11.008; Fein G, 2013,
ALCOHOL CLIN EXP RES, V37, P1930, DOI 10.1111/acer.12170; Gilmore CS, 2013, J
PSYCHOPHYSIOL, V27, P76, DOI 10.1027/0269-8803/a000089; Grant BF, 2009, MOL
PSYCHIATR, V14, P1051, DOI 10.1038/mp.2008.41; Grant BF, 2004, ARCH GEN PSYCHIAT,
V61, P1107, DOI 10.1001/archpsyc.61.11.1107; Grant BF, 2004, ARCH GEN PSYCHIAT,
V61, P807, DOI 10.1001/archpsyc.61.8.807; Grant BF, 2004, ARCH GEN PSYCHIAT, V61,
P361, DOI 10.1001/archpsyc.61.4.361; Grant BF, 2006, ALCOHOL RES HEALTH, V29, P74;
Greenfield SF, 1998, ARCH GEN PSYCHIAT, V55, P259, DOI 10.1001/archpsyc.55.3.259;
Hare TA, 2009, SCIENCE, V324, P646, DOI 10.1126/science.1168450; Hasin DS, 2007,
ARCH GEN PSYCHIAT, V64, P830, DOI 10.1001/archpsyc.64.7.830; Hasin DS, 2002, ARCH
GEN PSYCHIAT, V59, P794, DOI 10.1001/archpsyc.59.9.794; HELZER JE, 1988, J STUD
ALCOHOL, V49, P219, DOI 10.15288/jsa.1988.49.219; HESSELBROCK MN, 1985, ARCH GEN
PSYCHIAT, V42, P1050; Hill SY, 1998, BIOL PSYCHIAT, V43, P40, DOI 10.1016/S0006-
3223(97)00203-5; Himani A, 1999, Indian J Physiol Pharmacol, V43, P367; Iacono WG,
2003, INT J PSYCHOPHYSIOL, V48, P147, DOI 10.1016/S0167-8760(03)00052-7; LEVITAN
RD, 1991, CAN J PSYCHIAT, V36, P728; LOOSEN PT, 1990, AM J PSYCHIAT, V147, P1662;
MANN RE, 1985, DRUG ALCOHOL DEPEN, V15, P61, DOI 10.1016/0376-8716(85)90030-4;
Medalla M, 2009, NEURON, V61, P609, DOI 10.1016/j.neuron.2009.01.006; MUIR WJ,
1991, PSYCHOL MED, V21, P867, DOI 10.1017/S003329170002986X; Naqvi NH, 2010, BRAIN
STRUCT FUNCT, V214, P435, DOI 10.1007/s00429-010-0268-7; PENICK EC, 1988, J STUD
ALCOHOL, V49, P395, DOI 10.15288/jsa.1988.49.395; PFEFFERBAUM A, 1991, ALCOHOL CLIN
EXP RES, V15, P839, DOI 10.1111/j.1530-0277.1991.tb00611.x; REGIER DA, 1990, JAMA-J
AM MED ASSOC, V264, P2511; Robins L. N, 1995, DIAGNOSTIC INTERVIEW; Roschke J,
2003, NEUROPSYCHOPHARMACOL, V28, pS9, DOI 10.1038/sj.npp.1300139; ROUNSAVILLE BJ,
1987, ARCH GEN PSYCHIAT, V44, P505; Schneider W., 2002, E PRIME USERS GUIDE;
SCHUCKIT M, 1983, AM J PSYCHIAT, V140, P711; SKINNER HA, 1982, J STUD ALCOHOL, V43,
P1157, DOI 10.15288/jsa.1982.43.1157; SKINNER HA, 1982, J ABNORM PSYCHOL, V91,
P199, DOI 10.1037/0021-843X.91.3.199; Sobell LC, 1992, MEASURING ALCOHOL CO, P41,
DOI DOI 10.1007/978-1-4612-0357-5_3; SPSS Inc, 2009, SPSS STAT 18 0 REL 1;
Vandoolaeghe E, 1998, J AFFECT DISORDERS, V48, P105, DOI 10.1016/S0165-
0327(97)00165-1; Wagner EE, 2003, PSYCHOL REP, V92, P951, DOI 10.2466/PR0.92.3.951-
956 57 2 2 0 3 ELSEVIER SCIENCE INC NEW YORK 360 PARK AVE
SOUTH, NEW YORK, NY 10010-1710 USA 0741-8329 1873-6823 ALCOHOL
Alcohol SEP 2017 63 33 42
10.1016/j.alcohol.2017.03.004 10 Substance Abuse; Pharmacology
& Pharmacy; Toxicology Substance Abuse; Pharmacology & Pharmacy; Toxicology FH9RR
WOS:000411549900005 28847380 Green Accepted 2019-09-25
J Dutcher, CD; Vujanovic, AA; Paulus, DJ; Bartlett, BA
Dutcher, Christina D.; Vujanovic, Anka A.; Paulus, Daniel J.; Bartlett,
Brooke A. Childhood maltreatment severity and alcohol use in adult
psychiatric inpatients: The mediating role of emotion regulation difficulties
GENERAL HOSPITAL PSYCHIATRY English Article
Childhood maltreatment; Trauma; Emotion regulation; Alcohol;
Psychiatric inpatients POSTTRAUMATIC-STRESS-DISORDER; MINI-MENTAL-STATE; SUBSTANCE
USE; SEXUAL-ABUSE; PSYCHOMETRIC PROPERTIES; INDIVIDUAL-DIFFERENCES; TRAUMA
QUESTIONNAIRE; ANXIETY SENSITIVITY; COMMUNITY SAMPLE; SELF-MEDICATION Objective:
Emotion regulation difficulties are a potentially key mechanism underlying the
association between childhood maltreatment and alcohol use in adulthood. The
current study examined the mediating role of emotion regulation difficulties in the
association between childhood maltreatment severity (i.e., Childhood Trauma
Questionnaire total score) and past-month alcohol use severity, including alcohol
consumption frequency and alcohol-related problems (i.e., number of days of alcohol
problems, ratings of "bother" caused by alcohol problems, ratings of treatment
importance for alcohol problems). Method: Participants included 111 acute-care
psychiatric inpatients (45.0% female; Mage=33.5, SD=10.6), who reported at least
one DSM-5 posttraumatic stress disorder Criterion A traumatic event, indexed via
the Life Events Checklist for DSM-5. Participants completed questionnaires
regarding childhood maltreatment, emotion regulation difficulties, and alcohol use.
Results: A significant indirect effect of childhood maltreatment severity via
emotion regulation difficulties in relation to alcohol use severity (beta = 0.07,
SE = 0.04, 99% CI [0.01, 0.21]) was documented. Specifically, significant indirect
effects were found for childhood maltreatment severity via emotion regulation
difficulties in relation to alcohol problems (beta's between 0.05 and 0.12; all 99%
bootstrapped CIs with 10,000 resamples did not include 0) but not alcohol
consumption. Conclusion: Emotion regulation difficulties may play a significant
role in the association between childhood maltreatment severity and alcohol
outcomes. Clinical implications are discussed. [Dutcher, Christina D.] Univ Texas
Austin, Austin, TX 78712 USA; [Vujanovic, Anka A.; Paulus, Daniel J.; Bartlett,
Brooke A.] Univ Houston, Houston, TX 77204 USA Vujanovic, AA (reprint author),
Univ Houston, Dept Psychol, Trauma & Stress Studies Ctr, 3695 Cullen Blvd,126 Heyne
Bldg, Houston, TX 77204 USA. aavujano@central.uh.edu Paulus, Daniel/0000-
0002-8799-4372 Hogg Foundation for Mental Health [JRG-263] This study was
funded by the Hogg Foundation for Mental Health (JRG-263; PI: Vujanovic). Aldao
A, 2016, COGNITIVE THER RES, V40, P257, DOI 10.1007/s10608-016-9764-2; American
Psychiatric Association, 2013, AM PSYCH ASS DIAGN S; Arbuckle JL, 2011, IBM SPSS
AMOS 20 USE, V2011; Arens AM, 2014, CHILD MALTREATMENT, V19, P168, DOI
10.1177/1077559514548315; Banducci AN, 2014, CHILD ABUSE NEGLECT, V38, P928, DOI
10.1016/j.chiabu.2013.12.007; Berenz EC, 2016, PSYCHOL TRAUMA-US, V9, P1; Berking
M, 2011, J CONSULT CLIN PSYCH, V79, P307, DOI 10.1037/a0023421; Bernstein DP, 2003,
CHILD ABUSE NEGLECT, V27, P169, DOI 10.1016/S0145-2134(02)00541-0; BERNSTEIN DP,
1994, AM J PSYCHIAT, V151, P1132; Bhandari A, 2006, MED CARE RES REV, V63, P217,
DOI 10.1177/1077558705285298; Blanco C, 2013, DRUG ALCOHOL DEPEN, V132, P630, DOI
10.1016/j.drugalcdep.2013.04.016; Bloch L, 2010, EMOTION REGULATION P, P88; Bolin
JH, 2014, J EDUC MEAS, V51, P335, DOI 10.1111/jedm.12050; Bradley B, 2011, J CLIN
PSYCHIAT, V72, P685, DOI [10.4088/JCP.10m06409b1u, 10.4088/JCP.10m06409blu];
Bridgett DJ, 2015, PSYCHOL BULL, V141, P602, DOI 10.1037/a0038662; Chavarria J,
2015, J STUD ALCOHOL DRUGS, V76, P957, DOI 10.15288/jsad.2015.76.957; Clark DB,
1997, J AM ACAD CHILD PSY, V36, P1744, DOI 10.1097/00004583-199712000-00023;
Cloitre M, 2005, BEHAV THER, V36, P119, DOI 10.1016/S0005-7894(05)80060-7; Cloitre
M, 2008, J TRAUMA STRESS, V21, P282, DOI 10.1002/jts.20339; Cloitre M, 2009, J
TRAUMA STRESS, V22, P399, DOI 10.1002/jts.20444; COOPER ML, 1995, J PERS SOC
PSYCHOL, V69, P990, DOI 10.1037/0022-3514.69.5.990; Cross D, 2015, CHILD ABUSE
NEGLECT, V44, P26, DOI 10.1016/j.chiabu.2015.01.007; Deane FP, 2013, J ADDICT DIS,
V32, P194, DOI 10.1080/10550887.2013.795470; Dom G, 2007, COMPR PSYCHIAT, V48,
P178, DOI 10.1016/j.comppsych.2006.08.004; Eames SF, 2014, J CONSULT CLIN PSYCH,
V82, P441, DOI 10.1037/a0036291; Ehring T, 2010, BEHAV THER, V41, P587, DOI
10.1016/j.beth.2010.04.004; Eisenberg N, 2010, ANNU REV CLIN PSYCHO, V6, P495, DOI
10.1146/annurev.clinpsy.121208.131208; Ertl V, 2016, BMC PSYCHIAT, V16; Fein G,
2015, NEUROPSYCHOL REV, V25, P456, DOI 10.1007/s11065-015-9304-y; FOLSTEIN MF,
1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fossati A.,
2015, J PERS DISORD, DOI [10.1521/pedi_2105_29_184, DOI 10.1521/pedi_2105_29_184];
Fox HC, 2008, ADDICT BEHAV, V33, P388, DOI 10.1016/j.addbeh.2007.10.002; Garland
EL, 2013, J BEHAV MED, V36, P175, DOI 10.1007/s10865-012-9413-5; Gratz KL, 2004, J
PSYCHOPATHOL BEHAV, V26, P41, DOI 10.1023/B:JOBA.0000007455.08539.94; Gratz KL,
2010, EMOTION REGULATION M, P105; Gray MJ, 2004, ASSESSMENT, V11, P330, DOI
10.1177/1073191104269954; Grayson CE, 2005, J TRAUMA STRESS, V18, P137, DOI
10.1002/jts.20021; Greenfield SF, 2002, DRUG ALCOHOL DEPEN, V67, P227, DOI
10.1016/S0376-8716(02)00072-8; Heath AC, 2001, BRIT J PSYCHIAT, V178, pS33, DOI
10.1192/bjp.178.40.s33; Heim C, 2001, BIOL PSYCHIAT, V49, P1023, DOI 10.1016/S0006-
3223(01)01157-X; Heleniak C, 2016, COGNITIVE THER RES, V40, P394, DOI
10.1007/s10608-015-9735-z; Holahan CJ, 2001, J STUD ALCOHOL, V62, P190, DOI
10.15288/jsa.2001.62.190; Holl J, 2016, DEV PSYCHOPATHOL, P1, DOI
10.1017/S0954579416000432; Jackson KM, 2003, J ABNORM PSYCHOL, V112, P599, DOI
10.1037/0021-843X.112.4.599; John OP, 2004, J PERS, V72, P1301, DOI 10.1111/j.1467-
6494.2004.00298.x; Kaufman J, 2007, BIOL PSYCHIAT, V61, P1228, DOI
10.1016/j.biopsych.2006.06.039; Kaysen D, 2014, PSYCHOL ADDICT BEHAV, V28, P62, DOI
10.1037/a0033588; Kelley ML, 2013, DRUG ALCOHOL DEPEN, V133, P615, DOI
10.1016/j.drugalcdep.2013.08.002; Kendler KS, 2007, ARCH GEN PSYCHIAT, V64, P1313,
DOI 10.1001/archpsyc.64.11.1313; Keyes KM, 2011, PSYCHOPHARMACOLOGY, V218, P1, DOI
10.1007/s00213-011-2236-1; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI
10.3109/10673229709030550; Kraemer HC, 2008, HEALTH PSYCHOL, V27, pS101, DOI
10.1037/0278-6133.27.2(Suppl.).S101; Kulkarni M, 2013, PSYCHOL TRAUMA-US, V5, P359,
DOI 10.1037/a0027746; Lang AJ, 2008, BEHAV MED, V33, P125, DOI
10.3200/BMED.33.4.125-136; Lee DJ, 2016, J CLIN PSYCHOL, V72, P933, DOI
10.1002/jclp.22297; Lotzin A, 2016, ALCOHOL CLIN EXP RES, V40, P543, DOI
10.1111/acer.12990; Lyne JP, 2011, SUBST USE MISUSE, V46, P351, DOI
10.3109/10826081003754757; MacMillan HL, 2001, AM J PSYCHIAT, V158, P1878, DOI
10.1176/appi.ajp.158.11.1878; Mandavia A, 2016, J TRAUMA STRESS, V29, P422, DOI
10.1002/jts.22131; McLellan AT, 2006, AM J ADDICTION, V15, P113, DOI
10.1080/10550490500528316; MCLELLAN AT, 1992, J SUBST ABUSE TREAT, V9, P199, DOI
10.1016/0740-5472(92)90062-S; Newcomb MD, 2001, PROF PSYCHOL-RES PR, V32, P239, DOI
10.1037/0735-7028.32.3.239; Paivio SC, 2004, CHILD ABUSE NEGLECT, V28, P889, DOI
10.1016/j.chiabu.2004.01.011; Paulus DJ, 2016, J AFFECT DISORDERS, V190, P376, DOI
10.1016/j.jad.2015.10.014; Paulus DJ, 2016, COGN THER RES; POLUSNY MA, 1995, APPL
PREV PSYCHOL, V4, P143, DOI 10.1016/S0962-1849(05)80055-1; Potthast N, 2014, ADDICT
BEHAV, V39, P949, DOI 10.1016/j.addbeh.2014.01.015; Powers A, 2015, PSYCHIATRY,
V78, P251, DOI 10.1080/00332747.2015.1069656; Pratchett LC, 2011, DEV PSYCHOPATHOL,
V23, P477, DOI 10.1017/S0954579411000186; Preacher KJ, 2004, BEHAV RES METH INS C,
V36, P717, DOI 10.3758/BF03206553; Preacher KJ, 2008, BEHAV RES METHODS, V40, P879,
DOI 10.3758/BRM.40.3.879; Preacher KJ, 2011, PSYCHOL METHODS, V16, P93, DOI
10.1037/a0022658; Radomski Sharon A, 2016, Traumatology (Tallahass Fla), V22, P113;
Rodriguez N, 1997, J CONSULT CLIN PSYCH, V65, P53, DOI 10.1037/0022-006X.65.1.53;
Rosen CS, 2002, J STUD ALCOHOL, V63, P683, DOI 10.15288/jsa.2002.63.683;
Samochowiec J, 2014, NEUROPSYCHOBIOLOGY, V70, P77, DOI 10.1159/000364826; Sanchez
MM, 2001, DEV PSYCHOPATHOL, V13, P419, DOI 10.1017/S0954579401003029; Scher CD,
2001, J TRAUMA STRESS, V14, P843, DOI 10.1023/A:1013058625719; Shin SH, 2015, CHILD
ABUSE NEGLECT, V50, P94, DOI 10.1016/j.chiabu.2015.02.010; Shipman K, 2005, CHILD
ABUSE NEGLECT, V29, P1015, DOI 10.1016/j.chiabu.2005.01.006; Shipman K, 2000, DEV
PSYCHOPATHOL, V12, P47, DOI 10.1017/S0954579400001036; Shipman KL, 2007, SOC DEV,
V16, P268, DOI 10.1111/j.1467-9507.2007.00384.x; Short NA, 2015, COMPR PSYCHIAT,
V61, P15, DOI 10.1016/j.comppsych.2015.05.007; Smith KZ, 2014, PSYCHOL ADDICT
BEHAV, V28, P532, DOI 10.1037/a0035381; Stein MB, 2008, NEUROPSYCHOPHARMACOL, V33,
P312, DOI 10.1038/sj.npp.1301422; TOMBAUGH TN, 1992, J AM GERIATR SOC, V40, P922,
DOI 10.1111/j.1532-5415.1992.tb01992.x; Tull MT, 2007, BEHAV THER, V38, P303, DOI
10.1016/j.beth.2006.10.001; U. S. Department of Health and Human Services, 2016,
ANN UPD HHS POV GUID; Ullman SE, 2005, J STUD ALCOHOL, V66, P610, DOI
10.15288/jsa.2005.66.610; Wang MJ, 2013, EMOTION, V13, P1055, DOI 10.1037/a0033784;
Wardell JD, 2016, ADDICT BEHAV, V56, P1, DOI 10.1016/j.addbeh.2016.01.003; Weathers
F. W., 2013, LIFE EVENTS CHECKLIS; Wolff S, 2016, EUR ADDICT RES, V22, P292, DOI
10.1159/000447397 93 2 2 1 14 ELSEVIER SCIENCE INC NEW YORK
STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA 0163-8343 1873-7714
GEN HOSP PSYCHIAT Gen. Hosp. Psych. SEP 2017 48
42 50 10.1016/j.genhosppsych.2017.06.014 9
Psychiatry Psychiatry FH9UZ WOS:000411560600006 28917394
2019-09-25
J Jeanne, G; Purper-Ouakil, D; Rigole, H; Franc, N
Jeanne, G.; Purper-Ouakil, D.; Rigole, H.; Franc, N. New patterns
of substance use and abuse among French adolescents, a knowledge synthesis
ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE
French Article Adolescent; Addictive
behavior; Substance-related disorders OF-THE-LITERATURE; PRESCRIPTION
MEDICATIONS; UNITED-STATES; DEPENDENCE; DIVERSION; MISUSE; STIMULANTS; MEPHEDRONE;
TOXICITY; BEHAVIOR Aim. - There have been significant changes in adolescent
consumption habits over the past fifteen years. New molecules have been
synthesized, new devices created and a number of products have increased in
popularity; and as a result clinicians sometimes lack information. We chose to
focus on this population because of its vulnerability, as adolescents show low
sensitivity to long-term outcomes of their actions and may be easily influenced by
peers as regards experimentation of new drugs. The most consumed products by
adolescents in France are tobacco, alcohol and cannabis with the physiological
effects and consumption patterns of these drugs well documented. The purpose of
this review is to identify and describe other products that are frequently used by
adolescents to get high, to increase performance, for purposes of self-medication
or because of peer pressure. We summarized the current scientific evidence
regarding drug availability, physical and chemical properties, pharmacodynamics and
adverse effects. Method. - A literature review was conducted from 2000 to 2015
based on Pudmed, Google Scholar and governmental websites, using the following
keyword alone or in combination: "adolescent", "new", "misuse", "abuse",
"toxicity", "pharmacology" "cocaine", "MDMA", "inhalant", "poppers", "magic
mushroom", "psilocybin", "designer drug", "legal high", "smart drug", "cathinone",
"mephedrone", "cannabinoid", "prescription drug", "codeine", "opioid",
"methylphenidate", "cough syrup", "purple drank". Results. - New products,
including synthetic cannabis, cathinone or purple drank seem to be the most
dangerous. They are easily accessible and may lead to short-term severe or lethal
complications. Other substances do not pose a major short-term health risk by
themselves. However, their consumption may be an indication of other unhealthy risk
behaviors, such as prescription drug use, which may be related to psychiatric
comorbidity. Unfortunately, we do not have enough data to determine the long-term
consequences of the use of these substances. Moreover, these products have a strong
addictive potential and may be a risk factor for other addictions. For this reason,
increased supervision is justified, both for surveillance and reduction of harm.
Conclusion. - Taking care of an adolescent with substance abuse can be difficult.
Updated information regarding these new substances and the particular danger they
pose to adolescent health is needed. Informed clinicians can provide up to date and
accurate information to the patient and family, assess potential risk factors and
comorbidities, and provide appropriate support. Furthermore, because of the high
prevalence of substance abuse in the adolescent population, systematic screening of
adolescent consumption habit is useful to avoid or anticipate complications. Often,
problematic substance consumption behaviors are signs of more complicated
psychological or psychiatric issues. Substance abuse behaviors will often disappear
over time but they can also become a major problem as the adolescent moves into
adulthood. If problems persist, consultation with an addiction specialist may be
warranted. 2016 [Jeanne, G.; Purper-Ouakil, D.; Franc, N.] CHU St Eloi, Serv Med
Psychol Enfant & Adolescent MPEA, 80 Ave Augustin Fliche, F-34090 Montpellier,
France; [Rigole, H.] CHU St Eloi, Serv Med Interne & Addictol, 80 Ave Augustin
Fliche, F-34090 Montpellier, France Jeanne, G (reprint author), 18 Blvd Rabelais,
F-34000 Montpellier, France. gjeanne@chu-montpellier.fr; n-franc@chu-
montpellier.fr Agnich LE, 2013, ADDICT BEHAV, V38,
P2445, DOI 10.1016/j.addbeh.2013.03.020; Beck F, 2014, M S-MED SCI, V30, P916, DOI
10.1051/medsci/20143010020; Borges G, 2000, AM J EPIDEMIOL, V151, P781; Bowen SE,
2006, NEUROTOXICOL TERATOL, V28, P636, DOI 10.1016/j.ntt.2006.09.005; Boyd CJ,
2006, PEDIATRICS, V118, P2472, DOI 10.1542/peds.2006-1644; Brewer TL, 2014, J SPEC
PEDIATR NURS, V19, P119, DOI 10.1111/jspn.12057; Burns JM, 2013, SUBST ABUSE
REHABIL, V4, P75, DOI 10.2147/SAR.S36761; Casey BJ, 2008, DEV REV, V28, P62, DOI
10.1016/j.dr.2007.08.003; Collins DA, 2012, SUBST USE MISUSE, V47, P1339, DOI
10.3109/10826084.2012.716481; Currie C, 2008, SOC SCI MED, V66, P1429, DOI
10.1016/j.socscimed.2007.11.024; Dybdal-Hargreaves NF, 2013, EUR J PHARMACOL, V714,
P32, DOI 10.1016/j.ejphar.2013.05.024; Ennett ST, 2006, J RES ADOLESCENCE, V16,
P159, DOI 10.1111/j.1532-7795.2006.00127.x; European Monitoring Center for Drugs
and Drug Addiction (EMCDDA), 2015, 2015 ANN REP STAT DR; Franke AG, 2011,
PHARMACOPSYCHIATRY, V44, P60, DOI 10.1055/s-0030-1268417; Grenard JL, 2013,
PEDIATRICS, V131, pE369, DOI 10.1542/peds.2012-1480; Halpern JH, 1999, DRUG ALCOHOL
DEPEN, V53, P247, DOI 10.1016/S0376-8716(98)00129-X; Harris CR, 2013, J EMERG MED,
V44, P360, DOI 10.1016/j.jemermed.2012.07.061; Hibell B., 2012, 2011 ESPAD REPORT
SU; Hulvershorn Leslie A, 2015, Curr Drug Abuse Rev, V8, P41; Institut national de
la sante et de la recherche medicale (Inserm), 2014, COND ADD CHEZ AD US; Karila L,
2015, CURR NEUROPHARMACOL, V13, P12, DOI 10.2174/1570159X13666141210224137; Karila
L, 2015, PRESSE MED, V44, P383, DOI 10.1016/j.lpm.2014.09.020; Kaye S, 2012,
ADDICTION, V107, P467, DOI 10.1111/j.1360-0443.2011.03720.x; Kim AE, 2013, J PUBLIC
HEALTH MAN, V19, pE1, DOI 10.1097/PHH.0b013e3182980c47; Konghom S, 2010, COCHRANE
DB SYST REV, DOI 10.1002/14651858.CD007537.pub2; Krauss MJ, 2014, ALCOHOL CLIN EXP
RES, V38, P2630, DOI 10.1111/acer.12533; Lafaye Genevieve, 2014, Rev Prat, V64,
P509; Lahaie E, 2013, TENDANCES, V84, P18; Logan BK, 2012, J FORENSIC SCI, V57,
P1388, DOI 10.1111/j.1556-4029.2012.02133.x; Lopez-Arnau R, 2012, BRIT J PHARMACOL,
V167, P407, DOI 10.1111/j.1476-5381.2012.01998.x; Meyer JS, 2013, SUBST ABUSE
REHABIL, V4, P83, DOI 10.2147/SAR.S37258; Milhet M., USAGES DETOURNES MED; Miotto
K, 2013, DRUG ALCOHOL DEPEN, V132, P1, DOI 10.1016/j.drugalcdep.2013.06.016;
Nurnberger JI, 2004, ARCH GEN PSYCHIAT, V61, P1246, DOI
10.1001/archpsyc.61.12.1246; Phillips K, 2009, AM J CARDIOVASC DRUG, V9, P177, DOI
10.2165/00129784-200909030-00005; Pomara C, 2012, CURR MED CHEM, V19, P5647, DOI
10.2174/092986712803988811; Pousset M., 2012, COCAINE DONNESS ESSE; Spilka S, 2015,
TENDANCES, V100, P8; Stanis JJ, 2014, PSYCHOPHARMACOLOGY, V231, P1437, DOI
10.1007/s00213-013-3393-1; Steinkellner T, 2011, BIOL CHEM; Tittarelli R, 2015,
CURR NEUROPHARMACOL, V13, P26, DOI 10.2174/1570159X13666141210222409; van Amsterdam
J, 2011, REGUL TOXICOL PHARM, V59, P423, DOI 10.1016/j.yrtph.2011.01.006; Wilens
TE, 2008, J AM ACAD CHILD PSY, V47, P21, DOI 10.1097/chi.0b013e31815a56f1; Young
AM, 2012, J ADOLESCENT HEALTH, V51, P6, DOI 10.1016/j.jadohealth.2012.01.011; Zosel
A, 2013, J AM ACAD CHILD PSY, V52, P196, DOI 10.1016/j.jaac.2012.11.014 45
0 0 0 10 MASSON EDITEUR MOULINEAUX CEDEX 9 21 STREET
CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE 0013-7006
ENCEPHALE Enceph.-Rev. Psychiatr. Clin. Biol. Ther. AUG 2017 43 4
346 353 10.1016/j.encep.2016.05.012
8 Neurosciences; Psychiatry Neurosciences & Neurology; Psychiatry
FI0YY WOS:000411657000008 27720453 2019-09-25
J Tomaka, J; Magoc, D; Morales-Monks, SM; Reyes, AC
Tomaka, Joe; Magoc, Dejan; Morales-Monks, Stormy M.; Reyes, Anabel C.
Posttraumatic Stress Symptoms and Alcohol-Related Outcomes Among Municipal
Firefighters JOURNAL OF TRAUMATIC STRESS English Article
SELF-MEDICATION HYPOTHESIS; DISORDER SYMPTOMS;
FIT INDEXES; USE MOTIVES; DRINKING; RESPONSES; DISTRESS; ABUSE This study
examined levels of posttraumatic stress symptoms (PTSS) and relationships between
PTSS and alcohol-related outcomes in a near census of municipal firefighters. The
study also assessed substance-use coping and drinking to cope as potential
mediators of such outcomes. Firefighters (N = 740) completed measures that assessed
PTSS, alcohol risk behaviors, alcohol problems, drinking motives, and coping with
stress. Results showed that 32.4% of firefighters reported significant levels of
PTSS using National Center for PTSD (2014) screening cutoff scores. Correlational
analysis showed that PTSS was related to at-risk drinking (r = .18) and alcohol-
related problems (r = .33), as well as use of maladaptive coping strategies (r = .
58) and substance use coping (r = .40). Structural analyses comparing multiple
alternative models suggested that a model that included substance use coping and
drinking to cope as mediators of the association between PTSS and problem drinking
provided the best fit to the data. Tests of multigroup invariance confirmed this
model. Overall, PTSS were common in this population and they predicted maladaptive
coping patterns and alcohol-related consequences. One implication of these findings
is that fire departments might consider adding or enhancing screening and treatment
options for PTS, alcohol misuse, or both. [Tomaka, Joe] New Mexico State Univ, Dept
Publ Hlth Sci, Las Cruces, NM 88003 USA; [Magoc, Dejan] Stetson Univ, Dept Hlth
Sci, Deland, FL 32720 USA; [Morales-Monks, Stormy M.] Texas Tech Univ, Dept
Emergency Med, El Paso, TX USA; [Reyes, Anabel C.] Univ Texas El Paso, Dept Publ
Hlth Sci, El Paso, TX 79968 USA Tomaka, J (reprint author), New Mexico State
Univ, Dept Publ Hlth Sci, Las Cruces, NM 88003 USA. tomaka@nmsu.edu
American Psychiatric Association, 2013, DIAGN STAT MAN MENT; Anderson
KG, 2011, ADDICT BEHAV, V36, P972, DOI 10.1016/j.addbeh.2011.05.009; Arbuckle J.
L., 2014, AMOS VERSION 23 0 CO; Babor T. F., 2001, ALCOHOL USE DISORDER; Bacharach
SB, 2008, J APPL PSYCHOL, V93, P155, DOI 10.1037/0021-9010.93.1.155; Beaton R,
1999, J TRAUMA STRESS, V12, P293, DOI 10.1023/A:1024776509667; Berger W, 2012, SOC
PSYCH PSYCH EPID, V47, P1001, DOI 10.1007/s00127-011-0408-2; BOXER PA, 1993, SCAND
J WORK ENV HEA, V19, P121, DOI 10.5271/sjweh.1497; BROWN PJ, 1994, DRUG ALCOHOL
DEPEN, V35, P51, DOI 10.1016/0376-8716(94)90110-4; Byrne B. M., 2010, STRUCTURAL
EQUATION; Carver CS, 1997, INT J BEHAV MED, V4, P92, DOI
10.1207/s15327558ijbm0401_6; Cheung GW, 2002, STRUCT EQU MODELING, V9, P233, DOI
10.1207/S15328007SEM0902_5; Cooper M. L., 1994, PSYCHOL ASSESSMENT, V6, P117, DOI
[DOI 10.1037/1040-3590.6.2.117, 10.1037/1040-3590.6.2.117]; Del Ben KS, 2006, WORK
STRESS, V20, P37, DOI 10.1080/02678370600679512; Dixon LJ, 2009, ADDICT BEHAV, V34,
P1065, DOI 10.1016/j.addbeh.2009.06.008; Haller M, 2014, PSYCHOL ADDICT BEHAV, V28,
P841, DOI 10.1037/a0035878; HORN JL, 1965, PSYCHOMETRIKA, V30, P179, DOI
10.1007/BF02289447; Hruska B, 2011, PSYCHOL ADDICT BEHAV, V25, P405, DOI
10.1037/a0022439; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI
10.1080/10705519909540118; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259; Lazarus
R. S., 1984, STRESS APPRAISAL COP; MacCallum R. C., 1995, STRUCTURAL EQUATION, P76;
Maxwell SE, 2011, MULTIVAR BEHAV RES, V46, P816, DOI 10.1080/00273171.2011.606716;
Murphy SA, 1999, INT J STRESS MANAGE, V6, P179, DOI 10.1023/A:1021934725246; Patil
V. H., 2007, PARALLEL ANAL ENGINE; Perkins HW, 1999, J STUD ALCOHOL, V60, P219, DOI
10.15288/jsa.1999.60.219; Preacher KJ, 2008, BEHAV RES METHODS, V40, P879, DOI
10.3758/BRM.40.3.879; Ruggiero KJ, 2003, J TRAUMA STRESS, V16, P495, DOI
10.1023/A:1025714729117; SADAVA SW, 1993, CAN J BEHAV SCI, V25, P446, DOI
10.1037/h0078841; Stewart SH, 1996, PSYCHOL BULL, V120, P83, DOI 10.1037/0033-
2909.120.1.83; Suh JJ, 2008, PSYCHOANAL PSYCHOL, V25, P518, DOI 10.1037/0736-
9735.25.3.518; Tomaka J, 2012, SUBST USE MISUSE, V47, P1260, DOI
10.3109/10826084.2012.692754; U. S. Department of Veterans Affairs, 2014, US PTSD
CHECKL DSM 4; Vujanovic AA, 2011, J COGN PSYCHOTHER, V25, P130, DOI 10.1891/0889-
8391.25.2.130; WHITE HR, 1989, J STUD ALCOHOL, V50, P30, DOI
10.15288/jsa.1989.50.30 35 5 5 2 7 WILEY HOBOKEN 111 RIVER
ST, HOBOKEN 07030-5774, NJ USA 0894-9867 1573-6598 J TRAUMA STRESS
J. Trauma Stress AUG 2017 30 4 416 424
10.1002/jts.22203 9 Psychology, Clinical; Psychiatry
Psychology; Psychiatry FD6BI WOS:000407613200010 28699663
2019-09-25
J Bachrach, RL; Read, JP Bachrach, Rachel L.; Read, Jennifer
P. Peer Alcohol Behavior Moderates Within-Level Associations Between
Posttraumatic Stress Disorder Symptoms and Alcohol Use in College Students
PSYCHOLOGY OF ADDICTIVE BEHAVIORS English Article
alcohol; college; PTSD; social support; weekend drinking
PTSD SYMPTOMS; CONSEQUENCES QUESTIONNAIRE; 1ST YEAR; SUBSTANCE USE; LIFE
EVENTS; PSYCHOMETRIC PROPERTIES; PRELIMINARY VALIDATION; INJUNCTIVE NORMS; SOCIAL-
INFLUENCE; PREDICT ALCOHOL Self-medication theory (SMT) posits that individuals
exposed to trauma and resulting posttraumatic stress symptoms (PTSD) are at risk
for heavy drinking and associated negative consequences. Close peer alcohol use is
also a powerful predictor of alcohol involvement in college, particularly
influencing those with greater negative affect. As individuals with PTSD may rely
on peers for support, peer drinking behaviors are possibly putting them at further
risk for greater alcohol use and resulting consequences. To test self-medication
processes, the present study examined the relationship between weekday PTSD
symptoms, weekend alcohol behavior, and the influence of both emotionally
supportive peer and other friend drinking behavior by investigating: (a) whether
weekday PTSD symptoms predicted subsequent weekend alcohol use and consequences;
and (b) whether the relationship between weekday PTSD symptoms and weekend alcohol
behavior was moderated by various drinking behaviors of one's peers. Trauma-exposed
heavy-drinking college students (N = 128) completed a baseline assessment and 30
daily, Web-based assessments of alcohol use and related consequences, PTSD
symptoms, and peer alcohol behavior. Results directly testing SMT were not
supported. However, friend alcohol behavior moderated the relationship between
weekday PTSD and weekend alcohol behavior. Findings highlight the importance of
peer drinking as both a buffer and risk factor for problematic drinking and provide
useful information for interventions aimed at high-risk drinkers. [Bachrach,
Rachel L.; Read, Jennifer P.] Univ Buffalo State Univ New York, Dept Psychol,
Buffalo, NY 14260 USA; [Bachrach, Rachel L.] Pittsburgh Adolescent Alcohol Res Ctr,
Western Psychiat Inst & Clin, 3811 OHara St, Pittsburgh, PA 15213 USA Bachrach, RL
(reprint author), Univ Buffalo State Univ New York, Dept Psychol, Buffalo, NY 14260
USA.; Bachrach, RL (reprint author), Pittsburgh Adolescent Alcohol Res Ctr, Western
Psychiat Inst & Clin, 3811 OHara St, Pittsburgh, PA 15213 USA.
bachrachrl2@upmc.edu National Institute on Alcohol Abuse and
AlcoholismUnited States Department of Health & Human ServicesNational Institutes of
Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [F31
AA022272, T32 AA007453]; Mark Diamond Research Fund from the University at Buffalo
This research was supported in part by funding from the National Institute on
Alcohol Abuse and Alcoholism (F31 AA022272; T32 AA007453) and The Mark Diamond
Research Fund from the University at Buffalo awarded to Rachel Bachrach. All views
presented in this article are the sole responsibility of the authors, and not the
sources of funding. The ideas and data appearing in this article were presented at
the 2014 meeting of the Research Society on Alcoholism in Bellevue, WA. An abstract
from this poster presentation was published in a journal supplement associated with
this meeting (Alcoholism: Clinical and Experimental Research, 38, 183A). These data
also appear in the first author's doctoral dissertation at the University at
Buffalo. We thank Kate Carey and Debra Kaysen for their helpful comments on study
design and data analysis. American Psychiatric Association, 2000, DIAGN STAT
MAN MENT; Armeli S, 2003, PSYCHOL ADDICT BEHAV, V17, P266, DOI 10.1037/0893-
164X.17.4.266; Armeli S, 2010, PSYCHOL ADDICT BEHAV, V24, P38, DOI
10.1037/a0017530; Arnett JJ, 2005, J DRUG ISSUES, V35, P235, DOI
10.1177/002204260503500202; Avant E. M., 2011, J AGGRESS MALTREAT T, V20, P539, DOI
DOI 10.1080/10926771.2011.588153; Bachrach RL, 2012, J CLIN PSYCHOL, V68, P843, DOI
10.1002/jclp.21874; Bachrach RL, 2012, ADDICT BEHAV, V37, P1038, DOI
10.1016/j.addbeh.2012.04.013; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI
10.1016/0005-7967(96)00033-2; Borsari B, 2003, J STUD ALCOHOL, V64, P331, DOI
10.15288/jsa.2003.64.331; Borsari B, 2001, J SUBST ABUSE, V13, P391, DOI
10.1016/S0899-3289(01)00098-0; Borsari B, 2006, DRUG ALCOHOL REV, V25, P361, DOI
10.1080/09595230600741339; Breslau N, 2003, ARCH GEN PSYCHIAT, V60, P289, DOI
10.1001/archpsyc.60.3.289; Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI
10.1037/0022-006X.68.5.748; Buckner JD, 2011, J ANXIETY DISORD, V25, P631, DOI
10.1016/j.janxdis.2011.02.003; Carey KB, 2011, ADDICTION, V106, P528, DOI
10.1111/j.1360-0443.2010.03193.x; Carey KB, 1997, J STUD ALCOHOL, V58, P100, DOI
10.15288/jsa.1997.58.100; Cohn A, 2014, PSYCHOL ADDICT BEHAV, V28, P114, DOI
10.1037/a0035725; Conybeare D, 2012, J CLIN PSYCHOL, V68, P699, DOI
10.1002/jclp.21845; Dawson J., 2015, INTERPRETING INTERAC; Dawson JF, 2014, J BUS
PSYCHOL, V29, P1, DOI 10.1007/s10869-013-9308-7; Del Boca FK, 2004, J CONSULT CLIN
PSYCH, V72, P155, DOI 10.1037/0022-006X.72.2.155; Flood AM, 2009, J BEHAV MED, V32,
P234, DOI 10.1007/s10865-008-9195-y; Gaher RM, 2014, PSYCHOL ADDICT BEHAV, V28,
P1013, DOI 10.1037/a0037257; Gray MJ, 2004, ASSESSMENT, V11, P330, DOI
10.1177/1073191104269954; Hagman BT, 2010, J AM COLL HEALTH, V59, P82, DOI
10.1080/07448481.2010.483707; Hingson RW, 2009, J STUD ALCOHOL DRUGS, P12, DOI
10.15288/jsads.2009.s16.12; Hoeppner BB, 2012, J STUD ALCOHOL DRUGS, V73, P613, DOI
10.15288/jsad.2012.73.613; Hruska B, 2012, PSYCHOL ADDICT BEHAV, V26, P734, DOI
10.1037/a0027584; Hussong AM, 2003, J ABNORM CHILD PSYCH, V31, P413, DOI
10.1023/A:1023843618887; Hussong AM, 2001, J ABNORM PSYCHOL, V110, P449, DOI
10.1037//0021-843X.110.3.449; Hussong AM, 2011, PSYCHOL ADDICT BEHAV, V25, P390,
DOI 10.1037/a0024519; John O. P, 1999, HDB PERSONALITY THEO, P102, DOI DOI
10.1525/FQ.1998.51.4.04A00260; Johnston L. D., 2014, MONITORING FUTURE NA, VII;
Johnston LD, 2011, MONITORING FUTURE NA, VII; Kahler CW, 2008, J STUD ALCOHOL
DRUGS, V69, P611, DOI 10.15288/jsad.2008.69.611; Kahler CW, 2005, ALCOHOL CLIN EXP
RES, V29, P1180, DOI 10.1097/01.ALC.0000171940.95813.A5; Kaysen D, 2014, PSYCHOL
ADDICT BEHAV, V28, P62, DOI 10.1037/a0033588; Khantzian E. J., 2003, PRIMARY
PSYCHIAT, V10, p[47, 53]; Kubany ES, 2000, PSYCHOL ASSESSMENT, V12, P210, DOI
10.1037//1040-3590.12.2.210; Larimer ME, 2007, ADDICT BEHAV, V32, P2439, DOI
10.1016/j.addbeh.2007.05.006; Lau-Barraco C, 2011, ADDICT BEHAV, V36, P47, DOI
10.1016/j.addbeh.2010.08.017; Leonard KE, 2000, J STUD ALCOHOL, V61, P669, DOI
10.15288/jsa.2000.61.669; Lewis MA, 2004, PSYCHOL ADDICT BEHAV, V18, P334, DOI
10.1037/0893-164X.18.4.334; McDevitt-Murphy ME, 2007, ASSESSMENT, V14, P181, DOI
10.1177/1073191106295914; Merrill JE, 2013, PSYCHOL ADDICT BEHAV, V27, P42, DOI
10.1037/a0029898; Miller MW, 2006, J ABNORM PSYCHOL, V115, P369, DOI 10.1037/0021-
843X.115.2.369; Monahan CJ, 2013, ADDICT BEHAV, V38, P1719, DOI
10.1016/j.addbeh.2012.09.004; Naragon-Gainey K, 2012, PSYCHOL ASSESSMENT, V24,
P1041, DOI 10.1037/a0028518; National Institute of Alcohol Abuse and Alcoholism,
2004, NIH PUBLICATION, V04-5346; Neighbors C, 2006, J STUD ALCOHOL, V67, P290, DOI
10.15288/jsa.2006.67.290; Neighbors C, 2007, J STUD ALCOHOL DRUGS, V68, P556, DOI
10.15288/jsad.2007.68.556; Neighbors C, 2008, PSYCHOL ADDICT BEHAV, V22, P576, DOI
10.1037/a0013043; O'Grady MA, 2011, J STUD ALCOHOL DRUGS, V72, P633, DOI
10.15288/jsad.2011.72.633; Ozer EJ, 2003, PSYCHOL BULL, V129, P52, DOI
10.1037//0033-2909.129.1.52; Pietrzak RH, 2010, J AFFECT DISORDERS, V120, P188, DOI
10.1016/j.jad.2009.04.015; Possemato K, 2015, PSYCHOL ADDICT BEHAV, V29, P894, DOI
10.1037/adb0000129; Rankin LA, 2006, J YOUTH ADOLESCENCE, V35, P925, DOI
10.1007/s10964-006-9073-2; Raudenbush S. W., 2011, HLM 7 HIERARCHICAL L; Raudenbush
S. W., 2002, HIERARCHICAL LINEAR; Read JP, 2007, ADDICT BEHAV, V32, P2597, DOI
10.1016/j.addbeh.2007.06.021; Read JP, 2016, PSYCHOL TRAUMA-US, V8, P393, DOI
10.1037/tra0000087; Read JP, 2012, J CONSULT CLIN PSYCH, V80, P426, DOI
10.1037/a0028210; Read JP, 2011, PSYCHOL TRAUMA-US, V3, P148, DOI 10.1037/a0021260;
Read JP, 2006, J STUD ALCOHOL, V67, P169, DOI 10.15288/jsa.2006.67.169; Read JP,
2005, J STUD ALCOHOL, V66, P23, DOI 10.15288/jsa.2005.66.23; Reid AE, 2015, J
CONSULT CLIN PSYCH, V83, P36, DOI 10.1037/a0037634; Reifman A, 2006, PERS SOC
PSYCHOL B, V32, P820, DOI 10.1177/0146167206286219; Rutter LA, 2013, PSYCHOL
TRAUMA-US, V5, P56, DOI 10.1037/a0021996; SCHNURR PP, 1993, AM J PSYCHIAT, V150,
P479; Schulenberg J. E., 2006, EMERGING ADULTS AM C, P135, DOI DOI 10.1037/11381-
006; Simpson TL, 2014, J ABNORM PSYCHOL, V123, P237, DOI 10.1037/a0035193; Simpson
TL, 2012, PSYCHOL ADDICT BEHAV, V26, P724, DOI 10.1037/a0027169; Singer J. D, 2003,
APPL LONGITUDINAL DA; Smyth JM, 2008, J AM COLL HEALTH, V57, P69, DOI
10.3200/JACH.57.1.69-76; Stein MB, 1997, AM J PSYCHIAT, V154, P1114; Substance
Abuse and Mental Health Services Administration (Office of Applied Studies) U.S.
Department of Health and Human Services, 2014, DHHS PUBLICATION; Talbott LL, 2012,
SUBST ABUS, V33, P146, DOI 10.1080/08897077.2011.640204; TRACY EM, 1990, FAM SOC-J
CONTEMP H, V71, P461, DOI 10.1177/104438949007100802; Tremblay PF, 2010, J AM COLL
HEALTH, V58, P401, DOI 10.1080/07448480903540465; Weathers F., 1993, M INT SOC
TRAUM STRE; Weathers F. W., 1991, PTSD CHECKLIST CIVIL; Wechsler H, 2008, J STUD
ALCOHOL DRUGS, V69, P481, DOI 10.15288/jsad.2008.69.481; Wood MD, 2001, J STUD
ALCOHOL, V62, P32, DOI 10.15288/jsa.2001.62.32 83 3 3 0 6
EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC WASHINGTON
750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA 0893-164X 1939-1501
PSYCHOL
ADDICT BEHAV Psychol. Addict. Behav. AUG 2017 31 5
576 588 10.1037/adb0000285 13 Substance Abuse;
Psychology, Multidisciplinary Substance Abuse; Psychology FC9ZD
WOS:000407198700007 28703614 Green Accepted 2019-09-25
J Lazarus, SA; Beardslee, J; Pedersen, SL; Stepp, SD
Lazarus, Sophie A.; Beardslee, Jordan; Pedersen, Sarah L.; Stepp, Stephanie
D. A Within-Person Analysis of the Association between Borderline
Personality Disorder and Alcohol Use in Adolescents JOURNAL OF ABNORMAL CHILD
PSYCHOLOGY English Article
Borderline personality disorder; Adolescence; Alcohol use DIALECTICAL
BEHAVIOR-THERAPY; SUBSTANCE USE DISORDERS; DRUG-USE; SELF-MEDICATION; YOUNG-ADULTS;
COMORBIDITY; SYMPTOMS; DRINKING; MODEL; CONSEQUENCES Many studies examining the
association between borderline personality disorder (BPD) and alcohol use during
adolescence have focused on between-individual differences (rank order stability),
comparing whether adolescents with elevated rates of alcohol use have higher BPD
symptoms than those with lower rates of alcohol use. As such, the extent to which
an individual's alcohol use is associated with concurrent and future BPD symptoms
has been relatively unstudied. The current study assessed year-to-year fluctuations
in alcohol use and BPD symptoms in a large urban sample of girls from age 14 to age
17 (N = 2450). The primary aim was to examine whether increases in alcohol use were
associated with increases in adolescent girls' BPD symptoms in the same year and in
the following year. Results of fixed-effects (within-individual) models revealed
that even while controlling for the time-varying impact of symptoms of both
internalizing and externalizing disorders, prior and concurrent other substance
use, and all time invariant, pre-existing differences between individuals, higher
past-year alcohol use was associated with higher levels of BPD symptoms.
Furthermore, this association did not vary by age, or by sociodemographic factors,
including child race and socioeconomic status of the family. The results of this
study indicate heightened risk for the exacerbation of BPD symptoms following
increases in alcohol use frequency and highlight the potential utility of
interventions targeting drinking behavior for preventing escalations in BPD
symptoms. [Lazarus, Sophie A.; Beardslee, Jordan; Pedersen, Sarah L.; Stepp,
Stephanie D.] Univ Pittsburgh, Sch Med, Dept Psychiat, 3811 OHara St, Pittsburgh,
PA 15213 USA Lazarus, SA (reprint author), Univ Pittsburgh, Sch Med, Dept
Psychiat, 3811 OHara St, Pittsburgh, PA 15213 USA. lazaruss@upmc.edu Stepp,
Stephanie/D-4571-2014 National Institute of Mental HealthUnited States
Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
National Institute of Mental Health (NIMH) [MH056639]; National Institute on Drug
AbuseUnited States Department of Health & Human ServicesNational Institutes of
Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA012237];
[K01AA021135] This research was supported by grants from the National Institute
of Mental Health (MH056639) and the National Institute on Drug Abuse (DA012237).
Dr. Pedersen's effort was supported by K01AA021135. Allen JP, 2005, CHILD DEV,
V76, P747, DOI 10.1111/j.1467-8624.2005.00875.x; Allison P. D., 2009, FIXED EFFECTS
REGRES; American Psychiatric Association, 2013, DIAGN STAT MAN MENT; American
Psychiatric Association, 2000, DIAGN STAT MAN MENT; Beauchaine TP, 2009, DEV
PSYCHOPATHOL, V21, P735, DOI 10.1017/S0954579409000418; Bornovalova MA, 2007, CLIN
PSYCHOL REV, V27, P923, DOI 10.1016/j.cpr.2007.01.013; Bornovalova MA, 2013,
PERSONAL DISORD, V4, P23, DOI 10.1037/a0027178; Bornovalova MA, 2011, ASSESSMENT,
V18, P234, DOI 10.1177/1073191111398320; Chambers RA, 2003, AM J PSYCHIAT, V160,
P1041, DOI 10.1176/appi.ajp.160.6.1041; Chanen A. M., 2008, J PERSONALITY DISORD,
V22, P364, DOI [10.1521/353-pedi.2008.22.4.353, DOI 10.1521/353-
PEDI.2008.22.4.353]; Chanen AM, 2004, J PERS DISORD, V18, P526, DOI
10.1521/pedi.18.6.526.54798; Chanen AM, 2012, CURR PSYCHIAT REP, V14, P45, DOI
10.1007/s11920-011-0242-y; Cohen P, 2007, DRUG ALCOHOL DEPEN, V88, pS71, DOI
10.1016/j.drugalcdep.2006.12.012; Colder CR, 2002, J CONSULT CLIN PSYCH, V70, P976,
DOI 10.1037//0022-006X.70.4.976; COOPER ML, 1995, J PERS SOC PSYCHOL, V69, P990,
DOI 10.1037/0022-3514.69.5.990; DuRant RH, 1999, ARCH PEDIAT ADOL MED, V153, P286;
EPPRIGHT TD, 1993, AM J PSYCHIAT, V150, P1233; Farley J. P., 2015, J ADDICTION RES
THER, V6, DOI [10.4172/2155-6105.1000220, DOI 10.4172/2155-6105.1000220]; Gadow K.
D., 1998, ADOLESCENT SYMPTOM I; Galaif Elisha R, 2007, Int J Adolesc Med Health,
V19, P27; Gottfredson NC, 2013, J STUD ALCOHOL DRUGS, V74, P576, DOI
10.15288/jsad.2013.74.576; Gould LF, 2012, INT J EMOT EDUC, V4, P6; Grant BF, 2008,
J CLIN PSYCHIAT, V69, P533, DOI 10.4088/JCP.v69n0404; Grilo CM, 1996, AM J
PSYCHIAT, V153, P1089; HANSELL S, 1991, J HEALTH SOC BEHAV, V32, P288, DOI
10.2307/2136809; Hasin D, 2011, ARCH GEN PSYCHIAT, V68, P1158, DOI
10.1001/archgenpsychiatry.2011.78; Hersh MA, 2009, J ABNORM CHILD PSYCH, V37, P493,
DOI 10.1007/s10802-008-9291-z; Hussong AM, 2008, J STUD ALCOHOL DRUGS, V69, P296,
DOI 10.15288/jsad.2008.69.296; Jahng S, 2011, J ABNORM PSYCHOL, V120, P572, DOI
10.1037/a0024686; Johnson JG, 2000, ACTA PSYCHIAT SCAND, V102, P265, DOI
10.1034/j.1600-0447.2000.102004265.x; Johnston Lloyd D., 2016, MONITORING FUTURE
NA; Keenan K, 2010, J CLIN CHILD ADOLESC, V39, P506, DOI
10.1080/15374416.2010.486320; Korzekwa MI, 2008, COMPR PSYCHIAT, V49, P380, DOI
10.1016/j.comppsych.2008.01.007; Lenzenweger MF, 2005, DEV PSYCHOPATHOL, V17,
P1207, DOI 10.1017/S0954579405050571; Lenzenweger MF, 1997, ARCH GEN PSYCHIAT, V54,
P345; Linehan M., 1993, COGNITIVE BEHAV TREA; Linehan MM, 1999, AM J ADDICTION, V8,
P279; LINKS PS, 1995, CAN J PSYCHIAT, V40, P9, DOI 10.1177/070674379504000105;
Martinez-Raga J, 2002, ALCOHOL ALCOHOLISM, V37, P277, DOI 10.1093/alcalc/37.3.277;
PANDINA RJ, 1984, J DRUG ISSUES, V14, P253, DOI 10.1177/002204268401400206; Parker
EM, 2016, HEALTH EDUC BEHAV, V43, P528, DOI 10.1177/1090198115605308; Reimuller A,
2011, ADDICT BEHAV, V36, P203, DOI 10.1016/j.addbeh.2010.10.006; Rohde P, 2001, J
AM ACAD CHILD PSY, V40, P83, DOI 10.1097/00004583-200101000-00020; Schilling EA,
2009, J ADOLESCENT HEALTH, V44, P335, DOI 10.1016/j.jadohealth.2008.08.006; Serman
N, 2002, ADOLESCENCE, V37, P841; Simons-Morton B, 2006, ADDICT BEHAV, V31, P1211,
DOI 10.1016/j.addbeh.2005.09.006; Sinha R, 2009, NEUROPSYCHOPHARMACOL, V34, P1198,
DOI 10.1038/npp.2008.78; Smith DJ, 2005, J AFFECT DISORDERS, V87, P17, DOI
10.1016/j.jad.2005.02.019; Squeglia LM, 2015, AM J PSYCHIAT, V172, P531, DOI
10.1176/appi.ajp.2015.14101249; Steinberg L, 2010, BRAIN COGNITION, V72, P160, DOI
10.1016/j.bandc.2009.11.003; Stepp SD, 2005, J PERS DISORD, V19, P711, DOI
10.1521/pedi.2005.19.6.711; Stepp SD, 2014, BORDER PERS DIS EMOT, V1, DOI
10.1186/2051-6673-1-18; Stepp SD, 2014, DEV PSYCHOPATHOL, V26, P361, DOI
10.1017/S0954579413001041; Stepp SD, 2012, J ABNORM CHILD PSYCH, V40, P7, DOI
10.1007/s10802-011-9530-6; Tapert SF, 2001, J ADOLESCENT HEALTH, V28, P181, DOI
10.1016/S1054-139X(00)00169-5; Thatcher DL, 2005, ADDICT BEHAV, V30, P1709, DOI
10.1016/j.addbeh.2005.07.008; Tomko RL, 2014, J PERS DISORD, V28, P734, DOI
10.1521/pedi_2012_26_093; Trull TJ, 2010, J PERS DISORD, V24, P412, DOI
10.1521/pedi.2010.24.4.412; Trull TJ, 2004, EXP CLIN PSYCHOPHARM, V12, P65, DOI
10.1037/1064-1297.12.1.65; Trull TJ, 2000, CLIN PSYCHOL REV, V20, P235, DOI
10.1016/S0272-7358(99)00028-8; Trull TJ, 1997, J ABNORM PSYCHOL, V106, P307, DOI
10.1037/0021-843X.106.2.307; van den Bosch LMC, 2002, ADDICT BEHAV, V27, P911, DOI
10.1016/S0306-4603(02)00293-9; Yen S, 2003, J ABNORM PSYCHOL, V112, P375, DOI
10.1037/0021-843X.112.3.375; Zimmerman M, 2012, J CLIN PSYCHIAT, V73, P8, DOI
10.4088/JCP.10m06784 64 4 4 1 13 SPRINGER/PLENUM PUBLISHERS
NEW YORK 233 SPRING ST, NEW YORK, NY 10013 USA 0091-0627 1573-2835
J ABNORM CHILD PSYCH J. Abnorm. Child Psychol. AUG 2017 45 6
1157 1167 10.1007/s10802-016-0225-x
11 Psychology, Clinical; Psychology, Developmental Psychology FB5MC
WOS:000406185000009 27812907 Green Accepted 2019-09-25
J Berg, MK; Hobkirk, AL; Joska, JA; Meade, CS Berg, Martha
K.; Hobkirk, Andrca L.; Joska, John A.; Meade, Christina S. The Role of
Substance Use Coping in the Relation Between Childhood Sexual Abuse and Depression
Among Methamphetamine Users in South Africa PSYCHOLOGICAL TRAUMA-THEORY
RESEARCH PRACTICE AND POLICY English Article
South Africa; methamphetamine; coping; childhood sexual abuse;
depression POSTTRAUMATIC-STRESS-DISORDER; CAPE-TOWN; INTEGRATED TREATMENT;
COMORBID ANXIETY; SELF-MEDICATION; SCHOOL-STUDENTS; TRAUMA; CHILDREN; RISK;
INTERVENTION Objective: Childhood sexual abuse (CSA) is a critical global
health issue associated with poor psychosocial outcomes. Individuals with CSA
histories are at risk for drug use, which is a growing problem in the Western Cape
of South Africa. The present study of methamphetamine users in this region examined
whether substance use coping, a contextually relevant type of avoidance-based
coping, mediates the relation between CSA and depressive symptoms. Method:
Participants included 161 men and 108 women seeking treatment for methamphetamine
use. Participants completed a computer-assisted survey and a face-to-face interview
with clinic staff to evaluate history of CSA, current substance use severity and
coping, and current depressive symptoms. Results: Nearly a third of participants
reported a history of CSA, and the average methamphetamine use severity score
exceeded the threshold of high risk. A history of CSA was significantly associated
with higher substance use coping and more depression symptoms. Substance use coping
was a significant mediator of the association between CSA and depression symptoms.
Conclusions: In this study of high-risk methamphetamine users, substance use coping
emerged as a common means of managing stress, especially for those with a history
of CSA, which was further linked to depressive symptoms. These findings underscore
the potential benefit of integrating coping interventions and mental health
treatment into substance abuse treatment programs, particularly for those with a
history of childhood abuse and violence. [Berg, Martha K.; Hobkirk, Andrca L.;
Meade, Christina S.] Duke Univ, Duke Global Hlth Inst, Durham, NC 27706 USA;
[Hobkirk, Andrca L.; Meade, Christina S.] Duke Univ, Dept Psychiat & Behav Sci, Sch
Med, Erwin Terrace 2,2812 Erwin Rd,Suite 403, Durham, NC 27706 USA; [Joska, John
A.] Univ Cape Town, Dept Psychiat & Mental Hlth, Rondebosch, South Africa Meade,
CS (reprint author), Duke Univ, Dept Psychiat & Behav Sci, Sch Med, Erwin Terrace
2,2812 Erwin Rd,Suite 403, Durham, NC 27706 USA. christina.meade@duke.edu
Berg, Martha/0000-0002-6496-1703 Duke University Center for AIDS Research
Grant [P30-AI0645180]; National Institute on Drug Abuse GrantsUnited States
Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
National Institute on Drug Abuse (NIDA) [K23-DA028660, R03-DA033828, F32-DA038519];
Duke University; Duke Global Health Institute This study was funded by Duke
University Center for AIDS Research Grant P30-AI0645180, with additional support
from National Institute on Drug Abuse Grants K23-DA028660, R03-DA033828, and F32-
DA038519. An Atlantic Coast Conference Inter-Institutional Academic Collaborative
Fellowship from Duke University and a Bains Family Independent Research Grant from
the Duke Global Health Institute provided Martha K. Berg with funds for travel and
living expenses in South Africa. We thank Hetta Gouse, Daniella Cordero, and Ryan
Lion for their assistance with data collection and management. We also thank Warren
Burnhams, Sadieqa Barodien, and the Matrix clinic staff for their assistance with
participant recruitment and interviewing. This analysis was conducted as part of an
undergraduate honors thesis by Martha K. Berg. Amnesty International, 2015, VIOL
WOM END CYCL VI; Andersson N, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000754;
BERNSTEIN DP, 1994, AM J PSYCHIAT, V151, P1132; Brown DW, 2009, B WORLD HEALTH
ORGAN, V87, P447, DOI 10.2471/BLT.07.047423; Calvete E, 2008, VIOLENCE AGAINST WOM,
V14, P886, DOI 10.1177/1077801208320907; CARE, 2013, CARES WORK END GEND; Carey PD,
2008, EUR CHILD ADOLES PSY, V17, P93, DOI 10.1007/s00787-007-0641-0; CARVER CS,
1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; Choi KW, 2015,
ARCH WOMEN MENT HLTH, V18, P731, DOI 10.1007/s00737-015-0501-8; Cholera R, 2014, J
AFFECT DISORDERS, V167, P160, DOI [10.1016/j.jad.2014.06.003, 10.1016/]; City of
Cape Town, 2012, CITYS DELFT S MATR C; Collings S. J., 2014, J PSYCHIAT, V17, P1,
DOI DOI 10.4172/PSYCHIATRY.1000133; COLLINGS SJ, 1995, CHILD ABUSE NEGLECT, V19,
P1, DOI 10.1016/0145-2134(94)00098-F; Dada S, 2015, MONITORING ALCOHOL T; Danielson
CK, 2012, J FAM PSYCHOL, V26, P628, DOI 10.1037/a0028862; Darke S, 2008, DRUG
ALCOHOL REV, V27, P253, DOI 10.1080/09595230801923702; Hanekom T., 2015, POLICING
NEEDS PRIOR; Hobkirk AL, 2016, INT J DRUG POLICY, V30, P99, DOI
10.1016/j.drugpo.2015.10.006; Hobkirk AL, 2015, ADDICT BEHAV, V42, P167, DOI
10.1016/j.addbeh.2014.11.030; Hoffman WF, 2006, PSYCHOPHARMACOLOGY, V188, P162, DOI
10.1007/s00213-006-0494-0; Humeniuk R, 2010, ASSIST ALCOHOL SMOKI; Humeniuk R,
2008, ADDICTION, V103, P1039, DOI 10.1111/j.1360-0443.2007.02114.x; Jewkes RK,
2010, CHILD ABUSE NEGLECT, V34, P833, DOI 10.1016/j.chiabu.2010.05.002; JOHNSON BK,
1991, CHILD ABUSE NEGLECT, V15, P293, DOI 10.1016/0145-2134(91)90073-M; Khantzian
EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550; King G,
2004, CHILD ABUSE NEGLECT, V28, P683, DOI 10.1016/j.chiabu.2003.12.003; Kiser LJ,
2010, J TRAUMA STRESS, V23, P802, DOI 10.1002/jts.20587; Kort-Butler LA, 2009, J
YOUTH ADOLESCENCE, V38, P122, DOI 10.1007/s10964-008-9291-x; Kroenke K, 2001, J GEN
INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lazarus R. S.,
1999, STRESS COPING NEW SY; Leeies M, 2010, DEPRESS ANXIETY, V27, P731, DOI
10.1002/da.20677; Madu SN, 2000, CHILD ABUSE NEGLECT, V24, P259, DOI 10.1016/S0145-
2134(99)00128-3; Mbwambo J, 2012, SAHARA J-J SOC ASP H, V9, P154, DOI
10.1080/17290376.2012.743832; Meade CS, 2015, DRUG ALCOHOL DEPEN, V152, P79, DOI
10.1016/j.drugalcdep.2015.04.016; Meade CS, 2012, DRUG ALCOHOL DEPEN, V126, P232,
DOI 10.1016/j.drugalcdep.2012.05.024; Mills KL, 2012, JAMA-J AM MED ASSOC, V308,
P690, DOI 10.1001/jama.2012.9071; Min M, 2007, J TRAUMA STRESS, V20, P833, DOI
10.1002/jts.20250; Morley KC, 2016, ALCOHOL ALCOHOLISM, V51, P402, DOI
10.1093/alcalc/agv131; Morris MC, 2014, BRIT J CLIN PSYCHOL, V53, P245, DOI
10.1111/bjc.12038; NOVA Research Company, 2009, QDS VERS 2 6 MAN; Nummer G, 2001, Z
KINDER JUG-PSYCH, V29, P89, DOI 10.1024//1422-4917.29.2.89; Pluddemann A, 2008,
DRUG ALCOHOL REV, V27, P185, DOI 10.1080/09595230701829363; Pluddemann A, 2010,
DRUG ALCOHOL DEPEN, V109, P14, DOI 10.1016/j.drugalcdep.2009.11.021; Robinson J,
2011, ARCH GEN PSYCHIAT, V68, P800, DOI 10.1001/archgenpsychiatry.2011.75; ROTH S,
1986, AM PSYCHOL, V41, P813, DOI 10.1037/0003-066X.41.7.813; Salloum A, 2012, BEHAV
RES THER, V50, P169, DOI 10.1016/j.brat.2012.01.001; Sikkema KJ, 2013, J CONSULT
CLIN PSYCH, V81, P274, DOI 10.1037/a0030144; Singer MC, 2006, SOC SCI MED, V63,
P2010, DOI 10.1016/j.socscimed.2006.05.012; Statistics South Africa, 2013, CIT CAP
TOWN 2011 CE; Stoltenborgh M, 2011, CHILD MALTREATMENT, V16, P79, DOI
10.1177/1077559511403920; Swopes R. M., 2015, J INTERPERSONAL VIOL; Tol WA, 2008,
JAMA-J AM MED ASSOC, V300, P655, DOI 10.1001/jama.300.6.655; Turner HA, 2010, AM J
PREV MED, V38, P323, DOI 10.1016/j.amepre.2009.11.012; Ullman SE, 2013, ADDICT
BEHAV, V38, P2219, DOI 10.1016/j.addbeh.2013.01.027; United Nations, 2013, UNITE
END VIOL WOM; United Nations Office on Drugs and Crime, 2014, WORLD DRUG REP 2014;
van Dam D, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-172; Watt MH, 2016,
ARCH SEX BEHAV, V45, P923, DOI 10.1007/s10508-014-0418-8; Watt MH, 2014, INT J DRUG
POLICY, V25, P219, DOI 10.1016/j.drugpo.2013.10.007; Wolff N, 2015, J ANXIETY
DISORD, V30, P66, DOI 10.1016/j.janxdis.2014.10.009; Woodhead EL, 2014, J CLIN
PSYCHOL, V70, P1183, DOI 10.1002/jclp.21924; Wusthoff LE, 2014, BMC PSYCHIATRY,
V14, DOI 10.1186/1471-244X-14-67 62 7 7 0 12 EDUCATIONAL
PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC WASHINGTON 750 FIRST ST, NE,
WASHINGTON, DC 20002-4242 USA 1942-9681 1942-969X PSYCHOL TRAUMA-US
Psychol. Trauma JUL 2017 9 4 493 499
10.1037/tra0000207 7 Psychology, Clinical; Psychiatry
Psychology; Psychiatry FA4GG WOS:000405401200014 27710005 Green
Accepted 2019-09-25
J Bennett, AS; Golub, A; Elliott, L Bennett, Alex S.; Golub,
Andrew; Elliott, Luther A behavioral typology of opioid overdose risk
behaviors among recent veterans in New York City PLOS ONE
English Article LATENT CLASS
ANALYSIS; CENTERED MEDICAL HOME; HEALTH-CARE-SYSTEM; HEROIN OVERDOSE; SUBSTANCE
USE; DRUG-USE; NONFATAL OVERDOSE; MISUSE MEASURE; UNITED-STATES; PEER SUPPORT
Objective To identify meaningful classes of opioid-using military veterans in
terms of self-reported opioid overdose risk behaviors. Method The study recruited a
sample of 218 military veterans in the NYC area who were discharged from active
duty service after September 11, 2001 and reported past-month opioid use. Survey
data including measures of mental health, social stressors, substance use, and
opioid-related overdose risk behaviors were analyzed using Latent Class Analysis
(LCA). Results A five group solution had excellent fit scores and interpretability.
Factor analysis confirmed the existence of two major dimensions of variation: non-
adherence and heroin use. The five groups included lower-risk prescription opioid
users, non-adherent prescription opioid users and heroin users. The non-adherent
prescription opioid users and heroin user classes were both further subdivided into
"occasional" and "regular" use categories. In addition to endorsing a greater
number of overdose risk behaviors, users in the regular use classes were more
likely to screen positive for alcohol and substance use disorders, reported greater
self-medicating opioid use to relieve anxiety, reported greater problems with
physical pain, were more likely to have had mental health, alcohol and drug
treatment, and were less likely to be employed or in school. Heroin users also were
less likely to report stable housing. Conclusions Findings indicate that opioid
overdose risk classes are grounded in contextual factors related to experiences of
psychological, physiological, and social adjustment pain and distress which should
be addressed in tailored interventions targeting opioid users' unique
constellations of risk behaviors and comorbid conditions. [Bennett, Alex S.;
Golub, Andrew; Elliott, Luther] Natl Dev & Res Inst Inc, New York, NY 10013 USA;
[Bennett, Alex S.; Elliott, Luther] NYU, Rory Meyers Coll Nursing, Ctr Drug Use &
HIV HCV Res, New York, NY 10003 USA Bennett, AS (reprint author), Natl Dev & Res
Inst Inc, New York, NY 10013 USA.; Bennett, AS (reprint author), NYU, Rory Meyers
Coll Nursing, Ctr Drug Use & HIV HCV Res, New York, NY 10003 USA.
Bennett@ndri.org National Institutes of Health, National
Institute on Drug AbuseUnited States Department of Health & Human ServicesNational
Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [NIH
R01 DA 036754] Dr. Bennett's current project is a 4-year study of Opioid
Use/Misuse and Overdose Risk among veterans (R01DA036754) that will help determine
ecological, structural, and psychosocial aspects of opioid use and overdose risk.
Funding for this project is provided by the National Institutes of Health, National
Institute on Drug Abuse, awarded to Dr. Alex S. Bennett - (NIH R01 DA 036754). The
funder had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript. Agrawal A, 2007, ADDICTION, V102,
P94, DOI 10.1111/j.1360-0443.2006.01630.x; Army US. Army, 2020, ARM 2020 GEN HLTH
DI; Ashbury FD, 1998, PATIENT EDUC COUNS, V35, P89, DOI 10.1016/S0738-
3991(98)00035-4; Barber JA, 2008, COMMUNITY MENT HLT J, V44, P433, DOI
10.1007/s10597-008-9146-7; Bennett AS, 2013, SUBST USE MISUSE, V48, P894, DOI
10.3109/10826084.2013.796991; Bergen-Cico DK, 2011, WAR DRUGS ROLE MILIT;
Binswanger U., 2013, ANN INTERN MED, V159, P592, DOI DOI 10.7326/0003-4819-159-9-
201311050-00005; Bohnert ASB, 2012, AM J PSYCHIAT, V169, P64, DOI
10.1176/appi.ajp.2011.10101476; Britton PC, 2010, DRUG ALCOHOL DEPEN, V107, P51,
DOI 10.1016/j.drugalcdep.2009.09.005; Butler SF, 2008, J PAIN, V9, P360, DOI
10.1016/j.jpain.2007.11.014; Butler SF, 2007, PAIN, V130, P144, DOI
10.1016/j.pain.2007.01.014; Butler SF, 2010, CLIN J PAIN, V26, P770, DOI
10.1097/AJP.0b013e3181f195ba; Carlson RG, 2005, DRUG ALCOHOL DEPEN, V79, P167, DOI
10.1016/j.drugalcdep.2005.01.011; Cleeland CS, 2009, BRIEF PAIN INVENTORY; Connell
CM, 2009, J STUD ALCOHOL DRUGS, V70, P943, DOI 10.15288/jsad.2009.70.943; Connor
KM, 2003, DEPRESS ANXIETY, V18, P76, DOI 10.1002/da.10113; Darke S, 2005, DRUG
ALCOHOL REV, V24, P425, DOI 10.1080/09595230500286005; Darke S, 2003, J URBAN
HEALTH, V80, P189, DOI 10.1093/jurban/jtg022; Ferrante JM, 2010, ANN FAM MED, V8,
P108, DOI 10.1370/afm.1080; Frank D, 2015, INT J DRUG POLICY, V26, P84, DOI
10.1016/j.drugpo.2014.07.013; Green TC, 2010, DRUG ALCOHOL DEPEN, V110, P208, DOI
10.1016/j.drugalcdep.2010.02.020; Gugelmann HM, 2011, JAMA-J AM MED ASSOC, V306,
P2258, DOI 10.1001/jama.2011.1712; Hakkinen M, 2012, EUR J CLIN PHARMACOL, V68,
P301, DOI 10.1007/s00228-011-1122-4; Hall AJ, 2008, JAMA-J AM MED ASSOC, V300,
P2613, DOI 10.1001/jama.2008.802; Hamilton CM, 2011, AM J EPIDEMIOL, V174, P253,
DOI 10.1093/aje/kwr193; Institute of Medicine, 2012, SUBST US DIS US ARM; Jackson
GL, 2013, ANN INTERN MED, V158, P169, DOI 10.7326/0003-4819-158-3-201302050-00579;
Jones CM, 2013, JAMA-J AM MED ASSOC, V309, P657, DOI DOI 10.1001/JAMA.2013.272;
Jones JD, 2012, DRUG ALCOHOL DEPEN, V125, P8, DOI 10.1016/j.drugalcdep.2012.07.004;
Kerr T, 2007, DRUG ALCOHOL DEPEN, V87, P39, DOI 10.1016/j.drugalcdep.2006.07.009;
Lanza S. T., 2015, LCA STATA PLUGIN USE; Lee EH, 2012, ASIAN NURS RES, V6, P121,
DOI 10.1016/j.anr.2012.08.004; Li-Hui Chen HH, 2015, QUICKSTATS RATES DEA, P1999;
Meyer JP, 2011, J WOMENS HEALTH, V20, P991, DOI 10.1089/jwh.2010.2328; Monga N,
2007, DRUG ALCOHOL DEPEN, V88, P1, DOI 10.1016/j.drugalcdep.2006.08.029; Nelson LS,
2012, JAMA-J AM MED ASSOC, V308, P457, DOI 10.1001/jama.2012.8165; New York City
Department of Health and Mental Hygiene, 2015, UN DRUG POS OV DEATH, P2000; Norris
SL, 2006, DIABETIC MED, V23, P544, DOI 10.1111/j.1464-5491.2006.01845.x; Nutting
PA, 2009, ANN FAM MED, V7, P254, DOI 10.1370/afm.1002; O'Toole TP, 2003, J GEN
INTERN MED, V18, P929, DOI 10.1046/j.1525-1497.2003.21209.x; Oliva EM, REPORT
OPIOID OVERDO; PAVOT W, 1993, PSYCHOL ASSESSMENT, V5, P164, DOI DOI 10.1037/1040-
3590.5.2.164; Pedersen W, 1999, ADDICTION, V94, P1695, DOI 10.1046/j.1360-
0443.1999.941116957.x; Perlin JB, 2004, AM J MANAG CARE, V10, P828; Pham HH, 2009,
ANN INTERN MED, V150, P236, DOI 10.7326/0003-4819-150-4-200902170-00004; Pouget ER,
2015, ABSTRACTS DRUG ALCOH, V156, pe180; Pouget ER, 2016, UNDERSTANDING HIV AI,
P195; Pringle J. L, 2002, ADDICTIVE DISORDERS, V1, P109, DOI DOI 10.1097/00132576-
200211000-00001; Quinones S., 2015, HEALTH AFFAIR, V34, P9; Rivers JE, 1998, AM
BEHAV SCI, V41, P1136, DOI 10.1177/0002764298041008009; Robins LN, 2010, AM J
ADDICTION, V19, P203, DOI 10.1111/j.1521-0391.2010.00046.x; ROBINS LN, 1993,
ADDICTION, V88, P1041, DOI 10.1111/j.1360-0443.1993.tb02123.x; Rosenblum A, 2008,
EXP CLIN PSYCHOPHARM, V16, P405, DOI 10.1037/a0013628; Rosland A-M, 2013, AM J
MANAGED CARE, V19; Seal KH, 2012, JAMA-J AM MED ASSOC, V307, P940, DOI
10.1001/jama.2012.234; Seal KH, 2001, AM J PUBLIC HEALTH, V91, P1842, DOI
10.2105/AJPH.91.11.1842; Shin SH, 2010, DRUG ALCOHOL DEPEN, V109, P226, DOI
10.1016/j.drugalcdep.2010.01.013; Singer M, 2003, MED ANTHROPOL Q, V17, P423, DOI
10.1525/maq.2003.17.4.423; Singer M., 2016, FREE INQUIRY CREATIV, V28, P13; Singer
MC, 2006, SOC SCI MED, V63, P2010, DOI 10.1016/j.socscimed.2006.05.012; Substance
Abuse and Mental Health Services Administration (SAMHSA), 2013, RES 2012 NAT SURV
DR; U. S. Army, 2010, ARM HLTH PROM RISK R; Warner-Smith M, 2001, ADDICTION, V96,
P1113, DOI 10.1046/j.1360-0443.2001.96811135.x; Webster LR, 2011, PAIN MED, V12,
pS26, DOI 10.1111/j.1526-4637.2011.01134.x 64 2 2 0 3 PUBLIC
LIBRARY SCIENCE SAN FRANCISCO 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA
94111 USA 1932-6203 PLOS ONE PLoS One JUN 8 2017 12 6
e179054 10.1371/journal.pone.0179054
16 Multidisciplinary Sciences Science & Technology - Other Topics EX0PL
WOS:000402923200082 28594892 DOAJ Gold, Green Published
2019-09-25
J Ranganathan, T Ranganathan, Thirumalai A
STUDY OF SMOKING BEHAVIOUR AMONG MALES WITH SCHIZOPHRENIA JOURNAL OF EVOLUTION OF
MEDICAL AND DENTAL SCIENCES-JEMDS English Article
Smoking; Schizophrenia; Nicotine Dependence CIGARETTE-SMOKING;
PSYCHIATRIC-PATIENTS; INDUCED PARKINSONISM; NICOTINE DEPENDENCE; PREVALENCE;
INPATIENTS; DISORDERS; CLEARANCE; CAFFEINE BACKGROUND Nicotine dependence is
the commonest substance use disorder among individuals with schizophrenia. The
common co-occurrence of nicotine use and schizophrenia is a manifestation of shared
underlying neurobiology. Several studies point towards linkages between the effects
of nicotine and the neurobiology of schizophrenia. However, studies like these have
all come from the developed west with a different sociocultural milieu. It would be
of importance to study smoking by patients with schizophrenia in the non-western
developing countries like India. Such studies could evidence whether high smoking
in schizophrenia is a universal phenomenon and also help clarify the role of
cultural and other non-biological factors on the smoking behaviour. Aim-To study
the relationship between smoking status and clinical characteristics in males with
schizophrenia. MATERIALS AND METHODS 75 consenting patients with schizophrenia each
of those who smoked and those who did not were recruited for the study at the
outpatient department of Institute of Mental Health, Chennai. Patients were
assessed using well-validated scales. RESULTS Smokers with schizophrenia had a
significantly greater number of hospitalisations, longer duration of
hospitalisation, higher PANSS scores, greater depression and anxiety when compared
to non-smokers. Smokers also received a significantly higher mean dosage of
antipsychotic drugs than non-smokers. Smoking status had a high positive
correlation with positive syndrome, negative syndrome, general psychopathology,
high akathisia scores and antipsychotic dose. CONCLUSION Smoking status is
associated with a severe psychiatric illness. The clinical implications of this
study are: a) Smoking status should be addressed when evaluating data from studies
of antipsychotic dose, efficacy and side effects; b) Smoking possibly reflects
self-medication of underlying psychopathology or of medication side effects.
[Ranganathan, Thirumalai] Madras Med Coll & Govt Gen Hosp, Dept Psychiat,
Madras 600020, Tamil Nadu, India Ranganathan, T (reprint author), Madras Med
Coll & Govt Gen Hosp, Dept Psychiat, Madras 600020, Tamil Nadu, India.
drrangagh@gmail.com BRESLAU N, 1991, ARCH GEN
PSYCHIAT, V48, P1069; DECINA P, 1990, BIOL PSYCHIAT, V28, P502, DOI 10.1016/0006-
3223(90)90483-I; DELEON J, 1995, AM J PSYCHIAT, V152, P453; ERESHEFSKY L, 1985,
BIOL PSYCHIAT, V20, P329, DOI 10.1016/0006-3223(85)90063-0; GOFF DC, 1992, AM J
PSYCHIAT, V149, P1189; HUGHES JR, 1986, AM J PSYCHIAT, V143, P993; JANN MW, 1986,
PSYCHOPHARMACOLOGY, V90, P468; KOCZAPSKI A, 1989, SCHIZOPHRENIA BULL, V15, P339,
DOI 10.1093/schbul/15.2.339; LUCAS PB, 1990, BIOL PSYCHIAT, V28, P35, DOI
10.1016/0006-3223(90)90429-6; MENZA MA, 1991, BIOL PSYCHIAT, V30, P109, DOI
10.1016/0006-3223(91)90163-G; Narayan KMV, 1996, BRIT MED J, V312, P1576, DOI
10.1136/bmj.312.7046.1576; Nilsson A, 1997, BIOL PSYCHIAT, V41, P717, DOI
10.1016/S0006-3223(96)00289-2; OFARRELL TJ, 1983, ADDICT BEHAV, V8, P329, DOI
10.1016/0306-4603(83)90032-1; Rabinowitz J, 1998, PSYCHOL MED, V28, P1411, DOI
10.1017/S0033291798007399; SANDYK R, 1993, INT J NEUROSCI, V70, P193, DOI
10.3109/00207459309000574; Srinivasan TN, 2002, SCHIZOPHR RES, V56, P67, DOI
10.1016/S0920-9964(01)00187-6; WAGNER B, 1988, PHARMACOPSYCHIATRY, V21, P302, DOI
10.1055/s-2007-1016985; YASSA R, 1987, Biological Psychiatry, V22, P67, DOI
10.1016/0006-3223(87)90131-4; ZIEDONIS DM, 1994, HOSP COMMUNITY PSYCH, V45, P204
19 0 0 0 0 JOURNAL EVOLUTION MEDICAL & DENTAL SCIENCES
KARNATAKA C/O AKSHANTALA ENTERPRISES, NO 65, 1ST FL, SAHUKAR CHENNIAH RD,
MYSORE, KARNATAKA, 570 009, INDIA 2278-4748 2278-4802 J EVOL MED DENT
SCI- J. Evol. Med. Dent. Sci.-JEMDS JUN 5 2017 6 45
3534 3541 10.14260/Jemds/2017/762 8 Medicine, General
& Internal General & Internal Medicine FB1OY WOS:000405914300009 Bronze
2019-09-25
J Kearns, NT; Blumenthal, H; Rainey, EE; Bennett, MM; Powers, MB; Foreman, ML;
Warren, AM Kearns, Nathan T.; Blumenthal, Heidemarie; Rainey,
Evan E.; Bennett, Monica M.; Powers, Mark B.; Foreman, Michael L.; Warren, Ann
Marie Discrepancy in Caregiving Expectations Predicts Problematic
Alcohol Use Among Caregivers of Trauma Injury Patients Six Months After ICU
Admission PSYCHOLOGY OF ADDICTIVE BEHAVIORS English Article
alcohol; caregiver burden; traumatic injury;
intensive care unit; family members INTENSIVE-CARE-UNIT; IDENTIFICATION TEST AUDIT;
USE DISORDERS; FAMILY-MEMBERS; BRAIN-INJURY; SUBSTANCE USE; SUPPORT PROJECT; SELF-
MEDICATION; SCREENING-TEST; HEAD-INJURY This prospective study examined the
influence of caregiving variables on the development of problematic alcohol use
among family members of patients admitted to an urban Level I trauma center. Data
were collected from 124 caregivers 48 hrs after initial hospitalization of their
family member. The final sample included 81 participants (24.6% male; M-age = 47.8)
who completed their follow-up assessment at 6 months. Hierarchical linear and
logistic regression analyses assessed increases in consumption and odds of a
positive screen for problematic alcohol use in association with caregiver burden,
actual time spent in the caregiving role, and caregiving differential (i.e.,
anticipated time spent caregiving at baseline in relation to actual time caregiving
at 6 months). At 6 months, 24.7% of caregivers screened positive for problematic
alcohol use. Results uniquely highlighted caregiving differential as a significant
predictor of both increases in general alcohol consumption (Delta R-2 = .06, p < .
01) and odds of screening positive for problematic alcohol use at 6 months (Odds
Ratio = 1.05, 95% CI [1.02-1.09]). More specifically, our adjusted model found that
providing 10% more time caregiving, relative to expectations at baseline, was
associated with an increase in the probability of problematic alcohol use by 22%
(95% CI: 8-37%) at 6 months. These results suggest that a discrepancy in
expectations regarding anticipated time caregiving and actual time caregiving,
rather than solely the amount of caregiving or perceived caregiver burden, may be
an important predictor of caregiver alcohol use 6 months after a family member's
ICU hospitalization. [Kearns, Nathan T.; Blumenthal, Heidemarie] Univ North
Texas, Dept Psychol, 1155 Union Circle 311280, Denton, TX 76203 USA; [Rainey, Evan
E.; Powers, Mark B.; Foreman, Michael L.; Warren, Ann Marie] Baylor Univ, Med Ctr,
Div Trauma Crit Care & Acute Care Surg, Dallas, TX USA; [Bennett, Monica M.] Baylor
Univ, Med Ctr, Dallas, TX USA Kearns, NT (reprint author), Univ North Texas, Dept
Psychol, 1155 Union Circle 311280, Denton, TX 76203 USA. nathankearns@my.unt.edu
McShan, Evan Elizabeth/0000-0002-9250-3240 Ginger Murchison Traumatic
Brain Injury Fund of the Baylor Health Care System Foundation This research was
supported in part by the Ginger Murchison Traumatic Brain Injury Fund of the Baylor
Health Care System Foundation. AFFLECK G, 1987, J PERS SOC PSYCHOL, V53, P273,
DOI 10.1037/0022-3514.53.2.273; Azoulay E, 2005, AM J RESP CRIT CARE, V171, P987,
DOI 10.1164/rccm.200409-1295OC; Babor T, 2001, AUDIT ALCOHOL USE DI; BARUSCH AS,
1991, J GERONTOL SOC WORK, V17, P7; Biddle Bruce J., 2013, ROLE THEORY EXPECTAT;
Blom H, 2013, INTENS CRIT CARE NUR, V29, P1, DOI 10.1016/j.iccn.2012.04.002; BOHN
MJ, 1995, J STUD ALCOHOL, V56, P423, DOI 10.15288/jsa.1995.56.423; Bolton JM, 2009,
J AFFECT DISORDERS, V115, P367, DOI 10.1016/j.jad.2008.10.003; Bradley KA, 2003,
ARCH INTERN MED, V163, P821, DOI 10.1001/archinte.163.7.821; Brown R, 1999, J HEAD
TRAUMA REHAB, V14, P257, DOI 10.1097/00001199-199906000-00006; Bugge C, 1999,
STROKE, V30, P1517, DOI 10.1161/01.STR.30.8.1517; Bush K, 1998, ARCH INTERN MED,
V158, P1789, DOI 10.1001/archinte.158.16.1789; Chien LY, 2011, INT J GERIATR PSYCH,
V26, P1089, DOI 10.1002/gps.2660; Conner KR, 2009, J SUBST ABUSE TREAT, V37, P127,
DOI 10.1016/j.jsat.2008.11.007; Cooper M. L., 1994, PSYCHOL ASSESSMENT, V6, P117,
DOI [DOI 10.1037/1040-3590.6.2.117, 10.1037/1040-3590.6.2.117]; Cornwell EE, 1998,
AM SURGEON, V64, P461; Davidson JE, 2012, CRIT CARE MED, V40, P618, DOI
10.1097/CCM.0b013e318236ebf9; de Wit M, 2010, CHEST, V138, P994, DOI
10.1378/chest.09-1425; Elmstahl S, 1996, ARCH PHYS MED REHAB, V77, P177, DOI
10.1016/S0003-9993(96)90164-1; Empeno J, 2011, J PALLIAT MED, V14, P593, DOI
10.1089/jpm.2010.0520; Feldner MT, 2007, BEHAV MODIF, V31, P80, DOI
10.1177/0145445506295057; First M., 2014, STRUCTURED CLIN INTE; Frank D, 2008, J
GEN INTERN MED, V23, P781, DOI 10.1007/s11606-008-0594-0; Gallant MP, 1997, J AGING
HEALTH, V9, P373, DOI 10.1177/089826439700900306; Hajema KJ, 1998, ADDICTION, V93,
P1717, DOI 10.1046/j.1360-0443.1998.931117179.x; Halm M A, 1993, Clin Nurs Res, V2,
P414; Ham RJ, 1999, ALZ DIS ASSOC DIS, V13, pS27, DOI 10.1097/00002093-199911001-
00005; Hauser JM, 2004, CLIN GERIATR MED, V20, P671, DOI
10.1016/j.cger.2004.07.003; Houser A., 2008, VALUING INVALUABLE E; Institute for
Patient-and Family-Centered Care, 2015, FREQ ASK QUEST WHAT; Johnson P, 2001,
Intensive Crit Care Nurs, V17, P219, DOI 10.1054/iccn.2001.1577; Khantzian E. J.,
2003, PRIMARY PSYCHIAT, V10, p[47, 53]; Khantzian EJ, 1997, HARVARD REV PSYCHIAT,
V4, P231, DOI 10.3109/10673229709030550; Koolhaas JM, 2011, NEUROSCI BIOBEHAV R,
V35, P1291, DOI 10.1016/j.neubiorev.2011.02.003; KOSCIULEK JF, 1994, REHABIL
PSYCHOL, V39, P215, DOI 10.1037/h0080325; Kreutzer JS, 2009, ARCH PHYS MED REHAB,
V90, P939, DOI 10.1016/j.apmr.2009.01.010; Kushner MG, 2000, CLIN PSYCHOL REV, V20,
P149, DOI 10.1016/S0272-7358(99)00027-6; Lindvall K, 2014, PEDIATR BLOOD CANCER,
V61, P706, DOI 10.1002/pbc.24856; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48,
P876, DOI 10.1136/jnnp.48.9.876; MACKENZIE EJ, 1985, MED CARE, V23, P823, DOI
10.1097/00005650-198506000-00008; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI
10.1080/026990598122700; McAdam JL, 2012, AM J CRIT CARE, V21, P386, DOI
10.4037/ajcc2012582; Miller MW, 2006, J ABNORM PSYCHOL, V115, P369, DOI
10.1037/0021-843X.115.2.369; Mitchell GJ, 2000, NURS SCI QUART, V13, P216, DOI
10.1177/08943180022107591; Northouse Laurel L, 2012, Semin Oncol Nurs, V28, P236,
DOI 10.1016/j.soncn.2012.09.006; Pochard F, 2005, J CRIT CARE, V20, P90, DOI
10.1016/j.jcrc.2004.11.004; Powers MB, 2014, J ANXIETY DISORD, V28, P301, DOI
10.1016/j.janxdis.2014.01.003; Read JP, 2004, ADDICT BEHAV, V29, P1665, DOI
10.1016/j.addbeh.2004.02.061; ROBINSON NC, 1991, J NURS ADMIN, V21, P29; Robinson-
Whelen S, 2001, J ABNORM PSYCHOL, V110, P573, DOI 10.1037//0021-843X.110.4.573;
Rospenda KM, 2010, J ADDICT DIS, V29, P314, DOI 10.1080/10550887.2010.489450;
Rotondi AJ, 2007, J HEAD TRAUMA REHAB, V22, P14, DOI 10.1097/00001199-200701000-
00002; SAS Institute, 2014, BAS SAS 9 4 PROC GUI; SAUNDERS JB, 1993, ADDICTION,
V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; SOBELL LC, 1992, MEASURING
ALCOHOL CONSUMPTION, P41; THOMPSON SC, 1981, PSYCHOL BULL, V90, P89, DOI
10.1037/0033-2909.90.1.89; Verhaeghe S, 2005, J CLIN NURS, V14, P501, DOI
10.1111/j.1365-2702.2004.01081.x; Volk RJ, 1997, ADDICTION, V92, P197, DOI
10.1046/j.1360-0443.1997.9221978.x; Warren AM, 2016, REHABIL PSYCHOL, V61, P179,
DOI 10.1037/rep0000080; Wellard S J, 1999, Int J Nurs Pract, V5, P132, DOI
10.1046/j.1440-172x.1999.00163.x; Whittier Stephanie, 2005, J Aging Soc Policy,
V17, P45; Wilsnack S C, 1991, J Subst Abuse, V3, P133; Winstanley J, 2006, J HEAD
TRAUMA REHAB, V21, P453, DOI 10.1097/00001199-200611000-00001 63 0 0
2 5 EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
WASHINGTON 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA 0893-164X 1939-
1501 PSYCHOL ADDICT BEHAV Psychol. Addict. Behav. JUN 2017 31 4
497 505 10.1037/adb0000282 9
 Substance Abuse; Psychology, Multidisciplinary Substance Abuse; Psychology
EX8HN WOS:000403489600012 28493754 2019-09-25
J Rappeneau, V; Berod, A Rappeneau, Virginie; Berod, Anne
Reconsidering depression as a risk factor for substance use disorder:
Insights from rodent models NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
English Review Depression; Substance
use disorder; Psychostimulant; Comorbidity; Vulnerability; Rodent models; Behavior
CHRONIC MILD STRESS; CONDITIONED PLACE PREFERENCE; DEEP BRAIN-STIMULATION;
NATIONAL EPIDEMIOLOGIC SURVEY; CHRONIC SOCIAL STRESS; TREATMENT-RESISTANT
DEPRESSION; SELF-MEDICATION HYPOTHESIS; COCAINE-SEEKING BEHAVIOR; CHRONIC VARIABLE
STRESS; GENETIC ANIMAL-MODEL Depression and substance use disorder (SUD) often co-
exist and are typically associated with an inaccurate diagnosis, worsened clinical
course and poor medication adherence compared to either disorder alone. To date,
the biological mechanisms contributing to their strong association remain largely
unknown. In this review, we critically analyze preclinical literature on
psychostimulant drugs and reconsider the common view that depression is a risk
factor for drug use and the development of SUD. Unexpectedly, this investigation
led us to conclude that depressive-like states in rodents are associated with a low
predisposition to drug intake, at least when considering initial, voluntary and
regulated psychostimulant intake. We identified several conceptual gaps and
methodological challenges potentially misleading when modeling depression and SUD
comorbidity. On the basis of these observations, we propose new innovative
perspectives to guide future experiments and advance our knowledge in this field,
including the use of newly refined rodent models that better capture hallmarks of
depression and SUD. [Rappeneau, Virginie; Berod, Anne] Univ Lyon 1, Lyon
Neurosci Res Ctr, Team Physiopathol Neuronal Network Responsible Sl, INSERM
U1028,CNRS UMR 5292, Lyon, France Berod, A (reprint author), CNRS UMR5292, Lyon
Neurosci Res Ctr INSERM U1028, 7 Rue Guillaume Paradin, F-69372 Lyon 08, France.
anne.berod@univ-lyon1.fr INSERM (French National Institute
of Health and Medical Research)Institut National de la Sante et de la Recherche
Medicale (Inserm); CNRS (National Center for Scientific Research)Centre National de
la Recherche Scientifique (CNRS); University Lyon 1 This work was supported by
INSERM (French National Institute of Health and Medical Research), CNRS (National
Center for Scientific Research), and University Lyon 1. Abou-Saleh MT, 2004,
ACTA NEUROPSYCHIATR, V16, P19, DOI 10.1111/j.1601-5215.2004.0061.x; Ago Y, 2007, J
PHARMACOL SCI, V104, P153, DOI 10.1254/jphs.FP0070325; Ago Y, 2008,
NEUROPHARMACOLOGY, V55, P1355, DOI 10.1016/j.neuropharm.2008.08.026; Ahmed SH,
1998, SCIENCE, V282, P298, DOI 10.1126/science.282.5387.298; Alvers KM, 2012, BEHAV
PHARMACOL, V23, P650, DOI [10.1097/FBP.0b013e3263584765,
10.1097/FBP.0b013e3283584765]; American Psychiatric Association, 2013, DIAGN STAT
MAN MENT; Andersen SL, 2015, DEV PSYCHOPATHOL, V27, P477, DOI
10.1017/S0954579415000103; Anderson MH, 2012, COGN AFFECT BEHAV NE, V12, P373, DOI
10.3758/s13415-011-0076-4; Argyropoulos SV, 1997, PSYCHOPHARMACOLOGY, V134, P333,
DOI 10.1007/s002130050458; Arndt DL, 2015, PSYCHOPHARMACOLOGY, V232, P3741, DOI
10.1007/s00213-015-4031-x; Baarendse PJJ, 2014, PSYCHOPHARMACOLOGY, V231, P1695,
DOI 10.1007/s00213-013-3362-8; Badiani A, 2011, NAT REV NEUROSCI, V12, P685, DOI
10.1038/nrn3104; Bardo MT, 2013, PHARMACOL REV, V65, P255, DOI
10.1124/pr.111.005124; Bardo MT, 2000, PSYCHOPHARMACOLOGY, V153, P31, DOI
10.1007/s002130000569; Bardo MT, 2001, PSYCHOPHARMACOLOGY, V155, P278; Belin D,
2016, GENES BRAIN BEHAV, V15, P74, DOI 10.1111/gbb.12265; Belin D., 2012, COLD
SPRING HARBOR P; Belin D, 2008, SCIENCE, V320, P1352, DOI 10.1126/science.1158136;
Belin D, 2011, NEUROPSYCHOPHARMACOL, V36, P569, DOI 10.1038/npp.2010.188; Belin-
Rauscent A, 2016, BIOL PSYCHIAT, V79, P39, DOI 10.1016/j.biopsych.2015.01.004;
Belujon P, 2014, BIOL PSYCHIAT, V76, P927, DOI 10.1016/j.biopsych.2014.04.014;
Belzung C, 2011, BIOL MOOD ANXIETY DI, V1, DOI 10.1186/2045-5380-1-9; Bergstrom A,
2007, J MOL NEUROSCI, V33, P201, DOI 10.1007/s12031-007-0065-9; Bergstrom A, 2008,
BRAIN RES, V1196, P41, DOI 10.1016/j.brainres.2007.12.025; Berlim MT, 2014, J
AFFECT DISORDERS, V159, P31, DOI 10.1016/j.jad.2014.02.016; Berlin I, 1998, EUR
PSYCHIAT, V13, P303, DOI 10.1016/S0924-9338(98)80048-5; Berton O, 2006, SCIENCE,
V311, P864, DOI 10.1126/science.1120972; Berton O, 2012, SCIENCE, V338, P75, DOI
10.1126/science.1222940; Bougarel L, 2011, PSYCHOPHARMACOLOGY, V215, P595, DOI
10.1007/s00213-011-2218-3; BOYLE AE, 1991, PHARMACOL BIOCHEM BE, V39, P269, DOI
10.1016/0091-3057(91)90178-5; BOZARTH MA, 1989, PHARMACOL BIOCHEM BE, V33, P903,
DOI 10.1016/0091-3057(89)90490-5; Brenes JC, 2008, NEUROSCI LETT, V436, P278, DOI
10.1016/j.neulet.2008.03.045; BROWN SA, 1988, J STUD ALCOHOL, V49, P412, DOI
10.15288/jsa.1988.49.412; Charney DS, 2004, AM J PSYCHIAT, V161, P195, DOI
10.1176/appi.ajp.161.2.195; Chauvet C, 2009, NEUROPSYCHOPHARMACOL, V34, P2767, DOI
10.1038/npp.2009.127; Connor JP, 2014, CURR OPIN PSYCHIATR, V27, P269, DOI
10.1097/YCO.0000000000000069; Conway KP, 2006, J CLIN PSYCHIAT, V67, P247, DOI
10.4088/JCP.v67n0211; Covington HE, 2005, PSYCHOPHARMACOLOGY, V183, P331, DOI
10.1007/s00213-005-0190-5; Covington HE, 2001, PSYCHOPHARMACOLOGY, V158, P388, DOI
10.1007/s002130100858; Covington HE, 2008, PSYCHOPHARMACOLOGY, V197, P203, DOI
10.1007/s00213-007-1024-4; Cruz FC, 2011, PSYCHOPHARMACOLOGY, V215, P165, DOI
10.1007/s00213-010-2139-6; Cryan JF, 2005, NEUROSCI BIOBEHAV R, V29, P571, DOI
10.1016/j.neubiorev.2005.03.009; Cui MH, 2006, NEUROSCI LETT, V404, P208, DOI
10.1016/j.neulet.2006.05.048; de Kloet ER, 2016, NEURAL PLAST, DOI
10.1155/2016/6503162; Degenhardt L, 2003, WHAT IS COMORBIDITY; Der-Avakian A, 2013,
TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.74; Der-Avakian A, 2010, NEUROSCIENCE,
V170, P1189, DOI 10.1016/j.neuroscience.2010.08.002; Der-Avakian Andre, 2016, Curr
Top Behav Neurosci, V28, P231, DOI 10.1007/7854_2015_5004; Der-Avakian A, 2014,
BIOL PSYCHIAT, V76, P542, DOI 10.1016/j.biopsych.2014.01.013; Deroche-Gamonet V,
2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020; DeWilde KE, 2015, ANN NY
ACAD SCI, V1345, P47, DOI 10.1111/nyas.12646; Dichter GS, 2010, DEPRESS ANXIETY,
V27, P859, DOI 10.1002/da.20690; Dilleen R, 2012, PSYCHOPHARMACOLOGY, V222, P89,
DOI 10.1007/s00213-011-2626-4; Dimatelis JJ, 2012, METAB BRAIN DIS, V27, P351, DOI
10.1007/s11011-012-9288-8; Ding YJ, 2005, PHARMACOL BIOCHEM BE, V82, P673, DOI
10.1016/j.pbb.2005.11.007; El Yacoubi M, 2003, P NATL ACAD SCI USA, V100, P6227,
DOI 10.1073/pnas.1034823100; El Yacoubi M, 2013, BEHAV BRAIN RES, V256, P43, DOI
10.1016/j.bbr.2013.07.048; El Yacoubi M, 2011, PHARMACOL BIOCHEM BE, V100, P284,
DOI 10.1016/j.pbb.2011.08.001; Fagergren P, 2005, NEUROSCIENCE, V132, P1159, DOI
10.1016/j.neuroscience.2005.01.043; Faure J, 2009, METAB BRAIN DIS, V24, P541, DOI
10.1007/s11011-009-9158-1; Filip M, 2013, PHARMACOL REP, V65, P1529, DOI
10.1016/S1734-1140(13)71514-7; Flagel SB, 2003, NEUROPSYCHOPHARMACOL, V28, P1741,
DOI 10.1038/sj.npp.1300228; Fone KCF, 2008, NEUROSCI BIOBEHAV R, V32, P1087, DOI
10.1016/j.neubiorev.2008.03.003; Fox C, 2006, BEHAV BRAIN RES, V175, P1, DOI
10.1016/j.bbr.2006.08.016; Francis DD, 2002, J NEUROSCI, V22, P7840; Gauthier JM,
2017, ADDICT BIOL, V22, P152, DOI 10.1111/adb.12313; GAWIN FH, 1986, ARCH GEN
PSYCHIAT, V43, P107; Gerra G, 2009, NEUROSCI BIOBEHAV R, V33, P601, DOI
10.1016/j.neubiorev.2007.08.002; Gipson CD, 2011, PSYCHOPHARMACOLOGY, V214, P557,
DOI 10.1007/s00213-010-2060-z; Gorman J M, 1996, Depress Anxiety, V4, P160, DOI
10.1002/(SICI)1520-6394(1996)4:4<160::AID-DA2>3.0.CO;2-J; Gracia-Rubio I, 2016,
PROG NEURO-PSYCHOPH, V65, P104, DOI 10.1016/j.pnpbp.2015.09.003; Grant BF, 2004,
ARCH GEN PSYCHIAT, V61, P807, DOI 10.1001/archpsyc.61.8.807; Grant BF, 2016, JAMA
PSYCHIAT, V73, P39, DOI 10.1001/jamapsychiatry.2015.2132; Green TA, 2002,
PSYCHOPHARMACOLOGY, V162, P373, DOI 10.1007/s00213-002-1134-y; Grotewold SK, 2014,
PSYCHOPHARMACOLOGY, V231, P3041, DOI 10.1007/s00213-014-3470-0; Haile CN, 2001,
PSYCHOPHARMACOLOGY, V154, P213, DOI 10.1007/s002130000650; Hall FS, 1998,
PSYCHOPHARMACOLOGY, V139, P210, DOI 10.1007/s002130050706; Hall FS, 1997, PHYSIOL
BEHAV, V62, P291, DOI 10.1016/S0031-9384(97)00116-9; Hamani C, 2012, BIOL PSYCHIAT,
V71, P30, DOI 10.1016/j.biopsych.2011.08.025; Hammels C, 2015, NEUROSCI BIOBEHAV R,
V59, P111, DOI 10.1016/j.neubiorev.2015.10.006; Hasler G, 2004,
NEUROPSYCHOPHARMACOL, V29, P1765, DOI 10.1038/sj.npp.1300506; Hasler G, 2011, MOL
PSYCHIATR, V16, P604, DOI 10.1038/mp.2011.23; Hays SL, 2012, BEHAV BRAIN RES, V227,
P7, DOI 10.1016/j.bbr.2011.10.033; Henriques-Alves AM, 2016, FRONT BEHAV NEUROSCI,
V9, DOI 10.3339/Thbeh.2015.00364; Hensleigh E, 2014, BEHAV BRAIN RES, V268, P66,
DOI 10.1016/j.bbr.2014.03.045; Hermes G, 2011, PHYSIOL BEHAV, V104, P354, DOI
10.1016/j.physbeh.2010.12.019; Hollis F, 2014, ILAR J, V55, P221, DOI
10.1093/ilar/ilu002; Holly EN, 2016, J NEUROSCI, V36, P4093, DOI
10.1523/JNEUROSCI.2232-15.2016; Homberg JR, 2002, EUR J NEUROSCI, V15, P1542, DOI
10.1046/j.1460-9568.2002.01976.x; Howes SR, 2000, PSYCHOPHARMACOLOGY, V151, P55,
DOI 10.1007/s002130000451; Jastrzebska J, 2015, BEHAV BRAIN RES, V293, P62, DOI
10.1016/j.bbr.2015.06.040; Kawasaki T, 2011, NEUROPHARMACOLOGY, V60, P397, DOI
10.1016/j.neuropharm.2010.10.009; Kendler KS, 2003, ARCH GEN PSYCHIAT, V60, P929,
DOI 10.1001/archpsyc.60.9.929; Kendler KS, 2001, AM J PSYCHIAT, V158, P582, DOI
10.1176/appi.ajp.158.4.582; Kendler KS, 1999, AM J PSYCHIAT, V156, P837, DOI
10.1176/ajp.156.6.837; Kessler RC, 2004, BIOL PSYCHIAT, V56, P730, DOI
10.1016/j.biopsych.2004.06.034; Kessler RC, 1997, ANNU REV PSYCHOL, V48, P191, DOI
10.1146/annurev.psych.48.1.191; Kessler RC, 1997, PSYCHOL MED, V27, P1101, DOI
10.1017/S0033291797005588; Kessler RC,
2013, ANNU REV PUBL HEALTH, V34, P119, DOI 10.1146/annurev-publhealth-031912-
114409; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI
10.3109/10673229709030550; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259; Klengel
T, 2013, CAN J PSYCHIAT, V58, P76, DOI 10.1177/070674371305800203; Koda K, 2008,
PSYCHOPHARMACOLOGY, V196, P293, DOI 10.1007/s00213-007-0962-1; Koike H, 2009, BEHAV
BRAIN RES, V202, P114, DOI 10.1016/j.bbr.2009.03.028; Kokare DM, 2010,
NEUROPHARMACOLOGY, V58, P1009, DOI 10.1016/j.neuropharm.2010.01.006; Kosten TA,
2006, NEUROPSYCHOPHARMACOL, V31, P70, DOI 10.1038/sj.npp.1300779; Kosten TA, 2004,
BEHAV BRAIN RES, V151, P137, DOI 10.1016/j.bbr.2003.08.010; Kosten TA, 2000, BRAIN
RES, V875, P44, DOI 10.1016/S0006-8993(00)02595-6; Krishnan V, 2007, CELL, V131,
P391, DOI 10.1016/j.cell.2007.09.018; Krishnan V, 2011, CURR TOP BEHAV NEURO, V7,
P121, DOI 10.1007/7854_2010_108; Lahmame A, 1996, PSYCHOPHARMACOLOGY, V123, P191,
DOI 10.1007/BF02246177; Lai HMX, 2015, DRUG ALCOHOL DEPEN, V154, P1, DOI
10.1016/j.drugalcdep.2015.05.031; Lalanne L, 2016, PROG NEURO-PSYCHOPH, V65, DOI
10.1016/j.pnpbp.2015.10.009; Lapiz M D S, 2003, Neurosci Behav Physiol, V33, P13,
DOI 10.1023/A:1021171129766; Lehmann J, 2000, REV NEUROSCIENCE, V11, P383; Levine
S, 2000, EUR J PHARMACOL, V405, P149, DOI 10.1016/S0014-2999(00)00548-3; Lewis CR,
2016, BEHAV PHARMACOL, V27, P182, DOI 10.1097/FBP.0000000000000166; Lewis Candace
R, 2013, Front Psychiatry, V4, P55, DOI 10.3389/fpsyt.2013.00055; Lin SJ, 2012,
PHARMACOL BIOCHEM BE, V103, P380, DOI 10.1016/j.pbb.2012.09.008; Lohoff FW, 2010,
CURR PSYCHIAT REP, V12, P539, DOI 10.1007/s11920-010-0150-6; Lopez-Quintero C,
2011, DRUG ALCOHOL DEPEN, V115, P120, DOI 10.1016/j.drugalcdep.2010.11.004; Lopez-
Rubalcava C, 2000, NEUROPSYCHOPHARMACOL, V22, P191, DOI 10.1016/S0893-
133X(99)00100-1; Lynch WJ, 2005, NEUROPSYCHOPHARMACOL, V30, P322, DOI
10.1038/sj.npp.1300594; Malki K, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-73;
Markou Athina, 2002, Neurotox Res, V4, P297, DOI 10.1080/10298420290023963; Martin
AL, 2010, BEHAV BRAIN RES, V207, P196, DOI 10.1016/j.bbr.2009.10.006; Matthews K,
1999, PSYCHOPHARMACOLOGY, V141, P123, DOI 10.1007/s002130050816; Mayberg HS, 2009,
J CLIN INVEST, V119, P717, DOI 10.1172/JCI38454; Meaney MJ, 2001, ANNU REV
NEUROSCI, V24, P1161, DOI 10.1146/annurev.neuro.24.1.1161; Merikangas KR, 2007,
CURR OPIN PSYCHIATR, V20, P353, DOI 10.1097/YCO.0b013e3281c61dc5; Merikangas KR,
1998, ADDICT BEHAV, V23, P893, DOI 10.1016/S0306-4603(98)00076-8; MICZEK KA, 1979,
PSYCHOPHARMACOLOGY, V60, P253, DOI 10.1007/BF00426664; Miczek KA, 2011, J NEUROSCI,
V31, P9848, DOI 10.1523/JNEUROSCI.0637-11.2011; Miczek KA, 2008, PHARMACOL
THERAPEUT, V120, P102, DOI 10.1016/j.pharmthera.2008.07.006; Moffett MC, 2007,
BIOCHEM PHARMACOL, V73, P321, DOI 10.1016/j.bcp.2006.08.003; Moffett MC, 2006, J
PHARMACOL EXP THER, V317, P1210, DOI 10.1124/jpet.106.101139; Montagud-Romero S,
2015, PHARMACOL BIOCHEM BE, V135, P1, DOI 10.1016/j.pbb.2015.05.008; MOREAU JL,
1995, BEHAV PHARMACOL, V6, P682; Morilak DA, 2005, PROG NEURO-PSYCHOPH, V29, P1214,
DOI 10.1016/j.pnpbp.2005.08.007; Morley-Fletcher S, 2003, EUR J NEUROSCI, V18,
P3367, DOI 10.1046/j.1460-9568.2003.03070.x; Murray R, 2013, PHYSIOL BEHAV, V119,
P115, DOI 10.1016/j.physbeh.2013.05.042; Nam H, 2014, FRONT BEHAV NEUROSCI, V8, DOI
10.3389/fnbeh.2014.00109; Neisewander JL, 2012, PSYCHOPHARMACOLOGY, V224, P33, DOI
10.1007/s00213-012-2853-3; Nemeroff CB, 2016, NEURON, V89, P892, DOI
10.1016/j.neuron.2016.01.019; Nestler EJ, 2010, NAT NEUROSCI, V13, P1161, DOI
10.1038/nn.2647; Neumann ID, 2011, PROG NEURO-PSYCHOPH, V35, P1357, DOI
10.1016/j.pnpbp.2010.11.028; Newport DJ, 2002, AM J PSYCHIAT, V159, P1265, DOI
10.1176/appi.ajp.159.8.1265; Ng E., 2016, AM J DRUG ALCOHOL AB, P1, DOI DOI
10.1080/00952990.2016.1183020; Nollet M., 2013, CURR PROTOC PHARM, V5, P1; Nunes
EV, 2004, BIOL PSYCHIAT, V56, P793, DOI 10.1016/j.biopsych.2004.06.037; Nunes EV,
2004, JAMA-J AM MED ASSOC, V291, P1887, DOI 10.1001/jama.291.15.1887; Nylander I,
2013, PSYCHOPHARMACOLOGY, V229, P555, DOI 10.1007/s00213-013-3217-3; O'Connor RM,
2015, NEUROPHARMACOLOGY, V99, P168, DOI 10.1016/j.neuropharm.2015.07.012; OKAMOTO
KOZO, 1963, JAPAN CIRCULATION JOUR, V27, P282; Overstreet DH, 2013, PHARMACOL REV,
V65, P143, DOI 10.1124/pr.111.005397; Overstreet DH, 2012, METHODS MOL BIOL, V829,
P125, DOI 10.1007/978-1-61779-458-2_7; Overstreet DH, 2005, PHARMACOL BIOCHEM BE,
V82, P223, DOI 10.1016/j.pbb.2005.07.021; OVERSTREET DH, 1993, NEUROSCI BIOBEHAV R,
V17, P51, DOI 10.1016/S0149-7634(05)80230-1; OVERSTREET DH, 1979,
PSYCHOPHARMACOLOGY, V65, P15, DOI 10.1007/BF00491972; OVERSTREET DH, 1982,
PSYCHOPHARMACOLOGY, V78, P150, DOI 10.1007/BF00432254; Overstreet DH, 2005,
NEUROSCI BIOBEHAV R, V29, P739, DOI 10.1016/j.neubiorev.2005.03.015; Ozburn AR,
2015, ALCOHOL CLIN EXP RES, V39, P1863, DOI 10.1111/acer.12810; PAPP M, 1993,
PSYCHOPHARMACOLOGY, V110, P152, DOI 10.1007/BF02246965; PAPP M, 1991,
PSYCHOPHARMACOLOGY, V104, P255, DOI 10.1007/BF02244188; PARE WP, 1994, PHYSIOL
BEHAV, V55, P433, DOI 10.1016/0031-9384(94)90097-3; Paterson NE, 2007, NEUROTOX
RES, V11, P1, DOI 10.1007/BF03033479; Pergadia ML, 2014, JAMA PSYCHIAT, V71, P1238,
DOI 10.1001/jamapsychiatry.2014.1016; Pettinati HM, 2013, AM J PSYCHIAT, V170, P23,
DOI 10.1176/appi.ajp.2012.12010112; PHILLIPS GD, 1994, PSYCHOPHARMACOLOGY, V115,
P407, DOI 10.1007/BF02245084; Piazza PV, 1998, TRENDS PHARMACOL SCI, V19, P67, DOI
10.1016/S0165-6147(97)01115-2; PIAZZA PV, 1989, SCIENCE, V245, P1511, DOI
10.1126/science.2781295; Pierce RC, 2006, NEUROSCI BIOBEHAV R, V30, P215, DOI
10.1016/j.neubiorev.2005.04.016; Popa D, 2006, NEUROPSYCHOPHARMACOL, V31, P1637,
DOI 10.1038/sj.npp.1300948; Pryce CR, 2005, NEUROSCI BIOBEHAV R, V29, P649, DOI
10.1016/j.neubiorev.2005.03.011; Pryce CR, 2003, NEUROSCI BIOBEHAV R, V27, P57, DOI
10.1016/S0149-7634(03)00009-5; PUCILOWSKI O, 1993, PHYSIOL BEHAV, V54, P1215, DOI
10.1016/0031-9384(93)90351-F; PUCILOWSKI O, 1993, BRAIN RES BULL, V32, P471, DOI
10.1016/0361-9230(93)90293-K; Ranaldi R, 2011, BEHAV PHARMACOL, V22, P347, DOI
10.1097/FBP.0b013e3283487365; Rappeneau V, 2015, INT J NEUROPSYCHOPH, V18, DOI
10.1093/ijnp/pyv022; Rea E, 2014, BRAIN STIMUL, V7, P21, DOI
10.1016/j.brs.2013.09.002; REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511;
Renoir T, 2012, NEUROSCI BIOBEHAV R, V36, P696, DOI
10.1016/j.neubiorev.2011.10.003; Rizvi SJ, 2016, NEUROSCI BIOBEHAV R, V65, P21, DOI
10.1016/j.neubiorev.2016.03.004; Robbins TW, 1996, J PSYCHOPHARMACOL, V10, P39, DOI
10.1177/026988119601000107; Roth-Deri I, 2009, EUR J NEUROSCI, V30, P485, DOI
10.1111/j.1460-9568.2009.06840.x; Ruedi-Bettschen D, 2005, BEHAV BRAIN RES, V156,
P297, DOI 10.1016/j.bbr.2004.06.001; Rygula R, 2008, BEHAV PHARMACOL, V19, P183,
DOI 10.1097/FBP.0b013e3282fe8871; Rygula R, 2006, BEHAV BRAIN RES, V174, P188, DOI
10.1016/j.bbr.2006.07.017; SCHENK S, 1987, NEUROSCI LETT, V81, P227, DOI
10.1016/0304-3940(87)91003-2; SCHENK S, 1986, PHARMACOL BIOCHEM BE, V24, P1793, DOI
10.1016/0091-3057(86)90523-X; SCHENK S, 1988, PHARMACOL BIOCHEM BE, V31, P59, DOI
10.1016/0091-3057(88)90311-5; Schindler AG, 2012, J NEUROSCI, V32, P17582, DOI
10.1523/JNEUROSCI.3220-12.2012; Schmidt MV, 2010, PSYCHONEUROENDOCRINO, V35, P635,
DOI 10.1016/j.psyneuen.2009.10.002; Schmidt MV, 2011, PSYCHOPHARMACOLOGY, V214,
P131, DOI 10.1007/s00213-010-2096-0; Schuckit MA, 2006, ADDICTION, V101, P76, DOI
10.1111/j.1360-0443.2006.01592.x; Shalev U, 2002, PHARMACOL BIOCHEM BE, V73, P115,
DOI 10.1016/S0091-3057(02)00756-6; Shimamoto A, 2015, PSYCHOPHARMACOLOGY, V232,
P825, DOI 10.1007/s00213-014-3725-9; Slattery DA, 2014, ILAR J, V55, P297, DOI
10.1093/ilar/ilu026; Smith JK, 1997, PSYCHOPHARMACOLOGY, V131, P23, DOI
10.1007/s002130050261; Solberg LC, 2004, MAMM GENOME, V15, P648, DOI
10.1007/s00335-004-2326-z; Stairs DJ, 2006, BEHAV PHARMACOL, V17, P597, DOI
10.1097/01.fbp.0000236271.72300.0e; Strekalova T, 2004, NEUROPSYCHOPHARMACOL, V29,
P2007, DOI 10.1038/sj.npp.1300532; Strekalova T, 2006, BEHAV PHARMACOL, V17, P271,
DOI 10.1097/00008877-200605000-00008; Strekalova T, 2011, BEHAV BRAIN FUNCT, V7,
DOI 10.1186/1744-9081-7-9; Stuart SA, 2013, NEUROPSYCHOPHARMACOL, V38, P1625, DOI
10.1038/npp.2013.69; Swendsen J, 2010, ADDICTION, V105, P1117, DOI 10.1111/j.1360-
0443.2010.02902.x; Taylor SB, 2016, NEUROPHARMACOLOGY, V108, P353, DOI
10.1016/j.neuropharm.2016.05.003; Thiel KJ, 2011, PHARMACOL BIOCHEM BE, V97, P595,
DOI 10.1016/j.pbb.2010.09.014; Thomsen KR, 2015, FRONT BEHAV NEUROSCI, V9, DOI
10.3389/fnbeh.2015.00049; Tidey JW, 1997, PSYCHOPHARMACOLOGY, V130, P203, DOI
10.1007/s002130050230; Tizabi Y, 2012, NEUROSCIENCE, V213, P72, DOI
10.1016/j.neuroscience.2012.03.052; Tolliver BK, 2015, DIALOGUES CLIN NEURO, V17,
P181; Tornatzky W, 2000, PSYCHOPHARMACOLOGY, V148, P289, DOI 10.1007/s002130050053;
Tractenberg SG, 2016, NEUROSCI BIOBEHAV R, V68, P489, DOI
10.1016/j.neubiorev.2016.06.021; Treadway Michael T, 2016, Curr Top Behav Neurosci,
V27, P337; Treadway MT, 2012, J ABNORM PSYCHOL, V121, P553, DOI 10.1037/a0028813;
Tsankova NM, 2006, NAT NEUROSCI, V9, P519, DOI 10.1038/nn1659; Tzschentke TM, 2007,
ADDICT BIOL, V12, P227, DOI 10.1111/j.1369-1600.2007.00070.x; Vanderschuren LJMJ,
2004, SCIENCE, V305, P1017, DOI 10.1126/science.1098975; Veerakumar A, 2014, BIOL
PSYCHIAT, V76, P203, DOI 10.1016/j.biopsych.2013.12.009; Vetulani J, 2013,
PHARMACOL REP, V65, P1451, DOI 10.1016/S1734-1140(13)71505-6; Wagner FA, 2002,
NEUROPSYCHOPHARMACOL, V26, P479, DOI 10.1016/S0893-133X(01)00367-0; Weiss JM, 1998,
PHARMACOL BIOCHEM BE, V61, P49, DOI 10.1016/S0091-3057(98)00075-6; West CHK, 1998,
PHARMACOL BIOCHEM BE, V61, P67, DOI 10.1016/S0091-3057(98)00076-8; Whitaker LR,
2013, NEURON, V77, P335, DOI 10.1016/j.neuron.2012.11.022; WILLNER P, 1984,
PSYCHOPHARMACOLOGY, V83, P1, DOI 10.1007/BF00427414; Willner P, 2005,
NEUROPSYCHOBIOLOGY,
V52, P90, DOI 10.1159/000087097; WILLNER P, 1987, PSYCHOPHARMACOLOGY, V93, P358;
Willner P, 1997, PSYCHOPHARMACOLOGY, V134, P319, DOI 10.1007/s002130050456; Wingo
T, 2016, J NEUROIMMUNE PHARM, V11, P456, DOI 10.1007/s11481-015-9636-7;
WONGWITDECHA N, 1995, EUR J PHARMACOL, V279, P99, DOI 10.1016/0014-2999(95)00212-4;
Yildirim E, 2012, PHARMACOL BIOCHEM BE, V101, P278, DOI 10.1016/j.pbb.2011.12.017;
Zangen A, 2001, PSYCHOPHARMACOLOGY, V155, P434, DOI 10.1007/s002130100746; Zhang
XY, 2005, PSYCHOPHARMACOLOGY, V177, P391, DOI 10.1007/s00213-004-1963-y; Zimmerberg
B, 2003, DEV PSYCHOBIOL, V42, P52, DOI 10.1002/dev.10086 235 3 3 0
7 PERGAMON-ELSEVIER SCIENCE LTD OXFORD THE BOULEVARD, LANGFORD LANE,
KIDLINGTON, OXFORD OX5 1GB, ENGLAND 0149-7634 1873-7528 NEUROSCI BIOBEHAV
R Neurosci. Biobehav. Rev. JUN 2017 77
303 316 10.1016/j.neubiorev.2017.04.001 14
Behavioral Sciences; Neurosciences Behavioral Sciences; Neurosciences &
Neurology EV7QH WOS:000401973800023 28385601 Other Gold 2019-
09-25
J El-Rasheed, AH; ElAttar, KS; Elrassas, HH; Mahmoud, DAM; Mohamed, SY
El-Rasheed, Amany H.; ElAttar, Khled S.; Elrassas, Hanan H.; Mahmoud,
Dalia A. M.; Mohamed, Shierf Y. Mood Regulation, Alexithymia, and
Personality Disorders in Adolescent Male Addicts ADDICTIVE DISORDERS & THEIR
TREATMENT English Article
alexithymia; mood regulation; personality disorders; substance abuse;
adolescents PERCEIVED EMOTIONAL INTELLIGENCE; SUBSTANCE USE DISORDERS; SELF-
MEDICATION HYPOTHESIS; PSYCHOMETRIC PROPERTIES; ALCOHOL; ABUSERS; SCALE; USERS
Objectives: Adolescents with affect dysregulation, alexithymia, and
underlying personality disorders (PD) are more vulnerable to substance abuse due to
their emotional processing problems and interpersonal conflicts; thus, they abuse
illicit drugs through negative reinforcement. Therefore, this study assesses
alexithymia, mood dysregulation, and PDs in relation to substance use disorder in
adolescent male patients. Methods: In total, 30 adolescent male patients diagnosed
with substance use disorder by the Mini International Neuropsychiatric Interview,
and a sociodemographically matched control group, were compared using Toronto
Alexithymia Scale-20, Trait Meta Mood Scale, and Structured Clinical Interview for
the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition Axis II
(SCID-II) questionnaire. Results: Adolescent addicts showed statistically
significant differenceswith the control group in having multiple PDs (P=0.001);
with respect to mood regulation, they showed lower attention to their feelings (P=
0.02) and lower repair of mood (P= 0.009). Patients had low clarity of feelings (P=
0.02) and low mood repair significantly related to the first substance abused
(cannabinoids) (P< 0.01) and a significant relation between low attention to
feelings and the cause of drug abuse being peer pressure and novelty seeking (P=
0.001). There was also a statistically significant correlation between alexithymia
and obsessive compulsive PD among patients (P= 0.009). Conclusions: Adolescent male
addicts have impaired mood regulation compared with a control group, having lower
mood clarity and mood repair correlated with the first substance abused. They also
have lower attention to mood associated with drug seeking and higher rate of
multiple PDs, particularly cluster B. [El-Rasheed, Amany H.; Elrassas, Hanan
H.; Mahmoud, Dalia A. M.; Mohamed, Shierf Y.] Ain Shams Univ, Inst Psychiat, Dept
Neuropsychiat, Cairo, Egypt; [ElAttar, Khled S.] Ahmed Galal Armed Forces Hosp,
Cairo, Egypt Mahmoud, DAM (reprint author), WHO Collaborating Ctr Mental Hlth
Res & Training, Inst Psychiat, Ramses St Extens,POB 11657, Cairo, Egypt.
dollycage@hotmail.com Askar M, 1993, EGYPT J
PSYCHIAT, V16, P77; BAGBY RM, 1994, J PSYCHOSOM RES, V38, P33, DOI 10.1016/0022-
3999(94)90006-X; Baumeister RF, 2007, PERS SOC PSYCHOL REV, V11, P167, DOI
10.1177/1088868307301033; Brackett MA, 2004, PERS INDIV DIFFER, V36, P1387, DOI
10.1016/S0191-8869(03)00236-8; Cerutti R, 2014, PROCD SOC BEHV, V114, P372, DOI
10.1016/j.sbspro.2013.12.714; Ciarrochi C, 2006, J PSYCHOSOM RES, V38, P33; Clarke
PB, 2012, RELATIONSHIP WELLNES; Cleland C, 2005, J PSYCHOSOM RES, V58, P299, DOI
10.1016/j.jpsychores.2004.11.002; Coehlo KR, 2012, DEPRESS RES TREAT, V2012; de
Haan HA, 2014, PSYCHIAT RES, V216, P137, DOI 10.1016/j.psychres.2013.12.047; de
Haan HA, 2013, COMPR PSYCHIAT, V54, P911, DOI 10.1016/j.comppsych.2013.03.021;
Dimaggio G, 2007, CLIN PSYCHOL PSYCHOT, V14, P386, DOI 10.1002/cpp.541; El-Sherbiny
AAM, 2015, TANTA MED J, V43, P82; ELRASHEED AH, 2001, SUBST ABUS, V22, P11, DOI DOI
10.1080/08897070109511442; Fan Y, 2011, PSYCHOL MED, V41, P1641, DOI
10.1017/S003329171000228X; Fawzi M. M., 2011, EGYPTIAN J FORENSIC, V1, P99, DOI DOI
10.1016/J.EJFS.2011.04.016; First M. B., 1997, STRUCTURED CLIN INTE; Fox HC, 2008,
ADDICT BEHAV, V33, P388, DOI 10.1016/j.addbeh.2007.10.002; Franz M, 2008, SOC PSYCH
PSYCH EPID, V43, P54, DOI 10.1007/s00127-007-0265-1; Garland EL, 2015, J ADDICT
MED, V9, P61, DOI 10.1097/ADM.0000000000000090; Garno JL, 2005, J CLIN PSYCHIAT,
V66, P339, DOI 10.4088/JCP.v66n0310; Ghalehban M, 2011, PROCD SOC BEHV, V30, DOI
10.1016/j.sbspro.2011.10.008; Ghanem M, 1999, ANN INT C EG PSYCH A; GOLDBERG DP,
1970, BMJ-BRIT MED J, V2, P439, DOI 10.1136/bmj.2.5707.439; GRILO CM, 1995, J AM
ACAD CHILD PSY, V34, P1085, DOI 10.1097/00004583-199508000-00019; Haj Hosseini
Fatemeh, 2011, Addict Health, V3, P130; Hamdi E, 2013, SUBST ABUS, V34, P97, DOI
10.1080/08897077.2012.677752; Hamidi S, 2010, PROCD SOC BEHV, V5, P1367, DOI
10.1016/j.sbspro.2010.07.289; Handelsman L, 2000, ADDICT BEHAV, V25, P423, DOI
10.1016/S0306-4603(99)00010-6; Hatata H, 2004, DUAL DIAGNOSIS SUBST; Hathaway AD,
2003, ADDICT RES THEORY, V11, P441, DOI 10.1080/1606635021000041807; Hayes SC,
1996, J CONSULT CLIN PSYCH, V64, P1152, DOI 10.1037/0022-006X.64.6.1152; Honkalampi
K, 2009, COMPR PSYCHIAT, V50, P263, DOI 10.1016/j.comppsych.2008.08.007; Javani N,
2015, INT J ED PSYCHOL RES, V1, P161; Kafafi H, 2006, TRAIT META MOOD SCAL; Kaiser
AJ, 2012, ADDICT BEHAV, V37, P1075, DOI 10.1016/j.addbeh.2012.04.017; Khantzian EJ,
1997, HARVARD REV PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550; KHANTZIAN EJ,
1985, AM J PSYCHIAT, V142, P1259; Kornreich C, 2003, PSYCHIAT RES, V119, P251, DOI
10.1016/S0165-1781(03)00130-6; Kovacs M, 1998, J CHILD PSYCHOL PSYC, V39, P47, DOI
10.1111/1469-7610.00303; KRYSTAL H, 1995, PSYCHOL TREATMENT AD, P65; Kun B, 2010,
SUBST USE MISUSE, V45, P1131, DOI 10.3109/10826080903567855; Lahaye M, 2010, J PERS
ASSESS, V92, P317, DOI 10.1080/00223891.2010.482003; Langas AM, 2012, BMC
PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-180; Limonero JT, 2006, PSICOTHEMA, V18,
P95; Lumley MA, 1996, PSYCHOSOM MED, V58, P197, DOI 10.1097/00006842-199605000-
00001; Lumley MA, 2007, J PERS ASSESS, V89, P230, DOI 10.1080/00223890701629698;
MAYOU R, 1986, BRIT J PSYCHIAT, V149, P172, DOI 10.1192/bjp.149.2.172; Mohamed NR,
2015, MENOUFIA MED J, V28, P591; Moulavi P, 2010, J ARDABIL U MED SCI, V9, P325;
Mowrer S., 2007, THESIS; Narimani M, 2013, J CLIN PSYCHOL, V5, P55; Negm MG, 2014,
EGYPT J PSYCHIAT, V35, P161; Nikmanesh Z, 2015, IJMTFM, V5, P185; Nikmanesh Zahra,
2014, J Family Reprod Health, V8, P69; OKASHA A, 1988, OKASHAS CLIN PSYCHIA; Olsson
J., 2014, NARCISSISM BRAIN BEH; Picardi A, 2005, PSYCHOTHER PSYCHOSOM, V74, P371,
DOI 10.1159/000087785; Pinard L, 1996, AM J ADDICTION, V5, P32; Ramos NS, 2007,
COGNITION EMOTION, V21, P758, DOI 10.1080/02699930600845846; Rogstad JE, 2008, CLIN
PSYCHOL REV, V28, P1472, DOI 10.1016/j.cpr.2008.09.004; Salovey P, 2002, PSYCHOL
HEALTH, V17, P611, DOI 10.1080/08870440290025812; Salovey P., 1995, EMOTION
DISCLOSURE H, P125, DOI DOI 10.1037/10182-006; Sheehan DV, 1998, J CLIN PSYCHIAT,
V59, P22, DOI 10.4088/JCP.09m05305whi; Siegel JP, 2005, J CHILD ADOLES SUBST, V24,
P67; Sifneos PE, 1972, SHORT TERM PSYCHOPAT, V23, P45; Speranza M, 2005, PSYCHIAT
RES, V135, P153, DOI 10.1016/j.psychres.2005.04.001; SPSS, 2010, IBM CORP REL 2010
IB; Steinberg L, 2008, DEV REV, V28, P78, DOI 10.1016/j.dr.2007.08.002; Taylor J,
2005, AM J DRUG ALCOHOL AB, V31, P515, DOI 10.1081/ADA-200068107; Thorberg FA,
2009, ADDICT BEHAV, V34, P237, DOI 10.1016/j.addbeh.2008.10.016; Troisi A, 1998,
ADDICTION, V93, P487, DOI 10.1046/j.1360-0443.1998.9344874.x; Winters KC, 2002,
BEHAV RES THER, V40, P1443, DOI 10.1016/S0005-7967(02)00041-4; WURMSER L, 1995,
HIDDEN DIMENSION PSY; Zuckerman A., 1994, BEHAV EXPRESSIONS BI, V27, P477 75
1 1 0 0 LIPPINCOTT WILLIAMS & WILKINS PHILADELPHIA TWO
COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA 1531-5754 1535-1122
ADDICT DISORD TREAT Addict. Disord. Treat. JUN 2017 16 2
49 58 10.1097/ADT.0000000000000098 10
Substance Abuse Substance Abuse EV5MA WOS:000401809200002
2019-09-25
J Kogan, SM; Cho, JH; Oshri, A; MacKillop, J Kogan,
Steven M.; Cho, Junhan; Oshri, Assaf; MacKillop, James The
influence of substance use on depressive symptoms among young adult black men: The
sensitizing effect of early adversity AMERICAN JOURNAL ON ADDICTIONS
English Article COMORBIDITY SURVEY
REPLICATION; SELF-MEDICATION HYPOTHESIS; DRUG-USE; RACIAL DISPARITIES; LIFE-COURSE;
DISORDERS; EXPERIENCES; ADDICTION; DRINKING; STRESS Background and
ObjectivesDepressive symptoms have been identified as an important consequence of
substance use. Both heavy drinking and marijuana use have acute and short-term
effects on systems that regulate emotion, increasing the potential for substance
use to induce problems with negative affect and irritability. We investigated the
effects of alcohol and marijuana use on depressive symptoms among a sample of young
Black men. We also tested the stress sensitization hypothesis that exposure to
adverse childhood experiences would amplify the influence of substance use on men's
depressive symptoms. MethodsHypotheses were tested with 505 rural Black men who, at
ages 19-22 years, provided data on their substance use, adverse childhood
experiences, and depressive symptoms; they provided data again 18 months later.
ResultsSubstance use forecasted increases in depressive symptoms; cross-lagged
analyses yielded no evidence for the inverse path, depressive symptoms increasing
substance use. The impact of substance use on depressive symptoms was amplified
among young Black men who were exposed to adverse childhood experiences. Substance
use did not significantly predict depressive symptoms when adversity was low.
Discussion and ConclusionsOur findings suggest that, during young adulthood,
substance use increases depressive symptoms among Black men who were exposed to
childhood adversity. Because childhood adversity disproportionately affects Black
men, these findings inform future cross-group research designed to investigate
racial disparities in the consequences of substance use. Scientific
SignificanceDepressive symptoms may be understood as an effect as well as a cause
of substance use, particularly among vulnerable young Black men. (Am J Addict
2017;26:400-406). [Kogan, Steven M.; Oshri, Assaf] Univ Georgia, Dept Human Dev &
Family Sci, 123 Dawson Hall,305 Sanford Dr, Athens, GA 30602 USA; [Cho, Junhan]
Univ Southern Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA USA;
[MacKillop, James] McMaster Univ, Dept Psychiat & Behav Neurosci, Hamilton, ON,
Canada Kogan, SM (reprint author), Univ Georgia, Dept Human Dev & Family Sci,
123 Dawson Hall,305 Sanford Dr, Athens, GA 30602 USA. smkogan@uga.edu Kogan,
Steven/0000-0002-9562-5980 National Institute on Drug Abuse, Rockville, MDUnited
States Department of Health & Human ServicesNational Institutes of Health (NIH) -
USANIH National Institute on Drug Abuse (NIDA) [R01 DA029488, P30 DA027827]
Funding for this study was provided by Award Number R01 DA029488 to Steven M.
Kogan and Award Number P30 DA027827 to Gene H. Brody, Center for Family Research,
University of Georgia, from the National Institute on Drug Abuse, Rockville, MD.
[Anonymous], 2008, MPLUS US GUID; Bardo MT, 2013, PHARMACOL REV, V65, P255,
DOI 10.1124/pr.111.005124; Birkley EL, 2015, J STUD ALCOHOL DRUGS, V76, P799;
Bjorgvinsson T, 2013, ASSESSMENT, V20, P429, DOI 10.1177/1073191113481998; Center
for Behavioral Health Statistics and Quality, 2016, 2015 NAT SURV DRUG U; Chen FR,
2015, J ABNORM CHILD PSYCH, V43, P189, DOI 10.1007/s10802-014-9900-y; Child Trends,
2013, ADV EXP IND CHILDR Y; Child Trends Data Bank, 2006, DEPR SYMPT YOUNG AD;
Crockett LJ, 2016, ADV RESPONS ADOL DEV, P1, DOI 10.1007/978-3-319-20976-0_1; Dube
SR, 2003, PEDIATRICS, V111, P564, DOI 10.1542/peds.111.3.564; Goeders NE, 2003, EUR
NEUROPSYCHOPHARM, V13, P435, DOI 10.1016/j.euroneuro.2003.08.004; Green KM, 2012,
DRUG ALCOHOL DEPEN, V123, P239, DOI 10.1016/j.drugalcdep.2011.11.017; Heckathorn
DD, 2002, SOC PROBL, V49, P11, DOI 10.1525/sp.2002.49.1.11; Heim C, 1999, BIOL
PSYCHIAT, V46, P1509, DOI 10.1016/S0006-3223(99)00224-3; Joe GW, 2002, J SUBST
ABUSE TREAT, V22, P183, DOI 10.1016/S0740-5472(02)00232-5; Johnston L. D., 2015,
MONITORING FUTURE NA, VII, p[II, 19]; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62,
P593, DOI 10.1001/archpsyc.62.6.593; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4,
P231, DOI 10.3109/10673229709030550; Kogan SM, 2015, ARCH SEX BEHAV, V44, P609, DOI
10.1007/s10508-014-0410-3; Koob GF, 2013, CURR OPIN NEUROBIOL, V23, P559, DOI
10.1016/j.conb.2013.03.011; Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI
10.1038/npp.2009.110; Kuntsche E, 2005, CLIN PSYCHOL REV, V25, P841, DOI
10.1016/j.cpr.2005.06.002; Lembke A, 2012, AM J DRUG ALCOHOL AB, V38, P524, DOI
10.3109/00952990.2012.694532; Martin LA, 2013, JAMA PSYCHIAT, V70, P1100, DOI
10.1001/jamapsychiatry.2013.1985; Mitchell O, 2015, JUSTICE Q, V32, P288, DOI
10.1080/07418825.2012.761721; Myers B, 2014, PSYCHOL ADDICT BEHAV, V28, P1117, DOI
10.1037/a0037459; *NAT I DRUG AB, 2003, DRUG US RAC ETHN MIN; Salgado-Pineda P,
2005, CLIN NEUROPHARMACOL, V28, P228, DOI 10.1097/01.wnf.0000185824.57690.f0; Sher
KJ, 2007, J ABNORM PSYCHOL, V116, P362, DOI 10.1037/0021-843X.116.2.362; Sinha R,
2008, ANN NY ACAD SCI, V1141, P105, DOI 10.1196/annals.1441.030; Slopen N, 2016, AM
J PREV MED, V50, P47, DOI 10.1016/j.amepre.2015.06.013; Walsemann KM, 2009, J
HEALTH SOC BEHAV, V50, P82, DOI 10.1177/002214650905000106; Watkins DC, 2012, AM J
MENS HEALTH, V6, P194, DOI 10.1177/1557988311424072; Watt Toni Terling, 2008, J
Ethn Subst Abuse, V7, P93, DOI 10.1080/15332640802083303; Zapolski TCB, 2014,
PSYCHOL BULL, V140, P188, DOI 10.1037/a0032113 35 4 4 0 4 WILEY
HOBOKEN 111 RIVER ST, HOBOKEN 07030-5774, NJ USA 1055-0496 1521-0391
AM J ADDICTION Am. J. Addict. JUN 2017 26 4
400 406 10.1111/ajad.12555 7 Substance Abuse
Substance Abuse EU6SA WOS:000401162900014 28426146 Green Accepted
2019-09-25
J Earnshaw, VA; Elliott, MN; Reisner, SL; Mrug, S; Windle, M; Emery, ST;
Peskin, MF; Schuster, MA Earnshaw, Valerie A.; Elliott, Marc
N.; Reisner, Sari L.; Mrug, Sylvie; Windle, Michael; Emery, Susan Tortolero;
Peskin, Melissa F.; Schuster, Mark A. Peer Victimization,
Depressive Symptoms, and Substance Use: A Longitudinal Analysis PEDIATRICS
English Article SELF-MEDICATION
HYPOTHESIS; RISK BEHAVIOR SURVEILLANCE; PSYCHOSOCIAL ADJUSTMENT; BULLYING
VICTIMIZATION; SCHOOL VICTIMIZATION; ADOLESCENT HEALTH; UNITED-STATES; YOUTH;
DISORDERS; ALCOHOL BACKGROUND: Peer victimization is common among youth and
associated with substance use. Yet, few studies have examined these associations
longitudinally or the psychological processes whereby peer victimization leads to
substance use. The current study examined whether peer victimization in early
adolescence is associated with alcohol, marijuana, and tobacco use in mid- to late
adolescence, as well as the role of depressive symptoms in these associations.
METHODS: Longitudinal data were collected between 2004 and 2011 from 4297 youth in
Birmingham, Alabama; Houston, Texas; and Los Angeles County, California. Data were
analyzed by using structural equation modeling. RESULTS: The hypothesized model fit
the data well (Root Mean Square Error of Approximation [RMSEA] = 0.02; Comparative
Fit Index [CFI] = 0.95]. More frequent experiences of peer victimization in the
fifth grade were associated with greater depressive symptoms in the seventh grade
(B[SE] = 0.03[0.01]; P < .001), which, in turn, were associated with a greater
likelihood of alcohol use (B[SE] = 0.03[0.01]; P =.003), marijuana use (B[SE] =
0.05[0.01]; y<.001), and tobacco use (B[SE] = 0.05[0.01]; P < .001) in the tenth
grade. Moreover, fifth grade peer victimization was indirectly associated with
tenth-grade substance use via the mediator of seventh-grade depressive symptoms,
including alcohol use (B[SE] = 0.01[0.01]; P = .006), marijuana use (B[SE] =
0.01[0.01]; P < .001), and tobacco use (B[SE] = 0.02[0.01]; P <.001). CONCLUSIONS:
Youth who experienced more frequent peer victimization in the fifth grade were more
likely to use substances in the tenth grade, showing that experiences of peer
victimization in early adolescence may have a lasting impact by affecting substance
use behaviors during mid- to late adolescence. Interventions are needed to reduce
peer victimization among youth and to support youth who have experienced
victimization. [Earnshaw, Valerie A.; Reisner, Sari L.; Schuster, Mark A.]
Boston Childrens Hosp, Div Gen Pediat, Boston, MA USA; [Earnshaw, Valerie A.;
Reisner, Sari L.; Schuster, Mark A.] Harvard Med Sch, Dept Pediat, Boston, MA USA;
[Earnshaw, Valerie A.] Univ Delaware, Dept Human Dev & Family Studies, Newark, DE
USA; [Elliott, Marc N.] RAND Corp, Santa Monica, CA USA; [Reisner, Sari L.] Harvard
TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA; [Reisner, Sari L.] Fenway
Hlth, Fenway Inst, Boston, MA USA; [Mrug, Sylvie] Univ Alabama Birmingham, Dept
Psychol, Birmingham, AL 35294 USA; [Windle, Michael] Emory Univ, Rollins Sch Publ
Hlth, Atlanta, GA 30322 USA; [Emery, Susan Tortolero; Peskin, Melissa F.] Univ
Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Ctr Hlth Promot & Prevent Res, Houston,
TX 77030 USA Earnshaw, VA (reprint author), Boston Childrens Hosp, Gen Pediat,
BCH 3201, Boston, MA 02115 USA. valerie.earnshaw@gmail.com
Centers for Disease Control and PreventionUnited States Department of Health
& Human ServicesCenters for Disease Control & Prevention - USA [CCU409679,
CCU609653, CCU915773, U48DP000046, U48DP000057, U48DP000056, U19DP002663,
U19DP002664, U19DP002665]; Agency tor Healthcare Research and Quality [K12HS022986]
The Healthy Passages study was funded by the Centers for Disease Control and
Prevention (cooperative agreements CCU409679, CCU609653, CCU915773, U48DP000046,
U48DP000057, U48DP000056, U19DP002663, U19DP002664, and U19DP002665). Dr Earnshaw's
effort was supported by the Agency tor Healthcare Research and Quality
(K12HS022986). Acierno R, 2000, J TRAUMA STRESS, V13, P381, DOI
10.1023/A:1007772905696; Ammerman S, 2015, PEDIATRICS, V135, pE769, DOI
10.1542/peds.2014-4147; Binns HJ, 2009, PEDIATRICS, V124, P1474, DOI
10.1542/peds.2009-2114; Bogart LM, 2014, PEDIATRICS, V133, P440, DOI
10.1542/peds.2013-3510; Diego MA, 2003, ADOLESCENCE, V38, P35; Earnshaw VA, 2014,
SOC PSYCHOL EDUC, V17, P197, DOI 10.1007/s11218-014-9250-1; Fleming LC, 2010,
HEALTH PROMOT INT, V25, P73, DOI 10.1093/heapro/dap046; Flory K, 2004, DEV
PSYCHOPATHOL, V16, P193, DOI 10.1017/S0954579404044475; Floyd FJ, 2006, ARCH SEX
BEHAV, V35, P287, DOI 10.1007/s10508-006-9022-x; Grunbaum JA, 2002, J SCHOOL
HEALTH, V72, P313, DOI 10.1111/j.1746-1561.2002.tb07917.x; Hong JS, 2014, AM J
ORTHOPSYCHIAT, V84, P696, DOI 10.1037/ort0000036; Johnston L.D., 2011, MONITORING
FUTURE NA; Juvonen J, 2014, ANNU REV PSYCHOL, V65, P159, DOI 10.1146/annurev-psych-
010213-115030; Kann L, 2014, MMWR SURVEILL SUMM, V63, P1; Khantzian EJ, 1997,
HARVARD REV PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550; KHANTZIAN EJ, 1985,
AM J PSYCHIAT, V142, P1259; King SM, 2004, ADDICTION, V99, P1548, DOI
10.1111/j.1360-0443.2004.00893.x; Levy SJL, 2016, PEDIATRICS, V138, DOI
10.1542/peds.2016-1211; Lucas CP, 2001, J AM ACAD CHILD PSY, V40, P443, DOI
10.1097/00004583-200104000-00013; Luk JW, 2010, PREV SCI, V11, P355, DOI
10.1007/s11121-010-0179-0; Maggs JL, 2004, ALCOHOL RES HEALTH, V28, P195; Maxwell
SE, 2007, PSYCHOL METHODS, V12, P23, DOI 10.1037/1082-989X.12.1.23; Moss HB, 2014,
DRUG ALCOHOL DEPEN, V136, P51, DOI 10.1016/j.drugalcdep.2013.12.011; Nansel TR,
2001, JAMA-J AM MED ASSOC, V285, P2094, DOI 10.1001/jama.285.16.2094; Niemela S,
2011, ADDICT BEHAV, V36, P256, DOI 10.1016/j.addbeh.2010.10.012; Prinstein MJ,
2001, J CLIN CHILD PSYCHOL, V30, P479, DOI 10.1207/S15374424JCCP3004_05; Radliff
KM, 2012, ADDICT BEHAV, V37, P569, DOI 10.1016/j.addbeh.2012.01.001; Russell ST,
2012, AM J PUBLIC HEALTH, V102, P493, DOI 10.2105/AJPH.2011.300430; Russell ST,
2011, J SCHOOL HEALTH, V81, P223, DOI 10.1111/j.1746-1561.2011.00583.x; Salmon G,
1998, BRIT MED J, V317, P924; Schuster MA, 2015, NEW ENGL J MED, V372, P1872, DOI
10.1056/NEJMc1413064; Schuster MA, 2012, NEW ENGL J MED, V367, P735, DOI
10.1056/NEJMsa1114353; Seals D, 2003, ADOLESCENCE, V38, P735; Tandon M, 2009, CHILD
ADOL PSYCH CL, V18, P593, DOI 10.1016/j.chc.2009.03.004; Tharp-Taylor S, 2009,
ADDICT BEHAV, V34, P561, DOI 10.1016/j.addbeh.2009.03.012; Toomey RB, 2010, DEV
PSYCHOL, V46, P1580, DOI 10.1037/a0020705; Williams JF, 2010, PEDIATRICS, V125,
P1078, DOI 10.1542/peds.2010-0438; Windle M, 2004, AM J PREV MED, V27, P164, DOI
10.1016/j.amepre.2004.04.007 38 12 13 0 7 AMER ACAD PEDIATRICS
ELK GROVE VILLAGE 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-
1098 USA 0031-4005 1098-4275 PEDIATRICS Pediatrics JUN 2017 139
6 e20163426 10.1542/peds.2016-3426
8 Pediatrics Pediatrics EW5HJ WOS:000402536100019 28562268
Bronze 2019-09-25
J de Lint, W; Marmo, M; Groves, A; Pocrnic, A de Lint,
Willem; Marmo, Marinella; Groves, Andrew; Pocrnic, Adam Crime
victims' self-medication: Findings from a study in South Australia
INTERNATIONAL REVIEW OF VICTIMOLOGY English Article
Self-medication; informal support network; post-traumatic
stress disorder; alcohol and other drugs; repeat victimization INTIMATE PARTNER
VIOLENCE; POSTTRAUMATIC-STRESS-DISORDER; INFORMAL SOCIAL SUPPORT; SUBSTANCE USE
DISORDERS; SEXUAL ASSAULT; DOMESTIC VIOLENCE; ALCOHOL-CONSUMPTION; PREVENTION
RESEARCH; WOMEN; ABUSE While considerable literature has explored the complex
nature of victimisation, few empirical studies have examined the role of alcohol
and other drugs (AODs) in victims' experiences, specifically victims' self-
medication using AODs and its impact on ongoing health and welfare needs.
Addressing the dearth of empirical research on the nature and extent of victims'
self-medication, and drawing upon quantitative data from a survey (n = 102) of
victims from Adelaide, South Australia this article explores individuals'
experiences of victimisation and AOD use against type of victimisation, type of
peer support network and type of consumption. The findings indicate support for the
self-medication for trauma hypothesis, namely that victimisation is positively
associated with considerable increase in AOD consumption. On the other hand, there
is a lack of support for the supplementary hypothesis that network support is
associated with victimisation/re-victimisation. The authors demonstrate that
further empirical work is needed to deepen understanding of victims' AOD use and
expedite the development of evidence-based policy and support frameworks. [de
Lint, Willem; Marmo, Marinella; Pocrnic, Adam] Flinders Law Sch, GPO Box 2100,
Adelaide, SA 5001, Australia; [Groves, Andrew] Deakin Univ, Geelong, Vic, Australia
Marmo, M (reprint author), Flinders Law Sch, GPO Box 2100, Adelaide, SA 5001,
Australia. marinella.marmo@flinders.edu.au de Lint, Willem/0000-0002-
6586-3101 Flinders University's Faculty of Education, Humanities and Law's
research grant scheme The authors wish to thank Flinders University's Faculty of
Education, Humanities and Law's research grant scheme for financial support for
this study. Abbey A, 2004, AGGRESS VIOLENT BEH, V9, P271, DOI 10.1016/S1359-
1789(03)00011-9; Anderson KL, 2002, J MARRIAGE FAM, V64, P851, DOI 10.1111/j.1741-
3737.2002.00851.x; Australian Bureau of Statistics (ABS), 2016, ED AND WORK;
Australian Institute of Health and Welfare (AIHW), 2009, ENH ALC OTH DRUG TRE;
Bachman R., 2008, FUNDAMENTALS RES CRI; Back S.E., 2014, CONCURRENT TREATMENT;
Bazargan-Hejazi Shahrzad, 2013, J Inj Violence Res, V5, P38, DOI
10.5249/jivr.v5i1.139; Bowen E, 2011, AGGRESS VIOLENT BEH, V16, P214, DOI
10.1016/j.avb.2011.02.007; Braaf M, 2012, ELEPHANT ROOM RESPON; Budde S, 2004, J
INTERPERS VIOLENCE, V19, P341, DOI 10.1177/0886260503261157; Chermack ST, 2002,
DRUG ALCOHOL DEPEN, V66, P29, DOI 10.1016/S0376-8716(01)00180-6; Cohen LR, 2006,
PSYCHIAT SERV, V57, P100, DOI 10.1176/appi.ps.57.1.100; Cresswell J.W., 2003, RES
DESIGN QUALITATI; Cunradi CB, 2002, ALCOHOL CLIN EXP RES, V26, P493, DOI
10.1111/j.1530-0277.2002.tb02566.x; Danielson Carla Kmett, 2006, J Psychiatr Pract,
V12, P364, DOI 10.1097/00131746-200611000-00004; Dore G, 2012, DRUG ALCOHOL REV,
V31, P294, DOI 10.1111/j.1465-3362.2011.00314.x; FarraH ST., 2008, FEAR CRIME
PUNITIVIT, P3; Fink A, 2003, SURVEY KIT ASK SURVE; Flynn A, 2010, AGGRESS VIOLENT
BEH, V15, P239, DOI 10.1016/j.avb.2010.01.002; Friedman AS, 1998, AGGRESS VIOLENT
BEH, V3, P339, DOI 10.1016/S1359-1789(97)00012-8; GIDYCZ CA, 1995, PSYCHOL WOMEN
QUART, V19, P5, DOI 10.1111/j.1471-6402.1995.tb00276.x; Grayson CE, 2005, J TRAUMA
STRESS, V18, P137, DOI 10.1002/jts.20021; Guggisberg M, 2010, THESIS; Guterman NB,
2004, J INTERPERS VIOLENCE, V19, P299, DOI 10.1177/0886260503261153; Gutierres SE,
2006, AGGRESS VIOLENT BEH, V11, P497, DOI 10.1016/j.avb.2006.01.010; Harwin N,
2006, VIOLENCE AGAINST WOM, V12, P556, DOI 10.1177/1077801206289134; Jacobsen LK,
2001, AM J PSYCHIAT, V158, P1184, DOI 10.1176/appi.ajp.158.8.1184; Kaukinen C,
2004, J MARRIAGE FAM, V66, P452, DOI 10.1111/j.1741-3737.2004.00031.x; Kaysen D,
2007, ADDICT BEHAV, V32, P1272, DOI 10.1016/j.addbeh.2006.09.007; Kilpatrick DG,
1997, J CONSULT CLIN PSYCH, V65, P834, DOI 10.1037/0022-006X.65.5.834; Klostermann
KC, 2006, AGGRESS VIOLENT BEH, V11, P587, DOI 10.1016/j.avb.2005.08.008; KRUG
Etienne, 2002, WORLD REPORT VIOLENC; Kuhns JB, 2009, AGGRESS VIOLENT BEH, V14, P69,
DOI 10.1016/j.avb.2008.11.001; Laslett A. M., 2015, HIDDEN HARM ALCOHOLS; Latta RE,
2011, COUNS PSYCHOL, V39, P973, DOI 10.1177/0011000011398504; Liang B, 2005, AM J
COMMUN PSYCHOL, V36, P71, DOI 10.1007/s10464-005-6233-6; Lipsky Sherry, 2005,
Violence Vict, V20, P645, DOI 10.1891/088667005780927412; Logan TK, 2002, REV GEN
PSYCHOL, V6, P325, DOI 10.1037//1089-2680.6.4.325; Lugton J, 1997, J ADV NURS, V25,
P1184, DOI 10.1046/j.1365-2648.1997.19970251184.x; LURIGIO AJ, 1987, CRIME
DELINQUENCY, V33, P452, DOI 10.1177/0011128787033004003; McFarlane J., 2005, SEXUAL
ASSAULT INTIM; Messman-Moore TL, 2009, J INTERPERS VIOLENCE, V24, P499, DOI
10.1177/0886260508317199; Meyer D, 2010, SOCIOLOGY, V44, P980, DOI
10.1177/0038038510375737; MITCHELL RE, 1980, COMMUNITY MENT HLT J, V16, P27, DOI
10.1007/BF00780665; Morgan A., 2009, KEY ISSUES DOMESTIC; Morrison B, 2011, VICTIMS
CRIME RES DI, V4, P15; Murray CE, 2007, J INTERPERS VIOLENCE, V22, P1250, DOI
10.1177/0886260507304293; Nicholas R., 2012, BREAKING SILENCE ADD; O'Farrell TJ,
2003, J CONSULT CLIN PSYCH, V71, P92, DOI 10.1037/0022-006X.71.1.92; O'Sullivan
Chris S., 2013, VICTIMS CRIME, P3; Quadara A, 2015, ESTABLISHING CONNECT; Resnick
HS, 2007, ADDICT BEHAV, V32, P2032, DOI 10.1016/j.addbeh.2007.01.001; Schuck AM,
2001, CHILD ABUSE NEGLECT, V25, P1069, DOI 10.1016/S0145-2134(01)00257-5; SKOGAN
WG, 1987, CRIME DELINQUENCY, V33, P135, DOI 10.1177/0011128787033001008; Stewart S,
2001, VIOLENCE ADDICTION E, P102; Stewart SH, 1996, PSYCHOL BULL, V120, P83, DOI
10.1037/0033-2909.120.1.83; Stuart GL, 2003, J INTERPERS VIOLENCE, V18, P1113, DOI
10.1177/0886260503255550; Testa M, 2001, J FAM VIOLENCE, V16, P115, DOI
10.1023/A:1011154818394; Testa M, 2004, J INTERPERS VIOLENCE, V19, P1494, DOI
10.1177/0886260504269701; Testa M, 2003, ADDICT BEHAV, V28, P1649, DOI
10.1016/j.addbeh.2003.08.040; Testa M, 1996, AGGRESS VIOLENT BEH, V1, P217, DOI
10.1016/1359-1789(95)00017-8; Trujillo MP, 2008, J INTERPERS VIOLENCE, V23, P454,
DOI 10.1177/0886260507312943; UEHARA E, 1990, AM J SOCIOL, V96, P521, DOI
10.1086/229571; Ullman SE, 2007, PSYCHOL WOMEN QUART, V31, P23, DOI 10.1111/j.1471-
6402.2007.00328.x; Ullman SE, 2003, AGGRESS VIOLENT BEH, V8, P471, DOI
10.1016/S1359-1789(03)00032-6; White HR, 2002, J STUD ALCOHOL, V63, P205, DOI
10.15288/jsa.2002.63.205 66 3 3 1 1 SAGE PUBLICATIONS LTD
LONDON 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND 0269-
7580 2047-9433 INT REV VICT Int. Rev. Vict. MAY 2017 23 2
159 177 10.1177/0269758016686280
19 Criminology & Penology Criminology & Penology FV4SN
WOS:000424565600004 2019-09-25
J Torres, L; Mata-Greve, F Torres, Lucas; Mata-Greve,
Felicia Anxiety Sensitivity as a Predictor of Latino Alcohol Use: A
Moderated Mediational Model JOURNAL OF LATINA-O PSYCHOLOGY
English Article anxiety sensitivity;
anxiety; alcohol use; Latino mental health; acculturation ACCULTURATION-RATING-
SCALE; SUBSTANCE USE DISORDERS; MEXICAN-AMERICANS-II; DRINKING MOTIVES; PERCEIVED
DISCRIMINATION; PSYCHIATRIC-DISORDERS; MENTAL-HEALTH; UNITED-STATES; STRESS;
ASSOCIATION Although anxiety symptoms and alcohol use have been widely researched,
recent work has begun to examine the role of anxiety sensitivity in contributing to
these mental health indicators. Unfortunately, minimal research has investigated
the relationships between anxiety sensitivity, anxiety symptoms, and alcohol use
among Latinos. The role of acculturation within these 3 constructs together has yet
to be examined. Among a sample of 120 Latino adults, moderated mediational analyses
revealed statistically significant conditional indirect effects such that anxiety
symptoms mediated the relationship between anxiety sensitivity and alcohol use
while an Anglo orientation moderated the anxiety sensitivity to anxiety symptoms
link. The main findings indicated that the indirect effects were the most robust
within low Anglo orientation. Alternative models were tested but not supported
suggesting that the pattern of results were indicative of the self-medication
hypothesis. The discussion highlights theoretical and practical implications.
[Torres, Lucas; Mata-Greve, Felicia] Marquette Univ, Dept Psychol, POB 1881,
Milwaukee, WI 53202 USA Torres, L (reprint author), Marquette Univ, Dept Psychol,
POB 1881, Milwaukee, WI 53202 USA. lucas.torres@marquette.edu
Alamilla SG, 2010, HISPANIC J BEHAV SCI, V32, P55, DOI
10.1177/0739986309352770; Alderete E, 2000, AM J PUBLIC HEALTH, V90, P608, DOI
10.2105/AJPH.90.4.608; Alegria M, 2007, SOC SCI MED, V65, P214, DOI
10.1016/j.socscimed.2007.03.026; Allan NP, 2015, ADDICTION, V110, P260, DOI
10.1111/add.12739; Babor T, 2001, AUDIT ALCOHOL USE DI; Babor T.F., 1989, AUDIT
ALCOHOL USE DI; Bauer AM, 2012, GEN HOSP PSYCHIAT, V34, P323, DOI
10.1016/j.genhosppsych.2012.02.007; Bauman S, 2005, HISPANIC J BEHAV SCI, V27,
P426, DOI 10.1177/0739986305281423; Berry J, 2003, ACCULTURATION ADV TH, P17, DOI
DOI 10.1037/10472-004; Blume AW, 2009, ADDICT BEHAV, V34, P709, DOI
10.1016/j.addbeh.2009.03.039; CUELLAR I, 1995, HISPANIC J BEHAV SCI, V17, P275, DOI
10.1177/07399863950173001; DeHaas RAB, 2002, COGNITIVE THER RES, V26, DOI
10.1023/A:1016076911164; DeMartini KS, 2011, CLIN PSYCHOL REV, V31, P169, DOI
10.1016/j.cpr.2010.10.001; Hayes A.F., 2013, INTRO MEDIATION MODE; Hayes AF, 2015,
MULTIVAR BEHAV RES, V50, P1, DOI 10.1080/00273171.2014.962683; Horevitz E, 2013,
HISPANIC J BEHAV SCI, V35, P3, DOI 10.1177/0739986312460370; Hovey J D, 2000,
Cultur Divers Ethnic Minor Psychol, V6, P134, DOI 10.1037/1099-9809.6.2.134; Hwang
WC, 2008, CULT DIVERS ETHN MIN, V14, P147, DOI 10.1037/1099-9809.14.2.147; Kemper
CJ, 2012, ASSESSMENT, V19, P89, DOI 10.1177/1073191111429389; Kushner MG, 1999, AM
J PSYCHIAT, V156, P723; Kushner MG, 2000, CLIN PSYCHOL REV, V20, P149, DOI
10.1016/S0272-7358(99)00027-6; Kushner MG, 2001, ADDICT BEHAV, V26, P869, DOI
10.1016/S0306-4603(01)00240-4; Lara M, 2005, ANNU REV PUBL HEALTH, V26, P367, DOI
10.1146/annurev.publhealth.26.021304.144615; Meneses-Gaya Carolina de, 2009,
Psychol. Neurosci., V2, P83, DOI 10.3922/j.psns.2009.1.12; Morris EP, 2005, CLIN
PSYCHOL REV, V25, P734, DOI 10.1016/j.cpr.2005.05.004; Naragon-Gainey K, 2010,
PSYCHOL BULL, V136, P128, DOI 10.1037/a0018055; Novak A, 2003, J ANXIETY DISORD,
V17, P165, DOI 10.1016/S0887-6185(02)00175-5; Olatunji BO, 2006, J ANXIETY DISORD,
V20, P543, DOI 10.1016/j.janxdis.2005.08.002; Olatunji BO, 2009, PSYCHOL BULL,
V135, P974, DOI 10.1037/a0017428; Olthuis JV, 2015, ADDICT BEHAV, V46, P19, DOI
10.1016/j.addbeh.2015.02.018; Peterson R. A., 1992, ANXIETY SENSITIVITY; Preacher
KJ, 2008, BEHAV RES METHODS, V40, P879, DOI 10.3758/BRM.40.3.879; Preacher KJ,
2007, MULTIVAR BEHAV RES, V42, P185, DOI 10.1080/00273170701341316; Reinert DF,
2007, ALCOHOL CLIN EXP RES, V31, P185, DOI 10.1111/j.1530-0277.2006.00295.x; REISS
S, 1986, BEHAV RES THER, V24, P1, DOI 10.1016/0005-7967(86)90143-9; Ruglass LM,
2014, CURR PSYCHIAT REP, V16, DOI 10.1007/s11920-014-0505-5; Ryder AG, 2000, J PERS
SOC PSYCHOL, V79, P49, DOI 10.1037//0022-3514.79.1.49; Sandin B., 2007, REV
PSICOPATOLOGIA P, V12, P91; Schmidt NB, 2007, BEHAV MODIF, V31, P202, DOI
10.1177/0145445506297019; Schwartz SJ, 2014, AM J DRUG ALCOHOL AB, V40, P359, DOI
10.3109/00952990.2014.910521; Smith JP, 2012, ALCOHOL RES-CURR REV, V34, P414;
Stewart SH, 1999, LEA SER PER CLIN PSY, P287; Stewart SH, 2001, ADDICT BEHAV, V26,
P775, DOI 10.1016/S0306-4603(01)00236-2; Stewart SH, 2001, PERS INDIV DIFFER, V31,
P157, DOI 10.1016/S0191-8869(00)00213-0; Taylor S, 2007, PSYCHOL ASSESSMENT, V19,
P176, DOI 10.1037/1040-3590.19.2.176.supp; Torres L, 2012, CULT DIVERS ETHN MIN,
V18, P17, DOI 10.1037/a0026710; Torres L, 2010, CULT DIVERS ETHN MIN, V16, P256,
DOI 10.1037/a0017357; Tran AGTT, 2010, CULT DIVERS ETHN MIN, V16, P226, DOI
10.1037/a0016344; Unger JB, 2014, ADDICT BEHAV, V39, P1293, DOI
10.1016/j.addbeh.2014.04.014; US Census Bureau, 2013, STAT COUNT QUICK FAC; Varela
RE, 2009, CLIN CHILD FAM PSYCH, V12, P217, DOI 10.1007/s10567-009-0044-5; WATT M,
2006, J MENTAL HLTH, V15, P683, DOI DOI 10.1080/09638230600998938; Wheaton MG,
2012, J ANXIETY DISORD, V26, P401, DOI 10.1016/j.janxdis.2012.01.002; Wilkinson AV,
2014, HISPANIC J BEHAV SCI, V36, P316, DOI 10.1177/0739986314540455; Yoon E, 2013,
J COUNS PSYCHOL, V60, P15, DOI 10.1037/a0030652; ZUNG WWK, 1971, PSYCHOSOMATICS,
V12, P371 56 3 3 1 4 EDUCATIONAL PUBLISHING FOUNDATION-
AMERICAN PSYCHOLOGICAL ASSOC WASHINGTON 750 FIRST ST, NE, WASHINGTON, DC 20002-
4242 USA 2168-1678 2163-0070 J LAT O PSYCHOL J. Lat. Psychol. MAY
2017 5 2 61 75 10.1037/lat0000062
15 Psychology, Clinical; Psychology, Developmental;
Psychology, Multidisciplinary; Psychology, Social Psychology FA4FW
WOS:000405400200001 2019-09-25
J Kapitany-Foveny, M; Farkas, J; Pataki, PA; Kiss, A; Horvath, J; Urban, R;
Demetrovics, Z Kapitany-Foveny, Mate; Farkas, Judit; Pataki,
Patricia Andrea; Kiss, Anna; Horvath, Janka; Urban, Robert; Demetrovics, Zsolt
Novel psychoactive substance use among treatment-seeking opiate users:
The role of life events and psychiatric symptoms HUMAN PSYCHOPHARMACOLOGY-
CLINICAL AND EXPERIMENTAL English Article
life events; methadone; NPS; psychiatric symptoms SELF-MEDICATION
HYPOTHESIS; SYNTHETIC CANNABINOIDS; MEPHEDRONE; PATTERNS; HEROIN; ABUSE;
CATHINONES; DISORDERS; METHADONE; INJECTORS ObjectiveOver the past 5years, a
shift to the use of novel psychoactive substances (NPS) has been observed among
opioid users. The aim of this study was to assess the potential reasons for NPS use
among treatment-seeking patients receiving opiate substitution therapy. MethodA
structured questionnaire was filled out by a sample of 198 opiate dependent
patients of Hungary's National Institute of Psychiatry and Addiction. This
questionnaire assessed demographics, treatment characteristics, lifetime substance
use, potential reasons for NPS use, negative life events (Life Events Scale), and
psychiatric symptoms (Brief Symptom Inventory). ResultsThe most frequent reasons
for NPS use were curiosity, replacing other drugs, and easy availability. The
majority of the respondents used synthetic cathinones and chose practical reasons,
not psychopharmacological preferences. A series of binary logistic regressions
indicated that lifetime amphetamine use (OR=4.64, 95% CI [2.16, 9.96]) and more
severe psychiatric symptoms (OR=1.89, 95% CI [1.18, 3.04]) may predict NPS use.
Time spent in treatment was a minor protective factor (OR=0.92, 95% CI [0.86,
0.99]). ConclusionSynthetic cathinones might still substitute amphetamine-
derivatives, although these NPS are no longer legal. There is a need for the
regular screening of psychiatric symptoms and the use of family therapy among
participants on opioid substitution programs. [Kapitany-Foveny, Mate] Semmelweis
Univ, Fac Hlth Sci, Budapest, Hungary; [Kapitany-Foveny, Mate; Farkas, Judit;
Pataki, Patricia Andrea; Horvath, Janka; Urban, Robert; Demetrovics, Zsolt] Eotvos
Lorand Univ, Inst Psychol, Budapest, Hungary; [Kapitany-Foveny, Mate; Farkas,
Judit; Kiss, Anna] Nyiro Gyula Hosp, Natl Inst Psychiat & Addict, Budapest, Hungary
Kapitany-Foveny, M (reprint author), Semmelweis Univ, Fac Hlth Sci, Dept
Addictol, Vas Utca 17, H-1088 Budapest, Hungary. m.gabrilovics@gmail.com
Demetrovics, Zsolt/0000-0001-5604-7551; Kapitany-Foveny, Mate/0000-0002-0850-
8699 Hungarian National Research, Development and Innovation Office [K109375,
K111938] Hungarian National Research, Development and Innovation Office,
Grant/Award Number: K109375 and K111938 Applebaum Allison J, 2010, Neurobehav HIV
Med, V2010, P49; Barratt MJ, 2013, DRUG ALCOHOL REV, V32, P141, DOI 10.1111/j.1465-
3362.2012.00519.x; Booth RE, 2013, INT J DRUG POLICY, V24, P277, DOI
10.1016/j.drugpo.2013.05.009; Brunt TM, 2011, J PSYCHOPHARMACOL, V25, P1543, DOI
10.1177/0269881110378370; Carhart-Harris RL, 2011, DRUG ALCOHOL DEPEN, V118, P19,
DOI 10.1016/j.drugalcdep.2011.02.011; Center for Substance Abuse Treatment, 2004,
TREATMENT IMPROVEMEN, V39; Corazza O, 2014, J PSYCHOACTIVE DRUGS, V46, P287, DOI
10.1080/02791072.2014.944291; Cottencin O, 2014, CURR PHARM DESIGN, V20, P4106, DOI
10.2174/13816128113199990622; Csak R, 2013, J PSYCHOPHARMACOL, V27, P559, DOI
10.1177/0269881113480987; Derogatis L. R., 1975, BRIEF SYMPTOM INVENT; Dickson AJ,
2010, J ANAL TOXICOL, V34, P162, DOI 10.1093/jat/34.3.162; Dresen S, 2010, J MASS
SPECTROM, V45, P1186, DOI 10.1002/jms.1811; El-Bassel N, 2005, AM J PUBLIC HEALTH,
V95, P465, DOI 10.2105/AJPH.2003.023200; EMCDDA, 2010, DRUGN EUR 70, V70; EMCDDA
(European Monitoring Centre for Drugs and Drug Addiction), 2014, EUR DRUG REP
TRENDS; European Monitoring Centre for Drugs and DrugAddiction (EMCDDA), 2011, ANN
REP 2011 STAT DR; Faravelli C, 2007, PSYCHOTHER PSYCHOSOM, V76, P361, DOI
10.1159/000107564; Fattore L, 2011, FRONT BEHAV NEUROSCI, V5, DOI
10.3389/fnbeh.2011.00060; Franken IHA, 2001, J CLIN PSYCHOL, V57, P299, DOI
10.1002/jclp.1013; Ginsburg BC, 2012, J ANAL TOXICOL, V36, P66, DOI
10.1093/jat/bkr018; Gunderson EW, 2014, SUBST ABUS, V35, P184, DOI
10.1080/08897077.2013.846288; Harris M, 2013, INT J DRUG POLICY, V24, P281, DOI
10.1016/j.drugpo.2012.06.007; Hearne E, 2016, HARM REDUCT J, V13, DOI
10.1186/s12954-016-0105-2; Heikman P, 2016, HUM PSYCHOPHARM CLIN, V31, P44, DOI
10.1002/hup.2512; Johnson MW, 2013, EXP CLIN PSYCHOPHARM, V21, P112, DOI
10.1037/a0031692; Kapitany-Foveny M, 2015, HUM PSYCHOPHARM CLIN, V30, P233, DOI
10.1002/hup.2490; Kapitany-Foveny M, 2013, HUM PSYCHOPHARM CLIN, V28, P308, DOI
10.1002/hup.2297; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI
10.3109/10673229709030550; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259; KRUEGER
DW, 1981, J HUM STRESS, V7, P3, DOI 10.1080/0097840X.1981.9936820; Low NCP, 2012,
BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-116; McElrath K, 2011, INT J DRUG
POLICY, V22, P120, DOI 10.1016/j.drugpo.2010.11.001; McNamara S, 2010, Ir Med J,
V103, P136; Mutasa HCF, 2001, J ADV NURS, V35, P97, DOI 10.1046/j.1365-
2648.2001.01826.x; Nacca N, 2013, J ADDICT MED, V7, P296, DOI
10.1097/ADM.0b013e31828e1881; Ojanpera IA, 2011, THER DRUG MONIT, V33, P257, DOI
10.1097/FTD.0b013e318208b693; Papaseit E, 2016, NEUROPSYCHOPHARMACOL, V41, P2704,
DOI 10.1038/npp.2016.75; Paykel E. S., 1991, RISK FACTORS YOUTH S; Peterfi A, 2014,
DRUG TEST ANAL, V6, P825, DOI 10.1002/dta.1625; Ren JM, 2013, CURR MED RES OPIN,
V29, P731, DOI 10.1185/03007995.2013.796284; Schiff M, 2010, SOC WORK HEALTH CARE,
V49, P799, DOI 10.1080/00981381003745103; Simmler LD, 2013, BRIT J PHARMACOL, V168,
P458, DOI 10.1111/j.1476-5381.2012.02145.x; SPSS Inc. Released, 2008, SPSS STAT
WIND VERS; Urban R, 2014, PSYCHIAT RES, V216, P146, DOI
10.1016/j.psychres.2014.01.027; Van Hout MC, 2014, DRUG TEST ANAL, V6, P778, DOI
10.1002/dta.1622; Van Hout MC, 2012, INT J DRUG POLICY, V23, P188, DOI
10.1016/j.drugpo.2012.01.008; Wagner KD, 2014, DRUG ALCOHOL DEPEN, V141, P99, DOI
10.1016/j.drugalcdep.2014.05.007; Wardenaar KJ, 2014, J AFFECT DISORDERS, V156,
P126, DOI 10.1016/j.jad.2013.12.004; Watterson L. R., 2012, J ADDICTION RES TH S,
V9; Winstock A, 2011, ADDICTION, V106, P1991, DOI 10.1111/j.1360-0443.2011.03502.x;
Winstock AR, 2013, DRUG ALCOHOL DEPEN, V131, P106, DOI
10.1016/j.drugalcdep.2012.12.011; Yang F, 2013, HARM REDUCT J, V10, DOI
10.1186/1477-7517-10-3 52 2 2 0 2 WILEY HOBOKEN 111 RIVER
ST, HOBOKEN 07030-5774, NJ USA 0885-6222 1099-1077 HUM PSYCHOPHARM
CLIN Hum. Psychopharmacol.-Clin. Exp. MAY 2017 32 3
e2602 10.1002/hup.2602 8 Clinical Neurology;
Pharmacology & Pharmacy; Psychiatry; Psychology Neurosciences & Neurology;
Pharmacology & Pharmacy; Psychiatry; Psychology EZ0DH WOS:000404369000023
28618002 Bronze 2019-09-25
J Prior, K; Mills, K; Ross, J; Teesson, M Prior, Katrina;
Mills, Katherine; Ross, Joanne; Teesson, Maree Substance use disorders
comorbid with mood and anxiety disorders in the Australian general population
DRUG AND ALCOHOL REVIEW English Article
comorbidity; substance use disorder; mood disorder; anxiety disorder;
prevalence NATIONAL EPIDEMIOLOGIC SURVEY; ALCOHOL-USE DISORDERS; SELF-MEDICATION
HYPOTHESIS; DRUG-USE DISORDERS; MENTAL-HEALTH; UNITED-STATES; PSYCHIATRIC-
DISORDERS; LIFETIME PREVALENCE; SUICIDE ATTEMPTS; SOCIAL PHOBIA Introduction and
AimsSubstance use disorders (SUDs) are common and frequently co-occur with mood and
anxiety disorders. This paper provides a detailed analysis of patterns, prevalence
and correlates of mood and anxiety disorders among those with a (i) pure SUD; (ii)
SUD plus a mood or anxiety disorder (SUDs+1); and (iii) SUD plus a mood and anxiety
disorder (SUDs+2). Design and MethodsData came from the 2007 National Survey of
Mental Health and Wellbeing; a nationally representative household survey of 8841
Australians aged 16-85years. ResultsThe 12-month prevalence of SUDs was 5.1%. Of
those with a 12-month SUD, 65% met the criteria for pure SUDs, 19% for SUDs+1 and
16% for SUDs+2. Major depression was the most common mood disorder in both comorbid
groups. One-third of SUDs+1 experienced social phobia, while over half of SUDs+2
experienced generalised anxiety disorder. Compared with pure SUDs, SUDs+1
experienced two times more and SUDs+2 experienced over four times more days out of
role in the preceding 30days. Both comorbid groups were more likely to experience
severe levels of impairment. SUDs+2 were over 18 times more likely to experience
suicidal thoughts in the same year. SUDs+1 were over three times and SUDs+2 were
over 10 times more likely to have had one or more consultations with a health
professional in the previous year. Discussions and ConclusionsThese findings
highlight the complexities inherent with responding to and treating multiple
comorbidities among substance users and emphasise the need for coordinated,
cohesive responses from drug and alcohol treatment services.[Prior K, Mills K, Ross
J, Teesson M. Substance use disorders comorbid with mood and anxiety disorders in
the Australian general population. Drug Alcohol Rev 2017;36:317-324] [Prior,
Katrina; Mills, Katherine; Ross, Joanne; Teesson, Maree] Natl Hlth & Med Res
Council, Ctr Res Excellence Mental Hlth & Subst Use, Sydney, NSW, Australia;
[Prior, Katrina; Mills, Katherine; Ross, Joanne; Teesson, Maree] Univ New South
Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW, Australia Mills, K (reprint
author), Univ New South Wales, Natl Drug & Alcohol Res Ctr, POB 21, Randwick, NSW
2031, Australia. k.prior@unsw.edu.au Prior, Katrina/Y-5735-2019 Prior,
Katrina/0000-0002-7784-2885 Australian Government Department of Health and
AgeingAustralian GovernmentDepartment of Health & Ageing; Australian Government
under the Substance Misuse Prevention and Service Improvements Grants
FundAustralian Government; Australian Rotary Health; University of New South Wales;
Centre for Research Excellence in Mental Health and Substance Use; National Health
and Medical Research CouncilNational Health and Medical Research Council of
Australia The 2007 NSMHWB was funded by the Australian Government Department of
Health and Ageing and conducted by the Australian Bureau of Statistics. The authors
would like to thank the NSMHWB Reference Group for their input in the survey's
design. The authors would also like to thank those who participated in the survey.
National Drug and Alcohol Research Centre is supported by funding from the
Australian Government under the Substance Misuse Prevention and Service
Improvements Grants Fund. The funding for this study came from Australian Rotary
Health, the University of New South Wales and the Centre for Research Excellence in
Mental Health and Substance Use (funded by the National Health and Medical Research
Council). Molina MRAL, 2014, CAD SAUDE PUBLICA, V30, P2413, DOI 10.1590/0102-
311X00012614; Andreas JB, 2015, ADDICT BEHAV, V48, P71, DOI
10.1016/j.addbeh.2015.05.001; Australian Bureau of Statistics, 2009, NAT SURV MENT
HLTH W; Baillie AJ, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-199; Bolton
JM, 2008, J CLIN PSYCHIAT, V69, P1139, DOI 10.4088/JCP.v69n0714; Bolton JM, 2009, J
AFFECT DISORDERS, V115, P367, DOI 10.1016/j.jad.2008.10.003; Book SW, 2009, ADDICT
BEHAV, V34, P474, DOI 10.1016/j.addbeh.2008.12.011; Boschloo L, 2011, J AFFECT
DISORDERS, V131, P233, DOI 10.1016/j.jad.2010.12.014; BRONISCH T, 1994, EUR ARCH
PSY CLIN N, V244, P93, DOI 10.1007/BF02193525; Bunting BP, 2012, PSYCHOL MED, V42,
P1727, DOI 10.1017/S0033291711002510; Burns L, 2002, DRUG ALCOHOL DEPEN, V68, P299,
DOI 10.1016/S0376-8716(02)00220-X; Cerda M, 2008, EPIDEMIOL REV, V30, P155, DOI
10.1093/epirev/mxn003; Compton WM, 2007, ARCH GEN PSYCHIAT, V64, P566, DOI
10.1001/archpsyc.64.5.566; Conway KP, 2006, J CLIN PSYCHIAT, V67, P247, DOI
10.4088/JCP.v67n0211; Darke S, 2005, DRUG ALCOHOL DEPEN, V78, P177, DOI
10.1016/j.drugalcdep.2004.10.009; Degenhardt L, 2001, SOC PSYCH PSYCH EPID, V36,
P219, DOI 10.1007/s001270170052; Degenhardt L, 2012, LANCET, V379, P55, DOI
10.1016/S0140-6736(11)61138-0; Goodwin RD, 2004, J PSYCHIATR RES, V38, P295, DOI
10.1016/j.jpsychires.2003.09.002; Grant BF, 2004, ARCH GEN PSYCHIAT, V61, P807, DOI
10.1001/archpsyc.61.8.807; Hasin DS, 2007, ARCH GEN PSYCHIAT, V64, P830, DOI
10.1001/archpsyc.64.7.830; Jane-Llopis E, 2006, DRUG ALCOHOL REV, V25, P515, DOI
10.1080/09595230600944461; Johnston AK, 2009, AUST NZ J PSYCHIAT, V43, P635, DOI
10.1080/00048670902970874; Kaufman J, 2000, DEPRESS ANXIETY, V12, P69, DOI
10.1002/1520-6394(2000)12:1+<69::AID-DA9>3.0.CO;2-K; Kavanagh D, 2008, PSYCHOL
MANAGEMENT S; Kessler RC, 1997, ARCH GEN PSYCHIAT, V54, P313; Kessler RC, 2004, INT
J METH PSYCH RES, V13, P93, DOI 10.1002/mpr.168; Kessler RC, 2005, ARCH GEN
PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; KESSLER RC, 1994, ARCH GEN
PSYCHIAT, V51, P8; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI
10.3109/10673229709030550; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259; Lampe L,
2003, PSYCHOL MED, V33, P637, DOI 10.1017/S0033291703007621; Lawrence A, 2008,
OXFORD HDB ANXIETY R; Martins SS, 2011, DRUG ALCOHOL DEPEN, V119, P28, DOI
10.1016/j.drugalcdep.2011.05.010; McEvoy PM, 2011, AUST NZ J PSYCHIAT, V45, P957,
DOI 10.3109/00048674.2011.624083; McGovern MP, 2015, ADDICTION, V110, P1194, DOI
10.1111/add.12943; Merikangas KR, 2007, CURR OPIN PSYCHIATR, V20, P353, DOI
10.1097/YCO.0b013e3281c61dc5; Mills KL, 2012, JAMA-J AM MED ASSOC, V308, P690, DOI
10.1001/jama.2012.9071; Mills KL, 2006, AM J PSYCHIAT, V163, P652, DOI
10.1176/appi.ajp.163.4.652; Mills KL, 2009, GUIDELINES MANAGEMEN; Mojtabai R, 2002,
ARCH GEN PSYCHIAT, V59, P77, DOI 10.1001/archpsyc.59.1.77; Oquendo MA, 2010, J CLIN
PSYCHIAT, V71, P902, DOI 10.4088/JCP.09m05198gry; Raimo EB, 1998, ADDICT BEHAV,
V23, P933, DOI 10.1016/S0306-4603(98)00068-9; Randall CL, 2001, ALCOHOL CLIN EXP
RES, V25, P210, DOI 10.1097/00000374-200102000-00009; Robinson J, 2009, J ANXIETY
DISORD, V23, P38, DOI 10.1016/j.janxdis.2008.03.013; Schade A, 2005, ALCOHOL CLIN
EXP RES, V29, P794, DOI 10.1097/01.ALC.0000163511.24583.33; Schneier FR, 2010,
PSYCHOL MED, V40, P977, DOI 10.1017/S0033291709991231; Scott KM, 2006, AUST NZ J
PSYCHIAT, V40, P875, DOI 10.1080/j.1440-1614.2006.01906.x; Slade T, 2013, EPIDEMIOL
PSYCHIAT S, V24, P45; Slade T, 2009, NATL SURVEY MENTAL H; Slade T, 2009, AUST NZ J
PSYCHIAT, V43, P594, DOI 10.1080/00048670902970882; Staiger PK, 2014, BMC
PSYCHIATRY, V14, DOI 10.1186/1471-244X-14-43; StataCorp, 2013, STATA STAT SOFTW
REL; STOCKWELL T, 1982, BRIT J ADDICT, V77, P65; Teesson M, 2005, AUST PSYCHOL,
V40, P81, DOI 10.1080/00050060500094605; TEESSON M, 2003, COMORBID MENTAL DISO;
Teesson M, 2012, AUST NZ J PSYCHIAT, V46, P1182, DOI 10.1177/0004867412460591;
Teesson M, 2010, ADDICTION, V105, P2085, DOI 10.1111/j.1360-0443.2010.03096.x;
Teesson M, 2009, AUST NZ J PSYCHIAT, V43, P606, DOI 10.1080/00048670902970908;
Tiller JWG, 2013, MED J AUSTRALIA, V199, P28, DOI 10.5694/mjao12.10628; van Dam D,
2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-172; Wilcox HC, 2004, DRUG
ALCOHOL DEPEN, V76, pS11, DOI 10.1016/j.drugalcdep.2004.08.003 61 7 7
0 5 WILEY HOBOKEN 111 RIVER ST, HOBOKEN 07030-5774, NJ USA 0959-
5236 1465-3362 DRUG ALCOHOL REV Drug Alcohol Rev. MAY 2017 36 3
317 324 10.1111/dar.12419 8
Substance Abuse Substance Abuse EU7TV WOS:000401238500006 27324816
2019-09-25
J Smith, LL; Yan, FX; Charles, M; Mohiuddin, K; Tyus, D; Adekeye, O; Holden, KB
Smith, L. Lerissa; Yan, Fengxia; Charles, Mikayla;
Mohiuddin, Kamal; Tyus, Dawn; Adekeye, Oluwatoyosi; Holden, Kisha B.
Exploring the Link Between Substance Use and Mental Health Status: What Can
We Learn from the Self-medication Theory? JOURNAL OF HEALTH CARE FOR THE POOR AND
UNDERSERVED English Article Co-
occurring disorder; self-medication; unmet need; mental health; mental health care;
substance use; marijuana; illicit drugs; alcohol GENERAL-POPULATION; USE
DISORDERS; ILLNESS; HYPOTHESIS; HEROIN The high rate of co-occurring mental
health issues and substance-use disorders has been well documented. The primary
objective of this research was to evaluate the association between use of alcohol,
marijuana, and other illicit drugs, and unmet mental health need and service use. A
secondary aim of this research was to determine if the observed patterns of
alcohol, marijuana, and other illicit drugs use and unmet mental health need and
mental health service use are consistent with a theory of self-medication theory.
On the latter view, people use psychoactive substances as a self-regulation
strategy to alleviate distress. Research was conducted through secondary analysis
of 2014 National Survey on Drug Use and Health (NSDUH) data. Overall, study
findings supported the established correlation between mental health issues and
substance use as well as a theory of self-medication. This study focused on people
18-25 years of age. [Smith, L. Lerissa; Tyus, Dawn] Morehouse Sch Med,
Southeast Addict Technol Transfer Ctr, Natl Ctr Primary Care, 720 Westview Dr
SW,NCPC 236, Atlanta, GA 30310 USA; [Yan, Fengxia; Adekeye, Oluwatoyosi; Holden,
Kisha B.] Morehouse Sch Med, Dept Community Hlth & Prevent Med, Atlanta, GA 30310
USA; [Charles, Mikayla] Morehouse Sch Med, Primary Res Ctr, Atlanta, GA 30310 USA;
[Mohiuddin, Kamal] Jackson Pk Hosp, Dept Family Med, Chicago, IL USA; [Holden,
Kisha B.] Morehouse Sch Med, Satcher Hlth Leadership Inst, Atlanta, GA 30310 USA;
[Holden, Kisha B.] Morehouse Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA 30310
USA Smith, LL (reprint author), Morehouse Sch Med, Southeast Addict Technol
Transfer Ctr, Natl Ctr Primary Care, 720 Westview Dr SW,NCPC 236, Atlanta, GA 30310
USA. American Psychiatric Association, 2013, DIAGN
STAT MAN MENT; [Anonymous], 2016, SAS SOFTW VERS 9 3 L; Duncan D., 1982, DRUGS
WHOLE PERSON; Duncan D. F., 1974, CLIN TOXICOLOGY B, V4, P69; DUNCAN DF, 1974, AM J
PSYCHIAT, V131, P724; DUNCAN DF, 1994, J DRUG EDUC, V24, P281, DOI 10.2190/087G-
B4ET-08JY-T08Y; Fenichel O., 1995, PSYCHIOANALYTIC THEO; Frances RJ, 1997, HARVARD
REV PSYCHIAT, V4, P287, DOI 10.3109/10673229709030556; GLOVER E, 1956, EARLY DEV
MIND; Gold R. S., 1983, B SOC PSYCHOL ADDICT, V2, P143; Kessler RC, 2003, ARCH GEN
PSYCHIAT, V60, P184, DOI 10.1001/archpsyc.60.2.184; Kessler RC, 2002, PSYCHOL MED,
V32, P959, DOI 10.1017/S0033291702006074; Kessler RC, 2010, INT J METH PSYCH RES,
V19, P4, DOI 10.1002/mpr.310; Khantzian E J, 1990, Recent Dev Alcohol, V8, P255;
KHANTZIAN E J, 1977, National Institute on Drug Abuse Research Monograph, V12,
P101; Khantzian E. J., 1999, TREATING ADDICTION H; Khantzian E. J., 1975,
PSYCHIATRY DIGEST, V36, P19; KHANTZIAN EJ, 1974, AM J PSYCHIAT, V131, P160, DOI
10.1176/ajp.131.2.160; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI
10.3109/10673229709030550; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259; National
Institute of Mental Health, 2014, AN MENT ILLN AM US; National Institute of Mental
Health, 2005, MENT ILL EX HEAV TOO; National Institute on Drug Abuse, 2010, COM ADD
OTH MENT ILL; NATIONAL INSTITUTE ON DRUG ABUSE, 2014, DRUGS BRAINS BEH SCI;
Protester MA, 2016, J SUBST ABUSE TREAT, V61, P47; Radhakrishnan R, 2014, FRONT
PSYCHIATRY, V5, DOI 10.3389/fpsyt.2014.00054; Rado S., 1984, J SUBST ABUSE TREAT,
V1, P59; ROSENFELD H, 1965, PSYCHOTIC STATES; Saffer H, 2002, WORKING PAPER MENTAL;
Satcher D., 2016, J CLIN PSYCHOL MED S; Substance Abuse and Mental Health Services
Administration, 2016, COOCC DIS; Substance Abuse and Mental Health Services
Administration, 2015, BEH HLTH TRENDS US R; Substance Abuse and Mental Health
Services Administration, 2015, RAC ETHN DIFF MENT H; Substance Abuse and Mental
Health Services Administration, 2015, NAT SURV DRUG US HLT; U. S. Department of
Health and Human Services, 2010, AB HLTH PEOPL; U. S. Department of Health and
Human Services, 2010, HLTH PEOPL 2010 MENT; U.S. Department of Health & Human
Service, 2013, HLTH CARE; U. S. Department of Health & Human Services, 2016, SURG
GEN PRIOR; Vinson ES, 2016, J NERV MENT DIS, V204, P400, DOI
10.1097/NMD.0000000000000458; Volkow ND, 2009, SCHIZOPHRENIA BULL, V35, P469, DOI
10.1093/schbul/sbp016; World Health Organization, 2016, MENT HLTH STRENGTH O 41
2 2 1 6 JOHNS HOPKINS UNIV PRESS BALTIMORE JOURNALS
PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD 21218-4363 USA 1049-
2089 1548-6869 J HEALTH CARE POOR U J. Health Care Poor Underserved
MAY 2017 28 2 S 113 131
10.1353/hpu.2017.0056 19 Health Policy & Services; Public,
Environmental & Occupational Health Health Care Sciences & Services; Public,
Environmental & Occupational Health EU5NQ WOS:000401079400012 28458268
2019-09-25
J Odell, AP; Reynolds, GL; Fisher, DG; Huckabay, LM; Pedersen, WC; Xandre, P;
Miocevic, M Odell, Annie P.; Reynolds, Grace L.; Fisher, Dennis
G.; Huckabay, Loucine M.; Pedersen, William C.; Xandre, Pamela; Miocevic, Milica
Attention Deficit Hyperactivity Disorder, Aggression, and Illicit
Stimulant Use Is This Self-Medication? JOURNAL OF NERVOUS AND MENTAL DISEASE
English Article ADHD; aggression;
self-medication; crack; amphetamine SUBSTANCE USE DISORDERS; DEFICIT/HYPERACTIVITY
DISORDER; DISPLACED AGGRESSION; ADHD SYMPTOMS; DRUG; RELIABILITY; ABUSE;
IMPULSIVITY; DEPENDENCE; MAINTENANCE This study compares adults with and
without attention deficit hyperactivity disorder (ADHD) on measures of direct and
displaced aggression and illicit drug use. Three hundred ninety-six adults were
administered the Wender Utah Rating Scale, the Risk Behavior Assessment, the
Aggression Questionnaire (AQ), and the Displaced Aggression Questionnaire (DAQ).
Those with ADHD were higher on all scales of the AQ and DAQ, were younger at first
use of amphetamines, and were more likely to have ever used crack and amphetamines.
A Structural Equation Model found a significant interaction in that for those with
medium and high levels of verbal aggression, ADHD predicts crack and amphetamine.
Follow-up logistic regression models suggest that blacks self-medicate with crack
and whites and Hispanics self-medicate with amphetamine when they have ADHD and
verbal aggression. [Odell, Annie P.; Huckabay, Loucine M.; Xandre, Pamela]
Calif State Univ Long Beach, Sch Nursing, 1250 Bellflower Blvd, Long Beach, CA
90840 USA; [Reynolds, Grace L.; Fisher, Dennis G.] Calif State Univ Long Beach, Ctr
Behav Res & Serv, 1250 Bellflower Blvd, Long Beach, CA 90840 USA; [Fisher, Dennis
G.; Pedersen, William C.] Calif State Univ Long Beach, Dept Psychol, 1250
Bellflower Blvd, Long Beach, CA 90840 USA; [Miocevic, Milica] Arizona State Univ,
Dept Psychol, Tempe, AZ 85287 USA Fisher, DG (reprint author), Calif State Univ
Long Beach, Dept Psychol, 1250 Bellflower Blvd, Long Beach, CA 90840 USA.
Dennis.Fisher@csulb.edu Fisher, Dennis/N-1049-2019 Fisher, Dennis/0000-
0002-3813-2207 National Institute on Drug Abuse (NIDA)United States Department
of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National
Institute on Drug Abuse (NIDA) [R01DA030234]; National Institute of Minority Health
and Health Disparities (NIMHD) [P20MD003942]; California HIV Research Program
(CHRP) [ID10-CSULB-008] The project described was supported in part by award
numbers R01DA030234 from the National Institute on Drug Abuse (NIDA), P20MD003942
from the National Institute of Minority Health and Health Disparities (NIMHD), and
ID10-CSULB-008 from the California HIV Research Program (CHRP). The content is
solely the responsibility of the authors and does not necessarily represent the
official views of the National Institute on Drug Abuse, the National Institute of
Minority Health and Health Disparities, the National Institutes of Health, or the
California HIV Research Program. The NIDA, NIMHD, and CHRP had no role in the study
design, collection, analysis or interpretation of the data, writing of the
manuscript, or the decision to submit the article for publication. American
Psychiatric Association, 2013, DIAGN STAT MAN MENT, P280, DOI
[10.1176/appi.books.9780890425596.744053, DOI
10.1176/APPI.BOOKS.9780890425596.744053]; Bacskai E, 2012, PSYCHIAT RES, V200,
P719, DOI 10.1016/j.psychres.2012.06.005; Barkley RA, 2004, J CHILD PSYCHOL PSYC,
V45, P195, DOI 10.1111/j.1469-7610.2004.00214.x; BIEDERMAN J, 1995, AM J PSYCHIAT,
V152, P1652; Biederman J, 2005, BIOL PSYCHIAT, V57, P1215, DOI
10.1016/j.biopsych.2004.10.020; Biederman J, 1998, BIOL PSYCHIAT, V44, P269, DOI
10.1016/S0006-3223(97)00406-X; Bushman BJ, 1998, J APPL PSYCHOL, V83, P969, DOI
10.1037/0021-9010.83.6.969; BUSS AH, 1992, J PERS SOC PSYCHOL, V63, P452, DOI
10.1037/0022-3514.63.3.452; BUSS AH, 1957, J CONSULT PSYCHOL, V21, P343, DOI
10.1037/h0046900; Caci H, 2008, EUR PSYCHIAT, V23, pS367; Carlotta D, 2013, COMPR
PSYCHIAT, V54, P943, DOI 10.1016/j.comppsych.2013.03.025; CARROLL KM, 1993, COMPR
PSYCHIAT, V34, P75, DOI 10.1016/0010-440X(93)90050-E; Cicchetti D., 1994, PSYCHOL
ASSESSMENTS, V6, P284, DOI [10.1037/1040-3590.6.4.284, DOI 10.1037/1040-
3590.6.4.284]; CRONBACH LJ, 1951, PSYCHOMETRIKA, V16, P297; Dakwar E, 2012, J CLIN
PSYCHIAT, V73, P960, DOI [10.4088/JCP.11m07484, 10.4088/JCP.12m07895]; Denson TF,
2006, J PERS SOC PSYCHOL, V90, P1032, DOI 10.1037/0022-3514.90.6.1032; Denson TF,
2008, PERSONALITY PERSPECT; DOWLINGGUYER S, 1994, ASSESSMENT, V0001; Downey KK,
1997, J NERV MENT DIS, V185, P32, DOI 10.1097/00005053-199701000-00006; DUNCAN DF,
1974, AM J PSYCHIAT, V131, P724; DUNCAN DF, 1975, J PSYCHEDEL DRUG, V7, P209, DOI
10.1080/02791072.1975.10472000; Edwards JW, 2007, J SUBST ABUSE TREAT, V33, P7, DOI
10.1016/j.jsat.2006.11.007; Evren C, 2013, COMPR PSYCHIAT, V54, P158, DOI
10.1016/j.comppsych.2012.06.013; Falck RS, 2008, DRUG ALCOHOL DEPEN, V98, P24, DOI
10.1016/j.drugalcdep.2008.04.004; Fisher DG, 2007, SEX TRANSM DIS, V34, P389;
Freeman TW, 2001, J NERV MENT DIS, V189, P317, DOI 10.1097/00005053-200105000-
00008; Garcia-Leon A, 2002, SPAN J PSYCHOL, V5, P45, DOI 10.1017/S1138741600005825;
Giancola PR, 2002, J STUD ALCOHOL, V63, P696, DOI 10.15288/jsa.2002.63.696;
Giotakos O, 2005, J FORENSIC PSYCHI PS, V16, P423, DOI
10.1080/14789940412331337371; GITTELMAN R, 1985, ARCH GEN PSYCHIAT, V42, P937;
Gudjonsson GH, 2012, J CHILD PSYCHOL PSYC, V53, P304, DOI 10.1111/j.1469-
7610.2011.02489.x; HOSMER DW, 1980, COMMUN STAT A-THEOR, V9, P1043, DOI
10.1080/03610928008827941; Hosmer DW, 2013, WILEY SERIES PROBABI, P500; Huesmann L
Rowell, 2002, Crim Behav Ment Health, V12, P185, DOI 10.1002/cbm.496; HUESMANN LR,
1984, DEV PSYCHOL, V20, P1120, DOI 10.1037/0012-1649.20.6.1120; Jaffe Adi, 2009,
Open Addict J, V2, P39; Jaffe C, 2005, J ADDICT DIS, V24, P133, DOI
10.1300/J069v24n03_11; Byrne M, 2015, PSYCHIAT PSYCHOL LAW, V22, P407, DOI
10.1080/13218719.2014.960027; Khantzian E. J., 2003, PRIMARY PSYCHIAT, V10, p[47,
53]; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI
10.3109/10673229709030550; Marcus-Newhall A, 2000, J PERS SOC PSYCHOL, V78, P670,
DOI 10.1037//0022-3514.78.4.670; Mariani JJ, 2014, AM J ADDICTION, V23, P189, DOI
10.1111/j.1521-0391.2013.12086.x; Miguel CS, 2016, DRUG ALCOHOL DEPEN, V160, P97,
DOI 10.1016/j.drugalcdep.2015.12.040; Molina BSG, 2003, J ABNORM PSYCHOL, V112,
P497, DOI 10.1037/0021-843X.112.3.497; Muthen L. K., 1998, MPLUS USERS GUIDE;
Napper LE, 2010, ADDICT BEHAV, V35, P350, DOI 10.1016/j.addbeh.2009.12.006; NEEDLE
R, 1995, PSYCHOL ADDICT BEHAV, V9, P242, DOI 10.1037/0893-164X.9.4.242; Obermeit
LC, 2013, ADDICT BEHAV, V38, P2874, DOI 10.1016/j.addbeh.2013.08.010; Pedersen WC,
2000, J PERS SOC PSYCHOL, V78, P913, DOI 10.1037/0022-3514.78.5.913; Peles E, 2015,
J SUBST ABUSE TREAT, V54, P44, DOI 10.1016/j.jsat.2014.12.010; Rabiner DL, 2009, J
ATTEN DISORD, V13, P259, DOI 10.1177/1087054708320399; Ramirez CA, 1997, J ATTEN
DISORD, V2, P115, DOI DOI 10.1177/108705479700200205; Retz-Junginger P, 2007,
NERVENARZT, V78, P1046, DOI 10.1007/s00115-006-2242-4; Richards Tracy L, 2006, J
Atten Disord, V10, P54, DOI 10.1177/1087054705284244; Roozen HG, 2011, J SUBST
ABUSE TREAT, V40, P414, DOI 10.1016/j.jsat.2010.12.003; Roux P, 2016, HARM REDUCT
J, V13, DOI 10.1186/s12954-016-0100-7; Taylor A, 2011, RES DEV DISABIL, V32, P924,
DOI 10.1016/j.ridd.2010.12.036; Van Meer R, 2014, AUST NZ J PSYCHIAT, V48, P95, DOI
10.1177/0004867413492221; WARD MF, 1993, AM J PSYCHIAT, V150, P885; Wilens TE,
1997, J NERV MENT DIS, V185, P475, DOI 10.1097/00005053-199708000-00001; Wilens TE,
2007, AM J ADDICTION, V16, P14, DOI 10.1080/10550490601082742 61 2 2
1 4 LIPPINCOTT WILLIAMS & WILKINS PHILADELPHIA TWO COMMERCE SQ,
2001 MARKET ST, PHILADELPHIA, PA 19103 USA 0022-3018 1539-736X J NERV
MENT DIS J. Nerv. Ment. Dis. MAY 2017 205 5
372 379 10.1097/NMD.0000000000000668 8 Clinical
Neurology; Psychiatry Neurosciences & Neurology; Psychiatry ES8YU
WOS:000399843600006 28230564 Green Accepted 2019-09-25
J Read, JP; Radomski, S; Wardell, JD Read, Jennifer P.;
Radomski, Sharon; Wardell, Jeffrey D. Posttraumatic Stress and
Problem Drinking at the Transition Out of College PREVENTION SCIENCE
English Article Trauma; Posttraumatic
stress; Alcohol; College students; Transition from college; Maturing out
ALCOHOL-RELATED PROBLEMS; SELF-MEDICATION; PRELIMINARY VALIDATION; EMOTION
DYSREGULATION; NATIONAL SAMPLE; PTSD SYMPTOMS; RISK DRINKING; MENTAL-HEALTH;
SUBSTANCE USE; LIFE EVENTS The objective of the present study was to examine how
symptoms of posttraumatic stress disorder (PTSD) may confer drinking risk as
students with trauma histories complete college and move toward independent
adulthood. Students (N = 283) completed assessments of trauma, posttraumatic
stress, and alcohol use and consequences at four time points during the year
following their fourth year of college. Some students had transitioned out of the
college environment, whereas others had not. We examined how transition status
moderated within-person associations between changes in PTSD and corresponding
changes in alcohol outcomes over time. Using multilevel modeling, we examined
differences in within-person PTSD-alcohol associations comparing students who were
(1) continuing as fifth-year seniors, (2) graduated and pursuing graduate
education, and (3) graduated and left the university setting. Alcohol use and
consequences tended to decline on average from the fourth to fifth year post-
matriculation. Yet, within-person increases in posttraumatic stress symptomatology
across the fifth year were associated with greater alcohol consequences, but only
for those students who had left the university setting. These data suggest that the
transition out of college may be an important developmental context that is
associated with increased vulnerability for negative consequences from stress-
related drinking. Findings may have important implications for campus-based
prevention efforts geared toward the facilitation of a successful transition into
independent adulthood. [Read, Jennifer P.; Radomski, Sharon] SUNY Buffalo, Dept
Psychol, Buffalo, NY 14260 USA; [Wardell, Jeffrey D.] Campbell Family Mental Hlth
Res Inst, Ctr Addict & Mental Hlth, Toronto, ON, Canada Read, JP (reprint
author), SUNY Buffalo, Dept Psychol, Buffalo, NY 14260 USA.jpread@buffalo.edu
Wardell, Jeffrey/0000-0001-9792-280X National Institute on Drug
AbuseUnited States Department of Health & Human ServicesNational Institutes of
Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01DA018993] This
paper is an original empirical study, funded by the National Institute on Drug
Abuse (R01DA018993: Read, PI). Aiken LS, 1991, MULTIPLE REGRESSION; American
Psychiatric Association, 2000, DIAGN STAT MAN MENT; Armour C, 2015, J PSYCHIATR
RES, V61, P106, DOI 10.1016/j.jpsychires.2014.10.012; Arnett JJ, 2005, J DRUG
ISSUES, V35, P235, DOI 10.1177/002204260503500202; Arnett JJ, 2000, AM PSYCHOL,
V55, P469, DOI 10.1037/0003-066X.55.5.469; Bailey K.M., 2014, TRAUMA SUBSTANCE ABU,
P11; Barnett NP, 2014, J STUD ALCOHOL DRUGS, V75, P103, DOI
10.15288/jsad.2014.75.103; Beiter R, 2015, J AFFECT DISORDERS, V173, P90, DOI
10.1016/j.jad.2014.10.054; Bisby JA, 2009, PSYCHOPHARMACOLOGY, V204, P655, DOI
10.1007/s00213-009-1496-5; Blanchard EB, 1998, J ANXIETY DISORD, V12, P21, DOI
10.1016/S0887-6185(97)00047-9; Blanco C, 2008, ARCH GEN PSYCHIAT, V65, P1429, DOI
10.1001/archpsyc.65.12.1429; Borsari B, 2007, ADDICT BEHAV, V32, P2062, DOI
10.1016/j.addbeh.2007.01.017; Bremner JD, 1996, AM J PSYCHIAT, V153, P369; Breslau
N, 2013, PSYCHOL MED, V43, P1697, DOI 10.1017/S0033291712002632; Briere J, 1987, J
INTERPERS VIOLENCE, V2, P367, DOI DOI 10.1177/088626058700200403; BRONFENBRENNER U,
1979, AM PSYCHOL, V34, P844, DOI 10.1037/0003-066X.34.10.844; Chassin L, 2013, DEV
PSYCHOPATHOL, V25, P1567, DOI 10.1017/S0954579413000771; Colder CR, 2001, PSYCHOL
ADDICT BEHAV, V15, P237, DOI 10.1037/0893-164X.15.3.237; COOPER ML, 1995, J PERS
SOC PSYCHOL, V69, P990, DOI 10.1037/0022-3514.69.5.990; Curran PJ, 2011, ANNU REV
PSYCHOL, V62, P583, DOI 10.1146/annurev.psych.093008.100356; Eisenberg D, 2011, J
AM COLL HEALTH, V59, P700, DOI 10.1080/07448481.2010.546461; Elder GH, 1998, CHILD
DEV, V69, P1, DOI 10.2307/1132065; Ford JD, 2010, J ADOLESCENT HEALTH, V46, P545,
DOI 10.1016/j.jadohealth.2009.11.212; Fromme K, 2008, DEV PSYCHOL, V44, P1497, DOI
10.1037/a0012614; Galambos NL, 2009, J RES ADOLESCENCE, V19, P741, DOI
10.1111/j.1532-7795.2009.00618.x; Gottfredson NC, 2013, J STUD ALCOHOL DRUGS, V74,
P576, DOI 10.15288/jsad.2013.74.576; Hussong AM, 2008, J STUD ALCOHOL DRUGS, V69,
P296, DOI 10.15288/jsad.2008.69.296; IBM Corp, 2012, IBM SPSS STAT WIND V; John O.
P, 1999, HDB PERSONALITY THEO, P102, DOI DOI 10.1525/FQ.1998.51.4.04A00260;
Johnston L.D., 2012, MONITORING FUTURE NA, V2; Kaltman S, 2005, J TRAUMA STRESS,
V18, P547, DOI 10.1002/jts.20063; Kaysen D, 2014, PSYCHOL ADDICT BEHAV, V28, P62,
DOI 10.1037/a0033588; Ketoja J, 2013, ADDICT BEHAV, V38, P2115, DOI
10.1016/j.addbeh.2013.01.016; Khantzian E.J., 2003, PRIMARY PSYCHIAT, V10, P53;
Kubany ES, 2000, PSYCHOL ASSESSMENT, V12, P210, DOI 10.1037//1040-3590.12.2.210;
Larimer ME, 2007, J CONSULT CLIN PSYCH, V75, P285, DOI 10.1037/0022-006X.75.2.285;
Lee MR, 2013, DEV PSYCHOPATHOL, V25, P1137, DOI 10.1017/S0954579413000424; LERNER
RM, 1982, DEV REV, V2, P342, DOI 10.1016/0273-2297(82)90018-1; Littlefield AK,
2009, J ABNORM PSYCHOL, V118, P360, DOI 10.1037/a0015125; Martens MP, 2008, J STUD
ALCOHOL DRUGS, V69, P412, DOI 10.15288/jsad.2008.69.412; Martens MP, 2007, ADDICT
BEHAV, V32, P2563, DOI 10.1016/j.addbeh.2007.05.005; McDevitt-Murphy ME, 2007,
ASSESSMENT, V14, P181, DOI 10.1177/1073191106295914; Menary KR, 2015, ALCOHOL CLIN
EXP RES, V39, P1267, DOI 10.1111/acer.12762; Najdowski CJ, 2009, ADDICT BEHAV, V34,
P965, DOI 10.1016/j.addbeh.2009.05.004; Osgood D. W., 2005, YOUR OWN NET TRANSIT;
Read JP, 2014, AM J ADDICTION, V23, P108, DOI 10.1111/j.1521-0391.2013.12075.x;
Read JP, 2013, J ABNORM PSYCHOL, V122, P984, DOI 10.1037/a0034918; Read JP, 2012, J
CONSULT CLIN PSYCH, V80, P426, DOI 10.1037/a0028210; Read JP, 2011, PSYCHOL TRAUMA-
US, V3, P148, DOI 10.1037/a0021260; Read JP, 2006, J STUD ALCOHOL, V67, P169, DOI
10.15288/jsa.2006.67.169; Read JP, 2004, ADDICT BEHAV, V29, P1665, DOI
10.1016/j.addbeh.2004.02.061; Roodman AA, 2001, CLIN PSYCHOL REV, V21, P183, DOI
10.1016/S0272-7358(99)00045-8; Schulenberg JE, 2004, DEV PSYCHOPATHOL, V16, P1119,
DOI 10.1017/S0954579404040167; Settersten R. A., 2007, RES HUMAN DEV, V4, P239, DOI
DOI 10.1080/15427600701663098; Shah AA, 2009, SUBST ABUS, V30, P141, DOI
10.1080/08897070902802067; Simms LJ, 2002, J ABNORM PSYCHOL, V111, P637, DOI
10.1037//0021-843X.111.4.637; Simons JS, 2005, J STUD ALCOHOL, V66, P459, DOI
10.15288/jsa.2005.66.459; Simpson TL, 2014, J ABNORM PSYCHOL, V123, P237, DOI
10.1037/a0035193; Smyth JM, 2008, J AM COLL HEALTH, V57, P69, DOI
10.3200/JACH.57.1.69-76; U.S. Department of Education National Center for Education
Statistics, 2015, DIG ED STAT, V2013; Valdez CE, 2014, CHILD MALTREATMENT, V19,
P209, DOI 10.1177/1077559514551945; Wardell JD, 2013, ADDICT BEHAV, V38, P2772, DOI
10.1016/j.addbeh.2013.07.012; Weathers FW, 1993, ANN CONV INT SOC TRA, V462; Weiss
NH, 2013, DRUG ALCOHOL DEPEN, V128, P45, DOI 10.1016/j.drugalcdep.2012.07.017; Wood
MD, 2001, J STUD ALCOHOL, V62, P32, DOI 10.15288/jsa.2001.62.32; Zayfert C., 2012,
RETRAUMATIZATION ASS, P9; Zlotnick C, 1999, J TRAUMA STRESS, V12, P89, DOI
10.1023/A:1024746316245 67 1 1 0 0 SPRINGER/PLENUM PUBLISHERS
NEW YORK 233 SPRING ST, NEW YORK, NY 10013 USA 1389-4986 1573-6695
PREV SCI Prev. Sci. MAY 2017 18 4 440
449 10.1007/s11121-017-0778-0 10 Public,
Environmental & Occupational Health Public, Environmental & Occupational Health
ET2FA WOS:000400083600008 28378102 Green Accepted 2019-
09-25
J Hruska, B; Pacella, ML; George, RL; Delahanty, DL
Hruska, Bryce; Pacella, Maria L.; George, Richard L.; Delahanty, Douglas L.
The Association Between Daily PTSD Symptom Severity and Alcohol-Related
Outcomes in Recent Traumatic Injury Victims PSYCHOLOGY OF ADDICTIVE BEHAVIORS
English Article traumatic injury;
experience sampling; posttraumatic stress disorder; alcoholPOSTTRAUMATIC-STRESS-
DISORDER; FUNCTIONAL OUTCOMES; DRINKING; US; HOSPITALIZATION; COMORBIDITY;
DEPRESSION; DEPENDENCE; INFERENCE; MEDIATOR The self-medication hypothesis
proposes that individuals experiencing posttraumatic stress disorder (PTSD)
symptoms may use alcohol (or other substances) to self-medicate distress, while the
mutual maintenance hypothesis proposes that alcohol use also exacerbates or
maintains distress. Existing research largely supports the self-medication
hypothesis. However, findings are often based upon retrospective reporting of
problems and assessment of symptoms anchored to a trauma occurring in the remote
past. To improve on these retrospective designs, the current study examined the
relationship between daily PTSD symptom severity and alcohol-related outcomes
during the early phase of recovery following a traumatic physical injury.
Specifically, 36 injury victims reported on PTSD symptom severity, alcohol craving,
alcohol consumption, and negative drinking consequences thrice daily (morning,
afternoon, night) over 7 days beginning 6 weeks postinjury. Results indicated
relationships between PTSD symptom severity and alcohol craving/negative
consequences when these experiences were assessed concurrently within the same
signal (particularly during the nighttime assessments). Prospective models found
that nighttime PTSD symptom severity was related to negative drinking consequences
occurring the following morning, even after controlling for consumption level,
suggesting a more general behavioral regulation problem. Results were less
supportive of the mutual maintenance hypothesis. Collectively, these results
suggest that health interventions targeting PTSD symptom severity in recent injury
victims-particularly when delivered at night-may be able to prevent problematic
alcohol use. [Hruska, Bryce; Pacella, Maria L.; Delahanty, Douglas L.] Kent
State Univ, Dept Psychol Sci, 118 Kent Hall, Kent, OH 44242 USA; [George, Richard
L.] Northeastern Ohio Med Univ, Dept Gen Surg, Rootstown, OH USA; [George, Richard
L.] Summa Hlth Syst, Div Trauma Serv, Dept Surg, Akron, OH USA; [Delahanty, Douglas
L.] Northeastern Ohio Med Univ, Dept Psychiat, Rootstown, OH USA; [Hruska, Bryce]
Syracuse Univ, Dept Publ Hlth, David B Falk Coll Sport & Human Dynam, Syracuse, NY
USA; [Pacella, Maria L.] Univ Pittsburgh, Dept Emergency Med, Pittsburgh, PA USA
Delahanty, DL (reprint author), Kent State Univ, Dept Psychol Sci, 118 Kent
Hall, Kent, OH 44242 USA. ddelahan@kent.edu Hruska, Bryce/0000-0002-8651-
5827 American Psychiatric Association, 2000, DIAGN STAT MAN MENT;
Anderson CJ, 2010, APPL GEN LINEAR MIXE; Babor T. F., 2001, ALCOHOL USE DISORDER;
BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Baker
TB, 2004, PSYCHOL REV, V111, P33, DOI 10.1037/0033-295X.111.1.33; BLAKE DD, 1995, J
TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Blanco C, 2013, DRUG ALCOHOL DEPEN,
V132, P630, DOI 10.1016/j.drugalcdep.2013.04.016; BOHN MJ, 1995, ALCOHOL CLIN EXP
RES, V19, P600, DOI 10.1111/j.1530-0277.1995.tb01554.x; Bremner JD, 1996, AM J
PSYCHIAT, V153, P369; Coffey SF, 2010, EXP CLIN PSYCHOPHARM, V18, P340, DOI
10.1037/a0019790; Cumming G, 2014, PSYCHOL SCI, V25, P7, DOI
10.1177/0956797613504966; Cumming G, 2007, TEACH STAT, V29, P89, DOI
10.1111/j.1467-9639.2007.00267.x; Dawson DA, 1996, ADDICTION, V91, P1623; Enders
CK, 2007, PSYCHOL METHODS, V12, P121, DOI 10.1037/1082-989X.12.2.121; Epstein JN,
1998, CHILD ABUSE NEGLECT, V22, P223, DOI 10.1016/S0145-2134(97)00133-6; Fisher CD,
2012, J ORGAN BEHAV, V33, P865, DOI 10.1002/job.1803; Flood AM, 2009, J BEHAV MED,
V32, P234, DOI 10.1007/s10865-008-9195-y; Gaher RM, 2014, PSYCHOL ADDICT BEHAV,
V28, P1013, DOI 10.1037/a0037257; Gustafson DH, 2011, SUBST USE MISUSE, V46, P96,
DOI 10.3109/10826084.2011.521413; Haller M, 2014, PSYCHOL ADDICT BEHAV, V28, P841,
DOI 10.1037/a0035878; Hilbe J. M., 2014, MODELING COUNT DATA; Hruska B., 2014,
TRAUMA SUBSTANCE ABU, P35; Hruska B, 2012, PSYCHOL ADDICT BEHAV, V26, P734, DOI
10.1037/a0027584; Kanny Dafna, 2012, Morbidity and Mortality Weekly Report, V61,
P14; Kaysen D, 2006, J TRAUMA STRESS, V19, P399, DOI 10.1002/jts.20122; Khantzian
E. J., 2003, PRIMARY PSYCHIAT, V10, p[47, 53]; Kuhn E, 2014, ADM POLICY MENT HLTH,
V41, P800, DOI 10.1007/s10488-013-0532-2; Lang AJ, 2005, BEHAV RES THER, V43, P585,
DOI 10.1016/j.brat.2004.04.005; Leeies M, 2010, DEPRESS ANXIETY, V27, P731, DOI
10.1002/da.20677; Miller W. R., 1995, NIH PUBLICATION, V95-3911; Miner A, 2016,
PSYCHOL TRAUMA-US, V8, P384, DOI 10.1037/tra0000092; Muench F, 2014, J MED INTERNET
RES, V16, DOI 10.2196/jmir.2945; National Center for PTSD, 2014, US PTSD CHECKL DSM
4; Neal DJ, 2007, PSYCHOL ADDICT BEHAV, V21, P441, DOI 10.1037/0893-164X.21.4.441;
Nickerson A, 2014, J ABNORM PSYCHOL, V123, P821, DOI 10.1037/a0037920; Nosen E,
2014, BEHAV RES THER, V61, P35, DOI 10.1016/j.brat.2014.07.003; O'Donnell ML, 2004,
AM J PSYCHIAT, V161, P1390, DOI 10.1176/appi.ajp.161.8.1390; Ouimette P, 2006,
ADDICT BEHAV, V31, P1415, DOI 10.1016/j.addbeh.2005.11.010; Piasecki TM, 2010,
PSYCHOL ADDICT BEHAV, V24, P163, DOI 10.1037/a0017148; Pietrzak RH, 2011, J ANXIETY
DISORD, V25, P456, DOI 10.1016/j.janxdis.2010.11.010; Possemato K, 2015, PSYCHOL
ADDICT BEHAV, V29, P894, DOI 10.1037/adb0000129; Quanbeck A, 2014, ALCOHOL RES-CURR
REV, V36, P111; Reger GM, 2013, PSYCHOL SERV, V10, P342, DOI 10.1037/a0032774;
Riggs DS, 2003, ADDICT BEHAV, V28, P1717, DOI 10.1016/j.addbeh.2003.08.044; SALADIN
ME, 1995, ADDICT BEHAV, V20, P643, DOI 10.1016/0306-4603(95)00024-7; Scollon CN,
2009, SOC INDIC RES SER, V39, P157, DOI 10.1007/978-90-481-2354-4_8; Shih RA, 2010,
J TRAUMA, V69, P1560, DOI 10.1097/TA.0b013e3181e59c05; Simons JS, 2005, J STUD
ALCOHOL, V66, P459, DOI 10.15288/jsa.2005.66.459; Simpson TL, 2014, J ABNORM
PSYCHOL, V123, P237, DOI 10.1037/a0035193; Simpson TL, 2012, PSYCHOL ADDICT BEHAV,
V26, P724, DOI 10.1037/a0027169; Spiller SA, 2013, J MARKETING RES, V50, P277, DOI
10.1509/jmr.12.0420; StatCorp, 2013, STATA STAT SOFTW REL; Suffoletto B, 2012,
ALCOHOL CLIN EXP RES, V36, P552, DOI 10.1111/j.1530-0277.2011.01646.x; Todd M,
2005, J STUD ALCOHOL, V66, P121, DOI 10.15288/jsa.2005.66.121; Ullman Sarah E,
2006, Violence Vict, V21, P725, DOI 10.1891/vv-v21i6a004; Weathers F. W., 1993, 9
ANN C ISTSS SAN AN; Zatzick DF, 2002, ARCH SURG-CHICAGO, V137, P200, DOI
10.1001/archsurg.137.2.200; Zatzick DF, 2002, AM J PSYCHIAT, V159, P941, DOI
10.1176/appi.ajp.159.6.941; Zatzick DF, 2000, J TRAUMA, V49, P487, DOI
10.1097/00005373-200009000-00017; Zatzick D, 2008, ANN SURG, V248, P429, DOI
10.1097/SLA.0b013e318185a6b8; Zatzick DF, 2007, PSYCHOL MED, V37, P1469, DOI
10.1017/S0033291707000943 61 5 5 0 3 EDUCATIONAL PUBLISHING
FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC WASHINGTON 750 FIRST ST, NE, WASHINGTON,
DC 20002-4242 USA 0893-164X 1939-1501 PSYCHOL ADDICT BEHAV Psychol.
Addict. Behav. MAY 2017 31 3 326 335
10.1037/adb0000262 10 Substance Abuse; Psychology,
Multidisciplinary Substance Abuse; Psychology EU2ZZ WOS:000400899700010
28263624 2019-09-25
J Agrawal, A; Tillman, R; Grucza, RA; Nelson, EC; McCutcheon, VV; Few, L;
Conner, KR; Lynskey, MT; Dick, DM; Edenberg, HJ; Hesselbrock, VM; Kramer, JR;
Kuperman, S; Nurnberger, JI; Schuckit, MA; Porjesz, B; Bucholz, KK
 Agrawal, Arpana; Tillman, Rebecca; Grucza, Richard A.; Nelson, Elliot C.;
McCutcheon, Vivia V.; Few, Lauren; Conner, Kenneth R.; Lynskey, Michael T.; Dick,
Danielle M.; Edenberg, Howard J.; Hesselbrock, Victor M.; Kramer, John R.;
Kuperman, Samuel; Nurnberger, John I., Jr.; Schuckit, Marc A.; Porjesz, Bernice;
Bucholz, Kathleen K. Reciprocal relationships between substance use
and disorders and suicidal ideation and suicide attempts in the Collaborative Study
of the Genetics of Alcoholism JOURNAL OF AFFECTIVE DISORDERS
English Article Cannabis; Alcohol;
Nicotine; Suicide; Ideation; Attempt; COGA NATIONAL COMORBIDITY SURVEY; RISK-
FACTORS; CANNABIS USE; MAJOR DEPRESSION; SELF-MEDICATION; PSYCHIATRIC-DISORDERS;
NICOTINE DEPENDENCE; INVOLVEMENT; PREVALENCE; SMOKING Background: Substance use and
misuse and suicidal thoughts and behaviors tend to co-occur. The purpose of this
study was to examine whether (a) suicidal ideation and attempt are related to onset
of alcohol, nicotine and cannabis use and dependence; (b) early use of alcohol,
nicotine and cannabis is associated with onset of suicidal ideation and attempt;
and (c) whether these associations persist while controlling for covariates, such
as family history of alcohol problems, major depression and other internalizing and
externalizing disorders. Methods: The prospective cohort of the Collaborative Study
of the Genetics of Alcoholism (COGA; N=3277) was used. Cross-sectional and discrete
time logistic regression (i.e. survival) analyses examined associations between
suicidal ideation and attempt and onset of alcohol, nicotine and cannabis use and
dependence. Survival models also examined whether individual early substance use
was related to onset of ideation and attempt. Results: Ideation was related to
0.71-0.77 odds of onset of subsequent alcohol, nicotine and cannabis use. Attempt
was associated with 1.44-1.61 odds of later alcohol, nicotine and cannabis
dependence, even after accounting for covariates. Evidence for early substance use
being related to subsequent onset of ideation or attempt was limited. Several sex
and race differences emerged. Limitations: The sample was ascertained for family
history of alcoholism; not all participants had been followed up allowing for
censored observations; reporting bias. Conclusion: Suicide attempts are associated
with increased likelihood of onset of substance dependence.[Agrawal, Arpana;
McCutcheon, Vivia V.; Conner, Kenneth R.; Hesselbrock, Victor M.; Schuckit, Marc
A.] Washington Univ, Dept Psychiat, Sch Med, St Louis, MO USA; [Lynskey, Michael
T.; Nurnberger, John I., Jr.] Univ Rochester, Dept Emergency Med, Med Ctr,
Rochester, NY USA; [Nelson, Elliot C.; Conner, Kenneth R.; Dick, Danielle M.] Kings
Coll London, Inst Psychiat, Dept Addict, London, England; [Agrawal, Arpana; Conner,
Kenneth R.; Edenberg, Howard J.; Schuckit, Marc A.] Virginia Commonwealth Univ,
Dept African Amer Studies, Richmond, VA USA; [Dick, Danielle M.; Porjesz, Bernice]
Indiana Univ, Dept Biochem & Mol Biol, Indianapolis, IN USA; [Dick, Danielle M.;
Schuckit, Marc A.] Univ Connecticut Hlth, Dept Psychiat, Farmington, CT USA;
[Kuperman, Samuel] Univ Iowa Carver Coll Med, Dept Psychiat Div Psychol, Iowa City,
IA USA; [Porjesz, Bernice] Univ Iowa Carver Coll Med, Depts Psychiat & Pediat, Iowa
City, IA USA; [Lynskey, Michael T.; Dick, Danielle M.; Porjesz, Bernice] Univ Iowa
Carver Coll Med, Depts Psychiat & Pediat, Iowa City, IA USA; [Kuperman, Samuel]
Indiana Univ Sch Med, Dept Psychiat, Indianapolis, IN USA; [Edenberg, Howard J.;
Schuckit, Marc A.] Univ Calif San Diego, Dept Psychiat, San Diego, CA USA; [Conner,
Kenneth R.; Hesselbrock, Victor M.; Nurnberger, John I., Jr.] SONY Downstate Med
Ctr, Dept Psychiat, Brooklyn, NY USA Agrawal, A (reprint author), Washington
Univ, Dept Psychiat, Sch Med, St Louis, MO USA. arpana@wustl.edu Lynskey, michael
T/B-9179-2016; McCutcheon, Vivia/J-1161-2019 McCutcheon, Vivia/0000-0002-2694-
5438; Kuperman, Samuel/0000-0002-5995-1981 National Institutes of HealthUnited
States Department of Health & Human ServicesNational Institutes of Health (NIH) -
USA; National Institute on Drug AbuseUnited States Department of Health & Human
ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug
Abuse (NIDA) [DA040411, K02DA032573]; NIH from the National Institute on Alcohol
Abuse and Alcoholism (NIAAA)United States Department of Health & Human
ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol
Abuse & Alcoholism (NIAAA) [U10AA008401]; National Institute on Drug Abuse
(NIDA)United States Department of Health & Human ServicesNational Institutes of
Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) This research is
supported by grants from the National Institutes of Health, including DA040411,
K02DA032573 from the National Institute on Drug Abuse to AA.; We continue to be
inspired by our memories of Henri Begleiter and Theodore Reich, founding PI and Co-
PI of COGA, and also owe a debt of gratitude to other past organizers of COGA,
including Ting-Kai Li, P. Michael Conneally, Raymond Crowe, and Wendy Reich, for
their critical contributions. This national collaborative study is supported by NIH
Grant U10AA008401 from the National Institute on Alcohol Abuse and Alcoholism
(NIAAA) and the National Institute on Drug Abuse (NIDA). American Psychiatric
Association, 1994, DIAGN STAT MAN MENT; Bagge CL, 2008, CLIN PSYCHOL REV, V28,
P1283, DOI 10.1016/j.cpr.2008.06.002; Begleiter H, 1995, ALCOHOL HEALTH RES W, V19,
P228; Berlin I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122607; Bolton JM,
2009, J AFFECT DISORDERS, V115, P367, DOI 10.1016/j.jad.2008.10.003; Borges G,
2016, J AFFECT DISORDERS, V195, P63, DOI 10.1016/j.jad.2016.02.007; Borges G, 2010,
J CLIN PSYCHIAT, V71, P1617, DOI 10.4088/JCP.08m04967blu; Borges G, 2010, CURR OPIN
PSYCHIATR, V23, P195, DOI 10.1097/YCO.0b013e3283386322; Brady KT, 2005, AM J
PSYCHIAT, V162, P1483, DOI 10.1176/appi.ajp.162.8.1483; Brady KT, 1999, PSYCHIAT
CLIN N AM, V22, P241, DOI 10.1016/S0193-953X(05)70074-5; Breslau N, 2004, BIOL
PSYCHIAT, V55, P69, DOI 10.1016/S0006-3223(03)00317-2; BRESLAU N, 1993, ARCH GEN
PSYCHIAT, V50, P31; Bucholz KK, 2017, ALCOHOL CLIN EXP RES, V41, P359, DOI
10.1111/acer.13293; BUCHOLZ KK, 1994, J STUD ALCOHOL, V55, P149, DOI
10.15288/jsa.1994.55.149; Conner KR, 2014, AM J PREV MED, V47, pS204, DOI
10.1016/j.amepre.2014.06.007; Conner KR, 2006, J STUD ALCOHOL, V67, P95, DOI
10.15288/jsa.2006.67.95; Covey LS, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-
000876; Crum RM, 2013, JAMA PSYCHIAT, V70, P718, DOI
10.1001/jamapsychiatry.2013.1098; Darvishi N, 2015, PLOS ONE, V10, DOI
10.1371/journal.pone.0126870; Dawes MA, 2008, SUBST ABUS-RES TREAT, V2; Delforterie
MJ, 2015, DRUG ALCOHOL DEPEN, V150, P98, DOI 10.1016/j.drugalcdep.2015.02.019;
Edwards AC, 2011, PSYCHOL MED, V41, P395, DOI 10.1017/S0033291710000589; Ellis J,
2016, PSYCHOL MED, P1; Esposito-Smythers C, 2004, ALCOHOL CLIN EXP RES, V28, p77S,
DOI 10.1097/01.ALC.0000127417.99752.87; Fergusson DM, 2013, DRUG ALCOHOL DEPEN,
V133, P513, DOI 10.1016/j.drugalcdep.2013.07.015; Hesselbrock M, 1999, ADDICTION,
V94, P1361, DOI 10.1046/j.1360-0443.1999.94913618.x; Hughes JR, 2008, DRUG ALCOHOL
DEPEN, V98, P169, DOI 10.1016/j.drugalcdep.2008.06.003; Hussong AM, 2011, PSYCHOL
ADDICT BEHAV, V25, P390, DOI 10.1037/a0024519; Johnston Lloyd D., 2016, MONITORING
FUTURE NA; KANDEL DB, 1991, J YOUTH ADOLESCENCE, V20, P289, DOI 10.1007/BF01537613;
KENDLER KS, 1993, ARCH GEN PSYCHIAT, V50, P690; Kessler RC, 1999, ARCH GEN
PSYCHIAT, V56, P617, DOI 10.1001/archpsyc.56.7.617; Kessler RC, 1997, ARCH GEN
PSYCHIAT, V54, P313; Kessler RC, 2004, INT J METH PSYCH RES, V13, P60, DOI
10.1002/mpr.166; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI
10.3109/10673229709030550; Kuperman S, 2013, PEDIATRICS, V131, P242, DOI
10.1542/peds.2012-0880; Lopez-Castrornan J, 2016, DRUG ALCOHOL DEPEN, V160, P177,
DOI 10.1016/j.drugalcdep.2016.01.004; Lucas M, 2013, J AFFECT DISORDERS, V151,
P1053, DOI 10.1016/j.jad.2013.08.033; Nock MK, 2008, BRIT J PSYCHIAT, V192, P98,
DOI 10.1192/bjp.bp.107.040113; Nock MK, 2016, CLIN PSYCHOL-SCI PR, V23, P31, DOI
10.1111/cpsp.12133; Palmer CS, 1995, CLIN NEUROPHARMACOL, V18, pS25, DOI
10.1097/00002826-199518003-00004; Poorolajal J, 2016, PLOS ONE, V11, DOI
10.1371/journal.pone.0156348; Price C, 2009, BRIT J PSYCHIAT, V195, P492, DOI
10.1192/bjp.bp.109.065227; Reich T, 1996, ALCOHOL CLIN EXP RES, V20, pA133, DOI
10.1111/j.1530-0277.1996.tb01763.x; Rimkeviciene J, 2015, J AFFECT DISORDERS, V171,
P93, DOI 10.1016/j.jad.2014.08.044; Robinson J, 2011, ARCH GEN PSYCHIAT, V68, P800,
DOI 10.1001/archgenpsychiatry.2011.75; Shepard D.S., 2015, SUICIDE LIFE THREAT,
V10; Silins E, 2014, LANCET PSYCHIAT, V1, P286, DOI 10.1016/S2215-0366(14)70307-4;
Thornton L.M., 2016, SUICIDE LIFE THREAT, V10; Turecki G, 2005, J PSYCHIATR
NEUROSCI, V30, P398; United States Department of Health and Human Services, 2014,
NAT SURV DRUG US HLT; van Ours JC, 2013, J HEALTH ECON, V32, P524, DOI
10.1016/j.jhealeco.2013.02.002; World Health Organization, 2016, 6152016 WHO 53
4 4 0 11 ELSEVIER SCIENCE BV AMSTERDAM PO BOX 211, 1000
AE AMSTERDAM, NETHERLANDS 0165-0327 1573-2517 J AFFECT DISORDERS
 J. Affect. Disord. APR 15 2017 213
96 104 10.1016/j.jad.2016.12.060 9 Clinical
Neurology; Psychiatry Neurosciences & Neurology; Psychiatry ER5UH
WOS:000398868300013 28213124 Green Accepted 2019-09-25
J Marschall-Levesque, S; Castellanos-Ryan, N; Parent, S; Renaud, J; Vitaro, F;
Boivin, M; Tremblay, RE; Seguin, JR Marschall-Levesque, Shawn;
Castellanos-Ryan, Natalie; Parent, Sophie; Renaud, Johanne; Vitaro, Frank; Boivin,
Michel; Tremblay, Richard E.; Seguin, Jean R. Victimization, Suicidal
Ideation, and Alcohol Use From Age 13 to 15 Years: Support for the Self-Medication
Model JOURNAL OF ADOLESCENT HEALTH English Article
Adolescent; Alcohol use; Suicidal thoughts; Peer victimization;
Self-medication model; Secondary mental health model ADOLESCENT SUBSTANCE USE;
MENTAL-HEALTH; DRUG-USE; BIRTH COHORT; DEPRESSION; PEER; RISK; BEHAVIORS;
ASSOCIATIONS; EXPERIENCES Purpose: Recent years have seen increased coverage of
adolescent victimization and suicide. Both adolescent peer victimization and
substance use have been associated with suicidal ideation, with evidence suggesting
that all three factors are interrelated. There are at least four models which can
explain the associations between these factors (i.e., self-medication, secondary
mental disorder, bidirectional, and common factor). However, none of themis being
empirically supported as the dominant model because few longitudinal studies have
explored the association between these factors. Methods: The present study compared
longitudinal paths of all four models simultaneously using a cross-lagged model.
This was done using self-reported measures of peer victimization, suicidal
ideation, and alcohol use at age 13, 14, and 15 years in a longitudinal sample of
238 adolescents. Results: All three variables were moderately stable across time.
Significant cross-lagged associations were found, showing that frequent peer
victimization at age 13 years was associated with higher odds of having suicidal
ideation at age 14 years (odds ratio, 1.82; p <.05). In turn, presence of suicidal
ideation at age 14 years was significantly associated with higher alcohol use
frequency at age 15 years (beta = .13; p <.05). Conclusions: Results support
previous literature suggesting that peer victimization predates alcohol use and
extends it by showing clear directionality between suicidal ideation and alcohol
use over 1 year, supporting the self-medication model. Clarifying the empirical
basis of these underlying models could allow for earlier prevention strategies, by
targeting the risk factor that appears the earliest in the model. (C) 2016 Society
for Adolescent Health and Medicine. All rights reserved. [Marschall-Levesque,
Shawn] Univ Montreal, Dept Psychol, Montreal, PQ, Canada; [Castellanos-Ryan,
Natalie; Parent, Sophie; Vitaro, Frank] Univ Montreal, Sch Psychoeduc, Montreal,
PQ, Canada; [Renaud, Johanne] McGill Univ, Dept Psychiat, Montreal, PQ, Canada;
[Renaud, Johanne] Douglas Mental Hlth Univ Inst, Montreal, PQ, Canada; [Vitaro,
Frank; Tremblay, Richard E.; Seguin, Jean R.] CHU Ste Justine, Ctr Rech, Montreal,
PQ, Canada; [Boivin, Michel] Univ Laval, Dept Psychol, Quebec City, PQ, Canada;
[Tremblay, Richard E.] Univ Montreal, Dept Pediat & Psychol, Quebec City, PQ,
Canada; [Tremblay, Richard E.] Tomsk State Univ, Inst Genet Neurobiol, Social Fdn
Child Dev, Tomsk, Russia; [Tremblay, Richard E.] Univ Coll, Sch Publ Hlth & Populat
Sci, Dublin, Ireland; [Seguin, Jean R.] Univ Montreal, Dept Psychiat, Montreal, PQ,
Canada Castellanos-Ryan, N (reprint author), Univ Montreal, Ecole Psychoeduc,
Pavillon Marie Victorin C-464,90 Vincent Indy, Outremont, PQ H2V 2S9, Canada.
natalie.castellanos.ryan@umontreal.ca Tremblay, Richard/O-1360-2014;
Seguin, Jean R./B-5349-2008; Parent, Sophie/F-1309-2010; Castellanos-Ryan,
Natalie/J-3272-2012 Seguin, Jean R./0000-0003-3359-6202; Castellanos-Ryan,
Natalie/0000-0002-7077-1340; Boivin, Michel/0000-0001-8621-9844 Fonds de Recherche
en Sante du QuebecFonds de la Recherche en Sante du Quebec [981055, 991027]; Social
Sciences and Humanities Research Council of CanadaSocial Sciences and Humanities
Research Council of Canada (SSHRC) [839-2000-1008, 410-99-1048]; Fonds de recherche
du Quebec - Societe et culture [2002-RS-79238, 2009-RG-124779]; Fonds Monique
Gaumond pour la recherche en maladies affectives; Canadian Institutes for Health
ResearchCanadian Institutes of Health Research (CIHR) [MOP 44072, MOP-97910] This
study was supported by an award to SML from the Fonds Monique Gaumond pour la
recherche en maladies affectives and funded by the Canadian Institutes for Health
Research via a fellowship and Grants MOP 44072 and MOP-97910; the Fonds de
Recherche en Sante du Quebec via fellowships and Grants 981055 and 991027; the
Social Sciences and Humanities Research Council of Canada by Grants 839-2000-1008
and 410-99-1048; and the Fonds de recherche du Quebec - Societe et culture Grants
2002-RS-79238 and 2009-RG-124779. Arenliu A, 2014, J SUBST USE, V19, P358, DOI
10.3109/14659891.2013.820803; BERNARD HR, 1984, ANNU REV ANTHROPOL, V13, P495, DOI
10.1146/annurev.an.13.100184.002431; BOIVIN M, 1995, DEV PSYCHOPATHOL, V7, P765,
DOI 10.1017/S0954579400006830; Boivin M, 1997, DEV PSYCHOL, V33, P135, DOI
10.1037/0012-1649.33.1.135; Boivin M, 2013, CHILD DEV, V84, P1098, DOI
10.1111/cdev.12019; Borowsky IW, 2001, PEDIATRICS, V107, P485, DOI
10.1542/peds.107.3.485; Chung T, 2012, PEDIATRICS, V129, P205, DOI
10.1542/peds.2011-1828; Crick NR, 1996, DEV PSYCHOPATHOL, V8, P367, DOI
10.1017/S0954579400007148; Desseilles M, 2012, J AFFECT DISORDERS, V136, P398, DOI
10.1016/j.jad.2011.11.013; Dube Bordeleau M, 2008, ENQUETE QUEBECOISE T, P224;
Duncan SC, 1997, DRUG ALCOHOL DEPEN, V49, P39, DOI 10.1016/S0376-8716(97)00137-3;
Elgar FJ, 2014, JAMA PEDIATR, V168, P1015, DOI 10.1001/jamapediatrics.2014.1223;
Fergusson DM, 2005, PSYCHOL MED, V35, P983, DOI 10.1017/S0033291704004167;
Fergusson DM, 2000, PSYCHOL MED, V30, P23, DOI 10.1017/S003329179900135X; Fried LE,
2013, J SCH NURS, V29, P113, DOI 10.1177/1059840512461010; Gamez-Guadix M, 2013, J
ADOLESCENT HEALTH, V53, P446, DOI 10.1016/j.jadohealth.2013.03.030; Geoffroy MC,
2016, J AM ACAD CHILD PSY, V55, P99, DOI 10.1016/j.jaac.2015.11.010; Gilreath TD,
2014, PREV SCI, V15, P897, DOI 10.1007/s11121-013-0449-8; Hawkins EH, 2009, ANNU
REV PSYCHOL, V60, P197, DOI 10.1146/annurev.psych.60.110707.163456; Heikkila HK,
2013, EUR CHILD ADOLES PSY, V22, P95, DOI 10.1007/s00787-012-0327-0; Hertz MF,
2013, J ADOLESCENT HEALTH, V53, pS1, DOI 10.1016/j.jadohealth.2013.05.002;
Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550;
Kim Young Shin, 2008, Int J Adolesc Med Health, V20, P133; Kim YS, 2009, ARCH
SUICIDE RES, V13, P15, DOI 10.1080/13811110802572098; Klomek AB, 2009, J AM ACAD
CHILD PSY, V48, P254, DOI 10.1097/CHI.0b013e318196b91f; Liu RT, 2014, J PSYCHIATR
RES, V56, P65, DOI 10.1016/j.jpsychires.2014.05.001; Lothen-Kline C, 2003, J
ADOLESCENT HEALTH, V33, P385, DOI 10.1016/S1054-139X(03)00184-8; MacKinnon DP,
2007, BEHAV RES METHODS, V39, P384, DOI 10.3758/BF03193007; Mantel N, 2004,
CHALLENGE EPIDEMIOLO, V1, P533; Marschall-Levesque S, 2014, ADDICT BEHAV, V39, P48,
DOI 10.1016/j.addbeh.2013.09.025; Masten AS, 2010, DEV PSYCHOPATHOL, V22, P491, DOI
10.1017/S0954579410000222; Muthen L. K., 1998, MPLUS USERS GUIDE; Pedersen W, 2008,
ACTA PSYCHIAT SCAND, V118, P395, DOI 10.1111/j.1600-0447.2008.01259.x; Pinchevsky
GM, 2014, J INTERPERS VIOLENCE, V29, P299, DOI 10.1177/0886260513505150; Pompili M,
2010, INT J ENV RES PUB HE, V7, P1392, DOI 10.3390/ijerph7041392; Rasic D, 2013,
DRUG ALCOHOL DEPEN, V129, P49, DOI 10.1016/j.drugalcdep.2012.09.009; REIFMAN A,
1995, AM J COMMUN PSYCHOL, V23, P329, DOI 10.1007/BF02506948; Steinhausen HC, 2006,
J CHILD PSYCHOL PSYC, V47, P713, DOI 10.1111/j.1469-7610.2005.01569.x; Tharp-Taylor
S, 2009, ADDICT BEHAV, V34, P561, DOI 10.1016/j.addbeh.2009.03.012; Topper LR,
2011, ADDICT BEHAV, V36, P6, DOI 10.1016/j.addbeh.2010.08.016 40 6 6
0 7 ELSEVIER SCIENCE INC NEW YORK 360 PARK AVE SOUTH, NEW YORK,
NY 10010-1710 USA 1054-139X 1879-1972 J ADOLESCENT HEALTH J. Adolesc.
Health APR 2017 60 4 380 387
10.1016/j.jadohealth.2016.09.019 8 Psychology,
Developmental; Public, Environmental & Occupational Health; Pediatrics Psychology;
Public, Environmental & Occupational Health; Pediatrics EU5XS
WOS:000401108300005 27914973 Green Accepted 2019-09-25
J Cicero, TJ; Ellis, MS Cicero, Theodore J.; Ellis, Matthew
S. Understanding the demand side of the prescription opioid
epidemic: Does the initial source of opioids matter? DRUG AND ALCOHOL DEPENDENCE
English Article Opioid abuse;
Opioids; Iatrogenic abuse; Pharmacoepidemiology; Epidemiology; Psychiatric
epidemiology SELF-MEDICATION HYPOTHESIS; NONMEDICAL USE; UNITED-STATES;
SUBSTANCE USE; ABUSE; PAIN; DEPENDENCE; DISORDERS; ADDICTION; TRENDS Background:
These studies were carried out to examine whether the onset and progression of an
opioid substance use disorder (SUD) differed in those who first used opioids to get
"high" compared to those who received a prescription from a doctor to relieve pain
(Non-Rx vs. Rx groups, respectively). Methods: A subset of patients (N = 214) from
an ongoing larger study of patients entering one of 125 drug treatment programs for
opioid use disorder across the country agreed to give up their anonymity and
participate in structured and open-ended online interviews examining drug abuse
patterns. Results: With the exception that the Non-Rx group began their opioid
abuse at a younger age than the Rx group and more quickly evolved from initial
exposure to regular opioid abuse, there were relatively few differences in the
characteristics, patterns and trajectories of opioid abuse. The vast majority of
patients in both groups, most of whom had serious, antecedent psychiatric
disorders, indicated that they used opioids to self-medicate psychological problems
(67-73%) and/or stated that opioids provided a means to "escape" from the stresses
of everyday life (79-85%). As the SUD progressed, for many individuals any
"positive" attributes of opioids waned and avoidance of withdrawal became the
overriding concern, often serving as the impetus for treatment. Conclusions: Our
results suggest that self-treatment of co-morbid psychiatric disturbances is a
powerful motivating force to initiate and sustain abuse of opioids and that the
initial source of drugs a prescription or experimentation is largely irrelevant in
the progression to a SUD. (C) 2016 The Authors. Published by Elsevier Ireland Ltd.
[Cicero, Theodore J.; Ellis, Matthew S.] Washington Univ, Dept Psychiat,
Campus Box 8134,660 S Euclid Ave, St Louis, MO 63110 USA Cicero, TJ (reprint
author), Washington Univ, Dept Psychiat, Campus Box 8134,660 S Euclid Ave, St
Louis, MO 63110 USA. Cicerot@wustl.edu Denver Health and Hospital
Authority (DHHA); DHHA The national data were collected from a subset of
participants from the Survey of Key Informants' Patients (SKIP) Program, a
component of the RADARS (R) (Researched Misuse, Diversion and Addiction-Related
Surveillance) System, funded through an unrestricted research grant sponsored by
Denver Health and Hospital Authority (DHHA), which collects subscription fees from
14 pharmaceutical firms. The interview-driven Research and Patients Interacting
Directly (RAPID) Program received support from both DHHA and private university
funds. RADARS (R) had no role in the development of this manuscript. Adams EH,
2006, J PAIN SYMPTOM MANAG, V31, P465, DOI 10.1016/j.jpainsymman.2005.10.006;
Baumeister RF, 2015, ADDICT BEHAV, V44, P3, DOI 10.1016/j.addbeh.2014.09.011;
Beauchamp GA, 2014, AM J PUBLIC HEALTH, V104, P2023, DOI 10.2105/AJPH.2014.302147;
Boettke P., 2013, OREG LAW REV, V91, P1069; Bohnert ASB, 2013, ADDICT BEHAV, V38,
P1776, DOI 10.1016/j.addbeh.2012.11.005; Boyles S., 2009, WEBMD HLTH NEWS SEP; Cai
R, 2010, J Pain Palliat Care Pharmacother, V24, P293, DOI
10.3109/15360288.2010.503730; Cicero TJ, 2007, PAIN MED, V8, P157, DOI
10.1111/j.1526-4637.2006.00259.x; Cicero TJ, 2015, NEW ENGL J MED, V373, P1789, DOI
10.1056/NEJMc1505541; Dart RC, 2015, NEW ENGL J MED, V372, P241, DOI
[10.1056/NEJMsa1406143, 10.1056/NEJMc1501822]; FDA, 2013, GUID IND AB DET OP E;
Fowler CD, 2014, NEUROPHARMACOLOGY, V76, P533, DOI
10.1016/j.neuropharm.2013.09.008; Goldner EM, 2014, ADDICT BEHAV, V39, P520, DOI
10.1016/j.addbeh.2013.11.022; Hall DH, 2007, J PSYCHOACTIVE DRUGS, V39, P151, DOI
10.1080/02791072.2007.10399873; Kato K, 2006, ARCH INTERN MED, V166, P1649, DOI
10.1001/archinte.166.15.1649; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259;
Lembke A, 2012, AM J DRUG ALCOHOL AB, V38, P524, DOI 10.3109/00952990.2012.694532;
Manchikanti L, 2010, PAIN PHYSICIAN, V13, P401; McCabe SE, 2008, ADDICT BEHAV, V33,
P1297, DOI 10.1016/j.addbeh.2008.06.005; McCabe SE, 2012, J ADOLESCENT HEALTH, V51,
P445, DOI 10.1016/j.jadohealth.2012.02.004; MCLELLAN AT, 1992, J SUBST ABUSE TREAT,
V9, P199, DOI 10.1016/0740-5472(92)90062-S; Reifler LM, 2012, PAIN MED, V13, P434,
DOI 10.1111/j.1526-4637.2012.01327.x; Rogers Peter D, 2009, Adolesc Med State Art
Rev, V20, P1; Schulden JD, 2009, CURR PSYCHIAT REP, V11, P353, DOI 10.1007/s11920-
009-0053-6; Silva K, 2013, J DRUG ISSUES, V43, P483, DOI 10.1177/0022042613491099;
Skurtveit S, 2010, ANN EPIDEMIOL, V20, P890, DOI 10.1016/j.annepidem.2010.03.010;
Substance Abuse and Mental Health Services Administration, 2013, NSDUH SER H, VH-
46; Substance Abuse and Mental Health Services Administration, 2013, HHS PUBL,
V( SMA) 13- 4795; Turk DC, 2010, MAYO CLIN PROC, V85, pS42, DOI
10.4065/mcp.2009.0648; Wasan AD, 2015, ANESTHESIOLOGY, V123, P861, DOI
10.1097/ALN.0000000000000768; Zacny JP, 2008, J PAIN, V9, P473, DOI
10.1016/j.jpain.2007.12.008 31 11 11 0 15 ELSEVIER IRELAND LTD
CLARE ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND 0376-8716 1879-0046 DRUG ALCOHOL DEPEN Drug Alcohol
Depend. APR 1 2017 173 1 S4 S10
10.1016/j.drugalcdep.2016.03.014 7 Substance Abuse;
Psychiatry Substance Abuse; Psychiatry ET1PE WOS:000400040500002 28363319
Other Gold 2019-09-25
J Can, Y; Anli, I; Evren, C; Usta, O Can, Yesim; Anli, Irem;
Evren, Cuneyt; Usta, Oznur The Relation between Pathological
Narcissism and Alcohol Use Disorder ADDICTA-THE TURKISH JOURNAL ON ADDICTIONS
English Article Alcohol use disorder;
Self psychology; Pathological narcissism; Narcissism; Treatment SELF-MEDICATION
HYPOTHESIS; ADDICTION; DISSOCIATION; SYMPTOMS; TRAUMA; IMPACT; ABUSE The
objective of this study is to evaluate the relationship between alcohol use
disorder and self psychology by comparing inpatients with alcohol use disorder and
healthy individuals. A total of 308 individuals were included in this study. The
subject group consisted of 206 male inpatients in the Alcohol and Substance
Addiction Research Treatment and Education Center (ASAREC) of Bakirkoy Mental
Health and Neurological Diseases Education and Research Hospital who were diagnosed
with alcohol use disorder and a control group composed of 102 randomly selected
males with no alcohol use or other psychological disorders. The data collection
tools used in the study were Self Psychology Inventory and Socio-demographic Data
Form, which was created by the study's authors for the present study and solicited
information regarding participants' age, sex, alcohol use, family income, and
marital status in order to homogenize the data. The defensive grandiose self and
defensive idealized parental imago scores of participants with alcohol use
disorders were significantly higher than those of the control group. The healthy
grandiose self and healthy idealized parental imago scores of participants with
alcohol use disorders were significantly lower than those of the control group. The
results of the present study suggest that one of the reasons of alcohol use
disorders may be an inadequate self make up and weak ego defense mechanisms and
that alcohol use disorders may be related to pathological narcissism. [Can, Yesim;
Evren, Cuneyt] Bakirkoy AMATEM, Istanbul, Turkey; [Anli, Irem] Istanbul Bilim Univ,
Fac Sci & Literature, Dept Psychol, Istanbul, Turkey; [Can, Yesim; Evren, Cuneyt]
Bakirkoy Mental Hlth & Neurol Dis Educ & Res Hosp, Alcohol & Subst Addict Res
Treatment & Educ Ctr A, TR-34158 Istanbul, Turkey; [Usta, Oznur] Gulen Yuzler
Special Educ Rehabil & Counseling Ct, Istanbul, Turkey Anli, I (reprint
author), Istanbul Bilim Univ, Fac Sci & Literature, Dept Psychol, Istanbul, Turkey.
dryesimcan@yahoo.com; iremanli@superonline.com; cuneytevren@yahoo.com;
oznurustaa@gmail.com Anli I., 2009, BULGARIAN J PSYCHOL,
V3, P411; Basim E, 2013, MENT BOZ TAN SAY KIT; Bedard M, 2015, PSYCHIAT RES, V230,
P524, DOI 10.1016/j.psychres.2015.09.049; BLATT SJ, 1984, J NERV MENT DIS, V172,
P342, DOI 10.1097/00005053-198406000-00005; Bosson JK, 2008, SOC PERSONAL PSYCHOL,
V2, P1415, DOI 10.1111/j.1751-9004.2008.00089.x; Brodsky BS, 2001, AM J PSYCHIAT,
V158, P1871, DOI 10.1176/appi.ajp.158.11.1871; Craig R.J., 2000, SUBST ABUS, V21,
P87; Dodes LM, 2009, PSYCHODYN PRACT, V15, P381, DOI 10.1080/14753630903230468;
DODES LM, 1990, PSYCHOANAL QUART, V59, P398, DOI 10.1080/21674086.1990.11927278;
Dodes LM, 1996, J AM PSYCHOANAL ASS, V44, P815, DOI 10.1177/000306519604400307;
Erdem G., 2006, J DEPENDENCE, V7, P111; Evren C, 2011, PSYCHIAT RES, V190, P126,
DOI 10.1016/j.psychres.2011.08.002; Evren C, 2011, PSYCHIAT RES, V186, P85, DOI
10.1016/j.psychres.2010.07.004; Fine M., 1991, COMPR PSYCHIAT, V32, P431; Gabbard
G. O., 1994, PSYCHODYNAMIC PSYCHI; GLASSMAN M, 1988, J AM PSYCHOANAL ASS, V36,
P597, DOI 10.1177/000306518803600302; Goldman GF, 1997, PSYCHOANAL PSYCHOL, V14,
P81; Imbesi L, 1999, CLIN SOC WORK J, V27, P41, DOI 10.1023/A:1022809314267;
Johnson B, 1999, J AM PSYCHOANAL ASS, V47, P791, DOI 10.1177/00030651990470031301;
Kaplan H. I., 2004, KLIN PSIKIYATRI ICIN, P75; Khantzian E., 2003,
NEUROPSYCHOANALYSIS, V5, P5, DOI DOI 10.1080/15294145.2003.10773403; KHANTZIAN E J,
1985, Journal of Substance Abuse Treatment, V2, P83, DOI 10.1016/0740-
5472(85)90031-5; Khantzian E. J., 2015, TXB ADDICTION TREATM, V1, P811; Khantzian
E, 2009, PSYCHODYN PRACT, V15, P365, DOI 10.1080/14753630903230484; Khantzian EJ,
1997, HARVARD REV PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550; KHANTZIAN EJ,
1985, AM J PSYCHIAT, V142, P1259; Kohut H., 1980, THE COURSE OF LIFE, P425; Kohut
H., 2004, KENDILIGIN COZUMLENM; Kohut H., 1971, ANAL SELF SYSTEMATIC; Kohut Heinz,
1986, ESSENTIAL PAPERS NAR, P61; Levi S. H. R., 1994, THESIS; Shorey RC, 2014, CLIN
PSYCHOL PSYCHOT, V21, P341, DOI 10.1002/cpp.1843; Slyter S. L., 1989, DISS ABSTR
INT, V51; vanderKolk BA, 1996, AM J PSYCHIAT, V153, P83; Wu P, 2010, J STUD ALCOHOL
DRUGS, V71, P326, DOI 10.15288/jsad.2010.71.326; WURMSER L, 1974, J AM PSYCHOANAL
ASS, V22, P820, DOI 10.1177/000306517402200407 36 0 0 0 2
TURKISH GREEN CRESCENT SOC ISTANBUL SEPETCILER KASRIKENNEDY CAD NO 3
SARAYBURNU, FATIH, ISTANBUL, 34110, TURKEY 2148-7286 2149-1305
ADDICTA Addicta SPR 2017 4 1 128
135 10.15805/addicta.2017.4.1.0014 8 Substance
Abuse Substance Abuse FH4QK WOS:000411142700005 Bronze
2019-09-25
J Farmer, RF; Seeley, JR; Kosty, DB; Gau, JM; Duncan, SC; Sher, KJ; Lewinsohn,
PM Farmer, Richard F.; Seeley, John R.; Kosty, Derek B.; Gau,
Jeff M.; Duncan, Susan C.; Sher, Kenneth J.; Lewinsohn, Peter M. No
Reliable Evidence That Emotional Disorders Are Proximal Antecedents, Concomitants,
or Short-Term Consequences of First Episode Alcohol Use Disorders in a
Representative Community Sample JOURNAL OF STUDIES ON ALCOHOL AND DRUGS
English Article SUBSTANCE USE
DISORDERS; COMORBIDITY SURVEY REPLICATION; COMMON MENTAL-DISORDERS; AGE-OF-ONSET;
NATIONAL EPIDEMIOLOGIC SURVEY; BINGE DRINKING TRAJECTORIES; SELF-MEDICATION
HYPOTHESIS; HIGH-SCHOOL-STUDENTS; DSM-IV DISORDERS; ANXIETY DISORDERS Objective:
Emotional disorders and alcohol use disorders (AUDs) frequently demonstrate
significant 12-month and lifetime comorbid associations. This comorbidity has been
incorporated into influential theories of addiction processes that posit direct or
indirect causal associations between these disorder categories. There is currently
no consensus, however, about the sequencing of these disorders. In this research,
longitudinal data from a regionally representative community sample were used to
evaluate whether emotional disorders constitute a proximal antecedent, concomitant,
or short-term consequence of first episode (or index) AUDs. Method: Participants
were 131 persons with index AUD episodes lasting 12 months or more and 131 matched
controls. For each participant with an AUD, the presence or absence of an emotional
disorder was coded for three time intervals: (a) the 12 months preceding full
syndrome AUD episode onset; (b) the last 12 months of the AUD episode; and (c) the
12 months following complete symptom AUD episode offset. These intervals,
referenced to participant age, were matched to those of control participants, and
emotional disorder rate comparisons subsequently performed both within and between
groups. Results: Findings indicated an absence of significant within- or between
subject differences in emotional disorder rates, suggesting that the association
between AUDs and emotional disorders is neither directional nor systematic. There
was also no indication that the length of the AUD episode increased risk for an
emotional disorder in the year following AUD offset. Conclusions: Overall, this
research suggests that emotional disorders are generally independent events in
relation to the index AUD episode. [Farmer, Richard F.; Seeley, John R.; Kosty,
Derek B.; Gau, Jeff M.; Duncan, Susan C.; Lewinsohn, Peter M.] Oregon Res Inst,
1776 Millrace Dr, Eugene, OR 97403 USA; [Seeley, John R.] Univ Oregon, Coll Educ,
Dept Special Educ & Clin Sci, Eugene, OR 97403 USA; [Sher, Kenneth J.] Univ
Missouri Columbia, Dept Psychol Sci, Columbia, MO USA Farmer, RF (reprint author),
Oregon Res Inst, 1776 Millrace Dr, Eugene, OR 97403 USA. rfarmer@ori.org
National Institutes of HealthUnited States Department of Health & Human
ServicesNational Institutes of Health (NIH) - USA [MH40501, MH50522, DA12951];
[R01AA020968]; [K05AA017242] This research was supported by National Institutes of
Health Grants MH40501, MH50522, and DA12951 (to Peter M. Lewinsohn); R01AA020968
(to Richard F. Farmer and John R. Seeley); and K05AA017242 (to Kenneth J. Sher).
The content is solely the responsibility of the authors and does not necessarily
represent the official views of the National Institutes of Health. American
Psychiatric Association, 1987, DIAGN STAT MAN MENT; American Psychiatric
Association, 1994, DIAGN STAT MAN MENT; BENJAMINI Y, 1995, J R STAT SOC B, V57,
P289; BERKSON J, 1946, BIOMETRICS BULL, V2, P47, DOI 10.2307/3002000; Blume AW,
2000, COGN BEHAV PRACT, V7, P379, DOI 10.1016/S1077-7229(00)80048-6; Boden JM,
2011, ADDICTION, V106, P906, DOI 10.1111/j.1360-0443.2010.03351.x; BROWN SA, 1988,
J STUD ALCOHOL, V49, P412, DOI 10.15288/jsa.1988.49.412; Brown SA, 2008,
PEDIATRICS, V121, pS290, DOI 10.1542/peds.2007-2243D; Caspi A, 2014, CLIN PSYCHOL
SCI, V2, P119, DOI 10.1177/2167702613497473; CHAMBERS WJ, 1985, ARCH GEN PSYCHIAT,
V42, P696; Chassin L, 2002, J CONSULT CLIN PSYCH, V70, P67, DOI 10.1037//0022-
006X.70.1.67; CLONINGER CR, 1987, SCIENCE, V236, P410, DOI 10.1126/science.2882604;
Conner KR, 2011, ADDICTION, V106, P915, DOI 10.1111/j.1360-0443.2011.03385.x;
Curran GM, 2000, J SUBST ABUSE TREAT, V19, P259, DOI 10.1016/S0740-5472(00)00107-0;
DAVIDSON KM, 1995, BRIT J PSYCHIAT, V166, P199, DOI 10.1192/bjp.166.2.199; de
Timary P, 2008, PSYCHIAT RES, V157, P105, DOI 10.1016/j.psychres.2006.12.008;
Driessen M, 2001, ALCOHOL ALCOHOLISM, V36, P249, DOI 10.1093/alcalc/36.3.249; Falk
DE, 2008, DRUG ALCOHOL DEPEN, V94, P234, DOI 10.1016/j.drugalcdep.2007.11.022;
Farmer RF, 2016, DRUG ALCOHOL DEPEN, V164, P38, DOI
10.1016/j.drugalcdep.2016.04.021; Farmer RF, 2013, COMPR PSYCHIAT, V54, P523, DOI
10.1016/j.comppsych.2012.12.007; Farmer RF, 2013, J ABNORM PSYCHOL, V122, P573, DOI
10.1037/a0031429; Farmer RF, 2009, J ABNORM PSYCHOL, V118, P699, DOI
10.1037/a0017205; Fergusson DM, 2009, ARCH GEN PSYCHIAT, V66, P260, DOI
10.1001/archgenpsychiatry.2008.543; First M. B., 1994, STRUCTURED CLIN INTE; Grant
BF, 2004, ARCH GEN PSYCHIAT, V61, P807, DOI 10.1001/archpsyc.61.8.807; Grant BF,
2015, JAMA PSYCHIAT, V72, P757, DOI 10.1001/jamapsychiatry.2015.0584; Hill KG,
2000, ALCOHOL CLIN EXP RES, V24, P892, DOI 10.1111/j.1530-0277.2000.tb02071.x;
Jacob T, 2005, J STUD ALCOHOL, V66, P745, DOI 10.15288/jsa.2005.66.745; Jacob T,
2009, J STUD ALCOHOL DRUGS, V70, P859, DOI 10.15288/jsad.2009.70.859; Johnson BA,
2000, AM J ADDICTION, V9, P17; KELLER MB, 1987, ARCH GEN PSYCHIAT, V44, P540;
Kessler RC, 1996, AM J ORTHOPSYCHIAT, V66, P17, DOI 10.1037/h0080151; KESSLER RC,
1993, AM J COMMUN PSYCHOL, V21, P607, DOI 10.1007/BF00942174; Kessler RC, 2005,
ARCH GEN PSYCHIAT, V62, P617, DOI 10.1001/archpsyc.62.6.617; Kessler RC, 2005, ARCH
GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Kessler RC, 2011, ARCH GEN
PSYCHIAT, V68, P90, DOI 10.1001/archgenpsychiatry.2010.180; KHANTZIAN EJ, 1985, AM
J PSYCHIAT, V142, P1259; Koob GF, 2008, ANNU REV PSYCHOL, V59, P29, DOI
10.1146/annurev.psych.59.103006.093548; Koob GF, 2005, NAT NEUROSCI, V8, P1442, DOI
10.1038/nn1105-1442; Krueger RF, 1999, ARCH GEN PSYCHIAT, V56, P921, DOI
10.1001/archpsyc.56.10.921; Kushner MG, 1999, AM J PSYCHIAT, V156, P723; KUSHNER
MG, 1990, AM J PSYCHIAT, V147, P685; Kushner MG, 2000, CLIN PSYCHOL REV, V20, P149,
DOI 10.1016/S0272-7358(99)00027-6; LEWINSOHN PM, 1993, J ABNORM PSYCHOL, V102,
P133, DOI 10.1037/0021-843X.102.1.133; Lipsey MW, 2001, PRACTICAL METAANALYS; Low
NCP, 2008, BIOL PSYCHIAT, V63, P884, DOI 10.1016/j.biopsych.2007.08.011; McCarthy
DM, 2005, PSYCHOL ADDICT BEHAV, V19, P28, DOI 10.1037/0893-164X.19.1.28; Merikangas
KR, 1998, ADDICT BEHAV, V23, P893, DOI 10.1016/S0306-4603(98)00076-8; Merikangas
KR, 1996, BRIT J PSYCHIAT, V168, P58, DOI 10.1192/S0007125000298425; MERIKANGAS KR,
1994, PSYCHOL MED, V24, P69, DOI 10.1017/S0033291700026842; Moffitt TE, 2010,
PSYCHOL MED, V40, P899, DOI 10.1017/S0033291709991036; ORVASCHEL H, 1982, J AM ACAD
CHILD PSY, V21, P392, DOI 10.1016/S0002-7138(09)60944-4; QUITKIN FM, 1972, ARCH GEN
PSYCHIAT, V27, P159; Raimo EB, 1998, ADDICT BEHAV, V23, P933, DOI 10.1016/S0306-
4603(98)00068-9; Rohde P, 1996, J AM ACAD CHILD PSY, V35, P101, DOI
10.1097/00004583-199601000-00018; ROHDE P, 1991, J ABNORM PSYCHOL, V100, P214, DOI
10.1037/0021-843X.100.2.214; Rohde P, 2001, J AM ACAD CHILD PSY, V40, P83, DOI
10.1097/00004583-200101000-00020; Rohde P, 2007, PSYCHOL ADDICT BEHAV, V21, P155,
DOI 10.1037/0893-164X.21.2.155; Roysamb E, 2011, J ABNORM PSYCHOL, V120, P198, DOI
10.1037/a0021660; SCHINKA JA, 1994, J PERS ASSESS, V63, P413, DOI
10.1207/s15327752jpa6303_2; Seeley JR, 2011, J ABNORM PSYCHOL, V120, P308, DOI
10.1037/a0022621; Sher KJ, 2005, ANNU REV CLIN PSYCHO, V1, P493, DOI
10.1146/annurev.clinpsy.1.102803.144107; Slade T, 2006, PSYCHOL MED, V36, P1593,
DOI 10.1017/S0033291706008452; Stewart SH, 1996, PSYCHOL BULL, V120, P83, DOI
10.1037/0033-2909.120.1.83; Swendsen JD, 1998, COMPR PSYCHIAT, V39, P176, DOI
10.1016/S0010-440X(98)90058-X; Swendsen JD, 2000, CLIN PSYCHOL REV, V20, P173, DOI
10.1016/S0272-7358(99)00026-4; Tomlinson KL, 2006, ADDICT BEHAV, V31, P461, DOI
10.1016/j.addbeh.2005.05.028; Vollebergh WAM, 2001, ARCH GEN PSYCHIAT, V58, P597,
DOI 10.1001/archpsyc.58.6.597; Wang PS, 2005, ARCH GEN PSYCHIAT, V62, P603, DOI
10.1001/archpsyc.62.6.603; WEISS RD, 1992, AM J DRUG ALCOHOL AB, V18, P121, DOI
10.3109/00952999208992825; Wichers M, 2010, PSYCHOL MED, V40, P359, DOI
10.1017/S0033291709990420; Witkiewitz K, 2009, J CONSULT CLIN PSYCH, V77, P633, DOI
10.1037/a0015647; Zimmermann P, 2003, PSYCHOL MED, V33, P1211, DOI
10.1017/S0033291703008158; Zvolensky MJ, 2003, CLIN PSYCHOL-SCI PR, V10, P29, DOI
10.1093/clipsy/10.1.29 74 1 1 0 1 ALCOHOL RES DOCUMENTATION INC
CENT ALCOHOL STUD RUTGERS UNIV PISCATAWAY C/O DEIRDRE ENGLISH, 607 ALLISON
RD, PISCATAWAY, NJ 08854-8001 USA 1937-1888 1938-4114 J STUD ALCOHOL
DRUGS J. Stud. Alcohol Drugs MAR 2017 78 2 222
231 10.15288/jsad.2017.78.222 10 Substance Abuse;
Psychology Substance Abuse; Psychology EO6MC WOS:000396806100008 28317502
Green Published 2019-09-25
J Afzali, MH; Sunderland, M; Batterham, PJ; Carragher, N; Calear, A; Slade, T
Afzali, Mohammad H.; Sunderland, Matthew; Batterham, Philip J.;
Carragher, Natacha; Calear, Alison; Slade, Tim Network approach to the
symptom-level association between alcohol use disorder and posttraumatic stress
disorder SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY English
Article Network; Comorbidity; Alcohol; PTSD
SUBSTANCE USE DISORDERS; AUSTRALIAN NATIONAL-SURVEY; QUALITY-OF-LIFE;
PHYSICAL ASSAULT; MENTAL-HEALTH; RISK-FACTORS; POPULATION NORMS; CAUSAL PATHWAYS;
DRUG DISORDERS; PTSD TREATMENT The high prevalence of alcohol use disorder
among individuals with a history of trauma and posttraumatic stress disorder is
well documented. The current study applied network analysis to map the structure of
symptom associations between these disorders. Data come from a community sample of
449 Australian adults with a history of trauma and alcohol consumption during the
last 12 months. Data analysis consisted of the construction of the comorbidity
network of PTSD/AUD symptoms, identification of the bridging symptoms, computation
of the centrality measures, and evaluation of the robustness of the results.
Results highlighted two main symptom clusters, corresponding to two disorders, and
that only nine edges connected the two clusters. Bridging symptoms connecting the
two clusters were: alcohol use in dangerous situations, physical or mental health
problems as a result of alcohol use, loss of interest or reduced social activities,
and reckless/self-destructive behaviour. Identification of both central symptoms,
because of their key role in the constellation and strong associations with
majority of symptoms, and bridge symptoms, because of their mediating role between
two disorders, has some implications in terms of self-medication and risk-
taking/self-regulation theories of comorbidity and provides a number of clinical
implications, which warrants further exploration within clinical samples.
[Afzali, Mohammad H.; Sunderland, Matthew; Slade, Tim] UNSW Australia, NHMRC
Ctr Res Excellence Mental Hlth & Substance, Natl Drug & Alcohol Res Ctr, Sydney,
NSW 2052, Australia; [Batterham, Philip J.; Calear, Alison] Australian Natl Univ,
Natl Inst Mental Hlth Res, Canberra, ACT, Australia; [Carragher, Natacha] UNSW,
Faulty Med, Off Med Educ, Sydney, NSW, Australia Afzali, MH (reprint author),
UNSW Australia, NHMRC Ctr Res Excellence Mental Hlth & Substance, Natl Drug &
Alcohol Res Ctr, Sydney, NSW 2052, Australia. m.afzali@unsw.edu.au Slade,
Tim/O-2031-2019; Calear, Alison/D-4191-2009 Calear, Alison/0000-0002-7028-725X;
Sunderland, Matthew/0000-0001-8452-364X Endeavour research fellowship -
department of education and training-Australian GovernmentAustralian
GovernmentDepartment of Industry, Innovation and Science This project was funded
by the Endeavour research fellowship granted by department of education and
training-Australian Government. The sponsor had no role in study design, data
collection, analysis, interpretation of results, report writing, or manuscript
submission. Acierno R, 1999, J ANXIETY DISORD, V13, P541, DOI 10.1016/S0887-
6185(99)00030-4; Afzali MH, 2017, J AFFECT DISORDERS, V208, P490, DOI
10.1016/j.jad.2016.10.037; Amstadter AB, 2011, ADDICT BEHAV, V36, P814, DOI
10.1016/j.addbeh.2011.03.008; Back SE, 2003, AM J DRUG ALCOHOL AB, V29, P169, DOI
10.1081/ADA-120018845; Batterham PJ, 2016, J CLIN EPIDEMIOL, V71, P35, DOI
10.1016/j.jclinepi.2015.10.005; Beard C, 2016, PSYCHOL MED, V46, P3359, DOI
10.1017/S0033291716002300; Borsboom D, 2013, ANNU REV CLIN PSYCHO, V9, P91, DOI
10.1146/annurev-clinpsy-050212-185608; Borsboom D, 2011, PERSPECT PSYCHOL SCI, V6,
P610, DOI 10.1177/1745691611425012; Boschloo L, 2015, PLOS ONE, V10, DOI
10.1371/journal.pone.0137621; Breslau N, 2003, ARCH GEN PSYCHIAT, V60, P289, DOI
10.1001/archpsyc.60.3.289; Bringmann LF, 2015, PSYCHOL MED, V45, P747, DOI
10.1017/S0033291714001809; Bringmann LF, 2013, PLOS ONE, V8, DOI
10.1371/journal.pone.0060188; Chilcoat HD, 1998, ARCH GEN PSYCHIAT, V55, P913, DOI
10.1001/archpsyc.55.10.913; Chilcoat HD, 1998, ADDICT BEHAV, V23, P827, DOI
10.1016/S0306-4603(98)00069-0; Costantini G, 2015, J RES PERS, V54, P13, DOI
10.1016/j.jrp.2014.07.003; Cramer AOJ, 2010, BEHAV BRAIN SCI, V33, P137, DOI
10.1017/S0140525X09991567; Danielson CK, 2009, ADDICT BEHAV, V34, P395, DOI
10.1016/j.addbeh.2008.11.009; Elhai JD, 2011, J ANXIETY DISORD, V25, P404, DOI
10.1016/j.janxdis.2010.11.003; Epskamp S, 2016, HDB PSYCHOM IN PRESS; Epskamp S,
2016, ESTIMATING PSYCHOL N, V501, P1; Epskamp S, 2012, J STAT SOFTW, V48, P1; Evren
C, 2011, PSYCHIAT RES, V186, P85, DOI 10.1016/j.psychres.2010.07.004; Fried EI,
2017, SOC PSYCH PSYCH EPID, V52, P1, DOI 10.1007/s00127-016-1319-z; Fried EI, 2016,
J AFFECT DISORDERS, V189, P314, DOI 10.1016/j.jad.2015.09.005; FRUCHTERMAN TMJ,
1991, SOFTWARE PRACT EXPER, V21, P1129, DOI 10.1002/spe.4380211102; Gros DF, 2012,
PSYCHIAT RES, V196, P267, DOI 10.1016/j.psychres.2011.10.022; Hawthorne G, 2005,
AUST NZ J PUBL HEAL, V29, P136, DOI 10.1111/j.1467-842X.2005.tb00063.x; Hawthorne
G, 2013, AUST NZ J PUBL HEAL, V37, P7, DOI 10.1111/1753-6405.12004; Jacobsen LK,
2001, AM J PSYCHIAT, V158, P1184, DOI 10.1176/appi.ajp.158.8.1184; Kaysen D, 2006,
J TRAUMA STRESS, V19, P399, DOI 10.1002/jts.20122; Kessler RC, 2005, ARCH GEN
PSYCHIAT, V62, P617, DOI 10.1001/archpsyc.62.6.617; McCauley JL, 2012, CLIN
PSYCHOL-SCI PR, V19, P283, DOI 10.1111/cpsp.12006; McNally RJ, 2016, BEHAV RES
THER, V86, P95, DOI 10.1016/j.brat.2016.06.006; McNally RJ, 2015, CLIN PSYCHOL SCI,
V3, P836, DOI 10.1177/2167702614553230; Mills KL, 2006, AM J PSYCHIAT, V163, P652,
DOI 10.1176/appi.ajp.163.4.652; Ouimette P, 2003, J CONSULT CLIN PSYCH, V71, P410,
DOI 10.1037/0022-006X.71.2.410; Pietrzak RH, 2011, J ANXIETY DISORD, V25, P456, DOI
10.1016/j.janxdis.2010.11.010; Reed PL, 2007, ARCH GEN PSYCHIAT, V64, P1435, DOI
10.1001/archpsyc.64.12.1435; Reynolds M, 2005, DRUG ALCOHOL DEPEN, V77, P251, DOI
10.1016/j.drugalcdep.2004.08.017; Rhemtulla M, 2016, DRUG ALCOHOL DEPEN, V161,
P230, DOI 10.1016/j.drugalcdep.2016.02.005; Riggs DS, 2003, ADDICT BEHAV, V28,
P1717, DOI 10.1016/j.addbeh.2003.08.044; Rosen GM, 2008, BRIT J PSYCHIAT, V192, P3,
DOI 10.1192/bjp.bp.107.043083; Ruzzano L, 2015, J AUTISM DEV DISORD, V45, P192, DOI
10.1007/s10803-014-2204-9; SALADIN ME, 1995, ADDICT BEHAV, V20, P643, DOI
10.1016/0306-4603(95)00024-7; Santiago PN, 2010, PSYCHIAT SERV, V61, P575, DOI
10.1176/ps.2010.61.6.575; Slade T, 2009, AUST NZ J PSYCHIAT, V43, P594, DOI
10.1080/00048670902970882; Stewart SH, 1998, ADDICT BEHAV, V23, P797, DOI
10.1016/S0306-4603(98)00070-7; Stewart SH, 1999, PSYCHOL ADDICT BEHAV, V13, P78,
DOI 10.1037/0893-164X.13.2.78; STEWART SH, 2000, ALCOHOLISM TREATMENT, V18, P31,
DOI DOI 10.1300/J020V18N03; Thornton Louise, 2016, Internet Interv, V4, P72, DOI
10.1016/j.invent.2016.02.001; Tio P, 2016, INT J METH PSYCH RES, V25, P267, DOI
10.1002/mpr.1503; van Borkulo CD, 2014, SCI REP-UK, V4, DOI 10.1038/srep05918; Yuan
NP, 2006, J INTERPERS VIOLENCE, V21, P1566, DOI 10.1177/0886260506294239 53
7 7 0 6 SPRINGER HEIDELBERG HEIDELBERG TIERGARTENSTRASSE
17, D-69121 HEIDELBERG, GERMANY 0933-7954 1433-9285 SOC PSYCH PSYCH
EPID Soc. Psychiatry Psychiatr. Epidemiol. MAR 2017 52 3
329 339 10.1007/s00127-016-1331-3 11
Psychiatry Psychiatry EP7UH WOS:000397582200010 28013328
2019-09-25
J Ruda-Kucerova, J; Babinska, Z; Amchova, P; Stark, T; Drago, F; Sulcova, A;
Micale, V Ruda-Kucerova, Jana; Babinska, Zuzana; Amchova,
Petra; Stark, Tibor; Drago, Filippo; Sulcova, Alexandra; Micale, Vincenzo
 Reactivity to addictive drugs in the methylazoxymethanol (MAM) model of
schizophrenia in male and female rats WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY
English Article Abuse; alcohol;
methamphetamine; sex differences; schizophrenia SUBSTANCE USE DISORDERS;
DEVELOPMENTAL DISRUPTION MODEL; DUAL DIAGNOSIS SCHIZOPHRENIA; VENTRAL HIPPOCAMPAL-
LESIONS; SELF-MEDICATION HYPOTHESIS; SERIOUS MENTAL-ILLNESS; SEX-DIFFERENCES;
BEHAVIORAL SENSITIZATION; METHAMPHETAMINE SEEKING; ROTATIONAL BEHAVIOR Objectives:
Patients with schizophrenia often suffer comorbid substance abuse regardless of
gender. However, the vast majority of studies are only conducted in male subjects.
Therefore, the aim of these experiments is to assess addictive behaviors of both
sexes in a neurodevelopmental model of schizophrenia induced by prenatal
methylazoxymethanol (MAM) acetate exposure.Methods: MAM (22 mg/kg) was administered
intraperitoneally on gestational day 17. Two studies were performed in the
offspring: (1) an alcohol-drinking procedure to assess daily intake of 20% alcohol
and relapse-like behavior after a period of forced abstinence; (2) Methamphetamine
(METH) intravenous self administration (IVSA) followed by forced abstinence and
reinstatement phases.Results: MAM exposure during the prenatal period did not
change alcohol drinking regardless of sex. However, MAM females showed higher
alcohol consumption in comparison to MAM males. The METH IVSA study revealed only a
modest increase of drug consumption in MAM males, while there was no difference
between the female groups. Reinstatement data showed no effect of the MAM model in
either sex, but suggested increased responding in female rats.Conclusions: This
study suggests that female sex and schizophrenia-like phenotype may work
synergistically to enhance alcohol consumption. However, future research is needed
to establish paradigms in which these findings would be readily assessed to test
anti-addiction treatments. [Ruda-Kucerova, Jana; Babinska, Zuzana; Amchova,
Petra; Stark, Tibor] Masaryk Univ, Dept Pharmacol, Fac Med, Kamenice 5, Brno 62500,
Czech Republic; [Drago, Filippo; Micale, Vincenzo] Univ Catania, Sch Med, Pharmacol
Sect, Dept Biomed & Biotechnol Sci, Catania, Italy; [Sulcova, Alexandra; Micale,
Vincenzo] Masaryk Univ, Behav & Social Neurosci Grp, CEITEC Cent European Inst
Technol, Brno, Czech Republic Ruda-Kucerova, J (reprint author), Masaryk Univ, Dept
Pharmacol, Fac Med, Kamenice 5, Brno 62500, Czech Republic.jkucer@med.muni.cz
Ruda-Kucerova, Jana/D-5117-2012; Drago, Francesco/H-7563-2019; Sulcova,
Alexandra E/D-5143-2012 Ruda-Kucerova, Jana/0000-0002-1846-0799; Sulcova, Alexandra
E/0000-0001-8854-558X; Stark, Tibor/0000-0001-8118-9914 SoMoPro II Programme
grant from the People Programme (Marie Curie Action) [3SGA5789, 291782]; South-
Moravian RegionRegion Auvergne-Rhone-AlpesRegion Bourgogne-Franche-ComteRegion
Hauts-de-FranceRegion Nouvelle-Aquitaine; Ministry of Education, Youth and Sports
of the Czech Republic under the National Sustainability Programme II [LQ1601];
Specific University Research Grant [MUNI/A/1284/2015]; Ministry of Education, Youth
and Sports of the Czech RepublicMinistry of Education, Youth & Sports - Czech
Republic; Faculty of Medicine MU This work was supported by project No. 3SGA5789
financed from the SoMoPro II Programme that has acquired a financial grant from the
People Programme (Marie Curie Action) of the Seventh Framework Programme of EU
according to the REA Grant Agreement No. 291782 and was further co-financed by the
South-Moravian Region. This publication reflects only the authors' views and the
Union is not liable for any use that may be made of the information contained
therein. This research was also carried out under the project CEITEC 2020 (LQ1601)
with financial support from the Ministry of Education, Youth and Sports of the
Czech Republic under the National Sustainability Programme II. This study was
written at Masaryk university with co-financing of the project "Experimental
pharmacological development in neuropsychopharmacology and oncology'' number
MUNI/A/1284/2015 with the support of the Specific University Research Grant, as
provided by the Ministry of Education, Youth and Sports of the Czech Republic in
the year 2016 and funds from the Faculty of Medicine MU to junior researcher Jana
Ruda-Kucerova. Abel KM, 2010, INT REV PSYCHIATR, V22, P417, DOI
10.3109/09540261.2010.515205; Amchova P, 2014, FRONT PHARMACOL, V5, DOI
10.3389/fphar.2014.00044; Anderson ML, 2012, NEUROSCIENCE, V224, P202, DOI
10.1016/j.neuroscience.2012.08.018; Bahorik AL, 2013, ADDICTION, V108, P1259, DOI
10.1111/add.12153; Becker JB, 2012, BIOL SEX DIFFER, V3, DOI 10.1186/2042-6410-3-
14; Berg SA, 2011, BEHAV BRAIN RES, V218, P346, DOI 10.1016/j.bbr.2010.12.017;
Brady AM, 2008, PSYCHOPHARMACOLOGY, V200, P205, DOI 10.1007/s00213-008-1195-7;
Brisch R, 2014, FRONT PSYCHIATRY, V5, DOI 10.3389/fpsyt.2014.00047; Caspi A, 2005,
BIOL PSYCHIAT, V57, P1117, DOI 10.1016/j.biopsych.2005.01.026; Chambers RA, 2001,
BIOL PSYCHIAT, V50, P71, DOI 10.1016/S0006-3223(01)01134-9; Chambers RA, 2004, BIOL
PSYCHIAT, V56, P308, DOI 10.1016/j.biopsych.2004.05.019; Chambers RA, 2002,
NEUROPSYCHOPHARMACOL, V27, P889, DOI 10.1016/S0893-133X(02)00365-2; Conroy SK,
2007, PHARMACOL BIOCHEM BE, V86, P386, DOI 10.1016/j.pbb.2006.07.017; Cox BM, 2013,
PSYCHONEUROENDOCRINO, V38, P2343, DOI 10.1016/j.psyneuen.2013.05.005; Czachowski
CL, 2005, ALCOHOL CLIN EXP RES, V29, P1146, DOI 10.1097/01.ALC.0000171944.50381.86;
Di Chiara G, 2004, NEUROPHARMACOLOGY, V47, P227, DOI
10.1016/j.neuropharm.2004.06.032; Du YJ, 2013, NEUROPSYCHOPHARMACOL, V38, P1881,
DOI 10.1038/npp.2013.101; Featherstone RE, 2009, PHARMACOL BIOCHEM BE, V93, P382,
DOI 10.1016/j.pbb.2009.05.010; Ford MM, 2002, ALCOHOL, V26, P103, DOI
10.1016/S0741-8329(01)00203-8; Fuchs RA, 2006, J NEUROSCI, V26, P3584, DOI
10.1523/JNEUROSCI.5146-05.2006; Gomez JL, 2014, PHYSIOL BEHAV, V123, P47, DOI
10.1016/j.physbeh.2013.09.009; Grant KM, 2012, J NEUROIMMUNE PHARM, V7, P113, DOI
10.1007/s11481-011-9288-1; Gururajan A, 2012, AUST NZ J PSYCHIAT, V46, P1120, DOI
10.1177/0004867412455232; Hahn B, 2013, BIOL PSYCHIAT, V74, P436, DOI
10.1016/j.biopsych.2013.03.017; Hall W, 2015, BMJ-BRIT MED J, V350, DOI
10.1136/bmj.h1205; Harrod SB, 2005, PHARMACOL BIOCHEM BE, V82, P170, DOI
10.1016/j.pbb.2005.08.005; Hartz SM, 2014, JAMA PSYCHIAT, V71, P248, DOI
10.1001/jamapsychiatry.2013.3726; Hazane F, 2009, NEUROTOX RES, V15, P311, DOI
10.1007/s12640-009-9035-z; Holtz NA, 2012, DRUG ALCOHOL DEPEN, V120, P233, DOI
10.1016/j.drugalcdep.2011.07.010; Jeanblanc J, 2015, ADDICT BIOL, V20, P490, DOI
10.1111/adb.12146; Johnson JL, 2010, BMC PSYCHIATRY, V10, DOI 10.1186/1471-244X-10-
101; Juarez J, 1999, ALCOHOL, V19, P15, DOI 10.1016/S0741-8329(99)00010-5;
Kalejaiye O, 2013, J DRUG ALCOHOL RES, V1, DOI [10.4303/jdar/235709, DOI
10.4303/JDAR/235709]; Kalyoncu A, 2005, J PSYCHOPHARMACOL, V19, P301, DOI
10.1177/0269881105051542; Karlsson RM, 2013, PSYCHOPHARMACOLOGY, V226, P45, DOI
10.1007/s00213-012-2882-y; Kern AM, 2014, J DUAL DIAGN, V10, P52, DOI
10.1080/15504263.2013.867199; Kerner B, 2015, PSYCHIAT RES, V225, P395, DOI
10.1016/j.psychres.2014.12.006; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259;
Koskinen J, 2009, ACTA PSYCHIAT SCAND, V120, P85, DOI 10.1111/j.1600-
0447.2009.01385.x; Krystal JH, 2006, NEUROTOX RES, V10, P235, DOI
10.1007/BF03033360; Kucerova Jana, 2014, Recent Pat CNS Drug Discov, V9, P13;
Kucerova J, 2012, INT J NEUROPSYCHOPH, V15, P1503, DOI 10.1017/S1461145711001684;
Kucerova J, 2009, NEUROENDOCRINOL LETT, V30, P663; Liu X, 2004, NEUROREPORT, V15,
P203, DOI 10.1097/01.wnr.0000103454.27946.88; Lodge DJ, 2012, INT J NEUROPSYCHOPH,
V15, P69, DOI 10.1017/S1461145711000113; Lodge DJ, 2009, BEHAV BRAIN RES, V204,
P306, DOI 10.1016/j.bbr.2009.01.031; Lybrand J, 2009, PSYCHIAT CLIN N AM, V32,
P821, DOI 10.1016/j.psc.2009.09.002; Lynch WJ, 2004, NEUROPSYCHOPHARMACOL, V29,
P943, DOI 10.1038/sj.npp.1300389; Lynch WJ, 2000, PSYCHOPHARMACOLOGY, V148, P196,
DOI 10.1007/s002130050042; Mackowick KM, 2014, PROG NEURO-PSYCHOPH, V52, P79, DOI
10.1016/j.pnpbp.2013.07.010; Malave Lauren B., 2014, Journal of Caffeine Research,
V4, P35, DOI 10.1089/jcr.2014.0004; McLean D, 2012, AUST NZ J PSYCHIAT, V46, P132,
DOI 10.1177/0004867411433211; McLoughlin BC, 2014, COCHRANE DB SYST REV, DOI
10.1002/14651858.CD004837.pub3; Melle I, 2010, ARCH SUICIDE RES, V14, P158, DOI
10.1080/13811111003704787; Mendrek A, 2015, FRONT PSYCHIATRY, V6, DOI
10.3389/fpsyt.2015.00083; Mesholam-Gately RI, 2014, SCHIZOPHR RES, V155, P45, DOI
10.1016/j.schres.2014.03.002; Micale V, 2013, CELL TISSUE RES, V354, P309, DOI
10.1007/s00441-013-1692-9; Moore H, 2006, BIOL PSYCHIAT, V60, P253, DOI
10.1016/j.biopsych.2006.01.003; Murawski NJ, 2011, ALCOHOL CLIN EXP RES, V35,
P1160, DOI 10.1111/j.1530-0277.2011.01449.x; Ng E, 2013, NEUROSCI BIOBEHAV R, V37,
P896, DOI 10.1016/j.neubiorev.2013.03.025; O'Connor EC, 2011, NEUROSCI BIOBEHAV R,
V35, P912, DOI 10.1016/j.neubiorev.2010.10.012; Perez SM, 2014, J NEUROSCI, V34,
P9261, DOI 10.1523/JNEUROSCI.0588-14.2014; Perez SM, 2013, INT J NEUROPSYCHOPH,
V16, P1331, DOI 10.1017/S1461145712001344; Piano MR, 2007, CARDIOVASC TOXICOL, V7,
P247, DOI 10.1007/s12012-007-9002-y; Piano MR, 2005, ALCOHOL, V35, P113, DOI
10.1016/j.alcohol.2005.03.002; Pistovcakova J, 2008, PHARMACOPSYCHIATRY, V41, P54,
DOI 10.1055/s-2007-993212; REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511;
Reichel CM, 2012, PSYCHOPHARMACOLOGY, V223, P371, DOI 10.1007/s00213-012-2727-8;
Reichel Carmela M, 2009, Curr Drug Abuse Rev, V2, P184; Richtand NM, 2012,
PSYCHOPHARMACOLOGY, V222, P313, DOI 10.1007/s00213-012-2646-8;
ROBINSON TE, 1982, BRAIN RES, V253, P231, DOI 10.1016/0006-8993(82)90690-4;
ROBINSON TE, 1984, PSYCHOPHARMACOLOGY, V84, P466, DOI 10.1007/BF00431451; Roth ME,
2004, PSYCHOPHARMACOLOGY, V172, P443, DOI 10.1007/s00213-003-1670-0; Ruda-Kucerova
J, 2015, WORLD J BIOL PSYCHIA, V16, P521, DOI 10.3109/15622975.2015.1077991; Ruda-
Kucerova J, 2015, FRONT PSYCHIATRY, V6, DOI 10.3389/fpsyt.2015.00091; Samaha AN,
2014, PROG NEURO-PSYCHOPH, V52, P9, DOI 10.1016/j.pnpbp.2013.06.008; SAMSON HH,
1988, ALCOHOL CLIN EXP RES, V12, P591, DOI 10.1111/j.1530-0277.1988.tb00248.x;
Schindler CW, 2002, EUR J PHARMACOL, V442, P231, DOI 10.1016/S0014-2999(02)01550-9;
Schmidt LM, 2011, SCHIZOPHR RES, V130, P228, DOI 10.1016/j.schres.2011.04.011;
Semple DM, 2005, J PSYCHOPHARMACOL, V19, P187, DOI 10.1177/0269881105049040; Stohr
T, 1998, PHARMACOL BIOCHEM BE, V59, P813, DOI 10.1016/S0091-3057(97)00542-X; Tseng
KY, 2009, BEHAV BRAIN RES, V204, P295, DOI 10.1016/j.bbr.2008.11.039; VANHAAREN F,
1991, PHARMACOL BIOCHEM BE, V39, P923, DOI 10.1016/0091-3057(91)90054-6; VANHEST A,
1987, PHYSIOL BEHAV, V39, P263, DOI 10.1016/0031-9384(87)90019-9; Volkow ND, 2004,
BIOL PSYCHIAT, V56, P714, DOI 10.1016/j.biopsych.2004.07.007; Volkow ND, 2009,
SCHIZOPHRENIA BULL, V35, P469, DOI 10.1093/schbul/sbp016; Wedekind D, 2010, WORLD J
BIOL PSYCHIA, V11, P390, DOI 10.3109/15622970802176487; Wing VC, 2012, ANN NY ACAD
SCI, V1248, P89, DOI 10.1111/j.1749-6632.2011.06261.x; Yahyavi-Firouz-Abadi N,
2009, PHARMACOL THERAPEUT, V124, P235, DOI 10.1016/j.pharmthera.2009.06.014; Yui K,
2000, ANN NY ACAD SCI, V914, P1, DOI 10.1111/j.1749-6632.2000.tb05178.x 90
10 10 0 9 TAYLOR & FRANCIS LTD ABINGDON 2-4 PARK SQUARE,
MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND 1562-2975 1814-1412 WORLD
J BIOL PSYCHIA World J. Biol. Psychiatry MAR 2017 18 2
129 142 10.1080/15622975.2016.1190032 14
Psychiatry Psychiatry EM1UW WOS:000395103600004 27223864
2019-09-25
J Schnell, T; Gliese, R; Schroter, R; Kasten, E; Gouzoulis-Mayfrank, E
Schnell, Thomas; Gliese, Rajac; Schroeter, Romy; Kasten, Erich;
Gouzoulis-Mayfrank, Euphrosyne Motivational Changes of Cannabis
Use Prior to and During the Course of Schizophrenia AMERICAN JOURNAL ON
ADDICTIONS English Article
SELF-MEDICATION HYPOTHESIS; SUBSTANCE USE; DRUG-ABUSE; REASONS; PSYCHOSIS;
DISORDERS; SCALE; RISK; COHORT Background and Objectives: We investigated
subjective reasons/motivation for cannabis use in patients with schizophrenia (n =
51) compared to otherwise healthy cannabis users (n = 109). Moreover, we explored
possible changes in the motivational patterns of both groups over time. Methods: A
questionnaire was developed with six dimensions of motivations to use cannabis:
affect regulation, relaxation, habit, structuring everyday life, creativity, and
sociability. Participants filled out the instrument regarding their present and
initial use of cannabis. Results: At the time of onset of consumption, groups only
differed significantly in habit with higher ratings for patients with schizophrenia
and cannabis use (SCH+CAN group) and in sociability with higher ratings for
otherwise healthy users (CAN group). In respect of present use, the motivation to
consume cannabis was significantly higher for affect regulation and structuring
everyday life in the SCH+CAN group and for relaxation and sociability in the CAN
group. With reference to time-based variations, the SCH+CAN group reported
increased relevance of structuring everyday life over time. Furthermore, the CAN
group reported increased importance of habit over time, whereas the SCH+CAN
patients showed decreased ratings of habit over time. Conclusions and Scientific
Significance: Our findings must be considered preliminary because of the
retrospective nature of the assessment. Nevertheless, the present study provides an
indication of the time-dependent variation of cannabis-use motivation in
schizophrenia, which may provide a better understanding of the functions of
cannabis use within the population. Results argue for specific motivational based
interventions for the group of schizophrenia patients with regular cannabis use.
[Schnell, Thomas; Gouzoulis-Mayfrank, Euphrosyne] LVR Clin Cologne, Cologne,
Germany; [Schnell, Thomas; Gliese, Rajac; Schroeter, Romy; Kasten, Erich] Univ Appl
Sci & Med Univ, MSH, Kaiserkai 1, D-20457 Hamburg, Germany Schnell, T (reprint
author), Univ Appl Sci & Med Univ, MSH, Kaiserkai 1, D-20457 Hamburg, Germany.
thomas.schnell@medicalschool-hamburg.de Addington J,
2007, ACTA PSYCHIAT SCAND, V115, P304, DOI 10.1111/j.1600-0447.2006.00900.x;
Addington J, 1997, ACTA PSYCHIAT SCAND, V96, P329, DOI 10.1111/j.1600-
0447.1997.tb09925.x; AMERICAN PSYCHIATRIC ASSOCIATION (A.P.A), 2013, DIAGN STAT MAN
MENT; Arseneault L, 2002, BRIT MED J, V325, P1212, DOI 10.1136/bmj.325.7374.1212;
Bart DP, 2009, AUST NZ J PSYCHIAT, V43, P1155; Blanchard JJ, 1999, J NERV MENT DIS,
V187, P72, DOI 10.1097/00005053-199902000-00002; Dekker N, 2009, PSYCHOPATHOLOGY,
V42, P350, DOI 10.1159/000236906; DIXON L, 1991, AM J PSYCHIAT, V148, P224; Drake
RE, 2000, SCHIZOPHRENIA BULL, V26, P105, DOI 10.1093/oxfordjournals.schbul.a033429;
Frey A, 2010, Z THEORIE PRAXIS ERZ, V24, P224; Goswami S, 2004, AM J ADDICTION,
V13, P139, DOI 10.1080/10550490490435795; Green B, 2004, DRUG ALCOHOL REV, V23,
P445, DOI 10.1080/09595230412331324563; Gregg L, 2007, CLIN PSYCHOL REV, V27, P494,
DOI 10.1016/j.cpr.2006.09.004; Gregg L, 2009, ADDICT BEHAV, V34, P830, DOI
10.1016/j.addbeh.2009.03.004; HADDOCK G, 1995, PERS INDIV DIFFER, V19, P301, DOI
10.1016/0191-8869(95)00063-C; Hames A, 2012, EARLY INTERV PSYCHIA, V6, P38, DOI
10.1111/j.1751-7893.2011.00316.x; Hermle L, 2013, NERVENARZT, V84, P315, DOI
10.1007/s00115-011-3459-4; Kelly TM, 2012, ADDICT BEHAV, V37, P11, DOI
10.1016/j.addbeh.2011.09.010; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231,
DOI 10.3109/10673229709030550; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259;
Kolliakou A, 2011, INT J DEV NEUROSCI, V29, P335, DOI
10.1016/j.ijdevneu.2010.11.006; Lambert M, 1997, PSYCHIAT PRAX, V24, P185;
Lingjaerde O, 1987, Acta Psychiatr Scand Suppl, V334, P1; Meier MH, 2012, P NATL
ACAD SCI USA, V109, pE2657, DOI 10.1073/pnas.1206820109; MONTGOMERY SA, 1979, BRIT
J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382; Moore THM, 2007, LANCET, V370,
P319, DOI 10.1016/S0140-6736(07)61162-3; REGIER DA, 1990, JAMA-J AM MED ASSOC,
V264, P2511; Saddichha Sahoo, 2010, Prim Care Companion J Clin Psychiatry, V12, DOI
10.4088/PCC.09m00926gry; Schaub M, 2008, AUST NZ J PSYCHIAT, V42, P1060, DOI
10.1080/00048670802512016; Schnell T, 2010, NERVENARZT, V81, P323, DOI
10.1007/s00115-009-2862-6; Schofield D, 2006, AUST NZ J PSYCHIAT, V40, P570, DOI
10.1080/j.1440-1614.2006.01840.x; van Dijk D, 2012, SCHIZOPHR RES, V137, P50, DOI
10.1016/j.schres.2012.01.016; VENTURA J, 1993, INT J METH PSYCH RES, V3, P221;
Yucel M, 2012, SCHIZOPHRENIA BULL, V38, P316, DOI 10.1093/schbul/sbq079; Zammit S,
2002, BRIT MED J, V325, P1199, DOI 10.1136/bmj.325.7374.1199 35 0 0
0 5 WILEY HOBOKEN 111 RIVER ST, HOBOKEN 07030-5774, NJ USA 1055-
0496 1521-0391 AM J ADDICTION Am. J. Addict. MAR 2017 26 2
122 128 10.1111/ajad.12494 7
Substance Abuse Substance Abuse EP3QK WOS:000397296600005 28004866
2019-09-25
J Ortega, LA; Solano, JL; Torres, C; Papini, MR Ortega,
Leonardo A.; Solano, Jose L.; Torres, Carmen; Papini, Mauricio R.
Reward loss and addiction: Opportunities for cross-pollination PHARMACOLOGY
BIOCHEMISTRY AND BEHAVIOR English Review
Reward loss; Reward devaluation; Reward omission; Reward comparison;
Negative emotion; Addiction Substance use disorder SUCCESSIVE NEGATIVE CONTRAST;
HIGH-RHA-I; MEDIAL PREFRONTAL CORTEX; ANXIETY SELF-MEDICATION; OPIOID RECEPTOR
AGONIST; RATS RATTUS-NORVEGICUS; PARTIAL-REINFORCEMENT; NUCLEUS-ACCUMBENS; LATERAL
HABENULA; COCAINE-SEEKING Paradigms used to study the response to and
consequences of exposure to reward loss have been underutilized in approaches to
the psychobiology of substance use disorders. We propose here that bringing these
two areas into contact will help expanding our understanding of both reward loss
and addictive behavior, hence opening up opportunities for cross-pollination. This
review focuses on two lines of research that point to parallels. First, several
neurochemical systems involved in addiction are also involved in the modulation of
the behavioral effects of reward loss, including opioid, GABA, and dopamine
receptors. Second, there are extensive overlaps in the brain circuitry underlying
both reward loss and addiction. Common components of this system include, at least,
the amygdala, ventral and dorsal striatum, and various prefrontal cortex regions.
Four emerging avenues of research that benefit from emphasis on the common ground
between reward loss and addiction are reviewed, namely, the neural circuitry
involved in reward devaluation, the influence of genetic and reward history on the
behavioral vulnerability and resilience, the role of competing natural rewards, and
emotional self-medication, An understanding of the role of reward loss in addiction
will point to a deeper understanding of the initiation and maintenance of substance
use disorders. (C) 2017 Elsevier Inc. All rights reserved. [Ortega, Leonardo A.;
Solano, Jose L.] Fdn Univ Konrad Lorenz, Dept Psychol, Carrera 9 Bis 62-43, Bogota,
Colombia; [Torres, Carmen] Univ Jaen, Dept Psychol, Jaen 23071, Spain; [Papini,
Mauricio R.] Texas Christian Univ, Dept Psychol, Ft Worth, TX 76129 USA
Ortega, LA (reprint author), Fdn Univ Konrad Lorenz, Dept Psychol, Carrera 9
Bis 62-43, Bogota, Colombia. leonardoa.ortegam@konradlorenz.edu.co Torres,
Carmen/K-8250-2014 Torres, Carmen/0000-0001-8573-0990 Fundacion Universitaria
Konrad Lorenz, Colombia; Ministerio de Economia y Competitividad, Spain [PSI-2013-
44945-P]; TCU/IS, USA [66022] This work was supported by Fundacion Universitaria
Konrad Lorenz, Colombia [to LAO and JLS]; Ministerio de Economia y Competitividad,
Spain [grant number PSI-2013-44945-P; to CT); TCU/IS, USA [grant number 66022, to
MRP]. Correspondence concerning this article may be addressed to L A. Ortega,
Departmento de Psicologia, Fundacion Universitaria Konrad Lorenz, Bogota, Colombia.
(leonardoa.ortegam@ konradlorenz.edu.co). ADAMS CD, 1982, Q J EXP PSYCHOL-B, V34,
P77, DOI 10.1080/14640748208400878; Ahmed SH, 2012, NEUROSCIENCE, V211, P107, DOI
10.1016/j.neuroscience.2011.08.014; Ahmed SH, 1997, PSYCHOPHARMACOLOGY, V132, P289,
DOI 10.1007/s002130050347; ALEXANDER BK, 1981, PHARMACOL BIOCHEM BE, V15, P571, DOI
10.1016/0091-3057(81)90211-2; American Psychiatric Association, 2013, DSM 5 DIAGN
STAT MAN; Amsel A., 1992, FRUSTRATION THEORY A; ANISMAN H, 1974, PHARMACOL BIOCHEM
BE, V2, P27, DOI 10.1016/0091-3057(74)90131-2; Anthony James C., 1994, Experimental
and Clinical Psychopharmacology, V2, P244, DOI 10.1037/1064-1297.2.3.244; BANKS A,
1967, J COMP PHYSIOL PSYCH, V64, P262, DOI 10.1037/h0088013; Baratta MV, 2015,
NEUROBIOL STRESS, V2, P20, DOI 10.1016/j.ynstr.2015.03.002; Barker AT, 2016, DRUG
ALCOHOL DEPEN, V163, pS19, DOI 10.1016/j.drugalcdep.2015.11.040; Barr AM, 2002,
PHARMACOL BIOCHEM BE, V71, P293, DOI 10.1016/S0091-3057(01)00664-5; Barret ST,
2013, PHARMACOL BIOCHEM BE, V114, P9, DOI 10.1016/j.pbb.2013.10.012; BECK CHM,
1990, PSYCHOPHARMACOLOGY, V100, P323, DOI 10.1007/BF02244600; BECKER HC, 1982,
PSYCHOPHARMACOLOGY, V77, P253, DOI 10.1007/BF00464576; BECKER HC, 1983,
PSYCHOPHARMACOLOGY, V80, P35, DOI 10.1007/BF00427491; BECKER HC, 1984, PHYSIOL
BEHAV, V33, P707, DOI 10.1016/0031-9384(84)90035-0; Bentosela M, 2006, BEHAV
NEUROSCI, V120, P371, DOI 10.1037/0735-7044.120.2.371; Bentosela M., 2005, SUMA
PSICOL, V12, P87; BIALIK RJ, 1982, PHARMACOL BIOCHEM BE, V16, P279, DOI
10.1016/0091-3057(82)90161-7; Bielavska E, 1996, BEHAV BRAIN RES, V81, P25, DOI
10.1016/S0166-4328(96)00039-3; Biesdorf C, 2015, NEUROBIOL LEARN MEM, V123, P125,
DOI 10.1016/j.nlm.2015.06.002; BOSHKA SC, 1966, PSYCHOL REC, V16, P541; Brady KT,
2005, AM J PSYCHIAT, V162, P1483, DOI 10.1176/appi.ajp.162.8.1483; Brevers D, 2015,
BEHAV BRAIN RES, V278, P262, DOI 10.1016/j.bbr.2014.09.026; Brewer A, 2017, BEHAV
BRAIN RES, V319, P174, DOI 10.1016/j.bbr.2016.11.025; Burns LH, 1999, BEHAV BRAIN
RES, V100, P123, DOI 10.1016/S0166-4328(98)00119-3; Caldwell EE, 2010, ALCOHOL,
V44, P265, DOI 10.1016/j.alcohol.2010.02.012; Capriles N, 2003, PSYCHOPHARMACOLOGY,
V168, P66, DOI 10.1007/s00213-002-1283-z; Center for Behavioral Health Statistics
and Quality, 2015, HHS PUBL, V50; Cisler JM, 2013, PSYCHIAT RES-NEUROIM, V213, P39,
DOI 10.1016/j.pscychresns.2013.02.007; COE CL, 1983, BEHAV NEUROSCI, V97, P654, DOI
10.1037/0735-7044.97.4.654; Conrad S.E., 2016, SOC NEUROSCIENCE; COOVER GD, 1971,
PHYSIOL BEHAV, V6, P261, DOI 10.1016/0031-9384(71)90037-0; CRABBE JC, 1990, ALCOHOL
CLIN EXP RES, V14, P141, DOI 10.1111/j.1530-0277.1990.tb00461.x; Craig AD, 2002,
NAT REV NEUROSCI, V3, P655, DOI 10.1038/nrn894; Cuenya L, 2012, PHYSIOL BEHAV,
V105, P1112, DOI 10.1016/j.physbeh.2011.12.006; Cuenya L., 2014, INT J COMP
PSYCHOL, V27, P459; Cuenya L, 2015, LEARN MOTIV, V52, P22, DOI
10.1016/j.lmot.2015.08.003; Cunningham CL, 1998, PSYCHOPHARMACOLOGY, V139, P62, DOI
10.1007/s002130050690; Daniel AM, 2009, NEUROBIOL LEARN MEM, V92, P439, DOI
10.1016/j.nlm.2009.06.003; DAVIS H, 1976, PHYSIOL BEHAV, V17, P687, DOI
10.1016/0031-9384(76)90170-0; DREWNOWSKI A, 1975, PSYCHOPHARMACOLOGIA, V43, P233,
DOI 10.1007/BF00429256; Eagle DM, 1999, PSYCHOBIOLOGY, V27, P267; Edwards S, 2010,
FUTUR NEUROL, V5, P393, DOI 10.2217/FNL.10.14; Egli M, 2012, NEUROSCI BIOBEHAV R,
V36, P2179, DOI 10.1016/j.neubiorev.2012.07.010; Ersche KD, 2016, SCIENCE, V352,
P1468, DOI 10.1126/science.aaf3700; Everitt BJ, 2016, ANNU REV PSYCHOL, V67, P23,
DOI 10.1146/annurev-psych-122414-033457; Everitt BJ, 2013, NEUROSCI BIOBEHAV R,
V37, P1946, DOI 10.1016/j.neubiorev.2013.02.010; Everitt BJ, 2003, ANN NY ACAD SCI,
V985, P233; FELDON J, 1981, PSYCHOPHARMACOLOGY, V73, P269, DOI 10.1007/BF00422416;
Finger EC, 2008, NEUROIMAGE, V43, P748, DOI 10.1016/j.neuroimage.2008.08.021;
Fisher HE, 2010, J NEUROPHYSIOL, V104, P51, DOI 10.1152/jn.00784.2009; Flaherty
C.F., 1996, INCENTIVE RELATIVITY; FLAHERTY CF, 1986, ANIM LEARN BEHAV, V14, P315,
DOI 10.3758/BF03200073; Flaherty CF, 1996, PHYSIOL BEHAV, V60, P645, DOI
10.1016/S0031-9384(96)80043-6; FLAHERTY CF, 1990, Q J EXP PSYCHOL-B, V42, P87;
FLAHERTY CF, 1980, PSYCHOPHARMACOLOGY, V69, P161, DOI 10.1007/BF00427643; FLAHERTY
CF, 1982, PHYSIOL PSYCHOL, V10, P122; FLAHERTY CF, 1994, J EXP PSYCHOL-ANIM B, V20,
P3, DOI 10.1037/0097-7403.20.1.3; FLAHERTY CF, 1989, BEHAV NEURAL BIOL, V51, P145,
DOI 10.1016/S0163-1047(89)90782-6; FLAHERTY CF, 1988, ANIM LEARN BEHAV, V16, P47,
DOI 10.3758/BF03209042; FLAHERTY CF, 1982, ANIM LEARN BEHAV, V10, P177, DOI
10.3758/BF03212267; FLAHERTY CF, 1985, ANIM LEARN BEHAV, V13, P309, DOI
10.3758/BF03200025; FLYNN FW, 1988, BEHAV NEUROSCI, V102, P934, DOI 10.1037/0735-
7044.102.6.934; Fontanini A, 2009, J NEUROSCI, V29, P2486, DOI
10.1523/JNEUROSCI.3898-08.2009; Forget B, 2010, BIOL PSYCHIAT, V68, P265, DOI
10.1016/j.biopsych.2010.01.029; Freet CS, 2006, PHARMACOL BIOCHEM BE, V85, P378,
DOI 10.1016/j.pbb.2006.09.005; Friedman A, 2011, NEUROPHARMACOLOGY, V60, P381, DOI
10.1016/j.neuropharm.2010.10.006; Friedman A, 2010, NEUROPHARMACOLOGY, V59, P452,
DOI 10.1016/j.neuropharm.2010.06.008; Fullgrabe MW, 2007, PHARMACOL BIOCHEM BE,
V86, P320, DOI 10.1016/j.pbb.2006.10.004; Gabbott PLA, 2005, J COMP NEUROL, V492,
P145, DOI 10.1002/cne.20738; GANDELMAN R, 1968, J COMP PHYSIOL PSYCH, V66, P753,
DOI 10.1037/h0026527; Gao SB, 2011, BEHAV BRAIN RES, V223, P411, DOI
10.1016/j.bbr.2011.04.030; Genn RF, 2004, PSYCHOPHARMACOLOGY, V177, P93, DOI
10.1007/s00213-004-1932-5; Genn RF, 2004, BEHAV NEUROSCI, V118, P869, DOI
10.1037/0735-7044.118.4.869; Giorgi O, 2007, NEUROSCI BIOBEHAV R, V31, P148, DOI
10.1016/j.neubiorev.2006.07.008; Gipson C.D., 2016, DRUG ABUSE ADOLESCEN, P37;
GLAZER HI, 1972, PSYCHOPHARMACOLOGIA, V26, P387, DOI 10.1007/BF00421904; Glueck AC,
2015, NEUROSCI LETT, V587, P93, DOI 10.1016/j.neulet.2014.12.036; GOEDERS NE, 1994,
PSYCHOPHARMACOLOGY, V114, P63, DOI 10.1007/BF02245445; Goldstein RZ, 2011, NAT REV
NEUROSCI, V12, P652, DOI 10.1038/nrn3119; Gomez M., 2015, DRUG ALCOHOL DEPEN, V146,
pe123; Gomez MJ, 2009, PSICOLOGICA, V30, P181; GONZALEZ SC, 1971, PHARMACOLOGY, V6,
P186, DOI 10.1159/000136241; Gordon HW, 2002, PSYCHONEUROENDOCRINO, V27, P115, DOI
10.1016/S0306-4530(01)00039-7; Gray J. A., 1987, PSYCHOL FEAR STRESS; Gray JA,
2000, NEUROPSYCHOLOGY ANXI; Griffin AL, 2004, LEARN MEMORY, V11, P604, DOI
10.1101/lm.78404; Grigson PS, 2007, BEHAV NEUROSCI, V121, P1234, DOI 10.1037/0735-
7044.121.6.1234; Grigson Patricia Sue, 2008, Drug Discov Today Dis Models, V5,
P227; Grigson PS, 1997, BEHAV NEUROSCI, V111, P129, DOI 10.1037/0735-
7044.111.1.129; GRIGSON PS, 1994, BEHAV NEUROSCI, V108, P714, DOI 10.1037/0735-
7044.108.4.714; GUROWITZ EM, 1970, J COMP PHYSIOL PSYCH, V70, P476, DOI
10.1037/h0028702; Haack AK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092701;
Harloe JP, 2008, LEARN MEMORY, V15, P806, DOI 10.1101/lm.1113008;
Hassanbeigi A, 2013, PROCD SOC BEHV, V84, P1333, DOI 10.1016/j.sbspro.2013.06.752;
Hayaki J, 2005, DRUG ALCOHOL DEPEN, V78, P65, DOI 10.1016/j.drugalcdep.2004.09.002;
HEISE GA, 1970, PSYCHOPHARMACOLOGIA, V16, P345, DOI 10.1007/BF00404846; HERLING S,
1979, PSYCHOPHARMACOLOGY, V64, P261, DOI 10.1007/BF00427508; Holloway KS, 2012,
SOIOAFFECTIVE NEUROS, V2, DOI 10.3402/snp.v2i0.14874; HOLMES TH, 1967, J PSYCHOSOM
RES, V11, P213, DOI 10.1016/0022-3999(67)90010-4; Huston JP, 2013, NEUROSCI
BIOBEHAV R, V37, P2059, DOI 10.1016/j.neubiorev.2013.02.016; Jenney CB, 2016, BRAIN
RES BULL, V123, P61, DOI 10.1016/j.brainresbull.2015.10.008; Jimenez-Garcia AM,
2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164331; Jones LM, 2006, CURR OPIN
NEUROBIOL, V16, P420, DOI 10.1016/j.conb.2006.06.011; Gomez MJ, 2008, BEHAV BRAIN
RES, V194, P187, DOI 10.1016/j.bbr.2008.07.009; Gomez MJ, 2009, PHYSIOL BEHAV, V97,
P374, DOI 10.1016/j.physbeh.2009.03.003; Judice-Daher DM, 2013, BEHAV BRAIN RES,
V252, P439, DOI 10.1016/j.bbr.2013.06.028; Justel N, 2011, REV ARGENT CIENC COM,
V3, P7; Justel N, 2014, LEARN BEHAV, V42, P58, DOI 10.3758/s13420-013-0124-8;
Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403;
Kamenetzky GV, 2009, BEHAV PROCESS, V82, P352, DOI 10.1016/j.beproc.2009.08.001;
Kamenetzky GV, 2008, AV PSICOL LATINOAM, V26, P135; Kamenetzky GV, 2009, REV MEX
PSICOL, V26, P193; Kawasaki K, 2015, NEUROSCIENCE, V303, P73, DOI
10.1016/j.neuroscience.2015.06.053; Kawasaki K, 1997, LIFE SCI, V61, P1721, DOI
10.1016/S0024-3205(97)00778-9; Kawasaki K., 2017, REWARD LOSS BA UNPUB; Kelley AE,
2002, J NEUROSCI, V22, P3306; Kessler RC, 1997, ANNU REV PSYCHOL, V48, P191, DOI
10.1146/annurev.psych.48.1.191; Keyes KM, 2011, PSYCHOPHARMACOLOGY, V218, P1, DOI
10.1007/s00213-011-2236-1; Khantzian EJ, 2013, ADDICTION, V108, P668, DOI
10.1111/add.12004; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259; Kimura M, 2007,
NAT NEUROSCI, V10, P677, DOI 10.1038/nn0607-677; Konopka A, 2013, PROG NEURO-
PSYCHOPH, V40, P229, DOI 10.1016/j.pnpbp.2012.09.001; Koob GF, 2016, LANCET
PSYCHIAT, V3, P760, DOI 10.1016/S2215-0366(16)00104-8; Koob George F, 2013, Front
Psychiatry, V4, P72, DOI 10.3389/fpsyt.2013.00072; Koob GF, 2010,
NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110; Koob GF, 2001,
NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0; LADER M, 1994,
EUR NEUROPSYCHOPHARM, V4, P85, DOI 10.1016/0924-977X(94)90001-9; Lanciego J.L.,
2012, COLD SPRING HARB PER, V2, P1; Lecca S, 2014, EUR J NEUROSCI, V39, P1170, DOI
10.1111/ejn.12480; LEMOAL M, 1979, LIFE SCI, V24, P1631, DOI 10.1016/0024-
3205(79)90245-5; Leong KC, 2016, PHYSIOL BEHAV, V164, P330, DOI
10.1016/j.physbeh.2016.06.021; Leslie JC, 2005, J EXP ANAL BEHAV, V84, P327, DOI
10.1901/jeab.2005.71-04; Leslie JC, 2012, PSYCHOPHARMACOLOGY, V223, P223, DOI
10.1007/s00213-012-2710-4; Leszczuk MH, 2000, BEHAV BRAIN RES, V116, P61, DOI
10.1016/S0166-4328(00)00265-5; Liao RM, 2003, PHARMACOL BIOCHEM BE, V74, P953, DOI
10.1016/S0091-3057(03)00023-6; Lin JY, 2009, BEHAV NEUROSCI, V123, P810, DOI
10.1037/a0016460; Lu YL, 2014, NEUROSCIENCE, V277, P139, DOI
10.1016/j.neuroscience.2014.06.053; Lucantonio F, 2015, BIOL PSYCHIAT, V77, P912,
DOI 10.1016/j.biopsych.2014.11.017; Mantsch JR, 2007, BRAIN RES, V1167, P101, DOI
10.1016/j.brainres.2007.05.080; Manzo L., 2015, INT J COMP PSYCHOL, V28, P1; Manzo
L, 2015, BEHAV BRAIN RES, V278, P90, DOI 10.1016/j.bbr.2014.09.017; Manzo L, 2014,
PHYSIOL BEHAV, V123, P86, DOI 10.1016/j.physbeh.2013.10.002; Manzo L, 2012, PHYSIOL
BEHAV, V108, P1, DOI 10.1016/j.physbeh.2012.07.002; MARKSKAUFMAN R, 1984, ADDICT
BEHAV, V9, P235, DOI 10.1016/0306-4603(84)90015-7; Maroteaux M, 2012, J NEUROSCI,
V32, P12641, DOI 10.1523/JNEUROSCI.2405-12.2012; Matthews Keith, 1996, Physiology
and Behavior, V59, P99, DOI 10.1016/0031-9384(95)02069-1; MCCOY DF, 1972, PSYCHOL
REP, V30, P867, DOI 10.2466/pr0.1972.30.3.867; McDonald AJ, 1998, PROG NEUROBIOL,
V55, P257, DOI 10.1016/S0301-0082(98)00003-3; McLaughlin RJ, 2007, NEUROSCIENCE,
V146, P1484, DOI 10.1016/j.neuroscience.2007.03.025; Mendoza J, 2015, NEUROBIOL
LEARN MEM, V118, P198, DOI 10.1016/j.nlm.2014.12.006; Miceli M, 2015, EXPECTANCY
EMOTION; Mitchell C, 1998, PHYSIOL BEHAV, V64, P287, DOI 10.1016/S0031-
9384(98)00072-9; Mitchell CP, 2004, PHARMACOL BIOCHEM BE, V79, P523, DOI
10.1016/j.pbb.2004.09.004; MOLINENGO L, 1964, PSYCHOPHARMACOLOGIA, V6, P347, DOI
10.1007/BF00404245; MORALES A, 1992, PHARMACOL BIOCHEM BE, V43, P153, DOI
10.1016/0091-3057(92)90651-U; MORLEY BJ, 1978, PSYCHOPHARMACOLOGY, V56, P301, DOI
10.1007/BF00432853; Mustaca A.E., 2009, RECIENTES DESARROLLO, V2, P921; Mustaca AE,
2005, INT J COMP PSYCHOL, V18, P255; Naqvi NH, 2007, SCIENCE, V315, P531, DOI
10.1126/science.1135926; Naqvi NH, 2010, BRAIN STRUCT FUNCT, V214, P435, DOI
10.1007/s00429-010-0268-7; Naqvi NH, 2009, TRENDS NEUROSCI, V32, P56, DOI
10.1016/j.tins.2008.09.009; NASH JF, 1985, LIFE SCI, V37, P757; Nestler EJ, 2004,
NEUROPHARMACOLOGY, V47, P24, DOI 10.1016/j.neuropharm.2004.06.031; Nikiforuk A,
2009, EUR NEUROPSYCHOPHARM, V19, P41, DOI 10.1016/j.euroneuro.2008.08.002; Norris
JN, 2011, BEHAV BRAIN RES, V223, P348, DOI 10.1016/j.bbr.2011.05.001; Norris JN,
2009, PHARMACOL BIOCHEM BE, V94, P81, DOI 10.1016/j.pbb.2009.07.012; OLDS ME, 1970,
NEUROPHARMACOLOGY, V9, P519, DOI 10.1016/0028-3908(70)90002-X; Ortega LA, 2014, INT
J COMP PSYCHOL, V27, P18; Ortega LA, 2014, PHARMACOL BIOCHEM BE, V116, P96, DOI
10.1016/j.pbb.2013.11.031; Ortega LA, 2013, LEARN MOTIV, V44, P159, DOI
10.1016/j.lmot.2013.02.001; Ortega LA, 2013, BEHAV BRAIN RES, V244, P120, DOI
10.1016/j.bbr.2013.01.029; Ortega LA, 2011, BEHAV NEUROSCI, V125, P988, DOI
10.1037/a0025769; Ortega LA, 2011, LEARN MOTIV, V42, P203, DOI
10.1016/j.lmot.2011.03.003; Packard MG, 1996, NEUROBIOL LEARN MEM, V65, P65, DOI
10.1006/nlme.1996.0007; Panayi MC, 2014, NEUROBIOL LEARN MEM, V108, P78, DOI
10.1016/j.nlm.2013.08.002; Papini M., 2006, INT J PSYCHOL PSYCHO, V6, P189; Papini
M. R., 1997, REV GEN PSYCHOL, V1, P175, DOI [10.1037/1089-2680.1.2.175, DOI
10.1037/1089-2680.1.2.175]; Papini MR, 2015, NEUROSCI BIOBEHAV R, V48, P53, DOI
10.1016/j.neubiorev.2014.11.012; Papini MR, 2011, HANDBOOK OF BEHAVIOR, FOOD AND
NUTRITION, P1011, DOI 10.1007/978-0-387-92271-3_66; Papini MR, 2009, INT J COMP
PSYCHOL, V22, P170; Papini S, 2014, BEHAV BRAIN RES, V275, P212, DOI
10.1016/j.bbr.2014.09.006; Pare D, 2004, J NEUROPHYSIOL, V92, P1, DOI
10.1152/jn.00153.2004; Paulus MP, 2006, BIOL PSYCHIAT, V60, P383, DOI
10.1016/j.biopsych.2006.03.042; Pecoraro N, 2008, NEUROSCIENCE, V153, P901, DOI
10.1016/j.neuroscience.2008.03.043; Pecoraro N, 2005, BEHAV NEUROSCI, V119, P366,
DOI 10.1037/0735-7044.119.2.366; Pecoraro N, 2009, PHYSIOL BEHAV, V96, P651, DOI
10.1016/j.physbeh.2008.12.018; Pellegrini S, 2005, BEHAV BRAIN RES, V164, P239, DOI
10.1016/j.bbr.2005.06.035; Pellegrini S, 2004, LEARN MOTIV, V35, P303, DOI
10.1016/j.lmot.2004.04.001; Phelps CE, 2015, PSYCHOPHARMACOLOGY, V232, P2697, DOI
10.1007/s00213-015-3905-2; Piazza PV, 1998, TRENDS PHARMACOL SCI, V19, P67, DOI
10.1016/S0165-6147(97)01115-2; PIAZZA PV, 1991, P NATL ACAD SCI USA, V88, P2088,
DOI 10.1073/pnas.88.6.2088; Piazza PV, 1996, ANNU REV PHARMACOL, V36, P359, DOI
10.1146/annurev.pa.36.040196.002043; Picetti R, 2012, PSYCHOPHARMACOLOGY, V220,
P163, DOI 10.1007/s00213-011-2464-4; Pobbe RLH, 2008, LIFE SCI, V82, P1256, DOI
10.1016/j.lfs.2008.04.012; Ramot A, 2012, NEUROBIOL LEARN MEM, V97, P393, DOI
10.1016/j.nlm.2012.03.003; Reilly S, 2003, BEHAV NEUROSCI, V117, P606, DOI
10.1037/0735-7044.117.3.606; Rhodes SEV, 2007, EUR J NEUROSCI, V25, P2498, DOI
10.1111/j.1460-9568.2007.05486.x; Rhodes SEV, 2004, LEARN MEMORY, V11, P611, DOI
10.1101/lm.79704; Robbins TW, 2008, ANN NY ACAD SCI, V1141, P1, DOI
10.1196/annals.1441.020; Robinson TE, 2000, ADDICTION, V95, pS91; Rosas JM, 2007,
BEHAV BRAIN RES, V185, P1, DOI 10.1016/j.bbr.2007.07.027; Rosen A.J., 1967, PSYCHON
SCI, V9, P129; ROWAN GA, 1987, PSYCHOPHARMACOLOGY, V93, P51, DOI
10.1007/BF02439586; ROWAN GA, 1991, J COMP PSYCHOL, V105, P115, DOI 10.1037/0735-
7036.105.2.115; Ruetti E, 2010, REV ARGENT CIENC COM, V2, P45; Ruetti E, 2010, REV
LAT AM PSICOL, V42, P279; Ruetti E, 2009, BEHAV NEUROSCI, V123, P137, DOI
10.1037/a0013805; Sabariego M, 2013, BEHAV BRAIN RES, V257, P62, DOI
10.1016/j.bbr.2013.09.025; Sabariego M, 2011, NEUROSCI LETT, V504, P265, DOI
10.1016/j.neulet.2011.09.044; Saleem KS, 2002, NEURON, V34, P685, DOI
10.1016/S0896-6273(02)00718-3; Salinas JA, 1996, BRAIN RES, V742, P283, DOI
10.1016/S0006-8993(96)01030-X; Sartorius A, 2010, BIOL PSYCHIAT, V67, pE9, DOI
10.1016/j.biopsych.2009.08.027; Sbarra DA, 2008, PERS SOC PSYCHOL REV, V12, P141,
DOI 10.1177/1088868308315702; Schoenbaum G, 2006, TRENDS NEUROSCI, V29, P116, DOI
10.1016/j.tins.2005.12.006; Shaham Y, 2000, BRAIN RES REV, V33, P13, DOI
10.1016/S0165-0173(00)00024-2; SHANAB ME, 1979, J GEN PSYCHOL, V100, P13, DOI
10.1080/00221309.1979.9710521; Shumake J, 2003, Behav Cogn Neurosci Rev, V2, P198,
DOI 10.1177/1534582303259057; Sinha R, 2005, PSYCHOPHARMACOLOGY, V183, P171, DOI
10.1007/s00213-005-0147-8; Sinha R, 2008, ANN NY ACAD SCI, V1141, P105, DOI
10.1196/annals.1441.030; Sinha R, 2007, DRUG ALCOHOL REV, V26, P25, DOI
10.1080/09595230601036960; Smith MA, 2016, PHARMACOL BIOCHEM BE, V150, P94, DOI
10.1016/j.pbb.2016.10.001; SOUBRIE P, 1978, PSYCHOPHARMACOLOGY, V59, P95, DOI
10.1007/BF00428038; Spanagel R, 2014, TRENDS NEUROSCI, V37, P219, DOI
10.1016/j.tins.2014.02.006; Stopper CM, 2014, NAT NEUROSCI, V17, P33, DOI
10.1038/nn.3587; Tan KR, 2011, TRENDS NEUROSCI, V34, P188, DOI
10.1016/j.tins.2011.01.004; Tavares TF, 2014, BEHAV BRAIN RES, V266, P1, DOI
10.1016/j.bbr.2014.02.026; Torres C, 2005, PHYSIOL BEHAV, V85, P377, DOI
10.1016/j.physbeh.2005.02.023; Torres C, 1996, EUR J PHARMACOL, V314, P269, DOI
10.1016/S0014-2999(96)00564-X; Torres
C., 2016, NEUROPATHOLOGY DRUG, V1, P71; Torres C, 2014, INT J COMP PSYCHOL, V27,
P446; Torres C, 2016, NEUROSCIENCE, V332, P13, DOI
10.1016/j.neuroscience.2016.06.041; Tournier BB, 2013, INT J NEUROPSYCHOPH, V16,
P1819, DOI 10.1017/S1461145713000205; Tovote P, 2015, NAT REV NEUROSCI, V16, P317,
DOI 10.1038/nrn3945; Travers JB, 1997, NEUROSCI BIOBEHAV R, V21, P631, DOI
10.1016/S0149-7634(96)00045-0; Ungless MA, 2010, NEUROSCI BIOBEHAV R, V35, P151,
DOI 10.1016/j.neubiorev.2010.04.006; Valenza M, 2016, NEUROPHARMACOLOGY, V105,
P639, DOI 10.1016/j.neuropharm.2016.01.004; Velasquez KM, 2014, FRONT HUM NEUROSCI,
V8, DOI 10.3389/fnhum.2014.00174; Volkow ND, 2014, NEUROPHARMACOLOGY, V76, P235,
DOI 10.1016/j.neuropharm.2013.05.007; Volkow ND, 2000, CEREB CORTEX, V10, P318, DOI
10.1093/cercor/10.3.318; Volkow ND, 2015, CELL, V162, P712, DOI
10.1016/j.cell.2015.07.046; Waldrop AE, 2007, ADDICT BEHAV, V32, P3015, DOI
10.1016/j.addbeh.2007.07.006; WHITEHOU.JM, 1966, PSYCHOPHARMACOLOGIA, V9, P183, DOI
10.1007/BF02198478; WILLIAMS JH, 1990, BEHAV BRAIN RES, V41, P129, DOI
10.1016/0166-4328(90)90149-9; Wood M, 2005, BEHAV NEUROSCI, V119, P446, DOI
10.1037/0735-7044.119.2.446; Wood MD, 2008, BEHAV BRAIN RES, V193, P28, DOI
10.1016/j.bbr.2008.04.016; Yager LM, 2015, NEUROSCIENCE, V301, P529, DOI
10.1016/j.neuroscience.2015.06.033; YAMAMOTO T, 1984, EXP BRAIN RES, V56, P23; Yap
Jasmine J, 2008, Drug Discov Today Dis Models, V5, P259 251 8 8 0
9 PERGAMON-ELSEVIER SCIENCE LTD OXFORD THE BOULEVARD, LANGFORD LANE,
KIDLINGTON, OXFORD OX5 1GB, ENGLAND 0091-3057 PHARMACOL BIOCHEM BE
Pharmacol. Biochem. Behav. MAR 2017 154
39 52 10.1016/j.pbb2017.02.001 14 Behavioral
Sciences; Neurosciences; Pharmacology & Pharmacy Behavioral Sciences;
Neurosciences & Neurology; Pharmacology & Pharmacy EM9DJ WOS:000395611200005
28174137 2019-09-25
J Kaye, AD; Jones, MR; Kaye, AM; Ripoll, JG; Jones, DE; Galan, V; Beakley, BD;
Calixto, F; Bolden, JL; Urman, RD; Manchikanti, L Kaye, Alan
D.; Jones, Mark R.; Kaye, Adam M.; Ripoll, Juan G.; Jones, Donald E.; Galan,
Vincent; Beakley, Burton D.; Calixto, Francisco; Bolden, Jamie L.; Urman, Richard
D.; Manchikanti, Laxmaiah Prescription Opioid Abuse in Chronic
Pain: An Updated Review of Opioid Abuse Predictors and Strategies to Curb Opioid
Abuse (Part 2) PAIN PHYSICIAN English Review
Opioids; misuse; abuse; chronic pain; prevalence; risk
assessment; risk management; drug monitoring; aberrant drug-related behavior
CHRONIC NONCANCER PAIN; CHRONIC NONMALIGNANT PAIN; INTERLAMINAR EPIDURAL
INJECTIONS; EVIDENCE-BASED MEDICINE; MASS-SPECTROMETRY LC/MS/MS; LUMBAR DISC
HERNIATION; DRUG-RELATED BEHAVIORS; PRIMARY-CARE PATIENTS; MEDIAL BRANCH BLOCKS;
LOW-BACK-PAIN Chronic pain and prescription opioid abuse are extremely
prevalent in the United States and worldwide. The consequences of opioid misuse can
be life-threatening with significant morbidity and mortality, exacting a heavy toll
on patients, physicians, and society. The risk for misuse of prescribed opioids is
much higher in patients with chronic pain, especially those with concurrent
substance use and /or mental health disorders. Several reasons can account for the
occurrence of opioid abuse and misuse, including self-medication, use for reward,
compulsive use related to addiction, and diversion for profit. There is a need,
therefore, for therapeutic approaches that balance treating chronic pain, while
minimizing risks for opioid abuse, misuse, and diversion. Chronic opioid therapy
for chronic non-cancer pain has seen a dramatic increase throughout the past 2
decades in conjunction with associated increases in the abuse of prescribed opioids
and accidental opioid overdoses. Consequently, a validated screening instrument
that provides an effective and rational method for selecting patients for opioid
therapy, predicting risk, and identifying problems once they have arisen, could be
of enormous benefit in clinical practice. An instrument as such has the potential
to attenuate the risk of iatrogenic addiction. Despite the recent introduction of
various screening strategies and instruments, no single test or instrument can
reliably and accurately predict those patients unsuitable for opioid therapy or
pinpoint those requiring heightened degrees of surveillance and monitoring
throughout their therapy. Current opioid abuse screening tactics include assessing
premorbid and comorbid substance abuse; assessing aberrant drug-related behaviors;
stratification of risk factors; and utilizing opioid assessment screening tools.
Several authors have contributed numerous screening tools and instruments to aid
the assessment of appropriate opioid therapy. Additional essential measures include
urine drug testing, prescription practice monitoring programs, opioid treatment
agreements, and implementing universal precautions. Presently accepted
recommendations consist of a combination of strategies designed to stratify risk,
to identify and to understand aberrant drug-related behaviors, and to tailor
treatments accordingly. This manuscript, Part 2 of a 2 part update, builds on the
2012 opioid guidelines published in Pain Physician, and the 2016 guidelines
released by the Centers for Disease Control and Prevention. It reviews screening,
monitoring, and addressing opioid abuse and misuse in patients with chronic non-
cancer pain. [Kaye, Alan D.; Jones, Mark R.; Jones, Donald E.; Bolden, Jamie
L.] Louisiana State Univ Hlth, Dept Anesthesiol, 1542 Tulane Ave Rm 656, New
Orleans, LA 70112 USA; [Kaye, Adam M.] Univ Pacific, Stockton, CA 95211 USA;
[Ripoll, Juan G.] Mayo Clin, Dept Crit Care Med, Jacksonville, FL 32224 USA;
[Galan, Vincent; Beakley, Burton D.; Calixto, Francisco] Tulane Sch Med, Dept
Anesthesiol, New Orleans, LA USA; [Urman, Richard D.] Harvard Univ, Brigham &
Womens Hosp, Boston, MA 02115 USA; [Manchikanti, Laxmaiah] Pain Management Ctr
Paducah, Paducah, KY USA; [Manchikanti, Laxmaiah] Univ Louisville, Louisville, KY
40292 USA Kaye, AD (reprint author), Louisiana State Univ Hlth, Dept Anesthesiol,
1542 Tulane Ave Rm 656, New Orleans, LA 70112 USA. alankaye44@hotmail.com Jones,
Mark R/A-8052-2019 Jones, Mark/0000-0002-4781-2167 Adams LL,
2004, J PAIN SYMPTOM MANAG, V27, P440, DOI 10.1016/j.jpainsymman.2003.10.009;
Afilalo M, 2013, PAIN PHYSICIAN, V16, P27; Alexander L, 2014, DRUG ALCOHOL DEPEN,
V138, P1, DOI 10.1016/j.drugalcdep.2014.02.006; [Anonymous], 2005, GUID RISK MAN
SYST E; [Anonymous], 2013, HLTH US 2012 SPEC FE; [Anonymous], 2010, EXALGO
HYDROMORPHON; [Anonymous], 2009, QUEST ANSW REG IMPL; Arnold RM, 2006, AM J MED,
V119, P292, DOI 10.1016/j.amjmed.2005.09.019; Arria AM, 2011, PAIN MED, V12, P898,
DOI 10.1111/j.1526-4637.2011.01107.x; Ashburn MA, 2012, ANESTHESIOLOGY, V116, P248,
DOI 10.1097/ALN.0b013e31823c1030; Atluri Sairam, 2003, Pain Physician, V6, P407;
Atluri Sairam L, 2004, Pain Physician, V7, P333; Attal N, 2010, EUR J NEUROL, V17,
P1113, DOI 10.1111/j.1468-1331.2010.02999.x; Baldacchino A, 2010, ADDICT BEHAV,
V35, P270, DOI 10.1016/j.addbeh.2009.10.008; Ballantyne Jane C, 2007, Pain
Physician, V10, P479; Ballantyne JC, 2003, NEW ENGL J MED, V349, P1943, DOI
10.1056/NEJMra025411; Bates C, 2011, J UROLOGY, V185, P551, DOI
10.1016/j.juro.2010.09.088; Becker WC, 2013, PAIN, V154, P905, DOI
10.1016/j.pain.2013.02.031; Belgrade MJ, 2006, J PAIN, V7, P671, DOI
10.1016/j.jpain.2006.03.001; Bergstrom J, 2006, J ORTHOP RES, V24, P1193, DOI
10.1002/jor.20132; Bolen J, 2005, J OPIOID MANAG, V2, P193; Boyd CJ, 2009, J
ADOLESCENT HEALTH, V45, P543, DOI 10.1016/j.jadohealth.2009.03.023; Braker LS,
2009, FAM MED, V41, P729; Brown J, 2010, J OPIOID MANAG, V7, P467; Bruehl S, 2013,
J PAIN, V14, P103, DOI 10.1016/j.jpain.2012.10.016; Budman SH, 2009, HARM REDUCT J,
V6, DOI 10.1186/1477-7517-6-8; Butler SF, 2004, PAIN, V112, P65, DOI
10.1016/j.pain.2004.07.026; Butler SF, 2008, J PAIN, V9, P360, DOI
10.1016/j.jpain.2007.11.014; Butler SF, 2007, PAIN, V130, P144, DOI
10.1016/j.pain.2007.01.014; Butler SF, 2013, PAIN MED, V14, P1032, DOI
10.1111/pme.12098; Calcaterra S, 2013, DRUG ALCOHOL DEPEN, V131, P263, DOI
10.1016/j.drugalcdep.2012.11.018; Carter NJ, 2010, CNS DRUGS, V24, P337, DOI
10.2165/11202580-000000000-00000; Cerny EH, 2009, HUM VACCINES, V5, P200, DOI
10.4161/hv.5.4.7310; Chabal C, 1997, CLIN J PAIN, V13, P150, DOI 10.1097/00002508-
199706000-00009; Cheatle MD, 2014, J PAIN RES, V7, P301, DOI 10.2147/JPR.S37306;
Chou R, 2007, ANN INTERN MED, V147, P478, DOI 10.7326/0003-4819-147-7-200710020-
00006; Chou R, 2009, J PAIN, V10, P131, DOI 10.1016/j.jpain.2008.10.009; Chou R,
2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008; Christo PJ, 2011, PAIN
PHYSICIAN, V14, P123; Cicero TJ, 2008, PAIN, V139, P127, DOI
10.1016/j.pain.2008.03.021; Cicero TJ, 2007, PAIN MED, V8, P157, DOI
10.1111/j.1526-4637.2006.00259.x; Cicero TJ, 2015, JAMA PSYCHIAT, V72, P424, DOI
10.1001/jamapsychiatry.2014.3043; Coggeshall RE, 1997, BRAIN RES, V764, P126, DOI
10.1016/S0006-8993(97)00446-0; Collen M, 2009, J LAW MED ETHICS, V37, P841, DOI
10.1111/j.1748-720X.2009.00455.x; Compton P, 1998, J PAIN SYMPTOM MANAG, V16, P355,
DOI 10.1016/S0885-3924(98)00110-9; Cornish R, 2010, BMJ-BRIT MED J, P341; Dart RC,
2009, DRUG ALCOHOL DEPEN, V105, pS26, DOI 10.1016/j.drugalcdep.2009.08.011; Datta
S, 2009, PAIN PHYSICIAN, V12, P437; Deer T, 2010, PAIN PHYSICIAN, V14, pE283;
Dowell D, 2016, MMWR RECOMM REP, V65, P1, DOI 10.15585/mmwr.rr6501e1; Edlund MJ,
2010, DRUG ALCOHOL DEPEN, V112, P90, DOI 10.1016/j.drugalcdep.2010.05.017; Edmond
Charlton J, 2005, CORE CURRICULUM PROF; Energy Commission, 2014, COMMUNICATION;
Falco F, 2008, PAIN PHYSICIAN, V12, P323; Ferrell B, 2009, J AM GERIATR SOC, V57,
P1331, DOI [10.1111/j.1532-5415.2009.02376.x, 10.1111/j.1526-4637.2009.00699.x];
Fishman SM, 1999, J PAIN SYMPTOM MANAG, V18, P27, DOI 10.1016/S0885-3924(99)00035-
4; Friedman R, 2003, PAIN MED, V4, P182, DOI 10.1046/j.1526-4637.2003.03017.x;
Gentry WB, 2009, HUM VACCINES, V5, P206, DOI 10.4161/hv.5.4.7456; Gerges FJ, 2010,
PAIN PHYSICIAN, V13, P117; Ghods MP, 2015, PATIENT, V8, P349, DOI 10.1007/s40271-
014-0094-8; Gibler WB, 2005, CIRCULATION, V111, P2699, DOI
10.1161/01.CIR.0000165556.44271.BE; Gilbert JW, 2010, PAIN PHYSICIAN, V13, P167;
Gilbert JW, 2010, PAIN PHYSICIAN, V13, P187; Goniewicz ML, 2013, HUM VACC
IMMUNOTHER, V9, P13, DOI 10.4161/hv.22060; Gourlay DL, 2005, PAIN MED, V6, P107,
DOI 10.1111/j.1526-4637.2005.05031.x; Graziottin A, 2011, PAIN PRACT, V11, P574,
DOI 10.1111/j.1533-2500.2011.00449.x; Hamill-Ruth RJ, 2013, PAIN MED, V14, P1900,
DOI 10.1111/pme.12221; Hartrick CT, 2011, CNS DRUGS, V25, P359, DOI
10.2165/11589080-000000000-00000; Hayek S, 2010, PAIN PHYSICIAN, V14, P219; Hojsted
J, 2013, PAIN, V154, P2677, DOI 10.1016/j.pain.2013.07.046; Holmes Cara P, 2006,
Pain Pract, V6, P74; Inciardi JA, 2009, PAIN MED, V10, P537, DOI 10.1111/j.1526-
4637.2009.00603.x; Institute of Medicine, 2011, REL PAIN AM BLUEPR T; Ives TJ,
2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-46; Jamison RN, 2013, EXPERT
DECISION MAKI, P27; Jamison RN, 2015, MAYO CLIN PROC, V90, P957, DOI
10.1016/j.mayocp.2015.04.010; Jamison RN, 2013, CLIN NEUROPSYCHOL, V27, P60, DOI
10.1080/13854046.2012.715204; Jamison RN, 2010, PAIN, V150, P390, DOI
10.1016/j.pain.2010.02.033; Jan SA, 2010, J MANAGE CARE PHARM, V16, pS22; Jang DH,
2010, ANN EMERG MED, V55, P303, DOI 10.1016/j.annemergmed.2009.10.013; Johannes CB,
2010, J PAIN, V11, P1230, DOI 10.1016/j.jpain.2010.07.002; JORIS JL, 1987, ANESTH
ANALG, V66, P1277; Kahan M, 2013, CAN FAM PHYSICIAN, V59, pE231; Kalso E, 1997,
PAIN, V71, P127, DOI 10.1016/S0304-3959(97)03344-7; Kapural L, 2010, PAIN
PHYSICIAN, V13, P389; Katz N, 2002, CLIN J PAIN, V18, pS76, DOI 10.1097/00002508-
200207001-00009;
Katz N, 2011, AM J DRUG ALCOHOL AB, V37, P205, DOI 10.3109/00952990.2011.569623;
Katz NP, 2003, ANESTH ANALG, V97, P1097, DOI 10.1213/01.ANE.0000080159.83342.B5;
Kaye AM, 2013, OCHSNER J, V13, P525; Kinsey BM, 2009, IMMUNOL CELL BIOL, V87, P309,
DOI 10.1038/icb.2009.17; Kinsey BM, 2010, ANTICOCAINE VACCINE; Knisely JS, 2008, J
SUBST ABUSE TREAT, V35, P380, DOI 10.1016/j.jsat.2008.02.001; Kosten T, 2014, BRIT
J CLIN PHARMACO, V77, P368, DOI 10.1111/bcp.12115; Koyyalagunta D, 2013, PAIN MED,
V14, P667, DOI 10.1111/pme.12100; Koyyalagunta D, 2011, PAIN PHYSICIAN, V14, pE361;
Lewis ET, 2014, CLIN J PAIN, V30, P654, DOI 10.1097/01.ajp.0000435447.96642.f4;
Liebschutz JM, 2010, J PAIN, V11, P1047, DOI 10.1016/j.jpain.2009.10.012; Litten
RZ, 2012, ADDICT BIOL, V17, P513, DOI 10.1111/j.1369-1600.2012.00454.x; Loftus P,
2014, WALL ST J; Lourenco LM, 2013, EXPERT OPIN DRUG DEL, V10, P229, DOI
10.1517/17425247.2013.751095; Manchikanti L, 2004, ANESTH ANALG, V99, P304, DOI
10.1213/01.ane.0000127716.40469.c4; Manchikanti Laxmaiah, 2006, Pain Physician, V9,
P57; Manchikanti Laxmaiah, 2005, Pain Physician, V8, P335; Manchikanti Laxmaiah,
2004, Pain Physician, V7, P71; Manchikanti Laxmaiah, 2006, Pain Physician, V9,
P123; Manchikanti Laxmaiah, 2003, Pain Physician, V6, P425; Manchikanti L, 2014,
PAIN PHYSICIAN, V17, pE437; Manchikanti L, 2012, J SPINAL DISORD TECH, V25, P226,
DOI 10.1097/BSD.0b013e3182160068; Manchikanti L, 2011, SPINE, V36, P1897, DOI
10.1097/BRS.0b013e31823294f2; Manchikanti L, 2011, PAIN PHYSICIAN, V14, P259;
Manchikanti L, 2011, PAIN PHYSICIAN, V14, P175; Manchikanti L, 2011, PAIN
PHYSICIAN, V14, pE103; Manchikanti L, 2011, PAIN PHYSICIAN, V14, P91; Manchikanti
L, 2011, PAIN PHYSICIAN, V14, P25; Manchikanti L, 2010, PAIN PHYSICIAN, V13, pE357;
Manchikanti L, 2010, PAIN PHYSICIAN, V13, P535; Manchikanti L, 2010, PAIN
PHYSICIAN, V13, P509; Manchikanti L, 2010, PAIN PHYSICIAN, V13, P401; Manchikanti
L, 2010, PAIN PHYSICIAN, V13, P437; Manchikanti L, 2010, PAIN PHYSICIAN, V13,
pE215; Manchikanti L, 2010, PAIN PHYSICIAN, V13, pE279; Manchikanti L, 2010, PAIN
PHYSICIAN, V13, pE265; Manchikanti L, 2010, PAIN PHYSICIAN, V13, P343; Manchikanti
L, 2010, PAIN PHYSICIAN, V13, pE141; Manchikanti L, 2010, PAIN PHYSICIAN, V13,
pE91; Manchikanti L, 2010, PAIN PHYSICIAN, V13, P223; Manchikanti L, 2010, INT J
MED SCI, V7, P124; Manchikanti L, 2010, EXPERT REV NEUROTHER, V10, P775, DOI
10.1586/ERN.10.37; Manchikanti L, 2010, PAIN PHYSICIAN, V13, pE23; Manchikanti L,
2010, PAIN PHYSICIAN, V13, pE55; Manchikanti L, 2009, PAIN PHYSICIAN, V12, P929;
Manchikanti L, 2009, PAIN PHYSICIAN, V12, P819; Manchikanti L, 2009, PAIN
PHYSICIAN, V12, P35; Manchikanti L, 2009, PAIN PHYSICIAN, V12, P73; Manchikanti L,
2008, PAIN PHYSICIAN, V11, P717; McCabe SE, 2013, J PAIN, V14, P1208, DOI
10.1016/j.jpain.2013.05.004; McCarthy M, 2014, BMJ-BRIT MED J, P348; Meltzer EC,
2013, PAIN MED, V14, P982, DOI 10.1111/pme.12099; Meltzer EC, 2012, PAIN MED, V13,
P1436, DOI 10.1111/j.1526-4637.2012.01497.x; Mezei L, 2011, J PAIN, V12, P1199, DOI
10.1016/j.jpain.2011.06.006; Michna E, 2004, J PAIN SYMPTOM MANAG, V28, P250, DOI
10.1016/j.jpainsymman.2004.04.007; Moorman-Li Robin, 2012, P T, V37, P412; Morasco
B, 2014, J OPIOID MANAG, V11, P45; Morasco BJ, 2008, GEN HOSP PSYCHIAT, V30, P93,
DOI 10.1016/j.genhosppsych.2007.12.004; Morasco BJ, 2013, DRUG ALCOHOL DEPEN, V127,
P193, DOI 10.1016/j.drugalcdep.2012.06.032; Morley-Forster PK, 2013, J PAIN RES,
V6, P791, DOI 10.2147/JPR.S47192; Murphy J, 2014, UNDERSTANDING UPROAR; Murphy
Laura, 2013, Can Pharm J (Ott), V146, P26, DOI 10.1177/1715163512472310; Nakawaki
B, 2012, ADDICT BEHAV, V37, P716, DOI 10.1016/j.addbeh.2012.02.011; Nordmann S,
2011, THERAPIE, V66, P263, DOI 10.2515/therapie/2011045; Ogbu UC, 2015, WEST J
EMERG MED, V16, P76, DOI 10.5811/westjem.2014.11.24720; Olsen Y, 2014, NEW ENGL J
MED, V370, P2061, DOI 10.1056/NEJMp1404181; Passik S, 2004, J OPIOID MANAGEMENT,
V1, P257; Passik SD, 2004, CLIN THER, V26, P552, DOI 10.1016/S0149-2918(04)90057-4;
Passik SD, 2000, ADV THER, V17, P70, DOI 10.1007/BF02854840; Passik SD, 2008, EXP
CLIN PSYCHOPHARM, V16, P400, DOI 10.1037/a0013634; Passik SD, 2014, ADV THER, V31,
P264, DOI 10.1007/s12325-014-0099-7; Passik SD, 2011, J PAIN SYMPTOM MANAG, V41,
P116, DOI 10.1016/j.jpainsymman.2010.03.012; Passik SD, 2009, MAYO CLIN PROC, V84,
P593, DOI 10.1016/S0025-6196(11)60748-9; Paulozzi Leonard J., 2011, Morbidity and
Mortality Weekly Report, V60, P1487; Paulozzi LJ, 2011, J CLIN PSYCHIAT, V72, P589,
DOI 10.4088/JCP.10com06560; Pergolizzi J, 2010, PAIN PRACT, V10, P497, DOI
10.1111/j.1533-2500.2010.00375.x; Pergolizzi JV, 2012, J PSYCHOSOM RES, V72, P443,
DOI 10.1016/j.jpsychores.2012.02.009; Portenoy RK, 1996, J PAIN SYMPTOM MANAG, V11,
P203, DOI 10.1016/0885-3924(95)00187-5; Porucznik C. A., 2010, Morbidity and
Mortality Weekly Report, V59, P153; Raffa RB, 2012, PAIN RES TREAT, DOI
10.1155/2012/282981; Raffa RB, 2010, DRUGS, V70, P1657, DOI 10.2165/11537940-
000000000-00000; Ringwalt C, 2014, PAIN RES MANAG, V19, P179, DOI
10.1155/2014/857952; Ringwalt C, 2015, J PRIM PREV, V36, P287, DOI 10.1007/s10935-
015-0397-0; Ripamonti CI, 2011, ANN ONCOL, V22, pvi69, DOI 10.1093/annonc/mdr390;
Roskos SE, 2007, J PAIN, V8, P753, DOI 10.1016/j.jpain.2007.01.005; Ruetsch C,
2010, J MANAGE CARE PHARM, V16, pS26; Rutkow L, 2015, JAMA INTERN MED; Savage SR,
2009, CURR PSYCHIAT REP, V11, P377, DOI 10.1007/s11920-009-0057-2; Schaeffer T,
2012, J MED TOXICOL, V8, P400, DOI 10.1007/s13181-012-0270-y; Sehgal N, 2012, PAIN
PHYSICIAN, V15, pES67; Sehgal N, 2011, PAIN PHYSICIAN, V14, P249; Shen XY, 2012,
CLIN PHARMACOL THER, V91, P60, DOI 10.1038/clpt.2011.281; Smith H, 2008, J OPIOID
MANAG, V5, P287; Smith S, 2014, CNN HLTH; Stanos SP, 2012, MAYO CLIN PROC, V87,
P683, DOI 10.1016/j.mayocp.2012.02.022; Starrels JL, 2010, ANN INTERN MED, V152,
P712, DOI 10.7326/0003-4819-152-11-201006010-00004; Stein Christoph, 2009, Handb
Exp Pharmacol, P495, DOI 10.1007/978-3-540-79090-7_14; Substance Abuse and Mental
Health Services Administration Drug Abuse Warning Network, 2011, HHS PUBL; Thompson
CA, 2011, AM J HEALTH-SYST PH, V68, P963, DOI 10.2146/news110036; Toblin RL, 2010,
J CLIN PSYCHIAT, V71, P491, DOI 10.4088/JCP.09m05567blu; Trescot AM, 2008, PAIN
PHYSICIAN, V11, pS5; Turk DC, 2008, CLIN J PAIN, V24, P497, DOI
10.1097/AJP.0b013e31816b1070; Turk DC, 2014, PAIN MED, V15, P625, DOI
10.1111/pme.12352; Turk DC, 2012, PAIN, V153, P1997, DOI
10.1016/j.pain.2012.05.029; U.S. Food and Drug Administration, 2009, J Pain Palliat
Care Pharmacother, V23, P304, DOI 10.1080/15360280903099117; U.S. Food and Drug
Administration, 2013, FDA APPR EXT REL SIN; US Food and Drug Administration, FDA
APPR AB DET LAB; US Food and Drug Administration, GUID IND AB DET OP E; Volkow ND,
2011, JAMA-J AM MED ASSOC, V305, P1346, DOI 10.1001/jama.2011.369; Von Korff MR,
2013, BEST PRACT RES CL RH, V27, P663, DOI 10.1016/j.berh.2013.09.011; Walker JS,
2003, ADV EXP MED BIOL, V521, P148; Wallace L, 2006, J OPIOID MANAG, V3, P338;
Wallace LS, 2013, J PAIN RES, V6, P663, DOI 10.2147/JPR.S50715; Walwyn WM, 2010,
DRUG ALCOHOL DEPEN, V108, P156, DOI 10.1016/j.drugalcdep.2010.01.001; Wang J, 2009,
PAIN PHYSICIAN, V12, P507; Watt-Watson J, 2009, PAIN RES MANAG, V14, P439, DOI
10.1155/2009/307932; Webster LR, 2005, PAIN MED, V6, P432, DOI 10.1111/j.1526-
4637.2005.00072.x; Wheeler Eliza, 2012, Morbidity and Mortality Weekly Report, V61,
P101; White AG, 2009, AM J MANAG CARE, V15, P897; Wieczorkiewicz SM, 2013, ANN
PHARMACOTHER, V47, P482, DOI 10.1345/aph.1R706; Wu SM, 2006, J PAIN SYMPTOM MANAG,
V32, P342, DOI 10.1016/j.jpainsymman.2006.05.010; Zhang W, 2008, OSTEOARTHR
CARTILAGE, V16, P137, DOI 10.1016/j.joca.2007.12.013 208 27 27 2 18
AM SOC INTERVENTIONAL PAIN PHYSICIANS PADUCAH 81 LAKEVIEW DR, PADUCAH,
KY 42001 USA 1533-3159 PAIN PHYSICIAN Pain Physician FEB
2017 20 2 S SI S111 S133
23 Anesthesiology; Clinical Neurology Anesthesiology; Neurosciences &
Neurology ER2NV WOS:000398632000008 28226334 2019-09-25
J Kuss, DJ; Dunn, TJ; Wolfling, K; Muller, KW; Hedzelek, M; Marcinkowski, J
Kuss, Daria J.; Dunn, Thomas J.; Woelfling, Klaus; Mueller, Kai
W.; Hedzelek, Mateusz; Marcinkowski, Jerzy EXCESSIVE INTERNET USE
AND PSYCHOPATHOLOGY: THE ROLE OF COPING CLINICAL NEUROPSYCHIATRY
English Article excessive Internet use;
Internet addiction; psychopathology; coping; global severity index ADDICTION
COMPONENTS MODEL; COMPUTER GAME; BRIEF COPE; PSYCHIATRIC COMORBIDITY; GAMING
ADDICTION; SUBSTANCE USE; PREVALENCE; VALIDITY; ADOLESCENTS; RELIABILITY
Objective: In 2013, the American Psychiatric Association included Internet
Gaming Disorder in the diagnostic manual as a condition which requires further
research, indicating the scientific and clinical community are aware of potential
health concerns as a consequence of excessive Internet use. From a clinical point
of view, it appears that excessive/addictive Internet use is often comorbid with
further psychopathologies and assessing comorbidity is relevant in clinical
practice, treatment outcome and prevention as the probability to become addicted to
using the Internet accelerates with additional (sub) clinical symptoms. Moreover,
research indicates individuals play computer games excessively to cope with
everyday stressors and to regulate their emotions by applying media-focused coping
strategies, suggesting pathological computer game players play in order to relieve
stress and to avoid daily hassles. The aims of this research were to replicate and
extend previous findings and explanations of the complexities of the relationships
between excessive Internet use and Internet addiction, psychopathology and
dysfunctional coping strategies. Method: Participants included 681 Polish
university students sampled using an online battery of validated psychometric
instruments. Results: Results of structural equation models revealed dysfunctional
coping strategies (i.e., distraction, denial, self-blame, substance use, venting,
media use, and behavioural disengagement) significantly predict excessive Internet
use, and the data fit the theoretical model well. A second SEM showed media-focused
coping and substance use coping significantly mediate the relationship between
psychopathology (operationalised via the Global Severity Index) and excessive
Internet use. Conclusions: The findings lend support to the self-medication
hypothesis of addictive disorders, and suggest psychopathology and dysfunctional
coping have additive effects on excessive Internet use. [Kuss, Daria J.]
Nottingham Trent Univ, Nottingham NG1 4BU, England; [Dunn, Thomas J.] Bishops
Grotesste Univ, Longdales Rd, Lincoln LN1 3DY, England; [Woelfling, Klaus; Mueller,
Kai W.] Outpatient Clin Gaming Addict, Mainz, Germany; [Hedzelek, Mateusz;
Marcinkowski, Jerzy] Poznan Med Univ, Coll Maius, Fredry 10, PL-61701 Poznan,
Poland Kuss, DJ (reprint author), Nottingham Trent Univ, Nottingham NG1 4BU,
England. daria.kuss@ntu.ac.uk Dunn, Thomas/0000-0001-9974-869X;
Marcinkowski, Jerzy/0000-0001-6495-8988 American Psychiatric
Association, 2000, DIAGN STAT MAN MENT; Black DW, 1999, J CLIN PSYCHIAT, V60, P839,
DOI 10.4088/JCP.v60n1206; Bohnert D, 2010, CYBERPSYCH BEH SOC N, V13, P341, DOI
10.1089/cyber.2009.0193; Brand M, 2014, FRONT PSYCHOL, V5, DOI
10.3389/fpsyg.2014.01256; Carver C. S., 1981, ATTENTION SELF REGUL; Carver CS,
1997, INT J BEHAV MED, V4, P92, DOI 10.1207/s15327558ijbm0401_6; Cooper C, 2008, J
NERV MENT DIS, V196, P838, DOI 10.1097/NMD.0b013e31818b504c; Corr PJ, 2004,
NEUROSCI BIOBEHAV R, V28, P317, DOI 10.1016/j.neubiorev.2004.01.005; Derogatis L.
R., 1994, SCL 90 R ADM SCOR PR; Dunn TJ, 2014, BRIT J PSYCHOL, V105, P399, DOI
10.1111/bjop.12046; FOLKMAN S, 1980, J HEALTH SOC BEHAV, V21, P219, DOI
10.2307/2136617; Geertz C, 1973, INTERPRETATION CULTU; Griffiths M. D., 2005, J
SUBST USE, V10, P191, DOI DOI 10.1080/14659890500114359; Ha JH, 2006, J CLIN
PSYCHIAT, V67, P821, DOI 10.4088/JCP.v67n0517; Hall W, 2009, ADDICT BEHAV, V34,
P795, DOI 10.1016/j.addbeh.2009.03.040; Hardt J, 2008, GMS PSYCHOSOCIAL MED, V5,
P1; HARKNESS JA, 1998, ZUMA NACHRICHTEN SPE, V0003; Henn M., 2009, CRITICAL INTRO
SOCIA; Hoeft F, 2008, J PSYCHIATR RES, V42, P253, DOI
10.1016/j.jpsychires.2007.11.010; Jang KS, 2008, J SCHOOL HEALTH, V78, P165, DOI
10.1111/j.1746-1561.2007.00279.x; Johansson A, 2004, SCAND J PSYCHOL, V45, P223,
DOI 10.1111/j.1467-9450.2004.00398.x; Kardefelt-Winther D., 2016, PSYCHIAT CLIN
NEUROS; Kardefelt-Winther D, 2014, COMPUT HUM BEHAV, V38, P68, DOI
10.1016/j.chb.2014.05.020; Kardefelt-Winther D, 2014, COMPUT HUM BEHAV, V31, P351,
DOI 10.1016/j.chb.2013.10.059; Kelley K, 2012, METHODOLOGY-EUR, V8, P39, DOI
10.1027/1614-2241/a000036; Kenny DA, 2011, PERFORMANCE RMSEA MO; Kim EJ, 2008, EUR
PSYCHIAT, V23, P212, DOI 10.1016/j.eurpsy.2007.10.010; Kuss DJ, 2014, COMPUT HUM
BEHAV, V39, P312, DOI 10.1016/j.chb.2014.07.031; Kuss DJ, 2017, J BEHAV ADDICT, V6,
P103, DOI 10.1556/2006.5.2016.062; Kuss DJ, 2016, WORLD J PSYCHIATR, V6, P143, DOI
10.5498/wjp.v6.i1.143; Kuss DJ, 2014, INT J MENT HEALTH AD, V12, P351, DOI
10.1007/s11469-013-9459-9; Kuss DJ, 2013, COMPUT HUM BEHAV, V29, P1987, DOI
10.1016/j.chb.2013.04.002; Kuss DJ, 2012, BRAIN SCI, V2, P347, DOI
10.3390/brainsci2030347; Kuss DJ, 2013, COMPUT HUM BEHAV, V29, P959, DOI
10.1016/j.chb.2012.12.024; Kuss DJ, 2012, CYBERPSYCH BEH SOC N, V15, P480, DOI
10.1089/cyber.2012.0034; Kuss DJ, 2015, PALG STUD CYBERPSYCH, P1, DOI
10.1057/9781137465078; Lazarus R. S., 1986, DYNAMICS STRESS PHYS, P63, DOI [DOI
10.1007/978-1-4684-5122-1_4, 10.1007/978-1-4684-5122-1_4]; Lazarus RS, 1984, HDB
BEHAV MED, P282, DOI DOI 10.1002/9781118453940; Lee YS, 2008, J AFFECT DISORDERS,
V109, P165, DOI 10.1016/j.jad.2007.10.020; Lo SK, 2005, CYBERPSYCHOL BEHAV, V8,
P15, DOI 10.1089/cpb.2005.8.15; Meerkerk GJ, 2009, CYBERPSYCHOL BEHAV, V12, P1, DOI
10.1089/cpb.2008.0181; Muller KW, 2014, COMPR PSYCHIAT, V55, P770, DOI
10.1016/j.comppsych.2014.01.010; Muller KW, 2011, SUCHTTHERAPIE, V12, P57, DOI
10.1055/s-0031-1275314; Muller L, 2003, ENCEPHALE, V29, P507; Park SK, 2008,
ADOLESCENCE, V43, P895; Pasto L, 2000, INT J PSYCHOL, V35, P432; Quinn JF, 2005,
DEVIANT BEHAV, V26, P191, DOI 10.1080/01639620590888285; Rosseel Y, 2012, J STAT
SOFTW, V48, P1; Shaffer HJ, 2004, HARVARD REV PSYCHIAT, V12, P367, DOI
10.1080/10673220490905705; Shapira NA, 2000, J AFFECT DISORDERS, V57, P267, DOI
10.1016/S0165-0327(99)00107-X; van den Eijnden RJJM, 2008, DEV PSYCHOL, V44, P655,
DOI 10.1037/0012-1649.44.3.655; van Rooij AJ, 2014, J BEHAV ADDICT, V3, P157, DOI
10.1556/JBA.3.2014.013; Williams CD, 2007, ANN BEHAV MED, V33, pS153; Wolfling K,
2008, PSYCHIAT PRAX, V35, P226, DOI 10.1055/s-2007-986238; Wolfling K, 2010,
PREVENTION DIAGNOSTI, P212; World Health Organization, 1992, ICD 10 ICD 10 CLASS;
Yen JY, 2007, J ADOLESCENT HEALTH, V41, P93, DOI 10.1016/j.jadohealth.2007.02.002;
Young KS, 2004, AM BEHAV SCI, V48, P402, DOI 10.1177/0002764204270278; Zboralski K,
2009, POSTEP HIG MED DOSW, V63, P8; Zimmer-Gembeck MJ, 2016, DEV PSYCHOPATHOLOGY
60 9 9 4 9 GIOVANNI FIORITI EDITORE ROME VIA
ARCHIMEDE 179, ROME, 00197, ITALY 1724-4935 2385-0787 CLIN
NEUROPSYCHIATR Clin. Neuropsychiatr. FEB 2017 14 1
73 81 9 Clinical Neurology
Neurosciences & Neurology ET5TZ WOS:000400352100011 DOAJ Gold
2019-09-25
J Kaye, AD; Jones, MR; Kaye, AM; Ripoll, JG; Galan, V; Beakley, BD; Calixto, F;
Bolden, JL; Urman, RD; Manchikanti, L Kaye, Alan D.; Jones,
Mark R.; Kaye, Adam M.; Ripoll, Juan G.; Galan, Vincent; Beakley, Burton D.;
Calixto, Francisco; Bolden, Jamie L.; Urman, Richard D.; Manchikanti, Laxmaiah
Prescription Opioid Abuse in Chronic Pain: An Updated Review of Opioid
Abuse Predictors and Strategies to Curb Opioid Abuse: Part 1 PAIN PHYSICIAN
English Review Opioids; misuse;
abuse; chronic pain; prevalence; risk assessment; risk management; drug monitoring;
aberrant drug-related behavior CHRONIC NONCANCER PAIN; SUBSTANCE USE
DISORDERS; TANDEM MASS-SPECTROMETRY; NATIONAL EPIDEMIOLOGIC SURVEY; RECEPTOR GENE
POLYMORPHISM; DRUG OVERDOSE DEATHS; CHRONIC BACK-PAIN; NEW-YORK-CITY; NONMEDICAL
USE; UNITED-STATES Chronic pain and prescription opioid abuse are extremely
prevalent both in this country and worldwide. Consequences of opioid misuse can be
life-threatening with significant morbidity and mortality, exacting a heavy toll on
patients, physicians, and society. Individuals with chronic pain and co-occurring
substance use disorders and/or mental health disorders, are at a higher risk for
misuse of prescribed opioids. Opioid abuse and misuse occurs for a variety of
reasons, including self-medication, use for reward, compulsive use because of
addiction, and diversion for profit. There is a significant need for treatment
approaches that balance treating chronic pain; while minimizing risks for opioid
abuse, misuse, and diversion. The use of chronic opioid therapy for chronic non-
cancer pain has increased dramatically in the past 2 decades in conjunction with
associated increases in the abuse of prescribed opioids and accidental opioid
overdoses. Consequently, a validated screening instrument which provides an
effective and rational method of selecting patients for opioid therapy, predicting
risk, and identifying problems once they arise could be of enormous benefit in
clinical practice. Such an instrument could potentially curb the risk of iatrogenic
addiction. Although several screening instruments and strategies have been
introduced in recent years, there is no single test or instrument which can
reliably and accurately predict those patients not suitable for opioid therapy or
identify those who need increased vigilance or monitoring during therapy. At
present, screening for opioid abuse includes assessment of premorbid and comorbid
substance abuse; assessment of aberrant drug-related behaviors; risk factor
stratification; and utilization of opioid assessment screening tools. Multiple
opioid assessment screening tools and instruments have been developed by various
authors. In addition, urine drug testing, monitoring of prescribing practices,
prescription monitoring programs, opioid treatment agreements, and utilization of
universal precautions are essential. Presently, a combination of strategies is
recommended to stratify risk, to identify and understand aberrant drug related
behaviors, and to tailor treatments accordingly. This manuscript builds on the 2012
opioid guidelines published in Pain Physician and the 2016 guidelines released by
the Centers for Disease Control and Prevention. It reviews the current state of
knowledge regarding the growing problem of opioid abuse and misuse; known risk
factors; and methods of predicting, assessing, monitoring, and addressing opioid
abuse and misuse in patients with chronic non-cancer pain. [Kaye, Alan D.; Bolden,
Jamie L.] Louisiana State Univ Hlth, Dept Anesthesiol, 1542 Tulane Ave Rm 656, New
Orleans, LA 70112 USA; [Jones, Mark R.] Brigham & Womens Hosp, 75 Francis St,
Boston, MA 02115 USA; [Kaye, Adam M.] Univ Pacific, Stockton, CA 95211 USA;
[Ripoll, Juan G.] Mayo Clin, Dept Crit Care Med, Jacksonville, FL 32224 USA;
[Galan, Vincent; Beakley, Burton D.; Calixto, Francisco] Tulane Sch Med, Dept
Anesthesiol, New Orleans, LA USA; [Urman, Richard D.] Harvard Univ, Brigham &
Womens Hosp, Boston, MA 02115 USA; [Manchikanti, Laxmaiah] Pain Management Ctr
Paducah, Paducah, KY USA; [Manchikanti, Laxmaiah] Univ Louisville, Louisville, KY
40292 USA Kaye, AD (reprint author), Louisiana State Univ Hlth, Dept Anesthesiol,
1542 Tulane Ave Rm 656, New Orleans, LA 70112 USA. alankaye44@hotmail.com Jones,
Mark R/A-8052-2019 Jones, Mark/0000-0002-4781-2167 American
Psychiatric Association, 2013, DIAGN STAT MAN MENT; American Psychiatric
Publishing, 2013, SUBSTANCE RELATED AD; [Anonymous], 2003, PRESCR DRUGS OXY CON;
Back SE, 2010, ADDICT BEHAV, V35, P1001, DOI 10.1016/j.addbeh.2010.06.018; Bali V,
2013, RES SOC ADMIN PHARM, V9, P276, DOI 10.1016/j.sapharm.2012.04.008; Ballantyne
Jane C, 2007, Pain Physician, V10, P479; Ballantyne JC, 2012, ARCH INTERN MED,
V172, P1342, DOI 10.1001/archinternmed.2012.3212; Banta-Green CJ, 2010, CLIN J
PAIN, V26, P489, DOI 10.1097/AJP.0b013e3181e103d9; Bart G, 2004, MOL PSYCHIATR, V9,
P547, DOI 10.1038/sj.mp.4001504; Becker WC, 2008, DRUG ALCOHOL DEPEN, V94, P38, DOI
10.1016/j.drugalcdep.2007.09.018; Becker WC, 2008, DRUG ALCOHOL DEPEN, V94, P207,
DOI 10.1016/j.drugalcdep.2007.11.018; Becker WC, 2007, DRUG ALCOHOL DEPEN, V90,
P280, DOI 10.1016/j.drugalcdep.2007.04.009; Beer B, 2013, PLOS ONE, V8, DOI
10.1371/journal.pone.0075359; Beynon CM, 2009, AGE AGEING, V38, P8, DOI
10.1093/ageing/afn251; Blanco C, 2007, DRUG ALCOHOL DEPEN, V90, P252, DOI
10.1016/j.drugalcdep.2007.04.005; Bond C, 1998, P NATL ACAD SCI USA, V95, P9608,
DOI 10.1073/pnas.95.16.9608; Boscarino JA, 2010, ADDICTION, V105, P1776, DOI
10.1111/j.1360-0443.2010.03052.x; Breivik H, 2006, EUR J PAIN, V10, P287, DOI
10.1016/j.ejpain.2005.06.009; British Pain Society's, 2010, OP PERS PAIN GOOD PR;
Caudill-Slosberg MA, 2004, PAIN, V109, P514, DOI 10.1016/j.pain.2004.03.006; Center
for Substance Abuse Treatment, 2003, METH ASS MORT REP NA; Centers for Disease
Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P233; Cerda M,
2013, DRUG ALCOHOL DEPEN, V132, P53, DOI 10.1016/j.drugalcdep.2012.12.027; Chang
YP, 2013, ADDICT SCI CLIN PRAC, V8, DOI 10.1186/1940-0640-8-21; Cheatle MD, 2015,
PAIN MED; Chen I, 2005, J GEN INTERN MED, V20, P593, DOI 10.1111/j.1525-
1497.2005.0106.x; Chou R, 2009, USE CHRONIC OPIOID T; Chou R, 2009, J PAIN, V10,
P113, DOI 10.1016/j.jpain.2008.10.008; Christo PJ, 2011, PAIN PHYSICIAN, V14, P123;
Cicero TJ, 2008, PAIN, V139, P127, DOI 10.1016/j.pain.2008.03.021; Cicero TJ, 2007,
PAIN MED, V8, P157, DOI 10.1111/j.1526-4637.2006.00259.x; Cicero TJ, 2010,
PHARMACOEPIDEM DR S, V19, P1057, DOI 10.1002/pds.1989; Cobaugh DJ, 2014, AM J
HEALTH-SYST PH, V71, P1539, DOI 10.2146/ajhp140157; Colliver JD, 2008, J PAIN, V9,
P487, DOI 10.1016/j.jpain.2008.03.001; Colson J, 2011, PAIN PHYSICIAN, V14, pE86;
Comings DE, 1999, NEUROREPORT, V10, P1133, DOI 10.1097/00001756-199904060-00042;
Compton P, 2000, J PAIN SYMPTOM MANAG, V20, P237, DOI 10.1016/S0885-3924(00)00191-
3; Coolen P., 2009, Morbidity and Mortality Weekly Report, V58, P1171; Crissey SR,
2009, ED ATTAINMENT US 200; Dani JA, 2005, NAT NEUROSCI, V8, P1465, DOI
10.1038/nn1580; Dart RC, 2015, NEW ENGL J MED, V372, P241, DOI
[10.1056/NEJMsa1406143, 10.1056/NEJMc1501822]; Davis WR, 2008, DRUG ALCOHOL DEPEN,
V92, P267, DOI 10.1016/j.drugalcdep.2007.08.008; de Leon-Casasola OA, 2013, AM J
MED, V126, pS3, DOI 10.1016/j.amjmed.2012.11.011; Deer T, 2010, PAIN PHYSICIAN,
V14, pE283; Deer TR, 2010, PAIN PHYSICIAN, V13, pE175; Denisco RA, 2008, EXP CLIN
PSYCHOPHARM, V16, P417, DOI 10.1037/a0013636; Deyo RA, 2005, SPINE, V30, P1441, DOI
10.1097/01.brs.0000166503.37969.8a; Deyo RA, 2010, JAMA-J AM MED ASSOC, V303,
P1259, DOI 10.1001/jama.2010.338; Deyo RA, 2009, J AM BOARD FAM MED, V22, P62, DOI
10.3122/jabfm.2009.01.080102; Dhalla IA, 2009, CAN MED ASSOC J, V181, P891, DOI
10.1503/cmaj.090784; Dowell D, 2016, MMWR RECOMM REP, V65, P1, DOI
10.15585/mmwr.rr6501e1; Dunn KM, 2010, ANN INTERN MED, V152, P85, DOI 10.7326/0003-
4819-152-2-201001190-00006; Edlund MJ, 2007, PAIN MED, V8, P647, DOI
10.1111/j.1526-4637.2006.00200.x; Edlund MJ, 2010, DRUG ALCOHOL DEPEN, V112, P90,
DOI 10.1016/j.drugalcdep.2010.05.017; Enoch MA, 2008, PLOS ONE, V3, DOI
10.1371/journal.pone.0003620; *FED STAT MED BOAR, MOD GUID US CONTR SU; Fenton MC,
2012, ADDICTION, V107, P599, DOI 10.1111/j.1360-0443.2011.03638.x; Fillingim RB,
2003, SPINE, V28, P143, DOI 10.1097/00007632-200301150-00010; Finch James W, 2013,
N C Med J, V74, P243; Fingerhut LA, 2008, INCREASES POISONING; Fischer B, 2012, J
PAIN, V13, P1029, DOI 10.1016/j.jpain.2012.07.013; Fitzgibbon DR, 2010,
ANESTHESIOLOGY, V112, P948, DOI 10.1097/ALN.0b013e3181cdef98; Fleming MF, 2007, J
PAIN, V8, P573, DOI 10.1016/j.jpain.2007.02.432; Franke P, 1999, AM J MED GENET,
V88, P462, DOI 10.1002/(SICI)1096-8628(19991015)88:5<462::AID-AJMG4>3.0.CO;2-S;
Franklin GM, 2008, SPINE, V33, P199, DOI 10.1097/BRS.0b013e318160455c; Franklin GM,
2005, AM J IND MED, V48, P91, DOI 10.1002/ajim.20191; Frasco PE, 2005, ANESTH
ANALG, V100, P162, DOI 10.1213/01.ANE.0000139354.26208.1C; Gelernter J, 1999, MOL
PSYCHIATR, V4, P476, DOI 10.1038/sj.mp.4000556; Gilbert JW, 2010, PAIN PHYSICIAN,
V13, P167; Gilbert JW, 2010, PAIN PHYSICIAN, V13, P187; Gilson AM, 2009, PAIN MED,
V10, pS89, DOI 10.1111/j.1526-4637.2009.00668.x; Gourlay DL, 2008, J ADDICT DIS,
V27, P23, DOI 10.1080/10550880802122570; Grant BF, 2004, ARCH GEN PSYCHIAT, V61,
P807, DOI 10.1001/archpsyc.61.8.807; Grider JS, 2011, PAIN PHYSICIAN, V14, P343;
Hall AJ, 2008, JAMA-J AM MED ASSOC, V300, P2613, DOI 10.1001/jama.2008.802; Hayek
S, 2010, PAIN PHYSICIAN, V14, P219; Huang B, 2006, J CLIN PSYCHIAT; Hughes AA,
2007, CLIN TOXICOL, V45, P144, DOI 10.1080/15563650600981137; Hull MJ, 2007, J
FORENSIC SCI, V52, P1383, DOI 10.1111/j.1556-4029.2007.00564.x; Inciardi JA, 2009,
PAIN MED, V10, P537, DOI 10.1111/j.1526-4637.2009.00603.x; Jamison RN, 2010, PAIN,
V150, P390, DOI 10.1016/j.pain.2010.02.033;
Jamison RN, 2009, PAIN MED, V10, P1084, DOI 10.1111/j.1526-4637.2009.00679.x;
Johnson F, 2011, PAIN PHYSICIAN, V14, P391; Juurlink DN, 2012, J MED TOXICOL, V8,
P393, DOI 10.1007/s13181-012-0269-4; Katz C, 2013, DRUG ALCOHOL DEPEN, V132, P107,
DOI 10.1016/j.drugalcdep.2013.01.010; Katz NP, 2007, CLIN J PAIN, V23, P648, DOI
10.1097/AJP.0b013e318125c5e8; Kern AM, 2014, J DUAL DIAGN, V10, P52, DOI
10.1080/15504263.2013.867199; Khokhar JY, 2010, ANNU REV PHARMACOL, V50, P39, DOI
10.1146/annurev.pharmtox.010909.105826; Kirsh Kenneth, 2012, J Pain Palliat Care
Pharmacother, V26, P348; Koyyalagunta D, 2011, PAIN PHYSICIAN, V14, pE361; Kroutil
LA, 2006, DRUG ALCOHOL DEPEN, V84, P135, DOI 10.1016/j.drugalcdep.2005.12.011;
Kuehn BM, 2009, JAMA-J AM MED ASSOC, V301, P1213, DOI 10.1001/jama.2009.367; Kupfer
DJ, 2013, JAMA-J AM MED ASSOC, V309, P1691, DOI 10.1001/jama.2013.2298; Lanier WA,
2012, PAIN MED, V13, P1580, DOI 10.1111/j.1526-4637.2012.01518.x; Lee M, 2011, PAIN
PHYSICIAN, V14, P145; Levi-Minzi MA, 2013, PAIN MED, V14, P1719, DOI
10.1111/pme.12189; Levran O, 2008, GENES BRAIN BEHAV, V7, P720, DOI 10.1111/j.1601-
183X.2008.00410.x; Levran O, 2014, PSYCHONEUROENDOCRINO, V45, P67, DOI
10.1016/j.psyneuen.2014.03.017; Levran O, 2009, GENES BRAIN BEHAV, V8, P531, DOI
10.1111/j.1601-183X.2009.00501.x; Levran O, 2014, ANN HUM GENET, V78, P290, DOI
10.1111/ahg.12064; LIEBMANN P, 1994, LANCET, V344, P1031; Liebschutz JM, 2010, J
PAIN, V11, P1047, DOI 10.1016/j.jpain.2009.10.012; Mackesy-Amiti ME, 2015, AM J
DRUG ALCOHOL AB, V41, P100, DOI 10.3109/00952990.2014.940424; Maher BS, 2011, BIOL
PSYCHIAT, V70, P519, DOI 10.1016/j.biopsych.2011.02.023; Mahmud MA, 2000, J OCCUP
ENVIRON MED, V42, P1178, DOI 10.1097/00043764-200012000-00012; Manchikanti KN,
2007, J OPIOID MANAGEMENT, V4, P271; Manchikanti L, 2007, J OPIOID MANAG, V5, P8;
Manchikanti Laxmaiah, 2005, Pain Physician, V8, P257; Manchikanti L, 2011, PAIN
PHYSICIAN, V14, P259; Manchikanti L, 2011, PAIN PHYSICIAN, V14, pE133; Manchikanti
L, 2011, PAIN PHYSICIAN, V14, P175; Manchikanti L, 2011, PAIN PHYSICIAN, V14,
pE103; Manchikanti L, 2011, PAIN PHYSICIAN, V14, P91; Manchikanti L, 2010, PAIN
PHYSICIAN, V13, P401; Manchikanti L, 2010, PAIN PHYSICIAN, V13, pE215; Manchikanti
L, 2010, PAIN PHYSICIAN, V13, pE141; Manchikanti L, 2010, PAIN PHYSICIAN, V13,
P199; Manchikanti L, 2010, EXPERT REV NEUROTHER, V10, P775, DOI 10.1586/ERN.10.37;
Manchikanti L, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-84;
Manchikanti L, 2010, PAIN PHYSICIAN, V13, pE1; Manchikanti L, 2010, PAIN PHYSICIAN,
V13, pE23; Manchikanti L, 2010, PAIN PHYSICIAN, V13, pE55; Manchikanti L, 2009,
PAIN PHYSICIAN, V12, P929; Manchikanti L, 2009, PAIN PHYSICIAN, V12, P819;
Manchikanti L, 2009, PAIN PHYSICIAN, V12, P259; Manchikanti L, 2009, PAIN
PHYSICIAN, V12, P9; Martel MO, 2015, PAIN, V156, P1092, DOI
10.1097/j.pain.0000000000000154; Martins SS, 2012, PSYCHOL MED, V42, P1261, DOI
10.1017/S0033291711002145; Martins SS, 2009, DRUG ALCOHOL DEPEN, V103, P16, DOI
10.1016/j.drugalcdep.2009.01.019; Mateu-Gelabert P, 2015, J SUBST ABUSE TREAT, V48,
P13, DOI 10.1016/j.jsat.2014.07.002; Mayer P, 1997, NEUROREPORT, V8, P2547, DOI
10.1097/00001756-199707280-00025; McAdam-Marx Carrie, 2010, J Pain Palliat Care
Pharmacother, V24, P5, DOI 10.3109/15360280903544877; McCabe SE, 2006, J
PSYCHOACTIVE DRUGS, V38, P43, DOI 10.1080/02791072.2006.10399827; McCabe SE, 2013,
J PAIN, V14, P1208, DOI 10.1016/j.jpain.2013.05.004; McDonald DC, 2012, J PAIN,
V13, P988, DOI 10.1016/j.jpain.2012.07.007; Meyer R, 2014, POPUL HEALTH MANAG, V17,
P372, DOI 10.1089/pop.2013.0098; Morasco BJ, 2013, DRUG ALCOHOL DEPEN, V127, P193,
DOI 10.1016/j.drugalcdep.2012.06.032; Morasco BJ, 2011, PAIN, V152, P488, DOI
10.1016/j.pain.2010.10.009; MUESER KT, 1992, J CONSULT CLIN PSYCH, V60, P845, DOI
10.1037/0022-006X.60.6.845; Nikoshkov A, 2008, P NATL ACAD SCI USA, V105, P786, DOI
10.1073/pnas.0710902105; Nitsche JF, 2002, J NEUROSCI, V22, P10906; Noble M, 2010,
COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006605.pub2; Office of National Drug
Control Policy, EP RESP AM PRESCR DR; Olsen Y, 2006, J PAIN, V7, P225, DOI
10.1016/j.jpain.2005.11.006; Papaleontiou M, 2010, J AM GERIATR SOC, V58, P1353,
DOI 10.1111/j.1532-5415.2010.02920.x; Paulozzi L., 2007, Morbidity and Mortality
Weekly Report, V56, P93; Paulozzi LJ, 2006, PHARMACOEPIDEM DR S, V15, P618, DOI
10.1002/pds.1276; Paulozzi LJ, 2006, AM J PREV MED, V31, P506, DOI
10.1016/j.amepre.2006.08.017; Paulozzi LJ, 2009, ADDICTION, V104, P1541, DOI
10.1111/j.1360-0443.2009.02650.x; Pesce A, 2010, PAIN PHYSICIAN, V13, P283; Pesce
A, 2010, PAIN PHYSICIAN, V13, P273; Phillips DM, 2000, JAMA-J AM MED ASSOC, V284,
P428, DOI 10.1001/jama.284.4.428; Pletcher MJ, 2008, JAMA-J AM MED ASSOC, V299,
P70, DOI 10.1001/jama.2007.64; Pletcher MJ, 2006, DRUG ALCOHOL DEPEN, V85, P171,
DOI 10.1016/j.drugalcdep.2006.04.011; Pollak K, 2015, ANESTHESIOLOGY; Potter JS,
2008, AM J ADDICTION, V17, P121, DOI 10.1080/10550490701862902; Proudnikov D, 2008,
NEUROSCI LETT, V435, P234, DOI 10.1016/j.neulet.2008.02.042; Raebel MA, 2014,
PHARMACOEPIDEM DR S, V23, P1247, DOI 10.1002/pds.3625; Rathmell JP, 2011,
ANESTHESIOLOGY, V114, P918, DOI 10.1097/ALN.0b013e31820fc7f2; Ray LA, 2011, ALCOHOL
CLIN EXP RES, V35, P166, DOI 10.1111/j.1530-0277.2010.01333.x; REGIER DA, 1990,
JAMA-J AM MED ASSOC, V264, P2511; Reisfield GM, 2009, PAIN MED, V10, P1434, DOI
10.1111/j.1526-4637.2009.00726.x; Rhee Y, 2007, CLIN THER, V29, P2603, DOI
10.1016/j.clinthera.2007.12.006; Rice JB, 2014, APPL HEALTH ECON HEA, V12, P435,
DOI 10.1007/s40258-014-0102-0; Robinson RC, 2001, CLIN J PAIN, V17, P220, DOI
10.1097/00002508-200109000-00006; Rosenblum A, 2003, JAMA-J AM MED ASSOC, V289,
P2370, DOI 10.1001/jama.289.18.2370; Ruetsch C, 2010, J MANAGE CARE PHARM, V16,
pS9; Savage SR, 2003, J PAIN SYMPTOM MANAG, V26, P655, DOI 10.1016/S0885-
3924(03)00219-7; Schoedel KA, 2010, PAIN PHYSICIAN, V13, P561; Sehgal N, 2011, PAIN
PHYSICIAN, V14, P249; Sgarlato A, 2015, FORENSIC SCI MED PAT, V11, P388, DOI
10.1007/s12024-015-9699-z; Simoni-Wastila L, 2004, AM J PUBLIC HEALTH, V94, P266,
DOI 10.2105/AJPH.94.2.266; Simoni-Wastila L, 2004, SUBST USE MISUSE, V39, P1, DOI
10.1081/JA-120027764; Sinha R, 2006, ARCH GEN PSYCHIAT, V63, P324, DOI
10.1001/archpsyc.63.3.324; Sites BD, 2014, REGION ANESTH PAIN M, V39, P6, DOI
10.1097/AAP.0000000000000022; Skolek M., 2011, U WISCONSIN ETHICS V; Smith SM,
2013, PAIN, V154, P2287, DOI 10.1016/j.pain.2013.05.053; Solanki DR, 2011, PAIN
PHYSICIAN, V14, pE119; Spiller H, 2010, J ADDICT DIS, V29, P78, DOI
10.1080/10550880903436036; Spiller H, 2009, J ADDICT DIS, V28, P130, DOI
10.1080/10550880902772431; Strassels SA, 2009, J MANAGE CARE PHARM, V15, P556, DOI
10.18553/jmcp.2009.15.7.556; Substance Abuse and Mental Health Services
Administration, 2010, NSDUH SER H, VI; Substance Abuse and Mental Health Services
Administration and Office of Applied Studies, 2009, NSDUH REP ILL DRUG U; Substance
Abuse and Mental Health Services Administration Office of Applied Studies, 2009,
NSDUH SER H, V2009; Sullivan M, 2013, PAIN, V154, P2239, DOI
10.1016/j.pain.2013.07.045; Sullivan MD, 2010, PAIN, V150, P332, DOI
10.1016/j.pain.2010.05.020; Sullivan MD, 2010, PAIN, V149, P345, DOI
10.1016/j.pain.2010.02.037; Szeto CYK, 2001, NEUROREPORT, V12, P1103, DOI
10.1097/00001756-200105080-00011; Tetrault JM, 2008, ADDICTION, V103, P258, DOI
10.1111/j.1360-0443.2007.02056.x; Toblin RL, 2010, J CLIN PSYCHIAT, V71, P491, DOI
10.4088/JCP.09m05567blu; Trescot AM, 2008, PAIN PHYSICIAN, V11, pS5; Turk DC, 2008,
CLIN J PAIN, V24, P497, DOI 10.1097/AJP.0b013e31816b1070; *US DEP HHS, 2007, SUBST
AB MENT HLTH S; Vallejo R, 2011, PAIN PHYSICIAN, V14, pE343; Vogt MT, 2005, SPINE,
V30, P1075, DOI 10.1097/01.brs.0000160843.77091.07; Warner Margaret, 2009, NCHS
Data Brief, P1; Wasan AD, 2007, CLIN J PAIN, V23, P307, DOI
10.1097/AJP.0b013e3180330dc5; Wasan AD, 2009, CLIN J PAIN, V25, P193, DOI
10.1097/AJP.0b013e318193a6c4; Webster BS, 2007, SPINE, V32, P2127, DOI
10.1097/BRS.0b013e318145a731; West R, 2010, PAIN PHYSICIAN, V13, P71; Whitehead AJ,
2008, J PAIN SYMPTOM MANAG, V36, P39, DOI 10.1016/j.jpainsymman.2007.08.013; Woolf
Clifford J, 2004, Curr Opin Investig Drugs, V5, P61; Wunsch M, 2007, J OPIOID
MANAGEMENT, V4, P73; Yuferov V, 2004, PHARMACOGENETICS, V14, P793, DOI
10.1097/00008571-200412000-00002; Zacny J, 2003, DRUG ALCOHOL DEPEN, V69, P215, DOI
10.1016/S0376-8716(03)00003-6; Zhang H, 2008, MOL PSYCHIATR, V13, P531, DOI
10.1038/sj.mp.4002035 206 37 38 2 35 AM SOC INTERVENTIONAL PAIN
PHYSICIANS PADUCAH 81 LAKEVIEW DR, PADUCAH, KY 42001 USA 1533-3159
 PAIN PHYSICIAN Pain Physician FEB 2017 20 2 S SI
S93 S109 17 Anesthesiology; Clinical Neurology
Anesthesiology; Neurosciences & Neurology ER2NV WOS:000398632000007
28226333 2019-09-25
B Meyers, JL; Hasin, D Cohen, NL Meyers, Jacquelyn L.; Hasin,
Deborah Substance Use and Depressive Disorders PUBLIC HEALTH
PERSPECTIVES ON DEPRESSIVE DISORDERS English Article; Book
Chapter NATIONAL EPIDEMIOLOGIC SURVEY;
POSTTRAUMATIC-STRESS-DISORDER; SELF-MEDICATION HYPOTHESIS; COMMON MENTAL-DISORDERS;
ALCOHOL-USE DISORDERS; PSYCHIATRIC RESEARCH INTERVIEW; ENVIRONMENTAL RISK-FACTORS;
PLACEBO-CONTROLLED TRIAL; CHILDHOOD SEXUAL-ABUSE; CANNABIS USE DISORDERS
[Meyers, Jacquelyn L.] Suny Downstate Med Ctr, Dept Psychiat & Behav Sci,
Brooklyn, NY 11203 USA; [Hasin, Deborah] Columbia Univ, Coll Phys & Surg, Dept
Psychiat, New York, NY USA; [Hasin, Deborah] New York State Psychiat Inst & Hosp,
New York, NY 10032 USA Meyers, JL (reprint author), Suny Downstate Med Ctr, Dept
Psychiat & Behav Sci, Brooklyn, NY 11203 USA.
Abraham HD, 1999, COMPR PSYCHIAT, V40, P44, DOI 10.1016/S0010-440X(99)90076-
7; Afifi TO, 2012, CAN J PSYCHIAT, V57, P677, DOI 10.1177/070674371205701105;
Aharonovich E, 2002, AM J PSYCHIAT, V159, P1600, DOI 10.1176/appi.ajp.159.9.1600;
Arendt M, 2007, PSYCHOL MED, V37, P935, DOI 10.1017/S0033291706009688; Aseltine RH,
1998, DEV PSYCHOPATHOL, V10, P549, DOI 10.1017/S0954579498001746; Banducci AN,
2014, ADDICT BEHAV, V39, P1522, DOI 10.1016/j.addbeh.2014.05.023; Blanco C, 2014,
ADDICTION, V109, P284, DOI 10.1111/add.12382; Bobadilla L, 2013, ADDICT BEHAV, V38,
P2555, DOI 10.1016/j.addbeh.2013.05.014; Boden JM, 2011, ADDICTION, V106, P906, DOI
10.1111/j.1360-0443.2010.03351.x; Bremner JD, 1996, AM J PSYCHIAT, V153, P369;
Breslau N, 2004, BIOL PSYCHIAT, V55, P69, DOI 10.1016/S0006-3223(03)00317-2;
BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P1069; Breslau N, 2002, CAN J PSYCHIAT,
V47, P923; Bulik CM, 2001, BRIT J PSYCHIAT, V179, P444, DOI 10.1192/bjp.179.5.444;
Burns L, 2002, DRUG ALCOHOL DEPEN, V68, P299, DOI 10.1016/S0376-8716(02)00220-X;
CARON C, 1991, J CHILD PSYCHOL PSYC, V32, P1063, DOI 10.1111/j.1469-
7610.1991.tb00350.x; Cerda M, 2010, J AFFECT DISORDERS, V126, P14, DOI
10.1016/j.jad.2009.11.006; Childs E, 2011, ALCOHOL CLIN EXP RES, V35, P1794, DOI
10.1111/j.1530-0277.2011.01522.x; Clark DB, 1997, J AM ACAD CHILD PSY, V36, P1744,
DOI 10.1097/00004583-199712000-00023; Compton WM, 2007, ARCH GEN PSYCHIAT, V64,
P566, DOI 10.1001/archpsyc.64.5.566; Compton WM, 2006, AM J PSYCHIAT, V163, P2141,
DOI 10.1176/appi.ajp.163.12.2141; CORYELL W, 1992, J AFFECT DISORDERS, V24, P93,
DOI 10.1016/0165-0327(92)90023-Y; Crum RM, 2014, JAMA PSYCHIAT, V71, P205, DOI
10.1001/jamapsychiatry.2013.3521; Crum RM, 2013, JAMA PSYCHIAT, V70, P718, DOI
10.1001/jamapsychiatry.2013.1098; Davis L. L., 2010, AM J ADDICTION, V15, P278;
Davis LL, 2005, COMPR PSYCHIAT, V46, P81, DOI 10.1016/j.comppsych.2004.07.025;
Davis L, 2008, CURR OPIN PSYCHIATR, V21, P14, DOI 10.1097/YCO.0b013e3282f32408;
Davis LL, 2007, J CLIN PSYCHIAT, V68, P1931, DOI 10.4088/JCP.v68n1214; de Graaf R,
2004, ACTA PSYCHIAT SCAND, V109, P55, DOI 10.1046/j.0001-690X.2003.00222.x;
Degenhardt L, 2003, ADDICTION, V98, P1493, DOI 10.1046/j.1360-0443.2003.00437.x;
DEYKIN EY, 1987, AM J PUBLIC HEALTH, V77, P178, DOI 10.2105/AJPH.77.2.178; Drake
RE, 1996, PERSPECT PSYCHIATR C, V32, P30; Eaton NR, 2015, SOC PSYCH PSYCH EPID,
V50, P171, DOI 10.1007/s00127-014-1001-2; Eaton NR, 2013, SOC PSYCH PSYCH EPID,
V48, P701, DOI 10.1007/s00127-012-0595-5; Edwards AC, 2011, PSYCHOL MED, V41, P395,
DOI 10.1017/S0033291710000589; Edwards AC, 2012, J AFFECT DISORDERS, V142, P90, DOI
10.1016/j.jad.2012.03.048; Edwards AC, 2012, PSYCHIAT GENET, V22, P31, DOI
10.1097/YPG.0b013e32834acd07; Fava M, 1996, J AFFECT DISORDERS, V38, P129, DOI
10.1016/0165-0327(96)00004-3; Fenton MC, 2013, PSYCHOL MED, V43, P1045, DOI
10.1017/S0033291712001729; Fergusson DM, 2008, CHILD ABUSE NEGLECT, V32, P607, DOI
10.1016/j.chiabu.2006.12.018; Fergusson DM, 2009, ARCH GEN PSYCHIAT, V66, P260, DOI
10.1001/archgenpsychiatry.2008.543; Fetzner MG, 2011, DEPRESS ANXIETY, V28, P632,
DOI 10.1002/da.20852; Foulds JA, 2015, J AFFECT DISORDERS, V185, P47, DOI
10.1016/j.jad.2015.06.024; Fu QA, 2002, ARCH GEN PSYCHIAT, V59, P1125, DOI
10.1001/archpsyc.59.12.1125; Fu Q, 2007, TWIN RES HUM GENET, V10, P470, DOI
10.1375/twin.10.3.470; Gilman SE, 2001, DRUG ALCOHOL DEPEN, V63, P277, DOI
10.1016/S0376-8716(00)00216-7; Goodwin RD, 2012, AM J ADDICTION, V21, P416, DOI
10.1111/j.1521-0391.2012.00263.x; Grant B F, 1995, J Subst Abuse, V7, P481, DOI
10.1016/0899-3289(95)90017-9; Grant BF, 1997, J STUD ALCOHOL, V58, P464, DOI
10.15288/jsa.1997.58.464; GRANT BF, 1995, DRUG ALCOHOL DEPEN, V39, P197, DOI
10.1016/0376-8716(95)01160-4; Grant BF, 1998, J SUBST ABUSE, V10, P255, DOI
10.1016/S0899-3289(99)00006-1; Grant BF, 2004, ARCH GEN PSYCHIAT, V61, P807, DOI
10.1001/archpsyc.61.8.807; Grant BF, 2004, DRUG ALCOHOL DEPEN, V74, P223, DOI
10.1016/j.drugalcdep.2004.02.004; Grant BF, 2015, JAMA PSYCHIAT, V72, P757, DOI
10.1001/jamapsychiatry.2015.0584; Gratzer D, 2004, J AFFECT DISORDERS, V79, P209,
DOI 10.1016/S0165-0327(02)00355-5; Greenfield SF, 1998, ARCH GEN PSYCHIAT, V55,
P259, DOI 10.1001/archpsyc.55.3.259; Hamdi NR, 2014, PSYCHOL MED, V44, P315, DOI
10.1017/S0033291713000627; Hasin D, 2006, AM J PSYCHIAT, V163, P689, DOI
10.1176/appi.ajp.163.4.689; HASIN D, 1985, COMPR PSYCHIAT, V26, P283, DOI
10.1016/0010-440X(85)90073-2; Hasin D, 2002, ARCH GEN PSYCHIAT, V59, P375, DOI
10.1001/archpsyc.59.4.375; Hasin DS, 2007, ARCH GEN PSYCHIAT, V64, P830, DOI
10.1001/archpsyc.64.7.830; Hasin DS, 2015, SOC PSYCH PSYCH EPID, V50, P1609, DOI
10.1007/s00127-015-1088-0; Hasin DS, 2013, AM J PSYCHIAT, V170, P834, DOI
10.1176/appi.ajp.2013.12060782; Hasin DS, 2002, ARCH GEN PSYCHIAT, V59, P794, DOI
10.1001/archpsyc.59.9.794; Hasin DS, 1996, AM J PSYCHIAT, V153, P1195; Hasin DS,
2005, ARCH GEN PSYCHIAT, V62, P1097, DOI 10.1001/archpsyc.62.10.1097; HELZER JE,
1988, J STUD ALCOHOL, V49, P219, DOI 10.15288/jsa.1988.49.219; Hodgins DC, 1999,
ALCOHOL CLIN EXP RES, V23, P151, DOI 10.1097/00000374-199901000-00022; Hoge CW,
2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Holahan CJ,
2003, J ABNORM PSYCHOL, V112, P159, DOI 10.1037/0021-843X.112.1.159; Jamal M, 2015,
DRUG ALCOHOL DEPEN, V148, P150, DOI 10.1016/j.drugalcdep.2014.12.032; Kendler KS,
2008, ARCH GEN PSYCHIAT, V65, P1438, DOI 10.1001/archpsyc.65.12.1438; Kendler KS,
1997, BRIT J PSYCHIAT, V170, P541, DOI 10.1192/bjp.170.6.541; Kendler KS, 2003,
ARCH GEN PSYCHIAT, V60, P929, DOI 10.1001/archpsyc.60.9.929; Kendler KS, 2000, ARCH
GEN PSYCHIAT, V57, P953, DOI 10.1001/archpsyc.57.10.953; Kessler RC, 1996, AM J
ORTHOPSYCHIAT, V66, P17, DOI 10.1037/h0080151; Kessler RC, 1999, J HEALTH SOC
BEHAV, V40, P208, DOI 10.2307/2676349; Kessler RC, 1997, ARCH GEN PSYCHIAT, V54,
P313; Kessler RC, 1996, BRIT J PSYCHIAT, V168, P17, DOI 10.1192/S0007125000298371;
KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Kessler RC, 2003, JAMA-J AM MED
ASSOC, V289, P3095, DOI 10.1001/jama.289.23.3095; Keyes KM, 2013, PSYCHOL MED, V43,
P1673, DOI 10.1017/S0033291712002292; Keyes KM, 2012, BRIT J PSYCHIAT, V200, P107,
DOI 10.1192/bjp.bp.111.093062; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259;
Khoury L, 2010, DEPRESS ANXIETY, V27, P1077, DOI 10.1002/da.20751; Kiefer F, 2003,
ARCH GEN PSYCHIAT, V60, P92, DOI 10.1001/archpsyc.60.1.92; Kim HK, 2003, DEV
PSYCHOPATHOL, V15, P469, DOI 10.1017/S0954579403000257; King KM, 2008, J STUD
ALCOHOL DRUGS, V69, P629, DOI 10.15288/jsad.2008.69.629; Koob GF, 2015, EUR J
PHARMACOL, V753, P73, DOI 10.1016/j.ejphar.2014.11.044; Koob GF, 2005, NAT
NEUROSCI, V8, P1442, DOI 10.1038/nn1105-1442; Kotov R, 2011, ARCH GEN PSYCHIAT,
V68, P1003, DOI 10.1001/archgenpsychiatry.2011.107; Krueger RF, 1999, ARCH GEN
PSYCHIAT, V56, P921, DOI 10.1001/archpsyc.56.10.921; Kuo PH, 2006, PSYCHOL MED,
V36, P1153, DOI 10.1017/S0033291706007860; Lazareck S, 2012, J CLIN PSYCHIAT, V73,
pE588, DOI 10.4088/JCP.11m07345; Livesley WJ, 2008, PSYCHIAT CLIN N AM, V31, P545,
DOI 10.1016/j.psc.2008.03.014; Lynskey MT, 1998, DRUG ALCOHOL DEPEN, V52, P201, DOI
10.1016/S0376-8716(98)00095-7; Markou A, 1998, NEUROPSYCHOPHARMACOL, V18, P135, DOI
10.1016/S0893-133X(97)00113-9; Martins SS, 2012, PSYCHOL MED, V42, P1261, DOI
10.1017/S0033291711002145; McCall-Hosenfeld JS, 2014, PLOS ONE, V9, DOI
10.1371/journal.pone.0112416; McDermut W, 2001, J AFFECT DISORDERS, V65, P289, DOI
10.1016/S0165-0327(00)00220-2; McDonell MG, 2013, AM J PSYCHIAT, V170, P94, DOI
10.1176/appi.ajp.2012.11121831; McGee R, 2000, ADDICTION, V95, P491, DOI
10.1046/j.1360-0443.2000.9544912.x; MERIKANGAS KR, 1985, J STUD ALCOHOL, V46, P199,
DOI 10.15288/jsa.1985.46.199; Meyers JL, 2015, J PSYCHIATR RES, V68, P337, DOI
10.1016/j.jpsychires.2015.05.005; Miller NS, 1996, J PSYCHOACTIVE DRUGS, V28, P111,
DOI 10.1080/02791072.1996.10524384; Moak DH, 2003, J CLIN PSYCHOPHARM, V23, P553,
DOI 10.1097/01.jcp.0000095346.32154.41; Najt P, 2011, PSYCHIAT RES, V186, P159, DOI
10.1016/j.psychres.2010.07.042; NEALE MC, 1995, AM J HUM GENET, V57, P935; Neria Y,
2011, AM PSYCHOL, V66, P429, DOI [10.1037/a0024791, 10.1037/0024791]; Norman SB,
2007, DRUG ALCOHOL DEPEN, V90, P89, DOI 10.1016/j.drugalcdep.2007.03.002; Nunes EV,
2004, JAMA-J AM MED ASSOC, V291, P1887, DOI 10.1001/jama.291.15.1887; Pacek LR,
2013, J AFFECT DISORDERS, V148, P188, DOI 10.1016/j.jad.2012.11.059; Perlman SE,
2011, LANCET, V378, P925, DOI 10.1016/S0140-6736(11)60967-7; Pettinati HM, 2010, AM
J PSYCHIAT, V167, P668, DOI 10.1176/appi.ajp.2009.08060852; Pettinati HM, 2004,
BIOL PSYCHIAT, V56, P785, DOI 10.1016/j.biopsych.2004.07.016; Quello Susan B, 2005,
Sci Pract Perspect, V3, P13; REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511;
Rohrbach LA, 2009, PSYCHIATRY, V72, P222, DOI 10.1521/psyc.2009.72.3.222; Rohsenow
Damaris J, 2010, Curr Drug Abuse Rev, V3, P76; Rounsaville BJ, 2004, BIOL PSYCHIAT,
V56, P803, DOI 10.1016/j.biopsych.2004.05.009; Saunders J. B., 2007, DIAGNOSTIC
ISSUES SU; Scherrer
J. F., 2007, COMPR PSYCHIAT, V49, P297; SCHUCKIT MA, 1995, J STUD ALCOHOL, V56,
P218, DOI 10.15288/jsa.1995.56.218; Schuckit MA, 1997, AM J PSYCHIAT, V154, P948;
Schuckit MA, 1996, J STUD ALCOHOL, V57, P368, DOI 10.15288/jsa.1996.57.368;
Schuckit MA, 2013, J STUD ALCOHOL DRUGS, V74, P271, DOI 10.15288/jsad.2013.74.271;
Slade T, 2006, PSYCHOL MED, V36, P1593, DOI 10.1017/S0033291706008452; Swendsen JD,
1998, COMPR PSYCHIAT, V39, P176, DOI 10.1016/S0010-440X(98)90058-X; Tolliver BK,
2015, DIALOGUES CLIN NEURO, V17, P181; Torgersen S, 2008, PSYCHOL MED, V38, P1617,
DOI 10.1017/S0033291708002924; Vaidyanathan U, 2011, COMPR PSYCHIAT, V52, P527, DOI
10.1016/j.comppsych.2010.10.006; Vollebergh WAM, 2001, ARCH GEN PSYCHIAT, V58,
P597, DOI 10.1001/archpsyc.58.6.597; Weiss RD, 2007, AM J PSYCHIAT, V164, P100, DOI
10.1176/appi.ajp.164.1.100; Widom CS, 2007, ARCH GEN PSYCHIAT, V64, P49; Windle M,
1999, DEV PSYCHOPATHOL, V11, P823, DOI 10.1017/S0954579499002345; Wu LT, 1999, AM J
PSYCHIAT, V156, P1230; Wu P, 2008, J STUD ALCOHOL DRUGS, V69, P520, DOI
10.15288/jsad.2008.69.520; Wu P, 2006, PEDIATRICS, V118, P1907, DOI
10.1542/peds.2006-1221; Young-Wolff KC, 2009, ALCOHOL CLIN EXP RES, V33, P1476, DOI
10.1111/j.1530-0277.2009.00978.x; Zimmerman M, 2002, J CLIN PSYCHIAT, V63, P187,
DOI 10.4088/JCP.v63n0303; Zvolensky MJ, 2015, PSYCHIAT RES, V226, P73, DOI
10.1016/j.psychres.2014.11.064 141 0 0 2 2 JOHNS HOPKINS UNIV
PRESS BALTIMORE 2715 N CHARLES ST, BALTIMORE, MD 21218-4319 USA 978-1-
4214-2280-0; 978-1-4214-2281-7; 978-1-4214-2279-4 2017
89 114 26 Psychology,
Clinical; Health Policy & Services; Psychiatry Psychology; Health Care Sciences &
Services; Psychiatry BK8PS WOS:000443342900005 2019-
09-25
J Rougemont-Bucking, A; Grazioli, VS; Daeppen, JB; Gmel, G; Studer, J
Rougemont-Bucking, Ansgar; Grazioli, Veronique S.; Daeppen, Jean-
Bernard; Gmel, Gerhard; Studer, Joseph Family-Related Stress versus
External Stressors: Differential Impacts on Alcohol and Illicit Drug Use in Young
Men EUROPEAN ADDICTION RESEARCH English Article
Substance use disorders; Parental monitoring; Neglect; Stress;
Risky family setting; Trauma; Sexual assault; Physical assault SELF-MEDICATION
HYPOTHESIS; CHILDHOOD EMOTIONAL MALTREATMENT; SUBSTANCE USE; PSYCHOMETRIC
PROPERTIES; RISK-FACTORS; CANNABIS USE; ABUSE; TRAUMA; CHILDREN; NEGLECT
Intense stress increases substance use (SU). However, little is known about
the extent to which distinctive forms of stress should be weighted with regard to
their effects on SU. This study aimed to determine whether family-related stress
factors (FSF) influenced SU in a different way than external stress factors (ESF).
Data was drawn from a Swiss cohort study on SU risk factors (C-SURF), involving
5,308 young adult men. Twelve month use of alcohol and of illicit substances was
assessed. FSF and ESF for the time period preceding SU were measured. FSF and ESF
were both significantly associated with SU. FSF had a greater impact on the use of
most substances than did ESF. The FSF with the strongest association with SU was
lack of parental monitoring. Regarding ESF, the cumulative number of stressful
external events had a higher impact on SU than previous physical or sexual assault
by a stranger. In contrast, physical or sexual assault by a family member was not
found to be associated with subsequent SU. These findings have important
implications for SU prevention programmes focusing on male teenagers, as it is
difficult to screen and intervene in subtle forms of maltreatment in families. (C)
2017 S. Karger AG, Basel [Rougemont-Bucking, Ansgar; Grazioli, Veronique S.;
Daeppen, Jean-Bernard; Gmel, Gerhard; Studer, Joseph] Ctr Hosp Univ Vaudois CHUV,
Alcohol Treatment Ctr, Av Beaumont 21 Bis,Pavillon 2, CH-1011 Lausanne,
Switzerland; [Gmel, Gerhard] Addict Suisse, Lausanne, Switzerland; [Gmel, Gerhard]
Ctr Addict & Mental Hlth, Toronto, ON, Canada; [Gmel, Gerhard] Univ West England,
Frenchay Campus, Bristol, Avon, England Rougemont-Bucking, A (reprint author),
Ctr Hosp Univ Vaudois CHUV, Alcohol Treatment Ctr, Av Beaumont 21 Bis,Pavillon 2,
CH-1011 Lausanne, Switzerland. ansgar@dr-rougemont-buecking.eu Gachoud,
Celine/K-1104-2018; Grazioli, Veronique/Q-1942-2019 Grazioli, Veronique S./0000-
0003-1956-7712 Swiss National Science FoundationSwiss National Science
Foundation (SNSF) [FN 33CSC30-122679, FN 33CS30-139467] This study was funded by
the Swiss National Science Foundation (grants FN 33CSC30-122679 and FN 33CS30-
139467). Agrawal A, 2009, ADDICTION, V104, P518, DOI 10.1111/j.1360-
0443.2009.02504.x; Bahr Stephen J, 2005, J Prim Prev, V26, P529, DOI
10.1007/s10935-005-0014-8; Boning J, 2009, PHARMACOPSYCHIATRY, V42, pS66, DOI
10.1055/s-0029-1216357; Breslau Naomi, 2002, J Gend Specif Med, V5, P34; Broekman
BFP, 2007, NEUROSCI BIOBEHAV R, V31, P348, DOI 10.1016/j.neubiorev.2006.10.001;
Bureau J.-F., 2010, IMPACT EARLY LIFE TR, P48; Burnham K, 2002, MODEL SELECTION
MULT; C-SURF, 2015, FOLL UP 1 QUEST; Caldwell CH, 2004, AM J COMMUN PSYCHOL, V34,
P71, DOI 10.1023/B:AJCP.0000040147.69287.f7; Carliner H, 2016, J AM ACAD CHILD PSY,
V55, P701, DOI 10.1016/j.jaac.2016.05.010; Casajuana C, 2016, SUBST USE MISUSE,
V51, P1760, DOI 10.1080/10826084.2016.1197266; Charuvastra A, 2008, ANNU REV
PSYCHOL, V59, P301, DOI 10.1146/annurev.psych.58.110405.085650; Chassin L, 2013, J
ADOLESCENT HEALTH, V52, P689, DOI 10.1016/j.jadohealth.2012.11.018; Clark HK, 2012,
J PRIM PREV, V33, P67, DOI 10.1007/s10935-012-0266-z; Danielson CK, 2009, ADDICT
BEHAV, V34, P395, DOI 10.1016/j.addbeh.2008.11.009; Douglas KR, 2010, ADDICT BEHAV,
V35, P7, DOI 10.1016/j.addbeh.2009.07.004; Dube SR, 2003, PEDIATRICS, V111, P564,
DOI 10.1542/peds.111.3.564; Edenberg HJ, 2006, ADDICT BIOL, V11, P386, DOI
10.1111/j.1369-1600.2006.00035.x; Foa EB, 1997, PSYCHOL ASSESSMENT, V9, P445, DOI
10.1037/1040-3590.9.4.445; Fonzo GA, 2016, PSYCHOL MED, V46, P1037, DOI
10.1017/S0033291715002603; Gavranidou M, 2003, DEPRESS ANXIETY, V17, P130, DOI
10.1002/da.10103; Gilbert R, 2009, LANCET, V373, P167, DOI 10.1016/S0140-
6736(08)61707-9; Glaser D, 2002, CHILD ABUSE NEGLECT, V26, P697, DOI 10.1016/S0145-
2134(02)00342-3; GMEL G, 2015, SUCHT, V61, P251, DOI DOI 10.1024/0939-5911.A000380;
Gmel G, 2013, SUBST USE MISUSE, V48, P1085, DOI 10.3109/10826084.2013.799017; Gray
MJ, 2004, ASSESSMENT, V11, P330, DOI 10.1177/1073191104269954; Gual A, 2005,
ALCOHOL PRIMARY CARE; Herman J, 1997, TRAUMA RECOVERY AFTE; Heyne A, 2000, J NEURAL
TRANSM, V107, P613, DOI 10.1007/s007020070065; Hibell B, 2013, 2011 ESPAD REPORT
SU; Hooper LM, 2011, J LOSS TRAUMA, V16, P258, DOI 10.1080/15325024.2011.572035;
Iwaniec D., 2006, CHILD FAMILY SOCIAL, V11, P73, DOI [10.1111/j.1365-
2206.2006.00398.x, DOI 10.1111/J.1365-2206.2006.00398.X]; Johnson CS, 2010, J
TRAUMA STRESS, V23, P649, DOI 10.1002/jts.20563; Kassel J. D., 2010, HDB DRUG USE
ETIOLOG, P183; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI
10.1001/archpsyc.1995.03950240066012; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142,
P1259; Koob G, 2007, AM J PSYCHIAT, V164, P1149, DOI
10.1176/appi.ajp.2007.05030503; Lazarus R. S., 1984, STRESS APPRAISAL COP; Lee RS,
2014, NEUROENDOCRINOLOGY, V100, P278, DOI 10.1159/000369585; Lembke A, 2012, AM J
DRUG ALCOHOL AB, V38, P524, DOI 10.3109/00952990.2012.694532; Lilienfeld SO, 2002,
AM PSYCHOL, V57, P176, DOI 10.1037//0003-066X.57.3.176; Lupien SJ, 2007, BRAIN
COGNITION, V65, P209, DOI 10.1016/j.bandc.2007.02.007; Magnusson A, 2012, PSYCHOL
MED, V42, P381, DOI 10.1017/S0033291711001310; Maguire SA, 2015, CHILD CARE HLTH
DEV, V41, P641, DOI 10.1111/cch.12227; MCLELLAN AT, 1980, J NERV MENT DIS, V168,
P26, DOI 10.1097/00005053-198001000-00006; McMahon SD, 2003, J CHILD PSYCHOL PSYC,
V44, P107, DOI 10.1111/1469-7610.00105; Miller P.PlantM, 2003, J SUBST USE, V8,
P19, DOI DOI 10.1080/1465989021000067209; Murgatroyd C, 2010, EPIGENETICS-US, V5;
National Institute on Alcohol Abuse and Al-coholism, 2017, BING DRINK DEF; National
Institute on Alcohol Abuse and Al-coholism, 1995, NIH PUBL; National Institute on
Alcohol Abuse and Al-coholism, 2017, STAND DRINK DEF; Ondersma SJ, 2001, PSYCHOL
BULL, V127, P707, DOI 10.1037/0033-2909.127.6.707; Pedersen CA, 2004, ANN NY ACAD
SCI, V1036, P106, DOI 10.1196/annals.1330.006; Repetti RL, 2002, PSYCHOL BULL,
V128, P330, DOI 10.1037/0033-2909.128.2.330; Rind B, 1997, J SEX RES, V34, P237,
DOI 10.1080/00224499709551891; Rind B, 1998, PSYCHOL BULL, V124, P22, DOI
10.1037/0033-2909.124.1.22; Sapolsky RM, 2004, COGNITIVE NEUROSCIENCES III, THIRD
EDITION, P1031; Shin SH, 2012, ADDICT BEHAV, V37, P102, DOI
10.1016/j.addbeh.2011.09.006; Shors TJ, 2006, ANNU REV PSYCHOL, V57, P55, DOI
10.1146/annurev.psych.57.102904.190205; Simpson TL, 2002, CLIN PSYCHOL REV, V22,
P27, DOI 10.1016/S0272-7358(00)00088-X; Sinha R, 2008, ANN NY ACAD SCI, V1141,
P105, DOI 10.1196/annals.1441.030; Studer J, 2013, DRUG ALCOHOL DEPEN, V132, P316,
DOI 10.1016/j.drugalcdep.2013.02.029; Suh JJ, 2008, PSYCHOANAL PSYCHOL, V25, P518,
DOI 10.1037/0736-9735.25.3.518; Tornay L, 2013, EUR J PEDIATR, V172, P1229, DOI
10.1007/s00431-013-2029-0; Vachon DD, 2015, JAMA PSYCHIAT, V72, P1135, DOI
10.1001/jamapsychiatry.2015.1792; Van der Vorst H, 2006, PSYCHOL ADDICT BEHAV, V20,
P107, DOI 10.1037/0893-164X.20.2.107; van Harmelen AL, 2011, EUR J PSYCHOTRAUMATO,
V2, DOI 10.3402/ejpt.v2i0.7336; Verona E, 2015, PSYCHOL VIOLENCE; Wang C, 2015,
PLOS ONE, V10, DOI 10.1371/journal.pone.0119965; Wills TA, 1996, HDB COPING THEORY
RE, P279; World Health Organization, 2002, WORLD REPORT VIOLENC; Wright MO, 2009,
CHILD ABUSE NEGLECT, V33, P59, DOI 10.1016/j.chiabu.2008.12.007 72 2 2
0 3 KARGER BASEL ALLSCHWILERSTRASSE 10, CH-4009 BASEL,
SWITZERLAND 1022-6877 1421-9891 EUR ADDICT RES Eur. Addict. Res.
2017 23 6 284 297 10.1159/000485031
14 Substance Abuse; Psychiatry Substance Abuse; Psychiatry FW4CK
WOS:000425260000003 29275419 2019-09-25
B Lev-Ran, S; Feingold, D Preedy, VR Lev-Ran, S.; Feingold, D.
Cannabis Use and Its Association to Mental Illness: A Focus on Mood and
Anxiety Disorders HANDBOOK OF CANNABIS AND RELATED PATHOLOGIES: BIOLOGY,
PHARMACOLOGY, DIAGNOSIS, AND TREATMENT English Article; Book
Chapter SUBSTANCE USE DISORDERS; BIPOLAR
DISORDER; SOCIAL ANXIETY; UNITED-STATES; SELF-MEDICATION; GLOBAL BURDEN; RISK-
FACTOR; COMORBIDITY; PREVALENCE; DEPRESSION [Lev-Ran, S.; Feingold, D.]
Sheba Med Ctr, Dept Psychiat, Tel Hashomer, Israel; [Lev-Ran, S.] Tel Aviv Univ,
Sackler Fac Med, Tel Aviv, Israel; [Feingold, D.] Ariel Univ, Ariel, Israel Lev-
Ran, S (reprint author), Sheba Med Ctr, Dept Psychiat, Tel Hashomer, Israel.; Lev-
Ran, S (reprint author), Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.
ABLON SL, 1974, AM J PSYCHIAT, V131, P448; Agrawal A, 2011,
PSYCHIAT RES, V185, P459, DOI 10.1016/j.psychres.2010.07.007; American Psychiatric
Association, 2013, DIAGN STAT MAN MENT; Bolton JM, 2009, J AFFECT DISORDERS, V115,
P367, DOI 10.1016/j.jad.2008.10.003; Bovasso GB, 2001, AM J PSYCHIAT, V158, P2033,
DOI 10.1176/appi.ajp.158.12.2033; Bricker JB, 2007, DEPRESS ANXIETY, V24, P392, DOI
10.1002/da.20248; Buckner JD, 2008, J PSYCHIATR RES, V42, P230, DOI
10.1016/j.jpsychires.2007.01.002; Buckner JD, 2012, DRUG ALCOHOL DEPEN, V124, P128,
DOI 10.1016/j.drugalcdep.2011.12.023; Buckner JD, 2012, J ANXIETY DISORD, V26,
P297, DOI 10.1016/j.janxdis.2011.12.006; Buckner JD, 2009, PSYCHIAT RES, V166,
P238, DOI 10.1016/j.psychres.2008.01.009; Cerullo MA, 2007, SUBST ABUSE TREAT PR,
V2, DOI 10.1186/1747-597X-2-29; Chen CY, 2002, SOC PSYCH PSYCH EPID, V37, P199, DOI
10.1007/s00127-002-0541-z; Cheung JTW, 2010, AM J DRUG ALCOHOL AB, V36, P118, DOI
10.3109/00952991003713784; D'Souza DC, 2004, NEUROPSYCHOPHARMACOL, V29, P1558, DOI
10.1038/sj.npp.1300496; de Graaf R, 2004, J AFFECT DISORDERS, V82, P461, DOI
10.1016/j.jad.2004.03.001; Degenhardt L, 2003, ADDICTION, V98, P1493, DOI
10.1046/j.1360-0443.2003.00437.x; Degenhardt L, 2001, SOC PSYCH PSYCH EPID, V36,
P219, DOI 10.1007/s001270170052; Degenhardt L., 2000, 98 NDARC; Degenhardt L, 2013,
ADDICTION, V108, P124, DOI 10.1111/j.1360-0443.2012.04015.x; Degenhardt L, 2012,
LANCET, V379, P55, DOI 10.1016/S0140-6736(11)61138-0; Degenhardt L, 2011, DRUG
ALCOHOL DEPEN, V117, P85, DOI 10.1016/j.drugalcdep.2010.11.032; Etain Bruno, 2012,
J Clin Psychiatry, V73, pe561, DOI 10.4088/JCP.10m06504; Feingold D, 2015, J AFFECT
DISORDERS, V172, P211, DOI 10.1016/j.jad.2014.10.006; Fergusson DM, 1997,
ADDICTION, V92, P279; Fusar-Poli P, 2009, ARCH GEN PSYCHIAT, V66, P95, DOI
10.1001/archgenpsychiatry.2008.519; Gadermann AM, 2012, DEPRESS ANXIETY, V29, P797,
DOI 10.1002/da.21924; Georgiades K, 2007, J CHILD PSYCHOL PSYC, V48, P724, DOI
10.1111/j.1469-7610.2007.01740.x; Grant B, 2005, SOURCE ACCURACY STAT; Gruber AJ,
1997, SUBST USE MISUSE, V32, P249, DOI 10.3109/10826089709055849; Grucza RA, 2007,
ADDICTION, V102, P623, DOI 10.1111/j.1360-0443.2007.01745.x; Hammen C., 2003, HDB
PSYCHOL, V8, P121; Hathaway AD, 2003, ADDICT RES THEORY, V11, P441, DOI
10.1080/1606635021000041807; Hibell B., 2012, 2011 ESPAD REPORT SU; Hill MN, 2013,
BIOL MOOD ANXIETY DI, V3, DOI 10.1186/2045-5380-3-19; Horwood LJ, 2012, DRUG
ALCOHOL DEPEN, V126, P369, DOI 10.1016/j.drugalcdep.2012.06.002; Johns A, 2001,
BRIT J PSYCHIAT, V178, P116, DOI 10.1192/bjp.178.2.116; Kessler RC, 2002, PSYCHOL
MED, V32, P959, DOI 10.1017/S0033291702006074; Kessler RC, 2005, NEW ENGL J MED,
V352, P2515, DOI 10.1056/NEJMsa043266; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51,
P8; Khantzian E.J., 2008, UNDERSTANDING ADDICT; KHANTZIAN EJ, 1985, AM J PSYCHIAT,
V142, P1259; Lev-Ran S, 2014, PSYCHOL MED, V44, P797, DOI
10.1017/S0033291713001438; Lev-Ran S, 2013, PSYCHIAT RES, V209, P459, DOI
10.1016/j.psychres.2012.12.014; Lev-Ran S, 2013, COMPR PSYCHIAT, V54, P589, DOI
10.1016/j.comppsych.2012.12.021; Mariani JJ, 2011, DRUG ALCOHOL DEPEN, V113, P249,
DOI 10.1016/j.drugalcdep.2010.08.008; Marmorstein NR, 2010, J ABNORM CHILD PSYCH,
V38, P211, DOI 10.1007/s10802-009-9360-y; Moore THM, 2007, LANCET, V370, P319, DOI
10.1016/S0140-6736(07)61162-3; Ogborne AC, 2000, J PSYCHOACTIVE DRUGS, V32, P435,
DOI 10.1080/02791072.2000.10400245; Otten R, 2013, ADDICT BIOL, V18, P826, DOI
10.1111/j.1369-1600.2011.00380.x; REGIER DA, 1990, JAMA-J AM MED ASSOC, V264,
P2511; REGIER DA, 1984, ARCH GEN PSYCHIAT, V41, P934; Stinson FS, 2006, PSYCHOL
MED, V36, P1447, DOI 10.1017/S0033291706008361; Strakowski SM, 2007, ARCH GEN
PSYCHIAT, V64, P57, DOI 10.1001/archpsyc.64.1.57; Substance Abuse and Mental Health
Services Administration, 2007, NSDUH SER H; Substance Abuse and Mental Health
Services Administration, 2007, DHHS PUBL; SZUSTER RR, 1988, J CLIN PSYCHIAT, V49,
P427; Tijssen MJA, 2010, ACTA PSYCHIAT SCAND, V122, P255, DOI 10.1111/j.1600-
0447.2010.01539.x; Troisi A, 1998, ADDICTION, V93, P487, DOI 10.1046/j.1360-
0443.1998.9344874.x; United Nations Office on Drugs and Crime, 2012, WORLD DRUG REP
2012; van Laar M, 2007, ADDICTION, V102, P1251, DOI 10.1111/j.1360-
0443.2007.01875.x; van Rossum I, 2009, J NERV MENT DIS, V197, P35, DOI
10.1097/NMD.0b013e31819292a6; Whiteford HA, 2013, LANCET, V382, P1575, DOI
10.1016/S0140-6736(13)61611-6; Wittchen HU, 2007, DRUG ALCOHOL DEPEN, V88, pS60,
DOI 10.1016/j.drugalcdep.2006.12.013; World Health Organization, 1992, ICD 10 CLASS
MENT BE; World Health Organization, 2002, WORLD HLTH REP 2002; Zvolensky MJ, 2006,
J PSYCHIAT RES, V40, P477, DOI 10.1016/j.jpsychires.2005.09.005 66 0 0
0 0 ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD LONDON 24-28 OVAL
ROAD, LONDON NW1 7DX, ENGLAND 978-0-12-800827-0; 978-0-12-800756-3
2017 298 307
10.1016/B978-0-12-800756-3.00035-1 10 Criminology & Penology;
Substance Abuse; Pharmacology & Pharmacy Criminology & Penology; Substance Abuse;
Pharmacology & Pharmacy BJ3CI WOS:000422873500034 2019-
09-25
B Allen, J; Holder, MD; Walsh, Z Preedy, VR Allen, J.; Holder,
M. D.; Walsh, Z. Cannabis Use and Well-Being HANDBOOK OF CANNABIS AND
RELATED PATHOLOGIES: BIOLOGY, PHARMACOLOGY, DIAGNOSIS, AND TREATMENT
English Article; Book Chapter SELF-
MEDICATION HYPOTHESIS; MARIJUANA USE; MENTAL-HEALTH; DEPRESSIVE SYMPTOMS;
EPIDEMIOLOGIC EVIDENCE; ANXIETY DISORDERS; SUBSTANCE USE; YOUNG-PEOPLE; CHRONIC
PAIN; DRUG-USE [Allen, J.; Holder, M. D.; Walsh, Z.] Univ British
Columbia, Dept Psychol, IKBSAS, Kelowna, BC, Canada Allen, J (reprint author),
Univ British Columbia, Dept Psychol, IKBSAS, Kelowna, BC, Canada.
Allen J, 2014, J HAPPINESS STUD, V15, P301, DOI 10.1007/s10902-
013-9423-1; Arendt M, 2007, PSYCHOL MED, V37, P935, DOI 10.1017/S0033291706009688;
Argyle M, 2001, PSYCHOL HAPPINESS; Barnwell SS, 2006, SUBST ABUSE TREAT PR, V1, DOI
10.1186/1747-597X-1-29; Bonn-Miller MO, 2008, DEPRESS ANXIETY, V25, P862, DOI
10.1002/da.20370; Bonn-Miller MO, 2005, J PSYCHOPATHOL BEHAV, V27, P279, DOI
10.1007/s10862-005-2408-6; Bottorff JL, 2009, SUBST ABUSE TREAT PR, V4, DOI
10.1186/1747-597X-4-7; Bovasso GB, 2001, AM J PSYCHIAT, V158, P2033, DOI
10.1176/appi.ajp.158.12.2033; Boyd Andrew J, 2004, John Marshall Law Rev, V37,
P1253; Buckner JD, 2012, ADDICT BEHAV, V37, P1294, DOI
10.1016/j.addbeh.2012.06.013; Buckner JD, 2012, J BEHAV THER EXP PSY, V43, P647,
DOI 10.1016/j.jbtep.2011.09.010; Chabrol H, 2005, ADDICT BEHAV, V30, P829, DOI
10.1016/j.addbeh.2004.08.027; Chen CY, 2002, SOC PSYCH PSYCH EPID, V37, P199, DOI
10.1007/s00127-002-0541-z; Cheung JTW, 2010, AM J DRUG ALCOHOL AB, V36, P118, DOI
10.3109/00952991003713784; Crippa JA, 2009, HUM PSYCHOPHARM CLIN, V24, P515, DOI
10.1002/hup.1048; de Graaf R, 2010, AM J EPIDEMIOL, V172, P149, DOI
10.1093/aje/kwq096; Degenhardt L, 2001, ADDICTION, V96, P1603, DOI 10.1046/j.1360-
0443.2001.961116037.x; Degenhardt L, 2013, ADDICTION, V108, P124, DOI
10.1111/j.1360-0443.2012.04015.x; Degenhardt L, 2010, BRIT J PSYCHIAT, V196, P290,
DOI 10.1192/bjp.bp.108.056952; Demir M., 2007, J HAPPINESS STUD, V8, P181, DOI DOI
10.1007/S10902-006-9012-7; Denson TF, 2006, ADDICT BEHAV, V31, P738, DOI
10.1016/j.addbeh.2005.05.052; Durdle H, 2008, DEPRESS ANXIETY, V25, P241, DOI
10.1002/da.20297; Fairman BJ, 2012, J AFFECT DISORDERS, V138, P54, DOI
10.1016/j.jad.2011.12.031; Fergusson DM, 2008, ADDICTION, V103, P969, DOI
10.1111/j.1360-0443.2008.02221.x; Fergusson DM, 2002, ADDICTION, V97, P1123, DOI
10.1046/j.1360-0443.2002.00103.x; Fredrickson BL, 2004, PHILOS T R SOC B, V359,
P1367, DOI 10.1098/rstb.2004.1512; Georgiades K, 2007, J CHILD PSYCHOL PSYC, V48,
P724, DOI 10.1111/j.1469-7610.2007.01740.x; Green B, 2003, DRUG ALCOHOL REV, V22,
P453, DOI 10.1080/09595230310001613976; Gruber AJ, 2003, PSYCHOL MED, V33, P1415,
DOI 10.1017/S0033291703008560; Harder VS, 2006, ADDICTION, V101, P1463, DOI
10.1111/j.1360-0443.2006.01545.x; HARRIS D, 2000, ADV ALCOHOL SUBSTANC, V19, P89;
Hayatbakhsh MR, 2007, J AM ACAD CHILD PSY, V46, P408, DOI
10.1091/CHI.0b013e31802dc54d; Holder M., 2012, HAPPINESS CHILDREN M; Hooshmand S,
2012, J ADOLESCENT HEALTH, V50, P140, DOI 10.1016/j.jadohealth.2011.05.016; Johns
A, 2001, BRIT J PSYCHIAT, V178, P116, DOI 10.1192/bjp.178.2.116; Johnson JL, 2007,
BETTER SCI SEX GENDE; Keyes CLM, 2012, AM J PUBLIC HEALTH, V102, P2164, DOI
10.2105/AJPH.2012.300918; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259; Korthuis
PT, 2008, AIDS PATIENT CARE ST, V22, P859, DOI 10.1089/apc.2008.0005; KOURI E,
1995, BIOL PSYCHIAT, V38, P475, DOI 10.1016/0006-3223(94)00325-W; Lee CM, 2007,
ADDICT BEHAV, V32, P1384, DOI 10.1016/j.addbeh.2006.09.010; Marmorstein NR, 2010, J
CLIN CHILD ADOLESC, V39, P545, DOI 10.1080/15374416.2010.486325; Martins SS, 2011,
DRUG ALCOHOL DEPEN, V119, P28, DOI 10.1016/j.drugalcdep.2011.05.010; Moore TH,
2007, LANCET, V370, P319; Moreau J., 1973, HASHISH MENTAL ILLNE; Moussavi S, 2007,
LANCET, V370, P851, DOI 10.1016/S0140-6736(07)61415-9; NAIL RL, 1974, J NERV MENT
DIS, V159, P131; Patton GC, 2002, BRIT MED J, V325, P1195, DOI
10.1136/bmj.325.7374.1195; Pedersen W, 2008, ACTA PSYCHIAT SCAND, V118, P395, DOI
10.1111/j.1600-0447.2008.01259.x; Poulin C, 2005, ADDICTION, V100, P525, DOI
10.1111/j.1360-0443.2005.01033.x; Ranney ML, 2013, GEN HOSP PSYCHIAT, V35, P537,
DOI 10.1016/j.genhosppsych.2013.05.007; Reinarman C, 2011, J PSYCHOACTIVE DRUGS,
V43, P128, DOI 10.1080/02791072.2011.587700; Rey JM, 2002, BRIT J PSYCHIAT, V180,
P216, DOI 10.1192/bjp.180.3.216; Russo EB, 2007, CHEM BIODIVERS, V4, P1614, DOI
10.1002/cbdv.200790144; Scott KM, 2007, J AFFECT DISORDERS, V103, P113, DOI
10.1016/j.jad.2007.01.015; Sherbourne CD, 2000, AM J PSYCHIAT, V157, P248, DOI
10.1176/appi.ajp.157.2.248; Shrier LA, 2012, PSYCHOL ADDICT BEHAV, V26, P821, DOI
10.1037/a0029197; Simons J, 1998, J COUNS PSYCHOL, V45, P265, DOI 10.1037/0022-
0167.45.3.265; Steel P, 2008, PSYCHOL BULL, V134, P138, DOI 10.1037/0033-
2909.134.1.138; Tkach C., 2006, J HAPPINESS STUD, V7, P183, DOI DOI 10.1007/S10902-
005-4754-1; Tournier M, 2003, PSYCHIAT RES, V118, P1, DOI 10.1016/S0165-
1781(03)00052-0; Turk DC, 2002, J CONSULT CLIN PSYCH, V70, P678, DOI 10.1037//0022-
006X.70.3.678; van Laar M, 2007, ADDICTION, V102, P1251, DOI 10.1111/j.1360-
0443.2007.01875.x; Walsh Z, 2013, INT J DRUG POLICY, V24, P511, DOI
10.1016/j.drugpo.2013.08.010; Wittchen HU, 2007, DRUG ALCOHOL DEPEN, V88, pS60, DOI
10.1016/j.drugalcdep.2006.12.013; World Health Organization, 2013, WORLD HLTH STAT
2013; Zvolensky MJ, 2007, ADDICT BEHAV, V32, P3122, DOI
10.1016/j.addbeh.2007.06.010; Zvolensky MJ, 2011, AM J ADDICTION, V20, P538, DOI
10.1111/j.1521-0391.2011.00176.x 68 0 0 0 0 ACADEMIC PRESS
LTD-ELSEVIER SCIENCE LTD LONDON 24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND
 978-0-12-800827-0; 978-0-12-800756-3 2017
308 316 10.1016/B978-0-12-800756-3.00036-3
9 Criminology & Penology; Substance Abuse; Pharmacology & Pharmacy
Criminology & Penology; Substance Abuse; Pharmacology & Pharmacy BJ3CI
WOS:000422873500035 2019-09-25
J Brown, T; Shao, WD; Ayub, S; Chong, D; Cornelius, C Brown,
Tanida; Shao, Wanda; Ayub, Shehzad; Chong, David; Cornelius, Christian
A Physician's Attempt to Self-Medicate Bipolar Depression with N,N-
Dimethyltryptamine (DMT) JOURNAL OF PSYCHOACTIVE DRUGS English
Article Bipolar disorder; DMT; N; N-
dimethyltryptamine; phenelzine RECURRENT DEPRESSION; AYAHUASCA; DISPOSITION;
METABOLISM N,N-dimethyltryptamine (DMT) is a psychoactive substance that has been
gaining popularity in therapeutic and recreational use. This is a case of a
physician who chronically took DMT augmented with phenelzine in an attempt to self-
medicate refractory bipolar depression. His presentation of altered mental status,
mania, and psychosis is examined in regards to his DMT use. This case discusses
DMT, the possible uses of DMT, and the theorized mechanism of DMT in psychosis and
treatment of depression, particularly involving its agonist activity at 5-HT1A, 5-
HT2A, and 5-HT2C. It is also important to recognize the dangers of self-medication,
particularly amongst physicians. [Brown, Tanida; Shao, Wanda; Ayub, Shehzad;
Chong, David; Cornelius, Christian] Banner Univ, Med Ctr, Phoenix, AZ USA; [Shao,
Wanda; Chong, David] Univ Arizona, Coll Med, Phoenix, AZ USA; [Ayub, Shehzad;
Cornelius, Christian] Univ Arizona, Coll Med, Psychiat, Phoenix, AZ USA Brown,
T (reprint author), 1300 N 12th St, Phoenix, AZ 85006 USA.
Tanida.brown@bannerhealth.com Balon R, 2007,
PSYCHOTHER PSYCHOSOM, V76, P306, DOI 10.1159/000104707; De Lima Osorio F, 2011,
ETHNOPHARMACOLOGY AY, P75; Dominguez-Clave E, 2016, BRAIN RES BULL, V126, P89, DOI
10.1016/j.brainresbull.2016.03.002; dos Santos RG, 2017, THER ADV PSYCHOPHARM, V7,
P141, DOI 10.1177/2045125316689030; dos Santos RG, 2016, REV BRAS PSIQUIATR, V38,
P65, DOI 10.1590/1516-4446-2015-1701; Erowid, 2015, ER DMT VAULT DOS; Gonzalez-
Maeso J, 2009, CURR MED CHEM, V16, P1017, DOI 10.2174/092986709787581851; Jiang XL,
2013, DRUG METAB DISPOS, V41, P975, DOI 10.1124/dmd.112.050724; Liester MB, 2012, J
PSYCHOACTIVE DRUGS, V44, P200, DOI 10.1080/02791072.2012.704590; Osorio FD, 2015,
REV BRAS PSIQUIATR, V37, P13, DOI 10.1590/1516-4446-2014-1496; Palhano-Fontes F,
2014, THERAPEUTIC USE AYAH, P23, DOI DOI 10.1007/978-3-642-40426-9_2; Riba J, 2015,
DRUG TEST ANAL, V7, P401, DOI 10.1002/dta.1685; Riba J, 2012, DRUG TEST ANAL, V4,
P610, DOI 10.1002/dta.1344; Sanches RF, 2016, J CLIN PSYCHOPHARM, V36, P77, DOI
10.1097/JCP.0000000000000436; Straussman R., 2000, DMT SPIRIT MOL DOCTO; Szmulewicz
AG, 2015, INT J BIPOLAR DISORD, V3, DOI 10.1186/s40345-014-0020-y; Valle M, 2016,
EUR NEUROPSYCHOPHARM, V26, P1161, DOI 10.1016/j.euroneuro.2016.03.012; van den
Buuse M, 2011, NEUROPHARMACOLOGY, V61, P209, DOI 10.1016/j.neuropharm.2011.04.001;
Winstock AR, 2014, J PSYCHOPHARMACOL, V28, P49, DOI 10.1177/0269881113513852 19
1 1 2 15 ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD ABINGDON
2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND 0279-1072
2159-9777 J PSYCHOACTIVE DRUGS J. Psychoact. Drugs 2017
49 4 294 296
10.1080/02791072.2017.1344898 3 Psychology, Clinical;
Substance Abuse Psychology; Substance Abuse FL3ZT WOS:000414166300004
28686543 2019-09-25
J Proctor, SL; Llorca, GM; Perez, PK; Hoffmann, NG
Proctor, Steven L.; Llorca, Geoffrey M.; Perez, Patsy K.; Hoffmann, Norman G.
Associations between craving, trauma, and the DARNU scale:
Dissatisfied, anxious, restless, nervous, and uncomfortableJOURNAL OF SUBSTANCE USE
English Article Craving;
negative affect; PTSD; residential treatment; substance use disorders SUBSTANCE
USE DISORDERS; SELF-MEDICATION HYPOTHESIS; PTSD SYMPTOM SEVERITY; ALCOHOL
DEPENDENCE; STRESS; RELAPSE; UNCOPE; SCREEN; IMPACT; INDIVIDUALS This study
evaluated the clinical utility of a measure of negative emotionality, the DARNU
scale (Dissatisfied, Anxious, Restless, Nervous, and Uncomfortable), using data
from a naturalistic sample of consecutive admissions to a residential substance use
treatment program. Data derived fromroutine clinical assessments of 124 (55.6%
male) patients were analyzed to assess study aims. The DARNU scale in addition to
measures of drug and alcohol craving, severity of posttraumatic stress disorder
(PTSD), and severity of substance use disorder (SUD) were administered to all
patients. Results revealed significant positive correlations between DARNU and PTSD
(r =.783), craving (r =.366), and SUD (r =.331). The DARNU scale yielded a
Cronbach's alpha of.91. When patients were categorized into quartiles based on
DARNU elevations, 88.9% of patients in the highest quartile met diagnostic criteria
for PTSD, while 89.2% of patients in the lowest quartile did not receive a PTSD
diagnosis. Linear regression indicated that the affective vulnerability measured by
DARNU mediated the relationship between PTSD and craving. The DARNU scale may
identify patients at elevated risk for relapse, and may have the potential to serve
as a brief clinical indicator of PTSD without asking about a specific traumatic
event. [Proctor, Steven L.; Perez, Patsy K.] Albizu Univ, Inst Ctr Sci Res,
Miami Campus,2173 NW 99th Ave, Miami, FL 33172 USA; [Llorca, Geoffrey M.; Perez,
Patsy K.] Albizu Univ, Dept Psychol, Miami Campus, Miami, FL USA; [Hoffmann, Norman
G.] Western Carolina Univ, Dept Psychol, Cullowhee, NC 28723 USA Proctor, SL
(reprint author), Albizu Univ, Inst Ctr Sci Res, Miami Campus,2173 NW 99th Ave,
Miami, FL 33172 USA. sproctor@albizu.edu Proctor, Steven/0000-0002-
5485-4226 American Psychiatric Association, 2013, DIAGN STAT MAN
MENT; Anton RF, 2000, ADDICTION, V95, pS211; Atkins MS, 2006, CLIN PSYCHOL-SCI PR,
V13, P105, DOI 10.1111/j.1468-2850.2006.00012.x; Banducci AN, 2016, J ANXIETY
DISORD, V41, P73, DOI 10.1016/j.janxdis.2016.03.003; BARON RM, 1986, J PERS SOC
PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Ben-Porath Y. S., 2008,
MINNESOTA MULTIPHASI; Bottlender M, 2004, ALCOHOL ALCOHOLISM, V39, P357, DOI
10.1093/alcalc/agh073; Campbell TC, 2005, PRISON J, V85, P7, DOI
10.1177/0032885504274287; Connors GJ, 1996, ADDICTION, V91, pS5, DOI
10.1111/j.1360-0443.1996.tb02323.x; DeFife J, 2015, J PSYCHOTHER INTEGR, V25, P299,
DOI 10.1037/a0039564; Drobes DJ, 1999, ALCOHOL RES HEALTH, V23, P179; Flannery BA,
2003, J STUD ALCOHOL, V64, P120, DOI 10.15288/jsa.2003.64.120; Flannery BA, 1999,
ALCOHOL CLIN EXP RES, V23, P1289, DOI 10.1111/j.1530-0277.1999.tb04349.x; Fox HC,
2007, ALCOHOL CLIN EXP RES, V31, P395, DOI 10.1111/j.1530-0277.2006.00320.x; Gil-
Rivas V, 2009, PSYCHOL ADDICT BEHAV, V23, P303, DOI 10.1037/a0015355; Gordon SM,
2006, AM J ADDICTION, V15, P242, DOI 10.1080/10550490600626556; Hoffmann NG, 2003,
J DRUG ISSUES, V33, P29, DOI 10.1177/002204260303300102; Huhn AS, 2016, BRAIN RES
BULL, V123, P94, DOI 10.1016/j.brainresbull.2016.01.012; Hyman SM, 2009, J SUBST
ABUSE TREAT, V36, P400, DOI 10.1016/j.jsat.2008.08.005; Kaczkurkin AN, 2016, BEHAV
RES THER, V79, P7, DOI 10.1016/j.brat.2016.02.001; Kaysen D, 2014, PSYCHOL ADDICT
BEHAV, V28, P62, DOI 10.1037/a0033588; Khantzian EJ, 1997, HARVARD REV PSYCHIAT,
V4, P231, DOI 10.3109/10673229709030550; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142,
P1259; LUDWIG AM, 1974, Q J STUD ALCOHOL, V35, P899; Mee-Lee D, 2013, ASAM CRITERIA
TREATM; Miller MW, 2006, J ABNORM PSYCHOL, V115, P369, DOI 10.1037/0021-
843X.115.2.369; Norman SB, 2007, DRUG ALCOHOL DEPEN, V90, P89, DOI
10.1016/j.drugalcdep.2007.03.002; Nosen E, 2012, BEHAV MODIF, V36, P808, DOI
10.1177/0145445512446741; Nunnally JC, 1978, PSYCHOMETRIC THEORY; Oslin DW, 2009,
DRUG ALCOHOL DEPEN, V103, P131, DOI 10.1016/j.drugalcdep.2009.03.009; Ouimette P,
2007, ADDICT BEHAV, V32, P1719, DOI 10.1016/j.addbeh.2006.11.020; Pahwal P, 2008,
DRUG ALCOHOL DEPEN, V93, P252, DOI 10.1016/j.drugalcdep.2007.10.002; Pavlick M,
2009, ADDICT RES THEORY, V17, P591, DOI 10.3109/16066350802262630; Proctor SL,
2016, PSYCHOL ADDICT BEHAV, V30, P613, DOI 10.1037/adb0000170; Proctor SL, 2011, J
DRUG ISSUES, V41, P117, DOI 10.1177/002204261104100106; Read JP, 2004, ADDICT
BEHAV, V29, P1665, DOI 10.1016/j.addbeh.2004.02.061; Rosenberg H, 2009, CLIN
PSYCHOL REV, V29, P519, DOI 10.1016/j.cpr.2009.06.002; Saladin ME, 2003, ADDICT
BEHAV, V28, P1611, DOI 10.1016/j.addbeh.2003.08.037; Sayette MA, 2000, ADDICTION,
V95, pS189; Schmidt P, 2011, SUBST ABUSE TREAT PR, V6, DOI 10.1186/1747-597X-6-14;
Simpson TL, 2012, PSYCHOL ADDICT BEHAV, V26, P724, DOI 10.1037/a0027169; Sinha R,
2001, PSYCHOPHARMACOLOGY, V158, P343, DOI 10.1007/s002130100917; Sinha R, 2008, ANN
NY ACAD SCI, V1141, P105, DOI 10.1196/annals.1441.030; Urofsky R. I., 2007, J SCH
COUNSELING, V5; Yoon G, 2006, J STUD ALCOHOL, V67, P770, DOI
10.15288/jsa.2006.67.770 45 0 0 0 3 TAYLOR & FRANCIS INC
PHILADELPHIA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
1465-9891 1475-9942 J SUBST USE J. Subst. Use 2017 22
5 479 483 10.1080/14659891.2016.1246621
5 Substance Abuse Substance Abuse FK4AV WOS:000413430200004
2019-09-25
J Young, S; Gonzalez, RA; Wolff, K; Mutch, L; Malet-Lambert, I; Gudjonsson, GH
Young, Susan; Gonzalez, Rafael A.; Wolff, Kim; Mutch, Laura;
Malet-Lambert, Isabella; Gudjonsson, Gisli H. Transitions and
Motivations for Substance Misuse in Prison Inmates With ADHD and Conduct Disorder:
Validation of a New Instrument JOURNAL OF DUAL DIAGNOSIS
English Review Drug dependence;
motivations; ADHD; conduct disorder; transitions; self-medication DEFICIT
HYPERACTIVITY DISORDER; PSYCHIATRIC-DISORDERS; RISK BEHAVIORS; PREVALENCE; ABUSE;
METAANALYSIS; ADDICTION; ALCOHOL; FIT Objective: There is a reasonable
theoretical base for understanding the possible causes and motivations behind
substance misuse and its dependency. There is a need for a reliable and valid
measure that delineates the markers of substance use from its initiation and
identifies different motivations for drug use transitioning, maintenance, and
dependency. We addressed this gap in the United Kingdom by examining and validating
the Substance Transitions in Addiction Rating Scale (STARS). Methods: For this
review, 390 male prisoners were screened for conduct disorder and assessed with a
clinical diagnostic interview for attention deficit/hyperactivity disorder (ADHD).
They completed the four STARS subscales regarding their substance use. Exploratory
structural equation modeling was performed to assess the STARS structure and to
derive factors to assess validity against ADHD and conduct disorder diagnostic
categories. Results: Each of the subscales produced meaningful and reliable factors
that supported the self-medication and behavioral disinhibition hypotheses of
substance use motivation. The findings robustly show that ADHD is significantly
associated with the need for coping as a way of managing primary and comorbid
symptoms, but not conduct disorder. The findings were strongest for the combined
ADHD type. Discussion: STARS has a great potential to further the understanding of
the motivation behind substance use and its dependency in different populations.
[Young, Susan; Gonzalez, Rafael A.] Imperial Coll London, Div Brain Sci, Dept
Med, Ctr Mental Hlth, London, England; [Young, Susan] West London Mental Hlth
Trust, Broadmoor Hosp, London, United Kingdom; [Gonzalez, Rafael A.] Univ Puerto
Rico, Ctr Evaluat & Sociomed Res, Grad Sch Publ Hlth, San Juan, PR 00936 USA;
[Wolff, Kim] Kings Coll London, Inst Pharmaceut Sci, Fac Life Sci & Med, London,
England; [Mutch, Laura; Malet-Lambert, Isabella; Gudjonsson, Gisli H.] Kings Coll
London, Dept Psychol, Inst Psychiat Psychol & Neurosci, London, England Young,
S (reprint author), Ctr Mental Hlth, Dept Med, Div Brain Sci, 7th Floor
Commonwealth Bldg,Du Cane Rd, London W12 0NN, England.
susan.young1@imperial.ac.uk Wolff, Kim/0000-0001-9080-4720 Shire
Pharmaceutical Development Limited This study was funded by Shire Pharmaceutical
Development Limited. Abram KM, 2003, ARCH GEN PSYCHIAT, V60, P1097, DOI
10.1001/archpsyc.60.11.1097; Albizu-Garcia CE, 2012, SUBST ABUS, V33, P60, DOI
10.1080/08897077.2011.620462; American Educational Research Association American
Psychological Association National Councin on Measurement in Education, 2014, STAND
ED PSYCH TEST; American Psychiatric Association, 2013, DIAGN STAT MAN MENT;
Asparouhov T, 2009, STRUCT EQU MODELING, V16, P397, DOI 10.1080/10705510903008204;
Baillargeon J, 2010, ADM POLICY MENT HLTH, V37, P367, DOI 10.1007/s10488-009-0252-
9; Barkley R. A., 2011, BARKLEY ADULT ADHD R; BENTLER PM, 1980, PSYCHOL BULL, V88,
P588, DOI 10.1037/0033-2909.107.2.238; Biederman J, 2006, PSYCHOL MED, V36, P167,
DOI 10.1017/S0033291705006410; Binswanger IA, 2007, NEW ENGL J MED, V356, P157, DOI
10.1056/NEJMsa064115; Buttner A, 2011, NEUROPATH APPL NEURO, V37, P118, DOI
10.1111/j.1365-2990.2010.01131.x; Burt RD, 2007, J URBAN HEALTH, V84, P436, DOI
10.1007/s11524-007-9178-2; Charlson FJ, 2015, EPIDEMIOL PSYCH SCI, V24, P121, DOI
10.1017/S2045796014000687; Faraone SV, 2009, PSYCHOL MED, V39, P685, DOI
10.1017/S0033291708003917; Fazel S, 2006, ADDICTION, V101, P181, DOI
10.1111/j.1360-0443.2006.01316.x; Goldstein S., 2014, HDB EXECUTIVE FUNCTI, P159;
Gonzalez RA, 2015, J ATTEN DISORD, V19, P301, DOI 10.1177/1087054712461690; Grant
BF, 2004, ARCH GEN PSYCHIAT, V61, P807, DOI 10.1001/archpsyc.61.8.807; Grant JE,
2006, CNS SPECTRUMS, V11, P924, DOI 10.1017/S109285290001511X; Gullo MJ, 2008,
NEUROSCI BIOBEHAV R, V32, P1507, DOI 10.1016/j.neubiorev.2008.06.003; Handley ED,
2011, J ABNORM PSYCHOL, V120, P528, DOI 10.1037/a0024162; Hu LT, 1999, STRUCT EQU
MODELING, V6, P1, DOI 10.1080/10705519909540118; KHANTZIAN EJ, 1985, AM J PSYCHIAT,
V142, P1259; Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI
10.1038/npp.2009.110; Kooij JJS, 2010, DIAGNOSTIC INTERVIEW; Levin FR, 2004, ADDICT
BEHAV, V29, P1875, DOI 10.1016/j.addbeh.2004.03.041; Lynskey MT, 2001, ADDICTION,
V96, P815, DOI 10.1046/j.1360-0443.2001.9668153.x; Marsh HW, 2014, ANNU REV CLIN
PSYCHO, V10, P85, DOI 10.1146/annurev-clinpsy-032813-153700; Mumola C. J., 2006,
213530 NCJ BUR JUST; Muthen L. K., 2013, MPLUS USERS GUIDE; Pena-Orellana M, 2011,
J HEALTH CARE POOR U, V22, P962, DOI 10.1353/hpu.2011.0084; Polanczyk G, 2007, AM J
PSYCHIAT, V164, P942, DOI 10.1176/appi.ajp.164.6.942; Rice DP, 1999, P ASSOC AM
PHYSICIAN, V111, P119, DOI 10.1046/j.1525-1381.1999.09254.x; Silva N, 2014, CLIN
NUCL MED, V39, pE129, DOI 10.1097/RLU.0b013e31829f9119; Simon V, 2009, BRIT J
PSYCHIAT, V194, P204, DOI 10.1192/bjp.bp.107.048827; StataCorp, 2013, STATA STAT
SOFTW REL; Urcelay Gonzalo P, 2012, Curr Top Behav Neurosci, V9, P173, DOI
10.1007/7854_2011_119; van Emmerik-van Oortmerssen K, 2012, DRUG ALCOHOL DEPEN,
V122, P11, DOI 10.1016/j.drugalcdep.2011.12.007; van Emmerik-van Oortmerssen K,
2014, ADDICTION, V109, P262, DOI 10.1111/add.12370; Volkow ND, 2005, PHARMACOL
THERAPEUT, V108, P3, DOI 10.1016/j.pharmthera.2005.06.021; Volkow ND, 2010,
BIOESSAYS, V32, P748, DOI 10.1002/bies.201000042; Whiteford HA, 2015, PLOS ONE,
V10, DOI 10.1371/journal.pone.0116820; Wise RA, 2002, NEURON, V36, P229, DOI
10.1016/S0896-6273(02)00965-0; Young S, 2016, PSYCHOL MED, V46, P1449, DOI
10.1017/S0033291716000039; Young S, 2015, PSYCHOL MED, V45, P2499, DOI
10.1017/S0033291715000598; Young S, 2015, PSYCHOL MED, V45, P247, DOI
10.1017/S0033291714000762; Young S, 2011, J PSYCHOPHARMACOL, V25, P1524, DOI
10.1177/0269881110370502; Young S, 2015, EXPERT REV NEUROTHER, V15, P1005, DOI
10.1586/14737175.2015.1059756; Yu C., 2002, ANN M AM ED RES ASS 49 2 2
0 2 ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD ABINGDON 2-4 PARK
SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND 1550-4263 1550-4271
J DUAL DIAGN J. Dual Diagn. 2017 13 2
91 100 10.1080/15504263.2017.1290859 10 Psychology,
Clinical; Substance Abuse; Psychiatry Psychology; Substance Abuse; Psychiatry
EV0PM WOS:000401444500003 28418789 2019-09-25
J Sutter, M; Walter, M; Dursteler, KM; Strasser, J; Vogel, M
Sutter, Manuel; Walter, Marc; Duersteler, Kenneth M.; Strasser, Johannes;
Vogel, Marc Psychosis After Switch in Opioid Maintenance Agonist and
Risperidone-Induced Pisa Syndrome: Two Critical Incidents in Dual Diagnosis
Treatment JOURNAL OF DUAL DIAGNOSIS English Article
Schizophrenia; substance use disorder; opioid use disorder;
Pisa syndrome; risperidone; opioid maintenance treatment; methadone; slow release
morphine; QT prolongation; comorbidity RELEASE ORAL MORPHINE; SUBSTANCE USE
DISORDERS; CHRONIC-SCHIZOPHRENIA; EXTRAPYRAMIDAL SYMPTOMS; SYNDROME PLEUROTHOTONUS;
ENDOGENOUS MORPHINE; RECEPTOR AGONISTS; SELF-MEDICATION; QTC-INTERVAL; CO-MORBIDITY
Background and aims: Dual diagnosis commonly occurs among patients with an
opioid use disorder. Treatment is ideally performed in an integrated fashion. We
present a case that illustrates the complex and challenging psychiatric and medical
therapy of such patients in the light of the literature. Case description: We
report on a 56-year-old patient with schizophrenia and opioid dependence who
experienced both risperidone-induced Pisa syndrome and, 3years later, acute
psychosis after switching the opioid substitution medication from methadone to
slow-release oral morphine due to QT prolongation. Conclusions: With the current
availability of a diversity of substitution opioids in Switzerland (methadone,
buprenorphine, diacetylmorphine, sustained-release oral morphine), studies on
differential effectiveness of these agents in opioid-dependent subpopulations with
selective comorbidity profiles are desirable. The same is true for further
investigation of the involvement of the opioid receptor system in schizophrenia. In
clinical practice, any alteration of opioid medication in patients with dual
diagnosis and a history of schizophrenia should be accompanied by close observation
for psychotic symptoms. [Sutter, Manuel; Walter, Marc; Duersteler, Kenneth M.;
Strasser, Johannes; Vogel, Marc] Univ Basel, Hosp Psychiat, Div Substance Use
Disorders, Wilhelm Klein Str 27, CH-4012 Basel, SwitzerlandSutter, M (reprint
author), Univ Basel, Hosp Psychiat, Div Substance Use Disorders, Wilhelm Klein Str
27, CH-4012 Basel, Switzerland. manuel.sutter@upkbs.ch Vogel, Marc/0000-
0002-3088-0331 Mundipharma We declare that none of the authors had any conflict
of interest relating to the subject of this manuscript. Manuel Sutter, Johannes
Strasser, and Marc Walter do not report any compensation in any of the previous 3
years. Kenneth Dursteler reports a research grant by Mundipharma. Marc Vogel has
received travel support from Lundbeck and Reckitt Benckiser. In addition, he has
received personal fees from Mundipharma. None of the authors has to report any
additional income. ADAIR JC, 1994, J TOXICOL-CLIN TOXIC, V32, P325, DOI
10.3109/15563659409017968; Ansermot N, 2010, ARCH INTERN MED, V170, P529, DOI
10.1001/archinternmed.2010.26; Arora M, 2006, ANN PHARMACOTHER, V40, P2273, DOI
10.1345/aph.1H325; Arzneimittel-Kompendium, 2014, SEVR LONG; Beck T, 2014,
ADDICTION, V109, P617, DOI 10.1111/add.12440; Berg D, 2001, J NEURAL TRANSM, V108,
P1035, DOI 10.1007/s007020170022; BERKEN GH, 1978, AM J PSYCHIAT, V135, P248;
Bhidayasiri R, 2013, NEUROLOGY, V81, P463, DOI 10.1212/WNL.0b013e31829d86b6;
Boettcher C, 2005, P NATL ACAD SCI USA, V102, P8495, DOI 10.1073/pnas.0503244102;
Borentain S, 2002, EUR PSYCHIAT, V17, P419, DOI 10.1016/S0924-9338(02)00699-5;
BRIZER DA, 1985, AM J PSYCHIAT, V142, P1106; Chung AKK, 2011, J PSYCHOPHARMACOL,
V25, P646, DOI 10.1177/0269881110376685; Cobo J, 2006, ACTA NEUROPSYCHIATR, V18,
P50, DOI 10.1111/j.0924-2708.2006.00109.x; Cordeiro Q, 2008, ARQ NEURO-PSIQUIAT,
V66, P896, DOI 10.1590/S0004-282X2008000600026; DAVIS GC, 1977, SCIENCE, V197, P74,
DOI 10.1126/science.325650; Deik Andres, 2012, Curr Drug Abuse Rev, V5, P243; EKBOM
K, 1972, Z NEUROL, V202, P94, DOI 10.1007/BF00316159; EMCDDA, 2014, EUR DRUG REP
2014 TR; FEINBERG DT, 1991, AM J PSYCHIAT, V148, P1750; GASPARI J, 1985, J NERV
MENT DIS, V173, P373, DOI 10.1097/00005053-198506000-00008; GOLD MS, 1977, LANCET,
V2, P398; GOLD MS, 1978, LANCET, V1, P323; Hammig R, 2014, J SUBST ABUSE TREAT,
V47, P275, DOI 10.1016/j.jsat.2014.05.012; Harada K, 2002, J CLIN PSYCHIAT, V63,
P166, DOI 10.4088/JCP.v63n0213b; Heales S, 2004, MOVEMENT DISORD, V19, P1248, DOI
10.1002/mds.20158; Huvent-Grelle D, 2014, J AM GERIATR SOC, V62, P2450, DOI
10.1111/jgs.13168; Iuppa CA, 2013, ANN PHARMACOTHER, V47, P1223, DOI
10.1177/1060028013503132; Jagadheesan K, 2002, AUST NZ J PSYCHIAT, V36, P144;
JANOWSKY DS, 1977, AM J PSYCHIAT, V134, P926; JUDD LL, 1983, PSYCHIAT CLIN N AM,
V6, P393; Kanouse Andrew B, 2015, J Pain Palliat Care Pharmacother, V29, P102, DOI
10.3109/15360288.2015.1037521; Karila L, 2008, AM J PSYCHIAT, V165, P400, DOI
10.1176/appi.ajp.2007.07071103; Kaufmann A, 2012, J CLIN PSYCHOPHARM, V32, P418,
DOI 10.1097/JCP.0b013e318253e067; Kern AM, 2014, J DUAL DIAGN, V10, P52, DOI
10.1080/15504263.2013.867199; Koprich JB, 2011, MOVEMENT DISORD, V26, P1225, DOI
10.1002/mds.23631; Krantz MJ, 2008, J ADDICT DIS, V27, P5, DOI
10.1080/10550880802324317; Kream RM, 2006, MED SCI MONITOR, V12, pRA207; Kream RM,
2012, CURR DRUG TARGETS, V13, P1454; Kriegstein AR, 1999, NEUROLOGY, V53, P1765,
DOI 10.1212/WNL.53.8.1765; Lauterbach EC, 1999, CLIN NEUROPHARMACOL, V22, P87, DOI
10.1097/00002826-199903000-00004; Leucht S, 2013, LANCET, V382, P951, DOI
10.1016/S0140-6736(13)60733-3; LEVINSON I, 1995, J CLIN PSYCHIAT, V56, P73;
LINDSTROM LH, 1978, ACTA PSYCHIAT SCAND, V57, P153, DOI 10.1111/j.1600-
0447.1978.tb06883.x; MAGNAN J, 1982, N-S ARCH PHARMACOL, V319, P197, DOI
10.1007/BF00495865; Maremmani AGI, 2011, J ADDICT DIS, V30, P123, DOI
10.1080/10550887.2011.554779; MCKENNA GJ, 1982, ANN NY ACAD SCI, V398, P44, DOI
10.1111/j.1749-6632.1982.tb39472.x; Mehta A, 2001, J NEUROSCI, V21, P4436, DOI
10.1523/JNEUROSCI.21-12-04436.2001; Guerrero AM, 2013, CLIN NEUROPHARMACOL, V36,
P133, DOI 10.1097/WNF.0b013e318297593d; MIELKE DH, 1977, AM J PSYCHIAT, V134,
P1430; Nishimura K, 2007, J NEUROPSYCH CLIN N, V19, P202, DOI
10.1176/appi.neuropsych.19.2.202; Pacini M., 2005, HEROIN ADDICT REL CL, V7, P43;
Potvin S, 2006, J NEUROL NEUROSUR PS, V77, P796, DOI 10.1136/jnnp.2005.079228;
Quednow BB, 2008, INT J NEUROPSYCHOPH, V11, P655, DOI 10.1017/S1461145707008322;
Ranganathan M, 2012, BIOL PSYCHIAT, V72, P871, DOI 10.1016/j.biopsych.2012.06.012;
REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511; Roy AK, 2012, ADDICTION, V107,
P1132, DOI 10.1111/j.1360-0443.2011.03767.x; SANDYK R, 1986, SLEEP, V9, P370, DOI
10.1093/sleep/9.2.370; SANDYK R, 1985, LIFE SCI, V37, P1655, DOI 10.1016/0024-
3205(85)90292-9; Schmidt LM, 2011, SCHIZOPHR RES, V130, P228, DOI
10.1016/j.schres.2011.04.011; Shreeram SS, 2001, AM J PSYCHIAT, V158, P970, DOI
10.1176/appi.ajp.158.987.970; SIMPSON GM, 1977, CURR THER RES CLIN E, V22, P909;
SSAM, 2012, MED EMPF SUBST BEH S; Stefano GB, 2012, MED SCI MONITOR, V18, pHY23,
DOI 10.12659/MSM.883192; Stubner S, 2000, J Clin Psychiatry, V61, P569; Suzuki T,
1997, BIOL PSYCHIAT, V41, P234, DOI 10.1016/S0006-3223(96)00405-2; Suzuki T, 1999,
J CLIN PSYCHOPHARM, V19, P277, DOI 10.1097/00004714-199906000-00017; Suzuki T,
2002, CNS DRUGS, V16, P165, DOI 10.2165/00023210-200216030-00003; Tejeda HA, 2012,
CELL MOL LIFE SCI, V69, P857, DOI 10.1007/s00018-011-0844-x; Teng PR, 2013, J CLIN
PSYCHOPHARM, V33, P129, DOI 10.1097/01.jcp.0000426181.89572.18; Torrens M, 2012,
SUBST USE MISUSE, V47, P1005, DOI 10.3109/10826084.2012.663296; VEREBEY K, 1978,
ARCH GEN PSYCHIAT, V35, P877; Verthein U, 2015, EUR ADDICT RES, V21, P97, DOI
10.1159/000368572; Villarejo A, 2003, CLIN NEUROPHARMACOL, V26, P119, DOI
10.1097/00002826-200305000-00004; VOLAVKA J, 1977, SCIENCE, V196, P1227, DOI
10.1126/science.860138; Weibel Sebastien, 2012, J Clin Psychiatry, V73, pe756, DOI
10.4088/JCP.11cr07608; Westermeyer J, 2006, AM J ADDICTION, V15, P345, DOI
10.1080/10550490600860114; White KL, 2012, BIOL PSYCHIAT, V72, P797, DOI
10.1016/j.biopsych.2012.08.014; WHO UNODC and UNAIDS, 2004, SUBST MAINT THER MAN;
Williams AR, 2016, NEW ENGL J MED, V375, P813, DOI 10.1056/NEJMp1604223; YASSA R,
1991, BIOL PSYCHIAT, V29, P942, DOI 10.1016/0006-3223(91)90061-P; Zannas AS, 2014,
PHARMACOTHERAPY, V34, P272, DOI 10.1002/phar.1359; Zhornitsky S, 2010, MOVEMENT
DISORD, V25, P2188, DOI 10.1002/mds.23227; Zhu W, 2005, MED SCI MONITOR, V11,
pBR397; Zhu W, 2005, J IMMUNOL, V175, P7357, DOI 10.4049/jimmunol.175.11.7357
84 1 1 0 0 ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
ABINGDON 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
1550-4263 1550-4271 J DUAL DIAGN J. Dual Diagn. 2017
13 2 157 165
10.1080/15504263.2016.1269224 9 Psychology, Clinical;
Substance Abuse; Psychiatry Psychology; Substance Abuse; Psychiatry EV0PM
WOS:000401444500011 27935442 2019-09-25
J Homman, LE; Edwards, AC; Bin Cho, S; Dick, DM; Kendler, KS
Homman, Lina E.; Edwards, Alexis C.; Bin Cho, Seung; Dick, Danielle M.;
Kendler, Kenneth S. Gender and Direction of Effect of Alcohol
Problems and Internalizing Symptoms in a Longitudinal Sample of College Students
SUBSTANCE USE & MISUSE English Article
Alcohol; internalizing symptoms; depression; anxiety; longitudinal;
college sample; cross-lagged modeling SUBSTANCE USE DISORDERS; DEPRESSIVE
SYMPTOMS; YOUNG ADULTHOOD; EXTERNALIZING PSYCHOPATHOLOGY; PSYCHIATRIC-DISORDERS;
ANXIETY DISORDERS; EARLY ADOLESCENCE; MAJOR DEPRESSION; SELF-MEDICATION; MOOD
DISORDERS Background: Alcohol problems and internalizing symptoms are
consistently found to be associated but how they relate to each other is unclear.
Objective: The present study aimed to address limitations in the literature of
comorbidity of alcohol problems and internalizing symptoms by investigating the
direction of effect between the phenotypes and possible gender differences in
college students. Method: We utilized data from a large longitudinal study of
college students fromthe United States (N = 2607). Threewaves of questionnaire-
based datawere collected over the first two years of college (in 2011-2013). Cross-
lagged models were applied to examine the possible direction of effect of
internalizing symptoms and alcohol problems. Possible effects of gender were
investigated using multigroup modeling. Results: There were significant
correlations between alcohol problems and internalizing symptoms. A direction of
effect was found between alcohol problems and internalizing symptoms but differed
between genders. A unidirectional relationship varying with age was identified for
males where alcohol problems initially predicted internalizing symptoms followed by
internalizing symptoms predicting alcohol problems. For females, a unidirectional
relationship existed wherein alcohol problems predicted internalizing symptoms.
Conclusions/Importance: We conclude that the relationship between alcohol problems
and internalizing symptoms is complex and differ between genders. In males, both
phenotypes are predictive of each other, while in females the relationship is
driven by alcohol problems. Importantly, our study examines a population-based
sample, revealing that the observed relationships between alcohol problems and
internalizing symptoms are not limited to individuals with clinically diagnosed
mental health or substance use problems. [Homman, Lina E.] Queens Univ Belfast,
Inst Clin Sci, Belfast, Antrim, North Ireland; [Edwards, Alexis C.; Bin Cho, Seung;
Kendler, Kenneth S.] Virginia Commonwealth Univ, Dept Psychiat, Richmond, VA USA;
[Bin Cho, Seung; Dick, Danielle M.] Virginia Commonwealth Univ, Dept Psychol, Box
2018, Richmond, VA 23284 USA; [Bin Cho, Seung; Dick, Danielle M.] Virginia
Commonwealth Univ, Dept African Amer Studies, Richmond, VA USA Homman, LE
(reprint author), Queens Univ Belfast, Inst Clin Sci, Royal Victoria Hosp, Block
B,Room 02-032, Belfast BT12 6BA, Antrim, North Ireland. L.Homman@qub.ac.uk
Cho, Seung Bin/C-7140-2018 National Institute on Alcohol Abuse and
AlcoholismUnited States Department of Health & Human ServicesNational Institutes of
Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)
[R37AA011408]; National Institutes of HealthUnited States Department of Health &
Human ServicesNational Institutes of Health (NIH) - USA [P20AA107828]; Virginia
Commonwealth University; National Center for Research ResourcesUnited States
Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
National Center for Research Resources (NCRR) [UL1RR031990]; National Institutes of
Health Roadmap for Medical ResearchUnited States Department of Health & Human
ServicesNational Institutes of Health (NIH) - USA; National Institutes for
HealthUnited States Department of Health & Human ServicesNational Institutes of
Health (NIH) - USA [K01AA021399]; [K02AA018755] This study uses data from the
Spit for Science (S4S), a longitudinal study designed by Dr. Kenneth S. Kendler and
Dr. Danielle M. Dick. Grant support was received for Dr. Kenneth S. Kendler funded
by R37AA011408 from the National Institute on Alcohol Abuse and Alcoholism and Dr.
Danielle M. Dick funded by K02AA018755. Additional support for the project was
obtained through National Institutes of Health P20AA107828, Virginia Commonwealth
University, and UL1RR031990 from the National Center for Research Resources and
National Institutes of Health Roadmap for Medical Research. Dr. Alexis C. Edwards
was supported by K01AA021399 from the National Institutes for Health. Achenbach T.
M, 1992, INTERNALIZING DISORD, P19; ALLAN CA, 1995, ALCOHOL ALCOHOLISM, V30, P145;
American College Health Association, 2012, AM COLL HLTH ASS NAT; Angold A, 1999, J
CHILD PSYCHOL PSYC, V40, P57, DOI 10.1111/1469-7610.00424; Boden JM, 2011,
ADDICTION, V106, P906, DOI 10.1111/j.1360-0443.2010.03351.x; Brook JS, 1998, J AM
ACAD CHILD PSY, V37, P322, DOI 10.1097/00004583-199803000-00018; BUCHOLZ KK, 1994,
J STUD ALCOHOL, V55, P149, DOI 10.15288/jsa.1994.55.149; Buckner JD, 2009, J
PSYCHIATR RES, V43, P477, DOI 10.1016/j.jpsychires.2008.04.012; Carrigan MH, 2003,
ADDICT BEHAV, V28, P269, DOI 10.1016/S0306-4603(01)00235-0; Carter AC, 2010, J STUD
ALCOHOL DRUGS, V71, P742, DOI 10.15288/jsad.2010.71.742; Clark DB, 1997, J AM ACAD
CHILD PSY, V36, P1195, DOI 10.1097/00004583-199709000-00011; Costello EJ, 2003,
ARCH GEN PSYCHIAT, V60, P837, DOI 10.1001/archpsyc.60.8.837; Dawson DA, 2010, DRUG
ALCOHOL DEPEN, V112, P9, DOI 10.1016/j.drugalcdep.2010.04.019; DEROGATIS L R, 1973,
Psychopharmacology Bulletin, V9, P13; DEYKIN EY, 1992, AM J PSYCHIAT, V149, P1341;
Dick DM, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00047; Fergusson DM, 2009,
ARCH GEN PSYCHIAT, V66, P260, DOI 10.1001/archgenpsychiatry.2008.543; Foster JH,
1999, QUAL LIFE RES, V8, P255, DOI 10.1023/A:1008802711478; GEORGE DT, 1990, ACTA
PSYCHIAT SCAND, V81, P97, DOI 10.1111/j.1600-0447.1990.tb06460.x; Gilman SE, 2001,
DRUG ALCOHOL DEPEN, V63, P277, DOI 10.1016/S0376-8716(00)00216-7; Goodman A, 2010,
J ABNORM CHILD PSYCH, V38, P1179, DOI 10.1007/s10802-010-9434-x; Harris PA, 2009, J
BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; HARTKA E, 1991, BRIT J
ADDICT, V86, P1283, DOI 10.1111/j.1360-0443.1991.tb01704.x; Hu LT, 1999, STRUCT EQU
MODELING, V6, P1, DOI 10.1080/10705519909540118; Jackson KM, 2005, J ABNORM
PSYCHOL, V114, P612, DOI 10.1037/0021-843X.114.4.612; Keenan K, 1999, Clin Child
Fam Psychol Rev, V2, P3, DOI 10.1023/A:1021811307364; Kendler KS, 2003, ARCH GEN
PSYCHIAT, V60, P929, DOI 10.1001/archpsyc.60.9.929; Keyes KM, 2012, ALCOHOL RES-
CURR REV, V34, P391; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI
10.3109/10673229709030550; Kivimaki P, 2014, J ADOLESCENCE, V37, P945, DOI
10.1016/j.adolescence.2014.06.011; Krank M, 2011, ADDICT BEHAV, V36, P37, DOI
10.1016/j.addbeh.2010.08.010; Krueger RF, 2005, J ABNORM PSYCHOL, V114, P537, DOI
10.1037/0021-843X.114.4.537; Krueger RF, 1999, ARCH GEN PSYCHIAT, V56, P921, DOI
10.1001/archpsyc.56.10.921; Kushner MG, 2012, ALCOHOL CLIN EXP RES, V36, P325, DOI
10.1111/j.1530-0277.2011.01604.x; Lewinsohn PM, 1998, CLIN PSYCHOL REV, V18, P765,
DOI 10.1016/S0272-7358(98)00010-5; Marmorstein NR, 2011, ADDICT BEHAV, V36, P773,
DOI 10.1016/j.addbeh.2011.02.006; Marmorstein NR, 2010, ADDICT BEHAV, V35, P564,
DOI 10.1016/j.addbeh.2010.01.004; Marmorstein NR, 2010, DRUG ALCOHOL DEPEN, V107,
P154, DOI 10.1016/j.drugalcdep.2009.10.002; Marmorstein NR, 2009, ALCOHOL CLIN EXP
RES, V33, P49, DOI 10.1111/j.1530-0277.2008.00810.x; Mineka S, 1998, ANNU REV
PSYCHOL, V49, P377, DOI 10.1146/annurev.psych.49.1.377; Moscato BS, 1997, AM J
EPIDEMIOL, V146, P966; Muthen L. K., 2013, MPLUS USERS GUIDE; NEALE MC, 1995, AM J
HUM GENET, V57, P935; Needham BL, 2007, SOC SCI MED, V65, P1166, DOI
10.1016/j.socscimed.2007.04.037; O'Malley PM, 2002, J STUD ALCOHOL, P23, DOI
10.15288/jsas.2002.s14.23; O'Neil KA, 2011, CLIN PSYCHOL REV, V31, P104, DOI
10.1016/j.cpr.2010.08.002; Poulin C, 2005, ADDICTION, V100, P525, DOI
10.1111/j.1360-0443.2005.01033.x; Rao U, 2006, AM J PREV MED, V31, pS161, DOI
10.1016/j.amepre.2006.07.002; Schuckit MA, 1996, ALCOHOL HEALTH RES W, V20, P81;
Simonoff E, 1997, ARCH GEN PSYCHIAT, V54, P801; Stice E, 1998, J ABNORM PSYCHOL,
V107, P616, DOI 10.1037/0021-843X.107.4.616; Subramaniam GA, 2007, J AM ACAD CHILD
PSY, V46, P1062, DOI 10.1097/chi.0b013e31806c7ad0; Trautmann S, 2015, ADDICT BEHAV,
V43, P89, DOI 10.1016/j.addbeh.2014.12.013; Trim RS, 2007, PSYCHOL ADDICT BEHAV,
V21, P97, DOI 10.1037/0893-164X.21.1.97; Upcraft M. L., 1989, FRESHMAN SOURCE EXPE;
Watson D, 2005, J ABNORM PSYCHOL, V114, P522, DOI 10.1037/0021-843X.114.4.522;
Wechsler H, 2000, J AM COLL HEALTH, V48, P199, DOI 10.1080/07448480009599305;
Windle M, 2006, PERS INDIV DIFFER, V41, P15, DOI 10.1016/j.paid.2006.01.005;
Wolitzky-Taylor K, 2012, ADDICT BEHAV, V37, P982, DOI 10.1016/j.addbeh.2012.03.026;
Yu J, 2001, AM J DRUG ALCOHOL AB, V27, P775, DOI 10.1081/ADA-100107668 60 1
1 0 7 TAYLOR & FRANCIS INC PHILADELPHIA 530 WALNUT STREET,
STE 850, PHILADELPHIA, PA 19106 USA 1082-6084 1532-2491 SUBST USE MISUSE
Subst. Use Misuse 2017 52 4 429 438
10.1080/10826084.2016.1233983 10 Substance Abuse; Psychiatry;
Psychology Substance Abuse; Psychiatry; Psychology EL2EI WOS:000394432500003
27849409 Green Accepted 2019-09-25
J Trub, L; Starks, TJ Trub, Leora; Starks, Tyrel J.
Texting Under the Influence: Emotional Regulation as a Moderator of the
Association Between Binge Drinking and Drunk Texting CYBERPSYCHOLOGY BEHAVIOR AND
SOCIAL NETWORKING English Article
alcohol use; drunk texting; emotional regulation; sexual behavior; texting
PREDICT ALCOHOL-USE; COLLEGE-STUDENTS; SELF-MEDICATION; IMPULSE CONTROL; RISK
BEHAVIOR; SUBSTANCE USE; WOMENS; ATTACHMENT; PHONE; DISORDERS Texting and
alcohol have each been noted to increase perceptions of control, decrease
behavioral inhibition, and modulate unpleasant emotions. While drunk texting is a
well-known cultural phenomenon, it has received almost no attention in research. In
a sample of 211 young adult women, and using a new measure to operationalize drunk
texting, difficulty accessing strategies during moments of distress moderated the
relationship between binge drinking and drunk texting. Difficulties accessing
emotion regulation strategies were associated with drunk texting among those who
reported binge drinking. Among nonbinge drinkers, deficits in emotion regulation
strategies were not associated with drunk texting. In addition, drunk texting was
associated with sex in bivariate correlations. Given the lack of research on the
antecedents and consequences of drunk texting, this study suggests that drunk
texting may be used as a strategy for emotional regulation and may be predictive of
sexual behavior. Results inform several avenues for further inquiry into the
motivations and expectations underlying drunk texting and also imply potential
routes for intervention. [Trub, Leora] Pace Univ, Dept Psychol, 41 Pk Row,13th
Floor, New York, NY 10038 USA; [Starks, Tyrel J.] CUNY, Hunter Coll, Dept Psychol,
New York, NY 10021 USA; [Starks, Tyrel J.] CUNY, Grad Ctr, Hlth Psychol & Clin Sci
Doctoral Program, New York, NY USA; [Starks, Tyrel J.] Ctr HIV AIDS Educ Studies &
Training CHEST, New York, NY USA; [Starks, Tyrel J.] CUNY, Grad Ctr, Publ Hlth
Program, New York, NY USA Trub, L (reprint author), Pace Univ, Dept Psychol, 41
Pk Row,13th Floor, New York, NY 10038 USA. ltrub@pace.edu Trub, Leora/V-
2546-2019 Aldao A, 2010, CLIN PSYCHOL REV, V30, P217, DOI
10.1016/j.cpr.2009.11.004; Annis H., 1997, INVENTORY DRUG TAKIN; Babor T, 2001,
AUDIT ALCOHOL USE DI; Bartholow BD, 2012, J ABNORM PSYCHOL, V121, P173, DOI
10.1037/a0023664; Bartoli F, 2014, BIOMED RES INT, V2014, P1; Benotsch EG, 2013, J
ADOLESCENT HEALTH, V52, P307, DOI 10.1016/j.jadohealth.2012.06.011; Berking M,
2012, CURR OPIN PSYCHIATR, V25, P128, DOI 10.1097/YCO.0b013e3283503669; Berking M,
2011, J CONSULT CLIN PSYCH, V79, P307, DOI 10.1037/a0023421; Bolton JM, 2009, J
AFFECT DISORDERS, V115, P367, DOI 10.1016/j.jad.2008.10.003; Broaddus MR, 2013,
QUAL HEALTH RES, V23, P1344, DOI 10.1177/1049732313505712; BROWN JS, 1980, PHYSIOL
PSYCHOL, V8, P423; Campbell S. W., 2011, MOB COMMUN INT, P293; Center for
Behavioral Health Statistics and Quality, BEH HLTH STAT QUAL B; Center for Disease
Control and Prevention, EXC ALC US RISKS WOM; COOPER ML, 1995, J PERS SOC PSYCHOL,
V69, P990, DOI 10.1037/0022-3514.69.5.990; Crimmins DM, 2014, COMPUT HUM BEHAV,
V32, P268, DOI 10.1016/j.chb.2013.12.012; Curtin JJ, 2001, PSYCHOL SCI, V12, P527,
DOI 10.1111/1467-9280.00397; Davis KC, 2004, PSYCHOL WOMEN QUART, V28, P333, DOI
10.1111/j.1471-6402.2004.00150.x; Dir AL, 2013, COMPUT HUM BEHAV, V29, P1664, DOI
10.1016/j.chb.2013.01.039; Drouin M, 2014, COMPUT HUM BEHAV, V31, P412, DOI
10.1016/j.chb.2013.11.001; Dunne EM, 2015, ALCOHOL ALCOHOLISM, V50, P393, DOI
10.1093/alcalc/agv026; Dwyer-Lindgren L, 2015, AM J PUBLIC HEALTH, V105, P1120, DOI
10.2105/AJPH.2014.302313; Feldman G, 2011, PERS INDIV DIFFER, V51, P856, DOI
10.1016/j.paid.2011.07.020; Foster KT, 2015, PSYCHOL MED, V45, P3047, DOI
10.1017/S0033291715001014; Fox HC, 2008, ADDICT BEHAV, V33, P388, DOI
10.1016/j.addbeh.2007.10.002; Gratz KL, 2004, J PSYCHOPATHOL BEHAV, V26, P41, DOI
10.1023/B:JOBA.0000007455.08539.94; Greeley J, 1999, ALCOHOL TENSION REDU, P14;
Hayes SC, 1996, J CONSULT CLIN PSYCH, V64, P1152, DOI 10.1037/0022-006X.64.6.1152;
Houck CD, 2014, PEDIATRICS, V133, pE276, DOI 10.1542/peds.2013-1157; Hustad JTP,
2009, J STUD ALCOHOL DRUGS, V70, P373, DOI 10.15288/jsad.2009.70.373; Kaysen D,
2014, PSYCHOL ADDICT BEHAV, V28, P62, DOI 10.1037/a0033588; Kelly L, 2012,
QUALITATIVE RES REPO, V13, P1, DOI DOI 10.1080/17459435.2012.719203; KHANTZIAN EJ,
1985, AM J PSYCHIAT, V142, P1259; Mahatanankoon P, 2008, J COMPUT-MEDIAT COMM, V13,
P973, DOI 10.1111/j.1083-6101.2008.00427.x; Murdock KK, 2013, PSYCHOL POP MEDIA CU,
V2, P207, DOI 10.1037/ppm0000012; Murphy ST, 1998, PERS SOC PSYCHOL B, V24, P517,
DOI 10.1177/0146167298245007; [National Institute on Alcohol Abuse and Alcoholism
National Highway Traffic Safety Administration], 2000, SENT DISP YOUTH DUI;
National Institute on Alcohol Abuse and Alcoholism, 5 YEAR STRAT PLAN AL; Norris J,
2009, HEALTH PSYCHOL, V28, P20, DOI 10.1037/a0012649; Panek ET, 2015, MOB MEDIA
COMMUN, V3, P383, DOI 10.1177/2050157915576046; Pedersen ER, 2006, ADDICT BEHAV,
V31, P2105, DOI 10.1016/j.addbeh.2006.02.003; Pew Research Center, COUPL INT SOC
MED; Pew Research Center, DESP CLEAR BEN 54 SM; Reid DJ, 2007, CYBERPSYCHOL BEHAV,
V10, P424, DOI 10.1089/cpb.2006.9936; Rivis A, 2013, HEALTH PSYCHOL, V32, P571, DOI
10.1037/a0029859; Schade LC, 2013, J COUPLE RELATSH THE, V12, P314, DOI
10.1080/15332691.2013.836051; Smetaniuk P, 2014, J BEHAV ADDICT, V3, P41, DOI
10.1556/JBA.3.2014.004; Stappenbeck CA, 2013, ADDICT BEHAV, V38, P1831, DOI
10.1016/j.addbeh.2012.10.012; STEELE CM, 1985, J PERS SOC PSYCHOL, V48, P18, DOI
10.1037/0022-3514.48.1.18; STEELE CM, 1990, AM PSYCHOL, V45, P921, DOI
10.1037/0003-066X.45.8.921; Suler J, 2010, INT J APPL PSYCH STU, V7, P358, DOI
10.1002/aps.268; Testa M, 2000, EXP CLIN PSYCHOPHARM, V8, P185, DOI 10.1037/1064-
1297.8.2.185; Tice DM, 2001, J PERS SOC PSYCHOL, V80, P53, DOI 10.1037//0022-
3514.80.1.53; Trub L, 2016, COMPUT HUM BEHAV, V64, P663, DOI
10.1016/j.chb.2016.07.050; Tull MT, 2015, J ANXIETY DISORD, V29, P52, DOI
10.1016/j.janxdis.2014.11.003; van Deursen AJAM, 2015, COMPUT HUM BEHAV, V45, P411,
DOI 10.1016/j.chb.2014.12.039; Walker S, 2013, J ADOLESCENT HEALTH, V52, P697, DOI
10.1016/j.jadohealth.2013.01.026; Weisskirch RS, 2011, COMPUT HUM BEHAV, V27,
P1697, DOI 10.1016/j.chb.2011.02.008 58 0 0 0 5 MARY ANN
LIEBERT, INC NEW ROCHELLE 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY
10801 USA 2152-2715 2152-2723 CYBERPSYCH BEH SOC N Cyberpsychology
Behav. Soc. Netw. JAN 2017 20 1 3 9
10.1089/cyber.2016.0468 7 Psychology, Social Psychology
EI3YF WOS:000392428300002 27976922 2019-09-25
J Kvitland, LR; Ringen, PA; Aminoff, SR; Demmo, C; Hellvin, T; Lagerberg, TV;
Andreassen, OA; Melle, I Kvitland, Levi Rostad; Ringen,
Petter Andreas; Aminoff, Sofie Ragnhild; Demmo, Christine; Hellvin, Tone;
Lagerberg, Trine Vik; Andreassen, Ole Andreas; Melle, Ingrid
Duration of untreated illness in first-treatment bipolar I disorder in
relation to clinical outcome and cannabis use PSYCHIATRY RESEARCH
English Article First-treatment;
Duration of untreated illness; Bipolar disorder; Cannabis; Clinical outcome SELF-
MEDICATION HYPOTHESIS; SUBSTANCE USE DISORDERS; PREDOMINANT POLARITY; LONG-TERM;
GLOBAL ASSESSMENT; TREATMENT DELAY; 1ST EPISODE; FOLLOW-UP; ONSET; PSYCHOSIS There
is little knowledge about the role of the duration of untreated bipolar (DUB)
illness in first-treatment bipolar disorder I (BD I), its association with symptoms
at start of first treatment, and development over the first year, and limited
knowledge about factors that influence the length of DUB. Substance use has shown
to delay identification of primary psychiatric disorders, and while cannabis use is
common in BD the role of cannabis in relationship to DUB is unclear. The aim of the
present study is to examine the associations between DUB and key clinical outcomes
at baseline in BD I, and at one year follow-up, and to evaluate the influence of
cannabis use. Patients with first-treatment BD I (N=62) completed comprehensive
clinical evaluations, which included both DUB and the number of previous episodes.
There were no significant associations between DUB and key clinical outcomes.
Longer duration from first manic episode to treatment was associated with risk of
starting excessive cannabis use after onset of the bipolar disorder. The main
finding is the lack of significant associations between features of previous
illness episodes and clinical outcomes. Long duration of untreated mania seems to
increase the risk for later cannabis use. [Kvitland, Levi Rostad; Aminoff, Sofie
Ragnhild; Demmo, Christine; Hellvin, Tone; Lagerberg, Trine Vik; Andreassen, Ole
Andreas; Melle, Ingrid] Oslo Univ Hosp, Div Mental Hlth & Addict, KG Jebsen Ctr
Psychosis Res, NORMENT, Bldg 49,Kirkeveien 166,POB 4956, N-0424 Oslo, Norway;
[Kvitland, Levi Rostad; Aminoff, Sofie Ragnhild; Demmo, Christine; Hellvin, Tone;
Lagerberg, Trine Vik; Andreassen, Ole Andreas; Melle, Ingrid] Univ Oslo, Inst Clin
Med, Norway TOP Study, Oslo Univ Hosp, Bldg 49,Kirkeveien 166,POB 4956, N-0424
Oslo, Norway; [Aminoff, Sofie Ragnhild] Akershus Univ Hosp, Div Mental Hlth Serv,
Dept Specialized Inpatient Treatment, Akershus, Norway; [Ringen, Petter Andreas]
Oslo Univ Hosp, Div Mental Hlth & Addict, Oslo, Norway Kvitland, LR (reprint
author), Oslo Univ Hosp, Div Mental Hlth & Addict, KG Jebsen Ctr Psychosis Res,
NORMENT, Bldg 49,Kirkeveien 166,POB 4956, N-0424 Oslo, Norway.; Kvitland, LR
(reprint author), Univ Oslo, Inst Clin Med, Norway TOP Study, Oslo Univ Hosp, Bldg
49,Kirkeveien 166,POB 4956, N-0424 Oslo, Norway. l.r.lkvitland@medisin.uio.no;
p.a.ringen@medisin.uio.no; s.r.aminoff@medisin.uio.no;
thristine.demmo@medisin.uio.no; tone.hellvin@medisin.uio.no;
t.v.lagerberg@medisin.uio.no; o.a.andreassen@medisin.uio.no;
Ingrid.melle@medisin.uio.no Lagerberg, Trine Vik/L-1766-2017 Lagerberg, Trine
Vik/0000-0003-3579-0789 Norwegian Research Council grantResearch Council of Norway
[181831]; NASATS grant [217776]; NORMENT grant [223273]; South-Eastern Norway
Regional Health Authority grants [2007069, 2011033, 2011085] This work was
supported by Norwegian Research Council grant 181831, NASATS grant 217776, NORMENT
grant 223273, and South-Eastern Norway Regional Health Authority grants 2007069,
2011033, 2011085. Neither had any involvement in study design, collection of data,
analysis or interpretation of data, in the writing of the manuscript, or in the
decision to submit the article for publication. Addington J, 2015, PSYCHIAT SERV,
V66, P753, DOI 10.1176/appi.ps.201400124; Albanese Mark J, 2006, J Psychiatr Pract,
V12, P124, DOI 10.1097/00131746-200603000-00010; Altamura AC, 2007, INT J CLIN
PRACT, V61, P1697, DOI 10.1111/j.1742-1241.2007.01450.x; Altamura AC, 2015, J
AFFECT DISORDERS, V182, P70, DOI 10.1016/j.jad.2015.04.024; Altamura AC, 2010, EUR
ARCH PSY CLIN N, V260, P385, DOI 10.1007/s00406-009-0085-2; Altamura AC, 2015, NORD
J PSYCHIAT, V69, P1685, DOI 10.3109/08039488.2014.990919; Altamura AC, 2010, INT
CLIN PSYCHOPHARM, V25, P172, DOI 10.1097/YIC.0b013e3283384c74; Austin S. F., 2015,
SCHIZOPHR RES; Azorin JM, 2015, J AFFECT DISORDERS, V182, P57, DOI
10.1016/j.jad.2015.04.037; Baethge C, 2003, ACTA PSYCHIAT SCAND, V107, P260, DOI
10.1034/j.1600-0447.2003.02057.x; Baethge C, 2008, BIPOLAR DISORD, V10, P738, DOI
10.1111/j.1399-5618.2007.00575.x; Baldessarini R J, 1999, Bipolar Disord, V1, P91,
DOI 10.1034/j.1399-5618.1999.010206.x; Baldessarini RJ, 2007, BIPOLAR DISORD, V9,
P386, DOI 10.1111/j.1399-5618.2007.00385.x; Bally N, 2014, J AFFECT DISORDERS,
V165, P103, DOI 10.1016/j.jad.2014.04.038; Barrett EA, 2015, SCHIZOPHR RES, V162,
P97, DOI 10.1016/j.schres.2015.01.004; Berk M, 2007, J AFFECT DISORDERS, V103,
P181, DOI 10.1016/j.jad.2007.01.027; Berk M, 2014, BIPOLAR DISORD, V16, P471, DOI
10.1111/bdi.12099; Berk M, 2010, J MENT HEALTH, V19, P113, DOI
10.3109/09638230903469111; Braga RJ, 2012, PSYCHIAT RES, V200, P242, DOI
10.1016/j.psychres.2012.05.025; Carvalho AF, 2014, J AFFECT DISORDERS, V163, P56,
DOI 10.1016/j.jad.2014.03.035; Conus P., 2013, BIPOLAR DISORD; De Hert M, 2011,
SCHIZOPHR RES, V126, P270, DOI 10.1016/j.schres.2010.07.003; Dell'Osso B, 2013,
PSYCHOPATHOLOGY, V46, P14, DOI 10.1159/000338608; Drancourt N, 2013, ACTA PSYCHIAT
SCAND, V127, P136, DOI 10.1111/j.1600-0447.2012.01917.x; EGELAND JA, 1987, J AFFECT
DISORDERS, V12, P159, DOI 10.1016/0165-0327(87)90009-7; ENDICOTT J, 1976, ARCH GEN
PSYCHIAT, V33, P766; Etain Bruno, 2012, J Clin Psychiatry, V73, pe561, DOI
10.4088/JCP.10m06504; First M.B., 1997, STRUCTURAL CLIN INTE; FIRST MB, 1996,
STRUCTURAL CLIN INTE; Gibbs M, 2015, J AFFECT DISORDERS, V171, P39, DOI
10.1016/j.jad.2014.09.016; Goldberg JF, 2002, J CLIN PSYCHIAT, V63, P985, DOI
10.4088/JCP.v63n1105; Goodwin GM, 2009, J PSYCHOPHARMACOL, V23, P346, DOI
10.1177/0269881109102919; Gore FM, 2011, LANCET, V377, P2093, DOI 10.1016/S0140-
6736(11)60512-6; HAFNER H, 1992, EUR ARCH PSY CLIN N, V242, P109, DOI
10.1007/BF02191557; Heffner JL, 2012, BIPOLAR DISORD, V14, P99, DOI 10.1111/j.1399-
5618.2012.00985.x; Hellvin T, 2012, BIPOLAR DISORD, V14, P227, DOI 10.1111/j.1399-
5618.2012.01004.x; Henquet C, 2006, J AFFECT DISORDERS, V95, P103, DOI
10.1016/j.jad.2006.05.002; KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261, DOI
10.1093/schbul/13.2.261; Kessing LV, 2005, J AFFECT DISORDERS, V85, P293, DOI
10.1016/j.jad.2004.11.001; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI
10.3109/10673229709030550; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259; Kleber
Herbert D, 2007, Am J Psychiatry, V164, P5; Kvitland L.R., 2014, EARLY INTERV
PSYCHIA; Kvitland LR, 2015, BMC PSYCHIATRY, V15, DOI 10.1186/s12888-015-0389-x;
Lagerberg T.V., 2013, PSYCHIAT RES; Lagerberg TV, 2011, EUR ARCH PSY CLIN N, V261,
P397, DOI 10.1007/s00406-011-0188-4; Lagerberg TV, 2010, J NERV MENT DIS, V198,
P628, DOI 10.1097/NMD.0b013e3181ef3ef4; Larsson S, 2010, J AFFECT DISORDERS, V124,
P174, DOI 10.1016/j.jad.2009.10.031; Leboyer M, 2005, BIPOLAR DISORD, V7, P111, DOI
10.1111/j.1399-5618.2005.00181.x; LOEBEL AD, 1992, AM J PSYCHIAT, V149, P1183;
Maina G, 2013, PSYCHOSOMATICS, V54, P437, DOI 10.1016/j.psym.2012.10.011; Mantere
O, 2008, BIPOLAR DISORD, V10, P238, DOI 10.1111/j.1399-5618.2007.00501.x; McCraw S,
2014, J AFFECT DISORDERS, V168, P422, DOI 10.1016/j.jad.2014.07.025; Melle I, 2004,
ARCH GEN PSYCHIAT, V61, P143, DOI 10.1001/archpsyc.61.2.143; Melle I, 2008, ARCH
GEN PSYCHIAT, V65, P634, DOI 10.1001/archpsyc.65.6.634; Morken G, 2009, BRIT J
PSYCHIAT, V194, P559, DOI 10.1192/bjp.bp.108.054452; Murru A, 2015, J AFFECT
DISORDERS, V188, P319, DOI 10.1016/j.jad.2015.09.009; Najt P, 2011, PSYCHIAT RES,
V186, P159, DOI 10.1016/j.psychres.2010.07.042; Ostacher MJ, 2010, AM J PSYCHIAT,
V167, P289, DOI 10.1176/appi.ajp.2009.09020299; Oyffe I., 2014, PSYCHIAT Q;
Pedersen G, 2007, COMPR PSYCHIAT, V48, P88, DOI 10.1016/j.comppsych.2006.03.008;
Penttila M, 2014, BRIT J PSYCHIAT, V205, P88, DOI 10.1192/bjp.bp.113.127753;
Perkins DO, 2005, AM J PSYCHIAT, V162, P1785, DOI 10.1176/appi.ajp.162.10.1785;
Peters AK, 2014, INT CONF TEACH LEARN, P1, DOI 10.1109/LaTiCE.2014.9; Post RM,
2003, BIPOLAR DISORD, V5, P310, DOI 10.1034/j.1399-5618.2003.00051.x; POST RM,
1992, PHARMACOPSYCHIATRY, V25, P41, DOI 10.1055/s-2007-1014386; Post RM, 2008, BRIT
J PSYCHIAT, V192, P150, DOI 10.1192/bjp.bp.107.037820; Post RM, 2010, J CLIN
PSYCHIAT, V71, P864, DOI 10.4088/JCP.08m04994yel; Ringen PA, 2008, PSYCHOL MED,
V38, P1241, DOI 10.1017/S003329170700236X; RUSH AJ, 1986, PSYCHIAT RES, V18, P65;
SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Stewart
C, 2007, BIPOLAR DISORD, V9, P646, DOI 10.1111/j.1399-5618.2007.00465.x; Strakowski
SM, 2000, BIOL PSYCHIAT, V48, P477, DOI 10.1016/S0006-3223(00)00900-8; Suominen K,
2007, BIPOLAR DISORD, V9, P698, DOI 10.1111/j.1399-5618.2007.00388.x; ten Have M,
2002, J AFFECT DISORDERS, V68, P203, DOI 10.1016/S0165-0327(00)00310-4; Tohen M,
2010, J CLIN PSYCHIAT, V71, P255, DOI 10.4088/JCP.08m04580; Valmaggia LR, 2015,
BRIT J PSYCHIAT, V207, P130, DOI 10.1192/bjp.bp.114.150623; van der Pol P, 2013,
DRUG ALCOHOL DEPEN, V133, P776, DOI 10.1016/j.drugalcdep.2013.08.011; Volkert J,
2014, BMC PSYCHIATRY, V14, DOI 10.1186/s12888-014-0322-8; Weiss RB, 2015, J ABNORM
PSYCHOL, V124, P4, DOI 10.1037/abn0000014; YOUNG RC, 1978, BRIT J PSYCHIAT, V133,
P429, DOI 10.1192/bjp.133.5.429 81 4 4 0 9 ELSEVIER IRELAND
LTD CLARE ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND 0165-1781 PSYCHIAT RES Psychiatry Res. DEC 30
2016 246 762 768
10.1016/j.psychres.2016.07.064 7 Psychiatry Psychiatry
EG3TT WOS:000390968300121 27814886 2019-09-25
J James, PD; Fida, AS; Konovalov, P; Smyth, BP James,
Philip David; Fida, Ali Shaik; Konovalov, Pavel; Smyth, Bobby P. Non-
medical use of olanzapine by people on methadone treatment BJPSYCH BULLETIN
English Article PRESCRIPTION DRUG
MISUSE; SUBSTANCE-ABUSE; QUETIAPINE ABUSE; SCHIZOPHRENIA; DEPENDENCE; CLOZAPINE;
ARIPIPRAZOLE; MEDICATION; DISORDERS; ALCOHOL Aims and method We examined non-
medical use (NMU) of olanzapine among adults on methadone treatment. Information
was collected on patient demographics and NMU of olanzapine. The Alcohol, Smoking
and Substance Involvement Screening Test (ASSIST) was administered to assess risk
among current users of olanzapine. Results Ninety-two clients participated and 30%
reported lifetime history of NMU of olanzapine. Nine people reported doses of 30 mg
or higher on a typical day of use, with three typically using 100 mg. The most
common reasons for use were to relieve anxiety and to aid sleep, but a quarter used
it to 'get stoned'. Eleven participants (12%) reported NMU of olanzapine in the
preceding month. Eight completed the ASSIST with four scoring in the high-risk
zone. Clinical implications Self-medication is the dominant motivator for NMU of
olanzapine, but hedonic motivations also occur. A small minority show features of
dependency. All doctors should be aware of the potential NMU of olanzapine,
especially among patients with history of addiction. [James, Philip David] Hlth
Serv Execut, Clin Nurse, Louth, Meath, Ireland; [Konovalov, Pavel] Dublin North
City & Cty CAMHS, Dublin, Ireland; [Smyth, Bobby P.] Trinity Coll Dublin, Dept Publ
Hlth & Primary Care, Dublin, Ireland; [Smyth, Bobby P.] Hlth Serv Execut, Dublin,
Ireland James, PD (reprint author), Hlth Serv Execut, Clin Nurse, Louth, Meath,
Ireland. philip.james@hse.ie Smyth, Bobby/A-1634-2018 Smyth, Bobby/0000-
0003-3797-5541 Ali R, 2002, ADDICTION, V97, P1183; Apantaku-Olajide
T, 2013, J PSYCHOACTIVE DRUGS, V45, P340, DOI 10.1080/02791072.2013.825029; Basu D,
2000, Indian J Med Sci, V54, P59; Brunetti M, 2012, EUR REV MED PHARMACO, V16,
P1346; BUSTO U, 1986, BRIT J ADDICT, V81, P87; Darke S, 2013, ADDICTION, V108,
P659, DOI 10.1111/j.1360-0443.2012.04001.x; Drake RE, 2000, SCHIZOPHRENIA BULL,
V26, P441, DOI 10.1093/oxfordjournals.schbul.a033464; Evans EA, 2014, SUBST ABUSE
REHABIL, V5, P107, DOI 10.2147/SAR.S37917; Hajak G, 2003, ADDICTION, V98, P1371,
DOI 10.1046/j.1360-0443.2003.00491.x; Hanley MJ, 2008, AM J HEALTH-SYST PH, V65,
P611, DOI 10.2146/ajhp070112; Health Research Board, 2012, 2012 FIG NAT DRUG RE;
Holloway K, 2012, DRUG-EDUC PREV POLIC, V19, P137, DOI
10.3109/09687637.2011.594114; Hurwitz W, 2005, PAIN MED, V6, P152, DOI
10.1111/j.1526-4637.2005.05024.x; Hussain MZ, 2005, AM J PSYCHIAT, V162, P1755, DOI
10.1176/appi.ajp.162.9.1755-a; Kelly DL, 2003, CAN J PSYCHIAT, V48, P111; Kumsar
NA, 2013, SUBST ABUS, V34, P73, DOI 10.1080/08897077.2012.709222; Lai CH, 2010,
PROG NEURO-PSYCHOPH, V34, P1363, DOI 10.1016/j.pnpbp.2010.07.031; Littrell KH,
2001, J SUBST ABUSE TREAT, V21, P217, DOI 10.1016/S0740-5472(01)00205-7; Morin AK,
2007, AM J HEALTH-SYST PH, V64, P723, DOI 10.2146/ajhp060226; Morton W Alexander,
2000, Prim Care Companion J Clin Psychiatry, V2, P159; Petrakis IL, 2006, AM J
ADDICTION, V15, P44, DOI 10.1080/10550490500419052; Pierre JM, 2004, AM J PSYCHIAT,
V161, P1718, DOI 10.1176/appi.ajp.161.9.1718; Reeves RR, 2007, J PSYCHOACTIVE
DRUGS, V39, P297, DOI 10.1080/02791072.2007.10400617; Reeves RR, 2007, SOUTH MED J,
V100, P834, DOI 10.1097/SMJ.0b013e3180f62d53; Rothschild AJ, 2010, EVIDENCE BASED
GUIDE; Ryder N, 2009, BMC FAM PRACT, V10, DOI 10.1186/1471-2296-10-42;
SANTOLARIAFERNANDEZ FJ, 1995, DRUG ALCOHOL DEPEN, V38, P11, DOI 10.1016/0376-
8716(94)01088-3; Sattar SP, 2004, J PSYCHIATR NEUROSCI, V29, P452; Sheridan J,
2012, J PRIM HEALTH CARE, V4, P106, DOI 10.1071/HC12106; Smelson DA, 2002, CAN J
PSYCHIAT, V47, P671; Smyth BP, 1998, ADDICTION, V93, P1649, DOI 10.1046/j.1360-
0443.1998.931116493.x; Zimmet SV, 2000, J CLIN PSYCHOPHARM, V20, P94, DOI
10.1097/00004714-200002000-00016 32 3 3 0 2 ROYAL COLL
PSYCHIATRISTS LONDON 17 BELGRAVE SQ, LONDON, SW1X 8PG, ENGLAND 2056-4694
2056-4708 BJPSYCH BULL BJPsych Bull. DEC 2016 40 6
314 317 10.1192/pb.bp.115.052886
6 Psychiatry Psychiatry FE1CC WOS:000407955000007 28377810 DOAJ
Gold, Green Published 2019-09-25
J Wilkinson, AL; Halpern, CT; Herring, AH; Shanahan, M; Ennett, ST; Hussey, JM;
Harris, KM Wilkinson, Andra L.; Halpern, Carolyn Tucker;
Herring, Amy H.; Shanahan, Meghan; Ennett, Susan T.; Hussey, Jon M.; Harris,
Kathleen Mullan Testing Longitudinal Relationships Between Binge
Drinking, Marijuana Use, and Depressive Symptoms and Moderation by Sex JOURNAL OF
ADOLESCENT HEALTH English Article
HEAVY EPISODIC DRINKING; SUBSTANCE USE DISORDERS; GENDER-DIFFERENCES;
ADOLESCENT DEPRESSION; AFRICAN-AMERICANS; MENTAL-HEALTH; UNITED-STATES; CANNABIS
USE; RISK; TRAJECTORIES Purpose: Both substance use and depression are common in
adolescence and often comorbid. Past research has produced conflicting results on
whether there is a temporal relationship, and if so, in which direction it operates
and how it may vary by sex. We examined the longitudinal associations between
substance use frequency and depressive symptoms from adolescence into young
adulthood and whether the associations were moderated by sex. Methods: With data
from Waves I, III, and IV of the National Longitudinal Study of Adolescent to Adult
Health (n = 9,816), we used growth curve models to test if depressive symptoms
predicted marijuana use or binge drinking frequency (Self-Medication Model) or if
substance use frequency predicted depressive symptoms (Stress Model). Moderation by
sex and age was tested for both potential pathways. Results: Increases in
adolescent depressive symptoms, compared to no symptoms, were associated with a
steeper predicted increase in marijuana use frequency from adolescence to young
adulthood. Increases in persistent binge drinking or marijuana use frequency had
concurrent positive associations with depressive symptoms from adolescence to young
adulthood, and these associations were significantly stronger for females compared
to males. Conclusions: The results not only support the Self-Medication Model for
marijuana use but also provide modest support for the Stress Model, that substance
use is associated with depressive symptoms, especially for females. (C) 2016
Society for Adolescent Health and Medicine. All rights reserved. [Wilkinson, Andra
L.; Halpern, Carolyn Tucker; Herring, Amy H.; Hussey, Jon M.; Harris, Kathleen
Mullan] Univ North Carolina Chapel Hill, Carolina Populat Ctr, Chapel Hill, NC USA;
[Wilkinson, Andra L.; Halpern, Carolyn Tucker; Shanahan, Meghan; Hussey, Jon M.]
Univ North Carolina Chapel Hill, Gillings Sch Global Publ Hlth, Dept Maternal &
Child Hlth, CB 7400, Chapel Hill, NC 27599 USA; [Herring, Amy H.] Univ North
Carolina Chapel Hill, Gillings Sch Global Publ Hlth, Dept Biostat, Chapel Hill, NC
USA; [Shanahan, Meghan] Univ North Carolina Chapel Hill, Injury Prevent Res Ctr,
Chapel Hill, NC USA; [Ennett, Susan T.] Univ North Carolina Chapel Hill, Gillings
Sch Global Publ Hlth, Dept Hlth Behav, Chapel Hill, NC USA; [Harris, Kathleen
Mullan] Univ North Carolina Chapel Hill, Dept Sociol, Chapel Hill, NC USA
Wilkinson, AL (reprint author), Univ North Carolina Chapel Hill, Gillings Sch
Global Publ Hlth, Dept Maternal & Child Hlth, CB 7400, Chapel Hill, NC 27599 USA.
 wilkina@live.unc.edu Hussey, Jon M/A-9352-2009 Hussey, Jon M/0000-0003-
1799-9845 National Institute on Drug AbuseUnited States Department of Health &
Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on
Drug Abuse (NIDA) [F31DA036961]; Eunice Kennedy Shriver National Institute of Child
Health and Human DevelopmentUnited States Department of Health & Human
ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver
National Institute of Child Health & Human Development (NICHD) [R01 HD057046, P01-
HD31921] The authors are grateful to the Carolina Population Center for training
support (T32 HD007168) and for general support (R24 HD050924). Effort by A.L.W. was
supported by grant F31DA036961 from the National Institute on Drug Abuse, starting
August 15, 2014. Effort by C.T.H. and A.H.H. was supported by grant R01 HD057046
from the Eunice Kennedy Shriver National Institute of Child Health and Human
Development (PI: C.T.H.). This research was funded by grant P01-HD31921 from the
Eunice Kennedy Shriver National Institute of Child Health and Human Development,
with cooperative funding from 23 other federal agencies and foundations.
Armstrong TD, 2002, J CONSULT CLIN PSYCH, V70, P1224, DOI 10.1037//0022-
006X.70.6.1224; Boden JM, 2011, ADDICTION, V106, P906, DOI 10.1111/j.1360-
0443.2010.03351.x; Byrnes JP, 1999, PSYCHOL BULL, V125, P367, DOI 10.1037/0033-
2909.125.3.367; Chassin L., 2009, HDB ADOLESCENT PSYCH, P723, DOI DOI
10.1002/9780470479193.ADLPSY001022; Chen P., 2014, GUIDELINES ANAL ADD; Costello
DM, 2008, J CONSULT CLIN PSYCH, V76, P173, DOI 10.1037/0022-006X.76.2.173;
Courtenay WH, 2000, SOC SCI MED, V50, P1385, DOI 10.1016/S0277-9536(99)00390-1; de
Graaf R, 2003, SOC PSYCH PSYCH EPID, V38, P1, DOI 10.1007/s00127-003-0597-4;
Degenhardt L, 2003, ADDICTION, V98, P1493, DOI 10.1046/j.1360-0443.2003.00437.x;
Essau CA, 2010, J AFFECT DISORDERS, V127, P185, DOI 10.1016/j.jad.2010.05.016;
Evans-Polce RJ, 2015, ADDICT BEHAV, V41, P218, DOI 10.1016/j.addbeh.2014.10.029;
Fergusson DM, 2009, ARCH GEN PSYCHIAT, V66, P260, DOI
10.1001/archgenpsychiatry.2008.543; Fletcher JM, 2010, HEALTH ECON, V19, P855, DOI
10.1002/hec.1526; GE XJ, 1994, DEV PSYCHOL, V30, P467, DOI 10.1037/0012-
1649.30.4.467; Green KM, 2012, DRUG ALCOHOL DEPEN, V123, P239, DOI
10.1016/j.drugalcdep.2011.11.017; Hallfors DD, 2005, AM J PREV MED, V29, P163, DOI
10.1016/j.amepre.2005.06.002; Harris K. M., 2013, ADD HLTH STUDY DESIG; Haydon A,
2011, ENCY ADOLESCENCE, V3, P255; Hooshmand S, 2012, J ADOLESCENT HEALTH, V50,
P140, DOI 10.1016/j.jadohealth.2011.05.016; Hyde JS, 2008, PSYCHOL REV, V115, P291,
DOI 10.1037/0033-295X.115.2.291; Kann L, 2014, MMWR SURVEILL SUMM, V63, P1; KESSLER
RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4,
P231, DOI 10.3109/10673229709030550; Maruish ME, 2004, USE PSYCHOL TESTING, P363,
DOI DOI 10.1111/J.1083-6101.2007.00367.X; McDade TW, 2006, PSYCHOSOM MED, V68,
P376, DOI 10.1097/01.psy.0000221371.43607.64; Mushquash AR, 2013, ADDICT BEHAV,
V38, P2180, DOI 10.1016/j.addbeh.2012.11.008; Needham BL, 2007, SOC SCI MED, V65,
P1166, DOI 10.1016/j.socscimed.2007.04.037; Nolen-Hoeksema S, 2012, ANNU REV CLIN
PSYCHO, V8, P161, DOI 10.1146/annurev-clinpsy-032511-143109; Pahl K, 2011, PSYCHOL
MED, V41, P1775, DOI 10.1017/S0033291710002345; Patton GC, 2002, BRIT MED J, V325,
P1195, DOI 10.1136/bmj.325.7374.1195; Pratt Laura A, 2008, NCHS Data Brief, P1;
Repetto PB, 2008, J RES ADOLESCENCE, V18, P421, DOI 10.1111/j.1532-
7795.2008.00566.x; Rudolph KD, 2002, J ADOLESCENT HEALTH, V30, P3, DOI
10.1016/S1054-139X(01)00383-4; Stein JA, 2002, CHILD ABUSE NEGLECT, V26, P1011, DOI
10.1016/S0145-2134(02)00382-4; Substance abuse and mental health services
administration, 2014, RES 2013 NAT SUR DRU; Tamres LK, 2002, PERS SOC PSYCHOL REV,
V6, P2, DOI 10.1207/S15327957PSPR0601_1; Williams SB, 2009, PEDIATRICS, V123,
pE716, DOI 10.1542/peds.2008-2415 37 4 4 2 13 ELSEVIER SCIENCE
INC NEW YORK 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA 1054-139X 1879-
1972 J ADOLESCENT HEALTH J. Adolesc. Health DEC 2016 59 6
681 687 10.1016/j.jadohealth.2016.07.010
7 Psychology, Developmental; Public, Environmental & Occupational Health;
Pediatrics Psychology; Public, Environmental & Occupational Health; Pediatrics
EE3XM WOS:000389534900012 27567065 Green Accepted 2019-
09-25
J Shalit, N; Shoval, G; Shlosberg, D; Feingold, D; Lev-Ran, S
 Shalit, Nadav; Shoval, Gal; Shlosberg, Dan; Feingold, Daniel; Lev-Ran, Shaul
The association between cannabis use and suicidality among men and
women: A population-based longitudinal study JOURNAL OF AFFECTIVE DISORDERS
English Article SUBSTANCE
USE DISORDERS; ALCOHOL-USE DISORDER; NATIONAL EPIDEMIOLOGIC SURVEY; DRUG-USE;
AUDADIS-ADR; GENDER-DIFFERENCES; PREFRONTAL CORTEX; ANXIETY DISORDERS; SELF-
MEDICATION; SEX-DIFFERENCES Background: Evidence regarding the role of sex
differences in the association between cannabis use and suicidality is lacking. We
explored sex differences in the bidirectional association between cannabis use and
suicidality in a 3-year longitudinal study. Methods: Data were drawn from waves 1
and 2 of the National Epidemiologic Survey on Alcohol and Related Conditions
(NESARC). Bidirectional analyses were conducted separately by sex, exploring
incidence of suicidality among cannabis users (n=963 vs. 30,586 non-users) as well
as initiation of cannabis use among suicidal individuals (n=1805 vs. 25,729 non-
suicidal). Cannabis use was categorized based on frequency of use. Multivariate
logistic regression analyses controlling for multiple covariates were conducted.
Results: Cannabis use was significantly associated with increased incidence of
suicidality among men (Adjusted Odds Ratio [AOR] for any cannabis use =1.91[1.02-
3.56]) but not among women (AOR=1.19 [0.64-2.20]). Daily cannabis use was
significantly associated with increased incidence of suicidality among men
(AOR=4.28[1.32-13.82]) but not among women (AOR=0.75[0.28-2.05]). Conversely,
baseline suicidality was associated with initiation of cannabis use among women
(AOR=2.34[1.42-3.87]) but not among men (AOR=1.10[0.57-2.15]). Separate analyses of
suicidal ideation and suicide attempts demonstrated a significant association
between cannabis use and subsequent incidence of suicidal ideation in men, and a
significant association between baseline suicidal ideation and subsequent
initiation of cannabis use in women. No significant association was found for the
bidirectional association between cannabis use and suicide attempts in either sex.
Limitations: Suicidality was assessed only in individuals reporting depressed mood
and/or anhedonia. Conclusions: Our findings support a longitudinal association
between heavy cannabis use and the incidence of suicidality in men, but not in
women. Conversely, baseline suicidality is longitudinally associated with the
initiation of cannabis use in women, but not in men. This may have implications on
clinical and social aspects of cannabis use and merit further research into the
unique effects of sex differences on cannabis induced psychopathology. (C) 2016
Elsevier B.V. All rights reserved. [Shalit, Nadav; Shoval, Gal; Shlosberg, Dan]
Geha Mental Hlth Ctr, Helsinki St 1, IL-49100 Petah Tiqwa, Israel; [Shalit, Nadav;
Shoval, Gal; Shlosberg, Dan; Lev-Ran, Shaul] Tel Aviv Univ, Sackler Fac Med, IL-
69978 Tel Aviv, Israel; [Feingold, Daniel] Ariel Univ, Ariel, Israel; [Feingold,
Daniel; Lev-Ran, Shaul] Sheba Med Ctr, Dept Psychiat, Addict Med Serv, Tel
Hashomer, Israel Shalit, N (reprint author), Geha Mental Hlth Ctr, Helsinki St 1,
IL-49100 Petah Tiqwa, Israel. nashke@gmail.com Shalit, Nadav/0000-0002-3400-
1744 Agrawal A, 2014, ADDICTION, V109, P360, DOI 10.1111/add.12436;
ANDREASSON S, 1990, SCAND J SOC MED, V18, P9; Arseneault L, 2004, BRIT J PSYCHIAT,
V184, P110, DOI 10.1192/bjp.184.2.110; Baca-Garcia E, 2003, EUR ARCH PSY CLIN N,
V253, P281, DOI 10.1007/s00406-003-0441-6; Baca-Garcia E, 2010, J PSYCHIATR RES,
V44, P209, DOI 10.1016/j.jpsychires.2009.08.004; Baethge C, 2008, BIPOLAR DISORD,
V10, P738, DOI 10.1111/j.1399-5618.2007.00575.x; Bartoli F, 2014, DRUG ALCOHOL
DEPEN, V134, P12, DOI 10.1016/j.drugalcdep.2013.10.007; Beautrais AL, 1999,
ADDICTION, V94, P1155, DOI 10.1046/j.1360-0443.1999.94811555.x; Blanco C., 2016,
JAMA PSYCHIAT; Bolton JM, 2009, J AFFECT DISORDERS, V115, P367, DOI
10.1016/j.jad.2008.10.003; Borges G, 2016, J AFFECT DISORDERS, V195, P63, DOI
10.1016/j.jad.2016.02.007; Brown TT, 2002, J CLIN PHARMACOL, V42, p90S, DOI
10.1177/0091270002238799; Carra G, 2015, BIPOLAR DISORD, V17, P113, DOI
10.1111/bdi.12282; Carra G, 2014, J AFFECT DISORDERS, V167, P125, DOI
10.1016/j.jad.2014.05.066; Chabrol H, 2008, ADDICT BEHAV, V33, P152, DOI
10.1016/j.addbeh.2007.04.029; Chabrol H, 2014, ADDICT BEHAV, V39, P1766, DOI
10.1016/j.addbeh.2014.06.008; Chatterji S, 1997, DRUG ALCOHOL DEPEN, V47, P171, DOI
10.1016/S0376-8716(97)00088-4; Chatzittofis A, 2013, EUR NEUROPSYCHOPHARM, V23,
P1280, DOI 10.1016/j.euroneuro.2013.02.002; Chen C. M., 2010, US ALCOHOL EPIDEMIOL,
V8; Cottler LB, 1997, DRUG ALCOHOL DEPEN, V47, P195, DOI 10.1016/S0376-
8716(97)00090-2; Crane NA, 2015, J CLIN EXP NEUROPSYC, V37, P389, DOI
10.1080/13803395.2015.1020770; Crane NA, 2013, NEUROPSYCHOL REV, V23, P117, DOI
10.1007/s11065-012-9222-1; Degenhardt L, 2007, INT J METH PSYCH RES, V16, P43, DOI
10.1002/mpr.206; Delforterie MJ, 2015, DRUG ALCOHOL DEPEN, V150, P98, DOI
10.1016/j.drugalcdep.2015.02.019; Di Forti M, 2009, BRIT J PSYCHIAT, V195, P488,
DOI 10.1192/bjp.bp.109.064220; Donovan J. E., 1991, HLTH PSYCHOL; Fattore L, 2010,
BRIT J PHARMACOL, V160, P544, DOI 10.1111/j.1476-5381.2010.00776.x; Feingold D,
2016, EUR NEUROPSYCHOPHARM, V26, P493, DOI 10.1016/j.euroneuro.2015.12.037;
Feingold D, 2015, J AFFECT DISORDERS, V172, P211, DOI 10.1016/j.jad.2014.10.006;
FERGUSSON DM, 1994, J ABNORM CHILD PSYCH, V22, P339, DOI 10.1007/BF02168078;
Fergusson DM, 2003, PSYCHOL MED, V33, P61, DOI 10.1017/S0033291702006748; Frank E.,
2000, J CHEM INF MODEL AM; Galea S, 2007, AM J PREV MED, V32, pS195, DOI
10.1016/j.amepre.2007.04.003; Grant B, 2005, SOURCE ACCURACY STAT; Grant B.F.,
2003, SOURCE ACCURACY STAT; Grant BF, 2003, DRUG ALCOHOL DEPEN, V71, P7, DOI
10.1016/S0376-8716(03)00070-X; Grant BF, 2004, ARCH GEN PSYCHIAT, V61, P807, DOI
10.1001/archpsyc.61.8.807; Hasin D, 1997, DRUG ALCOHOL DEPEN, V44, P133, DOI
10.1016/S0376-8716(97)01332-X; Hays RD, 1996, ADDICT BEHAV, V21, P291, DOI
10.1016/0306-4603(95)00059-3; Hicks BM, 2011, BEHAV GENET, V41, P459, DOI
10.1007/s10519-010-9417-2; Hoertel N, 2015, MOL PSYCHIATR, V20, P718, DOI
10.1038/mp.2015.19; Hungund BL, 2004, MOL PSYCHIATR, V9, P184, DOI
10.1038/sj.mp.4001376; KENDALL DA, 1982, J NEUROSCI, V2, P354; Kessler RC, 1999,
ARCH GEN PSYCHIAT, V56, P617, DOI 10.1001/archpsyc.56.7.617; Khantzian EJ, 1997,
HARVARD REV PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550; Kidd SA, 2003, DEATH
STUD, V27, P449, DOI 10.1080/07481180390208658; Kim B, 2013, PSYCHIAT RES, V210,
P951, DOI 10.1016/j.psychres.2013.08.057; Kohn Laurence, 2004, Int J Adolesc Med
Health, V16, P359; Koskinen J, 2010, SCHIZOPHRENIA BULL, V36, P1115, DOI
10.1093/schbul/sbp031; Krueger R. F., 2002, J ABNORM PSYCHOL; Lev-Ran S, 2014,
PSYCHOL MED, V44, P797, DOI 10.1017/S0033291713001438; Lev-Ran S, 2012, AM J
ADDICTION, V21, P531, DOI 10.1111/j.1521-0391.2012.00283.x; Leventhal T, 2000,
PSYCHOL BULL, V126, P309, DOI 10.1037/0033-2909.126.2.309; Linehan M M, 1986, Ann N
Y Acad Sci, V487, P16; Lisdahl Krista M, 2013, Front Psychiatry, V4, P53, DOI
10.3389/fpsyt.2013.00053; Lynskey MT, 2004, ARCH GEN PSYCHIAT, V61, P1026, DOI
10.1001/archpsyc.61.10.1026; Maharajh HD, 2005, THESCIENTIFICWORLDJO, V5, P576, DOI
10.1100/tsw.2005.79; Marusich JA, 2015, EXP CLIN PSYCHOPHARM, V23, P206, DOI
10.1037/pha0000027; McDonald J, 2003, NEUROPSYCHOPHARMACOL, V28, P1356, DOI
10.1038/sj.npp.1300176; Meyer RE, 2010, J CLIN PSYCHIAT, V71, P1040, DOI
[10.4088/JCP.10cs06070blu, 10.4088/JCP.10cs06070ablu]; Moore THM, 2007, LANCET,
V370, P319, DOI 10.1016/S0140-6736(07)61162-3; Moran-Santa Maria MM, 2014, CURR
PSYCHIAT REP, V16, DOI 10.1007/s11920-014-0511-7; Morgan CJA, 2008, BRIT J
PSYCHIAT, V192, P306, DOI 10.1192/bjp.bp.107.046649; Mousavi Seyed Ghafur, 2014,
Adv Biomed Res, V3, P201, DOI 10.4103/2277-9175.142046; Murphy LL, 1998, NEUROBIOL
DIS, V5, P432, DOI 10.1006/nbdi.1998.0224; Pae CU, 2009, BIOMED PHARMACOTHER, V63,
P228, DOI 10.1016/j.biopha.2008.03.010; PALLIS DJ, 1976, J BIOSOC SCI, V8, P27, DOI
10.1017/S0021932000010427; Palmer BA, 2005, ARCH GEN PSYCHIAT, V62, P247, DOI
10.1001/archpsyc.62.3.247; Pedersen W, 2008, ACTA PSYCHIAT SCAND, V118, P395, DOI
10.1111/j.1600-0447.2008.01259.x; Price C, 2009, BRIT J PSYCHIAT, V195, P492, DOI
10.1192/bjp.bp.109.065227; Pull CB, 1997, DRUG ALCOHOL DEPEN, V47, P207, DOI
10.1016/S0376-8716(97)00091-4; Raphael Beverley, 2005, J Psychiatr Pract, V11,
P161; Rasic D, 2013, DRUG ALCOHOL DEPEN, V129, P49, DOI
10.1016/j.drugalcdep.2012.09.009; Rice T. R., 2015, INT J ADOLESC MED HL;
Schweinsburg Alecia D, 2008, Curr Drug Abuse Rev, V1, P99; Silins E, 2014, LANCET
PSYCHIAT, V1, P286, DOI 10.1016/S2215-0366(14)70307-4; Stinson FS, 2006, PSYCHOL
MED, V36, P1447, DOI 10.1017/S0033291706008361; Sznitman SR, 2015, HARM REDUCT J,
V12, DOI 10.1186/s12954-015-0082-x; Sznitman SR, 2015, INT J DRUG POLICY, V26,
P446, DOI 10.1016/j.drugpo.2015.01.010; Tu AW, 2008, SUBST USE MISUSE, V43, P1438,
DOI 10.1080/10826080802238140; United Nations Office on Drugs and Crime, 2015,
WORLD DRUG REP; Usall J, 2009, J AFFECT DISORDERS, V116, P144, DOI
10.1016/j.jad.2008.12.006; van Laar M, 2007, ADDICTION, V102, P1251, DOI
10.1111/j.1360-0443.2007.01875.x; van Ours JC, 2013, J HEALTH ECON, V32, P524, DOI
10.1016/j.jhealeco.2013.02.002; Vinod K. Y., 2012, NEUROLOGICAL BASIS S; Vinod KY,
2006, TRENDS PHARMACOL SCI, V27, P539, DOI 10.1016/j.tips.2006.08.006; Vinod KY,
2010, J PSYCHIATR RES, V44, P591, DOI 10.1016/j.jpsychires.2009.11.013; Vinod KY,
2005, BIOL PSYCHIAT, V57, P480, DOI 10.1016/j.biopsych.2004.11.033; Volkow N. D.,
2016, JAMA PSYCHIAT, P1; Volkow ND, 2014, NEW ENGL J MED, V370, P2219, DOI
10.1056/NEJMra1402309; Vrasti R, 1998, EUR ADDICT RES, V4, P144, DOI
10.1159/000018947;
Welberg L, 2014, NAT REV NEUROSCI, V15, P66, DOI 10.1038/nrn3681; Wilcox HC, 2004,
DRUG ALCOHOL DEPEN, V76, pS11, DOI 10.1016/j.drugalcdep.2004.08.003; Wunderlich U,
2001, ACTA PSYCHIAT SCAND, V104, P332, DOI 10.1034/j.1600-0447.2001.00432.x; Zhang
J, 2015, PHYSIOL BEHAV, V141, P40, DOI 10.1016/j.physbeh.2015.01.004; Zhang XY,
2014, DRUG ALCOHOL DEPEN, V142, P63, DOI 10.1016/j.drugalcdep.2014.05.025 96
10 10 0 15 ELSEVIER AMSTERDAM RADARWEG 29, 1043 NX
AMSTERDAM, NETHERLANDS 0165-0327 1573-2517 J AFFECT DISORDERS J.
Affect. Disord. NOV 15 2016 205 216 224
10.1016/j.jad.2016.07.010 9 Clinical Neurology;
Psychiatry Neurosciences & Neurology; Psychiatry DY9GC WOS:000385440900027
27449554 2019-09-25
J Haun, JN; Duffy, A; Lind, JD; Kisala, P; Luther, SL Haun,
Jolie N.; Duffy, Allyson; Lind, Jason D.; Kisala, Pamela; Luther, Stephen L.
Qualitative Inquiry Explores Health-Related Quality of Life of Female
Veterans With Post-Traumatic Stress Disorder MILITARY MEDICINE
English Article GENDER-
DIFFERENCES; OEF/OIF VETERANS; IRAQI FREEDOM; SYMPTOMS As the number of female
veterans increases, health care systems must be prepared to meet the individualized
needs of this population. To date, published data on health-related quality of life
(HRQOL) of veterans with post-traumatic stress disorder (PTSD) focus on
quantitative data and primarily represent the male population. The purpose of this
study was to qualitatively explore the impact of PTSD on female veterans' HRQOL. A
descriptive qualitative study used focus groups and demographic surveys to achieve
data collection in a sample of veterans with PTSD. This report focuses on the
analysis of a sample of 12 females to explore PTSD HRQOL experiences unique to
female veterans. Female veterans reported several areas in which their HRQOL was
impacted adversely in social participation, physical, cognitive, and emotional
aspects of their lives. Issues with self-medication and substance abuse were also
reported by participants. Female participants' perceptions about Veterans Health
Administration were also discussed, highlighting unmet needs when receiving care
for PTSD. These data provide unique insights from the perspective of female
veterans with PTSD about their HRQOL and receiving care within the Veterans Health
Administration health care system. These data can inform future research to better
address the needs of female veterans living with PTSD. [Haun, Jolie N.; Duffy,
Allyson; Lind, Jason D.; Luther, Stephen L.] Ctr Innovat Disabil & Rehabil Res,
8900 Grand Oak Circle, Tampa, FL 33637 USA; [Haun, Jolie N.] Univ S Florida, Dept
Community & Family Hlth, Coll Publ Hlth, 13201 Bruce B Downs Blvd,MDC 56, Tampa, FL
33612 USA; [Lind, Jason D.] Univ S Florida, Dept Anthropol, Tampa, FL 33612 USA;
[Kisala, Pamela] NYU, Dept Rehabil Med, Rusk Inst Rehabil, Langone Med Ctr, 240
East 38th St,17th Floor, New York, NY 10016 USA; [Luther, Stephen L.] Univ S
Florida, Dept Hlth Policy & Management, Coll Publ Hlth, 13201 Bruce B Downs
Blvd,MDC 56, Tampa, FL 33612 USA Haun, JN (reprint author), Ctr Innovat Disabil
& Rehabil Res, 8900 Grand Oak Circle, Tampa, FL 33637 USA.; Haun, JN (reprint
author), Univ S Florida, Dept Community & Family Hlth, Coll Publ Hlth, 13201 Bruce
B Downs Blvd,MDC 56, Tampa, FL 33612 USA. Department of Veterans
Affairs, Veterans Health Administration, Office of Research and Development, Health
Services Research and Development ServiceUS Department of Veteran Affairs [IIR 10-
169]; Health Services Research and Development Service Center of Innovation for
Disability and Rehabilitation Research at the James A. Haley Veterans Hospital,
Tampa FL This manuscript was supported by the Department of Veterans Affairs,
Veterans Health Administration, Office of Research and Development, Health Services
Research and Development Service (IIR 10-169) and the Health Services Research and
Development Service Center of Innovation for Disability and Rehabilitation Research
at the James A. Haley Veterans Hospital, Tampa FL. [Anonymous], 2012, PROMIS
INSTRUMENT DE; Conard PL, 2014, NURS FORUM, V49, P1, DOI 10.1111/nuf.12049; Crum-
Cianflone NF, 2014, EPIDEMIOL REV, V36, P5, DOI 10.1093/epirev/mxt005; Department
of Veterans Affairs, 2011, MIL SERV HIST VA BEN; Elbogen EB, 2010, AM J PSYCHIAT,
V167, P1051, DOI 10.1176/appi.ajp.2010.09050739; Fulton JJ, 2015, J ANXIETY DISORD,
V31, P98, DOI 10.1016/j.janxdis.2015.02.003; Hourani L, 2015, J ANXIETY DISORD,
V29, P101, DOI 10.1016/j.janxdis.2014.11.007; Katz LBL, 2007, PSYCHOL SERV, V4,
P239, DOI DOI 10.1037/1541-1559.4.4.239; King MW, 2013, J TRAUMA STRESS, V26, P175,
DOI 10.1002/jts.21802; Perez Lori, 2007, J Neurosci Nurs, V39, P342; Renshaw KD,
2009, ANXIETY STRESS COPIN, V22, P101, DOI 10.1080/10615800802354000; Rivera JC,
2014, MIL MED, V179, P133, DOI 10.7205/MILMED-D-13-00425; Rosen C, 2013, J TRAUMA
STRESS, V26, P640, DOI 10.1002/jts.21841; Scott JC, 2013, DRUG ALCOHOL DEPEN, V127,
P15, DOI 10.1016/j.drugalcdep.2012.06.003; Vogt D, 2011, J ABNORM PSYCHOL, V120,
P819, DOI 10.1037/a0024457 15 0 0 0 2 ASSOC MILITARY SURG US
BETHESDA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA 0026-4075 1930-
613X MIL MED Milit. Med. NOV 2016 181 11
E1470 E1475 10.7205/MILMED-D-16-00064 6 Medicine,
General & Internal General & Internal Medicine EL3DS WOS:000394500400004
27849478 Bronze 2019-09-25
J Sheerin, C; Berenz, EC; Knudsen, GP; Reichborn-Kjennerud, T; Kendler, KS;
Aggen, SH; Amstadter, AB Sheerin, Christina; Berenz, Erin
C.; Knudsen, Gun Peggy; Reichborn-Kjennerud, Ted; Kendler, Kenneth S.; Aggen,
Steven H.; Amstadter, Ananda B. A Population-Based Study of Help
Seeking and Self-Medication Among Trauma-Exposed Individuals PSYCHOLOGY OF
ADDICTIVE BEHAVIORS English Article
help seeking; potentially traumatic events; posttraumatic stress disorder;
self-medication; alcohol use disorder POSTTRAUMATIC-STRESS-DISORDER; NATIONAL
COMORBIDITY SURVEY; SUBSTANCE USE DISORDERS; PUBLIC-HEALTH TWIN; ALCOHOL-USE;
NORWEGIAN-INSTITUTE; USE MOTIVES; SAMPLE; ADULTS; VICTIMS Epidemiologic studies of
trauma highlight the imbalance between prevalence of psychiatric diagnoses and help
seeking. We investigated prevalence and correlates of help seeking and self-
medication in Norwegian adults with trauma history with a focus on common
posttrauma outcomes of posttraumatic stress disorder (PTSD) and substance use
disorders (alcohol or drug). Participants reporting at least 1 PTSD symptom (n =
307) were asked if they consulted with a doctor/another professional (help seeking)
or used drugs/alcohol (self-medication) for trauma-related problems. PTSD, alcohol
abuse or dependence (AUD), and drug use or dependence (DUD) were assessed via
structured diagnostic interviews. Help seeking and self-medication were endorsed by
37.4% and 10.4% of the sample, respectively. As compared to the full sample, help
seeking was endorsed at a greater rate in individuals with PTSD (chi(2) = 8.59, p =
.005) and at a lower rate in those with AUD (chi(2) = 7.34, p = .004). Self-
medication was more likely to be endorsed by individuals with PTSD than without
PTSD (chi(2) = 25.68, p = .001). In regression analyses, PTSD was associated with
increased likelihood of self-medication (odds ratio [OR] = 4.56) and help seeking
(OR = 2.29), while AUD was associated with decreased likelihood of help-seeking (OR
= .29). When self-medication was included as a predictor, PTSD was no longer
associated with help seeking, although AUD remained inversely associated. PTSD and
AUDs have a nuanced relationship with formal help seeking as well as the use of
substances to cope. Trauma-exposed individuals are likely engaging in adaptive and
maladaptive coping strategies, the latter of which may be compounding distress.
[Sheerin, Christina] Richmond Vet Affairs Med Ctr, Mental Illness Res Educ &
Clin Ctr, Richmond, VA USA; [Sheerin, Christina; Kendler, Kenneth S.; Aggen, Steven
H.; Amstadter, Ananda B.] Virginia Commonwealth Univ, Dept Psychiat, Virginia Inst
Psychiat & Behav Genet, 800 East Leigh St,Biotech One,POB 980126, Richmond, VA
23298 USA; [Berenz, Erin C.] Univ Virginia, Dev Pediat, Charlottesville, VA 22903
USA; [Knudsen, Gun Peggy; Reichborn-Kjennerud, Ted] Norwegian Inst Publ Hlth, Div
Mental Hlth, Oslo, Norway; [Reichborn-Kjennerud, Ted] Univ Oslo, Inst Clin Med, N-
0316 Oslo, Norway; [Kendler, Kenneth S.; Amstadter, Ananda B.] Virginia
Commonwealth Univ, Dept Human & Mol Genet, Richmond, VA 23284 USA Sheerin, C
(reprint author), Virginia Commonwealth Univ, Dept Psychiat, Virginia Inst Psychiat
& Behav Genet, 800 East Leigh St,Biotech One,POB 980126, Richmond, VA 23298 USA.
csheerin@vcu.edu National Institute of Mental Health, National
Institutes of HealthUnited States Department of Health & Human ServicesNational
Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH-
068643]; Norwegian Research CouncilResearch Council of Norway; Norwegian Foundation
for Health and Rehabilitation; European Commission under the program "Quality of
Life and Management of the Living Resources" of the 5th Framework Program [QLG2-CT-
2002-01254]; [T32 MH020030]; [K02 AA0023239] The original research from which
this study sampled was supported by grants from the National Institute of Mental
Health (MH-068643), National Institutes of Health, and funding in support of the
twin program of research at the Norwegian Institute of Public Health including
grants from the Norwegian Research Council, the Norwegian Foundation for Health and
Rehabilitation, and the European Commission under the program "Quality of Life and
Management of the Living Resources" of the 5th Framework Program (QLG2-CT-2002-
01254). Christina Sheerin's time is supported by Grant T32 MH020030. Ananda B.
Amstadter's time is supported by Grant K02 AA0023239. Amstadter AB, 2013, SOC PSYCH
PSYCH EPID, V48, P215, DOI 10.1007/s00127-012-0537-2; Amstadter AB, 2010, J ANXIETY
DISORD, V24, P900, DOI 10.1016/j.janxdis.2010.06.014; Amstadter AB, 2008, PSYCHIAT
SERV, V59, P1450, DOI 10.1176/appi.ps.59.12.1450; Berk-Clark C., 2015, TRAUMA
VIOLENCE ABUS; Blanco C, 2013, DRUG ALCOHOL DEPEN, V132, P630, DOI
10.1016/j.drugalcdep.2013.04.016; Bonn-Miller MO, 2007, ADDICT BEHAV, V32, P49, DOI
10.1016/j.addbeh.2006.03.018; Cooper M. L., 1994, PSYCHOL ASSESSMENT, V6, P117, DOI
[DOI 10.1037/1040-3590.6.2.117, 10.1037/1040-3590.6.2.117]; Dixon LJ, 2009, ADDICT
BEHAV, V34, P1065, DOI 10.1016/j.addbeh.2009.06.008; Fetzner MG, 2011, DEPRESS
ANXIETY, V28, P632, DOI 10.1002/da.20852; Goldstein AL, 2013, J STUD ALCOHOL DRUGS,
V74, P185, DOI 10.15288/jsad.2013.74.185; Harris JR, 2002, TWIN RES, V5, P415, DOI
10.1375/twin.5.5.415; Jacobsen LK, 2001, AM J PSYCHIAT, V158, P1184, DOI
10.1176/appi.ajp.158.8.1184; Kaysen D, 2011, J DUAL DIAGN, V7, P262, DOI
10.1080/15504263.2011.620449; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI
10.1001/archpsyc.1995.03950240066012; Koenen KC, 2003, J TRAUMA STRESS, V16, P5,
DOI 10.1023/A:1022051009330; Leeies M, 2010, DEPRESS ANXIETY, V27, P731, DOI
10.1002/da.20677; MacKillop J, 2011, PSYCHOPHARMACOLOGY, V216, P305, DOI
10.1007/s00213-011-2229-0; McCart MR, 2010, J TRAUMA STRESS, V23, P198, DOI
10.1002/jts.20509; Mojtabai R, 2002, ARCH GEN PSYCHIAT, V59, P77, DOI
10.1001/archpsyc.59.1.77; Perkonigg A, 2000, ACTA PSYCHIAT SCAND, V101, P46, DOI
10.1034/j.1600-0447.2000.101001046.x; PLOMIN R, 1977, PSYCHOL BULL, V84, P309, DOI
10.1037/0033-2909.84.2.309; Schiff M, 2007, AM J PUBLIC HEALTH, V97, P1852, DOI
10.2105/AJPH.2006.090514; Simpson TL, 2014, J ABNORM PSYCHOL, V123, P237, DOI
10.1037/a0035193; Tambs K, 2009, TWIN RES HUM GENET, V12, P158, DOI
10.1375/twin.12.2.158; Vlahov D, 2004, AM J PUBLIC HEALTH, V94, P253, DOI
10.2105/AJPH.94.2.253; Waldrop AE, 2007, ADDICT BEHAV, V32, P634, DOI
10.1016/j.addbeh.2006.06.001; Wang PS, 2005, ARCH GEN PSYCHIAT, V62, P603, DOI
10.1001/archpsyc.62.6.603 27 5 5 0 6 EDUCATIONAL PUBLISHING
FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC WASHINGTON 750 FIRST ST, NE, WASHINGTON,
DC 20002-4242 USA 0893-164X 1939-1501 PSYCHOL ADDICT BEHAV Psychol.
Addict. Behav. NOV 2016 30 7 771 777
10.1037/adb0000185 7 Substance Abuse; Psychology,
Multidisciplinary Substance Abuse; Psychology ED3HM WOS:000388740200007
27269293 Green Accepted 2019-09-25
J McBride, O; Cheng, HG; Slade, T; Lynskey, MT McBride,
Orla; Cheng, Hui G.; Slade, Tim; Lynskey, Michael T. The Role of
Specific Alcohol-Related Problems in Predicting Depressive Experiences in a Cross-
Sectional National Household Survey ALCOHOL AND ALCOHOLISM English
Article SUBSTANCE USE DISORDERS;
SELF-MEDICATION HYPOTHESIS; MAJOR DEPRESSION; PSYCHIATRIC-DISORDERS; MENTAL-HEALTH;
FIT TESTS; COMORBIDITY; DEPENDENCE; ANXIETY; MOOD This study examines the type
of alcohol-related problems that commonly occur before the onset of depressive
experiences to shed light on the mechanisms underlying the alcohol-depression
comorbidity relationship. Data were from the 1992 USA National Longitudinal Alcohol
Epidemiologic Survey. Analytical sample comprised of drinkers with a prior to past
year (PPY) history of alcohol-related problems with or without any experiences of
depressed mood in the past year (PY). The prevalence of PPY alcohol-related
problems was examined, as well as the ability of specific alcohol problems to
predict PY experiences of depressed mood. The type of depressed mood experienced by
drinkers with PPY history of alcohol-related problems was compared to those
without. All but one alcohol-related problem PPY was more frequently endorsed among
drinkers with PY experiences of depressed mood. Controlling for confounders, five
alcohol-related problems experienced PPY were significantly predictive of depressed
mood PY: tolerance, drinking longer than intended, inability to perform important
social and occupational roles/obligations, as well as drinking in physically
hazardous situations. Drinkers with alcohol-related problems PPY more frequently
experienced difficulties with concentration, energy, and thoughts of death, than
those without. Alcohol-related problems are likely associated with depressive
experiences through a complex network, whereby experiences of physical dependence
and negative consequences increase the likelihood of negative affect. Novel study
designs are necessary to fully understand the complex mechanisms underlying this
comorbidity. [McBride, Orla] Univ Ulster, Psychol Res Inst, Coleraine BT52
1SA, Londonderry, North Ireland; [Cheng, Hui G.] Michigan State Univ, Coll Human
Med, Dept Epidemiol & Biostat, E Lansing, MI 48824 USA; [Slade, Tim] Univ New South
Wales, Natl Drug & Alcohol Ctr, Sydney, NSW, Australia; [Lynskey, Michael T.] Kings
Coll London, Inst Psychiat Psychol & Neurosci, London, England McBride, O
(reprint author), Univ Ulster, Psychol Res Inst, Coleraine BT52 1SA, Londonderry,
North Ireland.; McBride, O (reprint author), Univ Ulster, Sch Psychol, Northland
Rd, Derry BT48 7JL, Londonderry, North Ireland. o.mcbride@ulster.ac.uk Lynskey,
michael T/B-9179-2016; Cheng, Hui G./I-2944-2019; Slade, Tim/O-2031-2019 Cheng,
Hui/0000-0001-7252-5090; McBride, Orla/0000-0003-3399-9466 Aggen SH,
2005, PSYCHOL MED, V35, P475, DOI 10.1017/S0033291704003563; Archer KJ, 2007,
COMPUT STAT DATA AN, V51, P4450, DOI 10.1016/j.csda.2006.07.006; Bell S, 2014, BMC
MED, V12, DOI 10.1186/1741-7015-12-91; Bentall RP, 2012, SCHIZOPHRENIA BULL, V38,
P734, DOI 10.1093/schbul/sbs049; Boden JM, 2011, ADDICTION, V106, P906, DOI
10.1111/j.1360-0443.2010.03351.x; Borsboom D, 2013, ANNU REV CLIN PSYCHO, V9, P91,
DOI 10.1146/annurev-clinpsy-050212-185608; Borsboom D, 2011, PLOS ONE, V6, DOI
10.1371/journal.pone.0027407; Boschloo L, 2015, PLOS ONE, V10, DOI
10.1371/journal.pone.0137621; Boschloo L, 2012, BRIT J PSYCHIAT, V200, P476, DOI
10.1192/bjp.bp.111.097550; Carragher N, 2011, J AFFECT DISORDERS, V130, P92, DOI
10.1016/j.jad.2010.09.033; Conner KR, 2011, ADDICTION, V106, P915, DOI
10.1111/j.1360-0443.2011.03385.x; Conner KR, 2009, J SUBST ABUSE TREAT, V37, P127,
DOI 10.1016/j.jsat.2008.11.007; Cramer AOJ, 2010, BEHAV BRAIN SCI, V33, P137, DOI
10.1017/S0140525X09991567; Cuijpers P, 2004, ACTA PSYCHIAT SCAND, V109, P325, DOI
10.1111/j.1600-0447.2004.00301.x; Davis L, 2008, CURR OPIN PSYCHIATR, V21, P14, DOI
10.1097/YCO.0b013e3282f32408; de Graaf R, 2013, J AFFECT DISORDERS, V149, P100, DOI
10.1016/j.jad.2013.01.009; Fairman BJ, 2012, J AFFECT DISORDERS, V138, P54, DOI
10.1016/j.jad.2011.12.031; Falk DE, 2008, DRUG ALCOHOL DEPEN, V94, P234, DOI
10.1016/j.drugalcdep.2007.11.022; Fergusson DM, 2009, ARCH GEN PSYCHIAT, V66, P260,
DOI 10.1001/archgenpsychiatry.2008.543; Flensborg-Madsen T, 2009, COMPR PSYCHIAT,
V50, P307, DOI 10.1016/j.comppsych.2008.09.003; Fried EI, 2015, ACTA PSYCHIAT
SCAND, V131, P465, DOI 10.1111/acps.12395; Fried EI, 2014, PSYCHOL MED, V44, P2067,
DOI 10.1017/S0033291713002900; Gilman SE, 2001, DRUG ALCOHOL DEPEN, V63, P277, DOI
10.1016/S0376-8716(00)00216-7; Grant BF, 1996, J AFFECT DISORDERS, V38, P113, DOI
10.1016/0165-0327(96)00002-X; GRANT BF, 1995, DRUG ALCOHOL DEPEN, V39, P197, DOI
10.1016/0376-8716(95)01160-4; Grant BF, 1992, ALCOHOL USE DISORDER; Hasin DS, 2013,
AM J PSYCHIAT, V170, P834, DOI 10.1176/appi.ajp.2013.12060782; HOSMER DW, 1980,
COMMUN STAT A-THEOR, V9, P1043, DOI 10.1080/03610928008827941; Howe LD, 2013,
EPIDEMIOLOGY, V24, P1, DOI 10.1097/EDE.0b013e31827623b1; Kessler RC, 1997, ARCH GEN
PSYCHIAT, V54, P313; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259; Kuo PH, 2006,
PSYCHOL MED, V36, P1153, DOI 10.1017/S0033291706007860; Lane SP, 2015, CLIN PSYCHOL
SCI, V3, P819, DOI 10.1177/2167702614553026; Lembke A, 2013, ADDICTION, V108, P670,
DOI 10.1111/add.12028; Lembke A, 2012, AM J DRUG ALCOHOL AB, V38, P524, DOI
10.3109/00952990.2012.694532; Lynskey MT, 1998, DRUG ALCOHOL DEPEN, V52, P201, DOI
10.1016/S0376-8716(98)00095-7; McBride O, 2011, ALCOHOL ALCOHOLISM, V46, P333, DOI
10.1093/alcalc/agr008; McBride O, 2009, ALCOHOL ALCOHOLISM, V44, P67, DOI
10.1093/alcalc/agn083; Merikangas KR, 1998, ADDICT BEHAV, V23, P893, DOI
10.1016/S0306-4603(98)00076-8; Raimo EB, 1998, ADDICT BEHAV, V23, P933, DOI
10.1016/S0306-4603(98)00068-9; Schmittmann VD, 2013, NEW IDEAS PSYCHOL, V31, P43,
DOI 10.1016/j.newideapsych.2011.02.007; Slade T, 2015, EPIDEMIOL PSYCH SCI, V24,
P45, DOI 10.1017/S2045796013000577; Sribney W, 2005, WHY SHOULD NOT LIKEL, V2014;
Stinson FS, 1998, 993519 NAT I ALC AB; Treeby M, 2012, PERS INDIV DIFFER, V53,
P613, DOI 10.1016/j.paid.2012.05.011; van Os J, 2014, PLOS ONE, V9, DOI
10.1371/journal.pone.0086652; van Os J, 2013, WORLD PSYCHIATRY, V12, P113, DOI
10.1002/wps.20046; Wichers M, 2014, PSYCHOL MED, V44, P1349, DOI
10.1017/S0033291713001979; Wichers M, 2012, BRIT J CLIN PSYCHOL, V51, P206, DOI
10.1111/j.2044-8260.2011.02021.x 49 2 2 0 18 OXFORD UNIV PRESS
OXFORD GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND 0735-0414 1464-
3502 ALCOHOL ALCOHOLISM Alcohol Alcohol. NOV 2016 51 6
655 663 10.1093/alcalc/agw010 9
Substance Abuse Substance Abuse ED0HQ WOS:000388524000004 26956426
Bronze 2019-09-25
J Gonzalez, VR; Martin, SR; del Prado, GRL; Moreno, MFM; Miranda, AV
Rubio Gonzalez, Veronica; Redondo Martin, Susana; Ruiz Lopez del Prado,
Gema; Munoz Moreno, Ma Fe; Velazquez Miranda, Alexander Hospital
Emergencies Associated with the Consumption of Hypnotics and Sedatives, Castilla y
Leon, 2009-2013 REVISTA ESPANOLA DE SALUD PUBLICA Spanish
Article Emergencies; Emergency medical
services; Substance abuse detection; Psychotropic drugs; Hypnotics and Sedatives;
Benzodiazepines; Drug Overdose; Suicide Attempted; Substance-Related Disorders;
Self Medication Background: Household Survey on Alcohol and Other Drugs
shows the progressive increase in the consumption of hypnotics, alone or in
combination with other substances. The aim of the research was to obtain
information about the consumption of hypnotics and sedatives in population of
Castilla y Leon treated in emergency medical services of four monitored hospitals
between 2009-2013, describing clinical and epidemiological characteristics of the
emergencies and what drugs were consumed, to provide information for future
interventions. Methods: A descriptive cross-sectional study was done by analyzing
3,089 emergencies related to consumption of hypnotics and sedatives, obtained from
Emergency Indicator related to the use of psychoactive substances of the National
Observatory on Drugs. There were used chi(2) test for comparing proportions and t
Student test for means. Results: The total number of emergencies was 3,089, ranging
in years of study. In 1,814 cases they were consumed only hypnosedatives; 64.7%
women and average age of 41 years. The most frequent diagnosis was
overdose/attempted suicide with benzodiazepines (29.3%), being lorazepam the most
consumed. In 23.3% of cases it was consumed more than one hypnosedative and 9% was
associated with psychiatric disorders. Conclusions: The number of emergencies
related to the consumption of at least one hypnosedative in the monitored hospitals
in the period studied presented high levels especially in middle-aged women with no
psychiatric disorder to justify their use. Benzodiazepines were the most consumed
hypnotics, cause of overdose/ attempted suicide episodes. [Rubio Gonzalez,
Veronica] Univ Valladolid, Hosp Clin, Serv Med Prevent & Salud Publ, Valladolid,
Spain; [Redondo Martin, Susana] Comisionado Reg Droga Castilla & Leon, Gerencia
Serv Sociales, Serv Evaluac & Prevenc Consumo Drogas, Leon, Spain; [Ruiz Lopez del
Prado, Gema] Gerencia Reg Salud SACYL, Serv Recursos Asistenciales, Valladolid,
Spain; [Munoz Moreno, Ma Fe] Univ Valladolid, Hosp Clin, Unidad Apoyo Invest,
Valladolid, Spain; [Velazquez Miranda, Alexander] Unidad Estadist Consejeria
Familia & Igualdad Opo, Valladolid, Spain Gonzalez, VR (reprint author), Enrique
4,8,2 B, Valladolid 47195, Spain. verorubi1984@gmail.com
American Psychiatric Association, 2002, MAN DIAGN EST TRAST; [Anonymous],
DICCIONARIO LENGUA E; Beneto Pascual A, 2004, VIGILIA SUENO S1, V16, P33; Cerda
Esteve Maria A, 2010, Endocrinol Nutr, V57, P155, DOI 10.1016/j.endonu.2010.01.006;
Ferrer AV, 2004, ACTAS ESP PSIQUIATRI, V32, P143; Fluvia X, 1994, REV PSIQUIATRIA
FACU, V21, P247; Gonzalez Luque JC, 2008, REV TRAFICO SEGURIDA, V216, P66;
Instituto Nacional de Estadistica, US SERV SAN CONS MED; Marquez-Calderon Soledad,
2014, Gac Sanit, V28 Suppl 1, P116, DOI 10.1016/j.gaceta.2014.01.012; Mateo
Fernandez R, 1997, ATEN PRIM, V19, P101; Ministerio de Sanidad Servicios Sociales e
Igualdad, ENC DOM ALC OTR DROG; Ministerio de Sanidad Servicios Sociales e
Igualdad, INF AN SIST NAC SAL; Ministerio de Sanidad Servicios Sociales e Igualdad,
ENC EST US DROG EST; Ministerio de Sanidad Servicios Sociales e Igualdad, IND URG
HOSP CONS SU; Mondon S, 2008, REV ADICC, V20, P143; Ochoa Mangado Enriqueta, 2008,
Med. segur. trab., V54, P25, DOI 10.4321/s0465-546x2008000400003; Oficina de las
Naciones Unidas contra la Droga y el Delito, INF MUND DROG 2013; Pedrero Perez E.
J., 2003, ADICCIONES, V15, P203; Petrovic M, 2002, INT J GERIATR PSYCH, V17, P733,
DOI 10.1002/gps.677; Plan Nacional sobre Drogas, OBS ESP DROG MAN PRO; Ruiz-
Olivares R, 2010, PSYCHOL SOC EDUC, V2, P25; Sicras-Mainar A, 2008, Farm Hosp, V32,
P96; Sociedad Espanola de Medicina Familiar y Comunitaria, VIOLENCIA DOMESTICA;
Sociedad Espanola para el Estudio de la Ansiedad y el Estres, ANS MED REC AD MISM;
Sanchez MPV, 2013, REV ESP SALUD PUBLIC, V87, P247; Villa Alcazar LF, 2016,
MEDIMECUM GUIA TERAP, P1005; Villa RS, 2003, PSICOTHEMA, V15, P650 27 1
1 0 0 MINISTERIO DE SANIDAD Y CONSUMO MADRID PASEO DEL
PRADO 18-20, MADRID, 28071, SPAIN 1135-5727 REV ESP SALUD PUBLIC
Rev. Esp. Salud Publica OCT 25 2016 90
12 Public, Environmental & Occupational
Health Public, Environmental & Occupational Health VC1WD
WOS:000431845600002 DOAJ Gold 2019-09-25
J Mandavia, A; Robinson, GGN; Bradley, B; Ressler, KJ; Powers, A
Mandavia, Amar; Robinson, Gabriella G. N.; Bradley, Bekh; Ressler, Kerry J.;
Powers, Abigail Exposure to Childhood Abuse and Later Substance Use:
Indirect Effects of Emotion Dysregulation and Exposure to Trauma JOURNAL OF
TRAUMATIC STRESS English Article
POSTTRAUMATIC-STRESS-DISORDER; ADULT MENTAL-HEALTH; ALCOHOL-USE; GENDER-
DIFFERENCES; SELF-MEDICATION; SEXUAL-ABUSE; ASSOCIATIONS; IMPACT; SAMPLE; WOMEN
Little is known about how emotion dysregulation (ED) and trauma exposure
differentially affect the relationship between abuse in childhood and adult
substance use. We examined associations between child abuse, trauma exposure, ED,
and current substance use in an already existing dataset. Participants (N = 2,014
adults, 90% African American) had been recruited from an urban hospital for a
parent study. Analyses showed that drug and alcohol use was significantly
positively correlated with child abuse (emotional, physical, and sexual), later
trauma exposure, and ED (all ps < .001). Linear regression showed that exposure to
abuse when older than a child was significantly associated with drug and alcohol
use independent of child abuse and demographic variables (R-2 = .08, p < .001; R-2
= .04, p < .001). ED was significantly associated with drug and alcohol use
independently of child abuse, nonabuse trauma, and demographic variables (R-2 = .
02, p < .001; R-2 = .04, p < .001). Multiple mediation analyses showed that ED and
later trauma exposure accounted for variance in the association between emotional
abuse and substance use (p < .001). A better understanding of vulnerabilities to
additional traumatization and emotion-regulation deficits in individuals who have
been exposed to child abuse and in addition have comorbid substance use problems
may inform treatments that lead to improved outcomes. [Mandavia, Amar; Robinson,
Gabriella G. N.; Bradley, Bekh; Ressler, Kerry J.; Powers, Abigail] Emory Univ, Sch
Med, Dept Psychiat & Behav Sci, Atlanta, GA USA; [Bradley, Bekh] Atlanta VA Med
Ctr, Atlanta, GA USA; [Ressler, Kerry J.] Harvard Univ, McLean Hosp, Boston, MA
02115 USA Powers, A (reprint author), Grady Trauma Project, 49 Jesse Hill Jr Dr,
Atlanta, GA 30303 USA. adpower@emory.edu National Institute of Mental
HealthUnited States Department of Health & Human ServicesNational Institutes of
Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH071537,
MH100122]; National Institute of Child Health and Human DevelopmentUnited States
Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
Eunice Kennedy Shriver National Institute of Child Health & Human Development
(NICHD) [HD071982]; Emory and Grady Memorial Hospital General Clinical Research
Center, NIH National Centers for Research ResourcesUnited States Department of
Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center
for Research Resources (NCRR) [M01 RR00039] This work was primarily supported
by the National Institute of Mental Health (MH071537; MH100122) and the National
Institute of Child Health and Human Development (HD071982). Support also included
Emory and Grady Memorial Hospital General Clinical Research Center, NIH National
Centers for Research Resources (M01 RR00039). The content is solely the
responsibility of the authors and does not necessarily represent the official views
of the National Institutes of Health. Additionally, the contents of this report do
not represent the views of the Department of Veterans Affairs or the United States
Government. Amar Mandavia and Gabriella G. N. Robinson contributed equally to the
work and are co-first authors. Banducci AN, 2014, CHILD ABUSE NEGLECT, V38,
P928, DOI 10.1016/j.chiabu.2013.12.007; Banyard VL, 2001, J TRAUMA STRESS, V14,
P697, DOI 10.1023/A:1013085904337; Bariola E, 2011, CLIN CHILD FAM PSYCH, V14,
P198, DOI 10.1007/s10567-011-0092-5; Bernstein D. P., 1998, CTQ CHILDHOOD TRAUMA;
Bernstein DP, 2003, CHILD ABUSE NEGLECT, V27, P169, DOI 10.1016/S0145-
2134(02)00541-0; Bohn M. J., 1991, DHHS PUBLICATION, V119, P233; Bonn-Miller MO,
2008, SUBST USE MISUSE, V43, P1656, DOI 10.1080/10826080802241292; Bradley B, 2011,
J CLIN PSYCHIAT, V72, P685, DOI [10.4088/JCP.10m06409b1u, 10.4088/JCP.10m06409blu];
Cloitre M, 2009, J TRAUMA STRESS, V22, P399, DOI 10.1002/jts.20444; Cole P M, 1994,
Monogr Soc Res Child Dev, V59, P73; DEMBO R, 1990, J PRISON JAIL HLTH, V0009;
Dvorak RD, 2014, AM J DRUG ALCOHOL AB, V40, P125, DOI 10.3109/00952990.2013.877920;
Edwards VJ, 2003, AM J PSYCHIAT, V160, P1453, DOI 10.1176/appi.ajp.160.8.1453;
Galaif ER, 2001, J STUD ALCOHOL, V62, P486, DOI 10.15288/jsa.2001.62.486; Garland
EL, 2013, J BEHAV MED, V36, P175, DOI 10.1007/s10865-012-9413-5; Gillespie CF,
2009, GEN HOSP PSYCHIAT, V31, P505, DOI 10.1016/j.genhosppsych.2009.05.003; Gross
J. J., 1998, REV GEN PSYCHOL, V2, P271, DOI DOI 10.1037/1089-2680.2.3.271;
Herrenkohl TI, 2013, J FAM VIOLENCE, V28, P191, DOI 10.1007/s10896-012-9474-9;
Horesh D, 2015, DEPRESS ANXIETY, V32, P38, DOI 10.1002/da.22267; Horwitz AV, 2001,
J HEALTH SOC BEHAV, V42, P184, DOI 10.2307/3090177; Jacobsen LK, 2001, AM J
PSYCHIAT, V158, P1184, DOI 10.1176/appi.ajp.158.8.1184; Kendler KS, 2000, ARCH GEN
PSYCHIAT, V57, P953, DOI 10.1001/archpsyc.57.10.953; Kevorkian S, 2015, PSYCHOL
ADDICT BEHAV, V29, P633, DOI 10.1037/adb0000110; Khantzian E. J., 2003, PRIMARY
PSYCHIAT, V10, p[47, 53]; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI
10.3109/10673229709030550; Khoury L, 2010, DEPRESS ANXIETY, V27, P1077, DOI
10.1002/da.20751; Kulkarni M, 2013, PSYCHOL TRAUMA-US, V5, P359, DOI
10.1037/a0027746; Lawson KM, 2013, AM J ADDICTION, V22, P127, DOI 10.1111/j.1521-
0391.2013.00319.x; Linehan MM, 1993, SKILLS TRAINING MANU; McAllister CL, 2009, AM
J PUBLIC HEALTH, V99, P205, DOI 10.2105/AJPH.2005.068569; PARKE RD, 1994, MERRILL
PALMER QUART, V40, P157; Powers A, 2015, PSYCHIAT RES, V225, P85, DOI
10.1016/j.psychres.2014.10.020; Preacher K. J, 2008, SAGE SOURCEBOOK ADV, P13, DOI
[DOI 10.4135/9781452272054.N2, 10.4135/978145227205.n2]; ROBERTS W, 1987, DEV
PSYCHOL, V23, P415, DOI 10.1037/0012-1649.23.3.415; SAUNDERS JB, 1993, ADDICTION,
V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Saxena P., 2011, J PROJECTIVE
PSYCHOL, V18, P147, DOI DOI 10.1016/J.CPR.2009.11.004; Shields A, 2001, DEV
PSYCHOL, V37, P321, DOI 10.1037//0012-1649.37.3.321; Shipman K, 2000, DEV
PSYCHOPATHOL, V12, P47, DOI 10.1017/S0954579400001036; Simpson TL, 2002, CLIN
PSYCHOL REV, V22, P27, DOI 10.1016/S0272-7358(00)00088-X; SKINNER HA, 1982, ADDICT
BEHAV, V7, P363, DOI 10.1016/0306-4603(82)90005-3; Sledjeski EM, 2008, J BEHAV MED,
V31, P341, DOI 10.1007/s10865-008-9158-3; Sprang G, 1997, J PSYCHOPATHOL BEHAV,
V19, P257, DOI 10.1007/BF02229182; Tabachnick B. G., 2007, USING MULTIVARIATE S;
Ullman SE, 2003, AGGRESS VIOLENT BEH, V8, P471, DOI 10.1016/S1359-1789(03)00032-6;
Weiss NH, 2013, CHILD ABUSE NEGLECT, V37, P944, DOI 10.1016/j.chiabu.2013.03.014;
Widom CS, 2006, PSYCHOL ADDICT BEHAV, V20, P394, DOI 10.1037/0893-164X.20.4.394
 46 13 13 0 19 WILEY HOBOKEN 111 RIVER ST, HOBOKEN 07030-
5774, NJ USA 0894-9867 1573-6598 J TRAUMA STRESS J. Trauma Stress
OCT 2016 29 5 422 429
10.1002/jts.22131 8 Psychology, Clinical; Psychiatry
Psychology; Psychiatry DZ9HO WOS:000386185600004 27622844 Green
Published, Green Accepted 2019-09-25
J Gielen, N; Krumeich, A; Tekelenburg, M; Nederkoorn, C; Havermans, RC
Gielen, Nele; Krumeich, Anja; Tekelenburg, Mignon; Nederkoorn, Chantal;
Havermans, Remco C. How patients perceive the relationship between
trauma, substance abuse, craving, and relapse: A qualitative study JOURNAL OF
SUBSTANCE USE English Article
Addiction; post-traumatic stress disorder; qualitative POSTTRAUMATIC-
STRESS-DISORDER; TREATMENT PROGRAMS; PTSD; PERCEPTIONS; PREVALENCE; ADDICTION;
SURVIVORS; SYMPTOM; ISSUES; INCEST In this qualitative study, patients with
comorbid substance use disorder (SUD) and post-traumatic stress disorder (PTSD)
were interviewed on their ideas about the link between SUD and PTSD. Although they
clearly reported self-medication, they also gave a more complex description of how
they believe their PTSD influences their SUD. The results suggest that SUD/PTSD
patients believe they did not start using substances because of their experienced
traumas or PTSD, but that PTSD symptoms are nonetheless important in the
maintenance of their addictions. A clear link exists between craving, relapse, and
PTSD symptoms. SUD/PTSD patients would prefer a "whole-person approach" when being
treated for their PTSD. It is suggested that the integration of skills training and
attention for patients who are fearful of PTSD treatment might improve SUD/PTSD
treatment results. [Gielen, Nele] Mondriaan, Trauma & Addict, F Kennedylaan
305, NL-6419 XZ Heerlen, Netherlands; [Gielen, Nele; Nederkoorn, Chantal;
Havermans, Remco C.] Maastricht Univ, Fac Psychol & Neurosci, Dept Clin Psychol
Sci, NL-6200 MD Maastricht, Netherlands; [Krumeich, Anja] Maastricht Univ, Fac Hlth
Med & Life Sci, Dept Hlth Eth & Soc, NL-6200 MD Maastricht, Netherlands;
[Tekelenburg, Mignon] Mondriaan, Radix, Heerlen, Netherlands Gielen, N (reprint
author), Mondriaan, Trauma & Addict, F Kennedylaan 305, NL-6419 XZ Heerlen,
Netherlands. n.gielen@mondriaan.eu Nederkoorn, Chantal/0000-0002-5522-
3944; Havermans, Remco/0000-0001-5832-8357 Bonin MF, 2000, J BEHAV
THER EXP PSY, V31, P55, DOI 10.1016/S0005-7916(00)00008-2; Brown PJ, 1998, J SUBST
ABUSE TREAT, V15, P445, DOI 10.1016/S0740-5472(97)00286-9; Dass-Brailsford P, 2010,
TRAUMA VIOLENCE ABUS, V11, P202, DOI 10.1177/1524838010381252; Gielen N., 2015,
COPING USE MOT UNPUB; Gielen N, 2012, EUR J PSYCHOTRAUMATO, V3, DOI
10.3402/ejpt.v3i0.17734; Gielen N, 2014, EUR J PSYCHOTRAUMATO, V5, DOI
10.3402/ejpt.v5.22821; Hall JM, 2000, QUAL HEALTH RES, V10, P612, DOI
10.1177/104973200129118688; Harris M, 2005, PSYCHIAT SERV, V56, P1292, DOI
10.1176/appi.ps.56.10.1292; JANIKOWSKI TP, 1994, J SUBST ABUSE TREAT, V11, P177,
DOI 10.1016/0740-5472(94)90074-4; Janikowski TP, 1997, ADDICT BEHAV, V22, P447, DOI
10.1016/S0306-4603(97)84428-0; Jarvis TJ, 1998, ADDICTION, V93, P865, DOI
10.1046/j.1360-0443.1998.9368658.x; Kleinman A, 1980, PATIENTS HEALERS CON;
LACOURSIERE RB, 1980, AM J PSYCHIAT, V137, P966; Larrabee JH, 2001, J NURS CARE
QUAL, V16, P34, DOI 10.1097/00001786-200110000-00005; Ouimette P, 2007, ADDICT
BEHAV, V32, P1719, DOI 10.1016/j.addbeh.2006.11.020; Ouimette PC, 1999, PSYCHOL
ADDICT BEHAV, V13, P105, DOI 10.1037/0893-164X.13.2.105; Ouimette PC, 1998, ADDICT
BEHAV, V23, P785, DOI 10.1016/S0306-4603(98)00064-1; Pope C, 2000, BMJ-BRIT MED J,
V320, P114, DOI 10.1136/bmj.320.7227.114; Sofaer S, 2005, ANNU REV PUBL HEALTH,
V26, P513, DOI 10.1146/annurev.publhealth.25.050503.153958; Staiger PK, 2009, J
SUBST ABUSE TREAT, V36, P220, DOI 10.1016/j.jsat.2008.05.008; TABER JI, 1987, INT J
ADDICT, V22, P71, DOI 10.3109/10826088709027414; Teusch R, 2001, PSYCHIATR SERV,
V52, P1530, DOI 10.1176/appi.ps.52.11.1530; Torchalla I, 2012, J SUBST ABUSE TREAT,
V42, P65, DOI 10.1016/j.jsat.2011.09.001; van Dam D, 2012, CLIN PSYCHOL REV, V32,
P202, DOI 10.1016/j.cpr.2012.01.004; Vanyukov MM, 2012, DRUG ALCOHOL DEPEN, V123,
pS3, DOI 10.1016/j.drugalcdep.2011.12.018; Young HE, 2005, J SUBST ABUSE TREAT,
V28, P313, DOI 10.1016/j.jsat.2005.02.006 26 2 2 1 30 TAYLOR &
FRANCIS INC PHILADELPHIA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106
USA 1465-9891 1475-9942 J SUBST USE J. Subst. Use OCT 2016 21
5 466 470 10.3109/14659891.2015.1063717
5 Substance Abuse Substance Abuse DO6ZH WOS:000377931500006
Green Published, Bronze 2019-09-25
J Fischer, B; Murphy, Y; Kurdyak, P; Goldner, EM Fischer,
Benedikt; Murphy, Yoko; Kurdyak, Paul; Goldner, Elliot M. Depression -
A major but neglected consequence contributing to the health toll from prescription
opioids? PSYCHIATRY RESEARCH English Article
Prescription opioid analgesics; Depression; Public health
CHRONIC NONCANCER PAIN; SUBSTANCE USE DISORDERS; SELF-MEDICATION HYPOTHESIS;
MENTAL-HEALTH; UNITED-STATES; DRUG-USE; MOOD DISORDERS; NONMEDICAL USE; INCREASED
RISK; PRIMARY-CARE Prescription opioid analgesic (POA) use is common
especially in North America, and associated with extensive morbidity and mortality.
While medical and non-medical POA use have been documented to be associated with
mental health problems, and specifically depression, newly emerging epidemiological
evidence suggests that incident depression post-initiation of POA use may be
common. Neurobiological specifically regarding impacts of POAs on brain functioning
and/or psycho-social processes may be relevant pathways; these must be better
understood, also to guide clinical practice for interventions. Incident depression
outcomes may be an added component to the extensive health toll from widespread POA
use. (C) 2016 Elsevier Ireland Ltd. All rights reserved. [Fischer, Benedikt;
Murphy, Yoko] Ctr Addict & Mental Hlth, Inst Mental Hlth Policy Res, Toronto, ON,
Canada; [Fischer, Benedikt] Univ Toronto, Dept Psychiat, Toronto, ON, Canada;
[Fischer, Benedikt] Univ Toronto, Inst Med Sci, Toronto, ON, Canada; [Kurdyak,
Paul] CAMH, Inst Mental Hlth Policy Res, Hlth Outcomes & Performance Evaluat HOPE
Res Unit, Toronto, ON, Canada; [Kurdyak, Paul] Inst Clin Evaluat Sci, Mental Hlth &
Addict Res Program, Toronto, ON, Canada; [Kurdyak, Paul] Univ Toronto, Dept
Psychiat, Toronto, ON, Canada; [Goldner, Elliot M.] Simon Fraser Univ, Ctr Appl Res
Mental Hlth & Addict, Vancouver, BC, Canada; [Goldner, Elliot M.] Simon Fraser
Univ, Fac Hlth Sci, Vancouver, BC, Canada Fischer, B (reprint author), Ctr Addict &
Mental Hlth, Inst Mental Hlth Policy Res, Toronto, ON, Canada.
benedikt.fischer@utoronto.ca Fischer, B/0000-0002-2186-4030
Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health
Research (CIHR) [SAF-94814]; Canadian Research Initiative in Substance Misuse
(CRISM) Ontario Node Team Grant [SMN-139150] Dr. Fischer acknowledges funding
support from the Canadian Institutes of Health Research (CIHR), specifically Team
Grant #SAF-94814 and the Canadian Research Initiative in Substance Misuse (CRISM)
Ontario Node Team Grant #SMN-139150. Ali MM, 2015, J MENT HEALTH POLICY, V18,
P3; Arnow BA, 2006, PSYCHOSOM MED, V68, P262, DOI
10.1097/01.psy.0000204851.15499.fc; Ballantyne JC, 2008, CLIN J PAIN, V24, P469,
DOI 10.1097/AJP.0b013e31816b2f26; Bawor M, 2015, DRUG ALCOHOL DEPEN, V149, P1, DOI
10.1016/j.drugalcdep.2015.01.038; Becker WC, 2008, DRUG ALCOHOL DEPEN, V94, P38,
DOI 10.1016/j.drugalcdep.2007.09.018; Braden JB, 2009, GEN HOSP PSYCHIAT, V31,
P564, DOI 10.1016/j.genhosppsych.2009.07.003; Brady KT, 2005, AM J PSYCHIAT, V162,
P1483, DOI 10.1176/appi.ajp.162.8.1483; Butelman ER, 2012, TRENDS NEUROSCI, V35,
P587, DOI 10.1016/j.tins.2012.05.005; Campbell G, 2015, PAIN, V156, P231, DOI
10.1097/01.j.pain.0000460303.63948.8e; Campbell LC, 2003, BIOL PSYCHIAT, V54, P399,
DOI 10.1016/S0006-3223(03)00545-6; Warner M, 2014, NCHS HLTH E STAT TRE; Chou R,
2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008; Dowell D, 2016, MMWR
RECOMM REP, V65, P1, DOI 10.15585/mmwr.rr6501e1; Drevets WC, 2008, BRAIN STRUCT
FUNCT, V213, P93, DOI 10.1007/s00429-008-0189-x; Edlund MJ, 2015, DRUG ALCOHOL
DEPEN, V152, P131, DOI 10.1016/j.drugalcdep.2015.04.010; Edlund MJ, 2010, CLIN J
PAIN, V26, P1, DOI 10.1097/AJP.0b013e3181b99f35; Fergusson DM, 2009, ARCH GEN
PSYCHIAT, V66, P260, DOI 10.1001/archgenpsychiatry.2008.543; Fischer B, 2014, BMC
HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-90; Fischer B, 2014, ADDICTION,
V109, P177, DOI 10.1111/add.12224; Fischer B, 2013, PHARMACOEPIDEM DR S, V22, P438,
DOI 10.1002/pds.3404; Fischer B, 2012, J PAIN, V13, P1029, DOI
10.1016/j.jpain.2012.07.013; Fischer B, 2012, PAIN PHYSICIAN, V15, pES191; Fishbain
DA, 1997, CLIN J PAIN, V13, P116, DOI 10.1097/00002508-199706000-00006; Franklin
GM, 2014, NEUROLOGY, V83, P1277, DOI 10.1212/WNL.0000000000000839; Goldner EM,
2014, ADDICT BEHAV, V39, P520, DOI 10.1016/j.addbeh.2013.11.022; Grattan A, 2012,
ANN FAM MED, V10, P304, DOI 10.1370/afm.1371; Grenald SA, 2014, EXPERT OPIN DRUG
DIS, V9, P1345, DOI 10.1517/17460441.2014.966076; Hamilton JP, 2008, MOL PSYCHIATR,
V13, P993, DOI 10.1038/mp.2008.57; Health Canada, 2014, CAN ALC DRUG US MON; Kenan
Kristen, 2012, Open Med, V6, pe41; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4,
P231, DOI 10.3109/10673229709030550; King NB, 2014, AM J PUBLIC HEALTH, V104, pE32,
DOI 10.2105/AJPH.2014.301966; Koob GF, 1997, SCIENCE, V278, P52, DOI
10.1126/science.278.5335.52; Kosten Thomas R, 2002, Sci Pract Perspect, V1, P13;
Kroenke K, 2008, PAIN, V134, P209, DOI 10.1016/j.pain.2007.09.021; Langbehn DR,
2006, DRUG ALCOHOL DEPEN, V83, P33, DOI 10.1016/j.drugalcdep.2005.10.006; Larance
B, 2015, J SUBST ABUSE TREAT, V58, P51, DOI 10.1016/j.jsat.2015.06.001; Le Merrer
J, 2009, PHYSIOL REV, V89, P1379, DOI 10.1152/physrev.00005.2009; Lingford-Hughes
A, 2003, BRIT J PSYCHIAT, V182, P97, DOI 10.1192/bjp.182.2.97; Lutz PE, 2013,
TRENDS NEUROSCI, V36, P195, DOI 10.1016/j.tins.2012.11.002; Mackesy-Amiti ME, 2015,
AM J DRUG ALCOHOL AB, V41, P100, DOI 10.3109/00952990.2014.940424; Manchikanti L,
2012, PAIN PHYSICIAN, V15, pES9; Markou A, 1998, NEUROPSYCHOPHARMACOL, V18, P135,
DOI 10.1016/S0893-133X(97)00113-9; Martins SS, 2012, PSYCHOL MED, V42, P1261, DOI
10.1017/S0033291711002145; Murphy Y, 2015, PAIN PHYSICIAN, V18, pE605; Pincus T,
2001, PSYCHOL BULL, V127, P599, DOI 10.1037//0033-2909.127.5.599; Pincus Tamar,
2002, Spine (Phila Pa 1976), V27, pE109, DOI 10.1097/00007632-200203010-00017;
Scherrer JF, 2016, J PAIN, V17, P473, DOI 10.1016/j.jpain.2015.12.012; Scherrer JF,
2016, ANN FAM MED, V14, P54, DOI 10.1370/afm.1885; Scherrer JF, 2015, PAIN, V156,
P348, DOI 10.1097/01.j.pain.0000460316.58110.a0; Scherrer JF, 2014, J GEN INTERN
MED, V29, P491, DOI 10.1007/s11606-013-2648-1; Schlaepfer TE, 1998, AM J PSYCHIAT,
V155, P470, DOI 10.1176/ajp.155.4.470; Shurman J, 2010, PAIN MED, V11, P1092, DOI
10.1111/j.1526-4637.2010.00881.x; Smith HS, 2012, PAIN PHYSICIAN, V15, pES145;
Substance Abuse and Mental Health Services Administration, 2014, BHSIS SER S;
Sullivan MD, 2006, ARCH INTERN MED, V166, P2087, DOI 10.1001/archinte.166.19.2087;
Sullivan MD, 2010, PAIN, V151, P567, DOI 10.1016/j.pain.2010.08.036; Sullivan MD,
2005, PAIN, V119, P95, DOI 10.1016/j.pain.2005.09.020; Upadhyay J, 2010, BRAIN,
V133, P2098, DOI 10.1093/brain/awq138; Volkow ND, 2011, JAMA-J AM MED ASSOC, V305,
P1346, DOI 10.1001/jama.2011.369; Webster LR, 2011, PAIN MED, V12, pS26, DOI
10.1111/j.1526-4637.2011.01134.x; WEISS F, 1992, BRAIN RES, V593, P314, DOI
10.1016/0006-8993(92)91327-B; Yokell MA, 2014, JAMA INTERN MED, V174, P2034, DOI
10.1001/jamainternmed.2014.5413; Younger JW, 2011, PAIN, V152, P1803, DOI
10.1016/j.pain.2011.03.028; Zellner MR, 2011, NEUROSCI BIOBEHAV R, V35, P2000, DOI
10.1016/j.neubiorev.2011.01.003 65 6 6 1 8 ELSEVIER IRELAND
LTD CLARE ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND 0165-1781 PSYCHIAT RES Psychiatry Res. SEP 30
2016 243 331 334
10.1016/j.psychres.2016.06.053 4 Psychiatry Psychiatry
DW7EA WOS:000383812800052 27434203 2019-09-25
J Wilkinson, AL; Halpern, CT; Herring, AH Wilkinson, Andra
L.; Halpern, Carolyn Tucker; Herring, Amy H. Directions of the
relationship between substance use and depressive symptoms from adolescence to
young adulthood ADDICTIVE BEHAVIORS English Article
Substance use; Depression; Adolescence; Young adulthood;
Gender SELF-MEDICATION HYPOTHESIS; GENDER-DIFFERENCES; MARIJUANA USE; AFRICAN-
AMERICANS; CIGARETTE-SMOKING; USE DISORDERS; HEALTH-RISK; BEHAVIOR;
PSYCHOPATHOLOGY; TRAJECTORIES Purpose: Both substance use and depression are common
in adolescence and often comorbid. Past research has produced conflicting results
on whether there is a temporal relationship and if so, in which direction it
operates and how it may vary by sex. The purpose of this paper is to explore the
longitudinal, potentially bidirectional, relationships between high-frequency
substance use and depressive symptoms from adolescence into young adulthood for
males and females. Methods: Using data from the National Longitudinal Study of
Adolescent to Adult Health we investigated longitudinal associations between high
frequency substance use (alcohol, cigarettes, and marijuana) and depressive
symptoms. The linear mixed effects models were stratified by sex and used a lagged
measure of the dependent variable to test temporal relationships. A random
intercept was used for respondent ID. Results: Increases in depressive symptoms
were significantly associated with a later increase of about a half day in
marijuana use frequency for males and nearly a two day increase in smoking
frequency for females. Conversely, increases in smoking frequency were
significantly associated with approximately a 0.6-point increase for females and
0.4-point increase for males in depressive symptoms at a later wave. Conclusions:
Results indicate a bidirectional relationship between smoking and depressive
symptoms for females. For males, there was evidence supporting self-medication with
marijuana and for smoking being associated with later increases in depressive
symptoms. Results inform how substance use and depression screening, prevention and
treatment efforts should be paired and targeted for males and females. (C) 2016
Elsevier Ltd. All rights reserved. [Wilkinson, Andra L.; Halpern, Carolyn Tucker;
Herring, Amy H.] Univ N Carolina, Carolina Populat Ctr, 206 West Franklin St,Room
208, Chapel Hill, NC 27516 USA; [Wilkinson, Andra L.; Halpern, Carolyn Tucker] Univ
N Carolina, Dept Maternal & Child Hlth, Gillings Sch Global Publ Hlth, 401 Rosenau
Hall,CB 7445, Chapel Hill, NC 27599 USA; [Herring, Amy H.] Univ N Carolina,
Gillings Sch Global Publ Hlth, Dept Biostat, 135 Dauer Dr,CB 7420, Chapel Hill, NC
27599 USA Wilkinson, AL (reprint author), Univ N Carolina, Carolina Populat Ctr,
206 West Franklin St,Room 208, Chapel Hill, NC 27516 USA. wilkina@live.unc.edu
National Institute on Drug AbuseUnited States Department of Health &
Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on
Drug Abuse (NIDA) [F31 DA036961]; Eunice Kennedy Shriver National Institute of
Child Health and Human DevelopmentUnited States Department of Health & Human
ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver
National Institute of Child Health & Human Development (NICHD) [R01 HD057046, R24
HD050924] Funding for this study was provided by the National Institute on Drug
Abuse (F31 DA036961) and the Eunice Kennedy Shriver National Institute of Child
Health and Human Development (R01 HD057046, R24 HD050924). The funders had no role
in the study design, collection, analysis or interpretation of the data, writing
the manuscript, or the decision to submit the paper for publication. Arendt M,
2007, PSYCHOL MED, V37, P935, DOI 10.1017/S0033291706009688; Audrain-McGovern J,
2015, ADDICTION, V110, P519, DOI 10.1111/add.12797; Brook DW, 2002, ARCH GEN
PSYCHIAT, V59, P1039, DOI 10.1001/archpsyc.59.11.1039; Burns JJ, 2004, PEDIATRICS,
V113, P1313, DOI 10.1542/peds.113.5.1313; Chaiton M, 2010, ADDICT BEHAV, V35,
P1054, DOI 10.1016/j.addbeh.2010.07.002; Chassin L., 2009, HDB ADOLESCENT PSYCH,
P723, DOI DOI 10.1002/9780470479193.ADLPSY001022; Chinet L, 2006, EUR CHILD ADOLES
PSY, V15, P149, DOI 10.1007/s00787-005-0516-1; Eaton W., 2004, USE PSYCHOL TESTING,
P363; Evans J, 2011, J MENS HEALTH, V8, P7, DOI 10.1016/j.jomh.2010.09.227;
Fergusson DM, 2009, ARCH GEN PSYCHIAT, V66, P260, DOI
10.1001/archgenpsychiatry.2008.543; Fitzmaurice GM, 2011, APPL LONGITUDINAL AN;
Fletcher JM, 2010, HEALTH ECON, V19, P855, DOI 10.1002/hec.1526; GE XJ, 1994, DEV
PSYCHOL, V30, P467, DOI 10.1037/0012-1649.30.4.467; Goodman E., 2000, PEDIATRICS;
Green BE, 2000, J HEALTH SOC BEHAV, V41, P40, DOI 10.2307/2676359; Green KM, 2012,
DRUG ALCOHOL DEPEN, V123, P239, DOI 10.1016/j.drugalcdep.2011.11.017; Hallfors DD,
2005, AM J PREV MED, V29, P163, DOI 10.1016/j.amepre.2005.06.002; Harris K. M.,
2013, ADD HLTH STUDY DESIG; Hedeker D, 2009, ADDICTION, V104, P297, DOI
10.1111/j.1360-0443.2008.02435.x; HENRY B, 1993, J ABNORM CHILD PSYCH, V21, P469,
DOI 10.1007/BF00916314; Hooshmand S, 2012, J ADOLESCENT HEALTH, V50, P140, DOI
10.1016/j.jadohealth.2011.05.016; Kann L, 2014, MMWR, V63; Keele L, 2006, POLIT
ANAL, V14, P186, DOI 10.1093/pan/mpj006; Khantzian EJ, 1997, HARVARD REV PSYCHIAT,
V4, P231, DOI 10.3109/10673229709030550; Killen JD, 1997, J CONSULT CLIN PSYCH,
V65, P1011, DOI 10.1037/0022-006X.65.6.1011; Levine SZ, 2013, SOC PSYCH PSYCH EPID,
V48, P1519, DOI 10.1007/s00127-012-0650-2; Mushquash AR, 2013, ADDICT BEHAV, V38,
P2180, DOI 10.1016/j.addbeh.2012.11.008; Needham BL, 2007, SOC SCI MED, V65, P1166,
DOI 10.1016/j.socscimed.2007.04.037; Nelson DE, 2008, AM J PUBLIC HEALTH, V98,
P905, DOI 10.2105/AJPH.2007.115931; Nolen-Hoeksema S, 1990, SEX DIFFERENCES DEPR;
Nolen-Hoeksema S, 2012, ANNU REV CLIN PSYCHO, V8, P161, DOI 10.1146/annurev-
clinpsy-032511-143109; Repetto PB, 2008, J RES ADOLESCENCE, V18, P421, DOI
10.1111/j.1532-7795.2008.00566.x; Rudolph KD, 2002, J ADOLESCENT HEALTH, V30, P3,
DOI 10.1016/S1054-139X(01)00383-4; Schuster RM, 2013, J YOUTH ADOLESCENCE, V42,
P1194, DOI 10.1007/s10964-012-9809-0; Schwinn T., 2012, ADDICT BEHAV, V35, P30;
Tamres LK, 2002, PERS SOC PSYCHOL REV, V6, P2, DOI 10.1207/S15327957PSPR0601_1;
Tomlinson KL, 2012, ADDICT BEHAV, V37, P179, DOI 10.1016/j.addbeh.2011.09.016; U.
S. Departmant of Health and Human Services, 2012, PREV SERV COV AFF CA; Weinstein
SM, 2013, PSYCHOL ADDICT BEHAV, V27, P1068, DOI 10.1037/a0031488; Williams SB,
2009, PEDIATRICS, V123, pE716, DOI 10.1542/peds.2008-2415; Zahn-Waxler C, 2008,
ANNU REV CLIN PSYCHO, V4, P275, DOI 10.1146/annurev.clinpsy.3.022806.091358 41
25 25 1 42 PERGAMON-ELSEVIER SCIENCE LTD OXFORD THE
BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND 0306-4603 1873-
6327 ADDICT BEHAV Addict. Behav. SEP 2016 60
64 70 10.1016/j.addbeh.2016.03.036 7
Psychology, Clinical; Substance Abuse Psychology; Substance Abuse DO4DH
WOS:000377731500012 27100470 Green Accepted 2019-09-25
J Rajashekharaiah, M; Verma, P Rajashekharaiah, Manjunath;
Verma, Pravin COMPARISON OF SOCIODEMOGRAPHIC AND CLINICAL VARIABLES
IN SCHIZOPHRENICS WITH AND WITHOUT SUBSTANCE ABUSE JOURNAL OF EVOLUTION OF
MEDICAL AND DENTAL SCIENCES-JEMDS English Article
Schizophrenia; Substance Abuse; Clinical Variable; Alcohol SELF-
MEDICATION HYPOTHESIS; PSYCHIATRIC-INPATIENTS; DUAL DIAGNOSIS; USE DISORDERS; DRUG-
ABUSE; PATTERNS; COMORBIDITY; PREVALENCE; SYMPTOMS; CANNABIS BACKGROUND
Substance abuse is associated with poor outcome in schizophrenia patients. Alcohol
and cannabis were reported to be most commonly abused substances in schizophrenics.
Great care is needed to manage these patients. Sociodemographic and clinical data
from India is sparse and therefore the need for this study. MATERIALS AND METHODS
Patients who gave written informed consent and met inclusion and exclusion criteria
were taken into study. They were administered sociodemographic proforma, clinical
profile sheet, and substance abuse proforma. Data was subjected to statistical
analysis. RESULTS Mean age of substance abusers was 27.96 yrs. and of non-abusers
group was 32.68 yrs. Non-abusers group had a later age of onset of schizophrenia
compared to the substance abusers group (mean age at onset: 25.56 vs. 22.88 yrs.).
Duration of schizophrenia in substance abusers was shorter compared to non-abusers
(mean duration in months: 65.00 vs. 89.88). Onset of schizophrenia was acute in 2
and insidious in 21 patients of non-abusers group. Commonest subtype of
schizophrenia was paranoid in 18 and 20 among substance abusers and non-abusers
respectively. Family history of substance abuse was present in 12 substance abusers
as compared to only 3 of non-abusers. Among substance abusers 60% abused alcohol,
28% cannabis, 28% opioids, and 16% were polysubstance abusers. Alcohol abuse had a
later age of onset than both cannabis and opioids. CONCLUSION Substance abusing
schizophrenics were younger than non-abusing. 60% of patients had completed middle
school and more than half had semiskilled jobs. Majority were married. Substance
abusers had earlier onset and shorter duration of schizophrenia than non-abusers.
Most patients had paranoid schizophrenia and insidious onset of illness. Alcohol
was commonest abused substance. Age of onset for alcohol abuse was higher than that
for cannabis. [Rajashekharaiah, Manjunath] Shimoga Inst Med Sci, Dept Psychiat,
Shimoga, Karnataka, India; [Verma, Pravin] Indira Gandhi Govt Med Coll & Hosp, Dept
Psychiat, Nagpur, Maharashtra, India Rajashekharaiah, M (reprint author),
SIMS, 404 Staff Quarters, Shimoga 577201, Karnataka, India.docmatic@gmail.com
Addington J, 1997, J PSYCHIATR NEUROSCI, V22, P99;
Aghajanian GK, 2000, BRAIN RES REV, V31, P302, DOI 10.1016/S0165-0173(99)00046-6;
Ahmadi J, 2001, PSYCHOL REP, V89, P363, DOI 10.2466/PR0.89.6.363-365; ANANTH J,
1989, HOSP COMMUNITY PSYCH, V40, P297; ARNDT S, 1992, PSYCHOL MED, V22, P379, DOI
10.1017/S0033291700030324; BAIGENT M, 1995, AUST NZ J PSYCHIAT, V29, P69, DOI
10.3109/00048679509075894; Bellack AS, 1998, ADDICT BEHAV, V23, P749, DOI
10.1016/S0306-4603(98)00066-5; BOWERS MB, 1987, PSYCHOPHARMACOLOGY 3, P819;
CASTANEDA R, 1991, AM J DRUG ALCOHOL AB, V17, P313, DOI 10.3109/00952999109027555;
CASTANEDA R, 1994, COMPR PSYCHIAT, V35, P180, DOI 10.1016/0010-440X(94)90189-9;
CATON CLM, 1989, HOSP COMMUNITY PSYCH, V40, P1037; Chambers RA, 2001, BIOL
PSYCHIAT, V50, P71, DOI 10.1016/S0006-3223(01)01134-9; CLEGHORN JM, 1991, J CLIN
PSYCHIAT, V52, P26; CUFFEL BJ, 1993, HOSP COMMUNITY PSYCH, V44, P247; DEQUARDO JR,
1994, J PSYCHIAT RES, V28, P267, DOI 10.1016/0022-3956(94)90010-8; Dixon L, 1999,
SCHIZOPHR RES, V35, pS93, DOI 10.1016/S0920-9964(98)00161-3; DIXON L, 1991, AM J
PSYCHIAT, V148, P224; DRAKE RE, 1989, HOSP COMMUNITY PSYCH, V40, P1041; DUBE KC,
1971, BRIT J PSYCHIAT, V118, P345, DOI 10.1192/bjp.118.544.345; FISCHMAN MW, 1976,
ARCH GEN PSYCHIAT, V33, P983; Fowler IL, 1998, SCHIZOPHRENIA BULL, V24, P443, DOI
10.1093/oxfordjournals.schbul.a033339; Hambrecht M, 1996, NERVENARZT, V67, P36;
HENSALA JD, 1967, ARCH GEN PSYCHIAT, V16, P554; Khantzian EJ, 1997, HARVARD REV
PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550; KNUDSEN P, 1984, ACTA PSYCHIAT
SCAND, V69, P162, DOI 10.1111/j.1600-0447.1984.tb02482.x; Lambert M, 1997, PSYCHIAT
PRAX, V24, P185; LEHMAN AF, 1994, COMPR PSYCHIAT, V35, P106, DOI 10.1016/0010-
440X(94)90054-L; LIEBERMAN JA, 1990, SCHIZOPHRENIA BULL, V16, P97, DOI
10.1093/schbul/16.1.97; LIEBERMAN JA, 1990, SCHIZOPHRENIA BULL, V16, P29, DOI
10.1093/schbul/16.1.29; LINSZEN DH, 1994, ARCH GEN PSYCHIAT, V51, P273; MILLER FT,
1989, AM J DRUG ALCOHOL AB, V15, P291, DOI 10.3109/00952998908993409; MUESER KT,
1990, SCHIZOPHRENIA BULL, V16, P31, DOI 10.1093/schbul/16.1.31; MUESER KT, 1992,
ACTA PSYCHIAT SCAND, V85, P48, DOI 10.1111/j.1600-0447.1992.tb01441.x; Patkar AA,
1999, AM J ADDICTION, V8, P65; Paul L, 1994, J NERV MENT DIS, V182, P109; REIGER
DA, 1990, JAMA-J AM MED ASSOC, V264, P2511; Samuel SG, 1990, SCHIZOPHRENIA B, V16,
P111; Sato M, 1990, SCHIZOPHRENIA B, V16, P111; Saylers MP, 2001, SCHIZOPHR RES,
V48, P109; SCHNEIER FR, 1987, J NERV MENT DIS, V175, P641, DOI 10.1097/00005053-
198711000-00001; SIRIS SG, 1992, THE JOURNAL OF NERVO, V180, P595; SMITH J, 1994,
BRIT J PSYCHIAT, V165, P13, DOI 10.1192/bjp.165.1.13; Soyka M, 1996, NERVENARZT,
V67, P891, DOI 10.1007/s001150050069; Swofford CD, 2000, AM J DRUG ALCOHOL AB, V26,
P343, DOI 10.1081/ADA-100100248; Trivedi J, 1978, INDIAN J PSYCHIAT, V21, P345;
Verdoux H, 1996, ENCEPHALE, V22, P95 46 0 0 0 0 JOURNAL
EVOLUTION MEDICAL & DENTAL SCIENCES KARNATAKA C/O AKSHANTALA ENTERPRISES, NO 65,
1ST FL, SAHUKAR CHENNIAH RD, MYSORE, KARNATAKA, 570 009, INDIA 2278-4748 2278-
4802 J EVOL MED DENT SCI- J. Evol. Med. Dent. Sci.-JEMDS AUG 18
2016 5 66 4681 4686
10.14260/jemds/2016/1067 6 Medicine, General & Internal
General & Internal Medicine EH4TS WOS:000391764100001 Bronze
2019-09-25
J Jones, TM; Hill, KG; Epstein, M; Lee, JO; Hawkins, JD; Catalano, RF
Jones, Tiffany M.; Hill, Karl G.; Epstein, Marina; Lee, Jungeun Olivia;
Hawkins, J. David; Catalano, Richard F. Understanding the interplay
of individual and social-developmental factors in the progression of substance use
and mental health from childhood to adulthood DEVELOPMENT AND PSYCHOPATHOLOGY
English Article GENE-
ENVIRONMENT CORRELATION; SELF-MEDICATION HYPOTHESIS; POSITIVE YOUTH DEVELOPMENT;
MAJOR DEPRESSIVE DISORDER; ALCOHOL-USE DISORDER; PROBLEM BEHAVIOR; CONDUCT
PROBLEMS; DRUG-USE; ROMANTIC RELATIONSHIPS; ANXIETY DISORDERS This study
examines the interplay between individual and social-developmental factors in the
development of positive functioning, substance use problems, and mental health
problems. This interplay is nested within positive and negative developmental
cascades that span childhood, adolescence, the transition to adulthood, and
adulthood. Data are drawn from the Seattle Social Development Project, a gender-
balanced, ethnically diverse community sample of 808 participants interviewed 12
times from ages 10 to 33. Path modeling showed short- and long-term cascading
effects of positive social environments, family history of depression, and
substance-using social environments throughout development. Positive family social
environments set a template for future partner social environment interaction and
had positive influences on proximal individual functioning, both in the next
developmental period and long term. Family history of depression adversely affected
mental health functioning throughout adulthood. Family substance use began a
cascade of substance-specific social environments across development, which was the
pathway through which increasing severity of substance use problems flowed. The
model also indicated that adolescent, but not adult, individual functioning
influenced selection into positive social environments, and significant cross-
domain effects were found in which substance-using social environments affected
subsequent mental health. [Jones, Tiffany M.; Hill, Karl G.; Epstein, Marina;
Hawkins, J. David; Catalano, Richard F.] Univ Washington, Seattle, WA 98195 USA;
[Lee, Jungeun Olivia] Univ Southern Calif, Los Angeles, CA 90089 USA Jones, TM
(reprint author), Univ Washington, Social Dev Res Grp, Sch Social Work, 9725 3rd
Ave NE,Suite 401, Seattle, WA 98115 USA. tjones03@uw.edu Hill, Karl/C-3688-2015
Hill, Karl/0000-0001-8342-1561 National Institute on Drug AbuseUnited
States Department of Health & Human ServicesNational Institutes of Health (NIH) -
USANIH National Institute on Drug Abuse (NIDA) [5R01DA003721-01-08, 1R01DA09679-01-
14, R01DA024411-01-06] Funding for this study was provided by grants from the
National Institute on Drug Abuse (5R01DA003721-01-08, 1R01DA09679-01-14, and
R01DA024411-01-06). The content of this paper is solely the responsibility of the
authors and does not necessarily represent the official views of the funding
agency. We gratefully acknowledge the Seattle Social Development Project study
participants for their continued contribution to the longitudinal study. We also
acknowledge the SDRG Survey Research Division for their hard work maintaining high
panel retention and the SDRG editorial and administrative staff for their editorial
and project support. Achenbach T.M., 2001, RATINGS RELATIONS DS; American
Psychiatric Association, 1987, DIAGN STAT MAN MENT; Bachman J. G., 2002, DECLINE
SUBSTANCE US; Bailey JA, 2006, J ABNORM CHILD PSYCH, V34, P273, DOI 10.1007/s10802-
006-9033-z; Bailey JA, 2011, DRUG ALCOHOL DEPEN, V118, P444, DOI
10.1016/j.drugalcdep.2011.05.002; Bandura A., 1977, SOCIAL LEARNING THEO; Beesdo K,
2010, ARCH GEN PSYCHIAT, V67, P47, DOI 10.1001/archgenpsychiatry.2009.177;
Bijttebier P, 2009, CLIN PSYCHOL REV, V29, P421, DOI 10.1016/j.cpr.2009.04.002;
Birmaher B, 1996, J AM ACAD CHILD PSY, V35, P1427, DOI 10.1097/00004583-199611000-
00011; Bornstein MH, 2010, DEV PSYCHOPATHOL, V22, P717, DOI
10.1017/S0954579410000416; Brady KT, 2005, AM J PSYCHIAT, V162, P1483, DOI
10.1176/appi.ajp.162.8.1483; Brown Eric C, 2005, Crim Behav Ment Health, V15, P221,
DOI 10.1002/cbm.27; BURKE JD, 1994, HOSP COMMUNITY PSYCH, V45, P451; Burt KB, 2008,
CHILD DEV, V79, P359, DOI 10.1111/j.1467-8624.2007.01130.x; Capaldi DM, 1999, DEV
PSYCHOPATHOL, V11, P59, DOI 10.1017/S0954579499001959; Catalano RF, 1996, J DRUG
ISSUES, V26, P429, DOI 10.1177/002204269602600207; Catalano RF, 2002, J ADOLESCENT
HEALTH, V31, P230, DOI 10.1016/S1054-139X(02)00496-2; Catalano RF, 1996,
DELINQUENCY CRIME CU, P149; Chassin L, 2004, J ABNORM PSYCHOL, V113, P483, DOI
10.1037/0021-843X.113.4.483; Colhoun HM, 2003, LANCET, V361, P865, DOI
10.1016/S0140-6736(03)12715-8; Compton WM, 2007, ARCH GEN PSYCHIAT, V64, P566, DOI
10.1001/archpsyc.64.5.566; Connolly J, 2000, CHILD DEV, V71, P1395, DOI
10.1111/1467-8624.00235; Criss MM, 2002, CHILD DEV, V73, P1220, DOI 10.1111/1467-
8624.00468; Dishion TJ, 2002, DEV PSYCHOL, V38, P480, DOI 10.1037//0012-
1649.38.4.480; Donnellan MB, 2005, J PERS SOC PSYCHOL, V88, P562, DOI 10.1037/0022-
3514.88.3.562; Duncan LE, 2014, AM PSYCHOL, V69, P249, DOI 10.1037/a0036320; Duncan
LE, 2011, AM J PSYCHIAT, V168, P1041, DOI 10.1176/appi.ajp.2011.11020191; Elder GH,
1998, CHILD DEV, V69, P1, DOI 10.2307/1132065; Englund MM, 2012, J ADOLESCENCE,
V35, P1123, DOI 10.1016/j.adolescence.2012.03.004; Epstein M, 2013, DEV PSYCHOL,
V49, P1151, DOI 10.1037/a0029309; Fleming CB, 2002, J QUANT CRIMINOL, V18, P423,
DOI 10.1023/A:1021173711746; Fleming CB, 2010, J HEALTH SOC BEHAV, V51, P153, DOI
10.1177/0022146510368930; Franken IHA, 2006, PERS INDIV DIFFER, V40, P1497, DOI
10.1016/j.paid.2005.12.005; Franken IHA, 2006, ADDICT BEHAV, V31, P399, DOI
10.1016/j.addbeh.2005.05.022; Furman W, 2002, CHILD DEV, V73, P241, DOI
10.1111/1467-8624.00403; Goodwin RD, 2003, PREV MED, V36, P698, DOI 10.1016/S0091-
7435(03)00042-2; Grant BF, 2009, MOL PSYCHIATR, V14, P1051, DOI 10.1038/mp.2008.41;
Graves PL, 1998, J PERS SOC PSYCHOL, V74, P1329, DOI 10.1037/0022-3514.74.5.1329;
Guo J, 2002, J AM ACAD CHILD PSY, V41, DOI 10.1097/00004583-200207000-00017; Haller
M, 2010, DEV PSYCHOPATHOL, V22, P899, DOI 10.1017/S0954579410000532; Handley ED,
2011, J ABNORM PSYCHOL, V120, P528, DOI 10.1037/a0024162; Harter SL, 2000, CLIN
PSYCHOL REV, V20, P311, DOI 10.1016/S0272-7358(98)00084-1; Hawkins JD, 2008, ARCH
PEDIAT ADOL MED, V162, P1133, DOI 10.1001/archpedi.162.12.1133; Hawkins JD, 1999,
ARCH PEDIAT ADOL MED, V153, P226, DOI 10.1001/archpedi.153.3.226; HAWKINS JD, 1992,
PSYCHOL BULL, V112, P64, DOI 10.1037/0033-2909.112.1.64; Herrenkohl TI, 2010, DEV
PSYCHOPATHOL, V22, P655, DOI 10.1017/S0954579410000349; Hicks BM, 2013, DEV
PSYCHOPATHOL, V25, P119, DOI 10.1017/S0954579412000946; Hill KG, 2010, DRUG ALCOHOL
DEPEN, V110, P62, DOI 10.1016/j.drugalcdep.2010.02.005; Hill KG, 2005, J ADOLESCENT
HEALTH, V37, P202, DOI 10.1016/j.jadohealth.2004.08.014; Hirschi T., 1969, CAUSES
DELINQUENCY; Horwitz AV, 1996, J MARRIAGE FAM, V58, P895, DOI 10.2307/353978; Huang
B, 2001, CRIMINOLOGY, V39, P75, DOI 10.1111/j.1745-9125.2001.tb00917.x; Iacono WG,
2008, ANNU REV CLIN PSYCHO, V4, P325, DOI 10.1146/annurev.clinpsy.4.022007.141157;
Jaffee SR, 2007, MOL PSYCHIATR, V12, P432, DOI 10.1038/sj.mp.4001950; Kendler KS,
2007, PSYCHOL MED, V37, P615, DOI 10.1017/S0033291706009524; Khantzian EJ, 1997,
HARVARD REV PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550; Kirisci L, 2009, AM
J DRUG ALCOHOL AB, V35, P145, DOI 10.1080/00952990902825405; Knafo A, 2013, DEV
PSYCHOPATHOL, V25, P1, DOI 10.1017/S0954579412000855; Knecht A, 2010, SOC DEV, V19,
P494, DOI 10.1111/j.1467-9507.2009.00564.x; Knecht AB, 2011, J RES ADOLESCENCE,
V21, P475, DOI 10.1111/j.1532-7795.2010.00685.x; Knight Kelly E., 2011, J FAMILY
THEORY REV, V3, P198, DOI DOI 10.1111/J.1756-2589.2011.00095.X; Kosterman R, 2014,
PSYCHOL ADDICT BEHAV, V28, P348, DOI 10.1037/a0034970; Kosterman R, 2010, J
PSYCHOPATHOL BEHAV, V32, P118, DOI 10.1007/s10862-009-9138-0; Lansford JE, 2010,
DEV PSYCHOPATHOL, V22, P593, DOI 10.1017/S0954579410000301; Lee JO, 2012, DRUG
ALCOHOL DEPEN, V121, P213, DOI 10.1016/j.drugalcdep.2011.08.028; Lembke A, 2012, AM
J DRUG ALCOHOL AB, V38, P524, DOI 10.3109/00952990.2012.694532; Leonard KE, 1999, J
STUD ALCOHOL, P139, DOI 10.15288/jsas.1999.s13.139; Leve LD, 2005, J ABNORM CHILD
PSYCH, V33, P505, DOI 10.1007/s10802-005-6734-7; Lewin-Bizan S, 2010, DEV
PSYCHOPATHOL, V22, P759, DOI 10.1017/S0954579410000441; Lewinsohn PM, 2003, J
ABNORM PSYCHOL, V112, P353, DOI 10.1037/0021-843X.112.3.353; Lewinsohn PM, 1999, J
AM ACAD CHILD PSY, V38, P56, DOI 10.1097/00004583-199901000-00020; Lynne-Landsman
SD, 2010, DEV PSYCHOPATHOL, V22, P933, DOI 10.1017/S0954579410000556; Macleod J,
2004, LANCET, V363, P1579, DOI 10.1016/S0140-6736(04)16200-4; Markou A, 1998,
NEUROPSYCHOPHARMACOL, V18, P135, DOI 10.1016/S0893-133X(97)00113-9; Mars B, 2012, J
AFFECT DISORDERS, V136, P44, DOI 10.1016/j.jad.2011.09.002; Mason WA, 2008, DRUG
ALCOHOL DEPEN, V96, P233, DOI 10.1016/j.drugalcdep.2008.03.012; Mason WA, 2007, J
RES ADOLESCENCE, V17, P541, DOI 10.1111/j.1532-7795.2007.00534.x; Mason WA, 2004, J
AM ACAD CHILD PSY, V43, P307, DOI 10.1097/01.chi.0000108623.24694.b4; Masten AS,
2006, INT J BEHAV DEV, V30, P47, DOI 10.1177/0165025406059974; Masten AS, 2010, DEV
PSYCHOPATHOL, V22, P491, DOI 10.1017/S0954579410000222; Masten AS, 2005, DEV
PSYCHOL, V41, P733, DOI 10.1037/0012-1649.41.5.733; McCauley E., 2001, DEPRESSED
CHILD ADOL, V2, P46; McGue M, 2006, BEHAV GENET, V36, P591, DOI 10.1007/s10519-006-
9061-z; McGue M, 2001, ALCOHOL CLIN EXP RES, V25, P1156, DOI 10.1097/00000374-
200108000-00010; Merline A, 2008, ADDICTION, V103, P84, DOI 10.1111/j.1360-
0443.2008.02178.x; Muthen L. K., 2008, MPLUS USERS GUIDE; Newman DL, 1996, J
CONSULT CLIN PSYCH, V64, P552, DOI 10.1037/0022-006X.64.3.552; Obradovic
J, 2010, J CLIN CHILD ADOLESC, V39, P90, DOI 10.1080/15374410903401120; Olds DL,
2007, J CHILD PSYCHOL PSYC, V48, P355, DOI 10.1111/j.1469-7610.2006.01702.x; Oxford
ML, 2001, AM J DRUG ALCOHOL AB, V27, P599, DOI 10.1081/ADA-100107658; Pardo Y,
2007, ADDICT BEHAV, V32, P2398, DOI 10.1016/j.addbeh.2007.02.010; Parker J. G.,
2006, DEV PSYCHOPATHOL, V2, P419, DOI DOI 10.1002/9780470939383.CH12; Patterson GR,
2010, DEV PSYCHOPATHOL, V22, P949, DOI 10.1017/S0954579410000568; Piehler TF, 2012,
J ABNORM CHILD PSYCH, V40, P1045, DOI 10.1007/s10802-012-9626-7; Pine DS, 1999, AM
J PSYCHIAT, V156, P133, DOI 10.1176/ajp.156.1.133; Pine DS, 1998, ARCH GEN
PSYCHIAT, V55, P56, DOI 10.1001/archpsyc.55.1.56; PLOMIN R, 1977, PSYCHOL BULL,
V84, P309, DOI 10.1037/0033-2909.84.2.309; Poulin F, 2011, J ADOLESCENCE, V34,
P249, DOI 10.1016/j.adolescence.2010.05.006; Reinherz Helen Z., 2000, Journal of
the American Academy of Child and Adolescent Psychiatry, V39, P223, DOI
10.1097/00004583-200002000-00023; Reinherz HZ, 2003, AM J PSYCHIAT, V160, P2141,
DOI 10.1176/appi.ajp.160.12.2141; Repetti RL, 2002, PSYCHOL BULL, V128, P330, DOI
10.1037/0033-2909.128.2.330; Rhule-Louie DM, 2007, CLIN CHILD FAM PSYCH, V10, P53,
DOI 10.1007/s10567-006-0016-y; Robins L. N., 1981, COMMUNICATION; Roza SJ, 2003, AM
J PSYCHIAT, V160, P2116, DOI 10.1176/appi.ajp.160.12.2116; Rubin K. H., 2011, HDB
PEER INTERACTION; Russek LG, 1997, J BEHAV MED, V20, P1, DOI
10.1023/A:1025525428213; Sameroff AJ, 2003, DEV PSYCHOPATHOL, V15, P613, DOI
10.1017/S0954579403000312; Schmitz N, 2004, PREV MED, V39, P1200, DOI
10.1016/j.ypmed.2004.04.034; Schwartz D, 1999, J ABNORM CHILD PSYCH, V27, P191, DOI
10.1023/A:1021948206165; Stone AL, 2012, ADDICT BEHAV, V37, P747, DOI
10.1016/j.addbeh.2012.02.014; Sullivan CJ, 2011, J RES CRIME DELINQ, V48, P566, DOI
10.1177/0022427810395149; SUTHERLAND EH, 1970, CRIMINOLOGY; Tarter RE, 2003, AM J
PSYCHIAT, V160, P1078, DOI 10.1176/appi.ajp.160.6.1078; Teo AR, 2013, PLOS ONE, V8,
DOI 10.1371/journal.pone.0062396; Tomlinson KL, 2012, ADDICT BEHAV, V37, P179, DOI
10.1016/j.addbeh.2011.09.016; Weissman MM, 2006, AM J PSYCHIAT, V163, P1001, DOI
10.1176/appi.ajp.163.6.1001; Wiesner M, 2006, J RES ADOLESCENCE, V16, P239, DOI
10.1111/j.1532-7795.2006.00131.x; Wolff JC, 2006, CLIN CHILD FAM PSYCH, V9, P201,
DOI 10.1007/s10567-006-0011-3; Yanovitzky I, 2005, HEALTH COMMUN, V17, P67, DOI
10.1207/s15327027hc1701_5; YOSHIKAWA H, 1994, PSYCHOL BULL, V115, P28, DOI
10.1037/0033-2909.115.1.28; Zahn-Waxler C, 2000, DEV PSYCHOPATHOL, V12, P443, DOI
10.1017/S0954579400003102; ZOCCOLILLO M, 1992, J AM ACAD CHILD PSY, V31, P547, DOI
10.1097/00004583-199205000-00024 122 5 6 1 14 CAMBRIDGE UNIV
PRESS NEW YORK 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA 0954-
5794 1469-2198 DEV PSYCHOPATHOL Dev. Psychopathol. AUG 2016 28
3 SI 721 741 10.1017/S0954579416000274
21 Psychology, Developmental Psychology DT2DV
WOS:000381291900008 27427802 Green Accepted 2019-09-25
J Gorka, SM; Lieberman, L; Phan, KL; Shankman, SA Gorka,
Stephanie M.; Lieberman, Lynne; Phan, K. Luan; Shankman, Stewart A.
Association between problematic alcohol use and reactivity to uncertain
threat in two independent samples DRUG AND ALCOHOL DEPENDENCE
English Article Alcohol use; Binge
drinking; Uncertain threat; Startle potentiation SUBSTANCE USE DISORDERS;
ANXIETY SENSITIVITY; STARTLE RESPONSE; PANIC DISORDER; SELF-MEDICATION;
UNPREDICTABLE THREAT; DRUG-ADDICTION; FEAR; STRESS; ANTICIPATION Background: Recent
laboratory studies have shown that acute alcohol intoxication selectively and
effectively dampens aversive responding to uncertain threat. Art emerging
hypothesis is that individuals who exhibit heightened reactivity to uncertain
threat may be especially motivated to use alcohol to dampen their distress, setting
the stage for negative reinforcement processes to drive excessive alcohol use.
However, no study to date has directly examined whether current problematic
drinkers exhibit heightened reactivity to uncertain threat as would be expected.
Methods: The present study was therefore designed to examine the association
between current problematic alcohol use and reactivity to uncertain threat during
sobriety in two, independent samples. In Study 1 (n=221) and Study 2 (n=74), adult
participants completed the same well-validated threat-of shock task which
separately probes responses to temporally predictable and unpredictable threat.
Startle potentiation was measured as an index of aversive responding. Problematic
alcohol use was defined as number of binge episodes within the past 30 days in
Study 1 and total scores on a self-report measure of hazardous drinking in Study 2.
Results: As hypothesized, across both studies greater levels of problematic
drinking were associated with greater startle potentiation to unpredictable threat.
In Study 2, hazardous drinking scores were also positively associated with startle
potentiation to predictable threat. Conclusions: The findings are notably
consistent with the notion that heightened reactivity to uncertain threat is an
important individual difference factor associated with the onset and/or maintenance
of problematic drinking behaviors and may therefore be a novel prevention and
intervention target. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
[Gorka, Stephanie M.; Phan, K. Luan; Shankman, Stewart A.] Univ Illinois,
Dept Psychiat, 1747 West Roosevelt Rd, Chicago, IL 60608 USA; [Lieberman, Lynne;
Phan, K. Luan; Shankman, Stewart A.] Univ Illinois, Dept Psychol, 1007 West
Harrison St,M-C 285, Chicago, IL 60607 USA; [Phan, K. Luan] Jesse Brown VA Med Ctr,
Mental Hlth Serv Line, 820 S Damen Ave, Chicago, IL 60612 USA; [Phan, K. Luan] Univ
Illinois, Dept Anat & Cell Biol, 808 S Wood St, Chicago, IL 60612 USA; [Phan, K.
Luan] Univ Illinois, Grad Program Neurosci, 808 S Wood St, Chicago, IL 60612 USA
Gorka, SM (reprint author), Univ Illinois, Dept Psychiat, 1747 West Roosevelt
Rd, Chicago, IL 60608 USA. sgorka2@uic.edu Shankman, Stewart A./B-8740-2012
Shankman, Stewart A./0000-0002-8097-4483 National Institute of Mental
HealthUnited States Department of Health & Human ServicesNational Institutes of
Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH101497,
R01MH098093]; National Institute on Alcohol Abuse and AlcoholismUnited States
Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
National Institute on Alcohol Abuse & Alcoholism (NIAAA) [F31AA22273]; University
of Illinois at Chicago (UIC) Center for Clinical and Translational Science (CCTS)
from National Center for Research Resources [UL1RR029879] This work was supported
by grants from the National Institute of Mental Health (R01MH101497 [PI: Phan] and
R01MH098093 [PI: Shankman]) and National Institute on Alcohol Abuse and Alcoholism
(F31AA22273 [PI: Gorka]). Other support for this work was provided by the
University of Illinois at Chicago (UIC) Center for Clinical and Translational
Science (CCTS) award number UL1RR029879 from the National Center for Research
Resources. The funding sources had no further role in study design; in the
collection, analysis and interpretation of data; in the writing of the report; or
in the decision to submit the paper for publication. Alvarez RP, 2011, NEUROIMAGE,
V55, P389, DOI 10.1016/j.neuroimage.2010.11.057; Babor T. F., 1989, AUDIT ALCOHOL
USE ID; Baker TB, 2004, PSYCHOL REV, V111, P33, DOI 10.1037/0033-295X.111.1.33;
Barlow DH, 2000, AM PSYCHOL, V55, P1247, DOI 10.1037/0003-066X.55.11.1247; BIBB JL,
1986, BEHAV RES THER, V24, P49, DOI 10.1016/0005-7967(86)90149-X; BLANCHARD RJ,
1993, BEHAV BRAIN RES, V58, P155, DOI 10.1016/0166-4328(93)90100-5; Blumenthal TD,
2005, PSYCHOPHYSIOLOGY, V42, P1, DOI 10.1111/j.1469-8986.2005.00271.x; Bradford DE,
2015, J ABNORM PSYCHOL, V124, P128, DOI 10.1037/abn0000007; Bradford DE, 2013,
PSYCHOL SCI, V24, P2541, DOI 10.1177/0956797613499923; Bradley M.M, 1999, STARTLE
MODIFICATION, P157, DOI [10.1017/CBO9780511665523.010, DOI
10.1017/CBO9780511665523.010]; Carleton RN, 2007, BEHAV RES THER, V45, P2307, DOI
10.1016/j.brat.2007.04.006; COX BJ, 1993, BEHAV RES THER, V31, P413, DOI
10.1016/0005-7967(93)90099-G; Curtin J. J., 2007, EMOTION PSYCHOPATHOL; Davis M,
1998, BIOL PSYCHIAT, V44, P1239, DOI 10.1016/S0006-3223(98)00288-1; Davis M, 2006,
AM PSYCHOL, V61, P741, DOI 10.1037/0003-066X.61.8.741; Davis M, 2010,
NEUROPSYCHOPHARMACOL, V35, P105, DOI 10.1038/npp.2009.109; DeMartini KS, 2011, CLIN
PSYCHOL REV, V31, P169, DOI 10.1016/j.cpr.2010.10.001; Gorka SM, 2015, INT J
PSYCHOPHYSIOL, V98, P87, DOI 10.1016/j.ijpsycho.2015.07.005; Gorka SM, 2013, DRUG
ALCOHOL DEPEN, V132, P216, DOI 10.1016/j.drugalcdep.2013.02.003; Greeley J, 1999,
PSYCHOL THEOR DRINKI, V2, P14; Grillon C, 2006, BIOL PSYCHIAT, V60, P760, DOI
10.1016/j.biopsych.2005.11.027; Grillon C, 2013, PLOS ONE, V8, DOI
10.1371/journal.pone.0070969; Grillon C, 2011, BIOL PSYCHIAT, V69, P549, DOI
10.1016/j.biopsych.2010.12.013; Grupe DW, 2013, NAT REV NEUROSCI, V14, P488, DOI
10.1038/nrn3524; Hachiya LY, 2010, ALCOHOL CLIN EXP RES, V34, p117A; HEDGES LV,
1982, PSYCHOL BULL, V92, P490, DOI 10.1037/0033-2909.92.2.490; Hefner KR, 2016, J
ABNORM PSYCHOL, V125, P138, DOI 10.1037/abn0000106; Hefner KR, 2013, J ABNORM
PSYCHOL, V122, P756, DOI 10.1037/a0033407; Hefner KR, 2012, J PSYCHOPHARMACOL, V26,
P232, DOI 10.1177/0269881111416691; Herry C, 2007, J NEUROSCI, V27, P5958, DOI
10.1523/JNEUROSCI.5218-06.2007; Hogle JM, 2010, BIOL PSYCHIAT, V68, P719, DOI
10.1016/j.biopsych.2010.06.003; Jackson F, 2015, EMOTION, V15, P12, DOI
10.1037/emo0000020; Jennison KM, 2004, AM J DRUG ALCOHOL AB, V30, P659, DOI
10.1081/ADA-200032331; Kassel JD, 2000, J STUD ALCOHOL, V61, P332, DOI
10.15288/jsa.2000.61.332; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI
10.3109/10673229709030550; Koob GF, 2013, CURR OPIN NEUROBIOL, V23, P559, DOI
10.1016/j.conb.2013.03.011; Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI
10.1038/npp.2009.110; Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI
10.1016/S0893-133X(00)00195-0; Koob GF, 2003, ALCOHOL CLIN EXP RES, V27, P232, DOI
10.1097/01.ALC.0000057122.36127.C2; Kraemer KM, 2015, ADDICT BEHAV, V42, P162, DOI
10.1016/j.addbeh.2014.11.033; Lejuez CW, 2000, J EXP PSYCHOL-APPL, V6, P349, DOI
10.1037//1076-898X.6.4.349; Melzig CA, 2008, BEHAV RES THER, V46, P1126, DOI
10.1016/j.brat.2008.07.002; Moberg CA, 2009, J ABNORM PSYCHOL, V118, P335, DOI
10.1037/a0015636; Nelson BD, 2015, J ANXIETY DISORD, V33, P62, DOI
10.1016/j.janxdis.2015.05.003; Quevedo K, 2010, DEV PSYCHOBIOL, V52, P78, DOI
10.1002/dev.20415; REISS S, 1986, BEHAV RES THER, V24, P1, DOI 10.1016/0005-
7967(86)90143-9; Robinson J, 2011, ARCH GEN PSYCHIAT, V68, P800, DOI
10.1001/archgenpsychiatry.2011.75; Robinson J, 2009, J ANXIETY DISORD, V23, P38,
DOI 10.1016/j.janxdis.2008.03.013; ROLLMAN GB, 1987, PERCEPT PSYCHOPHYS, V42, P257,
DOI 10.3758/BF03203077; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI
10.1111/j.1360-0443.1993.tb02093.x; SAUNDERS JB, 1993, ADDICTION, V88, P349, DOI
10.1111/j.1360-0443.1993.tb00822.x; Schmitz A, 2012, NAT PROTOC, V7, P527, DOI
10.1038/nprot.2012.001; Schroder KEE, 2007, SOC SCI MED, V65, P2588, DOI
10.1016/j.socscimed.2007.07.011; Shankman SA, 2013, J ABNORM PSYCHOL, V122, P322,
DOI 10.1037/a0030747; Sinha R, 2008, ANN NY ACAD SCI, V1141, P105, DOI
10.1196/annals.1441.030; Smith DP, 2005, J GERONTOL B-PSYCHOL, V60, pP49, DOI
10.1093/geronb/60.1.P49; SOBELL LC, 1992, MEASURING ALCOHOL CONSUMPTION, P41;
STEELE CM, 1990, AM PSYCHOL, V45, P921, DOI 10.1037/0003-066X.45.8.921; Watson D,
2007, PSYCHOL ASSESSMENT, V19, P253, DOI 10.1037/1040-3590.19.3.253; Watson D,
2012, ASSESSMENT, V19, P399, DOI 10.1177/1073191112449857 60 17 17 0
6 ELSEVIER IRELAND LTD CLARE ELSEVIER HOUSE, BROOKVALE PLAZA, EAST
PARK SHANNON, CO, CLARE, 00000, IRELAND 0376-8716 1879-0046 DRUG ALCOHOL
DEPEN Drug Alcohol Depend. JUL 1 2016 164 89
96 10.1016/j.drugalcdep.2016.04.034 8 Substance
Abuse; Psychiatry Substance Abuse; Psychiatry DP4MA WOS:000378468800012
27173662 Green Accepted 2019-09-25
J Elison, S; Weston, S; Dugdale, S; Ward, J; Davies, G
Elison, Sarah; Weston, Samantha; Dugdale, Stephanie; Ward, Jonathan; Davies,
Glyn A Qualitative Exploration of UK Prisoners' Experiences of
Substance Misuse and Mental Health Difficulties, and the Breaking Free Health and
Justice Interventions JOURNAL OF DRUG ISSUES English Article
computer-assisted therapy; substance misuse; prisons
CONTINUING CARE INTERVENTIONS; USE DISORDERS; SELF-MEDICATION; DRUG-USE;
EMOTION DYSREGULATION; DUAL DIAGNOSIS; ALCOHOL; ABUSE; CHILDHOOD; SYMPTOMS This
qualitative study explored prisoners' lived experiences of substance use and mental
health difficulties and aimed to examine perceived links between these two areas
and how they might be associated with recovery during engagement with the Breaking
Free Health and Justice (BFHJ) treatment programs. Interviews were conducted with
32 prisoners receiving treatment for substance use in North-West England. Emerging
from prisoners' interviews were themes relating to difficult life experiences from
childhood into adulthood, how these experiences played a role in the emergence of
their multiple and complex difficulties, their treatment experiences, and how their
current involvement with the criminal justice system acted as a catalyst for
positive change, including engagement with the BFHJ programs. This study identified
the roles of substance use and mental health difficulties in the lives of
participants, identified how their multiple and complex difficulties might be
addressed, and provided insights into prisoners' interpretations of their life
experiences. [Elison, Sarah] Breaking Free Grp, Res, Ongoing Program Res
Efficacy Breaking Free Hlth &, Manchester M3 4JB, Lancs, England; [Dugdale,
Stephanie; Ward, Jonathan; Davies, Glyn] Breaking Free Grp, 274 Deansgate,
Manchester M3 4JB, Lancs, England; [Weston, Samantha] Keele Univ, Criminol, Keele
ST5 5BG, Staffs, England Elison, S (reprint author), Breaking Free Grp, 274
Deansgate, Manchester M3 4JB, Lancs, England. selison@breakingfreegroup.com
Dugdale, Stephanie/0000-0001-7544-7454 Anda RF, 2006, EUR ARCH
PSY CLIN N, V256, P174, DOI 10.1007/s00406-005-0624-4; Andrews DA, 2006, CRIME
DELINQUENCY, V52, P7, DOI 10.1177/0011128705281756; Beck A. T., 2001, COGNITIVE
THERAPY SU; Beck J. S, 2011, COGNITIVE BEHAV THER; Best D, 2010, POTENTIAL RECOVERY
C; Boden JM, 2011, ADDICTION, V106, P906, DOI 10.1111/j.1360-0443.2010.03351.x;
Bolton JM, 2009, J AFFECT DISORDERS, V115, P367, DOI 10.1016/j.jad.2008.10.003;
Brady KT, 2005, AM J PSYCHIAT, V162, P1483, DOI 10.1176/appi.ajp.162.8.1483; Braun
V, 2006, QUALITATIVE RES PSYC, V3, P77, DOI [DOI 10.1191/1478088706QP0630A, DOI
10.1191/1478088706QP063OA]; Brookman F., 2014, LINKS MEPHEDRONE USE; Budd T., 2005,
LEVELS SELF REPORT O; Burns Jonathan K, 2013, Front Psychiatry, V4, P128, DOI
10.3389/fpsyt.2013.00128; Butler T, 2011, DRUG ALCOHOL REV, V30, P188, DOI
10.1111/j.1465-3362.2010.00216.x; Butzin CA, 2005, J SUBST ABUSE TREAT, V28, P351,
DOI 10.1016/j.jsat.2005.02.009; Butzin CA, 2006, J CRIM JUST, V34, P557, DOI
10.1016/j.jcrimjus.2006.09.010; Chen CY, 2009, ADDICT BEHAV, V34, P319, DOI
10.1016/j.addbeh.2008.10.021; Cloud W, 2008, SUBST USE MISUSE, V43, P1971, DOI
10.1080/10826080802289762; Davies G, 2015, SUBST ABUSE TREAT PR, V10, DOI
10.1186/1747-597X-10-2; Deas D, 2006, J CLIN PSYCHIAT, V67, P18, DOI
10.4088/JCP.0706e02; Department of Health (DoH), 2009, BRADL REP LORD BRADL; Drake
RE, 2007, WORLD PSYCHIATRY, V6, P131; Elison S, 2013, J SUBST USE, V19, P1; ELISON
S, 2015, ALCOHOLISM TREATMENT, V33, P185, DOI DOI 10.1080/07347324.2015.1023057;
Elison S, 2015, DRUGS ED PREVENTION, P1; Elison S, 2015, JMIR MENT HEALTH, V2, DOI
10.2196/mental.4355; Elison S, 2014, ADV DUAL DIAGN, V7, P52, DOI 10.1108/ADD-11-
2013-0025; Elison S, 2014, DRUGS ALCOHOL TODAY, V14, P207, DOI 10.1108/DAT-05-2014-
0025; Enoch MA, 2011, PSYCHOPHARMACOLOGY, V214, P17, DOI 10.1007/s00213-010-1916-6;
Fazel S, 2006, ADDICTION, V101, P181, DOI 10.1111/j.1360-0443.2006.01316.x; GARDNER
G, 2001, QUALITATIVE RES, V1, P185; Gilchrist E., 2003, FINDINGS 217 DOMESTI;
Grella CE, 2005, PSYCHOL ADDICT BEHAV, V19, P43, DOI 10.1037/0893-164X.19.1.43;
Guest C, 2011, ADV DUAL DIAGN, V4, P162, DOI 10.1108/17570971111197175; Hall W.,
1996, BOCSAR NSW CRIME JUS; Hamilton I, 2014, ADV DUAL DIAGN, V7, P118, DOI
10.1108/ADD-05-2014-0013; Hibell B, 2011, 2011 ESPAD REPORT SU; Hogan L, 2015, J
GROUPS ADDICT RECO, V10, P125, DOI 10.1080/1556035X.2015.1034821; Hughes E, 2008,
BMC PSYCHIATRY, V8, DOI 10.1186/1471-244X-8-12; Johnson RJ, 2006, CHILD ABUSE
NEGLECT, V30, P75, DOI 10.1016/j.chiabu.2005.08.013; Josselson R., 2011, 5 WAYS
DOING QUALITA, P224; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI
10.3109/10673229709030550; Kotov R, 2010, PSYCHOL BULL, V136, P768, DOI
10.1037/a0020327; Marlatt G., 2010, MINDFULNESS THERAPEU, P107; Mathews M., 2013,
SCHIZOPHRENIA ACUTE; Mckay JR, 2009, J SUBST ABUSE TREAT, V36, P131, DOI
10.1016/j.jsat.2008.10.004; McKay JR, 2001, EVALUATION REV, V25, P211, DOI
10.1177/0193841X0102500205; McLaren JA, 2010, INT J DRUG POLICY, V21, P10, DOI
10.1016/j.drugpo.2009.09.001; McMurran M., 2006, OFFENDING BEHAV PROG, P179;
McSweeney T., 2006, CRIMINOLOGY CRIMINAL, V6, P107, DOI DOI
10.1177/1748895806060669; Moore THM, 2007, LANCET, V370, P319, DOI 10.1016/S0140-
6736(07)61162-3; Mumola C. J, 2006, DRUG USE DEPENDENCE; National Treatment Agency
for Substance Misuse, 2010, ROUT REC PSYCH INT D; National Treatment Agency for
Substance Misuse, 2009, BREAK LINK ROL DRUG; Neale J, 2005, ADDICTION, V100, P1584,
DOI 10.1111/j.1360-0443.2005.01230.x; Nunkoosing K, 2005, QUAL HEALTH RES, V15,
P698, DOI 10.1177/1049732304273903; Parker H, 2002, SOCIOLOGY, V36, P941, DOI
10.1177/003803850203600408; Parker H, 2005, ADDICT RES THEORY, V13, P205, DOI
10.1080/16066350500053703; Peleg-Oren N, 2006, J SOC WORK PRACT ADD, V6, P49, DOI
10.1300/J160v06n01_03; Popovici I, 2008, EVALUATION REV, V32, P547, DOI
10.1177/0193841X08316311; Prison Reform Trust, 2011, BROML BRIEF PRIS FAC; Robinson
J, 2011, ARCH GEN PSYCHIAT, V68, P800, DOI 10.1001/archgenpsychiatry.2011.75;
Rosengard A., 2007, LIT REV MULTIPLE COM; Rutherford M, 2009, PUBLIC HEALTH, V123,
P415, DOI 10.1016/j.puhe.2009.04.006; Seddon T., 2010, IMPLICATIONS RES POL, P146;
SIGURDSSON JF, 1995, NORD J PSYCHIAT, V49, P33, DOI 10.3109/08039489509011881;
Singleton N., 1999, SUBSTANCE MISUSE PRI; Tiet QQ, 2007, ALCOHOL CLIN EXP RES, V31,
P513, DOI 10.1111/j.1530-0277.2007.00336.x; Torrens M, 2015, COMORBIDITY SUBSTANC;
Tripp JC, 2015, J DUAL DIAGN, V11, P107, DOI 10.1080/15504263.2015.1025013; Vinkers
DJ, 2011, CRIM BEHAV MENT HEAL, V21, P307, DOI 10.1002/cbm.819; Wahlstrom LC, 2015,
J DUAL DIAGN, V11, P118, DOI 10.1080/15504263.2015.1025026; Whiteley C., 2012,
CONTRIBUTION CLIN PS; Wickrama KAS, 2005, J GERONTOL B-PSYCHOL, V60, P125, DOI
10.1093/geronb/60.Special_Issue_2.S125; Wiesner M, 2005, DEV PSYCHOPATHOL, V17,
P251, DOI 10.1017/S095457905050133; Williams I, 2009, HEALTH SOC CARE COMM, V17,
P573, DOI 10.1111/j.1365-2524.2009.00857.x; Williams L, 2013, CHANGING LIVES CHANG;
World Health Organization (WHO), 2007, HLTH PRIS WHO GUID E; Young S, 2011, J
PSYCHOPHARMACOL, V25, P1524, DOI 10.1177/0269881110370502 78 7 7 0
23 SAGE PUBLICATIONS INC THOUSAND OAKS 2455 TELLER RD, THOUSAND
OAKS, CA 91320 USA 0022-0426 1945-1369 J DRUG ISSUES J. Drug
Issues JUL 2016 46 3 198 215
10.1177/0022042616630013 18 Substance Abuse Substance
Abuse DO5IL WOS:000377816700003 Green Accepted 2019-09-25
J Sarvet, AL; Hasin, D Sarvet, Aaron L.; Hasin, Deborah
The natural history of substance use disorders CURRENT OPINION IN
PSYCHIATRY English Editorial Material
incidence; persistence; relapse; remission; substance use disorder
ALCOHOL-USE DISORDERS; CANNABIS USE DISORDERS; NATIONAL EPIDEMIOLOGIC SURVEY;
SELF-MEDICATION HYPOTHESIS; 3-YEAR FOLLOW-UP; MAJOR DEPRESSION; NICOTINE
DEPENDENCE; MENTAL-DISORDERS; 1ST DRINKING; DRUG-USE Purpose of review Illicit
drugs, alcohol, and tobacco use disorders contribute substantially to the global
burden of disease. Knowledge about the major elements of the natural history of
substance use disorders (incidence, remission, persistence, and relapse) is crucial
to a broader understanding of the course and outcomes of substance use disorders.
Recent findings Prospective cohort studies in nonclinical samples indicate that
externalizing psychopathology in earlier life, including early disordered substance
use, delinquency, and personality disorders, are related to substance use disorders
later in life and chronic course. Externalizing psychopathology may be initiated by
early adverse experiences, for example, childhood maltreatment and stressful life
events. After controlling for confounders, 'age at first use' as a causal factor
for alcohol use disorder later in life and the 'drug substitution' hypothesis are
not supported in general population data. Summary Future research should focus on
elaborating the causal framework that leads to the development and persistence of
severe substance use disorders, with an emphasis on identifying modifiable factors
for intervention by policy makers or health professionals. More research is needed
on the natural history of substance use disorders in low-income and middle-income
countries. [Sarvet, Aaron L.; Hasin, Deborah] Columbia Univ, New York State
Psychiat Inst, New York, NY 10032 USA; [Hasin, Deborah] Columbia Univ, Dept
Psychiat, 1051 Riverside Dr 123, New York, NY 10032 USA; [Hasin, Deborah] Columbia
Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10032 USA Hasin, D
(reprint author), Columbia Univ, Dept Psychiat, 1051 Riverside Dr 123, New York, NY
10032 USA. deborah.hasin@gmail.com New York State Psychiatric
Institute; Member Companies of the Opioid PMR Consortium; [R01DA034244];
[T32DA031099]; [R01DA018652]; [R01AA023163]; [R01AA025309] This work was
funded by grant R01DA034244 (D.H.) and the New York State Psychiatric Institute
(D.H.). D.H. is currently Principal Investigator of the following grants:
T32DA031099, R01DA018652, R01AA023163, and R01AA025309. She is also Principal
Investigator of NCT02660619, a contract funded by Member Companies of the Opioid
PMR Consortium. Agusti AGN, 2003, EUR RESPIR J, V21, P347, DOI
10.1183/09031936.03.00405703; Beseler CL, 2008, ALCOHOL CLIN EXP RES, V32, P607,
DOI 10.1111/j.1530-0277.2008.00619.x; Bijl RV, 2002, SOC PSYCH PSYCH EPID, V37,
P372, DOI 10.1007/s00127-002-0566-3; Blanco C., 2016, JAMA PSYCHIAT; Blanco C,
2014, JAMA PSYCHIAT, V71, P1246, DOI 10.1001/jamapsychiatry.2014.1206; Boden JM,
2014, DRUG ALCOHOL DEPEN, V142, P154, DOI 10.1016/j.drugalcdep.2014.06.010; Bolton
JM, 2009, J AFFECT DISORDERS, V115, P367, DOI 10.1016/j.jad.2008.10.003; Bonn-
Miller MO, 2009, ADDICT BEHAV, V34, P782, DOI 10.1016/j.addbeh.2009.04.009; Brady
KT, 2005, AM J PSYCHIAT, V162, P1483, DOI 10.1176/appi.ajp.162.8.1483; Briere FN,
2014, COMPR PSYCHIAT, V55, P526, DOI 10.1016/j.comppsych.2013.10.007; Brook JS,
2015, ADDICT BEHAV, V42, P14, DOI 10.1016/j.addbeh.2014.10.038; Bulloch A, 2012,
DEPRESS ANXIETY, V29, P1058, DOI 10.1002/da.22001; Calabria B, 2010, ADDICT BEHAV,
V35, P741, DOI 10.1016/j.addbeh.2010.03.019; Carpenter KM, 1998, ADDICT BEHAV, V23,
P41, DOI 10.1016/S0306-4603(97)00015-4; Chen WJ, 1997, PSYCHOL MED, V27, P1363, DOI
10.1017/S0033291797005527; COOPER ML, 1995, J PERS SOC PSYCHOL, V69, P990, DOI
10.1037/0022-3514.69.5.990; Crum RM, 2005, J STUD ALCOHOL, V66, P795, DOI
10.15288/jsa.2005.66.795; Dawson DA, 2007, ALCOHOL CLIN EXP RES, V31, P2036, DOI
10.1111/j.1530-0277.2007.00536.x; Dawson DA, 2012, ALCOHOL CLIN EXP RES, V36,
P1268, DOI 10.1111/j.1530-0277.2011.01729.x; Duncan SC, 2015, DRUG ALCOHOL DEPEN,
V149, P80, DOI 10.1016/j.drugalcdep.2015.01.025; Eaton NR, 2011, PSYCHOL MED, V41,
P1041, DOI 10.1017/S0033291710001662; EATON WW, 1989, ACTA PSYCHIAT SCAND, V79,
P163, DOI 10.1111/j.1600-0447.1989.tb08584.x; Edens EL, 2008, DRUG ALCOHOL DEPEN,
V93, P1, DOI 10.1016/j.drugalcdep.2007.08.013; Elliott JC, 2015, ADDICTION; Elliott
JC, 2014, ADDICTION, V109, P842, DOI 10.1111/add.12477; Farmer RF, 2015, PSYCHOL
MED, V45, P63, DOI 10.1017/S003329171400107X; Farmer RF, 2016, PSYCHOL ADDICT
BEHAV, V30, P82, DOI 10.1037/adb0000151; Farmer RF, 2015, PSYCHOL ADDICT BEHAV,
V29, P541, DOI 10.1037/adb0000059; Feingold D, 2015, ADDICTION, V110, P1963, DOI
10.1111/add.13071; Fenton MC, 2012, ADDICTION, V107, P599, DOI 10.1111/j.1360-
0443.2011.03638.x; Fergusson DM, 2008, DRUG ALCOHOL DEPEN, V96, P165, DOI
10.1016/j.drugalcdep.2008.03.003; Fergusson DM, 2007, DRUG ALCOHOL DEPEN, V88,
pS14, DOI 10.1016/j.drugalcdep.2006.12.011; Fergusson DM, 2009, ARCH GEN PSYCHIAT,
V66, P260, DOI 10.1001/archgenpsychiatry.2008.543; Fischer JA, 2015, DRUG ALCOHOL
REV, V34, P388, DOI 10.1111/dar.12227; Flensborg-Madsen T, 2009, COMPR PSYCHIAT,
V50, P307, DOI 10.1016/j.comppsych.2008.09.003; Florez-Salamanca L, 2013, DRUG
ALCOHOL DEPEN, V132, P127, DOI 10.1016/j.drugalcdep.2013.01.013; Gilder DA, 2007, J
ADDICT DIS, V26, P23, DOI 10.1300/J069v26n04_04; Gilman SE, 2001, DRUG ALCOHOL
DEPEN, V63, P277, DOI 10.1016/S0376-8716(00)00216-7; Godley MD, 2005, PSYCHOL
ADDICT BEHAV, V19, P62, DOI 10.1037/0893-164X.19.1.62; Goodwin RD, 2014, NICOTINE
TOB RES, V16, P1606, DOI 10.1093/ntr/ntu115; Goodwin RD, 2011, DRUG ALCOHOL DEPEN,
V118, P127, DOI 10.1016/j.drugalcdep.2011.03.010; Gramenzi A, 2006, ALIMENT PHARM
THER, V24, P1151, DOI 10.1111/j.1365-2036.2006.03110.x; Grant BF, 2009, MOL
PSYCHIATR, V14, P1051, DOI 10.1038/mp.2008.41; Grant BF, 1997, J SUBST ABUSE, V9,
P103, DOI 10.1016/S0899-3289(97)90009-2; Grief SN, 2011, PRIMARY CARE, V38, P23,
DOI 10.1016/j.pop.2010.11.003; Guttmannova K, 2011, J STUD ALCOHOL DRUGS, V72,
P221, DOI 10.15288/jsad.2011.72.221; Hasin D, 2011, ARCH GEN PSYCHIAT, V68, P1158,
DOI 10.1001/archgenpsychiatry.2011.78; Hasin DS, 2002, ARCH GEN PSYCHIAT, V59,
P794, DOI 10.1001/archpsyc.59.9.794; HASIN DS, 1990, AM J PSYCHIAT, V147, P1537;
Kendler KS, 2014, PSYCHOL MED, V44, P647, DOI 10.1017/S0033291713000585; KHANTZIAN
EJ, 1985, AM J PSYCHIAT, V142, P1259; Krueger RF, 1999, ARCH GEN PSYCHIAT, V56,
P921, DOI 10.1001/archpsyc.56.10.921; Kuo PH, 2006, PSYCHOL MED, V36, P1153, DOI
10.1017/S0033291706007860; LADER M, 1972, BRIT J PSYCHIAT, V121, P481, DOI
10.1192/bjp.121.5.481; Li TK, 2008, J GASTROEN HEPATOL, V23, pS2, DOI
10.1111/j.1440-1746.2007.05298.x; Mackenzie CS, 2014, AM J GERIAT PSYCHIAT, V22,
P854, DOI 10.1016/j.jagp.2013.02.007; Maimaris W, 2014, J EPIDEMIOL COMMUN H, V68,
P268, DOI 10.1136/jech-2013-203402; Markou A, 1998, NEUROPSYCHOPHARMACOL, V18,
P135, DOI 10.1016/S0893-133X(97)00113-9; McCarty CA, 2009, GEN HOSP PSYCHIAT, V31,
P442, DOI 10.1016/j.genhosppsych.2009.05.013; McEwen BS, 2000,
NEUROPSYCHOPHARMACOL, V22, P108, DOI 10.1016/S0893-133X(99)00129-3; Moore BA, 2003,
J SUBST ABUSE TREAT, V25, P85, DOI 10.1016/S0740-5472(03)00083-7; Newman SC, 1998,
J PSYCHIATR RES, V32, P273, DOI 10.1016/S0022-3956(98)00011-9; Newton-Howes G,
2016, ADDICTION, V111, P637, DOI 10.1111/add.13230; Pacek LR, 2013, J AFFECT
DISORDERS, V148, P188, DOI 10.1016/j.jad.2012.11.059; Pedersen W, 1998, J STUD
ALCOHOL, V59, P32, DOI 10.15288/jsa.1998.59.32; Perkonigg A, 2008, ADDICTION, V103,
P439, DOI 10.1111/j.1360-0443.2007.02064.x; Prescott CA, 1999, ALCOHOL CLIN EXP
RES, V23, P101, DOI 10.1111/j.1530-0277.1999.tb04029.x; QUITKIN FM, 1972, ARCH GEN
PSYCHIAT, V27, P159; Rohde P, 2001, J AM ACAD CHILD PSY, V40, P83, DOI
10.1097/00004583-200101000-00020; Schuckit MA, 2011, DRUG ALCOHOL DEPEN, V113, P21,
DOI 10.1016/j.drugalcdep.2010.06.017; Schutte KK, 2001, J STUD ALCOHOL, V62, P322,
DOI 10.15288/jsa.2001.62.322; Tuithof M, 2014, DRUG ALCOHOL DEPEN, V140, P85, DOI
10.1016/j.drugalcdep.2014.03.035; United Nations Office on Drugs and Crime, 2015,
WORLD DRUG REP 2015; van der Pol P, 2015, EUR ADDICT RES, V21, P279, DOI
10.1159/000377625; Volkow ND, 2016, NEW ENGL J MED, V374, P363, DOI
10.1056/NEJMra1511480; von Sydow K, 2001, DRUG ALCOHOL DEPEN, V64, P347, DOI
10.1016/S0376-8716(01)00137-5; Warner LA, 2003, SUBST USE MISUSE, V38, P1983, DOI
10.1081/JA-120025123; Weinberger AH, 2015, ALCOHOL CLIN EXP RES, V39, P1989, DOI
10.1111/acer.12840; White Aaron M, 2004, Subst Abus, V25, P53, DOI
10.1300/J465v25n01_08; World Health Organization, 2008, GLOB BURD DIS 2004 U 80
8 9 0 19 LIPPINCOTT WILLIAMS & WILKINS PHILADELPHIA TWO
COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA 0951-7367 1473-6578
CURR OPIN PSYCHIATR Curr. Opin. Psychiatr. JUL 2016 29 4
 250 257 10.1097/YCO.0000000000000257 8
Psychiatry Psychiatry DN5LF WOS:000377108300004 27153126 Green
Accepted 2019-09-25
J Blumenthal, H; Ham, LS; Cloutier, RM; Bacon, AK; Douglas, ME
Blumenthal, Heidemarie; Ham, Lindsay S.; Cloutier, Renee M.; Bacon, Amy K.;
Douglas, Megan E. Social anxiety, disengagement coping, and alcohol-use
behaviors among adolescents ANXIETY STRESS AND COPING English
Article Alcohol use; coping; social
anxiety; adolescence USE DISORDERS; DRINKING MOTIVES; DSM-IV; DEVELOPMENTAL-
CHANGES; SUBSTANCE USE; ANXIOUS INDIVIDUALS; SELF-MEDICATION; NEGATIVE AFFECT;
RISK-FACTOR; STRESS Background and Objectives: Although research indicates that
social anxiety (SA) is associated with problematic drinking, few studies have
examined these relations among adolescents, and all alcohol-related assessments
have been retrospective. Socially anxious youth may be at risk to drink in an
effort to manage negative affectivity, and a proclivity toward disengagement coping
(e.g. avoidance of aversive stimuli) may enhance the desire to drink and learning
of coping-related use. Design: Adding to research addressing adolescent SA and
alcohol use, the current study examined (1) proportional drinking motives (subscale
scores divided by the sum of all subscales), (2) current desire to drink in a
socially relevant environment (introduction to research laboratory), and (3) the
indirect effect of retrospectively reported disengagement in social stress contexts
on proportional coping motives and desire to drink. Method: Participants were 70
community-recruited adolescents who reported recent alcohol use. Level of SA,
disengagement coping, drinking motives, and desire to drink following laboratory
introduction were assessed. Results: Proclivity toward disengagement in prior
socially stressful contexts accounted for significant variance in the positive
relations between SA and both proportional coping motives and current desire to
drink. Conclusions: These data complement existing work. Continued efforts in
building developmentally sensitive models of alcohol use are needed. [Blumenthal,
Heidemarie; Cloutier, Renee M.; Douglas, Megan E.] Univ N Texas, Dept Psychol, Teen
Stress & Alcohol Res Lab, Denton, TX 76203 USA; [Ham, Lindsay S.] Univ Arkansas,
Dept Psychol Sci, Fayetteville, AR 72701 USA; [Bacon, Amy K.] Bradley Univ, Dept
Psychol, Peoria, IL 61625 USA Blumenthal, H (reprint author), Univ N Texas, Dept
Psychol, Teen Stress & Alcohol Res Lab, Denton, TX 76203 USA.
heidemarie.blumenthal@unt.edu Cloutier, Renee/L-3601-2019; Cloutier, Renee
M/D-2249-2019 Cloutier, Renee/0000-0003-1795-9149; Cloutier, Renee M/0000-0003-
1795-9149; Douglas, Megan/0000-0002-1522-7991 National Institute on Alcohol Abuse
and Alcoholism National Research Service Award [F31 AA018589] This project was
partially supported by a National Institute on Alcohol Abuse and Alcoholism
National Research Service Award (F31 AA018589) awarded to the first author. Arnett
JJ, 1999, AM PSYCHOL, V54, P317, DOI 10.1037/0003-066X.54.5.317; Battista Susan R,
2010, Curr Drug Abuse Rev, V3, P3; Blumenthal Heidemarie, 2011, J Exp Psychopathol,
V2, P318; Blumenthal H, 2010, PSYCHOL ADDICT BEHAV, V24, P529, DOI
10.1037/a0019794; Buckner JD, 2008, J PSYCHIATR RES, V42, P230, DOI
10.1016/j.jpsychires.2007.01.002; Buckner JD, 2006, BEHAV THER, V37, P381, DOI
10.1016/j.beth.2006.02.007; Buckner JD, 2013, DEPRESS ANXIETY, V30, P276, DOI
10.1002/da.22032; Buckner JD, 2010, PSYCHOL ADDICT BEHAV, V24, P640, DOI
10.1037/a0020968; Buckner JD, 2011, ADDICT BEHAV, V36, P129, DOI
10.1016/j.addbeh.2010.08.015; Buckner JD, 2009, DRUG ALCOHOL DEPEN, V100, P128, DOI
10.1016/j.drugalcdep.2008.09.018; BuskeKirschbaum A, 1997, PSYCHOSOM MED, V59,
P419, DOI 10.1097/00006842-199707000-00012; Carpenter KM, 1999, J STUD ALCOHOL,
V60, P694, DOI 10.15288/jsa.1999.60.694; Carpenter KM, 1998, ADDICT BEHAV, V23,
P41, DOI 10.1016/S0306-4603(97)00015-4; Carrigan MH, 2003, ADDICT BEHAV, V28, P269,
DOI 10.1016/S0306-4603(01)00235-0; Castellanos N, 2006, J MENTAL HLTH, V15, P645,
DOI DOI 10.1080/09638230600998912; Chorpita BF, 2000, BEHAV RES THER, V38, P835,
DOI 10.1016/S0005-7967(99)00130-8; CHRISTIANSEN BA, 1982, J CONSULT CLIN PSYCH,
V50, P336, DOI 10.1037/0022-006X.50.3.336; Chung T, 2004, J STUD ALCOHOL, V65,
P105, DOI 10.15288/jsa.2004.65.105; CLARK DB, 1995, PSYCHIATR SERV, V46, P618;
Cludius B, 2013, PSYCHOL ADDICT BEHAV, V27, P806, DOI 10.1037/a0032295; Compas BE,
2001, PSYCHOL BULL, V127, P87, DOI 10.1037//0033-2909.127.1.87; Connor-Smith JK,
2002, COGNITIVE THER RES, V26, P39, DOI 10.1023/A:1013889504101; Connor-Smith JK,
2000, J CONSULT CLIN PSYCH, V68, P976, DOI 10.1037/0022-006X.68.6.976; Conrod PJ,
2006, J CLIN CHILD ADOLESC, V35, P550, DOI 10.1207/s15374424jccp3504_6; Conrod PJ,
2011, J CONSULT CLIN PSYCH, V79, P296, DOI 10.1037/a0022997; Cooper M. L., 1994,
PSYCHOL ASSESSMENT, V6, P117, DOI [DOI 10.1037/1040-3590.6.2.117, 10.1037/1040-
3590.6.2.117]; Cooper ML, 2008, J ABNORM PSYCHOL, V117, P485, DOI 10.1037/a0012592;
COOPER ML, 1995, J PERS SOC PSYCHOL, V69, P990, DOI 10.1037/0022-3514.69.5.990;
Deas D, 2000, ALCOHOL CLIN EXP RES, V24, P232, DOI 10.1111/j.1530-
0277.2000.tb04596.x; Duka T, 1999, PHARMACOL BIOCHEM BE, V64, P301, DOI
10.1016/S0091-3057(99)00080-5; ELKIND D, 1967, CHILD DEV, V38, P1025, DOI
10.2307/1127100; Essau CA, 1999, BEHAV RES THER, V37, P831, DOI 10.1016/S0005-
7967(98)00179-X; Gottfredson Denise C, 2003, Prev Sci, V4, P27, DOI
10.1023/A:1021782710278; Gunnar MR, 2009, DEV PSYCHOPATHOL, V21, P69, DOI
10.1017/S0954579409000054; Ham LS, 2007, J ANXIETY DISORD, V21, P991, DOI
10.1016/j.janxdis.2006.10.014; Ham Lindsay S., 2009, Cognitive Behaviour Therapy,
V38, P133, DOI 10.1080/16506070802610889; Hayes AF, 2008, INTRO MEDIATION MODE;
HUSELID RF, 1992, J HEALTH SOC BEHAV, V33, P348, DOI 10.2307/2137313; HUSSONG AM,
1994, J STUD ALCOHOL, V55, P707, DOI 10.15288/jsa.1994.55.707; Jackson KM, 2008,
PSYCHOL ADDICT BEHAV, V22, P68, DOI 10.1037/0893-164X.22.1.68; Kenkel D., 2004,
REDUCING UNDERAGE DR, P251; Kraemer HC, 2000, AM J PSYCHIAT, V157, P163, DOI
10.1176/appi.ajp.157.2.163; Kuntsche E, 2005, CLIN PSYCHOL REV, V25, P841, DOI
10.1016/j.cpr.2005.06.002; Kuntsche E, 2008, J STUD ALCOHOL DRUGS, V69, P388, DOI
10.15288/jsad.2008.69.388; Kushner MG, 2000, CLIN PSYCHOL REV, V20, P149, DOI
10.1016/S0272-7358(99)00027-6; Labouvie E., 2002, STAGES PATHWAYS DRUG, P19, DOI
[10.1017/CBO9780511499777.004, DOI 10.1017/CBO9780511499777.004]; Leen-Feldner EW,
2007, BEHAV MODIF, V31, P8, DOI 10.1177/0145445506295058; Lewis MA, 2008, PSYCHOL
ADDICT BEHAV, V22, P58, DOI 10.1037/0893-164X.22.1.58; Love A, 1998, ADDICTION,
V93, P1091, DOI 10.1046/j.1360-0443.1998.937109113.x; Lowman C, 2000, ADDICTION,
V95, pS45; Masten AS, 2009, ALCOHOL RES HEALTH, V32, P3; Moberg D. P., 2000, J STUD
ALCOHOL, V40, P291; Morris EP, 2005, CLIN PSYCHOL REV, V25, P734, DOI
10.1016/j.cpr.2005.05.004; National Institute on Alcohol Abuse and Alcoholism &
Office of Research on Minority Health, 2000, NIH PUBLICATION; Neighbors C, 2007,
ADDICT BEHAV, V32, P2667, DOI 10.1016/j.addbeh.2007.05.010; Nelson EC, 2000,
PSYCHOL MED, V30, P797, DOI 10.1017/S0033291799002275; Nisbett R, 1980, HUMAN
INFERENCE STRA; O'Grady MA, 2011, J SOC CLIN PSYCHOL, V30, P599, DOI
10.1521/jscp.2011.30.6.599; Ollendick TH, 2002, BIOL PSYCHIAT, V51, P44, DOI
10.1016/S0006-3223(01)01305-1; Ottenbreit ND, 2014, BEHAV RES THER, V56, P82, DOI
10.1016/j.brat.2014.03.005; Plasencia ML, 2011, BEHAV RES THER, V49, P665, DOI
10.1016/j.brat.2011.07.005; Preacher KJ, 2008, BEHAV RES METHODS, V40, P879, DOI
10.3758/BRM.40.3.879; Rohde P, 2001, J AM ACAD CHILD PSY, V40, P83, DOI
10.1097/00004583-200101000-00020; Sayette MA, 2000, ADDICTION, V95, pS189; Sayette
MA, 1999, ALCOHOL RES HEALTH, V23, P250; Schell TL, 2005, PSYCHOL ADDICT BEHAV,
V19, P217, DOI 10.1037/0893-164X.19.2.217; Schulze D, 2000, ADDICTION, V95, P1015,
DOI 10.1046/j.1360-0443.2000.95710154.x; Schwartz PD, 2008, ADOLESCENCE, V43, P441;
Silverman WK, 2001, J AM ACAD CHILD PSY, V40, P937, DOI 10.1097/00004583-200108000-
00016; Silverman WK, 1996, ANXIETY DISORDERS IN; Sobell L. C., 1996, TIMELINE
FOLLOWBACK; Stroud LR, 2000, ANN BEHAV MED, V22, P204, DOI 10.1007/BF02895115;
Tapert SF, 2004, ALCOHOL RES HEALTH, V28, P205; Tapert SF, 2003, ARCH GEN PSYCHIAT,
V60, P727, DOI 10.1001/archpsyc.60.7.727; Thomas S., 2013, WILEY BLACKWELL HDB, DOI
[10.1002/9781118384404.ch15, DOI 10.1002/9781118384404.CH15]; Thomas SE, 2003,
ALCOHOL CLIN EXP RES, V27, P1937, DOI 10.1097/01.ALC.0000100942.30743.8C; Thomas
SE, 2008, ALCOHOL CLIN EXP RES, V32, P77, DOI 10.1111/j.1530-0277.2007.00546.x;
Tomlinson KL, 2012, ADDICT BEHAV, V37, P179, DOI 10.1016/j.addbeh.2011.09.016;
Torres JM, 2004, PSYCHOPHARMACOLOGY, V172, P352, DOI 10.1007/s00213-003-1662-0;
Velting ON, 2001, J CHILD PSYCHOL PSYC, V42, P127, DOI 10.1111/1469-7610.00705;
VITALIANO PP, 1987, J BEHAV MED, V10, P1, DOI 10.1007/BF00845124; Walker EF, 2001,
DEV PSYCHOPATHOL, V13, P721, DOI 10.1017/S0954579401003169; WEBER MD, 1989, ADDICT
BEHAV, V14, P399, DOI 10.1016/0306-4603(89)90027-0; Windle M, 1996, J STUD ALCOHOL,
V57, P627, DOI 10.15288/jsa.1996.57.627; Windle M, 2012, ADDICT BEHAV, V37, P1003,
DOI 10.1016/j.addbeh.2012.04.009; Winters KC, 2003, ASSESSING ALCOHOL PR, P101;
Wittchen HU, 2008, INT J METH PSYCH RES, V17, pS16, DOI 10.1002/mpr.254; Zimmerman
MA, 2003, J RES ADOLESCENCE, V13, P185, DOI 10.1111/1532-7795.1302003; Zimmermann
P, 2003, PSYCHOL MED, V33, P1211, DOI 10.1017/S0033291703008158; Zvolensky M. J.,
2001, REV GEN PSYCHOL, V5, P371, DOI DOI 10.1037/1089-2680.5.4.371 90 8
8 2 19 TAYLOR & FRANCIS LTD ABINGDON 4 PARK SQUARE, MILTON
PARK, ABINGDON OX14 4RN, OXON, ENGLAND 1061-5806 1477-2205 ANXIETY
STRESS COPIN Anxiety Stress Coping JUL 2016 29 4
432 446 10.1080/10615806.2015.1058366 15
Neurosciences; Psychiatry; Psychology, Multidisciplinary Neurosciences &
Neurology; Psychiatry; Psychology DK5KW WOS:000374959800007 26235528 Green
Accepted 2019-09-25
J Ertl, V; Saile, R; Neuner, F; Catani, C Ertl, Verena;
Saile, Regina; Neuner, Frank; Catani, Claudia Drinking to ease the
burden: a cross-sectional study on trauma, alcohol abuse and psychopathology in a
post-conflict context BMC PSYCHIATRY English Article
Trauma; Addiction; Alcohol; Substance abuse; Self-
medication; Depression; PTSD; Mental health; Conflict; War POSTTRAUMATIC-STRESS-
DISORDER; SUBSTANCE USE DISORDER; INTERNALLY DISPLACED PERSONS; SELF-MEDICATION
HYPOTHESIS; HOPKINS SYMPTOM CHECKLIST; INTIMATE PARTNER VIOLENCE; MAJOR DEPRESSIVE
DISORDER; MENTAL-HEALTH SYMPTOMS; CHILDHOOD MALTREATMENT; FAMILY VIOLENCE
Background: It is likely that alcohol use and abuse increase during and after
violent conflicts. The most prominent explanation of this phenomenon has been
referred to as self-medication hypothesis. It predicts that psychotropic substances
are consumed to deal with conflict-related psychic strains and trauma. In northern
Uganda, a region that has been affected by a devastating civil war and is
characterized by high levels of alcohol abuse we examined the associations between
war-trauma, childhood maltreatment and problems related to alcohol use. Deducing
from the self-medication hypothesis we assumed alcohol consumption moderates the
relationship between trauma-exposure and psychopathology. Methods: A cross-
sectional epidemiological survey targeting war-affected families in post-conflict
northern Uganda included data of male (n = 304) and female (n = 365) guardians. We
used standardized questionnaires in an interview format to collect data on the
guardians' socio-demography, trauma-exposure, alcohol consumption and symptoms of
alcohol abuse, PTSD and depression. Results: Symptoms of current alcohol use
disorders were present in 46 % of the male and 1 % of the female respondents. A
multiple regression model revealed the unique contributions of emotional abuse in
the families of origin and trauma experienced outside the family-context in the
prediction of men's alcohol-related symptoms. We found that alcohol consumption
moderated the dose-effect relationship between trauma-exposure and symptoms of
depression and PTSD. Significant interactions indicated that men who reported more
alcohol-related problems experienced less increase in symptoms of PTSD and
depression with increasing trauma-exposure. Conclusions: The gradual attenuation of
the dose-effect the more alcohol-related problems were reported is consistent with
the self-medication hypothesis. Hence, the functionality of alcohol consumption has
to be considered when designing and implementing addiction treatment in post-
conflict contexts. [Ertl, Verena; Saile, Regina; Neuner, Frank; Catani,
Claudia] Univ Bielefeld, Dept Psychol, Clin Psychol & Psychotherapy, Univ Str 25,
D-33615 Bielefeld, Germany; [Ertl, Verena; Saile, Regina; Neuner, Frank; Catani,
Claudia] Vivo Int, Constance, Germany; [Ertl, Verena] Univ Bielefeld, Dept Psychol,
Clin Psychol & Psychotherapy, POB 10013133501, D-33615 Bielefeld, Germany Ertl,
V (reprint author), Univ Bielefeld, Dept Psychol, Clin Psychol & Psychotherapy,
Univ Str 25, D-33615 Bielefeld, Germany.; Ertl, V (reprint author), Vivo Int,
Constance, Germany.; Ertl, V (reprint author), Univ Bielefeld, Dept Psychol, Clin
Psychol & Psychotherapy, POB 10013133501, D-33615 Bielefeld, Germany.
verena.ertl@uni-bielefeld.de German Research Foundation
(DFG)German Research Foundation (DFG); Ein Herz fur Kinder Foundation This study
was supported by the German Research Foundation (DFG) and the Ein Herz fur Kinder
Foundation. The funding organizations had no role in the design and conduct of the
study as well as data analysis and interpretation. Abramsky T, 2012, TRIALS,
V13, DOI 10.1186/1745-6215-13-96; Allen JP, 1997, ALCOHOL CLIN EXP RES, V21, P613,
DOI 10.1097/00000374-199706000-00008; American Psychiatric Association, 1994, DIAGN
STAT MAN MENT; Anda RF, 2002, PSYCHIAT SERV, V53, P1001, DOI
10.1176/appi.ps.53.8.1001; [Anonymous], 2010, MHGAP INT GUID MENT; Babor T, 2001,
AUDIT ALCOHOL USE DI; BERNSTEIN DP, 1994, AM J PSYCHIAT, V151, P1132; Blake D.D.,
1990, BEHAV THER, V13, P187, DOI DOI 10.1007/BF02105408; Bolton P, 2002, J NERV
MENT DIS, V190, P631, DOI 10.1097/01.NMD.0000030568.45847.AE; Boscarino JA, 2006,
ADDICT BEHAV, V31, P606, DOI 10.1016/j.addbeh.2005.05.035; Bremner JD, 2000,
DEPRESS ANXIETY, V12, P1, DOI 10.1002/1520-6394(2000)12:1<1::AID-DA1>3.0.CO;2-W;
Bremner JD, 1996, AM J PSYCHIAT, V153, P369; Brown PJ, 1999, PSYCHOL ADDICT BEHAV,
V13, P115, DOI 10.1037/0893-164X.13.2.115; Carr CP, 2013, J NERV MENT DIS, V201,
P1007, DOI 10.1097/NMD.0000000000000049; Catani C, 2008, J MARITAL FAM THER, V34,
P165, DOI 10.1111/j.1752-0606.2008.00062.x; Catani C, 2009, J TRAUMA STRESS, V22,
P163, DOI 10.1002/jts.20415; Catani C, 2008, BMC PSYCHIATRY, V8, DOI 10.1186/1471-
244X-8-33; Chilcoat HD, 2003, TRAUMA AND SUBSTANCE ABUSE: CAUSES, CONSEQUENCES, AND
TREATMENT OF COMORBID DISORDERS, P9, DOI 10.1037/10460-001; Chilcoat HD, 1998,
ADDICT BEHAV, V23, P827, DOI 10.1016/S0306-4603(98)00069-0; Colder CR, 2001,
PSYCHOL ADDICT BEHAV, V15, P237, DOI 10.1037/0893-164X.15.3.237; COTTLER LB, 1992,
AM J PSYCHIAT, V149, P664; DEROGATIS LR, 1974, BEHAV SCI, V19, P1, DOI
10.1002/bs.3830190102; Dickstein BD, 2010, J TRAUMA STRESS, V23, P331, DOI
10.1002/jts.20523; Dolan CG., 2005, UNDERSTANDING WAR IT; Douglas KR, 2010, ADDICT
BEHAV, V35, P7, DOI 10.1016/j.addbeh.2009.07.004; Driessen M, 2008, ALCOHOL CLIN
EXP RES, V32, P481, DOI 10.1111/j.1530-0277.2007.00591.x; Edwards VJ, 2003, AM J
PSYCHIAT, V160, P1453, DOI 10.1176/appi.ajp.160.8.1453; Ertl V, 2015, ESTSS C TRAUM
CHANG; Ertl V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102786; Ertl V, 2010,
PSYCHOL ASSESSMENT, V22, P318, DOI 10.1037/a0018810; Ezard N, 2012, DISASTERS, V36,
P533, DOI 10.1111/j.1467-7717.2011.01261.x; Felitti VJ, 1998, AM J PREV MED, V14,
P245, DOI 10.1016/S0749-3797(98)00017-8; FLAHERTY JA, 1988, J NERV MENT DIS, V176,
P257; Foa EB., 1995, POSTTRAUMATIC DIAGNO; Fulu E, 2013, LANCET GLOB HEALTH, V1,
pE187, DOI 10.1016/S2214-109X(13)70074-3; Gage AJ, 2005, SOC SCI MED, V61, P343,
DOI 10.1016/j.socscimed.2004.11.078; Gilbert R, 2009, LANCET, V373, P68, DOI
10.1016/S0140-6736(08)61706-7; Gradus JL, 2008, J STUD ALCOHOL DRUGS, V69, P348,
DOI 10.15288/jsad.2008.69.348; Hahn JA, 2010, AIDS BEHAV, V14, P1265, DOI
10.1007/s10461-010-9768-y; Haj-Yahia M, 2003, CHILD ABUSE NEGLECT, V27, P781, DOI
10.1016/S0145-2134(03)00119-4; Haller M, 2014, PSYCHOL ADDICT BEHAV, V28, P841, DOI
10.1037/a0035878; Heidelberg Institute for International Conflict Research, 2015,
CONFL BAR 2014; Hodgins DC, 1999, ALCOHOL CLIN EXP RES, V23, P151, DOI
10.1097/00000374-199901000-00022; Human Rights Watch, 2005, UPR FORG, V17, P1;
Jakupcak M, 2010, ADDICT BEHAV, V35, P840, DOI 10.1016/j.addbeh.2010.03.023; Jewkes
R, 2002, SOC SCI MED, V55, P1603, DOI 10.1016/S0277-9536(01)00294-5; JMP, 1989, JMP
VERS 10 0; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI
10.3109/10673229709030550; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259; Koenig
MA, 2003, B WORLD HEALTH ORGAN, V81, P53; Kolassa IT, 2010, PSYCHOL TRAUMA-US, V2,
P169, DOI 10.1037/a0019362; Kozaric-Kovacic D, 2000, CROAT MED J, V41, P173; Leeies
M, 2010, DEPRESS ANXIETY, V27, P731, DOI 10.1002/da.20677; Lipschitz DS, 2003, J
NERV MENT DIS, V191, P714, DOI 10.1097/01.nmd.0000095123.68088.da; Maguen S, 2011,
PSYCHOL TRAUMA-US, V3, P21, DOI 10.1037/a0019897; Maguen S, 2010, J TRAUMA STRESS,
V23, P86, DOI 10.1002/jts.20434; MCFALL ME, 1992, J STUD ALCOHOL, V53, P357, DOI
10.15288/jsa.1992.53.357; McLeod DS, 2001, J TRAUMA STRESS, V14, P259, DOI
10.1023/A:1011157800050; Miller A, 2013, CLIN CHILD FAM PSYCH, V16, P146, DOI
10.1007/s10567-013-0131-5; Mollica RF, 1998, J NERV MENT DIS, V186, P543, DOI
10.1097/00005053-199809000-00005; Moore SE, 2015, CHILD ABUSE NEGLECT, V48, P208,
DOI 10.1016/j.chiabu.2015.05.006; Mugisha J, 2015, BMC PSYCHIATRY, V15, DOI
10.1186/s12888-015-0423-z; Neuner F, 2006, J TRAUMA STRESS, V19, P339, DOI
10.1002/jts.20121; Neuner F, 2004, BMC PSYCHIATRY, V4, DOI 10.1186/1471-244X-4-34;
Norman RE, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001349; Norman SB, 2007,
DRUG ALCOHOL DEPEN, V90, P89, DOI 10.1016/j.drugalcdep.2007.03.002; Obot IS, 2005,
ALCOHOL GENDER DRINK; Odenwald M, 2013, SUBST ABUSE TREAT PR, V8, DOI 10.1186/1747-
597X-8-14; Olema DK, 2014, J TRAUMA STRESS, V27, P35, DOI 10.1002/jts.21892; Onyut
Lamaro P, 2009, Confl Health, V3, P6, DOI 10.1186/1752-1505-3-6; Ouimette P, 2007,
ADDICT BEHAV, V32, P1719, DOI 10.1016/j.addbeh.2006.11.020; Ouimette P, 2010,
ADDICT BEHAV, V35, P64, DOI 10.1016/j.addbeh.2009.08.009; Ouimette PC, 1999,
PSYCHOL ADDICT BEHAV, V13, P105, DOI 10.1037/0893-164X.13.2.105; PALMER JA, 1995,
PSYCHOL REP, V76, P879, DOI 10.2466/pr0.1995.76.3.879; Perkonigg A, 2000, ACTA
PSYCHIAT SCAND, V101, P46, DOI 10.1034/j.1600-0447.2000.101001046.x; Porter M,
2005, JAMA-J AM MED ASSOC, V294, P602, DOI 10.1001/jama.294.5.602; Potthast N,
2014, ADDICT BEHAV, V39, P949, DOI 10.1016/j.addbeh.2014.01.015; Roberts B, 2014,
PLOS ONE, V9, DOI 10.1371/journal.pone.0098299; Roberts B, 2011, ADDICT BEHAV, V36,
P870, DOI 10.1016/j.addbeh.2011.03.006; Roberts B, 2008, BMC PSYCHIATRY, V8, DOI
10.1186/1471-244X-8-38; Roome E, 2014, CONFL HEALTH, V8, P1; Saile R, 2015, DEV
PSYCHOPATHOL, V27, P1; Saile R, 2014, CHILD ABUSE NEGLECT, V38, P135, DOI
10.1016/j.chiabu.2013.10.007; Saile R, 2013, SOC SCI MED, V86, P17, DOI
10.1016/j.socscimed.2013.02.046; SALADIN ME, 1995, ADDICT BEHAV, V20, P643, DOI
10.1016/0306-4603(95)00024-7; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI
10.1111/j.1360-0443.1993.tb02093.x; SAUNDERS JB, 1993, ADDICTION, V88, P349, DOI
10.1111/j.1360-0443.1993.tb00822.x; Saxena S, 2007, LANCET, V370, P878, DOI
10.1016/S0140-6736(07)61239-2; Sellman JD, 1996, AUST NZ J PSYCHIAT, V30, P573, DOI
10.3109/00048679609062652;
Silove D, 2007, J NERV MENT DIS, V195, P152, DOI
10.1097/01.nmd.0000254747.03333.70; Sriskandarajah V, 2015, SOC SCI MED, V146,
P257, DOI 10.1016/j.socscimed.2015.10.010; Stewart SH, 2003, TRAUMA AND SUBSTANCE
ABUSE: CAUSES, CONSEQUENCES, AND TREATMENT OF COMORBID DISORDERS, P29, DOI
10.1037/10460-002; Teicher MH, 2006, ANN NY ACAD SCI, V1071, P313, DOI
10.1196/annals.1364.024; Teicher MH, 2003, NEUROSCI BIOBEHAV R, V27, P33, DOI
10.1016/S0149-7634(03)00007-1; Tonmyr L, 2010, CURR PSYCHIATRY REV, V6, P223, DOI
10.2174/157340010791792581; van Ommeren M., 1999, TRANSCULT PSYCHIATRY, V36, P285,
DOI DOI 10.1177/136346159903600304; Vaughn MG, 2015, J INTERPERS VIOLENCE; Vinck P,
2007, JAMA-J AM MED ASSOC, V298, P543, DOI 10.1001/jama.298.5.543; Waldrop AE,
2007, ADDICT BEHAV, V32, P634, DOI 10.1016/j.addbeh.2006.06.001; Weaver H, 2010,
SUBST USE MISUSE, V45, P2340, DOI 10.3109/10826081003793920; WHO, 2014, GLOBAL
STATUS REPORT ON VIOLENCE PREVENTION 2014, P1; Widom CS, 2007, ARCH GEN PSYCHIAT,
V64, P49; Widom CS, 2015, CHILD ABUSE NEGLECT, V47, P59, DOI
10.1016/j.chiabu.2015.01.016; Wolitzky-Taylor K, 2012, ADDICT BEHAV, V37, P982, DOI
10.1016/j.addbeh.2012.03.026 104 7 8 0 17 BMC LONDON
CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND 1471-244X BMC
PSYCHIATRY BMC Psychiatry JUN 24 2016 16
202 10.1186/s12888-016-0905-7 13 Psychiatry
Psychiatry DP9TX WOS:000378841400001 27342048 DOAJ Gold, Green
Published 2019-09-25
J Swendsen, J Swendsen, Joel Contributions of
mobile technologies to addiction research DIALOGUES IN CLINICAL NEUROSCIENCE
English Article addiction; ecological
momentary assessment; EMA; ESM; experience-sampling method; mobile technology;
substance ECOLOGICAL MOMENTARY ASSESSMENT; NATIONAL EPIDEMIOLOGIC SURVEY;
SUBSTANCE USE DISORDERS; DECISION-MAKING; ALCOHOL-USE; DEPENDENT INDIVIDUALS; SELF-
MEDICATION; FEASIBILITY; VALIDITY; MOOD Mobile technologies are revolutionizing
the field of mental health, and particular progress has been made in their
application to addiction research and treatment. The use of smartphones and other
mobile devices has been shown to be feasible with individuals addicted to any of a
wide range of substances, with few biases being observed concerning the repeated
monitoring of daily life experiences, craving, or substance use. From a
methodological point of view, the use of mobile technologies overcomes longstanding
limitations of traditional clinical research protocols, including the more accurate
assessment of temporal relationships among variables, as well as the reduction in
both contextual constraints and discipline-specific methodological isolation. The
present article presents a conceptual review of these advances while using
illustrations of research applications that are capable of overcoming specific
methodological barriers. Finally, a brief review of both the benefits and risks of
mobile technology use for the treatment of patients will be addressed. (C) 2016,
AICH - Servier Research Group [Swendsen, Joel] Univ Bordeaux, CNRS UMR 5287,
Bordeaux, France; [Swendsen, Joel] EPHE Sorbonne, Paris, France Swendsen, J
(reprint author), UMR CNRS 5287, Neuroimaging & Human Cognit Lab, 146 Rue Leo
Saignat, F-33076 Bordeaux, France. Joel.Swendsen@u-bordeaux.fr
Bechara A, 2002, NEUROPSYCHOLOGIA, V40, P1675, DOI 10.1016/S0028-
3932(02)00015-5; Bechara A, 2002, NEUROPSYCHOLOGIA, V40, P1690, DOI 10.1016/S0028-
3932(02)00016-7; Childress A R, 1987, NIDA Res Monogr, V76, P137; CHILDRESS A R,
1986, Journal of Substance Abuse Treatment, V3, P173, DOI 10.1016/0740-
5472(86)90018-8; Crooke AHD, 2013, DRUG ALCOHOL REV, V32, P262, DOI
10.1111/dar.12034; CSIKSZENTMIHALYI M, 1987, J NERV MENT DIS, V175, P526, DOI
10.1097/00005053-198709000-00004; DEVRIES MW, 1987, ANXIOUS DEPRESSION A, P21; Dom
G, 2006, ALCOHOL CLIN EXP RES, V30, P1670, DOI 10.1111/j.1530-0277.2006.00202.x;
Ernst M, 2005, BIOL PSYCHIAT, V58, P597, DOI 10.1016/j.biopsych.2005.06.004; Ernst
M, 2003, AM J PSYCHIAT, V160, P33, DOI 10.1176/appi.ajp.160.1.33; Fatseas M, 2015,
ADDICTION, V110, P1035, DOI 10.1111/add.12882; Fatseas M, 2011, BIOL PSYCHIAT, V70,
P720, DOI 10.1016/j.biopsych.2011.05.015; Glantz MD, 2009, PSYCHOL MED, V39, P1365,
DOI 10.1017/S0033291708004510; Granholm E, 2008, SCHIZOPHRENIA BULL, V34, P507, DOI
10.1093/schbul/sbm113; Grant BF, 2015, JAMA PSYCHIAT, V72, P757, DOI
10.1001/jamapsychiatry.2015.0584; Grant S, 2000, NEUROPSYCHOLOGIA, V38, P1180, DOI
10.1016/S0028-3932(99)00158-X; Hart AB, 2015, ALCOHOL CLIN EXP RES, V39, P1312, DOI
10.1111/acer.12792; Hasin DS, 2007, ARCH GEN PSYCHIAT, V64, P830, DOI
10.1001/archpsyc.64.7.830; HELZER JE, 1988, J STUD ALCOHOL, V49, P219, DOI
10.15288/jsa.1988.49.219; HESSELBROCK MN, 1985, ARCH GEN PSYCHIAT, V42, P1050;
Husky MM, 2010, PSYCHIAT RES, V178, P440, DOI 10.1016/j.psychres.2010.04.045;
Jasinska AJ, 2014, NEUROSCI BIOBEHAV R, V38, P1, DOI
10.1016/j.neubiorev.2013.10.013; Johnson EI, 2009, INT J METH PSYCH RES, V18, P48,
DOI 10.1002/mpr.276; Johnson EI, 2009, DRUG ALCOHOL DEPEN, V99, P322, DOI
10.1016/j.drugalcdep.2008.06.010; Kushner MG, 1996, ARCH GEN PSYCHIAT, V53, P264;
Lagadec S, 2012, NEUROLOGY, V78, P322; McClure SM, 2014, ANN NY ACAD SCI, V1327,
P62, DOI 10.1111/nyas.12561; Merikangas KR, 1998, ADDICT BEHAV, V23, P893, DOI
10.1016/S0306-4603(98)00076-8; Papp LM, 2016, ADDICT BEHAV, V53, P161, DOI
10.1016/j.addbeh.2015.10.016; Parsons LH, 2015, NAT REV NEUROSCI, V16, P579, DOI
10.1038/nrn4004; Serre F, 2015, DRUG ALCOHOL DEPEN, V148, P1, DOI
10.1016/j.drugalcdep.2014.12.024; Serre F, 2012, DRUG ALCOHOL DEPEN, V126, P118,
DOI 10.1016/j.drugalcdep.2012.04.025; Shadur JM, 2015, DRUG ALCOHOL REV, V34, P571,
DOI 10.1111/dar.12260; Simons JS, 2005, J STUD ALCOHOL, V66, P459, DOI
10.15288/jsa.2005.66.459; Stone AA, 2003, CONTROL CLIN TRIALS, V24, P182, DOI
10.1016/S0197-2456(02)00320-3; Stone Arthur S., 1994, Annals of Behavioral
Medicine, V16, P199; Swendsen J, 2015, 23 EUR PSYCH ASS C M; Swendsen JD, 2000, J
ABNORM PSYCHOL, V109, P198, DOI 10.1037//0021-843X.109.2.198; Swendsen J, 2010,
ADDICTION, V105, P1117, DOI 10.1111/j.1360-0443.2010.02902.x; Volkow ND, 2015, ACS
CHEM NEUROSCI, V6, P522, DOI 10.1021/acschemneuro.5b00067; Yu J, 2007, PHARMACOL
BIOCHEM BE, V86, P485, DOI 10.1016/j.pbb.2007.01.008 41 5 5 2 11
INST CONFERENCE HIPPOCRATE SURESNESS-CEDEX 50 RUE CARNOT, SURESNESS-
CEDEX, 92284, FRANCE 1294-8322 1958-5969 DIALOGUES CLIN NEURO
Dialogues Clin. Neurosci. JUN 2016 18 2
213 221 9 Neurosciences Neurosciences &
Neurology EF2YY WOS:000390192700011 27489461 2019-09-25
J Thomas, P; Amad, A; Fovet, T Thomas, P.; Amad, A.; Fovet,
T. Schizophrenia and addictions: dangerous links ENCEPHALE-REVUE DE
PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE French
Article Schizophrenia; Addiction;
Comorbidity; Double diagnosis SUBSTANCE USE DISORDERS; CANNABIS USE; 1ST-EPISODE;
PSYCHOSIS; MORTALITY; BURDEN; ABUSE A majority of patients with schizophrenia are
comorbid with addictions. Addictive comorbidities impact prognosis and outcome of
the disease. They result in diagnostic and therapeutic challenges for caregivers
since they are causing a considerable proportion of cases of non-response to
treatment. These are the main causes of disability among adolescents and young
adults patients in the world and their socio economic impact represents a growing
challenge for all health systems. Double diagnosis are more frequent in homeless
populations and represent a major risk factor of suicidal behavior. Consumption of
psychoactive substances, Alcohol and illicit drugs contributes to excess mortality
of schizophrenic patients to both natural and unnatural causes. Many factors have
been identified to explain the reasons for this high comorbidity. Some genetic,
social and economic factors are common between schizophrenia and addiction.
Psychological and behavioral factors have mainly been studied in relation to the
specific links between schizophrenia and cannabis. Two complementary hypotheses are
argued, self -medication and damage hypothesis. Advances in brain imaging have
shown that chronic cannabis use alters the morphology of the brain regions whith
high concentration of cannabinoid receptors like hippocampus and amygdala. Though
effects of cannabis may interact with other vulnerability factors of schizophrenia.
The management of patients with schizophrenia and addiction requires clear
diagnosis identification and integrated care with an efficient coordination between
professionals. In regard of the impact on those who suffer, their entourages and
the medical and economic impact of these disorders, measures on organizational care
setting and promotion of research and evaluation are needed. (C) L'Encephale,
Paris, 2016 [Thomas, P.; Amad, A.; Fovet, T.] Univ Lille, CNRS, CHU Lille,UMR 9193,
SCALab,Pole Psychiat Med Legale Med Milieu Penite, F-59000 Lille, France
Thomas, P (reprint author), Univ Lille, CNRS, CHU Lille,UMR 9193, SCALab,Pole
Psychiat Med Legale Med Milieu Penite, F-59000 Lille, France.
pierre.thomas@chru-lille.fr Fovet, Thomas/I-6845-2019
Adriano F, 2012, NEUROSCIENTIST, V18, P180, DOI 10.1177/1073858410395147;
Awad AG, 2015, THER ADV PSYCHOPHARM, V5, P172, DOI 10.1177/2045125315583820; Bence
C, 2014, COMORBIDITES ADOLESC, P127; Bhattacharyya S, 2010, NEUROPSYCHOPHARMACOL,
V35, P764, DOI 10.1038/npp.2009.184; Galvez-Buccollini JA, 2012, SCHIZOPHR RES,
V139, P157, DOI 10.1016/j.schres.2012.06.007; Griffith-Lendering MFH, 2013,
ADDICTION, V108, P733, DOI 10.1111/add.12050; Hafner H, 2013, SOC PSYCH PSYCH EPID,
V48, P1021, DOI 10.1007/s00127-013-0700-4; Hunt GE, 2013, COCHRANE DB SYST REV, DOI
10.1002/14651858.CD001088.pub3; Kavanagh D, 2000, DRUGS, V62, P743; Kennedy JL,
2014, INT CLIN PSYCHOPHARM, V29, P63, DOI 10.1097/YIC.0b013e32836508e6; Kolliakou
A, 2011, INT J DEV NEUROSCI, V29, P335, DOI 10.1016/j.ijdevneu.2010.11.006; Melle
I, 2010, ARCH SUICIDE RES, V14, P158, DOI 10.1080/13811111003704787; Moore THM,
2007, LANCET, V370, P319, DOI 10.1016/S0140-6736(07)61162-3; MUESER KT, 1990,
SCHIZOPHRENIA BULL, V16, P31, DOI 10.1093/schbul/16.1.31; Nielsen RE, 2013,
SCHIZOPHR RES, V146, P22, DOI 10.1016/j.schres.2013.02.025; REGIER DA, 1990, JAMA-J
AM MED ASSOC, V264, P2511; Reininghaus U, 2015, SCHIZOPHRENIA BULL, V41, P664, DOI
10.1093/schbul/sbu138; Schobel SA, 2013, NEURON, V78, P81, DOI
10.1016/j.neuron.2013.02.011; Schofield D, 2006, AUST NZ J PSYCHIAT, V40, P570, DOI
10.1080/j.1440-1614.2006.01840.x; Sevy S, 2001, ACTA PSYCHIAT SCAND, V104, P367,
DOI 10.1034/j.1600-0447.2001.00452.x; Smith MJ, 2008, SCHIZOPHR RES, V106, P294,
DOI 10.1016/j.schres.2008.07.015; Tarbox SI, 2008, PSYCHOL BULL, V134, P561, DOI
10.1037/0033-2909.34.4.561; Thoma P, 2013, PSYCHIAT CLIN NEUROS, V67, P367, DOI
10.1111/pcn.12072; Whiteford HA, 2013, LANCET, V382, P1575, DOI 10.1016/S0140-
6736(13)61611-6; Yucel M, 2008, ARCH GEN PSYCHIAT, V65, P694, DOI
10.1001/archpsyc.65.6.694 25 2 2 1 16 MASSON EDITEUR
MOULINEAUX CEDEX 9 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX
CEDEX 9, FRANCE 0013-7006 ENCEPHALE Enceph.-Rev. Psychiatr. Clin.
Biol. Ther. JUN 2016 42 3 3S18 3S22
5 Neurosciences; Psychiatry Neurosciences & Neurology;
Psychiatry DS1UC WOS:000380385200005 2019-09-25
J Jauregui, P; Estevez, A; Urbiola, I Jauregui, Paula;
Estevez, Ana; Urbiola, Irache Pathological Gambling and Associated Drug
and Alcohol Abuse, Emotion Regulation, and Anxious-Depressive Symptomatology
JOURNAL OF BEHAVIORAL ADDICTIONS English Article
pathological gambling; drugs; alcohol; emotion regulation;
anxiety; depression SUBSTANCE USE DISORDERS; EXPERIENTIAL AVOIDANCE; SELF-
MEDICATION; IMPULSE CONTROL; MOTIVATIONAL MODEL; DYSREGULATION; DIFFICULTIES;
DRINKING; MINDFULNESS; GAMBLERS Background and aims: Pathological gambling is
associated with comorbid disorders, such as anxiety, depression, and drug and
alcohol abuse. Difficulties of emotion regulation may be one of the factors related
to the presence of addictive disorders, along with comorbid symptomatology in
pathological gamblers. Therefore, the aim of this study was to evaluate the
difficulties of emotion regulation, drug and alcohol abuse, and anxious and
depressive symptomatology in pathological gamblers, and the mediating role of
difficulties of emotion regulation between anxiety and pathological gambling.
Methods: The study sample included 167 male pathological gamblers (mean age = 39.29
years) and 107 non-gamblers (mean age = 33.43 years). Pathological gambling (SOGS),
difficulties of emotion regulation (DERS), drug and alcohol abuse (MUTICAGE CAD-4),
and anxious and depressive symptomatology (SA-45) were measured. Student's t,
Pearson's r, stepwise multiple linear regression and multiple mediation analyses
were conducted. The study was approved by an Investigational Review Board. Results:
Relative to non-gamblers, pathological gamblers exhibited greater difficulties of
emotion regulation, as well as more anxiety, depression, and drug abuse. Moreover,
pathological gambling correlated with emotion regulation difficulties, anxiety,
depression, and drug abuse. Besides, emotion regulation difficulties correlated
with and predicted pathological gambling, drug and alcohol abuse, and anxious and
depressive symptomatology. Finally, emotion regulation difficulties mediated the
relationship between anxiety and pathological gambling controlling the effect of
age, both when controlling and not controlling for the effect of other abuses.
Discussion and conclusions: These results suggest that difficulties of emotion
regulation may provide new keys to understanding and treating pathological gambling
and comorbid disorders. [Jauregui, Paula; Estevez, Ana; Urbiola, Irache] Univ
Deusto, Bilbao 48080, Spain Jauregui, P (reprint author), Univ Deusto, Dept
Psychol, Apartado 1, Bilbao 48080, Spain. paula.jauregui@deusto.es Estevez,
Ana/V-1236-2019; Jauregui, Paula/U-6465-2019; Jauregui, Paula/X-9350-2019
Estevez, Ana/0000-0003-0314-7086; Jauregui, Paula/0000-0002-9706-0274;
Jauregui, Paula/0000-0002-9706-0274 Aldao A, 2010, CLIN PSYCHOL REV,
V30, P217, DOI 10.1016/j.cpr.2009.11.004; Axelrod SR, 2011, AM J DRUG ALCOHOL AB,
V37, P37, DOI 10.3109/00952990.2010.535582; Barnes GM, 2015, INT GAMBL STUD, V15,
P55, DOI 10.1080/14459795.2014.990396; Blaszczynski A, 2002, ADDICTION, V97, P487,
DOI 10.1046/j.1360-0443.2002.00015.x; Bolling D, 2014, HDB EMOTION REGULATI, V2,
P428; Bradley SJ, 2000, AFFECT REGULATION DE; Caplan SE, 2010, COMPUT HUM BEHAV,
V26, P1089, DOI 10.1016/j.chb.2010.03.012; Colder CR, 2001, PSYCHOL ADDICT BEHAV,
V15, P237, DOI 10.1037/0893-164X.15.3.237; COOPER ML, 1995, J PERS SOC PSYCHOL,
V69, P990, DOI 10.1037/0022-3514.69.5.990; Cox WM, 1990, WHY PEOPLE DRINK PAR,
P291; Davison ML, 1997, ASSESSMENT, V4, P259, DOI 10.1177/107319119700400306;
Derogatis L, 2002, SCL 90 R CUESTIONARI; Echeburua E, 1994, ANALISIS MODIFICACIO,
V20, P769, DOI DOI 10.1037/T03938-000; El-Guebaly N, 2006, J GAMBL STUD, V22, P275,
DOI 10.1007/s10899-006-9016-6; Gutierrez AE, 2014, ADICCIONES, V26, P282, DOI
10.20882/adicciones.26; Fox HC, 2008, ADDICT BEHAV, V33, P388, DOI
10.1016/j.addbeh.2007.10.002; Fox HC, 2007, DRUG ALCOHOL DEPEN, V89, P298, DOI
10.1016/j.drugalcdep.2006.12.026; Gratz KL, 2004, J PSYCHOPATHOL BEHAV, V26, P41,
DOI 10.1023/B:JOBA.0000007455.08539.94; Griffiths M, 2011, INT J MENT HEALTH AD,
V9, P1, DOI 10.1007/s11469-009-9246-9; Gross J. J, 2013, HDB EMOTION REGULATI;
Hayes AM, 2004, CLIN PSYCHOL-SCI PR, V11, P255, DOI 10.1093/clipsy/bph080; Hervás
Gonzalo, 2008, Clínica y Salud, V19, P139; Hofmann SG, 2012, DEPRESS ANXIETY, V29,
P409, DOI 10.1002/da.21888; Howell AN, 2010, ADDICT BEHAV, V35, P1144, DOI
10.1016/j.addbeh.2010.07.003; Hsu SH, 2013, ADDICT BEHAV, V38, P1852, DOI
10.1016/j.addbeh.2012.11.002; Jessor R., 1977, PROBLEM BEHAV PSYCHO; KHANTZIAN EJ,
1985, AM J PSYCHIAT, V142, P1259; Kring A. M., 2009, EMOTION REGULATION P; Ladd GT,
2003, EXP CLIN PSYCHOPHARM, V11, P202, DOI 10.1037/1064-1297.11.3.202; LESIEUR HR,
1987, AM J PSYCHIAT, V144, P1184; Levin ME, 2012, J AM COLL HEALTH, V60, P443, DOI
10.1080/07448481.2012.673522; Lorains FK, 2011, ADDICTION, V106, P490, DOI
10.1111/j.1360-0443.2010.03300.x; Luciano C., 2010, INT J CLIN HLTH PSYC, V10,
P141; Lynch TR, 2006, J CLIN PSYCHOL, V62, P459, DOI 10.1002/jclp.20243; Messman-
Moore TL, 2010, CHILD ABUSE NEGLECT, V34, P967, DOI 10.1016/j.chiabu.2010.06.004;
Parhami I, 2014, J PSYCHIATR PRACT, V20, P207, DOI
10.1097/01.pra.0000450320.98988.7c; Pedrero E. J., 2007, TRASTORNOS ADICTIVOS, V9,
P269, DOI [10.1016/S1575-0973(07)75656-8, DOI 10.1016/S1575-0973(07)75656-8]; Petry
N. M., 2012, GAMBLING DRUG ABUSE, P489, DOI DOI 10.1007/978-1-4614-3375-0_; Petry
NM, 2007, AM J ADDICTION, V16, P1, DOI 10.1080/10550490601077668; Preacher KJ,
2008, BEHAV RES METHODS, V40, P879, DOI 10.3758/BRM.40.3.879; Riley B, 2014, J
GAMBL STUD, V30, P163, DOI 10.1007/s10899-012-9342-9; Robinson J, 2009, J ANXIETY
DISORD, V23, P38, DOI 10.1016/j.janxdis.2008.03.013; Rush BR, 2008, ADDICTION,
V103, P1847, DOI 10.1111/j.1360-0443.2008.02338.x; Sandin B, 2008, PSICOTHEMA, V20,
P290; Schreiber LRN, 2012, J PSYCHIATR RES, V46, P651, DOI
10.1016/j.jpsychires.2012.02.005; Shead NW, 2008, PERS INDIV DIFFER, V45, P536, DOI
10.1016/j.paid.2008.06.008; Silk JS, 2003, CHILD DEV, V74, P1869, DOI
10.1046/j.1467-8624.2003.00643.x; Simons JS, 2005, PSYCHOL ADDICT BEHAV, V19, P326,
DOI 10.1037/0893-164X.19.3.326; Stewart SH, 2008, ADDICTION, V103, P1110, DOI
10.1111/j.1360-0443.2008.02235.x; Stewart SH, 2008, PSYCHOL ADDICT BEHAV, V22,
P257, DOI 10.1037/0893-164X.22.2.257; Stinchfield R, 2001, J Gambl Stud, V17, P217;
Tice DM, 2001, J PERS SOC PSYCHOL, V80, P53, DOI 10.1037//0022-3514.80.1.53;
Trosper SE, 2009, CLIN CHILD FAM PSYCH, V12, P234, DOI 10.1007/s10567-009-0043-6;
Tull MT, 2007, BEHAV THER, V38, P378, DOI 10.1016/j.beth.2006.10.006; Veilleux JC,
2014, PERS INDIV DIFFER, V59, P96, DOI 10.1016/j.paid.2013.11.012; Wareham JD,
2010, AM J DRUG ALCOHOL AB, V36, P242, DOI 10.3109/00952991003721118; Weiss NH,
2013, DRUG ALCOHOL DEPEN, V128, P45, DOI 10.1016/j.drugalcdep.2012.07.017; Weiss
NH, 2012, J ANXIETY DISORD, V26, P453, DOI 10.1016/j.janxdis.2012.01.007; Whiteside
Ursula, 2007, Eat Behav, V8, P162, DOI 10.1016/j.eatbeh.2006.04.001; Williams AD,
2012, BRIT J CLIN PSYCHOL, V51, P223, DOI 10.1111/j.2044-8260.2011.02022.x;
Zangeneh M., 2008, IN THE PURSUIT OF WI; 1992, PSYCHOL BULL, V112, P155, DOI DOI
10.1037/0033-2909.112.1.155 62 13 13 2 24 AKADEMIAI KIADO ZRT
BUDAPEST BUDAFOKI UT 187-189-A-3, H-1117 BUDAPEST, HUNGARY 2062-5871
2063-5303 J BEHAV ADDICT J. Behav. Addict. JUN 2016 5 2
251 260 10.1556/2006.5.2016.038 10
Psychiatry Psychiatry DQ6UC WOS:000379339700010 27348555 DOAJ Gold,
Green Published, Green Accepted 2019-09-25
J Langdon, KJ; Fox, AB; King, LA; King, DW; Eisen, S; Vogt, D
Langdon, Kirsten J.; Fox, Annie B.; King, Lynda A.; King, Daniel W.; Eisen,
Susan; Vogt, Dawne Examination of the dynamic interplay between
posttraumatic stress symptoms and alcohol misuse among combat-exposed Operation
Enduring Freedom (OEF)/Operation Iraqi Freedom (OIF) Veterans JOURNAL OF
AFFECTIVE DISORDERS English Article
Posttraumatic stress disorder; Combat; Trauma; Alcohol; Structural equation
modeling MENTAL-HEALTH PROBLEMS; MILITARY PERSONNEL; PRIMARY-CARE; USE
DISORDERS; SUBSTANCE USE; FUNCTIONAL IMPAIRMENT; AFGHANISTAN VETERANS; HAZARDOUS
DRINKING; PTSD SYMPTOMS; DEPLOYMENT Background: Although alcohol misuse co-occurs
with PTSD symptoms at a strikingly high rate (i.e., nearly 52% of men and 28% of
women with PTSD also meet diagnostic criteria for an Alcohol Use Disorder), the
functional associations between these symptom types remain unclear. Methods: The
current study sought to clarify the nature of posttraumatic stress -alcohol misuse
relations by employing a prospective longitudinal methodology -the latent
difference score approach -to examine dynamic change in posttraumatic stress
symptoms and alcohol misuse among 478 combat -exposed Veterans completing a
longitudinal survey of post -deployment mental and physical health. This study
builds on the existing literature, as most prior research has been limited to
cross-sectional studies and has not explored prospective relations between specific
PTSD symptom clusters and alcohol misuse. Results: Consistent with the self
-medication model, results indicated that PTSD symptoms demonstrate a prospective
and proximal association with alcohol misuse during the assessment period; however,
alcohol misuse did not appear to be a unique contributor to overall PTSD symptom
exacerbation over time. Examination of individual PTSD symptom clusters revealed
that more severe symptoms of intrusion and numbing, but not avoidance and
hyperarousal, predicted greater alcohol misuse at subsequent time intervals.
Limitations: The constructs examined within this investigation relied on self
-report data; diagnostic criteria for PTSD and/or Alcohol Use Disorders were not
assessed. Future work may benefit from replicating these findings in clinical
populations formally diagnosed with PTSD via clinician -administered structured
interviews. Conclusions: Findings underscore the importance of addressing PTSD
symptoms in the context of alcohol treatment to facilitate improved drinking
outcomes. (C) 2016 Elsevier B.V. All rights reserved. [Langdon, Kirsten J.; Fox,
Annie B.; King, Lynda A.; Vogt, Dawne] VA Boston Healthcare Syst, Womens Hlth Sci
Div, Natl Ctr PTSD, 150 South Huntington Ave 116B-3, Boston, MA 02130 USA;
[Langdon, Kirsten J.; King, Lynda A.; King, Daniel W.; Vogt, Dawne] Boston Univ,
Sch Med, Dept Psychiat, Boston, MA 02215 USA; [King, Lynda A.; King, Daniel W.]
Boston Univ, Sch Med, Dept Psychol, Boston, MA 02215 USA; [King, Daniel W.] VA
Boston Healthcare, Behav Sci Div, Natl Ctr PTSD, Boston, MA USA; [Eisen, Susan]
Edith Nourse Rogers Mem Vet Hosp, Ctr Healthcare Org & Implementat Res, Bedford, MA
USA; [Eisen, Susan] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management,
Boston, MA 02215 USA Langdon, KJ (reprint author), VA Boston Healthcare Syst,
Womens Hlth Sci Div, Natl Ctr PTSD, 150 South Huntington Ave 116B-3, Boston, MA
02130 USA. kirstenjlangdon@gmail.com Fox, Annie/0000-0002-4776-1873
NIDA NIH HHSUnited States Department of Health & Human ServicesNational
Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [F31
DA026634] Babor TF, 1989, ALCOHOL HEALTH RES W, V13, P371; Back S, 2000, AM
J ADDICTION, V9, P51; Back SE, 2006, J NERV MENT DIS, V194, P690, DOI
10.1097/01.nmd.0000235794.12794.8a; Baker TB, 2004, PSYCHOL REV, V111, P33, DOI
10.1037/0033-295X.111.1.33; Blake D, 1990, CLIN ADM PTSD SCAL C; Blanco C, 2013,
DRUG ALCOHOL DEPEN, V132, P630, DOI 10.1016/j.drugalcdep.2013.04.016; Bradley KA,
2009, J GEN INTERN MED, V24, P881, DOI 10.1007/s11606-009-1014-9; Bray RM, 2007,
ADDICTION, V102, P1092, DOI 10.1111/j.1360-0443.2007.01841.x; Burnett-Zeigler I,
2011, ADDICT BEHAV, V36, P801, DOI 10.1016/j.addbeh.2010.12.032; Bush K, 1998, ARCH
INTERN MED, V158, P1789, DOI 10.1001/archinte.158.16.1789; Carter AC, 2011, J DUAL
DIAGN, V7, P285, DOI 10.1080/15504263.2011.620453; Dragan M., 2010, SUICIDAL BEHAV
ALCOH, P540; Eisen SV, 2012, AM J PUBLIC HEALTH, V102, pS66, DOI
10.2105/AJPH.2011.300609; Fetzner MG, 2013, CAN J PSYCHIAT, V58, P417, DOI
10.1177/070674371305800707; Goodwin L, 2012, J NERV MENT DIS, V200, P429, DOI
10.1097/NMD.0b013e31825322fe; Hall BJ, 2012, J ANXIETY DISORD, V26, P409, DOI
10.1016/j.janxdis.2011.12.015; Hamagami F., 2001, NEW DEV TECHNIQUES S, P203; Hoge
CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Jacobsen LK, 2001,
AM J PSYCHIAT, V158, P1184, DOI 10.1176/appi.ajp.158.8.1184; Jacobson IG, 2008,
JAMA-J AM MED ASSOC, V300, P663, DOI 10.1001/jama.300.6.663; Jakupcak M, 2010,
ADDICT BEHAV, V35, P840, DOI 10.1016/j.addbeh.2010.03.023; Kaysen D, 2011, J DUAL
DIAGN, V7, P262, DOI 10.1080/15504263.2011.620449; Khantzian E. J., 2003, PRIMARY
PSYCHIAT, V10, p[47, 53]; King DW, 2009, MULTIVAR BEHAV RES, V44, P437, DOI
10.1080/00273170903103308; King DW, 1998, PSYCHOL ASSESSMENT, V10, P90, DOI
10.1037/1040-3590.10.2.90; King DW, 2006, J TRAUMA STRESS, V19, P205, DOI
10.1002/jts.20112; King LA, 2006, MIL PSYCHOL, V18, P89, DOI
10.1207/s15327876mp1802_1; Kriston L, 2008, PRIMARY CARE COMMUN, V13, P100, DOI
10.1080/17468840802193050; Maguen S, 2009, MIL MED, V174, P779, DOI 10.7205/MILMED-
D-03-2808; Mansfield AJ, 2010, J TRAUMA STRESS, V23, P91, DOI 10.1002/jts.20492;
McArdle JJ, 2001, DECADE BEHAV, P139, DOI 10.1037/10409-005; McArdle JJ, 1990,
RAMPATH PATH DIAGRAM; McDevitt-Murphy ME, 2010, J TRAUMA STRESS, V23, P108, DOI
10.1002/jts.20482; MCFALL ME, 1992, J STUD ALCOHOL, V53, P357, DOI
10.15288/jsa.1992.53.357; McFarlane AC, 2009, J AFFECT DISORDERS, V118, P166, DOI
10.1016/j.jad.2009.01.017; Muthen B, 2013, MPLUS 7 1; Nickerson A, 2014, J ABNORM
PSYCHOL, V123, P821, DOI 10.1037/a0037920; Read JP, 2013, J ABNORM PSYCHOL, V122,
P984, DOI 10.1037/a0034918; Reinert DF, 2007, ALCOHOL CLIN EXP RES, V31, P185, DOI
10.1111/j.1530-0277.2006.00295.x; Ruggiero KJ, 2003, J TRAUMA STRESS, V16, P495,
DOI 10.1023/A:1025714729117; Scott JC, 2013, DRUG ALCOHOL DEPEN, V127, P15, DOI
10.1016/j.drugalcdep.2012.06.003; Seal KH, 2009, AM J PUBLIC HEALTH, V99, P1651,
DOI 10.2105/AJPH.2008.150284; Stewart SH, 1998, ADDICT BEHAV, V23, P797, DOI
10.1016/S0306-4603(98)00070-7; Stewart SH, 1996, PSYCHOL BULL, V120, P83, DOI
10.1037/0033-2909.120.1.83; Sundin J, 2011, INT REV PSYCHIATR, V23, P153, DOI
10.3109/09540261.2011.561303; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI
10.1001/archgenpsychiatry.2010.54; Weathers F., 1993, ANN CONV INT SOC TRA; Wilk
JE, 2010, DRUG ALCOHOL DEPEN, V108, P115, DOI 10.1016/j.drugalcdep.2009.12.003
48 9 9 0 17 ELSEVIER SCIENCE BV AMSTERDAM PO BOX 211,
1000 AE AMSTERDAM, NETHERLANDS 0165-0327 1573-2517 J AFFECT DISORDERS
J. Affect. Disord. MAY 15 2016 196
234 242 10.1016/j.jad.2016.02.048 9 Clinical
Neurology; Psychiatry Neurosciences & Neurology; Psychiatry DH3WF
WOS:000372716800028 26938966 Green Accepted 2019-09-25
J Crabbe, JC; Schlumbohm, JP; Hack, W; Barkley-Levenson, AM; Metten, P; Lattal,
KM Crabbe, John C.; Schlumbohm, Jason P.; Hack, Wyatt;
Barkley-Levenson, Amanda M.; Metten, Pamela; Lattal, K. Matthew Fear
conditioning in mouse lines genetically selected for binge-like ethanol drinking
ALCOHOL English Article
Ethanol binge drinking; Conditioned fear; Selective breeding; Drinking in the
dark; Mouse; Genetics POSTTRAUMATIC-STRESS-DISORDER; ANIMAL-MODEL; PTSD;
GLUCOCORTICOIDS; EXTINCTION; AMYGDALA; C57BL/6; MICE The comorbidity of substance-
and alcohol-use disorders (AUD) with other psychiatric conditions, especially those
related to stress such as post-traumatic stress disorder (PTSD), is well-
established. Binge-like intoxication is thought to be a crucial stage in the
development of the chronic relapsing nature of the addictions, and self-medication
through binge-like drinking is commonly seen in PTSD patients. We have selectively
bred two separate High Drinking in the Dark (HDID-1 and HDID-2) mouse lines to
reach high blood ethanol concentrations (BECs) after a 4-h period of access to 20%
ethanol starting shortly after the onset of circadian dark. As an initial step
toward the eventual goal of employing binge-prone HDID mice to study PTSD-like
behavior including alcohol binge drinking, we sought first to determine their
ability to acquire conditioned fear. We asked whether these mice acquired,
generalized, or extinguished conditioned freezing to a greater or lesser extent
than unselected control HS/Npt mice. In two experiments, we trained groups of 16
adult male mice in a standard conditioned fear protocol. Mice were tested for
context-elicited freezing, and then, in a novel context, for cue-induced freezing.
After extinction tests, renewal of conditioned fear was tested in the original
context. Mice of all three genotypes showed typical fear responding. Context paired
with shock elicited freezing behavior in a control experiment, but cue unpaired
with shock did not. These studies indicate that fear learning per se does not
appear to be influenced by genes causing predisposition to binge drinking,
suggesting distinct neural mechanisms. However, HDID mice are shown to be a
suitable model for studying the role of conditioned fear specifically in binge-like
drinking. Published by Elsevier Inc. [Crabbe, John C.; Schlumbohm, Jason P.;
Hack, Wyatt; Barkley-Levenson, Amanda M.; Metten, Pamela] VA Portland Hlth Care
Syst, Portland Alcohol Res Ctr, Portland, OR 97239 USA; [Crabbe, John C.;
Schlumbohm, Jason P.; Hack, Wyatt; Barkley-Levenson, Amanda M.; Metten, Pamela;
Lattal, K. Matthew] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239
USA Crabbe, JC (reprint author), Portland VA Med Ctr, Res R&D 12, 3710 SW US Vet
Hosp Rd, Portland, OR 97239 USA. crabbe@ohsu.edu Lattal, K/W-8386-2019
Schlumbohm, Jason/0000-0002-1794-1718 NIH-NIAAAUnited States Department
of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National
Institute on Alcohol Abuse & Alcoholism (NIAAA) [AA010760, AA013519, AA020245];
Department of Veterans AffairsUS Department of Veteran Affairs [101BX000313];
Department of the Army/DoD-TATRC grant [10245005.05] These studies were supported
by Grants AA010760, AA013519, and AA020245 from the NIH-NIAAA; by Grant
#101BX000313 the Department of Veterans Affairs; and by the Department of the
Army/DoD-TATRC grant 10245005.05. We thank Stephanie E. Spence and Lawrence C.
Huang for maintaining the colonies and supplying the mice for these experiments.
Barkley-Levenson AM, 2014, ALCOHOL, V48, P217, DOI
10.1016/j.alcohol.2013.10.007; Barkley-Levenson AM, 2015, ADDICT BIOL, V20, P80,
DOI 10.1111/adb.12079; Bouchery EE, 2011, AM J PREV MED, V41, P516, DOI
10.1016/j.amepre.2011.06.045; Camp MC, 2012, NEUROPSYCHOPHARMACOL, V37, P1534, DOI
10.1038/npp.2011.340; Clay R, 2011, NEUROBIOL LEARN MEM, V96, P367, DOI
10.1016/j.nlm.2011.06.012; Cohen H, 2012, NEUROPHARMACOLOGY, V62, P715, DOI
10.1016/j.neuropharm.2011.04.023; Crabbe JC, 2014, GENES BRAIN BEHAV, V13, P236,
DOI 10.1111/gbb.12105; Crabbe J. C, 2014, NEUROBIOLOGY ALCOHOL, P359; CRABBE JC,
1990, ALCOHOL CLIN EXP RES, V14, P141, DOI 10.1111/j.1530-0277.1990.tb00461.x;
Crabbe JC, 2011, ALCOHOL, V45, P427, DOI 10.1016/j.alcohol.2010.12.001; Crabbe JC,
2009, BIOL PSYCHIAT, V65, P662, DOI 10.1016/j.biopsych.2008.11.002; Cucciare MA,
2011, ADDICT BEHAV, V36, P362, DOI 10.1016/j.addbeh.2010.12.014; Davis TM, 2003,
PSYCHIAT SERV, V54, P214, DOI 10.1176/appi.ps.54.2.214; FANSELOW MS, 1980,
PAVLOVIAN J BIOL SCI, V15, P177; Gale GD, 2004, J NEUROSCI, V24, P3810, DOI
10.1523/JNEUROSCI.4100-03.2004; Goldman D, 2005, NAT REV GENET, V6, P521, DOI
10.1038/nrg1635; HITZEMANN B, 1994, J PHARMACOL EXP THER, V271, P969; Johnson LR,
2012, NEUROPHARMACOLOGY, V62, P638, DOI 10.1016/j.neuropharm.2011.07.004; Kaouane
N, 2012, SCIENCE, V335, P1510, DOI 10.1126/science.1207615; Kendler KS, 2003, ARCH
GEN PSYCHIAT, V60, P929, DOI 10.1001/archpsyc.60.9.929; Lattal KM, 2012, BEHAV
PROCESS, V90, P49, DOI 10.1016/j.beproc.2012.03.008; Mandyam CD, 2012, TRENDS
NEUROSCI, V35, P250, DOI 10.1016/j.tins.2011.12.005; Maren S, 2016,
NEUROPSYCHOPHARMACOL, V41, P58, DOI 10.1038/npp.2015.180; National Institute of
Alcohol Abuse and Alcoholism, 2004, NIAAA NEWSLETTER, P3, DOI DOI
10.1037/E306662005-004; Norman SB, 2012, NEUROPHARMACOLOGY, V62, P542, DOI
10.1016/j.neuropharm.2011.04.032; Olson VG, 2011, BIOL PSYCHIAT, V70, P441, DOI
10.1016/j.biopsych.2010.11.029; Pynoos RS, 1996, BIOL PSYCHIAT, V39, P129, DOI
10.1016/0006-3223(95)00088-7; Raybuck JD, 2011, PLOS ONE, V6, DOI
10.1371/journal.pone.0015982; Rhodes JS, 2005, PHYSIOL BEHAV, V84, P53, DOI
10.1016/j.physbeh.2004.10.007; Siegmund A, 2007, J PSYCHIATR RES, V41, P848, DOI
10.1016/j.jpsychires.2006.07.017; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614,
DOI 10.1001/archgenpsychiatry.2010.54; Tipps ME, 2015, ALCOHOL CLIN EXP RES, V39,
P282, DOI 10.1111/acer.12614; Tipps ME, 2014, LEARN MEMORY, V21, P380, DOI
10.1101/lm.035261.114; Warren K. R., 2009, NIAAA DIRECTORS STA 34 3 3
1 6 ELSEVIER SCIENCE INC NEW YORK STE 800, 230 PARK AVE, NEW
YORK, NY 10169 USA 0741-8329 1873-6823 ALCOHOL Alcohol MAY
2016 52 25 32
10.1016/j.alcohol.2016.01.004 8 Substance Abuse; Pharmacology
& Pharmacy; Toxicology Substance Abuse; Pharmacology & Pharmacy; Toxicology DL7JA
WOS:000375815800003 27139234 Green Accepted, Other Gold
2019-09-25
J Moore, AA; Neale, MC; Silberg, JL; Verhulst, B Moore,
Ashlee A.; Neale, Michael C.; Silberg, Judy L.; Verhulst, Brad
Substance Use and Depression Symptomatology: Measurement Invariance of the
Beck Depression Inventory (BDI-II) among Non-Users and Frequent-Users of Alcohol,
Nicotine and Cannabis PLOS ONE English Article
PSYCHOMETRIC EVALUATION; MAJOR DEPRESSION; SELF-MEDICATION;
USE DISORDERS; DRUG-ABUSE; COMORBIDITY; VALIDITY; AGE; HETEROGENEITY; MOOD
Depression is a highly heterogeneous condition, and identifying how symptoms
present in various groups may greatly increase our understanding of its etiology.
Importantly, Major Depressive Disorder is strongly linked with Substance Use
Disorders, which may ameliorate or exacerbate specific depression symptoms. It is
therefore quite plausible that depression may present with different symptom
profiles depending on an individual's substance use status. Given these
observations, it is important to examine the underlying construct of depression in
groups of substance users compared to non-users. In this study we use a non-
clinical sample to examine the measurement structure of the Beck Depression
Inventory (BDI-II) in non-users and frequent-users of various substances.
Specifically, measurement invariance was examined across those who do vs. do not
use alcohol, nicotine, and cannabis. Results indicate strict factorial invariance
across non-users and frequent-users of alcohol and cannabis, and metric invariance
across non-users and frequent-users of nicotine. This implies that the factor
structure of the BDI-II is similar across all substance use groups [Moore,
Ashlee A.] Virginia Commonwealth Univ, Ctr Clin & Translat Res, Richmond, VA USA;
[Moore, Ashlee A.; Neale, Michael C.; Silberg, Judy L.; Verhulst, Brad] Virginia
Commonwealth Univ, Virginia Inst Psychiat & Behav Genet, Richmond, VA USA; [Neale,
Michael C.; Silberg, Judy L.] Virginia Commonwealth Univ, Dept Human & Mol Genet,
Richmond, VA USA; [Neale, Michael C.; Verhulst, Brad] Virginia Commonwealth Univ,
Dept Psychiat, Richmond, VA USA Moore, AA (reprint author), Virginia
Commonwealth Univ, Ctr Clin & Translat Res, Richmond, VA USA.; Moore, AA (reprint
author), Virginia Commonwealth Univ, Virginia Inst Psychiat & Behav Genet,
Richmond, VA USA. mooreaa2@vcu.edu Moore, Ashlee/0000-0002-6577-3050
National Institutes of Health's National Center for Advancing Translational
Sciences [TR000058]; National Institutes of Health's National Institute on Drug
Abuse [DA018673, DA026119] This work was supported by the National Institutes of
Health's National Center for Advancing Translational Sciences (www.ncats.nih.gov;
AAM & JLS, grant number TR000058) and the National Institutes of Health's National
Institute on Drug Abuse (www.nida.nih.gov; MCN & BV, grant numbers DA018673 and
DA026119). The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript. Aggen SH, 2011, TWIN RES
HUM GENET, V14, P524, DOI 10.1375/twin.14.6.524; American Psychiatric Association,
2013, DIAGN STAT MAN MENT; Apesoa-Varano EC, 2015, SOC SCI MED, V124, P1, DOI
10.1016/j.socscimed.2014.10.054; Beck A. T., 1996, BECK DEPRESSION INVE; Bolton JM,
2009, J AFFECT DISORDERS, V115, P367, DOI 10.1016/j.jad.2008.10.003; BROWN J, 1992,
BRIT J ADDICT, V87, P1013; Buckley TC, 2001, J SUBST ABUSE TREAT, V20, P197, DOI
10.1016/S0740-5472(00)00169-0; Buhrmester M, 2011, PERSPECT PSYCHOL SCI, V6, P3,
DOI 10.1177/1745691610393980; CATTELL RB, 1966, MULTIVAR BEHAV RES, V1, P245, DOI
10.1207/s15327906mbr0102_10; Chen LS, 2000, J AFFECT DISORDERS, V59, P1, DOI
10.1016/S0165-0327(99)00132-9; Davis LL, 2005, COMPR PSYCHIAT, V46, P81, DOI
10.1016/j.comppsych.2004.07.025; Del Boca FK, 2000, ADDICTION, V95, pS347; Dozois
DJA, 1998, PSYCHOL ASSESSMENT, V10, P83, DOI 10.1037/1040-3590.10.2.83; Dum M,
2008, ADDICT BEHAV, V33, P381, DOI 10.1016/j.addbeh.2007.09.017; GALLO JJ, 1994, J
GERONTOL, V49, pP251, DOI 10.1093/geronj/49.6.P251; Ghaemi SN, 2011, ACTA PSYCHIAT
SCAND, V124, P497, DOI 10.1111/j.1600-0447.2011.01746.x; HORN JL, 1965,
PSYCHOMETRIKA, V30, P179, DOI 10.1007/BF02289447; Husain MM, 2005, AM J GERIAT
PSYCHIAT, V13, P852, DOI 10.1176/appi.ajgp.13.10.852; Johnson ME, 2006, ASSESSMENT,
V13, P168, DOI 10.1177/1073191106286951; KAISER HF, 1960, EDUC PSYCHOL MEAS, V20,
P141, DOI 10.1177/001316446002000116; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8;
Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550;
Little R. J. A., 1987, STAT ANAL MISSING DA; Little TD, 1997, MULTIVAR BEHAV RES,
V32, P53, DOI 10.1207/s15327906mbr3201_3; Mehta PD, 2004, PSYCHOL METHODS, V9,
P301, DOI 10.1037/1082-989X.9.3.301; MEREDITH W, 1993, PSYCHOMETRIKA, V58, P525,
DOI 10.1007/BF02294825; Merikangas KR, 1998, ADDICT BEHAV, V23, P893, DOI
10.1016/S0306-4603(98)00076-8; Muthen L. K., 2007, MPLUS USERS GUIDE; Neale MC,
2015, PSYCHOMETRI IN PRESS; R Core Team, 2014, R LANG ENV STAT COMP; REGIER DA,
1990, JAMA-J AM MED ASSOC, V264, P2511; Rice SM, INT J SOC P IN PRESS; Seignourel
PJ, 2008, DRUG ALCOHOL DEPEN, V93, P271, DOI 10.1016/j.drugalcdep.2007.10.016;
Skule C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088321; Steer RA, 1997,
PSYCHOL REP, V80, P443, DOI 10.2466/pr0.1997.80.2.443; Sullivan PF, 2013, MOL
PSYCHIATR, V18, P497, DOI 10.1038/mp.2012.21; Sullivan PF, 2000, AM J PSYCHIAT,
V157, P1552, DOI 10.1176/appi.ajp.157.10.1552; Wilkowska-Chmielewska J, 2013, J
AFFECT DISORDERS, V150, P142, DOI 10.1016/j.jad.2012.12.012; Basurto FZ, 2009,
PSICOTHEMA, V21, P213 39 3 3 0 23 PUBLIC LIBRARY SCIENCE SAN
FRANCISCO 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA 1932-6203
PLOS ONE PLoS One APR 5 2016 11 4
e0152118 10.1371/journal.pone.0152118 13
Multidisciplinary Sciences Science & Technology - Other Topics DI6HK
WOS:000373599600009 27046165 DOAJ Gold, Green Published
2019-09-25
J Conway, KP; Swendsen, J; Husky, MM; He, JP; Merikangas, KR
 Conway, Kevin P.; Swendsen, Joel; Husky, Mathilde M.; He, Jian-Ping;
Merikangas, Kathleen R. Association of Lifetime Mental Disorders and
Subsequent Alcohol and Illicit Drug Use: Results From the National Comorbidity
Survey-Adolescent Supplement JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND
ADOLESCENT PSYCHIATRY English Article
adolescence; alcohol use; comorbidity; drug use; epidemiology SUBSTANCE
USE DISORDERS; 10-YEAR FOLLOW-UP; AGE-OF-ONSET; SURVEY REPLICATION; NCS-A;
EPIDEMIOLOGIC SURVEY; SELF-MEDICATION; ANXIETY DISORDERS; UNITED-STATES; HEALTH
SURVEY Objective: To estimate the association of prior lifetime mental
disorders with transitions across stages of substance use in a cross-sectional,
nationally representative sample of US adolescents. Method: The sample includes
10,123 adolescents aged 13 to 18 years who participated in the National Comorbidity
Survey Adolescent Supplement (NCS-A), and who were directly interviewed with the
Composite International Diagnostic Interview (CIDI) Version 3.0 that generates
criteria for DSM-IV disorders. Results: Adolescents with prior lifetime mental
disorders had high rates of both alcohol (10.3%) and illicit drug (14.9%) abuse,
with or without dependence. Alcohol and drug abuse were highest among adolescents
with prior anxiety disorders (17.3% and 20%, respectively) and behavior disorders
(15.6% and 24%, respectively). Any prior disorder significantly increased the risk
of transition from nonuse to first use, and from use to problematic use of either
alcohol or illicit drugs. Multivariate models attenuated the magnitude of the risk
of transition associated with each disorder, although prior weekly smoking and
illicit drug use demonstrated significant risks of transitions across the 3 stages
of alcohol or drug use, as did behavior disorders. Conclusion: The findings provide
the first evidence from a nationally representative sample that prior mental
disorders represent risk factors for the transition from nonuse to use, and the
progression to drug-and alcohol-related problems. Treatment of primary mental
disorders is likely to be an important target for the prevention of secondary
substance use disorders in youth. [Conway, Kevin P.] NIDA, Div Epidemiol Serv &
Prevent Res, Rockville, MD USA; [Swendsen, Joel] Ecole Prat Hautes Etud, Paris,
France; [Swendsen, Joel] CNRS, Paris, France; [Swendsen, Joel] Univ Bordeaux,
Bordeaux, France; [Husky, Mathilde M.] Univ Paris 05, Paris, France; [He, Jian-
Ping; Merikangas, Kathleen R.] NIMH, Genet Epidemiol Res Branch, Intramural Res
Program, 35 Convent Dr,MSC 3720, Bethesda, MD 20892 USA Merikangas, KR (reprint
author), NIMH, Genet Epidemiol Res Branch, Intramural Res Program, 35 Convent
Dr,MSC 3720, Bethesda, MD 20892 USA. merikank@mail.nih.gov Conway,
Kevin/0000-0002-7638-339X; Husky, Mathilde/0000-0001-5314-1403 Intramural
Research Program of the National Institute of Mental HealthUnited States Department
of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National
Institute of Mental Health (NIMH) [Z01MH002808-08]; National Institute of Mental
HealthUnited States Department of Health & Human ServicesNational Institutes of
Health (NIH) - USANIH National Institute of Mental Health (NIMH) [U01-MH60220]
This work was supported by the Intramural Research Program of the National
Institute of Mental Health (Z01MH002808-08). The National Comorbidity Survey
Adolescent Supplement (NCS-A) and the larger program of related NCS surveys are
supported by the National Institute of Mental Health (U01-MH60220). The views and
opinions expressed in this article are those of the authors and should not be
construed to represent the views of any of the sponsoring organizations, agencies,
or US government. [Anonymous], 2013, Psychiatr Serv, V64, P1281, DOI
10.1176/appi.ps.6412News1; Armstrong TD, 2002, J CONSULT CLIN PSYCH, V70, P1224,
DOI 10.1037//0022-006X.70.6.1224; Audrain-McGovern J, 2009, ADDICTION, V104, P1743,
DOI 10.1111/j.1360-0443.2009.02617.x; Bachman JG, 2011, J STUD ALCOHOL DRUGS, V72,
P279, DOI 10.15288/jsad.2011.72.279; Behrendt S, 2011, PSYCHOL MED, V41, P1073, DOI
10.1017/S0033291710001418; Compton WM, 2007, ARCH GEN PSYCHIAT, V64, P566, DOI
10.1001/archpsyc.64.5.566; Compton WM, 2013, AM J PSYCHIAT, V170, P660, DOI
10.1176/appi.ajp.2012.12060737; Conway KP, 2006, J CLIN PSYCHIAT, V67, P247, DOI
10.4088/JCP.v67n0211; Conway KP, 2002, DRUG ALCOHOL DEPEN, V65, P225, DOI
10.1016/S0376-8716(01)00168-5; Copeland WE, 2012, PSYCHOL MED, V42, P1925, DOI
10.1017/S0033291711002790; Cotto JH, 2010, GENDER MED, V7, P402, DOI
10.1016/j.genm.2010.09.004; Crum RM, 2013, JAMA PSYCHIAT, V70, P718, DOI
10.1001/jamapsychiatry.2013.1098; Degenhardt L, 2007, INT J METH PSYCH RES, V16,
P43, DOI 10.1002/mpr.206; Dierker L, 2008, ANN BEHAV MED, V36, P87, DOI
10.1007/s12160-008-9051-x; Dierker L, 2012, ANN BEHAV MED, V43, P394, DOI
10.1007/s12160-011-9330-9; Donohue B, 2004, PSYCHOL ADDICT BEHAV, V18, P184, DOI
10.1037/0893-164X.18.2.184; EFRON B, 1988, J AM STAT ASSOC, V83, P414, DOI
10.2307/2288857; Fryar Cheryl D, 2009, Natl Health Stat Report, P1; Glantz MD,
2009, PSYCHOL MED, V39, P1365, DOI 10.1017/S0033291708004510; Hasin DS, 2007, ARCH
GEN PSYCHIAT, V64, P830, DOI 10.1001/archpsyc.64.7.830; Johnson EO, 2005, INT J
METH PSYCH RES, V14, P119, DOI 10.1002/mpr.2; Johnston L. D., 2010, MARIJUANA USE
IS RIS; Johnston L.D., 2009, MONITORING FUTURE NA, VI; Kalaydjian A, 2009, COMPR
PSYCHIAT, V50, P299, DOI 10.1016/j.comppsych.2008.09.012; Kessler RC, 2012, PSYCHOL
MED, V42, P1997, DOI 10.1017/S0033291712000025; Kessler RC, 2004, INT J METH PSYCH
RES, V13, P93, DOI 10.1002/mpr.168; Kessler RC, 2004, INT J METH PSYCH RES, V13,
P60, DOI 10.1002/mpr.166; Kessler RC, 2007, WORLD PSYCHIATRY, V6, P168; Kessler RC,
2009, INT J METH PSYCH RES, V18, P69, DOI 10.1002/mpr.279; Kessler RC, 2009, J AM
ACAD CHILD PSY, V48, P380, DOI 10.1097/CHI.0b013e3181999705; Lazareck S, 2012, J
CLIN PSYCHIAT, V73, pE588, DOI 10.4088/JCP.11m07345; McGee R, 2000, ADDICTION, V95,
P491, DOI 10.1046/j.1360-0443.2000.9544912.x; Merikangas KR, 2009, J AM ACAD CHILD
PSY, V48, P367, DOI 10.1097/CHI.0b013e31819996f1; Merikangas KR, 2010, J AM ACAD
CHILD PSY, V49, P980, DOI 10.1016/j.jaac.2010.05.017; Merikangas KR, 1998, ARCH GEN
PSYCHIAT, V55, P973, DOI 10.1001/archpsyc.55.11.973; REGIER DA, 1990, JAMA-J AM MED
ASSOC, V264, P2511; Robinson J, 2011, ARCH GEN PSYCHIAT, V68, P800, DOI
10.1001/archgenpsychiatry.2011.75; Substance Abuse and Mental Health
Administration, 2014, RES 2013 NAT SURV DR; Substance Abuse and Mental Health
Services Administration, 2011, RES 2010 NAT SURV DR; Sung MJ, 2004, DRUG ALCOHOL
DEPEN, V75, P287, DOI 10.1016/j.drugalcdep.2004.03.013; Swendsen J, 2008, PREV MED,
V47, P629, DOI 10.1016/j.ypmed.2008.09.009; Swendsen J, 2012, ARCH GEN PSYCHIAT,
V69, P390, DOI 10.1001/archgenpsychiatry.2011.1503; Swendsen J, 2010, ADDICTION,
V105, P1117, DOI 10.1111/j.1360-0443.2010.02902.x; Swendsen J, 2009, ADDICTION,
V104, P1346, DOI 10.1111/j.1360-0443.2009.02622.x; Tuithof M, 2012, DRUG ALCOHOL
DEPEN, V123, P115, DOI 10.1016/j.drugalcdep.2011.10.030; Wallace JM, 2003,
ADDICTION, V98, P225, DOI 10.1046/j.1360-0443.2003.00282.x; Wittchen HU, 2007, DRUG
ALCOHOL DEPEN, V88, pS60, DOI 10.1016/j.drugalcdep.2006.12.013; Wolters KM, 2007,
VARIANCE ESTIMATION, p[151, 384]; Zimmermann P, 2003, PSYCHOL MED, V33, P1211, DOI
10.1017/S0033291703008158 49 46 46 0 25 ELSEVIER SCIENCE INC
NEW YORK 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA 0890-8567 1527-
5418 J AM ACAD CHILD PSY J. Am. Acad. Child Adolesc. Psychiatr. APR
2016 55 4 280 288
10.1016/j.jaac.2016.01.006 9 Psychology, Developmental;
Pediatrics; Psychiatry Psychology; Pediatrics; Psychiatry DI2HD
WOS:000373315400006 27015718 2019-09-25
J Contractor, AA; Presseau, C; Capone, C; Reddy, MK; Shea, MT
Contractor, Ateka A.; Presseau, Candice; Capone, Christy; Reddy, Madhavi K.;
Shea, M. Tracie The moderating role of dysphoria in the relationship
between intrusions and alcohol use ADDICTIVE BEHAVIORS English
Article PTSD symptoms; Intrusions;
Dysphoria; Alcohol use; Veterans POSTTRAUMATIC-STRESS-DISORDER; SUBSTANCE USE
DISORDERS; RANDOMIZED CONTROLLED-TRIAL; ADMINISTERED PTSD SCALE; PRIMARY-CARE;
SYMPTOM DIMENSIONS; MAJOR DEPRESSION; SELF-MEDICATION; GULF-WAR; ABUSE
Posttraumatic Stress Disorder (PTSD) is frequently comorbid with alcohol use
disorders (AUD; Calabrese et al., 2011; McFall, Mackay, & Donovan, 1992). Among
several explanations for this comorbidity, the most empirically supported is the
self-medication theory which postulates that substances are used to medicate PTSD-
related distress (Keane & Wolfe, 1990; Khantzian, 1985; Stewart, 1996). The current
study examines the effects of trauma-related distress on alcohol use (total
drinking days, drinks per drinking day, heavy drinking days) in a sample of 127
trauma-exposed Veterans following deployment to Iraq or Afghanistan. The dysphoria
symptoms of PTSD were used as an indicator of distress, and examined as a moderator
in the relationship between intrusion symptoms of PTSD and alcohol use. The
proposed moderation model was tested using cross-sectional data from the first
month following return from deployment, and at 6 months and at 12 months post-
deployment. Results showed that dysphoria symptoms significantly moderated
relations between intrusions and total drinking days and heavy drinking days at one
month post-deployment; however, a significant pattern was not demonstrated at 6
months and 12 months. Further, dysphoria did not moderate the relation between
intrusion symptoms and drinks per drinking day at the three time points.
Theoretical and clinical implications are subsequently discussed. (C) 2015 Elsevier
Ltd. All rights reserved. [Contractor, Ateka A.] Univ Toledo, Dept Psychol,
2801 W Bancroft St, Toledo, OH 43606 USA; [Contractor, Ateka A.; Capone, Christy;
Reddy, Madhavi K.; Shea, M. Tracie] Brown Univ, Dept Psychiat & Human Behav, Warren
Alpert Med Sch, Box Box G-BH, Providence, RI 02912 USA; [Presseau, Candice; Capone,
Christy; Shea, M. Tracie] Providence VA Med Ctr, Dept Vet Affairs, 830 Chalkstone
Ave, Providence, RI 02908 USA; [Presseau, Candice] Lehigh Univ, Dept Educ & Human
Serv, Coll Educ, 111 Res Dr, Bethlehem, PA 18015 USA; [Reddy, Madhavi K.] Univ
Texas Hlth Sci Ctr Houston, Dept Psychiat & Behav Sci, 1941 East Rd, Houston, TX
77054 USA Contractor, AA (reprint author), VA Boston Healthcare Syst,
Massachusetts Vet Epidemiol Res & Informat Ctr, 150 South Huntington Ave, Jamaica
Plain, MA 02130 USA. ateka.c@gmail.com U.S. Army Medical Research
and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC)
[W81XWH-06-1-0573] This research was supported by grant W81XWH-06-1-0573, from
the U.S. Army Medical Research and Materiel Command. The views expressed in this
article are those of the authors and do not necessarily represent the views of the
Department of Veterans Affairs. Aiken LS, 1991, MULTIPLE REGRESSION; American
Psychiatric Association, 2013, DIAGN STAT MAN MENT; American Psychiatric
Association, 1994, DIAGN STAT MAN MENT; Back SE, 2010, AM J PSYCHIAT, V167, P11,
DOI 10.1176/appi.ajp.2009.09111602; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI
10.1007/BF02105408; Boyd-Ball AJ, 2006, J TRAUMA STRESS, V19, P937, DOI
10.1002/jts.20176; Breslau N, 1998, ARCH GEN PSYCHIAT, V55, P626, DOI
10.1001/archpsyc.55.7.626; Brewin CR, 2003, CLIN PSYCHOL REV, V23, P339, DOI
10.1016/S0272-7358(03)00033-3; BROWN PJ, 1994, DRUG ALCOHOL DEPEN, V35, P51, DOI
10.1016/0376-8716(94)90110-4; Calabrese JR, 2011, J CLIN PSYCHIAT, V72, P1072, DOI
10.4088/JCP.11m06956; Capone C, 2013, J TRAUMA STRESS, V26, P354, DOI
10.1002/jts.21817; Carey KB, 2006, J CONSULT CLIN PSYCH, V74, P943, DOI
10.1037/0022-006X.74.5.943; Chilcoat HD, 1998, ADDICT BEHAV, V23, P827, DOI
10.1016/S0306-4603(98)00069-0; Coffey SF, 2007, DRUG ALCOHOL DEPEN, V87, P241, DOI
10.1016/j.drugalcdep.2006.08.025; Contractor AA, 2014, PSYCHIAT RES, V215, P146,
DOI 10.1016/j.psychres.2013.10.015; Curran PJ, 1996, PSYCHOL METHODS, V1, P16, DOI
10.1037/1082-989X.1.1.16; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI
10.1017/S0033291700048017; Duncan D. F., 1974, CLIN TOXICOLOGY B, V4, P69; Durham
TA, 2015, PSYCHIAT RES, V228, P150, DOI 10.1016/j.psychres.2015.04.034; Elhai JD,
2015, J AFFECT DISORDERS, V175, P373, DOI 10.1016/j.jad.2015.01.034; Elhai JD,
2011, J ANXIETY DISORD, V25, P849, DOI 10.1016/j.janxdis.2011.04.007; Erbes C,
2007, MIL MED, V172, P359, DOI 10.7205/MILMED.172.4.359; Forbes D, 2011, J AFFECT
DISORDERS, V132, P165, DOI 10.1016/j.jad.2011.02.011; Gfroerer JC, 1997, AM J
PUBLIC HEALTH, V87, P62, DOI 10.2105/AJPH.87.1.62; Gootzeit J, 2011, CLIN PSYCHOL
REV, V31, P993, DOI 10.1016/j.cpr.2011.06.005; Grant BF, 1997, J SUBST ABUSE, V9,
P103, DOI 10.1016/S0899-3289(97)90009-2; GRANT BF, 1995, DRUG ALCOHOL DEPEN, V39,
P197, DOI 10.1016/0376-8716(95)01160-4; Grubaugh AL, 2005, J NERV MENT DIS, V193,
P658, DOI 10.1097/01.nmd.0000180740.02644.ab; Haller M, 2014, PSYCHOL ADDICT BEHAV,
V28, P841, DOI 10.1037/a0035878; Hayes AF, 2009, BEHAV RES METHODS, V41, P924, DOI
10.3758/BRM.41.3.924; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI
10.1056/NEJMoa040603; Jacobson IG, 2008, JAMA-J AM MED ASSOC, V300, P663, DOI
10.1001/jama.300.6.663; Jakupcak M, 2006, J TRAUMA STRESS, V19, P387, DOI
10.1002/jts.20125; Kaysen D, 2007, ADDICT BEHAV, V32, P1272, DOI
10.1016/j.addbeh.2006.09.007; KEANE TM, 1990, J APPL SOC PSYCHOL, V20, P1776, DOI
10.1111/j.1559-1816.1990.tb01511.x; Kerr WC, 2009, ADDICTION, V104, P27, DOI
10.1111/j.1360-0443.2008.02391.x; Khantzian E. J., 1975, PSYCHIATRY DIGEST, V36,
P19; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259; Kline R. B., 2011, PRINCIPLES
PRACTICE; Maguen S, 2009, MIL MED, V174, P779, DOI 10.7205/MILMED-D-03-2808;
Marshall-Berenz EC, 2011, PERS INDIV DIFFER, V50, P588, DOI
10.1016/j.paid.2010.11.033; McCauley JL, 2012, CLIN PSYCHOL-SCI PR, V19, P283, DOI
10.1111/cpsp.12006; MCFALL ME, 1992, J STUD ALCOHOL, V53, P357, DOI
10.15288/jsa.1992.53.357; McFarlane AC, 1998, ADDICT BEHAV, V23, P813, DOI
10.1016/S0306-4603(98)00098-7; Miller MW, 2010, J TRAUMA STRESS, V23, P631, DOI
10.1002/jts.20559; Moore AA, 2011, ADDICTION, V106, P111, DOI 10.1111/j.1360-
0443.2010.03229.x; Najt P, 2011, PSYCHIAT RES, V186, P159, DOI
10.1016/j.psychres.2010.07.042; O&rsquo;Connell RT, 1990, LINEAR STAT MODELS A;
Owens GP, 2014, J INTERPERS VIOLENCE, V29, P1318, DOI 10.1177/0886260513506274;
Read JP, 2004, ADDICT BEHAV, V29, P1665, DOI 10.1016/j.addbeh.2004.02.061; Robinson
J, 2011, ARCH GEN PSYCHIAT, V68, P800, DOI 10.1001/archgenpsychiatry.2011.75; Shea
MT, 2013, PSYCHIAT RES, V210, P1042, DOI 10.1016/j.psychres.2013.08.039; Shipherd
JC, 2005, ADDICT BEHAV, V30, P595, DOI 10.1016/j.addbeh.2004.07.004; Simms LJ,
2002, J ABNORM PSYCHOL, V111, P637, DOI 10.1037//0021-843X.111.4.637; Simons JS,
2005, AM J DRUG ALCOHOL AB, V31, P285, DOI 10.1081/ADA-200047937; Sobell L. C,
1992, MEASURING ALCOHOL CO; Sobell LC, 1996, DRUG ALCOHOL DEPEN, V42, P49, DOI
10.1016/0376-8716(96)01263-X; Spera C, 2011, J STUD ALCOHOL DRUGS, V72, P5, DOI
10.15288/jsad.2011.72.5; Steil R, 2011, J TRAUMA STRESS, V24, P102, DOI
10.1002/jts.20617; Stewart SH, 1998, ADDICT BEHAV, V23, P797, DOI 10.1016/S0306-
4603(98)00070-7; Stewart SH, 1999, PSYCHOL ADDICT BEHAV, V13, P78, DOI
10.1037/0893-164X.13.2.78; Stewart SH, 2004, J ANXIETY DISORD, V18, P51, DOI
10.1016/j.janxdis.2003.07.006; Stewart SH, 1996, PSYCHOL BULL, V120, P83, DOI
10.1037/0033-2909.120.1.83; Waldrop AE, 2007, ADDICT BEHAV, V32, P634, DOI
10.1016/j.addbeh.2006.06.001; Watson D, 2009, ANNU REV CLIN PSYCHO, V5, P221, DOI
10.1146/annurev.clinpsy.032408.153510; Weathers FW, 2001, DEPRESS ANXIETY, V13,
P132, DOI 10.1002/da.1029; Weiss NH, 2013, DRUG ALCOHOL DEPEN, V128, P45, DOI
10.1016/j.drugalcdep.2012.07.017; Yufik T, 2010, J ABNORM PSYCHOL, V119, P764, DOI
10.1037/a0020981 68 3 3 0 18 PERGAMON-ELSEVIER SCIENCE LTD OXFORD
THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND 0306-
4603 1873-6327 ADDICT BEHAV Addict. Behav. APR 2016 55
5 14 10.1016/j.addbeh.2015.12.010
10 Psychology, Clinical; Substance Abuse Psychology; Substance Abuse
DC8EU WOS:000369453500002 26735913 2019-09-25
J Hernandez, L; Cancilliere, MK; Graves, H; Chun, TH; Lewander, W; Spirito, A
Hernandez, Lynn; Cancilliere, Mary Kathryn; Graves, Hannah; Chun,
Thomas H.; Lewander, William; Spirito, Anthony Substance Use and
Depressive Symptoms Among Adolescents Treated in a Pediatric Emergency Department
JOURNAL OF CHILD & ADOLESCENT SUBSTANCE ABUSE English
Article gender; depressed mood;
adolescents; substance use NATIONALLY REPRESENTATIVE SAMPLE; ALCOHOL-USE;
GENDER-DIFFERENCES; USE DISORDERS; RISK-FACTORS; CANNABIS USE; COOCCURRING ALCOHOL;
CIGARETTE-SMOKING; PROBLEM DRINKING; SELF-MEDICATION The current study examined
associations between substance use and depressed mood by gender and type of
substance used (no use, alcohol, marijuana, or both alcohol and marijuana) in a
sample of 713 adolescents (M-age = 15.3) recruited from a Pediatric Emergency
Department (PED). Adolescents who reported any marijuana use had higher overall
depressed mood scores compared to all other adolescents. When examined by gender,
females with both alcohol and marijuana use reported the highest overall depressed
mood symptoms. These results suggest the usefulness of screening and identification
of depressive symptoms among adolescents presenting to a PED for substance use-
related problems. [Hernandez, Lynn; Cancilliere, Mary Kathryn; Graves, Hannah;
Chun, Thomas H.; Lewander, William; Spirito, Anthony] Brown Univ, Providence, RI
02912 USA; [Chun, Thomas H.; Lewander, William] Rhode Isl Hosp, Providence, RI USA
Hernandez, L (reprint author), Brown Univ, Alpert Med Sch, Ctr Alcohol &
Addict Studies, Dept Behav & Social Sci, Box GS-121-5, Providence, RI 02912 USA.
Lynn_Hernandez@Brown.edu National Institute of Alcohol Abuse
AlcoholismUnited States Department of Health & Human ServicesNational Institutes of
Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01
AA013385, R01 AA009892, K01 AA021081] Support for this study was provided by
the National Institute of Alcohol Abuse & Alcoholism (R01 AA013385, R01 AA009892,
and K01 AA021081). Audrain-McGovern J, 2009, ADDICTION, V104, P1743, DOI
10.1111/j.1360-0443.2009.02617.x; Babor T. F., 1992, ALCOHOL USE DISORDER, V92;
Brook DW, 2002, ARCH GEN PSYCHIAT, V59, P1039, DOI 10.1001/archpsyc.59.11.1039;
BUKSTEIN OG, 1993, ACTA PSYCHIAT SCAND, V88, P403, DOI 10.1111/j.1600-
0447.1993.tb03481.x; Clark DB, 1997, J AM ACAD CHILD PSY, V36, P1744, DOI
10.1097/00004583-199712000-00023; Clark HK, 2011, ADDICT BEHAV, V36, P488, DOI
10.1016/j.addbeh.2011.01.018; Cole SR, 2000, J CLIN EPIDEMIOL, V53, P285, DOI
10.1016/S0895-4356(99)00151-1; Conway KP, 2013, J ADOLESCENT HEALTH, V52, P716, DOI
10.1016/j.jadohealth.2012.12.006; Costello EJ, 2003, ARCH GEN PSYCHIAT, V60, P837,
DOI 10.1001/archpsyc.60.8.837; Crum RM, 2001, ADDICT BEHAV, V26, P765, DOI
10.1016/S0306-4603(00)00163-5; Crum RM, 2008, ADDICT BEHAV, V33, P24, DOI
10.1016/j.addbeh.2007.05.008; Cyranowski JM, 2000, ARCH GEN PSYCHIAT, V57, P21, DOI
10.1001/archpsyc.57.1.21; Degenhardt L, 2003, ADDICTION, V98, P1493, DOI
10.1046/j.1360-0443.2003.00437.x; DEYKIN EY, 1987, AM J PUBLIC HEALTH, V77, P178,
DOI 10.2105/AJPH.77.2.178; Diego MA, 2003, ADOLESCENCE, V38, P35; Fairlie Anne M,
2006, Int J Adolesc Med Health, V18, P115; Fergusson DM, 2002, ADDICTION, V97,
P1123, DOI 10.1046/j.1360-0443.2002.00103.x; Glied S, 2002, ARCH PEDIAT ADOL MED,
V156, P1009, DOI 10.1001/archpedi.156.10.1009; Goodman E, 2000, PEDIATRICS, V106,
P748, DOI 10.1542/peds.106.4.748; Grant BF, 2004, ARCH GEN PSYCHIAT, V61, P1107,
DOI 10.1001/archpsyc.61.11.1107; Hallfors DD, 2005, AM J PREV MED, V29, P163, DOI
10.1016/j.amepre.2005.06.002; Hallfors DD, 2004, AM J PREV MED, V27, P224, DOI
10.1016/j.amepre.2004.06.001; Hammer T, 1997, J DRUG ISSUES, V27, P713, DOI
10.1177/002204269702700403; Harrell ZAT, 2008, ADDICT BEHAV, V33, P359, DOI
10.1016/j.addbeh.2007.09.014; Hertzog C., 1990, PSYCHOL ASSESSMENT, V2, P64, DOI
DOI 10.1037/1040-3590.2.1.64; Hooshmand S, 2012, J ADOLESCENT HEALTH, V50, P140,
DOI 10.1016/j.jadohealth.2011.05.016; HUSSONG AM, 1994, J STUD ALCOHOL, V55, P707,
DOI 10.15288/jsa.1994.55.707; JESSOR R, 1980, AM J PUBLIC HEALTH, V70, P604, DOI
10.2105/AJPH.70.6.604; Johnston L, 2013, MONITORING FUTURE NA; Johnston L. D.,
2010, MONITORING FUTURE NA; Johnston L.D., 2011, MONITORING FUTURE NA; KANDEL DB,
1991, J YOUTH ADOLESCENCE, V20, P289, DOI 10.1007/BF01537613; Kaplow JB, 2001, J
CLIN CHILD PSYCHOL, V30, P316, DOI 10.1207/S15374424JCCP3003_4; Kelder SH, 2001, AM
J PUBLIC HEALTH, V91, P761, DOI 10.2105/AJPH.91.5.761; KESSLER RC, 1993, AM J
COMMUN PSYCHOL, V21, P607, DOI 10.1007/BF00942174; KHANTZIAN EJ, 1985, AM J
PSYCHIAT, V142, P1259; King CA, 1996, J AM ACAD CHILD PSY, V35, P743, DOI
10.1097/00004583-199606000-00014; Kosterman R, 2010, J PSYCHOPATHOL BEHAV, V32,
P118, DOI 10.1007/s10862-009-9138-0; Labouvie E W, 1990, J Subst Abuse, V2, P265;
LABOUVIE EW, 1986, INT J ADDICT, V21, P333, DOI 10.3109/10826088609074838; Locke
TF, 2001, PSYCHOL ADDICT BEHAV, V15, P227, DOI 10.1037/0893-164X.15.3.227; Masten
AS, 2009, ALCOHOL RES HEALTH, V32, P3; Measelle JR, 2006, J ABNORM PSYCHOL, V115,
P524, DOI 10.1037/0021-843X.115.3.524; Meririnne E, 2010, J ADOLESCENCE, V33, P221,
DOI 10.1016/j.adolescence.2009.07.010; Midanik LT, 2007, DRUG ALCOHOL DEPEN, V90,
P72, DOI 10.1016/j.drugalcdep.2007.02.024; Nolen-Hoeksema S, 2004, CLIN PSYCHOL
REV, V24, P981, DOI 10.1016/j.cpr.2004.08.003; Orlando M, 2001, J CONSULT CLIN
PSYCH, V69, P959, DOI 10.1037//0022-006X.69.6.959; Orton HD, 2009, CHILD YOUTH SERV
REV, V31, P649, DOI 10.1016/j.childyouth.2008.12.005; Pacek LR, 2013, J AFFECT
DISORDERS, V148, P188, DOI 10.1016/j.jad.2012.11.059; Pacek LR, 2012, AM J
ADDICTION, V21, P435, DOI 10.1111/j.1521-0391.2012.00249.x; Pomerleau CS, 2003,
ADDICT BEHAV, V28, P575, DOI 10.1016/S0306-4603(01)00257-X; Poulin C, 2005,
ADDICTION, V100, P525, DOI 10.1111/j.1360-0443.2005.01033.x; RADLOFF L S, 1977,
Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306;
RADLOFF LS, 1991, J YOUTH ADOLESCENCE, V20, P149, DOI 10.1007/BF01537606; Rao U,
2000, J AM ACAD CHILD PSY, V39, P215, DOI 10.1097/00004583-200002000-00022; Repetto
PB, 2004, J STUD ALCOHOL, V65, P169, DOI 10.15288/jsa.2004.65.169; Rohde P, 1996, J
AM ACAD CHILD PSY, V35, P101, DOI 10.1097/00004583-199601000-00018; Rudolph KD,
2002, J ADOLESCENT HEALTH, V30, P3, DOI 10.1016/S1054-139X(01)00383-4; Rudolph KD,
1999, CHILD DEV, V70, P660, DOI 10.1111/1467-8624.00048; Silberg J, 2003, J CHILD
PSYCHOL PSYC, V44, P664, DOI 10.1111/1469-7610.00153; Singer L, 1995, J Subst
Abuse, V7, P165, DOI 10.1016/0899-3289(95)90002-0; Spirito A, 2004, J PEDIATR-US,
V145, P396, DOI 10.1016/j.jpeds.2004.04.057; Spirito A, 2011, ARCH PEDIAT ADOL MED,
V165, P269, DOI 10.1001/archpediatrics.2010.296; Tolou-Shams M, 2008, J STUD
ALCOHOL DRUGS, V69, P58, DOI 10.15288/jsad.2008.69.58; Waller MW, 2006, ARCH WOMEN
MENT HLTH, V9, P139, DOI 10.1007/s00737-006-0121-4; Weinstein SM, 2013, J CLIN
CHILD ADOLESC, V42, P629, DOI 10.1080/15374416.2013.794698; Wills TA, 2002, HEALTH
PSYCHOL, V21, P122, DOI 10.1037//0278-6133.21.2.122; Windle M, 1999, DEV
PSYCHOPATHOL, V11, P823, DOI 10.1017/S0954579499002345 68 2 2 0
10 ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD ABINGDON 2-4 PARK SQUARE,
MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND 1067-828X 1547-0652 J
CHILD ADOLES SUBST J. Child Adolesc. Subst. Abus. MAR 3 2016 25 2
124 133 10.1080/1067828X.2014.889633
10 Substance Abuse Substance Abuse DE3ZG WOS:000370568400004
27152065 Green Accepted 2019-09-25
J Womack, SR; Shaw, DS; Weaver, CM; Forbes, EE Womack, Sean
R.; Shaw, Daniel S.; Weaver, Chelsea M.; Forbes, Erika E.
Bidirectional Associations Between Cannabis Use and Depressive Symptoms From
Adolescence Through Early Adulthood Among At-Risk Young MenJOURNAL OF STUDIES ON
ALCOHOL AND DRUGS English Article
MARIJUANA USE; SUBSTANCE USE; GENDER-DIFFERENCES; CONDUCT DISORDER; HEALTH
OUTCOMES; DRUG-USE; DEPENDENCE; REWARD; ABUSE; TRAJECTORIESObjective: Previous
studies have established a relationship between cannabis use and affective problems
among adolescents and young adults; however, the direction of these associations
remains a topic of debate. The present study sought to examine bidirectional
associations between cannabis use and depressive symptoms, specifically testing the
validity of two competing hypotheses: the cannabis effect hypothesis, which
suggests that cannabis use contributes to the onset of later depressive symptoms;
and the self-medication hypothesis, which posits that individuals increase their
use of a substance to alleviate distressing psychological symptoms. Method:
Participants in this study were 264 low-socioeconomic-status males assessed at ages
17, 20, and 22. Cross-lag panel models were fit to test bidirectional associations
between cannabis use frequency and depressive symptoms across the transition from
adolescence to early adulthood. In addition, analyses were conducted within two
high-risk subsamples to examine whether associations between cannabis use frequency
(ranging from never used to daily use) and depressive symptoms differed among
regular cannabis users (used cannabis more than once per week) or subjects
reporting at least mild levels of depressive symptoms. Results: Cannabis use and
depressive symptoms were concurrently correlated. Cannabis use predicted increases
in later depressive symptoms, but only among the mild-depression subsample.
Depressive symptoms predicted only slight increases in later cannabis use, among
the subsample of regular cannabis users. Conclusions: Temporal patterns of cannabis
use and depressive symptoms provide evidence for the cannabis effect but limited
evidence for the self-medication hypothesis. Adolescents higher in depressive
symptoms may be vulnerable to the adverse psychological effects of using cannabis.
Results are discussed in terms of implications for basic research, prevention, and
intervention. [Womack, Sean R.; Shaw, Daniel S.; Weaver, Chelsea M.; Forbes,
Erika E.] Univ Pittsburgh, Dept Psychol, Sennott Sq Off 4424,210 S Bouquet St,
Pittsburgh, PA 15206 USA; [Forbes, Erika E.] Univ Pittsburgh, Dept Psychiat,
Pittsburgh, PA 15206 USA Womack, SR (reprint author), Univ Pittsburgh, Dept
Psychol, Sennott Sq Off 4424,210 S Bouquet St, Pittsburgh, PA 15206 USA.
srw38@pitt.edu National Institute on Drug AbuseUnited States
Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
National Institute on Drug Abuse (NIDA) [DA25630, DA26222] This research was
supported by National Institute on Drug Abuse Grants DA25630 and DA26222 (to Daniel
S. Shaw and Erika E. Forbes). The authors have no potential or competing conflicts
of interest. American Psychiatric Association, 1980, DIAGN STAT MAN MENT;
Arnett JJ, 2000, AM PSYCHOL, V55, P469, DOI 10.1037/0003-066X.55.5.469; Bardone AM,
1998, J AM ACAD CHILD PSY, V37, P594, DOI 10.1097/00004583-199806000-00009; BECK
AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; Blum K,
1996, J ROY SOC MED, V89, P396; Bolla KI, 2002, NEUROLOGY, V59, P1337, DOI
10.1212/01.WNL.0000031422.66442.49; Bottorff JL, 2009, SUBST ABUSE TREAT PR, V4,
DOI 10.1186/1747-597X-4-7; Bovasso GB, 2001, AM J PSYCHIAT, V158, P2033, DOI
10.1176/appi.ajp.158.12.2033; Brook DW, 2002, ARCH GEN PSYCHIAT, V59, P1039, DOI
10.1001/archpsyc.59.11.1039; Cahalan D, 1969, AM DRINKING PRACTICE; Chen CY, 2002,
SOC PSYCH PSYCH EPID, V37, P199, DOI 10.1007/s00127-002-0541-z; Degenhardt L, 2003,
ADDICTION, V98, P1493, DOI 10.1046/j.1360-0443.2003.00437.x; Degenhardt L, 2006,
CAN J PSYCHIAT, V51, P556, DOI 10.1177/070674370605100903; Degenhardt L, 2008, PLOS
MED, V5, P1053, DOI 10.1371/journal.pmed.0050141; Dishion T. J., 2000, APPL DEV
SCI, V4, P89, DOI [10.1207/S1532480XADS0402_4, DOI 10.1207/S1532480XADS0402_4];
Elliott D. S., 1985, EXPLAINING DELINQUEN; Essau CA, 2010, J AFFECT DISORDERS,
V127, P185, DOI 10.1016/j.jad.2010.05.016; Fergusson DM, 2008, ADDICTION, V103,
P969, DOI 10.1111/j.1360-0443.2008.02221.x; Fergusson DM, 2008, ADDICTION, V103,
P977, DOI DOI 10.1111/J.1360-0443.2008.02221.X; Finlay AK, 2012, DRUG ALCOHOL
DEPEN, V121, P118, DOI 10.1016/j.drugalcdep.2011.08.020; Flom PL, 2001, J DRUG
ISSUES, V31, P425, DOI 10.1177/002204260103100204; Forbes EE, 2012, J CHILD PSYCHOL
PSYC, V53, P3, DOI 10.1111/j.1469-7610.2011.02477.x; Green BE, 2000, J HEALTH SOC
BEHAV, V41, P40, DOI 10.2307/2676359; Hankin BL, 1998, J ABNORM PSYCHOL, V107,
P128, DOI 10.1037/0021-843X.107.1.128; HENRY B, 1993, J ABNORM CHILD PSYCH, V21,
P469, DOI 10.1007/BF00916314; Hooper D., 2008, ELECT J BUSINESS RES, V6, P53, DOI
[DOI 10.1037/1082-989X.12.1.58, DOI 10.1016/J.INFBEH.2006.11.010]; Hussong AM,
2013, J CLIN CHILD ADOLESC, V42, P863, DOI 10.1080/15374416.2013.838772; Jackson
Benita, 2011, Race Soc Probl, V3, P119; Johnston L. D., 2014, MONITORING FUTURE NA,
VII; KANDEL DB, 1986, ARCH GEN PSYCHIAT, V43, P255; KHANTZIAN EJ, 1985, AM J
PSYCHIAT, V142, P1259; Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI
10.1016/S0893-133X(00)00195-0; LUKAS SE, 1995, DRUG ALCOHOL DEPEN, V37, P131, DOI
10.1016/0376-8716(94)01067-U; Maalouf FT, 2011, J AFFECT DISORDERS, V133, P625, DOI
10.1016/j.jad.2011.04.041; Marcotte D, 1999, SEX ROLES, V41, P31, DOI
10.1023/A:1018833607815; Marmorstein NR, 2011, ADDICT BEHAV, V36, P773, DOI
10.1016/j.addbeh.2011.02.006; Marmorstein NR, 2010, J CLIN CHILD ADOLESC, V39,
P545, DOI 10.1080/15374416.2010.486325; Matochik JA, 2005, DRUG ALCOHOL DEPEN, V77,
P23, DOI 10.1016/j.drugalcdep.2004.06.011; Medina KL, 2007, J CHILD PSYCHOL PSYC,
V48, P592, DOI 10.1111/j.1469-7610.2007.01728.x; Miller-Johnson S, 1998, J ABNORM
CHILD PSYCH, V26, P221, DOI 10.1023/A:1022676302865; Muthen L. K., 1998, MPLUS
USERS GUIDE; Nielsen T, 2007, NORD PSYCHOL, V59, P231, DOI 10.1027/1901-
2276.59.3.231; O'Hara MM, 1998, PSYCHOL REP, V82, P1395, DOI 10.2466/PR0.82.3.1395-
1401; Pacek LR, 2013, J AFFECT DISORDERS, V148, P188, DOI
10.1016/j.jad.2012.11.059; Patton GC, 2002, BRIT MED J, V325, P1195, DOI
10.1136/bmj.325.7374.1195; Perkonigg A, 2008, ADDICTION, V103, P450; Perkonigg A,
2008, ADDICTION, V103, P439, DOI 10.1111/j.1360-0443.2007.02064.x; Preacher K. J.,
2006, COMPUTING POWER MINI; Pujazon-Zazik M, 2009, AM J MENS HEALTH, V3, P265, DOI
10.1177/1557988309340577; Repetto PB, 2008, J RES ADOLESCENCE, V18, P421, DOI
10.1111/j.1532-7795.2008.00566.x; Sattler JM, 1992, ASSESSMENT CHILDREN; Shaw DS,
2003, DEV PSYCHOL, V39, P189, DOI 10.1037/0012-1649.39.2.189; Sitnick SL, 2014, DEV
PSYCHOPATHOL, V26, P125, DOI 10.1017/S0954579413000539; Steinberg L, 2005, TRENDS
COGN SCI, V9, P69, DOI 10.1016/j.tics.2004.12.005; Substance Abuse and Mental
Health Services Administration, 2013, NSDUH SER H, VH- 46; Tabachnick B. G., 2007,
USING MULTIVARIATE S; TELLEGEN A, 1967, J CONSULT PSYCHOL, V31, P499, DOI
10.1037/h0024963; Troisi A, 1998, ADDICTION, V93, P487, DOI 10.1046/j.1360-
0443.1998.9344874.x; Wechsler D., 1991, MANUAL WECHSLER INTE; WEISSMAN MM, 1993, J
AFFECT DISORDERS, V29, P77, DOI 10.1016/0165-0327(93)90025-F; WELTE JW, 1993,
ALCOHOL CLIN EXP RES, V17, P758, DOI 10.1111/j.1530-0277.1993.tb00836.x; White
Aaron M, 2004, Subst Abus, V25, P53, DOI 10.1300/J465v25n01_08; ZOCCOLILLO M, 1992,
J AM ACAD CHILD PSY, V31, P547, DOI 10.1097/00004583-199205000-00024 63 11
11 0 19 ALCOHOL RES DOCUMENTATION INC CENT ALCOHOL STUD RUTGERS
UNIV PISCATAWAY C/O DEIRDRE ENGLISH, 607 ALLISON RD, PISCATAWAY, NJ 08854-8001
USA 1937-1888 1938-4114 J STUD ALCOHOL DRUGS J. Stud. Alcohol Drugs
MAR 2016 77 2 287 297
 10.15288/jsad.2016.77.287 11 Substance Abuse; Psychology
Substance Abuse; Psychology DH4QG WOS:000372769900014 26997187 Green
Published 2019-09-25
J Lipsky, S; Kernic, MA; Qiu, Q; Hasin, DS Lipsky, Sherry;
Kernic, Mary A.; Qiu, Qian; Hasin, Deborah S. Posttraumatic stress
disorder and alcohol misuse among women: effects of ethnic minority stressors
SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY English
Article Posttraumatic stress disorder;
Alcohol misuse; Race/ethnicity; Longitudinal analysis NATIONAL EPIDEMIOLOGIC
SURVEY; SUBSTANCE USE DISORDERS; PSYCHIATRIC DIAGNOSTIC MODULES; REPORTED RACIAL-
DISCRIMINATION; SELF-MEDICATION HYPOTHESIS; GENERAL-POPULATION SAMPLE; INTIMATE
PARTNER VIOLENCE; DRUG-USE DISORDERS; IV AUDADIS-IV; UNITED-STATES The aims of
this study were to examine the relationship between adult-onset posttraumatic
stress disorder (PTSD) and subsequent alcohol use outcomes (frequent heavy
drinking, alcohol abuse, and alcohol dependence) in non-Hispanic white, non-
Hispanic black, and Hispanic US women, and whether this relationship was moderated
by ethnic minority stressors (discrimination and acculturation). The study sample
was drawn from two waves of the National Epidemiologic Surveys of Alcohol and
Related Conditions, employing time-dependent data to conduct multiple extended Cox
regression. Women with PTSD were over 50 % more likely than those without PTSD to
develop alcohol dependence [adjusted hazards ratio (aHR) 1.55; 95 % confidence
interval (CI) 1.15, 2.08]. Hispanic and black women were at lower risk of most
alcohol outcomes than white women. In race-/ethnic-specific analyses, however, PTSD
only predicted alcohol abuse among Hispanic women (aHR 3.02; CI 1.33, 6.84). Higher
acculturation was positively associated with all alcohol outcomes among Hispanic
women and discrimination was associated with AUD among Hispanic and black women.
Acculturation and discrimination modified the effect of PTSD on AUD among Hispanic
women: PTSD predicted alcohol dependence among those with low acculturation (aHR
10.2; CI 1.27, 81.80) and alcohol abuse among those without reported discrimination
(aHR 6.39; CI 2.76, 16.49). PTSD may influence the development of hazardous
drinking, especially among Hispanic women. The influence of PTSD on alcohol
outcomes is most apparent, however, when ethnic minority stressors are not present.
[Lipsky, Sherry; Qiu, Qian] Univ Washington, Dept Psychiat & Behav Sci,
Harborview Med Ctr, Seattle, WA 98195 USA; [Kernic, Mary A.] Univ Washington, Sch
Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA; [Hasin, Deborah S.] Columbia
Univ, New York State Psychiat Inst, New York, NY USA Lipsky, S (reprint author),
Univ Washington, Dept Psychiat & Behav Sci, Harborview Med Ctr, Seattle, WA 98195
USA. lipsky@u.washington.edu National Institutes of Health, National
Institute of Alcohol Abuse and Alcoholism (NIH/NIAAA) [R01 AA 018686] This study
was funded by the National Institutes of Health, National Institute of Alcohol
Abuse and Alcoholism (NIH/NIAAA) Grant R01 AA 018686. Its contents are solely the
responsibility of the authors and do not necessarily represent the official views
of NIH/NIAAA. Alcantara C, 2013, CLIN PSYCHOL REV, V33, P107, DOI
10.1016/j.cpr.2012.10.005; Alegria M, 2006, J CLIN PSYCHIAT, V67, P56, DOI
10.4088/JCP.v67n0109; Alegria M, 2008, AM J PSYCHIAT, V165, P359, DOI
10.1176/appi.ajp.2007.07040704; Alegria Margarita, 2007, Res Hum Dev, V4, P19;
Alegria M, 2007, AM J PUBLIC HEALTH, V97, P68, DOI 10.2105/AJPH.2006.087205;
Alegria M, 2013, MED CARE, V51, P1114, DOI 10.1097/MLR.0000000000000007; Amaro H,
2007, J URBAN HEALTH, V84, P508, DOI 10.1007/s11524-007-9160-z; Asnaani A, 2010, J
NERV MENT DIS, V198, P551, DOI 10.1097/NMD.0b013e3181ea169f; Badawi MA, 1999, SOC
PSYCH PSYCH EPID, V34, P91, DOI 10.1007/s001270050117; Bartoli F, 2015, ADDICT
BEHAV, V41, P46, DOI 10.1016/j.addbeh.2014.09.029; Bergman P, 2010, INT J SOC
PSYCHIATR, V56, P119, DOI 10.1177/0020764008098838; Borrell LN, 2007, AM J
EPIDEMIOL, V166, P1068, DOI 10.1093/aje/kwm180; Breslau J, 2006, PSYCHOL MED, V36,
P57, DOI 10.1017/S0033291705006161; Breslau J, 2005, PSYCHOL MED, V35, P317, DOI
10.1017/S0033291704003514; Breslau N, 1998, ARCH GEN PSYCHIAT, V55, P626, DOI
10.1001/archpsyc.55.7.626; BRESLAU N, 1992, AM J PSYCHIAT, V149, P671; Breslau N,
1997, ARCH GEN PSYCHIAT, V54, P81; Breslau N, 2003, ARCH GEN PSYCHIAT, V60, P289,
DOI 10.1001/archpsyc.60.3.289; Breslau N, 2008, ARCH GEN PSYCHIAT, V65, P431, DOI
10.1001/archpsyc.65.4.431; Breslau N, 2009, TRAUMA VIOLENCE ABUS, V10, P198, DOI
10.1177/1524838009334448; BROWN TN, 2000, RACE SOC, V0002; Caetano R, 2003,
ADDICTION, V98, P791, DOI 10.1046/j.1360-0443.2003.00407.x; Caetano R, 2008,
ALCOHOL CLIN EXP RES, V32, P314, DOI 10.1111/j.1530-0277.2007.00576.x; Caetano R,
2007, J INTERPERS VIOLENCE, V22, P1431, DOI 10.1177/0886260507305568; Caetano R,
2009, DRUG ALCOHOL DEPEN, V99, P215, DOI 10.1016/j.drugalcdep.2008.08.011; Cheng
HL, 2015, J COUNS PSYCHOL, V62, P38, DOI 10.1037/cou0000052; Cohen E, 2007, DRUG
ALCOHOL DEPEN, V86, P214, DOI 10.1016/j.drugalcdep.2006.06.008; Cohen LR, 2006,
PSYCHIAT SERV, V57, P100, DOI 10.1176/appi.ps.57.1.100; Coronado Gloria D, 2005,
Ethn Dis, V15, P53; Cranford JA, 2011, DRUG ALCOHOL DEPEN, V117, P145, DOI
10.1016/j.drugalcdep.2011.01.011; CUELLAR I, 1995, HISPANIC J BEHAV SCI, V17, P275,
DOI 10.1177/07399863950173001; Cuellar I, 2004, J AGING HEALTH, V16, P447, DOI
10.1177/0898264304265764; DEYO RA, 1985, AM J PUBLIC HEALTH, V75, P51, DOI
10.2105/AJPH.75.1.51; Dinenberg RE, 2014, AM J HEALTH PROMOT, V28, P294, DOI
10.4278/ajhp.121023-QUAN-511; Donovan RA, 2013, J CLIN PSYCHOL, V69, P397, DOI
10.1002/jclp.21936; Epstein JN, 1998, CHILD ABUSE NEGLECT, V22, P223, DOI
10.1016/S0145-2134(97)00133-6; ESCOBAR JI, 1983, AM J PSYCHIAT, V140, P47; Escobar
JI, 1998, ARCH GEN PSYCHIAT, V55, P781, DOI 10.1001/archpsyc.55.9.781; Finch BK,
2000, J HEALTH SOC BEHAV, V41, P295, DOI 10.2307/2676322; Freedman SA, 1999, BRIT J
PSYCHIAT, V174, P353, DOI 10.1192/bjp.174.4.353; Gee GC, 2007, SOC SCI MED, V64,
P1984, DOI 10.1016/j.socscimed.2007.02.013; Gee GC, 2006, AM J PUBLIC HEALTH, V96,
P1821, DOI 10.2105/AJPH.2005.080085; Gibbons FX, 2014, HEALTH PSYCHOL, V33, P11,
DOI 10.1037/a0033857; Gibbons FX, 2004, J PERS SOC PSYCHOL, V86, P517, DOI
10.1037/0022-3514.86.4.517; Gibbs TA, 2013, AM J PUBLIC HEALTH, V103, P330, DOI
10.2105/AJPH.2012.300891; Goldstein RB, 2012, J STUD ALCOHOL DRUGS, V73, P938, DOI
10.15288/jsad.2012.73.938; Grant BF, 2009, MOL PSYCHIATR, V14, P1051, DOI
10.1038/mp.2008.41; Grant BF, 2003, DRUG ALCOHOL DEPEN, V71, P7, DOI 10.1016/S0376-
8716(03)00070-X; Grant BF, 2006, ALCOHOL RES HEALTH, V29, P74; Greenfield TK, 2008,
ADDICTION, V103, P1082, DOI 10.1111/j.1360-0443.2008.02197.x; Hasin DS, 2007, ARCH
GEN PSYCHIAT, V64, P830, DOI 10.1001/archpsyc.64.7.830; Hasin DS, 2004, ARCH GEN
PSYCHIAT, V61, P891, DOI 10.1001/archpsyc.61.9.891; Heilemann MSV, 2005, J NERV
MENT DIS, V193, P665, DOI 10.1097/01.nmd.0000180741.93635.ab; Hien DA, 2010, DRUG
ALCOHOL DEPEN, V111, P114, DOI 10.1016/j.drugalcdep.2010.04.011; Huang BJ, 2006,
COMPR PSYCHIAT, V47, P254, DOI 10.1016/j.comppsych.2005.11.001; Karlsen S, 2002,
SOCIOL HEALTH ILL, V24, P1, DOI 10.1111/1467-9566.00001; Karlsen S, 2002, AM J
PUBLIC HEALTH, V92, P624, DOI 10.2105/AJPH.92.4.624; KESSLER RC, 1986, J HEALTH SOC
BEHAV, V27, P107, DOI 10.2307/2136310; Kessler RC, 1999, J HEALTH SOC BEHAV, V40,
P208, DOI 10.2307/2676349; Kessler RC, 1997, ARCH GEN PSYCHIAT, V54, P313; KESSLER
RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012;
Kessler RC, 1997, ANNU REV PSYCHOL, V48, P191, DOI 10.1146/annurev.psych.48.1.191;
Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593;
KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Keyes KM, 2012, BRIT J PSYCHIAT,
V200, P107, DOI 10.1192/bjp.bp.111.093062; Khantzian EJ, 1997, HARVARD REV
PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550; KHANTZIAN EJ, 1985, AM J
PSYCHIAT, V142, P1259; KRIEGER N, 1990, SOC SCI MED, V30, P1273, DOI 10.1016/0277-
9536(90)90307-E; Krieger N, 2005, SOC SCI MED, V61, P1576, DOI
10.1016/j.socscimed.2005.03.006; Krieger N, 1998, AM J PUBLIC HEALTH, V88, P1308,
DOI 10.2105/AJPH.88.9.1308; Krieger N, 1997, INT J HEALTH SERV, V27, P157, DOI
10.2190/HPB8-5M2N-VK6X-0FWN; Krueger RF, 1999, ARCH GEN PSYCHIAT, V56, P921, DOI
10.1001/archpsyc.56.10.921; Kwate NOA, 2003, J NATL MED ASSOC, V95, P450; Leggio L,
2009, NEUROPSYCHOL REV, V19, P115, DOI 10.1007/s11065-008-9080-z; Lipsky S, 2014, J
FAM VIOLENCE, V29, P815, DOI 10.1007/s10896-014-9635-0; Logie C, 2013, AIDS PATIENT
CARE ST, V27, P114, DOI 10.1089/apc.2012.0296; Loo CM, 2001, PSYCHOL ASSESSMENT,
V13, P503, DOI 10.1037//1040-3590.13.4.503; Lorenzo-Blanco EI, 2012, COMMUNITY MENT
HLT J, V48, P611, DOI 10.1007/s10597-011-9426-5; Maddox T, 2013, WOMEN HEALTH, V53,
P706, DOI 10.1080/03630242.2013.822455; MALDONADO G, 1993, AM J EPIDEMIOL, V138,
P923, DOI 10.1093/oxfordjournals.aje.a116813; Martin JK, 2003, J HEALTH SOC BEHAV,
V44, P408, DOI 10.2307/1519787; Mays VM, 2001, AM J PUBLIC HEALTH, V91, P1869, DOI
10.2105/AJPH.91.11.1869; McFarlane AC, 1998, ADDICT BEHAV, V23, P813, DOI
10.1016/S0306-4603(98)00098-7; McKinney CM, 2009, VIOLENCE VICTIMS, V24, P653, DOI
10.1891/0886-6708.24.5.653; McLaughlin KA, 2010, AM J PUBLIC HEALTH, V100, P1477,
DOI 10.2105/AJPH.2009.181586; Miller FS, 1992, PSYCHO SOCIAL DEV MI, P275; Milne
BJ, 2009, ARCH GEN PSYCHIAT, V66, P738, DOI 10.1001/archgenpsychiatry.2009.55;
Mojtabai R, 2007, AM J ADDICTION, V16, P300, DOI 10.1080/10550490701389815;
Mutschler J, 2013, AM J DRUG ALCOHOL AB, V39, P44, DOI
10.3109/00952990.2012.677889; Nazroo JY, 2003, AM J PUBLIC HEALTH, V93, P277, DOI
10.2105/AJPH.93.2.277; Ortega AN, 2000, J NERV MENT DIS, V188, P728, DOI
10.1097/00005053-200011000-00002; Pascoe EA, 2009, PSYCHOL BULL, V135, P531, DOI
10.1037/a0016059; Platt J, 2014, SOC PSYCH PSYCH EPID, V49, P1279, DOI
10.1007/s00127-013-0798-4; Roberts AL, 2011,
PSYCHOL MED, V41, P71, DOI 10.1017/S0033291710000401; Ruan WJ, 2008, DRUG ALCOHOL
DEPEN, V92, P27, DOI 10.1016/j.drugalcdep.2007.06.001; Rytwinski NK, 2013, J TRAUMA
STRESS, V26, P299, DOI 10.1002/jts.21814; Savage JE, 2014, DRUG ALCOHOL DEPEN,
V139, P71, DOI 10.1016/j.drugalcdep.2014.03.011; Schraedley PK, 2002, J HEALTH SOC
BEHAV, V43, P307, DOI 10.2307/3090206; Scribner R, 1996, AM J PUBLIC HEALTH, V86,
P303, DOI 10.2105/AJPH.86.3.303; Seawell AH, 2014, J BLACK PSYCHOL, V40, P3, DOI
10.1177/0095798412469227; Sellers RM, 2003, J HEALTH SOC BEHAV, V44, P302, DOI
10.2307/1519781; Shalev AY, 1998, AM J PSYCHIAT, V155, P630, DOI
10.1176/ajp.155.5.630; Siefert K, 2000, AM J ORTHOPSYCHIAT, V70, P510, DOI
10.1037/h0087688; Smith SM, 2006, PSYCHOL MED, V36, P987, DOI
10.1017/S0033291706007690; SOLIS JM, 1990, AM J PUBLIC HEALTH, V80, P11, DOI
10.2105/AJPH.80.Suppl.11; Soto JA, 2011, J ANXIETY DISORD, V25, P258, DOI
10.1016/j.janxdis.2010.09.011; Stewart SH, 1998, ADDICT BEHAV, V23, P797, DOI
10.1016/S0306-4603(98)00070-7; Thompson VLS, 2002, COMMUNITY MENT HLT J, V38, P111,
DOI 10.1023/A:1014539003562; Torvik FA, 2012, SOC PSYCH PSYCH EPID, V47, P805, DOI
10.1007/s00127-011-0387-3; Trocchio Sarah, 2013, J Addict Dis, V32, P180, DOI
10.1080/10550887.2013.795468; Turner RJ, 2006, DRUG ALCOHOL DEPEN, V83, P79, DOI
10.1016/j.drugalcdep.2005.11.003; Van Loon AJM, 2003, ANN EPIDEMIOL, V13, P105, DOI
10.1016/S1047-2797(02)00257-0; Vega WA, 2004, J NERV MENT DIS, V192, P532, DOI
10.1097/01.nmd.0000135477.57357.b2; Vega WA, 2003, AM J PUBLIC HEALTH, V93, P1057,
DOI 10.2105/AJPH.93.7.1057; Verissimo ADO, 2014, AM J PUBLIC HEALTH, V104, P1421,
DOI 10.2105/AJPH.2014.302011; Verissimo ADO, 2014, CULT DIVERS ETHN MIN, V20, P43,
DOI 10.1037/a0034674; Viruell-Fuentes EA, 2007, SOC SCI MED, V65, P1524, DOI
10.1016/j.socscimed.2007.05.010; Williams DR, 2003, AM J PUBLIC HEALTH, V93, P200,
DOI 10.2105/AJPH.93.2.200; Williams M, 2012, ADDICT BEHAV, V37, P47, DOI
10.1016/j.addbeh.2011.08.008; Yen IH, 1999, PUBLIC HEALTH REP, V114, P448, DOI
10.1093/phr/114.5.448; Zemore SE, 2007, ALCOHOL CLIN EXP RES, V31, P1968, DOI
10.1111/j.1530-0277.2007.00532.x; Zemore SE, 2005, ALCOHOL CLIN EXP RES, V29,
P2144, DOI 10.1097/01.alc.0000191775.01148.c0 122 2 2 0 20
SPRINGER HEIDELBERG HEIDELBERG TIERGARTENSTRASSE 17, D-69121 HEIDELBERG,
GERMANY 0933-7954 1433-9285 SOC PSYCH PSYCH EPID Soc. Psychiatry
Psychiatr. Epidemiol. MAR 2016 51 3 407 419
10.1007/s00127-015-1109-z 13 Psychiatry Psychiatry DI1CA
WOS:000373232400010 26266627 Green Accepted 2019-09-25
J Feingold, D; Weiser, M; Rehm, J; Lev-Ran, S Feingold,
Daniel; Weiser, Mark; Rehm, Juergen; Lev-Ran, Shaul The association
between cannabis use and anxiety disorders: Results from a population-based
representative sample EUROPEAN NEUROPSYCHOPHARMACOLOGY English
Article Cannabis use; Cannabis use
disorders; Anxiety disorders; Social anxiety; Panic disorder; NESARC NATIONAL
EPIDEMIOLOGIC SURVEY; SUBSTANCE USE DISORDERS; ALCOHOL-USE DISORDER; SOCIAL
ANXIETY; LIFETIME PREVALENCE; GENERAL-POPULATION; CONDITIONS NESARC; MENTAL-
DISORDERS; UNITED-STATES; DEPENDENCE The cross-sectional association between
cannabis use and anxiety disorders is well documented, yet less is known about the
longitudinal association between the two. This study explored the association
between cannabis use, cannabis use disorders (CUDs) and anxiety disorders in a 3
year prospective study. Data was drawn from waves 1 and 2 of the National
Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Anxiety disorders,
including generalized anxiety disorder, social anxiety, panic disorder and specific
phobias, were controlled for at baseline. Initiation of cannabis use was defined as
any cannabis use by former lifetime abstainers in the time period between baseline
and follow-up, CUDs were defined as a diagnosis of cannabis abuse or dependence.
Results indicate that cannabis use was not associated with increased incidence of
any anxiety disorder (Adjusted Odds Ratio (AOR)=1.12(0.63-0.98)). Though heavy
cannabis use was associated with increased incidence of social anxiety in most
models, this was not fully retained in the final adjusted model (AOR=1.98(0.99-
1.98)). Investigation of the association between baseline CUDs and anxiety
disorders at follow-up revealed similar results. Any baseline anxiety disorder was
not associated with future initiation of cannabis use (AOR=1.03(0.62-1.69)) or
onset of a CUD (AOR=0.68(0.41-1.14)), yet individuals with baseline panic disorder
were more prone to initiate cannabis use at follow-up (AOR=2.2(1.15-4.18)),
possibly as a means of self-medication. Our findings suggest that cannabis use and
CUDs are not associated with increased incidence of most anxiety disorders and
inversely, most anxiety disorders are not associated with increased incidence of
cannabis use or CUDs. (C) 2015 Elsevier B.V. and ECNP. All rights reserved.
[Feingold, Daniel] Ariel Univ, Ariel, Israel; [Feingold, Daniel; Lev-Ran,
Shaul] Chaim Sheba Med Ctr, Dept Psychiat, Addict Med & Dual Diag Serv, IL-52621
Tel Hashomer, Israel; [Weiser, Mark] Chaim Sheba Med Ctr, Dept Psychiat, IL-52621
Tel Hashomer, Israel; [Weiser, Mark; Lev-Ran, Shaul] Tel Aviv Univ, Sackler Fac
Med, IL-69978 Tel Aviv, Israel; [Rehm, Juergen; Lev-Ran, Shaul] Ctr Addict & Mental
Hlth, Social & Epidemiol Res Dept, Toronto, ON, Canada; [Rehm, Juergen] Univ
Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [Rehm, Juergen] Tech Univ
Dresden, Klin Psychol & Psychotherapie, D-01062 Dresden, Germany; [Feingold,
Daniel] Chaim Sheba Med Ctr, Dept Psychiat, Addict Med Serv, IL-52621 Tel Hashomer,
Israel Feingold, D (reprint author), Chaim Sheba Med Ctr, Dept Psychiat, IL-
52621 Tel Hashomer, Israel. d.y.feingold@gmail.com Akirav
I, 2013, NEUROSCI BIOBEHAV R, V37, P2554, DOI 10.1016/j.neubiorev.2013.08.002;
American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Arseneault L, 2004,
BRIT J PSYCHIAT, V184, P110, DOI 10.1192/bjp.184.2.110; Buckner JD, 2008, J
PSYCHIATR RES, V42, P230, DOI 10.1016/j.jpsychires.2007.01.002; Buckner JD, 2014,
AM J ADDICTION, V23, P598, DOI 10.1111/j.1521-0391.2014.12150.x; Buckner JD, 2012,
DRUG ALCOHOL DEPEN, V124, P128, DOI 10.1016/j.drugalcdep.2011.12.023; Buckner JD,
2012, J ANXIETY DISORD, V26, P297, DOI 10.1016/j.janxdis.2011.12.006; Budney Alan
J, 2007, Addict Sci Clin Pract, V4, P4; Carvalho AF, 2012, PROG NEURO-PSYCHOPH,
V38, P59, DOI 10.1016/j.pnpbp.2012.01.008; Chatterji S, 1997, DRUG ALCOHOL DEPEN,
V47, P171, DOI 10.1016/S0376-8716(97)00088-4; Compton WM, 2004, JAMA-J AM MED
ASSOC, V291, P2114, DOI 10.1001/jama.291.17.2114; Crippa JA, 2009, HUM PSYCHOPHARM
CLIN, V24, P515, DOI 10.1002/hup.1048; Degenhardt L, 2001, SOC PSYCH PSYCH EPID,
V36, P219, DOI 10.1007/s001270170052; Degenhardt L, 2007, INT J METH PSYCH RES,
V16, P43, DOI 10.1002/mpr.206; Degenhardt L, 2013, ADDICTION, V108, P124, DOI
10.1111/j.1360-0443.2012.04015.x; Degenhardt L, 2011, DRUG ALCOHOL DEPEN, V117,
P85, DOI 10.1016/j.drugalcdep.2010.11.032; Drenckhan I, 2015, PSYCHOL MED, V45,
P1675, DOI 10.1017/S0033291714002803; Feingold D, 2015, J AFFECT DISORDERS, V172,
P211, DOI 10.1016/j.jad.2014.10.006; Fergusson DM, 2008, ADDICTION, V103, P969, DOI
10.1111/j.1360-0443.2008.02221.x; Fergusson DM, 1997, ADDICTION, V92, P279; Goodwin
RD, 2004, J PSYCHIATR RES, V38, P295, DOI 10.1016/j.jpsychires.2003.09.002; Grant
B.F., 2003, SOURCE ACCURACY STAT; Grant BF, 2005, J CLIN PSYCHIAT, V66, P1351, DOI
10.4088/JCP.v66n1102; Grant BF, 2003, DRUG ALCOHOL DEPEN, V71, P7, DOI
10.1016/S0376-8716(03)00070-X; Grant BF, 2004, ARCH GEN PSYCHIAT, V61, P807, DOI
10.1001/archpsyc.61.8.807; Grant BF, 2005, J CLIN PSYCHIAT, V66, P1205, DOI
10.4088/JCP.v66n1001; Grant BF, 2008, J CLIN PSYCHIAT, V69, P533, DOI
10.4088/JCP.v69n0404; Gruber AJ, 2003, PSYCHOL MED, V33, P1415, DOI
10.1017/S0033291703008560; Grucza RA, 2007, ADDICTION, V102, P623, DOI
10.1111/j.1360-0443.2007.01745.x; Hathaway AD, 2003, ADDICT RES THEORY, V11, P441,
DOI 10.1080/1606635021000041807; Hill MN, 2005, NEUROPSYCHOPHARMACOL, V30, P508,
DOI 10.1038/sj.npp.1300601; Kaplan K. D, 2005, SOURCE AND ACCURACY; Kedzior KK,
2014, BMC PSYCHIATRY, V14, DOI 10.1186/1471-244X-14-136; Kessler RC, 2002, PSYCHOL
MED, V32, P959, DOI 10.1017/S0033291702006074; Kessler RC, 2005, ARCH GEN PSYCHIAT,
V62, P593, DOI 10.1001/archpsyc.62.6.593; Lev-Ran S, 2014, PSYCHOL MED, V44, P797,
DOI 10.1017/S0033291713001438; Lev-Ran S, 2013, AM J ADDICTION, V22, P93, DOI
10.1111/j.1521-0391.2013.00304.x; Lev-Ran S, 2012, DRUG ALCOHOL DEPEN, V123, P190,
DOI 10.1016/j.drugalcdep.2011.11.010; Marmorstein NR, 2010, J ABNORM CHILD PSYCH,
V38, P211, DOI 10.1007/s10802-009-9360-y; Moore THM, 2007, LANCET, V370, P319, DOI
10.1016/S0140-6736(07)61162-3; Morgan CJA, 2008, BRIT J PSYCHIAT, V192, P306, DOI
10.1192/bjp.bp.107.046649; Ramikie TS, 2012, NEUROSCIENCE, V204, P38, DOI
10.1016/j.neuroscience.2011.08.037; Research Triangle Institute, 2004, SOFTW SURV
DAT AN SU; Ruehle S, 2012, J PSYCHOPHARMACOL, V26, P23, DOI
10.1177/0269881111408958; SAMHSA, 2014, RES 2002 NAT SURV DR; Schepis TS, 2011,
ADDICTION, V106, P2146, DOI 10.1111/j.1360-0443.2011.03520.x; Scholten WD, 2013, J
AFFECT DISORDERS, V147, P180, DOI 10.1016/j.jad.2012.10.031; United Nations Office
on Drugs and Crime, 2012, WORLD DRUG REP 2012; van Laar M, 2007, ADDICTION, V102,
P1251, DOI 10.1111/j.1360-0443.2007.01875.x; Walsh K, 2014, COMPR PSYCHIAT, V55,
P621, DOI 10.1016/j.comppsych.2013.11.016; Whiteford HA, 2013, LANCET, V382, P1575,
DOI 10.1016/S0140-6736(13)61611-6; Wittchen HU, 2008, INT J METH PSYCH RES, V17,
pS16, DOI 10.1002/mpr.254; Wittchen HU, 2007, DRUG ALCOHOL DEPEN, V88, pS60, DOI
10.1016/j.drugalcdep.2006.12.013; Wittchen HU, 1998, SOC PSYCH PSYCH EPID, V33,
P568, DOI 10.1007/s001270050095; Zvolensky MJ, 2006, J PSYCHIAT RES, V40, P477, DOI
10.1016/j.jpsychires.2005.09.005 55 25 25 0 10 ELSEVIER SCIENCE
BV AMSTERDAM PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS 0924-977X 1873-
7862 EUR NEUROPSYCHOPHARM Eur. Neuropsychopharmacol. MAR 2016 26
3 493 505
10.1016/j.euroneuro.2015.12.037 13 Clinical Neurology;
Neurosciences; Pharmacology & Pharmacy; Psychiatry Neurosciences & Neurology;
Pharmacology & Pharmacy; Psychiatry DG2UI WOS:000371923800009 26775742
2019-09-25
J Parikh, V; Kutlu, MG; Gould, TJ Parikh, Vinay; Kutlu,
Munir Gunes; Gould, Thomas J. nAChR dysfunction as a common substrate
for schizophrenia and comorbid nicotine addiction: Current trends and perspectives
SCHIZOPHRENIA RESEARCH English Review
Schizophrenia; Smoking; Comorbidity; nAChRs; Cognition; Reward
ACETYLCHOLINE-RECEPTOR AGONIST; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER;
POSITIVE ALLOSTERIC MODULATOR; AUDITORY-EVOKED POTENTIALS; EYE TRACKING
DYSFUNCTION; SPATIAL WORKING-MEMORY; SUBSTANCE USE DISORDER; REACTION-TIME-TASK;
PROOF-OF-CONCEPT; CIGARETTE-SMOKING Introduction: The prevalence of tobacco use in
the population with schizophrenia is enormously high. Moreover, nicotine dependence
is found to be associated with symptom severity and poor outcome in patients with
schizophrenia. The neurobiological mechanisms that explain schizophrenia-nicotine
dependence comorbidity are not known. This study systematically reviews the
evidence highlighting the contribution of nicotinic acetylcholine receptors
(nAChRs) to nicotine abuse in schizophrenia. Methods: Electronic data bases
(Medline, Google Scholar, and Web of Science) were searched using the selected key
words that match the aims set forth for this review. A total of 276 articles were
used for the qualitative synthesis of this review. Results: Substantial evidence
from preclinical and clinical studies indicated that dysregulation of alpha 7 and
beta 2-subunit containing nAChRs account for the cognitive and affective symptoms
of schizophrenia and nicotine use may represent a strategy to remediate these
symptoms. Additionally, recent meta-analyses proposed that early tobacco use may
itself increase the risk of developing schizophrenia. Genetic studies demonstrating
that nAChR dysfunction that may act as a shared vulnerability factor for comorbid
tobacco dependence and schizophrenia were found to support this view. The
development of nAChR modulators was considered an effective therapeutic strategy to
ameliorate psychiatric symptoms and to promote smoking cessation in schizophrenia
patients. Conclusions: The relationship between schizophrenia and smoking is
complex. While the debate for the self-medication versus addiction vulnerability
hypothesis continues, it is widely accepted that a dysfunction in the central
nAChRs represent a common substrate for various symptoms of schizophrenia and
comorbid nicotine dependence. (C) 2016 Elsevier B.V. All rights reserved.
[Parikh, Vinay] Temple Univ, Dept Psychol, 1701 N 13th St,Weiss Hall,
Philadelphia, PA 19112 USA; [Parikh, Vinay] Temple Univ, Neurosci Program, 1701 N
13th St,Weiss Hall, Philadelphia, PA 19112 USA Parikh, V (reprint author), Temple
Univ, Dept Psychol, 1701 N 13th St,Weiss Hall, Philadelphia, PA 19112 USA.; Parikh,
V (reprint author), Temple Univ, Neurosci Program, 1701 N 13th St,Weiss Hall,
Philadelphia, PA 19112 USA. vinay.parikh@temple.edu Parikh, Vinay/M-1439-2016
National Institute of HealthUnited States Department of Health & Human
ServicesNational Institutes of Health (NIH) - USA [DA 017949, DA 037421]; Brain and
Behavior Research Foundation The authors' research was supported by grants from
the National Institute of Health (DA 017949 and DA 037421) and the Brain and
Behavior Research Foundation. Addington J, 2003, SCHIZOPHR RES, V62, P23, DOI
10.1016/S0920-9964(02)00408-5; ADLER LE, 1985, BIOL PSYCHIAT, V20, P1284, DOI
10.1016/0006-3223(85)90113-1; Adler LE, 1998, SCHIZOPHRENIA BULL, V24, P189, DOI
10.1093/oxfordjournals.schbul.a033320; AhnAllen CG, 2012, PSYCHIAT RES, V196, P9,
DOI 10.1016/j.psychres.2011.09.011; Alexander Kathleen S, 2012, Psychopharmacology
(Berl), V220, P627, DOI 10.1007/s00213-011-2539-2; Apostol G, 2012,
PSYCHOPHARMACOLOGY, V219, P715, DOI 10.1007/s00213-011-2393-2; Audrain-McGovern J,
2009, DRUG ALCOHOL DEPEN, V103, P99, DOI 10.1016/j.drugalcdep.2008.12.019; Avila
MT, 2006, J NEUROPHYSIOL, V95, P593, DOI 10.1152/jn.00369.2005; Avila MT, 2003,
NEUROPSYCHOPHARMACOL, V28, P2184, DOI 10.1038/sj.npp.1300265; Azzopardi E, 2013,
GENES BRAIN BEHAV, V12, P414, DOI 10.1111/gbb.12038; Bailey CDC, 2010, J NEUROSCI,
V30, P9241, DOI 10.1523/JNEUROSCI.2258-10.2010; Barak S, 2009,
NEUROPSYCHOPHARMACOL, V34, P1753, DOI 10.1038/npp.2008.232; Barr RS, 2008,
NEUROPSYCHOPHARMACOL, V33, P480, DOI 10.1038/sj.npp.1301423; Beinat C, 2015, CNS
DRUGS, V29, P529, DOI 10.1007/s40263-015-0260-0; Berrettine W, 2008, MOL PSYCHIATR,
V13, P368, DOI 10.1038/sj.mp.4002154; Bertrand C, 2008, CHEM-BIOL INTERACT, V175,
P113, DOI 10.1016/j.cbi.2008.04.002; Bickel WK, 1999, PSYCHOPHARMACOLOGY, V146,
P447, DOI 10.1007/PL00005490; Bitner RS, 2010, J PHARMACOL EXP THER, V334, P875,
DOI 10.1124/jpet.110.167213; Bitner RS, 2007, J NEUROSCI, V27, P10578, DOI
10.1523/JNEUROSCI.2444-07.2007; Blondel A, 2000, PSYCHOPHARMACOLOGY, V149, P293,
DOI 10.1007/s002130000378; Boess FG, 2007, J PHARMACOL EXP THER, V321, P716, DOI
10.1124/jpet.106.118976; Bowie CR, 2006, MT SINAI J MED, V73, P993; Braff DL, 1999,
AM J PSYCHIAT, V156, P596; Braff DL, 2001, PSYCHOPHARMACOLOGY, V156, P234, DOI
10.1007/s002130100810; Braff DL, 2001, SCHIZOPHR RES, V49, P171, DOI 10.1016/S0920-
9964(00)00139-0; Brasic JR, 2012, SYNAPSE, V66, P352, DOI 10.1002/syn.21520; Breese
CR, 2000, NEUROPSYCHOPHARMACOL, V23, P351, DOI 10.1016/S0893-133X(00)00121-4;
Brisch R, 2014, FRONT PSYCHIATRY, V5, DOI 10.3389/fpsyt.2014.00047; Brockhaus-Dumke
A, 2008, SCHIZOPHR RES, V99, P238, DOI 10.1016/j.schres.2007.10.034; Brooks JM,
2012, NEUROPSYCHOPHARMACOL, V37, P2476, DOI 10.1038/npp.2012.106; Brunzell DH,
2012, NEUROPSYCHOPHARMACOL, V37, P1134, DOI 10.1038/npp.2011.299; Buchanan RW,
2008, AM J PSYCHIAT, V165, P82, DOI 10.1176/appi.ajp.2007.07050724; Buisson B,
2001, J NEUROSCI, V21, P1819, DOI 10.1523/JNEUROSCI.21-06-01819.2001; Butt CM,
2003, ALCOHOL CLIN EXP RES, V27, P733, DOI 10.1097/01.ALC.0000067973.41153.BC;
Callahan PM, 2013, NEUROPHARMACOLOGY, V67, P201, DOI
10.1016/j.neuropharm.2012.10.019; Cao YJ, 2005, NEUROPHARMACOLOGY, V48, P72, DOI
10.1016/j.neuropharm.2004.09.005; CASTRO NG, 1995, BIOPHYS J, V68, P516, DOI
10.1016/S0006-3495(95)80213-4; Chambers RA, 2009, J DUAL DIAGN, V5, P139, DOI
10.1080/15504260902869808; Chambers RA, 2001, BIOL PSYCHIAT, V50, P71, DOI
10.1016/S0006-3223(01)01134-9; Chan WK, 2007, NEUROPHARMACOLOGY, V52, P1641, DOI
10.1016/j.neuropharm.2007.03.008; Changeux JP, 2010, NAT REV NEUROSCI, V11, P389,
DOI 10.1038/nrn2849; Chase HW, 2011, NICOTINE TOB RES, V13, P1321, DOI
10.1093/ntr/ntr114; Chen XS, 2011, PSYCHIAT RES, V188, P327, DOI
10.1016/j.psychres.2010.12.009; Coe JW, 2005, J MED CHEM, V48, P3474, DOI
10.1021/jm050069n; Cole RD, 2015, PSYCHOPHARMACOLOGY, V232, P1207, DOI
10.1007/s00213-014-3754-4; Connolly PM, 2003, BRAIN RES, V992, P85, DOI
10.1016/j.brainres.2003.08.035; Cosgrove KP, 2009, ARCH GEN PSYCHIAT, V66, P666,
DOI 10.1001/archgenpsychiatry.2009.41; Court J, 1999, J NEUROCHEM, V73, P1590, DOI
10.1046/j.1471-4159.1999.0731590.x; Croft RJ, 2001, BIOL PSYCHIAT, V50, P441, DOI
10.1016/S0006-3223(01)01082-4; D'Souza DC, 2012, AM J PSYCHIAT, V169, P326, DOI
10.1176/appi.ajp.2011.11020189; D'Souza MS, 2012, NEUROPHARMACOLOGY, V62, P1564,
DOI 10.1016/j.neuropharm.2011.01.044; Dalley JW, 2007, SCIENCE, V315, P1267, DOI
10.1126/science.1137073; Dani JA, 2001, PHARMACOL BIOCHEM BE, V70, P439, DOI
10.1016/S0091-3057(01)00652-9; Dani JA, 2007, ANNU REV PHARMACOL, V47, P699, DOI
10.1146/annurev.pharmtox.47.120505.105214; de Leon J, 2005, SCHIZOPHR RES, V76,
P135, DOI 10.1016/j.schres.2005.02.010; De Luca V, 2006, EUR NEUROPSYCHOPHARM, V16,
P268, DOI 10.1016/j.euroneuro.2005.09.007; De Luca V, 2004, NEUROPSYCHOPHARMACOL,
V29, P1522, DOI 10.1038/sj.npp.1300466; Depatie L, 2002, NEUROPSYCHOPHARMACOL, V27,
P1056, DOI 10.1016/S0893-133X(02)00372-X; Devrim-Uecok M, 2008, PROG NEURO-
PSYCHOPH, V32, P1952, DOI 10.1016/j.pnpbp.2008.09.018; Diaz FJ, 2006, PSYCHIAT
SERV, V57, P462, DOI 10.1176/appi.ps.57.4.462; Diergaarde L, 2008, BIOL PSYCHIAT,
V63, P301, DOI 10.1016/j.biopsych.2007.07.011; Dobelis P, 2002, MOL PHARMACOL, V62,
P334, DOI 10.1124/mol.62.2.334; Durany N, 2000, NEUROSCI LETT, V287, P109, DOI
10.1016/S0304-3940(00)01144-7; DUTAR P, 1988, NATURE, V332, P156, DOI
10.1038/332156a0; Dutra SJ, 2012, PSYCHOPHARMACOLOGY, V219, P25, DOI
10.1007/s00213-011-2373-6; Esterlis I, 2014, BIOL PSYCHIAT, V76, P495, DOI
10.1016/j.biopsych.2013.11.001; Evenden J, 1999, J PSYCHOPHARMACOL, V13, P180, DOI
10.1177/026988119901300211; Evins AE, 2014, JAMA-J AM MED ASSOC, V311, P145, DOI
10.1001/jama.2013.285113; Fenster CP, 1999, J NEUROSCI, V19, P4804; Fernandes C,
2006, GENES BRAIN BEHAV, V5, P433, DOI 10.1111/j.1601-183X.2005.00176.x; Flory JD,
2009, PSYCHOSOM MED, V71, P431, DOI 10.1097/PSY.0b013e3181988c2d; FREEDMAN R, 1995,
BIOL PSYCHIAT, V38, P22, DOI 10.1016/0006-3223(94)00252-X; Freedman R, 2001, AM J
MED GENET, V105, P20, DOI 10.1002/1096-8628(20010108)105:1<20::AID-
AJMG1047>3.0.CO;2-C; Freedman R, 2000, AM J MED GENET, V97, P58, DOI 10.1002/
(SICI)1096-8628(200021)97:1<58::AID-AJMG8>3.0.CO;2-Y; Freedman R, 2008, AM J
PSYCHIAT, V165, P1040, DOI 10.1176/appi.ajp.2008.07071135; Freedman R, 2014, ANNU
REV MED, V65, P245, DOI 10.1146/annurev-med-092112-142937; Gage SH, 2015, LANCET
PSYCHIAT, V2, P778, DOI 10.1016/S2215-0366(15)00333-8; Gallego X, 2012, AMINO
ACIDS, V43, P897, DOI 10.1007/s00726-011-1149-y; George TP, 2002,
NEUROPSYCHOPHARMACOL, V26, P75, DOI 10.1016/S0893-133X(01)00296-2; George TP, 2000,
CURR OPIN PSYCHIATR, V13, P327, DOI 10.1097/00001504-200005000-00015; Gilbert CD,
2007, NEURON, V54, P677, DOI 10.1016/j.neuron.2007.05.019; Gill-Thind JK, 2015, J
BIOL CHEM, V290, P3552, DOI 10.1074/jbc.M114.619221; Gold JM, 2008, SCHIZOPHRENIA
BULL, V34, P835, DOI 10.1093/schbul/sbn068; Gold JM, 2012, SCHIZOPHRENIA BULL, V38,
P144, DOI 10.1093/schbul/sbr142; Goldman-Rakic PS, 2004, PSYCHOPHARMACOLOGY, V174,
P3, DOI 10.1007/s00213-004-1793-y;
Gonzalez-Burgos G, 2008, SCHIZOPHRENIA BULL, V34, P944, DOI 10.1093/schbul/sbn070;
Gotti C, 2009, BIOCHEM PHARMACOL, V78, P703, DOI 10.1016/j.bcp.2009.05.024; Govind
AP, 2009, BIOCHEM PHARMACOL, V78, P756, DOI 10.1016/j.bcp.2009.06.011; Granon S,
2003, P NATL ACAD SCI USA, V100, P9596, DOI 10.1073/pnas.1533498100; Green AI,
2005, J CLIN PSYCHIAT, V66, P21; Grottick AJ, 2000, BEHAV BRAIN RES, V117, P197,
DOI 10.1016/S0166-4328(00)00305-3; Grottick AJ, 2000, J PHARMACOL EXP THER, V294,
P1112; Guan ZZ, 1999, NEUROREPORT, V10, P1779, DOI 10.1097/00001756-199906030-
00028; Guillem K, 2011, SCIENCE, V333, P888, DOI 10.1126/science.1207079; Gurillo
P, 2015, LANCET PSYCHIAT, V2, P718, DOI 10.1016/S2215-0366(15)00152-2; Hahn B,
2011, PSYCHOPHARMACOLOGY, V217, P75, DOI 10.1007/s00213-011-2258-8; Hajos M, 2010,
CURR PHARM DESIGN, V16, P538, DOI 10.2174/138161210790361434; Hartz SM, 2012, ARCH
GEN PSYCHIAT, V69, P854, DOI 10.1001/archgenpsychiatry.2012.124; Hauser TA, 2009,
BIOCHEM PHARMACOL, V78, P803, DOI 10.1016/j.bcp.2009.05.030; Heckers S, 2002, J
NEURAL TRANSM, V109, P891, DOI 10.1007/s007020200073; Hennekens Charles H, 2007,
Curr Atheroscler Rep, V9, P409, DOI 10.1007/s11883-007-0053-0; Hilario MRF, 2012,
NEUROPSYCHOPHARMACOL, V37, P2661, DOI 10.1038/npp.2012.130; Hill SK, 2010, EXPERT
REV NEUROTHER, V10, P43, DOI [10.1586/ern.09.143, 10.1586/ERN.09.143]; Howe WM,
2010, NEUROPSYCHOPHARMACOL, V35, P1391, DOI 10.1038/npp.2010.9; Howes OD, 2009,
SCHIZOPHRENIA BULL, V35, P549, DOI 10.1093/schbul/sbp006; Javitt DC, 2009,
SCHIZOPHRENIA BULL, V35, P1059, DOI 10.1093/schbul/sbp110; Jones KM, 2014,
PSYCHOPHARMACOLOGY, V231, P673, DOI 10.1007/s00213-013-3275-6; Karadsheh MS, 2004,
J NEUROCHEM, V91, P1138, DOI 10.1111/j.1471-4159.2004.02801.x; Kayir H, 2014, PROG
NEURO-PSYCHOPH, V48, P6, DOI 10.1016/j.pnpbp.2013.09.007; Keefe RSE, 2007,
SCHIZOPHRENIA BULL, V33, P912, DOI 10.1093/schbul/sbm046; Keefe RSE, 2015,
NEUROPSYCHOPHARMACOL, V40, P3053, DOI 10.1038/npp.2015.176; Keller JJ, 2005, BEHAV
BRAIN RES, V162, P143, DOI 10.1016/j.bbr.2005.03.004; Kelley RE, 2011, SOUTH MED J,
V104, P803, DOI 10.1097/SMJ.0b013e318236c35c; Kendler KS, 2015, AM J PSYCHIAT,
V172, P1092, DOI 10.1176/appi.ajp.2015.15010126; Kenny PJ, 2006,
NEUROPSYCHOPHARMACOL, V31, P1203, DOI 10.1038/sj.npp.1300905; Kim H, 2003,
NEUROPHARMACOLOGY, V45, P345, DOI 10.1016/S0028-3908(03)00167-9; Koike K, 2005,
SCHIZOPHR RES, V76, P67, DOI 10.1016/j.schres.2004.12.016; Kolokotroni KZ, 2014,
PSYCHOPHARMACOLOGY, V231, P567, DOI 10.1007/s00213-013-3270-y; Konradsson-Geuken A,
2009, SYNAPSE, V63, P1069, DOI 10.1002/syn.20693; Krenz I, 2001, J CHEM NEUROANAT,
V21, P239, DOI 10.1016/S0891-0618(01)00112-0; Krishnadas R, 2012, BRIT J PSYCHIAT,
V201, P306, DOI 10.1192/bjp.bp.111.107953; Kumari V, 2005, NEUROSCI BIOBEHAV R,
V29, P1021, DOI 10.1016/j.neubiorev.2005.02.006; Kumari V, 2001, HUM PSYCHOPHARM
CLIN, V16, P321, DOI 10.1002/hup.286; Kunii Y, 2015, AM J PSYCHIAT, V172, P1122,
DOI 10.1176/appi.ajp.2015.14080978; Kutlu MG, 2015, INT REV NEUROBIOL, V124, P171,
DOI 10.1016/bs.irn.2015.08.004; Labarca C, 2001, P NATL ACAD SCI USA, V98, P2786,
DOI 10.1073/pnas.041582598; Lambe EK, 2003, NEUROPSYCHOPHARMACOL, V28, P216, DOI
10.1038/sj.npp.1300032; Lasser K, 2000, JAMA-J AM MED ASSOC, V284, P2606, DOI
10.1001/jama.284.20.2606; Laviolette SR, 2004, NAT REV NEUROSCI, V5, P55, DOI
10.1038/nrn1298; Leonard S, 2000, EUR J PHARMACOL, V393, P237, DOI 10.1016/S0014-
2999(00)00035-2; Leonard S, 1998, AM J MED GENET, V81, P308, DOI 10.1002/
(SICI)1096-8628(19980710)81:4<308::AID-AJMG6>3.0.CO;2-P; Leonard S, 1998, RESTOR
NEUROL NEUROS, V12, P195; Leonard Sherry, 2007, J Dual Diagn, V3, P43, DOI
10.1300/J374v03n03_05; Leslie FM, 2013, MOL PHARMACOL, V83, P753, DOI
10.1124/mol.112.083659; Levin ED, 2002, NEUROSCIENCE, V109, P757, DOI
10.1016/S0306-4522(01)00538-3; Levin ED, 1999, BEHAV PHARMACOL, V10, P675, DOI
10.1097/00008877-199911000-00014; Levin ED, 2009, BEHAV BRAIN RES, V196, P207, DOI
10.1016/j.bbr.2008.08.048; Levy DL, 2010, CURR TOP BEHAV NEURO, V4, P311, DOI
10.1007/7854_2010_60; Levy DL, 2000, SCHIZOPHR RES, V42, P171, DOI 10.1016/S0920-
9964(99)00122-X; Levy RB, 2002, J NEUROSCI, V22, P5001, DOI 10.1523/JNEUROSCI.22-
12-05001.2002; Lewis DA, 2005, NAT REV NEUROSCI, V6, P312, DOI 10.1038/nrn1648;
Lewis DA, 1999, BIOL PSYCHIAT, V46, P616, DOI 10.1016/S0006-3223(99)00061-X; Li MD,
2008, BIOL PSYCHIAT, V64, P951, DOI 10.1016/j.biopsych.2008.04.026; Liberati A,
2009, ANN INTERN MED, V151, pW65, DOI 10.7326/0003-4819-151-4-200908180-00136;
Lieberman JA, 2013, NEUROPSYCHOPHARMACOL, V38, P968, DOI 10.1038/npp.2012.259;
Lijffijt M, 2009, PSYCHOPHYSIOLOGY, V46, P1059, DOI 10.1111/j.1469-
8986.2009.00845.x; Lin H, 2010, P NATL ACAD SCI USA, V107, P16661, DOI
10.1073/pnas.1007397107; Livingstone PD, 2010, J MOL NEUROSCI, V40, P172, DOI
10.1007/s12031-009-9232-5; Livingstone PD, 2009, EUR J NEUROSCI, V29, P539, DOI
10.1111/j.1460-9568.2009.06613.x; LOHR JB, 1992, SCHIZOPHR RES, V8, P93, DOI
10.1016/0920-9964(92)90024-Y; Luijten M, 2011, PLOS ONE, V6, DOI
10.1371/journal.pone.0018898; LUNTZLEYBMAN V, 1992, BRAIN RES, V587, P130, DOI
10.1016/0006-8993(92)91437-J; Mackowick KM, 2014, PROG NEURO-PSYCHOPH, V52, P79,
DOI 10.1016/j.pnpbp.2013.07.010; Mansvelder HD, 2002, NEURON, V33, P905, DOI
10.1016/S0896-6273(02)00625-6; Marchi M, 2010, PROG NEUROBIOL, V92, P105, DOI
10.1016/j.pneurobio.2010.06.004; MARKS MJ, 1983, J PHARMACOL EXP THER, V226, P817;
Marquis KL, 2011, PSYCHOPHARMACOLOGY, V218, P635, DOI 10.1007/s00213-011-2357-6;
McEvoy JP, 1999, BIOL PSYCHIAT, V46, P125, DOI 10.1016/S0006-3223(98)00377-1;
McGaughy J, 1999, PSYCHOPHARMACOLOGY, V144, P175, DOI 10.1007/s002130050991;
McGranahan TM, 2011, J NEUROSCI, V31, P10891, DOI 10.1523/JNEUROSCI.0937-11.2011;
McLean SL, 2012, J PSYCHOPHARMACOL, V26, P1265, DOI 10.1177/0269881111431747; Mexal
S, 2010, J MOL NEUROSCI, V40, P185, DOI 10.1007/s12031-009-9233-4; Mihalak KB,
2006, MOL PHARMACOL, V70, P801, DOI 10.1124/mol.106.025130; Mitchell SH, 1999,
PSYCHOPHARMACOLOGY, V146, P455, DOI 10.1007/PL00005491; Moghaddam B, 2012,
SCHIZOPHRENIA BULL, V38, P942, DOI 10.1093/schbul/sbs075; Moghaddam B, 2012,
NEUROPSYCHOPHARMACOL, V37, P4, DOI 10.1038/npp.2011.181; Mohler EG, 2010, PHARMACOL
BIOCHEM BE, V95, P146, DOI 10.1016/j.pbb.2009.12.019; Molas S, 2014, ACTA
NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0147-1; Myers CS, 2004,
PSYCHOPHARMACOLOGY, V174, P334, DOI 10.1007/s00213-003-1764-8; Myles N, 2012, J
CLIN PSYCHIAT, V73, P468, DOI 10.4088/JCP.11r07222; Nakazawa K, 2012,
NEUROPHARMACOLOGY, V62, P1574, DOI 10.1016/j.neuropharm.2011.01.022; Nashmi R,
2006, J MOL NEUROSCI, V30, P181, DOI 10.1385/JMN/30:1-2:181; Nasrallah HA, 2002, J
CLIN PSYCHIAT, V63, P12; Nikiforuk A, 2016, NEUROPHARMACOLOGY, V101, P389, DOI
10.1016/j.neuropharm.2015.07.034; Noroozian M, 2013, PSYCHOPHARMACOLOGY, V228,
P595, DOI 10.1007/s00213-013-3064-2; Novak G, 2010, SYNAPSE, V64, P794, DOI
10.1002/syn.20786; O'Driscoll GA, 2008, BRAIN COGNITION, V68, P359, DOI
10.1016/j.bandc.2008.08.023; Ohmura Y, 2012, J PHARMACOL SCI, V118, P413, DOI
10.1254/jphs.11R06CR; Olincy A, 1998, NEUROPSYCHOPHARMACOL, V18, P175, DOI
10.1016/S0893-133X(97)00095-X; Olincy A, 1997, BIOL PSYCHIAT, V42, P1, DOI
10.1016/S0006-3223(96)00302-2; Olincy A, 2003, PSYCHIAT RES, V117, P223, DOI
10.1016/S0165-1781(03)00022-2; Olincy A, 2007, BIOCHEM PHARMACOL, V74, P1192, DOI
10.1016/j.bcp.2007.07.015; Olincy A, 2006, ARCH GEN PSYCHIAT, V63, P630, DOI
10.1001/archpsyc.63.6.630; Olincy Ann, 2012, Handb Exp Pharmacol, P211, DOI
10.1007/978-3-642-25758-2_8; Oranje B, 2006, PSYCHIAT RES, V143, P147, DOI
10.1016/j.psychres.2005.11.002; Pachas GN, 2012, J DUAL DIAGN, V8, P117, DOI
10.1080/15504263.2012.663675; Papke RL, 2002, BRIT J PHARMACOL, V137, P49, DOI
10.1038/sj.bjp.0704833; Parikh V, 2008, J NEUROSCI, V28, P3769, DOI
10.1523/JNEUROSCI.5251-07.2008; Parikh V, 2010, J NEUROSCI, V30, P3518, DOI
10.1523/JNEUROSCI.5712-09.2010; Picciotto MR, 2008, PROG NEUROBIOL, V84, P329, DOI
10.1016/j.pneurobio.2007.12.005; Picciotto MR, 2015, NEUROPHARMACOLOGY, V96, P235,
DOI 10.1016/j.neuropharm.2014.12.028; Picciotto MR, 1998, NATURE, V391, P173;
POMERLEAU OF, 1993, J CONSULT CLIN PSYCH, V61, P723, DOI 10.1037/0022-
006X.61.5.723; Pons S, 2008, J NEUROSCI, V28, P12318, DOI 10.1523/JNEUROSCI.3918-
08.2008; Portugal GS, 2008, BEHAV BRAIN RES, V193, P1, DOI
10.1016/j.bbr.2008.05.006; Potter AS, 2014, BIOL PSYCHIAT, V75, P207, DOI
10.1016/j.biopsych.2013.06.002; Powell J, 2010, PSYCHOPHARMACOLOGY, V212, P537, DOI
10.1007/s00213-010-1975-8; Powell SB, 2009, BEHAV BRAIN RES, V204, P282, DOI
10.1016/j.bbr.2009.04.021; Preskorn SH, 2014, J PSYCHIATR PRACT, V20, P12, DOI
10.1097/01.pra.0000442935.15833.c5; Reynolds B, 2004, BEHAV PROCESS, V65, P35, DOI
10.1016/S0376-6357(03)00109-8; Rezvani AH, 2009, PROG NEURO-PSYCHOPH, V33, P269,
DOI 10.1016/j.pnpbp.2008.11.018; Riala K, 2005, J PSYCHIATR NEUROSCI, V30, P26;
Ripke S, 2014, NATURE, V511, P421, DOI 10.1038/nature13595; Romer D, 2010, DEV
PSYCHOBIOL, V52, P263, DOI 10.1002/dev.20442; Ross RG, 1998, SCHIZOPHR RES, V30,
P59, DOI 10.1016/S0920-9964(97)00133-3; Sacco KA, 2004, J PSYCHOPHARMACOL, V18,
P457, DOI 10.1177/0269881104047273; Sacco KA, 2005, ARCH GEN PSYCHIAT, V62, P649,
DOI 10.1001/archpsyc.62.6.649; Saccone NL, 2010, GENES BRAIN BEHAV, V9, P741, DOI
10.1111/j.1601-183X.2010.00608.x; Saccone SF, 2008, BIOINFORMATICS, V24, P1805, DOI
10.1093/bioinformatics/btn315; Saccone SF, 2007, AM J HUM GENET, V80, P856, DOI
10.1086/513703; Saha S, 2005, PLOS MED, V2, P413, DOI 10.1371/journal.pmed.0020141;
Sarantis K, 2009, NEUROSCIENCE, V163, P1135, DOI
10.1016/j.neuroscience.2009.07.056; Sarter M, 2011, BEHAV NEUROSCI, V125, P825, DOI
10.1037/a0026227; Schubert MH, 2006, BIOL PSYCHIAT, V60, P530, DOI
10.1016/j.biopsych.2006.04.006; SCHWARTZ RD, 1983, SCIENCE, V220, P214, DOI
10.1126/science.6828889; Seeman
MV, 2014, PROG NEURO-PSYCHOPH, V48, P155, DOI 10.1016/j.pnpbp.2013.10.003; SEGUELA
P, 1993, J NEUROSCI, V13, P596; Shanmugam G, 2007, PSYCHIAT CLIN N AM, V30, P761,
DOI 10.1016/j.psc.2007.07.008; Sharma G, 2008, CURR MED CHEM, V15, P2921, DOI
10.2174/092986708786848703; Sher E, 2004, CURR TOP MED CHEM, V4, P283, DOI
10.2174/1568026043451393; Sherr JD, 2002, BIOL PSYCHIAT, V52, P721, DOI
10.1016/S0006-3223(02)01342-2; Shiina A, 2010, ANN GEN PSYCHIATR, V9, DOI
10.1186/1744-859X-9-27; Shim JC, 2012, NEUROPSYCHOPHARMACOL, V37, P660, DOI
10.1038/npp.2011.238; Shytle RD, 2002, MOL PSYCHIATR, V7, P525, DOI
10.1038/sj.mp.4001035; Simon AE, 2007, SCHIZOPHRENIA BULL, V33, P761, DOI
10.1093/schbul/sbm018; Simosky JK, 2001, BIOL PSYCHIAT, V50, P493, DOI
10.1016/S0006-3223(01)01093-9; Smith RC, 2002, NEUROPSYCHOPHARMACOL, V27, P479, DOI
10.1016/S0893-133X(02)00324-X; Smucny J, 2013, SCHIZOPHR RES, V147, P196, DOI
10.1016/j.schres.2013.03.025; Spinella M, 2002, ADDICT BIOL, V7, P381, DOI
10.1080/1355621021000005964; Spring B, 2003, AM J PSYCHIAT, V160, P316, DOI
10.1176/appi.ajp.160.2.316; Stephens SH, 2012, BEHAV GENET, V42, P402, DOI
10.1007/s10519-011-9514-x; Stevens KE, 1998, PSYCHOPHARMACOLOGY, V136, P320, DOI
10.1007/s002130050573; Strand JE, 2005, EUR PSYCHIAT, V20, P50, DOI
10.1016/j.eurpsy.2004.09.005; Sweeney JA, 1999, BIOL PSYCHIAT, V46, P671, DOI
10.1016/S0006-3223(99)00132-8; Swerdlow NR, 1999, ANN NY ACAD SCI, V877, P202, DOI
10.1111/j.1749-6632.1999.tb09269.x; Swerdlow NR, 2006, NEUROPSYCHOPHARMACOL, V31,
P506, DOI 10.1038/sj.npp.1300841; Tapia L, 2007, MOL PHARMACOL, V71, P769, DOI
10.1124/mol.106.030445; Terry AV, 2015, BIOCHEM PHARMACOL, V97, P388, DOI
10.1016/j.bcp.2015.07.027; Terry AV, 2005, NEUROSCIENCE, V136, P519, DOI
10.1016/j.neuroscience.2005.08.006; Terry AV, 2003, NEUROPSYCHOPHARMACOL, V28,
P300, DOI 10.1038/sj.npp.1300039; Thoma P, 2013, PSYCHIAT CLIN NEUROS, V67, P367,
DOI 10.1111/pcn.12072; Tidey JW, 2014, NICOTINE TOB RES, V16, P326, DOI
10.1093/ntr/ntt152; Tietje KR, 2008, CNS NEUROSCI THER, V14, P65, DOI
10.1111/j.1527-3458.2008.00037.x; Tseng KY, 2004, J NEUROSCI, V24, P5131, DOI
10.1523/JNEUROSCI.1021-04.2004; Tsutsui-Kimura I, 2010, PSYCHOPHARMACOLOGY, V209,
P351, DOI 10.1007/s00213-010-1804-0; Umbricht D, 2014, NEUROPSYCHOPHARMACOL, V39,
P1568, DOI 10.1038/npp.2014.17; Uteshev VV, 2014, EUR J PHARMACOL, V727, P181, DOI
10.1016/j.ejphar.2014.01.072; VENABLES PH, 1960, BRAIN, V83, P77, DOI
10.1093/brain/83.1.77; Voineskos S, 2007, J PSYCHIATR NEUROSCI, V32, P412; Volkow
ND, 2009, SCHIZOPHRENIA BULL, V35, P469, DOI 10.1093/schbul/sbp016; Walling D.,
2015, SCHIZOPHR B; Walters CL, 2006, PSYCHOPHARMACOLOGY, V184, P339, DOI
10.1007/s00213-005-0295-x; Wehring HJ, 2012, SCHIZOPHR RES, V138, P285, DOI
10.1016/j.schres.2012.03.024; Weinberger AH, 2007, SCHIZOPHR RES, V91, P217, DOI
10.1016/j.schres.2006.12.007; Whiteside SP, 2001, PERS INDIV DIFFER, V30, P669, DOI
10.1016/S0191-8869(00)00064-7; Wilens TE, 1999, AM J PSYCHIAT, V156, P1931; Wilens
TE, 2007, BIOCHEM PHARMACOL, V74, P1212, DOI 10.1016/j.bcp.2007.07.002; Wilens TE,
2006, BIOL PSYCHIAT, V59, P1065, DOI 10.1016/j.biopsych.2005.10.029; Wilking JA,
2010, PHARMACOGENET GENOM, V20, P121, DOI 10.1097/FPC.0b013e3283369347; Williams
JM, 2012, J CLIN PSYCHIAT, V73, P654, DOI 10.4088/JCP.11m07522; Wing VC, 2013,
SCHIZOPHR RES, V149, P190, DOI 10.1016/j.schres.2013.06.032; Wing VC, 2012, ANN NY
ACAD SCI, V1248, P89, DOI 10.1111/j.1749-6632.2011.06261.x; Wing VC, 2011, PSYCHIAT
RES, V188, P320, DOI 10.1016/j.psychres.2011.05.037; Winklbaur Bernadette, 2006,
Dialogues Clin Neurosci, V8, P37; Winterer G, 2013, NEUROPHARMACOLOGY, V64, P197,
DOI 10.1016/j.neuropharm.2012.06.040; Wong AHC, 2003, PROG NEURO-PSYCHOPH, V27,
P1091, DOI 10.1016/j.pnpbp.2003.09.005; Wonnacott S, 1997, TRENDS NEUROSCI, V20,
P92, DOI 10.1016/S0166-2236(96)10073-4; Woznica AA, 2009, SCHIZOPHR RES, V112, P86,
DOI 10.1016/j.schres.2009.04.016; Yadon CA, 2009, COGN AFFECT BEHAV NE, V9, P448,
DOI 10.3758/CABN.9.4.448; Yates SL, 1995, BIOCHEM PHARMACOL, V50, P2001, DOI
10.1016/0006-2952(95)02100-0; Yin J., 2015, BRAIN IMAGING BEHAV; Young JW, 2011,
GENES BRAIN BEHAV, V10, P720, DOI 10.1111/j.1601-183X.2011.00711.x; Young JW, 2007,
EUR NEUROPSYCHOPHARM, V17, P145, DOI 10.1016/j.euroneuro.2006.03.008; Young JW,
2013, BIOCHEM PHARMACOL, V86, P1122, DOI 10.1016/j.bcp.2013.06.031; Yung AR, 1996,
SCHIZOPHRENIA BULL, V22, P353, DOI 10.1093/schbul/22.2.353; Zhang XY, 2012, AM J
PSYCHIAT, V169, P974, DOI 10.1176/appi.ajp.2012.11081289 276 33 34 0
32 ELSEVIER SCIENCE BV AMSTERDAM PO BOX 211, 1000 AE AMSTERDAM,
NETHERLANDS 0920-9964 1573-2509 SCHIZOPHR RES Schizophr. Res. MAR
2016 171 1-3 1 15
10.1016/j.schres.2016.01.020 15 Psychiatry Psychiatry DE1GS
WOS:000370375700001 26803692 Green Accepted 2019-09-25
J Pape, H; Norstrtom, T Pape, Hilde; Norstrtom, Thor
Associations between emotional distress and heavy drinking among young
people: A longitudinal study DRUG AND ALCOHOL REVIEW English
Article anxiety; depressed mood; heavy
drinking; adolescence; early adulthood ALCOHOL-USE DISORDERS; SUBSTANCE USE
DISORDERS; SELF-MEDICATION HYPOTHESIS; ANXIETY DISORDERS; MAJOR DEPRESSION; MENTAL-
HEALTH; LIFE EVENTS; DRUG-USE; LONELINESS; ADOLESCENTS Introduction and
AimsThis study adds to the meagre body of longitudinal research on the link between
emotional distress and alcohol use among young people. We address the following
research questions: Are symptoms of anxiety and depressed mood likely to be
causally related to heavy episodic drinking (HED)? Does the association change as
individuals move from adolescence to early adulthood? Design and MethodsData
stemmed from a national sample of young people in Norway that was assessed in 1992
(T1; mean age=14.9 years), 1994 (T2), 1999 (T3) and 2005 (T4) (response rate: 60%,
n=2171). We applied fixed-effects modelling, implying that intra-individual changes
in the frequency of HED were regressed on intra-individual changes in emotional
distress. Hence, confounding due to stable underlying influences was eliminated.
Self-perceived loneliness was included as a time-varying covariate.
ResultsEmotional distress was unrelated to HED in adolescence (T1 to T2). In the
transition from adolescence to early adulthood (T2 to T3), changes in
depressiveness were positively and independently associated with changes in HED,
whereas changes symptoms of anxiety were not. A similar pattern emerged in early
adulthood (T3 to T4). Discussion and ConclusionsThe potential causal relationship
between emotional distress and heavy drinking did not manifest itself in
adolescence, but increased symptoms of depressiveness were related to more frequent
HED in subsequent periods of life. Hence, this study provides conditional support
to the notion that emotional distress and HED may be causally related and indicates
that the association among young people may be specific to depressiveness. [Pape H,
Norstrom T. Associations between emotional distress and heavy drinking among young
people: A longitudinal study. Drug Alcohol Rev 2016;35:170-6] [Pape, Hilde;
Norstrtom, Thor] Norwegian Inst Alcohol & Drug Res SIRUS, PB 565 Sentrum, N-0105
Oslo, Norway; [Norstrtom, Thor] Stockholm Univ, Swedish Inst Social Res, S-10691
Stockholm, Sweden Pape, H (reprint author), Norwegian Inst Alcohol & Drug Res
SIRUS, PB 565 Sentrum, N-0105 Oslo, Norway. hp@sirus.no Norwegian
Institute for Alcohol and Drug Research (SIRUS); Stockholm University This
research was funded by the Norwegian Institute for Alcohol and Drug Research
(SIRUS) and Stockholm University. The data from the Young in Norway Longitudinal
Study were provided by Norwegian Social Research. None of the authors have any
conflict of interests to declare. Allison P., 1990, SOCIOL METHODOL, V20, P93,
DOI DOI 10.2307/271083; Bell S, 2015, ALCOHOL CLIN EXP RES, V39, P688, DOI
10.1111/acer.12681; Bell S, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-91; Boden
JM, 2011, ADDICTION, V106, P906, DOI 10.1111/j.1360-0443.2010.03351.x; Bonin MF,
2000, PSYCHOL ADDICT BEHAV, V14, P151, DOI 10.1037/0893-164X.14.2.151; Briere FN,
2014, COMPR PSYCHIAT, V55, P526, DOI 10.1016/j.comppsych.2013.10.007; Brown SA,
2008, PEDIATRICS, V121, pS290, DOI 10.1542/peds.2007-2243D; Burns L, 2002, DRUG
ALCOHOL DEPEN, V68, P299, DOI 10.1016/S0376-8716(02)00220-X; Cacioppo JT, 2002,
PSYCHOSOM MED, V64, P407, DOI 10.1097/00006842-200205000-00005; Cooper ML, 2008, J
ABNORM PSYCHOL, V117, P485, DOI 10.1037/a0012592; COOPER ML, 1995, J PERS SOC
PSYCHOL, V69, P990, DOI 10.1037/0022-3514.69.5.990; Crum RM, 2013, JAMA PSYCHIAT,
V70, P718, DOI 10.1001/jamapsychiatry.2013.1098; Dawson DA, 2005, ALCOHOL
ALCOHOLISM, V40, P453, DOI 10.1093/alcalc/agh176; DEROGATIS LR, 1974, BEHAV SCI,
V19, P1, DOI 10.1002/bs.3830190102; Edwards AC, 2014, J STUD ALCOHOL DRUGS, V75,
P758, DOI 10.15288/jsad.2014.75.758; Ernst JM, 1999, APPL PREV PSYCHOL, V8, P1, DOI
10.1016/S0962-1849(99)80008-0; Fergusson DM, 2009, ARCH GEN PSYCHIAT, V66, P260,
DOI 10.1001/archgenpsychiatry.2008.543; Fetzner MG, 2011, DEPRESS ANXIETY, V28,
P632, DOI 10.1002/da.20852; Flensborg-Madsen T, 2011, ADDICTION, V106, P916, DOI
10.1111/j.1360-0443.2011.03406.x; Flynn HA, 2000, ALCOHOL CLIN EXP RES, V24, P48,
DOI 10.1111/j.1530-0277.2000.tb04552.x; Frojd S, 2011, ALCOHOL ALCOHOLISM, V46,
P192, DOI 10.1093/alcalc/agq096; Galaif Elisha R, 2007, Int J Adolesc Med Health,
V19, P27; Goodwin RD, 2004, J PSYCHIATR RES, V38, P295, DOI
10.1016/j.jpsychires.2003.09.002; Gorka SM, 2014, DRUG ALCOHOL DEPEN, V140, P191,
DOI 10.1016/j.drugalcdep.2014.04.021; Graber J. A, 2004, HDB ADOLESCENT PSYCH,
P587; Graham K, 2007, ALCOHOL CLIN EXP RES, V31, P78, DOI 10.1111/j.1530-
0277.2006.00274.x; Grant BF, 2004, ARCH GEN PSYCHIAT, V61, P807, DOI
10.1001/archpsyc.61.8.807; Halaby CN, 2004, ANNU REV SOCIOL, V30, P507, DOI
10.1146/annurev.soc.30.012703.110629; HARTKA E, 1991, BRIT J ADDICT, V86, P1283,
DOI 10.1111/j.1360-0443.1991.tb01704.x; Hawkley LC, 2010, ANN BEHAV MED, V40, P218,
DOI 10.1007/s12160-010-9210-8; Heinrich LA, 2006, CLIN PSYCHOL REV, V26, P695, DOI
10.1016/j.cpr.2006.04.002; Holahan CJ, 2001, J STUD ALCOHOL, V62, P190, DOI
10.15288/jsa.2001.62.190; KANDEL DB, 1982, ARCH GEN PSYCHIAT, V39, P1205; Kaplow
JB, 2001, J CLIN CHILD PSYCHOL, V30, P316, DOI 10.1207/S15374424JCCP3003_4;
Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550;
Kuntsche E, 2005, CLIN PSYCHOL REV, V25, P841, DOI 10.1016/j.cpr.2005.06.002;
Kuntsche E, 2004, SOC SCI MED, V59, P113, DOI 10.1016/j.socscimed.2003.10.009;
Kuntsche E, 2014, J STUD ALCOHOL DRUGS, V75, P428, DOI 10.15288/jsad.2014.75.428;
Kuntsche E, 2012, EUR ADDICT RES, V18, P34, DOI 10.1159/000333036; KUSHNER MG,
1990, AM J PSYCHIAT, V147, P685; Kushner MG, 2000, CLIN PSYCHOL REV, V20, P149, DOI
10.1016/S0272-7358(99)00027-6; McBroom EM, 2008, J 1 YEAR EXP STUD TR, V20, P45;
Menary KR, 2011, J ANXIETY DISORD, V25, P335, DOI 10.1016/j.janxdis.2010.10.006;
Mushquash AR, 2013, ADDICT BEHAV, V38, P2180, DOI 10.1016/j.addbeh.2012.11.008;
Pape H, 1996, SCAND J PSYCHOL, V37, P362, DOI 10.1111/j.1467-9450.1996.tb00669.x;
Peirce RS, 2000, HEALTH PSYCHOL, V19, P28, DOI 10.1037/0278-6133.19.1.28;
Poikolainen K, 2001, ALCOHOL ALCOHOLISM, V36, P85, DOI 10.1093/alcalc/36.1.85;
RUSSELL D, 1980, J PERS SOC PSYCHOL, V39, P472, DOI 10.1037/0022-3514.39.3.472;
Schulenberg JE, 2002, J STUD ALCOHOL, P54, DOI 10.15288/jsas.2002.s14.54; Skogen
JC, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005357; Stewart SH, 2000, PERS
INDIV DIFFER, V29, P495, DOI 10.1016/S0191-8869(99)00210-X; Strand N. P., 2007,
YOUNG NORWAY LONGITU; Sullivan LE, 2005, AM J MED, V118, P330, DOI
10.1016/j.amjmed.2005.01.007; Swendsen JD, 2000, J ABNORM PSYCHOL, V109, P198, DOI
10.1037//0021-843X.109.2.198; Tennant C, 2002, AUST NZ J PSYCHIAT, V36, P173, DOI
10.1046/j.1440-1614.2002.01007.x; Wichstrom L, 2013, HEALTH PSYCHOL, V32, P775, DOI
10.1037/a0029465; Williams RL, 2000, BIOMETRICS, V56, P645, DOI 10.1111/j.0006-
341X.2000.00645.x 57 5 5 0 15 WILEY HOBOKEN 111 RIVER ST,
HOBOKEN 07030-5774, NJ USA 0959-5236 1465-3362 DRUG ALCOHOL REV Drug
Alcohol Rev. MAR 2016 35 2 170 176
10.1111/dar.12290 7 Substance Abuse Substance Abuse DI3GS
WOS:000373387600009 26094994 2019-09-25
J Imperatori, C; Fabbricatore, M; Vumbaca, V; Innamorati, M; Contardi, A;
Farina, B Imperatori, Claudio; Fabbricatore, Mariantonietta;
Vumbaca, Viviana; Innamorati, Marco; Contardi, Anna; Farina, Benedetto
Food Addiction: definition, measurement and prevalence in healthy subjects
and in patients with eating disorders RIVISTA DI PSICHIATRIA
English Article food addiction; food
craving; eating disorders; obesity; overweight SELF-MEDICATION HYPOTHESIS;
SUBSTANCE USE DISORDERS; ENERGY-DIET THERAPY; BODY-MASS INDEX; OBESE-PATIENTS;
BULIMIA-NERVOSA; GENDER-DIFFERENCES; PRELIMINARY VALIDATION; ANOREXIA-NERVOSA;
ELDERLY ADULTS The construct of "Food Addiction" (FA) has been introduced in the
last decades to better understand abnormal eating patterns in obese and overweight
people and in patients with Eating Disorders (EDs). Despite a substantial
parallelism between drug addiction and FA, there is still no agreement in
considering FA an independent ED or a useful convincing concept. Therefore, the
purpose of this review is to aggregate available data, in order to increase
knowledge about: 1) definition, measurement and general features of FA; 2)
prevalence of FA in clinical and non-clinical samples. Available data suggest that
FA seems to be a transnosografic construct and exists in all EDs, with higher
prevalence in Bulimia Nervosa. Although the discussion on the autonomous diagnosis
of FA within EDs remains open, studies have reported that comorbidity between FA
and other EDs is associated with worse clinical conditions and symptoms,
justifying, as a result, the usefulness of assessing and treating this condition.
[Imperatori, Claudio; Fabbricatore, Mariantonietta; Vumbaca, Viviana;
Innamorati, Marco; Contardi, Anna; Farina, Benedetto] European Univ, Dept Human
Sci, Rome, Italy Imperatori, C (reprint author), European Univ, Dept Human Sci,
Rome, Italy. imperatori.c@libero.it Innamorati, Marco/H-8877-2013 Innamorati,
Marco/0000-0003-1389-2290; CONTARDI, Anna/0000-0001-5021-2966; Imperatori,
Claudio/0000-0002-8207-6919 Adam TC, 2007, PHYSIOL BEHAV, V91, P449,
DOI 10.1016/j.physbeh.2007.04.011; American Psychiatric Association, 2013, DIAGN
STAT MAN MENT; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Avena
NM, 2008, NEUROSCI BIOBEHAV R, V32, P20, DOI 10.1016/j.neubiorev.2007.04.019; Avena
Nicole M, 2011, Curr Drug Abuse Rev, V4, P131; Avena Nicole M, 2011, Curr Drug
Abuse Rev, V4, P133; Avena NM, 2010, APPETITE, V55, P734, DOI
10.1016/j.appet.2010.09.010; Avena NM, 2009, J NUTR, V139, P623, DOI
10.3945/jn.108.097584; Bean MK, 2008, J CLIN PSYCHOL MED S, V15, P214, DOI
10.1007/s10880-008-9124-9; Bersani FS, 2015, BIOMED RES INT, DOI
10.1155/2015/120679; Bersani FS, 2016, DRUG TEST ANAL, V8, P177, DOI
10.1002/dta.1891; Biondi M, 2014, RIV PSICHIATR, V49, P57, DOI 10.1708/1461.16137;
Blum Kenneth, 2000, Journal of Psychoactive Drugs, V32, pi; Blume AW, 2000, COGN
BEHAV PRACT, V7, P379, DOI 10.1016/S1077-7229(00)80048-6; Blumenthal DM, 2010, CURR
OPIN CLIN NUTR, V13, P359, DOI 10.1097/MCO.0b013e32833ad4d4; Brunault P, 2014, CAN
J PSYCHIAT, V59, P276; Burmeister JM, 2013, APPETITE, V60, P103, DOI
10.1016/j.appet.2012.09.013; Cassin SE, 2007, APPETITE, V49, P687, DOI
10.1016/j.appet.2007.06.012; Cepeda-Benito A, 2003, APPETITE, V40, P47, DOI
10.1016/S0195-6663(02)00145-9; Cheetham A, 2010, CLIN PSYCHOL REV, V30, P621, DOI
10.1016/j.cpr.2010.04.005; Clark SM, 2013, EAT BEHAV, V14, P216, DOI
10.1016/j.eatbeh.2013.01.002; Corwin RL, 2009, J NUTR, V139, P617, DOI
10.3945/jn.108.097691; Dallman MF, 2010, TRENDS ENDOCRIN MET, V21, P159, DOI
10.1016/j.tem.2009.10.004; Dallman MF, 2005, BRAIN BEHAV IMMUN, V19, P275, DOI
10.1016/j.bbi.2004.11.004; Dallman MF, 2003, P NATL ACAD SCI USA, V100, P11696, DOI
10.1073/pnas.1934666100; Davis Caroline, 2013, ISRN Obes, V2013, P435027, DOI
10.1155/2013/435027; Davis C, 2013, CURR OBES REP, V2, P171, DOI 10.1007/s13679-
013-0049-8; Davis C, 2011, APPETITE, V57, P711, DOI 10.1016/j.appet.2011.08.017;
Davis C, 2009, APPETITE, V53, P1, DOI 10.1016/j.appet.2009.05.018; Dehghani-Arani
F, 2013, APPL PSYCHOPHYS BIOF, V38, P133, DOI 10.1007/s10484-013-9218-5; Di Segni
M, 2014, NUTRIENTS, V6, P4591, DOI 10.3390/nu6104591; DYE L, 1995, J AFFECT
DISORDERS, V34, P157, DOI 10.1016/0165-0327(95)00013-D; Eichen DM, 2013, APPETITE,
V67, P22, DOI 10.1016/j.appet.2013.03.008; Evans AH, 2006, ANN NEUROL, V59, P852,
DOI 10.1002/ana.20822; Fabbricatore M, 2011, OBES METAB-MILAN, V7, pE28;
Fabbricatore M, 2011, OBES METAB-MILAN, V7, pE21; Flegal KM, 2012, JAMA-J AM MED
ASSOC, V307, P491, DOI 10.1001/jama.2012.39; Flint AJ, 2014, AM J CLIN NUTR, V99,
P578, DOI 10.3945/ajcn.113.068965; Fortuna JL, 2012, J PSYCHOACTIVE DRUGS, V44,
P56, DOI 10.1080/02791072.2012.662092; Frank GKW, 2013, CURR PSYCHIAT REP, V15, DOI
10.1007/s11920-013-0396-x; Gearhardt AN, 2014, EAT BEHAV, V15, P427, DOI
10.1016/j.eatbeh.2014.05.001; Gearhardt AN, 2013, EAT BEHAV, V14, P508, DOI
10.1016/j.eatbeh.2013.07.002; Gearhardt AN, 2013, COMPR PSYCHIAT, V54, P500, DOI
10.1016/j.comppsych.2012.12.009; Gearhardt AN, 2012, INT J EAT DISORDER, V45, P657,
DOI 10.1002/eat.20957; Gearhardt Ashley N, 2011, Curr Drug Abuse Rev, V4, P201;
Gearhardt AN, 2011, ARCH GEN PSYCHIAT, V68, P808, DOI
10.1001/archgenpsychiatry.2011.32; Gearhardt AN, 2009, J ADDICT MED, V3, P1, DOI
10.1097/ADM.0b013e318193c993; Gearhardt AN, 2009, APPETITE, V52, P430, DOI
10.1016/j.appet.2008.12.003; Geliebter A, 2013, BEHAV BRAIN RES, V243, P91, DOI
10.1016/j.bbr.2012.12.023; Gendall KA, 1997, INT J EAT DISORDER, V22, P403; GOODMAN
A, 1990, BRIT J ADDICT, V85, P1403; Granero R, 2014, EUR EAT DISORD REV, V22, P389,
DOI 10.1002/erv.2311; Grob S, 2012, NEUROPSYCHOPHARMACOL, V37, P1945, DOI
10.1038/npp.2012.41; HARGROVE JT, 1982, J REPROD MED, V27, P721; HEATHERTON TF,
1991, PSYCHOL BULL, V110, P86, DOI 10.1037/0033-2909.110.1.86; Hone-Blanchet A,
2014, NEUROPHARMACOLOGY, V85, P81, DOI 10.1016/j.neuropharm.2014.05.019; Ifland JR,
2009, MED HYPOTHESES, V72, P518, DOI 10.1016/j.mehy.2008.11.035; Imperatori C,
2015, BRAIN IMAGING BEHAV, V9, P703, DOI 10.1007/s11682-014-9324-x; Imperatori C,
2014, COMPR PSYCHIAT, V55, P1358, DOI 10.1016/j.comppsych.2014.04.023; Imperatori
C, 2013, EAT WEIGHT DISORD-ST, V18, P297, DOI 10.1007/s40519-013-0054-7; Innamorati
M, 2015, EAT WEIGHT DISORD-ST, V20, P119, DOI 10.1007/s40519-014-0142-3; Isganaitis
E, 2005, ARTERIOSCL THROM VAS, V25, P2451, DOI 10.1161/01.ATV.0000186208.06964.91;
JAHANFAR S, 1995, GYNECOL ENDOCRINOL, V9, P113, DOI 10.3109/09513599509160199;
Jarosz Patricia A, 2007, Eat Behav, V8, P374, DOI 10.1016/j.eatbeh.2006.11.014;
Johnson PM, 2010, NAT NEUROSCI, V13, P635, DOI 10.1038/nn.2519; Khantzian EJ, 1997,
HARVARD REV PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550; KHANTZIAN EJ, 1985,
AM J PSYCHIAT, V142, P1259; KOZLOWSKI LT, 1987, BRIT J ADDICT, V82, P31; Lafay L,
2001, INT J EAT DISORDER, V29, P195, DOI 10.1002/1098-108X(200103)29:2<195::AID-
EAT1009>3.0.CO;2-N; Mathes WF, 2009, APPETITE, V52, P545, DOI
10.1016/j.appet.2009.03.005; Merlo LJ, 2009, J ADDICT MED, V3, P26, DOI
10.1097/ADM.0b013e31819638b0; Meule A., 2014, CURR ADDICT REP, V1, P193, DOI DOI
10.1007/S40429-014-0021-Z; Meule Adrian, 2015, Yale Journal of Biology and
Medicine, V88, P295; Meule A, 2014, EUR EAT DISORD REV, V22, P331, DOI
10.1002/erv.2306; Meule A, 2012, EUR EAT DISORD REV, V20, P419, DOI
10.1002/erv.2189; Meule A, 2012, DIAGNOSTICA, V58, P115, DOI 10.1026/0012-
1924/a000047; Meule A, 2012, EAT BEHAV, V13, P252, DOI
10.1016/j.eatbeh.2012.02.001; Meule Adrian, 2011, Front Psychiatry, V2, P61, DOI
10.3389/fpsyt.2011.00061; Michelmore KF, 2001, HUM REPROD, V16, P765, DOI
10.1093/humrep/16.4.765; Moore DJ, 2010, JABE, V10, P15; Moreno S, 2008,
ASSESSMENT, V15, P375, DOI 10.1177/1073191107312651; Moreno S, 2009, APPETITE, V52,
P588, DOI 10.1016/j.appet.2009.01.011; Morgan JF, 2002, FERTIL STERIL, V77, P928,
DOI 10.1016/S0015-0282(02)03063-7; Osman JL, 2006, APPETITE, V47, P290, DOI
10.1016/j.appet.2006.04.008; Parylak SL, 2011, PHYSIOL BEHAV, V104, P149, DOI
10.1016/j.physbeh.2011.04.063; Paxton SJ, 1997, INT J EAT DISORDER, V22, P83, DOI
10.1002/(SICI)1098-108X(199707)22:1<83::AID-EAT11>3.0.CO;2-J; Pedram P, 2013, PLOS
ONE, V8, DOI 10.1371/journal.pone.0074832; Pelchat ML, 2009, J NUTR, V139, P620,
DOI 10.3945/jn.108.097816; Pelchat ML, 1997, APPETITE, V28, P103, DOI
10.1006/appe.1996.0063; Pelchat ML, 2000, PHYSIOL BEHAV, V68, P353, DOI
10.1016/S0031-9384(99)00190-0; Pretlow Robert A, 2011, Eat Disord, V19, P295, DOI
10.1080/10640266.2011.584803; Pursey KM, 2014, NUTRIENTS, V6, P4552, DOI
10.3390/nu6104552; RANDOLPH TG, 1956, Q J STUD ALCOHOL, V17, P198; Ross SM, 2013,
HOLIST NURS PRACT, V27, P246, DOI 10.1097/HNP.0b013e3182971b7c; ROZIN P, 1991,
APPETITE, V17, P199, DOI 10.1016/0195-6663(91)90022-K; Schulte EM, 2015, PLOS ONE,
V10, DOI 10.1371/journal.pone.0117959; Simon GE, 2006, ARCH GEN PSYCHIAT, V63,
P824, DOI 10.1001/archpsyc.63.7.824; Speranza M, 2012, EUR EAT DISORD REV, V20,
P182, DOI 10.1002/erv.1140; Stice E, 2011, J NEUROSCI, V31, P4360, DOI
10.1523/JNEUROSCI.6604-10.2011; Stice E, 2010, J NEUROSCI, V30, P13105, DOI
10.1523/JNEUROSCI.2105-10.2010; SZMUKLER GI, 1984, BRIT J MED PSYCHOL, V57, P303,
DOI 10.1111/j.2044-8341.1984.tb02595.x; Umberg EN, 2012, J CLIN PSYCHOPHARM, V32,
P376, DOI 10.1097/JCP.0b013e318252464f; Vander Wal Jillon S, 2007, Eat Behav, V8,
P211, DOI 10.1016/j.eatbeh.2006.06.002; Volkow ND, 2013, OBES REV, V14, P2, DOI
10.1111/j.1467-789X.2012.01031.x; von Deneen KM, 2011, MATURITAS, V68, P342, DOI
10.1016/j.maturitas.2011.01.018; WALLIN GV, 1994, ACTA PSYCHIAT SCAND, V89, P376;
Wang GJ, 2009, P NATL ACAD SCI USA, V106, P1249, DOI 10.1073/pnas.0807423106; Wang
GJ, 2001, LANCET, V357, P354, DOI 10.1016/S0140-6736(00)03643-6; Waters A, 2001,
BEHAV RES THER, V39, P877, DOI 10.1016/S0005-7967(00)00059-0; WEINGARTEN HP,
1991, APPETITE, V17, P167, DOI 10.1016/0195-6663(91)90019-O; WEINGARTEN HP, 1990,
APPETITE, V15, P231, DOI 10.1016/0195-6663(90)90023-2; White MA, 2002, OBES RES,
V10, P107, DOI 10.1038/oby.2002.17; White Marney A, 2005, Eat Behav, V6, P239, DOI
10.1016/j.eatbeh.2005.01.001; Yau YHC, 2013, MINERVA ENDOCRINOL, V38, P255; Zellner
DA, 1999, APPETITE, V33, P61, DOI 10.1006/appe.1999.0234; Ziauddeen H, 2013, OBES
REV, V14, P19, DOI 10.1111/j.1467-789X.2012.01046.x; Ziauddeen H, 2012, NAT REV
NEUROSCI, V13, P279, DOI 10.1038/nrn3212 117 15 15 2 15 PENSIERO
SCIENTIFICO EDITOR ROME VIA BRADANO 3/C, 00199 ROME, ITALY 0035-6484 2038-
2502 RIV PSICHIATR Riv. Psichiatr. MAR-APR 2016 51 2
60 65 10.1708/2246.24196 6
Psychiatry Psychiatry DM5UN WOS:000376415800003 27183510
2019-09-25
J Farmer, RF; Kosty, DB; Seeley, JR; Gau, JM; Duncan, SC; Walker, DD;
Lewinsohn, PM Farmer, Richard F.; Kosty, Derek B.; Seeley,
John R.; Gau, Jeff M.; Duncan, Susan C.; Walker, Denise D.; Lewinsohn, Peter M.
Association of Comorbid Psychopathology With the Duration of Cannabis
Use Disorders PSYCHOLOGY OF ADDICTIVE BEHAVIORS English
Article cannabis use disorders (CUDs);
comorbidity; temporal sequencing; psychopathology; allostatic hypothesis
NATIONAL EPIDEMIOLOGIC SURVEY; CHILDHOOD BEHAVIOR PROBLEMS; SELF-MEDICATION
HYPOTHESIS; REWARD DEFICIENCY SYNDROME; PSYCHIATRIC-DISORDERS; SUBSTANCE USE;
HIERARCHICAL STRUCTURE; LIFETIME COMORBIDITY; MENTAL-DISORDERS; SOCIAL ANXIETY
Risk factors for the development of cannabis use disorders (CUDs) have been
well-researched. Comparatively little is known, however, about factors associated
with the persistence of CUDs over time. This research explored whether the temporal
sequencing of comorbid psychiatric disorders in relation to the onset of the index
CUD episode were associated with the length of this episode. Four comprehensive
diagnostic assessments were conducted between ages 16 and 30 with a large and
regionally representative community sample (n = 816), among which 173 persons were
diagnosed with a lifetime CUD. In separate unadjusted analyses, any internalizing
disorder and any mood disorder with onset prior to that of the index CUD episode
were each significantly and negatively associated with CUD duration. These effects,
however, were reduced to trend level in adjusted analyses that controlled for
putative confounders. Following the onset of the index CUD episode, the subsequent
occurrence of any Axis I disorder, internalizing disorder, externalizing disorder,
or other substance use disorder during the index CUD episode was significantly and
positively associated with the duration of that episode in both unadjusted and
adjusted analyses. These findings collectively suggest that the presence of
internalizing-spectrum disorders prior to the onset of the index CUD episode
affords some modest protection against protracted episodes, whereas the emergence
of broad-spectrum psychopathology within the index CUD episode, most notably
noncannabis substance use disorders, is associated with greater disorder
persistence. The relevance of these findings for various motivational models of
cannabis addiction is discussed. [Farmer, Richard F.; Kosty, Derek B.; Seeley,
John R.; Gau, Jeff M.; Duncan, Susan C.; Lewinsohn, Peter M.] Oregon Res Inst, 1776
Millrace Dr, Eugene, OR 97403 USA; [Walker, Denise D.] Univ Washington, Sch Social
Work, Seattle, WA 98195 USA Farmer, RF (reprint author), Oregon Res Inst, 1776
Millrace Dr, Eugene, OR 97403 USA. rfarmer@ori.org National
Institutes of HealthUnited States Department of Health & Human ServicesNational
Institutes of Health (NIH) - USA [MH40501, MH50522, DA12951, R01DA032659]
National Institutes of Health Grants MH40501, MH50522, and DA12951 to Peter
M. Lewinsohn and R01DA032659 to Richard F. Farmer and John R. Seeley supported this
research. The content is solely the responsibility of the authors and does not
necessarily represent the official views of the National Institutes of Health.
ACHENBACH TM, 1966, PSYCHOL MONOGRAPHS, V80; American Psychiatric
Association, 1987, DIAGN STAT MAN MENT; American Psychiatric Association, 1994,
DIAGN STAT MAN MENT; Angold A, 1999, J CHILD PSYCHOL PSYC, V40, P57, DOI
10.1111/1469-7610.00424; Arendt M, 2007, PSYCHOL MED, V37, P935, DOI
10.1017/S0033291706009688; Armstrong TD, 2002, J CONSULT CLIN PSYCH, V70, P1224,
DOI 10.1037//0022-006X.70.6.1224; Beauchaine TP, 2012, DEV PSYCHOPATHOL, V24,
P1003, DOI 10.1017/S0954579412000508; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289;
Blanco C, 2014, ADDICTION, V109, P284, DOI 10.1111/add.12382; BLASHFIELD RK, 1976,
J ABNORM PSYCHOL, V85, P140, DOI 10.1037/0021-843X.85.2.140; Blum K, 2000, J
PSYCHOACTIVE DRUGS, V32, P1, DOI DOI 10.1080/02791072.2000.10736099; Blum K, 2012,
CURR PHARM DESIGN, V18, P113, DOI 10.2174/138161212798919110; Brook JS, 2011, SUBST
ABUS, V32, P242, DOI 10.1080/08897077.2011.605696; Buckner JD, 2007, ADDICT BEHAV,
V32, P2238, DOI 10.1016/j.addbeh.2007.04.004; Buckner JD, 2012, ADDICT BEHAV, V37,
P1294, DOI 10.1016/j.addbeh.2012.06.013; CHAMBERS WJ, 1985, ARCH GEN PSYCHIAT, V42,
P696; Chartier KG, 2010, CHILD ADOL PSYCH CL, V19, P493, DOI
10.1016/j.chc.2010.03.004; Chen K, 1998, DRUG ALCOHOL DEPEN, V50, P109, DOI
10.1016/S0376-8716(98)00021-0; Colder CR, 2013, J ABNORM CHILD PSYCH, V41, P667,
DOI 10.1007/s10802-012-9701-0; Comings DE, 2000, PROG BRAIN RES, V126, P325; CONGER
JJ, 1956, Q J STUD ALCOHOL, V17, P296; Costello EJ, 1999, J CLIN CHILD PSYCHOL,
V28, P298, DOI 10.1207/S15374424jccp280302; Farmer RF, 2015, PSYCHOL MED, V45, P63,
DOI 10.1017/S003329171400107X; Farmer RF, 2015, PSYCHOL ADDICT BEHAV, V29, P541,
DOI 10.1037/adb0000059; Farmer RF, 2013, COMPR PSYCHIAT, V54, P523, DOI
10.1016/j.comppsych.2012.12.007; Farmer RF, 2013, J ABNORM PSYCHOL, V122, P573, DOI
10.1037/a0031429; Farmer RF, 2009, J ABNORM PSYCHOL, V118, P699, DOI
10.1037/a0017205; Fergusson DM, 2007, DRUG ALCOHOL DEPEN, V88, pS14, DOI
10.1016/j.drugalcdep.2006.12.011; Finn PR, 2002, ALCOHOL CLIN EXP RES, V26, P186,
DOI 10.1097/00000374-200202000-00006; First M. B., 1994, STRUCTURED CLIN INTE; Fite
PJ, 2006, ADDICT BEHAV, V31, P1454, DOI 10.1016/j.addbeh.2005.09.015; Florez-
Salamanca L, 2013, DRUG ALCOHOL DEPEN, V132, P127, DOI
10.1016/j.drugalcdep.2013.01.013; Fox CL, 2011, PSYCHOL ADDICT BEHAV, V25, P492,
DOI 10.1037/a0024331; Goldberg LR, 1993, STUDYING LIVES TIME, P169, DOI DOI
10.1037/10127-024; HAMPSON SE, 1986, J PERS SOC PSYCHOL, V51, P37, DOI
10.1037/0022-3514.51.1.37; Hariri AR, 2006, J NEUROSCI, V26, P13213, DOI
10.1523/JNEUROSCI.3446-06.2006; Hayatbakhsh MR, 2008, ADDICT BEHAV, V33, P422, DOI
10.1016/j.addbeh.2007.10.004; Hommer DW, 2011, ANN NY ACAD SCI, V1216, P50, DOI
10.1111/j.1749-6632.2010.05898.x; Jager G, 2013, J PSYCHOACTIVE DRUGS, V45, P156,
DOI 10.1080/02791072.2013.785837; Joseph JE, 2009, PSYCHOL SCI, V20, P215, DOI
10.1111/j.1467-9280.2009.02283.x; Kandel DB, 2000, J STUD ALCOHOL, V61, P367, DOI
10.15288/jsa.2000.61.367; KELLER MB, 1987, ARCH GEN PSYCHIAT, V44, P540; Kessler
RC, 2011, ARCH GEN PSYCHIAT, V68, P90, DOI 10.1001/archgenpsychiatry.2010.180;
KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259; Koob GF, 2008, ANNU REV PSYCHOL,
V59, P29, DOI 10.1146/annurev.psych.59.103006.093548; Koob GF, 2014,
NEUROPHARMACOLOGY, V76, P370, DOI 10.1016/j.neuropharm.2013.05.024; Koob GF, 2009,
NEUROPHARMACOLOGY, V56, P18, DOI 10.1016/j.neuropharm.2008.07.043; Koob GF, 2005,
NAT NEUROSCI, V8, P1442, DOI 10.1038/nn1105-1442; Krueger RF, 1999, ARCH GEN
PSYCHIAT, V56, P921, DOI 10.1001/archpsyc.56.10.921; Krueger RE, 2006, ANNU REV
CLIN PSYCHO, V2, P111, DOI 10.1146/annurev.clinpsy.2.022305.095213; KUSHNER MG,
1990, AM J PSYCHIAT, V147, P685; Lahey BB, 2008, J ABNORM CHILD PSYCH, V36, P187,
DOI 10.1007/s10802-007-9169-5; LEWINSOHN PM, 1993, J ABNORM PSYCHOL, V102, P133,
DOI 10.1037/0021-843X.102.1.133; Lopez-Quintero C, 2011, ADDICTION, V106, P657, DOI
10.1111/j.1360-0443.2010.03194.x; LORANGER AW, 1994, ARCH GEN PSYCHIAT, V51, P215;
LORANGER AW, 1988, PERSONALITY DISORDER; Lynskey MI, 2006, ADDICT BEHAV, V31, P984,
DOI 10.1016/j.addbeh.2006.03.048; Moffitt TE, 2010, PSYCHOL MED, V40, P899, DOI
10.1017/S0033291709991036; Newcomb MD, 2001, PROF PSYCHOL-RES PR, V32, P239, DOI
10.1037/0735-7028.32.3.239; ORVASCHEL H, 1982, J AM ACAD CHILD PSY, V21, P392, DOI
10.1016/S0002-7138(09)60944-4; Patten Scott B, 2006, Clin Pract Epidemiol Ment
Health, V2, P13, DOI 10.1186/1745-0179-2-13; Perkonigg A, 2008, ADDICTION, V103,
P439, DOI 10.1111/j.1360-0443.2007.02064.x; QUITKIN FM, 1972, ARCH GEN PSYCHIAT,
V27, P159; Roberts RE, 2007, DRUG ALCOHOL DEPEN, V88, pS4, DOI
10.1016/j.drugalcdep.2006.12.010; Seeley JR, 2011, J ABNORM PSYCHOL, V120, P308,
DOI 10.1037/a0022621; Solowij N, 2002, JAMA-J AM MED ASSOC, V287, P1123, DOI
10.1001/jama.287.9.1123; Tarter RE, 2008, J PSYCHOPATHOL BEHAV, V30, P272, DOI
10.1007/s10862-008-9083-3; Tomlinson KL, 2006, ADDICT BEHAV, V31, P461, DOI
10.1016/j.addbeh.2005.05.028; van den Bree MBM, 2005, ARCH GEN PSYCHIAT, V62, P311,
DOI 10.1001/archpsyc.62.3.311; Wills T A, 1994, J Subst Abuse, V6, P1, DOI
10.1016/S0899-3289(94)90039-6; WINDLE M, 1993, J STUD ALCOHOL, V54, P422, DOI
10.15288/jsa.1993.54.422; Wittchen HU, 2007, DRUG ALCOHOL DEPEN, V88, pS60, DOI
10.1016/j.drugalcdep.2006.12.013; Zinbarg RE, 2008, REINFORCEMENT SENSITIVITY
THEORY OF PERSONALITY, P360; Zucker RA, 2008, PEDIATRICS, V121, pS252, DOI
10.1542/peds.2007-2243B; Zvolensky MJ, 2003, CLIN PSYCHOL-SCI PR, V10, P29, DOI
10.1093/clipsy/10.1.29 75 4 4 0 7 EDUCATIONAL PUBLISHING
FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC WASHINGTON 750 FIRST ST, NE, WASHINGTON,
DC 20002-4242 USA 0893-164X 1939-1501 PSYCHOL ADDICT BEHAV Psychol.
Addict. Behav. FEB 2016 30 1 82 92
10.1037/adb0000151 11 Substance Abuse; Psychology,
Multidisciplinary Substance Abuse; Psychology DE3ZX WOS:000370570100009
26766543 Green Accepted 2019-09-25
J Babinska, Z; Ruda-Kucerova, J; Amchova, P; Merhautova, J; Dusek, L; Sulcova,
A Babinska, Zuzana; Ruda-Kucerova, Jana; Amchova, Petra;
Merhautova, Jana; Dusek, Ladislav; Sulcova, Alexandra Olfactory
bulbectomy increases reinstatement of methamphetamine seeking after a forced
abstinence in rats BEHAVIOURAL BRAIN RESEARCH English
Article methamphetamine; self-
administration; reinstatement; olfactory bulbectomy; depression; Sprague-Dawley
rats SELF-MEDICATION HYPOTHESIS; SUBSTANCE USE; ALCOHOL-SEEKING; DRUG-ABUSE;
DEPRESSION; MODEL; DISORDERS; ADDICTION; RELAPSE; COMORBIDITY Drug addiction is
commonly associated with depression and comorbid patients also suffer from higher
cravings and increased relapse rate. To address this issue preclinically we
combined the olfactory bulbectomy (OBX) model of depression and intravenous
methamphetamine self-administration procedure in rats to assess differences in
relapse-like behavior. Male Sprague-Dawley rats were divided randomly into two
groups; in one group the bilateral olfactory bulbectomy (OBX) was performed while
the other group was sham operated. After recovery, intracardiac catheter was
implanted. Intravenous self-administration procedure was conducted in operant boxes
using nose-poke operandi (Coulbourn Instruments, Inc., USA) under fixed ratio 1
schedule of reinforcement. Methamphetamine was available at dose 0.08
mg/kg/infusion. After stable methamphetamine intake was maintained, a period of
forced abstinence was initiated and rats were kept in their home-cages for 14 days.
Finally, one reinstatement session was conducted in operant boxes with no drug
delivery. In the reinstatement session the mean of 138.4 active nose-pokes was
performed by the OBX group, while the sham group displayed 41 responses, i.e. 140 %
and 48 % of basal nose-poking during maintenance phase in OBX and sham operated
group respectively. OBX group also showed significantly more passive nose-pokes
indicating hyperactive behavioral traits in bulbectomized rats. However, the % of
active operandum preference was equal in both groups. Olfactory bulbectomy model
significantly increased reinstatement of methamphetamine seeking behavior. This
paradigm can be used to evaluate potential drugs that are able to suppress the
drug-seeking behavior. (C) 2015 Elsevier B.V. All rights reserved. [Babinska,
Zuzana; Ruda-Kucerova, Jana; Amchova, Petra; Sulcova, Alexandra] Masaryk Univ,
CEITEC Cent European Inst Technol, Expt & Appl Neuropsychopharmacol Grp, Brno
62500, Czech Republic; [Babinska, Zuzana; Ruda-Kucerova, Jana; Amchova, Petra;
Merhautova, Jana] Masaryk Univ, Fac Med, Dept Pharmacol, Brno 62500, Czech
Republic; [Dusek, Ladislav] Masaryk Univ, Fac Med, Inst Biostat & Anal, Brno 62500,
Czech Republic Ruda-Kucerova, J (reprint author), Masaryk Univ, CEITEC, Kamenice
5, Brno 62500, Czech Republic. jkucer@med.muni.cz Ruda-Kucerova, Jana/D-
5117-2012; Sulcova, Alexandra E/D-5143-2012; Dusek, Ladislav/G-8794-2013 Ruda-
Kucerova, Jana/0000-0002-1846-0799; Sulcova, Alexandra E/0000-0001-8854-558X;
Dusek, Ladislav/0000-0002-8589-4378 project "CEITEC - Central European Institute of
Technology" from European Regional Development Fund [CZ.1.05/1.1.00/02.0068];
project of specific research at the Masaryk University [MUNI/A/1116/2014]; Internal
project of the Faculty of Medicine at Masaryk University [MUNI/11/InGA09/2012]
This work was supported by the project "CEITEC - Central European Institute
of Technology" (CZ.1.05/1.1.00/02.0068) from European Regional Development Fund,
project of specific research at the Masaryk University (MUNI/A/1116/2014) and the
Internal project of the Faculty of Medicine at Masaryk University
(MUNI/11/InGA09/2012). Amchova P, 2014, FRONT PHARMACOL, V5, DOI
10.3389/fphar.2014.00044; Babinska Z., 2014, ALKOHOL DROG ZAVIS, P127; Baicy K,
2005, INT REV NEUROBIOL, V65, P117, DOI 10.1016/S0074-7742(04)65005-7; Frankowska
M, 2014, BEHAV BRAIN RES, V266, P108, DOI 10.1016/j.bbr.2014.02.044; Fuchs RA,
2006, J NEUROSCI, V26, P3584, DOI 10.1523/JNEUROSCI.5146-05.2006; Gardner EL, 2000,
AM J ADDICTION, V9, P285, DOI 10.1080/105504900750047355; Grecksch G, 2015, BEHAV
BRAIN RES, V286, P271, DOI 10.1016/j.bbr.2015.03.015; Hall DH, 2007, J PSYCHOACTIVE
DRUGS, V39, P151, DOI 10.1080/02791072.2007.10399873; Haney M, 2008,
PSYCHOPHARMACOLOGY, V199, P403, DOI 10.1007/s00213-008-1079-x; Hendriksen H, 2015,
EUR J PHARMACOL, V753, P105, DOI 10.1016/j.ejphar.2014.10.033; Holmes PV, 2002,
SYNAPSE, V46, P4, DOI 10.1002/syn.10105; Kelly JP, 1997, PHARMACOL THERAPEUT, V74,
P299, DOI 10.1016/S0163-7258(97)00004-1; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142,
P1259; Koob GF, 2008, ANNU REV PSYCHOL, V59, P29, DOI
10.1146/annurev.psych.59.103006.093548; Kucerova J, 2012, INT J NEUROPSYCHOPH, V15,
P1503, DOI 10.1017/S1461145711001684; Kucerova J, 2009, NEUROENDOCRINOL LETT, V30,
P663; Leonard B E, 1981, Int Rev Neurobiol, V22, P251; Liu X, 2003,
PSYCHOPHARMACOLOGY, V168, P184, DOI 10.1007/s00213-002-1267-z; Markou A, 1998,
NEUROPSYCHOPHARMACOL, V18, P135, DOI 10.1016/S0893-133X(97)00113-9; McKernan
Lindsey Colman, 2015, Psychodyn Psychiatry, V43, P243, DOI
10.1521/pdps.2015.43.2.243; McKetin R, 2011, MED J AUSTRALIA, V195, pS51; Miller
ML, 2012, DRUG ALCOHOL DEPEN, V121, P90, DOI 10.1016/j.drugalcdep.2011.08.013;
Ortiz-Gomez LD, 2014, J AFFECT DISORDERS, V169, P10, DOI 10.1016/j.jad.2014.07.033;
Riga D, 2014, NEUROPSYCHOPHARMACOL, V39, P1115, DOI 10.1038/npp.2013.311; Ruda-
Kucerova J, 2015, WORLD J BIOL PSYCHIA, V16, P521, DOI
10.3109/15622975.2015.1077991; Ruda-Kucerova J, 2015, FRONT PSYCHIATRY, V6, DOI
10.3389/fpsyt.2015.00091; Schuckit MA, 2006, ADDICTION, V101, P76, DOI
10.1111/j.1360-0443.2006.01592.x; SHOAIB M, 1995, PSYCHOPHARMACOLOGY, V117, P240,
DOI 10.1007/BF02245193; Song C, 2005, NEUROSCI BIOBEHAV R, V29, P627, DOI
10.1016/j.neubiorev.2005.03.010; Testa A, 2013, EUR REV MED PHARMACO, V17, P65;
Thomsen Morgane, 2005, Curr Protoc Neurosci, VChapter 9, DOI
10.1002/0471142301.ns0920s32; van der Stelt HM, 2005, BIOL PSYCHIAT, V57, P1061,
DOI 10.1016/j.biopsych.2004.12.040; Volkow ND, 2004, BIOL PSYCHIAT, V56, P714, DOI
10.1016/j.biopsych.2004.07.007; Weiss Friedbert, 2001, V937, P1; Witkiewitz K,
2010, J CONSULT CLIN PSYCH, V78, P362, DOI 10.1037/a0019172; Yahyavi-Firouz-Abadi
N, 2009, PHARMACOL THERAPEUT, V124, P235, DOI 10.1016/j.pharmthera.2009.06.014; Yu
GL, 2014, PSYCHOPHARMACOLOGY, V231, P3189, DOI 10.1007/s00213-014-3501-x; Zimmer
BA, 2014, PSYCHOPHARMACOLOGY, V231, P949, DOI 10.1007/s00213-013-3305-4 38
2 2 0 8 ELSEVIER SCIENCE BV AMSTERDAM PO BOX 211, 1000
AE AMSTERDAM, NETHERLANDS 0166-4328 1872-7549 BEHAV BRAIN RES Behav.
Brain Res. JAN 15 2016 297 20 27
10.1016/j.bbr.2015.09.035 8 Behavioral Sciences;
Neurosciences Behavioral Sciences; Neurosciences & Neurology CZ4YB
WOS:000367107900004 26431766 2019-09-25
B Glahn, DC; Knowles, EEM; Mathias, SR; Almasy, L; Hodgson, K; Yao, NL; Olvera,
RL; Curran, JE; Blangero, J Lehner, T; Miller, BL; State, MW Glahn,
David C.; Knowles, Emma E. M.; Mathias, Samuel R.; Almasy, Laura; Hodgson, Karen;
Yao, Nailin; Olvera, Rene L.; Curran, Joanne E.; Blangero, John
Conceptualizing Major Depression: From Genes to Neuroanatomy to Epidemiology
GENOMICS, CIRCUITS, AND PATHWAYS IN CLINICAL NEUROPSYCHIATRY
English Article; Book Chapter
NATIONAL-COMORBIDITY-SURVEY; SUBSTANCE USE DISORDERS; POPULATION-BASED
SAMPLE; GENOME-WIDE LINKAGE; TREATMENT-RESISTANT DEPRESSION; SUBGENUAL PREFRONTAL
CORTEX; SELF-MEDICATION HYPOTHESIS; DEEP BRAIN-STIMULATION; STRESSFUL LIFE EVENTS;
ADRENAL AXIS ACTIVITY [Glahn, David C.] Hartford Hosp, Hartford, CT 06115
USA; [Glahn, David C.; Knowles, Emma E. M.; Mathias, Samuel R.; Hodgson, Karen;
Yao, Nailin] Yale Univ, Sch Med, New Haven, CT 06520 USA; [Almasy, Laura; Curran,
Joanne E.; Blangero, John] Univ Texas Rio Grand Valley, Brownsville, TX USA;
[Olvera, Rene L.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA
Glahn, DC (reprint author), Hartford Hosp, Hartford, CT 06115 USA.; Glahn, DC
(reprint author), Yale Univ, Sch Med, New Haven, CT 06520 USA. Knowles,
Emma/P-3821-2018; Almasy, Laura/V-3156-2019; Knowles, Emma/V-2567-2019 Knowles,
Emma/0000-0003-0642-267X; Hodgson, Karen/0000-0002-9433-7071
Alegria M, 2008, AM J PSYCHIAT, V165, P359, DOI
10.1176/appi.ajp.2007.07040704; Alexopoulos GS, 1997, ARCH GEN PSYCHIAT, V54, P915;
Anderson RJ, 2001, DIABETES CARE, V24, P1069, DOI 10.2337/diacare.24.6.1069;
ANESHENSEL CS, 1987, J HEALTH SOC BEHAV, V28, P232, DOI 10.2307/2136843; ANGST J,
1985, PSYCHOPATHOLOGY, V18, P140, DOI 10.1159/000284227; [Anonymous], 2013, ASS AP
DIAGN STAT MA; [Anonymous], 2010, ASS AP AM PSYCH ASS; Beck AT, 1996, MANUAL BECK
DEPRESSI; Belmaker RH, 2008, NEW ENGL J MED, V358, P55, DOI 10.1056/NEJMra073096;
Berman RM, 2000, BIOL PSYCHIAT, V47, P351, DOI 10.1016/S0006-3223(99)00230-9;
Bienvenu OJ, 2010, PSYCHOL MED, V4, P1; BLAZER DG, 1994, AM J PSYCHIAT, V151, P979;
Borovecki F, 2005, P NATL ACAD SCI USA, V102, P11023, DOI 10.1073/pnas.0504921102;
Bouckaert F, 2014, J ECT, V30, P143, DOI 10.1097/YCT.0000000000000129; Breen G,
2011, AM J PSYCHIAT, V168, P840, DOI 10.1176/appi.ajp.2011.10091342; BROMET EJ,
1986, ARCH GEN PSYCHIAT, V43, P435; Butler AC, 2006, CLIN PSYCHOL REV, V26, P17,
DOI 10.1016/j.cpr.2005.07.003; Cai CC, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-
2164-11-589; Cai N, 2015, NATURE, V523, P588, DOI 10.1038/nature14659; Camp NJ,
2005, AM J MED GENET B, V135B, P85, DOI 10.1002/ajmg.b.30177; Carmelli D, 1998,
STROKE, V29, P1177, DOI 10.1161/01.STR.29.6.1177; CARNEY RM, 1988, PSYCHOSOM MED,
V50, P627, DOI 10.1097/00006842-198811000-00009; Caspi A, 2003, SCIENCE, V301,
P386, DOI 10.1126/science.1083968; Chen LS, 2000, J AFFECT DISORDERS, V59, P1, DOI
10.1016/S0165-0327(99)00132-9; Cohen-Woods S, 2013, PSYCHOL MED, V43, P673, DOI
10.1017/S0033291712001286; Collins PY, 2011, NATURE, V475, P27, DOI
10.1038/475027a; Compton WM, 2007, ARCH GEN PSYCHIAT, V64, P566, DOI
10.1001/archpsyc.64.5.566; Cowen Phillip J, 2013, Curr Top Behav Neurosci, V14, P3,
DOI 10.1007/7854_2012_218; Davis LL, 2006, AM J ADDICTION, V15, P278, DOI
10.1080/10550490600754317; De Rubeis S, 2014, NATURE, V515, P209, DOI
10.1038/nature13772; Debette S, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c3666;
Deshaies RJ, 2009, ANNU REV BIOCHEM, V78, P399, DOI
10.1146/annurev.biochem.78.101807.093809; Desikan RS, 2006, NEUROIMAGE, V31, P968,
DOI 10.1016/j.neuroimage.2006.01.021; Doolittle MH, 2009, J LIPID RES, V50, P1173,
DOI 10.1194/jlr.M800603-JLR200; Dowlati Y, 2010, BIOL PSYCHIAT, V67, P446, DOI
10.1016/j.biopsych.2009.09.033; Drevets WC, 1997, NATURE, V386, P824, DOI
10.1038/386824a0; Eaton WW, 1997, ARCH GEN PSYCHIAT, V54, P993; Edwards AC, 2011,
PSYCHOL MED, V41, P395, DOI 10.1017/S0033291710000589; Edwards AC, 2012, J AFFECT
DISORDERS, V142, P90, DOI 10.1016/j.jad.2012.03.048; Ertekin-Taner N, 2011, MOL
NEURODEGENER, V6, DOI 10.1186/1750-1326-6-31; Eysenck H. J., 1975, MANUAL EYSENCK
PERSO; Falconer D. S., 1996, INTRO QUANTITATIVE G; FENNIG S, 1994, J AFFECT
DISORDERS, V30, P147, DOI 10.1016/0165-0327(94)90075-2; Flint J, 2014, NEURON, V81,
P484, DOI 10.1016/j.neuron.2014.01.027; Fried EI, 2013, PSYCHOL MED, V1, P10; Glahn
DC, 2008, BIOL PSYCHIAT, V64, P774, DOI 10.1016/j.biopsych.2008.03.031; Glahn DC,
2014, AM J MED GENET B, V165, P122, DOI 10.1002/ajmg.b.32221; Glahn DC, 2012, BIOL
PSYCHIAT, V71, P6, DOI 10.1016/j.biopsych.2011.08.022; Goring HHH, 2007, NAT GENET,
V39, P1208, DOI 10.1038/ng2119; Goldapple K, 2004, ARCH GEN PSYCHIAT, V61, P34, DOI
10.1001/archpsyc.61.1.34; Gottesman II, 2003, AM J PSYCHIAT, V160, P636, DOI
10.1176/appi.ajp.160.4.636; Grant BF, 2004, ARCH GEN PSYCHIAT, V61, P1107, DOI
10.1001/archpsyc.61.11.1107; Grant BF, 2004, ARCH GEN PSYCHIAT, V61, P807, DOI
10.1001/archpsyc.61.8.807; Grant BF, 2005, J CLIN PSYCHIAT, V66, P1205, DOI
10.4088/JCP.v66n1001; Greenberg PE, 2003, J CLIN PSYCHIAT, V64, P1465, DOI
10.4088/JCP.v64n1211; Hamani C, 2011, BIOL PSYCHIAT, V69, P301, DOI
10.1016/j.biopsych.2010.09.034; Hamilton JP, 2011, MOL PSYCHIATR, V16, P763, DOI
10.1038/mp.2010.46; Hamilton JP, 2012, AM J PSYCHIAT, V169, P693, DOI
10.1176/appi.ajp.2012.11071105; Harmer CJ, 2008, NEUROPHARMACOLOGY, V55, P1023, DOI
10.1016/j.neuropharm.2008.06.036; Hasin DS, 2007, ARCH GEN PSYCHIAT, V64, P830, DOI
10.1001/archpsyc.64.7.830; Hasler G, 2004, NEUROPSYCHOPHARMACOL, V29, P1765, DOI
10.1038/sj.npp.1300506; HAYS RD, 1995, ARCH GEN PSYCHIAT, V52, P11; Hirschfeld R.
M., 2002, NEUROPSYCHOPHARMACOL; Holmans P, 2004, AM J HUM GENET, V74, P1154, DOI
10.1086/421333; Holmans P, 2007, AM J PSYCHIAT, V164, P248, DOI
10.1176/appi.ajp.164.2.248; Hovey JD, 1996, J AM ACAD CHILD PSY, V35, P1183, DOI
10.1097/00004583-199609000-00016; Iossifov I, 2014, NATURE, V515, P216, DOI
10.1038/nature13908; Jamal M, 2012, DRUG ALCOHOL DEPEN, V126, P138, DOI
10.1016/j.drugalcdep.2012.05.001; Judd LL, 1997, ARCH GEN PSYCHIAT, V54, P989; Judd
LL, 2000, PHARMACOPSYCHIATRY, V33, P3, DOI 10.1055/s-2000-7967; Katon WJ, 2003,
BIOL PSYCHIAT, V54, P216, DOI 10.1016/S0006-3223(03)00273-7; Kempton MJ, 2011, ARCH
GEN PSYCHIAT, V68, P675, DOI 10.1001/archgenpsychiatry.2011.60; Kendler KS, 2006,
PSYCHOL MED, V36, P955, DOI 10.1017/S0033291706007720; Kendler KS, 2006, AM J
PSYCHIAT, V163, P115, DOI 10.1176/appi.ajp.163.1.115; KENDLER KS, 1993, ARCH GEN
PSYCHIAT, V50, P863; Kendler KS, 2001, PSYCHOL MED, V31, P617, DOI
10.1017/S0033291701003798; Kendler KS, 1996, ARCH GEN PSYCHIAT, V53, P391; Kendler
KS, 1999, AM J PSYCHIAT, V156, P837, DOI 10.1176/ajp.156.6.837; KESSLER RC, 1993, J
AFFECT DISORDERS, V29, P85, DOI 10.1016/0165-0327(93)90026-G; Kessler RC, 2005,
ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; KESSLER RC, 1994, ARCH
GEN PSYCHIAT, V51, P8; Kessler RC, 2003, JAMA-J AM MED ASSOC, V289, P3095, DOI
10.1001/jama.289.23.3095; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI
10.3109/10673229709030550; Kleinman A, 2004, NEW ENGL J MED, V351, P951, DOI
10.1056/NEJMp048078; Kochunov P, 2009, STROKE, V40, P3685, DOI
10.1161/STROKEAHA.109.565390; Koechlin E, 2007, TRENDS COGN SCI, V11, P229, DOI
10.1016/j.tics.2007.04.005; Kohli MA, 2011, NEURON, V70, P252, DOI
10.1016/j.neuron.2011.04.005; Kraemer HC, 2012, AM J PSYCHIAT, V169, P13, DOI
10.1176/appi.ajp.2011.11010050; Kriegsman DMW, 1996, J CLIN EPIDEMIOL, V49, P1407,
DOI 10.1016/S0895-4356(96)00274-0; Krishnan V, 2008, NATURE, V455, P894, DOI
10.1038/nature07455; Levinson DF, 2003, AM J MED GENET B, V119B, P118, DOI
10.1002/ajmg.b.20009; Levinson DF, 2007, AM J PSYCHIAT, V164, P259, DOI
10.1176/appi.ajp.164.2.259; Levinson DF, 2006, BIOL PSYCHIAT, V60, P84, DOI
10.1016/j.biopsych.2005.08.024; Lorant V, 2003, AM J EPIDEMIOL, V157, P98, DOI
10.1093/aje/kwf182; Lorant V, 2007, BRIT J PSYCHIAT, V190, P293, DOI
10.1192/bjp.bp.105.020040; Lyness JM, 1999, AM J GERIAT PSYCHIAT, V7, P252, DOI
10.1097/00019442-199908000-00010; Lynskey MT, 2004, ARCH GEN PSYCHIAT, V61, P1026,
DOI 10.1001/archpsyc.61.10.1026; Lyons M, 2008, NICOTINE TOB RES, V10, P97, DOI
10.1080/14622200701705332; Ma Y, 2015, MOL PSYCHIATR, V20, P311, DOI
10.1038/mp.2014.24; Maher B. S., 2002, EARLY ONSET MAJOR DE, V28, P711; Markou A,
1998, NEUROPSYCHOPHARMACOL, V18, P135, DOI 10.1016/S0893-133X(97)00113-9; Mayberg
HS, 2005, NEURON, V45, P651, DOI 10.1016/j.neuron.2005.02.014; Mayberg HS, 1997, J
NEUROPSYCH CLIN N, V9, P471; Mayberg HS, 1999, AM J PSYCHIAT, V156, P675; Mayberg
HS, 1997, NEUROREPORT, V8, P1057, DOI 10.1097/00001756-199703030-00048; McGuffin P,
1996, ARCH GEN PSYCHIAT, V53, P129; Merikangas KR, 1998, ADDICT BEHAV, V23, P893,
DOI 10.1016/S0306-4603(98)00076-8; MERIKANGAS KR, 1994, BRIT J PSYCHIAT, V164,
P342, DOI 10.1192/bjp.164.3.342; Middeldorp CM, 2008, MOL PSYCHIATR, V13, P84, DOI
10.1038/sj.mp.4002061; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI
10.1146/annurev.neuro.24.1.167; Morgan D, 2003, PSYCHOTHER RES, V13, P123, DOI
[10.1080/713869628, 10.1093/ptr/kpg004]; Morishita T, 2014, NEUROTHERAPEUTICS, V11,
P475, DOI 10.1007/s13311-014-0282-1; Murray C, 1996, GLOBAL BURDEN DIS CO; Murray
CJL, 2012, LANCET, V380, P2197, DOI 10.1016/S0140-6736(12)61689-4; Musselman DL,
1998, ARCH GEN PSYCHIAT, V55, P580, DOI 10.1001/archpsyc.55.7.580; Nelson JC, 2003,
J CLIN PSYCHIAT, V64, P5; Nestler EJ, 2002, NEURON, V34, P13, DOI 10.1016/S0896-
6273(02)00653-0; NOLENHOEKSEMA S, 1987, PSYCHOL BULL, V101, P259, DOI 10.1037/0033-
2909.101.2.259; Olvera RL, 2011, AM J MED GENET B, V156B, P561, DOI
10.1002/ajmg.b.31196; Ongur D, 2000, CEREB CORTEX, V10, P206, DOI
10.1093/cercor/10.3.206; Ongur D, 1998, P NATL ACAD SCI USA, V95, P13290, DOI
10.1073/pnas.95.22.13290; Pariante CM, 2008, TRENDS NEUROSCI, V31, P464, DOI
10.1016/j.tins.2008.06.006; Pariante
CM, 2001, BIOL PSYCHIAT, V49, P391, DOI 10.1016/S0006-3223(00)01088-X; Paus T,
2001, NAT REV NEUROSCI, V2, P417, DOI 10.1038/35077500; Pessoa L, 2010, NAT REV
NEUROSCI, V11, P773, DOI 10.1038/nrn2920; Prescott CA, 2000, ARCH GEN PSYCHIAT,
V57, P803, DOI 10.1001/archpsyc.57.8.803; Prigerson HG, 2009, PLOS MED, V6, DOI
10.1371/journal.pmed.1000121; PRUSOFF BA, 1984, PSYCHOPHARMACOL BULL, V20, P358;
Radich JP, 2004, GENOMICS, V83, P980, DOI 10.1016/j.ygeno.2003.12.013; Regier DA,
2013, AM J PSYCHIAT, V170, P59, DOI 10.1176/appi.ajp.2012.12070999; Riolo SA, 2005,
AM J PUBLIC HEALTH, V95, P998, DOI 10.2105/AJPH.2004.047225; Ripke S, 2014, NATURE,
V511, P421, DOI 10.1038/nature13595; Risch N, 2009, JAMA-J AM MED ASSOC, V301,
P2462, DOI 10.1001/jama.2009.878; Roberts SB, 1999, AM J HUM GENET, V65, P876, DOI
10.1086/302528; Rockman MV, 2002, MOL BIOL EVOL, V19, P1991, DOI
10.1093/oxfordjournals.molbev.a004023; SAPOLSKY RM, 1990, PROG BRAIN RES, V86, P13;
SCHLESSER MA, 1980, ARCH GEN PSYCHIAT, V37, P737; Schmaal L, 2015, MOL PSYCHIAT;
Schol-Gelok S, 2010, BIOL PSYCHIAT, V68, P187, DOI 10.1016/j.biopsych.2010.01.033;
Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Shi J,
2011, MOL PSYCHIATR, V16, P193, DOI 10.1038/mp.2009.124; Siegle GJ, 2007, BIOL
PSYCHIAT, V61, P198, DOI 10.1016/j.biopsych.2006.05.048; Steffens DC, 1999, STROKE,
V30, P2159, DOI 10.1161/01.STR.30.10.2159; Sullivan PF, 2013, MOL PSYCHIATR, V18,
P497, DOI 10.1038/mp.2012.21; Sullivan PF, 2000, AM J PSYCHIAT, V157, P1552, DOI
10.1176/appi.ajp.157.10.1552; Sweet RA, 2004, NEUROPSYCHOPHARMACOL, V29, P2242, DOI
10.1038/sj.npp.1300554; Treisman A, 1999, NEURON, V24, P105, DOI 10.1016/S0896-
6273(00)80826-0; Tsuang MT, 2001, HARVARD REV PSYCHIAT, V9, P267, DOI
10.1093/hrp/9.6.267; Vink JM, 2014, ADDICTION, V109, P1141, DOI 10.1111/add.12491;
Vreeburg SA, 2009, ARCH GEN PSYCHIAT, V66, P617, DOI
10.1001/archgenpsychiatry.2009.50; Walss-Bass C, 2005, AM J MED GENET B, V139B,
P54, DOI 10.1002/ajmg.b.30207; Ward R, 2002, NAT NEUROSCI, V5, P99, DOI
10.1038/nn794; WEISSMAN MM, 1986, ARCH GEN PSYCHIAT, V43, P430; Weissman MM, 1996,
JAMA-J AM MED ASSOC, V276, P293, DOI 10.1001/jama.276.4.293; WEISSMAN MM, 1984,
ARCH GEN PSYCHIAT, V41, P13; Wells JE, 2004, PSYCHOL MED, V34, P1001, DOI
10.1017/S0033291703001843; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI
10.1001/jama.262.7.914; Whitney AR, 2003, P NATL ACAD SCI USA, V100, P1896, DOI
10.1073/pnas.252784499; Williams DR, 2007, ARCH GEN PSYCHIAT, V64, P305, DOI
10.1001/archpsyc.64.3.305; Wolkowitz OM, 1999, AM J PSYCHIAT, V156, P646; Wray GA,
2007, NAT REV GENET, V8, P206, DOI 10.1038/nrg2063; Zarate CA, 2006, ARCH GEN
PSYCHIAT, V63, P856, DOI 10.1001/archpsyc.63.8.856; Zimmermann P, 2009, ARCH GEN
PSYCHIAT, V66, P1341, DOI 10.1001/archgenpsychiatry.2009.158; Zou F, 2010,
NEUROLOGY, V74, P480, DOI 10.1212/WNL.0b013e3181d07654; Zubenko GS, 2003, AM J MED
GENET B, V123B, P1, DOI 10.1002/ajmg.b.20073 165 0 0 0 0
ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD LONDON 24-28 OVAL ROAD, LONDON
NW1 7DX, ENGLAND 978-0-12-800530-9; 978-0-12-800105-9
2016 487 501 10.1016/B978-0-12-
800105-9.00031-7 15 Genetics & Heredity; Neurosciences; Psychiatry
Genetics & Heredity; Neurosciences & Neurology; Psychiatry BJ0MC
WOS:000416943300032 2019-09-25
J Katz, G; Kunyvsky, Y; Hornik-Lurie, T; Raskin, S; Abramowitz, MZ
Katz, Gregory; Kunyvsky, Yehuda; Hornik-Lurie, Tzipi; Raskin, Sergey;
Abramowitz, Moshe Z. Cannabis and Alcohol Abuse Among First
Psychotic Episode Inpatients ISRAEL JOURNAL OF PSYCHIATRY AND RELATED SCIENCES
English Article SELF-
MEDICATION HYPOTHESIS; SUBSTANCE USE; 1ST-EPISODE PSYCHOSIS; USE DISORDERS; FOLLOW-
UP; SCHIZOPHRENIA; PREDICTORS; MISUSE; DRUG; ASSOCIATION Background: Psychoactive
substance abuse, which includes abuse of alcohol and street drugs, is common among
first-episode psychosis patients, but the prevalence of cannabis abuse is
particularly high. However, there have been very few reported studies concerning
the occurrence of psychoactive substance abuse among first-episode psychotic
individuals using standard toxicological testing. We study the prevalence of
cannabis and alcohol abuse among first-psychotic-episode inpatients as well as
compare the demographic, diagnostic, and psychopathological profiles of substance
abusers versus nonusers. Methods: Subjects were recruited from the Jerusalem Mental
Health Center between 2012 and 2014. Ninety-one consecutively admitted psychiatric
patients diagnosed using the DSM-IV criteria with a first psychotic episode due to
schizophrenia, schizophreniform disorder, bipolar disorder, brief psychotic
episode, and psychosis NOS disorder entered the study. The diagnoses of
schizophrenia (all types), psychosis NOS disorder, brief psychotic episode, and
schizophreniform disorder were categorized as "only psychosis" and those of bipolar
disorder manic episode with psychotic features (congruent and incongruent) and
severe depression with psychotic features were categorized as "predominantly
affective symptoms." Urine tests for tetrahydrocannabinol (THC) were performed
during the first 48 hours of admission, and likewise self-report questionnaires
were administered. Alcohol abuse and dependence were diagnosed by self-report.
Results: Of the 91 subjects in the study, 49 (53.8%) did not abuse any illegal
psychoactive substance. Twenty patients (22%) abused only cannabis; 14 (15.4%)
abused cannabis and another psychoactive substance; 54 (59.3%) of the subjects
reported no alcohol abuse; 33 (36.3%) reported occasional drinking (between two and
ten times a month); and 4 (4.4%) reported continuous repeated drinking (more than
ten times a month). There was no correlation between the demographic
characteristics and the abuse of cannabis. Two-thirds of the "predominantly
affective symptoms" subjects were positive for THC, whereas only a third of the
"only psychosis" subjects screened positive for THC. Conclusions: The percentage of
cannabis and alcohol abuse in the study population is much higher than one would
expect to see in the general Israeli population (according to the Knesset Research
Department 7.6-10.2% of the adult Israeli population abuse cannabis). Different
patterns of cannabis abuse among "predominantly affective" and "psychotic only"
patients may lend credence to the preferential use of a specific substance per
diagnosis. [Katz, Gregory; Kunyvsky, Yehuda; Raskin, Sergey; Abramowitz, Moshe Z.]
Jerusalem Mental Hlth Ctr, IL-91060 Jerusalem, Israel; [Hornik-Lurie, Tzipi] Kfar
Shaul Hosp, Falk Inst Mental Hlth Studies, Jerusalem, Israel; [Hornik-Lurie, Tzipi]
Ben Gurion Univ Negev, Fac Hlth Sci, Dept Emergency Med, Leon & Mathilde Recanati
Sch Community Hlth Profe, Beer Sheva, Israel Katz, G (reprint author), Jerusalem
Mental Hlth Ctr, IL-91060 Jerusalem, Israel. ngkatz60@gmail.com
Hornik-Lurie, Tzipi/0000-0002-2122-5116 Research Grant of the Israel Anti-
Drug Authority The study was supported by the Research Grant of the Israel Anti-
Drug Authority Archie S, 2007, SCHIZOPHRENIA BULL, V33, P1354, DOI
10.1093/schbul/sbm011; Arendt M, 2008, ARCH GEN PSYCHIAT, V65, P1269, DOI
10.1001/archpsyc.65.11.1269; Arendt M, 2007, PSYCHOL MED, V37, P935, DOI
10.1017/S0033291706009688; Arseneault L, 2004, BRIT J PSYCHIAT, V184, P110, DOI
10.1192/bjp.184.2.110; Bahorik AL, 2014, PSYCHOL MED, V44, P61, DOI
10.1017/S0033291713000548; Bar-Hamburger R, 2009, ABUSE PSYCHOACTIVE S; Barnett JH,
2007, BRIT J PSYCHIAT, V190, P515, DOI 10.1192/bjp.bp.106.024448; Becker J, 2015,
BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2194-3; Caetano R, 2008, ACCIDENT
ANAL PREV, V40, P733, DOI 10.1016/j.aap.2007.09.010; DRAKE RE, 1989, J NERV MENT
DIS, V177, P408, DOI 10.1097/00005053-198907000-00004; Duncan SC, 2015, DRUG
ALCOHOL DEPEN, V149, P80, DOI 10.1016/j.drugalcdep.2015.01.025; Egan KL, 2015, AM J
DRUG ALCOHOL AB, V41, DOI 10.3109/00952990.2015.1043438; Fergusson DM, 2006, BRIT
MED J, V332, P172, DOI 10.1136/bmj.332.7534.172; Grant JD, 2012, ALCOHOL CLIN EXP
RES, V36, P1412, DOI 10.1111/j.1530-0277.2012.01752.x; Gregg L, 2007, CLIN PSYCHOL
REV, V27, P494, DOI 10.1016/j.cpr.2006.09.004; Hides L, 2004, DRUG ALCOHOL REV,
V23, P425, DOI 10.1080/09595230412331324545; Katz G, 2008, ISR MED ASSOC J, V10,
P672; Katz G, 2010, COMPR PSYCHIAT, V51, P37, DOI 10.1016/j.comppsych.2009.03.008;
Kelly AB, 2015, ADDICTION, V110, P627, DOI 10.1111/add.12829; Khantzian EJ, 2013,
ADDICTION, V108, P668, DOI 10.1111/add.12004; KHANTZIAN EJ, 1985, AM J PSYCHIAT,
V142, P1259; Kolliakou A, 2011, INT J DEV NEUROSCI, V29, P335, DOI
10.1016/j.ijdevneu.2010.11.006; Koskinen J, 2010, SCHIZOPHRENIA BULL, V36, P1115,
DOI 10.1093/schbul/sbp031; Lange EH, 2014, COMPR PSYCHIAT, V55, P274, DOI
10.1016/j.comppsych.2013.08.018; Lynskey MT, 1998, J CHILD PSYCHOL PSYC, V39, P995,
DOI 10.1017/S0021963098002960; Manrique-Garcia E, 2012, PSYCHOL MED, V42, P1321,
DOI 10.1017/S0033291711002078; Margolese HC, 2004, SCHIZOPHR RES, V67, P157, DOI
10.1016/S0920-9964(02)00523-6; Mauri M C, 2006, Clin Pract Epidemiol Ment Health,
V2, P4, DOI 10.1186/1745-0179-2-4; Moore E, 2012, AUST NZ J PSYCHIAT, V46, P864,
DOI 10.1177/0004867412443900; Moore THM, 2007, LANCET, V370, P319, DOI
10.1016/S0140-6736(07)61162-3; Pettersen H, 2013, INT J QUAL STUD HEAL, V8, DOI
10.3402/qhw.v8i0.21968; Ponizovsky AM, 2015, DRUG ALCOHOL DEPEN, V148, P203, DOI
10.1016/j.drugalcdep.2015.01.009; Rubio JM, 2011, DEPRESS ANXIETY, V28, P622, DOI
10.1002/da.20864; Sarrazin S, 2015, ANN GEN PSYCHIATR, V14, DOI 10.1186/s12991-015-
0083-x; Shalev A. Y., 1996, STRUCTURED CLIN INTE; Substance Abuse and Mental Health
Services Administration, 2014, NSDUH SER H, VH- 48; Swartz MS, 2006, PSYCHIAT SERV,
V57, P1110, DOI 10.1176/appi.ps.57.8.1110; Tucker P, 2009, AUSTRALAS PSYCHIATRY,
V17, P291, DOI 10.1080/10398560802657314; Van Mastrigt S, 2004, SOC PSYCH PSYCH
EPID, V39, P69, DOI 10.1007/s00127-004-0713-0; Zammit S, 2002, BRIT MED J, V325,
P1199, DOI 10.1136/bmj.325.7374.1199 40 1 1 0 6 MEDIAFARM
GROUP TEL-AVIV 23 ZAMENHOFF ST, TEL-AVIV, 64373, ISRAEL 0333-7308
ISR J PSYCHIATR REL Isr. J. Psychiatr. Relat. Sci. 2016 53
3 10 16 7
Psychiatry Psychiatry FF2NG WOS:000408733500002 28492376
2019-09-25
B Black, JJ; Chung, T; Clark, DB Kaminer, Y Black, Jessica J.;
Chung, Tammy; Clark, Duncan B. Anxiety Disorders and Substance Use
Disorders YOUTH SUBSTANCE ABUSE AND CO-OCCURRING DISORDERS
English Article; Book Chapter
ALCOHOL-USE DISORDERS; NATIONAL EPIDEMIOLOGIC SURVEY; COLLEGE HAZARDOUS
DRINKERS; SOCIAL ANXIETY; PANIC DISORDER; FOLLOW-UP; DSM-IV; INTERVIEW SCHEDULE;
SELF-MEDICATION; ADOLESCENTS [Black, Jessica J.; Chung, Tammy; Clark, Duncan
B.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15260 USA; [Black, Jessica J.]
Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15260 USA; [Chung, Tammy] Univ
Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA Black, JJ (reprint author),
Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15260 USA.; Black, JJ (reprint
author), Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15260 USA.
Alegria AA, 2010, J CLIN PSYCHIAT, V71, P1187, DOI
10.4088/JCP.09m05328gry; American Psychiatric Association, 2013, DIAGN STAT MAN
MENT; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; American
Psychiatric Association, 2000, DIAGN STAT MAN MENT; [Anonymous], 2007, J AM ACAD
CHILD PSY, V46, P267, DOI 10.1097/01.chi.0000246070.23695.06; Biegel GM, 2009, J
CONSULT CLIN PSYCH, V77, P855, DOI 10.1037/a0016241; Birmaher B, 1997, J AM ACAD
CHILD PSY, V36, P545, DOI 10.1097/00004583-199704000-00018; Black JJ, 2014, SUBST
ABUS, V35, P344, DOI 10.1080/08897077.2014.925029; Black JJ, 2012, ADDICT BEHAV,
V37, P248, DOI 10.1016/j.addbeh.2011.10.004; Blanco C, 2010, J CLIN PSYCHIAT, V71,
P1218, DOI 10.4088/JCP.08m04812gry; BLANE HT, 1987, PSYCHOL THEORIES DRI;
Blumenthal Heidemarie, 2011, J Exp Psychopathol, V2, P318; Blumenthal H, 2012,
PSYCHOL ADDICT BEHAV, V26, P683, DOI 10.1037/a0027364; Blumenthal H, 2010, PSYCHOL
ADDICT BEHAV, V24, P529, DOI 10.1037/a0019794; Bruce SE, 2005, AM J PSYCHIAT, V162,
P1179, DOI 10.1176/appi.ajp.162.6.1179; BUCHOLZ KK, 1994, J STUD ALCOHOL, V55,
P149, DOI 10.15288/jsa.1994.55.149; Chorpita BF, 1997, BEHAV RES THER, V35, P569,
DOI 10.1016/S0005-7967(96)00116-7; Clark D B, 1997, Depress Anxiety, V6, P47, DOI
10.1002/(SICI)1520-6394(1997)6:2<47::AID-DA1>3.0.CO;2-2; Clark D. B., 1997, AM ACAD
CHILD ADOLES, V36, P495, DOI DOI 10.1097/00004583-199704000-00012; Clark DB, 2004,
AM J PSYCHIAT, V161, P685, DOI 10.1176/appi.ajp.161.4.685; CLARK DB, 1994, J AM
ACAD CHILD PSY, V33, P354, DOI 10.1097/00004583-199403000-00009; CLARK DB, 1994,
CLIN PSYCHOL REV, V14, P113, DOI 10.1016/0272-7358(94)90012-4; CLARK DB, 1995,
PSYCHIATR SERV, V46, P618; Clark DB, 2012, CNS DRUGS, V26, P559, DOI
10.2165/11634330-000000000-00000; Compton SN, 2014, J CONSULT CLIN PSYCH, V82,
P212, DOI 10.1037/a0035458; Compton WM, 2003, AM J PSYCHIAT, V160, P890, DOI
10.1176/appi.ajp.160.5.890; Cornelius JR, 2003, ADDICT BEHAV, V28, P381, DOI
10.1016/S0306-4603(01)00247-7; Cosci F, 2007, J CLIN PSYCHIAT, V68, P874, DOI
10.4088/JCP.v68n0608; Crawford LA, 2013, J SOC PSYCHOL, V153, P109, DOI
10.1080/00224545.2012.711381; Davids E, 2002, PROG NEURO-PSYCHOPH, V26, P1079, DOI
10.1016/S0278-5846(02)00225-7; Dennis M, 2004, J SUBST ABUSE TREAT, V27, P197, DOI
10.1016/j.jsat.2003.09.005; Driessen M, 2001, ALCOHOL ALCOHOLISM, V36, P249, DOI
10.1093/alcalc/36.3.249; Ginsburg GS, 2014, JAMA PSYCHIAT, V71, P310, DOI
10.1001/jamapsychiatry.2013.4186; Goodwin RD, 2013, DRUG ALCOHOL DEPEN, V130, P201,
DOI 10.1016/j.drugalcdep.2012.11.009; Goodwin RD, 2011, J PSYCHIATR RES, V45,
P1123, DOI 10.1016/j.jpsychires.2011.01.017; Grant BF, 2004, ARCH GEN PSYCHIAT,
V61, P807, DOI 10.1001/archpsyc.61.8.807; Hannesdottir DK, 2007, CLIN CHILD FAM
PSYCH, V10, P275, DOI 10.1007/s10567-007-0024-6; Harford TC, 2005, ALCOHOL CLIN EXP
RES, V29, P810, DOI 10.1097/01.ALC.0000164381.67723.76; Hayward C, 1997, J ANXIETY
DISORD, V11, P17, DOI 10.1016/S0887-6185(96)00032-1; Isensee B, 2003, ARCH GEN
PSYCHIAT, V60, P692, DOI 10.1001/archpsyc.60.7.692; Jamal M, 2011, NICOTINE TOB
RES, V13, P809, DOI 10.1093/ntr/ntr077; Johnston L.D., 2011, MONITORING FUTURE NA;
Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-
00021; Kendall PC, 2004, J CONSULT CLIN PSYCH, V72, P276, DOI 10.1037/0022-
006X.72.2.276; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI
10.1001/archpsyc.62.6.593; Kinley DJ, 2011, DEPRESS ANXIETY, V28, P412, DOI
10.1002/da.20809; Kirisci L, 1996, J CHILD ADOLES SUBST, V5, P57; Kodish I, 2011,
PEDIATR CLIN N AM, V58, P55, DOI 10.1016/j.pcl.2010.10.002; Kushner MG, 2005,
ALCOHOL CLIN EXP RES, V29, P1432, DOI 10.1097/01.alc.0000175072.17623.f8; Kushner
MG, 2000, CLIN PSYCHOL REV, V20, P149, DOI 10.1016/S0272-7358(99)00027-6; Lindsay
DL, 2014, J CHILD ADOLES SUBST, V23, P200, DOI 10.1080/1067828X.2014.889515;
Merikangas KR, 1998, PSYCHOL MED, V28, P773, DOI 10.1017/S0033291798006941; Nauta
MH, 2004, BEHAV RES THER, V42, P813, DOI 10.1016/S0005-7967(03)00200-6; Robinson J,
2009, J ANXIETY DISORD, V23, P38, DOI 10.1016/j.janxdis.2008.03.013; Schry AR,
2013, ADDICT BEHAV, V38, P2690, DOI 10.1016/j.addbeh.2013.06.014; Shaffer D, 2000,
J AM ACAD CHILD PSY, V39, P28, DOI 10.1097/00004583-200001000-00014; Silverman WK,
2001, J AM ACAD CHILD PSY, V40, P937, DOI 10.1097/00004583-200108000-00016; Smith
JP, 2007, ADDICT BEHAV, V32, P2281, DOI 10.1016/j.addbeh.2007.01.019; Smith JP,
2010, ADDICT BEHAV, V35, P42, DOI 10.1016/j.addbeh.2009.07.002; Spence SH, 1998,
BEHAV RES THER, V36, P545, DOI 10.1016/S0005-7967(98)00034-5; Tomlinson KL, 2012,
ADDICT BEHAV, V37, P179, DOI 10.1016/j.addbeh.2011.09.016; Valentiner DP, 2004, J
ANXIETY DISORD, V18, P573, DOI 10.1016/j.janxdis.2003.04.001; VASEY MW, 1994,
COGNITIVE THER RES, V18, P529, DOI 10.1007/BF02355667; Waldron HB, 2008, J CLIN
CHILD ADOLESC, V37, P238, DOI 10.1080/15374410701820133; Windle M, 2012, ADDICT
BEHAV, V37, P1003, DOI 10.1016/j.addbeh.2012.04.009 65 0 0 0 1
AMER PSYCHIATRIC PUBLISHING, INC ARLINGTON 1000 WILSON BOULEVARD, STE
1825, ARLINGTON, VA 22209 USA 978-1-58562-497-3 2016
169 195 27
Psychology, Clinical; Substance Abuse; Psychiatry; Psychology Psychology;
Substance Abuse; Psychiatry BH7EE WOS:000402412700009
2019-09-25
J Preyde, M; Ashbourne, G; Penney, R; Carter, J; Frensch, K; Cameron, G
Preyde, Michele; Ashbourne, Graham; Penney, Randy; Carter, Jeff;
Frensch, Karen; Cameron, Gary Emerging Adults Post Discharge from
Residential Treatment: Subgroup Profiles of Substance Use RESIDENTIAL TREATMENT
FOR CHILDREN & YOUTH English Article
emerging adults; residential mental health treatment; concurrent disorders
FUNCTIONAL ASSESSMENT SCALE; ABUSE TREATMENT; ADOLESCENTS; DISORDERS;
PSYCHOPATHOLOGY; COMORBIDITY; COMMUNITY; PROGRAM; TRAUMA; CHILD The outcomes of
youth who accessed Residential Treatment are varied; many do not fare well in early
adulthood. The purpose for this report was to compare subgroups of substance use
behavior among emerging adults who had accessed RT as a child/adolescent on life
domains and symptoms gathered by interviews and gleaned from agency files. Of the
59 emerging adults, 11 were categorized as having persistent substance use, 19 as
moderate use and 26 as no/minimal use. The mean age at the time of the interview
was 19.96 years (SD 1.84), and most (n = 33; 61%) were male. By discharge, the
persistent substance use group had significantly greater impairment in functioning
in school, home, and self-harm subscales and overall functioning than the other two
groups. Fewer participants in the persistent group were employed as emerging
adults, and a greater number were self-medicating compared to the other two groups.
These results suggest that youth who accessed RT with substance use concerns
continue to have difficulties as emerging adults with functioning, symptom severity
and life domains. An exploration of specialized programs to address these
difficulties appears warranted. [Preyde, Michele] Univ Guelph, Dept Family
Relat & Appl Nutr, Guelph, ON N1G 2W1, Canada; [Ashbourne, Graham] Craigwood Youth
Serv, London, ON, Canada; [Penney, Randy] Lutherwood, Waterloo, ON, Canada;
[Carter, Jeff] Vanier Childrens Serv, London, ON, Canada; [Frensch, Karen; Cameron,
Gary] Wilfrid Laurier Univ, Fac Social Work, Kitchener, ON, Canada Preyde, M
(reprint author), Univ Guelph, Dept Family Relat & Appl Nutr, Guelph, ON N1G 2W1,
Canada. mpreyde@uoguelph.ca Social Sciences and Humanities
Research Council of CanadaSocial Sciences and Humanities Research Council of Canada
(SSHRC) [410-2011-0995] This research was made possible through a grant to Gary
Cameron (No. 410-2011-0995) from the Social Sciences and Humanities Research
Council of Canada. Andersen SM, 2014, J PSYCHOTHER INTEGR, V24, P13, DOI
10.1037/a0035968; Armstrong TD, 2002, J CONSULT CLIN PSYCH, V70, P1224, DOI
10.1037//0022-006X.70.6.1224; Arnett JJ, 2000, AM PSYCHOL, V55, P469, DOI
10.1037/0003-066X.55.5.469; Baiden P, 2014, J SUBST USE, V19, P18, DOI
10.3109/14659891.2012.727522; Cameron G, 2011, RESID TREAT CHILD YO, V28, P150, DOI
10.1080/0886571X.2011.577344; Catchpole REH, 2016, J CAN ACAD CHILD ADO, V25, P106;
Chan YF, 2008, J SUBST ABUSE TREAT, V34, P14, DOI 10.1016/j.jsat.2006.12.031;
Children's Mental Health Ontario (CMHO), 2001, EV BAS PRACT COND DI; Cicchetti D,
2002, J CONSULT CLIN PSYCH, V70, P6, DOI 10.1037//0022-006X.70.1.6; Cicchetti D.,
1995, WILEY SERIES PERSONA, V2, P677; Connor Daniel F, 2007, Ann Clin Psychiatry,
V19, P161, DOI 10.1080/10401230701465269; Cunningham C. E, 2002, BRIEF CHILD FAMILY
P; Daudin M, 2010, J CAN ACAD CHILD ADO, V19, P264; De Bellis MD, 2014, CHILD ADOL
PSYCH CL, V23, P185, DOI 10.1016/j.chc.2014.01.002; Deas D, 2001, AM J ADDICTION,
V10, P178; Diaz R, 2011, EUR CHILD ADOLES PSY, V20, P279, DOI 10.1007/s00787-011-
0173-5; Dow SJ, 2013, PSYCHOL ADDICT BEHAV, V27, P1122, DOI 10.1037/a0031065;
Eschmann S, 2011, J SUBST USE, V16, P295, DOI 10.3109/14659890903531253; European
Monitoring Centre for Drugs and Drug Addiction, 2009, PREV LAT SUBST US DI;
Fergusson DM, 2008, ADDICTION, V103, P969, DOI 10.1111/j.1360-0443.2008.02221.x;
Frensch K, 2009, CHILD YOUTH CARE FOR, V38, P287, DOI 10.1007/s10566-009-9083-9;
Goldstein BI, 2013, J AM ACAD CHILD PSY, V52, P1026, DOI
10.1016/j.jaac.2013.07.009; Grella CE, 2004, J CHILD ADOLES SUBST, V13, P13, DOI
10.1300/J029v13n04_02; Hall G. S., 1904, ADOLESCENCE PSYCHOL, V2; Hall G. S., 1904,
ADOLESCENCE PSYCHOL, V1; Hauser ST, 2006, PSYCHOANAL INQ, V26, P549, DOI
10.1080/07351690701310623; Hodges K, 2000, J ABNORM CHILD PSYCH, V28, P287, DOI
10.1023/A:1005100521818; Hodges K, 2000, J BEHAV HEALTH SER R, V27, P47, DOI
10.1007/BF02287803; Hodges K, 2000, CHILD ADOLESCENT FUN; Hodges K., 1996, J CHILD
FAM STUD, V5, P445, DOI DOI 10.1007/BF02233865; Hser YI, 2001, ARCH GEN PSYCHIAT,
V58, P689, DOI 10.1001/archpsyc.58.7.689; Joe GW, 2014, J SUBST ABUSE TREAT, V46,
P362, DOI 10.1016/j.jsat.2013.10.007; JOLIN A, 1987, INT J OFFENDER THER, V31,
P237; Luciana M, 2013, DEV PSYCHOPATHOL, V25, P1325, DOI 10.1017/S0954579413000643;
Mitchell D P, 2002, J Psychiatr Ment Health Nurs, V9, P191, DOI 10.1046/j.1365-
2850.2002.00466.x; Preyde M, 2011, J CHILD FAM STUD, V20, P660, DOI 10.1007/s10826-
010-9442-z; Preyde M, 2012, J CAN ACAD CHILD ADO, V21, P270; Preyde M, 2011, RESID
TREAT CHILD YO, V28, P55, DOI 10.1080/0886571X.2011.550171; Preyde M, 2008, PRACT
RESOUR MENT, P3, DOI 10.1016/B978-012373625-3.50003-6; Richards L., 1999, USING
NVIVO QUALITAT; Rush B, 2008, CAN J PSYCHIAT, V53, P810, DOI
10.1177/070674370805301207; Rush B, 2008, CAN J PSYCHIAT, V53, P800, DOI
10.1177/070674370805301206; Serowik KL, 2014, J MENT HEALTH, V23, P186, DOI
10.3109/09638237.2014.924046; Silins E, 2014, LANCET PSYCHIAT, V1, P286, DOI
10.1016/S2215-0366(14)70307-4; Silverman D., 1993, INTERPRETING QUALITA; Smetanin
P, 2011, LIFE EC IMPACT MAJOR; Stewart SL, 2013, SUBST USE MISUSE, V48, P404, DOI
10.3109/10826084.2013.765482; Watson GK, 2014, PATHWAYS CARE YOUTH; Woolcott H.F,
1994, TRANSFORMING QUALITA; Zubritsky C, 2013, J MENT HEALTH, V22, P12, DOI
10.3109/09638237.2012.670882; Zucker R. A., 1995, DEV PSYCHOPATHOLOGY 51 1
1 0 0 ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD ABINGDON 2-4
PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND 0886-571X 1541-0358
RESID TREAT CHILD YO Resid. Treat. Child. Youth 2016 33 3-4
206 224 10.1080/0886571X.2016.1204257
19 Psychology, Clinical Psychology ET8XM WOS:000400587600004
2019-09-25
J Rieckmann, T; Muench, J; McBurnie, MA; Leo, MC; Crawford, P; Ford, D; Stubbs,
J; O'Cleirigh, C; Mayer, KH; Fiscella, K; Wright, N; Doe-Simkins, M; Cuddeback, M;
Salisbury-Afshar, E; Nelson, C Rieckmann, Traci; Muench,
John; McBurnie, Mary Ann; Leo, Michael C.; Crawford, Phillip; Ford, Daren; Stubbs,
Jennifer; O'Cleirigh, Conall; Mayer, Kenneth H.; Fiscella, Kevin; Wright, Nicole;
Doe-Simkins, Maya; Cuddeback, Matthew; Salisbury-Afshar, Elizabeth; Nelson,
Christine Medication-assisted treatment for substance use disorders
within a national community health center research network SUBSTANCE ABUSE
English Article Community health
centers; medication-assisted treatment; substance use disorders PRIMARY-CARE;
HEPATITIS-C; ANXIETY DISORDERS; OPIOID ADDICTION; BUPRENORPHINE TREATMENT;
METHADONE-MAINTENANCE; ALCOHOL DEPENDENCE; SELF-MEDICATION; NALTREXONE; COMORBIDITY
Background: The Affordable Care Act increases access to treatment services
for people who suffer from substance use disorders (SUDs), including alcohol use
disorders (AUDs) and opioid use disorders (OUDs). This increased access to
treatment has broad implications for delivering health services and creates a
dramatic need for transformation in clinical care, service lines, and collaborative
care models. Medication-assisted treatments (MAT) are effective for helping SUD
patients reach better outcomes. This article uses electronic health record (EHR)
data to examine the prevalence of EHR-documented SUDs, patient characteristics, and
patterns of MAT prescribing and screening for patients within the Community Health
Applied Research Network (CHARN), a national network of 17 community health centers
that facilitates patient-centered outcomes research among underserved populations.
Methods: Hierarchical generalized linear models examined patient characteristics,
SUD occurrence rates, MAT prescription, and human immunodeficiency virus (HIV) and
hepatitis virus C screening for patients with AUDs or OUDs.Results: Among 572,582
CHARN adult patients, 16,947 (3.0%)had a documented AUD diagnosis and 6,080 (1.1%)
an OUD diagnosis. Alcohol MAT prescriptions were documented for 547 AUD patients
(3.2%) and opioid MAT for 1,764 OUD patients (29.0%). Among OUD patients, opioid
MAT was significantly associated with HIV screening (odds ratio [OR] = 1.31, P < .
001) in OUD patients, as was alcohol MAT among AUD patients (OR = 1.30, P = .013).
Conclusions: These findings suggest that effective opioid and alcohol MAT may be
substantially underprescribed among safety-net patients identified as having OUDs
or AUDs. [Rieckmann, Traci] Oregon Hlth & Sci Univ, Sch Med, Portland, OR 97201
USA; [Rieckmann, Traci; Ford, Daren; Stubbs, Jennifer] Oregon Hlth & Sci Univ, Sch
Publ Hlth, 3181 SW Sam Jackson Pk Rd,CB669, Portland, OR 97239 USA; [Muench, John]
Oregon Hlth & Sci Univ, Dept Family Med, Richmond Clin, Portland, OR 97201 USA;
[McBurnie, Mary Ann; Nelson, Christine] Oregon Community Hlth Informat Network,
Portland, OR USA; [Leo, Michael C.; Crawford, Phillip] CHARN Data Coordinating Ctr,
Portland, OR USA; [O'Cleirigh, Conall; Mayer, Kenneth H.] Harvard Med Sch, Fenway
Hlth, Boston, MA USA; [O'Cleirigh, Conall; Mayer, Kenneth H.] Massachusetts Gen
Hosp, Boston, MA 02114 USA; [Fiscella, Kevin] Univ Rochester, Med Ctr, Dept Family
Med, Rochester, NY 14642 USA; [Fiscella, Kevin] Univ Rochester, Med Ctr, Dept Publ
Hlth Sci, Rochester, NY 14642 USA; [Wright, Nicole] Assoc Asian Pacific Community
Hlth Organizat, Oakland, CA USA; [Doe-Simkins, Maya; Cuddeback, Matthew; Salisbury-
Afshar, Elizabeth] Alliance Chicago Community Hlth Serv, Chicago, IL USA
Rieckmann, T (reprint author), Oregon Hlth & Sci Univ, Sch Publ Hlth, 3181 SW
Sam Jackson Pk Rd,CB669, Portland, OR 97239 USA. rieckman@ohsu.edu
Health Resources and Services AdministrationUnited States Department of
Health & Human ServicesUnited States Health Resources & Service Administration
(HRSA) [HHSH250201400001C]; [UB3HA20236] This work was supported by the Health
Resources and Services Administration, contract HHSH250201400001C, and by grant
UB3HA20236. HRSA had no role in any of the listed activities in the study. Amass
L, 2000, DRUG ALCOHOL DEPEN, V58, P143, DOI 10.1016/S0376-8716(99)00074-5; Amato
Laura, 2013, J Evid Based Med, V6, P221, DOI 10.1111/jebm.12067; Armstrong GL,
2006, ANN INTERN MED, V144, P705, DOI 10.7326/0003-4819-144-10-200605160-00004;
Banerjea R, 2007, AM J DRUG ALCOHOL AB, V33, P807, DOI 10.1080/00952990701653701;
Batki SL, 2009, SCHIZOPHR RES, V107, P139, DOI 10.1016/j.schres.2008.10.016;
Beaglehole R, 2009, LANCET, V373, P2173, DOI 10.1016/S0140-6736(09)61168-5;
Bezchlibnyk-Butler KZ, 2007, CLIN HDB PSYCHOTROPI; Birrell L, 2015, J ANXIETY
DISORD, V31, P108, DOI 10.1016/j.janxdis.2015.02.008; Bonhomme J, 2012, J NATL MED
ASSOC, V104, P342, DOI 10.1016/S0027-9684(15)30175-9; Boothby LA, 2005, CLIN THER,
V27, P695, DOI 10.1016/j.clinthera.2005.06.015; Bouchery EE, 2011, AM J PREV MED,
V41, P516, DOI 10.1016/j.amepre.2011.06.045; Bowman S, 2013, AM J MED, V126, P565,
DOI 10.1016/j.amjmed.2012.11.031; Branson Bernard M., 2006, Morbidity and Mortality
Weekly Report, V55, P1; CHICK J, 1992, BRIT J PSYCHIAT, V161, P84, DOI
10.1192/bjp.161.1.84; Chou R, 2013, ANN INTERN MED, V158, P101, DOI 10.7326/0003-
4819-158-2-201301150-00574; Colvin HM, 2010, HEPATITIS AND LIVER CANCER: A NATIONAL
STRATEGY FOR PREVENTION AND CONTROL OF HEPATITIS B AND C, P1; Conway KP, 2006, J
CLIN PSYCHIAT, V67, P247, DOI 10.4088/JCP.v67n0211; Dean RL, 2005, FRONT BIOSCI-
LANDMRK, V10, P643, DOI 10.2741/1559; Elissen AMJ, 2013, J EVAL CLIN PRACT, V19,
P753, DOI 10.1111/j.1365-2753.2012.01817.x; Evon DM, 2010, ALIMENT PHARM THER, V32,
P1163, DOI 10.1111/j.1365-2036.2010.04460.x; Fernandez A, 2012, GEN HOSP PSYCHIAT,
V34, P227, DOI 10.1016/j.genhosppsych.2012.01.012; Fleming MF, 2007, J PAIN, V8,
P573, DOI 10.1016/j.jpain.2007.02.432; Gallagher Hugh, 2010, Br J Gen Pract, V60,
pe258, DOI 10.3399/bjgp10X502164; Garbutt JC, 1999, JAMA-J AM MED ASSOC, V281,
P1318, DOI 10.1001/jama.281.14.1318; Garfein RS, 1996, AM J PUBLIC HEALTH, V86,
P655, DOI 10.2105/AJPH.86.5.655; Ghitza UE, 2014, J HEALTH CARE POOR U, V25, P36,
DOI 10.1353/hpu.2014.0067; Grant BF, 2004, ARCH GEN PSYCHIAT, V61, P807, DOI
10.1001/archpsyc.61.8.807; Guo G, 2000, ANNU REV SOCIOL, V26, P441, DOI
10.1146/annurev.soc.26.1.441; Haddad MS, 2015, J URBAN HEALTH, V92, P193, DOI
10.1007/s11524-014-9924-1; Hasin D, 2012, CURR OPIN PSYCHIATR, V25, P165, DOI
10.1097/YCO.0b013e3283523dcc; Israelski DM, 2007, AIDS CARE, V19, P220, DOI
10.1080/09540120600774230; Jan Saira, 2011, Am J Manag Care, V17 Suppl 8, pS210;
JOHNSON RE, 1992, JAMA-J AM MED ASSOC, V267, P2750, DOI 10.1001/jama.267.20.2750;
JOHNSON RE, 1995, DRUG ALCOHOL DEPEN, V40, P17, DOI 10.1016/0376-8716(95)01186-2;
Kakko J, 2007, AM J PSYCHIAT, V164, P797, DOI 10.1176/appi.ajp.164.5.797; Khatri K,
2013, J HEALTH CARE POOR U, V24, P850, DOI 10.1353/hpu.2013.0093; Kranzler HR,
2001, ALCOHOL CLIN EXP RES, V25, P1335, DOI 10.1097/00000374-200109000-00014; Kuo
Shihchen, 2011, J Diabetes Sci Technol, V5, P501; Laws Reesa, 2014, EGEMS (Wash
DC), V2, P1097, DOI 10.13063/2327-9214.1097; Le Cook B, 2011, PSYCHIAT SERV, V62,
P1273, DOI 10.1176/ps.62.11.pss6211_1273; Lee J, 2015, BIOMED RES INT, DOI
10.1155/2015/137020; Liebschutz JM, 2014, JAMA INTERN MED, V174, P1369, DOI
10.1001/jamainternmed.2014.2556; Likumahuwa S, 2013, J AM BOARD FAM MED, V26, P579,
DOI 10.3122/jabfm.2013.05.130025; Ling W, 2003, DRUG ALCOHOL DEPEN, V70, pS49, DOI
10.1016/S0376-8716(03)00059-0; LIU Q, 1994, BIOMETRIKA, V81, P624; Lydiard R.B.,
1992, AM J ADDICTION, V1, P325; Manchikanti L, 2010, PAIN PHYSICIAN, V13, P401;
Mattick RP, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002207.pub3; Mayer
KH, 2016, AIDS PATIENT CARE ST, V30, P237, DOI 10.1089/apc.2015.0314; McCulloch CE,
2008, GEN LINEAR MIXED MOD; MELLO NK, 1985, DRUG ALCOHOL DEPEN, V14, P283, DOI
10.1016/0376-8716(85)90062-6; Morasco BJ, 2011, PAIN, V152, P488, DOI
10.1016/j.pain.2010.10.009; Moses K, DESIGNING MED HLTH H; Muench J., 2013,
ADDRESSING UNHEALTHY, P171; National Center on Addiction and Substance Abuse, 2000,
MISS OPP CASA NAT SU; National Institute on Drug Abuse (NIDA), DRUG FACTS TREATM
ST; Nelson PK, 2011, LANCET, V378, P571, DOI 10.1016/S0140-6736(11)61097-0; Nielsen
S, 2014, AM J ADDICTION, V23, P343, DOI [10.1111/j.1521-0391.2013.12105.x,
10.1111/j.1521-0391.2014.12105.x]; O'Cleirigh C, 2015, PSYCHOSOMATICS, V56, P470,
DOI 10.1016/j.psym.2014.08.004; O'Leary G, 2001, Curr Psychiatry Rep, V3, P484, DOI
10.1007/s11920-001-0042-x; OMALLEY SS, 1992, ARCH GEN PSYCHIAT, V49, P881; Rabe-
Hesketh S, 2005, J ECONOMETRICS, V128, P301, DOI 10.1016/j.jeconom.2004.08.017;
Raudenbush S. W., 2002, HIERARCHICAL LINEAR; Rehm J., 2007, J STUDIES ALCOHOL DR,
V68, P886, DOI DOI 10.15288/JSAD.2007.68.886; Rehm J, 2009, LANCET, V373, P2223,
DOI 10.1016/S0140-6736(09)60746-7; Reif S, 2005, AIDS CARE, V17, P558, DOI
10.1080/09540120412331319750; Rieckmann T, J BEHAV HLT IN PRESS; Rinaldo SG, ADV
ACCESS ADDICTION; Robinson J, 2011, ARCH GEN PSYCHIAT, V68, P800, DOI
10.1001/archgenpsychiatry.2011.75; Robinson J, 2009, J ANXIETY DISORD, V23, P38,
DOI 10.1016/j.janxdis.2008.03.013; SAMHSA (Substance Abuse and Mental Health
Services Administration), 2014, HHS PUBL, VSMA 14-4884; Saxon AJ, 2013, J FOOD DRUG
ANAL, V21, pS69, DOI 10.1016/j.jfda.2013.09.037; Sigmon SC, 2012, AM J DRUG ALCOHOL
AB, V38, P187, DOI 10.3109/00952990.2011.653426; Spandorfer JM, 1999, J FAM
PRACTICE, V48, P899; Stancliff S, 2012, J ADDICT DIS, V31, P278, DOI
10.1080/10550887.2012.694603; Stein MD, 1999, PSYCHIAT CLIN N AM, V22, P351, DOI
10.1016/S0193-953X(05)70081-2; Substance Abuse and Mental Health Services
Administration ( SAMHSA), 2013, HHS PUBL, V( SMA) 13- 4795; Sunaert P, 2010, BMC
HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-207;
Swenson-Britt E, 2000, Clin Nurse Spec, V14, P92, DOI 10.1097/00002800-200003000-
00014; Tai B, 2013, J FOOD DRUG ANAL, V21, pS13, DOI 10.1016/j.jfda.2013.09.023;
Tai B, 2013, SOC WORK PUBLIC HLTH, V28, P165, DOI 10.1080/19371918.2013.758975;
Taylor B, 2009, ADDICTION, V104, P1981, DOI 10.1111/j.1360-0443.2009.02694.x;
Thornton LK, 2012, ADDICT BEHAV, V37, P427, DOI 10.1016/j.addbeh.2011.11.039; Tkacz
J, 2012, AM J ADDICTION, V21, P55, DOI 10.1111/j.1521-0391.2011.00186.x; Vermani
Monica, 2011, Prim Care Companion CNS Disord, V13, DOI 10.4088/PCC.10m01013;
VOLPICELLI JR, 2002, NEUROPSYCHOPHARMACOL, P1445; WALSH SL, 1994, CLIN PHARMACOL
THER, V55, P569, DOI 10.1038/clpt.1994.71; Wittchen HU, 2002, J CLIN PSYCHIAT, V63,
P24; YANCOVITZ SR, 1991, AM J PUBLIC HEALTH, V81, P1185, DOI
10.2105/AJPH.81.9.1185; Zanis DA, 1998, DRUG ALCOHOL DEPEN, V52, P257, DOI
10.1016/S0376-8716(98)00097-0 90 6 6 0 5 ROUTLEDGE JOURNALS,
TAYLOR & FRANCIS LTD ABINGDON 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14
4RN, OXON, ENGLAND 0889-7077 1547-0164 SUBST ABUS Subst. Abus.
 2016 37 4 625 634
10.1080/08897077.2016.1189477 10 Substance Abuse Substance
Abuse ED5TQ WOS:000388915600022 27218678 2019-09-25
J Raheb, G; Khaleghi, E; Moghanibashi-Mansourieh, A; Farhoudian, A; Teymouri, R
Raheb, Ghoncheh; Khaleghi, Esmat; Moghanibashi-Mansourieh,
Amir; Farhoudian, Ali; Teymouri, Robab Effectiveness of social work
intervention with a systematic approach to improve general health in opioid addicts
in addiction treatment centers PSYCHOLOGY RESEARCH AND BEHAVIOR MANAGEMENT
English Article social work;
intervention; systematic approach; general health; opioid addicts SELF-
MEDICATION HYPOTHESIS; SUBSTANCE USE DISORDERS; DEPENDENCE Purpose: This study
takes a systematic approach to investigate the effect of social work intervention
aimed at increasing general health among opioid addicts in addiction treatment
centers. Patients and methods: This is an experimental plan (pretest to posttest
with a control group); the study sample included 60 patients with drug dependencies
undergoing treatment in addiction treatment centers. These patients were randomly
assigned as case (30) and control (30) groups. The case group was subjected to
intervention over ten sessions, whereas the control group received no intervention.
Both groups then passed through a posttest, while a follow-up was conducted after 4
months. Data were obtained via a General Health Questionnaire. Results: A
covariance analysis test and independent and dependent t-test results indicated
that a social work intervention adopting systematic approach was effective in
increasing the general health of drug-addicted patients under treatment.
Conclusion: Thus, the nature of the presence of social workers in addiction
treatment centers has been effective and can have a significant influence by
reducing anxiety and insomnia and somatic symptoms, improving patients' self-
understanding and self-recognition, and enhancing social functioning. [Raheb,
Ghoncheh; Khaleghi, Esmat; Moghanibashi-Mansourieh, Amir] Univ Social Welf &
Rehabil Sci, Dept Social Work, Tehran, Iran; [Raheb, Ghoncheh; Farhoudian, Ali]
Univ Social Welf & Rehabil Sci, Substance Abuse & Dependence Res Ctr, Tehran, Iran;
[Teymouri, Robab] Univ Social Welf & Rehabil Sci, Pediat Neurorehabil Res Ctr,
Koodakyar Ave,Daneshjoo Blvd, Tehran 1985713834, Iran Teymouri, R (reprint author),
Univ Social Welf & Rehabil Sci, Pediat Neurorehabil Res Ctr, Koodakyar
Ave,Daneshjoo Blvd, Tehran 1985713834, Iran. robab.teymouri@yahoo.com
moghanibashi, amir/Q-7164-2019; Farhoudian, Ali/M-4188-2017; raheb,
ghoncheh/E-1125-2017 University of Social Welfare and Rehabilitation
Sciences The authors sincerely thank the vice-chancellor for Research and
Technology, University of Social Welfare and Rehabilitation Sciences, for financial
support of this research project. The authors are grateful to directors, managers
of the drug addiction treatment centers in the Guilan Province who helped them
during implementing the tests, and all of the patients who participated in the
project. Alimoradi L, 2011, PROCD SOC BEHV, V30, DOI
10.1016/j.sbspro.2011.10.329; Amiri M, 2009, J RES ADDICT, V3, P101; Baker AL,
2010, ADDICTION, V105, P87, DOI 10.1111/j.1360-0443.2009.02757.x; Baschnagel JS,
2008, ADDICT BEHAV, V33, P1441, DOI 10.1016/j.addbeh.2008.03.004; Behravan H, 2010,
IRAN J SOC PROBL, V1, P45; Booth RE, 2004, DRUG ALCOHOL DEPEN, V74, P177, DOI
10.1016/j.drugalcdep.2003.12.009; Burns L, 2014, DRUG ALCOHOL REV, V33, P216, DOI
10.1111/dar.12110; Eghlima M, 2010, INDIVIDUAL WORK INDI; Eghlima M, 2010, METHODS
SOCIAL WORK; Erfani N, 2013, J CLIN PSYCHOL, V5, P25; Gastfriend David R., 1996,
P329; Glasner-Edwards S, 2010, HEALTH POLICY, V97, P93, DOI
10.1016/j.healthpol.2010.05.013; Goldberg D., 1978, MANUAL GEN HLTH QUES; GOLDBERG
DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; Graipaspong D,
2010, EUR PSYCHIAT, V25; Hepworth D. H., 2013, DIRECT SOCIAL WORK P; Hoseinifar J,
2011, PROCD SOC BEHV, V30, DOI 10.1016/j.sbspro.2011.10.375; Kaldi A, 2003, SOC
WELF, V3, P307; Kamarzarin H, 2012, RES ADDICT, V6, P75; Kessler RC, 2005, PSYCHOL
MED, V35, P1073, DOI 10.1017/S0033291705004538; Khantzian E.J., 2008, UNDERSTANDING
ADDICT; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI
10.3109/10673229709030550; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259;
Ma'arefvand MS, 2002, EXAMINING PERSONAL F; Ma'arefvand MS, 2011, EVALUATION
COMMUNITY; Middel B, 2010, NEDERLANDS TIJDSCHRI, V8, P9; Moallemi S, 2010, J SHAHID
SADOUGHI U, V18, P234; Moghanibashi-Mansourieh A, 2014, ADDICTION, V109, P854, DOI
10.1111/add.12505; Mollazadeh J, 2009, DANESHVAR RAFTAR, V16, P1; Pierson F. M.,
2008, PRINCIPLES TECHNIQUE; Pollack MH, 1996, CHALLENGES CLIN PRAC; SADOCK BJ,
2003, SYNOPSIS PSYCHIAT; Serajkhorami N, 2008, NAT C SOC PSYCH TEHR, P10; Shahidi
S, 2009, IRAN J PSYCHIAT, V4, P46; Sohrabi F, 2004, PROBLEM CIGARETTE MI; Velasquez
MM, 2001, GROUP TREATMENT SUBS; Wells EA, 2013, SOC WORK PUBLIC HLTH, V28, P279,
DOI 10.1080/19371918.2013.759033; Yazdani M, 2011, COMP SOCIAL SUPPORT 38 4
4 0 5 DOVE MEDICAL PRESS LTD ALBANY PO BOX 300-008, ALBANY,
AUCKLAND 0752, NEW ZEALAND 1179-1578 PSYCHOL RES BEHAV MA
Psychol. Res. Behav. Manag. 2016 9
309 315 10.2147/PRBM.S110705 7 Psychology,
Clinical; Psychiatry; Psychology, Multidisciplinary Psychology; Psychiatry ED0NJ
WOS:000388538900001 27895520 DOAJ Gold, Green Published
2019-09-25
J Jones, HW; Dean, AC; Price, KA; London, ED Jones,
Hannah W.; Dean, Andy C.; Price, Kimberly A.; London, Edythe D.
Increased self-reported impulsivity in methamphetamine users maintaining drug
abstinence AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE English
Article Drug abuse; impulsivity;
methamphetamine; withdrawal; self-medication; abstinence; stimulant SUBSTANCE-
USE DISORDERS; DEPENDENT SUBJECTS; COCAINE ADDICTION; BEHAVIOR; ABUSE; RATS;
METAANALYSIS; PERFORMANCE; WITHDRAWAL; HUMANS Background: Impulsivity has been
proposed as an important factor in the initiation and maintenance of addiction.
Indirect evidence suggests that some methamphetamine users report less impulsivity
when they are using methamphetamine compared to when abstaining from drug use, but
this hypothesis has not been directly tested. Objectives/Methods: In this study,
self-reports of impulsivity were obtained from 32 methamphetamine-dependent (DSM-
IV) research participants and 41 healthy control subjects, using the Barratt
Impulsiveness Scale-11. The methamphetamine users were assessed during an active
period of methamphetamine use, as determined through urinalysis, and again after
approximately 1 week of confirmed abstinence. Control subjects likewise completed
two assessments. A subset of participants also completed serial assessments of the
Beck Depression Inventory (Methamphetamine Group, N = 17, Control Group, N = 38)
and the Methamphetamine Withdrawal Questionnaire (Methamphetamine Group, N = 12).
Results: There was a significant interaction of group with time on impulsivity (p =
0.044), reflecting a significant increase from the first to the second assessment
in the methamphetamine users (p = 0.013), but no change among healthy control
subjects. In contrast, depressive and withdrawal symptoms significantly decreased
between the first and second assessments in the methamphetamine users (ps =0.01).
Change in impulsivity in methamphetamine users was not significantly correlated
with change in withdrawal or depression (ps >0.05). Conclusions: These findings
suggest that methamphetamine users report more impulsivity when abstaining from
drug use, an effect that is not significantly related to methamphetamine
withdrawal. Attenuation of impulsivity may reinforce continued methamphetamine use
in these individuals. [Jones, Hannah W.] Fuller Theol Seminary, Fuller Grad Sch
Psychol, Dept Clin Psychol, Pasadena, CA 91101 USA; [Dean, Andy C.; Price, Kimberly
A.; London, Edythe D.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Semel
Inst Neurosci, Los Angeles, CA 90024 USA; [London, Edythe D.] Univ Calif Los
Angeles, Dept Mol & Med Pharmacol, Semel Inst Neurosci, Los Angeles, CA USA; [Dean,
Andy C.; London, Edythe D.] Univ Calif Los Angeles, David Geffen Sch Med, Brain Res
Inst, Los Angeles, CA 90095 USA London, ED (reprint author), Univ Calif Los
Angeles, Dept Psychiat & Biobehav Sci, Semel Inst Neurosci & Human Behav, 760
Westwood Plaza, Los Angeles, CA 90095 USA. elondon@mednet.ucla.edu
NIHUnited States Department of Health & Human ServicesNational Institutes of
Health (NIH) - USA [P20 DA022539, R01 DA020726, K23DA027734, R21DA034928,
UL1TR000124]; Thomas P. and Katherine P. Pike Chair in Addiction Studies; Marjorie
Greene Trust The research was funded in part by NIH grants P20 DA022539, R01
DA020726 (EDL), K23DA027734 (ACD), R21DA034928 (ACD), UL1TR000124 (UCLA CTSI), and
endowments from the Thomas P. and Katherine P. Pike Chair in Addiction Studies, and
the Marjorie Greene Trust. None of the sponsors were involved with the design,
collection, analysis or interpretation of data, writing the manuscript, or the
decision to submit the manuscript for publications. Alfonso JP, 2011, DRUG
ALCOHOL DEPEN, V117, P78, DOI 10.1016/j.drugalcdep.2010.12.025; American
Psychiatric Association Diagnostic and Statistical Manual, 2013, DSM 5; Beck AT,
1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13; de Wit H, 2002,
NEUROPSYCHOPHARMACOL, V27, P813, DOI 10.1016/S0893-133X(02)00343-3; de Wit H, 2009,
ADDICT BIOL, V14, P22, DOI 10.1111/j.1369-1600.2008.00129.x; Dean AC, 2015, DRUG
ALCOHOL DEPEN, V151, P84, DOI 10.1016/j.drugalcdep.2015.03.004; Dean AC, 2013,
NEUROPSYCHOPHARMACOL, V38, P259, DOI 10.1038/npp.2012.179; Ghahremani DG, 2013, J
ADOLESCENT HEALTH, V53, P139, DOI 10.1016/j.jadohealth.2013.02.010; Goldstein RZ,
2010, P NATL ACAD SCI USA, V107, P16667, DOI 10.1073/pnas.1011455107; Hulka LM,
2015, PSYCHOL MED, V45, P3097, DOI 10.1017/S0033291715001063; Ivanov I, 2008, AM J
DRUG ALCOHOL AB, V34, P239, DOI 10.1080/00952990802013334; Jentsch JD, 1999,
PSYCHOPHARMACOLOGY, V146, P373, DOI 10.1007/PL00005483; Lee B, 2009, J NEUROSCI,
V29, P14734, DOI 10.1523/JNEUROSCI.3765-09.2009; Levine B, 2011, FRONT HUM
NEUROSCI, V5, DOI 10.3389/fnhum.2011.00009; Menary KR, 2015, ALCOHOL CLIN EXP RES,
V39, P1267, DOI 10.1111/acer.12762; Mitchell JT, 2017, J ATTEN DISORD, V21, P1105,
DOI 10.1177/1087054713513328; Moeller FG, 2005, NEUROPSYCHOPHARMACOL, V30, P610,
DOI 10.1038/sj.npp.1300617; Morales AM, 2012, DRUG ALCOHOL DEPEN, V125, P230, DOI
10.1016/j.drugalcdep.2012.02.017; Morris SB, 2002, PSYCHOL METHODS, V7, P105, DOI
10.1037//1082-989X.7.1.105; Pace-Schott EF, 2008, AM J DRUG ALCOHOL AB, V34, P109,
DOI 10.1080/00952990701764821; Pace-Schott EF, 2005, AM J DRUG ALCOHOL AB, V31,
P571, DOI 10.1081/ADA-200068120; Patton JH, 1995, J CLIN PSYCHOL, V51, P768, DOI
10.1002/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1; Perry JL, 2008,
PSYCHOPHARMACOLOGY, V200, P1, DOI 10.1007/s00213-008-1173-0; Perry JL, 2005,
PSYCHOPHARMACOLOGY, V178, P193, DOI 10.1007/s00213-004-1994-4; Reid RC, 2014,
ADDICT BEHAV, V39, P1640, DOI 10.1016/j.addbeh.2013.11.008; Reise SP, 2013, PSYCHOL
ASSESSMENT, V25, P631, DOI 10.1037/a0032161; Richards JB, 1999, PSYCHOPHARMACOLOGY,
V146, P432, DOI 10.1007/PL00005488; Scott JC, 2007, NEUROPSYCHOL REV, V17, P275,
DOI 10.1007/s11065-007-9031-0; Srisurapanont M, 1999, AUST NZ J PSYCHIAT, V33, P89,
DOI 10.1046/j.1440-1614.1999.00517.x; Stevens L, 2015, PSYCHOL MED, V45, P2083, DOI
10.1017/S003329171500001X; Verdejo-Garcia A, 2008, NEUROSCI BIOBEHAV R, V32, P777,
DOI 10.1016/j.neubiorev.2007.11.003; Vonmoos M, 2013, BRIT J PSYCHIAT, V203, P35,
DOI 10.1192/bjp.bp.112.118091; Wang GB, 2013, PLOS ONE, V8, DOI
10.1371/journal.pone.0068791; Whiteside SP, 2001, PERS INDIV DIFFER, V30, P669, DOI
10.1016/S0191-8869(00)00064-7; Winhusen T, 2013, J SUBST ABUSE TREAT, V44, P541,
DOI 10.1016/j.jsat.2012.12.005; Woicik PA, 2009, NEUROPSYCHOPHARMACOL, V34, P1112,
DOI 10.1038/npp.2008.60; Yates JR, 2012, PHARMACOL BIOCHEM BE, V100, P370, DOI
10.1016/j.pbb.2011.07.012; Zorick T, 2010, ADDICTION, V105, P1809, DOI
10.1111/j.1360-0443.2010.03066.x 38 5 6 1 5 TAYLOR & FRANCIS
INC PHILADELPHIA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
0095-2990 1097-9891 AM J DRUG ALCOHOL AB Am. J. Drug Alcohol
Abuse 2016 42 5 500 506
10.1080/00952990.2016.1192639 7 Psychology, Clinical;
Substance Abuse Psychology; Substance Abuse DU7XX WOS:000382429000004
27398730 Green Accepted 2019-09-25
J Herzog, E; Odenwald, M; Proescholdt, M; Haubold, A; Bohnacker, I; Flogel, M;
Linde, A; Muller, S; Wiesbeck, G; Lang, U; Walter, M; Vogel, M
Herzog, Eva; Odenwald, Michael; Proescholdt, Margit; Haubold, Anja;
Bohnacker, Isabelle; Floegel, Marlene; Linde, Andreas; Mueller, Sandra; Wiesbeck,
Gerhard; Lang, Undine; Walter, Marc; Vogel, Marc Stability of
trauma-related symptoms during acute substance use treatment JOURNAL OF
ADDICTIVE DISEASES English Article
Trauma; alcohol; addiction; PTSD; psychopathology; withdrawal
POSTTRAUMATIC-STRESS-DISORDER; SELF-MEDICATION HYPOTHESIS; DETOXIFICATION
TREATMENT; CHILDHOOD TRAUMA; ABUSE TREATMENT; GERMAN VERSION; ALCOHOL; COCAINE;
DEPENDENCE; ANXIETY It is unclear whether post-traumatic stress disorder
symptoms and reports of traumatic childhood experiences decline during substance
withdrawal. A convenience sample of 34 inpatients of the Psychiatric University
Clinics in Basel was recruited and general psychopathological and trauma-related
symptoms were assessed with the Brief Symptom Checklist, Post-Traumatic Stress
Diagnostic Scale, and Childhood Trauma Questionnaire in the 1st and 3rd week of
substance use treatment. The average age of the sample was 41.9 (SD = 9.1) years,
and 26.5% were female. Hyperarousal (M-t1 = 4.51 versus M-t2 = 3.61; z = -2.38, p =
.017) and avoidance symptoms (M-t1 = 6.24 versus M-t2 = 4.27; z = -2.59, p = .010)
declined significantly, but re-experiencing symptoms (M-t1 = 4.00 versus M-t2 =
3.45; z = -.50, p = .617) did not. Post-traumatic stress disorder assessment,
according to the Diagnostic and Statistical Manual of Mental Disorders-4th edition
criteria, remained constant for 28 of 34 patients. Likewise, self-reported
childhood trauma experiences decreased, yet the number of elevated subscale scores
remained stable. Post-traumatic stress disorder symptoms are not adequately treated
by substance withdrawal alone. Trauma-specific diagnostics can be initiated with
sufficient quality as early as the first week of withdrawal treatment. [Herzog,
Eva; Odenwald, Michael; Haubold, Anja; Bohnacker, Isabelle; Floegel, Marlene] Univ
Konstanz, Dept Psychol, Constance, Germany; [Proescholdt, Margit; Mueller, Sandra;
Wiesbeck, Gerhard; Lang, Undine; Walter, Marc; Vogel, Marc] Psychiat Univ Hosp
Basel, Wilhelm Klein Str 27, CH-4012 Basel, Switzerland; [Linde, Andreas] Psychiat
Serv Aargau, Brugg, Switzerland Vogel, M (reprint author), Psychiat Univ Hosp
Basel, Wilhelm Klein Str 27, CH-4012 Basel, Switzerland. Marc.Vogel@upkbs.ch
Vogel, Marc/0000-0002-3088-0331 American Psychiatric
Association, 2000, DIAGN STAT MAN MENT; Bernstein DP, 1998, CHILDHOOD TRAUMA QUE;
Brady KT, 2004, CURR DIR PSYCHOL SCI, V13, P206, DOI 10.1111/j.0963-
7214.2004.00309.x; BROWN SA, 1991, J STUD ALCOHOL, V52, P55, DOI
10.15288/jsa.1991.52.55; BROWN SA, 1988, J STUD ALCOHOL, V49, P412, DOI
10.15288/jsa.1988.49.412; Coffey SF, 2007, DRUG ALCOHOL DEPEN, V87, P241, DOI
10.1016/j.drugalcdep.2006.08.025; Coffey SF, 2006, PSYCHOL ADDICT BEHAV, V20, P425,
DOI 10.1037/0893-164X.20.4.425; Derogatis LR, 1977, SCL 90 ADM SCORING P; Driessen
M, 2001, ALCOHOL ALCOHOLISM, V36, P249, DOI 10.1093/alcalc/36.3.249; Ehlers A,
DTSCH UBERSETZ UNPUB; Foa E. B., 1995, POSTTRAUMATIC STRESS; Franke G H, 2000, BSI
BRIEF SYMPTOM IN; Griesel D, 2006, PSYCHOL ASSESSMENT, V18, P262, DOI 10.1037/1040-
3590.18.3.262; Hien DA, 2010, AM J PSYCHIAT, V167, P95, DOI
10.1176/appi.ajp.2009.09091261; Husband SD, 1996, J CONSULT CLIN PSYCH, V64, P221,
DOI 10.1037/0022-006X.64.1.221; Jacobsen LK, 2001, AM J PSYCHIAT, V158, P1184, DOI
10.1176/appi.ajp.158.8.1184; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231,
DOI 10.3109/10673229709030550; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259;
Klinitzke G, 2012, PSYCHOTHER PSYCH MED, V62, P47, DOI 10.1055/s-0031-1295495;
Lijffijt M, 2014, FRONT PSYCHIATRY, V5, DOI 10.3389/fpsyt.2014.00083; Najavits LM,
2005, J PSYCHOACTIVE DRUGS, V37, P425, DOI 10.1080/02791072.2005.10399816; OBrien
CP, 1996, LANCET, V347, P237, DOI 10.1016/S0140-6736(96)90409-2; Odenwald M, 2013,
SUBST ABUSE TREAT PR, V8, DOI 10.1186/1747-597X-8-14; Odenwald M, 2012, EUR ADDICT
RES, V18, P54, DOI 10.1159/000333336; Potthast N., 2012, SUCHT Z WISSENSCHAFT, V58,
P227, DOI DOI 10.1024/0939-5911.A000191; Schafer I, 2010, EUR ADDICT RES, V16,
P108, DOI 10.1159/000294362; Schafer I, 2011, SUCHT, V5, P353; Schuckit MA, 1997,
ADDICTION, V92, P1289; SIMPSON DD, 1979, AM J PSYCHIAT, V136, P1449; Stewart SH,
1999, PSYCHOL ADDICT BEHAV, V13, P78, DOI 10.1037/0893-164X.13.2.78; Tull MT, 2009,
DEPRESS ANXIETY, V26, P1158, DOI 10.1002/da.20637; Waldrop AE, 2007, ADDICT BEHAV,
V32, P634, DOI 10.1016/j.addbeh.2006.06.001 32 3 3 0 6
ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD ABINGDON 2-4 PARK SQUARE, MILTON
PARK, ABINGDON OX14 4RN, OXON, ENGLAND 1055-0887 1545-0848 J ADDICT DIS
J. Addict. Dis. 2016 35 3 161 168
10.1080/10550887.2015.1127718 8 Substance Abuse Substance
Abuse DS8IF WOS:000381026000002 26670631 2019-09-25
J Danovitch, I Danovitch, Itai Post-
traumatic stress disorder and opioid use disorder: A narrative review of conceptual
models JOURNAL OF ADDICTIVE DISEASES English Review
Comorbidity; neurobiology; opioid use disorder; post-
traumatic stress disorder (PTSD); self-medication CORTICOTROPIN-RELEASING-
FACTOR; NATIONAL COMORBIDITY SURVEY; PITUITARY-ADRENAL AXIS; PAIN MEDICATION USE;
SUBSTANCE USE; OPIATE WITHDRAWAL; LOCUS-COERULEUS; INDUCED RELAPSE; PTSD SYMPTOMS;
DEPENDENCE Post-traumatic stress disorder is highly prevalent among individuals
who suffer from opioid use disorder. Compared to individuals with opioid use
disorder alone, those with post-traumatic stress disorder have a worse course of
illness, occupational functioning, and physical health. The neurobiological
pathways underlying each disorder overlap substantially, and there are multiple
pathways through which these disorders may interact. This narrative review explores
evidence underpinning 3 explanatory perspectives on comorbid post-traumatic stress
disorder and opioid use disorder: The opioid susceptibility model (a.k.a.: the
Self-Medication Hypothesis), the post-traumatic stress disorder susceptibility
model, and the common factors model. Diagnostic implications, treatment
implications, and directions for future research are discussed. [Danovitch, Itai]
Cedars Sinai Med Ctr, Dept Psychiat & Behav Neurosci, 8730 Alden Dr,Rm E-135, Los
Angeles, CA 90048 USA Danovitch, I (reprint author), Cedars Sinai Med Ctr, Dept
Psychiat & Behav Neurosci, 8730 Alden Dr,Rm E-135, Los Angeles, CA 90048 USA.
itai.danovitch@cshs.org ABERCROMBIE ED, 1988, BRAIN
RES, V441, P362, DOI 10.1016/0006-8993(88)91415-1; Abraham IM, 2000, EUR J
NEUROSCI, V12, P3003, DOI 10.1046/j.1460-9568.2000.00176.x; Aerni A, 2004, AM J
PSYCHIAT, V161, P1488, DOI 10.1176/appi.ajp.161.8.1488; Asmundson GJG, 2002, CAN J
PSYCHIAT, V47, P930; Bentley KH, 2016, CLIN PSYCHOL REV, V43, P30, DOI
10.1016/j.cpr.2015.11.008; Bremner JD, 1997, AM J PSYCHIAT, V154, P624; Brown PJ,
1998, J SUBST ABUSE TREAT, V15, P445, DOI 10.1016/S0740-5472(97)00286-9; Chilcoat
HD, 1998, ARCH GEN PSYCHIAT, V55, P913, DOI 10.1001/archpsyc.55.10.913; Clark HW,
2001, J SUBST ABUSE TREAT, V20, P121, DOI 10.1016/S0740-5472(00)00156-2; COHEN MR,
1983, PSYCHIAT CLIN N AM, V6, P457; Contarino A, 2005, P NATL ACAD SCI USA, V102,
P18649, DOI 10.1073/pnas.0506999102; Contarino A, 1999, BRAIN RES, V835, P1, DOI
10.1016/S0006-8993(98)01158-5; Cornwell WS, 1975, MED RADIOGR PHOTOGR, V51, P46;
COTTLER LB, 1992, AM J PSYCHIAT, V149, P664; D'Elia M, 2003, CLIN IMMUNOL, V109,
P179, DOI 10.1016/S1521-6616(03)00177-3; Dahan A, 2006, PALLIATIVE MED, V20, pS3,
DOI 10.1191/0269216306pm1126oa; Duval F, 2004, PSYCHONEUROENDOCRINO, V29, P1281,
DOI 10.1016/j.psyneuen.2004.03.006; EISENMAN AJ, 1958, J PHARMACOL EXP THER, V124,
P305; GOLD MS, 1982, ANN NY ACAD SCI, V398, P140, DOI 10.1111/j.1749-
6632.1982.tb39488.x; GRAU JW, 1981, SCIENCE, V213, P1409, DOI
10.1126/science.7268445; GROSSMAN A, 1986, NEUROENDOCRINOLOGY, V42, P357, DOI
10.1159/000124463; Guarna M, 2004, INT J NEUROPSYCHOPH, V7, P311, DOI
10.1017/S1461145704004341; HEINRICHS SC, 1995, BEHAV PHARMACOL, V6, P74; HENRY C,
1994, J NEUROENDOCRINOL, V6, P341, DOI 10.1111/j.1365-2826.1994.tb00591.x; Hien DA,
2000, J SUBST ABUSE TREAT, V19, P31, DOI 10.1016/S0740-5472(99)00088-4; Hildebrand
A, 2015, PSYCHOTHER RES, V25, P565, DOI 10.1080/10503307.2014.923125; Houshyar H,
2004, J NEUROSCI, V24, P9414, DOI 10.1523/JNEUROSCI.1641-04.2004; Jacobsen LK,
2001, AM J PSYCHIAT, V158, P1184, DOI 10.1176/appi.ajp.158.8.1184; JELINEK J M,
1984, Journal of Substance Abuse Treatment, V1, P87, DOI 10.1016/0740-
5472(84)90031-X; Kasckow JW, 2001, PEPTIDES, V22, P845, DOI 10.1016/S0196-
9781(01)00399-0; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI
10.1001/archpsyc.1995.03950240066012; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62,
P617, DOI 10.1001/archpsyc.62.6.617; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142,
P1259; Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-
133X(00)00195-0; Kreek MJ, 1998, DRUG ALCOHOL DEPEN, V51, P23, DOI 10.1016/S0376-
8716(98)00064-7; Kreek MJ, 2002, J SUBST ABUSE TREAT, V23, P93, DOI 10.1016/S0740-
5472(02)00259-3; Krueger RE, 2006, ANNU REV CLIN PSYCHO, V2, P111, DOI
10.1146/annurev.clinpsy.2.022305.095213; Lanius RA, 2011, ACTA PSYCHIAT SCAND,
V124, P331, DOI 10.1111/j.1600-0447.2011.01755.x; Liberzon I, 2007, BIOL PSYCHIAT,
V61, P1030, DOI 10.1016/j.biopsych.2006.06.021; Logrip ML, 2012, NEUROPHARMACOLOGY,
V62, P552, DOI 10.1016/j.neuropharm.2011.07.007; Lu L, 2000, EUR J NEUROSCI, V12,
P4398; Lu L, 2000, NEUROREPORT, V11, P2373, DOI 10.1097/00001756-200008030-00008;
Lubin G, 2002, HUM PSYCHOPHARM CLIN, V17, P181, DOI 10.1002/hup.395; McNally GP,
2003, MOL BRAIN RES, V118, P152, DOI 10.1016/S0169-328X(03)00333-4; Mills KL, 2005,
PSYCHIAT SERV, V56, P940, DOI 10.1176/appi.ps.56.8.940; Mills KL, 2005, DRUG
ALCOHOL DEPEN, V77, P243, DOI 10.1016/j.drugalcdep.2004.08.016; Najavits LM, 2007,
PSYCHIAT SERV, V58, P1376, DOI 10.1176/appi.ps.58.10.1376; Nelson EC, 2006, PSYCHOL
MED, V36, P1473, DOI 10.1017/S0033291706008397; Nunes EV, 2004, BIOL PSYCHIAT, V56,
P793, DOI 10.1016/j.biopsych.2004.06.037; OWENS MJ, 1991, PHARMACOL REV, V43, P425;
Papaleo F, 2007, NEURON, V53, P577, DOI 10.1016/j.neuron.2007.01.022; Phifer J,
2011, PAIN, V152, P2233, DOI 10.1016/j.pain.2011.04.019; Piazza PV, 1997, BRAIN RES
REV, V25, P359, DOI 10.1016/S0165-0173(97)00025-8; Raison CL, 2003, AM J PSYCHIAT,
V160, P1554, DOI 10.1176/appi.ajp.160.9.1554; RASMUSSEN K, 1990, J NEUROSCI, V10,
P2308; Reddy MK, 2013, DRUG ALCOHOL DEPEN, V132, P597, DOI
10.1016/j.drugalcdep.2013.04.009; Reed PL, 2007, ARCH GEN PSYCHIAT, V64, P1435, DOI
10.1001/archpsyc.64.12.1435; Roberts NP, 2015, CLIN PSYCHOL REV, V38, P25, DOI
10.1016/j.cpr.2015.02.007; SABLEAMPLIS R, 1974, BIOCHEM PHARMACOL, V23, P2111, DOI
10.1016/0006-2952(74)90576-0; Sautter FJ, 2003, BIOL PSYCHIAT, V54, P1382, DOI
10.1016/S0006-3223(03)00571-7; Schelling G, 2006, ANN NY ACAD SCI, V1071, P46, DOI
10.1196/annals.1364.005; Schwartz AC, 2006, PSYCHOSOMATICS, V47, P136, DOI
10.1176/appi.psy.47.2.136; Seal KH, 2012, JAMA-J AM MED ASSOC, V307, P940, DOI
10.1001/jama.2012.234; Shaham Y, 1997, J NEUROSCI, V17, P2605; Shorter D, 2015, AM
J ADDICTION, V24, P705, DOI 10.1111/ajad.12306; Siegmund A, 2006, ANN NY ACAD SCI,
V1071, P324, DOI 10.1196/annals.1364.025; Sofuoglu M, 2014, ADDICT BEHAV, V39,
P428, DOI 10.1016/j.addbeh.2013.08.014; Trafton JA, 2006, J STUD ALCOHOL, V67,
P228, DOI 10.15288/jsa.2006.67.228; Valentino RJ, 2001, PSYCHOPHARMACOLOGY, V158,
P331, DOI 10.1007/s002130000673; Vetter S, 2008, BMC PUBLIC HEALTH, V8, DOI
10.1186/1471-2458-8-92; VILLAGOMEZ RE, 1995, J SUBST ABUSE TREAT, V12, P253, DOI
10.1016/0740-5472(95)00025-Z; VOLAVKA J, 1979, NEW ENGL J MED, V300, P1056; Will
MJ, 1998, PHARMACOL BIOCHEM BE, V60, P655, DOI 10.1016/S0091-3057(98)00027-6; Wolf
EJ, 2010, J ABNORM PSYCHOL, V119, P320, DOI 10.1037/a0019035; Work Group on ASD and
PTSD, 2004, PRACT GUID TREATM PA; Work Group on Substance Abuse Disorders, 2007, AM
J PSYCH S, V164, P75; Xu GP, 2004, J NEUROSCI, V24, P8193, DOI
10.1523/JNEUROSCI.1657-04.2004; Yehuda R, 2006, PSYCHONEUROENDOCRINO, V31, P447,
DOI 10.1016/j.psyneuen.2005.10.007; Yehuda R, 1997, ANN NY ACAD SCI, V821, P57, DOI
10.1111/j.1749-6632.1997.tb48269.x; ZIS AP, 1984, PSYCHONEUROENDOCRINO, V9, P423,
DOI 10.1016/0306-4530(84)90050-7 80 7 7 1 10 ROUTLEDGE
JOURNALS, TAYLOR & FRANCIS LTD ABINGDON 2-4 PARK SQUARE, MILTON PARK,
ABINGDON OX14 4RN, OXON, ENGLAND 1055-0887 1545-0848 J ADDICT DIS
J. Addict. Dis. 2016 35 3 169 179
10.1080/10550887.2016.1168212 11 Substance Abuse Substance
Abuse DS8IF WOS:000381026000003 27010975 2019-09-25
J Klanecky, AK; McChargue, DE; Tuliao, AP Klanecky, Alicia
K.; McChargue, Dennis E.; Tuliao, Antover P. Proposed pathways to
problematic drinking via post-traumatic stress disorder symptoms, emotion
dysregulation, and dissociative tendencies following child/adolescent sexual abuse
JOURNAL OF ADDICTIVE DISEASES English Article
Problematic drinking; college; child; adolescent sexual abuse;
PTSD; vulnerability COVARIANCE STRUCTURE-ANALYSIS; ALCOHOL-RELATED PROBLEMS;
COLLEGE-STUDENT SAMPLE; CHILDHOOD ABUSE; PSYCHOMETRIC PROPERTIES; REGULATION
DIFFICULTIES; CHEMICAL-DISSOCIATION; IDENTIFICATION TEST; TRAUMA EXPOSURE;
SUBSTANCE USE The relationship between early sexual abuse and college problem
drinking was examined using an integration of the self-medication and
vulnerability-stress models. Baseline survey data from parti-cipants (N = 213; 135
men and 78 college women) completing a mandated, brief alcohol intervention were
utilized. Representative of the self-medication model, post-traumatic stress
disorder symptoms mediated the early sexual abuse/problem drinking relationship.
Two psychological vulnerability factorsemotion dysregulation and dissociative
tendencieswere incorporated into self-medication findings via more advanced
mediational models. Results highlighted that problem drinking increased as
dissociative tendencies increased, and relations between the vulnerability factors
and post-traumatic stress disorder symptoms were in an unexpected direction.
[Klanecky, Alicia K.] Creighton Univ, Dept Psychol, 2500 Calif Plaza, Omaha,
NE 68178 USA; [McChargue, Dennis E.; Tuliao, Antover P.] Univ Nebraska, Dept
Psychol, Lincoln, NE 68588 USA Klanecky, AK (reprint author), Creighton Univ,
Dept Psychol, 2500 Calif Plaza, Omaha, NE 68178 USA. aliciaklanecky@creighton.edu
Tuliao, Antover/0000-0002-6906-8586 Aberson CL, 2010, APPL POWER
ANAL BEHA; Adkins JW, 2008, J ANXIETY DISORD, V22, P1393, DOI
10.1016/j.janxdis.2008.02.002; Axelrod SR, 2011, AM J DRUG ALCOHOL AB, V37, P37,
DOI 10.3109/00952990.2010.535582; Borsari B, 2008, J COLL STUD PSYCHOTH, V22, P61,
DOI 10.1080/87568220801960720; Bremner JD, 2007, J NERV MENT DIS, V195, P211, DOI
10.1097/01.nmd.0000243824.84651.6c; Brown L, 1999, AUST NZ J PSYCHIAT, V33, P521,
DOI 10.1080/j.1440-1614.1999.00589.x; Burns EE, 2012, CHILD ABUSE NEGLECT, V36,
P32, DOI 10.1016/j.chiabu.2011.08.005; Calkins SD, 2007, HDB EMOTION REGULATI,
P229; Carey KB, 2012, CLIN PSYCHOL REV, V32, P690, DOI 10.1016/j.cpr.2012.08.001;
Carey KB, 2009, J CONSULT CLIN PSYCH, V77, P74, DOI 10.1037/a0014281; Carlson E.B.,
1993, DISSOCIATION, V6, P16, DOI DOI 10.1016/J.YEBEH.2014.12.018; Cloitre M, 2013,
EUR J PSYCHOTRAUMATO, V4, DOI 10.3402/ejpt.v4i0.20706; Ehring T, 2010, BEHAV THER,
V41, P587, DOI 10.1016/j.beth.2010.04.004; Ford JD, 2008, ADDICT RES THEORY, V16,
P193, DOI 10.1080/16066350701615078; Ford JD, 2006, J INTERPERS VIOLENCE, V21,
P1399, DOI 10.1177/0886260506292992; Geisner IM, 2007, ADDICT BEHAV, V32, P2776,
DOI 10.1016/j.addbeh.2007.04.014; Ginzburg Karni, 2006, J Trauma Dissociation, V7,
P7, DOI 10.1300/J229v07n02_02; Goldstein AL, 2010, ADDICT BEHAV, V35, P636, DOI
10.1016/j.addbeh.2010.02.002; Gottfredson NC, 2013, J STUD ALCOHOL DRUGS, V74,
P576, DOI 10.15288/jsad.2013.74.576; Grant K. E., 2005, DEV PSYCHOPATHOL, P3; Grant
KE, 2003, PSYCHOL BULL, V129, P447, DOI 10.1037/0033-2909.129.3.447; Gratz KL,
2004, J PSYCHOPATHOL BEHAV, V26, P41, DOI 10.1023/B:JOBA.0000007455.08539.94;
Griffin MG, 1997, AM J PSYCHIAT, V154, P1081; Harrison PA, 1997, CHILD ABUSE
NEGLECT, V21, P529, DOI 10.1016/S0145-2134(97)00013-6; Hruska B, 2012, PSYCHOL
ADDICT BEHAV, V26, P734, DOI 10.1037/a0027584; Hu LT, 1999, STRUCT EQU MODELING,
V6, P1, DOI 10.1080/10705519909540118; Ingram R. E., 2005, DEV PSYCHOPATHOL, P32,
DOI DOI 10.4135/9781452231655.N2; Irwin HJ, 1999, J PSYCHOL, V133, P157, DOI
10.1080/00223989909599730; JOHNSTON LD, 2006, NIH PUBLICATION, V2; Kessler BL,
1999, J COUNS PSYCHOL, V46, P335, DOI 10.1037/0022-0167.46.3.335; Khantzian E. J.,
2003, PRIMARY PSYCHIAT, V10, p[47, 53]; Klanecky AK, 2008, AM J DRUG ALCOHOL AB,
V34, P277, DOI 10.1080/00952990802013441; Klanecky AK, 2015, AM J DRUG ALCOHOL AB,
V41, P188, DOI 10.3109/00952990.2014.998365; Luterek JA, 2005, J TRAUMA STRESS,
V18, P237, DOI 10.1002/jts.20027; Luterek JA, 2011, J TRAUMA DISSOCIATIO, V12,
P261, DOI 10.1080/15299732.2011.551504; Marx BP, 2005, REV GEN PSYCHOL, V9, P67,
DOI 10.1037/1089-2680.9.1.67; Marx BP, 2003, ADDICT BEHAV, V28, P1631, DOI
10.1016/j.addbeh.2003.08.039; Messman-Moore TL, 2014, AM J HEALTH BEHAV, V38, P553,
DOI 10.5993/AJHB.38.4.8; Messman-Moore TL, 2010, CHILD ABUSE NEGLECT, V34, P967,
DOI 10.1016/j.chiabu.2010.06.004; Messman-Moore TL, 2009, J INTERPERS VIOLENCE,
V24, P499, DOI 10.1177/0886260508317199; Miron LR, 2014, SELF IDENTITY, V13, P364,
DOI 10.1080/15298868.2013.836131; Moncrieff J, 1998, ALCOHOL ALCOHOLISM, V33, P592,
DOI 10.1093/alcalc/33.6.592; Muthen L. K., 2010, MPLUS USERS GUIDE; Najavits L. M,
2002, SEEKING SAFETY TREAT; Najdowski CJ, 2009, ADDICT BEHAV, V34, P965, DOI
10.1016/j.addbeh.2009.05.004; Paolucci EO, 2001, J PSYCHOL, V135, P17, DOI
10.1080/00223980109603677; POLUSNY MA, 1995, APPL PREV PSYCHOL, V4, P143, DOI
10.1016/S0962-1849(05)80055-1; Preacher KJ, 2004, BEHAV RES METH INS C, V36, P717,
DOI 10.3758/BF03206553; Preacher KJ, 2008, BEHAV RES METHODS, V40, P879, DOI
10.3758/BRM.40.3.879; Reinert DF, 2007, ALCOHOL CLIN EXP RES, V31, P185, DOI
10.1111/j.1530-0277.2006.00295.x; Rodriguez-Srednicki O, 2001, J Child Sex Abus,
V10, P75, DOI 10.1300/J070v10n03_05; ROESLER TA, 1993, J SUBST ABUSE TREAT, V10,
P537, DOI 10.1016/0740-5472(93)90057-9; Roth S, 1997, J TRAUMA STRESS, V10, P539,
DOI 10.1023/A:1024837617768; Sartor CE, 2008, J STUD ALCOHOL DRUGS, V69, P718, DOI
10.15288/jsad.2008.69.718; Satorra A., 2000, INNOVATIONS MULTIVAR, P233; SAUNDERS
JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Sheese Brad
E, 2009, Cogn Neuropsychiatry, V14, P332, DOI 10.1080/13546800902844064; Shipman K,
2000, DEV PSYCHOPATHOL, V12, P47, DOI 10.1017/S0954579400001036; Smith JP, 2007,
ADDICT BEHAV, V32, P2281, DOI 10.1016/j.addbeh.2007.01.019; Somer E, 2003, ADDICT
RES THEORY, V11, P339, DOI 10.1080/1606635031000141102; Streiner DL, 2003, J PERS
ASSESS, V80, P217, DOI 10.1207/S15327752JPA8003_01; Tabachnick B. G., 2001, USING
MULTIVARIATE S; Tull MT, 2007, BEHAV THER, V38, P303, DOI
10.1016/j.beth.2006.10.001; Ullman SE, 2005, CHILD ABUSE NEGLECT, V29, P767, DOI
10.1016/j.chiabu.2005.01.005; Walters ST, 2009, J CONSULT CLIN PSYCH, V77, P64, DOI
10.1037/a0014472; Widom CS, 1997, PSYCHOL ASSESSMENT, V9, P34, DOI 10.1037/1040-
3590.9.1.34; Yuan KH, 2005, SOCIOL METHOD RES, V34, P240, DOI
10.1177/0049124105280200; Zlotnick C, 2006, J TRAUMA STRESS, V19, P949, DOI
10.1002/jts.20177 68 1 1 0 8 ROUTLEDGE JOURNALS, TAYLOR &
FRANCIS LTD ABINGDON 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON,
ENGLAND 1055-0887 1545-0848 J ADDICT DIS J. Addict. Dis.
2016 35 3 180 193
10.1080/10550887.2016.1139428 14 Substance Abuse Substance
Abuse DS8IF WOS:000381026000004 26756960 2019-09-25
J Eiroa-Orosa, FJ; Giannoni-Pastor, A; Fidel-Kinori, SG; Arguello, JM
Eiroa-Orosa, Francisco Jose; Giannoni-Pastor, Anna; Guila Fidel-Kinori,
Sara; Maria Arguello, Jose Substance use and misuse in burn
patients: Testing the classical hypotheses of the interaction between post-
traumatic symptomatology and substance use JOURNAL OF ADDICTIVE DISEASES
English Article Burn patients; substance
use; substance misuse; trauma; coping strategies; self-medication STRESS-
DISORDER; NATIONAL SAMPLE; CAUSAL PATHWAYS; NEGATIVE AFFECT; PTSD SYMPTOMS; INJURY;
ADOLESCENTS; DEPRESSION; VALIDITY; EPIDEMIOLOGY The authors aimed to test whether
the three classical hypotheses of the interaction between post-traumatic
symptomatology and substance use (high risk of trauma exposure, susceptibility for
post-traumatic symptomatology, and self-medication of symptoms), may be useful in
the understanding of substance use among burn patients. Substance use data
(nicotine, alcohol, cannabis, amphetamines, cocaine, opiates, and tranquilizers)
and psychopathology measures among burn patients admitted to a burn unit and
enrolled in a longitudinal observational study were analyzed. Lifetime substance
use information (n = 246) was incorporated to analyses aiming to test the high risk
hypothesis. Only patients assessed for psychopathology in a 6-month follow-up (n =
183) were included in prospective analyses testing the susceptibility and self-
medication hypotheses. Regarding the high risk hypothesis, results show a higher
proportion of heroin and tranquilizer users compared to the general population.
Furthermore, in line with the susceptibility hypothesis, higher levels of
symptomatology were found in lifetime alcohol, tobacco, and drug users during
recovery. The self-medication hypothesis could be tested partially due to the
hospital stay cleaning effect, but severity of symptoms was linked to the amount of
caffeine, nicotine, alcohol, and cannabis use after discharge. It was found that
the 3 classical hypotheses could be used to understand the link between traumatic
experiences and substance use explaining different patterns of burn patient's risk
for trauma exposure and emergence of symptomatology. [Eiroa-Orosa, Francisco Jose]
Univ East London, Sch Psychol, Water Lane, London E15 4LZ, England; [Giannoni-
Pastor, Anna; Guila Fidel-Kinori, Sara; Maria Arguello, Jose] Univ Autonoma
Barcelona, Hosp Univ Vall dHebron, Dept Psychiat, CIBERSAM, Barcelona, Catalonia,
Spain; [Giannoni-Pastor, Anna] Univ Autonoma Barcelona, Vall dHebron Res Inst VHIR,
Barcelona, Catalonia, Spain; [Maria Arguello, Jose] Univ Autonoma Barcelona, Dept
Psychiat & Legal Med, Barcelona, Catalonia, Spain Eiroa-Orosa, FJ (reprint
author), Univ East London, Sch Psychol, Water Lane, London E15 4LZ, England.
f.eiroa-orosa@uel.ac.uk Eiroa-Orosa, Francisco Jose Eiroa-Orosa; Francisco
Jose/D-2510-2012 Eiroa-Orosa, Francisco Jose Eiroa-Orosa; Francisco Jose/0000-
0002-4163-6545 Research Institute of the University Hospital Vall d'Hebron
(VHIR) in Barcelona; Department of Health, Government of Catalonia,
SpainGeneralitat de Catalunya This work was supported by the Research Institute of
the University Hospital Vall d'Hebron (VHIR) in Barcelona and with a grant of the
Department of Health, Government of Catalonia, Spain. [Anonymous], 2007, 200708
EDADES, P1; Beck AT, 1996, J PERS ASSESS, V67, P588, DOI
10.1207/s15327752jpa6703_13; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561; Brezel B
S, 1988, J Burn Care Rehabil, V9, P169, DOI 10.1097/00004630-198803000-00009; BROWN
PJ, 1994, DRUG ALCOHOL DEPEN, V35, P51, DOI 10.1016/0376-8716(94)90110-4; CARVER
CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; Chilcoat
HD, 2003, TRAUMA AND SUBSTANCE ABUSE: CAUSES, CONSEQUENCES, AND TREATMENT OF
COMORBID DISORDERS, P9, DOI 10.1037/10460-001; Chilcoat HD, 1998, ARCH GEN
PSYCHIAT, V55, P913, DOI 10.1001/archpsyc.55.10.913; Chilcoat HD, 1998, ADDICT
BEHAV, V23, P827, DOI 10.1016/S0306-4603(98)00069-0; Cisler JM, 2011, J ANXIETY
DISORD, V25, P978, DOI 10.1016/j.janxdis.2011.06.006; Cisler JM, 2011, ADDICT
BEHAV, V36, P994, DOI 10.1016/j.addbeh.2011.05.014; Crawford JR, 2004, BRIT J CLIN
PSYCHOL, V43, P245, DOI 10.1348/0144665031752934; Davidson JRT, 1997, PSYCHOL MED,
V27, P153, DOI 10.1017/S0033291796004229; Dyster-Aas J, 2008, J TRAUMA, V64, P1349,
DOI 10.1097/TA.0b013e318047e005; Ehlers CL, 2013, J PSYCHIATR RES, V47, P155, DOI
10.1016/j.jpsychires.2012.10.002; Falder S, 2009, BURNS, V35, P618, DOI
10.1016/j.burns.2008.09.002; Fauerbach JA, 2001, J BURN CARE REHABIL, V22, P26, DOI
10.1097/00004630-200101000-00007; Fauerbach JA, 1997, PSYCHOSOMATICS, V38, P374,
DOI 10.1016/S0033-3182(97)71445-2; Fauerbach JA, 1999, J BEHAV MED, V22, P359, DOI
10.1023/A:1018726103302; Ferrando L, 1998, MINI INT NEUROPSYCHA; Ford JD, 2010, J
ADOLESCENT HEALTH, V46, P545, DOI 10.1016/j.jadohealth.2009.11.212; Keinan-Boker L,
2011, J PUBLIC HEALTH-UK, V33, P55, DOI 10.1093/pubmed/fdq099; KELLEY D, 1992,
Journal of Burn Care and Rehabilitation, V13, P218, DOI 10.1097/00004630-199203000-
00008; Lawrence JW, 2003, J BURN CARE REHABIL, V24, P63, DOI
10.1097/01.BCR.0000045663.57246.ED; Lecrubier Y, 1997, EUR PSYCHIAT, V12, P224, DOI
10.1016/S0924-9338(97)83296-8; Lu MK, 2007, BURNS, V33, P649, DOI
10.1016/j.burns.2006.09.004; MACARTHUR JD, 1975, JAMA-J AM MED ASSOC, V231, P259,
DOI 10.1001/jama.231.3.259; McKibben JBA, 2009, INT REV PSYCHIATR, V21, P512, DOI
10.3109/09540260903343794; Meyer WJ, 2007, PSYCHOSOM MED, V69, P377, DOI
10.1097/PSY.0b013e3180600a2e; Norman SB, 2012, NEUROPHARMACOLOGY, V62, P542, DOI
10.1016/j.neuropharm.2011.04.032; Palmu R, 2011, BURNS, V37, P601, DOI
10.1016/j.burns.2010.06.007; Palmu R, 2010, BURNS, V36, P1072, DOI
10.1016/j.burns.2010.04.004; Patterson DR, 2000, J BURN CARE REHABIL, V21, P490,
DOI 10.1067/mbc.2000.107641; Sartor CE, 2011, PSYCHOL MED, V41, P1497, DOI
10.1017/S0033291710002072; Sheehan DV, 1997, EUR PSYCHIAT, V12, P232, DOI
10.1016/S0924-9338(97)83297-X; Simpson TL, 2012, PSYCHOL ADDICT BEHAV, V26, P724,
DOI 10.1037/a0027169; Spanish Ministry of Health and Spanish National Plan on
Drugs, 2007, DRINK GUID; Spielberger C. D., 1983, MANUAL STATE TRAIT A; Stewart SH,
1998, ADDICT BEHAV, V23, P797, DOI 10.1016/S0306-4603(98)00070-7; Sveen J, 2010, J
BURN CARE RES, V31, P310, DOI 10.1097/BCR.0b013e3181d0f523; vanderDoes AJW, 1997, J
PSYCHOSOM RES, V43, P431, DOI 10.1016/S0022-3999(97)00173-6; VILLAGOMEZ RE, 1995, J
SUBST ABUSE TREAT, V12, P253, DOI 10.1016/0740-5472(95)00025-Z; WATSON D, 1988, J
PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; Weiss DS, 1997,
ASSESSING PSYCHOL TR, P399, DOI DOI 10.1037/T12199-000; WHO, 2011, GLOB STAT REP
ALC HL; World Medical Association declaration of Helsinki, 1997, JAMA-J AM MED
ASSOC, V277, P925, DOI DOI 10.1001/JAMA.1997.0354035007503846 2 2 0
1 ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD ABINGDON 2-4 PARK SQUARE,
MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND 1055-0887 1545-0848 J
ADDICT DIS J. Addict. Dis. 2016 35 3 194
204 10.1080/10550887.2015.1127717 11 Substance Abuse
Substance Abuse DS8IF WOS:000381026000005 26670348 Green Accepted
2019-09-25
J Tuliao, AP; Jaffe, AE; McChargue, DE Tuliao, Antover
P.; Jaffe, Anna E.; McChargue, Dennis E. Alcohol Expectancies,
Posttraumatic Stress Disorder, and Alcohol Use in College Students With a History
of Childhood Trauma JOURNAL OF DUAL DIAGNOSIS English
Article Alcohol abuse; alcohol outcome
expectancy; posttraumatic stress; gender differences; self-medication hypothesis
SELF-MEDICATION HYPOTHESIS; SUBSTANCE USE DISORDERS; SEXUAL-ABUSE;
PSYCHOMETRIC PROPERTIES; PARTNER VIOLENCE; PROBLEM DRINKING; WOMEN VETERANS;
PHYSICAL ABUSE; DRUG-USE; PTSD Objective: Prior research has emphasized that
the key mediator in the posttraumatic stress disorder (PTSD) symptom-alcohol use
relationship is the expectancy of alcohol's tension-reducing properties. This study
extends the literature by examining various alcohol outcome expectancies. Methods:
Cross-sectional data were obtained from 198 college students who reported
experiencing at least one traumatic event in childhood. Participants answered
surveys measuring PTSD symptoms, alcohol outcome expectancies, and three measures
of alcohol consumption and related problems. Results: Participants included 131
males (mean age = 19.65years, SD = 1.06, range = 18 to 24) and 67 females (mean age
= 19.43years, SD = 0.82, range = 18 to 23), who were predominantly European-
American (82%). For males and females, results of the multivariate analyses
suggested that self-perception expectancies mediated the effects of PTSD symptoms
on alcohol use severity, whereas sociability expectancies mediated the effects of
PTSD symptoms on monthly alcohol use. For women, risk and aggression and sexuality
expectancies mediated the relationship between PTSD symptoms and alcohol use
severity, while risk and aggression expectancies mediated the relationship between
PTSD symptoms and alcohol use consequences. For men, sociability expectancies
mediated the effects of PTSD symptoms on alcohol use severity. Across genders,
tension-reduction expectancies did not mediate the relationship between PTSD
symptom and the three alcohol measures. Conclusions: This study was unable to find
support for the self-medication hypothesis via the tension-reduction outcome
expectancy pathway. However, other significant findings can be interpreted in light
of the self-medication hypothesis. For example, alcohol may aid in coping with
social impairments related to PTSD symptoms, particularly in a college sample. This
study also highlighted gender differences in the association between PTSD symptoms
and alcohol consumption and related problems. [Tuliao, Antover P.; Jaffe, Anna
E.; McChargue, Dennis E.] Univ Nebraska, Lincoln, NE 68588 USA McChargue, DE
(reprint author), Univ Nebraska, Dept Psychol, 238 Burnett Hall,1220 T St, Lincoln,
NE 68588 USA. dmcchargue2@unl.edu Tuliao, Antover/0000-0002-6906-
8586; Jaffe, Anna/0000-0001-8679-7564 American Psychiatric
Association, 2000, DIAGN STAT MAN MENT; Babor T. F., 2001, ALCOHOL USE DISORDER;
Bedard-Gilligan M, 2011, ADDICT BEHAV, V36, P1076, DOI
10.1016/j.addbeh.2011.07.001; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI
10.1016/0005-7967(96)00033-2; Borsari B, 2008, J COLL STUD PSYCHOTH, V22, P61, DOI
10.1080/87568220801960720; Bradford K, 2012, CLIN GASTROENTEROL H, V10, P385, DOI
10.1016/j.cgh.2011.12.018; Bremner JD, 2007, J NERV MENT DIS, V195, P211, DOI
10.1097/01.nmd.0000243824.84651.6c; Bremner JD, 2000, DEPRESS ANXIETY, V12, P1, DOI
10.1002/1520-6394(2000)12:1<1::AID-DA1>3.0.CO;2-W; Bushman BJ, 2001, J PERS SOC
PSYCHOL, V81, P17, DOI 10.1037/0022-3514.81.1.17; Butterfield MI, 2000, J TRAUMA
STRESS, V13, P735, DOI 10.1023/A:1007874620024; Caetano R, 2003, J INTERPERS
VIOLENCE, V18, P240, DOI 10.1177/0886260502250074; CARROLL EM, 1985, J ABNORM
PSYCHOL, V94, P329, DOI 10.1037/0021-843X.94.3.329; Chilcoat HD, 1998, ADDICT
BEHAV, V23, P827, DOI 10.1016/S0306-4603(98)00069-0; COLLINS RL, 1985, J CONSULT
CLIN PSYCH, V53, P189, DOI 10.1037/0022-006X.53.2.189; Corbin WR, 2001, J INTERPERS
VIOLENCE, V16, P297, DOI 10.1177/088626001016004002; Coxe S, 2009, J PERS ASSESS,
V91, P121, DOI 10.1080/00223890802634175; Creech SK, 2014, ADDICT BEHAV, V39, P379,
DOI 10.1016/j.addbeh.2013.02.006; Debell F, 2014, SOC PSYCH PSYCH EPID, V49, P1401,
DOI 10.1007/s00127-014-0855-7; DiLillo D, 2001, CLIN PSYCHOL REV, V21, P553, DOI
10.1016/S0272-7358(99)00072-0; Dube SR, 2002, ADDICT BEHAV, V27, P713, DOI
10.1016/S0306-4603(01)00204-0; Dvorak RD, 2013, J DUAL DIAGN, V9, P281, DOI
10.1080/15504263.2013.835694; Earleywine M, 2008, ADDICT BEHAV, V33, P1249, DOI
10.1016/j.addbeh.2008.05.006; Elwood LS, 2009, CLIN PSYCHOL REV, V29, P87, DOI
10.1016/j.cpr.2008.10.002; Felitti VJ, 1998, AM J PREV MED, V14, P245, DOI
10.1016/S0749-3797(98)00017-8; Filipas HH, 2006, J INTERPERS VIOLENCE, V21, P652,
DOI 10.1177/0886260506286879; Fossos N, 2011, ADDICT BEHAV, V36, P1001, DOI
10.1016/j.addbeh.2011.06.001; Fromme K., 1993, PSYCHOL ASSESSMENT, V5, P19, DOI DOI
10.1037/1040-3590.5.1.19; Goldstein AL, 2010, ADDICT BEHAV, V35, P636, DOI
10.1016/j.addbeh.2010.02.002; Grayson CE, 2005, J TRAUMA STRESS, V18, P137, DOI
10.1002/jts.20021; Hruska B, 2012, PSYCHOL ADDICT BEHAV, V26, P734, DOI
10.1037/a0027584; Jones BT, 2001, ADDICTION, V96, P57, DOI 10.1046/j.1360-
0443.2001.961575.x; Kaysen D, 2007, ADDICT BEHAV, V32, P1272, DOI
10.1016/j.addbeh.2006.09.007; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI
10.1001/archpsyc.1995.03950240066012; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62,
P593, DOI 10.1001/archpsyc.62.6.593; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4,
P231, DOI 10.3109/10673229709030550; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142,
P1259; Lehavot K, 2014, PSYCHOL ADDICT BEHAV, V28, P42, DOI 10.1037/a0032266;
Lembke A, 2012, AM J DRUG ALCOHOL AB, V38, P524, DOI 10.3109/00952990.2012.694532;
Marx BP, 2003, ADDICT BEHAV, V28, P1631, DOI 10.1016/j.addbeh.2003.08.039; Marx BP,
2000, J APPL SOC PSYCHOL, V30, P1056, DOI 10.1111/j.1559-1816.2000.tb02510.x;
Maxwell SE, 2007, PSYCHOL METHODS, V12, P23, DOI 10.1037/1082-989X.12.1.23;
McFarlane AC, 1998, ADDICT BEHAV, V23, P813, DOI 10.1016/S0306-4603(98)00098-7;
McNair D. M., 1971, MANUAL PROFILE MOOD; Messman TL, 1996, CLIN PSYCHOL REV, V16,
P397, DOI 10.1016/0272-7358(96)00019-0; Monk RL, 2013, SUBST USE MISUSE, V48, P539,
DOI 10.3109/10826084.2013.787097; Monks SM, 2010, SUBST USE MISUSE, V45, P2258, DOI
10.3109/10826081003694854; Muthen L. K., 1998, MPLUS USERS GUIDE; Olff M, 2007,
PSYCHOL BULL, V133, P183, DOI 10.1037/0033-2909.133.2.183; Pedersen ER, 2014, J
PSYCHOACTIVE DRUGS, V46, P178, DOI 10.1080/02791072.2014.917750; Peters EN, 2012, J
INTERPERS VIOLENCE, V27, P2108, DOI 10.1177/0886260511432151; Roberts AL, 2011,
PSYCHOL MED, V41, P71, DOI 10.1017/S0033291710000401; Satorra A, 2000, ADV ST THEO,
V36, P233; SAUNDERS JB, 1993, ADDICTION, V88, P349, DOI 10.1111/j.1360-
0443.1993.tb00822.x; Shneyderman Y, 2013, HEALTH EDUC BEHAV, V40, P400, DOI
10.1177/1090198112447800; Simpson TL, 2002, CLIN PSYCHOL REV, V22, P27, DOI
10.1016/S0272-7358(00)00088-X; Slutske WS, 2005, ARCH GEN PSYCHIAT, V62, P321, DOI
10.1001/archpsyc.62.3.321; Stewart SH, 1998, ADDICT BEHAV, V23, P797, DOI
10.1016/S0306-4603(98)00070-7; Stewart SH, 1996, PSYCHOL BULL, V120, P83, DOI
10.1037/0033-2909.120.1.83; Tabachnick B. G., 2007, USING MULTIVARIATE S; Tofighi
D, 2011, BEHAV RES METHODS, V43, P692, DOI 10.3758/s13428-011-0076-x; Ullman SE,
2005, J STUD ALCOHOL, V66, P610, DOI 10.15288/jsa.2005.66.610; VRANA S, 1994, J
TRAUMA STRESS, V7, P289, DOI 10.1002/jts.2490070209; Weathers F., 1993, ANN CONV
INT SOC TRA; WHITE HR, 1989, J STUD ALCOHOL, V50, P30, DOI 10.15288/jsa.1989.50.30;
Whitfield CL, 2003, J INTERPERS VIOLENCE, V18, P166, DOI 10.1177/0886260502238733;
Widom CS, 1999, AM J PSYCHIAT, V156, P1223; Zamboanga BL, 2009, J PRIM PREV, V30,
P315, DOI 10.1007/s10935-009-0182-z; Zamboanga BL, 2010, COGNITIVE THER RES, V34,
P124, DOI 10.1007/s10608-009-9234-1 68 7 7 1 9 ROUTLEDGE
JOURNALS, TAYLOR & FRANCIS LTD ABINGDON 2-4 PARK SQUARE, MILTON PARK,
ABINGDON OX14 4RN, OXON, ENGLAND 1550-4263 1550-4271 J DUAL DIAGN
J. Dual Diagn. 2016 12 1 4 14
10.1080/15504263.2016.1146382 11 Psychology, Clinical;
Substance Abuse; Psychiatry Psychology; Substance Abuse; Psychiatry DK0BU
WOS:000374578200002 26829064 2019-09-25
J Clarke, T; Tickle, A; Gillott, A Clarke, Thomas; Tickle,
Anna; Gillott, Alinda Substance use disorder in Asperger syndrome: An
investigation into the development and maintenance of substance use disorder by
individuals with a diagnosis of Asperger syndrome INTERNATIONAL JOURNAL OF DRUG
POLICY English Article
Asperger syndrome; Autism; Autistic spectrum disorder; Drug; Alcohol;
Substances SELF-MEDICATION HYPOTHESIS; AUTISM SPECTRUM DISORDERS; ATTENTION-
DEFICIT/HYPERACTIVITY DISORDER; HIGH-FUNCTIONING CHILDREN; MENTAL-HEALTH PROBLEMS;
ALCOHOL EXPECTANCIES; ADULTS; ABUSE; COMORBIDITY; REWARD Background: Recent
research has suggested that the prevalence of problematic substance use within the
Asperger syndrome population has previously been underestimated. Furthermore, there
is some indication that problematic substance use might take place to manage the
traits of Asperger syndrome; however this possibility has yet to be examined in
detail. This study aimed to address this omission by exploring individuals'
perceptions of their substance use in relation to their diagnosis of Asperger
syndrome. Methods: Eight participants were recruited from either a specialist
Asperger syndrome service or a drug and alcohol service. Participants were
interviewed regarding their views of which factors led to their development and
maintenance of problematic substance use, specifically in relation to their
experience of having been diagnosed with Asperger syndrome. Thematic analysis was
conducted on the interview transcripts. Results: Six main themes were identified:
self-medication; social facilitation; discrepancy between need and support;
defining problematic substance use; substance use of peers, and recreational use of
substances. The two themes of social facilitation and self-medication are focused
on within this paper as they most closely reflect the more prominent bodies of
literature in relation to the research aim. Conclusions: Participants reported that
substances were used to act as a social facilitator to compensate for social
deficits by increasing confidence in social settings and increasing participants'
ease with which they communicate. The self-medication of psychological distress was
reported and was associated with depression, anxiety and sleep difficulties. The
study ends with a reflection on the method of data collection, the implications for
clinical practice and suggestions for future research. (C) 2015 Elsevier B.V. All
rights reserved. [Clarke, Thomas; Tickle, Anna] Univ Nottingham, Sch Med, Div
Psychiat & Appl Psychol, YANG Fujia Bldg,Jubilee Campus,Wollaton Rd, Nottingham NG8
1BB, England; [Gillott, Alinda] Highbury Hosp, Dept Learning Disabil, Nottingham
City Asperger Serv, Highbury Rd, Nottingham NG6 9DR, England; [Clarke, Thomas]
Diana Princess Wales Hosp, Psychol Consultancy, Hlth Psychol Serv, Scartho Rd,
Grimsby DN33 2BA, Lincs, England Clarke, T (reprint author), Univ Nottingham,
Sch Med, Div Psychiat & Appl Psychol, YANG Fujia Bldg,Jubilee Campus,Wollaton Rd,
Nottingham NG8 1BB, England.; Clarke, T (reprint author), Diana Princess Wales
Hosp, Psychol Consultancy, Hlth Psychol Serv, Scartho Rd, Grimsby DN33 2BA, Lincs,
England. clarke_thomas@hotmail.co.uk University of Nottingham as
part of Thomas Clarke's Doctoral training in Clinical Psychology The authors hereby
state that funding for this research was provided by the University of Nottingham
as part of Thomas Clarke's Doctoral training in Clinical Psychology. The authors
were not funded by any secondary financial sources. American Psychiatric
Association, 1994, DIAGN STAT MAN MENT; Antaki C., 2002, DAOL DISCOURSE ANAL, V1,
P1; Attwood T., 2006, COMPLETE GUIDE ASPER; Babor T. F., 1992, ALCOHOL USE
DISORDER; Baron-Cohen S, 2001, J AUTISM DEV DISORD, V31, P5, DOI
10.1023/A:1005653411471; Baron-Cohen S, 2000, APPL PSYCHOL, P181; Bauminger N,
2000, CHILD DEV, V71, P447, DOI 10.1111/1467-8624.00156; Bauminger N, 2003, J
AUTISM DEV DISORD, V33, P489, DOI 10.1023/A:1025827427901; Bellini S, 2006, FOCUS
AUTISM OTHER D, V21, P138, DOI DOI 10.1177/10883576060210030201; Benford P, 2009, J
ASSIST TECHNOL, V3, P44, DOI 10.1108/17549450200900015; Bhaskar R., 1979,
POSSIBILITY NATURALI; Bhaskar R., 1997, REALIST THEORY SCI; Biederman J, 2004, J
CLIN PSYCHIAT, V65, P3; Blume AW, 2000, COGN BEHAV PRACT, V7, P379, DOI
10.1016/S1077-7229(00)80048-6; Boyatzis R. E., 1998, TRANSFORMING QUALITA; Braun
V., 2006, QUALITATIVE RES PSYC, V3, P77, DOI DOI 10.1191/1478088706QP0630A; BROWN
SA, 1987, J STUD ALCOHOL, V48, P483, DOI 10.15288/jsa.1987.48.483; Brugha TS, 2011,
ARCH GEN PSYCHIAT, V68, P459, DOI 10.1001/archgenpsychiatry.2011.38; Buxbaum JD,
2013, NEUROSCIENCE OF AUTISM SPECTRUM DISORDERS, P215, DOI 10.1016/B978-0-12-
391924-3.00015-6; Carrigan MH, 2003, ADDICT BEHAV, V28, P269, DOI 10.1016/S0306-
4603(01)00235-0; Carter CS, 2007, BEHAV BRAIN RES, V176, P170, DOI
10.1016/j.bbr.2006.08.025; Cheslack-Postava K, 2012, SOC SCI MED, V74, P1667, DOI
10.1016/j.socscimed.2011.06.013; Clark T, 1999, EUR CHILD ADOLES PSY, V8, P50, DOI
10.1007/s007870050083; Damiano CR, 2012, J NEURODEV DISORD, V4, DOI 10.1186/1866-
1955-4-13; Dichter G, 2012, J NEURODEV DISORD, V4, DOI 10.1186/1866-1955-4-20;
Eisenmajer R, 1996, J AM ACAD CHILD PSY, V35, P1523, DOI 10.1097/00004583-
199611000-00022; Fakier N, 2011, J ADOLESCENCE, V34, P717, DOI
10.1016/j.adolescence.2010.09.010; Fereday J., 2006, INT J QUAL METH, V5, P80, DOI
DOI 10.1177/160940690600500107; Gargaro BA, 2011, NEUROSCI BIOBEHAV R, V35, P1081,
DOI 10.1016/j.neubiorev.2010.11.002; Giles DC, 2011, QUAL HEALTH RES, V21, P419,
DOI 10.1177/1049732310381388; Gilles DM, 2006, ADDICT BEHAV, V31, P388, DOI
10.1016/j.addbeh.2005.05.020; Green J, 2004, QUALITATIVE METHODS; Greene RW, 1999,
J CLIN CHILD PSYCHOL, V28, P349, DOI 10.1207/S15374424jccp280307; Guest G, 2006,
FIELD METHOD, V18, P59, DOI 10.1177/1525822X05279903; Ham LS, 2009, COGNITIVE THER
RES, V33, P615, DOI 10.1007/s10608-009-9248-8; Harris KM, 2005, HEALTH SERV RES,
V40, P117, DOI 10.1111/j.1475-6773.2005.00345.x; Hasler BP, 2012, SLEEP MED REV,
V16, P67, DOI 10.1016/j.smrv.2011.03.004; Holt N. L, 2005, RES METHODS SOCIAL S,
P49; Howlin P, 1999, DEV MED CHILD NEUROL, V41, P834, DOI
10.1017/S0012162299001656; Kalbag AS, 2005, SUBST USE MISUSE, V40, P1955, DOI
10.1080/10826080500294858; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI
10.3109/10673229709030550; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259; Kohls G,
2009, DEVELOPMENTAL SCI, V12, P614, DOI 10.1111/j.1467-7687.2009.00816.x; KUMPFER
KL, 1990, INT J ADDICT, V25, P435, DOI 10.3109/10826089009105124; Larson MJ, 2011,
PSYCHIAT RES, V187, P198, DOI 10.1016/j.psychres.2010.11.006; Lewis BA, 2000,
ADDICT BEHAV, V25, P295, DOI 10.1016/S0306-4603(99)00063-5; Lindner JL, 2006, J
AUTISM DEV DISORD, V36, P769, DOI 10.1007/s10803-006-0105-2; Lugnegard T, 2011, RES
DEV DISABIL, V32, P1910, DOI 10.1016/j.ridd.2011.03.025; Lundstrom S, 2011, PSYCHOL
MED, V41, P2423, DOI 10.1017/S0033291711000377; Mackintosh MA, 2006, ADDICT BEHAV,
V31, P1536, DOI 10.1016/j.addbeh.2005.11.009; Mayes SD, 2012, RES AUTISM SPECT DIS,
V6, P277, DOI 10.1016/j.rasd.2011.05.009; McCann BS, 2000, AM J ADDICTION, V9, P1;
Michaelson S., 1998, PSYCHIAT B, V22, P581; Milton DEM, 2013, MED SOCIOLOGY ONLINE,
V7, P61; Molloy H, 2002, DISABIL SOC, V17, P659, DOI 10.1080/0968759022000010434;
Muller E, 2008, AUTISM, V12, P173, DOI 10.1177/1362361307086664; OEI TPS, 1994, J
STUD ALCOHOL, V55, P525, DOI 10.15288/jsa.1994.55.525; Ohlmeier MD, 2008, ALCOHOL
ALCOHOLISM, V43, P300, DOI 10.1093/alcalc/agn014; RHODES JE, 1990, J CONSULT CLIN
PSYCH, V58, P395, DOI 10.1037/0022-006X.58.4.395; Rivet TT, 2011, RES AUTISM SPECT
DIS, V5, P957, DOI 10.1016/j.rasd.2010.12.003; Santosh PJ, 2006, EUR CHILD ADOLES
PSY, V15, P183, DOI 10.1007/s00787-005-0517-0; Sizoo B, 2010, DRUG ALCOHOL DEPEN,
V107, P44, DOI 10.1016/j.drugalcdep.2009.09.003; Sizoo BB, 2009, J AUTISM DEV
DISORD, V39, P1291, DOI 10.1007/s10803-009-0743-2; SKINNER HA, 1982, ADDICT BEHAV,
V7, P363, DOI 10.1016/0306-4603(82)90005-3; Staines GL, 2001, J ADDICT DIS, V20,
P53; Stewart ME, 2006, AUTISM, V10, P103, DOI 10.1177/1362361306062013; STRAUSS
Anselm, 1967, DISCOVERY GROUNDED T; Swendsen JD, 2000, CLIN PSYCHOL REV, V20, P173,
DOI 10.1016/S0272-7358(99)00026-4; TARTER RE, 1992, ALCOHOL CLIN EXP RES, V16,
P106, DOI 10.1111/j.1530-0277.1992.tb00645.x; Tinsley M., 2008, ASPERGER SYNDROME
AL; Whiteley P, 2010, AUTISM INSIGHTS, V2, P17, DOI DOI 10.4137/AUI.S3938; Wilens
TE, 1997, J NERV MENT DIS, V185, P475, DOI 10.1097/00005053-199708000-00001; Wilens
TE, 2004, PSYCHIAT CLIN N AM, V27, P283, DOI 10.1016/S0193-953X(03)00113-8; Wilens
TE, 2007, AM J ADDICTION, V16, P14, DOI 10.1080/10550490601082742; Wilens TE, 2011,
J AM ACAD CHILD PSY, V50, P141, DOI 10.1016/j.jaac.2010.11.010; Wilkinson L. A.,
2008, TEACHING EXCEPTIONAL, V4, P3; World Health Organisation, 2007, INT STAT CLASS
DIS R; Yardley L., 2008, QUALITATIVE PSYCHOL, P235, DOI DOI
10.1191/1478088706QP063OA 78 1 1 0 15 ELSEVIER AMSTERDAM
RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS 0955-3959 1873-4758
INT J DRUG POLICY Int. J. Drug Policy JAN 2016 27
154 163 10.1016/j.drugpo.2015.06.003 10
Substance Abuse Substance Abuse DC8HH WOS:000369460000020 26187185
2019-09-25
J Belin, D; Belin-Rauscent, A; Everitt, BJ; Dalley, JW Belin,
D.; Belin-Rauscent, A.; Everitt, B. J.; Dalley, J. W. In search of
predictive endophenotypes in addiction: insights from preclinical research GENES
BRAIN AND BEHAVIOR English Review
Alcohol; anxiety; impulsivity; novelty preference; opiates; psychostimulants;
sensation seeking; substance use disorder COCAINE-SEEKING BEHAVIOR; SUBSTANCE-USE
DISORDERS; ELEVATED PLUS-MAZE; REACTION-TIME-TASK; ATTENTION-DEFICIT/HYPERACTIVITY
DISORDER; CONDITIONED PLACE PREFERENCE; SELF-MEDICATION HYPOTHESIS; MEDIAL
PREFRONTAL CORTEX; COMPULSIVE DRUG SEEKING; CONTEXT-INDUCED RELAPSE Drug
addiction is widely recognized to afflict some but not all individuals by virtue of
underlying risk markers and traits involving multifaceted interactions between
polygenic and external factors. Remarkably, only a small proportion of individuals
exposed to licit and illicit drugs develop compulsive drug-seeking behavior,
maintained in the face of adverse consequences and associated detrimental patterns
of drug intake involving extended and repeated bouts of binge intoxication,
withdrawal and relapse. As a consequence, research has increasingly endeavored to
identify distinctive neurobehavioral mechanisms and endophenotypes that predispose
individuals to compulsive drug use. However, research in active drug users is
hampered by the difficulty in categorizing putatively causal behavioral traits
prior to the initiation of drug use. By contrast, research in experimental animals
is often hindered by the validity of approaches used to investigate the neural and
psychological mechanisms of compulsive drug-seeking habits in humans. Herein, we
survey and discuss the principal findings emanating from preclinical animal
research on addiction and highlight how specific behavioral endophenotypes of
presumed genetic origin (e.g. trait anxiety, novelty preference and impulsivity)
differentially contribute to compulsive forms of drug seeking and taking and, in
particular, how these differentiate between different classes of stimulant and non-
stimulant drugs of abuse. [Belin, D.; Belin-Rauscent, A.] Univ Cambridge, Dept
Pharmacol, Cambridge CB2 1QJ, England; [Belin, D.; Belin-Rauscent, A.; Everitt, B.
J.; Dalley, J. W.] Univ Cambridge, Behav & Clin Neurosci Inst, Cambridge CB2 3EB,
England; [Everitt, B. J.; Dalley, J. W.] Univ Cambridge, Dept Psychol, Cambridge
CB2 3EB, England; [Dalley, J. W.] Univ Cambridge, Dept Psychiat, Cambridge CB2 3EB,
England Dalley, JW (reprint author), Univ Cambridge, Dept Psychol, Downing St,
Cambridge CB2 3EB, England. jwd20@cam.ac.uk Belin, David/E-1231-2014 Belin,
David/0000-0002-7383-372X; Dalley, Jeffrey/0000-0002-2282-3660 UK Medical
Research CouncilMedical Research Council UK (MRC) [G9536855, G0701500, G0802729];
Newton-Cambridge Trust; Wellcome TrustWellcome Trust [WT109738MA, 093875/Z/10/Z];
Medical Research CouncilMedical Research Council UK (MRC) [G1000183]; Medical
Research CouncilMedical Research Council UK (MRC) [G0802729, G0001354, G1002231,
G0701500, G1000183B, G0001354B] The authors acknowledge funding support from
the UK Medical Research Council (grants G9536855, G0701500 and G0802729), the
Newton-Cambridge Trust and the Wellcome Trust (grant WT109738MA). The Behavioural
and Clinical Neuroscience Institute at Cambridge University is supported by a core
award from the Medical Research Council (G1000183) and Wellcome Trust
(093875/Z/10/Z). ADAMS CD, 1981, Q J EXP PSYCHOL-B, V33, P109, DOI
10.1080/14640748108400816; Ahmed SH, 2005, PSYCHOPHARMACOLOGY, V180, P473, DOI
10.1007/s00213-005-2180-z; Ahmed SH, 1998, SCIENCE, V282, P298, DOI
10.1126/science.282.5387.298; Ahmed SH, 2000, NEUROPSYCHOPHARMACOL, V22, P413, DOI
10.1016/S0893-133X(99)00133-5; AINSLIE G, 1975, PSYCHOL BULL, V82, P463, DOI
10.1037/h0076860; American Psychiatric Association, 2013, DIAGN STAT MAN MENT;
American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Anker JJ, 2009,
PHARMACOL BIOCHEM BE, V93, P343, DOI 10.1016/j.pbb.2009.05.013; Ansquer S, 2014,
BIOL PSYCHIAT, V75, P825, DOI 10.1016/j.biopsych.2013.09.031; Anthony James C.,
1994, Experimental and Clinical Psychopharmacology, V2, P244, DOI 10.1037/1064-
1297.2.3.244; ANTHONY JC, 1989, AM J EPIDEMIOL, V129, P543, DOI
10.1093/oxfordjournals.aje.a115166; ARNETT J, 1994, PERS INDIV DIFFER, V16, P289,
DOI 10.1016/0191-8869(94)90165-1; Arroyo M, 1998, PSYCHOPHARMACOLOGY, V140, P331,
DOI 10.1007/s002130050774; Atkins AL, 2000, ALCOHOL CLIN EXP RES, V24, P1743, DOI
10.1097/00000374-200012000-00001; Baarendse PJJ, 2014, PSYCHOPHARMACOLOGY, V231,
P1695, DOI 10.1007/s00213-013-3362-8; Ball SA, 1998, J PERS DISORD, V12, P1, DOI
10.1521/pedi.1998.12.1.1; Barkley-Levenson AM, 2015, ALCOHOL, V49, P29, DOI
10.1016/j.alcohol.2014.07.022; Belin D., 2010, DRUG ABUSE ADDICTION; Belin D, 2012,
COLD SPRING HARBOR P, V2, P1, DOI DOI 10.1101/CSHPERSPECTA011940; Belin D, 2008,
SCIENCE, V320, P1352, DOI 10.1126/science.1158136; Belin D, 2008, NEURON, V57,
P432, DOI 10.1016/j.neuron.2007.12.019; Belin D, 2011, NEUROMETHODS, V53, P337, DOI
10.1007/978-1-60761-934-5_13; Belin D, 2011, NEUROPSYCHOPHARMACOL, V36, P569, DOI
10.1038/npp.2010.188; Belin D, 2009, BIOL PSYCHIAT, V65, P863, DOI
10.1016/j.biopsych.2008.05.031; Belin D, 2009, BEHAV BRAIN RES, V199, P89, DOI
10.1016/j.bbr.2008.09.027; Belin-Rauscent A., 2012, ANIMAL MODELS DRUG A; Belin-
Rauscent A., 2015, BIOL PSYCHI IN PRESS; Bello EP, 2011, NAT NEUROSCI, V14, P1033,
DOI 10.1038/nn.2862; Besson M, 2010, NEUROPSYCHOPHARMACOL, V35, P560, DOI
10.1038/npp.2009.162; Bevilacqua L, 2013, PHILOS T R SOC B, V368, DOI
10.1098/rstb.2012.0380; Bevilacqua L, 2010, NATURE, V468, P1061, DOI
10.1038/nature09629; Bianchi M, 2006, EUR J NEUROSCI, V24, P2894, DOI
10.1111/j.1460-9568.2006.05170.x; Bickel WK, 1999, PSYCHOPHARMACOLOGY, V146, P447,
DOI 10.1007/PL00005490; Blakemore SJ, 2012, NAT NEUROSCI, V15, P1184, DOI
10.1038/nn.3177; BLANDER A, 1984, PSYCHOPHARMACOLOGY, V84, P124, DOI
10.1007/BF00432040; Bock R, 2013, NAT NEUROSCI, V16, P632, DOI 10.1038/nn.3369;
Boivin JR, 2015, NEUROPHARMACOLOGY, V97, P404, DOI
10.1016/j.neuropharm.2015.05.036; Bossert JM, 2005, EUR J PHARMACOL, V526, P36, DOI
10.1016/j.ejphar.2005.09.030; Braams BR, 2015, J NEUROSCI, V35, P7226, DOI
10.1523/JNEUROSCI.4764-14.2015; Bragina L, 2012, FRONT CELL NEUROSCI, V5, DOI
10.3389/fncel.2011.00032; Broos N, 2012, PLOS ONE, V7, DOI
10.1371/journal.pone.0036781; Bruchas MR, 2011, NEURON, V71, P498, DOI
10.1016/j.neuron.2011.06.011; Buckholtz JW, 2010, SCIENCE, V329, P532, DOI
10.1126/science.1185778; Bush DEA, 2007, PSYCHOPHARMACOLOGY, V194, P211, DOI
10.1007/s00213-007-0835-7; Capriles N, 2003, PSYCHOPHARMACOLOGY, V168, P66, DOI
10.1007/s00213-002-1283-z; Caprioli D, 2015, ADDICT BIOL, V20, P913, DOI
10.1111/adb.12220; Caprioli D, 2015, J NEUROSCI, V35, P3747, DOI
10.1523/JNEUROSCI.3890-14.2015; Caprioli D, 2014, BIOL PSYCHIAT, V75, P115, DOI
10.1016/j.biopsych.2013.07.013; Carroll ME, 2009, DRUG ALCOHOL DEPEN, V104, pS70,
DOI 10.1016/j.drugalcdep.2008.11.011; Casey BJ, 2010, J AM ACAD CHILD PSY, V49,
P1189, DOI 10.1016/j.jaac.2010.08.017; Caspi A, 2002, SCIENCE, V297, P851, DOI
10.1126/science.1072290; Chao J, 2004, ANNU REV MED, V55, P113, DOI
10.1146/annurev.med.55.091902.103730; Chesworth R, 2013, PLOS ONE, V8, DOI
10.1371/journal.pone.0068371; Clapper R L, 1994, J Subst Abuse, V6, P305, DOI
10.1016/S0899-3289(94)90491-X; CLONINGER CR, 1993, ARCH GEN PSYCHIAT, V50, P975;
Comeau N, 2001, ADDICT BEHAV, V26, P803, DOI 10.1016/S0306-4603(01)00238-6; Conway
KP, 2002, DRUG ALCOHOL DEPEN, V65, P225, DOI 10.1016/S0376-8716(01)00168-5; Corbit
LH, 2012, BIOL PSYCHIAT, V72, P389, DOI 10.1016/j.biopsych.2012.02.024; Covington
HE, 2011, NEURON, V71, P656, DOI 10.1016/j.neuron.2011.06.007; Cunningham JA, 2000,
ADDICT BEHAV, V25, P317, DOI 10.1016/S0306-4603(98)00130-0; Czoty PW, 2010,
PSYCHOPHARMACOLOGY, V208, P585, DOI 10.1007/s00213-009-1756-4; Dalley JW, 2012,
NEUROSCIENCE, V215, P42, DOI 10.1016/j.neuroscience.2012.03.065; Dalley JW, 2007,
SCIENCE, V315, P1267, DOI 10.1126/science.1137073; Dalley JW, 2011, NEURON, V69,
P680, DOI 10.1016/j.neuron.2011.01.020; Dalley JW, 2002, PSYCHOPHARMACOLOGY, V164,
P329, DOI 10.1007/s00213-002-1215-y; David V, 2006, NEUROPHARMACOLOGY, V50, P1030,
DOI 10.1016/j.neuropharm.2006.02.003; de Wit H, 2009, ADDICT BIOL, V14, P22, DOI
10.1111/j.1369-1600.2008.00129.x; Degenhardt L, 2008, PLOS MED, V5, P1053, DOI
10.1371/journal.pmed.0050141; Dellu F, 1996, NEUROPSYCHOBIOLOGY, V34, P136, DOI
10.1159/000119305; Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI
10.1126/science.1099020; DEWIT H, 1983, PSYCHOPHARMACOLOGY, V79, P29, DOI
10.1007/BF00433012; DEWIT H, 1981, PSYCHOPHARMACOLOGY, V75, P134, DOI
10.1007/BF00432175; Dickinson A, 2002, Q J EXP PSYCHOL-B, V55, P331, DOI
10.1080/0272499024400016; Diergaarde L, 2008, BIOL PSYCHIAT, V63, P301, DOI
10.1016/j.biopsych.2007.07.011; Diergaarde L, 2009, BEHAV NEUROSCI, V123, P794, DOI
10.1037/a0016504; Dilleen R, 2012, PSYCHOPHARMACOLOGY, V222, P89, DOI
10.1007/s00213-011-2626-4; Ducret E, 2016, BIOL PSYCHIAT, V80, P226, DOI
10.1016/j.biopsych.2015.09.019; Eagle DM, 2008, CEREB CORTEX, V18, P178, DOI
10.1093/cercor/bhm044; Economidou D, 2009, BIOL PSYCHIAT, V65, P851, DOI
10.1016/j.biopsych.2008.12.008; Enoch MA, 2006, ANN NY ACAD SCI, V1094, P193, DOI
10.1196/annals.1376.019; Ersche KD, 2013, CURR OPIN NEUROBIOL, V23, P615, DOI
10.1016/j.conb.2013.02.017; Ersche KD, 2012, SCIENCE, V335, P601, DOI
10.1126/science.1214463; Ersche KD, 2010, BIOL PSYCHIAT, V68, P770, DOI
10.1016/j.biopsych.2010.06.015; Evenden JL, 1999, PSYCHOPHARMACOLOGY, V146, P348,
DOI 10.1007/PL00005481; Everitt BJ, 2016, ANNU REV PSYCHOL, V67, P23, DOI
10.1146/annurev-psych-122414-033457; Everitt BJ, 2014, EUR J NEUROSCI, V40, P2163,
DOI 10.1111/ejn.12644; Everitt BJ, 2000, PSYCHOPHARMACOLOGY, V153, P17, DOI
10.1007/s002130000566;
Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579; Faraone Stephen V,
2005, J Atten Disord, V9, P384, DOI 10.1177/1087054705281478; Faraone SV, 2000,
BIOL PSYCHIAT, V48, P9, DOI 10.1016/S0006-3223(00)00889-1; Flagel SB, 2007,
PSYCHOPHARMACOLOGY, V191, P599, DOI 10.1007/s00213-006-0535-8; Flagel SB, 2009,
NEUROPHARMACOLOGY, V56, P139, DOI 10.1016/j.neuropharm.2008.06.027; Fone KCF, 2008,
NEUROSCI BIOBEHAV R, V32, P1087, DOI 10.1016/j.neubiorev.2008.03.003; Forsyth JP,
2003, ADDICT BEHAV, V28, P851, DOI 10.1016/S0306-4603(02)00216-2; Franques P, 2000,
ENCEPHALE, V26, P68; Fuchs RA, 2004, J NEUROSCI, V24, P6600, DOI
10.1523/JNEUROSCI.1924-04.2004; Fuchs RA, 2006, J NEUROSCI, V26, P3584, DOI
10.1523/JNEUROSCI.5146-05.2006; Fuchs RA, 1998, PSYCHOPHARMACOLOGY, V135, P151, DOI
10.1007/s002130050496; Fuchs RA, 2008, PSYCHOPHARMACOLOGY, V200, P545, DOI
10.1007/s00213-008-1234-4; Gerra G, 2004, SUBST USE MISUSE, V39, P345, DOI
10.1081/JA-120028493; Geyer Mark A., 1995, P787; Giuliano C., 2015, NEUROPSYCHO IN
PRESS; GOLDBERG SR, 1973, J PHARMACOL EXP THER, V186, P18; GOLDBERG SR, 1969,
SCIENCE, V166, P1303; GOSSOP M, 1978, DRUG ALCOHOL DEPEN, V3, P359, DOI
10.1016/0376-8716(78)90005-4; GREENE RL, 1993, J PERS ASSESS, V61, P224, DOI
10.1207/s15327752jpa6102_2; Hall FS, 1998, PHARMACOL BIOCHEM BE, V59, P859, DOI
10.1016/S0091-3057(97)00510-8; Hamilton KR, 2015, PERSONAL DISORD, V6, P168, DOI
10.1037/per0000100; Hamilton KR, 2015, PERSONAL DISORD, V6, P182, DOI
10.1037/per0000099; Hanson KL, 2008, DRUG ALCOHOL DEPEN, V96, P99, DOI
10.1016/j.drugalcdep.2008.02.003; Henniger MSH, 2002, NEUROPSYCHOPHARMACOL, V26,
P729, DOI 10.1016/S0893-133X(01)00408-0; Hittner JB, 2006, ADDICT BEHAV, V31,
P1383, DOI 10.1016/j.addbeh.2005.11.004; Holroyd KB, 2015, NEUROPSYCHOPHARMACOL,
V40, P1495, DOI 10.1038/npp.2014.336; Holter SM, 1998, BEHAV PHARMACOL, V9, P41;
Homberg JR, 2002, EUR J NEUROSCI, V15, P1542, DOI 10.1046/j.1460-9568.2002.01976.x;
Ipser JC, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007505.pub2; Isherwood
SN, 2015, PSYCHOPHARMACOLOGY, V232, P3327, DOI 10.1007/s00213-015-3984-0; Jentsch
JD, 1999, PSYCHOPHARMACOLOGY, V146, P373, DOI 10.1007/PL00005483; Johnson EO, 1996,
ALCOHOL CLIN EXP RES, V20, P1472, DOI 10.1111/j.1530-0277.1996.tb01151.x; Jupp B,
2014, NEUROPHARMACOLOGY, V76, P487, DOI 10.1016/j.neuropharm.2013.05.041; Jupp B,
2013, EUR J NEUROSCI, V37, P1519, DOI 10.1111/ejn.12146; Kalivas PW, 2011, MOL
PSYCHIATR, V16, P974, DOI 10.1038/mp.2011.46; Kalivas PW, 2003, PSYCHOPHARMACOLOGY,
V168, P44, DOI 10.1007/s00213-003-1393-2; Kasanetz F, 2013, MOL PSYCHIATR, V18,
P729, DOI 10.1038/mp.2012.59; Kasanetz F, 2010, SCIENCE, V328, P1709, DOI
10.1126/science.1187801; Khantzian E. J., 1990, RECENT DEV ALCOHOLIS, V8, P255;
Khantzian EJ, 2013, ADDICTION, V108, P668, DOI 10.1111/add.12004; Khantzian EJ,
1997, HARVARD REV PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550; KHANTZIAN EJ,
1985, AM J PSYCHIAT, V142, P1259; Kirby KN, 2004, ADDICTION, V99, P461, DOI
10.1111/j.1360-0443.2003.00669.x; Knackstedt LA, 2009, CURR OPIN PHARMACOL, V9,
P59, DOI 10.1016/j.coph.2008.12.003; Koob GF, 1998, NEURON, V21, P467, DOI
10.1016/S0896-6273(00)80557-7; Kreek MJ, 2012, J CLIN INVEST, V122, P3387, DOI
10.1172/JCI60390; Kreek MJ, 2005, NAT NEUROSCI, V8, P1450, DOI 10.1038/nn1583;
LABOUVIE EW, 1986, J CONSULT CLIN PSYCH, V54, P289, DOI 10.1037/0022-006X.54.3.289;
Lee B, 2009, J NEUROSCI, V29, P14734, DOI 10.1523/JNEUROSCI.3765-09.2009; Lejuez
CW, 2008, BEHAV RES THER, V46, P811, DOI 10.1016/j.brat.2008.03.010; Lejuez CW,
2010, ALCOHOL CLIN EXP RES, V34, P1334, DOI 10.1111/j.1530-0277.2010.01217.x;
Lenoir M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000698; Lesscher HMB, 2015,
BEHAV PHARMACOL, V26, P673, DOI 10.1097/FBP.0000000000000165; Liu JX, 2008,
EPILEPSY RES, V82, P111, DOI 10.1016/j.eplepsyres.2008.07.014; Loos M, 2009, GENES
BRAIN BEHAV, V8, P817, DOI 10.1111/j.1601-183X.2009.00528.x; Lovic V, 2011, BEHAV
BRAIN RES, V223, P255, DOI 10.1016/j.bbr.2011.04.006; Madden GJ, 1997, EXP CLIN
PSYCHOPHARM, V5, P256, DOI 10.1037/1064-1297.5.3.256; Mar Adam C, 2007, Curr Protoc
Neurosci, VChapter 8, DOI 10.1002/0471142301.ns0822s39; Marchant NJ, 2014, J
NEUROSCI, V34, P7447, DOI 10.1523/JNEUROSCI.0256-14.2014; Marchant NJ, 2013, CURR
OPIN NEUROBIOL, V23, P675, DOI 10.1016/j.conb.2013.01.003; Marchant NJ, 2013, BIOL
PSYCHIAT, V73, P256, DOI 10.1016/j.biopsych.2012.07.007; Maremmani I, 2009, J
AFFECT DISORDERS, V117, P186, DOI 10.1016/j.jad.2009.01.007; McNamara R, 2010,
PSYCHOPHARMACOLOGY, V212, P453, DOI 10.1007/s00213-010-1974-9; Meyer-Lindenberg A,
2006, NAT REV NEUROSCI, V7, P818, DOI 10.1038/nrn1993; Miles FJ, 2003, BEHAV
NEUROSCI, V117, P927, DOI 10.1037/0735-7044.117.5.927; Moeller FG, 2002, DRUG
ALCOHOL DEPEN, V68, P105; Moeller FG, 2001, AM J PSYCHIAT, V158, P1783, DOI
10.1176/appi.ajp.158.11.1783; Molander AC, 2011, PSYCHOPHARMACOLOGY, V215, P721,
DOI 10.1007/s00213-011-2167-x; Moreno M, 2010, NEUROPSYCHOPHARMACOL, V35, P1198,
DOI 10.1038/npp.2009.224; Muller CP, 2008, PHARMACOL BIOCHEM BE, V89, P218, DOI
10.1016/j.pbb.2007.12.013; Murray JE, 2014, BIOL PSYCHIAT, V76, P15, DOI
10.1016/j.biopsych.2013.09.011; Nader MA, 2006, NAT NEUROSCI, V9, P1050, DOI
10.1038/nn1737; Nees F, 2012, NEUROPSYCHOPHARMACOL, V37, P986, DOI
10.1038/npp.2011.282; Neumark YD, 2004, ALCOHOL CLIN EXP RES, V28, P10, DOI
10.1097/01.ALC.0000108667.79219.4D; Noel X, 2011, ALCOHOL ALCOHOLISM, V46, P407,
DOI 10.1093/alcalc/agr048; O'Leary TA, 2000, AM J DRUG ALCOHOL AB, V26, P179, DOI
10.1081/ADA-100100599; OBRIEN CP, 1992, RES P ARNMD, V70, P157; Ohlmeier MD, 2008,
ALCOHOL ALCOHOLISM, V43, P300, DOI 10.1093/alcalc/agn014; Paine TA, 2002, BEHAV
PHARMACOL, V13, P511, DOI 10.1097/00008877-200211000-00001; PARADA MA, 1994, J
NEUROSCI METH, V54, P1, DOI 10.1016/0165-0270(94)90154-6; Paradis S, 2007, NEURON,
V53, P217, DOI 10.1016/j.neuron.2006.12.012; Pattij T, 2008, TRENDS PHARMACOL SCI,
V29, P192, DOI 10.1016/j.tips.2008.01.002; Pelloux Y, 2007, PSYCHOPHARMACOLOGY,
V194, P127, DOI 10.1007/s00213-007-0805-0; Pelloux Y, 2009, BEHAV BRAIN RES, V197,
P311, DOI 10.1016/j.bbr.2008.08.029; PELLOW S, 1986, PHARMACOL BIOCHEM BE, V24,
P525, DOI 10.1016/0091-3057(86)90552-6; PELLOW S, 1985, J NEUROSCI METH, V14, P149,
DOI 10.1016/0165-0270(85)90031-7; Perry JL, 2008, PSYCHOPHARMACOLOGY, V200, P1, DOI
10.1007/s00213-008-1173-0; Perry JL, 2008, EXP CLIN PSYCHOPHARM, V16, P165, DOI
10.1037/1064-1297.16.2.165; Perry JL, 2005, PSYCHOPHARMACOLOGY, V178, P193, DOI
10.1007/s00213-004-1994-4; Petry NM, 2002, J STUD ALCOHOL, V63, P83; Petry NM,
2001, PSYCHOPHARMACOLOGY, V154, P243, DOI 10.1007/s002130000638; Phillips TJ, 2015,
GENES BRAIN BEHAV, V14, P98, DOI 10.1111/gbb.12189; Piazza PV, 2000, J NEUROSCI,
V20, P4226; PIAZZA PV, 1989, SCIENCE, V245, P1511, DOI 10.1126/science.2781295;
Potenza MN, 2010, ALCOHOL CLIN EXP RES, V34, P1303, DOI 10.1111/j.1530-
0277.2010.01214.x; Reyna VF, 2006, PSYCHOL SCI, P1, DOI 10.1111/j.1529-
1006.2006.00026.x; Richardson NR, 1996, J NEUROSCI METH, V66, P1, DOI 10.1016/0165-
0270(95)00153-0; Robbins TW, 2015, CURR OPIN NEUROBIOL, V30, P66, DOI
10.1016/j.conb.2014.09.005; Robbins T.W., 2015, DECISION NEUROSCIENC; Robbins TW,
2002, PSYCHOPHARMACOLOGY, V163, P362, DOI 10.1007/s00213-002-1154-7; Robbins TW,
2002, NEUROBIOL LEARN MEM, V78, P625, DOI 10.1006/nlme.2002.4103; Roberts A, 2000,
CLIN PSYCHOL REV, V20, P667, DOI 10.1016/S0272-7358(99)00020-3; Robinson ESJ, 2009,
BEHAV BRAIN RES, V196, P310, DOI 10.1016/j.bbr.2008.09.021; ROBINSON TE, 1993,
BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; Robinson TE, 2014,
NEUROPHARMACOLOGY, V76, P450, DOI 10.1016/j.neuropharm.2013.05.040; Rocha A, 2010,
EUR J NEUROSCI, V31, P903, DOI 10.1111/j.1460-9568.2010.07134.x; Rogers RD, 2001,
CURR OPIN NEUROBIOL, V11, P250, DOI 10.1016/S0959-4388(00)00204-X; ROSVOLD HE,
1956, J COMP PHYSIOL PSYCH, V49, P365, DOI 10.1037/h0087991; Russell VA, 2005,
BEHAV BRAIN FUNCT, V1, DOI 10.1186/1744-9081-1-9; Sargent JD, 2010, ADDICTION,
V105, P506, DOI 10.1111/j.1360-0443.2009.02782.x; Saunders BT, 2013, J NEUROSCI,
V33, P13989, DOI 10.1523/JNEUROSCI.0450-13.2013; Saunders BT, 2011,
NEUROPSYCHOPHARMACOL, V36, P1668, DOI 10.1038/npp.2011.48; SCHINKA JA, 1994, J PERS
ASSESS, V63, P413, DOI 10.1207/s15327752jpa6303_2; See RE, 2007,
PSYCHOPHARMACOLOGY, V194, P321, DOI 10.1007/s00213-007-0850-8; Selemon LD, 2013,
TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.7; Semple SJ, 2005, J SUBST ABUSE TREAT,
V29, P85, DOI 10.1016/j.jsat.2005.05.001; Shaham Y, 2003, PSYCHOPHARMACOLOGY, V168,
P3, DOI 10.1007/s00213-002-1224-x; Shaham Y, 2003, PSYCHOPHARMACOLOGY, V168, P1,
DOI 10.1007/s00213-003-1469-z; Shalev U, 2002, PHARMACOL REV, V54, P1, DOI
10.1124/pr.54.1.1; Sher KJ, 2000, J CONSULT CLIN PSYCH, V68, P818, DOI
10.1037/0022-006X.68.5.818; SHERMAN JE, 1989, ADDICT BEHAV, V14, P611, DOI
10.1016/0306-4603(89)90003-8; Sinha R, 2001, PSYCHOPHARMACOLOGY, V158, P343, DOI
10.1007/s002130100917; Skinstad AH, 2001, AM J DRUG ALCOHOL AB, V27, P45, DOI
10.1081/ADA-100103118; Somerville LH, 2010, BRAIN COGNITION, V72, P124, DOI
10.1016/j.bandc.2009.07.003; Spanagel R, 1995, PSYCHOPHARMACOLOGY, V122, P369, DOI
10.1007/BF02246268; SPEALMAN RD, 1978, ANNU REV PHARMACOL, V18, P313, DOI
10.1146/annurev.pa.18.040178.001525; Spear LP, 2000, NEUROSCI BIOBEHAV R, V24,
P417, DOI 10.1016/S0149-7634(00)00014-2; Spillane NS, 2012, ADDICT BEHAV, V37,
P1303, DOI 10.1016/j.addbeh.2012.06.021; Stead JDH, 2006, BEHAV GENET, V36, P697,
DOI 10.1007/s10519-006-9058-7; Stephenson MT, 2006, J DRUG EDUC, V36, P247, DOI
10.2190/Y223-2623-7716-2235; STEWART RB, 1981, PROG NEURO-PSYCHOPHA, V5, P609, DOI
10.1016/0364-7722(81)90057-6; STOLERMAN IP, 1985, PHARMACOL BIOCHEM BE, V23, P877,
DOI 10.1016/0091-3057(85)90086-3; Sullivan PF, 2012, NAT REV GENET, V13, P537, DOI
10.1038/nrg3240; Swann AC, 2002, BIOL PSYCHIAT, V51, P988,
DOI 10.1016/S0006-3223(01)01357-9; Terracciano A, 2008, BMC PSYCHIATRY, V8, DOI
10.1186/1471-244X-8-22; The Centre for Social Justice, 2013, NO QUICK FIX EXP DEP;
Tomie Y, 1989, CONT LEARNING THEORI, P191; Torregrossa MM, 2008, J PHARMACOL EXP
THER, V325, P556, DOI 10.1124/jpet.107.130310; Tran-Nguyen LTL, 1998,
NEUROPSYCHOPHARMACOL, V19, P48; Tunstall BJ, 2015, BEHAV BRAIN RES, V281, P222, DOI
10.1016/j.bbr.2014.12.034; Uhl George R, 2006, NeuroRx, V3, P295, DOI
10.1007/BF03206653; Uhl GR, 2004, NEUROPHARMACOLOGY, V47, P140, DOI
10.1016/j.neuropharm.2004.07.029; Uhl GR, 2004, ARCH GEN PSYCHIAT, V61, P223, DOI
10.1001/archpsyc.61.3.223; Uslaner JM, 2006, EUR J NEUROSCI, V24, P2345, DOI
10.1111/j.1460-9568.2006.05117.x; van Kerkhof LWM, 2013, NEUROPSYCHOPHARMACOL, V38,
P1899, DOI 10.1038/npp.2013.83; Vanderschuren LJMJ, 2005, EUR J PHARMACOL, V526,
P77, DOI 10.1016/j.ejphar.2005.09.037; Vanderschuren LJMJ, 2004, SCIENCE, V305,
P1017, DOI 10.1126/science.1098975; Vanhille N, 2015, NEUROPSYCHOPHARMACOL, V40,
P577, DOI 10.1038/npp.2014.204; Verdejo-Garcia A, 2008, NEUROSCI BIOBEHAV R, V32,
P777, DOI 10.1016/j.neubiorev.2007.11.003; Volkow ND, 2001, AM J PSYCHIAT, V158,
P2015, DOI 10.1176/appi.ajp.158.12.2015; Volkow ND, 2006, ARCH GEN PSYCHIAT, V63,
P999, DOI 10.1001/archpsyc.63.9.999; Volkow ND, 2012, SCIENCE, V335, P546, DOI
10.1126/science.1218170; Voon V, 2014, BIOL PSYCHIAT, V75, P148, DOI
10.1016/j.biopsych.2013.05.013; WEEKS JR, 1962, SCIENCE, V138, P143, DOI
10.1126/science.138.3537.143; White NM, 1996, ADDICTION, V91, P921, DOI
10.1046/j.1360-0443.1996.9179212.x; WHITE NM, 1985, PHARMACOL BIOCHEM BE, V23, P37,
DOI 10.1016/0091-3057(85)90127-3; WILKINSON RT, 1963, J EXP PSYCHOL, V66, P332, DOI
10.1037/h0044161; Wills T A, 1994, J Subst Abuse, V6, P1, DOI 10.1016/S0899-
3289(94)90039-6; Wills TA, 1998, J PERS SOC PSYCHOL, V74, P387, DOI 10.1037/0022-
3514.74.2.387; Winstanley CA, 2006, CLIN PSYCHOL REV, V26, P379, DOI
10.1016/j.cpr.2006.01.001; Winstanley CA, 2010, ALCOHOL CLIN EXP RES, V34, P1306,
DOI 10.1111/j.1530-0277.2010.01215.x; Wong CCY, 2008, PHILOS T R SOC B, V363,
P3213, DOI 10.1098/rstb.2008.0104; Zeeb FD, 2009, NEUROPSYCHOPHARMACOL, V34, P2329,
DOI 10.1038/npp.2009.62; Zernig G, 2007, PHARMACOLOGY, V80, P65, DOI
10.1159/000103923; Zhou WH, 2008, BIOL PSYCHIAT, V63, P338, DOI
10.1016/j.biopsych.2007.06.008; Zilberman ML, 2007, J ADDICT DIS, V26, P79, DOI
10.1300/J069v26n01_10; ZUCKERMAN M, 1990, J PERS, V58, P313, DOI 10.1111/j.1467-
6494.1990.tb00918.x; Zuckerman M, 1986, NIDA Res Monogr, V74, P59; Zuckerman M,
1974, Prog Exp Pers Res, V7, P79; ZUCKERMAN M, 1979, PSYCHIAT RES, V1, P255, DOI
10.1016/0165-1781(79)90007-6 257 39 39 1 25 WILEY HOBOKEN 111
RIVER ST, HOBOKEN 07030-5774, NJ USA 1601-1848 1601-183X GENES BRAIN
BEHAV Genes Brain Behav. JAN 2016 15 1 74
88 10.1111/gbb.12265 15 Behavioral Sciences;
Neurosciences Behavioral Sciences; Neurosciences & Neurology DB1HC
WOS:000368257900006 26482647 Green Accepted, Bronze 2019-
09-25
J Jiraporncharoen, W; Likhitsathian, S; Lerssrimongkol, C; Jiraniramai, S;
Siriluck, L; Angkurawaranon, C Jiraporncharoen, Wichuda;
Likhitsathian, Surinporn; Lerssrimongkol, Chawin; Jiraniramai, Surin; Siriluck,
Ladawan; Angkurawaranon, Chaisiri Sedative use: its association with
harmful alcohol use, harmful tobacco use and quality of life among health care
workers in Thailand JOURNAL OF SUBSTANCE USE English
Article Association; harmful alcohol and
tobacco use; quality of life; sedatives use NATIONAL EPIDEMIOLOGIC SURVEY;
SUBSTANCE USE DISORDERS; PRESCRIPTION DRUG-ABUSE; SCREENING-TEST ASSIST; UNITED-
STATES; ANXIETY DISORDERS; PREVALENCE; MISUSE; DEPENDENCE; SMOKING Background:
Health care workers (HCWs) may be at higher risk for sedative misuse due to
potential access and self-medication behavior. Objectives: To examine risk factors
for harmful sedative use (HSedU) and its association with harmful alcohol use
(HAlcU), harmful tobacco use (HTobU) and quality of life (QoL). Methods: A survey
was conducted in 2013 at an urban university hospital in Northern Thailand. Risk of
harm was measured using The Alcohol, Smoking and Substance Involvement Screening
Test (ASSIST). Harmful substance use defined as having at least moderate risk of
harm. QoL was measured using SF-36 questionnaire. Results: A sample of 3204 HCWs
(59.7% response) participated. The prevalence of HSedU in past 3 months was 4.2%.
Health professionals involved with prescribing or dispensing medication were at
higher risk of HSedU (OR 1.80, 95% CI 1.21-2.67). Adjusting for confounders, HSedU
was associated with HAlcU (OR 3.35, 95% CI 1.81-6.20) but not associated with
HTobU. HSedU was associated with lower QoL score which was 7.78 and 5.52 points
lower for physical (95% CI -10.4 to -5.18) and mental QoL (95% CI -7.11 to -3.93),
respectively. Conclusions: HCWs were at higher risk of HSedU. HSedU was associated
with HAlcU and associated with lower physical and mental health QoL.
[Jiraporncharoen, Wichuda; Lerssrimongkol, Chawin; Jiraniramai, Surin;
Angkurawaranon, Chaisiri] Chiang Mai Univ, Fac Med, Dept Family Med, Chiang Mai
50200, Thailand; [Likhitsathian, Surinporn] Chiang Mai Univ, Fac Med, Dept
Psychiat, Chiang Mai 50200, Thailand; [Siriluck, Ladawan] Maharaj Nakorn Chiang Mai
Hosp, Pharm Unit, Chiang Mai, Thailand Likhitsathian, S (reprint author), Chiang
Mai Univ, Fac Med, Dept Psychiat, Chiang Mai 50200, Thailand.
surinporn.l@cmu.ac.th Angkurawaranon, Chaisiri/I-6140-2015
Angkurawaranon, Chaisiri/0000-0003-4206-9164; Jiraporncharoen, Wichuda/0000-
0002-8131-6474; Likhitsathian, Surinporn/0000-0003-1668-1237; Jiraniramai,
Surin/0000-0003-0983-4290 Faculty of Medicine, Research Fund, Chiang Mai
University Thailand Funding was provided by Faculty of Medicine, Research Fund,
Chiang Mai University Thailand. Faculty of Medicine had no role in study design; in
the collection, analysis and interpretation of data; in the writing of the report;
or in the decision to prepare and submit this manuscript. Aekplakorn W, 2008,
ADDICT BEHAV, V33, P503, DOI 10.1016/j.addbeh.2007.10.010; Akvardar Y., 2003,
SOCIAL PSYCHIAT PSYC, V36, P502; Ali R, 2002, ADDICTION, V97, P1183; Angkurawaranon
C, 2014, CLIN EPIDEMIOL, V6, P277, DOI 10.2147/CLEP.S65338; Assanangkornchai S,
2010, DRUG ALCOHOL REV, V29, P101, DOI 10.1111/j.1465-3362.2009.00092.x; Babor T,
1994, LEXICON ALCOHOL DRUG; Baggio Stephanie, 2014, Int J Adolesc Med Health, V26,
P217, DOI 10.1515/ijamh-2013-0305; Barrett Sean P, 2008, Curr Drug Abuse Rev, V1,
P255, DOI 10.2174/1874473710801030255; Benotsch EG, 2013, DRUG ALCOHOL DEPEN, V132,
P391, DOI 10.1016/j.drugalcdep.2013.02.027; Cappell H., 1987, PSYCHOL THEORIES DRI,
P15; Casati A, 2012, EUR ADDICT RES, V18, P228, DOI 10.1159/000337028; Chang EML,
2007, INT J NURS STUD, V44, P1354, DOI 10.1016/j.ijnurstu.2006.06.003; Charlson F,
2009, PHARMACOEPIDEM DR S, V18, P93, DOI 10.1002/pds.1694; Chittrakarn S., 2000,
SITUATIONAL REV SUBS, P105; Crombie IK, 2007, ALCOHOL ALCOHOLISM, V42, P492, DOI
10.1093/alcalc/agm001; Davis L, 2008, CURR OPIN PSYCHIATR, V21, P14, DOI
10.1097/YCO.0b013e3282f32408; Dell'osso B, 2013, EUR PSYCHIAT, V28, P7, DOI
10.1016/j.eurpsy.2011.11.003; Drobes D, 2002, CONCURRENT ALCOHOL T; Goodwin RD,
2002, ADDICTION, V97, P555, DOI 10.1046/j.1360-0443.2002.00098.x; Grant BF, 2004,
ARCH GEN PSYCHIAT, V61, P807, DOI 10.1001/archpsyc.61.8.807; Hasin D., 2004, DUAL
DIAGNOSIS PSYCH, P1; Huang BJ, 2006, J CLIN PSYCHIAT, V67, P1062, DOI
10.4088/JCP.v67n0708; Humeniuk R, 2010, ALCOHOL SMOKING SUBS; Humeniuk R, 2008,
ADDICTION, V103, P1039, DOI 10.1111/j.1360-0443.2007.02114.x; Johansson BA, 2003,
ALCOHOL ALCOHOLISM, V38, P613, DOI 10.1093/alcalc/agg123; JOHNSON KA, 1992, INT J
ADDICT, V27, P749, DOI 10.3109/10826089209068767; Kavanagh DJ, 2009, ADDICT BEHAV,
V34, P838, DOI 10.1016/j.addbeh.2009.03.005; Kenna George A, 2004, J Am Pharm Assoc
(2003), V44, P684, DOI 10.1331/1544345042467281; Kenna GA, 2008, SUBST ABUSE TREAT
PR, V3, DOI 10.1186/1747-597X-3-3; Kokkevi A, 2012, EUR CHILD ADOLES PSY, V21,
P443, DOI 10.1007/s00787-012-0276-7; Kroenke K, 2001, J GEN INTERN MED, V16, P606,
DOI 10.1046/j.1525-1497.2001.016009606.x; Lader M, 2011, ADDICTION, V106, P2086,
DOI 10.1111/j.1360-0443.2011.03563.x; Lapham SC, 2000, J BEHAV HEALTH SER R, V27,
P131, DOI 10.1007/BF02287308; Laudet Alexandre B, 2011, Addict Sci Clin Pract, V6,
P44; Lim LLY, 2008, HEALTH QUAL LIFE OUT, V6, DOI 10.1186/1477-7525-6-52; Lotrakul
M, 2008, BMC PSYCHIATRY, V8, DOI 10.1186/1471-244X-8-46; Marshall EJ, 2008, OCCUP
MED-OXFORD, V58, P334, DOI 10.1093/occmed/kqn081; McCabe SE, 2008, ADDICT BEHAV,
V33, P1297, DOI 10.1016/j.addbeh.2008.06.005; McCabe SE, 2006, DRUG ALCOHOL DEPEN,
V84, P281, DOI 10.1016/j.drugalcdep.2006.03.006; McCabe SE, 2006, J STUD ALCOHOL,
V67, P529, DOI 10.15288/jsa.2006.67.529; McCabe SE, 2009, DRUG ALCOHOL DEPEN, V102,
P63, DOI 10.1016/j.drugalcdep.2009.01.007; McLarnon ME, 2011, PHARMACOTHERAPY, V31,
P262, DOI 10.1592/phco.31.3.262; Moolasart J, 2012, SE ASIAN J TROP MED, V43, P795;
Morgan TJ, 2003, AM J ADDICTION, V12, P198, DOI 10.1080/10550490390201803; Nattala
P, 2011, ADDICT BEHAV, V36, P103, DOI 10.1016/j.addbeh.2010.09.002; Ohayon MM,
1998, J CLIN EPIDEMIOL, V51, P273, DOI 10.1016/S0895-4356(97)00238-2; PARROTT AC,
1995, ADDICTION, V90, P233, DOI 10.1111/j.1360-0443.1995.tb01041.x; PARROTT AC,
1994, PSYCHOPHARMACOLOGY, V115, P389, DOI 10.1007/BF02245082; Raoof M, 2008, PLOS
ONE, V3, DOI 10.1371/journal.pone.0001804; Saatcioglu O, 2008, DRUG ALCOHOL REV,
V27, P83, DOI 10.1080/09595230701711140; Smith GW, 2011, DRUG ALCOHOL DEPEN, V113,
P222, DOI 10.1016/j.drugalcdep.2010.08.010; Smith KW, 2003, AM J DRUG ALCOHOL AB,
V29, P323, DOI 10.1081/ADA-120020517; Srisurapanont M., 2005, BMC FAMILY PRACTICE,
V6, P5; Srisurapanont M, 2012, ADDICT BEHAV, V37, P173, DOI
10.1016/j.addbeh.2011.09.014; Stinson FS, 2005, DRUG ALCOHOL DEPEN, V80, P105, DOI
10.1016/j.drugalcdep.2005.03.009; Suttajit S, 2012, ADDICT BEHAV, V37, P1395, DOI
10.1016/j.addbeh.2012.06.014; Tracy EM, 2012, DRUG ALCOHOL DEPEN, V124, P242, DOI
10.1016/j.drugalcdep.2012.01.010; United Nations Office on Drugs and Crime, 2012,
WORLD DRUG REP 2012; Victora CG, 1997, INT J EPIDEMIOL, V26, P224, DOI
10.1093/ije/26.1.224; WHO/UNDCP Global Initiative on Primary Prevention of
Substance Abuse, 2003, SUBST US S E AS KNOW; Wisetborisut A, 2014, OCCUP MED-
OXFORD, V64, P279, DOI 10.1093/occmed/kqu009; World Health Organization, 2008, MAN
SUBST AB OTH PSY; World Health Organization, 2010, ICD 10 CLASS MENT BE; World
Health Organization, 2004, NEUR PSYCH SUBST US; Yu HYE, 2012, CLIN LAB MED, V32,
P361, DOI 10.1016/j.cll.2012.06.006 65 3 3 1 11 TAYLOR & FRANCIS
INC PHILADELPHIA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
1465-9891 1475-9942 J SUBST USE J. Subst. Use 2016 21
4 414 422 10.3109/14659891.2015.1042081
9 Substance Abuse Substance Abuse DM6AB WOS:000376430900016
2019-09-25
J Lusk, SL; Koch, LC; Paul, TM Lusk, Stephanie L.; Koch,
Lynn C.; Paul, Teresia M. Recovery-Oriented Vocational
Rehabilitation Services for Individuals With Co-Occurring Psychiatric Disabilities
and Substance Use Disorders REHABILITATION RESEARCH POLICY AND EDUCATION
English Article VENTRAL TEGMENTAL
AREA; SEVERE MENTAL-ILLNESS; SELF-MEDICATION; SUPPORTED EMPLOYMENT; CANNABIS USE;
ALCOHOL; ABUSE; PEOPLE; OUTCOMES; DRUG Purpose: In this article, we examined how
individuals with co-occurring psychiatric disabilities and substance use disorders
encounter numerous challenges when it comes to the vocational rehabilitation (VR)
process. Method: A comprehensive review of the literature demonstrated barriers to
service delivery (e.g., access to services, exclusionary eligibility requirements)
and hindrances to VR planning (e.g., lack of training of VR counselors, lack of
work-related skills) which all serve to create obstacles through which they must
navigate. This article provides a brief overview of (a) the challenges that these
individuals face in treatment and VR and (b) general considerations for providing
more recovery-oriented VR services to increase their participation in the VR
process, facilitate recovery, and improve VR outcomes. Results: Our review
highlighted that VR participation and successful outcome rates among this group as
a whole are much lower than the rates of those with other types of disabilities.
Researchers have suggested a myriad of strategies that have proven advantageous
when working with these individuals all of which serve to increase rates of
sustained recovery and employment success. Conclusion: Additional research is still
needed to substantiate the barriers to service delivery for this underserved VR
population, evaluate how to implement more recovery-oriented practices within the
VR system, and determine if such changes do indeed lead to improved outcomes for
consumers with co-occurring disabilities. [Lusk, Stephanie L.; Koch, Lynn C.] Univ
Arkansas, Rehabil Educ & Res, Dept Rehabil Human Resources & Commun Disorders,
Fayetteville, AR 72701 USA; [Paul, Teresia M.] Univ Arkansas, Rehabil Educ & Res
Program, Fayetteville, AR 72701 USA Lusk, SL (reprint author), Univ Arkansas,
Rehabil Human Resources & Commun Disorders, 153 Grad Educ Bldg, Fayetteville, AR
72701 USA. sluskhe@uark.edu Adolphs R, 2010, ANN NY ACAD
SCI, V1191, P42, DOI 10.1111/j.1749-6632.2010.05445.x; Anthony W. A., 1993,
PSYCHOSOC REHABIL, V16, P11, DOI DOI 10.1037/H0095655; Antony R. W., 2011, J APPL
REHABILITATIO, V42, P15; Bartz A, 2008, J GROUPS ADDICT RECO, V3, P243, DOI
10.1080/15560350802425016; Becker D, 2007, PSYCHIAT SERV, V58, P922, DOI
10.1176/appi.ps.58.7.922; Becker DR, 2005, PSYCHIATR REHABIL J, V28, P332, DOI
10.2975/28.2005.332.338; Bolton JM, 2009, J AFFECT DISORDERS, V115, P367, DOI
10.1016/j.jad.2008.10.003; Bozikas VP, 2005, PROG NEURO-PSYCHOPH, V29, P1, DOI
10.1016/j.pnpbp.2004.08.002; Brady K. T., 2007, FOCUS, V5, P229; Brady KT, 2005, AM
J PSYCHIAT, V162, P1483, DOI 10.1176/appi.ajp.162.8.1483; Burnam MA, 2006, HEALTH
AFFAIR, V25, P648, DOI 10.1377/hlthaff.25.3.648; Center for Substance Abuse
Treatment, 2006, DHHS PUBL; Center for Substance Abuse Treatment, 2005, WORK DEF
REC; Chasek CL, 2012, J ADDICT OFFENDER CO, V33, P107, DOI 10.1002/j.2161-
1874.2012.00008.x; Cook JA, 2007, J REHABIL RES DEV, V44, P837, DOI
10.1682/JRRD.2006.07.0079; Denis CM, 2013, J SUBST ABUSE TREAT, V45, P444, DOI
10.1016/j.jsat.2013.06.003; Donnell CM, 2009, J REHABIL, V75, P41; Doweiko H. E.,
2012, CONCEPTS CHEM DEPEND; Drake RE, 2004, PSYCHIATR REHABIL J, V27, P360, DOI
10.2975/27.2004.360.374; Drebing CE, 2002, REHABIL COUNS BULL, V46, P5, DOI
10.1177/00343552020460010501; Duvarci S, 2009, J NEUROSCI, V29, P10357, DOI
10.1523/JNEUROSCI.2119-09.2009; Education Portal, 2014, HIPP DEF FUNCT LOC;
Evashwick C, 1989, Health Matrix, V7, P30; Fremstad S., 2013, FACTS SOCIAL SECURIT;
Frounfelker RL, 2011, PSYCHIAT SERV, V62, P545, DOI 10.1176/ps.62.5.pss6205_0545;
Glenn M., SUBSTANCE USE DISORD; Grelotti DJ, 2010, AM J PSYCHIAT, V167, P17, DOI
10.1176/appi.ajp.2009.08111695; Heinemann A., 2008, J APPL REHABILITATIO, V39, P5;
Heinernann AW, 2008, REHABIL PSYCHOL, V53, P63, DOI 10.1037/0090-5550.53.1.63;
Kavanagh DJ, 2000, AUST NZ J PSYCHIAT, V34, P279, DOI 10.1046/j.1440-
1614.2000.00711.x; Kelly TM, 2013, SOC WORK PUBLIC HLTH, V28, P388, DOI
10.1080/19371918.2013.774673; Khantzian EJ, 2013, ADDICTION, V108, P668, DOI
10.1111/add.12004; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259; Large M, 2011,
ARCH GEN PSYCHIAT, V68, P555, DOI 10.1001/archgenpsychiatry.2011.5; Lazowski LE,
1998, J PERS ASSESS, V71, P114, DOI 10.1207/s15327752jpa7101_8; LeDoux J, 2003,
CELL MOL NEUROBIOL, V23, P727, DOI 10.1023/A:1025048802629; Magura S, 2004, SUBST
USE MISUSE, V39, P2157, DOI 10.1081/LSUM-20034585; Markou A, 1998,
NEUROPSYCHOPHARMACOL, V18, P135, DOI 10.1016/S0893-133X(97)00113-9; Martin JK,
2000, J HEALTH SOC BEHAV, V41, P208, DOI 10.2307/2676306; Matthews LR, 2013,
DISABIL REHABIL, V35, P460, DOI 10.3109/09638288.2012.699583; McKay JR, 2001,
EVALUATION REV, V25, P113, DOI 10.1177/0193841X0102500202; Minkoff K., 2004, J DUAL
DIAGN, V1, P65; Moore THM, 2007, LANCET, V370, P319, DOI 10.1016/S0140-
6736(07)61162-3; Morrissey JP, 2005, PSYCHIAT SERV, V56, P1213, DOI
10.1176/appi.ps.56.10.1213; NAADAC, 2010, INT TREATM CO DIS IN; National Council
for Community Behavioral Health, 2006, BEH HLTH PRIM CAR IN; National Institute on
Drug Abuse, 2007, IMP DRUGS NEUR; National Institute on Drug Abuse, 2014, DRUG
FACTS BRAIN ADD; National Institute on Drug Abuse, HLTH EFF; Ong L., 2013, J
TEACHING ADDICTION, V7, P109; Pearson Publishing, 2014, QUAL POL; RachBeisel J,
1999, PSYCHIATR SERV, V50, P1427, DOI 10.1176/ps.50.11.1427; Robinson J, 2009, J
ANXIETY DISORD, V23, P38, DOI 10.1016/j.janxdis.2008.03.013; Saunders BT, 2011, J
NEUROSCI, V31, P18195, DOI 10.1523/JNEUROSCI.4924-11.2011; Sheidow AJ, 2012,
PSYCHIATR REHABIL J, V35, P235, DOI 10.2975/35.3.2012.235.243; Sheret C., 2013,
MENTAL HLTH PRACTICE, V17, P28; Shu J., 2008, PSYCHOANAL PSYCHOL, V25, P518;
SKINNER HA, 1982, ADDICT BEHAV, V7, P363, DOI 10.1016/0306-4603(82)90005-3; Smith
RC, 2002, NEUROPSYCHOPHARMACOL, V27, P479, DOI 10.1016/S0893-133X(02)00324-X;
Sprong ME, 2012, J REHABIL, V78, P13; Substance Abuse and Mental Health Services
Administration, 2010, SAMHSAS WORK DEF REC; Substance Abuse and Mental Health
Services Administration, 2012, NAT SURV SUBST AB TR; Substance Abuse and Mental
Health Services Administration, COOCC DIS SCREEN ASS; Substance Abuse and Mental
Health Services Administration, 2013, NSDUH; Substance Abuse and Mental Health
Services Administration, 2000, TREATMENT IMPROVEMEN, V38; Substance Abuse and
Mental Health Services Administration, 2005, SUBST AB TREATM PERS, V42; Substance
Abuse and Mental Health Services Administration, 2013, SAMHSAS WORK DEF REC;
Substance Abuse and Mental Health Services Administration, 2012, NSDUH SERIES H 45
HH; Substance Abuse and Mental Health Services Administration, SCREEN TOOLS;
Substance Abuse and Mental Health Services Administration, 2011, HHS PUBL, V11-
4658; Swendsen JD, 2000, J ABNORM PSYCHOL, V109, P198, DOI 10.1037//0021-
843X.109.2.198; The SASSI Institute, 2014, SUBST AB VOC REH SCR; van Os J, 2002, AM
J EPIDEMIOL, V156, P319, DOI 10.1093/aje/kwf043; Weiss RD, 2004, J AFFECT
DISORDERS, V79, P279, DOI 10.1016/S0165-0327(02)00454-8; Winterer G, 2010, CURR
OPIN PSYCHIATR, V23, P112, DOI 10.1097/YCO.0b013e3283366643; Wusthoff LE, 2014, BMC
PSYCHIATRY, V14, DOI 10.1186/1471-244X-14-67; Yun IA, 2004, J NEUROSCI, V24, P2923,
DOI 10.1523/JNEUROSCI.5282-03.2004; Zanis DA, 2001, J SUBST ABUSE TREAT, V21, P19,
DOI 10.1016/S0740-5472(01)00177-5 78 0 0 0 0 SPRINGER
PUBLISHING CO NEW YORK 11 WEST 42ND STREET, NEW YORK, NY 10036 USA 2168-
6653 2168-6661 REHABIL RES POL EDUC Rehabil. Res. Policy Educ.
2016 30 3 SI 243 258 10.1891/2168-
6653.30.3.243 16 Rehabilitation Rehabilitation VF6VP
WOS:000443419100005 2019-09-25
J Toftdahl, NG; Nordentoft, M; Hjorthoj, C Toftdahl, Nanna
Gilliam; Nordentoft, Merete; Hjorthoj, Carsten Prevalence of substance
use disorders in psychiatric patients: a nationwide Danish population-based study
SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY English
Article Psychiatric disorder; Substance use
disorder; Abuse; Comorbidity; Dual diagnosis SELF-MEDICATION HYPOTHESIS; SEVERE
MENTAL-ILLNESS; DRUG-USE DISORDERS; DUAL DIAGNOSIS; COMORBIDITY SURVEY;
EPIDEMIOLOGIC SURVEY; PSYCHOTIC DISORDERS; ALCOHOL-ABUSE; CANNABIS USE;
SCHIZOPHRENIA Purpose The present study established the national prevalence of
substance use disorders (SUDs) among Danish psychiatric patients. Furthermore,
patients with SUDs and those without SUDs were compared on a range of socio-
demographic, clinical, and treatment characteristics. Methods Data were obtained
from several Danish population-based registers. The study population was defined as
all individuals with incidents of schizophrenia, schizotypal disorder, other
psychoses, bipolar disorder, depression, anxiety, obsessive-compulsive disorder
(OCD), post-traumatic stress disorder (PTSD), and personality disorders since 1969.
The prevalence of SUDs was examined for the following psychoactive substances:
alcohol, opioids, cannabis, sedatives, cocaine, psycho-stimulants and
hallucinogens. Results A total of 463,003 patients were included in the analysis.
The prevalence of any lifetime SUD was: 37 % for schizophrenia, 35 % for
schizotypal disorder, 28 % for other psychoses, 32 % for bipolar disorder, 25 % for
depression, 25 % for anxiety, 11 % for OCD, 17% for PTSD, and 46 % for personality
disorders. Alcohol use disorder was the most dominating SUD in every psychiatric
category (25 % of all included patients). Patients with SUDs were more often men,
had fewer years of formal education, more often received disability pension and
died due to unnatural causes. Conclusions The study was the most comprehensive of
its kind so far to estimate the prevalence of SUDs in an unselected population-
based cohort, and it revealed remarkably high prevalence among the psychiatric
patients. The results should encourage continuous focus on possible comorbidity of
psychiatric patients, as well as specialised and integrated treatment along with
increased support of patients with comorbid disorders. [Toftdahl, Nanna
Gilliam; Nordentoft, Merete; Hjorthoj, Carsten] Copenhagen Univ Hosp, Mental Hlth
Ctr Copenhagen, Kildegardsvej 28, DK-2900 Hellerup, Denmark; [Toftdahl, Nanna
Gilliam; Nordentoft, Merete; Hjorthoj, Carsten] iPSYCH, Lundbeck Fdn Initiat
Integrat Psychiat Res, Aarhus, Denmark Toftdahl, NG (reprint author), Copenhagen
Univ Hosp, Mental Hlth Ctr Copenhagen, Kildegardsvej 28, DK-2900 Hellerup,
Denmark.; Toftdahl, NG (reprint author), iPSYCH, Lundbeck Fdn Initiat Integrat
Psychiat Res, Aarhus, Denmark. nannagilliam@gmail.com;
merete.nordentoft@regionh.dk; carsten.rygaard.hjorthoej@regionh.dk
Lundbeck FoundationLundbeckfonden; Lundbeck FoundationLundbeckfonden [R155-
2014-1724] Nanna Gilliam Toftdahl received a grant from the Lundbeck Foundation to
fund the work. The Lundbeck Foundation had no influence on the protocol, analysis,
interpretation, drafting of the manuscript, decision to publish, or any other areas
other than funding of the authors work. Buckley PF, 2006, J CLIN PSYCHIAT, V67,
P5; Curran GM, 2008, BMC EMERG MED, V8, DOI 10.1186/1471-227X-8-17; DIXON L, 1990,
SCHIZOPHRENIA BULL, V16, P69, DOI 10.1093/schbul/16.1.69; DRAKE RE, 1991, AM
PSYCHOL, V46, P1149, DOI 10.1037/0003-066X.46.11.1149; Drake RE, 2004, PSYCHIATR
REHABIL J, V27, P360, DOI 10.2975/27.2004.360.374; Drake RE, 1998, RECENT DEV
ALCOHOL, V14, P285, DOI 10.1007/0-306-47148-5_12; Drake RE, 2000, SCHIZOPHRENIA
BULL, V26, P105, DOI 10.1093/oxfordjournals.schbul.a033429; Drake RE, 2002, J NERV
MENT DIS, V190, P100, DOI 10.1097/00005053-200202000-00006; Druss BG, 2011, MED
CARE, V49, P599, DOI 10.1097/MLR.0b013e31820bf86e; Grant BF, 2004, ARCH GEN
PSYCHIAT, V61, P807, DOI 10.1001/archpsyc.61.8.807; Grant BF, 1996, J SUBST ABUSE,
V8, P195, DOI 10.1016/S0899-3289(96)90249-7; Hansen SS, 2000, ACTA PSYCHIAT SCAND,
V102, P432, DOI 10.1034/j.1600-0447.2000.102006432.x; Hartz SM, 2014, JAMA
PSYCHIAT, V71, P248, DOI 10.1001/jamapsychiatry.2013.3726; HAYWOOD TW, 1995, AM J
PSYCHIAT, V152, P856; Health U.S.D.o, 2003, HUM SERV SUBST MENT; Helweg-Larsen K,
2011, SCAND J PUBLIC HEALT, V39, P26, DOI 10.1177/1403494811399958; Henwood B,
2007, AM J ADDICTION, V16, P160, DOI 10.1080/10550490701375368; Hvidtfeldt U, 2008,
ALKOHOLFORBRUG DANMA; Jimenez-Castro L, 2010, SCHIZOPHR RES, V120, P87, DOI
10.1016/j.schres.2010.02.1053; Kavanagh DJ, 2004, SCHIZOPHR RES, V66, P115, DOI
10.1016/S0920-9964(03)00130-0; Kessler RC, 1997, ARCH GEN PSYCHIAT, V54, P313;
Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P617, DOI 10.1001/archpsyc.62.6.617;
KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259; Kildemoes HW, 2011, SCAND J PUBLIC
HEALT, V39, P38, DOI 10.1177/1403494810394717; Lai HMX, 2009, DRUG ALCOHOL REV,
V28, P235, DOI 10.1111/j.1465-3362.2008.00021.x; Laursen TM, 2007, J CLIN PSYCHIAT,
V68, P899, DOI 10.4088/JCP.v68n0612; Lembke A, 2012, AM J DRUG ALCOHOL AB, V38,
P524, DOI 10.3109/00952990.2012.694532; Lybrand J, 2009, PSYCHIAT CLIN N AM, V32,
P821, DOI 10.1016/j.psc.2009.09.002; Lynge E, 2011, SCAND J PUBLIC HEALT, V39, P30,
DOI 10.1177/1403494811401482; Macleod J, 2004, LANCET, V363, P1579, DOI
10.1016/S0140-6736(04)16200-4; Menezes PR, 1996, BRIT J PSYCHIAT, V168, P612, DOI
10.1192/bjp.168.5.612; Miles H, 2003, PSYCHIAT SERV, V54, P554, DOI
10.1176/appi.ps.54.4.554; Minassian A, 2013, J EMERG MED, V45, P520, DOI
10.1016/j.jemermed.2013.05.007; Moore E, 2012, AUST NZ J PSYCHIAT, V46, P864, DOI
10.1177/0004867412443900; Moore THM, 2007, LANCET, V370, P319, DOI 10.1016/S0140-
6736(07)61162-3; Mors O, 2011, SCAND J PUBLIC HEALT, V39, P54, DOI
10.1177/1403494810395825; Mueser KT, 1998, ADDICT BEHAV, V23, P717, DOI
10.1016/S0306-4603(98)00073-2; Nesvag R, 2015, SOC PSYCH PSYCH EPID, V50, P1267,
DOI 10.1007/s00127-015-1025-2; Nordentoft M, 2013, PLOS ONE, V8, DOI
10.1371/journal.pone.0055176; Parks J, 2006, MORBIDITY MORTALITY; Pedersen CB,
2011, SCAND J PUBLIC HEALT, V39, P22, DOI 10.1177/1403494810387965; REGIER DA,
1990, JAMA-J AM MED ASSOC, V264, P2511; RIDGELY MS, 1990, SCHIZOPHRENIA BULL, V16,
P123, DOI 10.1093/schbul/16.1.123; Saraceno Benedetto, 2002, Epidemiol Psichiatr
Soc, V11, P83; Soyka M, 2000, BRIT J PSYCHIAT, V176, P345, DOI
10.1192/bjp.176.4.345; Swendsen J, 2010, ADDICTION, V105, P1117, DOI
10.1111/j.1360-0443.2010.02902.x; The Danish health and medicines authority, 2012,
NARK DANM 2012; The International Classification of Diseases (ICD), 2008, INT CLASS
DIS ICD; The National Board of Social Services and the Ministry of Social Affairs,
2014, REG DRUG AB UND TREA; Thygesen LC, 2011, SCAND J PUBLIC HEALT, V39, P12, DOI
10.1177/1403494811399956; Whiteford HA, 2013, LANCET, V382, P1575, DOI
10.1016/S0140-6736(13)61611-6; Wittchen HU, 2011, EUR NEUROPSYCHOPHARM, V21, P655,
DOI 10.1016/j.euroneuro.2011.07.018; Zammit S, 2008, BRIT J PSYCHIAT, V193, P357,
DOI 10.1192/bjp.bp.107.046375 53 44 44 0 26 SPRINGER HEIDELBERG
HEIDELBERG TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY 0933-7954
1433-9285 SOC PSYCH PSYCH EPID Soc. Psychiatry Psychiatr.
Epidemiol. JAN 2016 51 1 129 140
10.1007/s00127-015-1104-4 12 Psychiatry Psychiatry DD8UR
WOS:000370202900014 26260950 2019-09-25
J Kang, T; Louden, JE; Ricks, EP; Jones, RL Kang, Tamara;
Louden, Jennifer Eno; Ricks, Elijah P.; Jones, Rachell L. Aggression,
Substance Use Disorder, and Presence of a Prior Suicide Attempt Among Juvenile
Offenders With Subclinical Depression LAW AND HUMAN BEHAVIOR
English Article aggression; juvenile
offenders; subclinical depression; substance abuse; suicideSELF-MEDICATION
HYPOTHESIS; MENTAL-HEALTH COURT; DSM-V; RISK; DELINQUENCY; RECIDIVISM; SAMPLE;
PSYCHOPATHY; ADOLESCENCE; PREVALENCE Juvenile justice agencies often use the
presence of a Diagnostic and Statistical Manual of Mental Disorders (DSM) diagnosis
as a criterion for offenders' eligibility for mental health treatment. However,
relying on diagnoses to sort offenders into discrete categories ignores subclinical
disorders-impairment that falls below the threshold of DSM criteria. The current
study used structured clinical interviews with 489 juvenile offenders to examine
aggression, presence of a prior suicide attempt, and substance use disorders among
juvenile offenders with subclinical depression compared with juvenile offenders
with major depression or no mood disorder. Analyses demonstrated that juvenile
offenders with subclinical depression reported significantly more aggression, abuse
of substances, and the presence of a prior suicide attempt compared to juvenile
offenders with no mood disorder, but did not differ significantly on aggression and
substance abuse compared with juvenile offenders with major depression. These
results have implications for correctional agencies' policies through which
offenders are offered mental health treatment, and provide a first step in
identifying early signs of problematic behavior before it worsens. Specifically,
the results support the notion that depressive disorders should be viewed along a
continuum when determining how to allocate services. [Kang, Tamara; Louden,
Jennifer Eno; Ricks, Elijah P.; Jones, Rachell L.] Univ Texas El Paso, Dept
Psychol, 500 West Univ Ave, El Paso, TX 79902 USA; [Ricks, Elijah P.] Roosevelt
Univ, Dept Psychol, Chicago, IL USA; [Jones, Rachell L.] US Army Res Inst Behav &
Social Sci, Ft Leavenworth, KS USA Kang, T (reprint author), Univ Texas El Paso,
Dept Psychol, 500 West Univ Ave, El Paso, TX 79902 USA. tkang2@miners.utep.edu
Abram KM, 2008, J AM ACAD CHILD PSY, V47, P291, DOI
10.1097/chi.0b013e318160bce; Almquist L, 2009, MENTAL HLTH COURTS G; American
Psychiatric Association, 2013, DIAGN STAT MAN MENT; American Psychiatric
Association, 2000, DIAGN STAT MAN MENT; Andrews DA, 2010, PSYCHOL PUBLIC POL L,
V16, P39, DOI 10.1037/a0018362; Andrews DA, 2006, CRIME DELINQUENCY, V52, P7, DOI
10.1177/0011128705281756; Arredondo DE, 2001, JUVENILE FAM COURT J, V52, P1, DOI
10.1111/j.1755-6988.2001.tb00047.x; BAILEY S, 1993, CRIM BEHAV MENT HEAL, V3, P349;
Banerjee M, 1999, CAN J STAT, V27, P3, DOI 10.2307/3315487; Becker S. P., 2012, J
CHILD ADOLESCENT T, V5, P145, DOI [10.1080/19361521.2012.671798, DOI
10.1080/19361521.2012.671798]; Bjorkenstam E, 2011, INT J EPIDEMIOL, V40, P1585,
DOI 10.1093/ije/dyr127; Bonta J., 2007, REHABILITATION, P1; Brown TA, 2005, J
ABNORM PSYCHOL, V114, P551, DOI 10.1037/0021-843X.114.4.551; Burriss FA, 2011, J
CHILD ADOL PS NURS, V24, P114, DOI 10.1111/j.1744-6171.2011.00276.x; Cauce AM,
2002, J CONSULT CLIN PSYCH, V70, P44, DOI 10.1037//0022-006X.70.1.44; Cocozza J.
J., 2000, JUVENILE JUSTICE, V7, P2; Cocozza J. J., 2006, JUVENILE MENTAL HLTH;
Colman I, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.a2981; Cottle CC, 2001, CRIM
JUSTICE BEHAV, V28, P367, DOI 10.1177/0093854801028003005; Cukrowicz KC, 2011, J AM
COLL HEALTH, V59, P575, DOI 10.1080/07448481.2010.483710; Demjaha A, 2009, PSYCHOL
MED, V39, P1943, DOI 10.1017/S0033291709990651; Fergusson DM, 2005, ARCH GEN
PSYCHIAT, V62, P66, DOI 10.1001/archpsyc.62.1.66; Grisso T., 2006, MASSACHUSETTS
YOUTH; Grisso T, 2008, FUTURE CHILD, V18, P143; Herinckx HA, 2005, PSYCHIAT SERV,
V56, P853, DOI 10.1176/appi.ps.56.7.853; Jackson J, 2011, J ABNORM CHILD PSYCH,
V39, P463, DOI 10.1007/s10802-010-9473-3; Kahneman D, 2009, AM PSYCHOL, V64, P515,
DOI 10.1037/a0016755; Kaufman J, 1996, KIDDIE SADS PRESENT; KHANTZIAN EJ, 1985, AM
J PSYCHIAT, V142, P1259; Kofler MJ, 2011, J CONSULT CLIN PSYCH, V79, P458, DOI
10.1037/a0024108; Krueger RF, 2007, INT J METH PSYCH RES, V16, pS65, DOI
10.1002/mpr.212; Lembke A, 2012, AM J DRUG ALCOHOL AB, V38, P524, DOI
10.3109/00952990.2012.694532; Lewinsohn PM, 2000, J ABNORM PSYCHOL, V109, P345, DOI
10.1037//0021-843X.109.2.345; Lilienfeld SO, 2013, CLIN PSYCHOL REV, V33, P883, DOI
10.1016/j.cpr.2012.09.008; Loeber R, 1999, J CLIN CHILD PSYCHOL, V28, P322, DOI
10.1207/S15374424jccp280304; Loeber R, 2000, J AM ACAD CHILD PSY, V39, P1468, DOI
10.1097/00004583-200012000-00007; Magruder KM, 2000, COMPR PSYCHIAT, V41, P14, DOI
10.1016/S0010-440X(00)80003-6; Mason WA, 2009, SUBST USE MISUSE, V44, P1142, DOI
10.1080/10826080802495211; Mattila VM, 2006, J ADOLESCENT HEALTH, V38, P617, DOI
10.1016/j.jadohealth.2005.03.007; McCracken J. T., 1993, DEPRESSION CHILDREN, V6,
P121; McReynolds LS, 2010, CRIM JUSTICE BEHAV, V37, P204, DOI
10.1177/0093854809354961; Merikangas KR, 2010, PEDIATRICS, V125, P75, DOI
10.1542/peds.2008-2598; Neal TMS, 2014, PSYCHOL PUBLIC POL L, V20, P200, DOI
10.1037/a0035824; Price SD, 2013, PERSONAL DISORD, V4, P261, DOI
10.1037/per0000011; Puzzanchera C., 2013, JUVENILE OFFENDERS V; Redlich AD, 2005,
PSYCHOL PUBLIC POL L, V11, P527, DOI 10.1037/1076-8971.11.4.527; Reinke WM, 2012, J
ABNORM CHILD PSYCH, V40, P1123, DOI 10.1007/s10802-012-9630-y; Salekin RT, 2004, J
ABNORM PSYCHOL, V113, P416, DOI 10.1037/0021-843x.113.3.416; Satcher D., 2001,
MENTAL HLTH CULTURE; Schubert CA, 2011, J AM ACAD CHILD PSY, V50, P925, DOI
10.1016/j.jaac.2011.06.006; Shankman SA, 2009, J CHILD PSYCHOL PSYC, V50, P1485,
DOI 10.1111/j.1469-7610.2009.02117.x; Skeem JL, 2011, LAW HUMAN BEHAV, V35, P110,
DOI 10.1007/s10979-010-9223-7; Skowyra K. R., 2007, 2001BRJX0001; Stringaris A,
2012, AM J PSYCHIAT, V169, P47, DOI 10.1176/appi.ajp.2011.10101549; Teplin LA,
2002, ARCH GEN PSYCHIAT, V59, P1133, DOI 10.1001/archpsyc.59.12.1133; Trull TJ,
2011, CURR PSYCHIAT REP, V13, P43, DOI 10.1007/s11920-010-0170-2; TVERSKY A, 1974,
SCIENCE, V185, P1124, DOI 10.1126/science.185.4157.1124; United States Census
Bureau, 2012, MEAS AM PEOPL PLAC O; URDANETA ML, 1995, HUM ORGAN, V54, P70, DOI
10.17730/humo.54.1.e216p6442857477q; van der Put CE, 2014, DRUG ALCOHOL DEPEN,
V134, P267, DOI 10.1016/j.drugalcdep.2013.10.012; Vanderloo M. J., 2012, TREATING
OFFENDERS M; Wasserman GA, 2006, SUICIDE LIFE-THREAT, V36, P239, DOI
10.1521/suli.2006.36.2.239; Widiger TA, 2005, J ABNORM PSYCHOL, V114, P494, DOI
10.1037/0021-843X.114.4.494; WIDIGER TA, 1987, ARCH GEN PSYCHIAT, V44, P557;
WIERSON M, 1995, BEHAV RES THER, V33, P63, DOI 10.1016/0005-7967(94)E0001-Y 65
6 6 0 10 AMER PSYCHOLOGICAL ASSOC WASHINGTON 750 FIRST ST
NE, WASHINGTON, DC 20002-4242 USA 0147-7307 1573-661X LAW HUMAN BEHAV
Law Hum. Behav. DEC 2015 39 6 593 601
10.1037/lhb0000145 9 Law; Psychology, Social Government &
Law; Psychology DC7NH WOS:000369406600006 26168168 2019-
09-25
J Garland, EL; Brown, S; Howard, MO Garland, Eric L.; Brown,
Samantha; Howard, Matthew O. Traumatic Experiences and Reduced Alcohol
Self-efficacy in Alcohol Dependent Inpatients: Attentional and Autonomic Mediators
KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY
English Article alcohol
dependence; attentional bias; heart rate variability; self-efficacy; traumatic
experiences; PTSD HEART-RATE-VARIABILITY; POSTTRAUMATIC-STRESS-DISORDER; CUE-
REACTIVITY; THOUGHT SUPPRESSION; SUBSTANCE USE; SOCIAL DRINKERS; FIT INDEXES;
MINDFULNESS; BIAS; PTSD Objective: Self-medication with alcohol has been documented
among individuals exposed to chronic trauma who may be unable to resist urges to
drink in high-risk situations. Persistent alcohol use can result in attentional
bias (AB) toward alcohol cues and psychophysiological reactivity such as changes in
cue-elicited heart rate variability (HRV).The present study tested the hypothesis
that individual differences in alcohol AB and HRV mediate the association between
lifetime exposure to traumatic events and alcohol-related self-efficacy among a
sample of alcohol dependent adults in inpatient treatment. Method: This paper
details a secondary data analysis from a sample of alcohol dependent adults (N =
58) who completed standardized psychosocial instruments, an affect-modulated cue
reactivity protocol, and a spatial cueing task. Results: Path analyses indicated
statistically significant direct effects of levels of lifetime trauma exposure on
Low Frequency/High Frequency-HRV cue-reactivity, alcohol AB, and alcohol self-
efficacy. A statistically significant indirect effect was found from lifetime
trauma exposure to alcohol-related self-efficacy through alcohol AB. Conclusions:
Results suggest that alcohol AB partially mediates the relationship between greater
lifetime trauma exposure and reduced alcohol self-efficacy. Hence, alcohol
dependent individuals with more extensive trauma histories may benefit from
therapies aimed at increasing self-awareness and self-regulation of attentional and
autonomic reactivity to prevent risk of relapse. [Garland, Eric L.] Univ Utah,
Coll Social Work, Salt Lake City, UT 84112 USA; [Garland, Eric L.] Univ Utah,
Huntsman Canc Inst, Salt Lake City, UT 84112 USA; [Brown, Samantha] Univ Denver,
Grad Sch Social Work, Denver, CO 80208 USA; [Howard, Matthew O.] Univ N Carolina,
Sch Social Work, Chapel Hill, NC USA Garland, EL (reprint author), Univ Utah,
Coll Social Work, Salt Lake City, UT 84112 USA. eric.garland@socwk.utah.edu
Brown, Samantha/0000-0002-7704-8120 Annis H. M., 1988,
SITUATIONAL CONFIDEN; Arbuckle JL, 2008, AMOS 17 0 UPDATE AMO; Back S, 2000, AM J
ADDICTION, V9, P51; BENTLER PM, 1990, PSYCHOL BULL, V107, P238, DOI 10.1037/0033-
2909.107.2.238; Berntson GG, 1997, PSYCHOPHYSIOLOGY, V34, P623, DOI 10.1111/j.1469-
8986.1997.tb02140.x; Bowen S, 2014, JAMA PSYCHIAT, V71, P547, DOI
10.1001/jamapsychiatry.2013.4546; Bremner JD, 1996, AM J PSYCHIAT, V153, P369;
Breslau N, 2002, CAN J PSYCHIAT, V47, P923; Carrasco M, 2006, PROG BRAIN RES, V154,
P33; Carter BL, 1999, ADDICTION, V94, P327, DOI 10.1046/j.1360-0443.1999.9433273.x;
Cheetham A, 2010, CLIN PSYCHOL REV, V30, P621, DOI 10.1016/j.cpr.2010.04.005;
Coffey SF, 2010, EXP CLIN PSYCHOPHARM, V18, P340, DOI 10.1037/a0019790; Cohen H,
1998, BIOL PSYCHIAT, V44, P1054, DOI 10.1016/S0006-3223(97)00475-7; Cohen H, 2000,
PSYCHIAT RES, V96, P1, DOI 10.1016/S0165-1781(00)00195-5; D'Andrea W, 2013, INT J
PSYCHOPHYSIOL, V90, P80, DOI 10.1016/j.ijpsycho.2013.07.008; Denver JW, 2007, BIOL
PSYCHOL, V74, P286, DOI 10.1016/j.biopsycho.2005.09.005; Fetzner MG, 2011, DEPRESS
ANXIETY, V28, P632, DOI 10.1002/da.20852; Field M, 2004, PSYCHOPHARMACOLOGY, V176,
P88, DOI 10.1007/s00213-004-1855-1; Field M, 2008, DRUG ALCOHOL DEPEN, V97, P1, DOI
10.1016/j.drugalcdep.2008.03.030; Field M, 2007, ALCOHOL ALCOHOLISM, V42, P560, DOI
10.1093/alcalc/agm064; Field M, 2007, PSYCHOPHARMACOLOGY, V192, P593, DOI
10.1007/s00213-007-0760-9; Field M, 2009, PSYCHOL BULL, V135, P589, DOI
10.1037/a0015843; Garland EL, 2014, FRONT PSYCHIATRY, V4, DOI
10.3389/fpsyt.2013.00173; Garland EL, 2014, J CONSULT CLIN PSYCH, V82, P448, DOI
10.1037/a0035798; Garland EL, 2013, ADDICT BEHAV, V38, P1555, DOI
10.1016/j.addbeh.2012.02.004; Garland EL, 2012, PSYCHOPHARMACOLOGY, V222, P17, DOI
10.1007/s00213-011-2618-4; Garland EL, 2012, EXP CLIN PSYCHOPHARM, V20, P225, DOI
10.1037/a0027199; Garland EL, 2012, COGNITIVE THER RES, V36, P441, DOI
10.1007/s10608-011-9378-7; Garland EL, 2011, J PSYCHOPHYSIOL, V25, P180, DOI
10.1027/0269-8803/a000060; Garland EL, 2012, BIOL PSYCHOL, V89, P87, DOI
10.1016/j.biopsycho.2011.09.010; Garland EL, 2011, MED HYPOTHESES, V76, P745, DOI
10.1016/j.mehy.2011.02.014; Garland EL, 2010, J PSYCHOACTIVE DRUGS, V42, P177, DOI
10.1080/02791072.2010.10400690; Ginty AT, 2013, INT J PSYCHOPHYSIOL, V90, P90, DOI
10.1016/j.ijpsycho.2013.06.008; Goldstein RZ, 2009, TRENDS COGN SCI, V13, P372, DOI
10.1016/j.tics.2009.06.004; Greenfield SF, 2000, J STUD ALCOHOL, V61, P345, DOI
10.15288/jsa.2000.61.345; Grossman P, 2007, BIOL PSYCHOL, V74, P263, DOI
10.1016/j.biopsycho.2005.11.014; Haller M, 2014, PSYCHOL ADDICT BEHAV, V28, P841,
DOI 10.1037/a0035878; Halligan SL, 2006, J TRAUMA STRESS, V19, P721, DOI
10.1002/jts.20167; Hauschildt M, 2011, BIOL PSYCHOL, V88, P215, DOI
10.1016/j.biopsycho.2011.08.004; Hopfinger JB, 2005, COGNITIVE BRAIN RES, V25, P48,
DOI 10.1016/j.cogbrainres.2005.04.010; Hu LT, 1999, STRUCT EQU MODELING, V6, P1,
DOI 10.1080/10705519909540118; Ingjaldsson JT, 2003, BIOL PSYCHIAT, V54, P1427, DOI
10.1016/S0006-3223(02)01926-1; Jacobsen LK, 2001, AM J PSYCHIAT, V158, P1184, DOI
10.1176/appi.ajp.158.8.1184; Laudet AB, 2010, J SUBST ABUSE TREAT, V38, P317, DOI
10.1016/j.jsat.2010.01.007; Leeies M, 2010, DEPRESS ANXIETY, V27, P731, DOI
10.1002/da.20677; Loeber S, 2006, BRIT J CLIN PSYCHOL, V45, P515, DOI
10.1348/014466505X82586; Malliani A, 2005, EUR J INTERN MED, V16, P12, DOI DOI
10.1016/J.EJIM.2004.06.016; MANUCK SB, 1989, HDB RES METHODS CARD, P365, DOI DOI
10.1007/978-1-4899-0906-0_23; McTeague LM, 2010, BIOL PSYCHIAT, V67, P346, DOI
10.1016/j.biopsych.2009.08.023; Nagpal M. L., 2013, TRAUMA TREAT, V3, P1, DOI
[10.4172/2167-1222.1000182, DOI 10.4172/2167-1222.1000182]; Orfei MD, 2008,
NEUROSCIENTIST, V14, P203, DOI 10.1177/1073858407309995; Ori Z, 1992, Cardiol Clin,
V10, P499; Quintana DS, 2013, DRUG ALCOHOL DEPEN, V132, P395, DOI
10.1016/j.drugalcdep.2013.02.025; Rajan I, 1998, BIOL PSYCHIAT, V43, P544, DOI
10.1016/S0006-3223(97)00399-5; Robinson TE, 2001, ADDICTION, V96, P103, DOI
10.1046/j.1360-0443.2001.9611038.x; Sahar T, 2001, BIOL PSYCHIAT, V49, P637, DOI
10.1016/S0006-3223(00)01045-3; Schlomer GL, 2010, J COUNS PSYCHOL, V57, P1, DOI
10.1037/a0018082; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI
10.4088/JCP.09m05305whi; Sobel M. E., 1982, SOCIOL METHODOL, P290, DOI DOI
10.2307/270723; THEEUWES J, 1991, PERCEPT PSYCHOPHYS, V49, P83, DOI
10.3758/BF03211619; TIFFANY ST, 1990, PSYCHOL REV, V97, P147, DOI 10.1037/0033-
295X.97.2.147; Zoladz PR, 2013, NEUROSCI BIOBEHAV R, V37, P860, DOI
10.1016/j.neubiorev.2013.03.024 62 0 0 0 11 KURE ILETISIM
GRUBU A S ISTANBUL SIRACEVIZLER CAD 43/3 SISLI, ISTANBUL, 34381, TURKEY 1017-
7833 KLIN PSIKOFARMAKOL B Klin. Psikofarmakol. Bul. DEC 2015
25 4 355 364
10.5455/bcp.20150502072931 10 Pharmacology & Pharmacy;
Psychiatry Pharmacology & Pharmacy; Psychiatry DA2PF WOS:000367637600006
2019-09-25
J Possemato, K; Maisto, SA; Wade, M; Barrie, K; McKenzie, S; Lantinga, LJ;
Ouimette, P Possemato, Kyle; Maisto, Stephen A.; Wade, Michael;
Barrie, Kimberly; McKenzie, Shannon; Lantinga, Larry J.; Ouimette, Paige
Ecological Momentary Assessment of PTSD Symptoms and Alcohol Use in Combat
Veterans PSYCHOLOGY OF ADDICTIVE BEHAVIORS English Article
PTSD; alcohol use; veterans; ecological momentary
assessment; self-medication POSTTRAUMATIC-STRESS-DISORDER; SUBSTANCE-ABUSE
PATIENTS; PREDICT ALCOHOL; TIMELINE FOLLOWBACK; DRINKING MOTIVES; MENTAL-HEALTH;
PRIMARY-CARE; 1ST YEAR; COLLEGE; SELF Despite high rates of comorbid hazardous
alcohol use and posttraumatic stress disorder (PTSD), the nature of the functional
relationship between these problems is not fully understood. Insufficient evidence
exists to fully support models commonly used to explain the relationship between
hazardous alcohol use and PTSD including the self-medication hypothesis and the
mutual maintenance model. Ecological momentary assessment (EMA) can monitor within-
day fluctuations of symptoms and drinking to provide novel information regarding
potential functional relationships and symptom interactions. This study aimed to
model the daily course of alcohol use and PTSD symptoms and to test theory-based
moderators, including avoidance coping and self-efficacy to resist drinking. A
total of 143 recent combat veterans with PTSD symptoms and hazardous drinking
completed brief assessments of alcohol use, PTSD symptoms, mood, coping, and self-
efficacy 4 times daily for 28 days. Our results support the finding that increases
in PTSD are associated with more drinking within the same 3-hr time block, but not
more drinking within the following time block. Support for moderators was found:
Avoidance coping strengthened the relationship between PTSD and later drinking,
while self-efficacy to resist drinking weakened the relationship between PTSD and
later drinking. An exploratory analysis revealed support for self-medication
occurring in certain times of the day: Increased PTSD severity in the evening
predicted more drinking overnight. Overall, our results provide mixed support for
the self-medication hypothesis. Also, interventions that seek to reduce avoidance
coping and increase patient self-efficacy may help veterans with PTSD decrease
drinking. [Possemato, Kyle; Maisto, Stephen A.; Wade, Michael; Barrie, Kimberly;
McKenzie, Shannon; Lantinga, Larry J.; Ouimette, Paige] Syracuse VA Med Ctr, Ctr
Integrated Healthcare, Syracuse, NY 13210 USA Barrie, K (reprint author),
Syracuse VA Med Ctr, Ctr Integrated Healthcare, 800 Irving Ave,116-C, Syracuse, NY
13210 USA. kimberly.barrie@va.gov Veterans Affairs Clinical Services
Research and Development grant (VHA CSRD) [1I01CX000175-01A1] This work was
funded by a Veterans Affairs Clinical Services Research and Development grant
awarded to Paige Ouimette (VHA CSR&D 1I01CX000175-01A1). The views expressed in
this article are those of the authors and do not necessarily reflect the position
or policy of the Department of Veterans Affairs or the United States government. We
would like to acknowledge several individuals who assisted in data collection:
Elizabeth Banks-Feldhousen, Emily Brooks, Tiffany Bruder, Clare Campbell, Leigha
DeStefano, Emily Kaier, Paul Knowlton, Andrea Pratt, Marissa Stroo, and Dr. Laura
Wray. American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Andreski P,
1998, PSYCHIAT RES, V79, P131, DOI 10.1016/S0165-1781(98)00026-2; Annis H. M.,
1988, SITUATIONAL CONFIDEN; Babor T. F., 2001, ALCOHOL USE DISORDER; Bailey K.M.,
2014, TRAUMA SUBSTANCE ABU, P11; Bandura A, 1986, SOCIAL FDN THOUGHT A; Beckham JC,
2008, NICOTINE TOB RES, V10, P1149, DOI 10.1080/14622200802123302; Blake D. D.,
1990, J TRAUMA STRESS, V3, P15, DOI DOI 10.1002/JTS.2490030103; BLAKE DD, 1995, J
TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Carey KB, 2004, J STUD ALCOHOL,
V65, P774, DOI 10.15288/jsa.2004.65.774; Chung T, 2001, J CONSULT CLIN PSYCH, V69,
P92, DOI 10.1037//0022-006X.69.1.92; Collins RL, 1998, EXP CLIN PSYCHOPHARM, V6,
P306, DOI 10.1037/1064-1297.6.3.306; Cooney NL, 2007, PSYCHOL ADDICT BEHAV, V21,
P277, DOI 10.1037/0893-164X.21.3.277; COOPER ML, 1995, J PERS SOC PSYCHOL, V69,
P990, DOI 10.1037/0022-3514.69.5.990; Curran PJ, 2011, ANNU REV PSYCHOL, V62, P583,
DOI 10.1146/annurev.psych.093008.100356; First M., 2002, STRUCTURED CLIN INTE;
Grubaugh AL, 2005, J NERV MENT DIS, V193, P658, DOI
10.1097/01.nmd.0000180740.02644.ab; Heron KE, 2010, BRIT J HEALTH PSYCH, V15, P1,
DOI 10.1348/135910709X466063; Hofmann SG, 2009, J ANXIETY DISORD, V23, P529, DOI
10.1016/j.janxdis.2008.10.011; Hruska B, 2011, PSYCHOL ADDICT BEHAV, V25, P405, DOI
10.1037/a0022439; Jakupcak M, 2008, J NERV MENT DIS, V196, P425, DOI
10.1097/NMD.0b013e31817108ed; Johnson DR, 2002, J NERV MENT DIS, V190, P683, DOI
10.1097/01.NMD.0000034743.93582.B6; Kaysen D, 2014, PSYCHOL ADDICT BEHAV, V28, P62,
DOI 10.1037/a0033588; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI
10.1001/archpsyc.1995.03950240066012; Khantzian E. J., 2003, PRIMARY PSYCHIAT, V10,
p[47, 53]; Kranzler HR, 1996, ADDICTION, V91, P859, DOI 10.1111/j.1360-
0443.1996.tb03580.x; Kulka RA, 1990, TRAUMA VIETNAM WAR G; Leeies M, 2010, DEPRESS
ANXIETY, V27, P731, DOI 10.1002/da.20677; Lobbestael J, 2011, CLIN PSYCHOL PSYCHOT,
V18, P75, DOI 10.1002/cpp.693; MAISTO SA, 1999, PSYCHOL THEORIES DRI, P106;
Marshall BDL, 2012, DRUG ALCOHOL DEPEN, V124, P193, DOI
10.1016/j.drugalcdep.2011.12.027; McDevitt-Murphy ME, 2010, J TRAUMA STRESS, V23,
P108, DOI 10.1002/jts.20482; McFarlane AC, 2009, J AFFECT DISORDERS, V118, P166,
DOI 10.1016/j.jad.2009.01.017; Miller WR, 2002, MOTIVATIONAL INTERVI; Mills KL,
2006, AM J PSYCHIAT, V163, P652, DOI 10.1176/appi.ajp.163.4.652; Moos R. H., 1993,
COPING RESPONSES INV; Ouimette P, 2007, ADDICT BEHAV, V32, P1719, DOI
10.1016/j.addbeh.2006.11.020; Ouimette PC, 1999, PSYCHOL ADDICT BEHAV, V13, P105,
DOI 10.1037/0893-164X.13.2.105; Ouimette PC, 1997, PSYCHOL ADDICT BEHAV, V11, P34,
DOI 10.1037/0893-164X.11.1.34; Possemato K, 2014, TRAUMA SUBSTANCE ABU, P305, DOI
DOI 10.1037/14273-015.; Possemato K, 2012, PSYCHOL SERV, V9, P185, DOI
10.1037/a0027144; Read JP, 2012, J CONSULT CLIN PSYCH, V80, P426, DOI
10.1037/a0028210; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-
0443.1993.tb02093.x; Seal KH, 2010, J TRAUMA STRESS, V23, P5, DOI
10.1002/jts.20493; Searles JS, 2002, J STUD ALCOHOL, V63, P352, DOI
10.15288/jsa.2002.63.352; Simonich H, 2004, CHILD ABUSE NEGLECT, V28, P803, DOI
10.1016/j.chiabu.2004.01.005; Simpson TL, 2005, DRUG ALCOHOL DEPEN, V79, P241, DOI
10.1016/j.drugalcdep.2005.02.001; Simpson TL, 2014, J ABNORM PSYCHOL, V123, P237,
DOI 10.1037/a0035193; Simpson TL, 2012, PSYCHOL ADDICT BEHAV, V26, P724, DOI
10.1037/a0027169; Sobell L. C., 1992, MEASURING ALCOHOL CO, Vxii, P41; Sobell LC,
1996, DRUG ALCOHOL DEPEN, V42, P49, DOI 10.1016/0376-8716(96)01263-X; Stappenbeck
CA, 2013, ADDICT BEHAV, V38, P1831, DOI 10.1016/j.addbeh.2012.10.012; STASIEWICZ
PR, 1993, BEHAV THER, V24, P337, DOI 10.1016/S0005-7894(05)80210-2; WATSON D, 1985,
PSYCHOL BULL, V98, P219, DOI 10.1037/0033-2909.98.2.219 54 29 29 0
19 EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
WASHINGTON 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA 0893-164X 1939-
1501 PSYCHOL ADDICT BEHAV Psychol. Addict. Behav. DEC 2015 29 4
894 905 10.1037/adb0000129 12
Substance Abuse; Psychology, Multidisciplinary Substance Abuse; Psychology
DA0BE WOS:000367460900008 26727007 2019-09-25
J Fischer, B; Kuganesan, S; Gallassi, A; Malcher-Lopes, R; van den Brink, W;
Wood, E Fischer, Benedikt; Kuganesan, Sharan; Gallassi,
Andrea; Malcher-Lopes, Renato; van den Brink, Wim; Wood, Evan
Addressing the stimulant treatment gap: A call to investigate the therapeutic
benefits potential of cannabinoids for crack-cocaine use INTERNATIONAL JOURNAL OF
DRUG POLICY English Editorial Material
Crack-cocaine; Treatment; Pharmacotherapy; Cannabinoids; Cannabidiol;
Americas COGNITIVE-BEHAVIORAL THERAPY; INJECTION-DRUG-USE; CONTINGENCY
MANAGEMENT; MEDICAL MARIJUANA; COMMUNITY SAMPLE; RISK BEHAVIORS; CANNABIDIOL;
DEPENDENCE; DISORDER; WITHDRAWAL Crack-cocaine use is prevalent in numerous
countries, yet concentrated primarily - largely within urban contexts - in the
Northern and Southern regions of the Americas. It is associated with a variety of
behavioral, physical and mental health and social problems which gravely affect
users and their environments. Few evidence-based treatments for crack-cocaine use
exist and are available to users in the reality of street drug use. Numerous
pharmacological treatments have been investigated but with largely disappointing
results. An important therapeutic potential for crack-cocaine use may rest in
cannabinoids, which have recently seen a general resurgence for varied possible
therapeutic usages for different neurological diseases. Distinct potential
therapeutic benefits for crack-cocaine use and common related adverse symptoms may
come specifically from cannabidiol (CBD) - one of the numerous cannabinoid
components found in cannabis - with its demonstrated anxiolytic, antipsychotic,
anti-convulsant effects and potential benefits for sleep and appetite problems. The
possible therapeutic prospects of cannabinoids are corroborated by observational
studies from different contexts documenting crack-cocaine users' 'self-medication'
efforts towards coping with crack-cocaine-related problems, including withdrawal
and craving, impulsivity and paranoia. Cannabinoid therapeutics offer further
benefits of being available in multiple formulations, are low in adverse risk
potential, and may easily be offered in community-based settings which may add to
their feasibility as interventions for predominantly marginalized - crack-cocaine
user populations. Supported by the dearth of current therapeutic options for crack-
cocaine use, we are advocating for the implementation of a rigorous research
program investigating the potential therapeutic benefits of cannabinoids for crack-
cocaine use. Given the high prevalence of this grave substance use problem in the
Americas, opportunities for such research should urgently be created and
facilitated there. (C) 2015 Elsevier B.V. All rights reserved. [Fischer,
Benedikt; Kuganesan, Sharan] CAMH, Dept Social & Epidemiol Res, Toronto, ON M5S
2S1, Canada; [Fischer, Benedikt] Univ Toronto, Dept Psychiat, Toronto, ON M5S 1A8,
Canada; [Fischer, Benedikt] Univ Toronto, IMS, Toronto, ON M5S 1A8, Canada;
[Gallassi, Andrea] Univ Brasilia, Program Hlth Sci & Hlth Technol, BR-70910900
Brasilia, DF, Brazil; [Gallassi, Andrea] Univ Brasilia, Fac Ceilanda, Ctr Drugs &
Associated Vulnerabil, BR-70910900 Brasilia, DF, Brazil; [Malcher-Lopes, Renato]
Univ Brasilia, Dept Physiol Sci, BR-70910900 Brasilia, DF, Brazil; [van den Brink,
Wim] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands; [van den
Brink, Wim] Amsterdam Inst Addict Res, NL-1100 DD Amsterdam, Netherlands; [Wood,
Evan] St Pauls Hosp, Urban Hlth Res Initiat, Vancouver, BC V6Z 1Y6, Canada; [Wood,
Evan] Univ British Columbia, Div Med, Vancouver, BC V6Z 1Y6, Canada Fischer, B
(reprint author), CAMH, Dept Social & Epidemiol Res, Toronto, ON M5S 2S1, Canada.
benedikt.fischer@utoronto.ca Fischer, B/0000-0002-2186-4030
CIHRCanadian Institutes of Health Research (CIHR) [SMN-139150]; CIHR/PHAC
Applied Public Health Research Chair award; Canada Research Chair (CRC) in Inner
City Medicine Dr. Fischer acknowledges research support from CIHR for the
Ontario CRISM Node Team (grant# SMN-139150) and a CIHR/PHAC Applied Public Health
Research Chair award. Dr. Wood acknowledges funding support from a Canada Research
Chair (CRC) in Inner City Medicine. Afonso L, 2007, AM J CARDIOL, V100, P1040, DOI
10.1016/j.amjcard.2007.04.049; Allsop DJ, 2014, JAMA PSYCHIAT, V71, P281, DOI
10.1001/jamapsychiatry.2013.3947; Almeida V, 2013, PROG NEURO-PSYCHOPH, V41, P30,
DOI 10.1016/j.pnpbp.2012.10.024; Alves J. A., 2015, PAN AFRICAN ISSUES D; Amar MB,
2006, J ETHNOPHARMACOL, V105, P1, DOI 10.1016/j.jep.2006.02.001; Amato L, 2011,
COCHRANE DB SYST REV, V7, P12, DOI DOI 10.1002/14651858.CD003352.PUB3]; Andrade T,
2011, DRUG-EDUC PREV POLIC, V18, P382, DOI 10.3109/09687637.2010.506898; Bastos FI,
2014, PESQUISA NACL USO CR; Bennett T, 2008, AGGRESS VIOLENT BEH, V13, P107, DOI
10.1016/j.avb.2008.02.001; Bergamaschi MM, 2011, NEUROPSYCHOPHARMACOL, V36, P1219,
DOI 10.1038/npp.2011.6; BHARGAVA HN, 1976, PSYCHOPHARMACOLOGY, V49, P267, DOI
10.1007/BF00426828; Booth RE, 2000, DRUG ALCOHOL DEPEN, V58, P219, DOI
10.1016/S0376-8716(99)00094-0; Borgelt LM, 2013, PHARMACOTHERAPY, V33, P195, DOI
10.1002/phar.1187; Bungay V, 2010, INT J DRUG POLICY, V21, P321, DOI
10.1016/j.drugpo.2009.12.008; Chagas MHN, 2014, J CLIN PHARM THER, V39, P564, DOI
10.1111/jcpt.12179; Chaves Tharcila V, 2011, Rev. Saúde Pública, V45, P1168, DOI
[10.1590/s0034-89102011005000066, 10.1590/S0034-89102011005000066]; Ciccarone D,
2011, PRIMARY CARE, V38, P41, DOI 10.1016/j.pop.2010.11.004; Coffey SF, 2000, DRUG
ALCOHOL DEPEN, V59, P277, DOI 10.1016/S0376-8716(99)00126-X; Cook JA, 2008, AIDS,
V22, P1355, DOI 10.1097/QAD.0b013e32830507f2; Cornish JW, 1996, ANNU REV PUBL
HEALTH, V17, P259; Corsi KF, 2010, J EVID-INFORM SOC WO, V7, P30, DOI
10.1080/15433710903175858; Cortesi M, 2007, MED HYPOTHESES, V68, P920, DOI
10.1016/j.mehy.2006.09.030; Crippa JAS, 2013, J CLIN PHARM THER, V38, P162, DOI
10.1111/jcpt.12018; Crippa JAS, 2011, J PSYCHOPHARMACOL, V25, P121, DOI
10.1177/0269881110379283; Cruz MS, 2013, INT J DRUG POLICY, V24, P432, DOI
10.1016/j.drugpo.2013.03.012; CUNHA JM, 1980, PHARMACOLOGY, V21, P175, DOI
10.1159/000137430; de Carvalho HB, 2009, CLINICS, V64, P857, DOI 10.1590/S1807-
59322009000900006; Degenhardt L, 2012, LANCET, V379, P55, DOI 10.1016/S0140-
6736(11)61138-0; Degenhardt L, 2011, DRUG ALCOHOL DEPEN, V113, P88, DOI
10.1016/j.drugalcdep.2010.07.026; Devinsky O, 2014, EPILEPSIA, V55, P791, DOI
10.1111/epi.12631; Dreher M., 2002, J CANNABIS THERAPEUT, V2; ElBatsh MM, 2012,
PSYCHOPHARMACOLOGY, V221, P239, DOI 10.1007/s00213-011-2566-z; Falck RS, 2004, J
NERV MENT DIS, V192, P503, DOI 10.1097/01.nmd.0000131913.94916.d5; Falck RS, 2003,
J PSYCHOACTIVE DRUGS, V35, P471, DOI 10.1080/02791072.2003.10400494; Farronato NS,
2013, J ADDICT DIS, V32, P274, DOI 10.1080/10550887.2013.824328; Fernandez-Ruiz J,
2012, REV NEUROLOGIA, V54, P613, DOI 10.33588/rn.5410.2011689; Fischer B, 2007,
ADDICTION, V102, P1340, DOI 10.1111/j.1360-0443.2007.01963.x; Fischer B, 2006,
ADDICTION, V101, P1760, DOI 10.1111/j.1360-0443.2006.01614.x; Fischer B, 2015, INT
J DRUG POLICY, V26, P352, DOI 10.1016/j.drugpo.2015.01.002; Fischer B, 2013, INT J
DRUG POLICY, V24, P631, DOI 10.1016/j.drugpo.2013.09.003; Ford JD, 2009, DRUG
ALCOHOL DEPEN, V99, P193, DOI 10.1016/j.drugalcdep.2008.07.004; Fusar-Poli P, 2009,
ARCH GEN PSYCHIAT, V66, P95, DOI 10.1001/archgenpsychiatry.2008.519; Goncalves JR,
2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2063-0; Grant Igor, 2012, Open
Neurol J, V6, P18, DOI 10.2174/1874205X01206010018; Grella CE, 2003, J SUBST ABUSE
TREAT, V25, P145, DOI 10.1016/S0740-5472(03)00128-4; Grogger J, 2000, REV ECON
STAT, V82, P519, DOI 10.1162/003465300558957; HAIM DY, 1995, CHEST, V107, P233, DOI
10.1378/chest.107.1.233; Henskens R, 2008, SUBST USE MISUSE, V43, P1464, DOI
10.1080/10826080500391613; Hoffman JA, 1996, J SUBST ABUSE TREAT, V13, P3, DOI
10.1016/0740-5472(95)02020-9; Hoffmann DE, 2010, NEW ENGL J MED, V362, P1453, DOI
10.1056/NEJMp1000695; Iseger TA, 2015, SCHIZOPHR RES, V162, P153, DOI
10.1016/j.schres.2015.01.033; Ivsins A, 2011, INT J DRUG POLICY, V22, P292, DOI
10.1016/j.drugpo.2011.05.005; Kampman KM, 2010, CURR PSYCHIAT REP, V12, P441, DOI
10.1007/s11920-010-0143-5; Karila L, 2011, CURR PHARM DESIGN, V17, P1359, DOI
10.2174/138161211796150873; KARLER R, 1981, J CLIN PHARMACOL, V21, pS437, DOI
10.1002/j.1552-4604.1981.tb02624.x; Katsidoni V, 2013, ADDICT BIOL, V18, P286, DOI
10.1111/j.1369-1600.2012.00483.x; Khan MR, 2013, AIDS BEHAV, V17, P1185, DOI
10.1007/s10461-012-0276-0; Koppel BS, 2014, NEUROLOGY, V82, P1556, DOI
10.1212/WNL.0000000000000363; Labigalini E, 1999, J PSYCHOACTIVE DRUGS, V31, P451,
DOI 10.1080/02791072.1999.10471776; Lange RA, 2001, NEW ENGL J MED, V345, P351, DOI
10.1056/NEJM200108023450507; Leweke FM, 2012, TRANSL PSYCHIAT, V2, DOI
10.1038/tp.2012.15; Malchy LA, 2011, CAN J PUBLIC HEALTH, V102, P188, DOI
10.1007/BF03404893; Malta M, 2011, CIENC SAUDE COLETIVA, V16, P4777, DOI
10.1590/S1413-81232011001300026; Mattick R. P., 2009, COCHRANE DATABASE SY, V3;
Maude-Griffin PM, 1998, J CONSULT CLIN PSYCH, V66, P832, DOI 10.1037/0022-
006X.66.5.832; McDermott MJ, 2009, J ANXIETY DISORD, V23, P591, DOI
10.1016/j.janxdis.2009.01.006; Mechoulam R, 2002, J CLIN PHARMACOL, V42, p11S, DOI
10.1177/0091270002238789; Milby JB, 2005, AM J PUBLIC HEALTH, V95, P1259, DOI
10.2105/AJPH.2004.039743; Morgan CJA, 2012, PSYCHOL MED, V42, P391, DOI
10.1017/S0033291711001322; Morgan CJA, 2013, ADDICT BEHAV, V38, P2433, DOI
10.1016/j.addbeh.2013.03.011; Morgan PT, 2010, AM J PSYCHIAT, V167, P331, DOI
10.1176/appi.ajp.2009.09050613; Nuijten M, 2011, BMC PSYCHIATRY, V11, DOI
10.1186/1471-244X-11-135; Nuijten M, 2015, J PSYCHOPHARMACOL, V29, P678, DOI
10.1177/0269881115582151; Nuijten M, 2014, DRUG ALCOHOL DEPEN, V138, P177, DOI
10.1016/j.drugalcdep.2014.02.024; Nutt DJ,
2012, J PSYCHOPHARMACOL, V26, P199, DOI 10.1177/0269881111410899; Parker LA, 2004,
PSYCHOPHARMACOLOGY, V175, P360, DOI 10.1007/s00213-004-1825-7; Pertwee RG, 2006,
BRIT J PHARMACOL, V147, pS163, DOI 10.1038/sj.bjp.0706406; Prendergast M, 2006,
ADDICTION, V101, P1546, DOI 10.1111/j.1360-0443.2006.01581.x; Prud'homme M, 2015,
SUBST ABUS-RES TREAT, V9, P33, DOI 10.4137/SART.S25081; Raupp L, 2011, CIENC SAUDE
COLETIVA, V16, P2613, DOI 10.1590/S1413-81232011000500031; Ren YH, 2009, J
NEUROSCI, V29, P14764, DOI 10.1523/JNEUROSCI.4291-09.2009; Ribeiro LA, 2010, BMC
PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-671; Richard AJ, 1995, J SUBST ABUSE
TREAT, V12, P401, DOI 10.1016/0740-5472(95)02013-6; Robertson MJ, 2004, AM J PUBLIC
HEALTH, V94, P1207, DOI 10.2105/AJPH.94.7.1207; Robson PJ, 2014, DRUG TEST ANAL,
V6, P24, DOI 10.1002/dta.1529; Russo EB, 2011, BRIT J PHARMACOL, V163, P1344, DOI
10.1111/j.1476-5381.2011.01238.x; Santos Cruz M., 2013, BMC HEALTH SERV RES, V13;
Scheinmann R, 2007, DRUG ALCOHOL DEPEN, V89, P1, DOI
10.1016/j.drugalcdep.2006.11.014; Schottenfeld RS, 2011, DRUG ALCOHOL DEPEN, V118,
P48, DOI 10.1016/j.drugalcdep.2011.02.019; Schubart CD, 2014, EUR NEUROPSYCHOPHARM,
V24, P51, DOI 10.1016/j.euroneuro.2013.11.002; Scuderi C, 2009, PHYTOTHER RES, V23,
P597, DOI 10.1002/ptr.2625; Shearer J, 2003, ADDICTION, V98, P1137, DOI
10.1046/j.1360-0443.2003.00447.x; Shorter D, 2011, BMC MED, V9, DOI 10.1186/1741-
7015-9-119; Story A, 2008, EMERG INFECT DIS, V14, P1466, DOI
10.3201/eid1409.070654; Strathdee Steffanie A, 2010, Curr HIV/AIDS Rep, V7, P99,
DOI 10.1007/s11904-010-0043-7; Ti LP, 2012, DRUG ALCOHOL REV, V31, P890, DOI
10.1111/j.1465-3362.2012.00446.x; United Nations Office on Drugs and Crime (UNODC),
2015, E15116 UNODC; van den Brink W, 2005, SUCHT, V51, P196, DOI
10.1024/2005.04.01; van der Poel A, 2006, J PSYCHOACTIVE DRUGS, V38, P123, DOI
10.1080/02791072.2006.10399836; Vogenthaler NS, 2010, PUBLIC HEALTH NUTR, V13,
P1478, DOI 10.1017/S1368980009993181; Volkow N. D., 2015, BIOL POTENTIAL THERA;
Wallace B., 2014, CRACK COCAINE PRACTI; Werb D, 2010, DRUG ALCOHOL REV, V29, P271,
DOI 10.1111/j.1465-3362.2009.00145.x; Whiting PF, 2015, JAMA-J AM MED ASSOC, V313,
P2456, DOI 10.1001/jama.2015.6358; Zuardi AW, 2008, REV BRAS PSIQUIATR, V30, P271,
DOI 10.1590/S1516-44462008000300015; ZUARDI AW, 1991, PSYCHOPHARMACOLOGY, V104,
P260, DOI 10.1007/BF02244189 106 11 11 3 23 ELSEVIER SCIENCE BV
AMSTERDAM PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS 0955-3959 1873-
4758 INT J DRUG POLICY Int. J. Drug Policy DEC 2015 26 12
1177 1182 10.1016/j.drugpo.2015.09.005 6
Substance Abuse Substance Abuse CZ0IA WOS:000366787100003 26500166
2019-09-25
J Carra, G; Bartoli, F; Clerici, M; El-Guebaly, N Carra, G.;
Bartoli, F.; Clerici, M.; el-Guebaly, N. Psychopathology of dual
diagnosis: new trumpets and old uncertainties JOURNAL OF PSYCHOPATHOLOGY-GIORNALE
DI PSICOPATOLOGIA English Article
Psychopathology; Dual diagnosis; Comorbidity; Severe mental disorders;
Addiction People suffering from severe mental illnesses, such as
schizophrenia and major affective disorders, have high rates of addictive
behaviours related to alcohol and illicit substance use. This overview summarises
new and old psychopathological issues on the comorbidity between mental and
substance use disorder, the so-called 'dual diagnosis' phenomenon. It represents an
unanswered challenge in terms of pathogenic models, treatment and long-term
clinical management. Dual diagnosis is a complex and heterogeneous entity and a
number of explanatory models of substance use among people with severe mental
disorders have been proposed, aiming to test the 'self medication' hypothesis, the
potential aetiological role of substance on occurrence of mental disorders, and the
common underlying environmental, genetic and biological factors. Furthermore, in
the literature attempts have been made to clarify psychopatho-logical
characteristics of people who suffer from dual diagnosis. Individuals with dual
diagnosis appear to be more often males, with an earlier onset of the mental
disorder and more severe clinical and social outcomes. The co-occurrence of mental
and substance use disorders complicates treatment, management and prognosis of both
disorders, but it remains often unrecognised and undertreated. Mental health and
addiction professionals should accurately assess and evaluate this comorbidity,
although aetiological links, temporal relationships and psychopathological
characteristics are still not entirely clear and, probably, heterogeneous and
multifactorial. [Carra, G.] UCL, Div Psychiat, 6thFloor,Maple House,149 Tottenham
Court Rd, London W1T7NF, England; [Bartoli, F.; Clerici, M.] Univ Milano Bicocca,
Dept Med & Surg, Monza, Italy; [el-Guebaly, N.] Univ Calgary, Dept Psychiat, Div
Addict, Calgary, AB, Canada; [el-Guebaly, N.] Alberta Gambling Res Inst, Calgary,
AB, Canada Carra, G (reprint author), UCL, Div Psychiat, 6thFloor,Maple House,149
Tottenham Court Rd, London W1T7NF, England. g.carra@ucl.ac.uk Carra, Giuseppe/M-
3200-2019; Clerici, Massimo/U-3074-2019; Bartoli, Francesco/K-5755-2016 Carra,
Giuseppe/0000-0002-6877-6169; Clerici, Massimo/0000-0001-8769-6474; Bartoli,
Francesco/0000-0003-2612-4119 Addington J, 1997, J PSYCHIATR NEUROSCI,
V22, P99; Addington J, 1997, ACTA PSYCHIAT SCAND, V96, P329, DOI 10.1111/j.1600-
0447.1997.tb09925.x; Arseneault L, 2004, BRIT J PSYCHIAT, V184, P110, DOI
10.1192/bjp.184.2.110; Arseneault L, 2003, BRIT J PSYCHIAT, V183, P520, DOI
10.1192/bjp.183.6.520; Baethge C, 2005, AM J PSYCHIAT, V162, P1008, DOI
10.1176/appi.ajp.162.5.1008; Baethge C, 2008, BIPOLAR DISORD, V10, P738, DOI
10.1111/j.1399-5618.2007.00575.x; Bartoli F, 2014, DRUG ALCOHOL DEPEN, V134, P12,
DOI 10.1016/j.drugalcdep.2013.10.007; Bizzarri JV, 2009, PSYCHIAT RES, V165, P88,
DOI 10.1016/j.psychres.2007.10.009; Bossong MG, 2010, PROG NEUROBIOL, V92, P370,
DOI 10.1016/j.pneurobio.2010.06.010; Bramness JG, 2012, BMC PSYCHIATRY, V12, DOI
10.1186/1471-244X-12-221; Brunette MF, 1997, COMPR PSYCHIAT, V38, P109, DOI
10.1016/S0010-440X(97)90090-0; Carra G, 2006, AM J ADDICTION, V15, P125, DOI
10.1080/10550490500528340; Carra G, 2009, PRAEGER INT COLLECTI, P287; Carra G,
2015, COMPR PSYCHIAT, V58, P152, DOI 10.1016/j.comppsych.2014.11.021; Carra G,
2015, SUBST ABUS, V36, P75, DOI 10.1080/08897077.2014.960551; Carra G, 2014, J
AFFECT DISORDERS, V167, P125, DOI 10.1016/j.jad.2014.05.066; Carra G, 2012, EUR
ARCH PSY CLIN N, V262, P607, DOI 10.1007/s00406-012-0305-z; D'Souza DC, 2009, EUR
ARCH PSY CLIN N, V259, P413, DOI 10.1007/s00406-009-0024-2; Davis LL, 2005, COMPR
PSYCHIAT, V46, P81, DOI 10.1016/j.comppsych.2004.07.025; de Leon J, 2005, SCHIZOPHR
RES, V76, P135, DOI 10.1016/j.schres.2005.02.010; Dervaux A, 2001, AM J PSYCHIAT,
V158, P492, DOI 10.1176/appi.ajp.158.3.492; DiNitto DM, 2002, J PSYCHOACTIVE DRUGS,
V34, P105, DOI 10.1080/02791072.2002.10399942; Dixon L, 1999, SCHIZOPHR RES, V35,
pS93, DOI 10.1016/S0920-9964(98)00161-3; Donoghue K, 2012, NEUROPSYCHOLOGY, V26,
P785, DOI 10.1037/a0029685; Drake RE, 2000, PSYCHIATR SERV, V51, P1126, DOI
10.1176/appi.ps.51.9.1126; Drake RE, 2002, ALCOHOL RES HEALTH, V26, P99; Dumais A,
2011, SCHIZOPHR RES, V130, P234, DOI 10.1016/j.schres.2011.02.024; ELGUEBALY N,
1992, CAN J PSYCHIAT, V37, P704, DOI 10.1177/070674379203701006; Fazel S, 2009,
PLOS MED, V6, DOI 10.1371/journal.pmed.1000120; Fazel S, 2009, JAMA-J AM MED ASSOC,
V301, P2016, DOI 10.1001/jama.2009.675; Fernandez-Espejo E, 2009,
PSYCHOPHARMACOLOGY, V206, P531, DOI 10.1007/s00213-009-1612-6; Gibbs M, 2015, J
AFFECT DISORDERS, V171, P39, DOI 10.1016/j.jad.2014.09.016; Gosden NP, 2005,
SCHIZOPHRENIA BULL, V31, P759, DOI 10.1093/schbul/sbi015; Grann M, 2004, BRIT MED
J, V328, P1233, DOI 10.1136/bmj.328.7450.1233; Gregg L, 2007, CLIN PSYCHOL REV,
V27, P494, DOI 10.1016/j.cpr.2006.09.004; Gurillo P, 2015, LANCET PSYCHIAT, V2,
P718, DOI 10.1016/S2215-0366(15)00152-2; Hall W, 2008, WORLD PSYCHIATRY, V7, P68;
Hambrecht M, 1996, BIOL PSYCHIAT, V40, P1155, DOI 10.1016/S0006-3223(95)00609-5;
Herbeck DM, 2005, AM J ADDICTION, V14, P195, DOI 10.1080/10550490590949488; Hurst
D, 2011, AM J PSYCHIAT, V168, P1119, DOI 10.1176/appi.ajp.2011.11010176; Iannitelli
Angela, 2002, Ann Ist Super Sanita, V38, P233; Kamali M, 2001, PSYCHIATR SERV, V52,
P161, DOI 10.1176/appi.ps.52.2.161; Kessler RC, 1996, AM J ORTHOPSYCHIAT, V66, P17,
DOI 10.1037/h0080151; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI
10.3109/10673229709030550; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259; Kuepper
R, 2010, SCHIZOPHR RES, V121, P107, DOI 10.1016/j.schres.2010.05.031; Kushner MG,
2000, CLIN PSYCHOL REV, V20, P149, DOI 10.1016/S0272-7358(99)00027-6; Lacro JP,
2002, J CLIN PSYCHIAT, V63, P892, DOI 10.4088/JCP.v63n1007; Large M, 2011, ARCH GEN
PSYCHIAT, V68, P555, DOI 10.1001/archgenpsychiatry.2011.5; Lev-Ran S, 2014, PSYCHOL
MED, V44, P797, DOI 10.1017/S0033291713001438; Maat A, 2008, PSYCHOPHARMACOL BULL,
V41, P5; Magura Stephen, 2011, Open Addict J, V4, P58; Marquenie LA, 2007, EUR
ADDICT RES, V13, P39, DOI 10.1159/000095814; Martinotti G, 2014, BIOMED RES INT,
DOI 10.1155/2014/815424; Martins SS, 2011, DRUG ALCOHOL DEPEN, V119, P28, DOI
10.1016/j.drugalcdep.2011.05.010; Meyer R. E., 1986, PSYCHOPATHOLOGY ADDI, P3;
Moore THM, 2007, LANCET, V370, P319, DOI 10.1016/S0140-6736(07)61162-3; Morojele
NK, 2012, CURR OPIN PSYCHIATR, V25, P181, DOI 10.1097/YCO.0b013e328351a429; Mueser
KT, 1998, ADDICT BEHAV, V23, P717, DOI 10.1016/S0306-4603(98)00073-2; Muller-Vahl
Kirsten R, 2008, Expert Rev Neurother, V8, P1037, DOI 10.1586/14737175.8.7.1037;
Myles N, 2012, CURR PHARM DESIGN, V18, P5055, DOI 10.2174/138161212802884816; Myles
N, 2012, J CLIN PSYCHIAT, V73, P468, DOI 10.4088/JCP.11r07222; Papanti D, 2013, HUM
PSYCHOPHARM CLIN, V28, P379, DOI 10.1002/hup.2312; Pasche S, 2012, CURR PSYCHIAT
REP, V14, P176, DOI 10.1007/s11920-012-0264-0; Pompili M, 2009, J ADDICT DIS, V28,
P13, DOI 10.1080/10550880802544757; Potenza MN, 2009, BIOL PSYCHIAT, V66, P714, DOI
10.1016/j.biopsych.2009.08.004; Potvin S, 2006, PSYCHOL MED, V36, P431, DOI
10.1017/S003329170500574X; Potvin S, 2003, ENCEPHALE, V29, P193; Potvin S, 2008,
SCHIZOPHR RES, V100, P242, DOI 10.1016/j.schres.2007.04.022; Potvin S, 2007, AUST
NZ J PSYCHIAT, V41, P792, DOI 10.1080/00048670701579041; Potvin S, 2009, SCHIZOPHR
RES, V113, P181, DOI 10.1016/j.schres.2009.06.010; Prince JD, 2009, AM J PUBLIC
HEALTH, V99, P160, DOI 10.2105/AJPH.2007.133249; REGIER DA, 1990, JAMA-J AM MED
ASSOC, V264, P2511; Robinson J, 2011, ARCH GEN PSYCHIAT, V68, P800, DOI
10.1001/archgenpsychiatry.2011.75; Rounsaville BJ, 2007, SCHIZOPHRENIA BULL, V33,
P947, DOI 10.1093/schbul/sbm054; Schuckit MA, 2006, ADDICTION, V101, P76, DOI
10.1111/j.1360-0443.2006.01592.x; SIRIS SG, 1990, SCHIZOPHRENIA BULL, V16, P111,
DOI 10.1093/schbul/16.1.111; Soyka M, 2001, EUR ARCH PSY CLIN N, V251, P232, DOI
10.1007/s004060170032; Swann AC, 2005, AM J PSYCHIAT, V162, P1680, DOI
10.1176/appi.ajp.162.9.1680; Swann AC, 2003, J AFFECT DISORDERS, V73, P105, DOI
10.1016/S0165-0327(02)00328-2; Swann AC, 2011, NEUROPSYCHIATRY-LOND, V1, P599, DOI
10.2217/NPY.11.69; Swann AC, 2010, ANN NY ACAD SCI, V1187, P276, DOI
10.1111/j.1749-6632.2009.05146.x; Talamo A, 2006, SCHIZOPHR RES, V86, P251, DOI
10.1016/j.schres.2006.04.004; Thoma P, 2008, ADDICTION, V103, P774, DOI
10.1111/j.1360-0443.2008.02156.x; Thoma P, 2007, SCHIZOPHR RES, V92, P168, DOI
10.1016/j.schres.2007.02.004; van Amsterdam J, 2015, J PSYCHOPHARMACOL, V29, P254,
DOI 10.1177/0269881114565142; Volkow ND, 2009, SCHIZOPHRENIA BULL, V35, P469, DOI
10.1093/schbul/sbp016; Westreich L, 1997, AM J ADDICTION, V6, P311, DOI
10.1111/j.1521-0391.1997.tb00412.x; Wittchen HU, 1996, BRIT J PSYCHIAT, V168, P9,
DOI 10.1192/S000712500029836X; Yaldizli O, 2010, DRUG ALCOHOL REV, V29, P64, DOI
10.1111/j.1465-3362.2009.00089.x; Zhornitsky S, 2012, PSYCHIAT RES, V200, P237, DOI
10.1016/j.psychres.2012.07.046 91 4 5 0 2 PACINI EDITORE
PISA VIA DELLA GHERARDESCA-ZONA INDUSTRIALE OSPEDALETTO, 56121 PISA, ITALY
1592-1107 2499-6904 J PSYCHOPATHOL-G PSI J. Psychopathol.-G.
Psicopatol. DEC 2015 21 4 SI 390 399
10 Psychiatry Psychiatry V6R9X WOS:000420561200012
2019-09-25
J Peacock, A; Cash, C; Bruno, R; Ferguson, SG Peacock,
Amy; Cash, Catherine; Bruno, Raimondo; Ferguson, Stuart G. Day-by-day
variation in affect, arousal and alcohol consumption in young adults DRUG AND
ALCOHOL REVIEW English Article
alcohol; affect; EMA; arousal ECOLOGICAL MOMENTARY ASSESSMENT; INDIVIDUAL-
DIFFERENCES; PERSONALITY-DISORDER; AFFECT VARIABILITY; DRINKING MOTIVES; COLLEGE-
STUDENTS; SUBSTANCE USE; CORE AFFECT; MOOD; MODEL Introduction and Aims.
Alcohol consumption has a well-established relationship with mood, with higher
positive and negative affect predicting alcohol use. More recently, researchers
have explored whether alcohol consumption occurs as a response to affect
variability as an attempt to self-medicate and stabilise affect. Studies have
revealed a positive association between alcohol use and intra-and inter-individual
affect variability in clinical and university student samples; however not much is
known of this relationship among the general community. Design and Methods.
Ecological Momentary Assessment (EMA) methods were used to investigate the
relationship between affect and arousal variability and alcohol use in 53 community
volunteers. Participants self-reported affect and arousal at three to five randomly
timed moments throughout the day, as well as every time they drank. Results. On a
day-to-day basis, higher positive affect was associated with increased alcohol
consumption. When analyses were restricted to self-reported affect prior to alcohol
consumption, only increased arousal and decreased variability in arousal predicted
the likelihood of alcohol consumption. Mean level of arousal was associated with
the extent of alcohol consumed. Discussion and Conclusions. In this moderate
drinking sample day-to-day affect and arousal, and arousal variability, were
associated with alcohol consumption. Analyses restricted to pre-drinking
observations provide further evidence that self-medication accounts of alcohol
consumption may explain drinking initiation but that the relationship between
affect factors and drinking behaviour may change around the point of first drink.
[Peacock, Amy; Cash, Catherine; Bruno, Raimondo; Ferguson, Stuart G.] Univ
Tasmania, Sch Med, Hobart, Tas 7001, Australia Ferguson, SG (reprint author), Univ
Tasmania, Sch Med, Private Bag 34, Hobart, Tas 7001, Australia.
Stuart.Ferguson@utas.edu.au Peacock, Amy/L-8523-2013; Bruno, Raimondo/A-
2381-2009; Ferguson, Stuart/H-8006-2013 Peacock, Amy/0000-0002-5705-2026; Bruno,
Raimondo/0000-0001-6673-833X; Ferguson, Stuart/0000-0001-7378-3497; Cash,
Catherine/0000-0002-3172-8956 internal University of Tasmania grant; Mundi Pharma;
PfizerPfizer This study was funded from an internal University of Tasmania
grant awarded to Dr Ferguson. R. B. has received an untied educational grant from
Mundi Pharma to conduct surveillance of the use of pharmaceutical opioids in
Australia. In this study, the design, conduct and interpretation of findings are
the work of the investigators. S. G. F. has consulted for GlaxoSmithKline on
matters relating to smoking cessation, and has an investigator-initiated grant from
Pfizer. The researchers have no other connections with the tobacco, alcohol,
pharmaceutical or gaming industries, or any body substantially funded by one of
these organisations. Armeli S, 2000, J STUD ALCOHOL, V61, P862, DOI
10.15288/jsa.2000.61.862; Armeli S, 2010, PSYCHOL ADDICT BEHAV, V24, P38, DOI
10.1037/a0017530; Baker TB, 2004, PSYCHOL REV, V111, P33, DOI 10.1037/0033-
295X.111.1.33; Carney MA, 2000, J CONSULT CLIN PSYCH, V68, P788, DOI 10.1037/0022-
006X.68.5.788; Chakroun N, 2010, PSYCHOL ADDICT BEHAV, V24, P129, DOI
10.1037/a0018184; COOPER ML, 1995, J PERS SOC PSYCHOL, V69, P990, DOI 10.1037/0022-
3514.69.5.990; Council N.H.M.R., 2009, AUSTR GUID RED HLTH; Ferguson SG, 2011,
SUBST USE MISUSE, V46, P87, DOI 10.3109/10826084.2011.521399; Gottfredson NC, 2013,
J STUD ALCOHOL DRUGS, V74, P576, DOI 10.15288/jsad.2013.74.576; Harder VS, 2014,
ALCOHOL ALCOHOLISM, V49, P60, DOI 10.1093/alcalc/agt069; Hussong AM, 2005, J STUD
ALCOHOL, V66, P344, DOI 10.15288/jsa.2005.66.344; Hussong AM, 2001, J ABNORM
PSYCHOL, V110, P449, DOI 10.1037//0021-843X.110.3.449; Jahng S, 2011, J ABNORM
PSYCHOL, V120, P572, DOI 10.1037/a0024686; Kuppens P, 2007, EMOTION, V7, P262, DOI
10.1037/1528-3542.7.2.262; Maggs J. L., 2005, ALCOHOL RES HEALTH, V28, P195;
Marczinski CA, 2013, ALCOHOL CLIN EXP RES, V37, P276, DOI 10.1111/j.1530-
0277.2012.01868.x; Mohr CD, 2005, PSYCHOL ADDICT BEHAV, V19, P392, DOI
10.1037/0893-164X.19.4.392; Mohr CD, 2001, J PERS SOC PSYCHOL, V80, P489, DOI
10.1037//0022-3514.80.3.489; Peacock A, 2014, APPETITE, V76, P60, DOI
10.1016/j.appet.2014.01.003; Rankin LA, 2006, J YOUTH ADOLESCENCE, V35, P925, DOI
10.1007/s10964-006-9073-2; RUSSELL JA, 1980, J PERS SOC PSYCHOL, V39, P1161, DOI
10.1037/h0077714; Schuz N, 2014, NICOTINE TOB RES, V16, pS88, DOI
10.1093/ntr/ntt142; Shiffman S, 2006, PSYCHOPHARMACOLOGY, V184, P637, DOI
10.1007/s00213-005-0184-3; Shiffman S, 2008, ANNU REV CLIN PSYCHO, V4, P1, DOI
10.1146/annurev.clinpsy.3.022806.091415; Shiffman S, 2009, PSYCHOL ASSESSMENT, V21,
P486, DOI 10.1037/a0017074; Simons JS, 2010, ADDICT BEHAV, V35, P1045, DOI
10.1016/j.addbeh.2010.07.001; Simons JS, 2005, J STUD ALCOHOL, V66, P459, DOI
10.15288/jsa.2005.66.459; Swendsen JD, 2000, J ABNORM PSYCHOL, V109, P198, DOI
10.1037//0021-843X.109.2.198; Thomas JG, 2011, OBESITY, V19, P1574, DOI
10.1038/oby.2010.335; Timmermans T, 2010, EUR J PERSONALITY, V24, P623, DOI
10.1002/per.756; Todd M, 2009, PSYCHOL ADDICT BEHAV, V23, P205, DOI
10.1037/a0014792; Tragesser SL, 2007, EXP CLIN PSYCHOPHARM, V15, P282, DOI
10.1037/1064-1297.15.3.282; Wiers RW, 2002, J ABNORM PSYCHOL, V111, P648, DOI
10.1037/0021-843X.111.4.648; ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI
10.2307/2531734 34 12 12 0 16 WILEY-BLACKWELL HOBOKEN 111
RIVER ST, HOBOKEN 07030-5774, NJ USA 0959-5236 1465-3362 DRUG ALCOHOL
REV Drug Alcohol Rev. NOV 2015 34 6 SI 588 594
10.1111/dar.12238 7 Substance Abuse Substance Abuse DA3JV
 WOS:000367693900004 25588504 2019-09-25
J Baskin-Sommers, AR; Foti, D Baskin-Sommers, Arielle R.;
Foti, Dan Abnormal reward functioning across substance use disorders
and major depressive disorder: Considering reward as a transdiagnostic mechanism
INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY English Article
Substance use disorders; Major depressive disorder;
Reward; 'Liking'; 'Wanting'; Learning ANTISOCIAL PERSONALITY-DISORDER;
INCENTIVE-SENSITIZATION THEORY; SELF-MEDICATION HYPOTHESIS; EVENT-RELATED
POTENTIALS; FRONTAL P300 DECREMENTS; NATIONAL EPIDEMIOLOGIC SURVEY; FEEDBACK-
RELATED NEGATIVITY; VENTRAL STRIATAL RESPONSE; CRACK COCAINE DEPENDENCE; ERROR-
RELATED NEGATIVITY A common criticism of the Diagnostic and Statistical Manual
of Mental Disorders (American Psychiatric Association, 2013) is that its criteria
are based more on behavioral descriptions than on underlying biological mechanisms.
Increasingly, calls have intensified for a more biologically-based approach to
conceptualizing, studying, and treating psychological disorders, as exemplified by
the Research Domain Criteria Project (RDoC). Among the most well-studied
neurobiological mechanisms is reward processing. Moreover, individual differences
in reward sensitivity are related to risk for substance abuse and depression. The
current review synthesizes the available preclinical, electrophysiological, and
neuroimaging literature on reward processing from a transdiagnostic,
multidimensional perspective. Findings are organized with respect to key reward
constructs within the Positive Valence Systems domain of the RDoC matrix, including
initial responsiveness to reward (physiological 'liking), approach motivation
(physiological 'wanting'), and reward learning/habit formation. In the current
review, we (a) describe the neural basis of reward, (b) elucidate differences in
reward activity in substance abuse and depression, and (c) suggest a framework for
integrating these disparate literatures and discuss the utility of shifting focus
from diagnosis to process for understanding liability and co-morbidity. Ultimately,
we believe that an integrative focus on abnormal reward functioning across the full
continuum of clinically heterogeneous samples, rather than within circumscribed
diagnostic categories, might actually help to refine the phenotypes and improve the
prediction of onset and recovery of these disorders. (C) 2015 Elsevier B.V. All
rights reserved. [Baskin-Sommers, Arielle R.] Yale Univ, Dept Psychol, New Haven,
CT 06520 USA; [Foti, Dan] Purdue Univ, Dept Psychol Sci, W Lafayette, IN 47907 USA
Baskin-Sommers, AR (reprint author), 2 Hillhouse Ave, New Haven, CT 06520
USA. arielle.baskin-sommers@yale.edu; foti@purdue.edu
Aldworth J, 2009, RESULTS 2007 NATL SU; ALPER KR, 1990, PSYCHIAT RES-NEUROIM,
V35, P95, DOI 10.1016/0165-1781(90)90153-V; American Psychiatric Association, 2013,
DIAGN STAT MAN MENT; Baskin-Sommers AR, 2014, BIOL PSYCHOL, V96, P86, DOI
10.1016/j.biopsycho.2013.12.005; BAUER L, 1994, PROG NEURO-PSYCHOPH, V18, P263, DOI
10.1016/0278-5846(94)90058-2; BAUER LO, 1994, ALCOHOL CLIN EXP RES, V18, P1300, DOI
10.1111/j.1530-0277.1994.tb01427.x; Bauer LO, 1997, DRUG ALCOHOL DEPEN, V44, P1,
DOI 10.1016/S0376-8716(96)01311-7; Bauer LO, 2001, CLIN NEUROPHYSIOL, V112, P1508,
DOI 10.1016/S1388-2457(01)00583-1; Beaver JD, 2006, J NEUROSCI, V26, P5160, DOI
10.1523/JNEUROSCI.0350-06.2006; Bechara A, 2002, NEUROPSYCHOLOGIA, V40, P1675, DOI
10.1016/S0028-3932(02)00015-5; Bechara A, 2002, NEUROPSYCHOLOGIA, V40, P1690, DOI
10.1016/S0028-3932(02)00016-7; Bechara A, 2000, BRAIN, V123, P2189, DOI
10.1093/brain/123.11.2189; Bechara Antoine, 2003, J Gambl Stud, V19, P23, DOI
10.1023/A:1021223113233; Becker MPI, 2014, J NEUROSCI, V34, P3005, DOI
10.1523/JNEUROSCI.3684-13.2014; Belin D, 2008, NEURON, V57, P432, DOI
10.1016/j.neuron.2007.12.019; Bernat EM, 2007, INT J PSYCHOPHYSIOL, V66, P161, DOI
10.1016/j.ijpsycho.2007.03.021; Berridge KC, 1998, BRAIN RES REV, V28, P309, DOI
10.1016/S0165-0173(98)00019-8; Berridge KC, 1996, NEUROSCI BIOBEHAV R, V20, P1, DOI
10.1016/0149-7634(95)00033-B; Berridge KC, 2003, TRENDS NEUROSCI, V26, P507, DOI
10.1016/S0166-2236(03)00233-9; Berridge KC, 2007, PSYCHOPHARMACOLOGY, V191, P391,
DOI 10.1007/s00213-006-0578-x; Berridge KC, 2009, CURR OPIN PHARMACOL, V9, P65, DOI
10.1016/j.coph.2008.12.014; Berrocoso E, 2013, INT J NEUROPSYCHOPH, V16, P151, DOI
10.1017/S1461145711001842; Berrocoso E, 2009, INT J NEUROPSYCHOPH, V12, P1033, DOI
10.1017/S1461145709000236; Bewernick BH, 2010, BIOL PSYCHIAT, V67, P110, DOI
10.1016/j.biopsych.2009.09.013; Bress J.N., 2015, J CLIN CHIL IN PRESS; Bress JN,
2013, PSYCHOPHYSIOLOGY, V50, P610, DOI 10.1111/psyp.12053; Bress JN, 2013,
PSYCHOPHYSIOLOGY, V50, P74, DOI 10.1111/j.1469-8986.2012.01485.x; Bress JN, 2012,
BIOL PSYCHOL, V89, P156, DOI 10.1016/j.biopsycho.2011.10.004; Buckholtz JW, 2010,
SCIENCE, V329, P532, DOI 10.1126/science.1185778; Buckholtz JW, 2010, NAT NEUROSCI,
V13, P419, DOI 10.1038/nn.2510; Carlson JM, 2011, NEUROIMAGE, V57, P1608, DOI
10.1016/j.neuroimage.2011.05.037; Carlson SR, 2002, BIOL PSYCHOL, V61, P203, DOI
10.1016/S0301-0511(02)00059-5; Carroll KM, 2004, BIOL PSYCHIAT, V56, P778, DOI
10.1016/j.biopsych.2004.07.010; Ceballos NA, 2009, CLIN EEG NEUROSCI, V40, P122,
DOI 10.1177/155005940904000210; CHILDRESS AR, 1994, J SUBST ABUSE TREAT, V11, P17,
DOI 10.1016/0740-5472(94)90060-4; Coffey SF, 2003, EXP CLIN PSYCHOPHARM, V11, P18,
DOI 10.1037/1064-1297.11.1.18; Costa L, 2000, BIOL PSYCHIAT, V47, P1064, DOI
10.1016/S0006-3223(99)00317-0; Couey JJ, 2007, NEURON, V54, P73, DOI
10.1016/j.neuron.2007.03.006; Cuthbert BN, 2013, BMC MED, V11, DOI 10.1186/1741-
7015-11-126; DAVIDSON RJ, 1992, BRAIN COGNITION, V20, P125, DOI 10.1016/0278-
2626(92)90065-T; Davidson RJ, 1998, COGNITION EMOTION, V12, P307, DOI
10.1080/026999398379628; De Bellis MD, 2013, DRUG ALCOHOL DEPEN, V133, P134, DOI
10.1016/j.drugalcdep.2013.05.020; Debener S, 2000, NEUROPSYCHOBIOLOGY, V41, P31,
DOI 10.1159/000026630; Di Chiara G, 2002, BEHAV BRAIN RES, V137, P75, DOI
10.1016/S0166-4328(02)00286-3; Dichter GS, 2012, J AFFECT DISORDERS, V136, P1126,
DOI 10.1016/j.jad.2011.09.048; Dodgen CE, 2000, SUBSTANCE USE DISORD; Domschke K,
2008, EUR NEUROPSYCHOPHARM, V18, P751, DOI 10.1016/j.euroneuro.2008.05.003;
Draganski B, 2008, J NEUROSCI, V28, P7143, DOI 10.1523/JNEUROSCI.1486-08.2008;
Drevets WC, 2001, BIOL PSYCHIAT, V49, P81, DOI 10.1016/S0006-3223(00)01038-6;
Dunning JP, 2011, EUR J NEUROSCI, V33, P1716, DOI 10.1111/j.1460-9568.2011.07663.x;
Easdon C, 2005, COGNITIVE BRAIN RES, V25, P873, DOI
10.1016/j.cogbrainres.2005.09.009; Eftekhari A, 2004, ADDICT BEHAV, V29, P1001, DOI
10.1016/j.addbeh.2004.02.050; Epstein J, 2006, AM J PSYCHIAT, V163, P1784, DOI
10.1176/appi.ajp.163.10.1784; Finn PR, 2009, J ABNORM PSYCHOL, V118, P100, DOI
10.1037/a0014656; FISCHMAN MW, 1992, CIBA F SYMP, V166, P165; Forbes EE, 2012, J
CHILD PSYCHOL PSYC, V53, P3, DOI 10.1111/j.1469-7610.2011.02477.x; Forbes EE, 2009,
AM J PSYCHIAT, V166, P64, DOI 10.1176/appi.ajp.2008.07081336; Foti D, 2014,
NEUROIMAGE, V101, P50, DOI 10.1016/j.neuroimage.2014.06.058; Foti D, 2011, J ABNORM
CHILD PSYCH, V39, P913, DOI 10.1007/s10802-011-9503-9; Foti D, 2010, NEUROREPORT,
V21, P143, DOI 10.1097/WNR.0b013e3283356448; Foti D, 2009, BIOL PSYCHOL, V81, P1,
DOI 10.1016/j.biopsycho.2008.12.004; Frank MJ, 2005, NEURON, V47, P495, DOI
10.1016/j.neuron.2005.06.020; Franken IHA, 2007, BIOL PSYCHOL, V75, P45, DOI
10.1016/j.biopsycho.2006.11.003; Gao Y, 2009, BIOL PSYCHOL, V82, P199, DOI
10.1016/j.biopsycho.2009.06.006; Garriock HA, 2010, AM J PSYCHIAT, V167, P565, DOI
10.1176/appi.ajp.2009.08081167; Gehring WJ, 2002, SCIENCE, V295, P2279, DOI
10.1126/science.1066893; Giordano LA, 2002, PSYCHOPHARMACOLOGY, V163, P174, DOI
10.1007/s00213-002-1159-2; Goldstein RZ, 2007, AM J PSYCHIAT, V164, P43, DOI
10.1176/appi.ajp.164.1.43; Goldstein RZ, 2006, INT J PSYCHOPHYSIOL, V62, P272, DOI
10.1016/j.ijpsycho.2006.05.006; Goldstein RZ, 2002, AM J PSYCHIAT, V159, P1642, DOI
10.1176/appi.ajp.159.10.1642; GORENSTEIN EE, 1980, PSYCHOL REV, V87, P301, DOI
10.1037/0033-295X.87.3.301; Gotlib IH, 2010, ARCH GEN PSYCHIAT, V67, P380, DOI
10.1001/archgenpsychiatry.2010.13; Gotlib IH, 1998, COGNITION EMOTION, V12, P449,
DOI 10.1080/026999398379673; Gouzoulis-Mayfrank E, 1999, NEUROPSYCHOPHARMACOL, V20,
P565, DOI 10.1016/S0893-133X(98)00089-X; Grant BF, 2004, ARCH GEN PSYCHIAT, V61,
P807, DOI 10.1001/archpsyc.61.8.807; Greenberg PE, 2003, J CLIN PSYCHIAT, V64,
P1465, DOI 10.4088/JCP.v64n1211; Grusser SM, 2004, PSYCHOPHARMACOLOGY, V175, P296,
DOI 10.1007/s00213-004-1828-4; Haber SN, 2010, NEUROPSYCHOPHARMACOL, V35, P4, DOI
10.1038/npp.2009.129; Hajcak G, 2006, BIOL PSYCHOL, V71, P148, DOI
10.1016/j.biopsycho.2005.04.001; Hasin DS, 2005, ARCH GEN PSYCHIAT, V62, P1097, DOI
10.1001/archpsyc.62.10.1097; Hasler G, 2004, NEUROPSYCHOPHARMACOL, V29, P1765, DOI
10.1038/sj.npp.1300506; Heller AS, 2013, AM J PSYCHIAT, V170, P197, DOI
10.1176/appi.ajp.2012.12010014; HENRIQUES JB, 1991, J ABNORM PSYCHOL, V100, P535,
DOI 10.1037/0021-843X.100.4.535; HENRIQUES JB, 1990, J ABNORM PSYCHOL, V99, P22,
DOI 10.1037/0021-843X.99.1.22; Henriques JB, 2000, COGNITION EMOTION, V14, P711,
DOI 10.1080/02699930050117684; Hicks BM, 2007, PSYCHOPHYSIOLOGY, V44, P98, DOI
10.1111/j.1469-8986.2006.00471.x; Hill MN, 2008, J NEUROCHEM, V106, P2322, DOI
10.1111/j.1471-4159.2008.05567.x; Hobbs M, 2005, PSYCHOPHARMACOLOGY, V178, P493,
DOI 10.1007/s00213-004-2026-0; Holroyd CB, 2002, PSYCHOL REV, V109, P679, DOI
[10.1037//0033-295X.109.4.679, 10.1037/0033-295X.109.4.679]; Holroyd CB, 2008,
PSYCHOPHYSIOLOGY, V45, P688, DOI 10.1111/j.1469-8986.2008.00668.x; Hommer DW, 2011,
ANN NY ACAD SCI, V1216, P50, DOI 10.1111/j.1749-6632.2010.05898.x; Hyman SE, 2005,
AM J PSYCHIAT, V162, P1414, DOI 10.1176/appi.ajp.162.8.1414; Iacono WG, 2002, ARCH
GEN PSYCHIAT, V59, P750, DOI 10.1001/archpsyc.59.8.750;
Iacono WG, 2003, INT J PSYCHOPHYSIOL, V48, P147, DOI 10.1016/S0167-8760(03)00052-
7; Iacono WG, 2008, ANNU REV CLIN PSYCHO, V4, P325, DOI
10.1146/annurev.clinpsy.4.022007.141157; Insel T, 2010, AM J PSYCHIAT, V167, P748,
DOI 10.1176/appi.ajp.2010.09091379; Iwanami A, 1998, J NERV MENT DIS, V186, P746,
DOI 10.1097/00005053-199812000-00002; IWANAMI A, 1994, PROG NEURO-PSYCHOPH, V18,
P465; Iyo M, 1997, PROG NEURO-PSYCHOPH, V21, P789, DOI 10.1016/S0278-5846(97)00079-
1; JERNIGAN TL, 1991, ALCOHOL CLIN EXP RES, V15, P418, DOI 10.1111/j.1530-
0277.1991.tb00540.x; JOHNSTON LD, 1986, J DRUG ISSUES, V16, P29, DOI
10.1177/002204268601600103; Kappenman E.S., 2014, OXFORD HDB EVENT REL, P3;
Keedwell PA, 2005, BIOL PSYCHIAT, V58, P843, DOI 10.1016/j.biopsych.2005.05.019;
Kendler KS, 2003, ARCH GEN PSYCHIAT, V60, P929, DOI 10.1001/archpsyc.60.9.929;
Kennedy SE, 2006, ARCH GEN PSYCHIAT, V63, P1199, DOI 10.1001/archpsyc.63.11.1199;
Kennerley SW, 2011, NAT NEUROSCI, V14, P1581, DOI 10.1038/nn.2961; Kenney JW, 2008,
BEHAV NEUROSCI, V122, P1158, DOI 10.1037/a0012807; Kessler R. C., 2009, HDB
DEPRESSION, P5; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259; Kim MS, 2001, CHILD
PSYCHIAT HUM D, V32, P93, DOI 10.1023/A:1012299822274; Knutson B, 2000, NEUROIMAGE,
V12, P20, DOI 10.1006/nimg.2000.0593; Knutson B, 2008, BIOL PSYCHIAT, V63, P686,
DOI 10.1016/j.biopsych.2007.07.023; Knyazev GG, 2012, NEUROSCI BIOBEHAV R, V36,
P677, DOI 10.1016/j.neubiorev.2011.10.002; Koob GF, 2001, NEUROPSYCHOPHARMACOL,
V24, P97, DOI 10.1016/S0893-133X(00)00195-0; Koob GF, 1997, SCIENCE, V278, P52, DOI
10.1126/science.278.5335.52; Kreek MJ, 2002, NAT REV DRUG DISCOV, V1, P710, DOI
10.1038/nrd897; Krishnan V, 2008, NATURE, V455, P894, DOI 10.1038/nature07455;
Krueger RF, 2002, J ABNORM PSYCHOL, V111, P411, DOI 10.1037//0021-843X.111.3.411;
Krueger RF, 2001, PERS INDIV DIFFER, V30, P1245, DOI 10.1016/S0191-8869(00)00106-9;
Krueger RF, 2007, J ABNORM PSYCHOL, V116, P645, DOI 10.1037/0021-843X.116.4.645;
Krueger RF, 2006, CURR DIR PSYCHOL SCI, V15, P113, DOI 10.1111/j.0963-
7214.2006.00418.x; Kujawa A., 2015, CLIN PSYCHO IN PRESS; Kujawa A, 2014, J ABNORM
PSYCHOL, V123, P287, DOI 10.1037/a0036285; Kumar P, 2008, BRAIN, V131, P2084, DOI
10.1093/brain/awn136; Lambert NM, 2006, ADDICTION, V101, P713, DOI 10.1111/j.1360-
0443.2006.01408.x; Lilienfeld SO, 2014, BEHAV RES THER, V62, P129, DOI
10.1016/j.brat.2014.07.019; Liu WH, 2014, NEUROPSYCHOLOGIA, V53, P213, DOI
10.1016/j.neuropsychologia.2013.11.023; Liu X, 1998, NEUROPSYCHOPHARMACOL, V18,
P243; London ED, 2000, CEREB CORTEX, V10, P334, DOI 10.1093/cercor/10.3.334; Lubman
DI, 2007, PSYCHOL MED, V37, P1203, DOI 10.1017/S0033291707009932; Ma N, 2010,
NEUROIMAGE, V49, P738, DOI 10.1016/j.neuroimage.2009.08.037; Markou A, 1998,
NEUROPSYCHOPHARMACOL, V18, P135, DOI 10.1016/S0893-133X(97)00113-9; Mathers C,
2008, GLOBAL BURDEN OF DISEASE: 2004 UPDATE, P1; McCabe C, 2009,
PSYCHOPHARMACOLOGY, V205, P667, DOI 10.1007/s00213-009-1573-9; McGue M, 2005, AM J
PSYCHIAT, V162, P1118, DOI 10.1176/appi.ajp.162.6.1118; Miltner WHR, 1997, J
COGNITIVE NEUROSCI, V9, P788, DOI 10.1162/jocn.1997.9.6.788; Moeller SJ, 2013, J
NEUROSCI, V33, P10027, DOI 10.1523/JNEUROSCI.0695-13.2013; Monk CS, 2008, AM J
PSYCHIAT, V165, P90, DOI 10.1176/appi.ajp.2007.06111917; Moses-Kolko EL, 2011, BIOL
PSYCHIAT, V70, P395, DOI 10.1016/j.biopsych.2011.02.021; Motzkin JC, 2014, HUM
BRAIN MAPP, V35, P4282, DOI 10.1002/hbm.22474; Murray EA, 2007, TRENDS COGN SCI,
V11, P489, DOI 10.1016/j.tics.2007.08.013; Nelson BD, 2013, J ABNORM PSYCHOL, V122,
P662, DOI 10.1037/a0033982; Nestler EJ, 2006, BIOL PSYCHIAT, V59, P1151, DOI
10.1016/j.biopsych.2005.09.018; Nestler EJ, 2002, NEURON, V34, P13, DOI
10.1016/S0896-6273(02)00653-0; Nunes EV, 2004, JAMA-J AM MED ASSOC, V291, P1887,
DOI 10.1001/jama.291.15.1887; OCONNOR S, 1994, PROG NEURO-PSYCHOPH, V18, P1307, DOI
10.1016/0278-5846(94)90095-7; Olino TM, 2011, PSYCHIAT RES-NEUROIM, V194, P393, DOI
10.1016/j.pscychresns.2011.04.009; Patrick CJ, 2006, PSYCHOPHYSIOLOGY, V43, P84,
DOI 10.1111/j.1469-8986.2006.00376.x; Pecina S, 2003, J NEUROSCI, V23, P9395;
Pecina S, 2008, PHYSIOL BEHAV, V94, P675, DOI 10.1016/j.physbeh.2008.04.006;
Perlstein WM, 2002, P NATL ACAD SCI USA, V99, P1736, DOI 10.1073/pnas.241650598;
Pfabigan DM, 2014, NEUROIMAGE, V96, P12, DOI 10.1016/j.neuroimage.2014.03.077;
Philibin SD, 2011, FRONT NEUROANAT, V5, DOI 10.3389/fnana.2011.00060; Pizzagalli
DA, 2014, ANNU REV CLIN PSYCHO, V10, P393, DOI 10.1146/annurev-clinpsy-050212-
185606; Pizzagalli DA, 2011, CONT TOP COGN NEUROS, P199; Pizzagalli DA, 2009, AM J
PSYCHIAT, V166, P702, DOI 10.1176/appi.ajp.2008.08081201; Pizzagalli DA, 2008, J
PSYCHIATR RES, V43, P76, DOI 10.1016/j.jpsychires.2008.03.001; Plichta MM, 2013, J
NEUROSCI, V33, P14526, DOI 10.1523/JNEUROSCI.0631-13.2013; Polich J, 2007, CLIN
NEUROPHYSIOL, V118, P2128, DOI 10.1016/j.clinph.2007.04.019; Prichep LS, 1996, J
ADDICT DIS, V15, P39, DOI 10.1300/J069v15n04_03; Proudfit G.H, 2015, PSYCHOPHYSI IN
PRESS; Rice DP, 1999, P ASSOC AM PHYSICIAN, V111, P119, DOI 10.1046/j.1525-
1381.1999.09254.x; Robinson OJ, 2012, AM J PSYCHIAT, V169, P152, DOI
10.1176/appi.ajp.2011.11010137; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI
10.1016/0165-0173(93)90013-P; ROEMER RA, 1995, PSYCHIAT RES, V58, P247, DOI
10.1016/0165-1781(95)02474-B; Rolls ET, 2000, CEREB CORTEX, V10, P284, DOI
10.1093/cercor/10.3.284; Russo SJ, 2013, NAT REV NEUROSCI, V14, P609, DOI
10.1038/nrn3381; Saal D, 2003, NEURON, V37, P577, DOI 10.1016/S0896-6273(03)00021-
7; Santesso DL, 2008, NEUROIMAGE, V42, P807, DOI 10.1016/j.neuroimage.2008.05.032;
Sapolsky R, 2003, SCI AM, V289, P86, DOI 10.1038/scientificamerican0903-86;
Schlaepfer TE, 2008, NEUROPSYCHOPHARMACOL, V33, P368, DOI 10.1038/sj.npp.1301408;
Schultz W, 1998, J NEUROPHYSIOL, V80, P1, DOI 10.1152/jn.1998.80.1.1; Shankman SA,
2007, J ABNORM PSYCHOL, V116, P95, DOI 10.1037/0021-843X.116.1.95; Shankman SA,
2013, J ABNORM PSYCHOL, V122, P322, DOI 10.1037/a0030747; Sharp C, 2014, J ABNORM
PSYCHOL, V123, P298, DOI 10.1037/a0036191; Sinha R, 2007, DRUG ALCOHOL REV, V26,
P25, DOI 10.1080/09595230601036960; Smoski MJ, 2009, J AFFECT DISORDERS, V118, P69,
DOI 10.1016/j.jad.2009.01.034; Sokhadze TM, 2008, APPL PSYCHOPHYS BIOF, V33, P1,
DOI 10.1007/s10484-007-9047-5; Steele JD, 2007, BRAIN, V130, P2367, DOI
10.1093/brain/awm150; Stuber GD, 2011, NATURE, V475, P377, DOI 10.1038/nature10194;
Suh JJ, 2008, PSYCHOANAL PSYCHOL, V25, P518, DOI 10.1037/0736-9735.25.3.518;
TIFFANY ST, 1990, PSYCHOL REV, V97, P147, DOI 10.1037/0033-295X.97.2.147; Torrens
M, 2005, DRUG ALCOHOL DEPEN, V78, P1, DOI 10.1016/j.drugalcdep.2004.09.004;
Treadway MT, 2011, NEUROSCI BIOBEHAV R, V35, P537, DOI
10.1016/j.neubiorev.2010.06.006; Vaidyanathan U, 2012, PSYCHOPATHOLOGY, V45, P361,
DOI 10.1159/000337265; Vaidyanathan U, 2011, COMPR PSYCHIAT, V52, P527, DOI
10.1016/j.comppsych.2010.10.006; Venables NC, 2011, BIOL PSYCHOL, V86, P279, DOI
10.1016/j.biopsycho.2010.12.009; Volkow ND, 2009, NEUROPHARMACOLOGY, V56, P3, DOI
10.1016/j.neuropharm.2008.05.022; Volkow ND, 2000, CEREB CORTEX, V10, P318, DOI
10.1093/cercor/10.3.318; Volkow ND, 2004, NEUROPHARMACOLOGY, V47, P3, DOI
10.1016/j.neuropharm.2004.07.019; Volkow ND, 2004, BIOL PSYCHIAT, V56, P714, DOI
10.1016/j.biopsych.2004.07.007; Volkow ND, 2004, MOL PSYCHIATR, V9, P557, DOI
10.1038/sj.mp.4001507; Volkow ND, 2003, J CLIN INVEST, V111, P1444, DOI
10.1172/JCI200318533; Volkow ND, 1997, NATURE, V386, P830, DOI 10.1038/386830a0;
Volkow ND, 2001, J NEUROSCI, V21, P9414, DOI 10.1523/JNEUROSCI.21-23-09414.2001;
Volkow ND, 2001, AM J PSYCHIAT, V158, P2015, DOI 10.1176/appi.ajp.158.12.2015;
Volkow ND, 2011, P NATL ACAD SCI USA, V108, P15037, DOI 10.1073/pnas.1010654108;
Vrieze E, 2013, BIOL PSYCHIAT, V73, P639, DOI 10.1016/j.biopsych.2012.10.014;
Warren CA, 1999, CLIN NEUROPHYSIOL, V110, P1570, DOI 10.1016/S1388-2457(99)00089-9;
Wassum KM, 2009, P NATL ACAD SCI USA, V106, P12512, DOI 10.1073/pnas.0905874106;
Watkins S S, 2000, Nicotine Tob Res, V2, P19; Watson D, 2005, J ABNORM PSYCHOL,
V114, P522, DOI 10.1037/0021-843X.114.4.522; Weinberg A, 2012, J ABNORM PSYCHOL,
V121, P885, DOI 10.1037/a0028270; Weissenborn R, 1997, PSYCHOPHARMACOLOGY, V134,
P242, DOI 10.1007/s002130050447; Wheeler RA, 2006, J NEUROPHYSIOL, V96, P2175, DOI
10.1152/jn.00727.2006; Wilson SJ, 2004, NAT NEUROSCI, V7, P211, DOI 10.1038/nn1200;
Wyvell CL, 2000, J NEUROSCI, V20, P8122; Yancey JR, 2013, J CRIM JUST, V41, P309,
DOI 10.1016/j.jcrimjus.2013.06.002; Yang QZ, 2011, NEUROSCI LETT, V489, P131, DOI
10.1016/j.neulet.2010.12.002; Zijlstra F, 2009, DRUG ALCOHOL DEPEN, V99, P183, DOI
10.1016/j.drugalcdep.2008.07.012 210 29 29 1 34 ELSEVIER SCIENCE
BV AMSTERDAM PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS 0167-8760 1872-
7697 INT J PSYCHOPHYSIOL Int. J. Psychophysiol. NOV 2015 98 2
2 SI 227 239 10.1016/j.ijpsycho.2015.01.011
13 Psychology, Biological; Neurosciences; Physiology; Psychology;
Psychology, Experimental Psychology; Neurosciences & Neurology; Physiology
DA0NG WOS:000367493400002 25655926 2019-09-25
J Forbes, MK; Flanagan, JC; Barrett, EL; Crome, E; Baillie, AJ; Mills, KL;
Teesson, M Forbes, Miriam K.; Flanagan, Julianne C.; Barrett,
Emma L.; Crome, Erica; Baillie, Andrew. J.; Mills, Katherine L.; Teesson, Maree
Smoking, posttraumatic stress disorder, and alcohol use disorders in a
nationally representative sample of Australian men and women DRUG AND ALCOHOL
DEPENDENCE English Article PTSD;
Alcohol use disorders; Smoking; Comorbidity SUBSTANCE USE DISORDERS; UNITED-
STATES; NICOTINE DEPENDENCE; CIGARETTE-SMOKING; ANXIETY DISORDERS; COLLEGE-
STUDENTS; RISK-FACTORS; TOBACCO USE; DRUG-USE; PSYCHOLOGICAL DISTRESS Background:
Posttraumatic stress disorder (PTSD) and alcohol use disorders (AUDs) often co-
occur with smoking and tobacco use disorders. Each of these disorders is known to
have negative health consequences and impairment independently, but little is known
about the impact of their co-occurrence. The aim of the present study is to examine
the prevalence, correlates, order of onset, and impact of co-occurring daily
smoking, PTSD, and AUDs. Method: The 2007 Australian National Survey of Mental
Health and Wellbeing (2007 NSMHVVB) was a nationally representative survey of 8841
Australians. The survey assessed for 12-month DSM-IV mental disorders; the age
respondents first started smoking daily, experienced a traumatic event, or
developed problems with alcohol; and self-reported mental and physical health and
impairment. Results: There were systematic patterns of co-occurrence between daily
smoking, PTSD, and AUDs. Daily smoking and problems with alcohol use tended to
develop after first trauma exposure, which is broadly consistent with the self-
medication hypothesis. Daily smoking, PTSD, and AUDs were also associated with
additive negative effects on mental and physical health and functioning, after
controlling for demographics. Conclusions: Smoking, PTSD, and AUDs commonly co-
occur in this nationally representative sample of Australian men and women, and
this comorbidity was associated with greater severity of mental and physical health
problems and impairment in several areas of functioning. This study highlights the
importance of identifying and eliminating these patterns of co-occurrence,
potentially through integrated interventions. (C) 2015 Elsevier Ireland Ltd. All
rights reserved. [Forbes, Miriam K.; Crome, Erica; Baillie, Andrew. J.] Macquarie
Univ, Ctr Emot Hlth, Sydney, NSW 2109, Australia; [Forbes, Miriam K.; Crome, Erica;
Baillie, Andrew. J.] Macquarie Univ, Ctr Res Excellence Mental Hlth & Subst Abuse,
Sydney, NSW 2109, Australia; [Flanagan, Julianne C.] Med Univ S Carolina,
Charleston, SC 29401 USA; [Barrett, Emma L.; Mills, Katherine L.; Teesson, Maree]
UNSW, Ctr Res Excellence Mental Hlth & Subst Abuse, Sydney, NSW 2052, Australia;
[Barrett, Emma L.; Mills, Katherine L.; Teesson, Maree] UNSW, Natl Drug & Alcohol
Res Ctr, Sydney, NSW 2052, Australia Forbes, MK (reprint author), Macquarie
Univ, Ctr Emot Hlth, Sydney, NSW 2109, Australia. miri.forbes@mq.edu.au;
hellmuth@musc.edu; e.barrett@unsw.edu.au; erica.crome@mq.edu.au;
andrew.baillie@mq.edu.au; k.mills@unsw.edu.au; m.teesson@unsw.edu.au Forbes,
Miriam K/H-3637-2019; Mills, Katherine/N-9333-2016 Forbes, Miriam K/0000-0002-
6954-3818; Baillie, Andrew/0000-0003-3424-5703 Macquarie University, Faculty of
Human Science Visiting International Research Fellowship; National Health Branch of
the Commonwealth Department of Health and Aged Care, Under the National Mental
Health Strategy Macquarie University, Faculty of Human Science Visiting
International Research Fellowship for supporting collaboration within this team.
The National Survey of Mental Health and Well Being was funded by the National
Health Branch of the Commonwealth Department of Health and Aged Care, Under the
National Mental Health Strategy. It was conducted by the Australian Bureau of
Statistics. Acierno R, 2000, J TRAUMA STRESS, V13, P381, DOI
10.1023/A:1007772905696; American Psychiatric Association, 2000, DIAGN STAT MAN
MENT; Andrews G, 2001, AUST NZ J PUBL HEAL, V25, P494, DOI 10.1111/j.1467-
842X.2001.tb00310.x; [Anonymous], 2014, HLTH CONSMOK 50 YE; Anthony JC, 2000,
ALCOHOL RES HEALTH, V24, P201; Australian Bureau of Statistics, 2007, NAT SURV MENT
HLTH W; Australian Bureau of Statistics, 2012, GEND IND; Australian Qualifications
Framework Council, 2013, AUSTR QUAL FRAM; Back S, 2000, AM J ADDICTION, V9, P51;
Back S. E., 2015, DRUG ALCOHOL DEPEN, V146, pe213; Back S.E., 2014, CONCURRENT
TREATMENT; Back SE, 2006, ADDICT BEHAV, V31, P351, DOI
10.1016/j.addbeh.2005.05.008; Back SE, 2006, J NERV MENT DIS, V194, P690, DOI
10.1097/01.nmd.0000235794.12794.8a; Barrett SP, 2006, DRUG ALCOHOL DEPEN, V81,
P197, DOI 10.1016/j.drugalcdep.2005.06.009; Beckham JC, 1996, ADDICT BEHAV, V21,
P93, DOI 10.1016/0306-4603(95)00038-0; Beckham JC, 2008, NICOTINE TOB RES, V10,
P1149, DOI 10.1080/14622200802123302; Breslau N, 2004, PSYCHOL MED, V34, P323, DOI
10.1017/S0033291703008869; Breslau N, 2003, ARCH GEN PSYCHIAT, V60, P289, DOI
10.1001/archpsyc.60.3.289; Chapman C, 2012, PSYCHOL MED, V42, P1695, DOI
10.1017/S0033291711002856; Cohen LR, 2006, PSYCHIAT SERV, V57, P100, DOI
10.1176/appi.ps.57.1.100; Cottler LB, 2001, COMPR PSYCHIAT, V42, P111, DOI
10.1053/comp.2001.21219; Darke S, 1998, DRUG ALCOHOL DEPEN, V51, P253, DOI
10.1016/S0376-8716(98)00028-3; Degenhardt L, 2001, Nicotine Tob Res, V3, P225;
Farrelly MC, 2013, AM J PUBLIC HEALTH, V103, P549, DOI 10.2105/AJPH.2012.300948;
Feldner MT, 2007, CLIN PSYCHOL REV, V27, P14, DOI 10.1016/j.cpr.2006.08.004;
Feldner MT, 2013, BEHAV THER, V44, P514, DOI 10.1016/j.beth.2013.04.003; Fu SS,
2007, NICOTINE TOB RES, V9, P1071, DOI 10.1080/14622200701488418; Grant BF, 2004,
ARCH GEN PSYCHIAT, V61, P1107, DOI 10.1001/archpsyc.61.11.1107; Hall WD, 2000, MED
J AUSTRALIA, V173, P528; Hanna EZ, 1999, ALCOHOL CLIN EXP RES, V23, P513, DOI
10.1111/j.1530-0277.1999.tb04146.x; Hapke U, 2005, J NERV MENT DIS, V193, P843, DOI
10.1097/01.nmd.0000188964.83476.e0; Hitsman B, 2009, CAN J PSYCHIAT, V54, P368, DOI
10.1177/070674370905400604; Hourani L, 2015, J ANXIETY DISORD, V29, P101, DOI
10.1016/j.janxdis.2014.11.007; Hu MC, 2006, AM J PUBLIC HEALTH, V96, P299, DOI
10.2105/AJPH.2004.057232; Hutton HE, 2011, NICOTINE TOB RES, V13, P227, DOI
10.1093/ntr/ntq252; Jamal M, 2011, NICOTINE TOB RES, V13, P809, DOI
10.1093/ntr/ntr077; Kalman D, 2010, CLIN PSYCHOL REV, V30, P12, DOI
10.1016/j.cpr.2009.08.009; Kessler RC, 2002, PSYCHOL MED, V32, P959, DOI
10.1017/S0033291702006074; Kessler RC, 2004, INT J METH PSYCH RES, V13, P93, DOI
10.1002/mpr.168; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI
10.3109/10673229709030550; King B, 2012, NICOTINE TOB RES, V14, P1213, DOI
10.1093/ntr/nts073; Lasser K, 2000, JAMA-J AM MED ASSOC, V284, P2606, DOI
10.1001/jama.284.20.2606; Lawrence D, 2010, AUST NZ J PSYCHIAT, V44, P520, DOI
10.3109/00048670903571580; Lawrence D, 2009, BMC PUBLIC HEALTH, V9, DOI
10.1186/1471-2458-9-285; Lechner WV, 2012, J AM COLL HEALTH, V60, P505, DOI
10.1080/07448481.2012.681816; Leeies M, 2010, DEPRESS ANXIETY, V27, P731, DOI
10.1002/da.20677; Malarcher A., 2009, Morbidity and Mortality Weekly Report, V58,
P1232; Marrero JA, 2005, J HEPATOL, V42, P218, DOI 10.1016/j.jhep.2004.10.005;
McKee SA, 2007, ARCH INTERN MED, V167, P716, DOI 10.1001/archinte.167.7.716; McKee
SA, 2006, PSYCHOPHARMACOLOGY, V189, P201, DOI 10.1007/s00213-006-0551-8; Meyer JP,
2011, J WOMENS HEALTH, V20, P991, DOI 10.1089/jwh.2010.2328; Mills KL, 2012, JAMA-J
AM MED ASSOC, V308, P690, DOI 10.1001/jama.2012.9071; Mills KL, 2006, AM J
PSYCHIAT, V163, P652, DOI 10.1176/appi.ajp.163.4.652; Moodie AR, 2008, MED J
AUSTRALIA, V189, P588; Morissette SB, 2007, PSYCHOL BULL, V133, P245, DOI
10.1037/0033-2909.133.2.245; National Center for Health Statistics. Health United
States, 2007, HLTH US 2007 CHARTBO; Newman MG, 2011, CLIN PSYCHOL REV, V31, P178,
DOI 10.1016/j.cpr.2010.10.002; O'Farrell TJ, 2003, ADDICT BEHAV, V28, P327, DOI
10.1016/S0306-4603(01)00226-X; Pelucchi C, 2006, ALCOHOL RES HEALTH, V29, P193;
Petrakis IL, 2011, AM J ADDICTION, V20, P185, DOI 10.1111/j.1521-0391.2011.00126.x;
Prochaska JJ, 2011, NEW ENGL J MED, V365, P196, DOI 10.1056/NEJMp1105248; Read JP,
2012, J CONSULT CLIN PSYCH, V80, P426, DOI 10.1037/a0028210; Sher K.J., 2007, HDB
EMOTION REGULATI, P654; Simmons VN, 2013, J CONSULT CLIN PSYCH, V81, P810, DOI
10.1037/a0032952; Slade T, 2009, AUST NZ J PSYCHIAT, V43, P594, DOI
10.1080/00048670902970882; Sobell LC, 2002, ALCOHOL CLIN EXP RES, V26, P1936, DOI
10.1097/01.ALC.0000041001.11773.49; Stewart SH, 1998, ADDICT BEHAV, V23, P797, DOI
10.1016/S0306-4603(98)00070-7; Teesson M, 2010, ADDICTION, V105, P2085, DOI
10.1111/j.1360-0443.2010.03096.x; U. S. Department of Health and Human Services,
2004, HLTH CONS SMOK REP S, P62; Vlahov D, 2002, AM J EPIDEMIOL, V155, P988, DOI
10.1093/aje/155.11.988; Wagner FA, 2002, AM J EPIDEMIOL, V155, P918, DOI
10.1093/aje/155.10.918; Witkiewitz K, 2012, PSYCHOL ADDICT BEHAV, V26, P649, DOI
10.1037/a0025363; World Health Organization, 2008, WHO REP GLOB TOB EP; Zvolensky
MJ, 2008, NICOTINE TOB RES, V10, P1415, DOI 10.1080/14622200802238951 74 8
8 0 16 ELSEVIER IRELAND LTD CLARE ELSEVIER HOUSE, BROOKVALE
PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND 0376-8716 1879-0046
DRUG ALCOHOL DEPEN Drug Alcohol Depend. NOV 1 2015 156
176 183 10.1016/j.drugalcdep.2015.09.007
8 Substance Abuse; Psychiatry Substance Abuse; Psychiatry CW5SN
WOS:000365057000024 26386825 Green Accepted 2019-09-25
J Nichter, B; Chassin, L Nichter, Brandon; Chassin, Laurie
Separate dimensions of anxiety differentially predict alcohol use among
male juvenile offenders ADDICTIVE BEHAVIORS English Article
Anxiety; Alcohol; Internalizing symptoms; Binge
drinking; Substance use; Juvenile offenders SELF-MEDICATION HYPOTHESIS;
SUBSTANCE USE; USE DISORDERS; ADOLESCENT; PSYCHOPATHOLOGY; ABUSE; WORRY; RISK
Introduction: Although research has documented robust prospective
relationships between externalizing symptomatology and subsequent adolescent
alcohol use, the extent to which internalizing symptoms such as anxiety may
increase risk for alcohol consumption remains controversial. Recent evidence
suggests that one possible reason for mixed findings is that separate dimensions of
anxiety differentially confer risk for alcohol use. The present study tested two
dimensions of anxiety, worry and physiological anxiety symptoms, as predictors of
alcohol use and misuse in a longitudinal sample of juvenile offenders. Methods:
Participants were 818 male juvenile offenders drawn from a larger multi-site,
longitudinal study. Zero-inflated Poisson regression models estimated the influence
of anxiety symptoms on typical drinking quantity, frequency of binge drinking, and
alcohol dependence symptoms. Results: Results indicate that physiological anxiety
and worry symptoms showed differential relations with alcohol use risk.
Physiological anxiety was positively associated with increased risk for typical
alcohol involvement, frequency of binge drinking, and alcohol dependence symptoms,
whereas worry was negatively associated with all alcohol use outcomes. Conclusions:
Current findings underscore the importance of considering anxiety as a
multidimensional construct when examining the prospective relation between anxiety
and adolescent alcohol use risk. (C) 2015 Elsevier Ltd. All rights reserved.
[Nichter, Brandon; Chassin, Laurie] Arizona State Univ, Dept Psychol, Tempe,
AZ 85287 USA Nichter, B (reprint author), Arizona State Univ, Dept Psychol,
950 S McCallister Rd, Tempe, AZ 85287 USA. bnichter@asu.edu;
laurie.chassin@asu.edu National Science FoundationNational Science
Foundation (NSF); Office of Juvenile Justice and Delinquency Prevention [2000-MU-
MU-0007]; National Institute of JusticeAdalet Bakanligi [199-IJ-CX-0053]; National
Institute of Drug AbuseUnited States Department of Health & Human ServicesNational
Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01
DA019697-01]; John D. and Catherine T. MacArthur Foundation; William T. Grant
Foundation; Robert Wood Johnson FoundationRobert Wood Johnson Foundation (RWJF);
Centers for Disease ControlUnited States Department of Health & Human
ServicesCenters for Disease Control & Prevention - USA; William Penn Foundation;
Arizona Governor's Justice Commission; Pennsylvania Commission on Crime and
Delinquency This research was supported by a National Science Foundation Graduate
Research Fellowship to Brandon Nichter. Funding for the Pathways to Desistance
project was provided by the Office of Juvenile Justice and Delinquency Prevention
(2000-MU-MU-0007), the National Institute of Justice (199-IJ-CX-0053), the National
Institute of Drug Abuse (R01 DA019697-01), the John D. and Catherine T. MacArthur
Foundation, the William T. Grant Foundation, the Robert Wood Johnson Foundation,
The Centers for Disease Control, The William Penn Foundation, The Arizona
Governor's Justice Commission, and the Pennsylvania Commission on Crime and
Delinquency. We are grateful for their support. The content of this paper, however,
is the sole responsibility of the authors and does not necessarily represent the
official views of these agencies. Aiken LS, 1991, MULTIPLE REGRESSION; Borkovec
TD, 1998, COGNITIVE THER RES, V22, P561, DOI 10.1023/A:1018790003416; Chassin L.,
2004, HDB ADOLESCENT PSYCH, V1, P723; Ciesla JA, 2011, COGNITIVE THER RES, V35,
P142, DOI 10.1007/s10608-011-9355-1; Cohen J., 2013, APPL MULTIPLE REGRES; Colder
CR, 2013, J ABNORM CHILD PSYCH, V41, P667, DOI 10.1007/s10802-012-9701-0; Costello
EJ, 1999, J CLIN CHILD PSYCHOL, V28, P298, DOI 10.1207/S15374424jccp280302; Coxe S,
2009, J PERS ASSESS, V91, P121, DOI 10.1080/00223890802634175; Curry GD, 2000,
CRIMINOLOGY, V38, P1253, DOI 10.1111/j.1745-9125.2000.tb01422.x; HUIZINGA D, 1994,
NATO ADV SCI INST SE, V76, P203; Hussong AM, 1998, J ABNORM CHILD PSYCH, V26, P453,
DOI 10.1023/A:1022699701996; HUSSONG AM, 1994, J STUD ALCOHOL, V55, P707, DOI
10.15288/jsa.1994.55.707; Hussong AM, 2011, PSYCHOL ADDICT BEHAV, V25, P390, DOI
10.1037/a0024519; Kaplow JB, 2001, J CLIN CHILD PSYCHOL, V30, P316, DOI
10.1207/S15374424JCCP3003_4; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231,
DOI 10.3109/10673229709030550; King SM, 2004, ADDICTION, V99, P1548, DOI
10.1111/j.1360-0443.2004.00893.x; Knight George P, 2004, Youth Violence Juv
Justice, V2, P273, DOI 10.1177/1541204004265878; Maner JK, 2007, PERS INDIV DIFFER,
V42, P665, DOI 10.1016/j.paid.2006.08.016; Maxfield MG, 2000, J QUANT CRIMINOL,
V16, P87, DOI 10.1023/A:1007577512038; Mulvey E. P., 2004, YOUTH VIOLENCE JUV J,
V2, P211; Muris P, 2002, BEHAV RES THER, V40, P753, DOI 10.1016/S0005-
7967(01)00056-0; Muthen L. K., 2008, MPLUS VERSION 5 1; NIAAA, 2004, NIAAA
NEWSLETTER, P3; Pardini D, 2007, DRUG ALCOHOL DEPEN, V88, pS38, DOI
10.1016/j.drugalcdep.2006.12.014; Piquero AR, 2001, J ADOLESCENT RES, V16, P54, DOI
10.1177/0743558401161005; Reynolds CR, 1997, J ABNORM CHILD PSYCH, V25, P15, DOI
10.1023/A:1025751206600; Schubert Carol A, 2004, Youth Violence Juv Justice, V2,
P237, DOI 10.1177/1541204004265875; Shoal GD, 2005, PERS INDIV DIFFER, V38, P475,
DOI 10.1016/j.paid.2004.05.005; Swendsen JD, 2000, J ABNORM PSYCHOL, V109, P198,
DOI 10.1037//0021-843X.109.2.198; Tarter RE, 2002, AM J ADDICTION, V11, P171, DOI
10.1080/10550490290087965; Teplin LA, 2002, ARCH GEN PSYCHIAT, V59, P1133, DOI
10.1001/archpsyc.59.12.1133 31 8 8 1 19 PERGAMON-ELSEVIER
SCIENCE LTD OXFORD THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB,
ENGLAND 0306-4603 1873-6327 ADDICT BEHAV Addict. Behav. NOV
2015 50 144 148
10.1016/j.addbeh.2015.06.031 5 Psychology, Clinical;
Substance Abuse Psychology; Substance Abuse CO4YO WOS:000359167000025
26135335 2019-09-25
J Shin, SH; Hassamal, S; Groves, LP Shin, Sunny H.;
Hassamal, Sameer; Groves, Lauren Peasley Examining the Role of
Psychological Distress in Linking Childhood Maltreatment and Alcohol Use in Young
Adulthood AMERICAN JOURNAL ON ADDICTIONS English Article
SELF-MEDICATION HYPOTHESIS; SUBSTANCE USE
DISORDERS; EMOTIONAL ABUSE; CHRONIC STRESS; SEXUAL-ABUSE; DRINKING; DEPRESSION;
ASSOCIATION; RISK; TWIN Background and Objectives: Childhood maltreatment is
related to alcohol use as well as psychological distress in young adulthood. Few
studies have examined whether psychological distress mediates the relationship
between child maltreatment and alcohol use. We examined the role of psychological
distress in linking child maltreatment subtypes (ie, emotional abuse, physical
abuse, sexual abuse, neglect) to four patterns of alcohol use, including frequency
of alcohol use, binge drinking, alcohol-related problems, and alcohol dependence.
Methods: We used a community sample of young adults (N = 337), who completed an
interview assessing exposure to childhood maltreatment, current psychological
distress, and drinking behaviors. Results: Emotional abuse was associated with
psychological distress, whereas psychological distress was related to more
pathological drinking behaviors such as alcohol-related problems and alcohol
dependence. Subsequent analyses indicated significant mediated effects between
emotional abuse and alcohol-related problems and alcohol dependence via
psychological distress, even after controlling for demographic factors, other
maltreatment subtypes, parental alcoholism, and peer alcohol use. Conclusions and
Scientific Significance: Findings suggest that among four types of childhood
maltreatment, emotional abuse might be the major driver of pathological drinking
among child maltreatment victims. Interventions aimed at negative emotionality may
be useful in preventing and treating problematic drinking among the victims of
childhood emotional abuse. [Shin, Sunny H.; Groves, Lauren Peasley] Virginia
Commonwealth Univ, Sch Social Work, Richmond, VA 23284 USA; [Shin, Sunny H.;
Hassamal, Sameer] Virginia Commonwealth Univ, Dept Psychiat, Richmond, VA USA
Shin, SH (reprint author), 1000 Floyd Ave,Third Floor, Richmond, VA 23284
USA. sshin@vcu.edu NIDAUnited States Department of Health & Human
ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug
Abuse (NIDA) [DA030884]; AMBRF/The Foundation for Alcohol Research This
research was supported by grants from NIDA DA030884 (Shin) and the AMBRF/The
Foundation for Alcohol Research (Shin). The Foundation had no role in the study
design, collection, analysis, or interpretation of the data, writing the
manuscript, or the decision to submit the paper for publication. Agrawal A, 2008,
ADDICTION, V103, P1069, DOI 10.1111/j.1360-0443.2008.02213.x; Allen B, 2008, CHILD
MALTREATMENT, V13, P307, DOI 10.1177/1077559508318394; Anda RF, 2006, EUR ARCH PSY
CLIN N, V256, P174, DOI 10.1007/s00406-005-0624-4; BERNSTEIN DP, 1994, AM J
PSYCHIAT, V151, P1132; Bernstein DP, 1998, CHILDHOOD TRAUMA QUE; Boden JM, 2011,
ADDICTION, V106, P906, DOI 10.1111/j.1360-0443.2010.03351.x; Borsari B, 2001, J
SUBST ABUSE, V13, P391, DOI 10.1016/S0899-3289(01)00098-0; Brady KT, 2005, AM J
PSYCHIAT, V162, P1483, DOI 10.1176/appi.ajp.162.8.1483; Breese GR, 2005,
PSYCHOPHARMACOLOGY, V178, P367, DOI 10.1007/s00213-004-2016-2; Briere FN, 2014,
COMPR PSYCHIAT, V55, P526, DOI 10.1016/j.comppsych.2013.10.007; Brown T., 2006,
CONFIRMATORY FACTOR; CAMATTA CD, 1995, ALCOHOL CLIN EXP RES, V19, P142, DOI
10.1111/j.1530-0277.1995.tb01482.x; Cruz JE, 2012, DEV PSYCHOL, V48, P1390, DOI
10.1037/a0027515; Derogatis L. R., 1993, BSI BRIEF SYMPTOM IN; Dick DM, 2010,
ADDICT BIOL, V15, P217, DOI 10.1111/j.1369-1600.2009.00190.x; Dube S. R., 2006, J
ADOLESCENT HEALTH, V38, P1; Enoch MA, 2006, ANN NY ACAD SCI, V1094, P193, DOI
10.1196/annals.1376.019; Etain B, 2010, J TRAUMA STRESS, V23, P376, DOI
10.1002/jts.20532; Gibb BE, 2001, COGNITIVE THER RES, V25, P425, DOI
10.1023/A:1005586519986; Graham K, 1999, J STUD ALCOHOL, V60, P345, DOI
10.15288/jsa.1999.60.345; Graham K, 2007, ALCOHOL CLIN EXP RES, V31, P78, DOI
10.1111/j.1530-0277.2006.00274.x; Grayson CE, 2005, J TRAUMA STRESS, V18, P137, DOI
10.1002/jts.20021; HODGINS DC, 1995, ADDICT BEHAV, V20, P267, DOI 10.1016/0306-
4603(94)00063-8; Holahan CJ, 2001, J STUD ALCOHOL, V62, P190, DOI
10.15288/jsa.2001.62.190; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI
10.1080/10705519909540118; Jackson KM, 2003, J ABNORM PSYCHOL, V112, P599, DOI
10.1037/0021-843X.112.4.599; Kaplow JB, 2007, J ABNORM PSYCHOL, V116, P176, DOI
10.1037/0021-843X.116.1.176; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231,
DOI 10.3109/10673229709030550; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259;
Lejuez CW, 2010, ALCOHOL CLIN EXP RES, V34, P1334, DOI 10.1111/j.1530-
0277.2010.01217.x; Lynskey MT, 2010, J AM ACAD CHILD PSY, V49, P1202, DOI
10.1016/j.jaac.2010.09.004; MACKINNON DP, 1993, EVALUATION REV, V17, P144, DOI
10.1177/0193841X9301700202; MacKinnon DP, 2002, PSYCHOL METHODS, V7, P83, DOI
10.1037//1082-989X.7.1.83; MacKinnon DP, 2008, INTRO STAT MEDIATION; Marmorstein
NR, 2010, ADDICT BEHAV, V35, P564, DOI 10.1016/j.addbeh.2010.01.004; Moran PB,
2004, CHILD ABUSE NEGLECT, V28, P565, DOI 10.1016/j.chiabu.2003.12.002; Mullings
JL, 2004, SUBST USE MISUSE, V39, P277, DOI 10.1081/JA-120028491; Muthen B. O.,
2001, TECHNICAL REPORT; Nanni V, 2012, AM J PSYCHIAT, V169, P141, DOI
10.1176/appi.ajp.2011.11020335; Nelson EC, 2002, ARCH GEN PSYCHIAT, V59, P139, DOI
10.1001/archpsyc.59.2.139; Pears K, 2005, J DEV BEHAV PEDIATR, V26, P112, DOI
10.1097/00004703-200504000-00006; Rothman EF, 2008, PEDIATRICS, V122, pE298, DOI
10.1542/peds.2007-3412; Sartor CE, 2007, DRUG ALCOHOL DEPEN, V89, P139, DOI
10.1016/j.drugalcdep.2006.12.022; Schuck AM, 2001, CHILD ABUSE NEGLECT, V25, P1069,
DOI 10.1016/S0145-2134(01)00257-5; Schwandt ML, 2013, ALCOHOL CLIN EXP RES, V37,
P984, DOI 10.1111/acer.12053; Shields A, 2001, J CLIN CHILD PSYCHOL, V30, P349, DOI
10.1207/S15374424JCCP3003_7; Shin SH, 2009, ADDICT BEHAV, V34, P277, DOI
10.1016/j.addbeh.2008.10.023; Simons JS, 2004, AM J DRUG ALCOHOL AB, V30, P685, DOI
10.1081/ADA-200032338; Sinha R, 2008, ANN NY ACAD SCI, V1141, P105, DOI
10.1196/annals.1441.030; Substance Abuse and Mental Health Services Administration
(SAMHSA), 2014, NSDUH SER H, VH-48, P13; Teicher MH, 2006, AM J PSYCHIAT, V163,
P993, DOI 10.1176/appi.ajp.163.6.993; Trickett PK, 2011, J RES ADOLESCENCE, V21,
P3, DOI 10.1111/j.1532-7795.2010.00711.x; Vujanovic AA, 2011, ADDICT BEHAV, V36,
P707, DOI 10.1016/j.addbeh.2011.01.033; WAGENAAR AC, 2002, J STUD ALCOHOL S, V14,
P206; WECHSLER H, 1994, JAMA-J AM MED ASSOC, V272, P1672, DOI
10.1001/jama.272.21.1672; White HR, 2008, J STUD ALCOHOL DRUGS, V69, P337, DOI
10.15288/jsad.2008.69.337; WHITE HR, 1989, J STUD ALCOHOL, V50, P30, DOI
10.15288/jsa.1989.50.30; Widom CS, 2007, J STUD ALCOHOL DRUGS, V68, P317, DOI
10.15288/jsad.2007.68.317; Widom CS, 2001, ALCOHOL RES HEALTH, V25, P52; Wiles NJ,
2007, ADDICTION, V102, P1546, DOI 10.1111/j.1360-0443.2007.01930.x; Young-Wolff KC,
2011, PSYCHOL MED, V41, P59, DOI 10.1017/S0033291710000425; Young-Wolff KC, 2012, J
STUD ALCOHOL DRUGS, V73, P559, DOI 10.15288/jsad.2012.73.559 62 3 3
1 20 WILEY-BLACKWELL HOBOKEN 111 RIVER ST, HOBOKEN 07030-5774,
NJ USA 1055-0496 1521-0391 AM J ADDICTION Am. J. Addict. OCT
2015 24 7 628 636 10.1111/ajad.12276
9 Substance Abuse Substance Abuse DB4SD
WOS:000368502500009 26346173 Green Accepted 2019-09-25
J Blumenthal, H; Cloutier, RM; Zamboanga, BL; Bunaciu, L; Knapp, AA
Blumenthal, Heidemarie; Cloutier, Renee M.; Zamboanga, Byron L.;
Bunaciu, Liviu; Knapp, Ashley A. A Laboratory-Based Test of the
Relation Between Adolescent Alcohol Use and Panic-Relevant Responding EXPERIMENTAL
AND CLINICAL PSYCHOPHARMACOLOGY English Article
alcohol; panic; adolescence; voluntary hyperventilation; IAPS
REVISED CHILD ANXIETY; VOLUNTARY HYPERVENTILATION; USE DISORDERS; SUBSTANCE
USE; DEVELOPMENTAL PERSPECTIVE; NICOTINE DEPENDENCE; BODILY SENSATIONS; PUBERTAL
STATUS; SOCIAL ANXIETY; MARIJUANA USE A burgeoning literature supports a link
between alcohol use and panic-spectrum problems (e.g., panic attacks, disorder)
among adolescents, but the direction of influence has yet to be properly examined.
From a theoretical perspective, panic-spectrum problems may increase risk for
problematic drinking via affect regulation efforts (e.g., self-medication), and
problematic consumption also may increase or initiate panic-relevant responding
(e.g., learning or kindling models). The objective of the current investigation was
to examine the role of prior alcohol use in predicting panic-relevant responding,
as well as panic symptom history in predicting the desire to consume alcohol, in
the context of either a voluntary hyperventilation or a low-arousal task.
Participants were community-recruited adolescents aged 12-17 years (n = 92, M-age =
15.42, SD = 1.51; 39.1% girls). Results indicated that prior alcohol use predicted
panic-relevant responding among those undergoing the hyperventilation task (but not
the low-arousal task), and that this finding was robust to the inclusion of
theoretically relevant covariates (i.e., age, sex, negative affectivity). However,
panic symptom history did not predict the desire to consume alcohol as a function
of either the hyperventilation or low-arousal condition. This work sheds further
light on the nature of the relation between panic-spectrum problems and problematic
alcohol use in adolescence. Specifically, the current findings suggest that
frequent alcohol use may increase panic vulnerability among adolescents, whereas
acute panic symptoms may not elicit the immediate (self-reported) desire to drink.
[Blumenthal, Heidemarie; Cloutier, Renee M.] Univ N Texas, Dept Psychol,
Denton, TX 76203 USA; [Zamboanga, Byron L.] Smith Coll, Dept Psychol, Northampton,
MA 01063 USA; [Bunaciu, Liviu] Houston OCD Program, Houston, TX USA; [Bunaciu,
Liviu] Brown Univ, Alpert Med Sch, Dept Psychiat & Human Behav, Providence, RI
02912 USA; [Knapp, Ashley A.] Univ Arkansas, Dept Psychol Sci, Fayetteville, AR
72701 USA Blumenthal, H (reprint author), Univ N Texas, Dept Psychol, Teen Stress
& Alcohol Res Lab, 1155 Union Circle 311280, Denton, TX 76203 USA.
heidemarie.blumenthal@unt.edu Cloutier, Renee M/D-2249-2019; Knapp, Ashley/Q-
4136-2019; Cloutier, Renee/L-3601-2019 Cloutier, Renee M/0000-0003-1795-9149;
Knapp, Ashley/0000-0002-0073-1466; Cloutier, Renee/0000-0003-1795-9149 National
Institute on Alcohol Abuse and Alcoholism National Research Service Award [F31
AA018589] This project was partially supported by a National Institute on Alcohol
Abuse and Alcoholism National Research Service Award (F31 AA018589) awarded to the
first author. The funding agency played no role in study design; the collection,
analysis, and interpretation of data; the writing of the report; or the decision to
submit the article for publication. All authors contributed in a significant way to
the manuscript, and all authors have read and approved the final manuscript. The
authors have no conflicts of interest to declare. ALLAN CA, 1995, ALCOHOL
ALCOHOLISM, V30, P145; Andrews J. A., 2011, HDB DRUG USE ETIOLOG, P403; Antony MM,
2006, BEHAV RES THER, V44, P85, DOI 10.1016/j.brat.2004.12.005; BEHAR D, 1983,
ALCOHOL CLIN EXP RES, V7, P404, DOI 10.1111/j.1530-0277.1983.tb05495.x; Bernstein
A, 2007, BEHAV MODIF, V31, P117, DOI 10.1177/0145445506295056; Blumenthal H, 2012,
PSYCHOL ADDICT BEHAV, V26, P683, DOI 10.1037/a0027364; Blumenthal H, 2010, PSYCHOL
ADDICT BEHAV, V24, P529, DOI 10.1037/a0019794; Bonn-Miller MO, 2009, J PSYCHOACTIVE
DRUGS, V41, P331, DOI 10.1080/02791072.2009.10399770; Bouton ME, 2001, PSYCHOL REV,
V108, P4, DOI 10.1037//0033-295X.108.1.4; Breslau N, 1999, ARCH GEN PSYCHIAT, V56,
P1141, DOI 10.1001/archpsyc.56.12.1141; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48,
P1069; Brown SA, 2008, PEDIATRICS, V121, pS290, DOI 10.1542/peds.2007-2243D;
Buckner JD, 2009, DRUG ALCOHOL DEPEN, V100, P128, DOI
10.1016/j.drugalcdep.2008.09.018; Bunaciu L, 2010, BEHAV RES THER, V48, P158, DOI
10.1016/j.brat.2009.10.001; Centers for Disease Control and Prevention, 2012,
TRENDS PREV ALC US N; Chen C. M., 2011, 96 NIAAA DIV EP PREV; Chilcoat HD, 1998,
ADDICT BEHAV, V23, P827, DOI 10.1016/S0306-4603(98)00069-0; Chorpita BF, 2005,
BEHAV RES THER, V43, P309, DOI 10.1016/j.brat.2004.02.004; Chorpita BF, 2000, BEHAV
RES THER, V38, P835, DOI 10.1016/S0005-7967(99)00130-8; Cicchetti D, 1999, J CLIN
CHILD PSYCHOL, V28, P355, DOI 10.1207/S15374424jccp280308; CLARK DB, 1995,
PSYCHIATR SERV, V46, P618; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI
10.1037/0033-2909.112.1.155; COLLINS D, 1991, PSYCHOL REP, V69, P191, DOI
10.2466/PR0.69.5.191-197; Comeau N, 2001, ADDICT BEHAV, V26, P803, DOI
10.1016/S0306-4603(01)00238-6; Conrod PJ, 2006, J CLIN CHILD ADOLESC, V35, P550,
DOI 10.1207/s15374424jccp3504_6; Cooper ML, 2008, J ABNORM PSYCHOL, V117, P485, DOI
10.1037/a0012592; Craske MG, 2001, J AM ACAD CHILD PSY, V40, P556, DOI
10.1097/00004583-200105000-00015; *CTR STUD EM ATT, 1995, INT AFF PICT SYST PH;
Cuijpers P, 2003, AM J PSYCHIAT, V160, P1385, DOI 10.1176/appi.ajp.160.8.1385; Deas
D, 2000, ALCOHOL CLIN EXP RES, V24, P232, DOI 10.1111/j.1530-0277.2000.tb04596.x;
DILLON DJ, 1987, PSYCHIAT RES, V20, P97, DOI 10.1016/0165-1781(87)90002-3; Duka T,
1999, PHARMACOL BIOCHEM BE, V64, P301, DOI 10.1016/S0091-3057(99)00080-5; Eaton
Danice K., 2012, Morbidity and Mortality Weekly Report, V61, P1; Falk DE, 2008,
DRUG ALCOHOL DEPEN, V94, P234, DOI 10.1016/j.drugalcdep.2007.11.022; First M.,
2002, STRUCTURED CLIN INTE; Fritz CO, 2012, J EXP PSYCHOL GEN, V141, P2, DOI
10.1037/a0024338; GARDNER DM, 1993, CAN J PSYCHIAT, V38, P113, DOI
10.1177/070674379303800208; Goodwin RD, 2004, AM J PSYCHIAT, V161, P2207, DOI
10.1176/appi.ajp.161.12.2207; Goodwin RD, 2004, ACTA PSYCHIAT SCAND, V109, P216,
DOI 10.1046/j.1600-0447.2003.00255.x; Gorka SM, 2013, DRUG ALCOHOL DEPEN, V132,
P216, DOI 10.1016/j.drugalcdep.2013.02.003; Grant B.F., 2003, SOURCE ACCURACY STAT;
Grimaldi J., 1993, PSYCHOL PHYSL BREATH; Hawks E, 2011, BEHAV THER, V42, P427, DOI
10.1016/j.beth.2010.11.002; Hayward C, 2004, J AM ACAD CHILD PSY, V43, P613, DOI
10.1097/00004583-200405000-00015; HAYWARD C, 1992, AM J PSYCHIAT, V149, P1239;
Hayward C, 1997, J AM ACAD CHILD PSY, V36, P255; HAYWARD C, 1995, J ANXIETY DISORD,
V9, P329, DOI 10.1016/0887-6185(95)00013-E; HORNSVELD H, 1995, BIOL PSYCHOL, V40,
P299, DOI 10.1016/0301-0511(95)05120-Y; Hussong AM, 2001, J ABNORM PSYCHOL, V110,
P449, DOI 10.1037//0021-843X.110.3.449; Isensee B, 2003, ARCH GEN PSYCHIAT, V60,
P692, DOI 10.1001/archpsyc.60.7.692; Jaffee SR, 2007, MOL PSYCHIATR, V12, P432, DOI
10.1038/sj.mp.4001950; Johnson JG, 2000, JAMA-J AM MED ASSOC, V284, P2348, DOI
10.1001/jama.284.18.2348; Joiner TE, 1996, J ABNORM PSYCHOL, V105, P401, DOI
10.1037/0021-843X.105.3.401; Kazdin A. E, 2003, RES DESIGN CLIN PSYC; KUSHNER MG,
1990, AM J PSYCHIAT, V147, P685; Kushner MG, 1996, ARCH GEN PSYCHIAT, V53, P264;
Kushner MG, 2000, ALCOHOL CLIN EXP RES, V24, P448, DOI 10.1097/00000374-200004000-
00018; Lang P. J, 2008, A8 U FLOR; Lang P. J., 1997, INT AFFECTIVE PICTUR; Leen-
Feldner E, 2005, COGNITIVE THER RES, V29, P593, DOI 10.1007/s10608-005-3510-5;
Leen-Feldner EW, 2007, BEHAV MODIF, V31, P8, DOI 10.1177/0145445506295058; Leen-
Feldner EW, 2006, J ABNORM CHILD PSYCH, V34, P799, DOI 10.1007/s10802-006-9079-y;
Leen-Feldner EW, 2004, J CLIN CHILD ADOLESC, V33, P783, DOI
10.1207/s15374424jccp3304_13; Lehman CL, 2002, BEHAV THER, V33, P447, DOI
10.1016/S0005-7894(02)80038-7; Love A, 1998, ADDICTION, V93, P1091, DOI
10.1046/j.1360-0443.1998.937109113.x; MacDonald AB, 2000, ALCOHOL CLIN EXP RES,
V24, P1656, DOI 10.1111/j.1530-0277.2000.tb01967.x; Masten AS, 2010, DEV
PSYCHOPATHOL, V22, P491, DOI 10.1017/S0954579410000222; Masten AS, 2009, ALCOHOL
RES HEALTH, V32, P3; Mathew AR, 2011, J COGN PSYCHOTHER, V25, P61, DOI
10.1891/0889-8391.25.1.61; Mathyssek CM, 2012, PLOS ONE, V7, DOI
10.1371/journal.pone.0051564; McManis MH, 2001, PSYCHOPHYSIOLOGY, V38, P222, DOI
10.1111/1469-8986.3820222; Moberg D., 1991, J ADOLESCENT CHEM DE, V2, P75, DOI DOI
10.1080/10678289109512338; Moberg D. P., 2000, ADOLESCENT ALCOHOL D; Mulligan ME,
2001, ADDICT BEHAV, V26, P375, DOI 10.1016/S0306-4603(00)00113-1; Nelson CB, 1998,
EUR ADDICT RES, V4, P42, DOI 10.1159/000018929; Nisbett R, 1980, HUMAN INFERENCE
STRA; Nixon K, 2010, CURR OPIN PSYCHIATR, V23, P227, DOI
10.1097/YCO.0b013e32833864fe; NORTON GR, 1986, BEHAV THER, V17, P239, DOI
10.1016/S0005-7894(86)80054-5; Olatunji B. O., 2007, HDB RES METHODS ABNO, P47;
Pine DS, 2000, ARCH GEN PSYCHIAT, V57, P960, DOI 10.1001/archpsyc.57.10.960; Pine
DS, 1998, ARCH GEN PSYCHIAT, V55, P123, DOI 10.1001/archpsyc.55.2.123; Rabian B,
1999, J CLIN CHILD PSYCHOL, V28, P105, DOI 10.1207/s15374424jccp2801_9; RAPEE RM,
1992, J ABNORM PSYCHOL, V101, P538, DOI 10.1037/0021-843X.101.3.538; Robinson J,
2009, J ANXIETY DISORD, V23, P38, DOI 10.1016/j.janxdis.2008.03.013; Schmidt NB,
2007, BEHAV MODIF, V31, P202, DOI 10.1177/0145445506297019; Schmidt NB, 2006, J
PSYCHIAT RES, V40, P691, DOI 10.1016/j.jpsychires.2006.07.009; Schry AR, 2014, PLOS
ONE, V9, DOI 10.1371/journal.pone.0115361; Schulze D, 2000, ADDICTION, V95, P1015,
DOI 10.1046/j.1360-0443.2000.95710154.x; Sharkansky EJ, 1999, PSYCHOL
ADDICT BEHAV, V13, P89, DOI 10.1037/0893-164X.13.2.89; Snyder L. B., 2011, HDB
DRUG USE ETIOLOG, P475; SOBELL LC, 1995, ADDICT BEHAV, V20, P233, DOI 10.1016/0306-
4603(94)00071-9; SPINHOVEN P, 1992, BEHAV RES THER, V30, P453, DOI 10.1016/0005-
7967(92)90029-G; STEWART SH, 1995, J ANXIETY DISORD, V9, P229, DOI 10.1016/0887-
6185(95)00004-8; Stewart SH, 2008, SER ANXIETY RELAT DI, P239, DOI 10.1007/978-0-
387-74290-8_13; Tanner J., 1962, GROWTH ADOLESCENCE; Tapert SF, 2003, ARCH GEN
PSYCHIAT, V60, P727, DOI 10.1001/archpsyc.60.7.727; U. S. Bureau of the Census,
2012, AM FACTFINDER FACT S; U. S. Bureau of the Census, 2010, AM FACTFINDER FACT S;
Unnewehr S, 1996, J ANXIETY DISORD, V10, P489, DOI 10.1016/S0887-6185(96)00025-4;
Verster JC, 2008, ALCOHOL ALCOHOLISM, V43, P124, DOI 10.1093/alcalc/agm163; Windle
M, 2008, PEDIATRICS, V121, pS273, DOI 10.1542/peds.2007-2243C; Zimmermann P, 2003,
PSYCHOL MED, V33, P1211, DOI 10.1017/S0033291703008158; Zvolensky M. J., 2001, REV
GEN PSYCHOL, V5, P371, DOI DOI 10.1037/1089-2680.5.4.371; Zvolensky MJ, 2008, J
PSYCHIATR RES, V42, P1017, DOI 10.1016/j.jpsychires.2007.10.012; Zvolensky MJ,
2006, J PSYCHIAT RES, V40, P477, DOI 10.1016/j.jpsychires.2005.09.005; Zvolensky
MJ, 2010, EXP CLIN PSYCHOPHARM, V18, P129, DOI 10.1037/a0019022; Zvolensky MJ,
2003, CLIN PSYCHOL-SCI PR, V10, P29, DOI 10.1093/clipsy/10.1.29 107 0 0
0 6 AMER PSYCHOLOGICAL ASSOC WASHINGTON 750 FIRST ST NE,
WASHINGTON, DC 20002-4242 USA 1064-1297 1936-2293 EXP CLIN PSYCHOPHARM
Exp. Clin. Psychopharmacol. OCT 2015 23 5
303 313 10.1037/pha0000022 11 Psychology,
Biological; Psychology, Clinical; Pharmacology & Pharmacy; Psychiatry Psychology;
Pharmacology & Pharmacy; Psychiatry CR8XQ WOS:000361638100001 26053320 Green
Accepted 2019-09-25
J Muller, M; Rodgers, S; Rossler, W; Castelao, E; Preisig, M; Ajdacic-Gross, V;
Vandeleur, C Mueller, Mario; Rodgers, Stephanie; Roessler,
Wulf; Castelao, Enrique; Preisig, Martin; Ajdacic-Gross, Vladeta; Vandeleur,
Caroline Discrepancies between clinical needs and helpseeking
behaviors' in co-occurring posttraurnatic stress and alcohol use disorders
COMPREHENSIVE PSYCHIATRY English Article
SUBSTANCE USE DISORDERS; CARDIOVASCULAR RISK-FACTORS; TEST-
RETEST RELIABILITY; GENETIC-STUDIES DIGS; POSTTRAUMATIC-STRESS; DIAGNOSTIC-
INTERVIEW; HELP-SEEKING; MENTAL-HEALTH; GENERAL-POPULATION; PTSD Objective: The aim
of the study was to compare subjects dually diagnosed with posttraumatic stress
disorder (PTSD) and alcohol use disorder (AUD) to those with only one or none of
these conditions regarding helpseeking needs and behaviors. Method: Data from a
large community sample (N = 3694) were used to assess the associations among
lifetime PTSD and AUD, other psychiatric disorders, clinical characteristics and
lifetime helpseeking behaviors derived from a semi-structured interview. Results:
Comorbid individuals had more severe clinical profiles and were more impaired than
individuals with either PTSD or AUD alone or those with no/other psychiatric
conditions. However, they did not differ in overall helpseeking behavior from any
other group. Those with comorbid PTSD/AUD were even less likely than the other
groups to seek help for depression and anxiety disorders through specific treatment
facilities or the use of prescribed psychotropic drugs. Conclusions: Despite a
greater need for treatment the comorbid group did not seek more help than the
others. Their lower use of prescribed drugs supports the self-medication
hypothesis, suggesting that those individuals relieve their symptoms through higher
alcohol use instead. Our findings underline the need for health care facilities to
encourage helpseeking behavior in the aftermath of stressful life events. (C) 2015
Elsevier Inc. All rights reserved. [Mueller, Mario; Rodgers, Stephanie; Roessler,
Wulf; Ajdacic-Gross, Vladeta] Zurich Univ Hosp Psychiat, Dept Psychiat
Psychotherapy & Psychosomat, CH-8021 Zurich, Switzerland; [Roessler, Wulf] Univ
Zurich, Coll Helveticum, Zurich, Switzerland; [Roessler, Wulf] Swiss Fed Inst
Technol, Zurich, Switzerland; [Roessler, Wulf] Univ Sao Paulo, Inst Psychiat, Lab
Neurosci LIM 27, Sao Paulo, Brazil; [Castelao, Enrique; Preisig, Martin; Vandeleur,
Caroline] Univ Lausanne Hosp, Dept Psychiat, Lausanne, Switzerland Muller, M
(reprint author), Zurich Univ Hosp Psychiat, Dept Psychiat Psychotherapy &
Psychosomat, POB 1930, CH-8021 Zurich, Switzerland. mario.mueller@dgsp.uzh.ch
Colaus, PsyColaus/K-6607-2013 Rodgers, Stephanie/0000-0003-2811-7991;
Castelao, Enrique/0000-0003-1966-3683 GlaxoSmithKlineGlaxoSmithKline; Faculty
of Biology and Medicine of Lausanne; Swiss National Science FoundationSwiss
National Science Foundation (SNSF) [3200B0-105993, 3200B0-118308, 33CSCO-122661,
33CS30-139468, 33CS30-148401] The PsyCoLaus study was and is supported by research
grants from GlaxoSmithKline, the Faculty of Biology and Medicine of Lausanne, and
the Swiss National Science Foundation (grants 3200B0-105993, 3200B0-118308, 33CSCO-
122661, 33CS30-139468 and 33CS30-148401). The funders had no role in the design of
the study; the collection, management, analysis, and interpretation of the data;
the preparation, review or approval of the manuscript; or the decision to submit
the manuscript for publication. ANDERSEN RM, 1995, J HEALTH SOC BEHAV, V36, P1,
DOI 10.2307/2137284; Beals J, 2005, ARCH GEN PSYCHIAT, V62, P99, DOI
10.1001/archpsyc.62.1.99; Berney A, 2002, DRUG ALCOHOL DEPEN, V65, P149, DOI
10.1016/S0376-8716(01)00156-9; Bettschard W, 1996, EVALUATION CLIN STAN, VI; Blanco
C, 2013, DRUG ALCOHOL DEPEN, V132, P630, DOI 10.1016/j.drugalcdep.2013.04.016;
Brugha TS, 1999, PSYCHOL MED, V29, P1013, DOI 10.1017/S0033291799008880; BUCHOLZ
KK, 1989, AM J PSYCHIAT, V146, P640; du Fort GG, 1999, J AFFECT DISORDERS, V52,
P31, DOI 10.1016/S0165-0327(98)00052-4; Eaton WW, 2000, ARCH GEN PSYCHIAT, V57,
P217, DOI 10.1001/archpsyc.57.3.217; ENDICOTT J, 1978, ARCH GEN PSYCHIAT, V35,
P837; Firmann M, 2008, BMC CARDIOVASC DISOR, V8, DOI 10.1186/1471-2261-8-6;
Galatzer-Levy IR, 2013, DEPRESS ANXIETY, V30, P489, DOI 10.1002/da.22048; Goldberg
D., 1972, DETECTION PSYCHIAT I; Hollingshead AB., 1975, 4 FACTOR INDEX UNPUB;
Khantzian E. J., 1999, TREATING ADDICTION H; Khantzian EJ, 1997, HARVARD REV
PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550; Langeland W, 2004, ALCOHOL CLIN
EXP RES, V28, P441, DOI 10.1097/01.ALC.0000117831.17383.72; LEBOYER M, 1991, EUR
ARCH PSY CLIN N, V241, P165, DOI 10.1007/BF02219716; Leboyer M, 1995, INTERVIEW
DIAGNOSTIQ; Leeies M, 2010, DEPRESS ANXIETY, V27, P731, DOI 10.1002/da.20677; LYONS
JS, 1989, HOSP COMMUNITY PSYCH, V40, P1067; Maguen S, 2012, J WOMENS HEALTH, V21,
P666, DOI 10.1089/jwh.2011.3113; McLean CP, 2014, J ANXIETY DISORD, V28, P894, DOI
10.1016/j.janxdis.2014.09.023; Mojtabai R, 2002, ARCH GEN PSYCHIAT, V59, P77, DOI
10.1001/archpsyc.59.1.77; Muller M, 2015, PSYCHIAT RES, V228, P251, DOI
10.1016/j.psychres.2015.06.034; Muller M, 2014, COMPR PSYCHIAT, V55, P837, DOI
10.1016/j.comppsych.2014.01.009; Muller M., 2015, CHILD ABUSE NEGL; Najavits LM,
1998, AM J PSYCHIAT, V155, P214; NURNBERGER JI, 1994, ARCH GEN PSYCHIAT, V51, P849;
Ouimette P, 2003, J CONSULT CLIN PSYCH, V71, P410, DOI 10.1037/0022-006X.71.2.410;
Ouimette P, 2010, ADDICT BEHAV, V35, P64, DOI 10.1016/j.addbeh.2009.08.009;
Ouimette PC, 2000, J STUD ALCOHOL, V61, P247, DOI 10.15288/jsa.2000.61.247; Perrin
M, 2014, SOC PSYCH PSYCH EPID, V49, P447, DOI 10.1007/s00127-013-0762-3; Preisig M,
1999, EUR ARCH PSY CLIN N, V249, P174, DOI 10.1007/s004060050084; Preisig M, 2009,
BMC PSYCHIATRY, V9, DOI 10.1186/1471-244X-9-9; Rusch N, 2014, EPIDEMIOL PSYCH SCI,
V23, P177, DOI 10.1017/S204579601300036X; Rusch N, 2013, PSYCHIAT RES, V210, P1313,
DOI 10.1016/j.psychres.2013.08.028; SALADIN ME, 1995, ADDICT BEHAV, V20, P643, DOI
10.1016/0306-4603(95)00024-7; Skodol AE, 1996, BRIT J PSYCHIAT, V169, P717, DOI
10.1192/bjp.169.6.717; StataCorp, 2011, STAT STAT SOFTW REL; Stewart SH, 1998,
ADDICT BEHAV, V23, P797, DOI 10.1016/S0306-4603(98)00070-7 41 2 2 0
10 W B SAUNDERS CO-ELSEVIER INC PHILADELPHIA 1600 JOHN F KENNEDY
BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA 0010-440X 1532-8384
COMPR PSYCHIAT Compr. Psychiat. OCT 2015 62
209 217 10.1016/j.comppsych.2015.07.013 9
Psychiatry Psychiatry CR4XM WOS:000361343400026 26343486
2019-09-25
J Lemaire-Hurtel, AS; Goulle, JP; Alvarez, JC; Mura, P; Verstraete, AG
Lemaire-Hurtel, Anne-Sophie; Goulle, Jean-Pierre; Alvarez, Jean-Claude;
Mura, Patrick; Verstraete, Alain G. Drug use and driving PRESSE
MEDICALE French Article
ANTIHISTAMINES; PERFORMANCE; ALCOHOL; ANTIDEPRESSANTS; PRESCRIPTION;
METAANALYSIS; DRIVERS; SAFETY; RISK Some drugs are known to impair driving because
they can change the vision or hearing, and/or disrupt the intellectual or motor
abilities: impaired vigilance, sedation, disinhibition effect, the coordination of
movement disorders and the balance. The doctor during prescribing and the
pharmacist during deliverance of drug treatment should inform their patients of the
potential risks of drugs on driving or operating machinery. The driver has direct
responsibility, who hired him and him alone, to follow the medical advice received.
The pictograms on the outer packaging of medicinal products intended to classify
substances according to their risk driving: The driver can whether to observe
simple precautions (level one "be prudent''), or follow the advice of a health
professional (level two "be very careful''), or if it is totally not drive (level
three "danger caution: do not drive''). This classification only evaluates the
intrinsic danger of drugs but not the individual variability. Medicines should be
taken into account also the conditions for which the medication is prescribed. It
is important to inform the patient on several points: not to change the prescribed
dose due to the increase in adverse effects and therefore the risks for driving;
respect the hours and conditions of slots: at bedtime to hypnotics and no
additional outlet when nocturnal awakening; to avoid self-medication, alcohol and
drugs particularly cannabis, whose dangerousness driving is demonstrated; not to
drive or stop driving when tired, sleepy, a feeling of heavy limbs, numb and
trembling. [Lemaire-Hurtel, Anne-Sophie] CHU Amiens, Lab Pharmacol & Toxicol, Ctr
Biol Humaine, F-80054 Amiens, France; [Goulle, Jean-Pierre] Fac Med & Pharm Rouen,
Toxicol Lab, F-76000 Rouen, France; [Alvarez, Jean-Claude] CHU Garches, Lab
Pharmacol & Toxicol, D-92380 Garches, Germany; [Mura, Patrick] CHU Poitiers, Lab
Pharmacol & Toxicol, F-86021 Poitiers, France; [Verstraete, Alain G.] Univ Gand,
Lab Biol Clin, Hop Univ Gand, Dept Biol Clin Microbiol & Immunol, B-9000 Ghent,
Belgium Lemaire-Hurtel, AS (reprint author), CHU Amiens, Lab Pharmacol &
Toxicol, Ave Laennec, F-80054 Amiens, France. Hurtel-Lemaire.Anne-Sophie@chu-
amiens.fr Verstraete, Alain/B-4150-2013 Verstraete, Alain/0000-0002-0956-3315;
ALVAREZ, jean claude/0000-0001-5344-9475 [Anonymous], 2001,
COM2000125C502482000; ANSM, 2009, MIS POINT MED COND A; Assum T., 2005, PREVALENCE
DRUG DRIV; Avalos M, 2014, PHARMACOEPIDEM DR S, V23, P140, DOI 10.1002/pds.3539;
Barbanoj MJ, 2006, HUM PSYCHOPHARM CLIN, V21, P13, DOI 10.1002/hup.741; Berger WE,
2005, DRUG SAFETY, V28, P1101, DOI 10.2165/00002018-200528120-00005; Dassanayake T,
2011, DRUG SAFETY, V34, P125, DOI 10.2165/11539050-000000000-00000; De Gier JJ,
1995, ESTIMATION PSYCHOTRO; Didier A, 2000, CURR THER RES CLIN E, V61, P770, DOI
10.1016/S0011-393X(00)90003-1; Dumont GJH, 2005, BRIT J CLIN PHARMACO, V59, P495,
DOI 10.1111/j.1365-2125.2005.02342.x; Elvik R, 2013, ACCIDENT ANAL PREV, V60, P254,
DOI 10.1016/j.aap.2012.06.017; GJERDE H, 1993, ACCIDENT ANAL PREV, V25, P479, DOI
10.1016/0001-4575(93)90078-B; Goulle J. -P., 2008, Annales Pharmaceutiques
Francaises, V66, P196, DOI 10.1016/j.pharma.2008.06.002; Kay GG, 2001, ALLERGY
ASTHMA PROC, V22, P281; Kay GG, 2000, J ALLERGY CLIN IMMUN, V105, pS622; Kuitunen
T, 1994, ALCOHOL DRUGS DRIVIN, V10, P135; Mura P, 2003, FORENSIC SCI INT, V133,
P79, DOI 10.1016/S0379-0738(03)00052-5; O'Hanlon JF, 1986, PERFORMANCE TESTING;
Orriols L, 2013, J CLIN PHARMACOL, V53, P339, DOI 10.1002/jcph.10; Orriols L, 2010,
PLOS MED, V7, DOI 10.1371/journal.pmed.1000366; Podewils LJ, 2002, PSYCHOSOMATICS,
V43, P31, DOI 10.1176/appi.psy.43.1.31; Richardson GS, 2002, J CLIN PSYCHOPHARM,
V22, P511, DOI 10.1097/01.jcp.0000033406.13191.e8; Rose EJ, 2006,
PSYCHOPHARMACOLOGY, V185, P339, DOI 10.1007/s00213-006-0334-2; Smink B E, 2008, J
Forensic Leg Med, V15, P483, DOI 10.1016/j.jflm.2008.04.002; Strik JJMH, 2006, ACTA
NEUROPSYCHIATR, V18, P1, DOI 10.1111/j.0924-2708.2006.00110.x; Vermeeren A, 2004,
CNS DRUGS, V18, P297, DOI 10.2165/00023210-200418050-00003; Verstraete A. G., 2014,
DRUG USE IMPAIRED DR; Vidal, 2015, DICT 2015 28 0 0 0 17 MASSON
EDITEUR MOULINEAUX CEDEX 9 21 STREET CAMILLE DESMOULINS, ISSY, 92789
MOULINEAUX CEDEX 9, FRANCE 0755-4982 2213-0276 PRESSE MED Presse Med.
OCT 2015 44 10 1055 1063
10.1016/j.lpm.2015.03.007 9 Medicine, General & Internal
General & Internal Medicine CV3KT WOS:000364158800014 25956300
2019-09-25
J Gomez, J; Becker, S; O'Brien, K; Spirito, A Gomez,
Judelysse; Becker, Sara; O'Brien, Kimberly; Spirito, Anthony
Interactive Effect of Child Maltreatment and Substance Use on Depressed Mood
Among Adolescents Presenting to Community-Based Substance Use Treatment
COMMUNITY MENTAL HEALTH JOURNAL English Article
Adolescents; Substance use; Childhood maltreatment;
Depressed mood community behavioral health SELF-MEDICATION HYPOTHESIS; USE
DISORDERS; MENTAL-DISORDERS; COMORBIDITY; ALCOHOL; ABUSE; RISK; PREVALENCE;
TRAJECTORIES; PERSISTENCE Adolescents referred to community behavioral health
centers (CBHC) for substance use (SU) problems report high rates of child
maltreatment. Although SU and maltreatment are independent risk factors for
adolescent depression, few studies have examined their interactive effects. This
study examined the interactive effects of SU (alcohol and marijuana) and exposure
to different types of trauma on depressed mood among 74 adolescents referred to a
CBHC for SU. Hierarchical regressions controlling for sex and common adolescent
comorbidities showed that sexual abuse had a stronger relationship with depressed
mood than other types of maltreatment. Although SU was not independently related to
depressed mood, consistent with the self-medication hypothesis, increased SU was
associated with lower levels of depressed mood among adolescents with greater
exposure to sexual abuse. Results suggest that teens presenting to CBHCs for SU
should be assessed for multiple forms of maltreatment and for depressed mood.
[Gomez, Judelysse; Becker, Sara; Spirito, Anthony] Brown Univ, Dept Psychiat
& Human Behav, Alpert Med Sch, Providence, RI 02912 USA; [Becker, Sara] Brown Univ,
Dept Behav & Social Sci, Ctr Alcohol & Addict Studies, Providence, RI 02912 USA;
[O'Brien, Kimberly] Harvard Univ, Sch Med, Boston Childrens Hosp, Simmons Sch
Social Work, Boston, MA 02115 USA Gomez, J (reprint author), Brown Univ, Dept
Psychiat & Human Behav, Alpert Med Sch, Box G-BH, Providence, RI 02912 USA.
Judelysse_gomez@brown.edu NIAAA NIH HHSUnited States
Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01 AA020705]; NIDA NIH
HHSUnited States Department of Health & Human ServicesNational Institutes of Health
(NIH) - USANIH National Institute on Drug Abuse (NIDA) [K23 DA031743]
Achenbach TM, 2001, MANUAL ASEBA SCH AGE; Aiken LS, 1991, MULTIPLE
REGRESSION; Beck AT, 1996, MANUAL BECK DEPRESSI; Bernstein DP, 2003, CHILD ABUSE
NEGLECT, V27, P169, DOI 10.1016/S0145-2134(02)00541-0; Bonn-Miller MO, 2007, J
TRAUMA STRESS, V20, P577, DOI 10.1002/jts.20243; Brown J, 1999, J AM ACAD CHILD
PSY, V38, P1490, DOI 10.1097/00004583-199912000-00009; Clark DB, 1997, J AM ACAD
CHILD PSY, V36, P1744, DOI 10.1097/00004583-199712000-00023; Degenhardt L, 2013,
ADDICTION, V108, P124, DOI 10.1111/j.1360-0443.2012.04015.x; Fletcher JM, 2009, SOC
SCI MED, V68, P799, DOI 10.1016/j.socscimed.2008.12.005; Ford JD, 2010, J
ADOLESCENT HEALTH, V46, P545, DOI 10.1016/j.jadohealth.2009.11.212; Green JG, 2010,
ARCH GEN PSYCHIAT, V67, P113, DOI 10.1001/archgenpsychiatry.2009.186; Hamburger ME,
2008, J STUD ALCOHOL DRUGS, V69, P291, DOI 10.15288/jsad.2008.69.291; Harrison PA,
1997, CHILD ABUSE NEGLECT, V21, P529, DOI 10.1016/S0145-2134(97)00013-6; Hodgins S,
2014, EUR CHILD ADOLES PSY, V23, P347, DOI 10.1007/s00787-013-0456-0; Holmbeck GN,
2002, J PEDIATR PSYCHOL, V27, P87, DOI 10.1093/jpepsy/27.1.87; Hussey JM, 2006,
PEDIATRICS, V118, P933, DOI 10.1542/peds.2005-2452; Jessor R., 1989, HLTH BEHAV
QUESTIONN; Kessler RC, 2012, ARCH GEN PSYCHIAT, V69, P372, DOI
10.1001/archgenpsychiatry.2011.160; Keyes KM, 2012, ALCOHOL RES-CURR REV, V34,
P391; Keyes KM, 2012, BRIT J PSYCHIAT, V200, P107, DOI 10.1192/bjp.bp.111.093062;
Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550;
KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259; Mangerud WL, 2014, J ADOLESCENCE,
V37, P1189, DOI 10.1016/j.adolescence.2014.08.007; Merikangas KR, 2010, J AM ACAD
CHILD PSY, V49, P980, DOI 10.1016/j.jaac.2010.05.017; Nakamura BJ, 2009, J
PSYCHOPATHOL BEHAV, V31, P178, DOI 10.1007/s10862-008-9119-8; Needham BL, 2007, SOC
SCI MED, V65, P1166, DOI 10.1016/j.socscimed.2007.04.037; O'Neil KA, 2011, CLIN
PSYCHOL REV, V31, P104, DOI 10.1016/j.cpr.2010.08.002; Seligman LD, 2004, J CLIN
CHILD ADOLESC, V33, P557, DOI 10.1207/s15374424jccp3303_13; Shin SH, 2013, DRUG
ALCOHOL DEPEN, V127, P31, DOI 10.1016/j.drugalcdep.2012.06.005; Shin SH, 2012, AM J
ADDICTION, V21, P202, DOI 10.1111/j.1521-0391.2012.00227.x; Shin SH, 2009, ADDICT
BEHAV, V34, P277, DOI 10.1016/j.addbeh.2008.10.023; Sobell LC, 1995, ALCOHOL
TIMELINE FOL; Sobell LS, 2003, ASSESSING ALCOHOL PR, P75; Subramaniam G, 2009, J
SUBST ABUSE TREAT, V37, P25, DOI 10.1016/j.jsat.2008.09.008; Swendsen J, 2012, ARCH
GEN PSYCHIAT, V69, P390, DOI 10.1001/archgenpsychiatry.2011.1503; Taylor OD, 2011,
J HUM BEHAV SOC ENVI, V21, P696, DOI 10.1080/10911359.2011.583519; Tims FM, 2002,
ADDICTION, V97, P46, DOI 10.1046/j.1360-0443.97.s01.7.x; Vilhena-Churchill N, 2014,
CHILD ABUSE NEGLECT, V38, P962, DOI 10.1016/j.chiabu.2013.10.009; Whitson ML, 2012,
J EMOT BEHAV DISORD, V20, P193, DOI 10.1177/1063426610380596; Widom CS, 2007, ARCH
GEN PSYCHIAT, V64, P49 40 2 2 0 16 SPRINGER DORDRECHT VAN
GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS 0010-3853 1573-2789
COMMUNITY MENT HLT J Community Ment. Health J. OCT 2015 51 7
833 840 10.1007/s10597-015-9894-0
8 Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry CR0JB WOS:000361003500010 26017474 Green Accepted
2019-09-25
J Mane, A; Fernandez-Exposito, M; Berge, D; Gomez-Perez, L; Sabate, A; Toll, A;
Diaz, L; Diez-Aja, C; Perez, V Mane, Anna; Fernandez-
Exposito, Miguel; Berge, Daniel; Gomez-Perez, Laura; Sabate, Agnes; Toll, Alba;
Diaz, Laura; Diez-Aja, Cristobal; Perez, Victor Relationship between
cannabis and psychosis: Reasons for use and associated clinical variables
PSYCHIATRY RESEARCH English Article
Cannabis; First-episode; Reasons for use; Schizophrenia; Self-
medication SELF-MEDICATION HYPOTHESIS; SUBSTANCE USE; UNTREATED PSYCHOSIS; USE
DISORDERS; 1ST-EPISODE PSYCHOSIS; 1ST EPISODE; SCHIZOPHRENIA; ONSET; PREVALENCE;
DURATION The mechanism underneath the relationship between cannabis and
psychosis remains controversial, for which several hypotheses have been proposed,
including cannabis as self-medication and cannabis as a risk for the development of
psychosis. The aim of this work was to study the relationship between cannabis and
psychosis in first-episode psychosis cannabis users and non-users, and non-
psychotic cannabis users. The age at the first psychotic episode, duration of
untreated psychosis, psychopathology and reasons for cannabis use were assessed.
First-episode psychosis cannabis users showed an earlier age at psychosis onset
than non-user patients. No significant differences in symptomatology were found.
The distinguishing reasons to use cannabis for patients with first-episode
psychosis with respect to non-psychotic users were to arrange their thoughts and
deal with hallucinations and suspiciousness. These findings are in agreement with
both hypotheses: self-medication and secondary psychosis hypothesis. However,
longitudinal prospective cohort studies assessing reasons for cannabis use are
needed to investigate both hypotheses and their complementarity. (C) 2015 Elsevier
Ireland Ltd. All rights reserved. [Mane, Anna; Berge, Daniel; Gomez-Perez, Laura;
Sabate, Agnes; Toll, Alba; Diaz, Laura; Diez-Aja, Cristobal; Perez, Victor] IMIM
Hosp Mar Med Res Inst Neurosci, Psychiat, Barcelona, Spain; [Mane, Anna; Berge,
Daniel; Perez, Victor] Ctr Invest Biomed Red Salud Mental CIBERSAM, Madrid, Spain;
[Fernandez-Exposito, Miguel] Univ Pompeu Fabra, Barcelona, Spain; [Fernandez-
Exposito, Miguel] Univ Autonoma Barcelona, E-08193 Barcelona, Spain Mane, A
(reprint author), Passeig Maritim Barceloneta 25-29, Barcelona 08003, Spain.
manesantacana@yahoo.es Berge, Daniel/J-8783-2017; Berge, David/P-2179-2017
Berge, Daniel/0000-0003-2544-1016; Berge, David/0000-0002-2918-1824; Perez,
Victor/0000-0002-5825-2337; mane santacana, anna/0000-0003-2127-349X
Addington J, 1997, ACTA PSYCHIAT SCAND, V96, P329, DOI 10.1111/j.1600-
0447.1997.tb09925.x; Amorim P, 1998, EUR PSYCHIAT, V13, P26, DOI 10.1016/S0924-
9338(97)86748-X; ANDREASSON S, 1989, ACTA PSYCHIAT SCAND, V79, P505, DOI
10.1111/j.1600-0447.1989.tb10296.x; Archie S, 2013, EARLY INTERV PSYCHIA, V7, P193,
DOI 10.1111/j.1751-7893.2012.00355.x; Barnes TRE, 2006, BRIT J PSYCHIAT, V188,
P237, DOI 10.1192/bjp.bp.104.007237; Barrowclough C, 2013, SCHIZOPHRENIA BULL, V39,
P339, DOI 10.1093/schbul/sbr152; Beavan V, 2010, J NERV MENT DIS, V198, P201, DOI
10.1097/NMD.0b013e3181d14612; Broussard B, 2013, SCHIZOPHR RES, V148, P93, DOI
10.1016/j.schres.2013.05.011; Brune M, 2012, EUR PSYCHIAT, V27, P358, DOI
10.1016/j.eurpsy.2010.10.002; Burns JK, 2010, AFR J PSYCHIATRY, V13, P395; Burns
JK, 2012, CURR PHARM DESIGN, V18, P5093; Caballero A, 2012, FRONT PHARMACOL, V3,
DOI 10.3389/fphar.2012.00101; Caspi A, 2005, BIOL PSYCHIAT, V57, P1117, DOI
10.1016/j.biopsych.2005.01.026; Compton MT, 2009, AM J PSYCHIAT, V166, P1251, DOI
10.1176/appi.ajp.2009.09030311; Di Forti M, 2014, SCHIZOPHRENIA BULL, V40, P1509,
DOI 10.1093/schbul/sbt181; Dickerson FB, 2007, J WOMEN AGING, V19, P49, DOI
10.1300/J074v19n01_04; DIXON L, 1991, AM J PSYCHIAT, V148, P224; Fowler IL, 1998,
SCHIZOPHRENIA BULL, V24, P443, DOI 10.1093/oxfordjournals.schbul.a033339; Gerretsen
P, 2014, INT J GERIATR PSYCH, V29, P1145, DOI 10.1002/gps.4154; Perez LG, 2014,
ACTAS ESP PSIQUIATRI, V42, P83; Goswami S, 2004, AM J ADDICTION, V13, P139, DOI
10.1080/10550490490435795; Grech A, 2005, EUR PSYCHIAT, V20, P349, DOI
10.1016/j.eurpsy.2004.09.013; Green B, 2004, DRUG ALCOHOL REV, V23, P445, DOI
10.1080/09595230412331324563; Haberstick BC, 2014, DRUG ALCOHOL DEPEN, V136, P158,
DOI 10.1016/j.drugalcdep.2013.11.022; KAY SR, 1990, J NERV MENT DIS, V178, P510,
DOI 10.1097/00005053-199017880-00007; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4,
P231, DOI 10.3109/10673229709030550; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142,
P1259; Kolliakou A, 2015, EUR PSYCHIAT, V30, DOI 10.1016/j.eurpsy.2014.10.007;
Koskinen J, 2010, SCHIZOPHRENIA BULL, V36, P1115, DOI 10.1093/schbul/sbp031; Large
M, 2011, ARCH GEN PSYCHIAT, V68, P555, DOI 10.1001/archgenpsychiatry.2011.5; Lewis
DA, 2000, NEURON, V28, P325, DOI 10.1016/S0896-6273(00)00111-2; LINSZEN DH, 1994,
ARCH GEN PSYCHIAT, V51, P273; Moore THM, 2007, LANCET, V370, P319, DOI
10.1016/S0140-6736(07)61162-3; Myles N, 2012, CURR PHARM DESIGN, V18, P5055, DOI
10.2174/138161212802884816; Rossler W, 2007, SCHIZOPHR RES, V92, P1, DOI
10.1016/j.schres.2007.01.002; Saddichha S., 2010, PRIM CARE COMPANION, V12, P5;
Schaub M, 2008, AUST NZ J PSYCHIAT, V42, P1060, DOI 10.1080/00048670802512016;
Schimmelmann BG, 2012, EUR PSYCHIAT, V27, P463, DOI 10.1016/j.eurpsy.2011.03.001;
SCHNEIER FR, 1987, J NERV MENT DIS, V175, P641, DOI 10.1097/00005053-198711000-
00001; Schofield D, 2006, AUST NZ J PSYCHIAT, V40, P570, DOI 10.1080/j.1440-
1614.2006.01840.x; Semple DM, 2005, J PSYCHOPHARMACOL, V19, P187, DOI
10.1177/0269881105049040; Spencer C, 2002, SCHIZOPHRENIA BULL, V28, P233, DOI
10.1093/oxfordjournals.schbul.a006934; Stone JM, 2014, PSYCHOL MED, V44, P499, DOI
10.1017/S0033291713000883; van Dijk D, 2012, SCHIZOPHR RES, V137, P50, DOI
10.1016/j.schres.2012.01.016; WARNER R, 1994, AM J ORTHOPSYCHIAT, V64, P30, DOI
10.1037/h0079489 45 11 11 2 37 ELSEVIER IRELAND LTD CLARE
 ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND
0165-1781 PSYCHIAT RES Psychiatry Res. SEP 30 2015
229 1-2 70 74
10.1016/j.psychres.2015.07.070 5 Psychiatry Psychiatry
CQ7HC WOS:000360772600009 26235479 2019-09-25
J Jester, JM; Steinberg, DB; Heitzeg, MM; Zucker, RA
Jester, Jennifer M.; Steinberg, Davia B.; Heitzeg, Mary M.; Zucker, Robert A.
Coping Expectancies, Not Enhancement Expectancies, Mediate Trauma
Experience Effects on Problem Alcohol Use: A Prospective Study From Early Childhood
to Adolescence JOURNAL OF STUDIES ON ALCOHOL AND DRUGS English
Article POSTTRAUMATIC-STRESS-
DISORDER; SUBSTANCE USE DISORDERS; DOMESTIC VIOLENCE; SEXUAL ASSAULT; ADULT WOMEN;
PARENTAL ALCOHOLISM; PARTNER VIOLENCE; PROBLEM DRINKING; PHYSICAL ABUSE; BINGE-
DRINKING Objective: The relationship between experiencing trauma and increased
alcohol consumption has been well established. Exposure to childhood trauma has
been linked to both early onset of drinking and problematic substance use. However,
the mechanisms underlying this relationship remain unclear. The results of early
work suggested that drinking to relieve negative affect (i.e., drinking to cope)
was driving this connection. However, the findings of more recent work suggest that
drinking might be used to enhance positive affect as a way of addressing the
aftereffects of early trauma. The current study looked at these two drinking
expectancies as indirect pathways between the experience in early childhood of
living in a home with parental violence and peak alcohol use in emerging adulthood.
Method: Participants were 1,064 children and their parents involved in a
longitudinal community study of children at high risk for the development of
alcoholism and a community contrast group of those at lower risk. Baseline
assessment was at age 3-5 years, self-reports of internalizing behavior and
drinking expectancies were obtained at age 12-14, and drinking measures were
assessed at age 18-20. Results: Results indicated that coping expectancy was a
mediator of the relationship between early childhood trauma and later peak alcohol
use, whereas enhancement expectancy was not. Conclusions: Children living in homes
with parental violence were more likely to develop ineffective coping strategies,
such as using alcohol to decrease negative affect. These results support the self-
medication theory. They also demonstrate the long-term effects of early life
experience on drinking behavior in early adulthood. [Jester, Jennifer M.;
Steinberg, Davia B.; Heitzeg, Mary M.; Zucker, Robert A.] Univ Michigan, Dept
Psychiat, Ann Arbor, MI 48109 USA Jester, JM (reprint author), Univ Michigan,
4250 Plymouth Rd, Ann Arbor, MI 48109 USA. jjester@med.umich.edu Heitzeg,
Mary/M-7154-2017 National Institutes of HealthUnited States Department of
Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 AA07065]
This research was supported by National Institutes of Health Grant R01
AA07065 (to Robert A. Zucker and Mary Heitzeg). Achenbach TM, 1991, INTEGRATIVE
GUIDE 19; Agrawal A, 2008, ADDICTION, V103, P194, DOI 10.1111/j.1360-
0443.2007.02074.x; American Psychiatric Association, 1994, DIAGN STAT MAN MENT;
BROWN SA, 1987, J STUD ALCOHOL, V48, P483, DOI 10.15288/jsa.1987.48.483; Caetano R,
2003, J INTERPERS VIOLENCE, V18, P240, DOI 10.1177/0886260502250074; Cooper M. L.,
1994, PSYCHOL ASSESSMENT, V6, P117, DOI [DOI 10.1037/1040-3590.6.2.117,
10.1037/1040-3590.6.2.117]; Cooper M. L., 1992, PSYCHOL ASSESSMENT, V4, P123, DOI
[DOI 10.1037/1040-3590.4.2.123, 10.1037/1040-3590.4.2.123]; Douglas KR, 2010,
ADDICT BEHAV, V35, P7, DOI 10.1016/j.addbeh.2009.07.004; DUBE SR, 2006, J
ADOLESCENT HEALTH, V38, P444, DOI DOI 10.1016/J.JADOHEALTH.2005.06.006; Edleson JL,
1999, J INTERPERS VIOLENCE, V14, P839, DOI 10.1177/088626099014008004; Epstein JN,
1998, CHILD ABUSE NEGLECT, V22, P223, DOI 10.1016/S0145-2134(97)00133-6; Fantuzzo
J, 1997, J AM ACAD CHILD PSY, V36, P116, DOI 10.1097/00004583-199701000-00025;
Fuller BE, 2003, J STUD ALCOHOL, V64, P472, DOI 10.15288/jsa.2003.64.472; Goldstein
AL, 2010, ADDICT BEHAV, V35, P636, DOI 10.1016/j.addbeh.2010.02.002; Graham-Bermann
SA, 2010, VIOLENCE VICTIMS, V25, P427, DOI 10.1891/0886-6708.25.4.427; Grayson CE,
2005, J TRAUMA STRESS, V18, P137, DOI 10.1002/jts.20021; Hamburger ME, 2008, J STUD
ALCOHOL DRUGS, V69, P291, DOI 10.15288/jsad.2008.69.291; Holden GW, 2003, CLIN
CHILD FAM PSYCH, V6, P151, DOI 10.1023/A:1024906315255; HUGHES HM, 1988, AM J
ORTHOPSYCHIAT, V58, P77, DOI 10.1111/j.1939-0025.1988.tb01568.x; Jester JM, 2015,
ADDICTION, V110, P71, DOI 10.1111/add.12704; Kendler KS, 2000, ARCH GEN PSYCHIAT,
V57, P953, DOI 10.1001/archpsyc.57.10.953; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142,
P1259; Kuntsche E, 2010, EXP CLIN PSYCHOPHARM, V18, P436, DOI 10.1037/a0019724;
Kuperman S, 1999, J AM ACAD CHILD PSY, V38, P686, DOI 10.1097/00004583-199906000-
00015; Leigh BC, 1990, PSYCHOL ADDICT BEHAV, V4, P91, DOI DOI 10.1037/H0080578;
Lindgren KP, 2012, ADDICT BEHAV, V37, P323, DOI 10.1016/j.addbeh.2011.10.009; Lo
CC, 2007, AM J DRUG ALCOHOL AB, V33, P139, DOI 10.1080/00952990601091119; McDonald
R, 2007, J FAM PSYCHOL, V21, P176, DOI 10.1037/0893-3200.21.2.176; Mezzich AC,
1997, DRUG ALCOHOL DEPEN, V44, P157, DOI 10.1016/S0376-8716(96)01333-6; Miranda
Robert Jr, 2002, Violence Vict, V17, P205, DOI 10.1891/vivi.17.2.205.33650; Moretti
MM, 2006, AGGRESSIVE BEHAV, V32, P385, DOI 10.1002/ab.20137; Muthen L. K., 1998,
MPLUS USERS GUIDE; Nugent NR, 2012, AIDS BEHAV, V16, P2171, DOI 10.1007/s10461-011-
0095-8; POLUSNY MA, 1995, APPL PREV PSYCHOL, V4, P143, DOI 10.1016/S0962-
1849(05)80055-1; REICH W, 1993, J AM ACAD CHILD PSY, V32, P995, DOI
10.1097/00004583-199309000-00017; Rodriguez-Srednicki O, 2001, J Child Sex Abus,
V10, P75, DOI 10.1300/J070v10n03_05; RUBIOSTIPEC M, 1991, J STUD ALCOHOL, V52, P78,
DOI 10.15288/jsa.1991.52.78; Sher KJ, 1997, J STUD ALCOHOL, V58, P414, DOI
10.15288/jsa.1997.58.414; Shin SH, 2009, ADDICT BEHAV, V34, P277, DOI
10.1016/j.addbeh.2008.10.023; Simpson TL, 2002, CLIN PSYCHOL REV, V22, P27, DOI
10.1016/S0272-7358(00)00088-X; Simpson TL, 2003, SUBST USE MISUSE, V38, P249, DOI
10.1081/JA-120017248; Simpson TL, 2014, J ABNORM PSYCHOL, V123, P237, DOI
10.1037/a0035193; Smith J, 1997, CHILD CARE HLTH DEV, V23, P113, DOI
10.1111/j.1365-2214.1997.tb00888.x; Sorocco KH, 2015, DRUG ALCOHOL DEPEN, V150,
P38, DOI 10.1016/j.drugalcdep.2015.02.001; Stephens DL, 1999, J INTERPERS VIOLENCE,
V14, P731, DOI 10.1177/088626099014007004; STRAUS MA, 1979, J MARRIAGE FAM, V41,
P75, DOI 10.2307/351733; Ullman SE, 2005, J STUD ALCOHOL, V66, P610, DOI
10.15288/jsa.2005.66.610; Wills T. A., 1985, COPING SUBSTANCE USE, P3; Wood SL,
2011, J CHILD ADOL PS NURS, V24, P223, DOI 10.1111/j.1744-6171.2011.00302.x;
Zlotnick C, 1997, AM J ORTHOPSYCHIAT, V67, P650, DOI 10.1037/h0080263; Zucker R.
A., 1990, DRINKING DRUG UNPUB; Zucker R. A., 2000, CHILDREN ADDICTION R, P109;
Zucker RA, 1996, DEV PSYCHOPATHOL, V8, P831, DOI 10.1017/S0954579400007458; Zucker
RA, 2011, CHILD DEV PERSPECT, V5, P248, DOI 10.1111/j.1750-8606.2011.00172.x 54
13 13 1 16 ALCOHOL RES DOCUMENTATION INC CENT ALCOHOL STUD
RUTGERS UNIV PISCATAWAY C/O DEIRDRE ENGLISH, 607 ALLISON RD, PISCATAWAY, NJ
08854-8001 USA 1937-1888 1938-4114 J STUD ALCOHOL DRUGS J. Stud.
Alcohol Drugs SEP 2015 76 5 781 789
9 Substance Abuse; Psychology Substance Abuse; Psychology
CS4OQ WOS:000362055800014 26402359 2019-09-25
J Birkley, EL; Zapolski, TCB; Smith, GT Birkley, Erica L.;
Zapolski, Tamika C. B.; Smith, Gregory T. Racial Differences in the
Transactional Relationship Between Depression and Alcohol Use From Elementary
School to Middle School JOURNAL OF STUDIES ON ALCOHOL AND DRUGS
English Article SUBSTANCE USE;
MAJOR DEPRESSION; SELF-MEDICATION; ADOLESCENT DEPRESSION; PSYCHIATRIC-DISORDERS;
GRADE STUDENTS; DRUG-USE; CES-D; RISK; DRINKING Objective: The aim of this
investigation was to test hypothesized reverse prospective relationships between
alcohol consumption and depressive symptomatology as a function of race among
youth. Method: In a two-wave prospective study, 328 European American, 328 African
American, and 144 Hispanic American youth were studied at the end of fifth grade
(last year of elementary school) and the end of sixth grade (first year of middle
school). Results: A positive correlation was observed between alcohol consumption
and depressive symptoms among all youth. However, the predictive relationship
differed based on race. For European American and Hispanic American youth,
depressive symptom levels at the end of elementary school predicted alcohol
consumption at the end of the first year of middle school, but the converse
relationship was not observed. For African American youth, the opposite pattern was
found. Alcohol consumption at the end of elementary school predicted depressive
symptom levels at the end of the first year of middle school, and the converse
relationship was not observed. Conclusions: These findings suggest the possibility
that etiological relationships between depression and alcohol use vary by race,
thus highlighting the importance of considering race when studying the risk
process. [Birkley, Erica L.] Purdue Univ, Dept Psychol Sci, W Lafayette, IN
47907 USA; [Zapolski, Tamika C. B.] Indiana Univ Purdue Univ, Dept Psychol,
Indianapolis, IN 46202 USA; [Smith, Gregory T.] Univ Kentucky, Dept Psychol,
Lexington, KY 40506 USA; [Smith, Gregory T.] Univ Kentucky, Ctr Drug & Alcohol Res,
Lexington, KY USA Zapolski, TCB (reprint author), Indiana Univ Purdue Univ, Dept
Psychol, Indianapolis, IN 46202 USA. tzapolsk@iupui.edu
National Institute on Alcohol Abuse and AlcoholismUnited States Department of
Health & Human ServicesNational Institutes of Health (NIH) - USANIH National
Institute on Alcohol Abuse & Alcoholism (NIAAA) [RO1 016166] This research was
supported by National Institute on Alcohol Abuse and Alcoholism Award RO1 016166
(to Gregory T. Smith and Tamika C. B. Zapolski). Alva S. A., 1995, HISPANIC
PSYCHOL CRI, P288; American Psychiatric Association, 1994, DIAGN STAT MAN MENT;
BAILEY SL, 1993, J STUD ALCOHOL, V54, P555, DOI 10.15288/jsa.1993.54.555; BARNES
GM, 1986, J STUD ALCOHOL, V47, P53, DOI 10.15288/jsa.1986.47.53; Boden JM, 2011,
ADDICTION, V106, P906, DOI 10.1111/j.1360-0443.2010.03351.x; Brook DW, 2002, ARCH
GEN PSYCHIAT, V59, P1039, DOI 10.1001/archpsyc.59.11.1039; CAETANO R, 1984,
HISPANIC J BEHAV SCI, V6, P345, DOI 10.1177/07399863840064002; Caspi A, 1996, ARCH
GEN PSYCHIAT, V53, P1033; Chabrol H, 2002, ENCEPHALE, V28, P429; Chen P, 2012, J
ADOLESCENT HEALTH, V50, P154, DOI 10.1016/j.jadohealth.2011.05.013; Chung T, 2012,
PEDIATRICS, V129, P205, DOI 10.1542/peds.2011-1828; Coleman L, 2002, J ADOLESCENCE,
V25, P535, DOI 10.1006/jado.2002.0494; Culbert KM, 2009, J ABNORM PSYCHOL, V118,
P788, DOI 10.1037/a0017207; DeWit DJ, 2000, PREV MED, V31, P455, DOI
10.1006/pmed.2000.0738; Dick DM, 2000, DEV PSYCHOL, V36, P180, DOI 10.1037//0012-
1649.36.2.180; Donovan JE, 2007, PREV SCI, V8, P192, DOI 10.1007/s11121-007-0072-7;
Donovan JE, 2011, J STUD ALCOHOL DRUGS, V72, P741, DOI 10.15288/jsad.2011.72.741;
Edwards AC, 2014, EUR CHILD ADOLES PSY, V23, P1219, DOI 10.1007/s00787-014-0600-5;
Ellickson PL, 2003, PEDIATRICS, V111, P949, DOI 10.1542/peds.111.5.949; Ellis BJ,
2000, CHILD DEV, V71, P485, DOI 10.1111/1467-8624.00159; Enders CK, 2006, PSYCHOSOM
MED, V68, P427, DOI 10.1097/01.psy.0000221275.75056.d8; FELIXORTIZ M, 1994, J CHILD
ADOLES SUBST, V3, P1; Fleming CB, 2008, PSYCHOL ADDICT BEHAV, V22, P186, DOI
10.1037/0893-164X.22.2.186; GARRISON CZ, 1990, J AM ACAD CHILD PSY, V29, P581, DOI
10.1097/00004583-199007000-00011; GARRISON CZ, 1991, J AM ACAD CHILD PSY, V30,
P636, DOI 10.1097/00004583-199107000-00017; Gilman SE, 2001, DRUG ALCOHOL DEPEN,
V63, P277, DOI 10.1016/S0376-8716(00)00216-7; Goldman MS, 1999, PSYCHOL SCI, V10,
P196, DOI 10.1111/1467-9280.00133; Goldman MS, 1999, PSYCHOL THEORIES DRI, V2,
P203; Grant BF, 1997, J SUBST ABUSE, V9, P103, DOI 10.1016/S0899-3289(97)90009-2;
Hallfors DD, 2004, AM J PREV MED, V27, P224, DOI 10.1016/j.amepre.2004.06.001;
HARTKA E, 1991, BRIT J ADDICT, V86, P1283, DOI 10.1111/j.1360-0443.1991.tb01704.x;
Hasin DS, 2002, ARCH GEN PSYCHIAT, V59, P794, DOI 10.1001/archpsyc.59.9.794;
Hooshmand S, 2012, J ADOLESCENT HEALTH, V50, P140, DOI
10.1016/j.jadohealth.2011.05.016; HOYLE RH, 1994, J CONSULT CLIN PSYCH, V62, P429,
DOI 10.1037/0022-006X.62.3.429; Hussong AM, 2008, J STUD ALCOHOL DRUGS, V69, P296,
DOI 10.15288/jsad.2008.69.296; Hussong AM, 2011, PSYCHOL ADDICT BEHAV, V25, P390,
DOI 10.1037/a0024519; Iacono WG, 1999, DEV PSYCHOPATHOL, V11, P869, DOI
10.1017/S0954579499002369; JonesWebb R, 1997, J STUD ALCOHOL, V58, P539, DOI
10.15288/jsa.1997.58.539; Kelder SH, 2001, AM J PUBLIC HEALTH, V91, P761, DOI
10.2105/AJPH.91.5.761; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI
10.3109/10673229709030550; Kidorf M, 1999, PSYCHOL ADDICT BEHAV, V13, P134, DOI
10.1037/0893-164X.13.2.134; King SM, 2004, ADDICTION, V99, P1548, DOI
10.1111/j.1360-0443.2004.00893.x; Kline R., 2005, PRINCIPLES PRACTICE; Kubik MY,
2003, AM J HEALTH BEHAV, V27, P546, DOI 10.5993/AJHB.27.5.6; Kuo PH, 2006, PSYCHOL
MED, V36, P1153, DOI 10.1017/S0033291706007860; Lewinsohn PM, 1999, J AM ACAD CHILD
PSY, V38, P56, DOI 10.1097/00004583-199901000-00020; Lynne-Landsman SD, 2010, DEV
PSYCHOL, V46, P853, DOI 10.1037/a0019667; Lynskey MT, 1998, DRUG ALCOHOL DEPEN,
V52, P201, DOI 10.1016/S0376-8716(98)00095-7; Muthen L. K., 1998, MPLUS USERS
GUIDE; PETERSEN AC, 1988, J YOUTH ADOLESCENCE, V17, P117, DOI 10.1007/BF01537962;
Pine DS, 1998, ARCH GEN PSYCHIAT, V55, P56, DOI 10.1001/archpsyc.55.1.56; Pitkanen
T, 2005, ADDICTION, V100, P652, DOI 10.1111/j.1360-0443.2005.01053.x; Poulin C,
2005, ADDICTION, V100, P525, DOI 10.1111/j.1360-0443.2005.01033.x; Prescott CA,
2000, ARCH GEN PSYCHIAT, V57, P803, DOI 10.1001/archpsyc.57.8.803; RADLOFF LS,
1991, J YOUTH ADOLESCENCE, V20, P149, DOI 10.1007/BF01537606; ROBERTS RE, 1991, J
AM ACAD CHILD PSY, V30, P58, DOI 10.1097/00004583-199101000-00009; Settles RE,
2014, J ABNORM PSYCHOL, V123, P141, DOI 10.1037/a0035670; Sher KJ, 2007, HDB
EMOTION REGULATI, P560; SMITH GT, 1995, J STUD ALCOHOL, V56, P383, DOI
10.15288/jsa.1995.56.383; SMITH GT, 1994, J RES ADOLESCENCE, V4, P229, DOI DOI
10.1207/S15327795JRA0402_4; Swendsen JD, 2000, J ABNORM PSYCHOL, V109, P198, DOI
10.1037//0021-843X.109.2.198; Swendsen JD, 2000, CLIN PSYCHOL REV, V20, P173, DOI
10.1016/S0272-7358(99)00026-4; Thapar A, 2012, LANCET, V379, P1056, DOI
10.1016/S0140-6736(11)60871-4; Tomlinson KL, 2012, ADDICT BEHAV, V37, P179, DOI
10.1016/j.addbeh.2011.09.016; US. Census Bureau Geography, 2013, KENT 2010 CENS
CENS; Wallace JM, 2003, ADDICTION, V98, P225, DOI 10.1046/j.1360-0443.2003.00282.x;
Wang JL, 2002, DEPRESS ANXIETY, V15, P42, DOI 10.1002/da.1084; Weissman MM, 1999,
JAMA-J AM MED ASSOC, V281, P1707, DOI 10.1001/jama.281.18.1707; Westling E, 2008, J
ADOLESCENT HEALTH, V42, P555, DOI 10.1016/j.jadohealth.2007.11.002; Zapolski TCB,
2014, PSYCHOL BULL, V140, P188, DOI 10.1037/a0032113; Zucker RA, 2008, PEDIATRICS,
V121, pS252, DOI 10.1542/peds.2007-2243B 71 1 1 0 7 ALCOHOL RES
DOCUMENTATION INC CENT ALCOHOL STUD RUTGERS UNIV PISCATAWAY C/O DEIRDRE
ENGLISH, 607 ALLISON RD, PISCATAWAY, NJ 08854-8001 USA 1937-1888 1938-4114
J STUD ALCOHOL DRUGS J. Stud. Alcohol Drugs SEP 2015 76 5
799 808 10 Substance Abuse;
Psychology Substance Abuse; Psychology CS4OQ WOS:000362055800016 26402361
2019-09-25
J Khan, M; Monaghan, M; Klein, N; Ruiz, G; John, AS Khan,
Munziba; Monaghan, Maureen; Klein, Nancy; Ruiz, George; John, Anitha S.
Associations among Depression Symptoms with Alcohol and Smoking Tobacco Use
in Adult Patients with Congenital Heart Disease CONGENITAL HEART DISEASE
English Article Adult Congenital Heart
Disease; Depression; Alcohol GENERAL-POPULATION; PREVALENCE; ANXIETY; RISK;
METAANALYSIS; DEPENDENCE; MORTALITY; HEALTH; IMPACT BackgroundAdult congenital
heart disease (ACHD) patients have high rates of untreated depression and anxiety
disorders. We evaluated associations among self-reported depression symptoms and
alcohol/smoking tobacco use. MethodsFrom 2009 to 2013, 202 ACHD patients (45% male)
completed questionnaires on depressive symptoms, anxiety symptoms, and substance
use as part of routine clinical care. Data were collected by retrospective chart
review. ResultsMean age was 31 10 years, 21% reported often feeling depressed and
33% reported feeling nervous or anxious. Sixty-one percent of patients reported
some alcohol intake; 25% reported current or previous smoking tobacco use. Patients
with depressive symptoms were 3x as likely to report drinking alcohol (OR 2.89; 95%
CI 1.29-6.5) and 5x more likely to report smoking tobacco use (OR 5.17; 95% CI
1.49-17.87). Fourteen percent of patients were prescribed
antidepressant/antianxiety medications; 43% of patients on medication reported
depressive symptoms. In patients reporting symptoms, those who consumed alcohol
were less likely to be on antidepressant/antianxiety medications (21%) than those
who did not consume alcohol (56%). ConclusionSelf-reported depressive symptoms are
associated with increased alcohol and smoking tobacco use by ACHD patients. Alcohol
use may be a means of self-medicating for untreated depression, but further
investigation is needed. Risk factors, including depressive symptoms and substance
use, should be routinely assessed and addressed in ACHD patients. [Khan,
Munziba; Klein, Nancy; Ruiz, George; John, Anitha S.] Childrens Natl Hlth Syst,
Childrens Natl Heart Inst, Washington, DC 20010 USA; [Monaghan, Maureen] George
Washington Univ, Sch Med, Childrens Natl Hlth Syst, Ctr Translat Sci, Washington,
DC USA; [Ruiz, George; John, Anitha S.] MedStar Washington Hosp Ctr, Div Cardiol,
Washington, DC USA John, AS (reprint author), Childrens Natl Hlth Syst, Div
Pediat Cardiol, 111 Michigan Ave NW, Washington, DC 20010 USA. anjohn@cnmc.org
 ANDA RF, 1990, JAMA-J AM MED ASSOC, V264, P1541, DOI
10.1001/jama.264.12.1541; Barth J, 2004, PSYCHOSOM MED, V66, P802, DOI
10.1097/01.psy.0000146332.53619.b2; Dixit AR, 2000, AM J PSYCHIAT, V157, P751, DOI
10.1176/appi.ajp.157.5.751; Graham K, 2007, CAN MED ASSOC J, V176, P633, DOI
10.1503/cmaj.060446; Harris KM, 2005, HEALTH SERV RES, V40, P117, DOI
10.1111/j.1475-6773.2005.00345.x; Khairy P, 2010, J AM COLL CARDIOL, V56, P1149,
DOI 10.1016/j.jacc.2010.03.085; Kovacs AH, 2009, INT J CARDIOL, V137, P158, DOI
10.1016/j.ijcard.2008.06.042; Luo XG, 2005, HUM MOL GENET, V14, P2421, DOI
10.1093/hmg/ddi244; Marelli AJ, 2007, CIRCULATION, V115, P163, DOI
10.1161/CIRCULATIONAHA.106.627224; Marelli AJ, 2014, CIRCULATION, V130, P749, DOI
10.1161/CIRCULATIONAHA.113.008396; Muller J, 2013, INT J CARDIOL, V165, P142, DOI
10.1016/j.ijcard.2011.08.005; Ostacher MJ, 2007, PSYCHIAT CLIN N AM, V30, P69, DOI
10.1016/j.psc.2006.12.009; Overgaard D, 2014, CONGENIT HEART DIS, V9, P75, DOI
10.1111/chd.12086; Reid Graham J, 2008, Congenit Heart Dis, V3, P16, DOI
10.1111/j.1747-0803.2007.00161.x; Roest AM, 2010, J AM COLL CARDIOL, V56, P38, DOI
10.1016/j.jacc.2010.03.034; Sullivan LE, 2005, AM J MED, V118, P330, DOI
10.1016/j.amjmed.2005.01.007; U. S. Department of Agriculture and U. S. Department
of Health and Human Services, 2010, DIET GUID AM, P30; Uzark K, 1989, J Pediatr
Health Care, V3, P137, DOI 10.1016/0891-5245(89)90063-1; Valente AM, 2013, INT J
CARDIOL, V168, P3236, DOI 10.1016/j.ijcard.2013.04.004; Webb GD, 2001, J AM COLL
CARDIOL, V37, P1166, DOI 10.1016/S0735-1097(01)01280-3 20 5 5 0
8 WILEY-BLACKWELL HOBOKEN 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
1747-079X 1747-0803 CONGENIT HEART DIS Congenit. Heart Dis.
SEP-OCT 2015 10 5 E243 E249
10.1111/chd.12282 7 Cardiac & Cardiovascular Systems
Cardiovascular System & Cardiology CT6HF WOS:000362913400008 26108339
2019-09-25
J Young, G Young, Gerald Science, Bias, and
Continuing to Educate PSYCHOLOGICAL INJURY & LAW English
Article Science; Law; Biases; Continuing
education; PTSD; Malingering This article introduces four papers in a
special series on the role of science in mental health work and research in the
area of psychological injury and law, and how it can help maintain an impartial
stance in the adversarial divide that marks the field. Two of the articles are on
malingering, and its assessment and two are issues related to posttraumatic stress
disorder (PTSD). All the articles are based on comprehensive reviews of the recent
literature. The first two articles find that the prevalence of malingering is not
as high as the frequently cited value of 40 +/- 10 %, yet tests used in concert may
be effective in detecting it. The third article discusses the comorbidity of PTSD
and substance use disorder, showing that the latter is most often the result of
self-medication for the former. The fourth article explores the factor structure of
the 20 PTSD symptoms in the DSM-5 (Diagnostic and Statistical Manual of Mental
Disorders, Fifth Edition; American Psychiatric Association, 2013), showing that the
research does not provide adequate support for the APA's four-factor model.
Clinical and forensic implications are discussed. [Young, Gerald] York Univ,
Glendon Coll, Dept Psychol, 2275 Bayview Ave, Toronto, ON M4N 3M6, Canada Young,
G (reprint author), York Univ, Glendon Coll, Dept Psychol, 2275 Bayview Ave,
Toronto, ON M4N 3M6, Canada. gyoung@glendon.yorku.ca
American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU; Young G, 2015,
PSYCHOL INJ LAW, V8, P200, DOI 10.1007/s12207-015-9230-6; Young G, 2015, PSYCHOL
INJ LAW, V8, P188, DOI 10.1007/s12207-015-9232-4; Young G, 2015, PSYCHOL INJ LAW,
V8, P233, DOI 10.1007/s12207-015-9229-z; Young G, 2015, PSYCHOL INJ LAW, V8, P219,
DOI 10.1007/s12207-015-9231-5 5 1 1 0 0 SPRINGER NEW YORK
233 SPRING ST, NEW YORK, NY 10013 USA 1938-971X 1938-9728
PSYCHOL INJ LAW Psychol. Inj. Law SEP 2015 8 3
185 187 10.1007/s12207-015-9228-0 3 Psychology,
Clinical Psychology VF6DR WOS:000443251900001 2019-
09-25
J Young, G; Wang, JX Young, Gerald; Wang, Jenny Xiaoting
 PTSD-SUD Comorbidities in the Context of Psychological Injury and Law
PSYCHOLOGICAL INJURY & LAW English Review
PTSD; Substance use disorder; Alcohol; Comorbidity; Psychological
injury; Law POSTTRAUMATIC-STRESS-DISORDER; COCAINE-DEPENDENT INPATIENTS; SEXUAL
EXPERIENCES SURVEY; SUBSTANCE USE DISORDERS; TRAUMA CUE EXPOSURE; ALCOHOL-USE;
EMOTION REGULATION; DRINKING MOTIVES; SELF-MEDICATION; NEGATIVE AFFECT
Posttraumatic stress disorder (PTSD) and substance use disorder (SUD) are
both common psychological problems and they are frequently comorbid. However, there
is little longitudinal research that can disentangle their temporal relationship
towards determining the mechanisms in their comorbidity. Furthermore, the extant
research does not consider possible confounds to diagnosis that are relevant to the
area of psychological injury and law, such as exclusion of cases of malingering
after appropriate assessment and testing. This paper reviews the literature on the
question of comorbidity of PTSD and SUD towards establishing preliminary
conclusions that could serve directions for needed research in the area, and with
potential application to individual assessment and court purposes. There are four
major models in how PTSD and SUD relate-self-medication, high risk, susceptibility,
and shared vulnerability. Overall, the self-medication model is supported, but not
exclusively. Recent research is examining the different models in these regards
with respect to individual differences, including in negative
emotionality/constraint, emotional/dysregulation, and patterns in PTSD's different
clusters. Further research is required from a forensic perspective that uses the
appropriate populations, rules out malingering in the cases studied, and controls
other confounds applicable to the forensic context. [Young, Gerald] York Univ,
Glendon Coll, Dept Psychol, 2275 Bayview Ave, Toronto, ON M4N 3M6, Canada Young,
G (reprint author), York Univ, Glendon Coll, Dept Psychol, 2275 Bayview Ave,
Toronto, ON M4N 3M6, Canada. gyoung@glendon.yorku.ca
American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU; American
Psychiatric Association, 1987, DIAGN STAT MAN MENT; American Psychiatric
Association, 1980, DIAGN STAT MAN MENT; American Psychiatric Association, 1994,
DIAGN STAT MAN MENT; American Psychiatric Association, 2000, DIAGN STAT MAN MENT;
Andrews G, 2001, BRIT J PSYCHIAT, V178, P145, DOI 10.1192/bjp.178.2.145;
Andrikopoulos J., 2012, FORENSIC NEUROPSYCHO, P365; Angkaw AC, 2015, MIL MED, V180,
P670, DOI 10.7205/MILMED-D-14-00473; Armour C, 2015, PSYCHIAT RES, V225, P476, DOI
10.1016/j.psychres.2014.11.063; Armour C, 2015, J PSYCHIATR RES, V61, P106, DOI
10.1016/j.jpsychires.2014.10.012; Babor TF, 1989, ALCOHOL USE DISORDER; Back SE,
2006, J NERV MENT DIS, V194, P690, DOI 10.1097/01.nmd.0000235794.12794.8a; Baker
TB, 2004, PSYCHOL REV, V111, P33, DOI 10.1037/0033-295X.111.1.33; Begle AM, 2011,
ADDICT BEHAV, V36, P682, DOI 10.1016/j.addbeh.2010.12.026; Ben-Porath Y. S., 2008,
MMPI 2 RF MANUAL ADM; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI
10.1007/BF02105408; BLOOM BL, 1985, FAM PROCESS, V24, P225, DOI 10.1111/j.1545-
5300.1985.00225.x; Boden MT, 2014, J SUBST ABUSE TREAT, V47, P160, DOI
10.1016/j.jsat.2014.03.006; Breslau N, 1998, ARCH GEN PSYCHIAT, V55, P626, DOI
10.1001/archpsyc.55.7.626; Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI
10.1037/0022-006X.68.5.748; Chilcoat HD, 1998, ARCH GEN PSYCHIAT, V55, P913, DOI
10.1001/archpsyc.55.10.913; Chilcoat HD, 1998, ADDICT BEHAV, V23, P827, DOI
10.1016/S0306-4603(98)00069-0; Cooper M. L., 1994, PSYCHOL ASSESSMENT, V6, P117,
DOI [DOI 10.1037/1040-3590.6.2.117, 10.1037/1040-3590.6.2.117]; COOPER ML, 1995, J
PERS SOC PSYCHOL, V69, P990, DOI 10.1037/0022-3514.69.5.990; CSIKSZENTMIHALYI M,
1987, J NERV MENT DIS, V175, P526, DOI 10.1097/00005053-198709000-00004; Davis KC,
2009, VIOLENCE AGAINST WOM, V15, P1106, DOI 10.1177/1077801209340759; Davis T. A,
2014, MENTAL HLTH SUBSTANC, V7, P286, DOI DOI 10.1080/17523281.2013.865663; Debell
F, 2014, SOC PSYCH PSYCH EPID, V49, P1401, DOI 10.1007/s00127-014-0855-7; Dimeff L.
A., 1999, BRIEF ALCOHOL SCREEN; Donbaek D. F., 2014, MENTAL HLTH SUBSTANC, V7,
P299; Dvorak RD, 2013, J DUAL DIAGN, V9, P281, DOI 10.1080/15504263.2013.835694;
Endicott J, 1975, FAMILY HIST DIAGNOST; Enman NM, 2014, PHARMACOL BIOCHEM BE, V117,
P61, DOI 10.1016/j.pbb.2013.12.001; Ferrier-Auerbach AG, 2009, ADDICT BEHAV, V34,
P625, DOI 10.1016/j.addbeh.2009.03.027; FINKELHOR D, 1979, AM J ORTHOPSYCHIAT, V49,
P692, DOI 10.1111/j.1939-0025.1979.tb02654.x; First M. B., 2004, COMPREHENSIVE HDB
PS, V2, P134, DOI DOI 10.1002/CPP; First M. B., 1995, STRUCTURED CLIN INTE; Foa EB,
1997, PSYCHOL ASSESSMENT, V9, P445, DOI 10.1037/1040-3590.9.4.445; FOA EB, 1993, J
TRAUMA STRESS, V6, P459, DOI 10.1007/BF00974317; Frances A., 2013, MAKING DSM 5
CONCEPT, P95; Gaher RM, 2014, PSYCHOL ADDICT BEHAV, V28, P1013, DOI
10.1037/a0037257; Grant BF, 2015, JAMA PSYCHIAT, V72, P757, DOI
10.1001/jamapsychiatry.2015.0584; Gratz KL, 2010, COMPR PSYCHIAT, V51, P275, DOI
10.1016/j.comppsych.2009.08.005; Gratz KL, 2004, J PSYCHOPATHOL BEHAV, V26, P41,
DOI 10.1023/B:JOBA.0000007455.08539.94; Gray MJ, 2004, ASSESSMENT, V11, P330, DOI
10.1177/1073191104269954; Grekin ER, 2006, PSYCHOL ADDICT BEHAV, V20, P415, DOI
10.1037/0893-164X.20.4.415; Haller M, 2014, PSYCHOL ADDICT BEHAV, V28, P841, DOI
10.1037/a0035878; Hein D. A., 1991, DRUG USE QUEST UNPUB; Hien D, 2005, CLIN
PSYCHOL REV, V25, P813, DOI 10.1016/j.cpr.2005.05.006; Hoge CW, 2014, LANCET
PSYCHIAT, V1, P269, DOI 10.1016/S2215-0366(14)70235-4; Hruska B., 2014, TRAUMA
SUBSTANCE ABU, P35; Hruska B, 2014, J ANXIETY DISORD, V28, P644, DOI
10.1016/j.janxdis.2014.06.009; Hruska B, 2011, PSYCHOL ADDICT BEHAV, V25, P405, DOI
10.1037/a0022439; Jacobson IG, 2008, JAMA-J AM MED ASSOC, V300, P663, DOI
10.1001/jama.300.6.663; Kaysen D, 2014, PSYCHOL ADDICT BEHAV, V28, P62, DOI
10.1037/a0033588; Kaysen D, 2011, J DUAL DIAGN, V7, P262, DOI
10.1080/15504263.2011.620449; Keane T M, 1988, Recent Dev Alcohol, V6, P27; Kessler
RC, 1997, ARCH GEN PSYCHIAT, V54, P313; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52,
P1048, DOI 10.1001/archpsyc.1995.03950240066012; Khantzian E. J., 2003, PRIMARY
PSYCHIAT, V10, p[47, 53]; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI
10.3109/10673229709030550; King DW, 1998, PSYCHOL ASSESSMENT, V10, P90, DOI
10.1037/1040-3590.10.2.90; King LA, 2006, MIL PSYCHOL, V18, P89, DOI
10.1207/s15327876mp1802_1; Koenen KC, 2007, PSYCHOL MED, V37, P181, DOI
10.1017/S0033291706009019; Koenen KC, 2002, J NERV MENT DIS, V190, P209, DOI
10.1097/01.NMD.0000012868.95340.32; KOSS MP, 1985, J CONSULT CLIN PSYCH, V53, P422,
DOI 10.1037/0022-006X.53.3.422; KOSS MP, 1982, J CONSULT CLIN PSYCH, V50, P455, DOI
10.1037/0022-006X.50.3.455; Kramer M. D., 2014, TRAUMA SUBSTANCE ABU, P53, DOI DOI
10.1037/14273-004; Kubany ES, 2000, PSYCHOL ASSESSMENT, V12, P210, DOI
10.1037//1040-3590.12.2.210; Leeies M, 2010, DEPRESS ANXIETY, V27, P731, DOI
10.1002/da.20677; Lehavot K, 2014, PSYCHOL ADDICT BEHAV, V28, P42, DOI
10.1037/a0032266; Lejuez CW, 2003, BEHAV THER, V26, P290, DOI DOI 10.1002/DA.20091;
Markus K. A., 2013, FRONTIERS TEST VALID; McCarthy D. E., 2010, SUBSTANCE ABUSE
EMOT, P15, DOI DOI 10.1037/12067-001; McDevitt-Murphy ME, 2015, ADDICT RES THEORY,
V23, P148, DOI 10.3109/16066359.2014.949696; McFarlane AC, 2009, J AFFECT
DISORDERS, V118, P166, DOI 10.1016/j.jad.2009.01.017; McFarlane AC, 1998, ADDICT
BEHAV, V23, P813, DOI 10.1016/S0306-4603(98)00098-7; McLean CP, 2015, J CONSULT
CLIN PSYCH, V83, P655, DOI 10.1037/ccp0000024; McNally RJ, 2015, CLIN PSYCHOL SCI,
V3, P836, DOI 10.1177/2167702614553230; Miller MW, 2006, J ABNORM PSYCHOL, V115,
P369, DOI 10.1037/0021-843X.115.2.369; Miller MW, 2003, CLIN PSYCHOL-SCI PR, V10,
P373, DOI 10.1093/clipsy/bpg040; MILLER WR, 1994, J STUD ALCOHOL, P112, DOI
10.15288/jsas.1994.s12.112; MILLER WR, 1995, DRINKER INVENTORY CO; Muller M, 2014,
COMPR PSYCHIAT, V55, P837, DOI 10.1016/j.comppsych.2014.01.009; Najavits L. M.,
2015, EVIDENCE BASED TREAT, P317; Nickerson A, 2014, J ABNORM PSYCHOL, V123, P821,
DOI 10.1037/a0037920; O'Hare T, 2011, ADDICT BEHAV, V36, P465, DOI
10.1016/j.addbeh.2011.01.006; Ouimette P, 2010, ADDICT BEHAV, V35, P64, DOI
10.1016/j.addbeh.2009.08.009; Pietrzak RH, 2011, J ANXIETY DISORD, V25, P456, DOI
10.1016/j.janxdis.2010.11.010; Polusny MA, 2011, PSYCHOL MED, V41, P687, DOI
10.1017/S0033291710002047; Read JP, 2014, AM J ADDICTION, V23, P108, DOI
10.1111/j.1521-0391.2013.12075.x; Read JP, 2012, J CONSULT CLIN PSYCH, V80, P426,
DOI 10.1037/a0028210; Reed PL, 2007, ARCH GEN PSYCHIAT, V64, P1435, DOI
10.1001/archpsyc.64.12.1435; Regier DA, 2013, AM J PSYCHIAT, V170, P59, DOI
10.1176/appi.ajp.2012.12070999; Roberts NP, 2015, CLIN PSYCHOL REV, V38, P25, DOI
10.1016/j.cpr.2015.02.007; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; Robins
LN, 1989, NATL I MENTAL HLTH D; ROOSA MW, 1988, J STUD ALCOHOL, V49, P422, DOI
10.15288/jsa.1988.49.422; Rosen GM, 2008, CLIN PSYCHOL REV, V28, P837, DOI
10.1016/j.cpr.2007.12.002; Sandler I., 1986, ANN M AM PSYCH ASS; Sartor CE, 2011,
PSYCHOL MED, V41, P1497, DOI 10.1017/S0033291710002072; Saxon A. J., 2015,
PRACTICAL GUIDE PTSD, P135; Schnurr P. P., 2015, EVIDENCE BASED TREAT, P87, DOI DOI
10.1007/978-3-319-07109-1_5; Schutte NS, 1998, PERS INDIV DIFFER, V25, P167, DOI
10.1016/S0191-8869(98)00001-4; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI
10.4088/JCP.09m05305whi; Sher K. J., 1987, UNPUB; Simpson TL, 2014, J ABNORM
PSYCHOL, V123, P237, DOI 10.1037/a0035193; SKINNER HA, 1982, J ABNORM PSYCHOL, V91,
P199, DOI 10.1037/0021-843X.91.3.199; Smith JP, 2012, ALCOHOL RES-CURR REV, V34,
P414; Stewart SH, 1998, ADDICT BEHAV, V23, P797, DOI 10.1016/S0306-4603(98)00070-7;
Stewart SH, 2003, TRAUMA AND SUBSTANCE
ABUSE: CAUSES, CONSEQUENCES, AND TREATMENT OF COMORBID DISORDERS, P29, DOI
10.1037/10460-002; Stewart SH, 1996, PSYCHOL BULL, V120, P83, DOI 10.1037/0033-
2909.120.1.83; Tull MT, 2007, BEHAV THER, V38, P303, DOI
10.1016/j.beth.2006.10.001; Tull MT, 2013, J EXP PSYCHOPATHOL, V4, P485, DOI
10.5127/jep.028812; Tull MT, 2015, J ANXIETY DISORD, V29, P52, DOI
10.1016/j.janxdis.2014.11.003; Tull MT, 2011, ADDICTION, V106, P1810, DOI
10.1111/j.1360-0443.2011.03508.x; Vandrey R, 2014, INT REV PSYCHIATR, V26, P237,
DOI 10.3109/09540261.2014.901300; Vogt DS, 2008, ASSESSMENT, V15, P381, DOI
10.1177/1073191108316030; Walsh K, 2012, J ADOLESCENT HEALTH, V50, P54, DOI
10.1016/j.jadohealth.2011.05.017; Wang L, 2015, J ANXIETY DISORD, V31, P90, DOI
10.1016/j.janxdis.2015.02.006; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI
10.1037/0022-3514.54.6.1063; Weathers FW, 1993, ANN M INT SOC TRAUM; WHITE HR,
1989, J STUD ALCOHOL, V50, P30, DOI 10.15288/jsa.1989.50.30; Whiteside SP, 2001,
PERS INDIV DIFFER, V30, P669, DOI 10.1016/S0191-8869(00)00064-7; WINDLE M, 1994,
ADDICTION, V89, P175, DOI 10.1111/j.1360-0443.1994.tb00876.x; Wisco BE, 2014, J
CLIN PSYCHIAT, V75, P1338, DOI 10.4088/JCP.14m09328; Wolitzky-Taylor K, 2012,
ADDICT BEHAV, V37, P982, DOI 10.1016/j.addbeh.2012.03.026; Young G., 2015, BIANN C
INT AC LAW M; Young G., 2016, UNIFYING PSYCHOL CAU; Young G, 2015, PSYCHOL INJ LAW,
V8, P219, DOI 10.1007/s12207-015-9231-5; Yufik T, 2010, J ABNORM PSYCHOL, V119,
P764, DOI 10.1037/a0020981; Zhou Q, 2006, J ABNORM PSYCHOL, V115, P320, DOI
10.1037/0021-843X.115.2.320; Zoellner LA, 2013, PSYCHOL INJ LAW, V6, P277, DOI
10.1007/s12207-013-9175-6 133 2 2 1 1 SPRINGER NEW YORK
233 SPRING ST, NEW YORK, NY 10013 USA 1938-971X 1938-9728
PSYCHOL INJ LAW Psychol. Inj. Law SEP 2015 8 3
233 251 10.1007/s12207-015-9229-z 19 Psychology,
Clinical Psychology VF6DR WOS:000443251900005 2019-
09-25
J Lo, CC; Cheng, TC; de la Rosa, IA Lo, Celia C.; Cheng,
Tyrone C.; de la Rosa, Ivan A. Depression and Substance Use: A
Temporal-Ordered Model SUBSTANCE USE & MISUSE English Article
substance use; self-medication hypothesis; temporal-
ordered model SELF-MEDICATION HYPOTHESIS; ALCOHOL-USE DISORDERS; MENTAL-HEALTH;
PSYCHIATRIC-DISORDERS; DUAL DIAGNOSIS; PSYCHOLOGICAL DISTRESS; ANXIETY DISORDERS;
BINGE DRINKING; ABUSE; STRESS Background and Objectives: This study sought
empirical evidence for the self-medication hypothesis. It asked whether diagnosis
of depression, together with the use of mental-health care, leads to substance use.
Methods: Data came from the 5-wave, longitudinal Fragile Families and Child
Wellbeing (FFCW) Study, an investigation of a cohort of nearly 5,000 births, which
oversampled non-marital births. FFCW examined newborns' biological mothers and
fathers, all of whom lived in the United States. The adults were initially
interviewed between 1998 and 2000 (the period of the cohort's births); they were
then re-interviewed for four times over 10years. FFCW measured mental health-
related variables, level of drug use, and social structural and demographic
factors, all of which are also measured by the present study. Respondents in our
study's two final subsamples had responded to every FFCW interview item we would
use in constructing our final model's variables. Our subsample of mothers totaled
3,477 women, from whom 5,987 person-waves were derived. Our subsample of fathers
totaled 2,096 men, yielding 3,543 person-waves. Results: We used STATA generalized
estimating equations for panel data, and found some evidence to support the self-
medication hypothesis. In addition, our results indicated that the relationship of
substance use to the use of mental-health care was gender-specific.
Conclusions/Importance: Empirical evidence from this study only partially supported
the self-medication hypothesis; the co-occurrence of depression and substance abuse
in our sample was also reflective of social structural and demographic variables
and of prior substance use variables. [Lo, Celia C.] Texas Womans Univ, Dept
Sociol & Social Work, Denton, TX 76204 USA; [Cheng, Tyrone C.] Univ Alabama, Sch
Social Work, Tuscaloosa, AL USA; [de la Rosa, Ivan A.] New Mexico State Univ, Sch
Social Work, Las Cruces, NM 88003 USA Lo, CC (reprint author), Texas Womans
Univ, Dept Sociol & Social Work, Denton, TX 76204 USA. clo@twu.edu Lo,
Celia/0000-0002-5785-6622 ANESHENSEL CS, 1992, ANNU REV SOCIOL,
V18, P15, DOI 10.1146/annurev.so.18.080192.000311; Bizzarri JV, 2009, PSYCHIAT RES,
V165, P88, DOI 10.1016/j.psychres.2007.10.009; Brady KT, 2005, AM J PSYCHIAT, V162,
P1483, DOI 10.1176/appi.ajp.162.8.1483; Buckley PF, 2006, J CLIN PSYCHIAT, V67, P5;
Carr D, 2010, J MARRIAGE FAM, V72, P743, DOI 10.1111/j.1741-3737.2010.00728.x;
Caspi A, 2005, BIOL PSYCHIAT, V57, P1117, DOI 10.1016/j.biopsych.2005.01.026;
Chilcoat HD, 1998, ARCH GEN PSYCHIAT, V55, P913, DOI 10.1001/archpsyc.55.10.913;
Costello EJ, 2003, ARCH GEN PSYCHIAT, V60, P837, DOI 10.1001/archpsyc.60.8.837;
Crum RM, 2001, AM J PSYCHIAT, V158, P1693, DOI 10.1176/appi.ajp.158.10.1693; Edlund
MJ, 2006, PSYCHIAT SERV, V57, P692, DOI 10.1176/appi.ps.57.5.692; Encrenaz G, 2007,
AM J HEALTH BEHAV, V31, P392, DOI 10.5993/AJHB.31.4.6; Farris C, 2003, PSYCHIAT
QUART, V74, P205, DOI 10.1023/A:1024162819540; Finkel S. E, 1995, CAUSAL ANAL PANEL
DA; Harris KM, 2005, HEALTH SERV RES, V40, P117, DOI 10.1111/j.1475-
6773.2005.00345.x; Hodgins DC, 1999, ALCOHOL CLIN EXP RES, V23, P151, DOI
10.1097/00000374-199901000-00022; HOUSE JS, 1988, SCIENCE, V241, P540, DOI
10.1126/science.3399889; Jane-Llopis E, 2006, DRUG ALCOHOL REV, V25, P515, DOI
10.1080/09595230600944461; Johnson NJ, 2000, ANN EPIDEMIOL, V10, P224, DOI
10.1016/S1047-2797(99)00052-6; Kanny Dafna, 2011, Morbidity and Mortality Weekly
Report, V60, P101; Kendler KS, 2003, ARCH GEN PSYCHIAT, V60, P929, DOI
10.1001/archpsyc.60.9.929; Kessler RC, 2004, BIOL PSYCHIAT, V56, P730, DOI
10.1016/j.biopsych.2004.06.034; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231,
DOI 10.3109/10673229709030550; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259;
Kushner MG, 1999, AM J PSYCHIAT, V156, P723; Lagoni L, 2011, ADDICT RES THEORY,
V19, P416, DOI 10.3109/16066359.2010.525332; Lembke A, 2012, AM J DRUG ALCOHOL AB,
V38, P524, DOI 10.3109/00952990.2012.694532; Lo CC, 2003, J DRUG ISSUES, V33, P237,
DOI 10.1177/002204260303300110; Lo CC, 2014, COMMUNITY MENT HLT J, V50, P251, DOI
10.1007/s10597-013-9593-7; Lo Celia C, 2012, Am J Addict, V21 Suppl 1, pS77, DOI
10.1111/j.1521-0391.2012.00292.x; Lo CC, 2013, J PSYCHOACTIVE DRUGS, V45, P39, DOI
10.1080/02791072.2013.763561; Lo CC, 2013, AGGRESS VIOLENT BEH, V18, P125, DOI
10.1016/j.avb.2012.11.006; Lo CC, 2012, SUBST USE MISUSE, V47, P734, DOI
10.3109/10826084.2012.666312; MILLER WR, 1992, J SUBST ABUSE TREAT, V9, P93, DOI
10.1016/0740-5472(92)90075-Y; Naimi TS, 2003, JAMA-J AM MED ASSOC, V289, P70, DOI
10.1001/jama.289.1.70; Ozawa MN, 2004, CHILD YOUTH SERV REV, V26, P785, DOI
10.1016/j.childyouth.2004.02.021; PEARLIN LI, 1989, J HEALTH SOC BEHAV, V30, P241,
DOI 10.2307/2136956; Reichman NE, 2001, CHILD YOUTH SERV REV, V23, P303, DOI
10.1016/S0190-7409(01)00141-4; Sullivan MD, 2005, PAIN, V119, P95, DOI
10.1016/j.pain.2005.09.020; Tenorio KA, 2011, AM J DRUG ALCOHOL AB, V37, P218, DOI
10.3109/00952990.2011.568079; Timko C, 2004, J STUD ALCOHOL, V65, P274, DOI
10.15288/jsa.2004.65.274; US Census Bureau, 2004, CURR POP SURV DEF EX; Volkow ND,
2004, BIOL PSYCHIAT, V56, P714, DOI 10.1016/j.biopsych.2004.07.007; Weissman MM,
1999, ARCH GEN PSYCHIAT, V56, P794, DOI 10.1001/archpsyc.56.9.794; Zimmermann P,
2003, PSYCHOL MED, V33, P1211, DOI 10.1017/S0033291703008158 44 7 7
0 15 TAYLOR & FRANCIS INC PHILADELPHIA 530 WALNUT STREET, STE
850, PHILADELPHIA, PA 19106 USA 1082-6084 1532-2491 SUBST USE MISUSE
Subst. Use Misuse AUG 24 2015 50 10 1274
1283 10.3109/10826084.2014.998236 10 Substance Abuse;
Psychiatry; Psychology Substance Abuse; Psychiatry; Psychology DD2KU
WOS:000369752100003 25594110 2019-09-25
J Muller, M; Vandeleur, C; Rodgers, S; Rossler, W; Castelao, E; Preisig, M;
Ajdacic-Gross, V Mueller, Mario; Vandeleur, Caroline; Rodgers,
Stephanie; Roessler, Wulf; Castelao, Enrique; Preisig, Martin; Ajdacic-Gross,
Vladeta Posttraumatic stress avoidance symptoms as mediators in the
development of alcohol use disorders after exposure to childhood sexual abuse in a
Swiss community sample CHILD ABUSE & NEGLECT English Article
Alcohol use disorders; Posttraumatic stress symptoms;
Comorbidity; Self-medication model; Childhood sexual abuse; Community sample
SUBSTANCE USE DISORDERS; DIAGNOSTIC INTERVIEW; LIFE EVENTS; DEPENDENCE; PTSD;
WOMEN; POPULATION; TRAUMA; ASSOCIATION; COMORBIDITY This study examined the role
of posttraumatic stress disorder (PTSD) symptoms of re-experience, avoidance, and
hyperarousal in the relationship between different types of trauma and alcohol use
disorders (AUD). We used data from 731 trauma-exposed individuals who participated
in the first wave of the PsyCoLaus-study. Trauma characteristics were assessed
relatively to the occurrence of lifetime PTSD symptoms and AUD. The results suggest
that lifetime and childhood sexual abuse as well as overall childhood trauma were
directly linked to AUD and PTSD symptoms, in particular to avoidance symptoms. From
single symptom clusters PTSD avoidance was found to specifically mediate the
trauma-AUD pathway. Both childhood and sexual trauma strongly contribute to the
comorbidity of PTSD and AUD and avoidance-type symptoms appear to play a central
role in maintaining this association. Hence, the alleviation of avoidance symptoms
might be an important target for therapeutic intervention among victims of sexual
abuse before specific addiction treatment is initiated. (C) 2015 Elsevier Ltd. All
rights reserved. [Mueller, Mario; Rodgers, Stephanie; Roessler, Wulf; Ajdacic-
Gross, Vladeta] Univ Zurich, Hosp Psychiat, Dept Psychiat Psychotherapy &
Psychosomat, CH-8021 Zurich, Switzerland; [Vandeleur, Caroline; Castelao, Enrique;
Preisig, Martin] CHU Vaudois, Dept Psychiat, CH-1008 Lausanne, Switzerland;
[Roessler, Wulf] Univ Zurich, Coll Helveticum, CH-8092 Zurich, Switzerland;
[Roessler, Wulf] Swiss Fed Inst Technol, CH-8092 Zurich, Switzerland; [Roessler,
Wulf] Univ Sao Paulo, Sch Med, Inst Psychiat, Lab Neurosci LIM 27, BR-05403010 Sao
Paulo, SP, Brazil Muller, M (reprint author), Univ Zurich, Hosp Psychiat, Dept
Psychiat Psychotherapy & Psychosomat, Mil Str 8, CH-8021 Zurich, Switzerland.
Colaus, PsyColaus/K-6607-2013 Rodgers, Stephanie/0000-0003-2811-7991;
Castelao, Enrique/0000-0003-1966-3683 GlaxoSmithKlineGlaxoSmithKline; Faculty
of Biology and Medicine of Lausanne; Swiss National Science FoundationSwiss
National Science Foundation (SNSF) [3200B0-105993, 3200B0-118308, 33CSCO-122661,
33CS30-139468, 33CS30-148401] The PsyCoLaus study was and is supported by research
grants from GlaxoSmithKline, the Faculty of Biology and Medicine of Lausanne, and
the Swiss National Science Foundation (grants 3200B0-105993, 3200B0-118308, 33CSCO-
122661, 33CS30-139468 and 33CS30-148401). APA, 1994, DIAGN STAT MAN MENT; Back SE,
2006, J NERV MENT DIS, V194, P690, DOI 10.1097/01.nmd.0000235794.12794.8a; Berney
A, 2002, DRUG ALCOHOL DEPEN, V65, P149, DOI 10.1016/S0376-8716(01)00156-9; Blanco
C, 2013, DRUG ALCOHOL DEPEN, V132, P630, DOI 10.1016/j.drugalcdep.2013.04.016;
BROWNE A, 1986, PSYCHOL BULL, V99, P66, DOI 10.1037/0033-2909.99.1.66; Clark DB,
1997, J AM ACAD CHILD PSY, V36, P1744, DOI 10.1097/00004583-199712000-00023; De
Bellis MD, 2002, PSYCHONEUROENDOCRINO, V27, P155, DOI 10.1016/S0306-4530(01)00042-
7; Dragan M, 2007, J TRAUMA STRESS, V20, P1041, DOI 10.1002/jts.20259; ENDICOTT J,
1978, ARCH GEN PSYCHIAT, V35, P837; Epstein JN, 1998, CHILD ABUSE NEGLECT, V22,
P223, DOI 10.1016/S0145-2134(97)00133-6; Fergusson DM, 1996, J AM ACAD CHILD PSY,
V35, P1365, DOI 10.1097/00004583-199610000-00024; Fetzner MG, 2011, DEPRESS
ANXIETY, V28, P632, DOI 10.1002/da.20852; Hardt J, 2004, J CHILD PSYCHOL PSYC, V45,
P260, DOI 10.1111/j.1469-7610.2004.00218.x; Haugland SH, 2013, BMC PUBLIC HEALTH,
V13, DOI 10.1186/1471-2458-13-1140; Hwang JY, 2014, ANN GEN PSYCHIATR, V13, DOI
10.1186/1744-859X-13-6; Jakupcak M, 2010, ADDICT BEHAV, V35, P840, DOI
10.1016/j.addbeh.2010.03.023; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231,
DOI 10.3109/10673229709030550; LEBOYER M, 1991, EUR ARCH PSY CLIN N, V241, P165,
DOI 10.1007/BF02219716; Leboyer M., 1995, INTERVIEW DIAG UNPUB; Leeies M, 2010,
DEPRESS ANXIETY, V27, P731, DOI 10.1002/da.20677; Lown EA, 2011, ALCOHOL CLIN EXP
RES, V35, P317, DOI 10.1111/j.1530-0277.2010.01347.x; MacKinnon DP, 2004, MULTIVAR
BEHAV RES, V39, P99, DOI 10.1207/s15327906mbr3901_4; McFarlane A, 2004, SOC PSYCH
PSYCH EPID, V39, P874, DOI 10.1007/s00127-004-0870-1; Molnar BE, 2001, AM J PUBLIC
HEALTH, V91, P753, DOI 10.2105/AJPH.91.5.753; Morina N, 2008, BEHAV CHANGE, V25,
P15, DOI 10.1375/bech.25.1.15; Mulvihill D, 2005, COMPR CHILD ADOLES N, V28, P115,
DOI 10.1080/01460860590950890; Murphy RA, 2014, J INTERPERS VIOLENCE, V29, P3, DOI
10.1177/0886260513504495; Muthen L. K., 1998, MPLUS USERS GUIDE; Najavits LM, 1997,
AM J ADDICTION, V6, P273; NURNBERGER JI, 1994, ARCH GEN PSYCHIAT, V51, P849;
Ouimette P, 2010, ADDICT BEHAV, V35, P64, DOI 10.1016/j.addbeh.2009.08.009; Perrin
M, 2014, SOC PSYCH PSYCH EPID, V49, P447, DOI 10.1007/s00127-013-0762-3; POLUSNY
MA, 1995, APPL PREV PSYCHOL, V4, P143, DOI 10.1016/S0962-1849(05)80055-1; Polusny
Melissa A, 2004, Violence Vict, V19, P109, DOI 10.1891/vivi.19.1.109.33238;
Preacher KJ, 2008, BEHAV RES METHODS, V40, P879, DOI 10.3758/BRM.40.3.879; Preisig
M, 2009, BMC PSYCHIATRY, V9, DOI 10.1186/1471-244X-9-9; Rorty M, 1996, PSYCHIAT
CLIN N AM, V19, P773, DOI 10.1016/S0193-953X(05)70381-6; Rosenthal M Zachary, 2005,
J Child Sex Abus, V14, P25, DOI 10.1300/J070v14n04_02; SORBOM D, 1989,
PSYCHOMETRIKA, V54, P371, DOI 10.1007/BF02294623; StataCorp, 2011, STAT STAT SOFTW
VERS; Stovall-McClough KC, 2006, J CONSULT CLIN PSYCH, V74, P219, DOI 10.1037/0022-
006X.74.2.219; Tomaka J, 2013, STRESS HEALTH, V29, P205, DOI 10.1002/smi.2448;
Walsh K, 2014, COMPR PSYCHIAT, V55, P621, DOI 10.1016/j.comppsych.2013.11.016;
Whiffen VE, 2005, TRAUMA VIOLENCE ABUS, V6, P24, DOI 10.1177/1524838004272543;
Zlotnick C, 2006, J TRAUMA STRESS, V19, P949, DOI 10.1002/jts.20177 45 5
5 0 16 PERGAMON-ELSEVIER SCIENCE LTD OXFORD THE BOULEVARD,
LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND 0145-2134 1873-7757
CHILD ABUSE NEGLECT Child Abuse Negl. AUG 2015 46
8 15 10.1016/j.chiabu.2015.03.006 8 Family
Studies; Psychology, Social; Social Work Family Studies; Psychology; Social Work
CO9PQ WOS:000359508100002 25828861 2019-09-25
J Benner, AD; Wang, YJ Benner, Aprile D.; Wang, Yijie
Adolescent Substance Use: The Role of Demographic Marginalization and
Socioemotional Distress DEVELOPMENTAL PSYCHOLOGY English
Article alcohol use; marijuana use;
depression; school attachment; school demographics ALCOHOL-USE DISORDERS; HIGH-
SCHOOL; YOUNG ADULTHOOD; GENDER DIFFERENCES; ANXIETY DISORDERS; AFRICAN-AMERICANS;
SELF-MEDICATION; RACE; SEGREGATION; TRANSITION We investigated the links between
racial/ethnic marginalization (i.e., having few same-race/ethnic peers at school)
and adolescents' socioemotional distress and subsequent initiation of substance use
(alcohol and marijuana) and substance use levels. Data from 7,731 adolescents (52%
female; 55% White, 21% African American, 16% Latino, 8% Asian American) were drawn
from the National Longitudinal Study of Adolescent to Adult Health. In our path
analysis model, we found that adolescents who were racially/ethnically marginalized
at school (i.e., who had less than 15% same-ethnicity peers) reported poorer school
attachment, which was linked to more depressive symptoms. More depressive symptoms
were associated with higher levels of subsequent marijuana and alcohol use. These
relationships showed some variation by students' gender, race/ethnicity, and age.
Findings suggest that the influence of school demographics extends beyond the
academic domain into the health and well-being of young people. [Benner, Aprile
D.; Wang, Yijie] Univ Texas Austin, Dept Human Dev & Family Sci, Austin, TX 78712
USA Benner, AD (reprint author), Univ Texas Austin, Dept Human Dev & Family Sci,
One Univ Stn Stop A2702, Austin, TX 78712 USA. abenner@prc.utexas.edu
National Institute on Drug AbuseUnited States Department of Health & Human
ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug
Abuse (NIDA) [R03DA032018]; National Institute of Child Health and Human
DevelopmentUnited States Department of Health & Human ServicesNational Institutes
of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health
& Human Development (NICHD) [R24 HD42849] We acknowledge the support of grants from
the National Institute on Drug Abuse to Aprile D. Benner (R03DA032018) and from the
National Institute of Child Health and Human Development to the University of Texas
at Austin Population Research Center (R24 HD42849). Aboud FE, 2003, INT J BEHAV
DEV, V27, P165, DOI 10.1080/01650250244000164; ALLAN CA, 1995, ALCOHOL ALCOHOLISM,
V30, P145; Amico EJD, 2008, DRUG ALCOHOL DEPEN, V93, P85, DOI
10.1016/j.drugalcdep.2007.09.006; Anderman EM, 2002, J EDUC PSYCHOL, V94, P795, DOI
10.1037//0022-0663.94.4.795; ASELTINE RH, 1995, J HEALTH SOC BEHAV, V36, P103, DOI
10.2307/2137219; Aud S., 2012, THE CONDITION OF EDU; BAUMEISTER RF, 1995, PSYCHOL
BULL, V117, P497, DOI 10.1037/0033-2909.117.3.497; Benner AD, 2007, J RES
ADOLESCENCE, V17, P207, DOI 10.1111/j.1532-7795.2007.00519.x; Benner AD, 2011, AM
EDUC RES J, V48, P621, DOI 10.3102/0002831210384838; Benner AD, 2011, CHILD DEV,
V82, P508, DOI 10.1111/j.1467-8624.2010.01524.x; Benner AD, 2009, CHILD DEV, V80,
P356, DOI 10.1111/j.1467-8624.2009.01265.x; Botticello AL, 2009, AM J COMMUN
PSYCHOL, V43, P85, DOI 10.1007/s10464-008-9226-4; Bronfenbrenner U., 1998, HDB
CHILD PSYCHOL, V1, P993, DOI DOI 10.1002/9780470147658.CHPSY0114; Bronlenbrenner U,
1979, THE ECOLOGY OF HUMAN; Brown BB, 2009, HDB ADOLESCENT PSYCH, P74, DOI DOI
10.1002/9780470479193.ADLPSY002004; Budescu DV, 2012, PSYCHOL METHODS, V17, P215,
DOI 10.1037/a0027129; Catalano RF, 2004, J SCHOOL HEALTH, V74, P252, DOI
10.1111/j.1746-1561.2004.tb08281.x; Chen P, 2012, J ADOLESCENT HEALTH, V50, P154,
DOI 10.1016/j.jadohealth.2011.05.013; Clark HK, 2011, ADDICT BEHAV, V36, P488, DOI
10.1016/j.addbeh.2011.01.018; Cleveland HH, 2003, CHILD DEV, V74, P279, DOI
10.1111/1467-8624.00535; Crosnoe R, 2004, SOC PROBL, V51, P288, DOI
10.1525/sp.2004.51.2.288; Crosnoe R., 2011, FITTING IN STANDING; Crosnoe R, 2012, J
HEALTH SOC BEHAV, V53, P150, DOI 10.1177/0022146511433507; Crosnoe R, 2009, AM
SOCIOL REV, V74, P709, DOI 10.1177/000312240907400502; Dishion TJ, 2002, DEV
PSYCHOL, V38, P480, DOI 10.1037//0012-1649.38.4.480; Dornbusch SM, 2001, J
ADOLESCENT RES, V16, P396, DOI 10.1177/0743558401164006; Eitle TM, 2004, SOCIOL
PERSPECT, V47, P269, DOI 10.1525/sop.2004.47.3.269; Elder Glen, 1985, LIFE COURSE
DYNAMICS; Enders CK, 2011, REHABIL PSYCHOL, V56, P267, DOI 10.1037/a0025579;
Erikson E, 1968, IDENTITY YOUTH AND C; Goldsmith PA, 2004, SOC PROBL, V51, P587,
DOI 10.1525/sp.2004.51.4.587; Graham JA, 1997, SOC DEV, V6, P355, DOI
10.1111/j.1467-9507.1997.tb00111.x; Grant BF, 1997, J SUBST ABUSE, V9, P103, DOI
10.1016/S0899-3289(97)90009-2; Hall G. S., 1904, ADOLESCENCE ITS PSYC, VI; Hall G.
S., 1904, ADOLESCENCE ITS PSYC, VII; Hanushek EA, 2004, J PUBLIC ECON, V88, P1721,
DOI 10.1016/S0047-2727(03)00063-X; Harris Kathleen Mullan, 2003, THE NATIONAL
LONGITU; Johnson MK, 2001, SOCIOL EDUC, V74, P318, DOI 10.2307/2673138; Johnston
L.D., 2013, MONITORING THE FUTUR, V1; Johnston LD, 2013, MONITORING THE FUTUR;
Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550;
King KM, 2007, J STUD ALCOHOL DRUGS, V68, P256, DOI 10.15288/jsad.2007.68.256; King
SM, 2004, ADDICTION, V99, P1548, DOI 10.1111/j.1360-0443.2004.00893.x; Krohn MD,
1997, J HEALTH SOC BEHAV, V38, P87, DOI 10.2307/2955363; Kushner MG, 2000, CLIN
PSYCHOL REV, V20, P149, DOI 10.1016/S0272-7358(99)00027-6; Latimer WW, 2002, EXP
CLIN PSYCHOPHARM, V10, P310, DOI 10.1037//1064-1297.10.3.310; Lee MA, 2009, SOC SCI
MED, V68, P1975, DOI 10.1016/j.socscimed.2009.02.040; Lee V. E., 2001,
RESTRUCTURING HIGH S; Lee VE, 1997, EDUC EVAL POLICY AN, V19, P205, DOI
10.2307/1164463; Libbey HP, 2004, J SCHOOL HEALTH, V74, P274, DOI 10.1111/j.1746-
1561.2004.tb08284.x; Linn R. L., 2007, RACE CONSCIOUS POLIC; Ludwig J, 2012,
SCIENCE, V337, P1505, DOI 10.1126/science.1224648; Maslowsky J, 2014, DEV PSYCHOL,
V50, P1179, DOI 10.1037/a0035085; McDermott M, 2005, ANNU REV SOCIOL, V31, P245,
DOI 10.1146/annurev.soc.31.041304.122322; Mehana M, 2004, CHILD YOUTH SERV REV,
V26, P93, DOI 10.1016/j.childyouth.2003.11.004; Monahan KC, 2009, DEV PSYCHOL, V45,
P1520, DOI 10.1037/a0017417; Moody J, 2001, AM J SOCIOL, V107, P679, DOI
10.1086/338954; Muthen B., 2011, APPLICATIONS OF CAUS; Muthen L. K., 1998, MPLUS
USERS GUIDE; Newman BM, 2007, ADOLESCENCE, V42, P441; NOLENHOEKSEMA S, 1994,
PSYCHOL BULL, V115, P424, DOI 10.1037/0033-2909.115.3.424; O'Malley PM, 2006, PREV
SCI, V7, P409, DOI 10.1007/s11121-006-0050-5; Oesterle S, 2004, J STUD ALCOHOL,
V65, P204, DOI 10.15288/jsa.2004.65.204; Orfield G., 2007, HISTORIC REVERSALS A; Ou
SR, 2008, SCHOOL PSYCHOL QUART, V23, P199, DOI 10.1037/1045-3830.23.2.199; Postmes
T, 2002, J PERS SOC PSYCHOL, V83, P735, DOI 10.1037//0022-3514.83.3.735; Radloff L.
S., 1986, COMMUNITY SURVEYS PS, P177; Resnick MD, 1997, JAMA-J AM MED ASSOC, V278,
P823, DOI 10.1001/jama.278.10.823; Rohde P, 2001, J AM ACAD CHILD PSY, V40, P83,
DOI 10.1097/00004583-200101000-00020; Rothstein R., 2004, CLASS AND SCHOOLS US;
Rumberger RW, 2005, TEACH COLL REC, V107, P1999, DOI 10.1111/j.1467-
9620.2005.00583.x; Satorra A, 2001, PSYCHOMETRIKA, V66, P507, DOI
10.1007/BF02296192; Satorra A, 2010, PSYCHOMETRIKA, V75, P243, DOI 10.1007/S11336-
009-9135-Y; Schulenberg JE, 2002, J STUD ALCOHOL, P54, DOI
10.15288/jsas.2002.s14.54; Shinn B. B., 2000, HDB COMMUNITY PSYCHO, P669; Shochet
IM, 2011, J CLIN CHILD ADOLESC, V40, P586, DOI 10.1080/15374416.2011.581616; Siegel
AW, 2000, DEV PSYCHOPATHOL, V12, P763, DOI 10.1017/S0954579400004119; Swendsen J,
2012, ARCH GEN PSYCHIAT, V69, P390, DOI 10.1001/archgenpsychiatry.2011.1503;
Tomlinson KL, 2012, ADDICT BEHAV, V37, P179, DOI 10.1016/j.addbeh.2011.09.016;
Walters GD, 2002, AM J DRUG ALCOHOL AB, V28, P557, DOI 10.1081/ADA-120006742; Young
SE, 2002, DRUG ALCOHOL DEPEN, V68, P309, DOI 10.1016/S0376-8716(02)00225-9 81
12 12 0 7 AMER PSYCHOLOGICAL ASSOC WASHINGTON 750 FIRST ST
NE, WASHINGTON, DC 20002-4242 USA 0012-1649 1939-0599 DEV PSYCHOL Dev.
Psychol. AUG 2015 51 8 1086 1097
10.1037/dev0000026 12 Psychology, Developmental
Psychology CN8IM WOS:000358683700006 26075631 Green Accepted
2019-09-25
J Jarvinen, M; Ravn, S Jarvinen, Margaretha; Ravn, Signe
Explanations and expectations: drug narratives among young cannabis
users in treatment SOCIOLOGY OF HEALTH & ILLNESS English
Article cannabis; youth; narratives;
typology; Mead SUBSTANCE USE DISORDERS; ILLNESS; IDENTITY; CONSTRUCTION;
INEQUALITIES; PATTERNS; ALCOHOL; STORIES; HEALTH; SAMPLE This article analyses
how young people enrolled in drug addiction treatment in Copenhagen, Denmark,
explain their cannabis careers and how they view their possibilities for quitting
drug use again. Inspired by Mead and narrative studies of health and illness, the
article identifies four different drug use aetiologies' drawn upon by the
interviewees. These cover childhood experiences, self-medication, the influence of
friends and cannabis use as a specific lifestyle. A central argument of the article
is that these explanations not only concern the past but also point towards the
future by assigning the interviewee a more or less agential position in relation to
drugs. Further, the drug narratives are viewed as interactional achievements,
related to the social context in which they were produced, namely, the
institutional setting of the treatment centres. The article is based on 30
qualitative interviews with young people in drug addiction treatment. [Jarvinen,
Margaretha] Univ Copenhagen, Dept Sociol, DK-1014 Copenhagen K, Denmark; [Jarvinen,
Margaretha; Ravn, Signe] SFI Danish Natl Ctr Social Res, Copenhagen, Denmark
Jarvinen, M (reprint author), Univ Copenhagen, Dept Sociol, Oster
Farimagsgade 5, DK-1014 Copenhagen K, Denmark. mj@soc.ku.dk Jarvinen,
Margaretha/0000-0002-2038-0747; Ravn, Signe/0000-0001-5289-2942 Danish Council for
Independent Research (Social Sciences)Det Frie Forskningsrad (DFF); Centre for
Alcohol and Drug Research, Aarhus University The authors would like to thank The
Danish Council for Independent Research (Social Sciences) for support of the first
author, and the Centre for Alcohol and Drug Research, Aarhus University, for
support of the second author. We also want to thank the anonymous reviewers of this
article for their very helpful comments which improved the article significantly.
Adam B., 2004, NEW SOCIOLOGY FUTURE; Adam B., 2004, KRONOSCOPE, V4, P297;
Andersen D, 2015, SOCIOLOGY HLTH ILLNE, V37, P5; Anderson KG, 2010, DRUG ALCOHOL
DEPEN, V107, P171, DOI 10.1016/j.drugalcdep.2009.10.005; Biederman J, 2000,
PEDIATRICS, V106, P792, DOI 10.1542/peds.106.4.792; Biernacki P, 1986, PATHWAYS
HEROIN ADDI; Blaxter M, 1997, SOC SCI MED, V44, P747, DOI 10.1016/S0277-
9536(96)00192-X; Bury M, 2001, SOCIOL HEALTH ILL, V23, P263, DOI 10.1111/1467-
9566.00252; Bury M, 1982, Sociol Health Illn, V4, P167, DOI 10.1111/1467-
9566.ep11339939; Chatwin C., 2013, CONTEMP DRUG PROBL, V40, P235; Davison C, 1992,
PRIVATE RISKS PUBLIC; Elkins IJ, 2007, ARCH GEN PSYCHIAT, V64, P1145, DOI
10.1001/archpsyc.64.10.1145; EMCDDA, 2012, EMCDDA ANN REP 2012; Fletcher A, 2013,
SOCIOL HEALTH ILL, V35, P699, DOI 10.1111/j.1467-9566.2012.01522.x; Flick U., 2007,
MANAGING QUALITY QUA; Gergen Mary, 1992, STORIED LIVES CULTUR; Gubrium JF, 1998,
SOCIOL QUART, V39, P163, DOI 10.1111/j.1533-8525.1998.tb02354.x; Hammersley R,
2006, ADDICT RES THEORY, V14, P189, DOI 10.1080/16066350500453309; Hammersley R,
2001, ADDICT RES THEORY, V9, P133, DOI 10.3109/16066350109141745; Hathaway AD,
2008, ADDICT RES THEORY, V16, P495, DOI 10.1080/16066350701867281; Heath S., 2009,
RES YOUNG PEOPLES LI; Holstein J., 1995, ACTIVE INTERVIEW; Hyden LC, 1997, SOCIOL
HEALTH ILL, V19, P48, DOI 10.1111/1467-9566.ep10934289; Jarvinen M, 2004, NARRAT
INQ, V14, P45, DOI 10.1075/ni.14.1.03jar; Jarvinen M, 2008, SOCIOL HEALTH ILL, V30,
P975, DOI 10.1111/j.1467-9566.2008.01094.x; Jarvinen M, 2011, SOCIOL HEALTH ILL,
V33, P554, DOI 10.1111/j.1467-9566.2010.01303.x; McIntosh J, 2000, SOC SCI MED,
V50, P1501, DOI 10.1016/S0277-9536(99)00409-8; MEAD GH, 1934, GH MEAD SOCIAL PSYCH;
Mead GH, 1938, PHILOS ACT; Mead GH, 1932, PHILOS PRESENT; Merikangas KR, 1998, ARCH
GEN PSYCHIAT, V55, P973, DOI 10.1001/archpsyc.55.11.973; Miller P, 2002, DRUG
ALCOHOL DEPEN, V65, P235, DOI 10.1016/S0376-8716(01)00165-X; Morris C. W., 1972,
PHILOS ACT; National Board of Health, 2012, NARK DANM 2012; National Board of
Health, 2005, NARK DANM 2005; Patra J, 2009, ADDICT RES THEORY, V17, P168, DOI
10.1080/16066350802372827; Pedersen W, 2013, SOCIOL HEALTH ILL, V35, P17, DOI
10.1111/j.1467-9566.2012.01476.x; Pennay A, 2010, ADDICT RES THEORY, V18, P557, DOI
10.3109/16066350903308415; Plumridge E, 1999, SOCIOL HEALTH ILL, V21, P329, DOI
10.1111/1467-9566.00159; Popay J, 2003, SOCIOL HEALTH ILL, V25, P1, DOI
10.1111/1467-9566.t01-1-00322; Ricoeur P, 1984, TIME NARRATIVE, V1; RIESSMAN CK,
1990, SOC SCI MED, V30, P1195, DOI 10.1016/0277-9536(90)90259-U; RIESSMAN CK, 2003,
QUALITATIVE RES, V3, P5, DOI DOI 10.1177/146879410300300101; Sandberg S, 2013,
CRIMINOL CRIM JUSTIC, V13, P63, DOI 10.1177/1748895812445620; Sandberg S, 2012,
ADDICT RES THEORY, V20, P372, DOI 10.3109/16066359.2011.638147; STONE DA, 1989,
POLIT SCI QUART, V104, P281, DOI 10.2307/2151585; STRAUSS A, 1964, GH MEAD SOCIAL
PSYCH; Terry P, 2007, ADDICT RES THEORY, V15, P113, DOI 10.1080/16066350601012681;
Tilly C., 2006, WHY; Wadsworth EJK, 2004, J PSYCHOPHARMACOL, V18, P238, DOI
10.1177/0269881104042628; WILKINSON DA, 1987, BRIT J ADDICT, V82, P259; WILLIAMS G,
1984, SOCIOL HEALTH ILL, V6, P175, DOI 10.1111/1467-9566.ep10778250; Yacoubian G.
S, 1999, W CRIMINOLOGY REV, V1, P1 53 4 4 0 21 WILEY HOBOKEN
111 RIVER ST, HOBOKEN 07030-5774, NJ USA 0141-9889 1467-9566 SOCIOL
HEALTH ILL Sociol. Health Ill. JUL 2015 37 6
870 887 10.1111/1467-9566.12239 18 Public,
Environmental & Occupational Health; Social Sciences, Biomedical; Sociology
Public, Environmental & Occupational Health; Biomedical Social Sciences;
Sociology CO1OV WOS:000358925800005 25688710 Green Published
2019-09-25
J Ogunbiyi, A; Adedokun, B Ogunbiyi, A.; Adedokun, B.
Perceived aetiological factors of folliculitis keloidalis nuchae (acne
keloidalis) and treatment options among Nigerian men BRITISH JOURNAL OF
DERMATOLOGY English Article
BLACK-POPULATION; SCALP DISEASE; PREVALENCE; RISK Background Folliculitis
keloidalis nuchae (FKN) also known as acne keloidalis is the commonest form of
scarring alopecia occurring in African males. It occurs mostly in individuals of
African descent. Its prevalence ranges from 1.6% to 16.1%. FKN is multifactorial in
origin: androgens, inflammation, trauma, ingrowing hairs and secondary infection
have all been implicated in its aetiology. The reason for its occurrence in the
occipital region is unclear although elevated androgens in the scalp have been
suggested. The occurrence of huge keloidal-like scars in the affected area has
earned the name 'Bumps' in this environment. Objectives To look at the community's
perception of the aetiological factors for bumps and perceived management options
available in our environment. Methods A community study was carried out among 1003
men residing in an urban community in Mokola, Ibadan, Oyo State, Nigeria. Data on
sociodemographiccharacteristics, knowledge about aetiology, and prevalence of
shaving bumps was obtained using a semi-structured questionnaire administered by
trained interviewers. The chi-squared test was used to test the associations
between presence of FKN and variables. Results The mean age of the respondents was
31.6 (SD = 8) years. When asked about the cause of shaving bumps, 420 (41.9%) felt
it was due to infection from barber's instruments, followed by heredity (110, 11%),
poor shaving technique (81, 8.1%), cuts from shaving (52, 5.2%) and inadequate
after shaving care (39, 3.9%). The prevalence of shaving bumps was 2.7%. The most
commonly reported symptom among those with shaving bumps was itching (71.1%). Other
symptoms include pain (9.6%) and bleeding (1.2%). Most of the patients (70.8%) who
had ever had shaving bumps practised self-medication. Medications applied included
oral and topical antibiotics (20.3%), Neo-medrol (10.9%), engine oil (9.4%) and
traditional leaves (9.4%). Conclusions About 50% of the responders believed FKN was
an infective disorder. Although bleeding occurred while having a haircut, some
individuals did not have their own personal shaving kits. Antibiotics, topical
steroids, herbs and caustic substances were used for treatment. There is an urgent
need to stimulate safer hair shaving practices and discourage the wrong treatment
of FKN. [Ogunbiyi, A.] Univ Ibadan, Univ Coll Hosp, Dept Med, Dermatol Unit,
Ibadan, Oyo State, Nigeria; [Adedokun, B.] Univ Ibadan, Coll Med, Dept Epidemiol &
Med Stat, Ibadan, Oyo State, Nigeria Ogunbiyi, A (reprint author), Univ
Ibadan, Univ Coll Hosp, Dept Med, Dermatol Unit, Ibadan, Oyo State, Nigeria.
adebolaogunbiyi@yahoo.com Adekanle O, 2010, SINGAP
MED J, V51, P944; Child FJ, 1999, BRIT J DERMATOL, V141, P512; GEORGE AO, 1993, INT
J DERMATOL, V32, P714, DOI 10.1111/j.1365-4362.1993.tb02739.x; Khumalo NP, 2007,
BRIT J DERMATOL, V157, P981, DOI 10.1111/j.1365-2133.2007.08146.x; Khumalo NP,
2007, BRIT J DERMATOL, V157, P106, DOI 10.1111/j.1365-2133.2007.07987.x; Khumalo
NP, 2011, INT J DERMATOL, V50, P1212, DOI 10.1111/j.1365-4632.2010.04655.x;
Ogunbiyi A, 2005, J NATL MED ASSOC, V97, P736; Ogunbiyi Adebola O, 2009, Int J
Adolesc Med Health, V21, P235, DOI 10.1515/IJAMH.2009.21.2.235; Ogunbiyi AO, 2005,
PEDIATR DERMATOL, V22, P6, DOI 10.1111/j.1525-1470.2005.22101.x; Ogunbiyi AO, 2004,
INT J DERMATOL, V43, P31, DOI 10.1111/j.1365-4632.2004.01967.x; Salami T, 2007, INT
J DERMATOL, V46, P482, DOI 10.1111/j.1365-4632.2007.03069.x; Verma SB, 2010, AM J
CLIN DERMATOL, V11, P433, DOI 10.2165/11537000-000000000-00000; Winter H, 2004, J
INVEST DERMATOL, V122, P652, DOI 10.1111/j.0022-202X.2004.22309.x 13 6
6 0 4 WILEY-BLACKWELL HOBOKEN 111 RIVER ST, HOBOKEN 07030-
5774, NJ USA 0007-0963 1365-2133 BRIT J DERMATOL Br. J. Dermatol.
JUL 2015 173 2 SI 22 25
10.1111/bjd.13422 4 Dermatology Dermatology CN6GZ
WOS:000358533900005 26207661 Bronze 2019-09-25
J Peles, E; Schreiber, S; Linzy, S; Domani, Y; Adelson, M
Peles, Einat; Schreiber, Shaul; Linzy, Shirley; Domani, Yoav; Adelson, Miriam
Differences in Methylphenidate Abuse Rates Among Methadone
Maintenance Treatment Patients in Two Clinics JOURNAL OF SUBSTANCE ABUSE
TREATMENT English Article
Methylphenidate; Methadone maintenance treatment; Abuse; Monitoring; ADHD;
Methylphenidate DEFICIT HYPERACTIVITY DISORDER; ATTENTION-DEFICIT/HYPERACTIVITY
DISORDER; TREATMENT MMT; SUBSTANCE-ABUSE; DRUG-ABUSE; ADULT ADHD; MEDICATIONS;
PRESCRIPTION; RETENTION; ISRAEL Methylphenidate, an amphetamine-like
prescription medication for attention deficit hyperactivity disorder (ADHD) was
suspected as being abused among methadone maintenance treatment (MMT) patients. We
tested its presence in the routine urine monitoring of all patients in both Tel
Aviv and Las Vegas MMT clinics. Data on demographic and addiction history, ADHD
(Wender Utah Rating Scale), cognitive impairment (Mini Mental State Exam), and
lifetime DSM-IV-TR psychiatric diagnosis from admission were retrieved, and
retention following 6 months. None of the 190 patients in Las Vegas tested positive
for methylphenidate, while 14.7% (45/306) did in Tel Aviv. Abusers were less
educated (p = 0.01), had higher ADHD scores (p = 0.02), lower cognitive scores (p =
0.05), and a higher benzodiazepine (BDZ) abuse rate (p < 0.0005), with no
difference in age, gender, duration in MMT, cannabis, opiates, and cocaine abuse
and infectious disease. Of the methylphenidate abuse 42.2% have take-home methadone
dose privileges. Not like opiate use, being methylphenidate positive did not relate
to 6-months retention. Compared to Tel Aviv, Las Vegas patients were more educated,
with lower BDZ, and cocaine abuse. The greater abuse of methylphenidate among ADHD
subjects might indicate their using it as self-medication, raising a possible
indication for its prescription for that subgroup of MMT patients. The high ;rate
of methylphenidate abuse in Israel needs future study. (C) 2015 Elsevier Inc. All
rights reserved. [Peles, Einat; Schreiber, Shaul; Domani, Yoav; Adelson, Miriam]
Dr Miriam & Sheldon G Adelson Clin Drug Abuse Tre, Tel Aviv, Israel; [Peles, Einat;
Schreiber, Shaul; Domani, Yoav] Tel Aviv Sourasky Med Ctr, Dept Psychiat, IL-
6492406 Tel Aviv, Israel; [Peles, Einat; Schreiber, Shaul; Domani, Yoav] Tel Aviv
Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel; [Linzy, Shirley; Adelson, Miriam]
Dr Miriam & Sheldon G Adelson Clin Drug Abuse Tre, Las Vegas, NV USA Peles, E
(reprint author), Tel Aviv Sourasky Med Ctr, Adelson Clin, 1 Henrietta Szold St,
IL-6492406 Tel Aviv, Israel. einatp@tlvmc.gov.il Schreiber, Shaul/E-5821-2010;
Schreiber, Shaul/L-6101-2019 Schreiber, Shaul/0000-0002-2189-0693; Adelson
Family Foundation The study was funded by the Adelson Family Foundation.
Adelson M, 2007, J ADDICT DIS, V26, P15, DOI 10.1300/J069v26n01_03; Adler
Lenard A, 2006, Ann Clin Psychiatry, V18, P145, DOI 10.1080/10401230600801077;
Dursteler-MacFarland KM, 2013, J CLIN PSYCHOPHARM, V33, P104, DOI
10.1097/JCP.0b013e31827bfff4; Elkins IJ, 2007, ARCH GEN PSYCHIAT, V64, P1145, DOI
10.1001/archpsyc.64.10.1145; FAGERSTROM KO, 1978, ADDICT BEHAV, V3, P235, DOI
10.1016/0306-4603(78)90024-2; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI
10.1016/0022-3956(75)90026-6; Frauger E, 2013, FUND CLIN PHARMACOL, V27, P672, DOI
10.1111/fcp.12024; Frauger E, 2011, CNS DRUGS, V25, P415, DOI 10.2165/11587640-
000000000-00000; HAGLUND RMJ, 1982, INT J ADDICT, V17, P349, DOI
10.3109/10826088209071018; Harel-Fisch Y, 2013, TREND SUBSTANCE USE; Hawks R. L,
1980, NIDA RES MONOGR, V73, P30; HOSMER DW, 1980, COMMUN STAT A-THEOR, V9, P1043,
DOI 10.1080/03610928008827941; Humphreys KL, 2013, JAMA PSYCHIAT, V70, P740, DOI
10.1001/jamapsychiatry.2013.1273; Imbert B, 2013, J CLIN PSYCHOPHARM, V33, P720,
DOI 10.1097/JCP.0b013e31829839a4; Kessler RC, 2005, PSYCHOL MED, V35, P245, DOI
10.1017/S0033291704002892; Kollins SH, 2008, CURR MED RES OPIN, V24, P1345, DOI
10.1185/030079908X280707 ; Kollins SH, 2007, AM J ADDICTION, V16, P35, DOI
10.1080/10550490601082775; Konova AB, 2013, JAMA PSYCHIAT, V70, P857, DOI
10.1001/jamapsychiatry.2013.1129; Levin FR, 2006, DRUG ALCOHOL DEPEN, V81, P137,
DOI 10.1016/j.drugalcdep.2005.06.012; Marti G, 2013, HUM EXP TOXICOL, V32, P332,
DOI 10.1177/0960327112467044; Martinez-Raga J, 2013, CNS DRUGS, V27, P15, DOI
10.1007/s40263-012-0019-9; McClernon FJ, 2008, ANN NY ACAD SCI, V1141, P131, DOI
10.1196/annals.1441.016; McLellan A T, 1984, NIDA Res Monogr, V55, P217; Mujtaba
Sobia, 2013, J Cardiovasc Dis Res, V4, P229, DOI 10.1016/j.jcdr.2013.10.001; Novak
SP, 2007, SUBST ABUSE TREAT PR, V2, DOI 10.1186/1747-597X-2-32; Peles E, 2006, DRUG
ALCOHOL DEPEN, V82, P211, DOI 10.1016/j.drugalcdep.2005.09.008; Peles E, 2008, J
ADDICT DIS, V27, P11, DOI 10.1080/10550880802324382; Peles E, 2008, EUR
NEUROPSYCHOPHARM, V18, P188, DOI 10.1016/j.euroneuro.2007.10.001; Peles E, 2012,
PSYCHOPATHOLOGY, V45, P327, DOI 10.1159/000336219; Peles E, 2010, DRUG ALCOHOL
DEPEN, V107, P141, DOI 10.1016/j.drugalcdep.2009.09.013; Rieppi R, 2002, J AM ACAD
CHILD PSY, V41, P269, DOI 10.1097/00004583-200203000-00006; Schelleman H, 2012, AM
J PSYCHIAT, V169, P178, DOI 10.1176/appi.ajp.2011.11010125; Schubiner H, 2005, CNS
DRUGS, V19, P643, DOI 10.2165/00023210-200519080-00001; Shalev A. Y., 1996, HEBREW
VERSION SCID; Spiller HA, 2013, CNS DRUGS, V27, P531, DOI 10.1007/s40263-013-0084-
8; WARD MF, 1993, AM J PSYCHIAT, V150, P885; Westover AN, 2013, J CLIN HYPERTENS,
V15, P124, DOI 10.1111/jch.12039; Wilens TE, 2003, PEDIATRICS, V111, P179, DOI
10.1542/peds.111.1.179; Wilens TE, 2004, J CLIN PSYCHIAT, V65, P38; Zosel A, 2013,
J AM ACAD CHILD PSY, V52, P196, DOI 10.1016/j.jaac.2012.11.014 40 9 11
0 7 PERGAMON-ELSEVIER SCIENCE LTD OXFORD THE BOULEVARD, LANGFORD
LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND 0740-5472 J SUBST ABUSE
TREAT J. Subst. Abus. Treat. JUL 2015 54 44
49 10.1016/j.jsat.2014.12.010 6 Psychology,
Clinical; Substance Abuse Psychology; Substance Abuse CJ6AE
WOS:000355574600006 25605438 2019-09-25
J Maremmani, AGI; Rovai, L; Rugani, F; Bacciardi, S; Massimetd, E; Gazzarrini,
D; Dell'Osso, L; Tang, FY; Akiskal, HS; Maremmani, I Maremmani,
Angelo G. I.; Rovai, Luca; Rugani, Fabio; Bacciardi, Silvia; Massimetd, Enrico;
Gazzarrini, Denise; Dell'Osso, Liliana; Tang, Fengyi; Akiskal, Hagop S.; Maremmani,
Icro Chronology of illness in dual diagnosis heroin addicts: The role
of mood disorders JOURNAL OF AFFECTIVE DISORDERS English
Article Heroin dependence; Dual diagnosis;
Mental disorder vs. heroin use temporal priority; Self medication hypothesis
PRIMARY MAJOR DEPRESSIONS; SUBSTANCE-ABUSE; BIPOLAR SPECTRUM; PAST COURSE;
TEMPERAMENT; COMORBIDITY; PSYCHOPATHOLOGY; EPIDEMIOLOGY; PREVALENCE; ANXIETY
 Background: Recent celebrity deaths have been widely reported in the media
and turned the public attention to the coexistence of mood, psychiatric and
substance-abuse disorders. These tragic and untimely deaths motivated us to examine
the scientific and clinical data, including our own work in this area. The self-
medication hypothesis states that individuals with psychiatric illness tend to use
heroin to alleviate their symptoms. This study examined the correlations between
heroin use, mood and psychiatric disorders, and their chronology in the context of
dual diagnosis. Methods: Out of 506 dual diagnosed heroin addicts, 362 patients
were implicated in heroin abuse with an onset of at least one year prior to the
associated mental disorder (HER-PR), and 144 patients were diagnosed of mental
illness at least one year prior to the associated onset of heroin use disorder (Ml-
PR). The retrospective cross-sectional analysis of the two groups compared their
demographic, clinical and diagnostic characteristics at univariate and multivariate
levels. Results: Dual diagnosis heroin addicts whose heroin dependences existed one
year prior to their diagnoses (HER-PR) reported more frequent somatic comorbidity
(p <= 0.001), less major problems at work (p =0.003), more legal problems (p
=0.004) and more failed treatment for their heroin dependence (p < 0.001) in the
past. More than 2/3 reached the third stage of heroin addiction (p= <0.001). Their
length of dependence was longer (p=0.004). HER-PR patients were diagnosed more
frequently as affected by mood disorders and less frequently as affected by
psychosis (p=0.004). At the multivariate level. HER-PR patients were characterized
by having reached stage 3 of heroin dependence (OR=2.45), diagnosis of mood
disorder (OR=2.25), unsuccessful treatment (OR=2.07) and low education (OR=1.79).
Limitations: The main limitation is its retrospective nature. Nonetheless, it does
shed light on what needs to be done from a clinical and public health perspective
and especially prevention. Conclusions: The data emerging from this study, does not
allow us to determine a causal relation between heroin use and mental illness
onset. However, this data, even if requiring longitudinal studies, suggest that
self-medication theory, in these patients, can be applied only for chronic
psychoses, but should not be applied to patients with mood disorders using heroin.
(C) 2015 Published by Elsevier B.V. [Maremmani, Angelo G. I.; Rovai, Luca; Rugani,
Fabio; Bacciardi, Silvia; Massimetd, Enrico; Gazzarrini, Denise; Maremmani, Icro]
Univ Pisa, Santa Chiara Univ Hosp, Dept Clin & Expt Med, Vincent P Dole Dual Diag
Unit, I-56100 Pisa, Italy; [Maremmani, Angelo G. I.] Assoc Applicat Neurosci
Knowledge Social Aims AU, Pietrasanta, Lucca, Italy; [Dell'Osso, Liliana] Univ
Pisa, Dept Clin & Expt Med, I-56100 Pisa, Italy; [Tang, Fengyi; Akiskal, Hagop S.]
Univ Calif San Diego, Int Mood Ctr, San Diego, CA 92103 USA; [Tang, Fengyi;
Akiskal, Hagop S.] Vet Adm Hosp, San Diego, CA USA; [Maremmani, Icro] G De Lisio
Inst Behav Sci Pisa, Pisa, Italy Maremmani, AGI (reprint author), Univ Pisa,
Santa Chiara Univ Hosp, Dept Clin & Expt Med, Vincent P Dole Dual Diag Unit, Via
Roma 67, I-56100 Pisa, Italy. angelogimaremmani@gmail.com Maremmani, Angelo
Giovanni Icro/0000-0001-7728-3705 Akiskal H. S., 1983, PSYCHIATRY
UPDATE AM, V2, P271; AKISKAL HS, 1987, PSYCHOPHARMACOL BULL, V23, P68; AKISKAL HS,
1989, J CLIN PSYCHIAT, V50, P6; AKISKAL HS, 1995, ARCH GEN PSYCHIAT, V52, P114;
AKISKAL HS, 1989, PSYCHOPATHOLOGY, V22, P268, DOI 10.1159/000284607; AKISKAL MJ,
1989, J CLIN PSYCHIAT, V50, P11; ALEXANDER BK, 1978, PSYCHOPHARMACOLOGY, V58, P175,
DOI 10.1007/BF00426903; Camacho A, 2005, J AFFECT DISORDERS, V85, P217, DOI
10.1016/j.jad.2003.10.014; CASSANO GB, 1989, PSYCHOPATHOLOGY, V22, P278, DOI
10.1159/000284608; CLOUET DH, 1982, ANN NY ACAD SCI, V398, P130, DOI
10.1111/j.1749-6632.1982.tb39487.x; Grant BF, 2004, ARCH GEN PSYCHIAT, V61, P807,
DOI 10.1001/archpsyc.61.8.807; Greenwood TA, 2012, BIOL PSYCHIAT, V72, P303, DOI
10.1016/j.biopsych.2012.01.018; HAGNELL O, 1990, COMORBIDITY OF MOOD AND ANXIETY
DISORDERS, P139; Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI
10.1176/appi.ajp.162.8.1403; Kessler RC, 1996, AM J ORTHOPSYCHIAT, V66, P17, DOI
10.1037/h0080151; Kessler RC, 2004, BIOL PSYCHIAT, V56, P730, DOI
10.1016/j.biopsych.2004.06.034; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8;
KHANTZIAN EJ, 1985, ARCH GEN PSYCHIAT, V42, P1067; KHANTZIAN EJ, 1985, AM J
PSYCHIAT, V142, P1259; KHANTZIAN EJ, 1980, NEW ENGL J MED, V302, P869; Lahmeyer H.
W., 1988, PSYCHIAT DIAGNOSIS T, P182; LEVINSON I, 1995, J CLIN PSYCHIAT, V56, P73;
Maremmani AGI, 2014, EUR REV MED PHARMACO, V18, P287; Maremmani AGI, 2011, J ADDICT
DIS, V30, P123, DOI 10.1080/10550887.2011.554779; Maremmani I, 2004, J PSYCHOACTIVE
DRUGS, V36, P235, DOI 10.1080/02791072.2004.10399734; Maremmani I, 2000, J ADDICT
DIS, V19, P29, DOI 10.1300/J069v19n02_03; Maremmani I., 2000, HEROIN ADDICT REL CL,
V2, P39; Maremmani I., 1994, NEW TRENDS EXPT CLIN, P179; Maremmani I., 1989, DAH Q
DRUG ADDICTION; Maremmani I., 2005, HEROIN ADDICT REL CL, V7, P33; Maremmani I.,
2000, HEROIN ADDICT REL CL, V2, P35; Maremmani I, 2006, J AFFECT DISORDERS, V93,
P1, DOI 10.1016/j.jad.2006.02.022; Maremmani I, 2012, ANN GEN PSYCHIATR, V11, DOI
10.1186/1744-859X-11-23; Maremmani I, 2009, J AFFECT DISORDERS, V117, P186, DOI
10.1016/j.jad.2009.01.007; Merikangas K., 1998, DRUG ADDICTION RES H, P245; Murphy
J. M., 1990, COMORBIDITY MOOD ANX, P139; Pani PP, 2010, J AFFECT DISORDERS, V122,
P185, DOI 10.1016/j.jad.2009.06.012; REGIER DA, 1990, JAMA-J AM MED ASSOC, V264,
P2511; Sareen J, 2001, CAN J PSYCHIAT, V46, P733; Swendsen JD, 2000, CLIN PSYCHOL
REV, V20, P173, DOI 10.1016/S0272-7358(99)00026-4; Weiss R D, 1985, Psychiatr Med,
V3, P357 41 5 5 0 25 ELSEVIER AMSTERDAM RADARWEG 29, 1043
NX AMSTERDAM, NETHERLANDS 0165-0327 1573-2517 J AFFECT DISORDERS
J. Affect. Disord. JUL 1 2015 179 156
160 10.1016/j.jad.2015.03.046 5 Clinical
Neurology; Psychiatry Neurosciences & Neurology; Psychiatry CI2VV
WOS:000354606500021 25863912 2019-09-25
J O'Brien, KHM; Salas-Wright, CP; Vaughn, MG; LeCloux, M
O'Brien, Kimberly H. McManama; Salas-Wright, Christopher P.; Vaughn, Michael
G.; LeCloux, Mary Childhood exposure to a parental suicide attempt and
risk for substance use disorders ADDICTIVE BEHAVIORS English
Article Substance use disorder; Parental
suicide attempt; Childhood adversity ALCOHOL-USE DISORDER; SELF-MEDICATION
HYPOTHESIS; INTERVIEW SCHEDULE AUDADIS; GENERAL-POPULATION SAMPLE; CONFIDENCE-
INTERVALS; GENDER-DIFFERENCES; ANXIETY DISORDERS; DRUG MODULES; BEHAVIOR;
DEPENDENCE Childhood exposure to parental suicidal behavior has been linked to a
variety of adverse behavioral and health outcomes. However, relatively little is
known about the degree to which such exposure may place individuals at risk for a
substance use disorder (SUD). Employing data from the National Epidemiologic Survey
on Alcohol and Related Conditions, we compared the prevalence of SUDs among those
who experienced childhood exposure to parental suicide attempts. Childhood exposure
to parental suicide attempts was not associated with increased risk for the
development of alcohol, cannabis, or cocaine use disorders. However, individuals
who were exposed to aparental suicide attempt as children were significantly more
likely to have met criteria for stimulant (AOR = 1.40, 95% CI = 1.18-1.67),
sedative (AOR = 1.24, 95% CI = 1.04-1.47), tranquilizer (AOR = 1.78, 95% CI = 1.45-
220), and opioid (AOR = 1.41, 95% CI = 1.19-1.67) use disorders in their lifetime.
No significant gender differences were identified with respect to the magnitude of
the relationship between exposure to parental suicide attempts and SUD risk among
men and women. Findings suggest that, controlling for an array of sociodemographic,
parental, mental health, and childhood adversity confounds, childhood exposure to
parental suicide attempts is a vulnerability factor for low prevalence illicit
drugs (i.e. stimulants, sedatives, tranquilizers, opioids), but not for more
commonly used substances. (C) 2015 Elsevier Ltd. All rights reserved. [O'Brien,
Kimberly H. McManama; LeCloux, Mary] Simmons Sch Social Work, Boston, MA USA;
[O'Brien, Kimberly H. McManama] Boston Childrens Hosp, Boston, MA USA; [O'Brien,
Kimberly H. McManama] Harvard Univ, Sch Med, Boston, MA USA; [Salas-Wright,
Christopher P.] Univ Texas Austin, Sch Social Work, Austin, TX 78712 USA; [Vaughn,
Michael G.] St Louis Univ, Sch Social Work, Coll Publ Hlth & Social Justice, St
Louis, MO 63103 USA O'Brien, KHM (reprint author), 300 Fenway, Boston, MA 02115
USA. obrik@simmons.edu Vaughn, Michael/W-2694-2019 National Institute on
Drug Abuse at the National Institutes of HealthUnited States Department of Health &
Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on
Drug Abuse (NIDA) [R25 DA026401] This research was supported in part by grant
number R25 DA026401 from the National Institute on Drug Abuse at the National
Institutes of Health. Alati R, 2006, ARCH GEN PSYCHIAT, V63, P1009, DOI
10.1001/archpsyc.63.9.1009; Allison PD, 1999, SOCIOL METHOD RES, V28, P186, DOI
10.1177/0049124199028002003; Brent DA, 2008, PSYCHIAT CLIN N AM, V31, P157, DOI
10.1016/j.psc.2008.02.001; Bronisch T, 2008, PSYCHIAT CLIN N AM, V31, P213, DOI
10.1016/j.psc.2008.01.003; Burke AK, 2010, J AM ACAD CHILD PSY, V49, P114, DOI
10.1016/j.jaac.2009.10.008; Cerel J., 2005, J ADOLESCENT HEALTH, V36, P352, DOI DOI
10.1016/J; Cerel J, 2008, CRISIS, V29, P38, DOI 10.1027/0227-5910.29.1.38;
Cerniglia L., 2014, CURRENT PSYCHOL; Cumming G, 2005, AM PSYCHOL, V60, P170, DOI
10.1037/0003-066X.60.2.170; DeLisi M, 2014, J CRIM JUST, V42, P10, DOI
10.1016/j.jcrimjus.2013.11.001; Ellis PD, 2010, ESSENTIAL GUIDE TO EFFECT SIZES:
STATISTICAL POWER, META-ANALYSIS AND THE INTERPRETATION OF RESEARCH RESULTS, P1;
Enoch MA, 2011, PSYCHOPHARMACOLOGY, V214, P17, DOI 10.1007/s00213-010-1916-6; Evans
GW, 2007, PSYCHOL SCI, V18, P953, DOI 10.1111/j.1467-9280.2007.02008.x; Flory K,
2003, PSYCHOL ADDICT BEHAV, V17, P151, DOI 10.1037/0893-164X.17.2.151; Galaif
Elisha R, 2007, Int J Adolesc Med Health, V19, P27; Grant BF, 2003, DRUG ALCOHOL
DEPEN, V71, P7, DOI 10.1016/S0376-8716(03)00070-X; GRANT BF, 1995, DRUG ALCOHOL
DEPEN, V39, P37, DOI 10.1016/0376-8716(95)01134-K; Grant BF, 2006, ALCOHOL RES
HEALTH, V29, P107; Hahesy AL, 2002, PSYCHIAT RES, V109, P245, DOI 10.1016/S0165-
1781(02)00015-X; Hasin D, 1997, DRUG ALCOHOL DEPEN, V44, P133, DOI 10.1016/S0376-
8716(97)01332-X; Hawkins D. J., 1992, AM PSYCHOL ASS, V112, P64, DOI DOI
10.1037/0033-2909.112.1.64; Hayatbakhsh MR, 2008, AUST NZ J PSYCHIAT, V42, P720,
DOI 10.1080/00048670802206346; Hofmann SG, 2009, J ANXIETY DISORD, V23, P529, DOI
10.1016/j.janxdis.2008.10.011; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231,
DOI 10.3109/10673229709030550; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259; King
SM, 2004, ADDICTION, V99, P1548, DOI 10.1111/j.1360-0443.2004.00893.x; Knol MJ,
2011, EUR J EPIDEMIOL, V26, P253, DOI 10.1007/s10654-011-9563-8; Kuramoto SJ, 2009,
SUICIDE LIFE-THREAT, V39, P137, DOI 10.1521/suli.2009.39.2.137; Lev-Ran S, 2013, AM
J ADDICTION, V22, P7, DOI 10.1111/j.1521-0391.2013.00321.x; McLaughlin KA, 2012,
BRIT J PSYCHIAT, V200, P290, DOI 10.1192/bjp.bp.111.101253; Molina BSG, 2003, J
ABNORM PSYCHOL, V112, P497, DOI 10.1037/0021-843X.112.3.497; Ratnarajah D, 2007, J
FAM STUD, V13, P78, DOI 10.5172/jfs.327.13.1.78; Resnick MD, 1997, JAMA-J AM MED
ASSOC, V278, P823, DOI 10.1001/jama.278.10.823; Shand FL, 2011, ADDICT BEHAV, V36,
P27, DOI 10.1016/j.addbeh.2010.08.008; Sher Leo, 2005, Int J Adolesc Med Health,
V17, P197; Sinha R, 2008, ANN NY ACAD SCI, V1141, P105, DOI
10.1196/annals.1441.030; StataCorp, 2013, STAT STAT SOFTW REL; Stone AL, 2012,
ADDICT BEHAV, V37, P747, DOI 10.1016/j.addbeh.2012.02.014; Timmermans M, 2008, J
CHILD PSYCHOL PSYC, V49, P386, DOI 10.1111/j.1469-7610.2007.01842.x; VANDERWAL J,
1989, OMEGA-J DEATH DYING, V20, P149, DOI 10.2190/5U9W-XMMP-31W5-J6HG; Wilcox HC,
2010, J AM ACAD CHILD PSY, V49, P514, DOI 10.1016/j.jaac.2010.01.020; Wu P, 2010, J
YOUTH ADOLESCENCE, V39, P177, DOI 10.1007/s10964-008-9385-542 5 5 0
16 PERGAMON-ELSEVIER SCIENCE LTD OXFORD THE BOULEVARD, LANGFORD LANE,
KIDLINGTON, OXFORD OX5 1GB, ENGLAND 0306-4603 1873-6327 ADDICT BEHAV
Addict. Behav. JUL 2015 46 70 76
10.1016/j.addbeh.2015.03.008 7 Psychology, Clinical;
Substance Abuse Psychology; Substance Abuse CH2MW WOS:000353860300013
25827333 Green Accepted 2019-09-25
J Rodriguez, AMI Muro i Rodriguez, A. Age,
sex and personality in early cannabis use EUROPEAN PSYCHIATRY
English Article Adolescent psychiatry;
Cannabis; Personality SENSATION SEEKING; SUBSTANCE USE; RISK; ADOLESCENCE;
PSYCHOSIS; HEALTH; ADULTHOOD; SYMPTOMS; DISORDER; PREDICT Previous studies
analysing personality and cannabis use in adult samples suggest that cannabis users
show significant higher levels of impulsivity, sensation seeking and schizotypy.
However, there are few studies exploring this relationship in adolescence using
psychobiological models of personality. Given the relevance of identifying
individual differences that lead adolescents to early cannabis use to prevent
future health problems, the present study aimed to explore the relationship between
age, sex, personality and early cannabis use using a psychobiological model of
personality in a sample of 415 students (51.8% boys) from 12 to 18 years. Chi(2)
tests showed significant higher prevalence of cannabis use in boys and in the group
aged 15-18 years. Multiple analysis of variance showed significant higher scores in
psychoticism, sensation seeking and in all its subscales in cannabis users group,
while an interaction with age was found for extraversion and neuroticism: cannabis
users scored higher than non-users in the youngest group (12-14 years) but lower in
the oldest group in both dimensions. Finally, regression analysis showed that
narrower traits of sensation seeking (experience seeking and disinhibition) were
the most associated to early cannabis use. Results are discussed in terms of early
cannabis users' personality profiles and in terms of the self-medication theory.
(C) 2015 Elsevier Masson SAS. All rights reserved. Univ Autonoma Barcelona, Dept
Clin & Hlth Psychol, Catalonia, Spain Rodriguez, AMI (reprint author), Univ
Autonoma Barcelona, Dept Clin & Hlth Psychol, Catalonia, Spain. anna.muro@uab.cat
Muro, Anna/L-6667-2015 Muro, Anna/0000-0002-1331-9921
Agrawal A, 2014, DRUG ALCOHOL DEPEN, V134, P362, DOI
10.1016/j.drugalcdep.2013.11.008; Agrawal A, 2009, ADDICTION, V104, P518, DOI
10.1111/j.1360-0443.2009.02504.x; American Psychiatric Association, 2014, DIAGN
STAT MAN MENT; Anglin DM, 2012, SCHIZOPHR RES, V137, P45, DOI
10.1016/j.schres.2012.01.019; Arendt M, 2007, PSYCHOL MED, V37, P935, DOI
10.1017/S0033291706009688; Arseneault L, 2002, BRIT MED J, V325, P1212, DOI
10.1136/bmj.325.7374.1212; Bailey EL, 2004, EUR PSYCHIAT, V19, P113, DOI
10.1016/j.eurpsy.2003.12.001; Barkus E., 2008, ADV SCHIZO CLIN PSY, V3, P84; Casas
M., 2011, SUBSTANCE ABUSE TREA, P51; Chabrol H, 2014, SUBST USE MISUSE; CHAPMAN JP,
1994, PERS INDIV DIFFER, V17, P369, DOI 10.1016/0191-8869(94)90284-4; Claridge G,
1996, BRIT J CLIN PSYCHOL, V35, P103, DOI 10.1111/j.2044-8260.1996.tb01166.x; Dumas
P, 2002, PSYCHIAT RES, V109, P27, DOI 10.1016/S0165-1781(01)00358-4; European
Monitoring Centre for Drugs and Drug, 2014, EUR DRUG REP; European Monitoring
Centre for Drugs and Drug Addiction and Spanish Government Delegation for the Drug
National Plan, 2009, PROBL CANN US SPAN S; Eysenck HJ, 1982, MANUAL EYSENCK PERSO;
Fridberg DJ, 2011, PSYCHIAT RES, V186, P46, DOI 10.1016/j.psychres.2010.07.035;
Gorzalka BB, 2012, ENDOCRINOLOGY, V153, P1016, DOI 10.1210/en.2011-1643; Hall W,
2009, LANCET, V374, P1383, DOI 10.1016/S0140-6736(09)61037-0; Hecimovic K, 2014,
ADDICT BEHAV, V39, P729, DOI 10.1016/j.addbeh.2013.11.025; Horwood LJ, 2010, DRUG
ALCOHOL DEPEN, V110, P247, DOI 10.1016/j.drugalcdep.2010.03.008; Hurd YL, 2014,
NEUROPHARMACOLOGY, V76, P416, DOI 10.1016/j.neuropharm.2013.07.028; Large M, 2011,
ARCH GEN PSYCHIAT, V68, P555, DOI 10.1001/archgenpsychiatry.2011.5; Malmberg M,
2012, J YOUTH ADOLESCENCE, V41, P1512, DOI 10.1007/s10964-012-9775-6; Moore THM,
2007, LANCET, V370, P319, DOI 10.1016/S0140-6736(07)61162-3; Muro A, 2012,
CHRONOBIOL INT, V29, P1376, DOI 10.3109/07420528.2012.728665; Patrick ME, 2011, J
STUD ALCOHOL DRUGS, V72, P106, DOI 10.15288/jsad.2011.72.106; PEREZ J, 1986, PERS
INDIV DIFFER, V7, P915, DOI 10.1016/0191-8869(86)90095-4; Romer D, 2011,
DEVELOPMENTAL SCI, V14, P1119, DOI 10.1111/j.1467-7687.2011.01061.x; Sawyer SM,
2012, LANCET, V379, P1630, DOI 10.1016/S0140-6736(12)60072-5; Valmaggia LR, 2014,
PSYCHOL MED, V44, P2503, DOI 10.1017/S0033291714000117; Zammit S, 2002, BRIT MED J,
V325, P1199, DOI 10.1136/bmj.325.7374.1199; ZUCKERMAN M, 1978, J CONSULT CLIN
PSYCH, V46, P139, DOI 10.1037/0022-006X.46.1.139; ZUCKERMAN M, 2005, PSYCHOBIOLOGY
PERSON; Zuckerman M, 1994, BEHAV EXPRESSIONS BI 35 4 4 1 19
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER PARIS 23 RUE
LINOIS, 75724 PARIS, FRANCE 0924-9338 1778-3585 EUR PSYCHIAT Eur.
Psychiat. JUN 2015 30 4 469 473
10.1016/j.eurpsy.2015.02.008 5 Psychiatry Psychiatry CJ7LB
WOS:000355675400005 25752726 2019-09-25
J Gill, KE; Poe, L; Azimov, N; Ben-David, S; Vadhan, NP; Girgis, R; Moore, H;
Cressman, V; Corcoran, CM Gill, Kelly E.; Poe, Lucy; Azimov,
Neyra; Ben-David, Shelly; Vadhan, Nehal P.; Girgis, Ragy; Moore, Holly; Cressman,
Victoria; Corcoran, Cheryl M. Reasons for cannabis use among youths at
ultra high risk for psychosis EARLY INTERVENTION IN PSYCHIATRY
English Article anhedonia; cannabis;
motivation; prodromal; psychosis; schizophrenia SUBSTANCE USE; SCHIZOPHRENIC-
PATIENTS; DRUG-ABUSE; SYMPTOMS; INDIVIDUALS; DISORDERS; PEOPLE; IMPACT AimCannabis
use is prevalent in schizophrenia and its risk states, despite its association with
anxiety and positive symptoms. While schizophrenia patients report using cannabis
for mood enhancement and social motives, it is not known what motivates clinical
high risk (CHR) patients to use cannabis. MethodsAmong 102 CHR patients, 24 (23%)
endorsed cannabis use, and were queried as to reasons for use, using a scale
previously administered in schizophrenia patients. We hypothesized a primary
motivation for mood enhancement related to anhedonia. We evaluated the self-
medication' hypothesis by examining if motivation for symptom relief was associated
with concurrent severity of symptoms. ResultsThe rank order of reasons for use in
CHR patients was similar to that previously reported by schizophrenia patients,
with mood enhancement and social motives as primary reasons for use, and the
motivation to use cannabis for symptom relief comparatively less common. Motivation
for mood enhancement had a trend association with anhedonia. Motivation for symptom
relief was entirely unrelated to concurrent severity of positive and anxiety
symptoms. ConclusionAs in schizophrenia, CHR patients primarily use cannabis for
mood enhancement, especially in the context of decreased motivation to seek
pleasure otherwise. Negative symptoms may drive cannabis use in schizophrenia and
its risk states, which may exacerbate positive symptoms. By contrast, CHR patients
do not report using cannabis to self-medicate' emergent positive symptoms. The
understanding of motives for cannabis use among CHR patients may be informative for
treatments aimed at reducing use, such as motivational interviewing. [Gill, Kelly
E.; Poe, Lucy; Azimov, Neyra; Ben-David, Shelly; Vadhan, Nehal P.; Girgis, Ragy;
Moore, Holly; Corcoran, Cheryl M.] Columbia Univ, New York State Psychiat Inst,
Dept Psychiat, New York, NY 10032 USA; [Cressman, Victoria] New York Harbor
Healthcare Syst, Dept Psychiat, New York, NY USA; [Cressman, Victoria] NYU, Sch
Med, New York, NY USA Corcoran, CM (reprint author), Columbia Univ, New York
State Psychiat Inst, Dept Psychiat, 1051 Riverside Dr Box 55, New York, NY 10032
USA. corcora@nyspi.columbia.edu Girgis, Ragy/N-3271-2016; Corcoran, Cheryl/M-
1397-2016 Corcoran, Cheryl/0000-0002-8902-4353; Ben-David, Shelly/0000-0002-7582-
2565; Ferreira, Kelly/0000-0002-9247-5980 National Institute of Health: Center for
Research Resources; National Institute of Health: National Center for Advancing
Translational Sciences [UL1 RR024156]; National Institute of HealthUnited States
Department of Health & Human ServicesNational Institutes of Health (NIH) - USA
[K23MH066279, R21MH086125-02, R01 093398-02]; National Institute of Health: Brain
and Behavior Research Foundation; National Institute of Health: Lieber Center for
Schizophrenia Research The project described was supported by the National
Institute of Health: (i) Center for Research Resources and the National Center for
Advancing Translational Sciences, UL1 RR024156; (ii) K23MH066279; (iii)
R21MH086125-02; (iv) R01 093398-02; as well as the (v) Brain and Behavior Research
Foundation; and (vi) the Lieber Center for Schizophrenia Research. Addington J,
2007, ACTA PSYCHIAT SCAND, V115, P304, DOI 10.1111/j.1600-0447.2006.00900.x;
Addington J, 1997, ACTA PSYCHIAT SCAND, V96, P329, DOI 10.1111/j.1600-
0447.1997.tb09925.x; Arseneault L, 2002, BRIT MED J, V325, P1212, DOI
10.1136/bmj.325.7374.1212; Beck N, 1988, J CONSULT CLIN PSYCH, V56, P893; Bodkin
LL, 2008, PRIM PSYCHIAT, V15, P51; Cannon TD, 2008, ARCH GEN PSYCHIAT, V65, P28,
DOI 10.1001/archgenpsychiatry.2007.3; CHAPMAN LJ, 1976, J ABNORM PSYCHOL, V85,
P374, DOI 10.1037/0021-843X.85.4.374; Corcoran CM, 2008, SCHIZOPHR RES, V106, P286,
DOI 10.1016/j.schres.2008.08.008; DIXON L, 1990, SCHIZOPHRENIA BULL, V16, P69, DOI
10.1093/schbul/16.1.69; DIXON L, 1991, AM J PSYCHIAT, V148, P224; Green B, 2005,
BRIT J PSYCHIAT, V187, P306, DOI 10.1192/bjp.187.4.306; Haroun N, 2006,
SCHIZOPHRENIA BULL, V32, P166, DOI 10.1093/schbul/sbj007; Hides L, 2006, BRIT J
PSYCHIAT, V189, P137, DOI 10.1192/bjp.bp.105.014308; Hjorthoj C, 2009, ADDICT
BEHAV, V34, P520, DOI 10.1016/j.addbeh.2009.02.001; Howes OD, 2009, ARCH GEN
PSYCHIAT, V66, P13, DOI 10.1001/archgenpsychiatry.2008.514; Machielsen M, 2010,
AUST NZ J PSYCHIAT, V44, P721, DOI 10.3109/00048671003689710; Miller TJ, 2003,
SCHIZOPHRENIA BULL, V29, P703, DOI 10.1093/oxfordjournals.schbul.a007040; Pencer A,
2008, EARLY INTERV PSYCHIA, V2, P42, DOI 10.1111/j.1751-7893.2007.00055.x; Phillips
LJ, 2002, AUST NZ J PSYCHIAT, V36, P800, DOI 10.1046/j.1440-1614.2002.01089.x;
Rosen JL, 2006, SCHIZOPHR RES, V85, P124, DOI 10.1016/j.schres.2006.03.034; Spencer
C, 2002, SCHIZOPHRENIA BULL, V28, P233, DOI 10.1093/oxfordjournals.schbul.a006934;
Walker DD, 2006, J CONSULT CLIN PSYCH, V74, P628, DOI 10.1037/0022-006X.74.3.628;
Yung AR, 2004, SCHIZOPHR RES, V67, P131, DOI 10.1016/S0920-9964(03)00192-0 23
14 14 2 14 WILEY-BLACKWELL HOBOKEN 111 RIVER ST, HOBOKEN
07030-5774, NJ USA 1751-7885 1751-7893 EARLY INTERV PSYCHIA Early
Interv. Psychiatry JUN 2015 9 3 207 210
10.1111/eip.12112 4 Psychiatry Psychiatry CH4FY
WOS:000353990400004 24274357 Green Accepted 2019-09-25
J Stewart, DG; Arlt, VK; Felleman, B; Athenour, DR; Arger, C
Stewart, David G.; Arlt, Virginia K.; Felleman, Benjamin; Athenour, Dylan R.;
Arger, Christopher Mechanisms of Alcohol Use Disorder Severity in
Adolescents with Co-occurring Depressive Symptoms: Findings from a School-Based
Substance Use Intervention SCHOOL MENTAL HEALTH English
Article Adolescents; Comorbidity;
Depressive symptoms; Alcohol DRUG-ABUSING ADOLESCENTS; AFFECT INTENSITY; SELF-
MEDICATION; MENTAL-HEALTH; FIT INDEXES; OUTCOMES; DRINKING; CARE; MOOD; RISK
Individuals with co-occurring alcohol abuse and depressive symptoms were
hypothesized to present to treatment with unique etiological pathways, contexts of
drinking, topography and consequences of drinking. Two hundred and seventy-three
(273) adolescents participated in a motivational enhancement therapy-based
intervention specifically developed for adolescent substance users in schools. Data
for the present study were collected at intake. The proposed serial mediation
multivariate path model included depressive symptoms, drinking to cope and typical
blood alcohol concentration (tBAC) as predictors of consequences resultant in
symptoms congruent with a DSM-5 alcohol use disorder (AUD). This path model
exhibited a good fit to the data when including covariates of alcohol consumption
and affective dysregulation, chi(2)((5,268)) = 3.45, p = 0.63; CFI = 1.00; NFI =
0.98; RFI = 0.93; RMSEA = 0.00 (0.07-0.87). The final model accounted for 44 % of
the variance in the prediction of AUD symptoms. The indirect effect of depressive
symptoms to AUD symptoms indicated that drinking to cope and tBAC fully mediated
the model. Co-occurring depressive symptoms create a unique pathway to increased
AUD severity in adolescents. This pathway provides a potential mechanism for
understanding the increased risk of comorbidity and highlights that the increased
risk imparted by depressive symptoms is underscored by affective dysregulation and
caused by an increased intensity of alcohol use in specific contexts. This
mechanism suggests that a specificity of treatment is needed, such that adolescents
with higher levels of AUD symptoms and elevated depressive symptoms who drink to
cope should receive appropriately tailored services. [Stewart, David G.; Arlt,
Virginia K.; Felleman, Benjamin; Athenour, Dylan R.; Arger, Christopher] Seattle
Pacific Univ, Seattle, WA 98119 USA Arlt, VK (reprint author), Seattle Pacific
Univ, 3307 Third Ave W,Ste 107, Seattle, WA 98119 USA. arltv@spu.edu
Stewart, David/0000-0003-0818-9509 Anderson KG, 2011, J CHILD
ADOLES SUBST, V20, P48, DOI 10.1080/1067828X.2011.534362; Arria AM, 2009, ARCH
SUICIDE RES, V13, P230, DOI 10.1080/13811110903044351; Aston ER, 2014, PSYCHOL
ADDICT BEHAV, V28, P359, DOI 10.1037/a0036511; Bellino S, 2008, CNS DRUGS, V22,
P671, DOI 10.2165/00023210-200822080-00005; BENTLER PM, 1990, PSYCHOL BULL, V107,
P238, DOI 10.1037/0033-2909.107.2.238; Brown SA, 1998, J STUD ALCOHOL, V59, P427,
DOI 10.15288/jsa.1998.59.427; BROWNE MW, 1989, MULTIVAR BEHAV RES, V24, P445, DOI
10.1207/s15327906mbr2404_4; Byrne B. M., 2010, STRUCTURAL EQUATION; Teresa
Carnevale, 2011, J CHILD ADOL PS NURS, V24, P51, DOI 10.1111/j.1744-
6171.2010.00256.x; Cheetham A, 2010, CLIN PSYCHOL REV, V30, P621, DOI
10.1016/j.cpr.2010.04.005; Cooper M. L., 1994, PSYCHOL ASSESSMENT, V6, P117, DOI
[DOI 10.1037/1040-3590.6.2.117, 10.1037/1040-3590.6.2.117]; Cuijpers P, 2008, EUR
CHILD ADOLES PSY, V17, P32, DOI 10.1007/s00787-007-0631-2; Devore CD, 2012,
PEDIATRICS, V129, P387, DOI 10.1542/peds.2011-3443; Diamond G, 2006, J CHILD ADOLES
SUBST, V15, P37, DOI 10.1300/J029v15n04_02; Dow SJ, 2013, PSYCHOL ADDICT BEHAV,
V27, P1122, DOI 10.1037/a0031065; Effinger JM, 2012, SUICIDE LIFE-THREAT, V42,
P353, DOI 10.1111/j.1943-278X.2012.00092.x; Giannotta F, 2014, J ADOLESCENT HEALTH,
V54, P565, DOI 10.1016/j.jadohealth.2013.10.009; Gijsen R, 2001, J CLIN EPIDEMIOL,
V54, P661, DOI 10.1016/S0895-4356(00)00363-2; Goldberg JF, 2001, J CLIN PSYCHIAT,
V62, P35; Goldstein AL, 2012, ADV MENT HEALTH, V11, P67, DOI
10.5172/jamh.2012.11.1.67; Grano N, 2014, NORD J PSYCHIAT, V68, P93, DOI
10.3109/08039488.2013.768294; Grella CE, 2004, J CHILD ADOLES SUBST, V13, P13, DOI
10.1300/J029v13n04_02; Guttmannova K, 2011, J STUD ALCOHOL DRUGS, V72, P221, DOI
10.15288/jsad.2011.72.221; Hall BC, 2014, PSYCHOL ADDICT BEHAV, V28, P307, DOI
10.1037/a0033845; Hawkins EH, 2009, ANNU REV PSYCHOL, V60, P197, DOI
10.1146/annurev.psych.60.110707.163456; Hoppes K, 2006, CNS SPECTRUMS, V11, P829,
DOI 10.1017/S1092852900014991; Hu L., 1995, STRUCTURAL EQUATION, P76, DOI DOI
10.1080/10705519909540118; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI
10.1080/10705519909540118; Hunter BD, 2014, PSYCHOL ADDICT BEHAV, V28, P507, DOI
10.1037/a0034199; Institute of Medicine, 2006, IMPR QUAL HLTH CAR M; Jerrell JM,
2015, EUR CHILD ADOLES PSY, V24, P65, DOI 10.1007/s00787-014-0541-z; Kann L, 2014,
MMWR SURVEILL SUMM, V63, P1; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231,
DOI 10.3109/10673229709030550; Kline R. B., 1998, PRINCIPLES PRACTICE; Knight DK,
2015, J YOUTH ADOLESCENCE, V44, P1024, DOI 10.1007/s10964-014-0127-6; Kuo ES, 2005,
ASSESSMENT, V12, P374, DOI 10.1177/1073191105279984; Marlatt G., 1985, B SOC
PSYCHOL ADDICT, V4, P123; Marlatt GA, 1996, ADDICTION, V91, pS37, DOI
10.1111/j.1360-0443.1996.tb02326.x; Melnyk BM, 2014, J CHILD ADOL PS NURS, V27, P3,
DOI 10.1111/jcap.12058; Meyers RJ, 1998, J SUBST ABUSE, V10, P291, DOI
10.1016/S0899-3289(99)00003-6; Mezzich AC, 2001, J CHILD ADOLES SUBST, V10, P35,
DOI 10.1300/J029v10n04_04; Minkoff K, 2004, PSYCHIAT CLIN N AM, V27, P727, DOI
10.1016/j.psc.2004.07.003; Moss HB, 2014, DRUG ALCOHOL DEPEN, V136, P51, DOI
10.1016/j.drugalcdep.2013.12.011; National Registry of Evidence-based Programs and
Practices, NAT REG EV BAS PROGR; Nock MK, 2009, J ABNORM PSYCHOL, V118, P816, DOI
10.1037/a0016948; Osman A, 2009, J PSYCHOPATHOL BEHAV, V31, P202, DOI
10.1007/s10862-008-9095-z; Patel V, 2013, J ADOLESCENT HEALTH, V52, P511, DOI
10.1016/j.jadohealth.2013.03.003; Pilowsky DJ, 2013, ADDICT BEHAV, V38, P2146, DOI
10.1016/j.addbeh.2013.01.015; RADLOFF L S, 1977, Applied Psychological Measurement,
V1, P385, DOI 10.1177/014662167700100306; Roberts A, 2005, PALGRAVE HIST LIT, P1;
Rose K, 2014, J CONSULT CLIN PSYCH, V82, P510, DOI 10.1037/a0035827; Selby EA,
2008, BEHAV RES THER, V46, P593, DOI 10.1016/j.brat.2008.02.002; Shiffman S, 2009,
PSYCHOL ASSESSMENT, V21, P486, DOI 10.1037/a0017074; Silk JS, 2003, CHILD DEV, V74,
P1869, DOI 10.1046/j.1467-8624.2003.00643.x; Simons JS, 2006, ADDICT BEHAV, V31,
P1578, DOI 10.1016/j.addbeh.2005.12.004; Smith GT, 2001, ADOLESCENTS, ALCOHOL, AND
SUBSTANCE ABUSE: REACHING TEENS THROUGH BRIEF INTERVENTIONS, P109; Snyder SM, 2014,
J PSYCHOACTIVE DRUGS, V46, P188, DOI 10.1080/02791072.2014.914610; Soleimanpour S,
2010, AM J PUBLIC HEALTH, V100, P1597, DOI 10.2105/AJPH.2009.186833; Sterling S,
2011, ALCOHOL RES HEALTH, V33, P338; Stewart DG, 2011, J DUAL DIAGN, V7, P130, DOI
10.1080/15504263.2011.596454; Substance Abuse and Mental Health Services
Administration (SAM-HSA) Office of Applied Studies, 2013, NSDUH SERIES H, VH-46;
Tarter RE, 2003, AM J PSYCHIAT, V160, P1078, DOI 10.1176/appi.ajp.160.6.1078;
Thorberg FA, 2006, ADDICT BEHAV, V31, P811, DOI 10.1016/j.addbeh.2005.06.008;
Thornton LK, 2012, ADDICT BEHAV, V37, P427, DOI 10.1016/j.addbeh.2011.11.039;
Tomlinson KL, 2012, ADDICT BEHAV, V37, P179, DOI 10.1016/j.addbeh.2011.09.016;
Turner NE, 1997, BEHAV RES THER, V35, P465, DOI 10.1016/S0005-7967(96)00119-2;
Valderas JM, 2009, ANN FAM MED, V7, P357, DOI 10.1370/afm.983; Vander Stoep A,
2005, J EMOT BEHAV DISORD, V13, P213, DOI 10.1177/10634266050130040301; Veilleux
JC, 2014, PERS INDIV DIFFER, V59, P96, DOI 10.1016/j.paid.2013.11.012; Weiner DA,
2001, PSYCHIAT SERV, V52, P793, DOI 10.1176/appi.ps.52.6.793; WHITE HR, 1989, J
STUD ALCOHOL, V50, P30, DOI 10.15288/jsa.1989.50.30; Willem L, 2012, J PSYCHOPATHOL
BEHAV, V34, P282, DOI 10.1007/s10862-012-9279-4; Winters KC, 2007, PSYCHOL ADDICT
BEHAV, V21, P249, DOI 10.1037/0893-164X.21.2.249; Winters KC, 2012, J SUBST ABUSE
TREAT, V42, P279, DOI 10.1016/j.jsat.2011.08.005; Witkiewitz K, 2004, AM PSYCHOL,
V59, P224, DOI 10.1037/0003-066X.59.4.224 75 3 3 0 12 SPRINGER
NEW YORK 233 SPRING ST, NEW YORK, NY 10013 USA 1866-2625 1866-2633
SCH MENT HEALTH School Ment. Health JUN 2015 7 2
147 159 10.1007/s12310-014-9138-4 13
Psychology, Educational; Psychology, Developmental Psychology CH3UF
WOS:000353955200006 2019-09-25
J Delforterie, MJ; Lynskey, MT; Huizink, AC; Creemers, HE; Grant, JD; Few, LR;
Glowinski, AL; Statham, DJ; Trull, TJ; Bucholz, KK; Madden, PAF; Martin, NG; Heath,
AC; Agrawal, A Delforterie, M. J.; Lynskey, M. T.; Huizink, A.
C.; Creemers, H. E.; Grant, J. D.; Few, L. R.; Glowinski, A. L.; Statham, D. J.;
Trull, T. J.; Bucholz, K. K.; Madden, P. A. F.; Martin, N. G.; Heath, A. C.;
Agrawal, A. The relationship between cannabis involvement and suicidal
thoughts and behaviors DRUG AND ALCOHOL DEPENDENCE English
Article Suicidal thoughts and behaviors;
Cannabis use; Cannabis use disorder symptoms SELF-MEDICATION HYPOTHESIS;
ENVIRONMENTAL-INFLUENCES; EPIDEMIOLOGIC EVIDENCE; YOUNG ADULTHOOD; UNITED-STATES;
SUBSTANCE USE; RISK-FACTORS; DRUG-USE; IDEATION; DEPENDENCEBackground: In the
present study, we examined the relationship between cannabis involvement and
suicidal ideation (SI), plan and attempt, differentiating the latter into planned
and unplanned attempt, taking into account other substance involvement and
psychopathology. Methods: We used two community-based twin samples from the
Australian Twin Registry, including 9583 individuals (58.5% female, aged between 27
and 40). The Semi-Structured Assessment of the Genetics of Alcoholism (SSAGA) was
used to assess cannabis involvement which was categorized into: (0) no cannabis use
(reference category); (1) cannabis use only; (2) 1-2 cannabis use disorder
symptoms; (3) 3 or more symptoms. Separate multinomial logistic regression analyses
were conducted for SI and suicide attempt with or without a plan. Twin analyses
examined the genetic overlap between cannabis involvement and SI. Results: All
levels of cannabis involvement were related to SI, regardless of duration (odds
ratios [ORs] = 1.28-2.00, p < 0.01). Cannabis use and endorsing >= 3 symptoms were
associated with unplanned (SANP; ORs = 1.95 and 2.51 respectively, p < 0.05), but
not planned suicide attempts (p > 0.10). Associations persisted even after
controlling for other psychiatric disorders and substance involvement. Overlapping
genetic (rG = 0.45) and environmental (rE = 0.21) factors were responsible for the
covariance between cannabis involvement and SI. Conclusions: Cannabis involvement
is associated, albeit modestly, with SI and unplanned suicide attempts. Such
attempts are difficult to prevent and their association with cannabis use and
cannabis use disorder symptoms requires further study, including in different
samples and with additional attention to confounders. (C) 2015 Published by
Elsevier Ireland Ltd. [Delforterie, M. J.; Huizink, A. C.] Vrije Univ Amsterdam,
Dept Dev Psychol, Amsterdam, Netherlands; [Delforterie, M. J.; Huizink, A. C.] EMGO
Inst Hlth & Care Res, Amsterdam, Netherlands; [Lynskey, M. T.] Kings Coll London,
Inst Psychiatty, Addict Dept, London WC2R 2LS, England; [Creemers, H. E.] Univ
Amsterdam, Res Inst Child Dev & Educ, Amsterdam, Netherlands; [Grant, J. D.; Few,
L. R.; Glowinski, A. L.; Bucholz, K. K.; Madden, P. A. F.; Heath, A. C.; Agrawal,
A.] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA; [Statham, D.
J.] Univ Sunshine Coast, Sch Social Sci, Sippy Downs, Qld, Australia; [Trull, T.
J.] Univ Missouri, Dept Psychol Sci, Columbia, MO USA; [Martin, N. G.] QIMR
Berghofer Med Res Inst, Brisbane, Qld, Australia Agrawal, A (reprint author),
Washington Univ, Sch Med, Dept Psychiat, 660 S Euclid,CB 8134, St Louis, MO 63110
USA. arpana@wustl.edu Lynskey, michael T/B-9179-2016; Martin, Nicholas/R-9235-
2019 Martin, Nicholas/0000-0003-4069-8020 ZonMW, the NetherlandsNetherlands
Organization for Health Research and DevelopmentNetherlands Government [60-60600-
97-154]; CDCCentre National de la Recherche Scientifique (CNRS)United States
Department of Health & Human ServicesCenters for Disease Control & Prevention - USA
[R49CE001510]; Australian NHMRC Centre for Research Excellence on Suicide
Prevention (CRESP)National Health and Medical Research Council of Australia;
National Institute on Drug Abuse (NIDA)United States Department of Health & Human
ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug
Abuse (NIDA) [DA18267]; National Health & Medical Research Council [628911];
[DA32573]; [DA23668]; [AA11998]; [AA07728]; [AA13221]; [T32DA007313];
[DA12854]; [K21DA00272] MD is supported by ZonMW, the Netherlands (60-60600-
97-154). We acknowledge funding from DA32573 and DA23668 (AA), AA11998, AA07728 and
AA13221 (ACH), T32DA007313 (LF). AG is supported by R49CE001510 (CDC). PAFM
received support from DA12854 and K21DA00272. NGM acknowledges support from the
Australian NHMRC Centre for Research Excellence on Suicide Prevention (CRESP, PI Dr
Helen Christensen). Sample 2 was funded by National Institute on Drug Abuse (NIDA)
grants. DA18267 (ML); data collection and facilitated through access to the
Australian Twin Registry, a national resource supported by an Enabling Grant (ID
628911) from the National Health & Medical Research Council. American
Foundation for Suicide Prevention, 2012, UNDERSTANDING SUICID; Borges G, 2000, AM J
EPIDEMIOL, V151, P781; BUCHOLZ KK, 1994, J STUD ALCOHOL, V55, P149, DOI
10.15288/jsa.1994.55.149; Byrne P, 2004, CURR OPIN PSYCHIATR, V17, P255, DOI
10.1097/01.yco.0000133827.11672.42; Calabria B, 2010, DRUG ALCOHOL REV, V29, P318,
DOI 10.1111/j.1465-3362.2009.00149.x; Chen CY, 2005, DRUG ALCOHOL DEPEN, V79, P11,
DOI 10.1016/j.drugalcdep.2004.11.014; Conner KR, 2007, J STUD ALCOHOL DRUGS, V68,
P654, DOI 10.15288/jsad.2007.68.654; Conner KR, 2004, SUICIDE LIFE-THREAT, V34,
P89, DOI 10.1521/suli.34.2.89.32780; Fergusson DM, 2002, ADDICTION, V97, P1123, DOI
10.1046/j.1360-0443.2002.00103.x; Gorzalka BB, 2011, PROG NEURO-PSYCHOPH, V35,
P1575, DOI 10.1016/j.pnpbp.2010.11.021; Harris EC, 1997, BRIT J PSYCHIAT, V170,
P205, DOI 10.1192/bjp.170.3.205; Harriss L, 2005, BRIT J PSYCHIAT, V186, P60, DOI
10.1192/bjp.186.1.60; Johns A, 2001, BRIT J PSYCHIAT, V178, P116, DOI
10.1192/bjp.178.2.116; Joiner TE, 2000, J CONSULT CLIN PSYCH, V68, P909, DOI
10.1037/0022-006X.68.5.909; Kendler KS, 1995, AM J MED GENET, V60, P588, DOI
10.1002/ajmg.1320600622; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI
10.3109/10673229709030550; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259; Kramer
JR, 2009, J STUD ALCOHOL DRUGS, V70, P623, DOI 10.15288/jsad.2009.70.623; Lynskey
MT, 2012, TWIN RES HUM GENET, V15, P631, DOI 10.1017/thg.2012.41; Lynskey MT, 2002,
PSYCHOL MED, V32, P195, DOI 10.1017/S0033291701005062; Lynskey MT, 2004, ARCH GEN
PSYCHIAT, V61, P1026, DOI 10.1001/archpsyc.61.10.1026; Maciejewski DF, 2014, JAMA
PSYCHIAT, V71, P699, DOI 10.1001/jamapsychiatry.2014.89; MAYFIELD DG, 1972, ARCH
GEN PSYCHIAT, V27, P349; Moore THM, 2007, LANCET, V370, P319, DOI 10.1016/S0140-
6736(07)61162-3; Muthen L. K., 1998, MPLUS USERS GUIDE; Neale M, 1992, METHODOLOGY
FOR GENE; Nelson EC, 2002, ARCH GEN PSYCHIAT, V59, P139, DOI
10.1001/archpsyc.59.2.139; Newcomb MD, 1999, J COMMUNITY PSYCHOL, V27, P405, DOI
10.1002/(SICI)1520-6629(199907)27:4<405::AID-JCOP4>3.0.CO;2-2; Nock MK, 2008,
EPIDEMIOL REV, V30, P133, DOI 10.1093/epirev/mxn002; Nock MK, 2008, BRIT J
PSYCHIAT, V192, P98, DOI 10.1192/bjp.bp.107.040113; Nock MK, 2006, J ABNORM
PSYCHOL, V115, P616, DOI 10.1037/0021-843X.115.3.616; Palmer CS, 1995, CLIN
NEUROPHARMACOL, V18, pS25, DOI 10.1097/00002826-199518003-00004; Pedersen W, 2008,
ACTA PSYCHIAT SCAND, V118, P395, DOI 10.1111/j.1600-0447.2008.01259.x; Pompili M,
2012, EUR ARCH PSY CLIN N, V262, P469, DOI 10.1007/s00406-012-0292-0; Price C,
2009, BRIT J PSYCHIAT, V195, P492, DOI 10.1192/bjp.bp.109.065227; Pulkkinen L,
2003, TWIN RES, V6, P106, DOI 10.1375/136905203321536236; ROSSOW I, 1994, SUICIDE
LIFE-THREAT, V24, P174; Satorra A, 2000, ADV ST THEO, V36, P233; Silins E, 2014,
LANCET PSYCHIAT, V1, P286, DOI 10.1016/S2215-0366(14)70307-4; Simon TR, 2001,
SUICIDE LIFE-THREAT, V32, P49, DOI 10.1521/suli.32.1.5.49.24212; Statham DJ, 1998,
PSYCHOL MED, V28, P839, DOI 10.1017/S0033291798006916; Suominen K, 2004, AM J
PSYCHIAT, V161, P562, DOI 10.1176/appi.ajp.161.3.562; van Ours JC, 2013, J HEALTH
ECON, V32, P524, DOI 10.1016/j.jhealeco.2013.02.002; Verweij KJH, 2010, ADDICTION,
V105, P417, DOI 10.1111/j.1360-0443.2009.02831.x; Wagner FA, 2002,
NEUROPSYCHOPHARMACOL, V26, P479, DOI 10.1016/S0893-133X(01)00367-0; Wilcox HC,
2004, DRUG ALCOHOL DEPEN, V76, pS53, DOI 10.1016/j.drugalcdep.2004.08.007; Wilcox
HC, 2010, J AFFECT DISORDERS, V127, P287, DOI 10.1016/j.jad.2010.04.017; World
Health Organization, 2014, PREVENTING SUICIDE A 48 19 19 1 13
ELSEVIER IRELAND LTD CLARE ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK
SHANNON, CO, CLARE, 00000, IRELAND 0376-8716 1879-0046 DRUG ALCOHOL DEPEN
Drug Alcohol Depend. MAY 1 2015 150 98
104 10.1016/j.drugalcdep.2015.02.019 7 Substance
Abuse; Psychiatry Substance Abuse; Psychiatry CG8YF WOS:000353600900013
25772435 Green Accepted 2019-09-25
J Maremmani, AGI; Bacciardi, S; Gehring, ND; Cambioli, L; Schutz, C; Akiskal,
HS; Jang, K; Krausz, M Maremmani, Angelo Giovanni Icro;
Bacciardi, Silvia; Gehring, Nicole D.; Cambioli, Luca; Schuetz, Christian; Akiskal,
Hagop S.; Jang, Kerry; Krausz, Michael The impact of mood
symptomatology on pattern of substance use among homeless JOURNAL OF AFFECTIVE
DISORDERS English Article
Homeless; Substance use; Bipolar depression; Unipolar depression; Mood
disorder; Self-medication SELF-MEDICATION HYPOTHESIS; COMORBID BIPOLAR
DISORDER; QUALITY-OF-LIFE; DRUG-ABUSE; MENTAL-ILLNESS; HEROIN-ADDICTS; PSYCHIATRIC-
DISORDERS; ALCOHOL DEPENDENCE; COCAINE ABUSE; AFFECTIVE TEMPERAMENTS Background:
Homeless individuals are an extremely vulnerable and underserved population
characterized by overlapping problems of mental illness and substance use. Given
the fact that mood disorders are frequently associated with substance use
disorders, we wanted to further highlight the role of excitement in substance
abuse. Patterns of substance abuse among homeless suffering from unipolar and
bipolar depression were compared. The "self-medication hypothesis" which would
predict no-differences in substance preference by unipolar (UP) and bipolar (BP)
depressed homeless was tested. Methods: Homeless individuals from the Vancouver At
Home/Chez Soi study were selected for lifetime UP and lifetime BP depression and
patterns of substances abused in the previous 12 months were identified with the
Mini-International Neuropsychiatric Interview. Differences in substance use between
BP-depressed homeless and UP-depressed homeless were tested using Chi-square and
logistic regression techniques. Results: No significant differences were observed
between UP and BP homeless demographics. The bipolar depressed homeless (BDH) group
displayed a higher percentage of Central Nervous System (CNS) Stimulants (chi 8.66,
p=0.004) and Opiates (chi 641, p=0.013) as compared to the unipolar depressed
homeless (UDH) group. CSN Stimulant was the only predictor within the BDH Group
(chi(2) 8.74 df 1 p < 0.003). Limitations: Data collected are self-reported and no
urinalyses were performed. Conclusions: The results support the hypothesis that
beyond the self-medication hypothesis, bipolarity is strictly correlated to
substance use; this correlation is also verified in a homeless population. (C) 2015
Elsevier B.V. All rights reserved. [Maremmani, Angelo Giovanni Icro; Bacciardi,
Silvia] Univ Pisa, Dept Clin & Expt Med, Vincent P Dole Dual Diag Unit, I-56100
Pisa, Italy; [Maremmani, Angelo Giovanni Icro] Assoc Applicat Neurosci Knowledge
Social Aims AU, Pietrasanta, Lucca, Italy; [Gehring, Nicole D.; Krausz, Michael] St
Pauls Hosp, Ctr Hlth Evaluat & Outcome Sci, Vancouver, BC V6Z 1Y6, Canada;
[Cambioli, Luca] Univ Bicocca, Milan, Italy; [Gehring, Nicole D.; Krausz, Michael]
Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC V5Z 1M9, Canada;
[Gehring, Nicole D.; Schuetz, Christian; Krausz, Michael] Univ British Columbia,
Dept Psychiat, Inst Mental Hlth, Vancouver, BC, Canada; [Schuetz, Christian; Jang,
Kerry; Krausz, Michael] Univ British Columbia, Dept Psychiat, Vancouver, BC,
Canada; [Akiskal, Hagop S.] Univ Calif San Diego, Int Mood Ctr, San Diego, CA 92103
USA; [Akiskal, Hagop S.] Vet Adm Hosp, San Diego, CA USA Maremmani, AGI (reprint
author), Univ Pisa, Santa Chiara Univ Hosp, Dept Clin & Expt Med, Vincent P Dole
Dual Diag Unit, Via Roma 67, I-56100 Pisa, Italy. angelogimaremmani@gmail.com
Gehring, Nicole/0000-0002-5275-3413; Maremmani, Angelo Giovanni Icro/0000-
0001-7728-3705 Mental Health Commission of Canada (MHCC)-a Health Canada The
database-source At Home/Chez Soi Vancouver was funded by the Mental Health
Commission of Canada (MHCC)-a Health Canada mandate. The Mental Health Commission
of Canada (MHCC) played no role in study design; nor in the collection, analysis
and interpretation of data; nor in the writing of the report; nor in the decision
to submit the paper for publication. Agrawal A, 2011, PSYCHIAT RES, V185,
P459, DOI 10.1016/j.psychres.2010.07.007; Albanese Mark J, 2006, J Psychiatr Pract,
V12, P124, DOI 10.1097/00131746-200603000-00010; APA, 1994, DIAGN STAT MAN MENT;
Appel PW, 2001, J PSYCHOACTIVE DRUGS, V33, P47, DOI 10.1080/02791072.2001.10400468;
Arias F, 2013, ACTAS ESP PSIQUIATRI, V41, P122; Ashton CH, 2005, J PSYCHOPHARMACOL,
V19, P293, DOI 10.1177/0269881105051541; Bacciardi S, 2013, HEROIN ADDICT REL CL,
V15, P29; Bally N, 2014, J AFFECT DISORDERS, V165, P103, DOI
10.1016/j.jad.2014.04.038; BERNADT MW, 1986, BRIT J PSYCHIAT, V148, P393, DOI
10.1192/bjp.148.4.393; Brousse G, 2008, PRESSE MED, V37, P1132, DOI
10.1016/j.lpm.2007.09.020; Brown ES, 2001, J AFFECT DISORDERS, V65, P105, DOI
10.1016/S0165-0327(00)00169-5; Brunette MF, 2003, PSYCHIAT SERV, V54, P1395, DOI
10.1176/appi.ps.54.10.1395; Camacho A, 2005, J AFFECT DISORDERS, V85, P217, DOI
10.1016/j.jad.2003.10.014; Carvalho AF, 2014, J AFFECT DISORDERS, V163, P56, DOI
10.1016/j.jad.2014.03.035; Cerullo MA, 2007, SUBST ABUSE TREAT PR, V2, DOI
10.1186/1747-597X-2-29; Chengappa KNR, 2000, BIPOLAR DISORD, V2, P191, DOI
10.1034/j.1399-5618.2000.020306.x; COCORES JA, 1987, J NERV MENT DIS, V175, P431,
DOI 10.1097/00005053-198707000-00007; Colom F, 2009, PSYCHOPATHOLOGY, V42, P209,
DOI 10.1159/000218518; COMFORT A, 1977, LANCET, V2, P448; Dell'osso L., 2012, J
AFFECTIVE DISORDER; DMELLO DA, 1995, AM J DRUG ALCOHOL AB, V21, P257, DOI
10.3109/00952999509002693; Do EK, 2013, J AFFECT DISORDERS, V150, P974, DOI
10.1016/j.jad.2013.05.023; Dorus W., 1980, AM J PSYCHIAT, V137, P669; DUNNER D L,
1979, American Journal of Psychiatry, V136, P583; Edens EL, 2011, WOMEN HEALTH ISS,
V21, P383, DOI 10.1016/j.whi.2011.03.004; EMRICH HM, 1982, LANCET, V2, P709;
ESTROFF TW, 1985, INT J PSYCHIAT MED, V15, P37; Farren CK, 2013, ALCOHOL
ALCOHOLISM, V48, P93, DOI 10.1093/alcalc/ags112; Fazel S, 2008, PLOS MED, V5,
P1670, DOI 10.1371/journal.pmed.0050225; Fichter MM, 2001, ACTA PSYCHIAT SCAND,
V103, P94, DOI 10.1034/j.1600-0447.2001.00217.x; FISCHER PJ, 1991, AM PSYCHOL, V46,
P1115, DOI 10.1037/0003-066X.46.11.1115; Fletcher K, 2013, J AFFECT DISORDERS,
V150, P50, DOI 10.1016/j.jad.2013.02.018; Folsom D, 2002, ACTA PSYCHIAT SCAND,
V105, P404, DOI 10.1034/j.1600-0447.2002.02209.x; Folsom DP, 2005, AM J PSYCHIAT,
V162, P370, DOI 10.1176/appi.ajp.162.2.370; Foster A, 2012, PSYCHIAT CLIN N AM,
V35, P717, DOI 10.1016/j.psc.2012.06.010; FREED EX, 1969, PSYCHOL REP, V25, P280,
DOI 10.2466/pr0.1969.25.1.280; Galvao F, 2013, COMPR PSYCHIAT, V54, P605, DOI
10.1016/j.comppsych.2012.12.023; Goering PN, 2011, BMJ OPEN, V1, DOI
10.1136/bmjopen-2011-000323; GOLD MS, 1982, ANN NY ACAD SCI, V398, P140, DOI
10.1111/j.1749-6632.1982.tb39488.x; Goldberg J F, 2001, J Psychiatr Pract, V7,
P109, DOI 10.1097/00131746-200103000-00004; Grant BF, 2004, ARCH GEN PSYCHIAT, V61,
P807, DOI 10.1001/archpsyc.61.8.807; HASIN D, 1985, COMPR PSYCHIAT, V26, P283, DOI
10.1016/0010-440X(85)90073-2; Haugland G, 1997, PSYCHIATR SERV, V48, P504; HELZER
JE, 1988, J STUD ALCOHOL, V49, P219, DOI 10.15288/jsa.1988.49.219; HENSEL B, 1979,
J AFFECT DISORDERS, V1, P105, DOI 10.1016/0165-0327(79)90029-6; Hesselbrock VM,
2006, ADDICTION, V101, P97, DOI 10.1111/j.1360-0443.2006.01596.x; Khantzian EJ,
2009, J CLIN PSYCHIAT, V70, P935, DOI 10.4088/JCP.08lr04878; Khantzian EJ, 1997,
HARVARD REV PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550; KHANTZIAN EJ, 1985,
AM J PSYCHIAT, V142, P1259; Khazaal Y, 2013, PSYCHIAT QUART, V84, P429, DOI
10.1007/s11126-013-9257-3; Kicanizian E.J., 2009, J CLIN PSYCHIAT, V70, P936;
Kilbourne AM, 2010, GEN HOSP PSYCHIAT, V32, P636, DOI
10.1016/j.genhosppsych.2010.09.011; KOEGEL P, 1988, ARCH GEN PSYCHIAT, V45, P1085;
KOSTEN TR, 1986, SUBSTANCE ABUSE PSIC, P515; Krausz RM, 2013, SOC PSYCH PSYCH EPID,
V48, P1235, DOI 10.1007/s00127-012-0649-8; Kushel MB, 2001, JAMA-J AM MED ASSOC,
V285, P200, DOI 10.1001/jama.285.2.200; LAMBERT EY, 1995, PUBLIC HEALTH REP, V110,
P455; Lee TC, 2005, CIRCULATION, V111, P2629, DOI
10.1161/CIRCULATIONAHA.104.510826; LEHMAN WX, 1972, P 4 NAT C METH TREAT, P95;
Leventhal AM, 2011, DRUG ALCOHOL DEPEN, V116, P163, DOI
10.1016/j.drugalcdep.2010.12.012; Lin SC, 2011, HUM PSYCHOPHARM CLIN, V26, P201,
DOI 10.1002/hup.1193; Maremmani AGI, 2014, EUROPEAN REV MED PHA; Maremmani AGI,
2013, HEROIN ADDICT REL CL, V15, P25; Maremmani AGI, 2014, J ADDICT MED, V8, P116,
DOI 10.1097/ADM.0000000000000019; Maremmani AGI, 2013, HEROIN ADDICT REL CL, V15,
P57; Maremmani I, 2004, J PSYCHOACTIVE DRUGS, V36, P235, DOI
10.1080/02791072.2004.10399734; Maremmani I, 2000, J ADDICT DIS, V19, P29, DOI
10.1300/J069v19n02_03; Maremmani I., 2000, HEROIN ADDICT REL CL, V2, P39; Maremmani
I., 1994, NEW TRENDS EXPT CLIN, P179; Maremmani I., 2005, HEROIN ADDICT REL CL, V7,
P33; Maremmani I., 2000, HEROIN ADDICT REL CL, V2, P35; Maremmani I, 2008, J AFFECT
DISORDERS, V106, P55, DOI 10.1016/j.jad.2007.03.015; Maremmani Icro, 2002, Ann Ist
Super Sanita, V38, P241; Maremmani I, 2006, J AFFECT DISORDERS, V93, P1, DOI
10.1016/j.jad.2006.02.022; Maremmani I, 2012, ANN GEN PSYCHIATR, V11, DOI
10.1186/1744-859X-11-23; Maremmani I, 2006, ADDICT DISORD TREAT, V5, P1, DOI
10.1097/01.adt.0000210703.70788.65; Maremmani I, 2009, J AFFECT DISORDERS, V117,
P186, DOI 10.1016/j.jad.2009.01.007; Merikangas KR, 2008, ARCH GEN PSYCHIAT, V65,
P47, DOI 10.1001/archgenpsychiatry.2007.18; MILLER FT, 1989, AM J DRUG ALCOHOL AB,
V15, P291, DOI 10.3109/00952998908993409; MIRIN SM, 1986, PSYCHIAT CLIN N AM, V9,
P503; MUESER KT, 1992, ACTA PSYCHIAT SCAND, V85, P48, DOI 10.1111/j.1600-
0447.1992.tb01441.x; Nallet A, 2013, EUR PSYCHIAT, V28, P147, DOI
10.1016/j.eurpsy.2011.07.004; Nery FG, 2010, J PSYCHIATR RES, V44, P278, DOI
10.1016/j.jpsychires.2009.09.006; North CS, 2010, SOC PSYCH PSYCH EPID, V45, P1055,
DOI 10.1007/s00127-009-0144-z; North CS, 2004, AM J PUBLIC
HEALTH, V94, P103, DOI 10.2105/AJPH.94.1.103; Nower L., 2014, J GAMBLING STUDIES;
NUNES EV, 1989, PSYCHIAT RES, V28, P105, DOI 10.1016/0165-1781(89)90202-3; O'Toole
TP, 2004, J URBAN HEALTH, V81, P606, DOI 10.1093/jurban/jth144; Olfson M, 2005, AM
J PSYCHIAT, V162, P2146, DOI 10.1176/appi.ajp.162.11.2146; Pacini M, 2010, ADDICT
DISORD TREAT, V9, P164, DOI 10.1097/ADT.0b013e3181f954f2; Palepu A, 2013, J URBAN
HEALTH, V90, P740, DOI 10.1007/s11524-012-9775-6; Pani PP, 2010, J AFFECT
DISORDERS, V122, P185, DOI 10.1016/j.jad.2009.06.012; Patterson M, 2013, SOC PSYCH
PSYCH EPID, V48, P1245, DOI 10.1007/s00127-013-0719-6; Perugi G, 2002, J CLIN
PSYCHOPHARM, V22, P584, DOI 10.1097/00004714-200212000-00008; Popovic D, 2014, ACTA
PSYCHIAT SCAND, V129, P366, DOI 10.1111/acps.12179; Post RM, 2013, BRIT J PSYCHIAT,
V202, P172, DOI 10.1192/bjp.bp.112.116855; Rastelli CPB, 2013, J AFFECT DISORDERS,
V150, P1120, DOI 10.1016/j.jad.2013.05.003; REGIER DA, 1990, JAMA-J AM MED ASSOC,
V264, P2511; Schlaff G, 2011, ANN GASTROENTEROL, V24, P89; Schutz C, 2013, BMC
HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-288; Scott EM, 2013, J AFFECT
DISORDERS, V144, P208, DOI 10.1016/j.jad.2012.06.031; Sheehan DV, 1998, J CLIN
PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Somers JM, 2013, TRIALS, V14, DOI
10.1186/1745-6215-14-365; STEER RA, 1980, DRUG ALCOHOL DEPEN, V5, P115, DOI
10.1016/0376-8716(80)90187-8; Strakowski SM, 2000, CLIN PSYCHOL REV, V20, P191, DOI
10.1016/S0272-7358(99)00025-2; Sullivan G, 2000, PSYCHIATR SERV, V51, P1135, DOI
10.1176/appi.ps.51.9.1135; Swann AC, 2004, BIPOLAR DISORD, V6, P204, DOI
10.1111/j.1399-5618.2004.00110.x; Taplin C., 2014, SUBSTANCE USE MISUSE; Torchalla
I, 2011, DRUG ALCOHOL DEPEN, V118, P173, DOI 10.1016/j.drugalcdep.2011.03.016;
Vazquez C, 1997, ACTA PSYCHIAT SCAND, V95, P523, DOI 10.1111/j.1600-
0447.1997.tb10141.x; Velasquez MM, 2000, J SUBST ABUSE TREAT, V19, P395, DOI
10.1016/S0740-5472(00)00133-1; Vila-Rodriguez F, 2013, AM J PSYCHIAT, V170, P1413,
DOI 10.1176/appi.ajp.2013.12111439; Weiss R.D, 1989, J CLIN PSYCHIAT S, V50, P9;
WEISS RD, 1989, J CLIN PSYCHIAT, V50, P4; WEISS RD, 1986, PSYCHIAT CLIN N AM, V9,
P491; WHO, 1992, ICD 10 CLASS MENT BE; Wieland W.F., 1970, P 3 NAT C METH TREAT,
P187 117 7 7 0 18 ELSEVIER SCIENCE BV AMSTERDAM PO BOX 211,
1000 AE AMSTERDAM, NETHERLANDS 0165-0327 1573-2517 J AFFECT DISORDERS
J. Affect. Disord. MAY 1 2015 176 164
170 10.1016/j.jad.2015.01.059 7 Clinical
Neurology; Psychiatry Neurosciences & Neurology; Psychiatry CD3JV
WOS:000350975500022 25723559 2019-09-25
J Gonzalez-Ortega, I; Alberich, S; Echeburua, E; Aizpuru, F; Millan, E; Vieta,
E; Matute, C; Gonzalez-Pinto, A Gonzalez-Ortega, Itxaso;
Alberich, Susana; Echeburua, Enrique; Aizpuru, Felipe; Millan, Eduardo; Vieta,
Eduard; Matute, Carlos; Gonzalez-Pinto, Ana Subclinical Depressive
Symptoms and Continued Cannabis Use: Predictors of Negative Outcomes in First
Episode Psychosis PLOS ONE English Article
SUBSTANCE USE DISORDERS; PSYCHIATRIC-DISORDERS; SELF-MEDICATION;
AXIS I; SCHIZOPHRENIA; ASSOCIATION; DEPENDENCE; SEVERITY; TRIAL; SCALE Background
Although depressive symptoms in first episode psychosis have been associated with
cannabis abuse, their influence on the long-term functional course of FEP patients
who abuse cannabis is unknown. The aims of the study were to examine the influence
of subclinical depressive symptoms on the long-term outcome in first episode-
psychosis patients who were cannabis users and to assess the influence of these
subclinical depressive symptoms on the ability to quit cannabis use. Methods 64 FEP
patients who were cannabis users at baseline were followed-up for 5 years. Two
groups were defined: (a) patients with subclinical depressive symptoms at least
once during follow-up (DPG), and (b) patients without subclinical depressive
symptoms during follow-up (NDPG). Psychotic symptoms were measured using the
Positive and Negative Syndrome Scale (PANSS), depressive symptoms using the
Hamilton Depression Rating Scale (HDRS)-17, and psychosocial functioning was
assessed using the Global Assessment of Functioning (GAF). A linear mixed-effects
model was used to analyze the combined influence of cannabis use and subclinical
depressive symptomatology on the clinical outcome. Results Subclinical depressive
symptoms were associated with continued abuse of cannabis during follow-up
(beta=4.45; 95% confidence interval [CI]: 1.78 to 11.17; P=.001) and with worse
functioning (beta=-5.50; 95% CI: -9.02 to -0.33; P=.009). Conclusions Subclinical
depressive symptoms and continued cannabis abuse during follow-up could be
predictors of negative outcomes in FEP patients. [Gonzalez-Ortega, Itxaso;
Alberich, Susana; Echeburua, Enrique; Gonzalez-Pinto, Ana] Univ Basque Country,
Univ Hosp Alava Santiago, CIBERSAM, Dept Psychiat, Vitoria, Spain; [Aizpuru,
Felipe] Osakidetza, Araba Res Unit, Vitoria, Spain; [Millan, Eduardo] Osakidetza,
Direcc Asistencia Sanit, Vitoria, Spain; [Vieta, Eduard] Univ Barcelona, Hosp Clin,
IDIBAPS, CIBERSAM,Inst Biosci,Bipolar Disorders Program, Barcelona, Spain; [Matute,
Carlos] Univ Basque Country, Achucarro Basque Ctr Neurosci, CIBERNED, Leioa, Spain
Gonzalez-Ortega, I (reprint author), Univ Basque Country, Univ Hosp Alava
Santiago, CIBERSAM, Dept Psychiat, Vitoria, Spain.
itxaso.gonzalezortega@osakidetza.net Matute, Carlos/N-5559-2014; Vieta,
Eduard/Y-2919-2019; Echeburua, Enrique/F-9033-2010; Vieta, Eduard/I-6330-2013
Echeburua, Enrique/0000-0001-7654-0781; Matute, Carlos/0000-0001-8672-711X;
Vieta, Eduard/0000-0002-0548-0053 Spanish GovernmentSpanish Government
[PS09/02002, EC10-333, PI10/01430, PI10/01746, PI11/01977, PI11/02708, 2011/1064,
11-BI-01, 1677-DJ-030, EC10-220]; European Regional Development FundsEuropean Union
(EU); Basque Country GovernmentBasque Government [2008111010, 2009111047,
2010111170, 2010112009, 2011111110, 2011111113, SAIO10-PC10BF01, SAIO11-PE11BF006,
SAIO11-PE11BF007, SAIO10-PR10BF01, GIC 10/80, KRONIK 11/010]; Basque Foundation for
Health Innovation and Research (BIOEF) [BIO09/EM/010]; Spanish Clinical Research
Network (CAIBER) [1392-D-079]; University of the Basque CountryUniversity of Basque
Country [GIC10/80, US10/08, EHU08/54]; Stanley Research Foundation [03-RC-003]
This work was supported by health research funds from the Spanish Government
(PS09/02002 CIBER Network; EC10-333, PI10/01430, PI10/01746, PI11/01977,
PI11/02708, 2011/1064, 11-BI-01, 1677-DJ-030, and EC10-220); European Regional
Development Funds, and local grants from the Basque Country Government (2008111010,
2009111047, 2010111170, 2010112009, 2011111110, 2011111113, SAIO10-PC10BF01,
SAIO11-PE11BF006, SAIO11-PE11BF007, SAIO10-PR10BF01, GIC 10/80, and KRONIK 11/010);
the Basque Foundation for Health Innovation and Research (BIOEF; BIO09/EM/010); the
Spanish Clinical Research Network (CAIBER; 1392-D-079) and the University of the
Basque Country (GIC10/80, US10/08, and EHU08/54). The psychiatric research
department in University Hospital of Alava-Santiago is supported by the Stanley
Research Foundation (03-RC-003). These institutions had no further role in the
study design, data collection, analysis or interpretation, writing of the report,
or in the decision to submit the paper for publication. Allsop DJ, 2012, PLOS
ONE, V7, DOI 10.1371/journal.pone.0044864; American Psychiatric Association, 2000,
DIAGN STAT MAN MENT; Arendt M, 2007, PSYCHOL MED, V37, P935, DOI
10.1017/S0033291706009688; Barrigon ML, 2010, J PSYCHIATR RES, V44, P413, DOI
10.1016/j.jpsychires.2009.10.004; Barrowclough C, 2013, SCHIZOPHRENIA BULL, V39,
P339, DOI 10.1093/schbul/sbr152; Birchwood M, 2005, EUR ARCH PSY CLIN N, V255,
P202, DOI 10.1007/s00406-005-0588-4; Bobes J, 2002, BANCO INSTRUMENTOS B; Bossong
MG, 2013, EUR NEUROPSYCHOPHARM, V23, P1687, DOI 10.1016/j.euroneuro.2013.06.009;
Campos AC, 2012, PHILOS T R SOC B, V367, P3364, DOI 10.1098/rstb.2011.0389; Chen
RQ, 2013, CELL, V155, P1154, DOI 10.1016/j.cell.2013.10.042; Clausen L, 2014,
PSYCHOL MED, V44, P117, DOI 10.1017/S0033291713000433; Cotton SM, 2012, SCHIZOPHR
RES, V134, P20, DOI 10.1016/j.schres.2011.08.018; D'Souza DC, 2005, BIOL PSYCHIAT,
V57, P594, DOI 10.1016/j.biopsych.2004.12.006; Degenhardt L, 2003, ADDICTION, V98,
P1493, DOI 10.1046/j.1360-0443.2003.00437.x; Degenhardt L, 2007, ADDICTION, V102,
P1076, DOI 10.1111/j.1360-0443.2007.01839.x; Denson TF, 2006, ADDICT BEHAV, V31,
P738, DOI 10.1016/j.addbeh.2005.05.052; ENDICOTT J, 1976, ARCH GEN PSYCHIAT, V33,
P766; First M. B., 1997, STRUCTURED CLIN INTE; Gonzalez-Pinto A, 2008, J CLIN
PSYCHIAT, V69, P1210, DOI 10.4088/JCP.v69n0802; Gonzalez-Pinto A, 2011,
SCHIZOPHRENIA BULL, V37, P631, DOI 10.1093/schbul/sbp126; Gregg L, 2014, PSYCHOL
ADDICT BEHAV, V28, P247, DOI 10.1037/a0034761; Hall W, 2009, LANCET, V374, P1383,
DOI 10.1016/S0140-6736(09)61037-0; HAMILTON M, 1967, BRIT J SOC CLIN PSYC, V6,
P278; Hartley S, 2013, ACTA PSYCHIAT SCAND, V128, P327, DOI 10.1111/acps.12080;
Hjorthoj CR, 2013, SCHIZOPHR RES, V151, P191, DOI 10.1016/j.schres.2013.10.014; KAY
SR, 1987, SCHIZOPHRENIA BULL, V13, P261, DOI 10.1093/schbul/13.2.261; Kokkevi A,
1995, EUR ADDICT RES, V1, P208, DOI DOI 10.1159/000259089; Kuepper R, 2013, PLOS
ONE, V8, DOI 10.1371/journal.pone.0070378; Lev-Ran S, 2014, PSYCHOL MED, V44, P797,
DOI 10.1017/S0033291713001438; Lynskey MT, 2004, ARCH GEN PSYCHIAT, V61, P1026, DOI
10.1001/archpsyc.61.10.1026; Madigan K, 2013, SCHIZOPHR RES, V143, P138, DOI
10.1016/j.schres.2012.10.018; MCLELLAN AT, 1992, J SUBST ABUSE TREAT, V9, P199, DOI
10.1016/0740-5472(92)90062-S; Moore THM, 2007, LANCET, V370, P319, DOI
10.1016/S0140-6736(07)61162-3; National Institute for Health and Clinical
Excellence, 2009, DEPR AD CHRON PHYS H; Otten R, 2013, ADDICT BIOL, V18, P826, DOI
10.1111/j.1369-1600.2011.00380.x; Peralta MV, 1994, ACTAS LUSO-ESP NEUR, V22, P171;
R Development, R LANG ENV STAT COMP; Ramos-Brieva J A, 1986, Actas Luso Esp Neurol
Psiquiatr Cienc Afines, V14, P324; Riedel M, 2012, WORLD J BIOL PSYCHIA, V13, P30,
DOI 10.3109/15622975.2011.552633; Romm KL, 2010, J NERV MENT DIS, V198, P67, DOI
10.1097/NMD.0b013e3181c81fc0; Ruiz-Veguilla M, 2013, J PSYCHIATR RES, V47, P1036,
DOI 10.1016/j.jpsychires.2013.03.003; Schofield D, 2006, AUST NZ J PSYCHIAT, V40,
P570, DOI 10.1080/j.1440-1614.2006.01840.x; Secora AM, 2010, J ADDICT DIS, V29,
P325, DOI 10.1080/10550887.2010.489444; Sonmez N, 2013, BMC PSYCHIATRY, V13, DOI
10.1186/1471-244X-13-106; Stone JM, 2014, PSYCHOL MED, V44, P499, DOI
10.1017/S0033291713000883; Tomlinson KL, 2006, ADDICT BEHAV, V31, P461, DOI
10.1016/j.addbeh.2005.05.028; Tosato S, 2013, J PSYCHIATR RES, V47, P438, DOI
10.1016/j.jpsychires.2012.11.009; Upthegrove R, 2010, ACTA PSYCHIAT SCAND, V122,
P211, DOI 10.1111/j.1600-0447.2009.01506.x; van Gastel WA, 2013, PSYCHOL MED, V43,
P1849, DOI 10.1017/S0033291712002723; Wu LT, 2013, J PSYCHIATR RES, V47, P1940, DOI
10.1016/j.jpsychires.2013.08.022; Wu LT, 2011, J PSYCHIATR RES, V45, P1453, DOI
10.1016/j.jpsychires.2011.06.012; Zimmerman M, 2013, J AFFECT DISORDERS, V150,
P384, DOI 10.1016/j.jad.2013.04.028 52 8 8 0 22 PUBLIC LIBRARY
SCIENCE SAN FRANCISCO 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111
USA 1932-6203 PLOS ONE PLoS One APR 15 2015 10 4
e0123707 10.1371/journal.pone.0123707
12 Multidisciplinary Sciences Science & Technology - Other Topics CG1EL
WOS:000353015800111 25875862 DOAJ Gold, Green Published
2019-09-25
J Posselt, M; Procter, N; Galletly, C; de Crespigny, C
Posselt, Miriam; Procter, Nicholas; Galletly, Cherrie; de Crespigny,
Charlotte Aetiology of Coexisting Mental Health and Alcohol and Other
Drug Disorders: Perspectives of Refugee Youth and Service Providers AUSTRALIAN
PSYCHOLOGIST English Article
comorbidity; mental health; refugee; service provision; substance use; youth
POSTTRAUMATIC-STRESS-DISORDER; SUBSTANCE-ABUSE; YOUNG REFUGEES; TRAUMA;
COMORBIDITY; PEOPLE In the general population, people with comorbid mental
health (MH) and alcohol and other drug (AOD) disorders (comorbidity) have great
difficulty accessing appropriate services, and poor outcomes. Little is known about
comorbidity in resettled refugees in Australia. This study was designed to identify
risk factors and patterns of comorbidity development in young people from refugee
backgrounds living in a disadvantaged urban region of Adelaide, South Australia.
This qualitative study utilised in-depth semi-structured interviews (n = 30) with
resettled refugee youth and workers from MH, AOD, and refugee support services.
Thematic analyses were conducted to investigate the aetiology of MH and AOD
disorders in young refugees. Interviews with both groups revealed how the
interrelated nature of risk factors may place young people from refugee backgrounds
at heightened risk of experiencing MH and AOD problems. The situations and
conditions described by both groups are discussed under six main themes: pre-
migration experiences of torture and trauma; familial factors of intergenerational
conflict; post-migration adjustment difficulties in terms of language, culture,
education, and employment; exposure to and availability of substances; maladaptive
coping strategies and self-medication; and access to information and services.
Implications for psychologists and MH professionals are identified, emphasising the
need for clinicians to understand the complexities surrounding the aetiology of
comorbidity in these youth. The initial assessment needs to be comprehensive,
including pre-and post-settlement experiences and cultural and family dimensions of
their current situation. Treatment may often need to simultaneously address
multiple contributing factors and involve culturally sensitive psychoeducation.
[Posselt, Miriam; Galletly, Cherrie] Univ Adelaide, Discipline Psychiat,
Adelaide, SA 5000, Australia; [Procter, Nicholas] Univ S Australia, Sch Nursing &
Midwifery, Adelaide, SA 5001, Australia; [Galletly, Cherrie; de Crespigny,
Charlotte] Univ Adelaide, Sch Nursing, Adelaide, SA 5000, Australia Posselt, M
(reprint author), Univ Adelaide, Discipline Psychiat, Sch Med, Level 4,Eleanor
Harrald Bldg,Frome Rd, Adelaide, SA 5000, Australia.
miriam.posselt@adelaide.edu.au Procter, Nicholas/G-1992-2011; Procter,
Nicholas/O-6227-2019; Ucar, Abdullah/P-8329-2017 Procter, Nicholas/0000-0002-
7289-3165; Procter, Nicholas/0000-0002-7289-3165; Posselt, Miriam/0000-0003-1668-
9933 Australian Research Council Linkage GrantAustralian Research Council We
wish to acknowledge an Australian Research Council Linkage Grant for supporting
this research. Allsop S., 2008, DRUG USE MENTAL HLTH; Athanasos Peter, 2010,
Aust Nurs J, V18, P38; Australian Bureau of Statistics, 2006, SOC ATL 2006 CENS PO;
Australian Bureau of Statistics, 2007, NAT SURV MENT HLTH W; BEYER L, 2000, DRUGS
MULTICULTURAL; Breslau N, 2003, ARCH GEN PSYCHIAT, V60, P289, DOI
10.1001/archpsyc.60.3.289; Brough M, 2003, AUST J SOC ISSUES, V38, P193, DOI
10.1002/j.1839-4655.2003.tb01142.x; Brune M, 2003, EUR ADDICT RES, V9, P144, DOI
10.1159/000070985; Burns J, 2009, COUNSELLING PSYCHOTH, V5, P171; Canaway R, 2010,
AUST HEALTH REV, V34, P262, DOI 10.1071/AH08723; Colucci E., 2012, BARRIESRS
FACILITATO; Crome IB, 2004, ACTA NEUROPSYCHIATR, V16, P47, DOI 10.1111/j.1601-
5215.2004.0058.x; Davidson N, 2004, J PAEDIATR CHILD H, V40, P562, DOI
10.1111/j.1440-1754.2004.00465.x; De Anstiss H, 2010, AUST PSYCHOL, V45, P29, DOI
10.1080/00050060903262387; Deady M., 2013, ONE PERSON DIVERSE N; Denzin NK, 1970,
RES ACT SOCIOLOGY TH; Department of Immigration and Border Protection, 2014, SETTL
REP FAC; Desmond K., 2004, BARRIERS SERVICE PRO; Dow HD, 2011, HOME HLTH CARE MAN
P, V23, P210, DOI 10.1177/1084822310390878; Fazel M, 2005, LANCET, V365, P1309, DOI
10.1016/S0140-6736(05)61027-6; Fazel M, 2003, BRIT MED J, V327, P134, DOI
10.1136/bmj.327.7407.134; Fossey E, 2002, AUST NZ J PSYCHIAT, V36, P717, DOI
10.1046/j.1440-1614.2002.01100.x; Glover J, 2006, SOCIAL HLTH ATLAS S; Howard M,
2000, J AM ACAD CHILD PSY, V39, P368, DOI 10.1097/00004583-200003000-00020;
KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259; Mario-Ring A, 2005, FUN FORGETTING
ALCOH; MCFALL ME, 1992, J STUD ALCOHOL, V53, P357, DOI 10.15288/jsa.1992.53.357;
McGorry P., 2006, YOUTH MENTAL HLTH SE; Merkes M, 2010, BMC HEALTH SERV RES, V10,
DOI 10.1186/1472-6963-10-325; Mills KL, 2006, AM J PSYCHIAT, V163, P652, DOI
10.1176/appi.ajp.163.4.652; Porter M, 2005, JAMA-J AM MED ASSOC, V294, P602, DOI
10.1001/jama.294.5.602; Reason P., 1994, HDB QUALITATIVE RES, P324; Refugee Council
of Australia, 2009, AMPL VOIC YOUNG REF; Rempfer M., 2002, OCCUPATIONAL THERAPY,
V17, P151, DOI [10.1300/J004v17n03_10, DOI 10.1300/J004V17N03_10]; Saint-Jean G,
2008, J IMMIGR MINOR HEALT, V10, P187, DOI 10.1007/s10903-007-9060-z; Schweitzer R,
2006, AUST NZ J PSYCHIAT, V40, P179, DOI 10.1111/j.1440-1614.2006.01766.x; Sowey
H., 2005, ARE REFUGEES INCREAS; Tamasese K, 2005, AUST NZ J PSYCHIAT, V39, P300,
DOI 10.1111/j.1440-1614.2005.01572.x; TEESSON M, 2001, NATL COMORBIDITY PRO;
TEESSON M, 2003, COMORBID MENTAL DISO; United Nations High Commissioner for
Refugees (UNHCR), 1951, CONV REL STAT REF; YEE BWK, 1987, J PSYCHOACTIVE DRUGS,
V19, P77, DOI 10.1080/02791072.1987.10472382; Zinberg N., 1984, DRUG SET SETTING
BAS 43 6 6 2 29 WILEY-BLACKWELL HOBOKEN 111 RIVER ST,
HOBOKEN 07030-5774, NJ USA 0005-0067 1742-9544 AUST PSYCHOL Aust.
Psychol. APR 2015 50 2 130 140
10.1111/ap.12096 11 Psychology, Multidisciplinary Psychology
CH3UL WOS:000353955800006 2019-09-25
J Khanra, S; Khess, CRJ; Srivastava, N Khanra, Sourav;
Khess, C. R. J.; Srivastava, Naveen Chronic non-fatal Datura abuse in a
patient of paranoid schizophrenia: A case report ADDICTIVE BEHAVIORS
English Article Datura stramonium; Non-
fatal; Abuse; Schizophrenia; Self-medication; Comorbidity SUBSTANCE-ABUSE; DUAL
DIAGNOSIS; USE DISORDER; PREVALENCE; INTOXICATION; ALCOHOL Introduction: A range of
psychoactive substances used by patients suffering from schizophrenia varies and
may include those which are fatal and may cause serious toxicity leading to death.
We here present a case report of a patient suffering from paranoid schizophrenia,
who was abusing Datura stramonium over a prolonged period. Case summaty: A 32 year
old male presented with aggressive behaviour, irritability for 6 years and regular
intake of Datura seeds for 3 years. After taking detailed history and mental status
examination (MSE), diagnoses of paranoid schizophrenia and mental and behavioral
disorder due to use of hallucinogen were made. He had shown improvement on standard
treatment with antipsychotics. Conclusion: D. stramonium is recognized among
emerging new psychoactive substances being used across the world. Among various
theories we discuss self-medication hypothesis as a mediating factor for this case.
Though D. stramonium is notorious for its life threatening sequelae, clinicians
should be aware of its chronic abuse as self-medication. (C) 2014 Elsevier Ltd. All
rights reserved. [Khanra, Sourav; Khess, C. R. J.; Srivastava, Naveen] Cent Inst
Psychiat, Ranchi 834006, Bihar, India Khanra, S (reprint author), Cent Inst
Psychiat, Ranchi 834006, Bihar, India. souravpsy@gmail.com; jmou@rediffmail.com;
navnsrivastava02@gmail.com Khanra, Sourav/0000-0002-8684-6773
Arnett A. M., 1995, CLIN TOXICOLOGY REV, V18; Arouko H, 2003, ANN MED
INTERNE, V154, pS46; Busch A. B., 2005, COOCCURRING SUBSTANC; Dalack GW, 1998, AM J
PSYCHIAT, V155, P1490, DOI 10.1176/ajp.155.11.1490; DeFrates LJ, 2005, ANN
PHARMACOTHER, V39, P173, DOI 10.1345/aph.1D536; Dixon L, 1999, SCHIZOPHR RES, V35,
pS93, DOI 10.1016/S0920-9964(98)00161-3; Drake RE, 1996, ALCOHOL HEALTH RES W, V20,
P87; Edwin S., 2007, TXB PHARM PHYTOCHEMI, P224; Forrester MB, 2006, J TOXICOL ENV
HEAL A, V69, P1757, DOI 10.1080/15287390600631284; FOWLES DC, 1992, ANNU REV
PSYCHOL, V43, P303, DOI 10.1146/annurev.ps.43.020192.001511; Green AI, 1999,
HARVARD REV PSYCHIAT, V6, P287, DOI 10.3109/10673229909017206; Green AI, 2007, AM J
PSYCHIAT, V164, P402, DOI 10.1176/appi.ajp.164.3.402; HUGHES JR, 1986, AM J
PSYCHIAT, V143, P993; Ivancheva S., 2006, Phytochemistry: advances in research,
P87; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI
10.3109/10673229709030550; Montcriol A, 2007, ANN FR ANESTH, V26, P810, DOI
10.1016/j.annfar.2007.04.006; Mueser KT, 1998, ADDICT BEHAV, V23, P717, DOI
10.1016/S0306-4603(98)00073-2; MUESER KT, 1990, SCHIZOPHRENIA BULL, V16, P31, DOI
10.1093/schbul/16.1.31; NISELL M, 1995, PHARMACOL TOXICOL, V76, P157, DOI
10.1111/j.1600-0773.1995.tb00123.x; Pandey M, 2011, J PHARM PHYTOTHERA, V3, P27;
Paolo M. G., 2001, J ETHNOPHARMACOL, V68, P183; Parissis D, 2003, EUR J NEUROL,
V10, P745, DOI 10.1046/j.1468-1331.2003.00614.x; Pichini S., 2010, SMARTS DRUGS;
REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511; Rosen CS, 2008, PSYCHIAT SERV,
V59, P290, DOI 10.1176/appi.ps.59.3.290; Roth Robert M, 2005, Curr Psychiatry Rep,
V7, P283, DOI 10.1007/s11920-005-0082-8; Sanjita Das, 2012, Journal of Drug
Delivery and Therapeutics, V2, P4; SELZER JA, 1993, PSYCHIAT CLIN N AM, V16, P401;
Soni Priyanka, 2012, Asian Pacific Journal of Tropical Biomedicine, V2, P1002, DOI
10.1016/S2221-1691(13)60014-3; Spina SP, 2007, CAN J EMERG MED, V9, P467; Stella L,
2010, J PSYCHOACTIVE DRUGS, V42, P507; Swofford CD, 2000, AM J DRUG ALCOHOL AB,
V26, P343, DOI 10.1081/ADA-100100248; Tiongson J, 1998, Del Med J, V70, P471;
United Nations Office on Drugs and Crime (UNODC), 2013, WORLD DRUG REP 34 5
6 0 15 PERGAMON-ELSEVIER SCIENCE LTD OXFORD THE BOULEVARD,
LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND 0306-4603 1873-6327
ADDICT BEHAV Addict. Behav. APR 2015 43
39 41 10.1016/j.addbeh.2014.12.002 3 Psychology,
Clinical; Substance Abuse Psychology; Substance Abuse CB4BC
WOS:000349572200008 25544354 2019-09-25
J Trautmann, S; Schonfeld, S; Behrendt, S; Heinrich, A; Hofler, M; Siegel, S;
Zimmermann, P; Wittchen, HU Trautmann, Sebastian; Schoenfeld,
Sabine; Behrendt, Silke; Heinrich, Anke; Hoefler, Michael; Siegel, Stefan;
Zimmermann, Peter; Wittchen, Hans-Ulrich Stress exposure and the risk
for the onset of alcohol use disorders and nicotine dependence in deployed military
personnel: The role of prior internalizing disorders ADDICTIVE BEHAVIORS
English Article Substance use disorders;
Stress; Alcohol; Nicotine; Moderator; Internalizing disorders SUBSTANCE USE
DISORDERS; ANXIETY SENSITIVITY; MENTAL-DISORDERS; SELF-MEDICATION; CIGARETTE;
HEALTH; VULNERABILITY; ASSOCIATION; ADOLESCENTS; EXPERIENCES Objective: This
prospective study aimed to investigate whether prior internalizing disorders (PIDs)
moderate the relationship between stress exposure (SE) and the onset of alcohol use
disorders (AUDs) and nicotine dependence (ND) in deployed military personnel.
Methods: 358 male soldiers were examined directly before and 12 months after return
from deployment using standardized interviews. Combat experiences, concerns about
family disruptions, and difficult living and working environment were assessed as
different aspects of SE. PID diagnoses (mood disorders (PMDs), anxiety disorders
(PADs)) and substance use disorders were defined according to the DSM-IV-TR.
Results: PMDs were related to a stronger association between concerns about family
disruptions and the risk of AUD onset (OR = 7.7,95% Cl 1.8-32.8, p = 0.006). The
number of PID diagnoses (OR per diagnosis: 1.7,95% CI 1.0-2.8, p = 0.036) and PADs
(OR: 2.6, 95% C11.1-63, p = 0.038) were further related to a stronger association
between difficult living and working environment and the risk of AUD onset. With
regard to ND, PMDs were related to a weaker association between difficult living
and working environment and the risk of ND onset (OR = 0.4,95% Cl 02-0.8, p =
0.013). Conclusions: PIDs might be related to an increased risk for the onset of
AUDs but not ND following SE. This effect is probably restricted to specific
constellations of PADs, PMDs, comorbid PIDs and specific aspects of SE. These
critical constellations of PIDs and SE might be a promising target for future
research and could contribute to the development of preventive measures to reduce
the risk of AUDs following SE. (C) 2014 Elsevier Ltd. All rights reserved.
[Trautmann, Sebastian; Schoenfeld, Sabine; Behrendt, Silke; Heinrich, Anke;
Hoefler, Michael; Wittchen, Hans-Ulrich] Tech Univ Dresden, Inst Clin Psychol &
Psychotherapy, D-01187 Dresden, Germany; [Siegel, Stefan; Zimmermann, Peter] Fed
Armed Forces Hosp Berlin, Ctr Psychiat & Posttraumat Stress, Berlin, Germany
Trautmann, S (reprint author), Tech Univ Dresden, Inst Clin Psychol &
Psychotherapy, Chemnitzer Str 46, D-01187 Dresden, Germany.Sebastian.Trautmann1@tu-
dresden.de Wittchen, Hans-Ulrich/A-8507-2014; Trautmann, Sebastian/I-1853-2019;
Trautmann, Sebastian/A-8116-2014 Wittchen, Hans-Ulrich/0000-0002-6311-7711;
Trautmann, Sebastian/0000-0002-8976-3244 German Defense Ministry [M/SAB X/9A004]
This study was funded by the German Defense Ministry, respectively the
Medical Office thereof (Bundesministerium der Verteidigung, represented by:
Sanitatsamt der Bundeswehr: Project funding number M/SAB X/9A004). The German
Defense Ministry had no further role in the study design; in the collection,
analysis and interpretation of data; in the writing of the report; or in the
decision to submit the paper for publication. Allen AP, 2014, NEUROSCI BIOBEHAV
R, V38, P94, DOI 10.1016/j.neubiorev.2013.11.005; Beekman ATF, 1998, INT J GERIATR
PSYCH, V13, P717, DOI 10.1002/(SICI)1099-1166(1998100)13:10<717::AID-
GPS857>3.0.CO;2-M; Bernstein DP, 2003, CHILD ABUSE NEGLECT, V27, P169, DOI
10.1016/S0145-2134(02)00541-0; BILLINGS AG, 1984, J PERS SOC PSYCHOL, V46, P877,
DOI 10.1037/0022-3514.46.4.877; Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748,
DOI 10.1037/0022-006X.68.5.748; Brielmaier J, 2012, PSYCHOPHARMACOLOGY, V219, P73,
DOI 10.1007/s00213-011-2378-1; Chaiton MO, 2009, BMC PUBLIC HEALTH, V9, DOI
10.1186/1471-2458-9-356; Comeau N, 2001, ADDICT BEHAV, V26, P803, DOI
10.1016/S0306-4603(01)00238-6; Costello EJ, 2002, BIOL PSYCHIAT, V52, P529, DOI
10.1016/S0006-3223(02)01372-0; DiMaggio C, 2009, ADDICTION, V104, P894, DOI
10.1111/j.1360-0443.2009.02526.x; Fear NT, 2009, EVID-BASED MENT HEAL, V12, P60,
DOI 10.1136/ebmh.12.2.60; Forgas LB, 1996, MIL MED, V161, P165; Garland EL, 2013, J
BEHAV MED, V36, P175, DOI 10.1007/s10865-012-9413-5; Garnefski N, 2002, J
ADOLESCENCE, V25, P603, DOI 10.1006/jado.0507; Hasin DS, 2007, AM J PUBLIC HEALTH,
V97, P2268, DOI 10.2105/AJPH.2006.100057; Hooper R, 2008, ADDICT BEHAV, V33, P1067,
DOI 10.1016/j.addbeh.2008.03.010; Institute of Medicine, 2012, SUBST US DIS US ARM;
Jacobson IG, 2008, JAMA-J AM MED ASSOC, V300, P663, DOI 10.1001/jama.300.6.663;
Jones M, 2013, PSYCHOL MED, V43, P1703, DOI 10.1017/S0033291712002619; Keyes KM,
2012, ALCOHOL RES-CURR REV, V34, P391; Khantzian EJ, 1997, HARVARD REV PSYCHIAT,
V4, P231, DOI 10.3109/10673229709030550; King LA, 2006, MIL PSYCHOL, V18, P89, DOI
10.1207/s15327876mp1802_1; KROUTIL LA, 1994, PREV MED, V23, P521, DOI
10.1006/pmed.1994.1071; Kuntsche E, 2005, CLIN PSYCHOL REV, V25, P841, DOI
10.1016/j.cpr.2005.06.002; LeardMann CA, 2009, BRIT MED J, V338, DOI
10.1136/bmj.b1273; Lijffijt M, 2014, FRONT PSYCHIATRY, V5, DOI
10.3389/fpsyt.2014.00083; Magid V, 2009, ADDICT BEHAV, V34, P973, DOI
10.1016/j.addbeh.2009.05.007; McGee R, 2013, NICOTINE TOB RES, V15, P1971, DOI
10.1093/ntr/ntt081; Mental Health Advisory Team (MHAT IV), 2006, 0507 MHAT 4 OFF
SURG; North CS, 2005, BRIT J PSYCHIAT, V186, P487, DOI 10.1192/bjp.186.6.487; Ozer
EJ, 2003, PSYCHOL BULL, V129, P52, DOI 10.1037//0033-2909.129.1.52; Pietrzak RH,
2011, J ANXIETY DISORD, V25, P456, DOI 10.1016/j.janxdis.2010.11.010; Romero N,
2014, J BEHAV THER EXP PSY, V45, P128, DOI 10.1016/j.jbtep.2013.09.008; ROYALL RM,
1986, INT STAT REV, V54, P221, DOI 10.2307/1403146; Sartor CE, 2011, PSYCHOL MED,
V41, P1497, DOI 10.1017/S0033291710002072; Sinha R, 2008, ANN NY ACAD SCI, V1141,
P105, DOI 10.1196/annals.1441.030; Spanagel R, 2014, TRENDS NEUROSCI, V37, P219,
DOI 10.1016/j.tins.2014.02.006; StataCorp, 2012, STAT STAT SOFTW REL; Stewart SH,
2001, ADDICT BEHAV, V26, P775, DOI 10.1016/S0306-4603(01)00236-2; Thomas SE, 2011,
PSYCHOPHARMACOLOGY, V218, P19, DOI 10.1007/s00213-010-2163-6; Trautmann S, 2014,
DRUG ALCOHOL DEPEN, V134, P128, DOI 10.1016/j.drugalcdep.2013.09.024; Vlahov D,
2006, SUBST USE MISUSE, V41, P1295, DOI 10.1080/10826080600754900; Vogt D, 2011, J
ABNORM PSYCHOL, V120, P797, DOI 10.1037/a0023452; Vogt D, 2011, J ABNORM PSYCHOL,
V120, P819, DOI 10.1037/a0024457; Wang PS, 2005, ARCH GEN PSYCHIAT, V62, P603, DOI
10.1001/archpsyc.62.6.603; Welch AE, 2014, DRUG ALCOHOL DEPEN, V140, P1, DOI
10.1016/j.drugalcdep.2014.04.013; Wilkinson PO, 2013, BMC PSYCHIATRY, V13, DOI
10.1186/1471-244X-13-250; Wittchen H.-U., 1997, DIA X INTERVIEWS MAN; Wittchen
H.U., 2013, J DEPRESSION ANXIETY, V2; Wittchen H.-U., 2009, CIDI MILITARVERSION;
Wittchen HU, 2012, DTSCH ARZTEBL INT, V109, P559, DOI 10.3238/arztebl.2012.0559;
Wittchen HU, 2012, INT J METH PSYCH RES, V21, P98, DOI 10.1002/mpr.1356 52
4 5 0 18 PERGAMON-ELSEVIER SCIENCE LTD OXFORD THE
BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND 0306-4603 1873-
6327 ADDICT BEHAV Addict. Behav. APR 2015 43
89 96 10.1016/j.addbeh.2014.12.013 8
Psychology, Clinical; Substance Abuse Psychology; Substance Abuse CB4BC
WOS:000349572200016 25588794 2019-09-25
J [Anonymous] [Anonymous] Substance Use Disorders
in the U.S. Armed Forces MILITARY MEDICINE English Article
The military has a keen interest in
ensuring that its men and women are fit for their challenging military missions.
Military leaders recognize that inappropriate substance use will negatively impact
fitness. Although illicit drug use has been held in check, abuse of alcohol remains
highly problematic, and inappropriate prescription drug use has soared in recent
years-often related to self-medication for pain experienced by military personnel,
many of whom have had several tours of duty in Iraq and Afghanistan. There have
been efforts at preventing medication and alcohol misuse, including treatment
programs within both the direct care system and the purchased care TRICARE program.
However, these approaches have not kept pace with newer models of care for managing
drug abuse and addiction. This study offers a clear picture of the present
challenges faced by the Department of Defense (DoD), acknowledges DoD prevention
and treatment efforts, and offers potential approaches for further mitigating
substance misuse in the military.
0 0 0 0 0 ASSOC MILITARY SURG US BETHESDA 9320 OLD
GEORGETOWN RD, BETHESDA, MD 20814 USA 0026-4075 1930-613X MIL MED
Milit. Med. MAR 2015 180 3 243 245
10.7205/MILMED-D-14-00517 3 Medicine, General & Internal
General & Internal Medicine CD3OI WOS:000350987700007 25735012
2019-09-25
J Audrain-McGovern, J; Rodriguez, D; Leventhal, AM
Audrain-McGovern, Janet; Rodriguez, Daniel; Leventhal, Adam M.
Gender differences in the relationship between affect and adolescent smoking
uptake ADDICTION English Article
Adolescent smoking; gender; positive affect; negative affect DEPRESSION-
PRONE SMOKERS; CIGARETTE-SMOKING; MAJOR DEPRESSION; SUBSTANCE USE; PSYCHIATRIC-
DISORDERS; HEDONIC CAPACITY; TRIPARTITE MODEL; SELF-MEDICATION; UNITED-STATES;
RISK-FACTORS AimsTo evaluate gender differences in the role of positive and
negative affect on smoking uptake. DesignProspective longitudinal cohort study of
adolescent health behaviors. SettingFour suburban secondary schools outside
Philadelphia, Pennsylvania, USA. ParticipantsAdolescents (n=1357) were surveyed
every 6months for 4years (age 14-18years). MeasurementsSmoking and affect were
measured via survey at each of the eight time-points. FindingsA two-group
associative process latent growth curve model revealed that baseline positive
affect was related negatively to smoking progression for females (b=-0.031, Z=-
4.00, P<0.0001) but not for males (P=0.33). This gender difference was significant,
(2)((df=1))=8.24, P=0.0041, indicating that for every standard deviation (SD)
decrease in positive affect (SD=2.90), there was a 10% increase [odds ratio
(OR)=1.10, 95% confidence interval (CI)=1.04, 1.14] in the odds of smoking
progression for females. Baseline negative affect was related significantly and
positively to smoking progression for males (b=0.038, Z =2.874, P=0.004) and
females (b=0.025, Z =3.609, P<0.0001), but the gender difference was not
significant, (2)((df=1))=0.82, P=0.37. Thus, on average, for every standard
deviation (SD=4.40) increase in baseline negative affect there was a 15% (OR=1.15,
95% CI=1.06, 1.26) increase in the odds of smoking progression for males and for
females. ConclusionsThe impact of affect on adolescent smoking uptake varies by
gender. Low positive affect (low experience of positive feelings or emotions) for
females and high negative affect (high experience of negative feelings or emotions)
for both males and females increases the risk for adolescent smoking. [Audrain-
McGovern, Janet] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104
USA; [Rodriguez, Daniel] La Salle Univ, Sch Nursing & Hlth Sci, Philadelphia, PA
USA; [Leventhal, Adam M.] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los
Angeles, CA 90033 USA; [Leventhal, Adam M.] Univ So Calif, Keck Sch Med, Dept
Psychol, Los Angeles, CA 90033 USA Audrain-McGovern, J (reprint author), Univ
Penn, Dept Psychiat, 3535 Market St,Suite 4100, Philadelphia, PA 19104 USA.
audrain@mail.med.upenn.edu National Cancer InstituteUnited
States Department of Health & Human ServicesNational Institutes of Health (NIH) -
USANIH National Cancer Institute (NCI) [RO1 CA126958]; National Institute on Drug
AbuseUnited States Department of Health & Human ServicesNational Institutes of
Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [K08 DA025041] This
study was supported by National Cancer Institute RO1 CA126958 (JAM) and National
Institute on Drug Abuse K08 DA025041 (AML). Acierno R, 2000, J TRAUMA STRESS,
V13, P381, DOI 10.1023/A:1007772905696; al'Absi M, 2004, DRUG ALCOHOL DEPEN, V73,
P267, DOI 10.1016/j.drugalcdep.2003.10.014; Ameringer KJ, 2010, NICOTINE TOB RES,
V12, P1183, DOI 10.1093/ntr/ntq174; [Anonymous], 2012, MMWR SURVEILL SUMM, V61, P1;
Audrain-McGovern J, 2004, CANCER EPIDEM BIOMAR, V13, P2023; Audrain-McGovern J,
2014, BIOL PSYCHIAT, V76, P689, DOI 10.1016/j.biopsych.2014.04.018; Audrain-
McGovern J, 2013, DRUG ALCOHOL DEPEN, V132, P471, DOI
10.1016/j.drugalcdep.2013.03.006; Audrain-McGovern J, 2012, NICOTINE TOB RES, V14,
P1187, DOI 10.1093/ntr/nts017; Audrain-McGovern J, 2012, DRUG ALCOHOL DEPEN, V120,
P181, DOI 10.1016/j.drugalcdep.2011.07.020; Audrain-McGovern J, 2011, ADDICTION,
V106, P178, DOI 10.1111/j.1360-0443.2010.03113.x; Audrain-McGovern J, 2009,
ADDICTION, V104, P1743, DOI 10.1111/j.1360-0443.2009.02617.x; Audrain-McGovern J,
2009, DRUG ALCOHOL DEPEN, V103, P99, DOI 10.1016/j.drugalcdep.2008.12.019; Brown
RA, 1996, J AM ACAD CHILD PSY, V35, P1602, DOI 10.1097/00004583-199612000-00011;
Cacioppo JT, 1999, ANNU REV PSYCHOL, V50, P191, DOI 10.1146/annurev.psych.50.1.191;
Caggiula AR, 2009, NEBR SYM MOTIV, V55, P91, DOI 10.1007/978-0-387-78748-0_6;
Chaudhri N, 2006, PSYCHOPHARMACOLOGY, V184, P353, DOI 10.1007/s00213-005-0178-1;
Choi WS, 1997, AM J PREV MED, V13, P385; CLARK LA, 1988, J PERS SOC PSYCHOL, V54,
P296, DOI 10.1037/0022-3514.54.2.296; CLARK LA, 1991, J ABNORM PSYCHOL, V100, P316,
DOI 10.1037/0021-843X.100.3.316; Cloninger C.R., 1994, TEMPERAMENT CHARACTE; Cook
JW, 2004, NICOTINE TOB RES, V6, P39, DOI 10.1080/14622200310001656849; DAVIDSON RJ,
1992, BRAIN COGNITION, V20, P125, DOI 10.1016/0278-2626(92)90065-T; Davidson RJ,
2002, BIOL PSYCHIAT, V52, P478, DOI 10.1016/S0006-3223(02)01458-0; DiClemente RJ,
2001, PEDIATRICS, V107, P1363, DOI 10.1542/peds.107.6.1363; Dolcini MM, 2003,
NICOTINE TOB RES, V5, P473, DOI 10.1080/1462220031000118586; Duncan T. E., 1999,
INTRO LATENT VARIABL; Duncan TE, 1995, STRUCT EQU MODELING, V2, P187, DOI
10.1080/10705519509540009; Eaton Danice K., 2006, Morbidity and Mortality Weekly
Report, V55, P1; Escobedo LG, 1998, ADDICTION, V93, P433, DOI 10.1046/j.1360-
0443.1998.93343311.x; Essau C. A., 2009, TREATMENTS ADOLESCEN, P3; Essau CA, 2010,
J AFFECT DISORDERS, V127, P185, DOI 10.1016/j.jad.2010.05.016; Fergusson DM, 2003,
PSYCHOL MED, V33, P1357, DOI 10.1017/S0033291703008596; Fernander AF, 2006, ETHNIC
DIS, V16, P41; Fletcher AC, 2004, CHILD DEV, V75, P781, DOI 10.1111/j.1467-
8624.2004.00706.x; Forbes EE, 2009, BIOL PSYCHIAT, V66, P199, DOI
10.1016/j.biopsych.2009.05.001; Franken IHA, 2006, PROG NEURO-PSYCHOPH, V30, P297,
DOI 10.1016/j.pnpbp.2005.10.011; Hankin BL, 2001, PSYCHOL BULL, V127, P773, DOI
10.1037//0033-2909.127.6.773; Hasler G, 2004, NEUROPSYCHOPHARMACOL, V29, P1765, DOI
10.1038/sj.npp.1300506; Hedeker D, 2009, ADDICTION, V104, P297, DOI 10.1111/j.1360-
0443.2008.02435.x; Heinz AJ, 2010, DRUG ALCOHOL DEPEN, V111, P128, DOI
10.1016/j.drugalcdep.2010.04.001; Johnston L, 2013, MONITORING FUTURE NA; Kenny PJ,
2006, NEUROPSYCHOPHARMACOL, V31, P1203, DOI 10.1038/sj.npp.1300905; Khantzian EJ,
1997, HARVARD REV PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550; Killen JD,
1997, J CONSULT CLIN PSYCH, V65, P1011, DOI 10.1037/0022-006X.65.6.1011; Kodl MM,
2004, ADDICT BEHAV, V29, P17, DOI 10.1016/S0306-4603(03)00087-X; Loehlin J. C.,
2004, LATENT VARIABLE MODE; Memelstein R. J., 2007, SCI REAL TIME DATA C, P117;
Muthen B., 1998, MPLUS USERS GUIDE; Muthen B. O., 1998, MPLUS MPLUS USERS GU;
Muthen B. O., 2001, NEW METHODS ANAL CHA, Vxxiv, P442; Nutt D, 2007, J
PSYCHOPHARMACOL, V21, P461, DOI 10.1177/0269881106069938; Perkins KA, 2001, CNS
DRUGS, V15, P391, DOI 10.2165/00023210-200115050-00005; Perkins KA, 2009, NEBR SYM
MOTIV, V55, P143, DOI 10.1007/978-0-387-78748-0_9; Poulin C, 2005, ADDICTION, V100,
P525, DOI 10.1111/j.1360-0443.2005.01033.x; RADLOFF L S, 1977, Applied
Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rohde P, 2004,
NICOTINE TOB RES, V6, P119, DOI 10.1080/14622200310001656948; Schafer JL, 2002,
PSYCHOL METHODS, V7, P147, DOI 10.1037//1082-989X.7.2.147; Seligman MEP, 2005, AM
PSYCHOL, V60, P410, DOI 10.1037/0003-066X.60.5.410; Shafer AB, 2006, J CLIN
PSYCHOL, V62, P123, DOI 10.1002/jclp.20213; Simons-Morton BG, 2004, HEALTH EDUC
RES, V19, P561, DOI 10.1093/her/cyg071; Skara S, 2003, PREV MED, V37, P451, DOI
10.1016/S0091-7435(03)00166-X; Spring B, 2008, PSYCHOPHARMACOLOGY, V196, P461, DOI
10.1007/s00213-007-0977-7; Sussman S, 1999, SUBST USE MISUSE, V34, P1469, DOI
10.3109/10826089909039411; Tercyak KP, 2002, J PEDIATR PSYCHOL, V27, P145, DOI
10.1093/jpepsy/27.2.145; Twenge JM, 2002, J ABNORM PSYCHOL, V111, P578, DOI
10.1037//0021-843X.111.4.578; VELICER WF, 1992, PSYCHOL BULL, V111, P23, DOI
10.1037/0033-2909.111.1.23; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI
10.1037/0022-3514.54.6.1063; Watson D, 1997, J PERS ASSESS, V68, P267, DOI
10.1207/s15327752jpa6802_4; WATSON D, 1988, J ABNORM PSYCHOL, V97, P346, DOI
10.1037/0021-843X.97.3.346; Weinstein S. M., 2013, J CLIN CHILD ADOLESC; Weinstein
SM, 2013, PSYCHOL ADDICT BEHAV, V27, P1068, DOI 10.1037/a0031488; Wills TA, 1997,
AM J PUBLIC HEALTH, V87, P56, DOI 10.2105/AJPH.87.1.56; Windle M, 2001, J CONSULT
CLIN PSYCH, V69, P215, DOI 10.1037//0022-006X.69.2.215 73 9 9 7
23 WILEY-BLACKWELL HOBOKEN 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
0965-2140 1360-0443 ADDICTION Addiction MAR 2015 110 3
519 529 10.1111/add.12797 11
Substance Abuse; Psychiatry Substance Abuse; Psychiatry CC1LC
WOS:000350101200027 25393395 Green Accepted 2019-09-25
J Magrys, SA; Olmstead, MC Magrys, S. A.; Olmstead, M.
C. Acute Stress Increases Voluntary Consumption of Alcohol in
Undergraduates ALCOHOL AND ALCOHOLISM English Article
SUBSTANCE USE DISORDERS; MALE SOCIAL DRINKERS;
DRINKING BEHAVIOR; INHIBITORY CONTROL; ANXIETY DISORDERS; SELF-MEDICATION; BINGE
DRINKING; IMPULSIVITY; COLLEGE; INTOXICATION Aims: The primary aim of this study
was to assess whether an acute stressor directly increases alcohol intake among
undergraduates. A secondary aim was to examine whether individual differences in
state anxiety predict alcohol intake. Method: Following random assignment,
undergraduate students (n = 75; 47% males; mean age = 20.1 +/- 2.8) completed the
Trier Social Stress Test or no-stress protocol, and then engaged in a 30-min free-
drinking session (alcohol, placebo, or non-alcoholic beverage). The State-Trait
Anxiety Inventory was completed upon arrival, post-stressor, and after drinking.
Results: Planned comparisons demonstrated that psychosocial stress increased
voluntary intake of alcohol, but not placebo or non-alcoholic beverages. In linear
regression analyses, individual differences in anxiety did not predict voluntary
alcohol consumption. Conclusion: A proximal relationship exists between acute
stress and single-session alcohol intake in undergraduates, which may explain the
relationship between life stressors and increased drinking in this group. These
findings demonstrate that stress management is an important target for reducing
heavy episodic drinking on university campuses. [Magrys, S. A.; Olmstead, M. C.]
Queens Univ, Dept Psychol, Kingston, ON K7L 3N6, Canada; [Olmstead, M. C.] Queens
Univ, Ctr Neurosci Studies, Kingston, ON K7L 3N6, Canada Olmstead, MC (reprint
author), Queens Univ, Dept Psychol, 62 Arch St, Kingston, ON K7L 3N6, Canada.
olmstead@queensu.ca Natural Sciences and Engineering Research
Council of CanadaNatural Sciences and Engineering Research Council of Canada
[203707] This work was supported by the Natural Sciences and Engineering
Research Council of Canada (Discovery Grant #203707) awarded to M.C.O. Abrams K,
2002, PSYCHOL ADDICT BEHAV, V16, P121, DOI 10.1037//0893-164X.16.2.121; Balodis IM,
2011, HORM BEHAV, V59, P465, DOI 10.1016/j.yhbeh.2011.01.004; Balodis IM, 2009,
BEHAV PHARMACOL, V20, P518, DOI 10.1097/FBP.0b013e328330c779; Boden JM, 2014, DRUG
ALCOHOL DEPEN, V142, P154, DOI 10.1016/j.drugalcdep.2014.06.010; Bot SM, 2005,
ADDICTION, V100, P1270, DOI 10.1111/j.1360-0443.2005.01152.x; Boys A, 2001, HEALTH
EDUC RES, V16, P457, DOI 10.1093/her/16.4.457; Christiansen P, 2013, J
PSYCHOPHARMACOL, V27, P84, DOI 10.1177/0269881112450787; de Wit H, 2003, ALCOHOL
CLIN EXP RES, V27, P1270, DOI 10.1097/01.ALC.0000081617.37539.D6; Enoch MA, 2011,
PSYCHOPHARMACOLOGY, V214, P17, DOI 10.1007/s00213-010-1916-6; Field M, 2010,
ALCOHOL CLIN EXP RES, V34, P1346, DOI 10.1111/j.1530-0277.2010.01218.x; Fox HC,
2010, ALCOHOL CLIN EXP RES, V34, P1376, DOI 10.1111/j.1530-0277.2010.01221.x; Gordh
AHVS, 2011, PHARMACOL BIOCHEM BE, V99, P696, DOI 10.1016/j.pbb.2011.05.028; Grant
BF, 2004, ARCH GEN PSYCHIAT, V61, P807, DOI 10.1001/archpsyc.61.8.807; Hamilton KR,
2013, STRESS, V16, P3, DOI 10.3109/10253890.2012.671397; HIGGINS RL, 1975, J ABNORM
PSYCHOL, V84, P644, DOI 10.1037/0021-843X.84.6.644; HULL JG, 1983, J PERS SOC
PSYCHOL, V44, P1097, DOI 10.1037/0022-3514.44.6.1097; Khantzian EJ, 1997, HARVARD
REV PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550; KIRSCHBAUM C, 1993,
NEUROPSYCHOBIOLOGY, V28, P76, DOI 10.1159/000119004; Kudielka BM, 2007, ENCY
STRESS, V3, P776; Magrys SA, 2013, PSYCHOPHYSIOLOGY, V50, P204, DOI
10.1111/psyp.12007; Mahoney MK, 2013, CURR OPIN NEUROBIOL, V23, P607, DOI
10.1016/j.conb.2013.03.006; Nesic J, 2006, PHARMACOL BIOCHEM BE, V83, P239, DOI
10.1016/j.pbb.2006.02.006; O'Neill SE, 2001, PSYCHOL ADDICT BEHAV, V15, P350, DOI
10.1037/0893-164X.15.4.350; OHARE TM, 1990, J STUD ALCOHOL, V51, P536, DOI
10.15288/jsa.1990.51.536; Ortner CNM, 2003, ALCOHOL ALCOHOLISM, V38, P151, DOI
10.1093/alcalc/agg041; Park CL, 2004, J STUD ALCOHOL, V65, P126, DOI
10.15288/jsa.2004.65.126; Pelham WE, 1997, J ABNORM CHILD PSYCH, V25, P413, DOI
10.1023/A:1025789108958; Robinson JA, 2009, J NERV MENT DIS, V197, P873, DOI
10.1097/NMD.0b013e3181c299c2; Robotham D, 2006, J FURTH HIGH EDUC, V30, P107, DOI
10.1080/03098770600617513; Silberman Y, 2009, ALCOHOL, V43, P509, DOI
10.1016/j.alcohol.2009.01.002; Spielberger C. D., 1983, STATE TRAIT ANXIETY;
Waldrop AE, 2007, ADDICT BEHAV, V32, P634, DOI 10.1016/j.addbeh.2006.06.001; Weafer
J, 2008, PSYCHOPHARMACOLOGY, V201, P315, DOI 10.1007/s00213-008-1284-7; Wechsler H,
2001, PSYCHOL ADDICT BEHAV, V15, P287, DOI 10.1037/0893-164X.15.4.287 34 16
16 3 47 OXFORD UNIV PRESS OXFORD GREAT CLARENDON ST, OXFORD
OX2 6DP, ENGLAND 0735-0414 1464-3502 ALCOHOL ALCOHOLISM Alcohol
Alcohol. MAR-APR 2015 50 2 213 218
10.1093/alcalc/agu101 6 Substance Abuse Substance Abuse
CE9KC WOS:000352161800015 25557606 Bronze 2019-09-25
J Fletcher, K; Nutton, J; Brend, D Fletcher, Kara; Nutton,
Jennifer; Brend, Denise Attachment, A Matter of Substance: The
Potential of Attachment Theory in the Treatment of Addictions CLINICAL SOCIAL
WORK JOURNAL English Article
Attachment; Substance use disorder; Addiction; Self-regulation; Treatment;
Self-medication ADVERSE CHILDHOOD EXPERIENCES; SELF-MEDICATION HYPOTHESIS; USE
DISORDERS; HOUSEHOLD DYSFUNCTION; FAMILY SYSTEMS; DRUG-ABUSE; COUPLES; DRINKING;
THERAPY; ALCOHOL In North America, substance abuse is a public health crisis with
annual costs in the billions. Individuals suffer from substance use disorders for
multiple years throughout their lifespan. This suggests that neither historical,
community-based interventions, nor current, evidence-based behavioral modalities
are successful in healing the causes of addiction. A growing corpus of research has
established that traumatic early-childhood experiences and insecure attachments are
both independent and interrelated risk factors for developing substance abuse
disorders. An impressive literature is emerging exploring potential applications of
attachment theory-informed intervention. There has yet to be widespread adoption of
such techniques. By examining the scholarly literature, this paper synthesizes
existing work on attachment theory in the treatment of substance use disorders. A
clinical case application is provided to highlight the potential for attachment-
informed therapy. Recommendations for using attachment-informed approaches in the
treatment of substance use disorders with various groups are offered. [Fletcher,
Kara; Nutton, Jennifer; Brend, Denise] McGill Univ, Sch Social Work, Montreal, PQ
H3A 2A7, Canada Fletcher, K (reprint author), McGill Univ, Sch Social Work, 3506
Univ St,Room 300, Montreal, PQ H3A 2A7, Canada. kara.fletcher@mail.mcgill.ca
Anda RF, 2002, PSYCHIAT SERV, V53, P1001, DOI
10.1176/appi.ps.53.8.1001; Basham K, 2004, SOC WORK HEALTH CARE, V39, P263, DOI
10.1300/J010v39n03_04; Bateman A, 2010, WORLD PSYCHIATRY, V9, P11; Bettmann JE,
2008, CLIN SOC WORK J, V36, P51, DOI 10.1007/s10615-007-0134-0; Bowlby J., 1979,
MAKING BREAKING AFFE; Bowlby J., 1988, SECURE BASE PARENT C; BRENNAN KA, 1991, J
SOC PERS RELAT, V8, P451, DOI 10.1177/026540759184001; BRETHERTON I, 1992, DEV
PSYCHOL, V28, P759, DOI 10.1037/0012-1649.28.5.759; Cunradi CB, 2012, J STUD
ALCOHOL DRUGS, V73, P731, DOI 10.15288/jsad.2012.73.731; Dennis ML, 2005, J SUBST
ABUSE TREAT, V28, pS51, DOI 10.1016/j.jsat.2004.10.013; Dube SR, 2003, PEDIATRICS,
V111, P564, DOI 10.1542/peds.111.3.564; Dube SR, 2006, J ADOLESCENT HEALTH, V38,
DOI [10.1016/j.jadohealth.2005.06.006, DOI 10.1016/J.JAD0HEALTH.2005.06.006];
Durrant R, 2009, AUST NZ J PSYCHIAT, V43, P1049, DOI 10.3109/00048670903270449;
Falk D, 2008, ALCOHOL RES HEALTH, V31, P100; Feld B, 2004, PSYCHOANAL INQ, V24,
P420, DOI 10.1080/07351692409349092; Felitti VJ, 1998, AM J PREV MED, V14, P245,
DOI 10.1016/S0749-3797(98)00017-8; Flores PJ, 2006, J GROUPS ADDICT RECO, V1, P5,
DOI 10.1300/J384v01n01_02; Flores PJ, 2004, ADDICTION ATTACHMENT; Fonagy P, 1996, J
CONSULT CLIN PSYCH, V64, P22, DOI 10.1037/0022-006X.64.1.22; Fonagy P, 2002, AFFECT
REGULATION ME; Frank M. L., 2009, THESIS PROQUEST; Glantz MD, 2010, HDB DRUG USE
ETIOLOG, P51; Heyman G, 2009, ADDICTION DISORDER C; Hofler DZ, 1996, J SUBST ABUSE
TREAT, V13, P511, DOI 10.1016/S0740-5472(96)00156-0; HUGHES D, 2007, ATTACHMENT
FOCUSED F; Johnson SM, 1999, CLIN PSYCHOL-SCI PR, V6, P67, DOI
10.1093/clipsy/6.1.67; Kazdin AE, 2011, AM PSYCHOL, V66, P685, DOI
10.1037/a0024975; Khantzian EJ, 2011, J GROUPS ADDICT RECO, V6, P264, DOI
10.1080/1556035X.2011.597199; Khantzian EJ, 2012, AM J ADDICTION, V21, P274, DOI
10.1111/j.1521-0391.2012.00234.x; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4,
P231, DOI 10.3109/10673229709030550; Landau-North M, 2011, EMOTIONALLY FOCUSED
CASEBOOK: NEW DIRECTIONS IN TREATING COUPLES, P193; Larkin M, 2006, ADDICT RES
THEORY, V14, P207, DOI 10.1080/16066350500151747; Lende DH, 2002, ADDICTION, V97,
P447, DOI 10.1046/j.1360-0443.2002.00022.x; Lipton B, 2011, J PSYCHOTHER INTEGR,
V21, P253, DOI 10.1037/a0025421; MacIntosh HB, 2008, J MARITAL FAM THER, V34, P298,
DOI 10.1111/j.1752-0606.2008.00074.x; Main M, 1995, ATTACHMENT THEORY, P407; McHugh
RK, 2010, PSYCHIAT CLIN N AM, V33, P511, DOI 10.1016/j.psc.2010.04.012; McKay JR,
2011, ALCOHOL RES HEALTH, V33, P356; McLellan AT, 2000, JAMA-J AM MED ASSOC, V284,
P1689, DOI 10.1001/jama.284.13.1689; McNally AM, 2003, ADDICT BEHAV, V28, P1115,
DOI 10.1016/S0306-4603(02)00224-1; MENICUCCI LD, 1989, AM J FAM THER, V17, P129,
DOI 10.1080/01926188908250759; National Drug Intelligence Center, 2010, NAT THREAT
ASS EC IM; *NIDA, 2007, DRUGS BRAINS BEH SCI; Padykula NL, 2012, INT J APPL PSYCH
STU, V9, P48, DOI 10.1002/aps.312; Padykula NL, 2010, CLIN SOC WORK J, V38, P351,
DOI 10.1007/s10615-009-0204-6; Piehler TF, 2012, J ABNORM CHILD PSYCH, V40, P1045,
DOI 10.1007/s10802-012-9626-7; Rehm J, 2006, COSTS SUBSTANCE ABUS, P1; Rehm J,
2009, LANCET, V373, P2223, DOI 10.1016/S0140-6736(09)60746-7; Saha TD, 2012, J STUD
ALCOHOL DRUGS, V73, P368, DOI 10.15288/jsad.2012.73.368; SAMHSA, 2011, NAT SURV
SUBST AB TR, P1; Schindler A, 2005, ATTACH HUM DEV, V7, P207, DOI
10.1080/14616730500173918; Schindler A, 2007, ATTACH HUM DEV, V9, P111, DOI
10.1080/14616730701349689; Spiegel B. R., 2004, CLIN WORK SUBSTANCE, V2, P125;
STEVENSONHINDE J, 1990, INF MENTAL HLTH J, V11, P218, DOI 10.1002/1097-
0355(199023)11:3<218::AID-IMHJ2280110304>3.0.CO;2-1; Stone AL, 2012, ADDICT BEHAV,
V37, P747, DOI 10.1016/j.addbeh.2012.02.014; Suh JJ, 2008, PSYCHOANAL PSYCHOL, V25,
P518, DOI 10.1037/0736-9735.25.3.518; Thompson R. A., 2008, HDB ATTACHMENT, P348;
Volkow ND, 2011, P NATL ACAD SCI USA, V108, P15037, DOI 10.1073/pnas.1010654108;
Vrecko S, 2010, HIST HUM SCI, V23, P52, DOI 10.1177/0952695110371598; Walant K. B.,
1995, CREATING CAPACITY AT; Wallin D. J., 2007, ATTACHMENT PSYCHOTHE; Watson JM,
2013, DRUG ALCOHOL REV, V32, P356, DOI 10.1111/dar.12037; Weegmann Martin, 2011, Am
J Psychother, V65, P163; Zeinali A, 2011, J RES MED SCI, V16, P1105 64 12
12 0 51 SPRINGER DORDRECHT VAN GODEWIJCKSTRAAT 30, 3311 GZ
DORDRECHT, NETHERLANDS 0091-1674 1573-3343 CLIN SOC WORK J Clin. Soc.
Work J. MAR 2015 43 1 109 117
10.1007/s10615-014-0502-5 9 Social Work Social Work CB2CL
WOS:000349434200010 2019-09-25
J Staton-Tindall, M; Harp, KLH; Minieri, A; Oser, C; Webster, JM; Havens, J;
Leukefeld, C Staton-Tindall, Michele; Harp, Kathi L. H.;
Minieri, Alexandra; Oser, Carrie; Webster, J. Matthew; Havens, Jennifer; Leukefeld,
Carl An Exploratory Study of Mental Health and HIV Risk Behavior Among
Drug-Using Rural Women in Jail PSYCHIATRIC REHABILITATION JOURNAL
English Article mental health; drug use;
HIV risk; rural women; jail SUBSTANCE USE DISORDERS; INCARCERATED WOMEN; GENDER-
DIFFERENCES; PSYCHIATRIC-DISORDERS; SERVICE UTILIZATION; SELF-MEDICATION; USERS;
INJECTION; OFFENDERS; ABUSE Objective: Rural women, particularly those in the
criminal justice system, are at risk for HIV related to the increasing prevalence
of injection drug use as well as limited services. Research on HIV risk correlates,
including drug use and mental health, has primarily focused on urban women
incarcerated in prisons. The purpose of this exploratory study is to examine dual
HIV risk by 3 different mental health problems (depression, anxiety, and
posttraumatic stress disorder [PTSD]) among drug-using women in rural jails.
Method: This study involved random selection, screening, and face-to-face
interviews with 136 women in 1 Appalachian state. Analyses focused on the
relationship between mental health and HIV risk. Results: Nearly 80% of women self-
reported symptoms of depression, and more than 60% endorsed symptoms consistent
with anxiety and PTSD symptoms. Mental health significantly correlated with
severity of certain types of drug use, as well as risky sexual activity. In
addition, for women experiencing anxiety and PTSD, injection drug use moderated the
relationship between mental health and risky sexual activity. Conclusions and
Implications for Practice: Based on these rates of drug use, mental health
problems, and the emergence of injection drug use in rural Appalachia, the need to
explore the relationships between these issues among vulnerable and understudied
populations, such as rural women, is critical. Because of service limitations in
rural communities, criminal justice venues such as jails provide opportune settings
for screening, assessment, and intervention for drug use, mental health, and HIV
education and prevention. [Staton-Tindall, Michele] Univ Kentucky, Coll Social
Work, 659 Patterson Off Tower, Lexington, KY 40506 USA; [Harp, Kathi L. H.] Univ
Kentucky, Ctr Drug & Alcohol Res, Dept Behav Sci, Lexington, KY 40506 USA;
[Minieri, Alexandra] Univ N Carolina, Charlotte Counseling Ctr, Charlotte, NC 28223
USA; [Oser, Carrie] Univ Kentucky, Coll Arts & Sci, Dept Sociol, Lexington, KY
40506 USA; [Webster, J. Matthew; Havens, Jennifer; Leukefeld, Carl] Univ Kentucky,
Coll Med, Dept Behav Sci, Lexington, KY 40506 USA Staton-Tindall, M (reprint
author), Univ Kentucky, Coll Social Work, 659 Patterson Off Tower, Lexington, KY
40506 USA. mstindall@uky.edu National Institute on Drug Abuse of the
National Institutes of HealthUnited States Department of Health & Human
ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug
Abuse (NIDA) [R01DA033866, K02DA35116, T32DA035200] Research reported in this
article was supported by the National Institute on Drug Abuse of the National
Institutes of Health under Awards R01DA033866, K02DA35116, and T32DA035200. The
content is solely the responsibility of the authors and does not necessarily
represent the official views of the National Institutes of Health. We would also
like to recognize the cooperation and partnership with the Kentucky Department of
Corrections and the local jails, including the Laurel County Detention Center,
Kentucky River Regional Jail, and the Leslie County Detention Center. Abram KM,
2003, AM J PSYCHIAT, V160, P1007, DOI 10.1176/appi.ajp.160.5.1007; Alemagno SA,
2001, AM J PUBLIC HEALTH, V91, P798, DOI 10.2105/AJPH.91.5.798; American
Psychological Association, BEH HLTH CAR NEEDS R; Appalachian Regional Commission,
2013, COUNT EC STAT APP; Binswanger IA, 2010, AM J PUBLIC HEALTH, V100, P476, DOI
10.2105/AJPH.2008.149591; Bowles MA, 2012, J FAM VIOLENCE, V27, P681, DOI
10.1007/s10896-012-9450-4; Bradley MV, 2008, PSYCHOSOM MED, V70, P186, DOI
10.1097/PSY.0b013e3181642a1c; De Groot A S, 2000, AIDS Read, V10, P287; De Groot A.
S., 2005, BODY COMPLETE HIV AI; Dennis M., 1998, GLOBAL APPRAISAL IND; Du J, 2013,
BIOMED ENVIRON SCI, V26, P32, DOI 10.3967/0895-3988.2013.01.004; El-Bassel N, 2012,
CURR OPIN HIV AIDS, V7, P326, DOI 10.1097/COH.0b013e3283536ab2; Evans JL, 2003, J
URBAN HEALTH, V80, P137, DOI 10.1093/jurban/jtg137; Gunter TD, 2012, BEHAV SCI LAW,
V30, P615, DOI 10.1002/bsl.2037; Hagan H, 2001, AM J PUBLIC HEALTH, V91, P42;
Harrison P., 2006, PUBLICATION US DEP J; Havens JR, 2007, DRUG ALCOHOL DEPEN, V87,
P98, DOI 10.1016/j.drugalcdep.2006.07.008; Havens Jennifer R, 2013, Am J Public
Health, V103, pe44, DOI 10.2105/AJPH.2012.300874; Horton A, 2011, SOC WORK PUBLIC
HLTH, V26, P176, DOI 10.1080/19371910903182773; Humeniuk R, 2006, VALIDATION
ALCOHOL S; Humeniuk R, 2008, ADDICTION, V103, P1039, DOI 10.1111/j.1360-
0443.2007.02114.x; Hutton HE, 2001, PSYCHIATR SERV, V52, P508, DOI
10.1176/appi.ps.52.4.508; Johnson H, 2006, DRUG ALCOHOL REV, V25, P433, DOI
10.1080/09595230600876598; Jordan BK, 1996, ARCH GEN PSYCHIAT, V53, P513; Khantzian
E J, 1990, Recent Dev Alcohol, V8, P255; Khantzian EJ, 1997, HARVARD REV PSYCHIAT,
V4, P231, DOI 10.3109/10673229709030550; Klein H, 2008, WOMEN HEALTH, V48, P167,
DOI 10.1080/03630240802313605; Latka MH, 2005, J SUBST ABUSE TREAT, V29, P329, DOI
10.1016/j.jsat.2005.08.008; Leukefeld CG, 2002, J BEHAV HEALTH SER R, V29, P167,
DOI 10.1007/BF02287703; MacDonald M, 2013, INT J LAW PSYCHIAT, V36, P293, DOI
10.1016/j.ijlp.2013.04.014; Maruschak L. M., 2004, PUBLICATION US DEP J; McClelland
GM, 2002, AM J PUBLIC HEALTH, V92, P818, DOI 10.2105/AJPH.92.5.818; Meade CS, 2009,
AIDS BEHAV, V13, P207, DOI 10.1007/s10461-007-9326-4; Miles DR, 2001, ALCOHOL CLIN
EXP RES, V25, P1012, DOI 10.1097/00000374-200107000-00010; Millay TA, 2009, J URBAN
HEALTH, V86, P810, DOI 10.1007/s11524-009-9381-4; Morton W Alexander, 1999, Prim
Care Companion J Clin Psychiatry, V1, P109; Mumola C. J., 2007, DRUG USE AND
DEPENDE; National Institute on Drug Abuse, 2009, NIDA MOD ASSIST; Neaigus A, 2013,
AIDS BEHAV, V17, P2501, DOI 10.1007/s10461-013-0496-y; O'Cleirigh C, 2013, J GAY
LESBIAN MENT H, V17, P314, DOI 10.1080/19359705.2012.755142; Oser CB, 2006, J RURAL
HEALTH, V22, P273, DOI 10.1111/j.1748-0361.2006.00045.x; Peters RH, 1997, J SUBST
ABUSE TREAT, V14, P339, DOI 10.1016/S0740-5472(97)00003-2; Plotzker RE, 2007, AM J
ADDICTION, V16, P431, DOI 10.1080/10550490701643161; Reyes JC, 2007, AIDS BEHAV,
V11, P145, DOI 10.1007/s10461-006-9090-x; Robinson JA, 2009, J NERV MENT DIS, V197,
P873, DOI 10.1097/NMD.0b013e3181c299c2; Sacks JY, 2004, BEHAV SCI LAW, V22, P449,
DOI 10.1002/bsl.597; Sagtani RA, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-
002763; SINGER MI, 1995, SOC WORK, V40, P103; Sipes L. A., 2012, STAT WOMEN
OFFENDERS; Staton M, 2003, INT J OFFENDER THER, V47, P224, DOI
10.1177/0306624X03251120; Staton-Tindall M., 2013, COLL PROBL DRUG DEP; Staton-
Tindall M, 2007, WOMEN HEALTH ISS, V17, P183, DOI 10.1016/j.whi.2007.02.004;
Staton-Tindall M, 2007, AM J DRUG ALCOHOL AB, V33, P237, DOI
10.1080/00952990601174865; Staton-Tindall M, 2011, WOMEN HEALTH ISS, V21, P230, DOI
10.1016/j.whi.2010.10.006; Strathdee SA, 2003, J URBAN HEALTH, V80, P7; Teplin LA,
1997, AM J PUBLIC HEALTH, V87, P604, DOI 10.2105/AJPH.87.4.604; Tobin KE, 2012, ANN
ASSOC AM GEOGR, V102, P1058, DOI 10.1080/00045608.2012.674902; Tompkins CNE, 2006,
DRUG-EDUC PREV POLIC, V13, P281, DOI 10.1080/09687630600700111; Tripodi SJ, 2013,
INT J LAW PSYCHIAT, V36, P30, DOI 10.1016/j.ijlp.2012.11.005; Young AM, 2013, AIDS
BEHAV, V17, P2341, DOI 10.1007/s10461-012-0371-2; Young AM, 2014, DRUG ALCOHOL
DEPEN, V134, P401, DOI 10.1016/j.drugalcdep.2013.10.013; Young AM, 2012, ADDICTION,
V107, P587, DOI 10.1111/j.1360-0443.2011.03635.x; Zhang Z, 2008, ANAL MENTAL HLTH
SUB; Zlotnick C, 2008, BEHAV SCI LAW, V26, P403, DOI 10.1002/bsl.831 64 24
25 2 11 CENTER PSYCHIATRIC REHABILITATION BOSTON BOSTON UNIV,
930 COMMONWEALTH AVE, BOSTON, MA 02215 USA 1095-158X 1559-3126
PSYCHIATR REHABIL J Psychiatr. Rehabil. J. MAR 2015 38 1
45 54 10.1037/prj0000107 10
Psychiatry; Rehabilitation Psychiatry; Rehabilitation DE1ND
WOS:000370392800006 25799305 Green Accepted 2019-09-25
J Parvaz, MA; Konova, AB; Proudfit, GH; Dunning, JP; Malaker, P; Moeller, SJ;
Maloney, T; Alia-Klein, N; Goldstein, RZ Parvaz, Muhammad A.;
Konova, Anna B.; Proudfit, Greg H.; Dunning, Jonathan P.; Malaker, Pias; Moeller,
Scott J.; Maloney, Tom; Alia-Klein, Nelly; Goldstein, Rita Z.
Impaired Neural Response to Negative Prediction Errors in Cocaine Addiction
JOURNAL OF NEUROSCIENCE English Article
addiction; cocaine; event-related potentials; feedback negativity;
reward-prediction error; self-medication SUBSTANCE USE DISORDERS; MEDIAL FRONTAL-
CORTEX; RISKY DECISION-MAKING; REWARD PREDICTION; DOPAMINE NEURONS; SEEKING
BEHAVIOR; WORKING-MEMORY; DRUG-ADDICTION; TEMPORAL PREDICTION; NUCLEUS-ACCUMBENS
Learning can be guided by unexpected success or failure, signaled via
dopaminergic positive reward prediction error (+RPE) and negative reward-prediction
error (-RPE) signals, respectively. Despite conflicting empirical evidence, RPE
signaling is thought to be impaired in drug addiction. To resolve this outstanding
question, we studied as a measure of RPE the feedback negativity (FN) that is
sensitive to both reward and the violation of expectation. We examined FN in 25
healthy controls; 25 individuals with cocaine-use disorder (CUD) whotested positive
for cocaine on the study day(CUD+), indicating cocaine use within the past 72 h;
and in 25 individuals with CUD who tested negative for cocaine (CUD-). EEG was
acquired while the participants performed a gambling task predicting whether they
would win or lose money on each trial given three known win probabilities (25, 50,
or 75%). FN was scored for the period in each trial when the actual outcome (win or
loss) was revealed. A significant interaction between prediction, outcome, and
group revealed that controls showed increased FN to unpredicted compared with
predicted wins (i.e., intact + RPE) and decreased FN to unpredicted compared with
predicted losses (i.e., intact - RPE). However, neither CUD subgroup showed FN
modulation to loss (i.e., impaired - RPE), and unlike CUD + individuals, CUD -
individuals also did not show FN modulation to win (i.e., impaired + RPE). Thus,
using FN, the current study directly documents - RPE deficits in CUD individuals.
The mechanisms underlying - RPE signaling impairments in addiction may contribute
to the disadvantageous nature of excessive drug use, which can persist despite
repeated unfavorable life experiences (e.g., frequent incarcerations). [Parvaz,
Muhammad A.; Malaker, Pias; Moeller, Scott J.; Maloney, Tom; Alia-Klein, Nelly;
Goldstein, Rita Z.] Icahn Sch Med Mt Sinai, Dept Psychiat & Neurosci, New York, NY
10029 USA; [Konova, Anna B.] NYU, Ctr Neural Sci, New York, NY 10003 USA;
[Proudfit, Greg H.] SUNY Stony Brook, Dept Psychol, Stony Brook, NY 11970 USA;
[Dunning, Jonathan P.] Nevada State Coll, Dept Psychol, Henderson, NV 89002 USA
Goldstein, RZ (reprint author), One Gustave Levy Pl, New York, NY 10029 USA.
rita.goldstein@mssm.edu Moeller, Scott/L-5549-2016; Alia-Klein, Nelly/C-3154-
2013 Moeller, Scott/0000-0002-4449-0844; Parvaz, Muhammad/0000-0002-2671-2327
National Institute on Drug AbuseUnited States Department of Health & Human
ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug
Abuse (NIDA) [F32DA033088, R21DA034954]; National Institute on Mental HealthUnited
States Department of Health & Human ServicesNational Institutes of Health (NIH) -
USANIH National Institute of Mental Health (NIMH) [5T32MH019524, R01MH090134]
This work was supported by grants from the National Institute on Drug Abuse
(F32DA033088 to M.A.P.; R21DA034954 to R.Z.G.) and from the National Institute on
Mental Health (5T32MH019524 to A.B.K.; R01MH090134 to N.A.K.). Munoz MA, 2012,
EXP CLIN PSYCHOPHARM, V20, P151, DOI 10.1037/a0025991; Balodis IM, 2012, BIOL
PSYCHIAT, V71, P749, DOI 10.1016/j.biopsych.2012.01.006; Beck AT, 1996, J PERS
ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13; Carlson JM, 2011, NEUROIMAGE,
V57, P1608, DOI 10.1016/j.neuroimage.2011.05.037; Chiu PH, 2008, NAT NEUROSCI, V11,
P514, DOI 10.1038/nn2067; Ciccocioppo R, 2001, P NATL ACAD SCI USA, V98, P1976, DOI
10.1073/pnas.98.4.1976; Cohen JY, 2012, NATURE, V482, P85, DOI 10.1038/nature10754;
Cools R, 2008, NEUROPSYCHOPHARMACOL, V33, P2291, DOI 10.1038/sj.npp.1301598; Daw
ND, 2002, NEURAL NETWORKS, V15, P603, DOI 10.1016/S0893-6080(02)00052-7; Di Chiara
G, 1998, J PSYCHOPHARMACOL, V12, P54, DOI 10.1177/026988119801200108; Dunning JP,
2011, EUR J NEUROSCI, V33, P1716, DOI 10.1111/j.1460-9568.2011.07663.x; Ersche KD,
2008, PSYCHOPHARMACOLOGY, V197, P421, DOI 10.1007/s00213-007-1051-1; Euser AS,
2013, DEV PSYCHOPATHOL, V25, P1119, DOI 10.1017/S0954579413000412; Euser AS, 2011,
PSYCHOPHARMACOLOGY, V217, P111, DOI 10.1007/s00213-011-2264-x; Everitt BJ, 2005,
NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579; Fein G, 2008, DRUG ALCOHOL DEPEN, V92,
P141, DOI 10.1016/j.drugalcdep.2007.07.017; FIRST MB, 1996, USERS GUIDE STRUCTUR;
Frank MJ, 2006, PSYCHOL REV, V113, P300, DOI 10.1037/0033-295X.113.2.300; Franken
IHA, 2010, ALCOHOL CLIN EXP RES, V34, P702, DOI 10.1111/j.1530-0277.2009.01139.x;
Garavan H, 2008, PHILOS T R SOC B, V363, P3267, DOI 10.1098/rstb.2008.0106; George
O, 2008, NEUROPSYCHOPHARMACOL, V33, P2474, DOI 10.1038/sj.npp.1301626; Glimcher PW,
2011, P NATL ACAD SCI USA, V108, P15647, DOI 10.1073/pnas.1014269108; Goldstein RZ,
2010, P NATL ACAD SCI USA, V107, P16667, DOI 10.1073/pnas.1011455107; GOSSOP M,
1992, BRIT J ADDICT, V87, P1527; Gradin VB, 2014, NEUROPSYCHOPHARMACOL, V39, P885,
DOI 10.1038/npp.2013.289; Hajcak G, 2007, PSYCHOPHYSIOLOGY, V44, P905, DOI
10.1111/j.1469-8986.2007.00567.x; Hart AS, 2014, J NEUROSCI, V34, P698, DOI
10.1523/JNEUROSCI.2489-13.2014; Hauser TU, 2014, NEUROIMAGE, V84, P159, DOI
10.1016/j.neuroimage.2013.08.028; Hollerman JR, 1998, NAT NEUROSCI, V1, P304;
Holroyd CB, 2003, NEUROREPORT, V14, P2481, DOI 10.1097/01.wnr.0000099601/41403.a5;
Holroyd CB, 2008, PSYCHOPHYSIOLOGY, V45, P688, DOI 10.1111/j.1469-
8986.2008.00668.x; Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI
10.1146/annurev.neuro.29.051605.113009; JONES SR, 1995, J PHARMACOL EXP THER, V274,
P396; Kampman KM, 1998, ADDICT BEHAV, V23, P449, DOI 10.1016/S0306-4603(98)00011-2;
Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550;
Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0;
Koob GF, 1998, NEURON, V21, P467, DOI 10.1016/S0896-6273(00)80557-7; Lawson RP,
2014, P NATL ACAD SCI USA, V111, P11858, DOI 10.1073/pnas.1323586111; LESIEUR HR,
1987, AM J PSYCHIAT, V144, P1184; Liu S, 2008, CEREB CORTEX, V18, P2109, DOI
10.1093/cercor/bhm236; Liu X, 2007, J NEUROSCI, V27, P4587, DOI
10.1523/JNEUROSCI.5227-06.2007; Maia TV, 2011, NAT NEUROSCI, V14, P154, DOI
10.1038/nn.2723; Martinez D, 2009, AM J PSYCHIAT, V166, P1170, DOI
10.1176/appi.ajp.2009.08121801; Matsumoto M, 2007, NATURE, V447, P1111, DOI
10.1038/nature05860; Matuskey D, 2014, BIOL PSYCHIAT, V76, P816, DOI
10.1016/j.biopsych.2013.11.022; McClure SM, 2003, NEURON, V38, P339, DOI
10.1016/S0896-6273(03)00154-5; MCLELLAN AT, 1992, J SUBST ABUSE TREAT, V9, P199,
DOI 10.1016/0740-5472(92)90062-S; Melis M, 2005, INT REV NEUROBIOL, V63, P101, DOI
10.1016/S0074-7742(05)63005-X; MIRENOWICZ J, 1994, J NEUROPHYSIOL, V72, P1024;
Moeller SJ, 2013, J NEUROSCI, V33, P10027, DOI 10.1523/JNEUROSCI.0695-13.2013;
Moeller SJ, 2010, BRAIN, V133, P1484, DOI 10.1093/brain/awq066; Montague PR, 2004,
NATURE, V431, P760, DOI 10.1038/nature03015; Nieuwenhuis S, 2004, NEUROSCI BIOBEHAV
R, V28, P441, DOI 10.1016/j.neubiorev.2004.05.003; Nieuwenhuis S, 2004, CEREB
CORTEX, V14, P741, DOI 10.1093/cercor/bhh034; Nolte G, 2001, PHYS MED BIOL, V46,
P2873, DOI 10.1088/0031-9155/46/11/308; Oliveira FTP, 2007, J COGNITIVE NEUROSCI,
V19, P1994, DOI 10.1162/jocn.2007.19.12.1994; Park SQ, 2010, J NEUROSCI, V30,
P7749, DOI 10.1523/JNEUROSCI.5587-09.2010; Parvaz MA, 2012, PSYCHIAT RES-NEUROIM,
V203, P75, DOI 10.1016/j.pscychresns.2012.01.001; Pfabigan DM, 2011,
PSYCHOPHYSIOLOGY, V48, P656, DOI 10.1111/j.1469-8986.2010.01136.x; Porter JN, 2011,
J NEUROSCI, V31, P4926, DOI 10.1523/JNEUROSCI.5426-10.2011; Reynolds JNJ, 2001,
NATURE, V413, P67, DOI 10.1038/35092560; Rice ME, 2004, NAT NEUROSCI, V7, P583, DOI
10.1038/nn1244; Rose EJ, 2014, NEUROPSYCHOPHARMACOL, V39, P1732, DOI
10.1038/npp.2014.21; Rose EJ, 2012, BIOL PSYCHIAT, V71, P206, DOI
10.1016/j.biopsych.2011.09.013; Schoenbaum G, 2004, EUR J NEUROSCI, V19, P1997, DOI
10.1111/j.1460-9568.2004.03274.x; SCHULTZ W, 1992, EXP BRAIN RES, V91, P363;
Schultz W, 1998, J NEUROPHYSIOL, V80, P1, DOI 10.1152/jn.1998.80.1.1; Schultz W,
2011, NEURON, V69, P603, DOI 10.1016/j.neuron.2011.02.014; STERN WC, 1981,
NEUROPHARMACOLOGY, V20, P979, DOI 10.1016/0028-3908(81)90029-0; Talmi D, 2013, J
NEUROSCI, V33, P8264, DOI 10.1523/JNEUROSCI.5695-12.2013; Tanabe J, 2013, AM J
PSYCHIAT, V170, P1356, DOI 10.1176/appi.ajp.2013.12091257; TIFFANY ST, 1993, DRUG
ALCOHOL DEPEN, V34, P19, DOI 10.1016/0376-8716(93)90042-O; Tomasi D, 2007, BRAIN
RES, V1171, P83, DOI 10.1016/j.brainres.2007.06.102; Tran-Nguyen LTL, 1998,
NEUROPSYCHOPHARMACOL, V19, P48; Velasquez KM, 2014, FRONT HUM NEUROSCI, V8, DOI
10.3389/fnhum.2014.00174; Volkow ND, 1997, NATURE, V386, P830, DOI
10.1038/386830a0; Wager TD, 2005, NEUROIMAGE, V26, P99, DOI
10.1016/j.neuroimage.2005.01.011; Watanabe M, 1996, NATURE, V382, P629, DOI
10.1038/382629a0; Woicik PA, 2009, NEUROPSYCHOPHARMACOL, V34, P1112, DOI
10.1038/npp.2008.60; Wu Y, 2009, BRAIN RES, V1286, P114, DOI
10.1016/j.brainres.2009.06.032 80 32 32 1 14 SOC NEUROSCIENCE
WASHINGTON 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA 0270-
6474 J NEUROSCI J. Neurosci. FEB 4 2015 35 5
1872 1879 10.1523/JNEUROSCI.2777-14.2015 8
Neurosciences Neurosciences & Neurology CB5MI WOS:000349671100006
25653348 Bronze, Green Published 2019-09-25
J Vorspan, F; Mehtelli, W; Dupuy, G; Bloch, V; Lepine, JP
Vorspan, Florence; Mehtelli, Wajdi; Dupuy, Gael; Bloch, Vanessa; Lepine,
Jean-Pierre Anxiety and Substance Use Disorders: Co-occurrence and
Clinical Issues CURRENT PSYCHIATRY REPORTS English Article
Substance use disorders; Anxiety; Epidemiology;
Association POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH DISORDERS; PRESCRIPTION
OPIOID-USE; CANNABIS USE DISORDERS; GENERAL-POPULATION; BENZODIAZEPINE
PRESCRIPTIONS; DRUG-USE; SMOKING; ASSOCIATION; ALCOHOL The co-occurrence of
substance use disorders (SUDs) and anxiety disorders has been now well established.
This association is frequent and can be explained by three models: the shared
vulnerability factors model, the self-medication model, and the substance-induced
model. General population epidemiological studies provide strong evidence of the
frequency of the association for the most used substances: tobacco, alcohol,
cannabis, and to a lesser extent sedatives, opiates, and cocaine. For substances
that are less commonly used in the general population, the frequency of the co-
occurrence can more precisely be studied in clinical samples. We provide the most
recent literature results on the association of SUDs and anxiety, and evidence for
one explicative model or the other when available. For substances with sedative
properties (alcohol, benzodiazepines, cannabis, opioids), both evidence for a self-
medication and for a toxic effect exist. For substances with psychostimulant
properties (tobacco, cocaine, and amphetamines), the literature favors the toxic
hypothesis to explain the association with anxiety disorders. We give practical
steps for the recognition of these dual diagnoses and present therapeutic issues,
although the strategies are rarely evidence based. [Vorspan, Florence; Mehtelli,
Wajdi] Hop Fernand Widal, AP HP, Serv Med Addictol, F-75010 Paris, France;
[Vorspan, Florence; Lepine, Jean-Pierre] Fac Med Paris Diderot, F-75010 Paris,
France; [Vorspan, Florence; Dupuy, Gael; Bloch, Vanessa; Lepine, Jean-Pierre] Univ
Paris Diderot, Univ Paris Descartes, INSERM, Variabilite Reponse Psychotropes 1144,
F-75006 Paris, France; [Dupuy, Gael; Lepine, Jean-Pierre] Hop Fernand Widal, AP HP,
Serv Psychiat, F-75010 Paris, France Vorspan, F (reprint author), Hop Fernand
Widal, AP HP, Serv Med Addictol, 200 Rue Faubourg St Denis, F-75010 Paris, France.
 florence.vorspan@lrb.aphp.fr Bloch, Vanessa VB/L-9407-2017 Vorspan,
Florence/0000-0001-5168-3727 French Ministry of Health; ANRFrench National
Research Agency (ANR); Lundbeck, SA; ServierServier; Valoriser votre Recherche
Florence Vorspan has received a grant from the French Ministry of Health and
from the ANR (PHRC 2012, SAMENTA 2013, ERANet Neuron 2014).; Wajdi Mehtelli has
received paid travel accommodations from Lundbeck, SA.; Jean-Pierre Lepine has
received payment for conferences and paid travel accommodations from Servier,
Valoriser votre Recherche. Allsop DJ, 2014, JAMA PSYCHIAT, V71, P281, DOI
10.1001/jamapsychiatry.2013.3947; Benyamina Amine, 2008, Expert Rev Neurother, V8,
P479, DOI 10.1586/14737175.8.3.479; Blanco C, 2013, DRUG ALCOHOL DEPEN, V133, P473,
DOI 10.1016/j.drugalcdep.2013.07.011; Bruijnzeel AW, 2012, NEUROSCI BIOBEHAV R,
V36, P1418, DOI 10.1016/j.neubiorev.2012.02.015; Buckner JD, 2012, DRUG ALCOHOL
DEPEN, V124, P128, DOI 10.1016/j.drugalcdep.2011.12.023; Cheung JTW, 2010, AM J
DRUG ALCOHOL AB, V36, P118, DOI 10.3109/00952991003713784; Copeland J, 2009, INT
REV PSYCHIATR, V21, P96, DOI 10.1080/09540260902782745; de Gage SB, 2014, BMJ-BRIT
MED J, V349, DOI 10.1136/bmj.g5205; Degenhardt L, 2013, ADDICTION, V108, P124, DOI
10.1111/j.1360-0443.2012.04015.x; Degenhardt L, 2008, PLOS MED, V5, P1053, DOI
10.1371/journal.pmed.0050141; Dell'Osso L, 2014, COMPR PSYCHIAT, V55, P1244, DOI
10.1016/j.comppsych.2014.03.012; Esposito E, 2009, EPIDEMIOL PSICHIAT S, V18, P248,
DOI 10.1017/S1121189X00000531; Fatseas M, 2010, J SUBST ABUSE TREAT, V38, P220, DOI
10.1016/j.jsat.2009.12.003; Fischer B, 2012, J PAIN, V13, P1029, DOI
10.1016/j.jpain.2012.07.013; Glasner-Edwards S, 2013, J DUAL DIAGN, V9, P123, DOI
10.1080/15504263.2013.779157; Goodwin RD, 2014, ANN EPIDEMIOL, V24, P493, DOI
10.1016/j.annepidem.2014.01.014; Guillem E, 2015, ENCEPHALE, V41, pS7, DOI
10.1016/j.encep.2014.06.004; Hayatbakhsh MR, 2007, J AM ACAD CHILD PSY, V46, P408,
DOI 10.1091/CHI.0b013e31802dc54d; Higgins DM, 2014, PAIN MED, V15, P782, DOI
10.1111/pme.12388; Jaussent I, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-212;
Kedzior KK, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/1471-244X-14-136; Kessler RC,
2010, CURR TOP BEHAV NEURO, V2, P21, DOI 10.1007/7854_2009_9; Lawrence D, 2009, BMC
PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-285; Levin FR, 2011, DRUG ALCOHOL DEPEN,
V116, P142, DOI 10.1016/j.drugalcdep.2010.12.010; Martel MO, 2013, DRUG ALCOHOL
DEPEN, V132, P335, DOI 10.1016/j.drugalcdep.2013.02.034; Martins SS, 2012, PSYCHOL
MED, V42, P1261, DOI 10.1017/S0033291711002145; Meier A, 2014, AM J DRUG ALCOHOL
AB, V40, P304, DOI 10.3109/00952990.2014.910519; Miech R, 2012, DRUG ALCOHOL DEPEN,
V124, P259, DOI 10.1016/j.drugalcdep.2012.01.020; Minichino A, 2013, INT J ENV RES
PUB HE, V10, P4790, DOI 10.3390/ijerph10104790; Moylan S, 2012, BMC MED, V10, DOI
10.1186/1741-7015-10-123; Mykletun A, 2008, EUR PSYCHIAT, V23, P77, DOI
10.1016/j.eurpsy.2007.10.005; Nordfjaern T, 2013, ADDICT BEHAV, V38, P2575, DOI
10.1016/j.addbeh.2013.06.010; Olfson M, 2013, J CLIN PSYCHIAT, V74, P932, DOI
10.4088/JCP.13m08349; Piper ME, 2011, ADDICTION, V106, P418, DOI 10.1111/j.1360-
0443.2010.03173.x; Richards CS, 2013, J CONSULT CLIN PSYCH, V81, P263, DOI
10.1037/a0027793; Rozet I, 2014, ANESTH ANALG, V119, P454, DOI
10.1213/ANE.0000000000000292; Sareen J, 2006, PSYCHIAT RES, V142, P11, DOI
10.1016/j.psychres.2006.01.009; Schaap MM, 2009, PUBLIC HEALTH, V123, P103, DOI
10.1016/j.puhe.2008.10.015; Seal KH, 2012, JAMA-J AM MED ASSOC, V307, P940, DOI
10.1001/jama.2012.234; Semple SJ, 2011, AIDS BEHAV, V15, P1153, DOI 10.1007/s10461-
010-9719-7; Swendsen J, 2012, ARCH GEN PSYCHIAT, V69, P390, DOI
10.1001/archgenpsychiatry.2011.1503; Tannenbaum C, 2014, JAMA INTERN MED, V174,
P890, DOI 10.1001/jamainternmed.2014.949; Tjora T, 2011, BMC PUBLIC HEALTH, V11,
DOI 10.1186/1471-2458-11-911; Vorspan F, 2012, PSYCHIAT RES, V200, P1074, DOI
10.1016/j.psychres.2012.04.008; Wakefield JC, 2014, FRONT PSYCHIATRY, V5, DOI
10.3389/fpsyt.2014.00010; Wang GB, 2013, PLOS ONE, V8, DOI
10.1371/journal.pone.0068791; Ziedonis D, 2008, NICOTINE TOB RES, V10, P1691, DOI
10.1080/14622200802443569 47 29 29 0 19 SPRINGER NEW YORK
233 SPRING ST, NEW YORK, NY 10013 USA 1523-3812 1535-1645 CURR
PSYCHIAT REP Curr. Psychiatry Rep. FEB 2015 17 2
4 10.1007/s11920-014-0544-y 7 Psychiatry
Psychiatry CD6XC WOS:000351232700004 25617040 2019-
09-25
J Trautmann, S; Schonfeld, S; Behrendt, S; Heinrich, A; Hofler, M; Siegel, S;
Zimmermann, P; Wittchen, HU Trautmann, S.; Schoenfeld, S.;
Behrendt, S.; Heinrich, A.; Hoefler, M.; Siegel, S.; Zimmermann, P.; Wittchen, H.
-U. Predictors of changes in daily alcohol consumption in the
aftermath of military deployment DRUG AND ALCOHOL DEPENDENCE
English Article Stressful experience;
Deployment; Alcohol consumption; Predictors; Decrease; Increase POSTTRAUMATIC-
STRESS-DISORDER; UK ARMED-FORCES; ACTION QUESTIONNAIRE-II; SUBSTANCE USE DISORDERS;
INTERVIEW M-CIDI; MENTAL-DISORDERS; TRAUMATIC EXPERIENCES; CHILDHOOD ADVERSITY;
SELF-MEDICATION; PTSD SYMPTOMS Background: Several studies have documented
factors related to increase in alcohol consumption in the context of stressful
experiences. However, little is known about predictors of different courses of
alcohol use in this context. This study aims to investigate diverse predictors and
correlates of increase and decrease of average daily alcohol consumption (aDAC) in
the aftermath of military deployment taking into account a variety of potentially
relevant factors. Methods: N=358 soldiers were examined before (T1) and 12 months
after return from deployment (T2) using standardized interviews. Change in aDAC was
categorized into decreased (n = 72), stable (n=215) and increased (n = 71) aDAC.
Results: Overall, aDAC did not change significantly between T1 and T2 (median
change = 0.0 g, inter quartile range = 11.3 g). Compared to stable aDAC, increase
was characterized by a lower proportion of high-educated individuals (OR: 0.3 (0.1-
0.7), p = 0.008), lower rank (marginally significant: OR: 2.0 (1.0-4.1), p =
0.050), and less acceptance (trend: MR: 0.97 (0.93-1.00), p = 0.053). Correlates of
increased aDAC were less social support (MR: 0.84(0.71-0.99), p = 0.043), more
sleeping problems (MR: 1.15 (1.00-1.31), p = 0.045) and more negative post-event
cognitions following deployment (MR: 2.32 (1.28-4.21), p = 0.006). Decrease in aDAC
was predicted by lower PTSD symptom severity before deployment (MR: 0.34(0.16-
0.72), p = 0.005) and less childhood emotional neglect (marginally significant: MR:
0.78 (0.60-1.00), p = 0.050). Conclusions: Increase and decrease in alcohol use
after stressful experiences might have differential risk factors and correlates.
Findings might stimulate future research that could result in improved measures to
prevent increases as well as in interventions that could foster decreases in
alcohol consumption in the context of stressful experiences. (C) 2014 Elsevier
Ireland Ltd. All rights reserved. [Trautmann, S.; Schoenfeld, S.; Behrendt, S.;
Heinrich, A.; Hoefler, M.; Wittchen, H. -U.] Tech Univ Dresden, Inst Clin Psychol &
Psychotherapy, D-01187 Dresden, Germany; [Trautmann, S.; Schoenfeld, S.; Behrendt,
S.; Heinrich, A.; Hoefler, M.; Wittchen, H. -U.] Tech Univ Dresden, Ctr Epidemiol &
Longitudinal Studies CELOS, D-01187 Dresden, Germany; [Siegel, S.; Zimmermann, P.]
Fed Armed Forces Hosp Berlin, Ctr Psychiat & Posttraumat Stress, Berlin, Germany
Trautmann, S (reprint author), Tech Univ Dresden, Inst Clin Psychol &
Psychotherapy, D-01187 Dresden, Germany. trautmann@psychologie.tu-dresden.de
Wittchen, Hans-Ulrich/A-8507-2014; Trautmann, Sebastian/I-1853-2019;
Trautmann, Sebastian/A-8116-2014 Wittchen, Hans-Ulrich/0000-0002-6311-7711;
Trautmann, Sebastian/0000-0002-8976-3244 German Federal Ministry of Defence;
Medical Office thereof (Bundesministerium der Verteidigung) [M/SAB X/9A004] This
study was funded by the German Federal Ministry of Defence, respectively the
Medical Office thereof (Bundesministerium der Verteidigung, represented by:
Sanitatsamt der Bundeswehr: Project Funding number M/SAB X/9A004). The German
Defense Ministry had no further role in study design; in the collection, analysis
and interpretation of data; in the writing of the report; or in the decision to
submit the paper for publication. Bernstein DP, 2003, CHILD ABUSE NEGLECT, V27,
P169, DOI 10.1016/S0145-2134(02)00541-0; Bliese PD, 2008, J CONSULT CLIN PSYCH,
V76, P272, DOI 10.1037/0022-006X.76.2.272; Bond FW, 2011, BEHAV THER, V42, P676,
DOI 10.1016/j.beth.2011.03.007; Bray RM, 2007, ADDICTION, V102, P1092, DOI
10.1111/j.1360-0443.2007.01841.x; Brewin CR, 2003, CLIN PSYCHOL REV, V23, P339, DOI
10.1016/S0272-7358(03)00033-3; Browne T, 2008, OCCUP ENVIRON MED, V65, P628, DOI
10.1136/oem.2007.036830; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI
10.1016/0165-1781(89)90047-4; Campbell-Sills L, 2009, J PSYCHIATR RES, V43, P1007,
DOI 10.1016/j.jpsychires.2009.01.013; Clarke-Walper K, 2014, ADDICT BEHAV, V39,
P414, DOI 10.1016/j.addbeh.2013.05.001; Clohessy S, 1999, BRIT J CLIN PSYCHOL, V38,
P251, DOI 10.1348/014466599162836; Crum RM, 2013, DEPRESS ANXIETY, V30, P174, DOI
10.1002/da.22024; Fear NT, 2007, ADDICTION, V102, P1749, DOI 10.1111/j.1360-
0443.2007.01978.x; Fear NT, 2010, LANCET, V375, P1783, DOI 10.1016/S0140-
6736(10)60672-1; Foa EB, 1999, PSYCHOL ASSESSMENT, V11, P303, DOI 10.1037/1040-
3590.11.3.303; German Federal Ministry of Defense, 2011, BUND EINS ENTST ENTW; Hoge
EA, 2007, DEPRESS ANXIETY, V24, P139, DOI 10.1002/da.20175; Hooper R, 2008, ADDICT
BEHAV, V33, P1067, DOI 10.1016/j.addbeh.2008.03.010; Iversen AC, 2009, BMC
PSYCHIATRY, V9, DOI 10.1186/1471-244X-9-68; Jacobson IG, 2008, JAMA-J AM MED ASSOC,
V300, P663, DOI 10.1001/jama.300.6.663; Jones E, 2011, INT REV PSYCHIATR, V23,
P166, DOI 10.3109/09540261.2010.550868; Keyes KM, 2011, PSYCHOPHARMACOLOGY, V218,
P1, DOI 10.1007/s00213-011-2236-1; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4,
P231, DOI 10.3109/10673229709030550; King LA, 2006, MIL PSYCHOL, V18, P89, DOI
10.1207/s15327876mp1802_1; Kline A, 2014, J PSYCHIATR RES, V50, P18, DOI
10.1016/j.jpsychires.2013.11.007; Lachner G, 1998, EUR ADDICT RES, V4, P28, DOI
10.1159/000018922; Lande RG, 2008, J ADDICT DIS, V27, P115, DOI
10.1080/10550880802122711; Lazareck S, 2012, J CLIN PSYCHIAT, V73, pE588, DOI
10.4088/JCP.11m07345; Linley PA, 2004, J TRAUMA STRESS, V17, P11, DOI
10.1023/B:JOTS.0000014671.27856.7e; Maguen S, 2006, J LOSS TRAUMA, V11, P373, DOI
10.1080/15325020600672004; Marshall BDL, 2012, DRUG ALCOHOL DEPEN, V124, P193, DOI
10.1016/j.drugalcdep.2011.12.027; Martin AM, 2014, J HOMOSEXUAL, V61, P251, DOI
10.1080/00918369.2013.839908; McKenzie D.P., 2009, SOC PSYCHIAT EPIDEMI, V45, P843;
McLaughlin KA, 2010, PSYCHOL MED, V40, P1647, DOI 10.1017/S0033291709992121; Mental
Health Advisory Team (MHAT IV), 2006, OP IR FREED 05 07; Meyer EC, 2013, PSYCHOL
TRAUMA-US, V5, P521, DOI 10.1037/a0030178; Mikulincer M, 2012, WORLD PSYCHIATRY,
V11, P11, DOI 10.1016/j.wpsyc.2012.01.003; Nordlokken A, 2013, BMC PUBLIC HEALTH,
V13, DOI 10.1186/1471-2458-13-58; North CS, 2011, ARCH GEN PSYCHIAT, V68, P173, DOI
10.1001/archgenpsychiatry.2010.131; Pietrzak RH, 2010, J AFFECT DISORDERS, V120,
P188, DOI 10.1016/j.jad.2009.04.015; Reed V, 1998, INT J METH PSYCH RES, V7, P142,
DOI DOI 10.1002/MPR.44; Riddle JR, 2007, J CLIN EPIDEMIOL, V60, P192, DOI
10.1016/j.jclinepi.2006.04.008; Roehrs T, 2001, ALCOHOL RES HEALTH, V25, P101;
ROYALL RM, 1986, INT STAT REV, V54, P221, DOI 10.2307/1403146; Russell DW, 2014,
DRUG ALCOHOL DEPEN, V139, P47, DOI 10.1016/j.drugalcdep.2014.03.004; Shipherd JC,
2005, ADDICT BEHAV, V30, P595, DOI 10.1016/j.addbeh.2004.07.004; Spera C, 2011, J
STUD ALCOHOL DRUGS, V72, P5, DOI 10.15288/jsad.2011.72.5; StataCorp, 2012, STAT
STAT SOFTW REL; Sundin J, 2011, INT REV PSYCHIATR, V23, P153, DOI
10.3109/09540261.2011.561303; Thompson RW, 2011, TRAUMA VIOLENCE ABUS, V12, P220,
DOI 10.1177/1524838011416375; Trautmann S, 2014, DRUG ALCOHOL DEPEN, V134, P128,
DOI 10.1016/j.drugalcdep.2013.09.024; Walser R. D., 2006, COGNITIVE BEHAV THER;
Wilk JE, 2010, DRUG ALCOHOL DEPEN, V108, P115, DOI
10.1016/j.drugalcdep.2009.12.003; Wittchen H, 1997, COMMUNICATION; Wittchen H.U.,
2013, J DEPRESS ANXIETY, V2, P2167; Wittchen H. U., 1997, DIA X SCREENING VERF;
Wittchen HU, 2012, DTSCH ARZTEBL INT, V109, P559, DOI 10.3238/arztebl.2012.0559;
Wittchen HU, 2012, INT J METH PSYCH RES, V21, P98, DOI 10.1002/mpr.1356; Wittchen
HU, 1998, SOC PSYCH PSYCH EPID, V33, P568, DOI 10.1007/s001270050095; ZIGMOND AS,
1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x 59
12 12 0 23 ELSEVIER IRELAND LTD CLARE ELSEVIER HOUSE,
BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND 0376-8716 1879-
0046 DRUG ALCOHOL DEPEN Drug Alcohol Depend. FEB 1 2015 147
175 182 10.1016/j.drugalcdep.2014.11.019
8 Substance Abuse; Psychiatry Substance Abuse; Psychiatry CA4RU
WOS:000348893000024 25499731 2019-09-25
J Overup, CS; DiBello, AM; Brunson, JA; Acitelli, LK; Neighbors, C
Overup, Camilla S.; DiBello, Angelo M.; Brunson, Julie A.; Acitelli, Linda
K.; Neighbors, Clayton Drowning the pain: Intimate partner violence
and drinking to cope prospectively predict problem drinkingADDICTIVE BEHAVIORS
English Article Alcohol-related
problems; Drinking problems; Drinking to cope; Intimate partner violence;
Longitudinal mediation POSTTRAUMATIC-STRESS-DISORDER; SELF-MEDICATION HYPOTHESIS;
ALCOHOL-USE; SUBSTANCE USE; DATING VIOLENCE; COLLEGE-STUDENT; GENDER-DIFFERENCES;
DOMESTIC VIOLENCE; HEAVY DRINKING; SEXUAL ASSAULT Introduction: The present
study examined the longitudinal association among drinking problems, drinking to
cope, and degree of intimate partner violence (IPV). Two competing models were
tested; the first model posited that drinking to cope leads to greater drinking
problems and this subsequently leads to more violence in the relationship (an
intoxication violence model). The second model speculated that violence in the
relationship leads to drinking to cope, which in turn leads to greater drinking
problems (a self-medication model). Methods: Eight hundred and eighteen
undergraduate students at a large north-western university participated in the
study over a two year period, completing assessments of IPV, alcohol related
problems and drinking to cope at five time points over a two year period as part of
a larger social norms intervention study. Results: Analyses examined two competing
models; analyses indicated that there was support for the self-mediation model,
whereby people who have experienced violence have more drinking problems later, and
this association is temporally mediated by drinking to cope. Discussion: The
current results are discussed in light of past research on the self-medication
model. (C) 2014 Elsevier Ltd. All rights reserved. [Overup, Camilla S.; DiBello,
Angelo M.; Acitelli, Linda K.; Neighbors, Clayton] Univ Houston, Houston, TX 77204
USA; [Brunson, Julie A.] Penn State Univ, University Pk, PA 16802 USA Overup, CS
(reprint author), Univ Houston, Dept Psychol, Houston, TX 77204 USA.
coverup@uh.edu Overup, Camilla/I-6946-2019 Overup, Camilla/0000-0002-
5557-2597; Brunson, Julie/0000-0001-8186-7463 National Institute on Alcohol Abuse
and Alcoholism (NIAAA)United States Department of Health & Human ServicesNational
Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse &
Alcoholism (NIAAA) [R01AA014576] Funding for this study was provided by the
National Institute on Alcohol Abuse and Alcoholism (NIAAA) Grant R01AA014576. NIAAA
had no role in the study design, collection, analysis or interpretation of the
data, writing the manuscript, or the decision to submit the paper for publication.
Anderson KL, 2002, J MARRIAGE FAM, V64, P851, DOI 10.1111/j.1741-
3737.2002.00851.x; Arias I., 1987, J INTERPERS VIOLENCE, V2, P82, DOI DOI
10.1177/088626087002001005; Atkins DC, 2007, J FAM PSYCHOL, V21, P726, DOI
10.1037/0893-3200.21.4.726; Bachman J. G., 2002, DECLINE SUBSTANCE US; Baker C. R.,
2008, J AGGRESS MALTREAT T, V17, P227, DOI DOI 10.1080/10926770802344836; Bonomi
AE, 2007, J WOMENS HEALTH, V16, P987, DOI 10.1089/jwh.2006.0239; Breiding MJ, 2008,
AM J PREV MED, V34, P112, DOI 10.1016/j.amepre.2007.10.001; BURNAM MA, 1988, J
CONSULT CLIN PSYCH, V56, P843, DOI 10.1037/0022-006X.56.6.843; Caetano R, 2001,
ALCOHOL RES HEALTH, V25, P58; CAMPBELL JC, 1989, NURS RES, V38, P18; CANNON DS,
1992, ADDICT BEHAV, V17, P517, DOI 10.1016/0306-4603(92)90061-Y; COCORES JA, 1987,
J CLIN PSYCHIAT, V48, P376; Collins R. L., 1985, J CONSULT CLIN PSYCH, V43, P405;
Cooper M. L., 1994, PSYCHOL ASSESSMENT, V6, P117, DOI [DOI 10.1037/1040-
3590.6.2.117, 10.1037/1040-3590.6.2.117]; COOPER ML, 1995, J PERS SOC PSYCHOL, V69,
P990, DOI 10.1037/0022-3514.69.5.990; Cyr M, 2006, J INTERPERS VIOLENCE, V21,
P1000, DOI 10.1177/0886260506290201; Duncan D. F., 1974, CLIN TOXICOLOGY B, V4,
P69; DUNCAN DF, 1974, AM J PSYCHIAT, V131, P724; Foran HM, 2008, CLIN PSYCHOL REV,
V28, P1222, DOI 10.1016/j.cpr.2008.05.001; Frances RJ, 1997, HARVARD REV PSYCHIAT,
V4, P287, DOI 10.3109/10673229709030556; Goldstein AL, 2010, ADDICT BEHAV, V35,
P636, DOI 10.1016/j.addbeh.2010.02.002; Grant VV, 2007, ADDICT BEHAV, V32, P2611,
DOI 10.1016/j.addbeh.2007.07.004; Grayson CE, 2005, J TRAUMA STRESS, V18, P137, DOI
10.1002/jts.20021; Harned MS, 2002, J INTERPERS VIOLENCE, V17, P1179, DOI
10.1177/088626002237401; Hilbe J, 2011, NEGATIVE BINOMIAL RE; Johnson EO, 2006,
NICOTINE TOB RES, V8, P257, DOI 10.1080/14622200600576644; KANTOR GK, 1989, AM J
DRUG ALCOHOL AB, V15, P173, DOI 10.3109/00952998909092719; Kaysen D, 2007, ADDICT
BEHAV, V32, P1272, DOI 10.1016/j.addbeh.2006.09.007; KHANTZIAN EJ, 1985, AM J
PSYCHIAT, V142, P1259; Kilpatrick DG, 1997, J CONSULT CLIN PSYCH, V65, P834, DOI
10.1037/0022-006X.65.5.834; Krull JL, 2001, MULTIVAR BEHAV RES, V36, P249, DOI
10.1207/S15327906MBR3602_06; Leonard K. E., 1993, RES MONOGRAPH 24 ALC, P253;
Leonard KE, 2005, ADDICTION, V100, P422, DOI 10.1111/j.1360-0443.2005.00994.x;
Luthra R, 2006, J INTERPERS VIOLENCE, V21, P717, DOI 10.1177/0886260506287312;
Magdol L, 1997, J CONSULT CLIN PSYCH, V65, P68, DOI 10.1037/0022-006X.65.1.68;
Marlatt GA, 1998, J CONSULT CLIN PSYCH, V66, P604, DOI 10.1037/0022-006X.66.4.604;
MILLER BA, 1993, ALCOHOL HEALTH RES W, V17, P137; Munoz-Rivas MJ, 2007, J
ADOLESCENT HEALTH, V40, P298, DOI 10.1016/j.jadohealth.2006.11.137; Neighbors C,
2004, J STUD ALCOHOL, V65, P736, DOI 10.15288/jsa.2004.65.736; Neighbors C, 2010, J
CONSULT CLIN PSYCH, V78, P898, DOI 10.1037/a0020766; Nishith P, 2001, J TRAUMA
STRESS, V14, P469, DOI 10.1023/A:1011152405048; O'Leary KD, 1999, CLIN PSYCHOL-SCI
PR, V6, P400, DOI 10.1093/clipsy.6.4.400; Raudenbush S. W., 2002, HIERARCHICAL
LINEAR; RIGGS DS, 1990, J INTERPERS VIOLENCE, V5, P61, DOI DOI
10.1177/088626090005001005; RUSSELL MN, 1989, PSYCHOTHER, V26, P81, DOI
10.1037/h0085409; Simons JS, 2006, AM J DRUG ALCOHOL AB, V32, P41, DOI
10.1080/00952990500328539; Smit F, 2004, ADDICTION, V99, P425, DOI 10.1111/j.1360-
0443.2004.00683.x; Smith PH, 2012, PSYCHOL ADDICT BEHAV, V26, P236, DOI
10.1037/a0024855; Sorenson SB, 1996, AM J PUBLIC HEALTH, V86, P35, DOI
10.2105/AJPH.86.1.35; Stappenbeck CA, 2010, ADDICT BEHAV, V35, P479, DOI
10.1016/j.addbeh.2009.12.027; STAR B, 1979, SOC CASEWORK-JCSW, V60, P479; STEWART
SH, 2000, ALCOHOLISM TREATMENT, V18, P31, DOI DOI 10.1300/J020V18N03; Straus M. A.,
1989, J FAMILY VIOLENCE, V4, P161, DOI DOI 10.1007/BF01006627; Straus MA, 2008,
CHILD YOUTH SERV REV, V30, P252, DOI 10.1016/j.childyouth.2007.10.004; Straus
Murray A, 2004, Violence Vict, V19, P507; Stuart GL, 2013, J CONSULT CLIN PSYCH,
V81, P681, DOI 10.1037/a0032876; Temple JR, 2008, ADDICT BEHAV, V33, P1244, DOI
10.1016/j.addbeh.2008.05.005; Testa M, 2001, J FAM VIOLENCE, V16, P115, DOI
10.1023/A:1011154818394; Testa M, 2003, ADDICT BEHAV, V28, P1649, DOI
10.1016/j.addbeh.2003.08.040; Testa M, 2011, AGGRESSIVE BEHAV, V37, P362, DOI
10.1002/ab.20391; Tofighi D, 2011, BEHAV RES METHODS, V43, P692, DOI
10.3758/s13428-011-0076-x; Wechsler H, 2001, PSYCHOL ADDICT BEHAV, V15, P287, DOI
10.1037/0893-164X.15.4.287; WHITE HR, 1989, J STUD ALCOHOL, V50, P30, DOI
10.15288/jsa.1989.50.30; White J W, 1991, Violence Vict, V6, P247; Yeater EA, 2010,
PSYCHOL TRAUMA-US, V2, P307, DOI 10.1037/a0021779 65 11 11 2 29
PERGAMON-ELSEVIER SCIENCE LTD OXFORD THE BOULEVARD, LANGFORD LANE,
KIDLINGTON, OXFORD OX5 1GB, ENGLAND 0306-4603 1873-6327 ADDICT BEHAV
Addict. Behav. FEB 2015 41 152 161
10.1016/j.addbeh.2014.10.006 10 Psychology, Clinical;
Substance Abuse Psychology; Substance Abuse AY3PZ WOS:000347496500026
25452060 Green Accepted 2019-09-25
J Manzo, L; Donaire, R; Sabariego, M; Papini, MR; Torres, C
Manzo, Lidia; Donaire, Rocio; Sabariego, Marta; Papini, Mauricio R.; Torres,
Carmen Anti-anxiety self-medication in rats: Oral consumption of
chlordiazepoxide and ethanol after reward devaluation BEHAVIOURAL BRAIN RESEARCH
English Article Self-medication;
Incentive loss; Successive negative contrast; Anxiety; Chlordiazepoxide; Ethanol
SUCCESSIVE NEGATIVE CONTRAST; HIGH-RHA-I; SUBSTANCE USE; INDIVIDUAL-
DIFFERENCES; PARTIAL-REINFORCEMENT; ROMAN HIGH-(RHA); NOVELTY-SEEKING; AVOIDANCE
RATS; STRESS; ALCOHOL Rats increased preference for ethanol after sessions of
appetitive extinction, but not after acquisition (reinforced) sessions (Manzo et
al., 2014). Drinking was not influenced by appetitive extinction in control groups
with postsession access to water, rather than ethanol. Because ethanol has
anxiolytic properties in tasks involving reward loss, these results were
interpreted as anti-anxiety self-medication. The present experiment tested the
potential for self-medication with the prescription anxiolytic chlordiazepoxide, a
benzodiazepine with an addictive profile used in the treatment of anxiety
disorders. To test this hypothesis, Wistar rats exposed to a 32-to-4% sucrose
devaluation received a two-bottle, 2-h preference test immediately after
consummatory training. One bottle contained 1 mg/kg of chlordiazepoxide, 2%
ethanol, or water for different groups (the second bottle contained water for all
groups). Three additional groups received the same postsession preference tests,
but were exposed to 4% sucrose during consummatory training. Rats showed
suppression of consummatory behavior after reward devaluation relative to unshifted
controls. This effect was accompanied by a selective increase in preference for
chlordiazepoxide and ethanol. Downshifted animals with access to water or unshifted
controls with access to the anxiolytics failed to exhibit postsession changes in
preference. Similar results were observed in terms of absolute consumption and
consumption relative to body weight. This study shows for the first time that a
prescription anxiolytic supports enhanced voluntary consumption during periods of
emotional distress triggered by reward loss. Such anti-anxiety self-medication
provides insights into the early stages of addictive behavior. (C) 2014 Elsevier
B.V. All rights reserved. [Manzo, Lidia; Donaire, Rocio; Sabariego, Marta;
Torres, Carmen] Univ Jaen, Dept Psychol, Jaen 23071, Spain; [Papini, Mauricio R.]
Texas Christian Univ, Dept Psychol, Ft Worth, TX 76129 USA Papini, MR (reprint
author), Texas Christian Univ, Dept Psychol, Ft Worth, TX 76129 USA.
m.papini@tcu.edu Torres, Carmen/K-8250-2014; Sabariego, Marta/L-1786-2017
Torres, Carmen/0000-0001-8573-0990; Sabariego, Marta/0000-0003-2544-3708
Junta de AndaluciaJunta de Andalucia [HUM-642]; Ministerio de Ciencia e
Innovacion, SpainMinistry of Science and Innovation, Spain (MICINN) [PSI2010-
15787]; Universidad Michoacana, Mexico L. Manzo and R. Donaire contributed
equally to the research reported here. This research was supported by grants from
Junta de Andalucia (HUM-642) and Ministerio de Ciencia e Innovacion (PSI2010-
15787), Spain. L. Manzo's participation was made possible by a grant from
Universidad Michoacana, Mexico. American Psychiatric Association, 2013, DIAGN
STAT MAN MENT; Amsel A., 1992, FRUSTRATION THEORY A; ANISMAN H, 1974, PHARMACOL
BIOCHEM BE, V2, P27, DOI 10.1016/0091-3057(74)90131-2; Bardo MT, 1996, BEHAV BRAIN
RES, V77, P23, DOI 10.1016/0166-4328(95)00203-0; BECKER HC, 1986, PHARMACOL BIOCHEM
BE, V24, P1057, DOI 10.1016/0091-3057(86)90455-7; Becker HC, 2011,
PSYCHOPHARMACOLOGY, V218, P131, DOI 10.1007/s00213-011-2443-9; BOYD TL, 1989, BEHAV
RES THER, V27, P35, DOI 10.1016/0005-7967(89)90117-4; Briand LA, 2010, BRAIN RES,
V1314, P219, DOI 10.1016/j.brainres.2009.11.002; Caldwell EE, 2010, ALCOHOL, V44,
P265, DOI 10.1016/j.alcohol.2010.02.012; COCHRANE R, 1973, J PSYCHOSOM RES, V17,
P135, DOI 10.1016/0022-3999(73)90014-7; Cuenya L, 2012, PHYSIOL BEHAV, V105, P1112,
DOI 10.1016/j.physbeh.2011.12.006; DANTZER R, 1981, HORM BEHAV, V15, P386, DOI
10.1016/0018-506X(81)90003-9; Darke S, 2013, ADDICTION, V108, P659, DOI
10.1111/j.1360-0443.2012.04001.x; Dayan J, 2010, J PHYSIOL-PARIS, V104, P279, DOI
10.1016/j.jphysparis.2010.08.007; Dickinson A., 2002, STEVENS HDB EXPT PSY, V3,
P497, DOI DOI 10.1002/0471214426.PAS0312; Donaire R, 2013, REV ARGENT CIENC COM,
V5, P40; Egli M, 2012, NEUROSCI BIOBEHAV R, V36, P2179, DOI
10.1016/j.neubiorev.2012.07.010; Enman NM, 2014, PHARMACOL BIOCHEM BE, V117, P61,
DOI 10.1016/j.pbb.2013.12.001; Ewan EE, 2013, NEUROSCI LETT, V557, P60, DOI
10.1016/j.neulet.2013.08.018; Flaherty C.F., 1996, INCENTIVE RELATIVITY; FLAHERTY
CF, 1986, ANIM LEARN BEHAV, V14, P315, DOI 10.3758/BF03200073; FLAHERTY CF, 1990, Q
J EXP PSYCHOL-B, V42, P87; Freet CS, 2006, PHARMACOL BIOCHEM BE, V85, P378, DOI
10.1016/j.pbb.2006.09.005; Gomez MJ, 2009, PSICOLOGICA, V30, P181; Gordon HW, 2002,
PSYCHONEUROENDOCRINO, V27, P115, DOI 10.1016/S0306-4530(01)00039-7; Gray J. A.,
1987, PSYCHOL FEAR STRESS; Gutierrez T, 2011, PAIN, V152, P1976, DOI
10.1016/j.pain.2011.03.038; Hassanbeigi A, 2013, PROCD SOC BEHV, V84, P1333, DOI
10.1016/j.sbspro.2013.06.752; Hien DA, 2010, AM J PSYCHIAT, V167, P95, DOI
10.1176/appi.ajp.2009.09091261; Gomez MJ, 2008, BEHAV BRAIN RES, V194, P187, DOI
10.1016/j.bbr.2008.07.009; Gomez MJ, 2009, PHYSIOL BEHAV, V97, P374, DOI
10.1016/j.physbeh.2009.03.003; Khantzian EJ, 2013, ADDICTION, V108, P668, DOI
10.1111/add.12004; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259; Konopka A, 2013,
PROG NEURO-PSYCHOPH, V40, P229, DOI 10.1016/j.pnpbp.2012.09.001; Koob GF, 2013,
CURR OPIN NEUROBIOL, V23, P559, DOI 10.1016/j.conb.2013.03.011; LEVINE S, 1979,
PSYCHONEUROENDOCRINO, V4, P275, DOI 10.1016/0306-4530(79)90012-X; Lynch WJ, 1999,
EXP CLIN PSYCHOPHARM, V7, P318, DOI 10.1037/1064-1297.7.4.318; Mantsch JR, 2014,
NEUROPHARMACOLOGY, V76, P383, DOI 10.1016/j.neuropharm.2013.07.021; Manzo L, 2014,
PHYSIOL BEHAV, V133, P53, DOI 10.1016/j.physbeh.2014.05.003; Manzo L, 2014, PHYSIOL
BEHAV, V123, P86, DOI 10.1016/j.physbeh.2013.10.002; Manzo L, 2012, PHYSIOL BEHAV,
V108, P1, DOI 10.1016/j.physbeh.2012.07.002; Mitchell C, 1998, PHYSIOL BEHAV, V64,
P287, DOI 10.1016/S0031-9384(98)00072-9; Mustaca AE, 2006, INT J PSYCHOL PSYCHO,
V6, P343; NASH JF, 1985, LIFE SCI, V37, P757; Norris JN, 2009, PHARMACOL BIOCHEM
BE, V94, P81, DOI 10.1016/j.pbb.2009.07.012; Ortega LA, 2014, PHARMACOL BIOCHEM BE,
V116, P96, DOI 10.1016/j.pbb.2013.11.031; OSBORNE B, 1979, BEHAV NEURAL BIOL, V25,
P227, DOI 10.1016/S0163-1047(79)90584-3; Ouimette P, 2007, ADDICT BEHAV, V32,
P1719, DOI 10.1016/j.addbeh.2006.11.020; Papini M., 2006, INT J PSYCHOL PSYCHO, V6,
P189; Papini M. R., 1997, REV GEN PSYCHOL, V1, P175, DOI [10.1037/1089-
2680.1.2.175, DOI 10.1037/1089-2680.1.2.175]; Papini MR, 2003, BRAIN BEHAV EVOLUT,
V62, P83, DOI 10.1159/000072439; Papini MR, 2009, INT J COMP PSYCHOL, V22, P170;
Papini MR, 2014, BEHAV NEUROSCI UNPUB; Papini S, 2014, BEHAV BRAIN IN PRESS; Parker
LA, 1998, PHARMACOL BIOCHEM BE, V59, P33, DOI 10.1016/S0091-3057(97)00333-X; PARKER
LF, 1974, PHYSIOL BEHAV, V12, P1, DOI 10.1016/0031-9384(74)90060-2; Pawlak CR,
2008, NEUROSCI BIOBEHAV R, V32, P1544, DOI 10.1016/j.neubiorev.2008.06.007; Pellon
R, 2011, BEHAV BRAIN RES, V217, P195, DOI 10.1016/j.bbr.2010.10.010; Ravindran LN,
2010, J CLIN PSYCHIAT, V71, P839, DOI 10.4088/JCP.10r06218blu; Reagan-Shaw S, 2008,
FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Rosas JM, 2007, BEHAV BRAIN RES,
V185, P1, DOI 10.1016/j.bbr.2007.07.027; ROSKE I, 1994, ALCOHOL, V11, P113, DOI
10.1016/0741-8329(94)90052-3; Scully JA, 2000, EDUC PSYCHOL MEAS, V60, P864, DOI
10.1177/00131640021970952; Siegmund S, 2005, ALCOHOL CLIN EXP RES, V29, P1139, DOI
10.1097/01.ALC.0000171928.40418.46; Steimer T, 2005, NEUROSCI BIOBEHAV R, V29, P99,
DOI 10.1016/j.neubiorev.2004.07.002; Tan KR, 2011, TRENDS NEUROSCI, V34, P188, DOI
10.1016/j.tins.2011.01.004; THOMKA ML, 1975, ANIM LEARN BEHAV, V3, P380, DOI
10.3758/BF03213463; Torres C, 2005, PHYSIOL BEHAV, V85, P377, DOI
10.1016/j.physbeh.2005.02.023; Torres C, 2014, INT J COMP PSYCHOL, V27, P446;
Vengeliene V, 2003, ALCOHOL CLIN EXP RES, V27, P1048, DOI
10.1097/01.ALC.0000075829.81211.0C; Volkow ND, 2014, NEUROPHARMACOLOGY, V76, P235,
DOI 10.1016/j.neuropharm.2013.05.007; VOLPICELLI JR, 1982, PHYSIOL PSYCHOL, V10,
P114; Yap Jasmine J, 2008, Drug Discov Today Dis Models, V5, P259 73 18
18 1 11 ELSEVIER SCIENCE BV AMSTERDAM PO BOX 211, 1000 AE
AMSTERDAM, NETHERLANDS 0166-4328 1872-7549 BEHAV BRAIN RES Behav. Brain
Res. FEB 1 2015 278 90 97
10.1016/j.bbr.2014.09.017 8 Behavioral Sciences;
Neurosciences Behavioral Sciences; Neurosciences & Neurology AY5AQ
WOS:000347586300011 25242284 2019-09-25
J Feingold, D; Weiser, M; Rehm, J; Lev-Ran, S Feingold,
Daniel; Weiser, Mark; Rehm, Juergen; Lev-Ran, Shaul The association
between cannabis use and mood disorders: A longitudinal study JOURNAL OF
AFFECTIVE DISORDERS English Article
Cannabis; Major depressive disorder; Bipolar disorder; Longitudinal
association NATIONAL EPIDEMIOLOGIC SURVEY; SUBSTANCE USE DISORDERS; ALCOHOL-USE
DISORDER; BIPOLAR-I DISORDER; MARIJUANA USE; DRUG-USE; AUDADIS-ADR; DEPRESSIVE
EPISODE; ANXIETY DISORDERS; SELF-MEDICATION Background: The association between
cannabis use and mood disorders is well documented, yet evidence regarding
causality is conflicting. This study explored the association between cannabis use,
major depressive disorder (MDD) and bipolar disorder (BED) in a 3-year prospective
study. Methods: Data was drawn from waves 1 and 2 of the National Epidemiologic
Survey on Alcohol and Related Conditions (NESARC). MDD and BED were controlled at
baseline and defined as meeting full criteria in the 12 months prior to the follow-
up. Initiation of cannabis use was defined as any cannabis used by former lifetime
abstainers in the time period between baseline and follow-up. Results: Cannabis use
was not significantly associated with increased incidence of MDD (Adjusted Odds
Ratio (AOR) for daily use=0.58(0.22-1.51). Weekly to almost daily cannabis use was
associated with increased incidence of BED ((AOR for weekly to daily use=2.47(1.03-
5.92)); daily use was not (AOR=0.52(0.17-1.55)). Baseline MDD was associated with
initiation of cannabis use (AOR=1.72(1.1-2.69). A crude association between
baseline BED and incidence of cannabis use was not maintained in adjusted models
(AOR=0.61(0.36-1.04)). Limitations: Lack of information regarding frequency of
cannabis use at follow-up and limitations regarding generalization of the results.
Conclusions: Our findings do not support a longitudinal association between
cannabis use and incidence of MDD. Results regarding the association between
cannabis use and incidence of BED are conflicting and require further
investigation. Baseline MDD, but not BED, may be associated with future initiation
of cannabis use. This may have implications for clinical, social and legislative
aspects of cannabis use. (C) 2014 Elsevier B.V. All rights reserved. [Feingold,
Daniel] Ariel Univ, Ariel, Israel; [Feingold, Daniel; Lev-Ran, Shaul] Chaim Sheba
Med Ctr, Dept Psychiat, Addict Med Serv, IL-52621 Tel Hashomer, Israel; [Weiser,
Mark] Chaim Sheba Med Ctr, Dept Psychiat, IL-52621 Tel Hashomer, Israel; [Weiser,
Mark; Lev-Ran, Shaul] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel;
[Rehm, Juergen; Lev-Ran, Shaul] Ctr Addict & Mental Hlth, Social & Epidemiol Res
Dept, Toronto, ON, Canada; [Rehm, Juergen] Univ Toronto, Dann Lana Sch Publ Hlth,
Toronto, ON, Canada Feingold, D (reprint author), Chaim Sheba Med Ctr, Dept
Psychiat, Addict Med Serv, IL-52621 Tel Hashomer, Israel. d.y.feingold@gmail.com
American Psychiatric Association, 2000, DIAGN STAT MAN
MENT; Arseneault L, 2004, BRIT J PSYCHIAT, V184, P110, DOI 10.1192/bjp.184.2.110;
Baethge C, 2008, BIPOLAR DISORD, V10, P738, DOI 10.1111/j.1399-5618.2007.00575.x;
Baldessarini RJ, 2012, J AFFECT DISORDERS, V136, P149, DOI
10.1016/j.jad.2011.08.037; Bizzarri JV, 2007, BIPOLAR DISORD, V9, P213, DOI
10.1111/j.1399-5618.2007.00383.x; Bizzarri JV, 2009, PSYCHIAT RES, V165, P88, DOI
10.1016/j.psychres.2007.10.009; Bolton JM, 2009, J AFFECT DISORDERS, V115, P367,
DOI 10.1016/j.jad.2008.10.003; Bovasso GB, 2001, AM J PSYCHIAT, V158, P2033, DOI
10.1176/appi.ajp.158.12.2033; Brook DW, 2002, ARCH GEN PSYCHIAT, V59, P1039, DOI
10.1001/archpsyc.59.11.1039; Brook JS, 2011, PSYCHOL REP, V108, P339, DOI
10.2466/10.18.PR0.108.2.339-357; Carvalho AF, 2012, PROG NEURO-PSYCHOPH, V38, P59,
DOI 10.1016/j.pnpbp.2012.01.008; Cerda M, 2012, DRUG ALCOHOL DEPEN, V120, P22, DOI
10.1016/j.drugalcdep.2011.06.011; Cerullo MA, 2007, SUBST ABUSE TREAT PR, V2, DOI
10.1186/1747-597X-2-29; Chatterji S, 1997, DRUG ALCOHOL DEPEN, V47, P171, DOI
10.1016/S0376-8716(97)00088-4; Chen CY, 2002, SOC PSYCH PSYCH EPID, V37, P199, DOI
10.1007/s00127-002-0541-z; Cottler LB, 1997, DRUG ALCOHOL DEPEN, V47, P195, DOI
10.1016/S0376-8716(97)00090-2; Degenhardt L, 2003, ADDICTION, V98, P1493, DOI
10.1046/j.1360-0443.2003.00437.x; Degenhardt L, 2007, INT J METH PSYCH RES, V16,
P43, DOI 10.1002/mpr.206; Degenhardt L, 2013, ADDICTION, V108, P124, DOI
10.1111/j.1360-0443.2012.04015.x; Degenhardt L, 2012, LANCET, V379, P55, DOI
10.1016/S0140-6736(11)61138-0; Degenhardt L, 2011, DRUG ALCOHOL DEPEN, V117, P85,
DOI 10.1016/j.drugalcdep.2010.11.032; Di Marzo V, 2011, HANDB EXP PHARMACOL, V203,
P75, DOI 10.1007/978-3-642-17214-4_4; Duffy A, 2012, J AFFECT DISORDERS, V142, P57,
DOI 10.1016/j.jad.2012.04.010; Etain Bruno, 2012, J Clin Psychiatry, V73, pe561,
DOI 10.4088/JCP.10m06504; Fergusson DM, 1997, ADDICTION, V92, P279; Georgiades K,
2007, J CHILD PSYCHOL PSYC, V48, P724, DOI 10.1111/j.1469-7610.2007.01740.x; Grant
B, 2005, SOURCE ACCURACY STAT; Grant B F, 1995, J Subst Abuse, V7, P481, DOI
10.1016/0899-3289(95)90017-9; Grant B.F., 2003, SOURCE ACCURACY STAT; Grant BF,
2003, DRUG ALCOHOL DEPEN, V71, P7, DOI 10.1016/S0376-8716(03)00070-X; Grant BF,
2004, ARCH GEN PSYCHIAT, V61, P807, DOI 10.1001/archpsyc.61.8.807; Grant BF, 2005,
J CLIN PSYCHIAT, V66, P1205, DOI 10.4088/JCP.v66n1001; Grant BF, 2008, J CLIN
PSYCHIAT, V69, P533, DOI 10.4088/JCP.v69n0404; Grimes DA, 2002, LANCET, V359, P248,
DOI 10.1016/S0140-6736(02)07451-2; Gruber A J, 1996, Depression, V4, P77, DOI
10.1002/(SICI)1522-7162(1996)4:2<77::AID-DEPR7>3.3.CO;2-T; Gruber AJ, 1997, SUBST
USE MISUSE, V32, P249, DOI 10.3109/10826089709055849; Hall W, 2009, LANCET, V374,
P1383, DOI 10.1016/S0140-6736(09)61037-0; Harder VS, 2008, AM J EPIDEMIOL, V168,
P592, DOI 10.1093/aje/kwn184; Harder VS, 2006, ADDICTION, V101, P1463, DOI
10.1111/j.1360-0443.2006.01545.x; Hasin D, 1997, ALCOHOL CLIN EXP RES, V21, P213,
DOI 10.1097/00000374-199704000-00006; Henquet C, 2006, J AFFECT DISORDERS, V95,
P103, DOI 10.1016/j.jad.2006.05.002; Hibell B., 2012, 2011 ESPAD REPORT SU; Hofstra
MB, 2002, J AM ACAD CHILD PSY, V41, P182, DOI 10.1097/00004583-200202000-00012;
Kandel DB, 2000, J STUD ALCOHOL, V61, P367, DOI 10.15288/jsa.2000.61.367; Kaymaz N,
2009, ACTA PSYCHIAT SCAND, V120, P249, DOI 10.1111/j.1600-0447.2009.01472.x;
Khantzian E.J., 2008, UNDERSTANDING ADDICT; Khantzian EJ, 1997, HARVARD REV
PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550; Krabbendam L, 2005, SCHIZOPHR
RES, V80, P137, DOI 10.1016/j.schres.2005.08.004; Lev-Ran S, 2014, PSYCHOL MED,
V44, P797, DOI 10.1017/S0033291713001438; Lev-Ran S, 2012, DRUG ALCOHOL DEPEN,
V123, P190, DOI 10.1016/j.drugalcdep.2011.11.010; Manrique-Garcia E, 2012, BMC
PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-112; Marmorstein NR, 2011, ADDICT BEHAV,
V36, P773, DOI 10.1016/j.addbeh.2011.02.006; Miller-Johnson S, 1998, J ABNORM CHILD
PSYCH, V26, P221, DOI 10.1023/A:1022676302865; Moore THM, 2007, LANCET, V370, P319,
DOI 10.1016/S0140-6736(07)61162-3; Morgan CJA, 2008, BRIT J PSYCHIAT, V192, P306,
DOI 10.1192/bjp.bp.107.046649; Murray RM, 2004, SCHIZOPHR RES, V71, P405, DOI
10.1016/j.schres.2004.03.002; Ogborne AC, 2000, J PSYCHOACTIVE DRUGS, V32, P435,
DOI 10.1080/02791072.2000.10400245; Patten SB, 2012, J AFFECT DISORDERS, V140,
P277, DOI 10.1016/j.jad.2012.02.006; Pedersen W, 2008, ACTA PSYCHIAT SCAND, V118,
P395, DOI 10.1111/j.1600-0447.2008.01259.x; Pull CB, 1997, DRUG ALCOHOL DEPEN, V47,
P207, DOI 10.1016/S0376-8716(97)00091-4; Research Triangle Institute, 2004, SOFTW
SURV DAT AN SU; Tijssen MJA, 2010, ACTA PSYCHIAT SCAND, V122, P255, DOI
10.1111/j.1600-0447.2010.01539.x; United Nations Office on Drugs and Crime, 2012,
WORLD DRUG REPORT 20; van Laar M, 2007, ADDICTION, V102, P1251, DOI 10.1111/j.1360-
0443.2007.01875.x; Vrasti R, 1998, EUR ADDICT RES, V4, P144, DOI 10.1159/000018947;
Weiser Mark, 2005, Dialogues Clin Neurosci, V7, P81; Whiteford HA, 2013, LANCET,
V382, P1575, DOI 10.1016/S0140-6736(13)61611-6; Witkin JM, 2005, BEHAV PHARMACOL,
V16, P315, DOI 10.1097/00008877-200509000-00005 68 55 55 2 24
ELSEVIER SCIENCE BV AMSTERDAM PO BOX 211, 1000 AE AMSTERDAM,
NETHERLANDS 0165-0327 1573-2517 J AFFECT DISORDERS J. Affect. Disord.
FEB 1 2015 172 211 218
10.1016/j.jad.2014.10.006 8 Clinical Neurology;
Psychiatry Neurosciences & Neurology; Psychiatry AX0LD WOS:000346643000033
25451420 2019-09-25
J Maremmani, AGI; Rugani, F; Bacciardi, S; Rovai, L; Massimetti, E; Gazzarrini,
D; Dell'Osso, L; Maremmani, I Maremmani, Angelo Giovanni Icro;
Rugani, Fabio; Bacciardi, Silvia; Rovai, Luca; Massimetti, Enrico; Gazzarrini,
Denise; Dell'Osso, Liliana; Maremmani, Icro Differentiating Between
the Course of Illness in Bipolar 1 and Chronic-Psychotic Heroin-Dependent Patients
at Their First Agonist Opioid Treatment JOURNAL OF ADDICTIVE DISEASES
English Article Dual-diagnosis heroin-
dependent patients; "self-medication hypothesis"; bipolar 1 disorder; chronic
psychosis; course and severity of addictive illness SELF-MEDICATION HYPOTHESIS;
PRIMARY MAJOR DEPRESSIONS; SUBSTANCE-ABUSE; SYMPTOMATOLOGICAL FEATURES;
PSYCHIATRIC-DISORDERS; PAST COURSE; METHADONE; ADDICTS; CANNABIS; OPIATES In an
effort to inquiry the "self-medication hypothesis" in heroin-dependent patients
suffering from chronic psychosis and bipolar disorder, a naturalistic comparative
cohort study was designed with the aim of comparing, according to the presence of
dual diagnosis, the clinical characteristics of heroin-dependent patients
presenting for their first agonist opioid treatment. The main finding was that
addictive (heroin) illness was more severe in bipolar 1 patients and less severe in
chronic psychotic patients when compared with heroin-dependent patients without
dual diagnoses. In the case of chronic psychotic patients, these differences do not
allow us to exclude a therapeutic heroin use, at least at the beginning of their
toxicomanic career, with limited progression of their addictive disease. This
occurrence seems to be excluded for bipolar 1 heroin-dependent patients, who come
to their first agonist opioid treatment with a more severe addictive disease.
[Maremmani, Angelo Giovanni Icro; Rugani, Fabio; Bacciardi, Silvia; Rovai,
Luca; Massimetti, Enrico; Gazzarrini, Denise; Maremmani, Icro] Univ Pisa, Santa
Chiara Univ Hosp, Dept Neurosci, Vincent P Dole Dual Diag Unit, I-56100 Pisa,
Italy; [Maremmani, Angelo Giovanni Icro; Maremmani, Icro] Assoc Applicat Neurosci
Knowledge Social Aims AU, Pietrasanta, Lucca, Italy; [Dell'Osso, Liliana] Univ
Pisa, Sect Psychiat, Dept Clin & Expt Med, I-56100 Pisa, Italy; [Maremmani, Icro] G
De Lisio Inst Behav Sci, Pisa, Italy Maremmani, I (reprint author), Univ Pisa,
Santa Chiara Univ Hosp, Dept Neurosci, Vincent P Dole Dual Diag Unit, Via Roma 67,
I-56100 Pisa, Italy. maremman@med.unipi.it Maremmani, Angelo Giovanni
Icro/0000-0001-7728-3705 Akiskal H. S., 1983, PSYCHIATRY UPDATE
AM, V2, P271; AKISKAL HS, 1987, PSYCHOPHARMACOL BULL, V23, P68; AKISKAL HS, 1989,
PSYCHOPATHOLOGY, V22, P268, DOI 10.1159/000284607; BERGER PA, 1980, ARCH GEN
PSYCHIAT, V37, P635; Berrocoso E, 2009, CURR PHARM DESIGN, V15, P1612, DOI
10.2174/138161209788168100; BODKIN JA, 1995, J CLIN PSYCHOPHARM, V15, P49, DOI
10.1097/00004714-199502000-00008; Callaway E, 1996, BIOL PSYCHIAT, V39, P989, DOI
10.1016/0006-3223(96)00158-8; Carls KA, 2006, AM J DRUG ALCOHOL AB, V32, P673, DOI
10.1080/00952990600920177; CASSANO GB, 1989, PSYCHOPATHOLOGY, V22, P278, DOI
10.1159/000284608; CLOUET DH, 1982, ANN NY ACAD SCI, V398, P130, DOI
10.1111/j.1749-6632.1982.tb39487.x; EMRICH HM, 1984, PSYCHIAT DEV, V2, P97; EXTEIN
I, 1982, ANN NY ACAD SCI, V398, P113, DOI 10.1111/j.1749-6632.1982.tb39484.x;
FEINBERG DT, 1991, AM J PSYCHIAT, V148, P1750; First M. B., 1997, STRUCTURED CLIN
INTE; Floyd AG, 2006, J PSYCHIAT RES, V40, P178, DOI
10.1016/j.jpsychires.2005.05.001; GOLD MS, 1978, AM J PSYCHIAT, V135, P1415; GOLD
MS, 1982, ANN NY ACAD SCI, V398, P140, DOI 10.1111/j.1749-6632.1982.tb39488.x;
Grimwood S, 2011, J PHARMACOL EXP THER, V339, P555, DOI 10.1124/jpet.111.185108;
Hall DH, 2007, J PSYCHOACTIVE DRUGS, V39, P151, DOI 10.1080/02791072.2007.10399873;
Hall W, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d719; Henwood B, 2007, AM J
ADDICTION, V16, P160, DOI 10.1080/10550490701375368; Kalivas PW, 2005, AM J
PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403; Karila L, 2010, PRESSE MED,
V39, P1246, DOI 10.1016/j.lpm.2010.09.003; KHANTZIAN EJ, 1985, ARCH GEN PSYCHIAT,
V42, P1067; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259; KHANTZIAN EJ, 1980, NEW
ENGL J MED, V302, P869; Khantzian EJ, 1980, NIDA RES MONOGR, V30, P184; Krausz M,
1996, Crisis, V17, P175, DOI 10.1027/0227-5910.17.4.175; Kuepper R, 2010, SCHIZOPHR
RES, V121, P107, DOI 10.1016/j.schres.2010.05.031; Lahmeyer H. W., 1988, PSYCHIAT
DIAGNOSIS T, P182; Lembke A, 2012, AM J DRUG ALCOHOL AB, V38, P524, DOI
10.3109/00952990.2012.694532; LEVINSON I, 1995, J CLIN PSYCHIAT, V56, P73; Loga S,
2010, PSYCHIAT DANUB, V22, P296; Maremmani AGI, 2014, EUR REV MED PHARMACO, V18,
P287; Maremmani AGI, 2011, ANN GEN PSYCHIATR, V10, DOI 10.1186/1744-859X-10-17;
Maremmani AGI, 2011, J ADDICT DIS, V30, P123, DOI 10.1080/10550887.2011.554779;
Maremmani I, 2004, J PSYCHOACTIVE DRUGS, V36, P235, DOI
10.1080/02791072.2004.10399734; Maremmani I, 2000, J ADDICT DIS, V19, P29, DOI
10.1300/J069v19n02_03; Maremmani I., 2000, HEROIN ADDICT REL CL, V2, P39; Maremmani
I., 1994, NEW TRENDS EXPT CLIN, P179; Maremmani I, 2009, PRINCIPLES PRACTICE, P21;
Maremmani I., 1989, DAH Q DRUG ADDICTION; Maremmani I., 2005, HEROIN ADDICT REL CL,
V7, P33; Maremmani I., 2006, HEROIN ADDICT REL CL, V8, P31; Maremmani I., 2000,
HEROIN ADDICT REL CL, V2, P35; Maremmani I, 2003, MAINTENANCE TREATMEN, P221;
Maremmani I, 2006, J AFFECT DISORDERS, V93, P1, DOI 10.1016/j.jad.2006.02.022;
Maremmani I, 2012, ANN GEN PSYCHIATR, V11, DOI 10.1186/1744-859X-11-23; Maremmani
I, 2009, J ADDICT DIS, V28, P382, DOI 10.1080/10550880903183000; Maremmani Icro,
2007, Ann Gen Psychiatry, V6, P31, DOI 10.1186/1744-859X-6-31; Maremmani I, 2009, J
AFFECT DISORDERS, V117, P186, DOI 10.1016/j.jad.2009.01.007; McKenna G J, 1973,
Proc Natl Conf Methadone Treat, V2, P1317; MUESER KT, 1990, SCHIZOPHRENIA BULL,
V16, P31, DOI 10.1093/schbul/16.1.31; Pacini M., 2005, HEROIN ADDICT REL CL, V7,
P43; Pani P. P., 1999, HEROIN ADDICT REL CL, V1, P43; Pani PP, 2010, J AFFECT
DISORDERS, V122, P185, DOI 10.1016/j.jad.2009.06.012; Pomara N, 2010, BRIT J
PHARMACOL, V161, P768, DOI 10.1111/j.1476-5381.2010.00948.x; RESNICK RB, 1979,
COMPR PSYCHIAT, V20, P116, DOI 10.1016/0010-440X(79)90042-7; RESNICK RB, 1970, AM J
PSYCHIAT, V126, P1256, DOI 10.1176/ajp.126.9.1256; Rugani F, 2012, INT J ENV RES
PUB HE, V9, P2283, DOI 10.3390/ijerph9072283; Schep LJ, 2010, CLIN TOXICOL, V48,
P675, DOI 10.3109/15563650.2010.516752; Smith MJ, 2009, COMPR PSYCHIAT, V50, P245,
DOI 10.1016/j.comppsych.2008.07.009; SPENSLEY J, 1976, INT J ADDICT, V11, P191, DOI
10.3109/10826087109045540; Srisurapanont M, 2011, PROG NEURO-PSYCHOPH, V35, P959,
DOI 10.1016/j.pnpbp.2011.01.014; Stoll AL, 1999, AM J PSYCHIAT, V156, P2017; Tenore
PL, 2008, J ADDICT DIS, V27, P49, DOI 10.1080/10550880802122646; VANLIMBEEK J,
1992, J SUBST ABUSE TREAT, V9, P43; Volovka SJ, 1982, ANN NY ACAD SCI, V398, P143;
Woolf Clifford J, 2004, Curr Opin Investig Drugs, V5, P61; ZIS AP, 1991, BAILLIERE
CLIN ENDOC, V5, P97, DOI 10.1016/S0950-351X(05)80099-0 70 2 2 0
7 ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD ABINGDON 2-4 PARK SQUARE,
MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND 1055-0887 1545-0848 J
ADDICT DIS J. Addict. Dis. JAN 2 2015 34 1 43
54 10.1080/10550887.2014.975608 12 Substance Abuse
Substance Abuse CG6FK WOS:000353392400004 25424434
 2019-09-25
J Symmes, A; Winters, KC; Fahnhorst, T; Botzet, AM; Lee, S; August, GJ;
Realmuto, GM Symmes, Amanda; Winters, Ken C.; Fahnhorst,
Tamara; Botzet, Andria M.; Lee, Susanne; August, Gerald J.; Realmuto, George M.
The Association Between Attention Deficit Hyperactivity Disorder and
Nicotine Use Among Adolescents and Young Adults JOURNAL OF CHILD & ADOLESCENT
SUBSTANCE ABUSE English Article
nicotine; externalizing disorder; self-medication hypothesis; ADHD
SUBSTANCE USE DISORDERS; NON-ADHD PARTICIPANTS; DEFICIT/HYPERACTIVITY
DISORDER; DRUG-USE; CIGARETTE-SMOKING; COMMUNITY SAMPLES; SELF-REPORT; RISK-FACTOR;
TOBACCO USE; FOLLOW-UP Previous research indicates that youths with attention
deficit hyperactivity disorder (ADHD) are more susceptible to nicotine use compared
to those without ADHD, and one explanation for this association is the self-
medication theory. The present study examines nicotine use in a prospective sample
derived from a community sampling procedure rather than a clinical setting.
Nicotine use was measured through young adulthood (mean ages: 18, 20, and 22), and
three groups were compared based on childhood status: ADHD only, ADHD
externalizers, and control groups. Results indicated that at all three data points,
individuals with childhood ADHD plus an externalizing disorder reported higher
nicotine use on all variables compared to the ADHD group absent of an externalizing
disorder and the comparison group of non-ADHD youths. The group differences were
significant even after controlling for possible confounding variables (age, gender,
and current treatment with psychostimulant medication). Study results are discussed
in light of the self-medication hypothesis and of the importance of including
nicotine prevention programs for adolescents and young adults with ADHD and
externalizing problems. [Symmes, Amanda] Augsburg Coll, Minneapolis, MN USA;
[Winters, Ken C.; Fahnhorst, Tamara; Botzet, Andria M.; Lee, Susanne; August,
Gerald J.; Realmuto, George M.] Univ Minnesota, Minneapolis, MN USA Winters, KC
(reprint author), Univ Minnesota Med Sch, Dept Psychiat, F282-2A West,2450
Riverside Ave, Minneapolis, MN 55454 USA. winte001@umn.edu NIDA NIH
HHSUnited States Department of Health & Human ServicesNational Institutes of Health
(NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01 DA012995, K02 DA015347,
P50 DA027841] American Psychiatric Association, 1994, DIAGN STAT MAN
MENT; August GJ, 2006, J AM ACAD CHILD PSY, V45, P824, DOI
10.1097/01.chi.0000219831.16226.f8; AUGUST GJ, 1995, J ABNORM CHILD PSYCH, V23,
P521, DOI 10.1007/BF01447212; Barkley R. A., 1991, J AM ACAD CHILD ADOL, V35, P343;
Barkley RA, 2004, J CHILD PSYCHOL PSYC, V45, P195, DOI 10.1111/j.1469-
7610.2004.00214.x; Biederman J, 1997, J AM ACAD CHILD PSY, V36, P21, DOI
10.1097/00004583-199701000-00013; Brook JS, 1996, J AM ACAD CHILD PSY, V35, P1584,
DOI 10.1097/00004583-199612000-00009; Burke JD, 2001, J CHILD PSYCHOL PSYC, V42,
P493, DOI 10.1111/1469-7610.00743; Burke JD, 2007, J ABNORM PSYCHOL, V116, P249,
DOI 10.1037/0021-843X.116.2.249; CAIRNS RB, 1988, DEV PSYCHOL, V24, P815, DOI
10.1037/0012-1649.24.6.815; Castle Lon, 2007, J Atten Disord, V10, P335, DOI
10.1177/1087054707299597; Charach A, 2011, J AM ACAD CHILD PSY, V50, P9, DOI
10.1016/j.jaac.2010.09.019; Clark DB, 1999, J CLIN CHILD PSYCHOL, V28, P333, DOI
10.1207/S15374424jccp280305; Conners CK, 1996, PSYCHOPHARMACOL BULL, V32, P67;
Froehlich TE, 2007, ARCH PEDIAT ADOL MED, V161, P857, DOI
10.1001/archpedi.161.9.857; Fuemmeler BF, 2007, J PEDIATR PSYCHOL, V32, P1203, DOI
10.1093/jpepsy/jsm051; GOYETTE CH, 1978, J ABNORM CHILD PSYCH, V6, P221, DOI
10.1007/BF00919127; HENNINGFIELD JE, 1995, NEW ENGL J MED, V333, P1196, DOI
10.1056/NEJM199511023331807; Hollingshead A., 1975, 4 FACTOR INDEX SOCIA; Johnston
L.D., 2011, MONITORING FUTURE NA; JOHNSTON LD, 2009, NIH PUBLICATION; Kollins SH,
2005, ARCH GEN PSYCHIAT, V62, P1142, DOI 10.1001/archpsyc.62.10.1142; Lambert N,
2005, ETHICAL HUMAN PSYCHO, V7, P197; Lambert NM, 1998, J LEARN DISABIL-US, V31,
P533, DOI 10.1177/002221949803100603; Lee SS, 2011, CLIN PSYCHOL REV, V31, P328,
DOI 10.1016/j.cpr.2011.01.006; Lerman C, 2001, Nicotine Tob Res, V3, P353; Levin
ED, 1996, PSYCHOPHARMACOLOGY, V123, P55, DOI 10.1007/BF02246281; Levin ED, 2001,
EXP CLIN PSYCHOPHARM, V9, P83, DOI 10.1037/1064-1297.9.1.83; LYNSKEY MT, 1995, J
ABNORM CHILD PSYCH, V23, P281, DOI 10.1007/BF01447558; Maisto SA, 1995, ALCOHOL
CLIN EXP RES, V19, P1510, DOI 10.1111/j.1530-0277.1995.tb01015.x; Marshal MP, 2003,
PSYCHOL ADDICT BEHAV, V17, P293, DOI 10.1037/0893-164X.17.4.293; McMahon R J, 1999,
Nicotine Tob Res, V1 Suppl 2, pS45; Milberger S, 1997, J AM ACAD CHILD PSY, V36,
P37, DOI 10.1097/00004583-199701000-00015; Molina BSG, 2005, J PEDIATR PSYCHOL,
V30, P345, DOI 10.1093/jpepsy/jsi029; Molina BSG, 2003, J ABNORM PSYCHOL, V112,
P497, DOI 10.1037/0021-843X.112.3.497; Pomerleau O F, 1995, J Subst Abuse, V7,
P373, DOI 10.1016/0899-3289(95)90030-6; REICH W, 1992, DIAGNOSTIC INTERVIEW;
Reynolds CR, 1992, BEHAV ASSESSMENT SYS; Robinson TE, 2000, ADDICTION, V95, pS91;
*SAMHSA, 2004, NSDUH SER H, V25; Smith BH, 2000, J CONSULT CLIN PSYCH, V68, P489,
DOI 10.1037//0022-006X.68.3.489; Tercyak KP, 2002, J AM ACAD CHILD PSY, V41, DOI
10.1097/00004583-200207000-00011; *USDHHS, 2000, HLTH PEOPL 2010 UND; Vansickel AR,
2007, PSYCHOPHARMACOLOGY, V193, P305, DOI 10.1007/s00213-007-0786-z; Weinberg NZ,
1998, J AM ACAD CHILD PSY, V37, P252, DOI 10.1097/00004583-199803000-00009; Whalen
CK, 2003, PSYCHOL ADDICT BEHAV, V17, P332, DOI 10.1037/0893-164X.17.4.332; Wilens
TE, 2007, AM J ADDICTION, V16, P14, DOI 10.1080/10550490601082742; Winters K. C.,
2005, CIGARETTE USE QUESTI; Winters KC, 2011, J CHILD ADOLES SUBST, V20, P314, DOI
10.1080/1067828X.2011.598834 49 4 4 0 13 ROUTLEDGE JOURNALS,
TAYLOR & FRANCIS LTD ABINGDON 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN,
OXFORDSHIRE, ENGLAND 1067-828X 1547-0652 J CHILD ADOLES SUBST J.
Child Adolesc. Subst. Abus. JAN 2 2015 24 1 37
45 10.1080/1067828X.2012.756442 9 Substance Abuse
Substance Abuse AU1EY WOS:000345365000005 25632218 Green Accepted
2019-09-25
J Nakamura, Y; Lipschitz, DL; Kanarowski, E; McCormick, T; Sutherland, D;
Melow-Murchie, M Nakamura, Yoshio; Lipschitz, David L.;
Kanarowski, Elizabeth; McCormick, Theresa; Sutherland, Debbie; Melow-Murchie,
Melinda Investigating Impacts of Incorporating an Adjuvant Mind-
Body Intervention Method Into Treatment as Usual at a Community-Based Substance
Abuse Treatment Facility: A Pilot Randomized Controlled Study SAGE OPEN
English Article substance use/misuse;
craving; trauma; stress; mind-body intervention; mindfulness; awareness SELF-
MEDICATION HYPOTHESIS; DEFAULT MODE NETWORK; USE DISORDERS; RELAPSE PREVENTION;
PSYCHOMETRIC PROPERTIES; MINDFULNESS MEDITATION; CONTROLLED-TRIAL; DEPRESSION;
ALCOHOL; SMOKERS Treatment of substance use/misuse (SUM) continues to pose a
difficult challenge. This exploratory pilot study evaluated whether a novel mind-
body intervention program called "Mind-Body Bridging" (MBB) could be an effective
short-term adjuvant intervention for managing SUM and coexisting symptoms in women
undergoing residential and outpatient substance use treatment in a community
setting. Thirty-eight women attending a local substance abuse (SA) facility were
recruited and randomly assigned to either (a) treatment as usual (TAU) or (b) MBB
and TAU. The MBB program consisted of 20 sessions and lasted for 10 weeks.
Participants were asked to complete a set of self-report questionnaires designed to
assess drug/alcohol cravings, impact of past trauma, depression, sleep disturbance,
mindfulness, self-compassion, and well-being. They completed the questionnaires at
three time points: preintervention, midintervention (after the fifth week), and
postintervention. MBB + TAU significantly reduced drug/alcohol cravings, trauma-
related thinking, and disturbed sleep in comparison with TAU. Furthermore, MBB +
TAU significantly increased mindfulness, self-compassion, and well-being in
comparison with TAU. MBB for SUM appears promising as a complementary adjuvant
intervention, warranting future larger scale randomized controlled trials of MBB
for SUM populations. SUM is a difficult condition to treat and manage clinically,
especially given the multiple comorbid conditions that frequently affect those with
SUM. In the search to develop effective adjuvant interventions for SUM, the present
pilot study suggested that adding MBB to standard SUM treatment in community-based
settings could enhance therapeutic efficacy and quality of care. [Nakamura, Yoshio;
Lipschitz, David L.] Univ Utah, Sch Med, Pain Res Ctr, 615 Arapeen Dr,Suite 200,
Salt Lake City, UT 84108 USA; [Sutherland, Debbie; Melow-Murchie, Melinda] House
Hope, Salt Lake City, UT USA; [McCormick, Theresa] Assoc Mind Body Bridging, Salt
Lake City, UT USA Nakamura, Y (reprint author), Univ Utah, Sch Med, Pain Res Ctr,
615 Arapeen Dr,Suite 200, Salt Lake City, UT 84108 USA. yn5@utah.edu
Mind-Body Research Program through the University of Utah Health Sciences
Development Office The author(s) disclosed receipt of the following financial
support for the research and/or authorship of this article: The study reported was
in part supported by the Mind-Body Research Program through the University of Utah
Health Sciences Development Office. American Psychiatric Association, 1994, DIAGN
STAT MAN MENT; Baer RA, 2006, ASSESSMENT, V13, P27, DOI 10.1177/1073191105283504;
Bech P, 2003, INT J METH PSYCH RES, V12, P85, DOI 10.1002/mpr.145; Begley S, 2007,
TRAIN YOUR MIND CHAN; Blanchard KA, 2003, PSYCHOL ADDICT BEHAV, V17, P328, DOI
10.1037/0893-164X.17.4.328; Block S. H., 2010, MIND BODY WORKBOOK P; Block SH,
2007, COME YOUR SENSES DEM; Bohlmeijer E, 2010, J PSYCHOSOM RES, V68, P539, DOI
10.1016/j.jpsychores.2009.10.005; Bowen S, 2006, PSYCHOL ADDICT BEHAV, V20, P343,
DOI 10.1037/0893-164X.20.3.343; Bowen S, 2014, JAMA PSYCHIAT, V71, P547, DOI
10.1001/jamapsychiatry.2013.4546; Bowen S, 2014, ADDICT BEHAV, V39, P532, DOI
10.1016/j.addbeh.2013.10.026; Bowen S, 2009, SUBST ABUS, V30, P295, DOI
10.1080/08897070903250084; Bowen S, 2009, PSYCHOL ADDICT BEHAV, V23, P666, DOI
10.1037/a0017127; Brewer JA, 2011, DRUG ALCOHOL DEPEN, V119, P72, DOI
10.1016/j.drugalcdep.2011.05.027; Brewer JA, 2009, SUBST ABUS, V30, P306, DOI
10.1080/08897070903250241; Broadus AD, 2010, J DRUG EDUC, V40, P281, DOI
10.2190/DE.40.3.e; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-
1781(89)90047-4; Chiesa A, 2014, SUBST USE MISUSE, V49, P492, DOI
10.3109/10826084.2013.770027; Dass-Brailsford P, 2010, TRAUMA VIOLENCE ABUS, V11,
P202, DOI 10.1177/1524838010381252; Davis James M, 2007, BMC Complement Altern Med,
V7, P2, DOI 10.1186/1472-6882-7-2; Davis JM, 2014, J SUBST ABUSE TREAT, V47, P213,
DOI 10.1016/j.jsat.2014.04.005; Davis JM, 2014, SUBST USE MISUSE, V49, P571, DOI
10.3109/10826084.2013.770025; Donaldson GW, 2005, J CLIN ONCOL, V23, P7380, DOI
10.1200/JCO.2005.07.022; Flannery BA, 1999, ALCOHOL CLIN EXP RES, V23, P1289, DOI
10.1111/j.1530-0277.1999.tb04349.x; Garland EL, 2012, J SOC WORK PRACT ADD, V12,
P242, DOI 10.1080/1533256X.2012.702638; Garland EL, 2014, J CONSULT CLIN PSYCH,
V82, P448, DOI 10.1037/a0035798; Garland EL, 2010, J PSYCHOACTIVE DRUGS, V42, P177,
DOI 10.1080/02791072.2010.10400690; Grossman P, 2008, J PSYCHOSOM RES, V64, P405,
DOI 10.1016/j.jpsychores.2008.02.001; Hall DH, 2007, J PSYCHOACTIVE DRUGS, V39,
P151, DOI 10.1080/02791072.2007.10399873; Hamilton JP, 2011, BIOL PSYCHIAT, V70,
P327, DOI 10.1016/j.biopsych.2011.02.003; Hays RD, 2005, SLEEP MED, V6, P41, DOI
10.1016/j.sleep.2004.07.006; Heyman GM, 2013, ANNU REV CLIN PSYCHO, V9, P29, DOI
10.1146/annurev-clinpsy-032511-143041; Hides L, 2010, DRUG ALCOHOL REV, V29, P508,
DOI 10.1111/j.1465-3362.2010.00207.x; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209,
DOI 10.1097/00006842-197905000-00004; Kabat-Zinn J, 1991, FULL CATASTROPHE LIV;
Keyes K., 2011, ADDICTION MED, P23; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4,
P231, DOI 10.3109/10673229709030550; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142,
P1259; Little RJA, 2002, STAT ANAL MISSING DA; McLellan AT, 2000, JAMA-J AM MED
ASSOC, V284, P1689, DOI 10.1001/jama.284.13.1689; Merikangas KR, 2012, HUM GENET,
V131, P779, DOI 10.1007/s00439-012-1168-0; Miller W. R., 1995, PROJECT MATCH
MONOGR, V4; Moore TM, 2014, PSYCHOL ADDICT BEHAV, V28, P619, DOI 10.1037/a0034127;
Nakamura Y, 2013, J CANCER SURVIV, V7, P165, DOI 10.1007/s11764-012-0252-8;
Nakamura Y, 2011, J PSYCHOSOM RES, V70, P335, DOI 10.1016/j.jpsychores.2010.09.007;
Neff KD, 2003, SELF IDENTITY, V2, P223, DOI 10.1080/15298860390209035; RADLOFF L S,
1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306;
Sheline YI, 2009, P NATL ACAD SCI USA, V106, P1942, DOI 10.1073/pnas.0812686106;
Spreng RN, 2010, J COGNITIVE NEUROSCI, V22, P1112, DOI 10.1162/jocn.2009.21282;
Teasdale JD, 2000, J CONSULT CLIN PSYCH, V68, P615, DOI 10.1037/0022-006X.68.4.615;
Teasdale JD, 2002, J CONSULT CLIN PSYCH, V70, P275, DOI 10.1037//0022-
006X.70.2.275; Tiffany ST, 2000, ADDICTION, V95, pS145; Tiffany ST, 2012, ANN NY
ACAD SCI, V1248, P1, DOI 10.1111/j.1749-6632.2011.06298.x; Tollefson D.R., 2009, J
AGGRESS MALTREAT T, V18, P17, DOI DOI 10.1080/10926770802610657; Weiss D. S., 1996,
ASSESSING PSYCHOL TR, P399; Westbrook C, 2013, SOC COGN AFFECT NEUR, V8, P73, DOI
10.1093/scan/nsr076; Whitfield-Gabrieli S, 2012, ANNU REV CLIN PSYCHO, V8, P49, DOI
10.1146/annurev-clinpsy-032511-143049; Witkiewitz K, 2004, AM PSYCHOL, V59, P224,
DOI 10.1037/0003-066X.59.4.224; Witkiewitz K, 2013, ADDICT BEHAV, V38, P1563, DOI
10.1016/j.addbeh.2012.04.001; Zeidan F, 2011, J NEUROSCI, V31, P5540, DOI
10.1523/JNEUROSCI.5791-10.2011; Zeidan F, 2010, J PAIN, V11, P199, DOI
10.1016/j.jpain.2009.07.015; Zgierska A, 2009, SUBST ABUS, V30, P266, DOI
10.1080/08897070903250019 62 6 6 0 8 SAGE PUBLICATIONS INC
THOUSAND OAKS 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA 2158-2440
SAGE OPEN SAGE Open JAN-MAR 2015 5 1
UNSP 2158244015572489 10.1177/2158244015572489
18 Social Sciences, Interdisciplinary Social Sciences - Other Topics
DC8NM WOS:000369476300049 DOAJ Gold 2019-09-25
J Young, S; Sedgwick, O Young, Susan; Sedgwick, Ottilie
Attention deficit hyperactivity disorder and substance misuse: an
evaluation of causal hypotheses and treatment considerations EXPERT REVIEW OF
NEUROTHERAPEUTICS English Review
attention deficit hyperactivity disorder; behavioral disinhibition;
comorbidity; drugs; self-medication; sensitization; stimulant; substance use;
treatment PLACEBO-CONTROLLED TRIAL; NON-ADHD PARTICIPANTS; DEFICIT/HYPERACTIVITY
DISORDER; DOUBLE-BLIND; DRUG-USE; ADULT ADHD; BEHAVIORAL DISINHIBITION; PSYCHIATRIC
COMORBIDITY; STIMULANT THERAPY; CIGARETTE-SMOKING Attention deficit
hyperactivity disorder (ADHD) is known to co-occur with substance misuse at a high
rate. This has important health and legal implications for those with ADHD.
Mechanisms that may influence drug use among those with ADHD are discussed and
evaluated in this review, including self-medication, behavioral disinhibition,
comorbidity, and sensitization. While no one hypothesis is able to explain the
complex phenomenon of drug taking behaviors, it is likely that self-medication,
disinhibition and comorbidity play a part, with little evidence for sensitization.
The development of efficacious treatment is necessary to help those with this
debilitating comorbidity, as there are currently few evidence-based interventions.
[Young, Susan] Univ London Imperial Coll Sci Technol & Med, Div Brain Sci,
Ctr Mental Hlth, Dept Med, London, England; [Young, Susan; Sedgwick, Ottilie] West
London Mental Hlth Trust, Broadmoor Hosp, Crowthorne, Berks, England; [Sedgwick,
Ottilie] Kings Coll London, Dept Psychol, Inst Psychiat Psychol & Neurosci, London,
England Young, S (reprint author), Univ London Imperial Coll Sci Technol & Med,
Div Brain Sci, Ctr Mental Hlth, Dept Med, London, England.
susan.young1@imperial.ac.uk Sedgwick, Ottilie/0000-0001-5604-8239
National Institute for Health Research (NIHR) Mental Health Biomedical
Research Centre at South London and Maudsley National Health Service (NHS)
Foundation Trust and King's College London S Young has received honoraria for
consultancy, travel, educational talks and/or research from Janssen, Eli Lilly,
Shire, Novartis, HB Pharma, Flynn Pharma and/or Shire. O Sedgwick receives funding
support from the National Institute for Health Research (NIHR) Mental Health
Biomedical Research Centre at South London and Maudsley National Health Service
(NHS) Foundation Trust and King's College London. The views expressed are those of
the author(s) and not necessarily those of the NHS, the NIHR or the Department of
Health. The authors have no other relevant affiliations or financial involvement
with any organization or entity with a financial interest in or financial conflict
with the subject matter or materials discussed in the manuscript apart from those
disclosed. Ashare RL, 2012, PSYCHOPHARMACOLOGY, V219, P537, DOI 10.1007/s00213-
011-2324-2; August GJ, 2006, J AM ACAD CHILD PSY, V45, P824, DOI
10.1097/01.chi.0000219831.16226.f8; Baird AA, 2004, PHILOS T R SOC B, V359, P1797,
DOI 10.1098/rstb.2004.1549; Barkley RA, 2004, J CHILD PSYCHOL PSYC, V45, P195, DOI
10.1111/j.1469-7610.2004.00214.x; Barkley RA, 2003, PEDIATRICS, V111, P97, DOI
10.1542/peds.111.1.97; BIEDERMAN J, 1995, AM J PSYCHIAT, V152, P1652; Biederman J,
2004, J CONSULT CLIN PSYCH, V72, P757, DOI 10.1037/0022-006X.72.5.757; Biederman J,
1999, PEDIATRICS, V104, P20; Biederman J, 2008, AM J PSYCHIAT, V165, P597, DOI
10.1176/appi.ajp.2007.07091486; Bizzarri JV, 2007, ADDICT BEHAV, V32, P384, DOI
10.1016/j.addbeh.2006.04.005; Bolea-Alamanac B, 2014, J PSYCHOPHARMACOL, V28, P179,
DOI 10.1177/0269881113519509; Chang Z, 2012, J ABNORM CHILD PSYCH, V40, P425, DOI
10.1007/s10802-011-9575-6; Conners C. K., 1999, CONNERS ADULT ADHD R; Cunill R,
2015, J PSYCHOPHARMACOL, V29, P15, DOI 10.1177/0269881114544777; Elton A, 2014,
ADDICT BIOL, V19, P427, DOI 10.1111/adb.12011; Ersche KD, 2010, BIOL PSYCHIAT, V68,
P770, DOI 10.1016/j.biopsych.2010.06.015; Faraone SV, 2009, PSYCHOL MED, V39, P685,
DOI 10.1017/S0033291708003917; Faraone SV, 2010, J CLIN PSYCHIAT, V71, P754, DOI
[10.4088/JCP08m04902pur, 10.4088/JCP.08m04902pur]; Fayyad J, 2007, BRIT J PSYCHIAT,
V190, P402, DOI 10.1192/bjp.bp.106.034389; Ginsberg Y, 2012, BRIT J PSYCHIAT, V200,
P68, DOI 10.1192/bjp.bp.111.092940; Gordon MS, 2004, AM J DRUG ALCOHOL AB, V30,
P39, DOI 10.1081/ADA-120029865; Gordon V, 2012, PUBLIC HEALTH, V126, P343, DOI
10.1016/j.puhe.2012.01.004; Gudjonsson GH, 2012, J CHILD PSYCHOL PSYC, V53, P304,
DOI 10.1111/j.1469-7610.2011.02489.x; Gudjonsson GH, 2009, J ATTEN DISORD, V12,
P507, DOI 10.1177/1087054708323018; Handley ED, 2011, J ABNORM PSYCHOL, V120, P528,
DOI 10.1037/a0024162; Hodgins S, 2009, ACTA PSYCHIAT SCAND, V119, P484, DOI
10.1111/j.1600-0447.2008.01327.x; Horner BR, 1997, J AM ACAD CHILD PSY, V36, P30,
DOI 10.1097/00004583-199701000-00014; Huntley Z, 2012, BMC PSYCHIATRY, V12, P223;
Huntley Z, 2014, J ATTEN DISORD, V18, P82, DOI 10.1177/1087054712446171; Jensen PS,
2001, J AM ACAD CHILD PSY, V40, P147, DOI 10.1097/00004583-200102000-00009; Kessler
RC, 2006, AM J PSYCHIAT, V163, P716, DOI 10.1176/appi.ajp.163.4.716; Koesters M,
2009, J PSYCHOPHARMACOL, V23, P733, DOI 10.1177/0269881108092338; Kollins SH, 2014,
J ATTEN DISORD, V18, P158, DOI 10.1177/1087054712440320; Konstenius M, 2014,
ADDICTION, V109, P440, DOI 10.1111/add.12369; Konstenius M, 2010, DRUG ALCOHOL
DEPEN, V108, P130, DOI 10.1016/j.drugalcdep.2009.11.006; Lambert NM, 2006,
ADDICTION, V101, P713, DOI 10.1111/j.1360-0443.2006.01408.x; Lambert NM, 1998, J
LEARN DISABIL-US, V31, P533, DOI 10.1177/002221949803100603; Levin ED, 1996,
PSYCHOPHARMACOLOGY, V123, P55, DOI 10.1007/BF02246281; Levin FR, 2002, J ADDICT
DIS, V21, P1, DOI 10.1300/J069v21n02_01; Levin FR, 2007, DRUG ALCOHOL DEPEN, V87,
P20, DOI 10.1016/j.drugalcdep.2006.07.004; MANNUZZA S, 1993, ARCH GEN PSYCHIAT,
V50, P565; Manuzza S, 2008, AM J PSYCHIAT, V165, P604; McRae-Clark AL, 2010, AM J
ADDICTION, V19, P481, DOI 10.1111/j.1521-0391.2010.00076.x; Molina BSG, 2013, J AM
ACAD CHILD PSY, V52, P250, DOI 10.1016/j.jaac.2012.12.014; Molina BSG, 2003, J
ABNORM PSYCHOL, V112, P497, DOI 10.1037/0021-843X.112.3.497; National Institute for
Health and Clinical Excellence, 2009, ATT DEF HYP DIS DIAG; Palmer RHC, 2013,
ADDICT BEHAV, V38, P2415, DOI 10.1016/j.addbeh.2013.03.021; Pliszka SR, 1998, J
CLIN PSYCHIAT, V59, P50; Riggs PD, 2011, J AM ACAD CHILD PSY, V50, P903, DOI
10.1016/j.jaac.2011.06.010; Rose E, 2009, RES DEV DISABIL, V30, P496, DOI
10.1016/j.ridd.2008.07.009; Schubert CA, 2011, J AM ACAD CHILD PSY, V50, P925, DOI
10.1016/j.jaac.2011.06.006; Schubiner H, 2002, EXP CLIN PSYCHOPHARM, V10, P286, DOI
10.1037//1064-1297.10.3.286; Serra-Pinheiro MA, 2013, J ATTEN DISORD, V17, P459,
DOI 10.1177/1087054711435362; Silva N, 2014, CLIN NUCL MED, V39, pE129, DOI
10.1097/RLU.0b013e31829f9119; Smith DG, 2013, TRANSL PSYCHIAT, V3, DOI
10.1038/tp.2013.32; Sousa NO, 2011, J PSYCHIATR RES, V45, P829, DOI
10.1016/j.jpsychires.2010.10.012; Spencer TJ, 2005, BIOL PSYCHIAT, V57, P1293, DOI
10.1016/j.biopsych.2005.03.036; Steketee JD, 2011, PHARMACOL REV, V63, P348, DOI
10.1124/pr.109.001933; Szobot CM, 2007, ADDICTION, V102, P1122, DOI 10.1111/j.1360-
0443.2007.01850.x; Tarter RE, 2004, DRUG ALCOHOL DEPEN, V73, P121, DOI
10.1016/j.drugalcdep.2003.07.004; Thurstone C, 2010, J AM ACAD CHILD PSY, V49,
P573, DOI 10.1016/j.jaac.2010.02.013; Upadhyaya HP, 2008, AM J ADDICTION, V17,
P195, DOI 10.1080/10550490802021937; Upadhyaya HP, 2005, J CHILD ADOL PSYCHOP, V15,
P799, DOI 10.1089/cap.2005.15.799; van Emmerik-van Oortmerssen K, 2012, DRUG
ALCOHOL DEPEN, V122, P11, DOI 10.1016/j.drugalcdep.2011.12.007; van Emmerik-van
Oortmerssen K, 2014, ADDICTION, V109, P262, DOI 10.1111/add.12370; Wilens TE, 2003,
PEDIATRICS, V111, P179, DOI 10.1542/peds.111.1.179; Wilens TE, 2008, ARCH PEDIAT
ADOL MED, V162, P916, DOI 10.1001/archpedi.162.10.916; Wilens TE, 2008, DRUG
ALCOHOL DEPEN, V96, P145, DOI 10.1016/j.drugalcdep.2008.02.009; Wilens TE, 2007, AM
J ADDICTION, V16, P14, DOI 10.1080/10550490601082742; Wilens TE, 2011, J AM ACAD
CHILD PSY, V50, P141, DOI 10.1016/j.jaac.2010.11.010; Winhusen TM, 2010, J CLIN
PSYCHIAT, V71, P1680, DOI 10.4088/JCP.09m05089gry; Wood Alexis C., 2011, Frontiers
in Genetics, V2, P6, DOI 10.3389/fgene.2011.00006; Xenitidis K, 2011, ADHD IN
ADULTS: CHARACTERIZATION, DIAGNOSIS, AND TREATMENT, P168; Young S, 2011, J
PSYCHOPHARMACOL, V25, P1524, DOI 10.1177/0269881110370502; Young S, 2014, PSYCHOL
MED; Young S, 2012, COGNITIVE BEHAV THER; Young S, 2015, PSYCHOL MED; Young SE,
2000, AM J MED GENET, V96, P684, DOI 10.1002/1096-8628(20001009)96:5<684::AID-
AJMG16>3.3.CO;2-7; Young S, 2007, NEUROPSYCHOLOGY, V21, P581, DOI 10.1037/0894-
4105.21.5.581; Young S, 2006, PERS INDIV DIFFER, V41, P1377, DOI
10.1016/j.paid.2006.01.010; Young S, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-
248; Young S, 2009, PERS INDIV DIFFER, V46, P265, DOI 10.1016/j.paid.2008.10.003
82 5 5 0 6 TAYLOR & FRANCIS LTD ABINGDON 2-4 PARK
SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND 1473-7175 1744-8360
EXPERT REV NEUROTHER Expert Rev. Neurother. 2015 15 9
1005 1014 10.1586/14737175.2015.1059756 10
Clinical Neurology; Pharmacology & Pharmacy Neurosciences & Neurology;
Pharmacology & Pharmacy CQ5LC WOS:000360644500006 26289485
2019-09-25
J Tripp, JC; McDevitt-Murphy, ME; Avery, ML; Bracken, KL
Tripp, Jessica C.; McDevitt-Murphy, Meghan E.; Avery, Megan L.; Bracken,
Katherine L. PTSD Symptoms, Emotion Dysregulation, and Alcohol-
Related Consequences Among College Students With a Trauma History JOURNAL OF
DUAL DIAGNOSIS English Article
posttraumatic stress disorder; emotion dysregulation; alcohol-related
consequences; sex differences POSTTRAUMATIC-STRESS-DISORDER; SUBSTANCE DEPENDENT
INPATIENTS; NEGATIVE MOOD REGULATION; PSYCHOMETRIC PROPERTIES; REGULATION
DIFFICULTIES; NONCLINICAL SAMPLE; CHILDHOOD ABUSE; SELF-MEDICATION; PREDICT
ALCOHOL; HARVARD SCHOOL Objective: Posttraumatic stress disorder (PTSD), alcohol
use, and alcohol-related consequences have been linked to emotion dysregulation.
Sex differences exist in both emotion regulation dimensions and alcohol use
patterns. This investigation examined facets of emotion dysregulation as potential
mediators of the relationship between PTSD symptoms and alcohol-related
consequences and whether differences may exist across sexes. Methods: Participants
were 240 college students with a trauma history who reported using alcohol within
the past three months and completed measures of PTSD symptoms, emotion
dysregulation, alcohol consumption, alcohol-related consequences, and negative
affect. The six facets of emotion dysregulation were examined as mediators of the
relationship between PTSD symptoms and alcohol-related consequences in the full
sample and by sex. Results: There were differences in sexes on several variables,
with women reporting higher PTSD scores and lack of emotional awareness. Men
reported significantly more drinks per week in a typical week and a heavy week.
There were significant associations between the variables for the full sample, with
PTSD showing associations with five facets of emotion dysregulation subscales:
impulse control difficulties when upset, difficulties engaging in goal-directed
behavior, nonacceptance of emotional responses, lack of emotional clarity, and
limited access to emotion regulation strategies. Alcohol-related consequences were
associated with four aspects of emotion dysregulation: impulse control difficulties
when upset, difficulties engaging in goal-directed behavior, nonacceptance of
emotional reponses, and limited access to emotion regulation strategies. Two
aspects of emotion regulation, impulse control difficulties and difficulties
engaging in goal directed behavior, mediated the relationship between PTSD symptoms
and alcohol-related consequences in the full sample, even after adjusting for the
effects of negative affect. When examined separately by gender, impulse control
difficulties remained a mediator for men and difficulties engaging in goal directed
behavior for women. Conclusions: These analyses shed light on processes that may
underlie self-medication of PTSD symptoms. Gender-specific interventions targeting
emotion dysregulation may be effective in reducing alcohol-related consequences in
individuals with PTSD. Women may possibly benefit from interventions that focus on
difficulties engaging in goal-directed behavior, while men may benefit from
interventions that target impulse control difficulties when upset. [Tripp,
Jessica C.; McDevitt-Murphy, Meghan E.; Avery, Megan L.] Univ Memphis, Memphis, TN
38152 USA; [Bracken, Katherine L.] Fellowship Hlth Resources Inc, Durham, NC USA
McDevitt-Murphy, ME (reprint author), Univ Memphis, 202 Psychol Bldg,
Memphis, TN 38152 USA. mmcdvttm@memphis.edu National Institute on
Alcohol Abuse and Alcoholism (NIAAA)United States Department of Health & Human
ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol
Abuse & Alcoholism (NIAAA) [K23AA016120] This material is based on work funded by
the National Institute on Alcohol Abuse and Alcoholism (NIAAA) #K23AA016120 awarded
to Meghan McDevitt-Murphy, PhD. Adkins JW, 2008, J ANXIETY DISORD, V22, P1393,
DOI 10.1016/j.janxdis.2008.02.002; American Psychiatric Association, 2013, DIAGN
STAT MAN MENT; American Psychiatric Association, 2001, DIAGN STAT MAN MENT; Axelrod
SR, 2011, AM J DRUG ALCOHOL AB, V37, P37, DOI 10.3109/00952990.2010.535582; Benton
SL, 2004, J STUD ALCOHOL, V65, P115, DOI 10.15288/jsa.2004.65.115; Berking M, 2011,
J CONSULT CLIN PSYCH, V79, P307, DOI 10.1037/a0023421; Bernat JA, 1998, J TRAUMA
STRESS, V11, P645, DOI 10.1023/A:1024485130934; BLAKE DD, 1995, J TRAUMA STRESS,
V8, P75, DOI 10.1007/BF02105408; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI
10.1016/0005-7967(96)00033-2; Boden MT, 2013, J SOC CLIN PSYCHOL, V32, P296, DOI
10.1521/jscp.2013.32.3.296; Bollinger A. R., 2008, J PSYCHOL TRAUMA, V7, P213, DOI
[10.1080/19322880802384251, DOI 10.1080/19322880802384251]; Brady KT, 2004, CURR
DIR PSYCHOL SCI, V13, P206, DOI 10.1111/j.0963-7214.2004.00309.x; Breslau Naomi,
2002, J Gend Specif Med, V5, P34; Cloitre M, 2002, J CONSULT CLIN PSYCH, V70,
P1067, DOI 10.1037//0022-006X.70.5.1067; Cohn A, 2014, PSYCHOL ADDICT BEHAV, V28,
P114, DOI 10.1037/a0035725; COLLINS RL, 1985, J CONSULT CLIN PSYCH, V53, P189, DOI
10.1037/0022-006X.53.2.189; Corbin WR, 2013, ADDICT BEHAV, V38, P1912, DOI
10.1016/j.addbeh.2012.12.005; Corbin WR, 2011, ADDICT BEHAV, V36, P222, DOI
10.1016/j.addbeh.2010.11.004; Duranceau S, 2014, COGNITIVE THER RES, V38, P280, DOI
10.1007/s10608-013-9591-7; Dvorak RD, 2014, AM J DRUG ALCOHOL AB, V40, P125, DOI
10.3109/00952990.2013.877920; Edwards C, 2006, ADDICT BEHAV, V31, P2094, DOI
10.1016/j.addbeh.2006.02.009; Fox HC, 2008, ADDICT BEHAV, V33, P388, DOI
10.1016/j.addbeh.2007.10.002; Frazier P, 2009, J COUNS PSYCHOL, V56, P450, DOI
10.1037/a0016412; Gratz KL, 2012, J COGN PSYCHOTHER, V26, P365, DOI 10.1891/0889-
8391.26.4.365; Gratz KL, 2004, J PSYCHOPATHOL BEHAV, V26, P41, DOI
10.1023/B:JOBA.0000007455.08539.94; Grayson CE, 2005, J TRAUMA STRESS, V18, P137,
DOI 10.1002/jts.20021; GROSS JJ, 1995, CLIN PSYCHOL-SCI PR, V2, P151, DOI
10.1111/j.1468-2850.1995.tb00036.x; Hayes A.F., 2013, INTRO MEDIATION MODE; Hingson
R, 2005, ANNU REV PUBL HEALTH, V26, P259, DOI
10.1146/annurev.publhealth.26.021304.144652; Jerud AB, 2014, J CONSULT CLIN PSYCH,
V82, P721, DOI 10.1037/a0036520; Kahler CW, 2005, ALCOHOL CLIN EXP RES, V29, P1180,
DOI 10.1097/01.ALC.0000171940.95813.A5; Kassel JD, 2000, J STUD ALCOHOL, V61, P332,
DOI 10.15288/jsa.2000.61.332; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI
10.1001/archpsyc.1995.03950240066012; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4,
P231, DOI 10.3109/10673229709030550; Klemanski DH, 2012, DEPRESS ANXIETY, V29,
P621, DOI 10.1002/da.21914; Kulkarni M, 2013, PSYCHOL TRAUMA-US, V5, P359, DOI
10.1037/a0027746; Kuntsche E, 2005, CLIN PSYCHOL REV, V25, P841, DOI
10.1016/j.cpr.2005.06.002; Leadbeater BJ, 1999, DEV PSYCHOL, V35, P1268, DOI
10.1037/0012-1649.35.5.1268; Leeies M, 2010, DEPRESS ANXIETY, V27, P731, DOI
10.1002/da.20677; Lilly MM, 2014, PSYCHOL TRAUMA-US, V6, P644, DOI
10.1037/a0036460; Magar ECE, 2008, PERS INDIV DIFFER, V45, P153, DOI
10.1016/j.paid.2008.03.014; Marlatt GA, 1998, J CONSULT CLIN PSYCH, V66, P604, DOI
10.1037/0022-006X.66.4.604; Marshall-Berenz EC, 2011, PERS INDIV DIFFER, V50, P588,
DOI 10.1016/j.paid.2010.11.033; Martens MP, 2008, J STUD ALCOHOL DRUGS, V69, P412,
DOI 10.15288/jsad.2008.69.412; McDevitt-Murphy ME, 2010, J DUAL DIAGN, V6, P94, DOI
10.1080/15504261003701445; Muraven M, 2002, PSYCHOL ADDICT BEHAV, V16, P113, DOI
10.1037//0893-164X.16.2.113; Murphy JG, 2004, J STUD ALCOHOL, V65, P200, DOI
10.15288/jsa.2004.65.200; Neumann A, 2010, ASSESSMENT, V17, P138, DOI
10.1177/1073191109349579; O'Hara RE, 2014, J STUD ALCOHOL DRUGS, V75, P606, DOI
10.15288/jsad.2014.75.606; O'Malley PM, 2002, J STUD ALCOHOL, P23, DOI
10.15288/jsas.2002.s14.23; Park CL, 2012, J ADULT DEV, V19, P40, DOI
10.1007/s10804-011-9133-z; Perkins HW, 2002, J STUD ALCOHOL, P164, DOI
10.15288/jsas.2002.s14.164; Preacher KJ, 2004, BEHAV RES METH INS C, V36, P717, DOI
10.3758/BF03206553; Price JL, 2006, J ANXIETY DISORD, V20, P661, DOI
10.1016/j.janxdis.2005.04.004; Read JP, 2014, AM J ADDICTION, V23, P108, DOI
10.1111/j.1521-0391.2013.12075.x; Read JP, 2012, J CONSULT CLIN PSYCH, V80, P426,
DOI 10.1037/a0028210; Ruggiero KJ, 2003, J TRAUMA STRESS, V16, P495, DOI
10.1023/A:1025714729117; Salsman NL, 2012, J PSYCHOPATHOL BEHAV, V34, P260, DOI
10.1007/s10862-012-9275-8; Stoltenberg SF, 2008, ADDICT BEHAV, V33, P252, DOI
10.1016/j.addbeh.2007.09.004; Tabachnick B. G., 2007, USING MULTIVARIATE S; Tull
MT, 2007, BEHAV THER, V38, P303, DOI 10.1016/j.beth.2006.10.001; Turrisi R, 2007,
PSYCHOL ADDICT BEHAV, V21, P453, DOI 10.1037/0893-164X.21.4.453; U. S. Department
of Veterans Affairs National Center for PTSD, 2014, US PTSD CHECKL PCL; VRANA S,
1994, J TRAUMA STRESS, V7, P289, DOI 10.1002/jts.2490070209; WATSON D, 1988, J PERS
SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; Weathers F., 1993, M INT
SOC TRAUM STRE; Wechsler H, 2000, J AM COLL HEALTH, V48, P199, DOI
10.1080/07448480009599305; Wechsler H, 2008, J STUD ALCOHOL DRUGS, V69, P481, DOI
10.15288/jsad.2008.69.481; Weiss N. H., 2014, J TRAUMATIC STRESS D, V3, DOI
[10.4172/2324-8947.1000116, DOI 10.4172/2324-8947.1000116]; Weiss NH, 2013, CHILD
ABUSE NEGLECT, V37, P944, DOI 10.1016/j.chiabu.2013.03.014; Weiss NH, 2013, DRUG
ALCOHOL DEPEN, V128, P45, DOI 10.1016/j.drugalcdep.2012.07.017; Weiss NH, 2012, J
ANXIETY DISORD, V26, P453, DOI 10.1016/j.janxdis.2012.01.007; Weiss Nicole H.,
2012, Cognitive Behaviour Therapy, V41, P5, DOI 10.1080/16506073.2011.621970;
Wilkins KC, 2011, DEPRESS ANXIETY, V28, P596, DOI 10.1002/da.20837 74 23
23 3 24 ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD ABINGDON 2-4
PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND 1550-4263 1550-4271
J DUAL DIAGN J. Dual Diagn. 2015 11 2
107 117 10.1080/15504263.2015.1025013 11 Psychology,
Clinical; Substance Abuse; Psychiatry Psychology;
Substance Abuse; Psychiatry CI5GP WOS:000354782900003 25793550 Green
Accepted 2019-09-25
J Tull, MT; Bardeen, JR; DiLillo, D; Messman-Moore, T; Gratz, KL
Tull, Matthew T.; Bardeen, Joseph R.; DiLillo, David; Messman-Moore, Terri;
Gratz, Kim L. A prospective investigation of emotion dysregulation
as a moderator of the relation between posttraumatic stress symptoms and substance
use severity JOURNAL OF ANXIETY DISORDERS English Article
Emotion regulation; Longitudinal; Moderation;
posttraumatic stress disorder; Self-medication; Trauma BORDERLINE PERSONALITY-
DISORDER; RISKY SEXUAL-BEHAVIOR; COCAINE-DEPENDENT INPATIENTS; TRAUMA CUE EXPOSURE;
DISTRESS TOLERANCE; REGULATION DIFFICULTIES; NEGATIVE AFFECT; ALCOHOL-USE;
PSYCHOMETRIC PROPERTIES; PTSD SYMPTOMS Despite strong evidence for an
association between the experience of posttraumatic stress (PTS) symptoms and
substance use, little is known about the particular individuals most at-risk for
problematic substance use in response to PTS symptoms. Consequently, the goal of
this study was to conduct a prospective investigation of the moderating role of
emotion dysregulation (assessed through self-report and behavioral measures) in the
relation between PTS symptoms and substance use 8-months later within a sample of
106 young adult women. No main effect of PTS symptoms on substance use was found.
Instead, PTS symptoms were only associated with later substance use in the context
of heightened emotion dysregulation, Results provide support for emotion
dysregulation as a key factor that may increase risk for substance use among women
experiencing PTS symptoms and highlight a target for future interventions aimed at
reducing risk for the development of maladaptive behaviors stemming from PTS
symptoms. (C) 2014 Elsevier Ltd. All rights reserved. [Tull, Matthew T.; Gratz, Kim
L.] Univ Mississippi, Med Ctr, Dept Psychiat & Human Behav, Jackson, MS 39216 USA;
[Bardeen, Joseph R.] Auburn Univ, Dept Psychol, Auburn, AL 36849 USA; [DiLillo,
David] Univ Nebraska, Dept Psychol, Lincoln, NE 68588 USA; [Messman-Moore, Terri]
Miami Univ, Dept Psychol, Oxford, OH 45056 USA Tull, MT (reprint author), Univ
Mississippi, Med Ctr, Dept Psychiat & Human Behav, 2500 North State St, Jackson, MS
39216 USA. mtull@umc.edu Gratz, Kim/0000-0002-2659-6784; Tull,
Matthew/0000-0002-1382-117X National Institute of Child Health and Human
DevelopmentUnited States Department of Health & Human ServicesNational Institutes
of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health
& Human Development (NICHD) [R01 HD062226] This research was supported by
National Institute of Child Health and Human Development Grant R01 HD062226,
awarded to the third author (DD). Aiken LS, 1991, MULTIPLE REGRESSION; *AM
PSYCHIAT ASS, 2000, DIAGN STAT MAN MENT; Ameral V., 2014, J CONSCIOUSNESS THEO;
Anestis MD, 2012, COMPR PSYCHIAT, V53, P1208, DOI 10.1016/j.comppsych.2012.04.004;
Anestis MD, 2012, ARCH SUICIDE RES, V16, P198, DOI 10.1080/13811118.2012.695269;
Baker TB, 2004, PSYCHOL REV, V111, P33, DOI 10.1037/0033-295X.111.1.33; Bardeen JR,
2013, J ANXIETY DISORD, V27, P188, DOI 10.1016/j.janxdis.2013.01.003; Baumeister
RF, 2002, SELF IDENTITY, V1, P129, DOI 10.1080/152988602317319302; Blake D.D.,
1990, BEHAV THER, V13, P187, DOI DOI 10.1007/BF02105408; Blanchard EB, 1996, BEHAV
RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Bonn-Miller Marcel O., 2011,
Cognitive Behaviour Therapy, V40, P34, DOI 10.1080/16506073.2010.525253;
Bornovalova MA, 2008, J PSYCHIATR RES, V42, P717, DOI
10.1016/j.jpsychires.2007.07.014; Bornovalova MA, 2011, PSYCHOL TRAUMA-US, V3,
P349, DOI 10.1037/a0021579; Bornovalova MA, 2009, ADDICT BEHAV, V34, P685, DOI
10.1016/j.addbeh.2009.04.005; Brady KT, 2004, CURR DIR PSYCHOL SCI, V13, P206, DOI
10.1111/j.0963-7214.2004.00309.x; Breslau N, 1998, ARCH GEN PSYCHIAT, V55, P626,
DOI 10.1001/archpsyc.55.7.626; Broman-Fulks JJ, 2006, BEHAV THER, V37, P364, DOI
10.1016/j.beth.2006.02.006; Brown TA, 1997, BEHAV RES THER, V35, P79, DOI
10.1016/S0005-7967(96)00068-X; Carey KB, 1997, PSYCHOL ADDICT BEHAV, V11, P26, DOI
10.1037/0893-164X.11.1.26; Chilcoat HD, 1998, ARCH GEN PSYCHIAT, V55, P913, DOI
10.1001/archpsyc.55.10.913; Coffey SF, 2002, DRUG ALCOHOL DEPEN, V65, P115, DOI
10.1016/S0376-8716(01)00157-0; Daughters SB, 2005, J ABNORM PSYCHOL, V114, P729,
DOI 10.1037/0021-843X.114.4.729; Daughters SB, 2005, PSYCHOL ADDICT BEHAV, V19,
P208, DOI 10.1037/0893-164X.19.2.208; Dixon-Gordon KL, 2013, COMPR PSYCHIAT, V54,
P639, DOI 10.1016/j.comppsych.2012.12.019; Ehring T, 2010, BEHAV THER, V41, P587,
DOI 10.1016/j.beth.2010.04.004; First M. B., 2004, COMPREHENSIVE HDB PS, V2, P134,
DOI DOI 10.1002/CPP; Foa E. B., 2007, PROLONGED EXPOSURE T; Forbes D, 2005, J
TRAUMA STRESS, V18, P647, DOI 10.1002/jts.20073; Gorka SM, 2012, PSYCHOL ADDICT
BEHAV, V26, P621, DOI 10.1037/a0026386; Gratz KL, 2014, PSYCHOL MED, V44, P2099,
DOI 10.1017/S0033291713002134; Gratz KL, 2008, COMPR PSYCHIAT, V49, P603, DOI
10.1016/j.comppsych.2008.04.005; Gratz KL, 2007, BEHAV THER, V38, P256, DOI
10.1016/j.beth.2006.08.006; Gratz KL, 2006, J ABNORM PSYCHOL, V115, P850, DOI
10.1037/0021-843X.115.4.850; Gratz KL, 2010, COMPR PSYCHIAT, V51, P275, DOI
10.1016/j.comppsych.2009.08.005; Gratz KL, 2004, J PSYCHOPATHOL BEHAV, V26, P41,
DOI 10.1023/B:JOBA.0000007455.08539.94; Gratz KL, 2010, ASSESSING MINDFULNES; Gray
MJ, 2004, ASSESSMENT, V11, P330, DOI 10.1177/1073191104269954; Grubaugh AL, 2007,
DEPRESS ANXIETY, V24, P124, DOI 10.1002/da.20226; Haller M, 2013, PSYCHOL TRAUMA-
US, V5, P484, DOI 10.1037/a0029335; Hien DA, 1991, DRUG USE QUEST UNPUB; Jacobsen
LK, 2001, AM J PSYCHIAT, V158, P1184, DOI 10.1176/appi.ajp.158.8.1184; Jakupcak M,
2010, ADDICT BEHAV, V35, P840, DOI 10.1016/j.addbeh.2010.03.023; Joseph S, 1997,
PERS INDIV DIFFER, V22, P279, DOI 10.1016/S0191-8869(96)00213-9; Kaysen D, 2007,
ADDICT BEHAV, V32, P1272, DOI 10.1016/j.addbeh.2006.09.007; Kaysen D, 2014, PSYCHOL
ADDICT BEHAV, V28, P62, DOI 10.1037/a0033588; Khantzian EJ, 1997, HARVARD REV
PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550; Kline R. B., 2011, PRINCIPLES
PRACTICE; Leeies M, 2010, DEPRESS ANXIETY, V27, P731, DOI 10.1002/da.20677; Lejuez
CW, 2007, EXP CLIN PSYCHOPHARM, V15, P165, DOI 10.1037/1064-1297.15.2.165; Lejuez
CW, 2003, BEHAV THER, V26, P290, DOI DOI 10.1002/DA.20091; MacCallum RC, 2002,
PSYCHOL METHODS, V7, P19, DOI 10.1037//1082-989X.7.1.19; Marshall-Berenz EC, 2010,
J TRAUMA STRESS, V23, P623, DOI 10.1002/jts.20568; McCarthy D. E., 2010, SUBSTANCE
ABUSE EMOT, P15, DOI DOI 10.1037/12067-001; McDermott MJ, 2009, J ANXIETY DISORD,
V23, P591, DOI 10.1016/j.janxdis.2009.01.006; McHugh RK, 2011, COGNITIVE THER RES,
V35, P266, DOI 10.1007/s10608-010-9295-1; Messman-Moore TL, 2010, CHILD ABUSE
NEGLECT, V34, P967, DOI 10.1016/j.chiabu.2010.06.004; Orsillo SM, 2004, J TRAUMA
STRESS, V17, P241, DOI 10.1023/B:JOTS.0000029267.61240.94; Palmieri PA, 2007, J
ABNORM PSYCHOL, V116, P329, DOI 10.1037/0021-843X.116.2.329; Pimlott-Kubiak S,
2003, J CONSULT CLIN PSYCH, V71, P528, DOI 10.1037/0022-006X.71.3.528; Resick P.
A., 2007, COGNITIVE PROCESSING; Roemer L., 2001, PRACTITIONERS GUIDE, P49; Ruscio
AM, 2002, J ABNORM PSYCHOL, V111, P290, DOI 10.1037//0021-843X.111.2.290; Saladin
ME, 2003, ADDICT BEHAV, V28, P1611, DOI 10.1016/j.addbeh.2003.08.037; Schloss
Heather M, 2011, J Ration Emot Cogn Behav Ther, V29, P53, DOI 10.1007/s10942-011-
0127-3; SHAPIRO SS, 1965, BIOMETRIKA, V52, P591, DOI 10.2307/2333709; Simpson TL,
2014, J ABNORM PSYCHOL, V123, P237, DOI 10.1037/a0035193; Stasiewicz PR, 2013, J
SUBST ABUSE TREAT, V45, P433, DOI 10.1016/j.jsat.2013.05.012; Stewart SH, 1996,
PSYCHOL BULL, V120, P83, DOI 10.1037/0033-2909.120.1.83; Tull MT, 2007, BEHAV THER,
V38, P303, DOI 10.1016/j.beth.2006.10.001; Tull MT, 2013, J EXP PSYCHOPATHOL, V4,
P485, DOI 10.5127/jep.028812; Tull MT, 2013, PSYCHOL ADDICT BEHAV, V27, P763, DOI
10.1037/a0029911; Tull MT, 2013, COGNITIVE THER RES, V37, P483, DOI 10.1007/s10608-
012-9490-3; Tull MT, 2012, ADDICT BEHAV, V37, P1084, DOI
10.1016/j.addbeh.2012.05.001; Tull MT, 2011, ADDICTION, V106, P1810, DOI
10.1111/j.1360-0443.2011.03508.x; Tull MT, 2010, PERS INDIV DIFFER, V49, P989, DOI
10.1016/j.paid.2010.08.010; Tull MT, 2009, DEPRESS ANXIETY, V26, P1158, DOI
10.1002/da.20637; Tull MT, 2008, HDB RES METHODS ABNO; Ullman SE, 2005, J STUD
ALCOHOL, V66, P610, DOI 10.15288/jsa.2005.66.610; Waldrop AE, 2007, ADDICT BEHAV,
V32, P634, DOI 10.1016/j.addbeh.2006.06.001; Walsh K, 2012, J INTERPERS VIOLENCE,
V27, P3054, DOI 10.1177/0886260512441081; WATSON D, 1988, J PERS SOC PSYCHOL, V54,
P1063, DOI 10.1037/0022-3514.54.6.1063; Weathers FW, 1993, ANN M INT SOC TRAUM;
Weiss NH, 2013, DRUG ALCOHOL DEPEN, V128, P45, DOI
10.1016/j.drugalcdep.2012.07.017; Weiss NH, 2012, J ANXIETY DISORD, V26, P453, DOI
10.1016/j.janxdis.2012.01.007; Yeater EA, 2010, PSYCHOL TRAUMA-US, V2, P307, DOI
10.1037/a0021779 85 22 23 2 16 PERGAMON-ELSEVIER SCIENCE LTD OXFORD
THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND 0887-
6185 1873-7897 J ANXIETY DISORD J. Anxiety Disord. JAN 2015 29
52 60 10.1016/j.janxdis.2014.11.003
9 Psychology, Clinical; Psychiatry Psychology; Psychiatry CC3RC
WOS:000350265700008 25483275 Green Accepted 2019-09-25
J Kolliakou, A; Castle, D; Sallis, H; Joseph, C; O'Connor, J; Wiffen, B; Gayer-
Anderson, C; McQueen, G; Taylor, H; Bonaccorso, S; Gaughran, F; Smith, S;
Greenwood, K; Murray, RM; Di Forti, M; Atakan, Z; Ismail, K
Kolliakou, A.; Castle, D.; Sallis, H.; Joseph, C.; O'Connor, J.; Wiffen, B.;
Gayer-Anderson, C.; McQueen, G.; Taylor, H.; Bonaccorso, S.; Gaughran, F.; Smith,
S.; Greenwood, K.; Murray, R. M.; Di Forti, M.; Atakan, Z.; Ismail, K.
Reasons for cannabis use in first-episode psychosis: Does strength of
endorsement change over 12 months? EUROPEAN PSYCHIATRY English
Article Psychosis; Schizophrenia; Cannabis
use; Reasons for cannabis use; Self-medication; Alleviation of dysphoria SELF-
MEDICATION HYPOTHESIS; SUBSTANCE USE DISORDER; RECENT-ONSET PSYCHOSIS;
SCHIZOPHRENIC DISORDERS; MENTAL-DISORDERS; DRUG-ABUSE; PEOPLE; INDIVIDUALS;
ALCOHOL; MISUSE Background: Why patients with psychosis use cannabis remains
debated. The self-medication hypothesis has received some support but other
evidence points towards an alleviation of dysphoria model. This study investigated
the reasons for cannabis use in first-episode psychosis (FEP) and whether strength
in their endorsement changed over time. Methods: FEP inpatients and outpatients at
the South London and Maudsley, Oxleas and Sussex NHS Trusts UK, who used cannabis,
rated their motives at baseline (n = 69), 3 months (n = 29) and 12 months (n = 36).
A random intercept model was used to test the change in strength of endorsement
over the 12 months. Paired-sample t-tests assessed the differences in mean scores
between the five subscales on the Reasons for Use Scale (enhancement, social
motive, coping with unpleasant affect, conformity and acceptance and relief of
positive symptoms and side effects), at each time-point. Results: Time had a
significant effect on scores when controlling for reason; average scores on each
subscale were higher at baseline than at 3 months and 12 months. At each time-
point, patients endorsed 'enhancement' followed by 'coping with unpleasant affect'
and 'social motive' more highly for their cannabis use than any other reason.
'Conformity and acceptance' followed closely. 'Relief of positive symptoms and side
effects' was the least endorsed motive. Conclusions: Patients endorsed their
reasons for use at 3 months and 12 months less strongly than at baseline. Little
support for the self-medication or alleviation of dysphoria models was found.
Rather, patients rated 'enhancement' most highly for their cannabis use. (C) 2014
Elsevier Masson SAS. All rights reserved. [Kolliakou, A.; Ismail, K.] Kings Coll
London, Inst Psychiat, Dept Psychol Med, London SE5 8AF, England; [Castle, D.] Univ
Melbourne, Dept Psychiat, Melbourne, Vic, Australia; [Sallis, H.] Univ Bristol, Sch
Social & Community Med, MRC Integrat Epidemiol Unit, Bristol, Avon, England;
[Joseph, C.; O'Connor, J.; Wiffen, B.; McQueen, G.; Taylor, H.; Bonaccorso, S.;
Gaughran, F.; Murray, R. M.; Di Forti, M.] Kings Coll London, Inst Psychiat, Dept
Psychosis Studies, London SE5 8AF, England; [Gayer-Anderson, C.] Kings Coll London,
Inst Psychiat, Dept Hlth Serv & Populat Res, London SE5 8AF, England; [Smith, S.]
Kings Coll London, Inst Psychiat, Dept Forens & Neurodev Sci, London SE5 8AF,
England; [Greenwood, K.] Univ Sussex, Sch Psychol, Brighton, Sussex, England;
[Atakan, Z.] Kings Coll London, Inst Psychiat, Dept Neuroimaging, London SE5 8AF,
England Kolliakou, A (reprint author), Kings Coll London, Inst Psychiat, Dept
Psychol Med, PO92,De Crespigny Pk, London SE5 8AF, England.anna.kolliakou@kcl.ac.uk
greenwood, kathryn/I-8638-2012; murray, robin/F-8658-2012; Gayer-Anderson,
Charlotte/M-4335-2015; Gaughran, Fiona/H-5495-2011 greenwood, kathryn/0000-0001-
7899-8980; Smith, Shubulade/0000-0002-3797-6985; murray, robin/0000-0003-0829-0519;
Di Forti, Marta/0000-0002-3218-6925; ismail, khalida/0000-0001-6084-449X; Gayer-
Anderson, Charlotte/0000-0003-1636-889X; Sallis, Hannah/0000-0002-4793-6290;
Kolliakou, Anna/0000-0003-1234-4129; Gaughran, Fiona/0000-0001-7414-5569
National Institute for Health Research (NIHR) under its IMPACT
ProgrammeNational Institute for Health Research (NIHR) [RP-PG-0606-1049] This
paper summarises independent research funded by the National Institute for Health
Research (NIHR) under its IMPACT Programme (Grant Reference Number RP-PG-0606-
1049). The views expressed are those of the authors and not necessarily those of
the National Health Service, the NIHR or the Department of Health. Addington J,
1997, ACTA PSYCHIAT SCAND, V96, P329, DOI 10.1111/j.1600-0447.1997.tb09925.x;
Archie S, 2013, EARLY INTERV PSYCHIA, V7, P193, DOI 10.1111/j.1751-
7893.2012.00355.x; Bahorik AL, 2014, PSYCHOL MED, V44, P61, DOI
10.1017/S0033291713000548; BAIGENT M, 1995, AUST NZ J PSYCHIAT, V29, P69, DOI
10.3109/00048679509075894; Barnett JH, 2007, BRIT J PSYCHIAT, V190, P515, DOI
10.1192/bjp.bp.106.024448; Cooper M. L., 1994, PSYCHOL ASSESSMENT, V6, P117, DOI
[DOI 10.1037/1040-3590.6.2.117, 10.1037/1040-3590.6.2.117]; DIXON L, 1991, AM J
PSYCHIAT, V148, P224; Donovan DM, 2012, ADDICTION, V107, P694, DOI 10.1111/j.1360-
0443.2011.03473.x; Fowler IL, 1998, SCHIZOPHRENIA BULL, V24, P443, DOI
10.1093/oxfordjournals.schbul.a033339; Perez LG, 2014, ACTAS ESP PSIQUIATRI, V42,
P83; Goswami S, 2004, AM J ADDICTION, V13, P139, DOI 10.1080/10550490490435795;
Grech A, 2005, EUR PSYCHIAT, V20, P349, DOI 10.1016/j.eurpsy.2004.09.013; Green B,
2005, BRIT J PSYCHIAT, V187, P306, DOI 10.1192/bjp.187.4.306; Green B, 2004, DRUG
ALCOHOL REV, V23, P445, DOI 10.1080/09595230412331324563; Gregg L, 2009, MENTAL
HLTH SUBSTANC, V2, P24; Gregg L, 2007, CLIN PSYCHOL REV, V27, P494, DOI
10.1016/j.cpr.2006.09.004; Harrison I, 2007, PSYCHOL MED, V38, P79; Hides L, 2006,
BRIT J PSYCHIAT, V189, P137, DOI 10.1192/bjp.bp.105.014308; KAY SR, 1987,
SCHIZOPHRENIA BULL, V13, P261, DOI 10.1093/schbul/13.2.261; Khantzian EJ, 1997,
HARVARD REV PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550; KHANTZIAN EJ, 1985,
AM J PSYCHIAT, V142, P1259; Kolliakou A, 2012, CURR PHARM DESIGN, V18, P4950, DOI
10.2174/138161212802884807; Kolliakou A, 2011, INT J DEV NEUROSCI, V29, P335, DOI
10.1016/j.ijdevneu.2010.11.006; Kot T, 2002, J NERV MENT DIS, V190, P282, DOI
10.1097/01.NMD.0000016251.95250.0F; Laudet AB, 2004, AM J ORTHOPSYCHIAT, V74, P365,
DOI 10.1037/0002-9432.74.3.365; Leucht S, 2005, SCHIZOPHR RES, V79, P231, DOI
10.1016/j.schres.2005.04.008; LINSZEN DH, 1994, ARCH GEN PSYCHIAT, V51, P273;
McCreadie RG, 2002, BRIT J PSYCHIAT, V181, P321, DOI 10.1192/bjp.181.4.321; McHugo
GJ, 2006, SCHIZOPHRENIA BULL, V32, P655, DOI 10.1093/schbul/sbl009; Miles H, 2003,
PSYCHIAT SERV, V54, P554, DOI 10.1176/appi.ps.54.4.554; Mueser KT, 1998, ADDICT
BEHAV, V23, P717, DOI 10.1016/S0306-4603(98)00073-2; Pencer A, 2008, EARLY INTERV
PSYCHIA, V2, P42, DOI 10.1111/j.1751-7893.2007.00055.x; REGIER DA, 1990, JAMA-J AM
MED ASSOC, V264, P2511; Schaub M, 2008, AUST NZ J PSYCHIAT, V42, P1060, DOI
10.1080/00048670802512016; SCHNEIER FR, 1987, J NERV MENT DIS, V175, P641, DOI
10.1097/00005053-198711000-00001; Schofield D, 2006, AUST NZ J PSYCHIAT, V40, P570,
DOI 10.1080/j.1440-1614.2006.01840.x; Seddon LJ, 2013, MENTAL HLTH SUBST US, V6,
P47; Selten JP, 2002, EUR NEUROPSYCHOPHARM, V12, P27, DOI 10.1016/S0924-
977X(01)00129-8; Sevy S, 2001, ACTA PSYCHIAT SCAND, V104, P367, DOI 10.1034/j.1600-
0447.2001.00452.x; Sorbara F, 2003, EUR PSYCHIAT, V18, P133, DOI 10.1016/S0924-
9338(03)00027-0; Spencer C, 2002, SCHIZOPHRENIA BULL, V28, P233, DOI
10.1093/oxfordjournals.schbul.a006934; SPSS Inc, 2011, STAT PACK SOC SCI VE; Swartz
MS, 2003, PSYCHIAT SERV, V54, P891, DOI 10.1176/appi.ps.54.6.891; Swendsen J, 2011,
AM J PSYCHIAT, V168, P202, DOI 10.1176/appi.ajp.2010.10030463; TEST MA, 1989,
SCHIZOPHRENIA BULL, V15, P465, DOI 10.1093/schbul/15.3.465; Thornton LK, 2012,
ADDICT BEHAV, V37, P427, DOI 10.1016/j.addbeh.2011.11.039; Tietz N., 1986, TXB CLIN
CHEM; Wolford GL, 1999, PSYCHOL ADDICT BEHAV, V13, P313, DOI 10.1037/0893-
164X.13.4.313; Zammit S, 2008, BRIT J PSYCHIAT, V193, P357, DOI
10.1192/bjp.bp.107.046375 49 5 5 0 10 ELSEVIER FRANCE-EDITIONS
SCIENTIFIQUES MEDICALES ELSEVIER PARIS 23 RUE LINOIS, 75724 PARIS, FRANCE 0924-
9338 1778-3585 EUR PSYCHIAT Eur. Psychiat. JAN 2015 30 1
10.1016/j.eurpsy.2014.10.007
8 Psychiatry Psychiatry AZ1YX WOS:000348032300024 25541346
2019-09-25
J Pickard, H Pickard, Hanna Psychopathology
and the Ability to Do Otherwise PHILOSOPHY AND PHENOMENOLOGICAL RESEARCH
English Article NATIONAL
COMORBIDITY SURVEY; SELF-MEDICATION HYPOTHESIS; SUBSTANCE USE DISORDERS; DSM-IV
DISORDERS; DRUG-USE; UNITED-STATES; YOUNG-PEOPLE; EPIDEMIOLOGIC SURVEY; COCAINE
DEPENDENCE; SURVEY REPLICATION When philosophers want an example of a person
who lacks the ability to do otherwise, they turn to psychopathology. Addicts,
agoraphobics, kleptomaniacs, neurotics, obsessives, and even psychopathic serial
murderers, are all purportedly subject to irresistible desires that compel the
person to act: no alternative possibility is supposed to exist. I argue that this
conception of psychopathology is false and offer an empirically and clinically
informed understanding of disorders of agency which preserves the ability to do
otherwise. First, I appeal to standard clinical treatment for disorders of agency
and argue that it undermines this conception of psychopathology. Second, I offer a
detailed discussion of addiction, where our knowledge of the neurobiological
mechanisms underpinning the disorder is relatively advanced. I argue that
neurobiology notwithstanding, addiction is not a form of compulsion and I explain
how addiction can impair behavioural control without extinguishing it. Third, I
step back from addiction, and briefly sketch what the philosophical landscape more
generally looks like without psychopathological compulsion: we lose our standard
purported real-world example of psychologically determined action. I conclude by
reflecting on the centrality of choice and free will to our concept of action, and
their potency within clinical treatment for disorders of agency. Univ Oxford,
Oxford OX1 2JD, England Pickard, H (reprint author), Univ Oxford, Oxford OX1 2JD,
England. Pickard, Hanna/0000-0001-5926-1377 Wellcome TrustWellcome
Trust [090768] Ahmed SH, 2012, NEUROSCIENCE, V211, P107, DOI
10.1016/j.neuroscience.2011.08.014; Ahmed SH, 2010, NEUROSCI BIOBEHAV R, V35, P172,
DOI 10.1016/j.neubiorev.2010.04.005; Ainslie G, 2000, LAW PHILOS, V19, P77;
Alexander B. K., 1985, MEANING ADDICTION, P77; ALEXANDER BK, 1978,
PSYCHOPHARMACOLOGY, V58, P175, DOI 10.1007/BF00426903; Alvarez M, 2009, AUSTRALAS J
PHILOS, V87, P61, DOI 10.1080/00048400802215505; American Psychiatric Association,
2000, DIAGN STAT MAN MENT; Aneshenshel C. S., 2006, HDB SOCIOLOGY MENTAL;
[Anonymous], OXFORD HDB PHILOS PS; ANTHONY JC, 1991, PSYCHIAT DISORDERS A, P116;
Arpaly N, 2006, MERIT, MEANING, AND HUMAN BONDAGE: AN ESSAY ON FREE WILL, P1;
Bandura A., 1997, SELF EFFICACY EXERCI; Barnes J., 1984, COMPLETE WORKS ARIST, V2;
BAUMEISTER RF, 1995, PSYCHOL BULL, V117, P497, DOI 10.1037/0033-2909.117.3.497;
BIRKE SA, 1990, BRIT J ADDICT, V85, P1299; Blum N, 2008, AM J PSYCHIAT, V165, P468,
DOI 10.1176/appi.ajp.2007.07071079; Bonn-Miller MO, 2007, ADDICT BEHAV, V32, P49,
DOI 10.1016/j.addbeh.2006.03.018; Boyd CJ, 2009, J ADDICT DIS, V28, P232, DOI
10.1080/10550880903028452; Boys A, 1999, ADDICTION, V94, P1043, DOI 10.1046/j.1360-
0443.1999.94710439.x; Boys A, 2001, HEALTH EDUC RES, V16, P457, DOI
10.1093/her/16.4.457; Capes JA, 2012, PHILOS STUD, V158, P1, DOI 10.1007/s11098-
010-9662-5; Charland Louis C., 2002, American Journal of Bioethics, V2, P37, DOI
10.1162/152651602317533686; Compton WM, 2007, ARCH GEN PSYCHIAT, V64, P566, DOI
10.1001/archpsyc.64.5.566; COOPER ML, 1988, J ABNORM PSYCHOL, V97, P218, DOI
10.1037/0021-843X.97.2.218; CUMMINGS KM, 1985, PREV MED, V14, P195, DOI
10.1016/0091-7435(85)90035-0; Davidson D, 1980, HOW IS WEAKNESS OF T, P21; Davies
J. B, 1992, MYTH ADDICTION; Dimeff L., 2001, CALIFORNIA PSYCHOL, V34, P10; EDWARDS
G, 1976, BRIT MED J, V1, P1058, DOI 10.1136/bmj.1.6017.1058; Elliott Carl, 2002,
American Journal of Bioethics, V2, P48, DOI 10.1162/152651602317533695; Everitt BJ,
2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579; Fara M, 2008, MIND, V117, P843,
DOI 10.1093/mind/fzn078; Flanagan O, 2011, ADDICTION RESPONSIBI, P269, DOI DOI
10.7551/MITPRESS/9780262015509.001.0001; Flanagan O., ADDICTION SELF CONTR; Foddy
B, 2006, BIOETHICS, V20, P1, DOI 10.1111/j.1467-8519.2006.00470.x; Foddy B, 2010,
PHILOS PSYCHIATR PSY, V17, P1, DOI 10.1353/ppp.0.0282; Frankfurt H., 2003, FREE
WILL, P322; Frankfurt Harry, 2003, FREE WILL, P167; Goldie P, 2000, MIND, V109,
P25, DOI 10.1093/mind/109.433.25; Gros Daniel F, 2006, Curr Psychiatry Rep, V8,
P298, DOI 10.1007/s11920-006-0066-3; Heyman G, 2009, ADDICTION DISORDER C; HIGGINS
ST, 1994, ARCH GEN PSYCHIAT, V51, P568; HIGGINS ST, 1991, AM J PSYCHIAT, V148,
P1218; Higgins Stephen T., 1995, Experimental and Clinical Psychopharmacology, V3,
P205, DOI 10.1037/1064-1297.3.2.205; Hobbes Thomas, 1999, HOBBES BRAMHALL LIBE;
Holton R., 2009, WILLING WANTING WAIT; HUGHES JR, 1986, AM J PSYCHIAT, V143, P993;
Hume David, 1975, ENQUIRY HUMAN UNDERS; Hyman SE, 2005, AM J PSYCHIAT, V162, P1414,
DOI 10.1176/appi.ajp.162.8.1414; Ito LM, 2001, BRIT J PSYCHIAT, V178, P331, DOI
10.1192/bjp.178.4.331; Jacobsen LK, 2001, AM J PSYCHIAT, V158, P1184, DOI
10.1176/appi.ajp.158.8.1184; Kant I, 1960, RELIG BOUNDS REASON; Kennett J, 2001,
AGENCY RESPONSIBILIT; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P617, DOI
10.1001/archpsyc.62.6.617; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI
10.1001/archpsyc.62.6.593; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI
10.3109/10673229709030550; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259; Kuntsche
E, 2006, ADDICT BEHAV, V31, P1844, DOI 10.1016/j.addbeh.2005.12.028; Lacey N, 2013,
OXFORD J LEGAL STUD, V33, P1, DOI 10.1093/ojls/gqs028; Lees J, 1999, THERAPEUTIC
COMMUNIT; Lehrer Keith, 1968, ANALYSIS, V29, P29, DOI DOI 10.1093/ANALYS/29.1.29;
Leshner AI, 1997, SCIENCE, V278, P45, DOI 10.1126/science.278.5335.45; Levy N.,
2011, ADDICTION RESPONSIBI, P89, DOI DOI 10.7551/MITPRESS/9780262015509.001.0001;
Levy N., 2011, COMPANION PHILOS ACT, P267; Mackie J. L., 1977, ETHICS INVENTING
RIG; Markou A, 1998, NEUROPSYCHOPHARMACOL, V18, P135, DOI 10.1016/S0893-
133X(97)00113-9; MELE AR, 1990, NOUS, V24, P455, DOI 10.2307/2215775; Miller WR,
1996, ADDICTION, V91, pS15, DOI 10.1111/j.1360-0443.1996.tb02324.x; Motz A., 2009,
MANAGING SELF HARM; Muller CP, 2011, BEHAV BRAIN SCI, V34, P293, DOI
10.1017/S0140525X11000057; National Institute on Drug Abuse, 2009, PRINC DRUG ADD
TREAT; O'Connor T., 2010, STANFORD ENCY PHILOS; Pearce S, 2013, INT J SOC
PSYCHIATR, V59, P636, DOI 10.1177/0020764012450992; Pearce S, 2010, J MED ETHICS,
V36, P831, DOI 10.1136/jme.2010.035865; Peele Stanton, 1985, MEANING ADDICTION;
Perkins HW, 1999, J STUD ALCOHOL, V60, P219, DOI 10.15288/jsa.1999.60.219; Petersen
T., 2002, WORKING SUBSTANCE MI; Petry N, 2011, ADDICTION RESPONSIBI, P225; Pickard
H., ADDICTION SELF CONTR; Pickard H., 2011, ADDICTION RESPONSIBI; Pickard H., 2012,
AM J BIOETHICS NEURO, V3, P30; Pickard H., 2009, PSYCHIAT COGNITIVE N, P83; Pickard
H, 2011, PHILOS PSYCHIATR PSY, V18, P209, DOI 10.1353/ppp.2011.0032; REGIER DA,
1990, JAMA-J AM MED ASSOC, V264, P2511; Reid T., 1994, WORKS T REID, V2; ROBINS LN,
1993, ADDICTION, V88, P1041, DOI 10.1111/j.1360-0443.1993.tb02123.x; Sinnott-
Armstrong W., OXFORD HDB PHILOS PS; Smith M., 2003, WEAKNESS WILL PRACTI, P17;
Solinas M, 2008, P NATL ACAD SCI USA, V105, P17145, DOI 10.1073/pnas.0806889105;
Spiegel H, 2004, TRANCE TREATMENT CLI; Steward H, 2009, NOUS, V43, P64, DOI
10.1111/j.1468-0068.2008.01696.x; Steward Helen, 2012, METAPHYSICS FREEDOM; Stinson
FS, 2005, DRUG ALCOHOL DEPEN, V80, P105, DOI 10.1016/j.drugalcdep.2005.03.009;
WARNER LA, 1995, ARCH GEN PSYCHIAT, V52, P219; West R., 2006, THEORY ADDICTION;
Williams B., 2005, MAKING SENSE HUMANIT; WOODS JH, 1978, PSYCHOPHARMACOLOGY G;
World Health Organization, 2004, NEUR PSYCH SUBST US; Yaffe G., 2011, ADDICTION
RESPONSIBI, P113 99 17 17 0 15 WILEY-BLACKWELL HOBOKEN 111
RIVER ST, HOBOKEN 07030-5774, NJ USA 0031-8205 1933-1592 PHILOS
PHENOMEN RES Philos. Phenomenol. Res. JAN 2015 90 1
135 163 10.1111/phpr.12025 29 Philosophy
 Philosophy AY0WO WOS:000347315200007 25929318 Green Accepted
2019-09-25
J Mackesy-Amiti, ME; Donenberg, GR; Ouellet, LJ Mackesy-
Amiti, Mary E.; Donenberg, Geri R.; Ouellet, Lawrence J. Prescription
opioid misuse and mental health among young injection drug users AMERICAN JOURNAL
OF DRUG AND ALCOHOL ABUSE English Article
Heroin; injection drug use; mental health; prescription opioids
PSYCHIATRIC RESEARCH INTERVIEW; POSTTRAUMATIC-STRESS-DISORDER; NATIONAL
EPIDEMIOLOGIC SURVEY; SUBSTANCE USE DISORDERS; NONMEDICAL USE; UNITED-STATES;
ANXIETY DISORDERS; SELF-MEDICATION; ILLICIT USE; HEROIN USEBackground: Prescription
opioid (PO) misuse is a significant concern in the United States. Objectives: This
study describes the prevalence and timing of PO misuse, diagnoses of opiate abuse
and dependence, and their associations with psychiatric disorders in a sample of
young people who inject drugs (PWID). Methods: Participants were 570 young (18-25
years) PWID, primarily heroin users, recruited through outreach and respondent-
driven sampling. Trained interviewers administered a semi-structured psychiatric
interview. Diagnoses of substance use and mental disorders were based on DSM-IV
diagnostic criteria. Results: Estimated rates of lifetime PO abuse and dependence
were 19% and 17%, respectively. Past year PO misuse was significantly associated
with anti-social personality disorder (ASPD, OR = 2.15, 95% CI 1.43-3.24), past
year substance-induced major depression (SIMD, OR = 1.81, 95% CI 1.16-2.83), and
prior post-traumatic stress disorder (PTSD, OR = 2.45, 95% CI 1.31-4.60). Among
male PO users, PTSD was a significant predictor of PO abuse (prior, OR = 7.62, 95%
CI 2.16-26.88; past year, OR = 21.67 95% CI 2.46-190.75), and dependence (prior, OR
= 4.82, 95% CI 1.48-15.67; past year, OR = 9.65, 95% CI 1.75-53.32). Conclusion:
Among young PWID, PTSD is a significant risk factor for PO misuse for both men and
women, and men with PTSD are in addition at increased risk for PO abuse and
dependence. These findings have implications for harm reduction and substance abuse
prevention efforts. [Mackesy-Amiti, Mary E.; Donenberg, Geri R.; Ouellet,
Lawrence J.] Univ Illinois, Sch Publ Hlth, Div Epidemiol & Biostat, Community
Outreach Intervent Projects, Chicago, IL 60612 USA Mackesy-Amiti, ME (reprint
author), Univ Illinois, Sch Publ Hlth, MC 923,1603 W Taylor St, Chicago, IL 60612
USA. mmamiti@uic.edu Mackesy-Amiti, Mary/B-7208-2008 Mackesy-Amiti,
Mary/0000-0002-7238-5240 National Institute on Drug AbuseUnited States
Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
National Institute on Drug Abuse (NIDA) [R01DA020368] This research was supported
by a grant from the National Institute on Drug Abuse (R01DA020368). The content of
this paper is solely the responsibility of the authors and does not necessarily
represent the official views of the National Institute on Drug Abuse or the
National Institutes of Health. We thank study participants for the time and effort
they contributed to this study, and acknowledge the dedication of our staff members
who administered RDS, collected data, and otherwise operated field sites in a
manner welcoming to potential participants. Al-Tayyib AA, 2014, DRUG ALCOHOL
DEPEN, V134, P406, DOI 10.1016/j.drugalcdep.2013.10.027; Becker WC, 2008, DRUG
ALCOHOL DEPEN, V94, P38, DOI 10.1016/j.drugalcdep.2007.09.018; Bolton J, 2006, J
NERV MENT DIS, V194, P818, DOI 10.1097/01.nmd.0000244481.63148.98; Bremner JD,
1996, AM J PSYCHIAT, V153, P369; Broz D, 2008, DRUG ALCOHOL DEPEN, V94, P221, DOI
10.1016/j.drugalcdep.2007.11.020; Catalano RF, 2011, ADDICT BEHAV, V36, P79, DOI
10.1016/j.addbeh.2010.08.028; Caton CLM, 2005, ARCH GEN PSYCHIAT, V62, P137, DOI
10.1001/archpsyc.62.2.137; Cerda M, 2013, DRUG ALCOHOL DEPEN, V132, P53, DOI
10.1016/j.drugalcdep.2012.12.027; Chilcoat HD, 1998, ARCH GEN PSYCHIAT, V55, P913,
DOI 10.1001/archpsyc.55.10.913; Chilcoat HD, 1998, ADDICT BEHAV, V23, P827, DOI
10.1016/S0306-4603(98)00069-0; Darke S, 2004, DRUG ALCOHOL DEPEN, V74, P77, DOI
10.1016/j.drugalcdep.2003.12.002; Darke S, 1997, DRUG ALCOHOL DEPEN, V48, P135, DOI
10.1016/S0376-8716(97)00117-8; Dowling K, 2006, CLIN J PAIN, V22, P776, DOI
10.1097/01.ajp.0000210926.41406.2c; FENDRICH M, 1994, J ABNORM CHILD PSYCH, V22,
P425, DOI 10.1007/BF02168083; Fendrich M, 2000, J SUBST ABUSE, V11, P161, DOI
10.1016/S0899-3289(00)00018-3; Fischer B, 2012, PUBLIC HEALTH, V126, P749, DOI
10.1016/j.puhe.2012.04.010; Fischer B, 2012, J PAIN, V13, P1029, DOI
10.1016/j.jpain.2012.07.013; Ford JA, 2008, J DRUG ISSUES, V38, P493, DOI
10.1177/002204260803800206; Grau LE, 2007, AM J ADDICTION, V16, P166, DOI
10.1080/10550490701375293; Grella CE, 2009, ADDICT BEHAV, V34, P498, DOI
10.1016/j.addbeh.2009.01.002; Hasin D, 2006, AM J PSYCHIAT, V163, P689, DOI
10.1176/appi.ajp.163.4.689; Hasin D, 1998, PSYCHOPHARMACOL BULL, V34, P3; Hasin DS,
1996, AM J PSYCHIAT, V153, P1195; Heckathorn DD, 2002, SOC PROBL, V49, P11, DOI
10.1525/sp.2002.49.1.11; Heckathorn DD, 1997, SOC PROBL, V44, P174, DOI
10.1525/sp.1997.44.2.03x0221m; Huang BJ, 2006, J CLIN PSYCHIAT, V67, P1062, DOI
10.4088/JCP.v67n0708; Jacobsen LK, 2001, AM J PSYCHIAT, V158, P1184, DOI
10.1176/appi.ajp.158.8.1184; Jones CM, 2013, DRUG ALCOHOL DEPEN, V132, P95, DOI
10.1016/j.drugalcdep.2013.01.007; Khantzian E. J., 2003, PRIMARY PSYCHIAT, V10,
p[47, 53]; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI
10.3109/10673229709030550; Khosla N, 2011, ADDICT BEHAV, V36, P1282, DOI
10.1016/j.addbeh.2011.07.046; Lankenau SE, 2012, J URBAN HEALTH, V89, P1004, DOI
10.1007/s11524-012-9691-9; Lankenau SE, 2012, INT J DRUG POLICY, V23, P37, DOI
10.1016/j.drugpo.2011.05.014; LOWINSON J, 2005, SUBSTANCE ABUSE COMP; Mackesy-Amiti
ME, 2012, DRUG ALCOHOL DEPEN, V124, P70, DOI 10.1016/j.drugalcdep.2011.12.012;
Mackesy-Amiti ME, PSYCHOL ADDICT BEHAV; Mars SG, 2014, INT J DRUG POLICY, V25,
P257, DOI 10.1016/j.drugpo.2013.10.004; Marsden J, 2000, BRIT J PSYCHIAT, V176,
P285, DOI 10.1192/bjp.176.3.285; Martins SS, 2012, PSYCHOL MED, V42, P1261, DOI
10.1017/S0033291711002145; Martins SS, 2009, DRUG ALCOHOL DEPEN, V103, P16, DOI
10.1016/j.drugalcdep.2009.01.019; McCabe SE, 2005, J SUBST ABUSE TREAT, V28, P225,
DOI 10.1016/j.jsat.2004.12.009; McCauley JL, 2010, J CHILD PSYCHOL PSYC, V51, P84,
DOI 10.1111/j.1469-7610.2009.02134.x; McCauley JL, 2009, ADDICT BEHAV, V34, P641,
DOI 10.1016/j.addbeh.2009.03.026; Mills KL, 2005, DRUG ALCOHOL DEPEN, V77, P243,
DOI 10.1016/j.drugalcdep.2004.08.016; National Institute on Drug Abuse (NIDA),
2011, PRESCR DRUGS AB ADD; National Institute on Drug Abuse (NIDA), 2011, NIH
PUBLICATION; Paulozzi Leonard J., 2011, Morbidity and Mortality Weekly Report, V60,
P1487; Peavy KM, 2012, J PSYCHOACTIVE DRUGS, V44, P259, DOI
10.1080/02791072.2012.704591; Peindl Kathleen S, 2007, J Opioid Manag, V3, P215;
Pollini RA, 2011, SUBST ABUSE REHABIL, V2, P173, DOI 10.2147/SAR.S24800; Schepis
TS, 2011, ADDICTION, V106, P2146, DOI 10.1111/j.1360-0443.2011.03520.x; Schonlau M,
2012, STATA J, V12, P72, DOI 10.1177/1536867X1201200106; Shand FL, 2011, ADDICT
BEHAV, V36, P27, DOI 10.1016/j.addbeh.2010.08.008; StataCorp, 2011, STAT STAT SOFTW
REL; Subramaniam GA, 2009, DRUG ALCOHOL DEPEN, V101, P13, DOI
10.1016/j.drugalcdep.2008.10.015; Substance Abuse and Mental Health Services
Administration (SAMHSA), 2009, NSDUH REP TRENDS NON; Substance Abuse and Mental
Health Services Administration (SAMHSA). Drug Abuse Warning Network, 2009, DAWN SER
D, VD-35; Substance Abuse and Mental Health Services Administration (SAMHSA) Office
of Applied Studies, 2009, OAS SER S; Sullivan MD, 2005, PAIN, V119, P95, DOI
10.1016/j.pain.2005.09.020; Sung HE, 2005, J ADOLESCENT HEALTH, V37, P44, DOI
10.1016/j.jadohealth.2005.02.013; Tetrault JM, 2008, ADDICTION, V103, P258, DOI
10.1111/j.1360-0443.2007.02056.x; Tomlinson KL, 2006, ADDICT BEHAV, V31, P461, DOI
10.1016/j.addbeh.2005.05.028; Villagonzalo KA, 2011, COMPR PSYCHIAT, V52, P562, DOI
10.1016/j.comppsych.2010.10.001; Warner M, 2009, NCHS DATA BRIEF, V22; West R,
2013, ADDICT PRESS SER, P1, DOI 10.1002/9781118484890; Wong CF, 2013, DRUG ALCOHOL
DEPEN, V132, P165, DOI 10.1016/j.drugalcdep.2013.01.024; Wu LT, 2011, J ADDICT MED,
V5, P28, DOI 10.1097/ADM.0b013e3181e0364e 67 16 16 0 27 TAYLOR &
FRANCIS INC PHILADELPHIA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106
USA 0095-2990 1097-9891 AM J DRUG ALCOHOL AB Am. J. Drug Alcohol
Abuse JAN 2015 41 1 100 106
10.3109/00952990.2014.940424 7 Psychology, Clinical;
Substance Abuse Psychology; Substance Abuse AW1TQ WOS:000346073600014
25105884 Green Accepted 2019-09-25
S Le Foll, B; Ng, E; Trigo, JM; Di Ciano, P Lipina, TV; Roder, JC
Le Foll, Bernard; Ng, Enoch; Trigo, Jose M.; Di Ciano, Patricia
The Self-medication Hypothesis in Schizophrenia: What Have We Learned from
Animal Models? DRUG DISCOVERY FOR SCHIZOPHRENIA RSC Drug Discovery Series
English Article; Book Chapter
 SUBSTANCE USE DISORDERS; NICOTINIC RECEPTOR MECHANISMS; SENSORIMOTOR GATING
DEFICITS; ACOUSTIC STARTLE RESPONSE; PREPULSE INHIBITION; CANNABIS USE; DOPAMINE
TRANSPORTER; CIGARETTE-SMOKING; ACETYLCHOLINE-RECEPTOR; COGNITIVE DEFICITS
[Le Foll, Bernard; Trigo, Jose M.; Di Ciano, Patricia] Ctr Addict & Mental
Hlth, Translat Addict Res Lab, 33 Russell St, Toronto, ON M5S 2S1, Canada; [Le
Foll, Bernard] Ctr Addict & Mental Hlth, Ambulatory Care & Struct Treatment
Program, Ctr Addict & Mental Hlth, Toronto, ON M5S 2S1, Canada; [Le Foll, Bernard]
Univ Toronto, Inst Med Sci, Dept Family Med, Pharmacol,Psychiat,Inst Med Sci,
Toronto, ON, Canada; [Le Foll, Bernard] Univ Toronto, Inst Med Sci, Dept Community
Med, Pharmacol,Psychiat,Inst Med Sci, Toronto, ON, Canada; [Ng, Enoch] Mt Sinai
Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5G 1X5, Canada Le Foll, B
(reprint author), Ctr Addict & Mental Hlth, Translat Addict Res Lab, 33 Russell St,
Toronto, ON M5S 2S1, Canada. bernard.lefoll@camh.ca Le Foll, Bernard/K-2952-2014
Le Foll, Bernard/0000-0002-6406-4973 ACRI JB, 1995, PHARMACOL
BIOCHEM BE, V50, P191, DOI 10.1016/0091-3057(94)00285-Q; Arguello PA, 2006, NEURON,
V52, P179, DOI 10.1016/j.neuron.2006.09.023; Arnold JC, 2012, CURR PHARM DESIGN,
V18, P5113, DOI 10.2174/138161212802884726; Ballmaier M, 2007,
NEUROPSYCHOPHARMACOL, V32, P2098, DOI 10.1038/sj.npp.1301344; Barr RS, 2008,
NEUROPSYCHOPHARMACOL, V33, P480, DOI 10.1038/sj.npp.1301423; Berg SA, 2008,
NEUROPHARMACOLOGY, V54, P1201, DOI 10.1016/j.neuropharm.2008.03.011; Berg SA, 2014,
ADDICT BIOL, V19, P1020, DOI 10.1111/adb.12082; Biscaia M, 2003,
PSYCHOPHARMACOLOGY, V170, P301, DOI 10.1007/s00213-003-1550-7; Black MD, 2011,
PSYCHOPHARMACOLOGY, V215, P149, DOI 10.1007/s00213-010-2124-0; Boucher AA, 2007,
PSYCHOPHARMACOLOGY, V192, P325, DOI 10.1007/s00213-007-0721-3; BRAFF D, 1978,
PSYCHOPHYSIOLOGY, V15, P339, DOI 10.1111/j.1469-8986.1978.tb01390.x; Braff DL,
2001, PSYCHOPHARMACOLOGY, V156, P234, DOI 10.1007/s002130100810; Brown RW, 2012,
DEV NEUROSCI-BASEL, V34, P140, DOI 10.1159/000338830; Brown RW, 2011, BEHAV
PHARMACOL, V22, P374, DOI 10.1097/FBP.0b013e328348737b; Brzozka MM, 2011, BEHAV
BRAIN RES, V218, P280, DOI 10.1016/j.bbr.2010.11.003; Burns Jonathan K, 2013, Front
Psychiatry, V4, P128, DOI 10.3389/fpsyt.2013.00128; Camarasa J, 2009, BEHAV
PHARMACOL, V20, P623, DOI 10.1097/FBP.0b013e328331ba5b; Campolongo P, 2011,
PSYCHOPHARMACOLOGY, V214, P5, DOI 10.1007/s00213-010-1892-x; Chambers RA, 2009, J
DUAL DIAGN, V5, P139, DOI 10.1080/15504260902869808; Cope ZA, 2010, SYNAPSE, V64,
P289, DOI 10.1002/syn.20729; CURZON P, 1994, PHARMACOL BIOCHEM BE, V49, P877, DOI
10.1016/0091-3057(94)90237-2; D'Souza DC, 2005, BIOL PSYCHIAT, V57, P594, DOI
10.1016/j.biopsych.2004.12.006; de Haan L, 2006, PSYCHOPHARMACOLOGY, V183, P500,
DOI 10.1007/s00213-005-0218-x; del Arco I, 2000, NEUROIMMUNOMODULAT, V7, P16, DOI
10.1159/000026416; DELEON J, 1995, AM J PSYCHIAT, V152, P453; Duke PJ, 2001, BRIT J
PSYCHIAT, V179, P509, DOI 10.1192/bjp.179.6.509; Edwards CR, 2009, BEHAV NEUROSCI,
V123, P894, DOI 10.1037/a0016328; Faraday MM, 1998, PHARMACOL BIOCHEM BE, V61,
P281, DOI 10.1016/S0091-3057(98)00094-X; Faraday MM, 1999, PHARMACOL BIOCHEM BE,
V62, P273, DOI 10.1016/S0091-3057(98)00159-2; Fischer B., 2015, J PUBLIC HL IN
PRESS; Foti DJ, 2010, AM J PSYCHIAT, V167, P987, DOI
10.1176/appi.ajp.2010.09020189; Gainetdinov RR, 2008, N-S ARCH PHARMACOL, V377,
P301, DOI 10.1007/s00210-007-0216-0; Gainetdinov RR, 1999, BIOL PSYCHIAT, V46,
P303, DOI 10.1016/S0006-3223(99)00122-5; George TP, 2006, SCHIZOPHR RES, V87, P307,
DOI 10.1016/j.schres.2006.05.022; Geyer MA, 2001, PSYCHOPHARMACOLOGY, V156, P117,
DOI 10.1007/s002130100811; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0;
Gleason KA, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.122; Goldman-Rakic PS,
2004, PSYCHOPHARMACOLOGY, V174, P3, DOI 10.1007/s00213-004-1793-y; Gordon A., 2008,
DRUG ALCOHOL SERVICE; Green AI, 2005, J CLIN PSYCHIAT, V66, P21; Green B, 2004,
DRUG ALCOHOL REV, V23, P445, DOI 10.1080/09595230412331324563; Hahn B, 2013, BIOL
PSYCHIAT, V74, P436, DOI 10.1016/j.biopsych.2013.03.017; Haller J, 2005, BEHAV
PHARMACOL, V16, P415, DOI 10.1097/00008877-200509000-00014; Han J, 2012, CELL,
V148, P1039, DOI 10.1016/j.cell.2012.01.037; Harris JG, 2004, NEUROPSYCHOPHARMACOL,
V29, P1378, DOI 10.1038/sj.npp.1300450; Heishman SJ, 2010, PSYCHOPHARMACOLOGY,
V210, P453, DOI 10.1007/s00213-010-1848-1; Hoffman AF, 2007, LEARN MEMORY, V14,
P63, DOI 10.1101/lm.439007; HOFFMAN DC, 1995, PSYCHOPHARMACOLOGY, V120, P128, DOI
10.1007/BF02246184; Hong LE, 2008, NEUROPSYCHOPHARMACOL, V33, P2167, DOI
10.1038/sj.npp.1301601; Howes OD, 2012, ARCH GEN PSYCHIAT, V69, P776, DOI
10.1001/archgenpsychiatry.2012.169; JABLENSKY A, 1992, PSYCHOL MED, P1; Kayir H,
2011, BEHAV BRAIN RES, V216, P275, DOI 10.1016/j.bbr.2010.08.004; Khantzian EJ,
1997, HARVARD REV PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550; KOSTRZEWA RM,
1991, PHARMACOL BIOCHEM BE, V39, P517, DOI 10.1016/0091-3057(91)90219-R; Krystal
JH, 1999, SCHIZOPHR RES, V35, pS35, DOI 10.1016/S0920-9964(98)00162-5; Kuepper R,
2012, HANDB EXP PHARMACOL, V212, P1, DOI 10.1007/978-3-642-25761-2_1; Kumari V,
2005, NEUROSCI BIOBEHAV R, V29, P1021, DOI 10.1016/j.neubiorev.2005.02.006; Kumari
V, 2001, HUM PSYCHOPHARM CLIN, V16, P321, DOI 10.1002/hup.286; Lev-Ran S, 2013, AM
J ADDICTION, V22, P93, DOI 10.1111/j.1521-0391.2013.00304.x; Lev-Ran S, 2013, AM J
ADDICTION, V22, P7, DOI 10.1111/j.1521-0391.2013.00321.x; Levin E. D., 2002,
Current Drug Targets - CNS and Neurological Disorders, V1, P423, DOI
10.2174/1568007023339102; Levin ED, 2006, PSYCHOPHARMACOLOGY, V184, P523, DOI
10.1007/s00213-005-0164-7; Levin ED, 2002, J NEUROBIOL, V53, P633, DOI
10.1002/neu.10151; Levin Edward D, 2006, EXS, V98, P185; Lichtman AH, 1996,
PSYCHOPHARMACOLOGY, V126, P125, DOI 10.1007/BF02246347; Liebig M, 2010, OBESITY,
V18, P1952, DOI 10.1038/oby.2010.17; Light G A, 1999, Curr Psychiatry Rep, V1, P31,
DOI 10.1007/s11920-999-0008-y; Lipska Barbara K., 2002, Neurotox Res, V4, P469, DOI
10.1080/1029842021000022089; Lipska BK, 2002, NEUROPSYCHOPHARMACOL, V27, P47, DOI
10.1016/S0893-133X(02)00282-8; Madsen MV, 2011, NEUROPHARMACOLOGY, V60, P418, DOI
10.1016/j.neuropharm.2010.10.014; Martin LF, 2007, INT REV NEUROBIOL, V78, P225,
DOI 10.1016/S0074-7742(06)78008-4; Maskos U, 2005, NATURE, V436, P103, DOI
10.1038/nature03694; Meltzer HY, 2004, AM J PSYCHIAT, V161, P975, DOI
10.1176/appi.ajp.161.6.975; Menezes PR, 1996, REV SAUDE PUBL, V30, P304, DOI
10.1590/S0034-89101996000400003; Mirza NR, 2000, EUR J PHARMACOL, V407, P73, DOI
10.1016/S0014-2999(00)00658-0; Nestler EJ, 2010, NAT NEUROSCI, V13, P1161, DOI
10.1038/nn.2647; Ng E, 2013, NEUROSCI BIOBEHAV R, V37, P896, DOI
10.1016/j.neubiorev.2013.03.025; Olincy A, 2006, ARCH GEN PSYCHIAT, V63, P630, DOI
10.1001/archpsyc.63.6.630; Patrick G, 1999, BIOL PSYCHIAT, V45, P1307, DOI
10.1016/S0006-3223(98)00155-3; Patrick G, 2000, CLIN ELECTROENCEPHAL, V31, P88, DOI
10.1177/155005940003100207; Pencer A, 2005, PSYCHIAT RES, V133, P35, DOI
10.1016/j.psychres.2004.10.004; Perna MK, 2008, PSYCHOPHARMACOLOGY, V199, P67, DOI
10.1007/s00213-008-1128-5; Picciotto MR, 1998, NATURE, V391, P173; Poels EMP, 2014,
MOL PSYCHIATR, V19, P20, DOI 10.1038/mp.2013.136; Postma P, 2006,
PSYCHOPHARMACOLOGY, V184, P589, DOI 10.1007/s00213-006-0307-5; Potvin S, 2006,
PSYCHOL MED, V36, P431, DOI 10.1017/S003329170500574X; Puighermanal E, 2009, NAT
NEUROSCI, V12, P1152, DOI 10.1038/nn.2369; Rabin RA, 2011, SCHIZOPHR RES, V128,
P111, DOI 10.1016/j.schres.2011.02.017; Rentzsch J, 2007, EXP NEUROL, V205, P241,
DOI 10.1016/j.expneurol.2007.02.004; ROBINSON TE, 1993, BRAIN RES REV, V18, P247,
DOI 10.1016/0165-0173(93)90013-P; RUBIO P, 1995, LIFE SCI, V56, P2169, DOI
10.1016/0024-3205(95)00204-J; Sacco KA, 2005, ARCH GEN PSYCHIAT, V62, P649, DOI
10.1001/archpsyc.62.6.649; Salyers MP, 2001, SCHIZOPHR RES, V48, P109, DOI
10.1016/S0920-9964(00)00063-3; Samaha AN, 2014, PROG NEURO-PSYCHOPH, V52, P9, DOI
10.1016/j.pnpbp.2013.06.008; SamsDodd F, 1997, PSYCHOPHARMACOLOGY, V132, P303, DOI
10.1007/s002130050349; Schneider M, 2005, NEUROPSYCHOPHARMACOL, V30, P944, DOI
10.1038/sj.npp.1300634; Schneider M, 2003, NEUROPSYCHOPHARMACOL, V28, P1760, DOI
10.1038/sj.npp.1300225; Schneider M, 2002, BEHAV PHARMACOL, V13, P29, DOI
10.1097/00008877-200202000-00003; SCHNEIER FR, 1987, J NERV MENT DIS, V175, P641,
DOI 10.1097/00005053-198711000-00001; Schoeler T, 2013, SUBST ABUSE REHABIL, V4,
P11, DOI 10.2147/SAR.S25869; Schofield D, 2006, AUST NZ J PSYCHIAT, V40, P570, DOI
10.1080/j.1440-1614.2006.01840.x; Schreiber R, 2002, PSYCHOPHARMACOLOGY, V159,
P248, DOI 10.1007/s00213-001-0927-8; Shrivastava A, 2014, INDIAN J PSYCHIAT, V56,
P8, DOI 10.4103/0019-5545.124708; Smith R. C., 2001, SUBST ABUS, V22, P175, DOI
[10.1080/08897070109511457, DOI 10.1080/08897070109511457]; Smith RC, 2006,
NEUROPSYCHOPHARMACOL, V31, P637, DOI 10.1038/sj.npp.1300881; Smith RC, 2002,
NEUROPSYCHOPHARMACOL, V27, P479, DOI 10.1016/S0893-133X(02)00324-X; STIGLICK A,
1982, PSYCHOPHARMACOLOGY, V77, P124, DOI 10.1007/BF00431933; STIGLICK A, 1982,
PSYCHOPHARMACOLOGY, V77, P117, DOI 10.1007/BF00431932; STIGLICK A, 1985,
PSYCHOPHARMACOLOGY, V85, P436, DOI 10.1007/BF00429660; Suarez-Pinilla P, 2014,
BRAIN BEHAV IMMUN, V40, P269, DOI 10.1016/j.bbi.2014.01.018; SUEMARU K, 1993,
PHARMACOL BIOCHEM BE, V46, P135; Tapper AR, 2004, SCIENCE, V306, P1029, DOI
10.1126/science.1099420; Umbricht D, 2014, NEUROPSYCHOPHARMACOL, V39, P1568, DOI
10.1038/npp.2014.17; Volkow ND, 2009, SCHIZOPHRENIA
BULL, V35, P469, DOI 10.1093/schbul/sbp016; Wallace TL, 2013, EXPERT OPIN THER
TAR, V17, P139, DOI 10.1517/14728222.2013.736498; Wallace TL, 2011, BIOCHEM
PHARMACOL, V82, P891, DOI 10.1016/j.bcp.2011.06.034; Weiner I, 2009, BEHAV BRAIN
RES, V204, P369, DOI 10.1016/j.bbr.2009.05.004; Weiss S, 2007,
NEUROPSYCHOPHARMACOL, V32, P2465, DOI 10.1038/sj.npp.1301385; Wing VC, 2012, ANN NY
ACAD SCI, V1248, P89, DOI 10.1111/j.1749-6632.2011.06261.x; Winterer G, 2010, CURR
OPIN PSYCHIATR, V23, P112, DOI 10.1097/YCO.0b013e3283366643; Yucel M, 2012,
SCHIZOPHRENIA BULL, V38, P316, DOI 10.1093/schbul/sbq079; Zamberletti E, 2012, CURR
PHARM DESIGN, V18, P4980, DOI 10.2174/138161212802884744; Zammit S, 2008, BRIT J
PSYCHIAT, V193, P357, DOI 10.1192/bjp.bp.107.046375; Zarrindast MR, 1999, EUR
NEUROPSYCHOPHARM, V9, P235, DOI 10.1016/S0924-977X(98)00027-3; Ziedonis D, 2008,
NICOTINE TOB RES, V10, P1691, DOI 10.1080/14622200802443569; Zullino DF, 2002, INT
CLIN PSYCHOPHARM, V17, P141, DOI 10.1097/00004850-200205000-00008 126 0
0 0 0 ROYAL SOC CHEMISTRY CAMBRIDGE THOMAS GRAHAM HOUSE,
SCIENCE PARK, CAMBRIDGE CB4 4WF, CAMBS, ENGLAND 2041-3203 978-1-78262-249-9;
978-1-78262-026-6 RSC DRUG DISCOV RSC Drug Discov. 2015 44
70 88 10.1039/9781782622499 19
Chemistry, Medicinal; Neurosciences; Pharmacology & Pharmacy; Psychiatry
Pharmacology & Pharmacy; Neurosciences & Neurology; Psychiatry BG3OO
WOS:000388099700005 2019-09-25
J Garland, EL; Hanley, AW; Thomas, EA; Knoll, P; Ferraro, J
Garland, Eric L.; Hanley, Adam W.; Thomas, Elizabeth A.; Knoll, Paul;
Ferraro, Jeffrey Low Dispositional Mindfulness Predicts Self-
medication of Negative Emotion With Prescription Opioids JOURNAL OF ADDICTION
MEDICINE English Article
addiction; chronic pain; mindfulness; opioid dependence; self-medication
NATIONAL EPIDEMIOLOGIC SURVEY; SUBSTANCE USE DISORDERS; DRUG-USE DISORDERS;
CHRONIC PAIN; THOUGHT SUPPRESSION; ANXIETY DISORDERS; ALCOHOL; ADDICTION;
HYPOTHESIS; SYMPTOMS Objectives: Although evidence is mounting that opioids are
abused to self-medicate negative emotions, little is known about the traits and
factors linked to opioid self-medication. One potentially crucial psychological
correlate is dispositional mindfulness. Thus, the purpose of this study was to
describe the prevalence of opioid self-medication among a treatment-seeking sample
of prescription opioid-dependent individuals and specifically examine the
relationship between dispositional mindfulness and opioid self-medication. Methods:
Participants in acute detoxification or intensive outpatient treatment for
prescription opioid dependence (n = 79) were recruited from a regional hospital's
addictions treatment unit for this cross-sectional study. Sociodemographic data
were collected along with surveys of opioid self-medication, pain level, and
dispositional mindfulness. Results: Self-medication of negative affective states
with opioids was quite common, with 94.9% of individuals sampled reporting self-
medication behaviors. In adjusted analyses, individuals engaging in more frequent
opioid use tended to self-medicate negative emotions with opioids more often than
those engaging in more intermittent opioid use (beta = 0.33; P < 0.05).
Importantly, irrespective of opioid use frequency and other clinical and
sociodemographic covariates, dispositional mindfulness was inversely associated
with opioid self-medication (beta = -0.42; P < 0.001), such that less mindful
individuals reported using opioids more frequently to self-medicate negative
emotions. Conclusions: Self-medication of negative emotions with opioids was
prevalent in this sample and related to low dispositional mindfulness. Plausibly,
increasing mindfulness may decrease opioid self-medication. Addictive automaticity
and emotion regulation are discussed as potential mechanisms linking low
dispositional mindfulness and self-medication. [Garland, Eric L.; Thomas,
Elizabeth A.] Univ Utah, Salt Lake City, UT 84112 USA; [Hanley, Adam W.] Florida
State Univ, Tallahassee, FL 32306 USA; [Knoll, Paul; Ferraro, Jeffrey] Tallahassee
Mem Hosp, Recovery Ctr, Tallahassee, FL USA Garland, EL (reprint author), Univ
Utah, Huntsman Canc Inst, 395 South,1500 East, Salt Lake City, UT 84112 USA.
elgarlan@gmail.com National Institute on Drug AbuseUnited
States Department of Health & Human ServicesNational Institutes of Health (NIH) -
USANIH National Institute on Drug Abuse (NIDA) [R34DA037005] Dr Garland was
supported by grant R34DA037005 from the National Institute on Drug Abuse during the
preparation of this article. Baer RA, 2006, ASSESSMENT, V13, P27, DOI
10.1177/1073191105283504; Bargh JA, 1999, AM PSYCHOL, V54, P462, DOI 10.1037/0003-
066X.54.7.462; Black DS, 2012, ASSESSMENT, V19, P42, DOI 10.1177/1073191111415365;
Bolton JM, 2009, J AFFECT DISORDERS, V115, P367, DOI 10.1016/j.jad.2008.10.003;
Bowen S, 2009, SUBST ABUS, V30, P295, DOI 10.1080/08897070903250084; Brown KW,
2003, J PERS SOC PSYCHOL, V84, P822, DOI 10.1037/0022-3514.84.4.822; Carmody J,
2008, J BEHAV MED, V31, P23, DOI 10.1007/s10865-007-9130-7; Centers for Disease
Control and Prevention, 2012, PRIM CAR PUBL HLTH I; Conway KP, 2006, J CLIN
PSYCHIAT, V67, P247, DOI 10.4088/JCP.v67n0211; Dias-Ferreira E, 2009, SCIENCE,
V325, P621, DOI 10.1126/science.1171203; Dowling K, 2006, CLIN J PAIN, V22, P776,
DOI 10.1097/01.ajp.0000210926.41406.2c; Garland EL, 2014, FRONT PSYCHIATRY, V4, DOI
10.3389/fpsyt.2013.00173; Garland EL, 2014, J CONSULT CLIN PSYCH, V82, P448, DOI
10.1037/a0035798; Garland EL, 2014, SUBST USE MISUSE, V49, P525, DOI
10.3109/10826084.2014.850309; Garland EL, 2013, NEUROSCI BIOBEHAV R, V37, P2597,
DOI 10.1016/j.neubiorev.2013.08.006; Garland EL, 2013, J BEHAV MED, V36, P611, DOI
10.1007/s10865-012-9455-8; Garland EL, 2013, ADDICT BEHAV, V38, P1555, DOI
10.1016/j.addbeh.2012.02.004; Garland EL, 2012, COGNITIVE THER RES, V36, P441, DOI
10.1007/s10608-011-9378-7; Garland EL, 2012, BIOL PSYCHOL, V89, P87, DOI
10.1016/j.biopsycho.2011.09.010; Garland EL, 2010, J PSYCHOACTIVE DRUGS, V42, P177,
DOI 10.1080/02791072.2010.10400690; Grant B, 2005, SOURCE ACCURACY STAT; Green TC,
2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027244; Greeson J, 2014, WILEY
BLACKWELL HANDBOOK OF MINDFULNESS, VOLS I AND II, P533; Hall DH, 2007, J
PSYCHOACTIVE DRUGS, V39, P151, DOI 10.1080/02791072.2007.10399873; Hanley AW, 2014,
PERS INDIV DIFFER, V66, P146, DOI 10.1016/j.paid.2014.03.014; Hansen RN, 2011, CLIN
J PAIN, V27, P194, DOI 10.1097/AJP.0b013e3181ff04ca; Huang BJ, 2006, J CLIN
PSYCHIAT, V67, P1062, DOI 10.4088/JCP.v67n0708; Jensen MP, 1999, PAIN, V83, P157,
DOI 10.1016/S0304-3959(99)00101-3; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259;
Koob GF, 2008, ANNU REV PSYCHOL, V59, P29, DOI
10.1146/annurev.psych.59.103006.093548; Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24,
P97, DOI 10.1016/S0893-133X(00)00195-0; LANGER EJ, 1992, CONSCIOUS COGN, V1, P289,
DOI 10.1016/1053-8100(92)90066-J; Leeies M, 2010, DEPRESS ANXIETY, V27, P731, DOI
10.1002/da.20677; Lembke A, 2012, AM J DRUG ALCOHOL AB, V38, P524, DOI
10.3109/00952990.2012.694532; Manubay JM, 2011, PRIMARY CARE, V38, P71, DOI
10.1016/j.pop.2010.11.006; Martins SS, 2012, PSYCHOL MED, V42, P1261, DOI
10.1017/S0033291711002145; McCabe SE, 2005, ADDICTION, V100, P96, DOI
10.1111/j.1360-0443.2005.00944.x; Merlo LJ, 2013, J ADDICT MED, V7, P349, DOI
10.1097/ADM.0b013e31829da074; Modinos G, 2010, SOC COGN AFFECT NEUR, V5, P369, DOI
10.1093/scan/nsq006; Robinson J, 2011, ARCH GEN PSYCHIAT, V68, P800, DOI
10.1001/archgenpsychiatry.2011.75; Substance Abuse and Mental Health Services
Administration, 2011, RES 2010 NAT SURV DR; Sullivan MD, 2005, PAIN, V119, P95, DOI
10.1016/j.pain.2005.09.020; TIFFANY ST, 1990, PSYCHOL REV, V97, P147, DOI
10.1037/0033-295X.97.2.147; Walach H, 2006, PERS INDIV DIFFER, V40, P1543, DOI
10.1016/j.paid.2005.11.025; Witkiewitz K, 2013, ADDICT BEHAV, V38, P1563, DOI
10.1016/j.addbeh.2012.04.001 45 14 14 0 20 LIPPINCOTT WILLIAMS &
WILKINS PHILADELPHIA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA
19103 USA 1932-0620 1935-3227 J ADDICT MED J. Addict. Med. JAN-
FEB 2015 9 1 61 67
10.1097/ADM.0000000000000090 7 Substance Abuse Substance
Abuse CB0TP WOS:000349340500008 25469652 Green Accepted 2019-
09-25
J Cui, RF; Tate, SR; Cummins, K; Skidmore, JR; Brown, SA
Cui, Ruifeng; Tate, Susan R.; Cummins, Kevin; Skidmore, Jessica R.; Brown,
Sandra A. Chronic Physical Health Problems Moderate Changes in
Depression and Substance Use Among Dual Diagnosed Individuals During and After
Treatment SUBSTANCE USE & MISUSE English Article
physical health; depression; substance use disorder; treatment
COMORBIDITY SURVEY REPLICATION; RANDOMIZED CONTROLLED-TRIAL; CHRONIC MEDICAL
ILLNESS; USE DISORDERS; MAJOR DEPRESSION; LEARNED HELPLESSNESS; DEPENDENT PATIENTS;
SELF-MEDICATION; RATING SCALE; PRIMARY-CARE Background: Physical illnesses
frequently co-occur with depression and substance use disorders and may impact
their improvement. Physical illness symptoms may overlap with or exacerbate somatic
symptoms of depression. Individuals may use substances to cope with symptoms of
physical illness. Objectives: We examined whether chronic physical health problems
moderated changes in depression and substance use among dual diagnosed individuals
during and in the year following treatment. Methods: Participants were recruited
from a Veterans Affairs dual diagnosis outpatient program between March 2000 and
November 2007 and were randomized to either Integrated Cognitive-Behavioral Therapy
or Twelve-Step Facilitation Therapy. A total of 214 veterans with assessment data
for the variables of interest were included in analyses. Participants completed
quarterly depression, substance use, and health assessments over an 18 month
period. We used linear-mixed effects models to analyze patterns of change for
depression and substance use. Results: Individuals with severe chronic health
problems and higher intake depression showed slower improvements in both nonsomatic
and somatic depression symptoms. Individuals with severe chronic health problems
and higher midtreatment substance use showed less improvement in substance use.
Conclusions: Assessing and addressing physical health issues during depression and
substance use disorder treatment may improve outcomes. [Cui, Ruifeng; Skidmore,
Jessica R.] Vet Affairs San Diego Healthcare Syst, Res Serv, San Diego, CA 92161
USA; [Tate, Susan R.] Vet Affairs San Diego Healthcare Syst, Psychol Serv, San
Diego, CA 92161 USA; [Tate, Susan R.] Univ Calif San Diego, Dept Psychiat, La
Jolla, CA 92093 USA; [Cummins, Kevin] Univ Calif San Diego, Dept Psychol, La Jolla,
CA 92093 USA; [Brown, Sandra A.] Univ Calif San Diego, Off Res Affairs, La Jolla,
CA 92093 USA Tate, SR (reprint author), Vet Affairs San Diego Healthcare Syst,
Psychol Serv, 3350 La Jolla Village Dr, San Diego, CA 92161 USA. srtate@ucsd.edu
Department of Veterans Affairs, Veterans Health Administration, Office
of Research and Development, Clinical Sciences Research & Development Merit Review
Awards; NIAAA T32 training grant [5T32AA013525-08] This material is based upon
work funded by the Department of Veterans Affairs, Veterans Health Administration,
Office of Research and Development, Clinical Sciences Research & Development Merit
Review Awards to Sandra A. Brown, Ph.D. and Susan R. Tate, Ph.D. and a NIAAA T32
training grant (5T32AA013525-08) to Jessica R. Skidmore., Ph.D. Address
correspondence to Dr. Susan R. Tate, Psychology Service, Veterans Affairs San Diego
Healthcare System, 3350 La Jolla Village Drive mc 116B, San Diego, CA 92161; E-
mail: srtate@ucsd.edu. Aharonovich E, 2002, AM J PSYCHIAT, V159, P1600, DOI
10.1176/appi.ajp.159.9.1600; Bair MJ, 2004, PSYCHOSOM MED, V66, P17, DOI
10.1097/01.PSY.0000106883.94059.C5; Beck A. T., 1993, MANUAL BECK DEPRESSI; BECK
AT, 1961, ARCH GEN PSYCHIAT, V4, P561; Bockting CLH, 2005, J CONSULT CLIN PSYCH,
V73, P647, DOI 10.1037/0022-006X.73.4.647; Brennan PL, 2005, ADDICTION, V100, P777,
DOI 10.1111/j.1360-0443.2005.01074.x; Brower KJ, 2001, AM J PSYCHIAT, V158, P399,
DOI 10.1176/appi.ajp.158.3.399; Brown G. W., 1978, SOCIAL ORIGINS DEPRE; Bus BAA,
2011, PSYCHOL MED, V41, P1419, DOI 10.1017/S0033291710002151; Carey KB, 2004, J
STUD ALCOHOL, V65, P774, DOI 10.15288/jsa.2004.65.774; Casella G., 2002, STAT
INFERENCE; Chaney JM, 1999, J PEDIATR PSYCHOL, V24, P259, DOI
10.1093/jpepsy/24.3.259; CLARK DC, 1983, J NERV MENT DIS, V171, P705, DOI
10.1097/00005053-198312000-00001; Cleary P, 1977, DRUGS EXP CLIN RES, V1, P115;
Coelho R, 2000, PSYCHOPATHOLOGY, V33, P103, DOI 10.1159/000029129; Currie SR, 2005,
CAN J PSYCHIAT, V50, P660, DOI 10.1177/070674370505001013; Currie SR, 2003, ALCOHOL
CLIN EXP RES, V27, P1262, DOI 10.1097/01.ALC.0000081622.03973.57; Darves-Bornoz JM,
2008, J TRAUMA STRESS, V21, P455, DOI 10.1002/jts.20357; Dodge R, 2005, J SUBST
ABUSE TREAT, V28, P189, DOI 10.1016/j.jsat.2004.12.005; Drapkin ML, 2008, J SUBST
ABUSE TREAT, V35, P343, DOI 10.1016/j.jsat.2007.12.005; Erfan S, 2010, SUBST ABUS,
V31, P162, DOI 10.1080/08897077.2010.495311; Frees EW, 2004, LONGITUDINAL PANEL D;
Gagnon LM, 2002, CAN J PSYCHIAT, V47, P149, DOI 10.1177/070674370204700204;
Glasner-Edwards S, 2007, J STUD ALCOHOL DRUGS, V68, P663, DOI
10.15288/jsad.2007.68.663; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI
10.1136/jnnp.23.1.56; HAMILTON M, 1967, BRIT J SOC CLIN PSYC, V6, P278; Hasin D,
2002, ARCH GEN PSYCHIAT, V59, P375, DOI 10.1001/archpsyc.59.4.375; HERMANN BP,
1979, MED HYPOTHESES, V5, P723, DOI 10.1016/0306-9877(79)90094-X; HIRSCHFIELD RMA,
1977, MODIFIED LIFE EVENTS; Kadden R. M., 1992, COGNITIVE BEHAV COPI; Katon W,
2007, GEN HOSP PSYCHIAT, V29, P147, DOI 10.1016/j.genhosppsych.2006.11.005; Keaney
F, 2011, J SUBST USE, V16, P27, DOI 10.3109/14659890903580474; Kessler RC, 2005,
ARCH GEN PSYCHIAT, V62, P617, DOI 10.1001/archpsyc.62.6.617; Kessler RC, 2003,
JAMA-J AM MED ASSOC, V289, P3095, DOI 10.1001/jama.289.23.3095; Liu ETH, 2009,
COGNITIVE THER RES, V33, P449, DOI 10.1007/s10608-008-9228-4; Lorig KR, 1999, MED
CARE, V37, P5, DOI 10.1097/00005650-199901000-00003; Lydecker KP, 2010, PSYCHOL
ADDICT BEHAV, V24, P453, DOI 10.1037/a0019943; McLellan AT, 2000, JAMA-J AM MED
ASSOC, V284, P1689, DOI 10.1001/jama.284.13.1689; MOFFETT LA, 1990, ADDICT BEHAV,
V15, P179, DOI 10.1016/0306-4603(90)90023-Q; MOWBRAY RM, 1972, PSYCHOL MED, V2,
P272, DOI 10.1017/S0033291700042574; Munoz R. F., 1993, GROUP THERAPY MANUAL;
Murray CJL, 2013, JAMA-J AM MED ASSOC, V310, P591, DOI 10.1001/jama.2013.13805;
Nowinski J., 1994, NIH PUBLICATION; ROBINS LN, 1988, ARCH GEN PSYCHIAT, V45, P1069;
Rosenblum A, 2003, JAMA-J AM MED ASSOC, V289, P2370, DOI 10.1001/jama.289.18.2370;
SOBELL LC, 1992, MEASURING ALCOHOL CONSUMPTION, P41; StataCorp, 2013, STAT STAT
SOFTW REL; Swendsen JD, 2000, CLIN PSYCHOL REV, V20, P173, DOI 10.1016/S0272-
7358(99)00026-4; Tate SR, 2011, AM J ADDICTION, V20, P357, DOI 10.1111/j.1521-
0391.2011.00137.x; Trafton JA, 2004, DRUG ALCOHOL DEPEN, V73, P23, DOI
10.1016/j.drugalcdep.2003.08.007; WEISS RD, 1992, AM J DRUG ALCOHOL AB, V18, P121,
DOI 10.3109/00952999208992825; Wetherell JL, 2011, PAIN, V152, P2098, DOI
10.1016/j.pain.2011.05.016; WILLENBRING ML, 1986, J STUD ALCOHOL, V47, P367, DOI
10.15288/jsa.1986.47.367; Wittchen HU, 1999, J CLIN PSYCHIAT, V60, P29; Worley MJ,
2012, J SUBST ABUSE TREAT, V43, P291, DOI 10.1016/j.jsat.2011.12.010; Zimmerman M,
2002, AM J PSYCHIAT, V159, P469, DOI 10.1176/appi.ajp.159.3.469 56 2 2
0 15 TAYLOR & FRANCIS INC PHILADELPHIA 530 WALNUT STREET, STE
850, PHILADELPHIA, PA 19106 USA 1082-6084 1532-2491 SUBST USE MISUSE
Subst. Use Misuse JAN 2015 50 2 174 183
10.3109/10826084.2014.962052 10 Substance Abuse; Psychiatry;
Psychology Substance Abuse; Psychiatry; Psychology AU9GN WOS:000345899900005
25290658 Green Accepted 2019-09-25
J Clark, TT; Salas-Wright, CP; Vaughn, MG; Whitfield, KE
Clark, Trenette T.; Salas-Wright, Christopher P.; Vaughn, Michael G.;
Whitfield, Keith E. Everyday discrimination and mood and substance
use disorders: A latent profile analysis with African Americans and Caribbean
Blacks ADDICTIVE BEHAVIORS English Article
Discrimination; Blacks; Generalized anxiety disorder; Major
depressive disorder; Substance use disorders; Depression SELF-MEDICATION
HYPOTHESIS; PERCEIVED DISCRIMINATION; MENTAL-HEALTH; COPING STRATEGIES; PREVALENCE;
SYMPTOMS; CHILDREN; STATES; YOUTH Background: Perceived discrimination is a major
source of health-related stress. The purpose of this study was to model the
heterogeneity of everyday-discrimination experiences among African American and
Caribbean Blacks and to identify differences in the prevalence of mood and
substance use outcomes, including generalized anxiety disorder, major depressive
disorder, alcohol-use disorder, and illicit drug-use disorder among the identified
subgroups. Method: The study uses data from the National Survey of American Life
obtained from a sample of African American and Caribbean Black respondents (N =
4,462) between 18 and 65 years. Results: We used latent profile analysis and
multinomial regression analyses to identify and validate latent subgroups and test
hypotheses, yielding 4 classes of perceived everyday discrimination: Low
Discrimination, Disrespect and Condescension, General Discrimination, and Chronic
Discrimination. Findings show significant differences exist between the Low
Discrimination and General Discrimination classes for major depressive disorder,
alcohol-use disorder, and illicit drug-use disorder. Moreover, we find significant
differences exist between the Low Discrimination and Chronic Discrimination classes
for the four disorders examined. Compared with the Chronic Discrimination class,
members of the other classes were significantly less likely to meet criteria for
generalized anxiety disorder, major depressive disorder, alcohol-use disorder, and
illicit drug-use disorder. Conclusions: Findings suggest elevated levels of
discrimination increase risk for mood and substance-use disorders. Importantly,
results suggest the prevalence of mood and substance-use disorders is a function of
the type and frequency of discrimination that individuals experience. (C) 2014
Elsevier Ltd. All rights reserved. [Clark, Trenette T.] Univ N Carolina, Sch
Social Work, Chapel Hill, NC USA; [Salas-Wright, Christopher P.] Univ Texas Austin,
Sch Social Work, Austin, TX 78712 USA; [Vaughn, Michael G.] St Louis Univ, Coll
Publ Hlth & Social Justice, Sch Social Work, St Louis, MO 63103 USA; [Whitfield,
Keith E.] Duke Univ, Ctr Biobehav Hlth Dispar Res, Durham, NC USA Clark, TT
(reprint author), 325 Pittsboro St,CB 3550, Chapel Hill, NC 27599 USA.
ttclark@email.unc.edu Vaughn, Michael/W-2694-2019 NIDA NIH HHSUnited
States Department of Health & Human ServicesNational Institutes of Health (NIH) -
USANIH National Institute on Drug Abuse (NIDA) [K01 DA035895, P30 DA027827]
Aharonovich E, 2001, AM J ADDICTION, V10, P327; American Psychiatric
Association, 1994, DIAGN STAT MAN MENT; Clark R, 1999, AM PSYCHOL, V54, P805, DOI
10.1037/0003-066X.54.10.805; Clark TT, 2014, ADDICT BEHAV, V39, P1021, DOI
10.1016/j.addbeh.2014.01.013; Ferrari AJ, 2013, PLOS MED, V10, DOI
10.1371/journal.pmed.1001547; Gaylord-Harden NK, 2009, J YOUTH ADOLESCENCE, V38,
P532, DOI 10.1007/s10964-008-9377-5; Gee GC, 2007, AM J PUBLIC HEALTH, V97, P1275,
DOI 10.2105/AJPH.2006.091827; Gibbons FX, 2004, J PERS SOC PSYCHOL, V86, P517, DOI
10.1037/0022-3514.86.4.517; Hunte Haslyn E R, 2012, Am J Public Health, V102,
pe111, DOI 10.2105/AJPH.2012.300780; Jackson JS, 2004, INT J METH PSYCH RES, V13,
P196, DOI 10.1002/mpr.177; Jones J. M., 1997, PREJUDICE RACISM; Kessler RC, 1999, J
HEALTH SOC BEHAV, V40, P208, DOI 10.2307/2676349; Kessler RC, 2004, INT J METH
PSYCH RES, V13, P93, DOI 10.1002/mpr.168; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62,
P617, DOI 10.1001/archpsyc.62.6.617; Khantzian E. J., 2003, PRIMARY PSYCHIAT, V10,
p[47, 53]; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI
10.3109/10673229709030550; Long J. S., 2006, REGRESSION MODELS CA; Martin JK, 2003,
J HEALTH SOC BEHAV, V44, P408, DOI 10.2307/1519787; McLachlan G., 2000, FINITE
MIXTURE MODEL; Muthen B, 2006, ADDICT BEHAV, V31, P1050, DOI
10.1016/j.addbeh.2006.03.026; Schulz AJ, 2006, AM J PUBLIC HEALTH, V96, P1265, DOI
10.2105/AJPH.2005.064543; Seaton EK, 2008, DEV PSYCHOL, V44, P1288, DOI
10.1037/a0012747; Soto JA, 2011, J ANXIETY DISORD, V25, P258, DOI
10.1016/j.janxdis.2010.09.011; StataCorp, 2013, STAT STAT SOFTW REL; Suh JJ, 2008,
PSYCHOANAL PSYCHOL, V25, P518, DOI 10.1037/0736-9735.25.3.518; Vermunt JK, 2008, LG
SYNTAX USERS GUID; Wethington E., 1995, MEASURING STRESS GUI, P59; Whitbeck LB,
2001, J HEALTH SOC BEHAV, V42, P405, DOI 10.2307/3090187; Williams D R, 1997, J
Health Psychol, V2, P335, DOI 10.1177/135910539700200305; Zhang J, 1998, JAMA-J AM
MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690 30 25 25 0 29
PERGAMON-ELSEVIER SCIENCE LTD OXFORD THE BOULEVARD, LANGFORD LANE,
KIDLINGTON, OXFORD OX5 1GB, ENGLAND 0306-4603 1873-6327 ADDICT BEHAV
Addict. Behav. JAN 2015 40 119 125
10.1016/j.addbeh.2014.08.006 7 Psychology, Clinical;
Substance Abuse Psychology; Substance Abuse AT3GO WOS:000344824100020
25254321 Green Accepted 2019-09-25